<h1 >ESC Guideline NSTEMI</h1>
<ul>
<li><p><a
href="https://academic.oup.com/eurheartj/article-pdf/42/36/3599/40594787/ehab368.pdf"><img
src="https://oup.silverchair-cdn.com/UI/app/svg/pdf.svg"
alt="pdf" />PDF</a></p></li>
<li><p>Split View</p></li>
<li><ul>
<li>Figures &amp; tables</li>
<li>Supplementary Data</li>
</ul></li>
<li><p><a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#">Cite</a></p>
<h3 >Cite</h3>
<p>Theresa A McDonagh and others, 2021 ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure: Developed by the Task
Force for the diagnosis and treatment of acute and chronic heart failure
of the European Society of Cardiology (ESC) With the special
contribution of the Heart Failure Association (HFA) of the ESC,
<em>European Heart Journal</em>, Volume 42, Issue 36, 21 September 2021,
Pages 3599–3726, <a
href="https://doi.org/10.1093/eurheartj/ehab368">https://doi.org/10.1093/eurheartj/ehab368</a></p>
<p>Close</p></li>
</ul>
<p>Theresa A McDonagh,</p>
<p>Theresa A McDonagh</p>
<p>Chairperson United Kingdom</p>
<p>Theresa McDonagh, Cardiology Department, King’s College Hospital,
Denmark Hill, London, SE5 9RS, United Kingdom. Tel: +44 203 299 325,
E-mail: <a
href="mailto:theresa.mcdonagh@kcl.ac.uk">theresa.mcdonagh@kcl.ac.uk</a></p>
<p>Search for other works by this author on:</p>
<p>Marco Metra,</p>
<p>Marco Metra</p>
<p>Chairperson Italy</p>
<p>Marco Metra, Institute of Cardiology, ASST Spedali Civili di Brescia
and Department of Medical and Surgical Specialties, Radiological
Sciences and Public Health, University of Brescia, Brescia, Italy. Tel:
+39 303 07221, E-mail: <a
href="mailto:metramarco@libero.it">metramarco@libero.it</a></p>
<p>Search for other works by this author on:</p>
<p>Marianna Adamo,</p>
<p>Marianna Adamo</p>
<p>Task Force Coordinator Italy</p>
<p>Search for other works by this author on:</p>
<p>Roy S Gardner,</p>
<p>Roy S Gardner</p>
<p>Task Force Coordinator United Kingdom</p>
<p>Search for other works by this author on:</p>
<p>Andreas Baumbach,</p>
<p>Andreas Baumbach</p>
<p>United Kingdom</p>
<p>Search for other works by this author on:</p>
<p>Michael Böhm,</p>
<p>Search for other works by this author on:</p>
<p>Haran Burri,</p>
<p>Search for other works by this author on:</p>
<p>Javed Butler,</p>
<p>Javed Butler</p>
<p>United States of America</p>
<p>Search for other works by this author on:</p>
<p>Jelena Čelutkienė,</p>
<p>Jelena Čelutkienė</p>
<p>Lithuania</p>
<p>Search for other works by this author on:</p>
<p>Ovidiu Chioncel,</p>
<p>Search for other works by this author on:</p>
<p><a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#">…
Show more</a></p>
<p>* Corresponding authors: The two chairpersons contributed equally to
the document.</p>
<p>Author Notes</p>
<p>Published:</p>
<p>27 August 2021</p>
<ul>
<li><p><a
href="https://academic.oup.com/eurheartj/article-pdf/42/36/3599/40594787/ehab368.pdf"><img
src="https://oup.silverchair-cdn.com/UI/app/svg/pdf.svg"
alt="pdf" />PDF</a></p></li>
<li><p>Split View</p></li>
<li><ul>
<li>Figures &amp; tables</li>
<li>Supplementary Data</li>
</ul></li>
<li><p><a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#">Cite</a></p>
<h3 >Cite</h3>
<p>Theresa A McDonagh and others, 2021 ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure: Developed by the Task
Force for the diagnosis and treatment of acute and chronic heart failure
of the European Society of Cardiology (ESC) With the special
contribution of the Heart Failure Association (HFA) of the ESC,
<em>European Heart Journal</em>, Volume 42, Issue 36, 21 September 2021,
Pages 3599–3726, <a
href="https://doi.org/10.1093/eurheartj/ehab368">https://doi.org/10.1093/eurheartj/ehab368</a></p>
<p>Close</p></li>
</ul>
<p>Navbar Search Filter Mobile Enter search term Search</p>
<p>Guidelines, heart failure, natriuretic peptides, ejection fraction,
diagnosis, pharmacotherapy, neuro-hormonal antagonists, cardiac
resynchronization therapy, mechanical circulatory support,
transplantation, arrhythmias, comorbidities, hospitalization,
multidisciplinary management, advanced heart failure, acute heart
failure</p>
<p>Topic:</p>
<ul>
<li><a
href="https://academic.oup.com/eurheartj/search-results?f_SemanticFilterTopics=heart%20failure">heart
failure</a></li>
<li><a
href="https://academic.oup.com/eurheartj/search-results?f_SemanticFilterTopics=diagnosis">diagnosis</a></li>
<li><a
href="https://academic.oup.com/eurheartj/search-results?f_SemanticFilterTopics=heart%20failure%20with%20reduced%20ejection%20fraction">heart
failure with reduced ejection fraction</a></li>
</ul>
<p>All experts involved in the development of these guidelines have
submitted declarations of interest. These have been compiled in a report
and published in a supplementary document simultaneously to the
guidelines. The report is also available on the ESC website <a
href="http://www.escardio.org/guidelines">www.escardio.org/guidelines</a></p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf3.jpeg?Expires=1689850106&amp;Signature=NFZNidrPRSq83~WqBUtnVWxs7p33wtfk0U-uEPxqxmdlk9AxirmbF1ArpUn6GoWm4B9eg2Dhee91RY0FZ-If844eUribWPuXM0668CwNpYIhBcAsmkJtM0LwPqjo6lai4UnvHqbKj8dumNfPdM4Kh~iRKynvx8GKCn45YkjrP07K2-oM~dqcaUE-Ko0S-2C2Pb-4bBuIiBP1H5XK0aeV8AXqds0~KSPbzYiv~RZKHn94EXVhArJlbmwoqESCKw7wIoAVwUooLUY1Q0dg-WIgfp0gGpljwBHaZy4xuUihmJUraHi2Jd21t2ZYaBOVF4jxPXEcNT~c-n7zwooXGgg5lw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" />  For the <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Data</a> which include background information and detailed discussion of
the data that have provided the basis for the guidelines see
<em>European Heart Journal</em> online</p>
<h2 >Table of contents</h2>
<ul>
<li><p>1 Preamble  3607</p></li>
<li><p>2 Introduction  3609</p></li>
<li><p> 2.1 What is new  3609</p></li>
<li><p>3 Definition, epidemiology and prognosis  3612</p></li>
<li><p> 3.1 Definition of heart failure  3612</p></li>
<li><p> 3.2 Terminology  3612</p></li>
<li><p>  3.2.1 Heart failure with preserved, mildly reduced, and reduced
ejection fraction  3612</p></li>
<li><p>  3.2.2 Right ventricular dysfunction  3613</p></li>
<li><p>  3.2.3 Other common terminology used in heart
failure  3613</p></li>
<li><p>  3.2.4 Terminology related to the symptomatic severity of heart
failure  3613</p></li>
<li><p> 3.3 Epidemiology and natural history of heart
failure  3613</p></li>
<li><p>  3.3.1 Incidence and prevalence 3613</p></li>
<li><p>  3.3.2 Aetiology of heart failure  3614</p></li>
<li><p>  3.3.3 Natural history and prognosis  3614</p></li>
<li><p>4 Chronic heart failure  3614</p></li>
<li><p> 4.1 Key steps in the diagnosis of chronic heart
failure  3614</p></li>
<li><p> 4.2 Natriuretic peptides  3616</p></li>
<li><p>  4.2.1 Use in the non-acute setting  3617</p></li>
<li><p> 4.3 Investigations to determine the underlying aetiology of
chronic heart failure  3617</p></li>
<li><p>5 Heart failure with reduced ejection fraction  3619</p></li>
<li><p> 5.1 The diagnosis of heart failure with reduced ejection
fraction  3619</p></li>
<li><p> 5.2 Pharmacological treatments for patients with heart failure
with reduced ejection fraction  3619</p></li>
<li><p>  5.2.1 Goals of pharmacotherapy for patients with heart failure
with reduced ejection fraction  3619</p></li>
<li><p>  5.2.2 General principles of pharmacotherapy for heart failure
with reduced ejection fraction  3619</p></li>
<li><p> 5.3 Drugs recommended in all patients with heart failure with
reduced ejection fraction  3620</p></li>
<li><p>  5.3.1 Angiotensin-converting enzyme inhibitors  3621</p></li>
<li><p>  5.3.2 Beta-blockers  3621</p></li>
<li><p>  5.3.3 Mineralocorticoid receptor antagonists  3621</p></li>
<li><p>  5.3.4 Angiotensin receptor-neprilysin inhibitor  3621</p></li>
<li><p>  5.3.5 Sodium-glucose co-transporter 2 inhibitors  3622</p></li>
<li><p> 5.4 Other drugs recommended or to be considered in selected
patients with heart failure with reduced ejection
fraction  3622</p></li>
<li><p>  5.4.1 Diuretics  3623</p></li>
<li><p>  5.4.2 Angiotensin II type 1 receptor blockers  3623</p></li>
<li><p>  5.4.3 I_<sub>f</sub>_-channel inhibitor  3623</p></li>
<li><p>  5.4.4 Combination of hydralazine and isosorbide
dinitrate  3623</p></li>
<li><p>  5.4.5 Digoxin  3623</p></li>
<li><p>  5.4.6 Recently reported advances from trials in heart failure
with reduced ejection fraction  3624</p></li>
<li><p> 5.5 Strategic phenotypic overview of the management of heart
failure with reduced ejection fraction  3624</p></li>
<li><p>6 Cardiac rhythm management for heart failure with reduced
ejection fraction  3624</p></li>
<li><p> 6.1 Implantable cardioverter-defibrillator  3625</p></li>
<li><p>  6.1.1 Secondary prevention of sudden cardiac
death  3626</p></li>
<li><p>  6.1.2 Primary prevention of sudden cardiac death  3626</p></li>
<li><p>  6.1.3 Patient selection for implantable cardioverter-
defibrillator therapy  3626</p></li>
<li><p>  6.1.4 Implantable cardioverter-defibrillator
programming  3626</p></li>
<li><p>  6.1.5 Subcutaneous and wearable implantable
cardioverter-defibrillators  3626</p></li>
<li><p> 6.2 Cardiac resynchronization therapy  3627</p></li>
<li><p> 6.3 Devices under evaluation  3628</p></li>
<li><p>7 Heart failure with mildly reduced ejection
fraction  3628</p></li>
<li><p> 7.1 The diagnosis of heart failure with mildly reduced ejection
fraction  3628</p></li>
<li><p> 7.2 Clinical characteristics of patients with heart failure with
mildly reduced ejection fraction  3629</p></li>
<li><p> 7.3 Treatments for patients with heart failure with mildly
reduced ejection fraction  3629</p></li>
<li><p>  7.3.1 Angiotensin-converting enzyme inhibitors  3629</p></li>
<li><p>  7.3.2 Angiotensin receptor II type 1 receptor
blockers  3629</p></li>
<li><p>  7.3.3 Beta-blockers  3629</p></li>
<li><p>  7.3.4 Mineralocorticoid receptor antagonists  3629</p></li>
<li><p>  7.3.5 Angiotensin receptor-neprilysin inhibitor  3629</p></li>
<li><p>  7.3.6 Other drugs  3630</p></li>
<li><p>  7.3.7 Devices  3630</p></li>
<li><p>8 Heart failure with preserved ejection fraction  3630</p></li>
<li><p> 8.1 The background to heart failure with preserved ejection
fraction  3630</p></li>
<li><p> 8.2 Clinical characteristics of patients with heart failure with
preserved ejection fraction  3630</p></li>
<li><p> 8.3 The diagnosis of heart failure with preserved ejection
fraction  3630</p></li>
<li><p> 8.4 Treatment of heart failure with preserved ejection
fraction  3631</p></li>
<li><p>9 Multidisciplinary team management for the prevention and
treatment of chronic heart failure  3633</p></li>
<li><p> 9.1 Prevention of heart failure  3633</p></li>
<li><p> 9.2 Multidisciplinary management of chronic heart
failure  3633</p></li>
<li><p>  9.2.1 Models of care  3633</p></li>
<li><p>  9.2.2 Characteristics and components of a heart failure
management programme  3633</p></li>
<li><p> 9.3 Patient education, self-care and lifestyle
advice  3633</p></li>
<li><p> 9.4 Exercise rehabilitation  3636</p></li>
<li><p> 9.5 Follow-up of chronic heart failure  3636</p></li>
<li><p>  9.5.1 General follow-up  3636</p></li>
<li><p>  9.5.2 Monitoring with biomarkers  3636</p></li>
<li><p> 9.6 Telemonitoring  3636</p></li>
<li><p>10 Advanced heart failure  3637</p></li>
<li><p> 10.1 Epidemiology, diagnosis, and prognosis  3637</p></li>
<li><p> 10.2 Management  3639</p></li>
<li><p>  10.2.1 Pharmacological therapy and renal
replacement  3639</p></li>
<li><p>  10.2.2 Mechanical circulatory support  3639</p></li>
<li><p>  10.2.3 Heart transplantation  3643</p></li>
<li><p>  10.2.4 Symptom control and end-of-life care  3644</p></li>
<li><p>11 Acute heart failure  3644</p></li>
<li><p> 11.1 Epidemiology, diagnosis and prognosis  3644</p></li>
<li><p> 11.2 Clinical presentations  3646</p></li>
<li><p>  11.2.1 Acute decompensated heart failure  3646</p></li>
<li><p>  11.2.2 Acute pulmonary oedema  3647</p></li>
<li><p>  11.2.3 Isolated right ventricular failure  3647</p></li>
<li><p>  11.2.4 Cardiogenic shock  3647</p></li>
<li><p> 11.3 Management  3649</p></li>
<li><p>  11.3.1 General aspects  3649</p></li>
<li><p>  11.3.2 Oxygen therapy and/or ventilatory support  3650</p></li>
<li><p>  11.3.3 Diuretics  3652</p></li>
<li><p>  11.3.4 Vasodilators  3654</p></li>
<li><p>  11.3.5 Inotropes  3655</p></li>
<li><p>  11.3.6 Vasopressors  3655</p></li>
<li><p>  11.3.7 Opiates  3655</p></li>
<li><p>  11.3.8 Digoxin  3656</p></li>
<li><p>  11.3.9 Thromboembolism prophylaxis  3656</p></li>
<li><p>  11.3.10 Short-term mechanical circulatory
support  3656</p></li>
<li><p>  11.3.11 Pre-discharge assessment and post-discharge management
planning  3657</p></li>
<li><p>12 Cardiovascular comorbidities  3657</p></li>
<li><p> 12.1 Arrhythmias and conduction disturbances  3657</p></li>
<li><p>  12.1.1 Atrial fibrillation  3657</p></li>
<li><p>  12.1.2 Ventricular arrhythmias  3660</p></li>
<li><p>  12.1.3 Symptomatic bradycardia, pauses and atrio-ventricular
block  3660</p></li>
<li><p> 12.2 Chronic coronary syndromes  3660</p></li>
<li><p>  12.2.1 Medical therapy  3661</p></li>
<li><p>  12.2.2 Myocardial revascularization  3662</p></li>
<li><p> 12.3 Valvular heart disease  3662</p></li>
<li><p>  12.3.1 Aortic stenosis  3662</p></li>
<li><p>  12.3.2 Aortic regurgitation  3664</p></li>
<li><p>  12.3.3 Mitral regurgitation  3664</p></li>
<li><p>  12.3.4 Tricuspid regurgitation  3666</p></li>
<li><p> 12.4 Hypertension  3666</p></li>
<li><p> 12.5 Stroke  3666</p></li>
<li><p>13 Non-cardiovascular comorbidities  3666</p></li>
<li><p> 13.1 Diabetes  3666</p></li>
<li><p> 13.2 Thyroid disorders  3667</p></li>
<li><p> 13.3 Obesity  3668</p></li>
<li><p> 13.4 Frailty, cachexia, sarcopenia  3668</p></li>
<li><p> 13.5 Iron deficiency and anaemia  3668</p></li>
<li><p> 13.6 Kidney dysfunction  3669</p></li>
<li><p> 13.7 Electrolyte disorders: hypokalaemia, hyperkalaemia,
hyponatraemia, hypochloraemia  3670</p></li>
<li><p> 13.8 Lung disease, sleep-disordered breathing  3671</p></li>
<li><p> 13.9 Hyperlipidaemia and lipid-modifying therapy  3671</p></li>
<li><p> 13.10 Gout and arthritis  3672</p></li>
<li><p> 13.11 Erectile dysfunction  3672</p></li>
<li><p> 13.12 Depression  3672</p></li>
<li><p> 13.13 Cancer  3672</p></li>
<li><p> 13.14 Infection  3675</p></li>
<li><p>14 Special conditions  3675</p></li>
<li><p> 14.1 Pregnancy  3675</p></li>
<li><p>  14.1.1 Pregnancy in pre-existing heart failure  3675</p></li>
<li><p>  14.1.2 New heart failure presenting during
pregnancy  3675</p></li>
<li><p> 14.2 Cardiomyopathies  3677</p></li>
<li><p>  14.2.1 Epidemiology and diagnosis  3677</p></li>
<li><p>  14.2.2 Treatment  3677</p></li>
<li><p> 14.3 Left ventricular non-compaction  3681</p></li>
<li><p> 14.4 Atrial disease  3682</p></li>
<li><p>  14.4.1 Definition  3682</p></li>
<li><p>  14.4.2 Diagnosis  3682</p></li>
<li><p>  14.4.3 Management  3682</p></li>
<li><p> 14.5 Myocarditis  3682</p></li>
<li><p>  14.5.1 Epidemiology and diagnosis  3682</p></li>
<li><p>  14.5.2 Treatment  3682</p></li>
<li><p> 14.6 Amyloidosis  3682</p></li>
<li><p>  14.6.1 Epidemiology and diagnosis  3682</p></li>
<li><p>  14.6.2 Therapy of amyloidosis and heart failure  3685</p></li>
<li><p> 14.7 Iron overload cardiomyopathy  3685</p></li>
<li><p> 14.8 Adult congenital heart disease  3686</p></li>
<li><p>15 Key messages  3688</p></li>
<li><p>16 Gaps in evidence  3689</p></li>
<li><p>17 ‘What to do’ and ‘what not to do’ messages from the
guidelines  3690</p></li>
<li><p>18 Quality indicators  3693</p></li>
<li><p>19 Supplementary data  3694</p></li>
<li><p>20 Author information  3694</p></li>
<li><p>21 Appendix  3694</p></li>
<li><p>22 References  3695</p></li>
</ul>
<h3 >List of recommendations</h3>
<ul>
<li><p>Recommended diagnostic tests in all patients with suspected
chronic heart failure  3617</p></li>
<li><p>Recommendations for specialized diagnostic tests for selected
patients with chronic heart failure to detect reversible/treatable
causes of heart failure  3618</p></li>
<li><p>Pharmacological treatments indicated in patients with (NYHA class
II–IV) heart failure with reduced ejection fraction (LVEF
≤40%)  3620</p></li>
<li><p>Other pharmacological treatments indicated in selected patients
with NYHA class II–IV heart failure with reduced ejection fraction (LVEF
≤40%)  3622</p></li>
<li><p>Recommendations for an implantable cardioverter-defibrillator in
patients with heart failure  3625</p></li>
<li><p>Recommendations for cardiac resynchronization therapy
implantation in patients with heart failure  3627</p></li>
<li><p>Pharmacological treatments to be considered in patients with
(NYHA class II–IV) heart failure with mildly reduced ejection
fraction  3629</p></li>
<li><p>Recommendations for the treatment of patients with heart failure
with preserved ejection fraction  3632</p></li>
<li><p>Recommendations for the primary prevention of heart failure in
patients with risk factors for its development  3632</p></li>
<li><p>Multidisciplinary interventions recommended for the management of
chronic heart failure  3633</p></li>
<li><p>Recommendations for exercise rehabilitation in patients with
chronic heart failure  3636</p></li>
<li><p>Recommendations for telemonitoring  3637</p></li>
<li><p>Recommendations for the treatment of patients with advanced heart
failure  3643</p></li>
<li><p>Recommendations for the initial treatment of acute heart
failure  3655</p></li>
<li><p>Recommendations for the use of short-term mechanical circulatory
support in patients with cardiogenic shock  3656</p></li>
<li><p>Recommendations for pre-discharge and early post-discharge
follow-up of patients hospitalized for acute heart
failure  3657</p></li>
<li><p>Recommendations for the treatment of atrial fibrillation in
patients with heart failure  3660</p></li>
<li><p>Recommendations for myocardial revascularization in patients with
heart failure with reduced ejection fraction  3662</p></li>
<li><p>Recommendations for the management of valvular heart disease in
patients with heart failure  3665</p></li>
<li><p>Recommendations for the treatment of diabetes in heart
failure  3667</p></li>
<li><p>Recommendations for the management of anaemia and iron deficiency
in patients with heart failure  3669</p></li>
<li><p>Recommendations for the management of patients with cancer and
heart failure  3675</p></li>
<li><p>Recommendations for the treatment of transthyretin
amyloidosis-cardiac amyloidosis  3686</p></li>
</ul>
<h3 >List of tables</h3>
<ul>
<li><p>Table 1 Classes of recommendations  3608</p></li>
<li><p>Table 2 Levels of evidence  3608</p></li>
<li><p>Table 3 Definition of heart failure with reduced ejection
fraction, mildly reduced ejection fraction and preserved ejection
fraction  3613</p></li>
<li><p>Table 4 New York Heart Association functional classification
based on severity of symptoms and physical activity  3614</p></li>
<li><p>Table 5 Causes of heart failure, common modes of presentation and
specific investigations  3616</p></li>
<li><p>Table 6 Symptoms and signs typical of heart
failure  3617</p></li>
<li><p>Table 7 Causes of elevated concentrations of natriuretic
peptides  3618</p></li>
<li><p>Table 8 Evidence-based doses of disease-modifying drugs in key
randomized trials in patients with heart failure with reduced ejection
fraction  3621</p></li>
<li><p>Table 9 Objective evidence of cardiac structural, functional and
serological abnormalities consistent with the presence of left
ventricular diastolic dysfunction/raised left ventricular filling
pressures  3631</p></li>
<li><p>Table 10 Risk factors for the development of heart failure and
potential corrective actions  3632</p></li>
<li><p>Table 11 Important characteristics and components in a heart
failure management programme  3634</p></li>
<li><p>Table 12 Patient education and self-care  3634</p></li>
<li><p>Table 13 Criteria for definition of advanced heart
failure  3638</p></li>
<li><p>Table 14 Interagency Registry for Mechanically Assisted
Circulatory Support profile descriptions of patients with advanced heart
failure  3638</p></li>
<li><p>Table 15 Terms describing various indications for mechanical
circulatory support  3642</p></li>
<li><p>Table 16 Patients potentially eligible for implantation of a left
ventricular assist device  3642</p></li>
<li><p>Table 17 Heart transplantation: indications and
contraindications  3643</p></li>
<li><p>Table 18 Patients with heart failure in whom end-of-life care
should be considered  3644</p></li>
<li><p>Table 19 Key components of palliative care service in patients
with advanced heart failure  3644</p></li>
<li><p>Table 20 Diagnostic tests in patients with acute heart
failure  3646</p></li>
<li><p>Table 21 Clinical presentations of acute heart
failure  3647</p></li>
<li><p>Table 22 Inotropes and/or vasopressors used to treat acute heart
failure  3655</p></li>
<li><p>Table 23 Cancer drugs causing heart failure  3673</p></li>
<li><p>Table 24 Infections in patients with heart failure  3675</p></li>
<li><p>Table 25 Possible causes and disease modifiers of most frequent
cardiomyopathies  3678</p></li>
<li><p>Table 26 Initial diagnostic assessment in patients with suspected
cardiomyopathy  3678</p></li>
<li><p>Table 27 Dilated cardiomyopathy or hypokinetic non-dilated
cardiomyopathy: specific aspects of diagnosis and
treatment  3679</p></li>
<li><p>Table 28 Hypertrophic cardiomyopathy: specific aspects of
diagnosis and treatment  3680</p></li>
<li><p>Table 29 Arrhythmogenic cardiomyopathy: specific aspects of
diagnosis and Treatment  3681</p></li>
<li><p>Table 30 Aetiologies to be considered triggering acute
myocarditis  3682</p></li>
<li><p>Table 31 Diagnostic workup in suspected acute
myocarditis  3683</p></li>
<li><p>Table 32 Endomyocardial biopsy in patients with suspected
myocarditis  3684</p></li>
<li><p>Table 33 Cardiac magnetic resonance in patients with suspected
myocarditis  3685</p></li>
<li><p>Table 34 Treatment and follow-up of acute
myocarditis  3685</p></li>
<li><p>Table 35 “Red flags” for most common forms of cardiac
amyloidosis  3686</p></li>
<li><p>Table 36 Treatment of adult congenital heart disease and heart
failure in specialized centres  3688</p></li>
<li><p>Table 37 Main European Society of Cardiology Quality Indicators
for the evaluation of care and outcomes for patients with heart
failure  3693</p></li>
</ul>
<h3 >List of figures</h3>
<ul>
<li><p>Figure 1 The diagnostic algorithm for heart
failure  3615</p></li>
<li><p>Figure 2 Therapeutic algorithm of Class I Therapy Indications for
a patient with heart failure with reduced ejection
fraction  3620</p></li>
<li><p>Figure 3 Central illustration. Strategic phenotypic overview of
the management of heart failure with reduced ejection
fraction  3624</p></li>
<li><p>Figure 4 Algorithm for the treatment of patients with advanced
heart failure  3640</p></li>
<li><p>Figure 5 Triage of patients with advanced heart failure and
appropriate timing of referral  3641</p></li>
<li><p>Figure 6 Diagnostic workup of new onset acute heart
failure  3645</p></li>
<li><p>Figure 7 Management of acute decompensated heart
failure  3648</p></li>
<li><p>Figure 8 Management of pulmonary oedema  3649</p></li>
<li><p>Figure 9 Management of right ventricular failure  3650</p></li>
<li><p>Figure 10 Management of cardiogenic shock  3651</p></li>
<li><p>Figure 11 Stages of management of patients with acute heart
failure  3652</p></li>
<li><p>Figure 12 Initial management of acute heart
failure  3653</p></li>
<li><p>Figure 13 Diuretic therapy (furosemide) in acute heart
failure  3654</p></li>
<li><p>Figure 14 Management of atrial fibrillation in patients with
heart failure with reduced ejection fraction  3658</p></li>
<li><p>Figure 15 Algorithm for the medical treatment of chronic coronary
syndrome in patients with heart failure with reduced ejection
fraction  3661</p></li>
<li><p>Figure 16 Management of patients with severe low-flow
low-gradient aortic stenosis and heart failure  3663</p></li>
<li><p>Figure 17 Management of secondary mitral regurgitation in
patients with heart failure with reduced ejection
fraction  3664</p></li>
<li><p>Figure 18 Management of patients with cancer and heart
failure  3674</p></li>
<li><p>Figure 19 Management of patients with heart failure before and
during pregnancy  3676</p></li>
<li><p>Figure 20 Management of patients with heart failure and acute
myocarditis  3684</p></li>
<li><p>Figure 21 Diagnosis and treatment of cardiac amyloidosis in heart
failure patients  3687</p></li>
</ul>
<h2 >Abbreviations and acronyms</h2>
<p> - 6MWT</p>
<p> - <sup>99m</sup>Tc-PYP</p>
<pre><code>Technetium-labelled pyrophosphate</code></pre>
<p> - AATAC</p>
<pre><code>Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD (trial)</code></pre>
<p> - AC</p>
<pre><code>Arrhythmogenic cardiomyopathy</code></pre>
<p> - ACE</p>
<pre><code>Angiotensin-converting enzyme</code></pre>
<p> - ACE-I</p>
<pre><code>Angiotensin-converting enzyme inhibitor</code></pre>
<p> - ACHD</p>
<pre><code>Adult congenital heart disease</code></pre>
<p> - ACS</p>
<p> - ADHF</p>
<pre><code>Acutely decompensated heart failure</code></pre>
<p> - AF</p>
<p> - AF-CHF</p>
<pre><code>Atrial fibrillation – Congestive Heart Failure (trial)</code></pre>
<p> - AFFIRM</p>
<pre><code>Atrial Fibrillation Follow-up Investigation of Rhythm Management (trial)</code></pre>
<p> - AFFIRM-AHF</p>
<pre><code>A Randomized, Double-blind Placebo-controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalizations and Mortality in Iron-deficient Subjects Admitted for Acute Heart Failure (trial)</code></pre>
<p> - AHF</p>
<p> - AL</p>
<pre><code>Light chain immunoglobulin</code></pre>
<p> - AL-CA</p>
<pre><code>Light chain immunoglobulin cardiac amyloidosis</code></pre>
<p> - AMICA</p>
<pre><code>Atrial Fibrillation Management in Congestive Heart Failure With Ablation (trial)</code></pre>
<p> - ANCA</p>
<pre><code>Antineutrophil cytoplasmic antibody</code></pre>
<p> - ARB</p>
<pre><code>Angiotensin-receptor blocker</code></pre>
<p> - ARNI</p>
<pre><code>Angiotensin receptor-neprilysin inhibitor</code></pre>
<p> - ARVC</p>
<pre><code>Arrhythmogenic right ventricular cardiomyopathy</code></pre>
<p> - ATTR</p>
<pre><code>Transthyretin amyloidosis</code></pre>
<p> - AV</p>
<p> - b.i.d.</p>
<p> - BAG3</p>
<pre><code>Bcl2-associated athanogene 3</code></pre>
<p> - BiVAD</p>
<pre><code>Biventricular assist device</code></pre>
<p> - BMI</p>
<p> - BNP</p>
<pre><code>B-type natriuretic peptide</code></pre>
<p> - BP</p>
<p> - b.p.m.</p>
<p> - BTB</p>
<p> - BTC</p>
<p> - BTD</p>
<p> - BTR</p>
<p> - BTT</p>
<pre><code>Bridge to transplantation</code></pre>
<p> - CA</p>
<pre><code>Cardiac amyloidosis (or amyloid cardiomyopathy)</code></pre>
<p> - CABANA</p>
<pre><code>Catheter ABlation vs. ANti-arrhythmic drug therapy for Atrial fibrillation (trial)</code></pre>
<p> - CABG</p>
<pre><code>Coronary artery bypass graft</code></pre>
<p> - CAD</p>
<p> - CANVAS-R</p>
<pre><code>CANagliflozin cardioVascular Assessment Study - Renal</code></pre>
<p> - CARE-HF</p>
<pre><code>CArdiac REsynchronization in Heart Failure</code></pre>
<p> - CASTLE-AF</p>
<pre><code>Catheter Ablation versus Standard conventional Treatment in patients with LEft ventricular and Atrial Fibrillation (trial)</code></pre>
<p> - CCB</p>
<p> - CCS</p>
<pre><code>Chronic coronary syndrome</code></pre>
<p> - CHA<sub>2</sub>DS<sub>2</sub>-VASc</p>
<pre><code>Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female) (score)</code></pre>
<p> - CHAMPIT</p>
<pre><code>Acute Coronary syndrome/Hypertension emergency/Arrhythmia/acute Mechanical cause/Pulmonary embolism/Infections/Tamponade</code></pre>
<p> - CHARM</p>
<pre><code>Candesartan in Heart Failure - Assessment of moRtality and Morbidity (trial)</code></pre>
<p> - CHF</p>
<p> - CI</p>
<p> - CKD</p>
<p> - CMP</p>
<p> - CMR</p>
<pre><code>Cardiac magnetic resonance</code></pre>
<p> - CMV</p>
<p> - COAPT</p>
<pre><code>Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for HF patients with functional mitral regurgitation (trial)</code></pre>
<p> - COC</p>
<pre><code>Cardio-Oncology Council (part of the European Society of Cardiology)</code></pre>
<p> - COMMANDER-HF</p>
<pre><code>A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (trial)</code></pre>
<p> - COMPASS</p>
<pre><code>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (trial)</code></pre>
<p> - COPD</p>
<pre><code>Chronic obstructive pulmonary disease</code></pre>
<p> - CORONA</p>
<pre><code>COntrolled ROsuvastatin multiNAtional (trial)</code></pre>
<p> - COVID-19</p>
<p> - CR</p>
<p> - CREDENCE</p>
<pre><code>Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (trial)</code></pre>
<p> - CRT</p>
<pre><code>Cardiac resynchronization therapy</code></pre>
<p> - CRT-D</p>
<pre><code>Cardiac resynchronization therapy with defibrillator</code></pre>
<p> - CRT-P</p>
<pre><code>Cardiac resynchronization therapy pacemaker</code></pre>
<p> - CSA</p>
<p> - CT</p>
<p> - CTCA</p>
<pre><code>Computed tomography coronary angiography</code></pre>
<p> - CV</p>
<p> - DAPA-HF</p>
<pre><code>Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (trial)</code></pre>
<p> - DCM</p>
<p> - DECLARE- TIMI 58</p>
<pre><code>Dapagliflozin Effect on CardiovascuLAR Events (Thrombolysis in Myocardial Infarction) (trial)</code></pre>
<p> - DIAMOND</p>
<pre><code>Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (trial)</code></pre>
<p> - DIG</p>
<pre><code>Digitalis Investigation Group (trial)</code></pre>
<p> - DNA</p>
<p> - DOAC</p>
<pre><code>Direct-acting oral anticoagulant</code></pre>
<p> - DPD</p>
<pre><code>3,3-diphosphono-1,2-propanodicarboxylic acid</code></pre>
<p> - DPP-4</p>
<p> - DSC2</p>
<p> - DSG2</p>
<p> - DSP</p>
<p> - DT</p>
<p> - E/e′ (ratio)</p>
<pre><code>E/e′ (ratio) = early filling velocity on transmitral Doppler/early relaxation velocity on tissue Doppler</code></pre>
<p> - EACVI</p>
<pre><code>European Association of Cardiovascular Imaging (part of the European Society of Cardiology)</code></pre>
<p> - EAST-AFNET 4</p>
<pre><code>Early Treatment of Atrial Fibrillation for Stroke Prevention Trial 4 (trial)</code></pre>
<p> - ECG</p>
<p> - EchoCRT</p>
<pre><code>Echocardiography Guided Cardiac Resynchronization Therapy (trial)</code></pre>
<p> - ECLS</p>
<pre><code>Extracorporeal life support</code></pre>
<p> - ECMO</p>
<pre><code>Extracorporeal membrane oxygenation</code></pre>
<p> - EF</p>
<p> - eGFR</p>
<pre><code>Estimated glomerular filtration rate</code></pre>
<p> - EHRA</p>
<pre><code>European Heart Rhythm Association</code></pre>
<p> - EMA</p>
<pre><code>European Medicines Agency</code></pre>
<p> - EMB</p>
<p> - EMPA-REG OUTCOME</p>
<pre><code>Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (trial)</code></pre>
<p> - EMPEROR- Reduced</p>
<pre><code>EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (trial)</code></pre>
<p> - EROA</p>
<pre><code>Effective regurgitant orifice area</code></pre>
<p> - ESC</p>
<pre><code>European Society of Cardiology</code></pre>
<p> - EU</p>
<p> - EuroSCORE II</p>
<pre><code>European System for Cardiac Operative Risk Evaluation II (score)</code></pre>
<p> - FDA</p>
<pre><code>Food and Drug Administration</code></pre>
<p> - FDG</p>
<p> - FiO<sub>2</sub></p>
<pre><code>Fraction of inspired oxygen</code></pre>
<p> - FLN</p>
<p> - FLNC</p>
<p> - GGT</p>
<pre><code>Gamma-glutamyl transferase</code></pre>
<p> - GISSI-HF</p>
<pre><code>Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico – Heart Failure (trial)</code></pre>
<p> - GLP-1</p>
<p> - GUIDE-HF</p>
<pre><code>Hemodynamic-GUIDEd Management of Heart Failure (trial)</code></pre>
<p> - h</p>
<p> - H<sub>2</sub>FPEF</p>
<pre><code>Heavy (BMI &gt;30 kg/m&lt;sup&gt;2&lt;/sup&gt;), Hypertensive (use of ≥2 antihypertensive medications), atrial Fibrillation (paroxysmal or persistent), Pulmonary hypertension (Doppler Echocardiographic estimated Pulmonary Artery Systolic Pressure &gt;35 mmHg), Elderly (age &gt;60 years), Filling pressure (Doppler Echocardiographic E/e′ &gt;9) (score)</code></pre>
<p> - HbA1c</p>
<p> - HCM</p>
<pre><code>Hypertrophic cardiomyopathy</code></pre>
<p> - HEART</p>
<pre><code>Heart Failure Revascularisation Trial</code></pre>
<p> - HER2</p>
<pre><code>Human epidermal growth factor receptor 2</code></pre>
<p> - HF</p>
<p> - HFA</p>
<pre><code>Heart Failure Association</code></pre>
<p> - HFA-PEFF</p>
<pre><code>Heart Failure Association of ESC diagnostic algorithm, P – Initial Workup (Step 1: Pretest Assessment), E - Diagnostic Workup (Step 2: Echocardiographic and Natriuretic Peptide score), F1 – Advanced Workup (Step 3: Functional testing in Case of Uncertainty), F2 – Aetiological Workup (Step 4: Final Aetiology)</code></pre>
<p> - HF-MP</p>
<pre><code>Heart failure management programme</code></pre>
<p> - HFmrEF</p>
<pre><code>Heart failure with mildly reduced ejection fraction</code></pre>
<p> - HFpEF</p>
<pre><code>Heart failure with preserved ejection fraction</code></pre>
<p> - HFrEF</p>
<pre><code>Heart failure with reduced ejection fraction</code></pre>
<p> - HHV</p>
<p> - HIV</p>
<pre><code>Human immunodeficiency virus</code></pre>
<p> - HLA-DR</p>
<pre><code>Human leukocyte antigen-DR isotype</code></pre>
<p> - HMDP</p>
<pre><code>Hydroxyl-methylene-diphosphonate</code></pre>
<p> - HR</p>
<p> - HT</p>
<p> - HTM</p>
<p> - i.v.</p>
<p> - IABP</p>
<pre><code>Intra-aortic balloon pump</code></pre>
<p> - ICCU</p>
<pre><code>Intensive coronary care unit</code></pre>
<p> - ICD</p>
<pre><code>Implantable cardioverter-defibrillator</code></pre>
<p> - ICU</p>
<p> - IHD</p>
<p> - INR</p>
<pre><code>International normalized ratio</code></pre>
<p> - INTERMACS</p>
<pre><code>Interagency Registry for Mechanically Assisted Circulatory Support</code></pre>
<p> - INTrEPID</p>
<pre><code>Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent (trial)</code></pre>
<p> - IOCM</p>
<pre><code>Iron overload cardiomyopathy</code></pre>
<p> - IPD</p>
<p> - I-PRESERVE</p>
<pre><code>Irbesartan in Patients with Heart Failure and PRESERVEd Ejection Fraction (trial)</code></pre>
<p> - KCNH2</p>
<pre><code>Potassium voltage-gated channel subfamily H member 2</code></pre>
<p> - KCNQ1</p>
<pre><code>Potassium voltage-gated channel subfamily Q member 1</code></pre>
<p> - LA</p>
<p> - LAE</p>
<p> - LBBB</p>
<p> - LDB3</p>
<p> - LFT</p>
<p> - LGE</p>
<pre><code>Late gadolinium enhancement</code></pre>
<p> - LMNA</p>
<p> - LMWH</p>
<pre><code>Low-molecular-weight heparin</code></pre>
<p> - LUS</p>
<p> - LV</p>
<pre><code>Left ventricular/ventricle</code></pre>
<p> - LVAD</p>
<pre><code>Left ventricular assist device</code></pre>
<p> - LVEDP</p>
<pre><code>Left ventricular end-diastolic pressure</code></pre>
<p> - LVEF</p>
<pre><code>Left ventricular ejection fraction</code></pre>
<p> - LVESD</p>
<pre><code>Left ventricular end-systolic diameter</code></pre>
<p> - LVH</p>
<pre><code>Left ventricular hypertrophy</code></pre>
<p> - LVNC</p>
<pre><code>Left ventricular non-compaction</code></pre>
<p> - LVOT</p>
<pre><code>Left ventricular outflow tract</code></pre>
<p> - LVOTO</p>
<pre><code>Left ventricular outflow tract obstruction</code></pre>
<p> - MADIT-CRT</p>
<pre><code>Multicenter Automatic Deﬁbrillator Implantation Trial with Cardiac Resynchronization Therapy (trial)</code></pre>
<p> - MADIT-II</p>
<pre><code>Multicenter Automatic Defibrillator Implantation Trial II (trial)</code></pre>
<p> - MADIT-RIT</p>
<pre><code>Multicenter Automatic Defibrillator Implantation Trial – Reduce Inappropriate Therapy (trial)</code></pre>
<p> - MAGGIC</p>
<pre><code>Meta-Analysis Global Group in Chronic Heart Failure</code></pre>
<p> - MCS</p>
<pre><code>Mechanical circulatory support</code></pre>
<p> - MEK</p>
<pre><code>Mitogen-activated protein kinase</code></pre>
<p> - MI</p>
<p> - MITRA-FR</p>
<pre><code>Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (trial)</code></pre>
<p> - MMR</p>
<p> - MR</p>
<p> - MRA</p>
<pre><code>Mineralocorticoid receptor antagonist</code></pre>
<p> - MRI</p>
<pre><code>Magnetic resonance imaging</code></pre>
<p> - mRNA</p>
<pre><code>Messenger ribonucleic acid</code></pre>
<p> - MR-proANP</p>
<pre><code>Mid-regional pro-atrial natriuretic peptide</code></pre>
<p> - MT</p>
<p> - MV</p>
<p> - mWHO</p>
<pre><code>Modified World Health Organization</code></pre>
<p> - MYPC</p>
<p> - NICM</p>
<pre><code>Non-ischaemic cardiomyopathy</code></pre>
<p> - NKX2-5</p>
<pre><code>NK2 transcription factor related, locus 5</code></pre>
<p> - NP</p>
<p> - NSAID</p>
<pre><code>Non-steroidal anti-inflammatory drug</code></pre>
<p> - NSVT</p>
<pre><code>Non-sustained ventricular tachycardia</code></pre>
<p> - NT-proBNP</p>
<pre><code>N-terminal pro-B-type natriuretic peptide</code></pre>
<p> - NYHA</p>
<pre><code>New York Heart Association</code></pre>
<p> - o.d</p>
<p> - OMT</p>
<p> - OSA</p>
<p> - PA</p>
<p> - PaO<sub>2</sub></p>
<pre><code>Partial pressure of oxygen</code></pre>
<p> - PARADIGM-HF</p>
<pre><code>Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (trial)</code></pre>
<p> - pCO<sub>2</sub></p>
<pre><code>Partial pressure of carbon dioxide</code></pre>
<p> - PCI</p>
<pre><code>Percutaneous coronary intervention</code></pre>
<p> - PCR</p>
<pre><code>Polymerase chain reaction</code></pre>
<p> - PCWP</p>
<pre><code>Pulmonary capillary wedge pressure</code></pre>
<p> - PEP-CHF</p>
<pre><code>Perindopril in Elderly People with Chronic Heart Failure (trial)</code></pre>
<p> - PET</p>
<pre><code>Positron emission tomography</code></pre>
<p> - PKP2</p>
<p> - PLN</p>
<p> - PPCM</p>
<pre><code>Peripartum cardiomyopathy</code></pre>
<p> - PREVEND</p>
<pre><code>Prevention of REnal and Vascular ENd-stage Disease (trial)</code></pre>
<p> - PV</p>
<p> - PVC</p>
<pre><code>Premature ventricular contraction</code></pre>
<p> - PVI</p>
<p> - pVO<sub>2</sub></p>
<pre><code>Peak exercise oxygen consumption</code></pre>
<p> - QI</p>
<p> - QOL</p>
<p> - QRS</p>
<pre><code>Q, R, and S waves of an ECG</code></pre>
<p> - RAAS</p>
<pre><code>Renin-angiotensin-aldosterone system</code></pre>
<p> - RACE II</p>
<pre><code>Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II (trial)</code></pre>
<p> - RAFT</p>
<pre><code>Resynchronization/Deﬁbrillation for Ambulatory Heart Failure Trial (trial)</code></pre>
<p> - RASi</p>
<pre><code>Renin-angiotensin system inhibitor</code></pre>
<p> - RATE-AF</p>
<pre><code>Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (trial)</code></pre>
<p> - RBM20</p>
<pre><code>Ribonucleic acid binding motif 20</code></pre>
<p> - RCT</p>
<pre><code>Randomized controlled trial</code></pre>
<p> - REMATCH</p>
<pre><code>Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (trial)</code></pre>
<p> - REVERSE</p>
<pre><code>REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (trial)</code></pre>
<p> - REVIVED</p>
<pre><code>REVascularization for Ischaemic VEntricular Dysfunction (trial)</code></pre>
<p> - RNA</p>
<p> - RRT</p>
<pre><code>Renal replacement therapy</code></pre>
<p> - RV</p>
<pre><code>Right ventricular/ventricle</code></pre>
<p> - RVAD</p>
<pre><code>Right ventricular assist device</code></pre>
<p> - RVEDP</p>
<pre><code>Right ventricular end-diastolic pressure</code></pre>
<p> - SARS-CoV-2</p>
<pre><code>Severe acute respiratory syndrome coronavirus 2</code></pre>
<p> - SAVR</p>
<pre><code>Surgical aortic valve replacement</code></pre>
<p> - SBP</p>
<p> - SCN5a</p>
<pre><code>Sodium channel alpha subunit 5</code></pre>
<p> - SCORED</p>
<pre><code>Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (trial)</code></pre>
<p> - SENIORS</p>
<pre><code>Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalizations in Seniors with Heart Failure (trial)</code></pre>
<p> - SERVE-HF</p>
<pre><code>Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure (trial)</code></pre>
<p> - SGLT2</p>
<pre><code>Sodium-glucose co-transporter 2</code></pre>
<p> - S-ICD</p>
<pre><code>Subcutaneous implantable cardioverter-defibrillator</code></pre>
<p> - SMR</p>
<pre><code>Secondary mitral regurgitation</code></pre>
<p> - SPECT</p>
<pre><code>Single-photon emission computed tomography</code></pre>
<p> - SpO<sub>2</sub></p>
<pre><code>Transcutaneous oxygen saturation</code></pre>
<p> - SR</p>
<p> - STEMI</p>
<pre><code>ST-elevation myocardial infarction</code></pre>
<p> - STICH</p>
<pre><code>Surgical Treatment for Ischemic Heart Failure (trial)</code></pre>
<p> - STICHES</p>
<pre><code>Extended follow-up of patients from the STICH trial</code></pre>
<p> - STS-PROM</p>
<pre><code>Society of Thoracic Surgeons Predicted Risk of Mortality</code></pre>
<p> - SZC</p>
<pre><code>Sodium zirconium cyclosilicate</code></pre>
<p> - T2DM</p>
<p> - TAVI</p>
<pre><code>Transcatheter aortic valve implantation</code></pre>
<p> - TFT</p>
<p> - t.i.d.</p>
<pre><code>Ter in die (three times a day)</code></pre>
<p> - TKI</p>
<pre><code>Tyrosine kinase inhibitor</code></pre>
<p> - TMEM43</p>
<p> - TNNT</p>
<p> - TR</p>
<p> - TRPM4</p>
<pre><code>Transient receptor potential cation channel subfamily M member 4</code></pre>
<p> - TSAT</p>
<p> - TSH</p>
<pre><code>Thyroid-stimulating hormone</code></pre>
<p> - TTN</p>
<p> - TTR</p>
<p> - UK</p>
<p> - US</p>
<p> - VAD</p>
<pre><code>Ventricular assist device</code></pre>
<p> - Val-HeFT</p>
<pre><code>Valsartan Heart Failure Trial (trial)</code></pre>
<p> - VEGF</p>
<pre><code>Vascular endothelial growth factor</code></pre>
<p> - VERTIS-CV</p>
<pre><code>Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease (trial)</code></pre>
<p> - VEST</p>
<pre><code>Vest Prevention of Early Sudden Death Trial (trial)</code></pre>
<p> - VKA</p>
<p> - VO<sub>2</sub></p>
<p> - VPB</p>
<pre><code>Ventricular premature beat</code></pre>
<p> - vs.</p>
<p> - VV interval</p>
<pre><code>Interventricular delay interval</code></pre>
<p> - WARCEF</p>
<pre><code>Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (trial)</code></pre>
<p> - wtTTR-CA</p>
<pre><code>Wild-type transthyretin cardiac amyloidosis</code></pre>
<p> - XL</p>
<h2 >1 Preamble</h2>
<p>Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in proposing the best management
strategies for an individual patient with a given condition. Guidelines
and their recommendations should facilitate decision making of health
professionals in their daily practice. However, the final decisions
concerning an individual patient must be made by the responsible health
professional(s) in consultation with the patient and caregiver as
appropriate.</p>
<p>A great number of guidelines have been issued in recent years by the
European Society of Cardiology (ESC), as well as by other societies and
organizations. Because of their impact on clinical practice, quality
criteria for the development of guidelines have been established in
order to make all decisions transparent to the user. The recommendations
for formulating and issuing ESC Guidelines can be found on the ESC
website (<a
href="https://www.escardio.org/Guidelines">https://www.escardio.org/Guidelines</a>).
The ESC Guidelines represent the official position of the ESC on a given
topic and are regularly updated.</p>
<p>In addition to the publication of Clinical Practice guidelines, the
ESC carries out the EURObservational Research Programme of international
registries of cardiovascular (CV) diseases and interventions which are
essential to assess diagnostic/therapeutic processes, use of resources
and adherence to guidelines. These registries aim at providing a better
understanding of medical practice in Europe and around the world, based
on high-quality data collected during routine clinical practice.</p>
<p>Furthermore, the ESC has developed and embedded in this document a
set of quality indicators (QIs), which are tools to evaluate the level
of implementation of the guidelines and may be used by the ESC,
hospitals, healthcare providers and professionals to measure clinical
practice as well as used in educational programmes, alongside the key
messages from the guidelines, to improve quality of care and clinical
outcomes.</p>
<p>The Members of this Task Force were selected by the ESC, including
representation from its relevant ESC sub-specialty groups, in order to
represent professionals involved with the medical care of patients with
this pathology. Selected experts in the field undertook a comprehensive
review of the published evidence for management of a given condition
according to ESC Clinical Practice Guidelines (CPG) Committee policy. A
critical evaluation of diagnostic and therapeutic procedures was
performed, including assessment of the risk–benefit ratio. The level of
evidence and the strength of the recommendation of particular management
options were weighed and graded according to predefined scales, as
outlined below.</p>
<p>Table 1</p>
<p>Classes of recommendations</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf1.jpeg?Expires=1689850106&amp;Signature=ePii7f4KH96s~RdjBCj9k27atBTLoqz0Nm09NHZTU6fGdIuMsEXyHUZPy4PPJ6Rdh7xtU-lQFbuRdZhLEeiLtNWBsc8Lr6yWsTwrLEnZh4Djtr2Wq5N9pBF2vIwSROL20dKtH5zeQ5CWIAxShMA7Llmd12~sNnEqt2lhBWFMK2RFbevCh8IbLAaa-mVwvS8Nmsrqfx~LkegqkNInH9SCMVE39bKLpDUDoJn7cy8KDJRyrovommbOAnn5WWlXWVI990VnRFFl6j48JJfLlIIOYKMSzU8Bw8fBxoHqiu2MTRi16tHIPziG1vPyW5NctXOcbMtCIhzAcIiycyxSczGNnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf1.jpeg?Expires=1689850106&amp;Signature=ePii7f4KH96s~RdjBCj9k27atBTLoqz0Nm09NHZTU6fGdIuMsEXyHUZPy4PPJ6Rdh7xtU-lQFbuRdZhLEeiLtNWBsc8Lr6yWsTwrLEnZh4Djtr2Wq5N9pBF2vIwSROL20dKtH5zeQ5CWIAxShMA7Llmd12~sNnEqt2lhBWFMK2RFbevCh8IbLAaa-mVwvS8Nmsrqfx~LkegqkNInH9SCMVE39bKLpDUDoJn7cy8KDJRyrovommbOAnn5WWlXWVI990VnRFFl6j48JJfLlIIOYKMSzU8Bw8fBxoHqiu2MTRi16tHIPziG1vPyW5NctXOcbMtCIhzAcIiycyxSczGNnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>Table 1</p>
<p>Classes of recommendations</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf1.jpeg?Expires=1689850106&amp;Signature=ePii7f4KH96s~RdjBCj9k27atBTLoqz0Nm09NHZTU6fGdIuMsEXyHUZPy4PPJ6Rdh7xtU-lQFbuRdZhLEeiLtNWBsc8Lr6yWsTwrLEnZh4Djtr2Wq5N9pBF2vIwSROL20dKtH5zeQ5CWIAxShMA7Llmd12~sNnEqt2lhBWFMK2RFbevCh8IbLAaa-mVwvS8Nmsrqfx~LkegqkNInH9SCMVE39bKLpDUDoJn7cy8KDJRyrovommbOAnn5WWlXWVI990VnRFFl6j48JJfLlIIOYKMSzU8Bw8fBxoHqiu2MTRi16tHIPziG1vPyW5NctXOcbMtCIhzAcIiycyxSczGNnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf1.jpeg?Expires=1689850106&amp;Signature=ePii7f4KH96s~RdjBCj9k27atBTLoqz0Nm09NHZTU6fGdIuMsEXyHUZPy4PPJ6Rdh7xtU-lQFbuRdZhLEeiLtNWBsc8Lr6yWsTwrLEnZh4Djtr2Wq5N9pBF2vIwSROL20dKtH5zeQ5CWIAxShMA7Llmd12~sNnEqt2lhBWFMK2RFbevCh8IbLAaa-mVwvS8Nmsrqfx~LkegqkNInH9SCMVE39bKLpDUDoJn7cy8KDJRyrovommbOAnn5WWlXWVI990VnRFFl6j48JJfLlIIOYKMSzU8Bw8fBxoHqiu2MTRi16tHIPziG1vPyW5NctXOcbMtCIhzAcIiycyxSczGNnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>Table 2</p>
<p>Levels of evidence</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf2.jpeg?Expires=1689850106&amp;Signature=X5OhPmsoXYgbEjbvH1MyBG8zsyyNIVpNYiVIOE~xVe-I86-8XsbkB30IbpN~bCWnES3pMq3YZrdqjHX4UgrBdlSNQf7mCap0TcPD94GjLPgWEuLuZKNlM9Lr1qR3nfhdox5aWEvVfJb7vvFR-gythHutJTjsoFjQmIepc8dxVs8WygmxYMNFg3bHhaJ4-rF11t3OO1ZHIhYZ4FcEAviKbIg2~RkHRekP5ZTqWUPpe3Uqtr~A8rerweICmAaA7Bw3dG56fmucDmUCfvITIommh7dnNG5JE6e5--O0S9VlBAVCeyCZzSyyW3GvmjSA~GQ27QkDXTgf0JbWOm2JX7zbuQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf2.jpeg?Expires=1689850106&amp;Signature=X5OhPmsoXYgbEjbvH1MyBG8zsyyNIVpNYiVIOE~xVe-I86-8XsbkB30IbpN~bCWnES3pMq3YZrdqjHX4UgrBdlSNQf7mCap0TcPD94GjLPgWEuLuZKNlM9Lr1qR3nfhdox5aWEvVfJb7vvFR-gythHutJTjsoFjQmIepc8dxVs8WygmxYMNFg3bHhaJ4-rF11t3OO1ZHIhYZ4FcEAviKbIg2~RkHRekP5ZTqWUPpe3Uqtr~A8rerweICmAaA7Bw3dG56fmucDmUCfvITIommh7dnNG5JE6e5--O0S9VlBAVCeyCZzSyyW3GvmjSA~GQ27QkDXTgf0JbWOm2JX7zbuQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>Table 2</p>
<p>Levels of evidence</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf2.jpeg?Expires=1689850106&amp;Signature=X5OhPmsoXYgbEjbvH1MyBG8zsyyNIVpNYiVIOE~xVe-I86-8XsbkB30IbpN~bCWnES3pMq3YZrdqjHX4UgrBdlSNQf7mCap0TcPD94GjLPgWEuLuZKNlM9Lr1qR3nfhdox5aWEvVfJb7vvFR-gythHutJTjsoFjQmIepc8dxVs8WygmxYMNFg3bHhaJ4-rF11t3OO1ZHIhYZ4FcEAviKbIg2~RkHRekP5ZTqWUPpe3Uqtr~A8rerweICmAaA7Bw3dG56fmucDmUCfvITIommh7dnNG5JE6e5--O0S9VlBAVCeyCZzSyyW3GvmjSA~GQ27QkDXTgf0JbWOm2JX7zbuQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368ilf2.jpeg?Expires=1689850106&amp;Signature=X5OhPmsoXYgbEjbvH1MyBG8zsyyNIVpNYiVIOE~xVe-I86-8XsbkB30IbpN~bCWnES3pMq3YZrdqjHX4UgrBdlSNQf7mCap0TcPD94GjLPgWEuLuZKNlM9Lr1qR3nfhdox5aWEvVfJb7vvFR-gythHutJTjsoFjQmIepc8dxVs8WygmxYMNFg3bHhaJ4-rF11t3OO1ZHIhYZ4FcEAviKbIg2~RkHRekP5ZTqWUPpe3Uqtr~A8rerweICmAaA7Bw3dG56fmucDmUCfvITIommh7dnNG5JE6e5--O0S9VlBAVCeyCZzSyyW3GvmjSA~GQ27QkDXTgf0JbWOm2JX7zbuQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>The experts of the writing and reviewing panels provided declaration
of interest forms for all relationships that might be perceived as real
or potential sources of conflicts of interest. Their declarations of
interest were reviewed according to the ESC declaration of interest
rules and can be found on the ESC website (<a
href="http://www.escardio.org/guidelines">http://www.escardio.org/guidelines</a>)
and have been compiled in a report and published in a supplementary
document simultaneously to the guidelines.</p>
<p>This process ensures transparency and prevents potential biases in
the development and review processes. Any changes in declarations of
interest that arise during the writing period were notified to the ESC
and updated. The Task Force received its entire financial support from
the ESC without any involvement from the healthcare industry.</p>
<p>The ESC CPG supervises and coordinates the preparation of new
guidelines. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive review
by the CPG and external experts. After appropriate revisions the
guidelines are signed-off by all the experts involved in the Task Force.
The finalized document is signed-off by the CPG for publication in the
European Heart Journal. The guidelines were developed after careful
consideration of the scientific and medical knowledge and the evidence
available at the time of their dating.</p>
<p>The task of developing ESC Guidelines also includes the creation of
educational tools and implementation programmes for the recommendations
including condensed pocket guideline versions, summary slides, summary
cards for non-specialists and an electronic version for digital
applications (smartphones, etc.). These versions are abridged and thus,
for more detailed information, the user should always access to the full
text version of the guidelines, which is freely available via the ESC
website and hosted on the European Heart Journal website. The National
Cardiac Societies of the ESC are encouraged to endorse, adopt, translate
and implement all ESC Guidelines. Implementation programmes are needed
because it has been shown that the outcome of disease may be favourably
influenced by the thorough application of clinical recommendations.</p>
<p>Health professionals are encouraged to take the ESC Guidelines fully
into account when exercising their clinical judgment, as well as in the
determination and the implementation of preventive, diagnostic, or
therapeutic medical strategies. However, the ESC Guidelines do not
override in any way whatsoever the individual responsibility of health
professionals to make appropriate and accurate decisions in
consideration of each patient’s health condition and in consultation
with that patient or the patient’s caregiver where appropriate and/or
necessary. It is also the health professional’s responsibility to verify
the rules and regulations applicable in each country to drugs and
devices at the time of prescription.</p>
<h2 >2 Introduction</h2>
<p>The aim of this ESC Guideline is to help health professionals manage
people with heart failure (HF) according to the best available evidence.
Fortunately, we now have a wealth of clinical trials to help us select
the best management to improve the outcomes for people with HF; for
many, it is now both preventable and treatable. This guideline provides
practical, evidence-based recommendations.</p>
<p>We have revised the format of the previous 2016 ESC HF
Guidelines<sup>1</sup> to make each phenotype of HF stand-alone in terms
of its diagnosis and management. The therapy recommendations mention the
treatment effect supported by the class and level of evidence and are
presented in tables. For HF with reduced ejection fraction (HFrEF), the
tabular recommendations focus on mortality and morbidity outcomes. Where
there are symptomatic benefits, these are highlighted in the text and/or
in the web appendices. Detailed summaries of the trials underpinning the
recommendations are available in the web appendices. For diagnostic
indications, we have suggested investigations that all patients with HF
should receive, and investigations that can be targeted to specific
circumstances. As diagnostic tests have rarely been subject to
randomized controlled trials (RCTs), most of the evidence would be
regarded as level C. However, that does not mean that there has not been
appropriate rigorous evaluation of diagnostic tests.</p>
<p>In this guideline, we have decided to focus on the diagnosis and
treatment of HF, not on its prevention. Management of CV risk and many
CV diseases [especially systemic hypertension, diabetes mellitus,
coronary artery disease, myocardial infarction (MI), atrial fibrillation
(AF), and asymptomatic left ventricular (LV) systolic dysfunction] will
reduce the risk of developing HF, which is addressed by many other ESC
Guidelines and in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-9.1">section 9.1</a>
of the current guideline.<sup>2–7</sup></p>
<p>This guideline is the result of a collaboration between the Task
Force (including two patient representatives), the reviewers, and the
ESC CPG Committee. As such, it is a consensus/majority opinion of the
experts consulted in its development.</p>
<h3 >2.1 What is new</h3>
<p>In addition to the recommendations listed below, the following table
lists some new concepts compared with the 2016 version.</p>
<table role="presentation">
<tbody>
<tr>
<td>
A change of the term ‘heart failure with mid-range ejection fraction’ to
‘heart failure with mildly reduced ejection fraction’ (HFmrEF). 
</td>
</tr>
<tr>
<td>
A new simplified treatment algorithm for HFrEF. 
</td>
</tr>
<tr>
<td>
The addition of a treatment algorithm for HFrEF according to
phenotypes. 
</td>
</tr>
<tr>
<td>
Modified classification for acute HF. 
</td>
</tr>
<tr>
<td>
Updated treatments for most non-cardiovascular comorbidities including
diabetes, hyperkalaemia, iron deficiency, and cancer. 
</td>
</tr>
<tr>
<td>
Updates on cardiomyopathies including the role of genetic testing and
new treatments. 
</td>
</tr>
<tr>
<td>
The addition of key quality indicators. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
A change of the term ‘heart failure with mid-range ejection fraction’ to
‘heart failure with mildly reduced ejection fraction’ (HFmrEF). 
</td>
</tr>
<tr>
<td>
A new simplified treatment algorithm for HFrEF. 
</td>
</tr>
<tr>
<td>
The addition of a treatment algorithm for HFrEF according to
phenotypes. 
</td>
</tr>
<tr>
<td>
Modified classification for acute HF. 
</td>
</tr>
<tr>
<td>
Updated treatments for most non-cardiovascular comorbidities including
diabetes, hyperkalaemia, iron deficiency, and cancer. 
</td>
</tr>
<tr>
<td>
Updates on cardiomyopathies including the role of genetic testing and
new treatments. 
</td>
</tr>
<tr>
<td>
The addition of key quality indicators. 
</td>
</tr>
</tbody>
</table>
<table role="presentation">
<tbody>
<tr>
<td>
A change of the term ‘heart failure with mid-range ejection fraction’ to
‘heart failure with mildly reduced ejection fraction’ (HFmrEF). 
</td>
</tr>
<tr>
<td>
A new simplified treatment algorithm for HFrEF. 
</td>
</tr>
<tr>
<td>
The addition of a treatment algorithm for HFrEF according to
phenotypes. 
</td>
</tr>
<tr>
<td>
Modified classification for acute HF. 
</td>
</tr>
<tr>
<td>
Updated treatments for most non-cardiovascular comorbidities including
diabetes, hyperkalaemia, iron deficiency, and cancer. 
</td>
</tr>
<tr>
<td>
Updates on cardiomyopathies including the role of genetic testing and
new treatments. 
</td>
</tr>
<tr>
<td>
The addition of key quality indicators. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
A change of the term ‘heart failure with mid-range ejection fraction’ to
‘heart failure with mildly reduced ejection fraction’ (HFmrEF). 
</td>
</tr>
<tr>
<td>
A new simplified treatment algorithm for HFrEF. 
</td>
</tr>
<tr>
<td>
The addition of a treatment algorithm for HFrEF according to
phenotypes. 
</td>
</tr>
<tr>
<td>
Modified classification for acute HF. 
</td>
</tr>
<tr>
<td>
Updated treatments for most non-cardiovascular comorbidities including
diabetes, hyperkalaemia, iron deficiency, and cancer. 
</td>
</tr>
<tr>
<td>
Updates on cardiomyopathies including the role of genetic testing and
new treatments. 
</td>
</tr>
<tr>
<td>
The addition of key quality indicators. 
</td>
</tr>
</tbody>
</table>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; CABG = coronary artery bypass graft;
CCS = chronic coronary syndrome;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); CMP = cardiomyopathy; CV = cardiovascular; DPP-4 = dipeptidyl
peptidase-4; HF = heart failure; HFmrEF = heart failure with mildly
reduced ejection fraction; HFpEF = heart failure with preserved ejection
fraction; HFrEF = heart failure with reduced ejection fraction;
HTM = home telemonitoring; hTTR = hereditary transthyretin; LAD = left
anterior descending artery; LV = left ventricular; LVAD = left
ventricular assist device; LVEF = left ventricular ejection fraction;
MCS = mechanical circulatory support; MRA = mineralocorticoid receptor
antagonist; NYHA = New York Heart Association; OMT = optimal medical
therapy; PCI = percutaneous coronary intervention; SAVR = surgical
aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2;
T2DM = type 2 diabetes mellitus; TAVI = transcatheter aortic valve
implantation; TSAT = transferrin saturation; wtTTR-CA = wild-type
transthyretin cardiac amyloidosis.</p>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; CABG = coronary artery bypass graft;
CCS = chronic coronary syndrome;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); CMP = cardiomyopathy; CV = cardiovascular; DPP-4 = dipeptidyl
peptidase-4; HF = heart failure; HFmrEF = heart failure with mildly
reduced ejection fraction; HFpEF = heart failure with preserved ejection
fraction; HFrEF = heart failure with reduced ejection fraction;
HTM = home telemonitoring; hTTR = hereditary transthyretin; LAD = left
anterior descending artery; LV = left ventricular; LVAD = left
ventricular assist device; LVEF = left ventricular ejection fraction;
MCS = mechanical circulatory support; MRA = mineralocorticoid receptor
antagonist; NYHA = New York Heart Association; OMT = optimal medical
therapy; PCI = percutaneous coronary intervention; SAVR = surgical
aortic valve replacement; SGLT2 = sodium-glucose co-transporter 2;
T2DM = type 2 diabetes mellitus; TAVI = transcatheter aortic valve
implantation; TSAT = transferrin saturation; wtTTR-CA = wild-type
transthyretin cardiac amyloidosis.</p>
<p>Changes in recommendations</p>
<p>AF = atrial fibrillation; AHF = acute heart failure;
AV = atrio-ventricular; BTB = bridge to bridge; BTD = bridge to
decision; BTR = bridge to cardiac recovery; CAD = coronary artery
disease; CCS = chronic coronary syndrome;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); CRT =  cardiac resynchronization therapy; CT = computed
tomography; CTCA = computed tomography coronary angiography;
CV = cardiovascular; DCM = dilated cardiomyopathy; DOAC = direct oral
anticoagulant; HF = heart failure; HFrEF = heart failure with reduced
ejection fraction; ICD = implantable cardioverter-defibrillator;
LBBB = left bundle branch block; LVEF = left ventricular ejection
fraction; MCS = mechanical circulatory support; NOAC = non-vitamin K
antagonist oral anticoagulant; NYHA = New York Heart Association;
OMT = optimal medical therapy; QRS = Q, R, and S waves of an ECG;
RV = right ventricular/ventricle; SBP = systolic blood pressure;
SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes
mellitus; VKA = vitamin K antagonist.</p>
<p>Changes in recommendations</p>
<p>AF = atrial fibrillation; AHF = acute heart failure;
AV = atrio-ventricular; BTB = bridge to bridge; BTD = bridge to
decision; BTR = bridge to cardiac recovery; CAD = coronary artery
disease; CCS = chronic coronary syndrome;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); CRT =  cardiac resynchronization therapy; CT = computed
tomography; CTCA = computed tomography coronary angiography;
CV = cardiovascular; DCM = dilated cardiomyopathy; DOAC = direct oral
anticoagulant; HF = heart failure; HFrEF = heart failure with reduced
ejection fraction; ICD = implantable cardioverter-defibrillator;
LBBB = left bundle branch block; LVEF = left ventricular ejection
fraction; MCS = mechanical circulatory support; NOAC = non-vitamin K
antagonist oral anticoagulant; NYHA = New York Heart Association;
OMT = optimal medical therapy; QRS = Q, R, and S waves of an ECG;
RV = right ventricular/ventricle; SBP = systolic blood pressure;
SGLT2 = sodium-glucose co-transporter 2; T2DM = type 2 diabetes
mellitus; VKA = vitamin K antagonist.</p>
<h2 >3 Definition,
epidemiology and prognosis</h2>
<h3 >3.1 Definition of heart
failure</h3>
<p>Heart failure is not a single pathological diagnosis, but a clinical
syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle
swelling, and fatigue) that may be accompanied by signs (e.g. elevated
jugular venous pressure, pulmonary crackles, and peripheral oedema). It
is due to a structural and/or functional abnormality of the heart that
results in elevated intracardiac pressures and/or inadequate cardiac
output at rest and/or during exercise.</p>
<p>Identification of the aetiology of the underlying cardiac dysfunction
is mandatory in the diagnosis of HF as the specific pathology can
determine subsequent treatment. Most commonly, HF is due to myocardial
dysfunction: either systolic, diastolic, or both. However, pathology of
the valves, pericardium, and endocardium, and abnormalities of heart
rhythm and conduction can also cause or contribute to HF.</p>
<h3 >3.2 Terminology</h3>
<p><strong>3.2.1 Heart failure with preserved, mildly reduced, and
reduced ejection fraction</strong></p>
<p>Traditionally, HF has been divided into distinct phenotypes based on
the measurement of left ventricular ejection fraction (LVEF)
(<em>Table 3</em>). The rationale behind this relates to the original
treatment trials in HF that demonstrated substantially improved outcomes
in patients with LVEF ≤40%. However, HF spans the entire range of LVEF
(a normally distributed variable), and measurement by echocardiography
is subject to substantial variability. We have decided on the following
classification of HF (<em>Table 3</em>):</p>
<ul>
<li><p>Reduced LVEF is defined as ≤40%, i.e. those with a significant
reduction in LV systolic function. This is designated as HFrEF.</p></li>
<li><p>Patients with a LVEF between 41% and 49% have <em>mildly</em>
reduced LV systolic function, i.e. HFmrEF. Retrospective analyses from
RCTs in HFrEF or HF with preserved ejection fraction (HFpEF) that have
included patients with ejection fractions in the 40–50% range suggest
that they may benefit from similar therapies to those with LVEF
≤40%.<sup>8–13</sup> This supports the renaming of HFmrEF from ‘heart
failure with mid-range ejection fraction’ to ‘heart failure with mildly
reduced ejection fraction’.<sup>14</sup></p></li>
<li><p>Those with symptoms and signs of HF, with evidence of structural
and/or functional cardiac abnormalities and/or raised natriuretic
peptides (NPs), and with an LVEF ≥50%, have HFpEF.</p></li>
</ul>
<p>The diagnosis of HFrEF, HFmrEF, and HFpEF is covered in more detail
in their respective sections (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections 5</a>,
<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-7">7</a>,
and <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-8">8</a>,
respectively). These definitions are consistent with a recent report on
the Universal Definition of Heart Failure.<sup>15</sup></p>
<p>Table 3</p>
<p>Definition of heart failure with reduced ejection fraction, mildly
reduced ejection fraction and preserved ejection fraction</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type of HF</th>
<th>HFrEF</th>
<th>HFmrEF</th>
<th>HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRITERIA </td>
<td><strong>1</strong> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
</tr>
<tr>
<td><strong>2</strong> </td>
<td>LVEF ≤40% </td>
<td>LVEF 41–49%<sup>b</sup> </td>
<td>LVEF ≥50% </td>
</tr>
<tr>
<td><strong>3</strong> </td>
<td>– </td>
<td>– </td>
<td>Objective evidence of cardiac structural and/or functional
abnormalities consistent with the presence of LV diastolic
dysfunction/raised LV filling pressures, including raised natriuretic
peptides<sup>c</sup> </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type of HF</th>
<th>HFrEF</th>
<th>HFmrEF</th>
<th>HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRITERIA </td>
<td><strong>1</strong> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
</tr>
<tr>
<td><strong>2</strong> </td>
<td>LVEF ≤40% </td>
<td>LVEF 41–49%<sup>b</sup> </td>
<td>LVEF ≥50% </td>
</tr>
<tr>
<td><strong>3</strong> </td>
<td>– </td>
<td>– </td>
<td>Objective evidence of cardiac structural and/or functional
abnormalities consistent with the presence of LV diastolic
dysfunction/raised LV filling pressures, including raised natriuretic
peptides<sup>c</sup> </td>
</tr>
</tbody>
</table>
<p>HF = heart failure; HFmrEF = heart failure with mildly reduced
ejection fraction; HFpEF = heart failure with preserved ejection
fraction; HFrEF = heart failure with reduced ejection fraction;
LV = left ventricle; LVEF = left ventricular ejection fraction.</p>
<p>a</p>
<p>Signs may not be present in the early stages of HF (especially in
HFpEF) and in optimally treated patients.</p>
<p>b</p>
<p>For the diagnosis of HFmrEF, the presence of other evidence of
structural heart disease (e.g. increased left atrial size, LV
hypertrophy or echocardiographic measures of impaired LV filling) makes
the diagnosis more likely.</p>
<p>c</p>
<p>For the diagnosis of HFpEF, the greater the number of abnormalities
present, the higher the likelihood of HFpEF.</p>
<p>Table 3</p>
<p>Definition of heart failure with reduced ejection fraction, mildly
reduced ejection fraction and preserved ejection fraction</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type of HF</th>
<th>HFrEF</th>
<th>HFmrEF</th>
<th>HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRITERIA </td>
<td><strong>1</strong> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
</tr>
<tr>
<td><strong>2</strong> </td>
<td>LVEF ≤40% </td>
<td>LVEF 41–49%<sup>b</sup> </td>
<td>LVEF ≥50% </td>
</tr>
<tr>
<td><strong>3</strong> </td>
<td>– </td>
<td>– </td>
<td>Objective evidence of cardiac structural and/or functional
abnormalities consistent with the presence of LV diastolic
dysfunction/raised LV filling pressures, including raised natriuretic
peptides<sup>c</sup> </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type of HF</th>
<th>HFrEF</th>
<th>HFmrEF</th>
<th>HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRITERIA </td>
<td><strong>1</strong> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
<td>Symptoms ± Signs<sup>a</sup> </td>
</tr>
<tr>
<td><strong>2</strong> </td>
<td>LVEF ≤40% </td>
<td>LVEF 41–49%<sup>b</sup> </td>
<td>LVEF ≥50% </td>
</tr>
<tr>
<td><strong>3</strong> </td>
<td>– </td>
<td>– </td>
<td>Objective evidence of cardiac structural and/or functional
abnormalities consistent with the presence of LV diastolic
dysfunction/raised LV filling pressures, including raised natriuretic
peptides<sup>c</sup> </td>
</tr>
</tbody>
</table>
<p>HF = heart failure; HFmrEF = heart failure with mildly reduced
ejection fraction; HFpEF = heart failure with preserved ejection
fraction; HFrEF = heart failure with reduced ejection fraction;
LV = left ventricle; LVEF = left ventricular ejection fraction.</p>
<p>a</p>
<p>Signs may not be present in the early stages of HF (especially in
HFpEF) and in optimally treated patients.</p>
<p>b</p>
<p>For the diagnosis of HFmrEF, the presence of other evidence of
structural heart disease (e.g. increased left atrial size, LV
hypertrophy or echocardiographic measures of impaired LV filling) makes
the diagnosis more likely.</p>
<p>c</p>
<p>For the diagnosis of HFpEF, the greater the number of abnormalities
present, the higher the likelihood of HFpEF.</p>
<p>Patients with non-CV disease, e.g. anaemia, pulmonary, renal,
thyroid, or hepatic disease may have symptoms and signs very similar to
those of HF, but in the absence of cardiac dysfunction, they do not
fulfil the criteria for HF. However, these pathologies can coexist with
HF and exacerbate the HF syndrome.</p>
<p><strong>3.2.2 Right ventricular dysfunction</strong></p>
<p>Heart failure can also be a result of right ventricular (RV)
dysfunction. RV mechanics and function are altered in the setting of
either pressure or volume overload.<sup>16</sup> Although the main
aetiology of chronic RV failure is LV dysfunction-induced pulmonary
hypertension, there are a number of other causes of RV dysfunction
[e.g. MI, arrhythmogenic right ventricular cardiomyopathy (ARVC), or
valve disease].<sup>17</sup> The diagnosis is determined by a
quantitative assessment of global RV function, most commonly by
echocardiography, using at least one of the following measurements:
fractional area change (FAC); tricuspid annular plane systolic excursion
(TAPSE); and Doppler tissue imaging-derived systolic S′ velocity of the
tricuspid annulus. The diagnosis and management of RV dysfunction is
covered comprehensively in a recent Heart Failure Association (HFA)
position paper.<sup>18</sup></p>
<p><strong>3.2.3 Other common terminology used in heart
failure</strong></p>
<p>Heart failure is usually divided into two presentations: chronic
heart failure (CHF) and acute heart failure (AHF). CHF describes those
who have had an established diagnosis of HF or who have a more gradual
onset of symptoms. If CHF deteriorates, either suddenly or slowly, the
episode may be described as ‘decompensated’ HF. This can result in a
hospital admission or treatment with intravenous (i.v.) diuretic therapy
in the outpatient setting. In addition, HF can present more acutely.
Both of these are considered in the section on AHF (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-11">section 11</a>).</p>
<p>Some individuals with HF may recover completely [e.g. those due to
alcohol-induced cardiomyopathy (CMP), viral myocarditis, Takotsubo
syndrome, peripartum cardiomyopathy (PPCM), or tachycardiomyopathy].
Other patients with LV systolic dysfunction may show a substantial or
even complete recovery of LV systolic function after receiving drug and
device therapy.</p>
<p><strong>3.2.4 Terminology related to the symptomatic severity of
heart failure</strong></p>
<p>The simplest terminology used to describe the severity of HF is the
New York Heart Association (NYHA) functional classification
(<em>Table 4</em>). However, this relies solely on symptoms and there
are many other better prognostic indicators in HF.<sup>19</sup>
Importantly, patients with mild symptoms may still have a high risk of
hospitalization and death.<sup>20</sup> Predicting outcome is
particularly important in advanced HF to guide selection of cardiac
transplantation and device therapies. This will be covered in detail in
the section on advanced HF (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-10">section 10</a>).</p>
<p>Table 4</p>
<p>New York Heart Association functional classification based on
severity of symptoms and physical activity</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Class I</strong> 
</td>
<td>
No limitation of physical activity. Ordinary physical activity does not
cause undue breathlessness, fatigue, or palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class II</strong> 
</td>
<td>
Slight limitation of physical activity. Comfortable at rest, but
ordinary physical activity results in undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class III</strong> 
</td>
<td>
Marked limitation of physical activity. Comfortable at rest, but less
than ordinary activity results undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class IV</strong> 
</td>
<td>
Unable to carry on any physical activity without discomfort. Symptoms at
rest can be present. If any physical activity is undertaken, discomfort
is increased. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Class I</strong> 
</td>
<td>
No limitation of physical activity. Ordinary physical activity does not
cause undue breathlessness, fatigue, or palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class II</strong> 
</td>
<td>
Slight limitation of physical activity. Comfortable at rest, but
ordinary physical activity results in undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class III</strong> 
</td>
<td>
Marked limitation of physical activity. Comfortable at rest, but less
than ordinary activity results undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class IV</strong> 
</td>
<td>
Unable to carry on any physical activity without discomfort. Symptoms at
rest can be present. If any physical activity is undertaken, discomfort
is increased. 
</td>
</tr>
</tbody>
</table>
<p>Table 4</p>
<p>New York Heart Association functional classification based on
severity of symptoms and physical activity</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Class I</strong> 
</td>
<td>
No limitation of physical activity. Ordinary physical activity does not
cause undue breathlessness, fatigue, or palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class II</strong> 
</td>
<td>
Slight limitation of physical activity. Comfortable at rest, but
ordinary physical activity results in undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class III</strong> 
</td>
<td>
Marked limitation of physical activity. Comfortable at rest, but less
than ordinary activity results undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class IV</strong> 
</td>
<td>
Unable to carry on any physical activity without discomfort. Symptoms at
rest can be present. If any physical activity is undertaken, discomfort
is increased. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Class I</strong> 
</td>
<td>
No limitation of physical activity. Ordinary physical activity does not
cause undue breathlessness, fatigue, or palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class II</strong> 
</td>
<td>
Slight limitation of physical activity. Comfortable at rest, but
ordinary physical activity results in undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class III</strong> 
</td>
<td>
Marked limitation of physical activity. Comfortable at rest, but less
than ordinary activity results undue breathlessness, fatigue, or
palpitations. 
</td>
</tr>
<tr>
<td>
<strong>Class IV</strong> 
</td>
<td>
Unable to carry on any physical activity without discomfort. Symptoms at
rest can be present. If any physical activity is undertaken, discomfort
is increased. 
</td>
</tr>
</tbody>
</table>
<h3 >3.3
Epidemiology and natural history of heart failure</h3>
<p><strong>3.3.1 Incidence and prevalence</strong></p>
<p>In developed countries, the age-adjusted incidence of HF may be
falling, presumably reflecting better management of CV disease, but due
to ageing, the overall incidence is increasing.<sup>21–24</sup>
Currently, the incidence of HF in Europe is about 3/1000 person-years
(all age-groups) or about 5/1000 person-years in
adults.<sup>25</sup><sup>,</sup><sup>26</sup> The prevalence of HF
appears to be 1–2% of adults.<sup>21</sup><sup>,</sup><sup>27–31</sup>
As studies only usually include recognized/diagnosed HF cases, the true
prevalence is likely to be higher.<sup>32</sup> The prevalence increases
with age: from around 1% for those aged &lt;55 years to &gt;10% in those
aged 70 years or over.<sup>33–36</sup> It is generally believed that, of
those with HF, about 50% have HFrEF and 50% have HFpEF/HFmrEF, mainly
based on studies in hospitalized
patients.<sup>32</sup><sup>,</sup><sup>35</sup><sup>,</sup><sup>37</sup><sup>,</sup><sup>38</sup>
The ESC Long-Term Registry, in the outpatient setting, reports that 60%
have HFrEF, 24% have HFmrEF, and 16% have HFpEF.<sup>39</sup> Somewhat
more than 50% of HF patients are
female.<sup>21</sup><sup>,</sup><sup>40</sup><sup>,</sup><sup>41</sup></p>
<p><strong>3.3.2 Aetiology of heart failure</strong></p>
<p>The most common causes (as well as some key investigations) of HF are
shown in <em>Table 5</em>. The aetiology of HF varies according to
geography. In Western-type and developed countries, coronary artery
disease (CAD) and hypertension are predominant factors.<sup>27</sup></p>
<p>With regard to ischaemic aetiology, HFmrEF resembles HFrEF, with a
higher frequency of underlying CAD compared to those with
HFpEF.<sup>38</sup><sup>,</sup><sup>42</sup><sup>,</sup><sup>43</sup></p>
<p><strong>3.3.3 Natural history and prognosis</strong></p>
<p>The prognosis of patients with HF has improved considerably since the
publication of the first treatment trials a few decades ago. However, it
remains poor, and quality of life (QOL) is also markedly reduced. The
improvement in prognosis has been confined to those with HFrEF.</p>
<p>Mortality rates are higher in observational studies than in clinical
trials.<sup>44</sup> In the Olmsted County cohort, 1-year and 5-year
mortality rates after diagnosis, for all types of HF patients, were 20%
and 53%, respectively, between 2000 and 2010.<sup>45</sup> A study
combining the Framingham Heart Study (FHS) and Cardiovascular Health
Study (CHS) cohorts reported a 67% mortality rate within 5 years
following diagnosis.<sup>46</sup> Despite receiving less evidence-based
treatment, women have a better survival than men.<sup>47</sup></p>
<p>Overall prognosis is better in HFmrEF compared to HFrEF.<sup>39</sup>
Of note, transition in ejection fraction over time is common, and
patients who progress from HFmrEF to HFrEF have a worse prognosis than
those who remain stable or transition to a higher ejection fraction
category.<sup>48–52</sup></p>
<p>HFpEF is generally considered to confer a better survival than HFrEF,
but most observational studies show that this difference is
negligible.<sup>45</sup><sup>,</sup><sup>46</sup> In contrast, the large
MAGGIC meta-analysis concluded that the adjusted mortality risk for
patients with HFpEF was considerably lower than in patients with
HFrEF.<sup>53</sup></p>
<p>Studies from several countries have shown that between 1980 and 2000
survival in HF patients has improved
markedly.<sup>41</sup><sup>,</sup><sup>54–57</sup> However, this
positive trend may have levelled off since then.<sup>45</sup></p>
<p>After the initial diagnosis, HF patients are hospitalized once every
year on average.<sup>54</sup> From 2000 to 2010, the mean rate of
hospitalization in the Olmsted County cohort was 1.3 per person-year.
Interestingly, the majority (63%) of hospitalizations were related to
non-CV causes.<sup>45</sup> Studies from several European countries and
the United States (US) have shown that HF hospitalization rates peaked
in the 1990s, and then
declined.<sup>54</sup><sup>,</sup><sup>55</sup>*<sup>,</sup><sup>58–60</sup>
However, in a recent study of incident HF conducted between 1998 and
2017 in the United Kingdom (UK), age-adjusted rates of first
hospitalizations increased by 28% for both all-cause and HF admissions,
and by 42% for non-CV admissions.<sup>61</sup> These increases were
higher in women, perhaps related to higher comorbidity rates. The risk
of HF hospitalization is 1.5 times higher in patients with diabetes
compared to controls. AF, a higher body mass index (BMI), and higher
glycated haemoglobin (HbA1c), as well as a low estimated glomerular
filtration rate (eGFR) are strong predictors of HF
hospitalizations.<sup>29</sup></p>
<p>Due to population growth, ageing, and the increasing prevalence of
comorbidities, the absolute number of hospital admissions for HF is
expected to increase considerably in the future, perhaps by as much as
50% in the next 25 years.<sup>24</sup><sup>,</sup><sup>62</sup></p>
<h2 >4 Chronic heart failure</h2>
<h3 >4.1 Key
steps in the diagnosis of chronic heart failure</h3>
<p>The diagnosis of CHF requires the presence of symptoms and/or signs
of HF and objective evidence of cardiac dysfunction (<em>Figure 1</em>).
Typical symptoms include breathlessness, fatigue, and ankle swelling
(<em>Table 6</em>). Symptoms and signs lack sufficient accuracy to be
used alone to make the diagnosis of HF.<sup>63–66</sup></p>
<p>The diagnosis of CHF is made more likely in patients with a history
of MI, arterial hypertension, CAD, diabetes mellitus, alcohol misuse,
chronic kidney disease (CKD), cardiotoxic chemotherapy, and in those
with a family history of CMP or sudden death.</p>
<p>Figure 1</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f1.jpeg?Expires=1689850106&amp;Signature=y8dvlc6eys4kcM3-TTRGnI471mYGxgvK8TtOZcM1Y9nZ7QMt-MCqGad9Wvy~~FsVMapFj3Uao6ylNcCwdJuUZVzlz1ByaVWhhqTP4pQ3EsXz9P1lJdPiqhiMyM-3dcikUX58fhZZWNGZKVHacBm0hnVG1l8XcqVIxPFBbWS2x~oIRPzy20Ealqta58Mn8nhH5ElL5aQm41hi0oBUNScS-gR7BZ5-mpVjAbAyoYOqobM4inDZtSYb2IW0zQlgymk57V1canIlZ~XLYQ0LpgFlEA23rV3yqB05GkOABnK9OZBzm38Aqazc2AiJ4JXA7vWYVGzDqTZ0BYqC8jlFTt-AKw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="The diagnostic algorithm for heart failure. BNP = B-type natriuretic peptide; ECG = electrocardiogram; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B type natriuretic peptide. The abnormal echocardiographic findings are described in more detail in the respective sections on HFrEF (section 5), HFmrEF (section 7), and HFpEF (section 8)." />
<figcaption aria-hidden="true">The diagnostic algorithm for heart
failure. BNP = B-type natriuretic peptide; ECG = electrocardiogram;
HFmrEF = heart failure with mildly reduced ejection fraction;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; LVEF = left ventricular ejection
fraction; NT-proBNP = N-terminal pro-B type natriuretic peptide. The
abnormal echocardiographic findings are described in more detail in the
respective sections on HFrEF (section 5), HFmrEF (section 7), and HFpEF
(section 8).</figcaption>
</figure>
<p>The diagnostic algorithm for heart failure. BNP = B-type natriuretic
peptide; ECG = electrocardiogram; HFmrEF = heart failure with mildly
reduced ejection fraction; HFpEF = heart failure with preserved ejection
fraction; HFrEF = heart failure with reduced ejection fraction;
LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-B
type natriuretic peptide. The abnormal echocardiographic findings are
described in more detail in the respective sections on HFrEF (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">section 5</a>),
HFmrEF (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-7">section 7</a>),
and HFpEF (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-9">section 8</a>).</p>
<p>Table 5</p>
<p>Causes of heart failure, common modes of presentation and specific
investigations</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Cause</th>
<th>Examples of presentations</th>
<th>Specific investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD </td>
<td>Myocardial infarction Angina or “angina-equivalent”
Arrhythmias </td>
<td>Invasive coronary angiography CT coronary angiography Imaging stress
tests (echo, nuclear, CMR) </td>
</tr>
<tr>
<td>Hypertension </td>
<td>Heart failure with preserved systolic function Malignant
hypertension/acute pulmonary oedema </td>
<td>24 h ambulatory BP</td>
</tr>
</tbody>
</table>
<ul>
<li><p>Plasma metanephrines, renal artery imaging</p></li>
<li><p>Renin and aldosterone</p></li>
</ul>
<p>  | | Valve disease  | Primary valve disease e.g., aortic stenosis
Secondary valve disease, e.g. functional regurgitation Congenital valve
disease  | Echo – transoesophageal/stress  | | Arrhythmias  | Atrial
tachyarrhythmias Ventricular arrhythmias  | Ambulatory ECG recording
Electrophysiology study, if indicated  | | CMPs  | All Dilated
Hypertrophic Restrictive ARVC Peripartum Takotsubo syndrome Toxins:
alcohol, cocaine, iron, copper  | CMR, genetic testing Right and left
heart catheterization CMR, angiography Trace elements, toxicology, LFTs,
GGT  | | Congenital heart disease  | Congenitally corrected/repaired
transposition of great arteries Shunt lesions Repaired tetralogy of
Fallot Ebstein’s anomaly  | CMR  | | Infective  | Viral myocarditis
Chagas disease HIV Lyme disease  | CMR, EMB Serology  | | Drug-induced 
| Anthracyclines Trastuzumab VEGF inhibitors Immune checkpoint
inhibitors Proteasome inhibitors RAF+MEK inhibitors  |   | |
Infiltrative  | Amyloid Sarcoidosis Neoplastic  | Serum electrophoresis
and serum free light chains, Bence Jones protein, bone scintigraphy,
CMR, CT-PET, EMB Serum ACE, CMR, FDG-PET, chest CT, EMB CMR, EMB  | |
Storage disorders  | Haemochromatosis Fabry disease Glycogen storage
diseases  | Iron studies, genetics, CMR (T2* imaging), EMB
α-galactosidase A, genetics, CMR (T1 mapping)  | | Endomyocardial
disease  | Radiotherapy Endomyocardial fibrosis/eosinophilia Carcinoid 
| CMR EMB 24 h urine 5-HIAA  | | Pericardial disease  | Calcification
Infiltrative  | Chest CT, CMR, right and left heart catheterization  | |
Metabolic  | Endocrine disease Nutritional disease (thiamine, vitamin B1
and selenium deficiencies) Autoimmune disease  | TFTs, plasma
metanephrines, renin and aldosterone, cortisol Specific plasma nutrients
ANA, ANCA, rheumatology review  | | Neuromuscular disease  |
Friedreich’s ataxia Muscular dystrophy  | Nerve conduction studies,
electromyogram, genetics CK, electromyogram, genetics  |</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Cause</th>
<th>Examples of presentations</th>
<th>Specific investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD </td>
<td>Myocardial infarction Angina or “angina-equivalent”
Arrhythmias </td>
<td>Invasive coronary angiography CT coronary angiography Imaging stress
tests (echo, nuclear, CMR) </td>
</tr>
<tr>
<td>Hypertension </td>
<td>Heart failure with preserved systolic function Malignant
hypertension/acute pulmonary oedema </td>
<td>24 h ambulatory BP</td>
</tr>
</tbody>
</table>
<ul>
<li><p>Plasma metanephrines, renal artery imaging</p></li>
<li><p>Renin and aldosterone</p></li>
</ul>
<p>  | | Valve disease  | Primary valve disease e.g., aortic stenosis
Secondary valve disease, e.g. functional regurgitation Congenital valve
disease  | Echo – transoesophageal/stress  | | Arrhythmias  | Atrial
tachyarrhythmias Ventricular arrhythmias  | Ambulatory ECG recording
Electrophysiology study, if indicated  | | CMPs  | All Dilated
Hypertrophic Restrictive ARVC Peripartum Takotsubo syndrome Toxins:
alcohol, cocaine, iron, copper  | CMR, genetic testing Right and left
heart catheterization CMR, angiography Trace elements, toxicology, LFTs,
GGT  | | Congenital heart disease  | Congenitally corrected/repaired
transposition of great arteries Shunt lesions Repaired tetralogy of
Fallot Ebstein’s anomaly  | CMR  | | Infective  | Viral myocarditis
Chagas disease HIV Lyme disease  | CMR, EMB Serology  | | Drug-induced 
| Anthracyclines Trastuzumab VEGF inhibitors Immune checkpoint
inhibitors Proteasome inhibitors RAF+MEK inhibitors  |   | |
Infiltrative  | Amyloid Sarcoidosis Neoplastic  | Serum electrophoresis
and serum free light chains, Bence Jones protein, bone scintigraphy,
CMR, CT-PET, EMB Serum ACE, CMR, FDG-PET, chest CT, EMB CMR, EMB  | |
Storage disorders  | Haemochromatosis Fabry disease Glycogen storage
diseases  | Iron studies, genetics, CMR (T2* imaging), EMB
α-galactosidase A, genetics, CMR (T1 mapping)  | | Endomyocardial
disease  | Radiotherapy Endomyocardial fibrosis/eosinophilia Carcinoid 
| CMR EMB 24 h urine 5-HIAA  | | Pericardial disease  | Calcification
Infiltrative  | Chest CT, CMR, right and left heart catheterization  | |
Metabolic  | Endocrine disease Nutritional disease (thiamine, vitamin B1
and selenium deficiencies) Autoimmune disease  | TFTs, plasma
metanephrines, renin and aldosterone, cortisol Specific plasma nutrients
ANA, ANCA, rheumatology review  | | Neuromuscular disease  |
Friedreich’s ataxia Muscular dystrophy  | Nerve conduction studies,
electromyogram, genetics CK, electromyogram, genetics  |</p>
<p>5-HIAA = 5-hydroxyindoleacetic acid; ACE = angiotensin-converting
enzyme; ANA = anti-nuclear antibody; ANCA = anti-nuclear cytoplasmic
antibody; ARVC = arrhythmogenic right ventricular cardiomyopathy;
BP = blood pressure; CAD = coronary artery disease;
CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CK = creatinine
kinase; CT = computed tomography; ECG = electrocardiogram;
Echo = echocardiography; EMB = endomyocardial biopsy;
FDG = fluorodeoxyglucose; GGT = gamma-glutamyl transferase; HIV = human
immunodeficiency virus; h = hour; LFT = liver function test; LGE = late
gadolinium enhancement; MEK = mitogen-activated protein kinase;
PET = positron emission tomography; TFT = thyroid function test;
VEGF = vascular endothelial growth factor.</p>
<p>Table 5</p>
<p>Causes of heart failure, common modes of presentation and specific
investigations</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Cause</th>
<th>Examples of presentations</th>
<th>Specific investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD </td>
<td>Myocardial infarction Angina or “angina-equivalent”
Arrhythmias </td>
<td>Invasive coronary angiography CT coronary angiography Imaging stress
tests (echo, nuclear, CMR) </td>
</tr>
<tr>
<td>Hypertension </td>
<td>Heart failure with preserved systolic function Malignant
hypertension/acute pulmonary oedema </td>
<td>24 h ambulatory BP</td>
</tr>
</tbody>
</table>
<ul>
<li><p>Plasma metanephrines, renal artery imaging</p></li>
<li><p>Renin and aldosterone</p></li>
</ul>
<p>  | | Valve disease  | Primary valve disease e.g., aortic stenosis
Secondary valve disease, e.g. functional regurgitation Congenital valve
disease  | Echo – transoesophageal/stress  | | Arrhythmias  | Atrial
tachyarrhythmias Ventricular arrhythmias  | Ambulatory ECG recording
Electrophysiology study, if indicated  | | CMPs  | All Dilated
Hypertrophic Restrictive ARVC Peripartum Takotsubo syndrome Toxins:
alcohol, cocaine, iron, copper  | CMR, genetic testing Right and left
heart catheterization CMR, angiography Trace elements, toxicology, LFTs,
GGT  | | Congenital heart disease  | Congenitally corrected/repaired
transposition of great arteries Shunt lesions Repaired tetralogy of
Fallot Ebstein’s anomaly  | CMR  | | Infective  | Viral myocarditis
Chagas disease HIV Lyme disease  | CMR, EMB Serology  | | Drug-induced 
| Anthracyclines Trastuzumab VEGF inhibitors Immune checkpoint
inhibitors Proteasome inhibitors RAF+MEK inhibitors  |   | |
Infiltrative  | Amyloid Sarcoidosis Neoplastic  | Serum electrophoresis
and serum free light chains, Bence Jones protein, bone scintigraphy,
CMR, CT-PET, EMB Serum ACE, CMR, FDG-PET, chest CT, EMB CMR, EMB  | |
Storage disorders  | Haemochromatosis Fabry disease Glycogen storage
diseases  | Iron studies, genetics, CMR (T2* imaging), EMB
α-galactosidase A, genetics, CMR (T1 mapping)  | | Endomyocardial
disease  | Radiotherapy Endomyocardial fibrosis/eosinophilia Carcinoid 
| CMR EMB 24 h urine 5-HIAA  | | Pericardial disease  | Calcification
Infiltrative  | Chest CT, CMR, right and left heart catheterization  | |
Metabolic  | Endocrine disease Nutritional disease (thiamine, vitamin B1
and selenium deficiencies) Autoimmune disease  | TFTs, plasma
metanephrines, renin and aldosterone, cortisol Specific plasma nutrients
ANA, ANCA, rheumatology review  | | Neuromuscular disease  |
Friedreich’s ataxia Muscular dystrophy  | Nerve conduction studies,
electromyogram, genetics CK, electromyogram, genetics  |</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Cause</th>
<th>Examples of presentations</th>
<th>Specific investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD </td>
<td>Myocardial infarction Angina or “angina-equivalent”
Arrhythmias </td>
<td>Invasive coronary angiography CT coronary angiography Imaging stress
tests (echo, nuclear, CMR) </td>
</tr>
<tr>
<td>Hypertension </td>
<td>Heart failure with preserved systolic function Malignant
hypertension/acute pulmonary oedema </td>
<td>24 h ambulatory BP</td>
</tr>
</tbody>
</table>
<ul>
<li><p>Plasma metanephrines, renal artery imaging</p></li>
<li><p>Renin and aldosterone</p></li>
</ul>
<p>  | | Valve disease  | Primary valve disease e.g., aortic stenosis
Secondary valve disease, e.g. functional regurgitation Congenital valve
disease  | Echo – transoesophageal/stress  | | Arrhythmias  | Atrial
tachyarrhythmias Ventricular arrhythmias  | Ambulatory ECG recording
Electrophysiology study, if indicated  | | CMPs  | All Dilated
Hypertrophic Restrictive ARVC Peripartum Takotsubo syndrome Toxins:
alcohol, cocaine, iron, copper  | CMR, genetic testing Right and left
heart catheterization CMR, angiography Trace elements, toxicology, LFTs,
GGT  | | Congenital heart disease  | Congenitally corrected/repaired
transposition of great arteries Shunt lesions Repaired tetralogy of
Fallot Ebstein’s anomaly  | CMR  | | Infective  | Viral myocarditis
Chagas disease HIV Lyme disease  | CMR, EMB Serology  | | Drug-induced 
| Anthracyclines Trastuzumab VEGF inhibitors Immune checkpoint
inhibitors Proteasome inhibitors RAF+MEK inhibitors  |   | |
Infiltrative  | Amyloid Sarcoidosis Neoplastic  | Serum electrophoresis
and serum free light chains, Bence Jones protein, bone scintigraphy,
CMR, CT-PET, EMB Serum ACE, CMR, FDG-PET, chest CT, EMB CMR, EMB  | |
Storage disorders  | Haemochromatosis Fabry disease Glycogen storage
diseases  | Iron studies, genetics, CMR (T2* imaging), EMB
α-galactosidase A, genetics, CMR (T1 mapping)  | | Endomyocardial
disease  | Radiotherapy Endomyocardial fibrosis/eosinophilia Carcinoid 
| CMR EMB 24 h urine 5-HIAA  | | Pericardial disease  | Calcification
Infiltrative  | Chest CT, CMR, right and left heart catheterization  | |
Metabolic  | Endocrine disease Nutritional disease (thiamine, vitamin B1
and selenium deficiencies) Autoimmune disease  | TFTs, plasma
metanephrines, renin and aldosterone, cortisol Specific plasma nutrients
ANA, ANCA, rheumatology review  | | Neuromuscular disease  |
Friedreich’s ataxia Muscular dystrophy  | Nerve conduction studies,
electromyogram, genetics CK, electromyogram, genetics  |</p>
<p>5-HIAA = 5-hydroxyindoleacetic acid; ACE = angiotensin-converting
enzyme; ANA = anti-nuclear antibody; ANCA = anti-nuclear cytoplasmic
antibody; ARVC = arrhythmogenic right ventricular cardiomyopathy;
BP = blood pressure; CAD = coronary artery disease;
CMP = cardiomyopathy; CMR = cardiac magnetic resonance; CK = creatinine
kinase; CT = computed tomography; ECG = electrocardiogram;
Echo = echocardiography; EMB = endomyocardial biopsy;
FDG = fluorodeoxyglucose; GGT = gamma-glutamyl transferase; HIV = human
immunodeficiency virus; h = hour; LFT = liver function test; LGE = late
gadolinium enhancement; MEK = mitogen-activated protein kinase;
PET = positron emission tomography; TFT = thyroid function test;
VEGF = vascular endothelial growth factor.</p>
<p>The following diagnostic tests are recommended for the assessment of
patients with suspected chronic HF:</p>
<ol type="1">
<li><p>Electrocardiogram (ECG). A normal ECG makes the diagnosis of HF
unlikely.<sup>63</sup> The ECG may reveal abnormalities such as AF, Q
waves, LV hypertrophy (LVH), and a widened QRS complex
(<em>Table 7</em>) that increase the likelihood of a diagnosis of HF and
also may guide therapy.</p></li>
<li><p>Measurement of NPs are recommended, if available. A plasma
concentration of B-type natriuretic peptide (BNP) &lt;35 pg/mL,
N-terminal pro-B-type natriuretic peptide (NT-proBNP) &lt;125 pg/mL, or
mid-regional pro-atrial natriuretic peptide (MR-proANP) &lt;40
pmol/L<sup>68</sup> make a diagnosis of HF unlikely. These will be
discussed in more detail in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-4.2">section 4.2</a>.<sup>69</sup><sup>,</sup><sup>70</sup></p></li>
<li><p>Basic investigations such as serum urea and electrolytes,
creatinine, full blood count, liver and thyroid function tests are
recommended to differentiate HF from other conditions, to provide
prognostic information, and to guide potential therapy.</p></li>
<li><p>Echocardiography is recommended as the key investigation for the
assessment of cardiac function. As well as the determination of the
LVEF, echocardiography also provides information on other parameters
such as chamber size, eccentric or concentric LVH, regional wall motion
abnormalities (that may suggest underlying CAD, Takotsubo syndrome, or
myocarditis), RV function, pulmonary hypertension, valvular function,
and markers of diastolic
function.<sup>16</sup><sup>,</sup><sup>71</sup></p></li>
<li><p>A chest X-ray is recommended to investigate other potential
causes of breathlessness (e.g. pulmonary disease). It may also provide
supportive evidence of HF (e.g. pulmonary congestion or
cardiomegaly).</p></li>
</ol>
<p>Recommended diagnostic tests in all patients with suspected chronic
heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table19.jpeg?Expires=1689850106&amp;Signature=wKy2-Fzp2NHR56bv9C-2NQWIf~5KYKZNOBgnI-4VIg~GSE5PAdSKsIXy8QjbviZE~u3MXxjMukfgUGKUlZsISi4CrN0qV9Gl-2vC1PHTVbT4uXbpMV6qJcbOKP97jzZ-6HFood5IeG4iD7zXH~v4b7p3h5e6IgR8sClsizoZTNtPUGFMoib2RNWS-NWEWKLyHW-s3bIS9IEwmwVECDLjaa4mUT-DW1O5jOgv80xt5abTBg-9Wag5guilUlHJNUC6xjzxGJQ~yR5c1ELkOd4ZPgtC8U2YLSjnBN5VAX92G9cyUWuvWFOwL--AzlReZKOUQPxwYxfkIjEDQue3qXoBnA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table19.jpeg?Expires=1689850106&amp;Signature=wKy2-Fzp2NHR56bv9C-2NQWIf~5KYKZNOBgnI-4VIg~GSE5PAdSKsIXy8QjbviZE~u3MXxjMukfgUGKUlZsISi4CrN0qV9Gl-2vC1PHTVbT4uXbpMV6qJcbOKP97jzZ-6HFood5IeG4iD7zXH~v4b7p3h5e6IgR8sClsizoZTNtPUGFMoib2RNWS-NWEWKLyHW-s3bIS9IEwmwVECDLjaa4mUT-DW1O5jOgv80xt5abTBg-9Wag5guilUlHJNUC6xjzxGJQ~yR5c1ELkOd4ZPgtC8U2YLSjnBN5VAX92G9cyUWuvWFOwL--AzlReZKOUQPxwYxfkIjEDQue3qXoBnA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>BNP = B-type natriuretic peptide; ECG = electrocardiogram;
HbA1c = glycated haemoglobin; NT-proBNP = N-terminal pro-B-type
natriuretic peptide; TSAT = transferrin saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>References are listed in section 4.2 for this item.</p>
<p>Recommended diagnostic tests in all patients with suspected chronic
heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table19.jpeg?Expires=1689850106&amp;Signature=wKy2-Fzp2NHR56bv9C-2NQWIf~5KYKZNOBgnI-4VIg~GSE5PAdSKsIXy8QjbviZE~u3MXxjMukfgUGKUlZsISi4CrN0qV9Gl-2vC1PHTVbT4uXbpMV6qJcbOKP97jzZ-6HFood5IeG4iD7zXH~v4b7p3h5e6IgR8sClsizoZTNtPUGFMoib2RNWS-NWEWKLyHW-s3bIS9IEwmwVECDLjaa4mUT-DW1O5jOgv80xt5abTBg-9Wag5guilUlHJNUC6xjzxGJQ~yR5c1ELkOd4ZPgtC8U2YLSjnBN5VAX92G9cyUWuvWFOwL--AzlReZKOUQPxwYxfkIjEDQue3qXoBnA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table19.jpeg?Expires=1689850106&amp;Signature=wKy2-Fzp2NHR56bv9C-2NQWIf~5KYKZNOBgnI-4VIg~GSE5PAdSKsIXy8QjbviZE~u3MXxjMukfgUGKUlZsISi4CrN0qV9Gl-2vC1PHTVbT4uXbpMV6qJcbOKP97jzZ-6HFood5IeG4iD7zXH~v4b7p3h5e6IgR8sClsizoZTNtPUGFMoib2RNWS-NWEWKLyHW-s3bIS9IEwmwVECDLjaa4mUT-DW1O5jOgv80xt5abTBg-9Wag5guilUlHJNUC6xjzxGJQ~yR5c1ELkOd4ZPgtC8U2YLSjnBN5VAX92G9cyUWuvWFOwL--AzlReZKOUQPxwYxfkIjEDQue3qXoBnA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>BNP = B-type natriuretic peptide; ECG = electrocardiogram;
HbA1c = glycated haemoglobin; NT-proBNP = N-terminal pro-B-type
natriuretic peptide; TSAT = transferrin saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>References are listed in section 4.2 for this item.</p>
<h3 >4.2 Natriuretic peptides</h3>
<p>Plasma concentrations of NPs are recommended as initial diagnostic
tests in patients with symptoms suggestive of HF to rule out the
diagnosis. Elevated concentrations support a diagnosis of HF, are useful
for prognostication,<sup>72</sup> and may guide further cardiac
investigation.<sup>73</sup> However, it should be noted that there are
many causes of an elevated NP—both CV and non-CV—that might reduce their
diagnostic accuracy (<em>Table 7</em>). These causes include AF,
increasing age, and acute or chronic kidney disease.<sup>74</sup>
Conversely, NP concentrations may be disproportionately low in obese
patients.<sup>75</sup></p>
<p><strong>4.2.1 Use in the non-acute setting</strong></p>
<p>The diagnostic value of NPs, in addition to signs and symptoms and
other diagnostic tests, such as an ECG, has been assessed in several
studies in the primary care
setting.<sup>68</sup><sup>,</sup><sup>76–80</sup> The aim of these
studies was to either exclude or establish a diagnosis of HF. The Task
Force considered studies of adequate quality that included NP cut-off
points in their diagnostic algorithms, below which the probability of
having HF was extremely low. The upper limits of normal in the non-acute
setting are 35 pg/mL for BNP, and 125 pg/mL for NT-proBNP. In these
studies, the negative predictive values of NP concentrations below these
thresholds range from 0.94 to 0.98.<sup>76–78</sup> Fewer data are
available for MR-proANP in CHF than in AHF. A concentration of &lt;40
pmol/L can be used to rule out HF.<sup>68</sup></p>
<h3
>4.3
Investigations to determine the underlying aetiology of chronic heart
failure</h3>
<p>Recommended tests to determine the underlying aetiology of CHF are
summarized in <em>Table 5</em>.</p>
<p>Exercise or pharmacological stress echocardiography may be used for
the assessment of inducible ischaemia in those who are considered
suitable for coronary revascularization.<sup>81</sup> In patients with
HFpEF, valve disease, or unexplained dyspnoea, stress echocardiography
might help clarify the diagnosis.<sup>82</sup></p>
<p>Cardiac magnetic resonance (CMR) imaging with late gadolinium
enhancement (LGE), T1 mapping and extracellular volume will identify
myocardial fibrosis/scar, which are typically subendocardial for
patients with ischaemic heart disease (IHD) in contrast to the mid-wall
scar typical of dilated cardiomyopathy (DCM). In addition, CMR allows
myocardial characterization in, e.g. myocarditis, amyloidosis,
sarcoidosis, Chagas disease, Fabry disease, LV non-compaction CMP,
haemochromatosis, and arrhythmogenic cardiomyopathy
(AC).<sup>83</sup><sup>,</sup><sup>84</sup></p>
<p>Computed tomography coronary angiography (CTCA) may be considered in
patients with a low to intermediate pre-test probability of CAD, or
those with equivocal non-invasive stress tests in order to exclude the
diagnosis of CAD.<sup>5</sup></p>
<p>Single-photon emission CT (SPECT) can also be used to assess
myocardial ischaemia and viability, myocardial inflammation or
infiltration. Scintigraphy with technetium (Tc)-labelled bisphosphonate
has shown high sensitivity and specificity for imaging cardiac
transthyretin amyloid.<sup>85</sup></p>
<p>Coronary angiography is recommended in patients with HF, who have
angina pectoris or an ‘angina equivalent’ despite pharmacological
therapy, in order to establish the diagnosis of CAD and its severity.
Coronary angiography may also be considered in patients with HFrEF who
have an intermediate to high pre-test probability of CAD and who are
considered potentially suitable for coronary
revascularization.<sup>5</sup></p>
<p>Table 6</p>
<p>Symptoms and signs typical of heart failure</p>
<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Typical</strong> </td>
<td><strong>More specific</strong> </td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p> Breathlessness</p></li>
<li><p> Orthopnoea</p></li>
<li><p> Paroxysmal nocturnal dyspnoea</p></li>
<li><p> Reduced exercise tolerance</p></li>
<li><p> Fatigue, tiredness, increased time to recover after
exercise</p></li>
<li><p> Ankle swelling</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Elevated jugular venous pressure</p></li>
<li><p>Hepatojugular reflux</p></li>
<li><p>Third heart sound (gallop rhythm)</p></li>
<li><p>Laterally displaced apical impulse</p></li>
</ul>
<p>  | | <strong>Less typical</strong>  | <strong>Less
specific</strong>  | |</p>
<ul>
<li><p> Nocturnal cough</p></li>
<li><p> Wheezing</p></li>
<li><p> Bloated feeling</p></li>
<li><p> Loss of appetite</p></li>
<li><p> Confusion (especially in the elderly)</p></li>
<li><p> Depression</p></li>
<li><p> Palpitation</p></li>
<li><p> Dizziness</p></li>
<li><p> Syncope</p></li>
<li><p> Bendopnea<sup>a</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Weight gain (&gt;2 kg/week)</p></li>
<li><p>Weight loss (in advanced HF)</p></li>
<li><p>Tissue wasting (cachexia)</p></li>
<li><p>Cardiac murmur</p></li>
<li><p>Peripheral oedema (ankle, sacral, scrotal)</p></li>
<li><p>Pulmonary crepitations</p></li>
<li><p>Pleural effusion</p></li>
<li><p>Tachycardia</p></li>
<li><p>Irregular pulse</p></li>
<li><p>Tachypnoea</p></li>
<li><p>Cheyne-Stokes respiration</p></li>
<li><p>Hepatomegaly</p></li>
<li><p>Ascites</p></li>
<li><p>Cold extremities</p></li>
<li><p>Oliguria</p></li>
<li><p>Narrow pulse pressure</p></li>
</ul>
<p>  |</p>
<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Typical</strong> </td>
<td><strong>More specific</strong> </td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p> Breathlessness</p></li>
<li><p> Orthopnoea</p></li>
<li><p> Paroxysmal nocturnal dyspnoea</p></li>
<li><p> Reduced exercise tolerance</p></li>
<li><p> Fatigue, tiredness, increased time to recover after
exercise</p></li>
<li><p> Ankle swelling</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Elevated jugular venous pressure</p></li>
<li><p>Hepatojugular reflux</p></li>
<li><p>Third heart sound (gallop rhythm)</p></li>
<li><p>Laterally displaced apical impulse</p></li>
</ul>
<p>  | | <strong>Less typical</strong>  | <strong>Less
specific</strong>  | |</p>
<ul>
<li><p> Nocturnal cough</p></li>
<li><p> Wheezing</p></li>
<li><p> Bloated feeling</p></li>
<li><p> Loss of appetite</p></li>
<li><p> Confusion (especially in the elderly)</p></li>
<li><p> Depression</p></li>
<li><p> Palpitation</p></li>
<li><p> Dizziness</p></li>
<li><p> Syncope</p></li>
<li><p> Bendopnea<sup>a</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Weight gain (&gt;2 kg/week)</p></li>
<li><p>Weight loss (in advanced HF)</p></li>
<li><p>Tissue wasting (cachexia)</p></li>
<li><p>Cardiac murmur</p></li>
<li><p>Peripheral oedema (ankle, sacral, scrotal)</p></li>
<li><p>Pulmonary crepitations</p></li>
<li><p>Pleural effusion</p></li>
<li><p>Tachycardia</p></li>
<li><p>Irregular pulse</p></li>
<li><p>Tachypnoea</p></li>
<li><p>Cheyne-Stokes respiration</p></li>
<li><p>Hepatomegaly</p></li>
<li><p>Ascites</p></li>
<li><p>Cold extremities</p></li>
<li><p>Oliguria</p></li>
<li><p>Narrow pulse pressure</p></li>
</ul>
<p>  |</p>
<p>HF = heart failure.</p>
<p>a</p>
<p>This symptom of advanced HF corresponds to shortness of breath when
leaning forward.<sup>67</sup></p>
<p>Table 6</p>
<p>Symptoms and signs typical of heart failure</p>
<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Typical</strong> </td>
<td><strong>More specific</strong> </td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p> Breathlessness</p></li>
<li><p> Orthopnoea</p></li>
<li><p> Paroxysmal nocturnal dyspnoea</p></li>
<li><p> Reduced exercise tolerance</p></li>
<li><p> Fatigue, tiredness, increased time to recover after
exercise</p></li>
<li><p> Ankle swelling</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Elevated jugular venous pressure</p></li>
<li><p>Hepatojugular reflux</p></li>
<li><p>Third heart sound (gallop rhythm)</p></li>
<li><p>Laterally displaced apical impulse</p></li>
</ul>
<p>  | | <strong>Less typical</strong>  | <strong>Less
specific</strong>  | |</p>
<ul>
<li><p> Nocturnal cough</p></li>
<li><p> Wheezing</p></li>
<li><p> Bloated feeling</p></li>
<li><p> Loss of appetite</p></li>
<li><p> Confusion (especially in the elderly)</p></li>
<li><p> Depression</p></li>
<li><p> Palpitation</p></li>
<li><p> Dizziness</p></li>
<li><p> Syncope</p></li>
<li><p> Bendopnea<sup>a</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Weight gain (&gt;2 kg/week)</p></li>
<li><p>Weight loss (in advanced HF)</p></li>
<li><p>Tissue wasting (cachexia)</p></li>
<li><p>Cardiac murmur</p></li>
<li><p>Peripheral oedema (ankle, sacral, scrotal)</p></li>
<li><p>Pulmonary crepitations</p></li>
<li><p>Pleural effusion</p></li>
<li><p>Tachycardia</p></li>
<li><p>Irregular pulse</p></li>
<li><p>Tachypnoea</p></li>
<li><p>Cheyne-Stokes respiration</p></li>
<li><p>Hepatomegaly</p></li>
<li><p>Ascites</p></li>
<li><p>Cold extremities</p></li>
<li><p>Oliguria</p></li>
<li><p>Narrow pulse pressure</p></li>
</ul>
<p>  |</p>
<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Typical</strong> </td>
<td><strong>More specific</strong> </td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p> Breathlessness</p></li>
<li><p> Orthopnoea</p></li>
<li><p> Paroxysmal nocturnal dyspnoea</p></li>
<li><p> Reduced exercise tolerance</p></li>
<li><p> Fatigue, tiredness, increased time to recover after
exercise</p></li>
<li><p> Ankle swelling</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Elevated jugular venous pressure</p></li>
<li><p>Hepatojugular reflux</p></li>
<li><p>Third heart sound (gallop rhythm)</p></li>
<li><p>Laterally displaced apical impulse</p></li>
</ul>
<p>  | | <strong>Less typical</strong>  | <strong>Less
specific</strong>  | |</p>
<ul>
<li><p> Nocturnal cough</p></li>
<li><p> Wheezing</p></li>
<li><p> Bloated feeling</p></li>
<li><p> Loss of appetite</p></li>
<li><p> Confusion (especially in the elderly)</p></li>
<li><p> Depression</p></li>
<li><p> Palpitation</p></li>
<li><p> Dizziness</p></li>
<li><p> Syncope</p></li>
<li><p> Bendopnea<sup>a</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Weight gain (&gt;2 kg/week)</p></li>
<li><p>Weight loss (in advanced HF)</p></li>
<li><p>Tissue wasting (cachexia)</p></li>
<li><p>Cardiac murmur</p></li>
<li><p>Peripheral oedema (ankle, sacral, scrotal)</p></li>
<li><p>Pulmonary crepitations</p></li>
<li><p>Pleural effusion</p></li>
<li><p>Tachycardia</p></li>
<li><p>Irregular pulse</p></li>
<li><p>Tachypnoea</p></li>
<li><p>Cheyne-Stokes respiration</p></li>
<li><p>Hepatomegaly</p></li>
<li><p>Ascites</p></li>
<li><p>Cold extremities</p></li>
<li><p>Oliguria</p></li>
<li><p>Narrow pulse pressure</p></li>
</ul>
<p>  |</p>
<p>HF = heart failure.</p>
<p>a</p>
<p>This symptom of advanced HF corresponds to shortness of breath when
leaning forward.<sup>67</sup></p>
<p>Table 7</p>
<p>Causes of elevated concentrations of natriuretic
peptides<sup>86-88</sup></p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Heart failure
</p>
</li>
<li>
<p>
ACS
</p>
</li>
<li>
<p>
Pulmonary embolism
</p>
</li>
<li>
<p>
Myocarditis
</p>
</li>
<li>
<p>
Left ventricular hypertrophy
</p>
</li>
<li>
<p>
Hypertrophic or restrictive cardiomyopathy
</p>
</li>
<li>
<p>
Valvular heart disease
</p>
</li>
<li>
<p>
Congenital heart disease
</p>
</li>
<li>
<p>
Atrial and ventricular tachyarrhythmias
</p>
</li>
<li>
<p>
Heart contusion
</p>
</li>
<li>
<p>
Cardioversion, ICD shock
</p>
</li>
<li>
<p>
Surgical procedures involving the heart
</p>
</li>
<li>
<p>
Pulmonary hypertension
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Non-cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Advanced age
</p>
</li>
<li>
<p>
Ischaemic stroke
</p>
</li>
<li>
<p>
Subarachnoid haemorrhage
</p>
</li>
<li>
<p>
Renal dysfunction
</p>
</li>
<li>
<p>
Liver dysfunction (mainly liver cirrhosis with ascites)
</p>
</li>
<li>
<p>
Paraneoplastic syndrome
</p>
</li>
<li>
<p>
COPD
</p>
</li>
<li>
<p>
Severe infections (including pneumonia and sepsis)
</p>
</li>
<li>
<p>
Severe burns
</p>
</li>
<li>
<p>
Anaemia
</p>
</li>
<li>
<p>
Severe metabolic and hormone abnormalities (e.g. thyrotoxicosis,
diabetic ketosis)
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Heart failure
</p>
</li>
<li>
<p>
ACS
</p>
</li>
<li>
<p>
Pulmonary embolism
</p>
</li>
<li>
<p>
Myocarditis
</p>
</li>
<li>
<p>
Left ventricular hypertrophy
</p>
</li>
<li>
<p>
Hypertrophic or restrictive cardiomyopathy
</p>
</li>
<li>
<p>
Valvular heart disease
</p>
</li>
<li>
<p>
Congenital heart disease
</p>
</li>
<li>
<p>
Atrial and ventricular tachyarrhythmias
</p>
</li>
<li>
<p>
Heart contusion
</p>
</li>
<li>
<p>
Cardioversion, ICD shock
</p>
</li>
<li>
<p>
Surgical procedures involving the heart
</p>
</li>
<li>
<p>
Pulmonary hypertension
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Non-cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Advanced age
</p>
</li>
<li>
<p>
Ischaemic stroke
</p>
</li>
<li>
<p>
Subarachnoid haemorrhage
</p>
</li>
<li>
<p>
Renal dysfunction
</p>
</li>
<li>
<p>
Liver dysfunction (mainly liver cirrhosis with ascites)
</p>
</li>
<li>
<p>
Paraneoplastic syndrome
</p>
</li>
<li>
<p>
COPD
</p>
</li>
<li>
<p>
Severe infections (including pneumonia and sepsis)
</p>
</li>
<li>
<p>
Severe burns
</p>
</li>
<li>
<p>
Anaemia
</p>
</li>
<li>
<p>
Severe metabolic and hormone abnormalities (e.g. thyrotoxicosis,
diabetic ketosis)
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>ACS = acute coronary syndrome; COPD = chronic obstructive pulmonary
disease; ICD = implantable cardioverter-defibrillator.</p>
<p>Table 7</p>
<p>Causes of elevated concentrations of natriuretic
peptides<sup>86-88</sup></p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Heart failure
</p>
</li>
<li>
<p>
ACS
</p>
</li>
<li>
<p>
Pulmonary embolism
</p>
</li>
<li>
<p>
Myocarditis
</p>
</li>
<li>
<p>
Left ventricular hypertrophy
</p>
</li>
<li>
<p>
Hypertrophic or restrictive cardiomyopathy
</p>
</li>
<li>
<p>
Valvular heart disease
</p>
</li>
<li>
<p>
Congenital heart disease
</p>
</li>
<li>
<p>
Atrial and ventricular tachyarrhythmias
</p>
</li>
<li>
<p>
Heart contusion
</p>
</li>
<li>
<p>
Cardioversion, ICD shock
</p>
</li>
<li>
<p>
Surgical procedures involving the heart
</p>
</li>
<li>
<p>
Pulmonary hypertension
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Non-cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Advanced age
</p>
</li>
<li>
<p>
Ischaemic stroke
</p>
</li>
<li>
<p>
Subarachnoid haemorrhage
</p>
</li>
<li>
<p>
Renal dysfunction
</p>
</li>
<li>
<p>
Liver dysfunction (mainly liver cirrhosis with ascites)
</p>
</li>
<li>
<p>
Paraneoplastic syndrome
</p>
</li>
<li>
<p>
COPD
</p>
</li>
<li>
<p>
Severe infections (including pneumonia and sepsis)
</p>
</li>
<li>
<p>
Severe burns
</p>
</li>
<li>
<p>
Anaemia
</p>
</li>
<li>
<p>
Severe metabolic and hormone abnormalities (e.g. thyrotoxicosis,
diabetic ketosis)
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Heart failure
</p>
</li>
<li>
<p>
ACS
</p>
</li>
<li>
<p>
Pulmonary embolism
</p>
</li>
<li>
<p>
Myocarditis
</p>
</li>
<li>
<p>
Left ventricular hypertrophy
</p>
</li>
<li>
<p>
Hypertrophic or restrictive cardiomyopathy
</p>
</li>
<li>
<p>
Valvular heart disease
</p>
</li>
<li>
<p>
Congenital heart disease
</p>
</li>
<li>
<p>
Atrial and ventricular tachyarrhythmias
</p>
</li>
<li>
<p>
Heart contusion
</p>
</li>
<li>
<p>
Cardioversion, ICD shock
</p>
</li>
<li>
<p>
Surgical procedures involving the heart
</p>
</li>
<li>
<p>
Pulmonary hypertension
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Non-cardiac</strong> 
</td>
<td>
<ul>
<li>
<p>
Advanced age
</p>
</li>
<li>
<p>
Ischaemic stroke
</p>
</li>
<li>
<p>
Subarachnoid haemorrhage
</p>
</li>
<li>
<p>
Renal dysfunction
</p>
</li>
<li>
<p>
Liver dysfunction (mainly liver cirrhosis with ascites)
</p>
</li>
<li>
<p>
Paraneoplastic syndrome
</p>
</li>
<li>
<p>
COPD
</p>
</li>
<li>
<p>
Severe infections (including pneumonia and sepsis)
</p>
</li>
<li>
<p>
Severe burns
</p>
</li>
<li>
<p>
Anaemia
</p>
</li>
<li>
<p>
Severe metabolic and hormone abnormalities (e.g. thyrotoxicosis,
diabetic ketosis)
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>ACS = acute coronary syndrome; COPD = chronic obstructive pulmonary
disease; ICD = implantable cardioverter-defibrillator.</p>
<p>Recommendations for specialized diagnostic tests for selected
patients with chronic heart failure to detect reversible/treatable
causes of heart failure</p>
<p>CAD = coronary artery disease; CMR = cardiac magnetic resonance;
CTCA = computed tomography coronary angiography; DCM = dilated
cardiomyopathy; EMB = endomyocardial biopsy; HF = heart failure;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; LGE = late gadolinium
enhancement; LV = left ventricular; MCS = mechanical circulatory
support; PET = positron emission tomography; SPECT = single-photon
emission computed tomography.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for specialized diagnostic tests for selected
patients with chronic heart failure to detect reversible/treatable
causes of heart failure</p>
<p>CAD = coronary artery disease; CMR = cardiac magnetic resonance;
CTCA = computed tomography coronary angiography; DCM = dilated
cardiomyopathy; EMB = endomyocardial biopsy; HF = heart failure;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; LGE = late gadolinium
enhancement; LV = left ventricular; MCS = mechanical circulatory
support; PET = positron emission tomography; SPECT = single-photon
emission computed tomography.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h2 >5 Heart failure
with reduced ejection fraction</h2>
<h3
>5.1
The diagnosis of heart failure with reduced ejection fraction</h3>
<p>The diagnosis of HFrEF requires the presence of symptoms and/or signs
of HF and a reduced ejection fraction (LVEF ≤40%). This is most usually
obtained by echocardiography. Details about the quality standards that
should be adhered to when determining the presence of reduced LV
systolic function by echocardiography can be found in the European
Association of Cardiovascular Imaging (EACVI) position
paper.<sup>99</sup> If assessment of EF is not possible by
echocardiography, then CMR or rarely, nuclear techniques can be
employed.</p>
<p>An algorithm for the diagnosis of HFrEF is depicted in
<em>Figure 1</em>. For the investigation of the underlying aetiology,
please refer to <em>Table 5</em>.</p>
<h3
>5.2
Pharmacological treatments for patients with heart failure with reduced
ejection fraction</h3>
<h4
>5.2.1
Goals of pharmacotherapy for patients with heart failure with reduced
ejection fraction</h4>
<p>Pharmacotherapy is the cornerstone of treatment for HFrEF and should
be implemented before considering device therapy, and alongside
non-pharmacological interventions.</p>
<p>There are three major goals of treatment for patients with HFrEF: (i)
reduction in mortality, (ii) prevention of recurrent hospitalizations
due to worsening HF, and (iii) improvement in clinical status,
functional capacity, and QOL.<sup>100–102</sup></p>
<p>The key evidence supporting the recommendations in this section for
patients with symptomatic HFrEF is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 1</a>.</em></p>
<p><em>Figure 2</em> depicts the algorithm for the treatment strategy,
including drugs and devices in patients with HFrEF, for Class I
indications for the reduction of mortality (either all-cause or CV). The
recommendations for each treatment are summarized below.</p>
<p>Figure 2</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f2.jpeg?Expires=1689850106&amp;Signature=PBAErC0u4o26BnXqGt9Er1SqNt-F0z96HEO52ymLaLhpsemiwV18qbb58ftyetMpp8x1MZtw22zr5uM4bAIQ~jO9tF3cYWt9aBJYBMXHVxJ1m2LsnQl-V3GG2Y~Lm4N~2rb7~S8Vzrf32BbQutWQR58lEedzP6Llm48QPk9LTwpmOGPsHPkuXCLLB~r7yUIs-J5Gc0wm2P~6Bv8vgG0bE4v4pch8cH7HxVJ~L6YeNVyoFlagmVYOLccmbeIOMyri9oQlDwYdqtWm08u6bs09gt3wCiMbWjC4zz1rcwQeqJr7KgCGoDOP6hLLQ3yNfWK8fqsm~~8ujsRtPBhhIFSpdA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Therapeutic algorithm of Class I Therapy Indications for a patient with heart failure with reduced ejection fraction. ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin receptor-neprilysin inhibitor; CRT-D =cardiac resynchronization therapy with defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; ICD = implantable cardioverter-defibrillator; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; QRS = Q, R, and S waves of an ECG; SR = sinus rhythm. aAs a replacement for ACE-I. bWhere appropriate. Class I = green. Class IIa = Yellow." />
<figcaption aria-hidden="true">Therapeutic algorithm of Class I Therapy
Indications for a patient with heart failure with reduced ejection
fraction. ACE-I = angiotensin-converting enzyme inhibitor;
ARNI = angiotensin receptor-neprilysin inhibitor; CRT-D =cardiac
resynchronization therapy with defibrillator; CRT-P = cardiac
resynchronization therapy pacemaker; ICD = implantable
cardioverter-defibrillator; HFrEF = heart failure with reduced ejection
fraction; MRA = mineralocorticoid receptor antagonist; QRS = Q, R, and S
waves of an ECG; SR = sinus rhythm. aAs a replacement for ACE-I. bWhere
appropriate. Class I = green. Class IIa = Yellow.</figcaption>
</figure>
<p>Therapeutic algorithm of Class I Therapy Indications for a patient
with heart failure with reduced ejection fraction.
ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin
receptor-neprilysin inhibitor; CRT-D =cardiac resynchronization therapy
with defibrillator; CRT-P = cardiac resynchronization therapy pacemaker;
ICD = implantable cardioverter-defibrillator; HFrEF = heart failure with
reduced ejection fraction; MRA = mineralocorticoid receptor antagonist;
QRS = Q, R, and S waves of an ECG; SR = sinus rhythm. <sup>a</sup>As a
replacement for ACE-I. <sup>b</sup>Where appropriate. Class I = green.
Class IIa = Yellow.</p>
<h4
>5.2.2
General principles of pharmacotherapy for heart failure with reduced
ejection fraction</h4>
<p>Modulation of the renin-angiotensin-aldosterone (RAAS) and
sympathetic nervous systems with angiotensin-converting enzyme
inhibitors (ACE-I) or an angiotensin receptor-neprilysin inhibitor
(ARNI), beta-blockers, and mineralocorticoid receptor antagonists (MRA)
has been shown to improve survival, reduce the risk of HF
hospitalizations, and reduce symptoms in patients with HFrEF. These
drugs serve as the foundations of pharmacotherapy for patients with
HFrEF. The triad of an ACE-I/ARNI, a beta-blocker, and an MRA is
recommended as cornerstone therapies for these patients, unless the
drugs are contraindicated or not tolerated.<sup>103–105</sup> They
should be uptitrated to the doses used in the clinical trials (or to
maximally tolerated doses if that is not possible). This guideline still
recommends the use of ARNI as a replacement for ACE-I in suitable
patients who remain symptomatic on ACE-I, beta-blocker, and MRA
therapies; however, an ARNI may be considered as a first-line therapy
instead of an ACE-I.<sup>106</sup><sup>,</sup><sup>107</sup> The
recommended doses of these drugs are given in <em>Table 8</em>.
Angiotensin-receptor blockers (ARBs) still have a role in those who are
intolerant to ACE-I or ARNI.</p>
<p>The sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin
and empagliflozin added to therapy with ACE-I/ARNI/beta-blocker/MRA
reduced the risk of CV death and worsening HF in patients with
HFrEF.<sup>108</sup><sup>,</sup><sup>109</sup> Unless contraindicated or
not tolerated, dapagliflozin or empagliflozin are recommended for all
patients with HFrEF already treated with an ACE-I/ARNI, a beta-blocker,
and an MRA, regardless of whether they have diabetes or not.</p>
<p>Other drugs may be used for selected patients with HFrEF. These are
discussed in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5.4">section
5.4</a>.</p>
<p>Table 8</p>
<p>Evidence-based doses of disease-modifying drugs in key randomized
trials in patients with heart failure with reduced ejection fraction</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Starting dose</th>
<th>Target dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE-I</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril<sup>a</sup> </td>
<td>6.25 mg <em>t.i.d.</em> </td>
<td>50 mg <em>t.i.d.</em> </td>
</tr>
<tr>
<td>Enalapril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>10_–_20 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Lisinopril<sup>b</sup> </td>
<td>2.5–5 mg <em>o.d.</em> </td>
<td>20_–_35 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Ramipril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Trandolapril<sup>a</sup> </td>
<td>0.5 mg <em>o.d.</em> </td>
<td>4 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>ARNI</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan </td>
<td>49/51 mg <em>b.i.d.</em><sup>c</sup> </td>
<td>97/103 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td><strong>Beta-blockers</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisoprolol </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Carvedilol </td>
<td>3.125 mg <em>b.i.d.</em> </td>
<td>25 mg <em>b.i.d.</em><sup>e</sup> </td>
</tr>
<tr>
<td>Metoprolol succinate (CR/XL) </td>
<td>12.5–25 mg <em>o.d.</em> </td>
<td>200 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Nebivolol<sup>d</sup> </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>MRA</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eplerenone </td>
<td>25 mg <em>o.d.</em> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Spironolactone </td>
<td>25 mg <em>o.d.</em><sup>f</sup> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>SGLT2 inhibitor</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Empagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>Other agents</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candesartan </td>
<td>4 mg <em>o.d.</em> </td>
<td>32 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Losartan </td>
<td>50 mg <em>o.d.</em> </td>
<td>150 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Valsartan </td>
<td>40 mg <em>b.i.d.</em> </td>
<td>160 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Ivabradine </td>
<td>5 mg <em>b.i.d.</em> </td>
<td>7.5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Vericiguat </td>
<td>2.5 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Digoxin </td>
<td>62.5 µg <em>o.d.</em> </td>
<td>250 µg <em>o.d.</em> </td>
</tr>
<tr>
<td>Hydralazine/ Isosorbide dinitrate </td>
<td>37.5 mg <em>t.i.d.</em>/20 mg <em>t.i.d.</em> </td>
<td>75 mg <em>t.i.d.</em>/40 mg <em>t.i.d.</em> </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Starting dose</th>
<th>Target dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE-I</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril<sup>a</sup> </td>
<td>6.25 mg <em>t.i.d.</em> </td>
<td>50 mg <em>t.i.d.</em> </td>
</tr>
<tr>
<td>Enalapril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>10_–_20 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Lisinopril<sup>b</sup> </td>
<td>2.5–5 mg <em>o.d.</em> </td>
<td>20_–_35 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Ramipril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Trandolapril<sup>a</sup> </td>
<td>0.5 mg <em>o.d.</em> </td>
<td>4 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>ARNI</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan </td>
<td>49/51 mg <em>b.i.d.</em><sup>c</sup> </td>
<td>97/103 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td><strong>Beta-blockers</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisoprolol </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Carvedilol </td>
<td>3.125 mg <em>b.i.d.</em> </td>
<td>25 mg <em>b.i.d.</em><sup>e</sup> </td>
</tr>
<tr>
<td>Metoprolol succinate (CR/XL) </td>
<td>12.5–25 mg <em>o.d.</em> </td>
<td>200 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Nebivolol<sup>d</sup> </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>MRA</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eplerenone </td>
<td>25 mg <em>o.d.</em> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Spironolactone </td>
<td>25 mg <em>o.d.</em><sup>f</sup> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>SGLT2 inhibitor</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Empagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>Other agents</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candesartan </td>
<td>4 mg <em>o.d.</em> </td>
<td>32 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Losartan </td>
<td>50 mg <em>o.d.</em> </td>
<td>150 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Valsartan </td>
<td>40 mg <em>b.i.d.</em> </td>
<td>160 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Ivabradine </td>
<td>5 mg <em>b.i.d.</em> </td>
<td>7.5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Vericiguat </td>
<td>2.5 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Digoxin </td>
<td>62.5 µg <em>o.d.</em> </td>
<td>250 µg <em>o.d.</em> </td>
</tr>
<tr>
<td>Hydralazine/ Isosorbide dinitrate </td>
<td>37.5 mg <em>t.i.d.</em>/20 mg <em>t.i.d.</em> </td>
<td>75 mg <em>t.i.d.</em>/40 mg <em>t.i.d.</em> </td>
</tr>
</tbody>
</table>
<p>ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin
receptor-neprilysin inhibitor; <em>b.i.d.</em> = bis in die (twice
daily); CR = controlled release; CV = cardiovascular;
MRA = mineralocorticoid receptor antagonist; <em>o.d.</em> = omne in die
(once daily); SGLT2 = sodium-glucose co-transporter 2;
<em>t.i.d.</em> = ter in die (three times a day); XL = extended
release.</p>
<p>a</p>
<p>Indicates an ACE-I where the dosing target is derived from
post-myocardial infarction trials.</p>
<p>b</p>
<p>Indicates drugs where a higher dose has been shown to reduce
morbidity/mortality compared with a lower dose of the same drug, but
there is no substantive randomized, placebo-controlled trial and the
optimum dose is uncertain.</p>
<p>c</p>
<p>Sacubitril/valsartan may have an optional lower starting dose of
24/26 mg <em>b.i.d.</em> for those with a history of symptomatic
hypotension.</p>
<p>d</p>
<p>Indicates a treatment not shown to reduce CV or all-cause mortality
in patients with heart failure (or shown to be non-inferior to a
treatment that does).</p>
<p>e</p>
<p>A maximum dose of 50 mg twice daily can be administered to patients
weighing over 85 kg.</p>
<p>f</p>
<p>Spironolactone has an optional starting dose of 12.5 mg in patients
where renal status or hyperkalaemia warrant caution.</p>
<p>Table 8</p>
<p>Evidence-based doses of disease-modifying drugs in key randomized
trials in patients with heart failure with reduced ejection fraction</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Starting dose</th>
<th>Target dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE-I</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril<sup>a</sup> </td>
<td>6.25 mg <em>t.i.d.</em> </td>
<td>50 mg <em>t.i.d.</em> </td>
</tr>
<tr>
<td>Enalapril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>10_–_20 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Lisinopril<sup>b</sup> </td>
<td>2.5–5 mg <em>o.d.</em> </td>
<td>20_–_35 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Ramipril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Trandolapril<sup>a</sup> </td>
<td>0.5 mg <em>o.d.</em> </td>
<td>4 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>ARNI</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan </td>
<td>49/51 mg <em>b.i.d.</em><sup>c</sup> </td>
<td>97/103 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td><strong>Beta-blockers</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisoprolol </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Carvedilol </td>
<td>3.125 mg <em>b.i.d.</em> </td>
<td>25 mg <em>b.i.d.</em><sup>e</sup> </td>
</tr>
<tr>
<td>Metoprolol succinate (CR/XL) </td>
<td>12.5–25 mg <em>o.d.</em> </td>
<td>200 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Nebivolol<sup>d</sup> </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>MRA</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eplerenone </td>
<td>25 mg <em>o.d.</em> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Spironolactone </td>
<td>25 mg <em>o.d.</em><sup>f</sup> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>SGLT2 inhibitor</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Empagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>Other agents</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candesartan </td>
<td>4 mg <em>o.d.</em> </td>
<td>32 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Losartan </td>
<td>50 mg <em>o.d.</em> </td>
<td>150 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Valsartan </td>
<td>40 mg <em>b.i.d.</em> </td>
<td>160 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Ivabradine </td>
<td>5 mg <em>b.i.d.</em> </td>
<td>7.5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Vericiguat </td>
<td>2.5 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Digoxin </td>
<td>62.5 µg <em>o.d.</em> </td>
<td>250 µg <em>o.d.</em> </td>
</tr>
<tr>
<td>Hydralazine/ Isosorbide dinitrate </td>
<td>37.5 mg <em>t.i.d.</em>/20 mg <em>t.i.d.</em> </td>
<td>75 mg <em>t.i.d.</em>/40 mg <em>t.i.d.</em> </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Starting dose</th>
<th>Target dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE-I</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril<sup>a</sup> </td>
<td>6.25 mg <em>t.i.d.</em> </td>
<td>50 mg <em>t.i.d.</em> </td>
</tr>
<tr>
<td>Enalapril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>10_–_20 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Lisinopril<sup>b</sup> </td>
<td>2.5–5 mg <em>o.d.</em> </td>
<td>20_–_35 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Ramipril </td>
<td>2.5 mg <em>b.i.d.</em> </td>
<td>5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Trandolapril<sup>a</sup> </td>
<td>0.5 mg <em>o.d.</em> </td>
<td>4 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>ARNI</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan </td>
<td>49/51 mg <em>b.i.d.</em><sup>c</sup> </td>
<td>97/103 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td><strong>Beta-blockers</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisoprolol </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Carvedilol </td>
<td>3.125 mg <em>b.i.d.</em> </td>
<td>25 mg <em>b.i.d.</em><sup>e</sup> </td>
</tr>
<tr>
<td>Metoprolol succinate (CR/XL) </td>
<td>12.5–25 mg <em>o.d.</em> </td>
<td>200 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Nebivolol<sup>d</sup> </td>
<td>1.25 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>MRA</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eplerenone </td>
<td>25 mg <em>o.d.</em> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Spironolactone </td>
<td>25 mg <em>o.d.</em><sup>f</sup> </td>
<td>50 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>SGLT2 inhibitor</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Empagliflozin </td>
<td>10 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td><strong>Other agents</strong> </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candesartan </td>
<td>4 mg <em>o.d.</em> </td>
<td>32 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Losartan </td>
<td>50 mg <em>o.d.</em> </td>
<td>150 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Valsartan </td>
<td>40 mg <em>b.i.d.</em> </td>
<td>160 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Ivabradine </td>
<td>5 mg <em>b.i.d.</em> </td>
<td>7.5 mg <em>b.i.d.</em> </td>
</tr>
<tr>
<td>Vericiguat </td>
<td>2.5 mg <em>o.d.</em> </td>
<td>10 mg <em>o.d.</em> </td>
</tr>
<tr>
<td>Digoxin </td>
<td>62.5 µg <em>o.d.</em> </td>
<td>250 µg <em>o.d.</em> </td>
</tr>
<tr>
<td>Hydralazine/ Isosorbide dinitrate </td>
<td>37.5 mg <em>t.i.d.</em>/20 mg <em>t.i.d.</em> </td>
<td>75 mg <em>t.i.d.</em>/40 mg <em>t.i.d.</em> </td>
</tr>
</tbody>
</table>
<p>ACE-I = angiotensin-converting enzyme inhibitor; ARNI = angiotensin
receptor-neprilysin inhibitor; <em>b.i.d.</em> = bis in die (twice
daily); CR = controlled release; CV = cardiovascular;
MRA = mineralocorticoid receptor antagonist; <em>o.d.</em> = omne in die
(once daily); SGLT2 = sodium-glucose co-transporter 2;
<em>t.i.d.</em> = ter in die (three times a day); XL = extended
release.</p>
<p>a</p>
<p>Indicates an ACE-I where the dosing target is derived from
post-myocardial infarction trials.</p>
<p>b</p>
<p>Indicates drugs where a higher dose has been shown to reduce
morbidity/mortality compared with a lower dose of the same drug, but
there is no substantive randomized, placebo-controlled trial and the
optimum dose is uncertain.</p>
<p>c</p>
<p>Sacubitril/valsartan may have an optional lower starting dose of
24/26 mg <em>b.i.d.</em> for those with a history of symptomatic
hypotension.</p>
<p>d</p>
<p>Indicates a treatment not shown to reduce CV or all-cause mortality
in patients with heart failure (or shown to be non-inferior to a
treatment that does).</p>
<p>e</p>
<p>A maximum dose of 50 mg twice daily can be administered to patients
weighing over 85 kg.</p>
<p>f</p>
<p>Spironolactone has an optional starting dose of 12.5 mg in patients
where renal status or hyperkalaemia warrant caution.</p>
<h3
>5.3
Drugs recommended in all patients with heart failure with reduced
ejection fraction</h3>
<p>Pharmacological treatments indicated in patients with (NYHA class
II–IV) heart failure with reduced ejection fraction (LVEF
<strong>≤</strong>40%)</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table22.jpeg?Expires=1689850106&amp;Signature=LfgOae64xYVUotBpXEMvUmYcPkKnQTBZTg02IGThQBpLL0XLBVEa72uq~rLpi8QP7gGblnSV0-1VACCtrw1tKbp70g3~WOU2Sg3FaxOOMvOziBgsZjljZTr3KVZZiceORVUTBWVKeVDAdnH0Owb8twk7tLBq9H9E4HqH-TkxCln7yrESxqPKWFGjdyC59oRWdHl5MMP9lYToirAn5q3TVstQlze7vhtdME48T29BhcXPiEQLWRUzKuawIgzMDxBwRqRVBphenK4xS6fYoiQb0rxXypX2c59mDz9xbDVJtL6z5QH1gkOchiEDydlgwHS8B7AfQ6KTgIQK2INWPlBd0A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table22.jpeg?Expires=1689850106&amp;Signature=LfgOae64xYVUotBpXEMvUmYcPkKnQTBZTg02IGThQBpLL0XLBVEa72uq~rLpi8QP7gGblnSV0-1VACCtrw1tKbp70g3~WOU2Sg3FaxOOMvOziBgsZjljZTr3KVZZiceORVUTBWVKeVDAdnH0Owb8twk7tLBq9H9E4HqH-TkxCln7yrESxqPKWFGjdyC59oRWdHl5MMP9lYToirAn5q3TVstQlze7vhtdME48T29BhcXPiEQLWRUzKuawIgzMDxBwRqRVBphenK4xS6fYoiQb0rxXypX2c59mDz9xbDVJtL6z5QH1gkOchiEDydlgwHS8B7AfQ6KTgIQK2INWPlBd0A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>ACE-I = angiotensin-converting enzyme inhibitor; HF = heart failure;
HFrEF = heart failure with reduced ejection fraction; LVEF = left
ventricular ejection fraction; MRA = mineralocorticoid receptor
antagonist; NYHA = New York Heart Association.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Pharmacological treatments indicated in patients with (NYHA class
II–IV) heart failure with reduced ejection fraction (LVEF
<strong>≤</strong>40%)</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table22.jpeg?Expires=1689850106&amp;Signature=LfgOae64xYVUotBpXEMvUmYcPkKnQTBZTg02IGThQBpLL0XLBVEa72uq~rLpi8QP7gGblnSV0-1VACCtrw1tKbp70g3~WOU2Sg3FaxOOMvOziBgsZjljZTr3KVZZiceORVUTBWVKeVDAdnH0Owb8twk7tLBq9H9E4HqH-TkxCln7yrESxqPKWFGjdyC59oRWdHl5MMP9lYToirAn5q3TVstQlze7vhtdME48T29BhcXPiEQLWRUzKuawIgzMDxBwRqRVBphenK4xS6fYoiQb0rxXypX2c59mDz9xbDVJtL6z5QH1gkOchiEDydlgwHS8B7AfQ6KTgIQK2INWPlBd0A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table22.jpeg?Expires=1689850106&amp;Signature=LfgOae64xYVUotBpXEMvUmYcPkKnQTBZTg02IGThQBpLL0XLBVEa72uq~rLpi8QP7gGblnSV0-1VACCtrw1tKbp70g3~WOU2Sg3FaxOOMvOziBgsZjljZTr3KVZZiceORVUTBWVKeVDAdnH0Owb8twk7tLBq9H9E4HqH-TkxCln7yrESxqPKWFGjdyC59oRWdHl5MMP9lYToirAn5q3TVstQlze7vhtdME48T29BhcXPiEQLWRUzKuawIgzMDxBwRqRVBphenK4xS6fYoiQb0rxXypX2c59mDz9xbDVJtL6z5QH1gkOchiEDydlgwHS8B7AfQ6KTgIQK2INWPlBd0A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>ACE-I = angiotensin-converting enzyme inhibitor; HF = heart failure;
HFrEF = heart failure with reduced ejection fraction; LVEF = left
ventricular ejection fraction; MRA = mineralocorticoid receptor
antagonist; NYHA = New York Heart Association.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4 >5.3.1
Angiotensin-converting enzyme inhibitors</h4>
<p>ACE-Is were the first class of drugs shown to reduce mortality and
morbidity in patients with HFrEF.<sup>110–113</sup> They have also been
shown to improve symptoms.<sup>111</sup> They are recommended in all
patients unless contraindicated or not tolerated. They should be
uptitrated to the maximum tolerated recommended doses.</p>
<p>Practical guidance on how to use ACE-Is is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 2</a></em>.</p>
<h4 >5.3.2 Beta-blockers</h4>
<p>Beta-blockers have been shown to reduce mortality and morbidity in
patients with HFrEF, in addition to treatment with an ACE-I and
diuretic.<sup>114–120</sup> They also improve symptoms.<sup>123</sup>
There is consensus that ACE-I and beta-blockers can be commenced
together as soon as the diagnosis of symptomatic HFrEF is established.
There is no evidence favouring the initiation of a beta-blocker before
an ACE-I and vice versa.<sup>124</sup> Beta-blockers should be initiated
in clinically stable, euvolaemic, patients at a low dose and gradually
uptitrated to the maximum tolerated dose. In patients admitted with AHF,
beta-blockers should be cautiously initiated in hospital, once the
patient is haemodynamically stabilized.</p>
<p>An individual patient data (IPD) meta-analysis of all major
beta-blocker trials in HFrEF has shown no benefit on hospital admissions
and mortality in the subgroup of patients with HFrEF with
AF.<sup>125</sup> However, since this is a retrospective subgroup
analysis, and because beta-blockers did not increase risk, the guideline
committee decided not to make a separate recommendation according to
heart rhythm.</p>
<p>Practical guidance on how to use beta-blockers is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 3</a></em>.</p>
<h4 >5.3.3 Mineralocorticoid
receptor antagonists</h4>
<p>MRAs (spironolactone or eplerenone) are recommended, in addition to
an ACE-I and a beta-blocker, in all patients with HFrEF to reduce
mortality and the risk of HF
hospitalization.<sup>121</sup><sup>,</sup><sup>122</sup> They also
improve symptoms.<sup>121</sup> MRAs block receptors that bind
aldosterone and, with different degrees of affinity, other steroid
hormones (e.g. corticosteroid and androgen) receptors. Eplerenone is
more specific for aldosterone blockade and, therefore, causes less
gynaecomastia.</p>
<p>Caution should be exercised when MRAs are used in patients with
impaired renal function and in those with serum potassium concentrations
&gt;5.0 mmol/L.</p>
<p>Practical guidance on how to use MRAs is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 4</a></em>.</p>
<h4 >5.3.4 Angiotensin
receptor-neprilysin inhibitor</h4>
<p>In the PARADIGM-HF trial, sacubitril/valsartan, an ARNI, was shown to
be superior to enalapril in reducing hospitalizations for worsening HF,
CV mortality, and all-cause mortality in patients with ambulatory HFrEF
with LVEF ≤40% (changed to ≤35% during the study). Patients in the trial
had elevated plasma NP concentrations, an eGFR ≥30 mL/min/1.73
m<sup>2</sup> and were able to tolerate enalapril and then
sacubitril/valsartan during the run-in period.<sup>105</sup> Additional
benefits of sacubitril/valsartan included an improvement in symptoms and
QOL,<sup>105</sup> a reduction in the incidence of diabetes requiring
insulin treatment,<sup>126</sup> and a reduction in the decline in
eGFR,<sup>127</sup> as well as a reduced rate of
hyperkalaemia.<sup>128</sup> Additionally, the use of
sacubitril/valsartan may allow a reduction in loop diuretic
requirement.<sup>129</sup> Symptomatic hypotension was reported more
commonly in patients treated with sacubitril/valsartan as compared to
enalapril, but despite developing hypotension, these patients also
gained clinical benefits from sacubitril/valsartan
therapy.<sup>128</sup><sup>,</sup><sup>130</sup></p>
<p>Therefore, it is recommended that an ACE-I or ARB is replaced by
sacubitril/valsartan in ambulatory patients with HFrEF, who remain
symptomatic despite optimal treatment outlined above. Two studies have
examined the use of ARNI in hospitalized patients, some of whom had not
been previously treated with ACE-I. Initiation in this setting appears
safe and reduces subsequent CV death or HF hospitalizations by 42%
compared to
enalapril.<sup>106</sup><sup>,</sup><sup>107</sup><sup>,</sup><sup>131</sup>
As such, initiation of sacubitril/valsartan in ACE-I naive (i.e. <em>de
novo</em>) patients with HFrEF may be considered (class of
recommendation IIb, level of evidence B). Patients being commenced on
sacubitril/valsartan should have an adequate blood pressure (BP), and an
eGFR ≥30 mL/min/1.73 m<sup>2</sup>. A washout period of at least 36 h
after ACE-I therapy is required in order to minimize the risk of
angioedema.</p>
<p>Practical guidance on how to use ARNI is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 5</a>.</em></p>
<h4 >5.3.5 Sodium-glucose
co-transporter 2 inhibitors</h4>
<p>The DAPA-HF trial investigated the long-term effects of dapagliflozin
(SGLT2 inhibitor) compared to placebo in addition to optimal medical
therapy (OMT), on morbidity and mortality in patients with ambulatory
HFrEF.<sup>108</sup> Patients participated in the trial if they were in
NYHA class II–IV, and had an LVEF ≤40% despite OMT. Patients were also
required to have an elevated plasma NT-proBNP and an eGFR
≥30 mL/min/1.73 m<sup>2</sup>.<sup>108</sup></p>
<p>Therapy with dapagliflozin resulted in a 26% reduction in the primary
endpoint: a composite of worsening HF (hospitalization or an urgent
visit resulting in i.v. therapy for HF) or CV death. Both of these
components were significantly reduced. Moreover, dapagliflozin reduced
all-cause mortality,<sup>108</sup> alleviated HF symptoms, improved
physical function and QOL in patients with symptomatic
HFrEF.<sup>132</sup> Benefits were seen early after the initiation of
dapagliflozin, and the absolute risk reduction was large. Survival
benefits were seen to the same extent in patients with HFrEF with and
without diabetes, and across the whole spectrum of HbA1c
values.<sup>108</sup></p>
<p>Subsequently, the EMPEROR-Reduced trial found that empagliflozin
reduced the combined primary endpoint of CV death or HF hospitalization
by 25% in patients with NYHA class II–IV symptoms, and an LVEF ≤40%
despite OMT.<sup>109</sup> This trial included patients with an eGFR
&gt;20 mL/min/1.73 m<sup>2</sup> and there was also a reduction in the
decline in eGFR in individuals receiving empagliflozin. It was also
associated with an improvement in QOL.<sup>133</sup> Although there was
not a significant reduction in CV mortality in the EMPEROR-Reduced
trial, a recent meta-analysis of the DAPA-HF and EMPEROR-Reduced trials
found no heterogeneity in CV mortality.<sup>134</sup></p>
<p>Therefore, dapagliflozin or empagliflozin are recommended, in
addition to OMT with an ACE-I/ARNI, a beta-blocker and an MRA, for
patients with HFrEF regardless of diabetes status. The
diuretic/natriuretic properties of SGLT2 inhibitors may offer additional
benefits in reducing congestion and may allow a reduction in loop
diuretic requirement.<sup>135</sup></p>
<p>The combined SGLT-1 and 2 inhibitor, sotagliflozin, has also been
studied in patients with diabetes who were hospitalized with HF. The
drug reduced CV death and hospitalization for HF.<sup>136</sup> It is
discussed further in the AHF and comorbidity sections.</p>
<p>Therapy with SGLT2 inhibitors may increase the risk of recurrent
genital fungal infections. A small reduction in eGFR following
initiation is expected and is reversible and should not lead to
premature discontinuation of the drug.</p>
<p>Practical guidance on how to use the SGLT2 inhibitors dapagliflozin
and empagliflozin are given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 6</a></em>.</p>
<h3
>5.4
Other drugs recommended or to be considered in selected patients with
heart failure with reduced ejection fraction</h3>
<p>Other pharmacological treatments indicated in selected patients with
NYHA class II–IV heart failure with reduced ejection fraction (LVEF
≤40%)</p>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; b.p.m. = beats per minute;
CV = cardiovascular; HF = heart failure; HFrEF = heart failure with
reduced ejection fraction; LVEF = left ventricular ejection fraction;
MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart
Association; SR = sinus rhythm.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>The ARBs with evidence in HFrEF are candesartan, losartan, and
valsartan.</p>
<p>Other pharmacological treatments indicated in selected patients with
NYHA class II–IV heart failure with reduced ejection fraction (LVEF
≤40%)</p>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; b.p.m. = beats per minute;
CV = cardiovascular; HF = heart failure; HFrEF = heart failure with
reduced ejection fraction; LVEF = left ventricular ejection fraction;
MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart
Association; SR = sinus rhythm.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>The ARBs with evidence in HFrEF are candesartan, losartan, and
valsartan.</p>
<h4 >5.4.1 Diuretics</h4>
<p>Loop diuretics are recommended to reduce the signs and/or symptoms of
congestion in patients with HFrEF. The quality of the evidence regarding
diuretics is poor and their effects on morbidity and mortality have not
been studied in RCTs. However, it should also be remembered that the
major disease-modifying treatment trials for HFrEF were conducted with a
high background use of loop diuretic therapy. One meta-analysis has
shown that in patients with HFrEF, loop and thiazide diuretics appear to
reduce the risk of death and worsening HF compared with a placebo, and
compared with an active control, diuretics improve exercise
capacity.<sup>137</sup></p>
<p>Loop diuretics produce a more intense and shorter diuresis than
thiazides, although they act synergistically (sequential nephron
blockade) and the combination may be used to treat diuretic resistance.
However, adverse effects are more likely, and these combinations should
only be used with care. Of note, ARNI, MRAs, and SGLT2 inhibitors may
also possess diuretic
properties.<sup>129</sup><sup>,</sup><sup>145</sup></p>
<p>The aim of diuretic therapy is to achieve and maintain euvolaemia
with the lowest diuretic dose. In some euvolaemic/hypovolaemic patients,
the use of a diuretic drug might be reduced or
discontinued.<sup>146</sup> Patients should be trained to self-adjust
their diuretic dose based on monitoring of symptoms/signs of congestion
and daily weight measurements.</p>
<p>Practical guidance on how to use diuretics is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 7</a></em>.</p>
<h4 >5.4.2 Angiotensin II
type 1 receptor blockers</h4>
<p>The place of ARBs in the management of HFrEF has changed over the
last few years. They are now recommended for patients who cannot
tolerate ACE-I or ARNI because of serious side effects. Candesartan in
the CHARM-Alternative study reduced CV deaths and HF hospitalizations in
patients who were not receiving an ACE-I due to previous
intolerance.<sup>138</sup> Valsartan, in addition to usual therapy,
including ACE-I, reduced HF hospitalizations in the Val-HeFT
trial.<sup>147</sup> However, no ARB has reduced all-cause mortality in
any trial.</p>
<h4 >5.4.3 I_<sub>f</sub>_-channel
inhibitor</h4>
<p>Ivabradine slows heart rate by inhibition of the I_<sub>f</sub>_
channel in the sinus node and is therefore only effective in patients in
SR. Ivabradine reduced the combined endpoint of CV mortality and HF
hospitalization in patients with symptomatic HFrEF with an LVEF ≤35%,
with HF hospitalization in recent 12 months, in sinus rhythm (SR) and
with a heart rate ≥70 b.p.m. who were on evidence-based therapy
including an ACE-I (or ARB), a beta-blocker, and an
MRA.<sup>139</sup><sup>,</sup><sup>140</sup> Our recommendation is based
on the heart rate of ≥70 b.p.m. used in the SHIFT trial. However, the
European Medicines Agency (EMA) approved ivabradine for use in Europe in
patients with HFrEF with LVEF ≤35% and in SR with a resting heart rate
≥75 b.p.m., because in this group ivabradine conferred a survival
benefit<sup>148</sup> based on a retrospective subgroup analysis. Every
effort should be made to commence and uptitrate beta-blocker therapy to
guideline recommended/maximally tolerated doses prior to considering
ivabradine.</p>
<p>Practical guidance on how to use ivabradine is given in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 8</a></em>.</p>
<h4 >5.4.4
Combination of hydralazine and isosorbide dinitrate</h4>
<p>There is no clear evidence to suggest the use of this fixed-dose
combination therapy in all patients with HFrEF. A small RCT conducted in
self-identified black patients showed that an addition of the
combination of hydralazine and isosorbide dinitrate to conventional
therapy (an ACE-I, a beta-blocker, and an MRA) reduced mortality and HF
hospitalizations in patients with HFrEF and NYHA classes
III–IV.<sup>142</sup> These results are difficult to translate to
patients of other racial or ethnic origins.</p>
<p>Additionally, a combination of hydralazine and isosorbide dinitrate
may be considered in symptomatic patients with HFrEF who cannot tolerate
any of an ACE-I, ARNI, or an ARB (or if they are contraindicated) to
reduce mortality. However, this recommendation is based on the results
of the relatively small Veterans Administration Cooperative Study, which
included only male patients with symptomatic HFrEF who were treated with
digoxin and diuretics.<sup>143</sup></p>
<h4 >5.4.5 Digoxin</h4>
<p>Digoxin may be considered in patients with HFrEF in SR to reduce the
risk of hospitalization,<sup>144</sup> although its effect on those
routinely treated with beta-blockers has not been tested. In the DIG
trial, the overall effect on mortality with digoxin was neutral.</p>
<p>The effects of digoxin in patients with HFrEF and AF have not been
studied in RCTs. Some studies have suggested a potentially higher risk
of events in patients with AF receiving
digoxin,<sup>149</sup><sup>,</sup><sup>150</sup> whereas another
meta-analysis concluded, on the basis of non-RCTs, that digoxin has no
deleterious effect on mortality in patients with AF and HF, most of whom
had HFrEF.<sup>151</sup> Therefore, in patients with symptomatic HF and
AF, digoxin may be useful for the treatment of patients with HFrEF and
AF with rapid ventricular rate, when other therapeutic options cannot be
pursued.<sup>150</sup><sup>,</sup><sup>152–155</sup></p>
<p>Digoxin has a narrow therapeutic window and so levels should be
checked aiming for a serum digoxin concentration
&lt;1.2 ng/mL.<sup>156</sup><sup>,</sup><sup>157</sup> Caution should
also be exercised when using it in females, the elderly, frail,
hypokalaemic, and malnourished subjects. In patients with reduced renal
function, digitoxin could be considered. Digitoxin use in HF and SR is
currently being investigated.<sup>158</sup></p>
<h4
>5.4.6
Recently reported advances from trials in heart failure with reduced
ejection fraction</h4>
<p><strong>Soluble guanylate cyclase receptor stimulator</strong></p>
<p>The VICTORIA study assessed the efficacy and safety of the oral
soluble guanylate cyclase receptor stimulator, vericiguat, in patients
with a reduced EF and recently decompensated CHF. The incidence of the
primary endpoint of death from CV causes or hospitalization for HF was
lower among those who received vericiguat than among those who received
placebo.<sup>141</sup> There was no reduction in either all-cause or CV
mortality. Thus, vericiguat may be considered, in addition to standard
therapy for HFrEF, to reduce the risk of CV mortality and
hospitalizations for HF.</p>
<p><strong>Cardiac myosin activator</strong></p>
<p>The GALACTIC-HF study assessed the efficacy and safety of the cardiac
myosin activator, omecamtiv mecarbil, in HFrEF patients, enrolling
patients in both the inpatient and outpatient settings. The primary
endpoint of a first HF event or CV death was reduced by 8%. There was no
significant reduction in CV mortality. Currently, this drug is not
licensed for use in HF. However, in the future it may be able to be
considered, in addition to standard therapy for HFrEF to reduce the risk
of CV mortality and hospitalization for HF.<sup>159</sup></p>
<h3
>5.5
Strategic phenotypic overview of the management of heart failure with
reduced ejection fraction</h3>
<p>In addition to the general therapies considered in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">section
5</a>, other therapies are appropriate to consider in selected patients.
These are covered in detail in later sections. Some of the main ones
(i.e. those with Class I and IIa Mortality/Hospitalization indications)
are depicted in <em>Figure 3</em>. The effect of some interventions on
symptoms/QOL are outlined in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 9</a></em>.</p>
<p>Figure 3</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f3.jpeg?Expires=1689850106&amp;Signature=vP2MoAA0BSY16563fhMw~6~f4V2Zu52I1FfYQ4kbOjnn6BmXbTa1xs4D7-BGbJebNmqsgIcn-KpnZAPvxBuGGZQ955-o7cqeU92uJXBRcPyrNbsWfD3-XZKlgbc8hseNX-wmIRJdN9u2Tr9Vua-2WikYp~zMoDP7MOo2LNNcDAotLeLdJI9O5tB20iOu3vBb5iF9c2nvl7y4g6SZ4jCbF~eY6f241eEXLGlHX3Fw7563u~hl49vs8zv76fwR3Ly2Kv3oCDL7XiyoLSb6iT8iLLieKzamEOqnRRcD7Ijth2KLmB9xxokDQMGRAyaF49xCKo8z16Pyh0SSu36rnI0zMg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Central illustration. Strategic phenotypic overview of the management of heart failure with reduced ejection fraction. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BB = beta-blocker; b.p.m. = beats per minute; BTC = bridge to candidacy; BTT = bridge to transplantation; CABG = coronary artery bypass graft; CRT-D = cardiac resynchronization therapy with defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; DT = destination therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; ISDN = isosorbide dinitrate; LBBB = left bundle branch block; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; MV = mitral valve; PVI = pulmonary vein isolation; QOL = quality of life; SAVR = surgical aortic valve replacement; SGLT2i = sodium-glucose co-transporter 2 inhibitor; SR = sinus rhythm; TAVI = transcatheter aortic valve replacement; TEE = transcatheter edge to edge. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation). The Figure shows management options with Class I and IIa recommendations. See the specific Tables for those with Class IIb recommendations." />
<figcaption aria-hidden="true">Central illustration. Strategic
phenotypic overview of the management of heart failure with reduced
ejection fraction. ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; BB = beta-blocker; b.p.m. = beats per
minute; BTC = bridge to candidacy; BTT = bridge to transplantation;
CABG = coronary artery bypass graft; CRT-D = cardiac resynchronization
therapy with defibrillator; CRT-P = cardiac resynchronization therapy
pacemaker; DT = destination therapy; HF = heart failure; HFrEF = heart
failure with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; ISDN = isosorbide dinitrate; LBBB = left
bundle branch block; MCS = mechanical circulatory support;
MRA = mineralocorticoid receptor antagonist; MV = mitral valve;
PVI = pulmonary vein isolation; QOL = quality of life; SAVR = surgical
aortic valve replacement; SGLT2i = sodium-glucose co-transporter 2
inhibitor; SR = sinus rhythm; TAVI = transcatheter aortic valve
replacement; TEE = transcatheter edge to edge. Colour code for classes
of recommendation: Green for Class of recommendation I; Yellow for Class
of recommendation IIa (see Table 1 for further details on classes of
recommendation). The Figure shows management options with Class I and
IIa recommendations. See the specific Tables for those with Class IIb
recommendations.</figcaption>
</figure>
<p>Central illustration. Strategic phenotypic overview of the management
of heart failure with reduced ejection fraction.
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin
receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor;
BB = beta-blocker; b.p.m. = beats per minute; BTC = bridge to candidacy;
BTT = bridge to transplantation; CABG = coronary artery bypass graft;
CRT-D = cardiac resynchronization therapy with defibrillator;
CRT-P = cardiac resynchronization therapy pacemaker; DT = destination
therapy; HF = heart failure; HFrEF = heart failure with reduced ejection
fraction; ICD = implantable cardioverter-defibrillator;
ISDN = isosorbide dinitrate; LBBB = left bundle branch block;
MCS = mechanical circulatory support; MRA = mineralocorticoid receptor
antagonist; MV = mitral valve; PVI = pulmonary vein isolation;
QOL = quality of life; SAVR = surgical aortic valve replacement;
SGLT2i = sodium-glucose co-transporter 2 inhibitor; SR = sinus rhythm;
TAVI = transcatheter aortic valve replacement; TEE = transcatheter edge
to edge. Colour code for classes of recommendation: Green for Class of
recommendation I; Yellow for Class of recommendation IIa (see
<em>Table 1</em> for further details on classes of recommendation). The
Figure shows management options with Class I and IIa recommendations.
See the specific Tables for those with Class IIb recommendations.</p>
<h2
>6
Cardiac rhythm management for heart failure with reduced ejection
fraction</h2>
<p>This section provides recommendations on the use of implantable
cardioverter-defibrillators (ICD) and cardiac resynchronization therapy
(CRT). Other implantable devices will be discussed at the end of this
section.</p>
<h3 >6.1 Implantable
cardioverter- defibrillator</h3>
<p>A high proportion of deaths among patients with HF, especially in
those with milder symptoms, occur suddenly and unexpectedly. Many of
these may be due to electrical disturbances, including ventricular
arrhythmias, bradycardia, and asystole, although some are due to other
acute vascular events. Treatments that improve or delay the progression
of CV disease have been shown to reduce the annual rate of sudden
death,<sup>105</sup><sup>,</sup><sup>160</sup> but they do not treat
arrhythmic events when they occur. ICDs are effective at correcting
potentially lethal ventricular arrhythmias, and in the case of
transvenous systems, also prevent bradycardia. Some antiarrhythmic drugs
might reduce the rate of tachyarrhythmias and sudden death, but they do
not reduce overall mortality,<sup>161</sup> and may increase it.</p>
<p>Recommendations for an implantable cardioverter-defibrillator in
patients with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table27.jpeg?Expires=1689850106&amp;Signature=O4r8r3dZYdPKlESGlyQ7LwW80KmzKnvYdlxrF-LhxGULaigWj~c~N56zlonGov0gkXRXtXe-A8bfyiJWYGVeAP89yQrzcVp~KR~chKP54ZMAdUBfPZ5SIwvIvaTAJrds-uhWNj2KFj2AdNleXwDEm38Nzzst5bA1~6tNA9VQ~8cdlLJm1MzM7X2Zy1xhFs2qygk00eJUaCad1UuAHjTufwXoHPHAR4dTWV3EY2vOzjGWfxbvU9RzfmkQeh4Kquhhf3BxVy-QBJdIvxmemS9q7IPQWXnUIyqKAiluJnifoe6INlTdaesLIHvAyULe-kzZhTXt3WJjbqa-6mQQjceWqw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table27.jpeg?Expires=1689850106&amp;Signature=O4r8r3dZYdPKlESGlyQ7LwW80KmzKnvYdlxrF-LhxGULaigWj~c~N56zlonGov0gkXRXtXe-A8bfyiJWYGVeAP89yQrzcVp~KR~chKP54ZMAdUBfPZ5SIwvIvaTAJrds-uhWNj2KFj2AdNleXwDEm38Nzzst5bA1~6tNA9VQ~8cdlLJm1MzM7X2Zy1xhFs2qygk00eJUaCad1UuAHjTufwXoHPHAR4dTWV3EY2vOzjGWfxbvU9RzfmkQeh4Kquhhf3BxVy-QBJdIvxmemS9q7IPQWXnUIyqKAiluJnifoe6INlTdaesLIHvAyULe-kzZhTXt3WJjbqa-6mQQjceWqw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CRT = cardiac resynchronization therapy; HF = heart failure;
ICD = implantable cardioverter-defibrillator; LVEF = left ventricular
ejection fraction; MI = myocardial infarction; NYHA = New York Heart
Association; OMT = optimal medical therapy; VAD = ventricular assist
device.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for an implantable cardioverter-defibrillator in
patients with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table27.jpeg?Expires=1689850106&amp;Signature=O4r8r3dZYdPKlESGlyQ7LwW80KmzKnvYdlxrF-LhxGULaigWj~c~N56zlonGov0gkXRXtXe-A8bfyiJWYGVeAP89yQrzcVp~KR~chKP54ZMAdUBfPZ5SIwvIvaTAJrds-uhWNj2KFj2AdNleXwDEm38Nzzst5bA1~6tNA9VQ~8cdlLJm1MzM7X2Zy1xhFs2qygk00eJUaCad1UuAHjTufwXoHPHAR4dTWV3EY2vOzjGWfxbvU9RzfmkQeh4Kquhhf3BxVy-QBJdIvxmemS9q7IPQWXnUIyqKAiluJnifoe6INlTdaesLIHvAyULe-kzZhTXt3WJjbqa-6mQQjceWqw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table27.jpeg?Expires=1689850106&amp;Signature=O4r8r3dZYdPKlESGlyQ7LwW80KmzKnvYdlxrF-LhxGULaigWj~c~N56zlonGov0gkXRXtXe-A8bfyiJWYGVeAP89yQrzcVp~KR~chKP54ZMAdUBfPZ5SIwvIvaTAJrds-uhWNj2KFj2AdNleXwDEm38Nzzst5bA1~6tNA9VQ~8cdlLJm1MzM7X2Zy1xhFs2qygk00eJUaCad1UuAHjTufwXoHPHAR4dTWV3EY2vOzjGWfxbvU9RzfmkQeh4Kquhhf3BxVy-QBJdIvxmemS9q7IPQWXnUIyqKAiluJnifoe6INlTdaesLIHvAyULe-kzZhTXt3WJjbqa-6mQQjceWqw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CRT = cardiac resynchronization therapy; HF = heart failure;
ICD = implantable cardioverter-defibrillator; LVEF = left ventricular
ejection fraction; MI = myocardial infarction; NYHA = New York Heart
Association; OMT = optimal medical therapy; VAD = ventricular assist
device.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4 >6.1.1 Secondary
prevention of sudden cardiac death</h4>
<p>Compared with amiodarone treatment, ICDs reduce mortality in
survivors of cardiac arrest and in patients who have experienced
sustained symptomatic ventricular arrhythmias. An ICD is recommended in
such patients when the intent is to increase survival; the decision to
implant should take into account the patient’s view and their QOL, the
LVEF (survival benefit is uncertain when LVEF &gt;35%) and the absence
of other diseases likely to cause death within the following
year.<sup>162–164</sup><sup>,</sup><sup>184</sup></p>
<h4 >6.1.2 Primary
prevention of sudden cardiac death</h4>
<p>In an analysis of over 40 000 patients from 12 pivotal HF trials,
rates of sudden cardiac death decreased by 44% over the 20-year period
(from the mid-1990s to 2015).<sup>160</sup> This is almost certainly due
to advances in HF treatment, as many key guideline-recommended
therapies, including beta-blockers, MRAs, sacubitril/valsartan, and CRT
pacemakers (CRT-P), reduce the risk of sudden death. While the
afore-mentioned HF therapies have been shown to reduce mortality in
patients with HFrEF, amiodarone has not.<sup>161</sup> However, if it is
to be used, it should be with caution due to its significant side-effect
profile. Conversely, dronedarone<sup>185</sup> and the class I
antiarrhythmic agents disopyramide, encainide, and
flecainide<sup>186</sup> should not be used for prevention of
arrhythmias due to the increase in mortality seen in clinical
studies.</p>
<p>Although an ICD reduces the rate of sudden arrhythmic death in
patients with HFrEF,<sup>187</sup> it would be expected that, in
well-managed patients, the additional benefit afforded by an ICD would
be lower. In the DANISH trial, rates of sudden death were low in
patients with non-ischaemic cardiomyopathy (NICM); only 70 patients out
of 1116 followed up over 5 years had sudden death.<sup>166</sup> Whilst
there was a modest absolute reduction in sudden death with a
defibrillator-containing device, this did not significantly improve the
overall risk of mortality. However, subgroup analysis suggested there
was a benefit in those ≤70 years.<sup>188</sup> In a recent
meta-analysis of studies that examined the effect of ICDs in NICM a
survival benefit was still seen, although the effect was significantly
weakened by the inclusion of the DANISH trial.<sup>167</sup></p>
<p>On average, patients with IHD are at greater risk of sudden death
than patients with NICM and therefore, although the relative benefits
are similar, the absolute benefit is greater in patients with
IHD.<sup>187</sup> Two RCTs showed no benefit in patients who had an ICD
implanted within 40 days after a
MI.<sup>177</sup><sup>,</sup><sup>178</sup> Although sudden arrhythmic
deaths were reduced, this was balanced by an increase in non-arrhythmic
deaths. Accordingly, an ICD for primary prevention is contraindicated in
this time period. Furthermore, ICD implantation is recommended only if a
minimum of 3 months of OMT has failed to increase the LVEF to &gt;35%.
OMT ideally includes the use of Class I recommended drugs for HFrEF.
However, the ICD trials we cite predate the use of ARNI and SGLT2
inhibitors. Whether implantation of ICDs reduces mortality in those with
an LVEF &gt;35% is unknown. There is an ongoing trial of ICD therapy in
such patients with the presence of scar on CMR
imaging.<sup>189</sup></p>
<h4
>6.1.3
Patient selection for implantable cardioverter-defibrillator
therapy</h4>
<p>Patients with HFrEF and a QRS duration ≥130 ms can be considered for
CRT with a defibrillator (CRT-D) rather than ICD. See the section on CRT
for further details (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6.2">section 6.2</a>).</p>
<p>In patients with moderate or severe HF, a reduction in sudden death
may be partially or wholly offset by an increase in death due to
worsening HF.<sup>161</sup> As such, ICD therapy is not recommended in
patients in NYHA class IV, with severe symptoms refractory to
pharmacological therapy, who are not candidates for a ventricular assist
device (VAD) or cardiac transplantation. Such patients have a very
limited life expectancy and are likely to die from pump failure.
Similarly, patients with serious comorbidities who are unlikely to
survive substantially more than 1 year with good QOL are unlikely to
obtain substantial benefit from an ICD.<sup>179–183</sup></p>
<p>Although the DANISH trial did not show a significant benefit from ICD
therapy in patients with NICM, it should be remembered that NICM is a
heterogeneous condition, and certain subgroups (e.g. laminopathies,
sarcoidosis) are at higher risk of sudden death and therefore merit
careful consideration of ICD implantation. Tools to help risk
stratification (e.g. scar burden on magnetic resonance imaging) can be
helpful in that regard.<sup>190–192</sup></p>
<p>Patients should be counselled as to the purpose of an ICD and
involved in the decision-making process. They should also be aware of
the potential complications related to implantation, any additional
implications for driving, and the risk of inappropriate shocks.
Furthermore, patients should be informed about the circumstances where
the defibrillator (or defibrillator component of a CRT-D) might be
deactivated (e.g. terminal disease) or explanted (e.g. infection or
recovery of LV function).<sup>193</sup> Subsequent timely conversations
regarding defibrillator deactivation should be held with the patient and
caregiver(s).</p>
<p>When an ICD generator reaches its end of life or requires
explantation, it should not be replaced automatically. Rather, shared
decision making should be undertaken.<sup>168–172</sup> Patients should
be carefully evaluated by an experienced cardiologist as treatment goals
may have changed since implantation (the risk of fatal arrhythmia may be
lower, or the risk of non-arrhythmic death may be higher). It is a
matter of some controversy whether patients whose LVEF has greatly
improved and who have not required device therapy during the lifetime of
the ICD should have another device implanted.<sup>168–172</sup></p>
<h4 >6.1.4
Implantable cardioverter-defibrillator programming</h4>
<p>Routine defibrillation threshold testing is no longer performed
following implantation of an ICD or CRT-D as it does not improve shock
efficacy or reduce arrhythmic death.<sup>194</sup> Conservative
programming with long delays<sup>195</sup> between detection and the ICD
delivering therapy dramatically reduces the risk of both inappropriate
and appropriate but unnecessary
shocks.<sup>194</sup><sup>,</sup><sup>196</sup><sup>,</sup><sup>197</sup>
Generally, for primary prevention, defibrillators are programmed to
minimize pacing (e.g. ventricular demand pacing VVI at 40/min), and with
a tachycardia treatment zone
&gt;200/min.<sup>194</sup><sup>,</sup><sup>198</sup> Ultimately—and
particularly for secondary prevention—programming should be adapted
according to the patient’s specific needs.</p>
<h4
>6.1.5
Subcutaneous and wearable implantable cardioverter-defibrillators</h4>
<p>Subcutaneous ICDs (S-ICDs) appear to be as effective as conventional
transvenous ICDs with a similar complication rate. Although the risk of
inappropriate shocks appeared to be higher initially, improved patient
selection has shown S-ICDs are non-inferior to transvenous ICDs in this
regard.<sup>199–202</sup> They may be the preferred option for patients
with difficult venous access or those who require ICD explantation due
to infection. Patients must be carefully selected, as S-ICDs cannot
treat bradyarrhythmia (except post-shock pacing) and cannot deliver
either anti-tachycardia pacing or CRT. Substantial RCTs with these
devices and more long-term data on safety and efficacy are awaited.</p>
<p>A wearable cardioverter-defibrillator that is able to recognize and
treat ventricular arrhythmias may be considered for a limited period of
time in selected patients with HF who are at high risk for sudden death
but otherwise are not suitable for ICD
implantation.<sup>162</sup><sup>,</sup><sup>175</sup><sup>,</sup><sup>176</sup><sup>,</sup><sup>203</sup>
However, the large VEST trial failed to show that the wearable
cardioverter-defibrillator reduced arrhythmic death in patients with an
LVEF ≤35% following a recent acute MI.<sup>204</sup></p>
<p>For more detailed recommendations on the use/indications of ICD we
refer the reader to the ESC/European Heart Rhythm Association (EHRA)
Guidelines on ventricular tachyarrhythmias and sudden cardiac
death.<sup>201</sup></p>
<h3 >6.2 Cardiac resynchronization
therapy</h3>
<p>Recommendations for cardiac resynchronization therapy implantation in
patients with heart failure</p>
<p>AF = atrial fibrillation; AV = atrio-ventricular; CRT = cardiac
resynchronization therapy; HF = heart failure; HFrEF = heart failure
with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left
ventricular ejection fraction; NYHA = New York Heart Association;
OMT = optimal medical therapy (class I recommended medical therapies for
at least 3 months); QRS = Q, R, and S waves of an ECG; RV = right
ventricular; SR = sinus rhythm.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for cardiac resynchronization therapy implantation in
patients with heart failure</p>
<p>AF = atrial fibrillation; AV = atrio-ventricular; CRT = cardiac
resynchronization therapy; HF = heart failure; HFrEF = heart failure
with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left
ventricular ejection fraction; NYHA = New York Heart Association;
OMT = optimal medical therapy (class I recommended medical therapies for
at least 3 months); QRS = Q, R, and S waves of an ECG; RV = right
ventricular; SR = sinus rhythm.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>In appropriately selected individuals, CRT reduces morbidity and
mortality.<sup>211</sup> Furthermore, CRT improves cardiac function, and
enhances QOL.<sup>209</sup><sup>,</sup><sup>225</sup></p>
<p>Whilst the CARE-HF<sup>206</sup><sup>,</sup><sup>208</sup> and
COMPANION<sup>210</sup> trials compared the effect of CRT with medical
therapy (MT), the majority of CRT studies have compared CRT-D with ICD,
and a few have compared CRT-P with backup pacing. The prevention of
fatal bradycardia might be an important mechanism of benefit shared by
all pacing devices. In CARE-HF, at baseline, 25% of patients had a
resting heart rate of ≤60
b.p.m.<sup>206</sup><sup>,</sup><sup>208</sup><sup>,</sup><sup>209</sup>
If prevention of bradycardia is important, the effect of CRT will appear
greater in trials where there is no device in the control group.
However, in MADIT-II, 35% of those who died with an ICD did so suddenly
even though they were protected from both brady- and
tachyarrhythmia.<sup>226</sup></p>
<p>Most studies of CRT have specified that the LVEF should be ≤35%, but
RAFT<sup>212</sup> and MADIT-CRT<sup>213</sup><sup>,</sup><sup>214</sup>
specified an LVEF ≤30%, while
REVERSE<sup>207</sup><sup>,</sup><sup>215</sup><sup>,</sup><sup>227</sup>
specified ≤40% and BLOCK-HF<sup>216</sup> ≤50%. Relatively few patients
with an LVEF of 35–40% have been randomized, but an IPD meta-analysis
suggests no diminution of the effect of CRT in this
group.<sup>211</sup></p>
<p>Assessing the ‘response’ to CRT is challenging. Indeed, many who do
not appear to ‘respond’ favourably in terms of their symptoms or LV
function may well have experienced the mortality benefit. Several
characteristics predict improvement in morbidity and mortality. The
extent of reverse remodelling is one of the most important mechanisms of
action of CRT. Patients with HFrEF of an ischaemic aetiology have less
improvement in LV function due to myocardial scar tissue, which is less
likely to undergo favourable remodelling.<sup>228</sup> Conversely,
women may be more likely to respond than men, possibly due to smaller
body and heart
size.<sup>220</sup><sup>,</sup><sup>224</sup><sup>,</sup><sup>229</sup>
QRS width predicts CRT response and was the inclusion criterion in all
randomized trials,<sup>211</sup> but QRS morphology has also been
related to a beneficial response to CRT. Several studies have shown that
patients with left bundle branch block (LBBB) morphology are more likely
to respond favourably to CRT, whereas there is less certainty about
patients with non-LBBB morphology.<sup>230</sup> This latter group is
also underrepresented in the large CRT
trials.<sup>206</sup><sup>,</sup><sup>210</sup><sup>,</sup><sup>213</sup>
However, patients with LBBB morphology often have wider QRS durations,
and there is a current debate about whether QRS durations or QRS
morphology is the main predictor of a beneficial response to CRT.
Evidence from two IPD meta-analyses indicates that after accounting for
QRS duration, there is little evidence to suggest that QRS morphology or
aetiology of disease influence the effect of CRT on morbidity or
mortality.<sup>211</sup><sup>,</sup><sup>220</sup> In addition, none of
the landmark trials selected patients for inclusion according to QRS
morphology, sex, or ischaemic aetiology, nor were they powered for
subgroup analyses.</p>
<p>The Echo-CRT trial<sup>222</sup><sup>,</sup><sup>223</sup> and an IPD
meta-analysis<sup>213</sup> suggest possible harm from CRT when QRS
duration is &lt;130 ms, thus implantation of CRT is not recommended if
QRS duration is &lt;130 ms.</p>
<p>If a patient is scheduled to receive an ICD and is in SR, with a
LBBB, CRT-D should be considered if the QRS is between 130 and 149 ms
and is recommended if QRS is ≥150 ms. However, clinical practice varies
widely among countries and if the primary reason for implanting CRT is
for the relief of symptoms, then the clinician should choose CRT-P or
CRT-D, whichever they consider appropriate. The only randomized trial to
compare CRT-P and CRT-D<sup>210</sup> did not demonstrate a difference
in morbidity or mortality between these technologies (although the trial
was not powered to show such a difference). Furthermore, in the DANISH
study in patients with NICM where 58% of patients received CRT there was
no suggestion from subgroup analysis that CRT-P was inferior to
CRT-D.<sup>166</sup><sup>,</sup><sup>167</sup></p>
<p>When LVEF is reduced, RV pacing may exacerbate cardiac dyssynchrony.
This can be prevented by CRT, which might improve patient
outcomes.<sup>216–218</sup><sup>,</sup><sup>231</sup> However, a
difference in outcome was not observed between CRT and RV pacing in a
subgroup analysis of RAFT.<sup>212</sup> On balance, CRT rather than RV
pacing is recommended for patients with HFrEF regardless of NYHA class
who have an indication for ventricular pacing in order to reduce
morbidity, although no clear effect on mortality was observed. Patients
with HFrEF who have received a conventional pacemaker or an ICD and
subsequently develop worsening HF with a high proportion of RV pacing,
despite OMT, should be considered for ‘upgrading’ to CRT.</p>
<p>Only two small trials have compared pharmacological therapy alone
vs. CRT in patients with AF, with conflicting results. Several studies
have indicated that CRT is superior to RV pacing in patients undergoing
atrio-ventricular (AV) node
ablation.<sup>217</sup><sup>,</sup><sup>218</sup><sup>,</sup><sup>231</sup>
However, AF is not an indication to carry out AV node ablation in
patients with CRT except in a few cases when ventricular rate remains
persistently high despite attempts at pharmacological rate control. A
subgroup analysis of patients with AF from the RAFT study found no
benefit from CRT-D compared with ICD, although less than half of
patients had &gt;90% biventricular capture.<sup>219</sup> In view of the
paucity of evidence for the efficacy of CRT in patients with AF, it may
be an option in selected patients—particularly those with a QRS
≥150 ms—ensuring a proportion of biventricular pacing as high as
possible.</p>
<p>Observational studies report that when biventricular capture is
&lt;98%, the prognosis of patients with CRT
declines.<sup>218</sup><sup>,</sup><sup>232</sup> Whether this
association reflects a loss of resynchronization (which might be
remedied by device programming), poor placement of the LV lead, or
greater difficulty in pacing severely diseased myocardium is uncertain.
This observation has not been confirmed in any randomized trial.</p>
<p>Early studies suggested that imaging tests for dyssynchrony were not
of value in selecting patients for CRT.<sup>233</sup> However, a recent
study has suggested that two novel markers of dyssynchrony (apical
rocking and septal flash) are associated with a response to CRT, but
these have not been tested as selection criteria or as prespecified
subgroups in a randomized trial.<sup>234</sup> Patients with extensive
myocardial scar will have less improvement in LV function with CRT, but
this is true of any treatment for HFrEF and does not reliably predict
less clinical benefit. Pacing thresholds are higher in scarred
myocardium and, if possible, lead placement should avoid such
regions.<sup>235</sup><sup>,</sup><sup>236</sup> Although patients with
extensive scarring have an intrinsically worse prognosis, there is
little evidence that they obtain less prognostic benefit from
CRT.<sup>211</sup></p>
<p>The value of trying to optimize AV intervals or interventricular
delay intervals (VV intervals) after implantation using echo- or
electrocardiographic criteria or BP response is uncertain but may be
considered for patients who have had a disappointing response to
CRT.<sup>237</sup><sup>,</sup><sup>238</sup> Other options to consider
to optimize response to CRT are covered in a recently published
practical article.<sup>239</sup></p>
<p>Following CRT implantation, a review of diuretic therapy is advised
as a reduction in dose or its discontinuation may be required. In
addition, CRT implantation may afford an opportunity to further optimize
MT for HFrEF.<sup>240</sup></p>
<p>The reader is directed to guidelines on pacing and CRT for
recommendations on device implantation procedures.<sup>240a</sup></p>
<h3 >6.3 Devices under evaluation</h3>
<p>Cardiac contractility modulation (CCM) has been evaluated in patients
with NYHA class III–IV HF, with an LVEF ≥25% to ≤45% and QRS duration
&lt;130 ms, and was associated with a small improvement in exercise
tolerance and QOL.<sup>241</sup><sup>,</sup><sup>242</sup></p>
<p>Technologies that involve modification of the activity of the
autonomic nervous system, e.g. baroreflex activation
therapy,<sup>243</sup><sup>,</sup><sup>244</sup> have also been shown to
offer a modest improvement in effort capacity and QOL. However,
currently, the evidence is considered insufficient to support specific
guideline recommendations for a reduction in mortality or
hospitalization for these and a variety of other implantable electrical
therapeutic technologies (see also Gaps in Evidence in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-16">section 16_)._</a></p>
<h2 >7 Heart
failure with mildly reduced ejection fraction</h2>
<h3
>7.1
The diagnosis of heart failure with mildly reduced ejection
fraction</h3>
<p>The diagnosis of HFmrEF requires the presence of symptoms and/or
signs of HF, and a mildly reduced EF (41–49%) The presence of elevated
NPs (BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL) and other evidence of
structural heart disease [e.g. increased left atrial (LA) size, LVH or
echocardiographic measures of LV filling] make the diagnosis more likely
but are not mandatory for diagnosis if there is certainty regarding the
measurement of LVEF.</p>
<p>An algorithm for the diagnosis of HFmrEF is depicted in
<em>Figure 1</em>. For the investigation of the underlying aetiology,
please refer to <em>Table 5</em> (which refers to investigations
regardless of LVEF).</p>
<h3
>7.2
Clinical characteristics of patients with heart failure with mildly
reduced ejection fraction</h3>
<p>There is a substantial overlap of clinical characteristics, risk
factors, patterns of cardiac remodelling, and outcomes among the LVEF
categories in HF. Patients with HFmrEF have, on average, features that
are more similar to HFrEF than HFpEF, in that they are more commonly
men, younger, and are more likely to have CAD
(50–60%),<sup>38</sup><sup>,</sup><sup>42</sup><sup>,</sup><sup>43</sup>
and less likely to have AF and non-cardiac comorbidities (<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 10</a></em>). However, ambulatory patients with HFmrEF have a
lower mortality than those with HFrEF, more akin to those with
HFpEF.</p>
<p>Patients with HFmrEF may include patients whose LVEF has improved
from ≤40% or declined from ≥50%.<sup>50</sup></p>
<h3
>7.3
Treatments for patients with heart failure with mildly reduced ejection
fraction</h3>
<p>As in other forms of HF, diuretics should be used to control
congestion. No substantial prospective RCT has been performed
exclusively in patients with HFmrEF (<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 11</a></em>). Some data can be gleaned from subgroup analysis of
trials in HFpEF, none of which have met their primary endpoint. Although
strong recommendations cannot be made about specific therapies at this
point in time, we have included a Table of Recommendations to help guide
the management of patients in this category.</p>
<p>Pharmacological treatments to be considered in patients with (NYHA
class II–IV) heart failure with mildly reduced ejection fraction</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table31.jpeg?Expires=1689850106&amp;Signature=kfdItNlSosGR2x9vdHWGFhekMvyTqyoEKn59W887VdBfknE656MXRZHrpSfRcEUeh-hEh1ZHP9hlPJXQ~zoIMRrzIdvQNoXJhA3UIdmgzvqs1KgJCw70dLR6pWs0VmUYOPkUO8CNdt389QyEhAr40HkekfezeI1RnaI5dzR4fnTvliAH1wDvSSWqYxRz8-6igLwGUN3MCwWgZ7oj5Ki~I0b0g0MClXizsE0nfmLm51Rb6PPfL0jsFIf0S8UPl~mpU2kEcJjIsdxsZh62~CaeCuhizDi0I6y2~QypfKJurkgh5YMaJ2KQtvnsKyl35FEExjtwK8JxnlJPFRC-kx95HA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table31.jpeg?Expires=1689850106&amp;Signature=kfdItNlSosGR2x9vdHWGFhekMvyTqyoEKn59W887VdBfknE656MXRZHrpSfRcEUeh-hEh1ZHP9hlPJXQ~zoIMRrzIdvQNoXJhA3UIdmgzvqs1KgJCw70dLR6pWs0VmUYOPkUO8CNdt389QyEhAr40HkekfezeI1RnaI5dzR4fnTvliAH1wDvSSWqYxRz8-6igLwGUN3MCwWgZ7oj5Ki~I0b0g0MClXizsE0nfmLm51Rb6PPfL0jsFIf0S8UPl~mpU2kEcJjIsdxsZh62~CaeCuhizDi0I6y2~QypfKJurkgh5YMaJ2KQtvnsKyl35FEExjtwK8JxnlJPFRC-kx95HA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; HF = heart failure; HFmrEF = heart
failure with mildly reduced ejection fraction; MRA = mineralocorticoid
receptor antagonist; NYHA = New York Heart Association.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Pharmacological treatments to be considered in patients with (NYHA
class II–IV) heart failure with mildly reduced ejection fraction</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table31.jpeg?Expires=1689850106&amp;Signature=kfdItNlSosGR2x9vdHWGFhekMvyTqyoEKn59W887VdBfknE656MXRZHrpSfRcEUeh-hEh1ZHP9hlPJXQ~zoIMRrzIdvQNoXJhA3UIdmgzvqs1KgJCw70dLR6pWs0VmUYOPkUO8CNdt389QyEhAr40HkekfezeI1RnaI5dzR4fnTvliAH1wDvSSWqYxRz8-6igLwGUN3MCwWgZ7oj5Ki~I0b0g0MClXizsE0nfmLm51Rb6PPfL0jsFIf0S8UPl~mpU2kEcJjIsdxsZh62~CaeCuhizDi0I6y2~QypfKJurkgh5YMaJ2KQtvnsKyl35FEExjtwK8JxnlJPFRC-kx95HA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table31.jpeg?Expires=1689850106&amp;Signature=kfdItNlSosGR2x9vdHWGFhekMvyTqyoEKn59W887VdBfknE656MXRZHrpSfRcEUeh-hEh1ZHP9hlPJXQ~zoIMRrzIdvQNoXJhA3UIdmgzvqs1KgJCw70dLR6pWs0VmUYOPkUO8CNdt389QyEhAr40HkekfezeI1RnaI5dzR4fnTvliAH1wDvSSWqYxRz8-6igLwGUN3MCwWgZ7oj5Ki~I0b0g0MClXizsE0nfmLm51Rb6PPfL0jsFIf0S8UPl~mpU2kEcJjIsdxsZh62~CaeCuhizDi0I6y2~QypfKJurkgh5YMaJ2KQtvnsKyl35FEExjtwK8JxnlJPFRC-kx95HA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; HF = heart failure; HFmrEF = heart
failure with mildly reduced ejection fraction; MRA = mineralocorticoid
receptor antagonist; NYHA = New York Heart Association.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4 >7.3.1
Angiotensin-converting enzyme inhibitors</h4>
<p>There are no specific trials of ACE-I in patients with HFmrEF.
Although, the PEP-CHF trial was conducted in patients with HFpEF and
included patients with an LVEF &gt;40%, it did not report outcomes
according to LVEF.<sup>11</sup></p>
<p>However, in patients with HFmrEF, many will also have CAD,
hypertension, or post-MI LV systolic dysfunction and will, therefore,
already be treated with ACE-I.</p>
<p>Therefore, ACE-I use may be considered in patients with HFmrEF.</p>
<h4 >7.3.2
Angiotensin receptor II type 1 receptor blockers</h4>
<p>There are no specific trials of ARBs in HFmrEF. The CHARM-Preserved
trial missed its primary endpoint of CV death or HF
hospitalizations.<sup>245</sup> However, a retrospective analysis showed
that candesartan reduced the number of patients hospitalized for HF
among those with HFmrEF (with similar trends for CV and all-cause
mortality).<sup>8</sup> Moreover, a recurrent-event analysis suggested a
reduction in hospitalizations for HF among the entire CHARM-Preserved
cohort, including those with HFmrEF.<sup>248</sup></p>
<p>As for ACE-I, many with HFmrEF will already be on an ARB for other CV
indications. Therefore, treatment with ARBs may be considered in
patients with HFmrEF.</p>
<h4 >7.3.3 Beta-blockers</h4>
<p>There is no specific trial of beta-blockade in HFmrEF. An IPD
meta-analysis of landmark trials of beta-blockers suggested similar
reductions in CV and all-cause mortality (of 50%) for patients in SR
with HFrEF and HFmrEF.<sup>12</sup> This IPD meta-analysis included the
SENIORS trial where nebivolol reduced the composite primary endpoint of
all-cause mortality or CV hospital admissions in the overall population.
No interaction between LVEF (35% of patients had an LVEF of 35–50%) and
the effect of nebivolol on the primary outcome was
observed.<sup>119</sup><sup>,</sup><sup>249</sup> Many patients with
HFmrEF may have another CV indication, such as AF or angina, for a
beta-blocker. Therefore, treatment with beta-blockers may be considered
in patients with HFmrEF.</p>
<h4 >7.3.4
Mineralocorticoid receptor antagonists</h4>
<p>There is no specific trial of MRAs in HFmrEF. In a retrospective
analysis of the TOPCAT trial in patients with an LVEF ≥45%,<sup>9</sup>
spironolactone reduced hospitalizations for HF in those with an LVEF
&lt;55%. There was a similar trend for CV but not all-cause
mortality.</p>
<p>Treatment with an MRA may be considered in patients with HFmrEF.</p>
<h4 >7.3.5 Angiotensin
receptor-neprilysin inhibitor</h4>
<p>There is no specific trial of ARNI in HFmrEF. In the PARAGON-HF
trial, which included patients with EF ≥45%, although the trial missed
its primary endpoint overall, a significant EF-by-treatment interaction
was observed. Sacubitril/valsartan, compared with valsartan, reduced the
likelihood of the primary composite outcome of CV death and total HF
hospitalizations by 22% in those with an EF below or equal to the median
of 57%.<sup>13</sup> Further data are available from a combined analysis
of the PARADIGM-HF and PARAGON-HF trials showing that
sacubitril/valsartan, compared to other forms of RAAS blockade, has a
beneficial effect, especially on hospitalizations for HF in those with
HFmrEF.<sup>247</sup></p>
<p>Treatment with an ARNI may be considered in patients with HFmrEF.</p>
<h4 >7.3.6 Other drugs</h4>
<p>In the DIG trial,<sup>10</sup> for those with HFmrEF in SR, there was
a trend to fewer hospitalizations for HF in those assigned to digoxin,
but no reduction in mortality and a trend to an excess of CV deaths.
Therefore, there are insufficient data to recommend its use.</p>
<p>There are also insufficient data on ivabradine in HFmrEF to draw any
conclusions.</p>
<h4 >7.3.7 Devices</h4>
<p>While post hoc analyses of landmark CRT trials suggest that CRT may
benefit patients with LVEF &gt;35%, trials of CRT for HFmrEF were
abandoned due to poor recruitment.<sup>250</sup> There are no
substantial trials of ICDs for primary prevention of ventricular
arrhythmias for HFmrEF; trials conducted more than 20 years ago
suggested no benefit from ICD implantation for secondary prevention of
ventricular arrhythmias for HFmrEF.</p>
<p>Therefore, there is insufficient evidence to advise CRT or ICD
therapy in patients with HFmrEF.</p>
<p>In HF patients with an LVEF ≥40%, the implantation of an interatrial
shunt device was found to be safe, and this device is subject to
investigation in a larger study before any recommendation on their use
in HFpEF or HFmrEF can be given.<sup>251</sup></p>
<h2 >8 Heart failure
with preserved ejection fraction</h2>
<h3
>8.1
The background to heart failure with preserved ejection fraction</h3>
<p>This guideline acknowledges the historical changes in nomenclature
and the lack of consensus on the optimal LVEF cut-off to define the
group of patients with HF without overtly reduced EF. The term
‘preserved’ was originally proposed in the Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM) Programme to
refer to patients with an EF (&gt;40%) that was not clearly ‘reduced’ or
completely ‘normal’.<sup>252</sup> While the current guidelines have
designated patients with an LVEF 41–49% as HFmrEF, we recognize that
there will be debate about what constitutes ‘mildly reduced’ EF, what
these EF cut-offs should be, and whether they should be different for
men and women.<sup>14</sup><sup>,</sup><sup>253</sup> The EACVI defines
systolic dysfunction as being &lt;52% for males and &lt;54% for
females.<sup>16</sup></p>
<p>Whether patients with higher EFs and HF should be named HF with
‘normal’ EF has also been
considered.<sup>14</sup><sup>,</sup><sup>254</sup> However, given the
known variability of echocardiographic measurements of LVEF, the
difficulties in interpreting LVEF measured using different imaging
modalities, and remaining controversies regarding the precise LVEF
cut-off to define ‘normal’ , which may vary not only with sex but also
with other factors such as age and ethnicity,<sup>255</sup> this
guideline has kept the nomenclature of HFpEF using an EF cut-off of 50%.
Importantly, clinicians should be aware that LVEF is a continuous
variable with a normal distribution in the general population, and the
EF cut-offs used in definitions are therefore arbitrary. Moreover, while
the LVEF cut-off to define ‘normal’ will likely be higher than 50%, the
presence of a very high EF (e.g. above 65–70%) should also prompt a
search for pathology, such as cardiac amyloidosis (CA) or hypertrophic
cardiomyopathy (HCM), where a ‘supra-normal’ EF may result from
shrinkage of the LV end-diastolic volume (denominator of
EF).<sup>256</sup><sup>,</sup><sup>257</sup></p>
<h3
>8.2
Clinical characteristics of patients with heart failure with preserved
ejection fraction</h3>
<p>HFpEF differs from HFrEF and HFmrEF in that HFpEF patients are older
and more often female. AF, CKD, and non-CV comorbidities are more common
in patients with HFpEF than in those with HFrEF.<sup>258</sup></p>
<p>There are numerous potential causes of HFpEF (<em>Table 5</em>). The
pathophysiology of various HFpEF syndromes differs, and thus they
require distinct therapies. Red flags for the potential presence of CA
include low normal BP in patients with a history of hypertension,
intolerance to beta-blockers or ACE-I, history of bilateral carpal
tunnel syndrome, low voltage on ECG and echocardiographic features such
as thickening of the septum, posterior wall, or RV wall, enlarged atria,
a small pericardial effusion, or valve thickening [for more details see
the section on CMP (<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.2">section 14.2</a>)].
Furthermore, it is important to exclude other conditions that might
mimic the HFpEF syndrome (e.g. lung disease, anaemia, obesity, and
deconditioning). For a more comprehensive overview on HFpEF, see the
ESC/HFA position statement.<sup>259</sup></p>
<h3
>8.3
The diagnosis of heart failure with preserved ejection fraction</h3>
<p>The diagnosis of HFpEF remains challenging. Several diagnostic
criteria have been proposed by societies and in clinical
trials.<sup>260</sup> These criteria vary widely in their sensitivities
and specificities for diagnosing HFpEF. More recently, two score-based
algorithms (H<sub>2</sub>FPEF and HFA-PEFF) have been proposed to aid
the diagnosis.<sup>259</sup><sup>,</sup><sup>261</sup> While the
generalizability of the scores has been tested in various trial and
observational cohorts, their diagnostic performance has
varied.<sup>262–269</sup></p>
<p>Both scores assign a substantial proportion of suspected HFpEF
patients as intermediate likelihood, wherein additional diagnostics are
proposed. Thus, depending on which score is used, different patients
will be referred for additional testing or allocated as having HFpEF.
Furthermore, physicians may not have access to all the specialized tests
recommended by the specific diagnostic algorithms. This limits the broad
clinical applicability of the scores and demonstrates the ongoing
diagnostic uncertainty in HFpEF.<sup>267</sup></p>
<p>To facilitate broad clinical application, this guideline recommends a
simplified pragmatic approach that distils the common major elements in
prior diagnostic criteria and emphasizes the most frequently used
variables widely available to clinicians. Some of these variables, in
particular, LA size (LA volume index &gt;32 mL/m<sup>2</sup>), mitral E
velocity &gt;90 cm/s, septal e′ velocity &lt;9 cm/s, E/e′ ratio &gt;9
have been shown to be pivot points beyond which the risk of CV mortality
is increased, underscoring their value.<sup>270</sup> This
recommendation is therefore consistent with the consensus document of
the HFA, and does not represent a new algorithm or diagnostic score but
rather a simplified approach. Physicians with access to expertise may
refer to the full diagnostic approach recommended by the
HFA.<sup>259</sup></p>
<p>This simplified diagnostic approach starts with assessment of
pre-test probability (see clinical characteristics above). The diagnosis
should include the following:</p>
<ol type="1">
<li><p>Symptoms and signs of HF.</p></li>
<li><p>An LVEF ≥50%.*</p></li>
<li><p>Objective evidence of cardiac structural and/or functional
abnormalities consistent with the presence of LV diastolic
dysfunction/raised LV filling pressures, including raised NPs
(<em>Table 9</em>).</p></li>
</ol>
<p>*Of note, patients with a history of overtly reduced LVEF (≤40%), who
later present with LVEF ≥50%, should be considered to have recovered
HFrEF or ‘HF with improved LVEF’ (rather than HFpEF). Continued
treatment for HFrEF is recommended in these patients.<sup>271</sup> It
is not known whether starting HF therapy in patients with recovered LVEF
is beneficial. Patients with HFpEF tend to have stable trajectory of
LVEF over time.<sup>272</sup> However, in those who develop a clinical
indication for a repeat echo during follow-up, around one third have a
decline in LVEF.<sup>273</sup></p>
<p>Table 9</p>
<p>Objective evidence of cardiac structural, functional and serological
abnormalities consistent with the presence of left ventricular diastolic
dysfunction/raised left ventricular filling
pressures<sup>259</sup><sup>,</sup><sup>261</sup></p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Parameter<sup>a</sup></th>
<th>Threshold</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LV mass index Relative wall thickness</strong> </td>
<td><span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>95</strong>
g/m<sup>2</sup> (Female), <span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>115</strong> g/m<sup>2</sup>
(Male) &gt;<strong>0.42</strong> </td>
<td>Although the presence of concentric LV remodelling or hypertrophy is
supportive, the absence of LV hypertrophy does not exclude the diagnosis
of HFpEF </td>
</tr>
<tr>
<td><strong>LA volume index<sup>a</sup></strong> </td>
<td>&gt;<strong>34</strong> mL/m<sup>2</sup> (SR) </td>
<td>In the absence of AF or valve disease, LA enlargement reflects
chronically elevated LV filling pressure (in the presence of AF, the
threshold is &gt;40 mL/m<sup>2</sup>) </td>
</tr>
<tr>
<td><strong>E/e’ ratio at rest<sup>a</sup></strong> </td>
<td><strong>&gt;9</strong> </td>
<td>Sensitivity 78%, specificity 59% for the presence of HFpEF by
invasive exercise testing, although reported accuracy has varied. A
higher cut-off of 13 had lower sensitivity (46%) but higher specificity
(86%).<sup>71</sup><sup>,</sup><sup>259</sup><sup>,</sup><sup>274</sup> </td>
</tr>
<tr>
<td><strong>NT-proBNP BNP</strong> </td>
<td>&gt;<strong>125</strong> (SR) or</td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>&gt;<strong>365</strong> (AF) pg/mL</p></li>
<li><p>&gt;<strong>35</strong> (SR) or</p></li>
<li><p>&gt;<strong>105</strong> (AF) pg/mL</p></li>
</ul>
<p>  | Up to 20% of patients with invasively proven HFpEF have NPs below
diagnostic thresholds, particularly in the presence of obesity  | |
<strong>PA systolic pressure TR velocity at rest<sup>a</sup></strong>  |
&gt;<strong>35</strong> mmHg &gt;<strong>2.8</strong> m/s  | Sensitivity
54%, specificity 85% for the presence of HFpEF by invasive exercise
testing<sup>259</sup><sup>,</sup><sup>261</sup>  |</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Parameter<sup>a</sup></th>
<th>Threshold</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LV mass index Relative wall thickness</strong> </td>
<td><span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>95</strong>
g/m<sup>2</sup> (Female), <span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>115</strong> g/m<sup>2</sup>
(Male) &gt;<strong>0.42</strong> </td>
<td>Although the presence of concentric LV remodelling or hypertrophy is
supportive, the absence of LV hypertrophy does not exclude the diagnosis
of HFpEF </td>
</tr>
<tr>
<td><strong>LA volume index<sup>a</sup></strong> </td>
<td>&gt;<strong>34</strong> mL/m<sup>2</sup> (SR) </td>
<td>In the absence of AF or valve disease, LA enlargement reflects
chronically elevated LV filling pressure (in the presence of AF, the
threshold is &gt;40 mL/m<sup>2</sup>) </td>
</tr>
<tr>
<td><strong>E/e’ ratio at rest<sup>a</sup></strong> </td>
<td><strong>&gt;9</strong> </td>
<td>Sensitivity 78%, specificity 59% for the presence of HFpEF by
invasive exercise testing, although reported accuracy has varied. A
higher cut-off of 13 had lower sensitivity (46%) but higher specificity
(86%).<sup>71</sup><sup>,</sup><sup>259</sup><sup>,</sup><sup>274</sup> </td>
</tr>
<tr>
<td><strong>NT-proBNP BNP</strong> </td>
<td>&gt;<strong>125</strong> (SR) or</td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>&gt;<strong>365</strong> (AF) pg/mL</p></li>
<li><p>&gt;<strong>35</strong> (SR) or</p></li>
<li><p>&gt;<strong>105</strong> (AF) pg/mL</p></li>
</ul>
<p>  | Up to 20% of patients with invasively proven HFpEF have NPs below
diagnostic thresholds, particularly in the presence of obesity  | |
<strong>PA systolic pressure TR velocity at rest<sup>a</sup></strong>  |
&gt;<strong>35</strong> mmHg &gt;<strong>2.8</strong> m/s  | Sensitivity
54%, specificity 85% for the presence of HFpEF by invasive exercise
testing<sup>259</sup><sup>,</sup><sup>261</sup>  |</p>
<p>AF = atrial fibrillation; BNP = B-type natriuretic peptide;
E/e’ratio = early filling velocity on transmitral Doppler/early
relaxation velocity on tissue Doppler; HFpEF = heart failure with
preserved ejection fraction; LA = left atrial; LV = left ventricular;
NP = natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic
peptide; PA = pulmonary artery; SR = sinus rhythm; TR = tricuspid
regurgitation.</p>
<p>Note: The greater the number of abnormalities present, the higher the
likelihood of HFpEF.</p>
<p>a</p>
<p>Only commonly used indices are listed in the table; for less commonly
used indices refer to the consensus document of the
ESC/HFA.<sup>259</sup></p>
<p>Table 9</p>
<p>Objective evidence of cardiac structural, functional and serological
abnormalities consistent with the presence of left ventricular diastolic
dysfunction/raised left ventricular filling
pressures<sup>259</sup><sup>,</sup><sup>261</sup></p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Parameter<sup>a</sup></th>
<th>Threshold</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LV mass index Relative wall thickness</strong> </td>
<td><span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>95</strong>
g/m<sup>2</sup> (Female), <span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>115</strong> g/m<sup>2</sup>
(Male) &gt;<strong>0.42</strong> </td>
<td>Although the presence of concentric LV remodelling or hypertrophy is
supportive, the absence of LV hypertrophy does not exclude the diagnosis
of HFpEF </td>
</tr>
<tr>
<td><strong>LA volume index<sup>a</sup></strong> </td>
<td>&gt;<strong>34</strong> mL/m<sup>2</sup> (SR) </td>
<td>In the absence of AF or valve disease, LA enlargement reflects
chronically elevated LV filling pressure (in the presence of AF, the
threshold is &gt;40 mL/m<sup>2</sup>) </td>
</tr>
<tr>
<td><strong>E/e’ ratio at rest<sup>a</sup></strong> </td>
<td><strong>&gt;9</strong> </td>
<td>Sensitivity 78%, specificity 59% for the presence of HFpEF by
invasive exercise testing, although reported accuracy has varied. A
higher cut-off of 13 had lower sensitivity (46%) but higher specificity
(86%).<sup>71</sup><sup>,</sup><sup>259</sup><sup>,</sup><sup>274</sup> </td>
</tr>
<tr>
<td><strong>NT-proBNP BNP</strong> </td>
<td>&gt;<strong>125</strong> (SR) or</td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>&gt;<strong>365</strong> (AF) pg/mL</p></li>
<li><p>&gt;<strong>35</strong> (SR) or</p></li>
<li><p>&gt;<strong>105</strong> (AF) pg/mL</p></li>
</ul>
<p>  | Up to 20% of patients with invasively proven HFpEF have NPs below
diagnostic thresholds, particularly in the presence of obesity  | |
<strong>PA systolic pressure TR velocity at rest<sup>a</sup></strong>  |
&gt;<strong>35</strong> mmHg &gt;<strong>2.8</strong> m/s  | Sensitivity
54%, specificity 85% for the presence of HFpEF by invasive exercise
testing<sup>259</sup><sup>,</sup><sup>261</sup>  |</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Parameter<sup>a</sup></th>
<th>Threshold</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LV mass index Relative wall thickness</strong> </td>
<td><span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>95</strong>
g/m<sup>2</sup> (Female), <span >$&lt;math
xmlns="http://www.w3.org/1998/Math/MathML"&gt;&lt;mo
xmlns=""&gt;≥&lt;/mo&gt;&lt;/math&gt;$</span><strong>115</strong> g/m<sup>2</sup>
(Male) &gt;<strong>0.42</strong> </td>
<td>Although the presence of concentric LV remodelling or hypertrophy is
supportive, the absence of LV hypertrophy does not exclude the diagnosis
of HFpEF </td>
</tr>
<tr>
<td><strong>LA volume index<sup>a</sup></strong> </td>
<td>&gt;<strong>34</strong> mL/m<sup>2</sup> (SR) </td>
<td>In the absence of AF or valve disease, LA enlargement reflects
chronically elevated LV filling pressure (in the presence of AF, the
threshold is &gt;40 mL/m<sup>2</sup>) </td>
</tr>
<tr>
<td><strong>E/e’ ratio at rest<sup>a</sup></strong> </td>
<td><strong>&gt;9</strong> </td>
<td>Sensitivity 78%, specificity 59% for the presence of HFpEF by
invasive exercise testing, although reported accuracy has varied. A
higher cut-off of 13 had lower sensitivity (46%) but higher specificity
(86%).<sup>71</sup><sup>,</sup><sup>259</sup><sup>,</sup><sup>274</sup> </td>
</tr>
<tr>
<td><strong>NT-proBNP BNP</strong> </td>
<td>&gt;<strong>125</strong> (SR) or</td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>&gt;<strong>365</strong> (AF) pg/mL</p></li>
<li><p>&gt;<strong>35</strong> (SR) or</p></li>
<li><p>&gt;<strong>105</strong> (AF) pg/mL</p></li>
</ul>
<p>  | Up to 20% of patients with invasively proven HFpEF have NPs below
diagnostic thresholds, particularly in the presence of obesity  | |
<strong>PA systolic pressure TR velocity at rest<sup>a</sup></strong>  |
&gt;<strong>35</strong> mmHg &gt;<strong>2.8</strong> m/s  | Sensitivity
54%, specificity 85% for the presence of HFpEF by invasive exercise
testing<sup>259</sup><sup>,</sup><sup>261</sup>  |</p>
<p>AF = atrial fibrillation; BNP = B-type natriuretic peptide;
E/e’ratio = early filling velocity on transmitral Doppler/early
relaxation velocity on tissue Doppler; HFpEF = heart failure with
preserved ejection fraction; LA = left atrial; LV = left ventricular;
NP = natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic
peptide; PA = pulmonary artery; SR = sinus rhythm; TR = tricuspid
regurgitation.</p>
<p>Note: The greater the number of abnormalities present, the higher the
likelihood of HFpEF.</p>
<p>a</p>
<p>Only commonly used indices are listed in the table; for less commonly
used indices refer to the consensus document of the
ESC/HFA.<sup>259</sup></p>
<p>In the presence of AF, the threshold for LA volume index is &gt;40
mL/m<sup>2</sup>. Exercise stress thresholds include E/e′ ratio at peak
stress ≥15 or tricuspid regurgitation (TR) velocity at peak stress
&gt;3.4 m/s.<sup>275</sup> LV global longitudinal strain &lt;16% has a
sensitivity of 62% and a specificity of 56% for the diagnosis of HFpEF
by invasive testing.<sup>261</sup></p>
<p>The approach to the diagnosis should involve additional confirmatory
tests in cases of diagnostic uncertainty, such as cardiopulmonary
exercise testing (to confirm a reduction in exercise capacity and to
help differentiate the cause of dyspnoea), exercise stress testing, and
invasive haemodynamic testing.<sup>259</sup></p>
<p>If resting echocardiographic and laboratory markers are equivocal, a
diastolic stress test is
recommended.<sup>259</sup><sup>,</sup><sup>274</sup> The confirmatory
test for the diagnosis of HFpEF is invasive haemodynamic exercise
testing. An invasively measured pulmonary capillary wedge pressure
(PCWP) of ≥15 mmHg (at rest) or ≥25 mmHg (with exercise) or LV
end-diastolic pressure ≥16 mmHg (at rest) is generally considered
diagnostic.<sup>266</sup> However, instead of an exercise PCWP cut-off,
some have used an index of PCWP to cardiac output for the invasive
diagnosis of HFpEF<sup>260</sup><sup>,</sup><sup>276</sup>. Recognizing
that invasive haemodynamic exercise testing is not available in many
centres worldwide, and is associated with risks, its main use is limited
to the research setting. In the absence of any disease-modifying
treatments, the current guidelines do not mandate gold standard testing
in every patient to make the diagnosis, but emphasize that the greater
the number of objective non-invasive markers of raised LV filling
pressures (<em>Table 9</em>), the higher the probability of a diagnosis
of HFpEF.</p>
<h3 >8.4
Treatment of heart failure with preserved ejection fraction</h3>
<p>To date, no treatment has been shown to convincingly reduce mortality
and morbidity in patients with HFpEF, although improvements have been
seen for some specific phenotypes of patients within the overall HFpEF
umbrella. However, none of the large RCTs conducted in HFpEF have
achieved their primary endpoints. These include PEP-CHF
(perindopril),<sup>277</sup> CHARM-Preserved
(candesartan),<sup>245</sup> I-PRESERVE (irbesartan),<sup>278</sup>
TOPCAT (spironolactone),<sup>246</sup> DIG-Preserved
(digoxin),<sup>279</sup> and PARAGON-HF
(sacubitril/valsartan)<sup>13</sup> (see <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 12</a></em> for the details about these and additional trials).
Hospitalizations for HF were reduced by candesartan and spironolactone
and there was a trend towards reduction with sacubitril/valsartan,
although as these trials were neutral for their primary endpoints, these
are hypothesis-generating findings only. Although nebivolol
significantly reduced the combined primary endpoint of all-cause
mortality or CV hospital admission in the SENIORS trial, this trial
included only 15% with an LVEF
&gt;50%.<sup>119</sup><sup>,</sup><sup>249</sup> Trials targeting the
nitric oxide-cyclic guanosine monophosphate pathway have also failed to
improve exercise capacity or QOL in HFpEF,
e.g. NEAT-HFpEF,<sup>280</sup> INDIE-HFpEF,<sup>281</sup>
VITALITY-HFpEF,<sup>282</sup> and CAPACITY-HFpEF
(praliciguat).<sup>283</sup></p>
<p>Despite the lack of evidence for specific disease-modifying therapies
in HFpEF, as the vast majority of HFpEF patients have underlying
hypertension and/or CAD, many are already treated with ACE-I/ARB,
beta-blockers, or MRAs. In the PARAGON-HF study at baseline, more than
86% of patients were on ACE-I/ARBs, 80% were on beta-blockers, and more
than 24% were on MRAs.<sup>13</sup></p>
<p>The Task Force acknowledge that the treatment options for HFpEF are
being revised as this guideline is being published. We note that the
Food and Drug Administration (FDA) has endorsed the use of
sacubitril/valsartan and spironolactone in those with an LVEF ‘less than
normal’. These statements relate to patients within both the HFmrEF and
HFpEF categories. For sacubitril/valsartan, this decision was based on
the subgroup analysis from the PARAGON-HF study, which showed a
reduction in HF hospitalizations in those with an LVEF &lt;57%, and a
meta-analysis of the PARADIGM-HF and PARAGON-HF studies, showing a
reduction in CV death and HF hospitalization in those with an LVEF below
the normal range.<sup>247</sup> Regarding spironolactone, the subgroup
of individuals in the TOPCAT study recruited in the Americas had a
significant reduction in the primary endpoint of CV death and HF
hospitalization, and a subsequent post hoc analysis by EF showed a
significant reduction in outcomes for those with an LVEF
&lt;55%.<sup>9</sup><sup>,</sup><sup>247</sup> There are also ongoing
trials with SGLT2 inhibitors. These developments may well accelerate a
redefinition of HFpEF in the future and have therapeutic
implications.</p>
<p>In the absence of recommendations regarding disease-modifying
therapies, treatment should be aimed at reducing symptoms of congestion
with diuretics. Loop diuretics are preferred, although thiazide
diuretics may be useful for managing hypertension. Reducing body weight
in obese patients and increasing exercise may further improve symptoms
and exercise capacity and should therefore be considered in appropriate
patients.<sup>284</sup><sup>,</sup><sup>285</sup></p>
<p>It is important to identify and treat the underlying risk factors,
aetiology, and coexisting comorbidities in HFpEF (e.g. hypertension in
<a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.4">section
12.4</a>, CAD in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.2">section
12.2</a>, amyloidosis in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section
14.6</a>, AF in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.1.1">section
12.1.1</a>, and valvular heart disease in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.3">section 12.3</a>).
Undoubtably, treatment of some of the underlying phenotypes of the the
HFpEF syndrome leads to improved outcomes.</p>
<p>Recommendations for the treatment of patients with heart failure with
preserved ejection fraction</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34a.jpeg?Expires=1689850106&amp;Signature=a8qd4UpMX5E0IU2wfhQ9U7YCU4wgQzN1uB5ehPlDtds7RoQpkU4HapcyFO4WzQDVDZLSZqbMg9ZnPHtRQtZ4PO1yB8frs7jrgRkDba6qiVhGqNctD7Atuv6dFT1LwBQCwSuWVe77bgxFKJUSardGvm-wXxSd2-RMwIPi9-MVr~00-qoQHd4K4HzJ91RPkxKChQ-OPPCYI16EZfqBXetaqZa8zypqIiySQ5xrY7upQjaQS8GcjzY-3~tGvjKQtLRnYFAV30~0cHtej~z5ITpb-6ohHOebo0HQrFujB4yBIZrsjV4ldsBgSveEtXrmczGSob~3D1CqqOB6HdUkmkqEXw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34a.jpeg?Expires=1689850106&amp;Signature=a8qd4UpMX5E0IU2wfhQ9U7YCU4wgQzN1uB5ehPlDtds7RoQpkU4HapcyFO4WzQDVDZLSZqbMg9ZnPHtRQtZ4PO1yB8frs7jrgRkDba6qiVhGqNctD7Atuv6dFT1LwBQCwSuWVe77bgxFKJUSardGvm-wXxSd2-RMwIPi9-MVr~00-qoQHd4K4HzJ91RPkxKChQ-OPPCYI16EZfqBXetaqZa8zypqIiySQ5xrY7upQjaQS8GcjzY-3~tGvjKQtLRnYFAV30~0cHtej~z5ITpb-6ohHOebo0HQrFujB4yBIZrsjV4ldsBgSveEtXrmczGSob~3D1CqqOB6HdUkmkqEXw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HFpEF = heart failure with preserved ejection fraction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the treatment of patients with heart failure with
preserved ejection fraction</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34a.jpeg?Expires=1689850106&amp;Signature=a8qd4UpMX5E0IU2wfhQ9U7YCU4wgQzN1uB5ehPlDtds7RoQpkU4HapcyFO4WzQDVDZLSZqbMg9ZnPHtRQtZ4PO1yB8frs7jrgRkDba6qiVhGqNctD7Atuv6dFT1LwBQCwSuWVe77bgxFKJUSardGvm-wXxSd2-RMwIPi9-MVr~00-qoQHd4K4HzJ91RPkxKChQ-OPPCYI16EZfqBXetaqZa8zypqIiySQ5xrY7upQjaQS8GcjzY-3~tGvjKQtLRnYFAV30~0cHtej~z5ITpb-6ohHOebo0HQrFujB4yBIZrsjV4ldsBgSveEtXrmczGSob~3D1CqqOB6HdUkmkqEXw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34a.jpeg?Expires=1689850106&amp;Signature=a8qd4UpMX5E0IU2wfhQ9U7YCU4wgQzN1uB5ehPlDtds7RoQpkU4HapcyFO4WzQDVDZLSZqbMg9ZnPHtRQtZ4PO1yB8frs7jrgRkDba6qiVhGqNctD7Atuv6dFT1LwBQCwSuWVe77bgxFKJUSardGvm-wXxSd2-RMwIPi9-MVr~00-qoQHd4K4HzJ91RPkxKChQ-OPPCYI16EZfqBXetaqZa8zypqIiySQ5xrY7upQjaQS8GcjzY-3~tGvjKQtLRnYFAV30~0cHtej~z5ITpb-6ohHOebo0HQrFujB4yBIZrsjV4ldsBgSveEtXrmczGSob~3D1CqqOB6HdUkmkqEXw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HFpEF = heart failure with preserved ejection fraction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h2
>9
Multidisciplinary team management for the prevention and treatment of
chronic heart failure</h2>
<h3 >9.1 Prevention of heart
failure</h3>
<p>General advice about risk factors for the development of HF (see
<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Figure 1</a></em>) and strategies to prevent HF early in the CV
continuum are summarized in <em>Table 10</em>.</p>
<p>Table 10</p>
<p>Risk factors for the development of heart failure and potential
corrective actions</p>
<table>
<thead>
<tr>
<th>Risk factors for heart failure</th>
<th>Preventive strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedentary habit </td>
<td>Regular physical activity </td>
</tr>
<tr>
<td>Cigarette smoking </td>
<td>Cigarette smoking cessation </td>
</tr>
<tr>
<td>Obesity </td>
<td>Physical activity and healthy diet </td>
</tr>
<tr>
<td>Excessive alcohol intake<sup>286</sup> </td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>General population: no/light alcohol intake is
beneficial</p></li>
<li><p>Patients with alcohol-induced CMP should abstain from
alcohol</p></li>
</ul>
<p>  | | Influenza  | Influenza vaccination  | | Microbes
(e.g. <em>Trypanosoma cruzi</em>, Streptococci)  | Early diagnosis,
specific antimicrobial therapy for either prevention and/or treatment  |
| Cardiotoxic drugs (e.g., anthracyclines)  | Cardiac function and side
effect monitoring, dose adaptation, change of chemotherapy  | | Chest
radiation  | Cardiac function and side effect monitoring, dose
adaptation  | | Hypertension  | Lifestyle changes, antihypertensive
therapy  | | Dyslipidaemia  | Healthy diet, statins  | | Diabetes
mellitus  | Physical activity and healthy diet, SGLT2 inhibitors  | |
CAD  | Lifestyle changes, statin therapy  |</p>
<table>
<thead>
<tr>
<th>Risk factors for heart failure</th>
<th>Preventive strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedentary habit </td>
<td>Regular physical activity </td>
</tr>
<tr>
<td>Cigarette smoking </td>
<td>Cigarette smoking cessation </td>
</tr>
<tr>
<td>Obesity </td>
<td>Physical activity and healthy diet </td>
</tr>
<tr>
<td>Excessive alcohol intake<sup>286</sup> </td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>General population: no/light alcohol intake is
beneficial</p></li>
<li><p>Patients with alcohol-induced CMP should abstain from
alcohol</p></li>
</ul>
<p>  | | Influenza  | Influenza vaccination  | | Microbes
(e.g. <em>Trypanosoma cruzi</em>, Streptococci)  | Early diagnosis,
specific antimicrobial therapy for either prevention and/or treatment  |
| Cardiotoxic drugs (e.g., anthracyclines)  | Cardiac function and side
effect monitoring, dose adaptation, change of chemotherapy  | | Chest
radiation  | Cardiac function and side effect monitoring, dose
adaptation  | | Hypertension  | Lifestyle changes, antihypertensive
therapy  | | Dyslipidaemia  | Healthy diet, statins  | | Diabetes
mellitus  | Physical activity and healthy diet, SGLT2 inhibitors  | |
CAD  | Lifestyle changes, statin therapy  |</p>
<p>CAD = coronary artery disease; CMP = cardiomyopathy;
SGLT2 = sodium-glucose co-transporter 2.</p>
<p>Table 10</p>
<p>Risk factors for the development of heart failure and potential
corrective actions</p>
<table>
<thead>
<tr>
<th>Risk factors for heart failure</th>
<th>Preventive strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedentary habit </td>
<td>Regular physical activity </td>
</tr>
<tr>
<td>Cigarette smoking </td>
<td>Cigarette smoking cessation </td>
</tr>
<tr>
<td>Obesity </td>
<td>Physical activity and healthy diet </td>
</tr>
<tr>
<td>Excessive alcohol intake<sup>286</sup> </td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>General population: no/light alcohol intake is
beneficial</p></li>
<li><p>Patients with alcohol-induced CMP should abstain from
alcohol</p></li>
</ul>
<p>  | | Influenza  | Influenza vaccination  | | Microbes
(e.g. <em>Trypanosoma cruzi</em>, Streptococci)  | Early diagnosis,
specific antimicrobial therapy for either prevention and/or treatment  |
| Cardiotoxic drugs (e.g., anthracyclines)  | Cardiac function and side
effect monitoring, dose adaptation, change of chemotherapy  | | Chest
radiation  | Cardiac function and side effect monitoring, dose
adaptation  | | Hypertension  | Lifestyle changes, antihypertensive
therapy  | | Dyslipidaemia  | Healthy diet, statins  | | Diabetes
mellitus  | Physical activity and healthy diet, SGLT2 inhibitors  | |
CAD  | Lifestyle changes, statin therapy  |</p>
<table>
<thead>
<tr>
<th>Risk factors for heart failure</th>
<th>Preventive strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedentary habit </td>
<td>Regular physical activity </td>
</tr>
<tr>
<td>Cigarette smoking </td>
<td>Cigarette smoking cessation </td>
</tr>
<tr>
<td>Obesity </td>
<td>Physical activity and healthy diet </td>
</tr>
<tr>
<td>Excessive alcohol intake<sup>286</sup> </td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>General population: no/light alcohol intake is
beneficial</p></li>
<li><p>Patients with alcohol-induced CMP should abstain from
alcohol</p></li>
</ul>
<p>  | | Influenza  | Influenza vaccination  | | Microbes
(e.g. <em>Trypanosoma cruzi</em>, Streptococci)  | Early diagnosis,
specific antimicrobial therapy for either prevention and/or treatment  |
| Cardiotoxic drugs (e.g., anthracyclines)  | Cardiac function and side
effect monitoring, dose adaptation, change of chemotherapy  | | Chest
radiation  | Cardiac function and side effect monitoring, dose
adaptation  | | Hypertension  | Lifestyle changes, antihypertensive
therapy  | | Dyslipidaemia  | Healthy diet, statins  | | Diabetes
mellitus  | Physical activity and healthy diet, SGLT2 inhibitors  | |
CAD  | Lifestyle changes, statin therapy  |</p>
<p>CAD = coronary artery disease; CMP = cardiomyopathy;
SGLT2 = sodium-glucose co-transporter 2.</p>
<p>Recommendations for the primary prevention of heart failure in
patients with risk factors for its development</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34b.jpeg?Expires=1689850106&amp;Signature=kWe5HM~MW2JugEfkZv8PTcP4431VtYTRrcaL-lxCrq8gDf~uZNVnlIzCoyWHtYCLKsHgPkP7LHQeRlI66KQtDkLaRO5o13B0CyqFuRiSKqmOuOE-ff1bzG-BI~i9Bq5K9PUQgfF1ovUWMW6KP1KqgmVWQhOykuL19gj0fVl8Ub1L72SDJA2Q6P~qLwj2GKm~O0APKg1FOvahAXrC7ESO9rfDvXXurorj76EfYZpvXII2f73faRWvJ2fcp4PqRzmPQUV-yYxQU73hj-ikE~uzSMVW0vgpfdXnBxhknDuXu9DAVamIIhZ1lTOtMCu2GHCzpyKqXT64jr7ba2rKstv-yg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34b.jpeg?Expires=1689850106&amp;Signature=kWe5HM~MW2JugEfkZv8PTcP4431VtYTRrcaL-lxCrq8gDf~uZNVnlIzCoyWHtYCLKsHgPkP7LHQeRlI66KQtDkLaRO5o13B0CyqFuRiSKqmOuOE-ff1bzG-BI~i9Bq5K9PUQgfF1ovUWMW6KP1KqgmVWQhOykuL19gj0fVl8Ub1L72SDJA2Q6P~qLwj2GKm~O0APKg1FOvahAXrC7ESO9rfDvXXurorj76EfYZpvXII2f73faRWvJ2fcp4PqRzmPQUV-yYxQU73hj-ikE~uzSMVW0vgpfdXnBxhknDuXu9DAVamIIhZ1lTOtMCu2GHCzpyKqXT64jr7ba2rKstv-yg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CV = cardiovascular; HF = heart failure; SGLT2 = sodium-glucose
co-transporter 2.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the primary prevention of heart failure in
patients with risk factors for its development</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34b.jpeg?Expires=1689850106&amp;Signature=kWe5HM~MW2JugEfkZv8PTcP4431VtYTRrcaL-lxCrq8gDf~uZNVnlIzCoyWHtYCLKsHgPkP7LHQeRlI66KQtDkLaRO5o13B0CyqFuRiSKqmOuOE-ff1bzG-BI~i9Bq5K9PUQgfF1ovUWMW6KP1KqgmVWQhOykuL19gj0fVl8Ub1L72SDJA2Q6P~qLwj2GKm~O0APKg1FOvahAXrC7ESO9rfDvXXurorj76EfYZpvXII2f73faRWvJ2fcp4PqRzmPQUV-yYxQU73hj-ikE~uzSMVW0vgpfdXnBxhknDuXu9DAVamIIhZ1lTOtMCu2GHCzpyKqXT64jr7ba2rKstv-yg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table34b.jpeg?Expires=1689850106&amp;Signature=kWe5HM~MW2JugEfkZv8PTcP4431VtYTRrcaL-lxCrq8gDf~uZNVnlIzCoyWHtYCLKsHgPkP7LHQeRlI66KQtDkLaRO5o13B0CyqFuRiSKqmOuOE-ff1bzG-BI~i9Bq5K9PUQgfF1ovUWMW6KP1KqgmVWQhOykuL19gj0fVl8Ub1L72SDJA2Q6P~qLwj2GKm~O0APKg1FOvahAXrC7ESO9rfDvXXurorj76EfYZpvXII2f73faRWvJ2fcp4PqRzmPQUV-yYxQU73hj-ikE~uzSMVW0vgpfdXnBxhknDuXu9DAVamIIhZ1lTOtMCu2GHCzpyKqXT64jr7ba2rKstv-yg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CV = cardiovascular; HF = heart failure; SGLT2 = sodium-glucose
co-transporter 2.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>It is widely recognized that, in addition to optimizing medical and
device therapies for HF, attention should also be given to how HF care
is delivered. The HFA of the ESC has issued several position papers that
cover non-pharmacological management, discharge planning, and standards
for delivering HF care.<sup>303–305</sup> It has also underscored the
need for specialist HF cardiologists and specialist HF nurses to help
provide care. Detailed curricula, to aid training of these, are
available to be adapted for national
implementation.<sup>306</sup><sup>,</sup><sup>307</sup> This section
focuses on areas where recommendations with an evidence level can be
given: multidisciplinary team management, lifestyle advice, exercise
training, follow-up, and monitoring.</p>
<h3 >9.2
Multidisciplinary management of chronic heart failure</h3>
<p><strong>9.2.1 Models of care</strong></p>
<p>In order to reduce hospitalizations and mortality, earlier
guidelines<sup>1</sup> recommended the use of multidisciplinary HF
management programmes (HF-MPs), which enable patients to have the
correct investigations, an accurate diagnosis, appropriate
evidence-based therapy, education, and suitable follow-up. The optimal
implementation of a HF-MP requires a multidisciplinary team that is
active along the whole HF trajectory; from onset, through critical
events, periods of apparent stability, and its terminal
stages.<sup>303</sup> Since the 2016 guidelines, new studies have been
published that underscore the need for HF-MPs and reveal more insights
into how care can be delivered.</p>
<p>A network meta-analysis including 53 randomized trials published in
2017, concluded that both disease-management clinics and home visits by
nurses reduced all-cause mortality compared to usual care; home visits
being most effective.<sup>308</sup> An IPD meta-analysis of 20 studies,
including 5624 patients, concluded that self-management interventions in
HF patients improve outcomes despite heterogeneity in the intensity,
content, and the personnel who deliver the
interventions.<sup>309</sup></p>
<p>HF-MPs vary in their components and can apply different service
models, such as clinic-based approaches (in primary, secondary, or
tertiary care), home-based programmes, case management, or hybrids of
these. Components used in the services vary, e.g. some HF-MPs use
telemonitoring that may be applied at a local, regional, or national
level. No service model has been shown to be consistently superior to
others.<sup>310</sup> While home visits and HF clinics do reduce
all-cause admissions and mortality, educational programmes, used alone,
do not.<sup>308</sup><sup>,</sup><sup>309</sup> HF-MPs should be
patient-centred and take a holistic approach to the patient rather than
focussing solely on HF; management of comorbid conditions, such as
arrhythmias, hypertension, diabetes, renal dysfunction, and depression,
improve patient well-being and self-management, leading to better
outcomes.<sup>309</sup><sup>,</sup><sup>311</sup> The organization of a
HF-MP should be adapted to the healthcare system, available resources
(infrastructure, facilities, staff, and finances), administrative
policies, and tailored to the patient’s needs.</p>
<p>Many patients with HF would derive benefit from the early integration
of a palliative and supportive approach within the care provided by all
members of the HF multidisciplinary
team.<sup>312</sup><sup>,</sup><sup>313</sup> Palliative and supportive
care should be thought about for all patients with HF, regardless of
stage of their illness. Patients in the advanced stages and those
considered for mechanical circulatory support (MCS) or heart
transplantation should receive a palliative care consultation before
such interventions as a matter of protocol (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-10.2.4">section
10.2.4</a>).</p>
<p><strong>9.2.2 Characteristics and components of a heart failure
management programme</strong></p>
<p>Clinical trials have included complex, bundled interventions, making
it difficult to determine the efficiency and effectiveness of each
specific component. <em>Table 11</em> presents an overview of
characteristics and components that are important to consider in a
HF-MP.</p>
<p>Multidisciplinary interventions recommended for the management of
chronic heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table35.jpeg?Expires=1689850106&amp;Signature=0LkTGta6etawvPq1fQYzJdFlIjmwltry~byEDKn5w5JRDMaMznKU7wYBgXb-fFSKgYoc2AMaRsm249m7vT~sO1vZKDtwEHv7rIeCZow43Ldx~g7NmX4jcPkLQWz0rm7Pm2Iyk0kGB~EmVCUDrEd-oez9glrmysGbZlspSm3VI4do1Wczq79MpERqfuIcMjlh~T~Xclii6x4kcZBWeXNzfgi1YxT60siY-FlCz4K9X~x4bWs85AV7J1GsSETN~UXfV~LpfN2ep6WEdmygrWxsfATEfog47zPluwXzNrqksNrWfeshWYGdwCVTxJEQXfMGJRsj9FVnLoaaVJkcLxrSTQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table35.jpeg?Expires=1689850106&amp;Signature=0LkTGta6etawvPq1fQYzJdFlIjmwltry~byEDKn5w5JRDMaMznKU7wYBgXb-fFSKgYoc2AMaRsm249m7vT~sO1vZKDtwEHv7rIeCZow43Ldx~g7NmX4jcPkLQWz0rm7Pm2Iyk0kGB~EmVCUDrEd-oez9glrmysGbZlspSm3VI4do1Wczq79MpERqfuIcMjlh~T~Xclii6x4kcZBWeXNzfgi1YxT60siY-FlCz4K9X~x4bWs85AV7J1GsSETN~UXfV~LpfN2ep6WEdmygrWxsfATEfog47zPluwXzNrqksNrWfeshWYGdwCVTxJEQXfMGJRsj9FVnLoaaVJkcLxrSTQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Multidisciplinary interventions recommended for the management of
chronic heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table35.jpeg?Expires=1689850106&amp;Signature=0LkTGta6etawvPq1fQYzJdFlIjmwltry~byEDKn5w5JRDMaMznKU7wYBgXb-fFSKgYoc2AMaRsm249m7vT~sO1vZKDtwEHv7rIeCZow43Ldx~g7NmX4jcPkLQWz0rm7Pm2Iyk0kGB~EmVCUDrEd-oez9glrmysGbZlspSm3VI4do1Wczq79MpERqfuIcMjlh~T~Xclii6x4kcZBWeXNzfgi1YxT60siY-FlCz4K9X~x4bWs85AV7J1GsSETN~UXfV~LpfN2ep6WEdmygrWxsfATEfog47zPluwXzNrqksNrWfeshWYGdwCVTxJEQXfMGJRsj9FVnLoaaVJkcLxrSTQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table35.jpeg?Expires=1689850106&amp;Signature=0LkTGta6etawvPq1fQYzJdFlIjmwltry~byEDKn5w5JRDMaMznKU7wYBgXb-fFSKgYoc2AMaRsm249m7vT~sO1vZKDtwEHv7rIeCZow43Ldx~g7NmX4jcPkLQWz0rm7Pm2Iyk0kGB~EmVCUDrEd-oez9glrmysGbZlspSm3VI4do1Wczq79MpERqfuIcMjlh~T~Xclii6x4kcZBWeXNzfgi1YxT60siY-FlCz4K9X~x4bWs85AV7J1GsSETN~UXfV~LpfN2ep6WEdmygrWxsfATEfog47zPluwXzNrqksNrWfeshWYGdwCVTxJEQXfMGJRsj9FVnLoaaVJkcLxrSTQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Table 11</p>
<p>Important characteristics and components in a heart failure
management programme</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Characteristics</strong>
<ol>
<li>
<p>
 1. Patient/person-centred<span
></span><span><sup>318</sup></span>
</p>
</li>
<li>
<p>
 2. Multidisciplinary
</p>
</li>
<li>
<p>
 3. The focus of the programme should be flexible and include:
</p>
<ul>
<li>
<p>
prevention of disease progression
</p>
</li>
<li>
<p>
symptom control
</p>
</li>
<li>
<p>
maintaining patients in their preferred place of care for end-stage
heart failure
</p>
</li>
</ul>
</li>
<li>
<p>
 4. Competent and professionally educated staff
</p>
</li>
<li>
<p>
 5. Encourage patient/carer engagement in the understanding and
management of their condition
</p>
</li>
</ol>
 
</td>
</tr>
<tr>
<td>
<strong>Components</strong>
<ol>
<li>
<p>
 1. Optimized management; lifestyle choices, pharmacological, and
devices
</p>
</li>
<li>
<p>
 2. Patient education, with special emphasis on self-care and symptom
management
</p>
</li>
<li>
<p>
 3. Provision of psychosocial support to patients and family caregivers
</p>
</li>
<li>
<p>
 4. Follow-up after discharge (clinic; home visits; telephone support or
telemonitoring)
</p>
</li>
<li>
<p>
 5. Easy access to healthcare, especially to prevent and manage
decompensation
</p>
</li>
<li>
<p>
 6. Assessment of (and appropriate intervention in response to) an
unexplained change in weight, nutritional and functional status, quality
of life, sleep problems, psychosocial problems or other findings (e.g.,
laboratory values)
</p>
</li>
<li>
<p>
 7. Access to advanced treatment options; supportive and palliative care
</p>
</li>
</ol>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Characteristics</strong>
<ol>
<li>
<p>
 1. Patient/person-centred<span
></span><span><sup>318</sup></span>
</p>
</li>
<li>
<p>
 2. Multidisciplinary
</p>
</li>
<li>
<p>
 3. The focus of the programme should be flexible and include:
</p>
<ul>
<li>
<p>
prevention of disease progression
</p>
</li>
<li>
<p>
symptom control
</p>
</li>
<li>
<p>
maintaining patients in their preferred place of care for end-stage
heart failure
</p>
</li>
</ul>
</li>
<li>
<p>
 4. Competent and professionally educated staff
</p>
</li>
<li>
<p>
 5. Encourage patient/carer engagement in the understanding and
management of their condition
</p>
</li>
</ol>
 
</td>
</tr>
<tr>
<td>
<strong>Components</strong>
<ol>
<li>
<p>
 1. Optimized management; lifestyle choices, pharmacological, and
devices
</p>
</li>
<li>
<p>
 2. Patient education, with special emphasis on self-care and symptom
management
</p>
</li>
<li>
<p>
 3. Provision of psychosocial support to patients and family caregivers
</p>
</li>
<li>
<p>
 4. Follow-up after discharge (clinic; home visits; telephone support or
telemonitoring)
</p>
</li>
<li>
<p>
 5. Easy access to healthcare, especially to prevent and manage
decompensation
</p>
</li>
<li>
<p>
 6. Assessment of (and appropriate intervention in response to) an
unexplained change in weight, nutritional and functional status, quality
of life, sleep problems, psychosocial problems or other findings (e.g.,
laboratory values)
</p>
</li>
<li>
<p>
 7. Access to advanced treatment options; supportive and palliative care
</p>
</li>
</ol>
 
</td>
</tr>
</tbody>
</table>
<p>HF = heart failure; QOL = quality of life.</p>
<p>Table 11</p>
<p>Important characteristics and components in a heart failure
management programme</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Characteristics</strong>
<ol>
<li>
<p>
 1. Patient/person-centred<span
></span><span><sup>318</sup></span>
</p>
</li>
<li>
<p>
 2. Multidisciplinary
</p>
</li>
<li>
<p>
 3. The focus of the programme should be flexible and include:
</p>
<ul>
<li>
<p>
prevention of disease progression
</p>
</li>
<li>
<p>
symptom control
</p>
</li>
<li>
<p>
maintaining patients in their preferred place of care for end-stage
heart failure
</p>
</li>
</ul>
</li>
<li>
<p>
 4. Competent and professionally educated staff
</p>
</li>
<li>
<p>
 5. Encourage patient/carer engagement in the understanding and
management of their condition
</p>
</li>
</ol>
 
</td>
</tr>
<tr>
<td>
<strong>Components</strong>
<ol>
<li>
<p>
 1. Optimized management; lifestyle choices, pharmacological, and
devices
</p>
</li>
<li>
<p>
 2. Patient education, with special emphasis on self-care and symptom
management
</p>
</li>
<li>
<p>
 3. Provision of psychosocial support to patients and family caregivers
</p>
</li>
<li>
<p>
 4. Follow-up after discharge (clinic; home visits; telephone support or
telemonitoring)
</p>
</li>
<li>
<p>
 5. Easy access to healthcare, especially to prevent and manage
decompensation
</p>
</li>
<li>
<p>
 6. Assessment of (and appropriate intervention in response to) an
unexplained change in weight, nutritional and functional status, quality
of life, sleep problems, psychosocial problems or other findings (e.g.,
laboratory values)
</p>
</li>
<li>
<p>
 7. Access to advanced treatment options; supportive and palliative care
</p>
</li>
</ol>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Characteristics</strong>
<ol>
<li>
<p>
 1. Patient/person-centred<span
></span><span><sup>318</sup></span>
</p>
</li>
<li>
<p>
 2. Multidisciplinary
</p>
</li>
<li>
<p>
 3. The focus of the programme should be flexible and include:
</p>
<ul>
<li>
<p>
prevention of disease progression
</p>
</li>
<li>
<p>
symptom control
</p>
</li>
<li>
<p>
maintaining patients in their preferred place of care for end-stage
heart failure
</p>
</li>
</ul>
</li>
<li>
<p>
 4. Competent and professionally educated staff
</p>
</li>
<li>
<p>
 5. Encourage patient/carer engagement in the understanding and
management of their condition
</p>
</li>
</ol>
 
</td>
</tr>
<tr>
<td>
<strong>Components</strong>
<ol>
<li>
<p>
 1. Optimized management; lifestyle choices, pharmacological, and
devices
</p>
</li>
<li>
<p>
 2. Patient education, with special emphasis on self-care and symptom
management
</p>
</li>
<li>
<p>
 3. Provision of psychosocial support to patients and family caregivers
</p>
</li>
<li>
<p>
 4. Follow-up after discharge (clinic; home visits; telephone support or
telemonitoring)
</p>
</li>
<li>
<p>
 5. Easy access to healthcare, especially to prevent and manage
decompensation
</p>
</li>
<li>
<p>
 6. Assessment of (and appropriate intervention in response to) an
unexplained change in weight, nutritional and functional status, quality
of life, sleep problems, psychosocial problems or other findings (e.g.,
laboratory values)
</p>
</li>
<li>
<p>
 7. Access to advanced treatment options; supportive and palliative care
</p>
</li>
</ol>
 
</td>
</tr>
</tbody>
</table>
<p>HF = heart failure; QOL = quality of life.</p>
<h3 >9.3 Patient
education, self-care and lifestyle advice</h3>
<p>Adequate patient self-care is essential in the effective management
of HF and allows patients to understand what is beneficial, and to agree
to self-monitoring and management plans.<sup>319</sup> HF patients who
report more effective self-care have a better QOL, lower readmission
rates, and reduced mortality.<sup>309</sup></p>
<p>Misunderstandings, misconceptions, and lack of knowledge all
contribute to insufficient self-care and therefore patient education is
vital. Improving patients’ knowledge of their condition is fundamental
for the development of self-care skills.<sup>304</sup></p>
<p>Education to improve self-care should be tailored to the individual
patient and based on, where available, scientific evidence or expert
opinion. There is little evidence that specific lifestyle advice
improves QOL or prognosis; however, providing this information has
become a key component of education for self-care.</p>
<p>General educational approaches include:</p>
<ul>
<li><p>Providing information in a variety of formats that take into
account educational grade and health literacy. Consider approaches with
active roles for patients and caregivers such as ‘ask-tell-ask’, ‘teach
back’, or motivational interviewing. Reinforce messages at regular time
intervals.</p></li>
<li><p>Recognizing barriers to communication (language, social skills,
cognition, anxiety/depression, hearing or visual challenges).</p></li>
<li><p>Recommending ‘HFmatters.org’. Offer help and guidance to use it
and offer discussion of questions arising.</p></li>
<li><p>Inviting patients to be accompanied by a family member or
friend.</p></li>
</ul>
<p>Key topics to include are recommended in <em>Table 12</em>.</p>
<p>Table 12</p>
<p>Patient education and self-care</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Education topic</th>
<th>Goal for the patient and caregiver</th>
<th>Professional behaviour and educational tools</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Explanation about HF</strong> </td>
<td>To understand the cause of their HF, symptoms and treatment
choice. </td>
<td>Provide tailored information. </td>
</tr>
<tr>
<td><strong>The HF trajectory</strong> </td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>To understand prognosis and the different possible phases in the
HF trajectory.</p></li>
<li><p>To make joint treatment decisions that recognise the patient’s
position on the HF trajectory.</p></li>
</ul>
<p>  | Sensitively communicate information on prognosis at time of
diagnosis, during decision making about treatment options, when there is
a change in the clinical condition and whenever the patient requests.  |
| <strong>Medical treatment</strong>  | | <strong>Medication</strong> 
|</p>
<ul>
<li><p>To be able to make joint decisions about medication.</p>
<p>To understand the indications, benefits, the need for long-term
adherence to certain drugs, and the dosing and side effects of
medication.</p></li>
<li><p>To be able to recognize the common side effects of medication and
know what actions to take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information on indication, benefits,
dosing, effects and side effects.</p></li>
<li><p>Discuss practical issues such as optimal time-schedule, what to
do in case of a missed dose etc.</p></li>
<li><p>Discuss possible barriers for medication taking.</p></li>
<li><p>Advise on support aids such as dosette box, electronic reminders
etc. when appropriate.<sup>320</sup></p></li>
</ul>
<p>  | | <strong>Implanted devices</strong>  |</p>
<ul>
<li><p>To be able to make joint decisions on device
implantation.</p></li>
<li><p>To understand the indications, importance, expectations and
check-up routine for implanted devices, and any exception
management.</p></li>
<li><p>To be able to recognize the common complications (including the
risk of inappropriate defibrillator shocks), and know what actions to
take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information about the importance and
expectations of implanted devices, and possible ways of follow-up
(remote monitoring).</p></li>
<li><p>Discuss expectations and any possible impact on driving.</p></li>
<li><p>Clearly identify situations where the device might be deactivated
or explanted.</p></li>
<li><p>Involve patient and caregiver in decision making.</p></li>
</ul>
<p>  | | <strong>Self-care aspects</strong>  | | <strong>Activity and
exercise</strong>  |</p>
<ul>
<li><p>To undertake regular exercise and be physically active.</p></li>
<li><p>To be able to adapt physical activity to symptom status and
personal circumstances.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Advise on exercise that recognizes physical and functional
limitations, such as frailty, comorbidities.</p></li>
<li><p>Refer to exercise programme or other activity modes.</p></li>
<li><p>Discuss possible barriers, side-effects and
opportunities.</p></li>
</ul>
<p>  | | <strong>Sleep and breathing</strong>  |</p>
<ul>
<li><p>To recognize the importance of sleep and rest for (CV)
health.</p></li>
<li><p>To be able to recognize problems with sleeping and how to
optimize sleep.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Review sleep history.</p></li>
<li><p>Advise and discuss the importance of good sleep and provide
advice on ‘sleep health’ (including timing of diuretics).</p></li>
<li><p>Consider and carefully discuss the benefits and deleterious
effects of sleep medication.</p></li>
</ul>
<p>  | | <strong>Fluids</strong>  |</p>
<ul>
<li><p>To avoid large volumes of fluid intake. A fluid restriction of
1.5–2 L/day may be considered in patients with severe HF/hyponatraemia
to relieve symptoms and congestion.</p></li>
<li><p>To avoid dehydration: where fluids are restricted, increase
intake during periods of high heat/humidity and/or
nausea/vomiting.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide information and discuss the advantages and disadvantages
of fluid restriction.</p></li>
<li><p>Advise to adapt fluid intake to weight, and in times of high heat
and humidity, nausea/vomiting.</p></li>
<li><p>Adjust advice during periods of acute decompensation and consider
altering this advice towards end-of-life.</p></li>
</ul>
<p>  | | <strong>Healthy diet</strong>  | To be able to prevent
malnutrition and know how to eat healthily, avoiding excessive salt
intake (&gt;5 g/day) and maintaining a healthy body weight.  |</p>
<ul>
<li><p>Discuss current food intake, role of salt, role of
micronutrients.</p></li>
<li><p>Discuss the need for supplementing in case of nutrient
deficiencies but there is no clear role for routine micronutrient
supplementation.<sup>321</sup></p></li>
<li><p>Discuss maintaining a healthy body weight.</p></li>
</ul>
<p>  | | <strong>Alcohol</strong>  |</p>
<ul>
<li><p>To be able to abstain from or avoid excessive alcohol intake,
especially for alcohol-induced CMP.</p></li>
<li><p>To restrict alcohol according to CV prevention
guidelines.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Tailor alcohol advice to aetiology of HF; e.g. abstinence in
alcoholic CMP.</p></li>
<li><p>Inform and discuss alcohol intake according to CV prevention
guidelines (2 units per day in men or 1 unit per day in
women)<sup>a</sup>.</p></li>
</ul>
<p>  | | <strong>Immunization</strong>  | To be aware of the need for
immunization for influenza and pneumococcal disease.  |</p>
<ul>
<li><p>Discuss benefits and possible barriers.</p></li>
<li><p>Advise on local immunization practice.</p></li>
</ul>
<p>  | | <strong>Smoking and recreational drugs</strong>  |</p>
<ul>
<li><p>To be aware of the consequences for health of smoking and use of
recreational drugs.</p></li>
<li><p>Stop smoking (including e-cigarettes) and taking recreational
drugs.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform, discuss and help in decision making.</p></li>
<li><p>Refer for specialist advice for smoking cessation and drug
withdrawal and replacement therapy.</p></li>
<li><p>Consider referral for cognitive behavioural theory and
psychological support if patient wishes to stop smoking or taking
drugs.</p></li>
</ul>
<p>  | | <strong>Travel, leisure, driving</strong>  |</p>
<ul>
<li><p>To be able to prepare travel and leisure activities according to
physical capacity.</p></li>
<li><p>To be able to take an informed decision about driving.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss practical issues related to long haul travel,
staying abroad, exposure to sun (amiodarone effects), high humidity or
heat (dehydration), and high altitude (oxygenation).</p></li>
<li><p>Provide practical advice related to travel with
medication/devices (keep medicines in hand luggage, have a list with
medication, device name/card and treating centres).</p></li>
<li><p>Inform about local/national/international regulation related to
driving.</p></li>
</ul>
<p>  | | <strong>Sexual activity</strong>  |</p>
<ul>
<li><p>To be able to resume or adapt sexual activity according to
physical capacity.</p></li>
<li><p>To recognize possible problems with sexual activity and their
relationship with HF or its treatment.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss that sexual activity is safe for stable HF
patients.</p></li>
<li><p>Provide advice on eliminating factors predisposing to sexual
problems.</p></li>
<li><p>Discuss and provide available pharmacological treatment for
sexual problems.</p></li>
<li><p>Refer to specialist for sexual counselling when
necessary.</p></li>
</ul>
<p>  | | <strong>Symptom monitoring and symptom
self-management</strong>  |</p>
<ul>
<li><p>Monitor and recognize change in signs and symptoms.</p></li>
<li><p>Being able to react adequately to change in signs and
symptoms.</p></li>
<li><p>Know how and when to contact a healthcare professional.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide individualized information to support self-management
such as:</p></li>
<li><p>In the case of increasing dyspnoea or oedema or a sudden
unexpected weight gain of &gt;2 kg in 3 days, patients may increase
their diuretic dose and/or alert their healthcare team.</p></li>
</ul>
<p>  | | <strong>Living with HF</strong>  | | <strong>Psychological
issues</strong>  |</p>
<ul>
<li><p>To be able to live a good life with HF.</p></li>
<li><p>To be able to seek help in case of psychological problems such as
depressive symptoms, anxiety or low mood which may occur in the course
of the HF trajectory.</p></li>
<li><p>To recognise that the carer or family members may be greatly
affected and need to seek help.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Regularly communicate information on disease, treatment options
and self-care.</p></li>
<li><p>Regularly discuss the need for support.</p></li>
<li><p>Treat or referral to specialist for psychological support when
necessary.</p></li>
</ul>
<p>  | | <strong>Family and informal caregivers</strong>  | To be able
to ask for support.  |</p>
<ul>
<li><p>Discuss the preference of caregiver/family involvement.</p></li>
<li><p>Involve patients and caregivers in a respectful way.</p></li>
</ul>
<p>  |</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Education topic</th>
<th>Goal for the patient and caregiver</th>
<th>Professional behaviour and educational tools</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Explanation about HF</strong> </td>
<td>To understand the cause of their HF, symptoms and treatment
choice. </td>
<td>Provide tailored information. </td>
</tr>
<tr>
<td><strong>The HF trajectory</strong> </td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>To understand prognosis and the different possible phases in the
HF trajectory.</p></li>
<li><p>To make joint treatment decisions that recognise the patient’s
position on the HF trajectory.</p></li>
</ul>
<p>  | Sensitively communicate information on prognosis at time of
diagnosis, during decision making about treatment options, when there is
a change in the clinical condition and whenever the patient requests.  |
| <strong>Medical treatment</strong>  | | <strong>Medication</strong> 
|</p>
<ul>
<li><p>To be able to make joint decisions about medication.</p>
<p>To understand the indications, benefits, the need for long-term
adherence to certain drugs, and the dosing and side effects of
medication.</p></li>
<li><p>To be able to recognize the common side effects of medication and
know what actions to take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information on indication, benefits,
dosing, effects and side effects.</p></li>
<li><p>Discuss practical issues such as optimal time-schedule, what to
do in case of a missed dose etc.</p></li>
<li><p>Discuss possible barriers for medication taking.</p></li>
<li><p>Advise on support aids such as dosette box, electronic reminders
etc. when appropriate.<sup>320</sup></p></li>
</ul>
<p>  | | <strong>Implanted devices</strong>  |</p>
<ul>
<li><p>To be able to make joint decisions on device
implantation.</p></li>
<li><p>To understand the indications, importance, expectations and
check-up routine for implanted devices, and any exception
management.</p></li>
<li><p>To be able to recognize the common complications (including the
risk of inappropriate defibrillator shocks), and know what actions to
take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information about the importance and
expectations of implanted devices, and possible ways of follow-up
(remote monitoring).</p></li>
<li><p>Discuss expectations and any possible impact on driving.</p></li>
<li><p>Clearly identify situations where the device might be deactivated
or explanted.</p></li>
<li><p>Involve patient and caregiver in decision making.</p></li>
</ul>
<p>  | | <strong>Self-care aspects</strong>  | | <strong>Activity and
exercise</strong>  |</p>
<ul>
<li><p>To undertake regular exercise and be physically active.</p></li>
<li><p>To be able to adapt physical activity to symptom status and
personal circumstances.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Advise on exercise that recognizes physical and functional
limitations, such as frailty, comorbidities.</p></li>
<li><p>Refer to exercise programme or other activity modes.</p></li>
<li><p>Discuss possible barriers, side-effects and
opportunities.</p></li>
</ul>
<p>  | | <strong>Sleep and breathing</strong>  |</p>
<ul>
<li><p>To recognize the importance of sleep and rest for (CV)
health.</p></li>
<li><p>To be able to recognize problems with sleeping and how to
optimize sleep.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Review sleep history.</p></li>
<li><p>Advise and discuss the importance of good sleep and provide
advice on ‘sleep health’ (including timing of diuretics).</p></li>
<li><p>Consider and carefully discuss the benefits and deleterious
effects of sleep medication.</p></li>
</ul>
<p>  | | <strong>Fluids</strong>  |</p>
<ul>
<li><p>To avoid large volumes of fluid intake. A fluid restriction of
1.5–2 L/day may be considered in patients with severe HF/hyponatraemia
to relieve symptoms and congestion.</p></li>
<li><p>To avoid dehydration: where fluids are restricted, increase
intake during periods of high heat/humidity and/or
nausea/vomiting.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide information and discuss the advantages and disadvantages
of fluid restriction.</p></li>
<li><p>Advise to adapt fluid intake to weight, and in times of high heat
and humidity, nausea/vomiting.</p></li>
<li><p>Adjust advice during periods of acute decompensation and consider
altering this advice towards end-of-life.</p></li>
</ul>
<p>  | | <strong>Healthy diet</strong>  | To be able to prevent
malnutrition and know how to eat healthily, avoiding excessive salt
intake (&gt;5 g/day) and maintaining a healthy body weight.  |</p>
<ul>
<li><p>Discuss current food intake, role of salt, role of
micronutrients.</p></li>
<li><p>Discuss the need for supplementing in case of nutrient
deficiencies but there is no clear role for routine micronutrient
supplementation.<sup>321</sup></p></li>
<li><p>Discuss maintaining a healthy body weight.</p></li>
</ul>
<p>  | | <strong>Alcohol</strong>  |</p>
<ul>
<li><p>To be able to abstain from or avoid excessive alcohol intake,
especially for alcohol-induced CMP.</p></li>
<li><p>To restrict alcohol according to CV prevention
guidelines.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Tailor alcohol advice to aetiology of HF; e.g. abstinence in
alcoholic CMP.</p></li>
<li><p>Inform and discuss alcohol intake according to CV prevention
guidelines (2 units per day in men or 1 unit per day in
women)<sup>a</sup>.</p></li>
</ul>
<p>  | | <strong>Immunization</strong>  | To be aware of the need for
immunization for influenza and pneumococcal disease.  |</p>
<ul>
<li><p>Discuss benefits and possible barriers.</p></li>
<li><p>Advise on local immunization practice.</p></li>
</ul>
<p>  | | <strong>Smoking and recreational drugs</strong>  |</p>
<ul>
<li><p>To be aware of the consequences for health of smoking and use of
recreational drugs.</p></li>
<li><p>Stop smoking (including e-cigarettes) and taking recreational
drugs.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform, discuss and help in decision making.</p></li>
<li><p>Refer for specialist advice for smoking cessation and drug
withdrawal and replacement therapy.</p></li>
<li><p>Consider referral for cognitive behavioural theory and
psychological support if patient wishes to stop smoking or taking
drugs.</p></li>
</ul>
<p>  | | <strong>Travel, leisure, driving</strong>  |</p>
<ul>
<li><p>To be able to prepare travel and leisure activities according to
physical capacity.</p></li>
<li><p>To be able to take an informed decision about driving.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss practical issues related to long haul travel,
staying abroad, exposure to sun (amiodarone effects), high humidity or
heat (dehydration), and high altitude (oxygenation).</p></li>
<li><p>Provide practical advice related to travel with
medication/devices (keep medicines in hand luggage, have a list with
medication, device name/card and treating centres).</p></li>
<li><p>Inform about local/national/international regulation related to
driving.</p></li>
</ul>
<p>  | | <strong>Sexual activity</strong>  |</p>
<ul>
<li><p>To be able to resume or adapt sexual activity according to
physical capacity.</p></li>
<li><p>To recognize possible problems with sexual activity and their
relationship with HF or its treatment.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss that sexual activity is safe for stable HF
patients.</p></li>
<li><p>Provide advice on eliminating factors predisposing to sexual
problems.</p></li>
<li><p>Discuss and provide available pharmacological treatment for
sexual problems.</p></li>
<li><p>Refer to specialist for sexual counselling when
necessary.</p></li>
</ul>
<p>  | | <strong>Symptom monitoring and symptom
self-management</strong>  |</p>
<ul>
<li><p>Monitor and recognize change in signs and symptoms.</p></li>
<li><p>Being able to react adequately to change in signs and
symptoms.</p></li>
<li><p>Know how and when to contact a healthcare professional.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide individualized information to support self-management
such as:</p></li>
<li><p>In the case of increasing dyspnoea or oedema or a sudden
unexpected weight gain of &gt;2 kg in 3 days, patients may increase
their diuretic dose and/or alert their healthcare team.</p></li>
</ul>
<p>  | | <strong>Living with HF</strong>  | | <strong>Psychological
issues</strong>  |</p>
<ul>
<li><p>To be able to live a good life with HF.</p></li>
<li><p>To be able to seek help in case of psychological problems such as
depressive symptoms, anxiety or low mood which may occur in the course
of the HF trajectory.</p></li>
<li><p>To recognise that the carer or family members may be greatly
affected and need to seek help.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Regularly communicate information on disease, treatment options
and self-care.</p></li>
<li><p>Regularly discuss the need for support.</p></li>
<li><p>Treat or referral to specialist for psychological support when
necessary.</p></li>
</ul>
<p>  | | <strong>Family and informal caregivers</strong>  | To be able
to ask for support.  |</p>
<ul>
<li><p>Discuss the preference of caregiver/family involvement.</p></li>
<li><p>Involve patients and caregivers in a respectful way.</p></li>
</ul>
<p>  |</p>
<p>CMP = cardiomyopathy; CV = cardiovascular; HF = heart failure.</p>
<p>a</p>
<p>1 unit is 10 mL of pure alcohol (e.g., 1 glass of wine, ½ pint of
beer, 1 measure of spirit).</p>
<p>Table 12</p>
<p>Patient education and self-care</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Education topic</th>
<th>Goal for the patient and caregiver</th>
<th>Professional behaviour and educational tools</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Explanation about HF</strong> </td>
<td>To understand the cause of their HF, symptoms and treatment
choice. </td>
<td>Provide tailored information. </td>
</tr>
<tr>
<td><strong>The HF trajectory</strong> </td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>To understand prognosis and the different possible phases in the
HF trajectory.</p></li>
<li><p>To make joint treatment decisions that recognise the patient’s
position on the HF trajectory.</p></li>
</ul>
<p>  | Sensitively communicate information on prognosis at time of
diagnosis, during decision making about treatment options, when there is
a change in the clinical condition and whenever the patient requests.  |
| <strong>Medical treatment</strong>  | | <strong>Medication</strong> 
|</p>
<ul>
<li><p>To be able to make joint decisions about medication.</p>
<p>To understand the indications, benefits, the need for long-term
adherence to certain drugs, and the dosing and side effects of
medication.</p></li>
<li><p>To be able to recognize the common side effects of medication and
know what actions to take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information on indication, benefits,
dosing, effects and side effects.</p></li>
<li><p>Discuss practical issues such as optimal time-schedule, what to
do in case of a missed dose etc.</p></li>
<li><p>Discuss possible barriers for medication taking.</p></li>
<li><p>Advise on support aids such as dosette box, electronic reminders
etc. when appropriate.<sup>320</sup></p></li>
</ul>
<p>  | | <strong>Implanted devices</strong>  |</p>
<ul>
<li><p>To be able to make joint decisions on device
implantation.</p></li>
<li><p>To understand the indications, importance, expectations and
check-up routine for implanted devices, and any exception
management.</p></li>
<li><p>To be able to recognize the common complications (including the
risk of inappropriate defibrillator shocks), and know what actions to
take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information about the importance and
expectations of implanted devices, and possible ways of follow-up
(remote monitoring).</p></li>
<li><p>Discuss expectations and any possible impact on driving.</p></li>
<li><p>Clearly identify situations where the device might be deactivated
or explanted.</p></li>
<li><p>Involve patient and caregiver in decision making.</p></li>
</ul>
<p>  | | <strong>Self-care aspects</strong>  | | <strong>Activity and
exercise</strong>  |</p>
<ul>
<li><p>To undertake regular exercise and be physically active.</p></li>
<li><p>To be able to adapt physical activity to symptom status and
personal circumstances.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Advise on exercise that recognizes physical and functional
limitations, such as frailty, comorbidities.</p></li>
<li><p>Refer to exercise programme or other activity modes.</p></li>
<li><p>Discuss possible barriers, side-effects and
opportunities.</p></li>
</ul>
<p>  | | <strong>Sleep and breathing</strong>  |</p>
<ul>
<li><p>To recognize the importance of sleep and rest for (CV)
health.</p></li>
<li><p>To be able to recognize problems with sleeping and how to
optimize sleep.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Review sleep history.</p></li>
<li><p>Advise and discuss the importance of good sleep and provide
advice on ‘sleep health’ (including timing of diuretics).</p></li>
<li><p>Consider and carefully discuss the benefits and deleterious
effects of sleep medication.</p></li>
</ul>
<p>  | | <strong>Fluids</strong>  |</p>
<ul>
<li><p>To avoid large volumes of fluid intake. A fluid restriction of
1.5–2 L/day may be considered in patients with severe HF/hyponatraemia
to relieve symptoms and congestion.</p></li>
<li><p>To avoid dehydration: where fluids are restricted, increase
intake during periods of high heat/humidity and/or
nausea/vomiting.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide information and discuss the advantages and disadvantages
of fluid restriction.</p></li>
<li><p>Advise to adapt fluid intake to weight, and in times of high heat
and humidity, nausea/vomiting.</p></li>
<li><p>Adjust advice during periods of acute decompensation and consider
altering this advice towards end-of-life.</p></li>
</ul>
<p>  | | <strong>Healthy diet</strong>  | To be able to prevent
malnutrition and know how to eat healthily, avoiding excessive salt
intake (&gt;5 g/day) and maintaining a healthy body weight.  |</p>
<ul>
<li><p>Discuss current food intake, role of salt, role of
micronutrients.</p></li>
<li><p>Discuss the need for supplementing in case of nutrient
deficiencies but there is no clear role for routine micronutrient
supplementation.<sup>321</sup></p></li>
<li><p>Discuss maintaining a healthy body weight.</p></li>
</ul>
<p>  | | <strong>Alcohol</strong>  |</p>
<ul>
<li><p>To be able to abstain from or avoid excessive alcohol intake,
especially for alcohol-induced CMP.</p></li>
<li><p>To restrict alcohol according to CV prevention
guidelines.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Tailor alcohol advice to aetiology of HF; e.g. abstinence in
alcoholic CMP.</p></li>
<li><p>Inform and discuss alcohol intake according to CV prevention
guidelines (2 units per day in men or 1 unit per day in
women)<sup>a</sup>.</p></li>
</ul>
<p>  | | <strong>Immunization</strong>  | To be aware of the need for
immunization for influenza and pneumococcal disease.  |</p>
<ul>
<li><p>Discuss benefits and possible barriers.</p></li>
<li><p>Advise on local immunization practice.</p></li>
</ul>
<p>  | | <strong>Smoking and recreational drugs</strong>  |</p>
<ul>
<li><p>To be aware of the consequences for health of smoking and use of
recreational drugs.</p></li>
<li><p>Stop smoking (including e-cigarettes) and taking recreational
drugs.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform, discuss and help in decision making.</p></li>
<li><p>Refer for specialist advice for smoking cessation and drug
withdrawal and replacement therapy.</p></li>
<li><p>Consider referral for cognitive behavioural theory and
psychological support if patient wishes to stop smoking or taking
drugs.</p></li>
</ul>
<p>  | | <strong>Travel, leisure, driving</strong>  |</p>
<ul>
<li><p>To be able to prepare travel and leisure activities according to
physical capacity.</p></li>
<li><p>To be able to take an informed decision about driving.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss practical issues related to long haul travel,
staying abroad, exposure to sun (amiodarone effects), high humidity or
heat (dehydration), and high altitude (oxygenation).</p></li>
<li><p>Provide practical advice related to travel with
medication/devices (keep medicines in hand luggage, have a list with
medication, device name/card and treating centres).</p></li>
<li><p>Inform about local/national/international regulation related to
driving.</p></li>
</ul>
<p>  | | <strong>Sexual activity</strong>  |</p>
<ul>
<li><p>To be able to resume or adapt sexual activity according to
physical capacity.</p></li>
<li><p>To recognize possible problems with sexual activity and their
relationship with HF or its treatment.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss that sexual activity is safe for stable HF
patients.</p></li>
<li><p>Provide advice on eliminating factors predisposing to sexual
problems.</p></li>
<li><p>Discuss and provide available pharmacological treatment for
sexual problems.</p></li>
<li><p>Refer to specialist for sexual counselling when
necessary.</p></li>
</ul>
<p>  | | <strong>Symptom monitoring and symptom
self-management</strong>  |</p>
<ul>
<li><p>Monitor and recognize change in signs and symptoms.</p></li>
<li><p>Being able to react adequately to change in signs and
symptoms.</p></li>
<li><p>Know how and when to contact a healthcare professional.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide individualized information to support self-management
such as:</p></li>
<li><p>In the case of increasing dyspnoea or oedema or a sudden
unexpected weight gain of &gt;2 kg in 3 days, patients may increase
their diuretic dose and/or alert their healthcare team.</p></li>
</ul>
<p>  | | <strong>Living with HF</strong>  | | <strong>Psychological
issues</strong>  |</p>
<ul>
<li><p>To be able to live a good life with HF.</p></li>
<li><p>To be able to seek help in case of psychological problems such as
depressive symptoms, anxiety or low mood which may occur in the course
of the HF trajectory.</p></li>
<li><p>To recognise that the carer or family members may be greatly
affected and need to seek help.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Regularly communicate information on disease, treatment options
and self-care.</p></li>
<li><p>Regularly discuss the need for support.</p></li>
<li><p>Treat or referral to specialist for psychological support when
necessary.</p></li>
</ul>
<p>  | | <strong>Family and informal caregivers</strong>  | To be able
to ask for support.  |</p>
<ul>
<li><p>Discuss the preference of caregiver/family involvement.</p></li>
<li><p>Involve patients and caregivers in a respectful way.</p></li>
</ul>
<p>  |</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr>
<th>Education topic</th>
<th>Goal for the patient and caregiver</th>
<th>Professional behaviour and educational tools</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Explanation about HF</strong> </td>
<td>To understand the cause of their HF, symptoms and treatment
choice. </td>
<td>Provide tailored information. </td>
</tr>
<tr>
<td><strong>The HF trajectory</strong> </td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>To understand prognosis and the different possible phases in the
HF trajectory.</p></li>
<li><p>To make joint treatment decisions that recognise the patient’s
position on the HF trajectory.</p></li>
</ul>
<p>  | Sensitively communicate information on prognosis at time of
diagnosis, during decision making about treatment options, when there is
a change in the clinical condition and whenever the patient requests.  |
| <strong>Medical treatment</strong>  | | <strong>Medication</strong> 
|</p>
<ul>
<li><p>To be able to make joint decisions about medication.</p>
<p>To understand the indications, benefits, the need for long-term
adherence to certain drugs, and the dosing and side effects of
medication.</p></li>
<li><p>To be able to recognize the common side effects of medication and
know what actions to take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information on indication, benefits,
dosing, effects and side effects.</p></li>
<li><p>Discuss practical issues such as optimal time-schedule, what to
do in case of a missed dose etc.</p></li>
<li><p>Discuss possible barriers for medication taking.</p></li>
<li><p>Advise on support aids such as dosette box, electronic reminders
etc. when appropriate.<sup>320</sup></p></li>
</ul>
<p>  | | <strong>Implanted devices</strong>  |</p>
<ul>
<li><p>To be able to make joint decisions on device
implantation.</p></li>
<li><p>To understand the indications, importance, expectations and
check-up routine for implanted devices, and any exception
management.</p></li>
<li><p>To be able to recognize the common complications (including the
risk of inappropriate defibrillator shocks), and know what actions to
take.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide written and oral information about the importance and
expectations of implanted devices, and possible ways of follow-up
(remote monitoring).</p></li>
<li><p>Discuss expectations and any possible impact on driving.</p></li>
<li><p>Clearly identify situations where the device might be deactivated
or explanted.</p></li>
<li><p>Involve patient and caregiver in decision making.</p></li>
</ul>
<p>  | | <strong>Self-care aspects</strong>  | | <strong>Activity and
exercise</strong>  |</p>
<ul>
<li><p>To undertake regular exercise and be physically active.</p></li>
<li><p>To be able to adapt physical activity to symptom status and
personal circumstances.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Advise on exercise that recognizes physical and functional
limitations, such as frailty, comorbidities.</p></li>
<li><p>Refer to exercise programme or other activity modes.</p></li>
<li><p>Discuss possible barriers, side-effects and
opportunities.</p></li>
</ul>
<p>  | | <strong>Sleep and breathing</strong>  |</p>
<ul>
<li><p>To recognize the importance of sleep and rest for (CV)
health.</p></li>
<li><p>To be able to recognize problems with sleeping and how to
optimize sleep.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Review sleep history.</p></li>
<li><p>Advise and discuss the importance of good sleep and provide
advice on ‘sleep health’ (including timing of diuretics).</p></li>
<li><p>Consider and carefully discuss the benefits and deleterious
effects of sleep medication.</p></li>
</ul>
<p>  | | <strong>Fluids</strong>  |</p>
<ul>
<li><p>To avoid large volumes of fluid intake. A fluid restriction of
1.5–2 L/day may be considered in patients with severe HF/hyponatraemia
to relieve symptoms and congestion.</p></li>
<li><p>To avoid dehydration: where fluids are restricted, increase
intake during periods of high heat/humidity and/or
nausea/vomiting.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide information and discuss the advantages and disadvantages
of fluid restriction.</p></li>
<li><p>Advise to adapt fluid intake to weight, and in times of high heat
and humidity, nausea/vomiting.</p></li>
<li><p>Adjust advice during periods of acute decompensation and consider
altering this advice towards end-of-life.</p></li>
</ul>
<p>  | | <strong>Healthy diet</strong>  | To be able to prevent
malnutrition and know how to eat healthily, avoiding excessive salt
intake (&gt;5 g/day) and maintaining a healthy body weight.  |</p>
<ul>
<li><p>Discuss current food intake, role of salt, role of
micronutrients.</p></li>
<li><p>Discuss the need for supplementing in case of nutrient
deficiencies but there is no clear role for routine micronutrient
supplementation.<sup>321</sup></p></li>
<li><p>Discuss maintaining a healthy body weight.</p></li>
</ul>
<p>  | | <strong>Alcohol</strong>  |</p>
<ul>
<li><p>To be able to abstain from or avoid excessive alcohol intake,
especially for alcohol-induced CMP.</p></li>
<li><p>To restrict alcohol according to CV prevention
guidelines.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Tailor alcohol advice to aetiology of HF; e.g. abstinence in
alcoholic CMP.</p></li>
<li><p>Inform and discuss alcohol intake according to CV prevention
guidelines (2 units per day in men or 1 unit per day in
women)<sup>a</sup>.</p></li>
</ul>
<p>  | | <strong>Immunization</strong>  | To be aware of the need for
immunization for influenza and pneumococcal disease.  |</p>
<ul>
<li><p>Discuss benefits and possible barriers.</p></li>
<li><p>Advise on local immunization practice.</p></li>
</ul>
<p>  | | <strong>Smoking and recreational drugs</strong>  |</p>
<ul>
<li><p>To be aware of the consequences for health of smoking and use of
recreational drugs.</p></li>
<li><p>Stop smoking (including e-cigarettes) and taking recreational
drugs.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform, discuss and help in decision making.</p></li>
<li><p>Refer for specialist advice for smoking cessation and drug
withdrawal and replacement therapy.</p></li>
<li><p>Consider referral for cognitive behavioural theory and
psychological support if patient wishes to stop smoking or taking
drugs.</p></li>
</ul>
<p>  | | <strong>Travel, leisure, driving</strong>  |</p>
<ul>
<li><p>To be able to prepare travel and leisure activities according to
physical capacity.</p></li>
<li><p>To be able to take an informed decision about driving.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss practical issues related to long haul travel,
staying abroad, exposure to sun (amiodarone effects), high humidity or
heat (dehydration), and high altitude (oxygenation).</p></li>
<li><p>Provide practical advice related to travel with
medication/devices (keep medicines in hand luggage, have a list with
medication, device name/card and treating centres).</p></li>
<li><p>Inform about local/national/international regulation related to
driving.</p></li>
</ul>
<p>  | | <strong>Sexual activity</strong>  |</p>
<ul>
<li><p>To be able to resume or adapt sexual activity according to
physical capacity.</p></li>
<li><p>To recognize possible problems with sexual activity and their
relationship with HF or its treatment.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inform and discuss that sexual activity is safe for stable HF
patients.</p></li>
<li><p>Provide advice on eliminating factors predisposing to sexual
problems.</p></li>
<li><p>Discuss and provide available pharmacological treatment for
sexual problems.</p></li>
<li><p>Refer to specialist for sexual counselling when
necessary.</p></li>
</ul>
<p>  | | <strong>Symptom monitoring and symptom
self-management</strong>  |</p>
<ul>
<li><p>Monitor and recognize change in signs and symptoms.</p></li>
<li><p>Being able to react adequately to change in signs and
symptoms.</p></li>
<li><p>Know how and when to contact a healthcare professional.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Provide individualized information to support self-management
such as:</p></li>
<li><p>In the case of increasing dyspnoea or oedema or a sudden
unexpected weight gain of &gt;2 kg in 3 days, patients may increase
their diuretic dose and/or alert their healthcare team.</p></li>
</ul>
<p>  | | <strong>Living with HF</strong>  | | <strong>Psychological
issues</strong>  |</p>
<ul>
<li><p>To be able to live a good life with HF.</p></li>
<li><p>To be able to seek help in case of psychological problems such as
depressive symptoms, anxiety or low mood which may occur in the course
of the HF trajectory.</p></li>
<li><p>To recognise that the carer or family members may be greatly
affected and need to seek help.</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Regularly communicate information on disease, treatment options
and self-care.</p></li>
<li><p>Regularly discuss the need for support.</p></li>
<li><p>Treat or referral to specialist for psychological support when
necessary.</p></li>
</ul>
<p>  | | <strong>Family and informal caregivers</strong>  | To be able
to ask for support.  |</p>
<ul>
<li><p>Discuss the preference of caregiver/family involvement.</p></li>
<li><p>Involve patients and caregivers in a respectful way.</p></li>
</ul>
<p>  |</p>
<p>CMP = cardiomyopathy; CV = cardiovascular; HF = heart failure.</p>
<p>a</p>
<p>1 unit is 10 mL of pure alcohol (e.g., 1 glass of wine, ½ pint of
beer, 1 measure of spirit).</p>
<h3 >9.4 Exercise rehabilitation</h3>
<p>There is consistent evidence that physical conditioning by exercise
training improves exercise tolerance, and health-related QOL in patients
with HF. Clinical trials and meta-analyses in people with HFrEF show
that exercise rehabilitation improves exercise capacity and QOL. Several
meta-analyses also show that it reduces all-cause and HF
hospitalizations, although uncertainty persists about its effects on
mortality.<sup>322–328</sup> The effect on hospitalization is seen in
those who are highly adherent to the exercise programme.<sup>329</sup>
High-intensity interval training, in patients who are able and willing,
may improve peak oxygen consumption
(VO<sub>2</sub>).<sup>330</sup><sup>,</sup><sup>331</sup> Supervised
exercise-based rehabilitation should be considered in those who are
frail, who have more severe disease or comorbidities.<sup>95</sup></p>
<p>Recommendations for exercise rehabilitation in patients with chronic
heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table38.jpeg?Expires=1689850106&amp;Signature=uTZ2SbtwTkt8MmEowntM~7JCtpbShsVwBhRhaGGpGX1boeltW9J0Jg7MwctZBed4fGPlPEHnEr07z65AxPy9De6-XWoHJAa170GQ6VJwwFhViHvL206sGy0ohdvJb8u1H3vu5z0tZagn0avYY-c00w~-MXnKquigdGaCZbQejTAQJYxrDLifn4I1HdUwan6uRtKopHz2nGlpqogciu1D4TEfiA4pwfAa4Fl27GfVdvfhBJ32UF8ouetcH9rnGMugkfHiX8e84QuEsHLs-p~h2cvJ-g4uSK84snCTTrb6qxCYHm4Aavlukkx7kO4Gzw8H-efDU-CZZAmSq5n6ca8duQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table38.jpeg?Expires=1689850106&amp;Signature=uTZ2SbtwTkt8MmEowntM~7JCtpbShsVwBhRhaGGpGX1boeltW9J0Jg7MwctZBed4fGPlPEHnEr07z65AxPy9De6-XWoHJAa170GQ6VJwwFhViHvL206sGy0ohdvJb8u1H3vu5z0tZagn0avYY-c00w~-MXnKquigdGaCZbQejTAQJYxrDLifn4I1HdUwan6uRtKopHz2nGlpqogciu1D4TEfiA4pwfAa4Fl27GfVdvfhBJ32UF8ouetcH9rnGMugkfHiX8e84QuEsHLs-p~h2cvJ-g4uSK84snCTTrb6qxCYHm4Aavlukkx7kO4Gzw8H-efDU-CZZAmSq5n6ca8duQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure; QOL = quality of life.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>In those who are able to adhere to the exercise programme.</p>
<p>Recommendations for exercise rehabilitation in patients with chronic
heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table38.jpeg?Expires=1689850106&amp;Signature=uTZ2SbtwTkt8MmEowntM~7JCtpbShsVwBhRhaGGpGX1boeltW9J0Jg7MwctZBed4fGPlPEHnEr07z65AxPy9De6-XWoHJAa170GQ6VJwwFhViHvL206sGy0ohdvJb8u1H3vu5z0tZagn0avYY-c00w~-MXnKquigdGaCZbQejTAQJYxrDLifn4I1HdUwan6uRtKopHz2nGlpqogciu1D4TEfiA4pwfAa4Fl27GfVdvfhBJ32UF8ouetcH9rnGMugkfHiX8e84QuEsHLs-p~h2cvJ-g4uSK84snCTTrb6qxCYHm4Aavlukkx7kO4Gzw8H-efDU-CZZAmSq5n6ca8duQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table38.jpeg?Expires=1689850106&amp;Signature=uTZ2SbtwTkt8MmEowntM~7JCtpbShsVwBhRhaGGpGX1boeltW9J0Jg7MwctZBed4fGPlPEHnEr07z65AxPy9De6-XWoHJAa170GQ6VJwwFhViHvL206sGy0ohdvJb8u1H3vu5z0tZagn0avYY-c00w~-MXnKquigdGaCZbQejTAQJYxrDLifn4I1HdUwan6uRtKopHz2nGlpqogciu1D4TEfiA4pwfAa4Fl27GfVdvfhBJ32UF8ouetcH9rnGMugkfHiX8e84QuEsHLs-p~h2cvJ-g4uSK84snCTTrb6qxCYHm4Aavlukkx7kO4Gzw8H-efDU-CZZAmSq5n6ca8duQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure; QOL = quality of life.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>In those who are able to adhere to the exercise programme.</p>
<p>Physical conditioning also improves exercise capacity and
QOL.<sup>332–335</sup> No data on HFmrEF are available, but benefits
observed in the other groups of HF should also apply to this group.</p>
<h3 >9.5 Follow-up of chronic
heart failure</h3>
<p><strong>9.5.1 General follow-up</strong></p>
<p>This is a relatively understudied area. Patients with HF, even if
symptoms are well controlled and stable, require follow-up to ensure
continued optimization of therapy, to detect asymptomatic progression of
HF or its comorbidities and to discuss any new advances in care. These
guidelines recommend follow-up at intervals no longer than 6 months to
check symptoms, heart rate and rhythm, BP, full blood count,
electrolytes, and renal function. For patients recently discharged from
hospital, or in those undergoing uptitration of medication, follow-up
intervals should be more frequent. Whether such stable patients need to
be followed-up by cardiologists is uncertain. Some studies suggest that
follow-up in primary care may be
appropriate.<sup>303</sup><sup>,</sup><sup>339</sup> However, uptake of
evidence-based interventions is poor in many
settings<sup>340</sup><sup>,</sup><sup>104</sup> and several studies
suggest that care and follow-up provided by HF specialists, and use of
quality improvement registries can lead to higher rates of optimal
therapy and improved outcomes.<sup>341–343</sup></p>
<p>An ECG should be done annually to detect QRS
prolongation<sup>344</sup> as such patients may become candidates for
CRT. Furthermore, it may identify conduction disturbances and AF.</p>
<p>Serial echocardiography is generally not necessary, although an
echocardiogram should be repeated if there has been a deterioration in
clinical status. An echocardiogram is also advised 3–6 months after
optimization of standard therapies for HFrEF to determine the need for
addition of newer pharmacological agents and implanted devices.</p>
<p><strong>9.5.2 Monitoring with biomarkers</strong></p>
<p>Trials investigating the use of biomarkers (particularly BNP and/or
NT-proBNP) to guide pharmacotherapy for HFrEF have produced conflicting
results.<sup>345–352</sup> They are undoubtedly good prognostic
markers.<sup>72</sup><sup>,</sup><sup>353</sup><sup>,</sup><sup>354</sup>
Conceptually, it is not clear what a biomarker-supported strategy might
offer in addition to assiduous application of guideline-recommended
therapy. Current evidence, therefore, does not support the routine
measurement of BNP or NT-proBNP to guide titration of therapy.</p>
<h3 >9.6 Telemonitoring</h3>
<p>Telemonitoring enables patients to provide, remotely, digital health
information to support and optimize their care. Data such as symptoms,
weight, heart rate, and BP, can be collected frequently, stored in an
electronic health record and used to guide patients (directly or through
a healthcare professional), to adjust therapy or to seek further advice.
Home telemonitoring (HTM) can help maintain quality of care, facilitate
rapid access to care when needed, reduce patient travel costs, and
minimize the frequency of clinic visits.<sup>355</sup> Enforced
cessation of face-to-face consultations in many countries during the
recent COVID-19 pandemic have highlighted some of the potential
advantages of HTM.<sup>356</sup></p>
<p>Trials of HTM are diverse. Patients are usually required to make
measurements and, as for many other aspects of HF management, adherence
may be incomplete. HTM may be provided as a local, regional, or national
service. Systems that focus on optimizing management rather than
detecting and managing medical emergencies need only to be staffed
during standard working hours. Some systems are designed also to offer
support at any time requested by the patient. The comparative
effectiveness and cost effectiveness of each strategy is uncertain.
Systems that focus on continuous optimization of care (a health
maintenance approach) rather than trying to anticipate and manage
episodes of worsening (a strategy that is plagued by a large number of
false-positive alerts), appear more successful.<sup>357</sup> HTM is an
efficient method for providing patient education and motivation and
aiding delivery of care, but it should be adapted to work in synergy
with existing healthcare provision.<sup>358</sup></p>
<p>A Cochrane systematic review conducted in 2017 identified 39 relevant
trials of HTM, largely based on assessments of symptoms, weight, heart
rate and rhythm, and BP and found that HTM was associated with a
reduction in all-cause mortality of 20% and HF hospitalization of
37%.<sup>359</sup> Since then, several neutral trials and at least one
positive trial have been published.<sup>357</sup><sup>,</sup>360–364
These are unlikely to change the positive results of the systematic
review. Importantly, if social distancing and the ‘green’ agenda are
important, HTM only needs to show that it is not inferior to
contemporary methods of delivering care to be an appropriate means of
supporting care.<sup>356</sup></p>
<p>Whether wearable technologies for monitoring heart rate and rhythm or
lung congestion (bio-impedance or lung radar) offer additional benefits
to conventional HTM described above is
uncertain.<sup>365</sup><sup>,</sup><sup>–</sup><sup>367</sup></p>
<p>Many implanted therapeutic devices can provide, wirelessly and
remotely, information either on the device itself (generator and lead
function), arrhythmias, or on patient physiology (heart rate, activity,
heart sounds, bio-impedance). There is strong evidence that monitoring
can detect device malfunction earlier than by conventional monitoring
and that it may be useful for detecting arrhythmias such as AF. However,
there is little evidence that device monitoring reduces admissions for
HF or mortality.<sup>368–370</sup><sup>,</sup><sup>371</sup></p>
<p>Devices that only provide a monitoring function are also available.
Implantable loop-recorders can be injected subcutaneously and used to
monitor heart rate and rhythm, activity, and bio-impedance. Monitoring
devices can also be placed in the pulmonary artery to monitor pressure
wirelessly, although the external reader required to detect the device
signal is rather bulky and requires patient co-operation. A rise in
diastolic pulmonary artery pressure may be one of the earliest signs of
congestion. A preliminary, but fairly substantial, trial showed a
reduction in the risk of recurrent HF hospitalization.<sup>372</sup> A
much larger trial has completed recruitment
(GUIDE-HF).<sup>373</sup></p>
<p>Thus, non-invasive HTM may be considered for patients with HF in
order to reduce the risk of recurrent CV and HF hospitalizations and CV
death; further evidence on management guided by implanted systems is
awaited.<sup>374</sup></p>
<p>Recommendations for telemonitoring</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table39.jpeg?Expires=1689850106&amp;Signature=JFEasFwi9mgJLXIP~f00n3lbPHCrH5R-7fu19aFJnqg6y~hoSacsWjIFRKsxZ209bwa4t135UmmrQZzaOeMh84HGfl~GLXtDJB6UzXi~YQbUDKJqsF~G-CyX6yMnzlH8D~lB~UZMEAJYafxHYC5NeYd6dGjFOKAItrXpX0FPm1ip5C48Vlk-An~bpFce0Htl4yHf5D0dzKa~vn2ldAxgRXIAD7SPmJMmj0FTT8jzu~zUvJQwTCtNONbKfHzmoFbP28mMHZ08~ySl~8m0vrAE2gWAC0LHDax6V-FKYv5ePWMpunZAM8wzcTkIKUNuXDzHe99CcKsEOfxLEgbwz2NQcg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table39.jpeg?Expires=1689850106&amp;Signature=JFEasFwi9mgJLXIP~f00n3lbPHCrH5R-7fu19aFJnqg6y~hoSacsWjIFRKsxZ209bwa4t135UmmrQZzaOeMh84HGfl~GLXtDJB6UzXi~YQbUDKJqsF~G-CyX6yMnzlH8D~lB~UZMEAJYafxHYC5NeYd6dGjFOKAItrXpX0FPm1ip5C48Vlk-An~bpFce0Htl4yHf5D0dzKa~vn2ldAxgRXIAD7SPmJMmj0FTT8jzu~zUvJQwTCtNONbKfHzmoFbP28mMHZ08~ySl~8m0vrAE2gWAC0LHDax6V-FKYv5ePWMpunZAM8wzcTkIKUNuXDzHe99CcKsEOfxLEgbwz2NQcg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CV = cardiovascular; HF = heart failure; HFrEF = heart failure with
reduced ejection fraction; HTM = home telemonitoring; LVEF = left
ventricular ejection fraction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for telemonitoring</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table39.jpeg?Expires=1689850106&amp;Signature=JFEasFwi9mgJLXIP~f00n3lbPHCrH5R-7fu19aFJnqg6y~hoSacsWjIFRKsxZ209bwa4t135UmmrQZzaOeMh84HGfl~GLXtDJB6UzXi~YQbUDKJqsF~G-CyX6yMnzlH8D~lB~UZMEAJYafxHYC5NeYd6dGjFOKAItrXpX0FPm1ip5C48Vlk-An~bpFce0Htl4yHf5D0dzKa~vn2ldAxgRXIAD7SPmJMmj0FTT8jzu~zUvJQwTCtNONbKfHzmoFbP28mMHZ08~ySl~8m0vrAE2gWAC0LHDax6V-FKYv5ePWMpunZAM8wzcTkIKUNuXDzHe99CcKsEOfxLEgbwz2NQcg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table39.jpeg?Expires=1689850106&amp;Signature=JFEasFwi9mgJLXIP~f00n3lbPHCrH5R-7fu19aFJnqg6y~hoSacsWjIFRKsxZ209bwa4t135UmmrQZzaOeMh84HGfl~GLXtDJB6UzXi~YQbUDKJqsF~G-CyX6yMnzlH8D~lB~UZMEAJYafxHYC5NeYd6dGjFOKAItrXpX0FPm1ip5C48Vlk-An~bpFce0Htl4yHf5D0dzKa~vn2ldAxgRXIAD7SPmJMmj0FTT8jzu~zUvJQwTCtNONbKfHzmoFbP28mMHZ08~ySl~8m0vrAE2gWAC0LHDax6V-FKYv5ePWMpunZAM8wzcTkIKUNuXDzHe99CcKsEOfxLEgbwz2NQcg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CV = cardiovascular; HF = heart failure; HFrEF = heart failure with
reduced ejection fraction; HTM = home telemonitoring; LVEF = left
ventricular ejection fraction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h2 >10 Advanced heart failure</h2>
<h3 >10.1 Epidemiology,
diagnosis, and prognosis</h3>
<p>Many patients with HF progress into a phase of advanced HF,
characterized by persistent symptoms despite maximal
therapy.<sup>375–377</sup> The prevalence of advanced HF is increasing
due to the growing number of patients with HF, ageing of the population,
and better treatment and survival of HF. Prognosis remains poor, with a
1-year mortality ranging from 25% to
75%.<sup>378</sup><sup>,</sup><sup>–</sup><sup>380</sup></p>
<p>The updated HFA-ESC 2018 criteria for the definition of advanced HF
are reported in <em>Table 13</em>.<sup>376</sup> A severely reduced LVEF
is common but not required for a diagnosis of advanced HF as it may
develop in patients with HFpEF as well. In addition to the reported
criteria, extra-cardiac organ dysfunction due to HF (e.g. cardiac
cachexia, liver or kidney dysfunction) or type II pulmonary hypertension
may be present, but are not required for the definition of advanced
HF.<sup>376</sup></p>
<p>Table 13</p>
<p>Criteria for definition of advanced heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
All the following criteria must be present despite optimal medical
treatment: 
</td>
</tr>
<tr>
<td>
<ol type="1">
<li>Severe and persistent symptoms of heart failure [NYHA class III
(advanced) or IV]. 
</td>
</tr>
<tr>
<td>
<ol start="2" type="1">
<li>Severe cardiac dysfunction defined by at least one of the following:
<ul>
<li>
<p>
LVEF ≤30%
</p>
</li>
<li>
<p>
Isolated RV failure (e.g., ARVC)
</p>
</li>
<li>
<p>
Non-operable severe valve abnormalities
</p>
</li>
<li>
<p>
Non-operable severe congenital abnormalities
</p>
</li>
<li>
<p>
Persistently high (or increasing) BNP or NT-proBNP values and severe LV
diastolic dysfunction or structural abnormalities (according to the
definitions of HFpEF).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ol start="3" type="1">
<li>Episodes of pulmonary or systemic congestion requiring high-dose
i.v. diuretics (or diuretic combinations) or episodes of low output
requiring inotropes or vasoactive drugs or malignant arrhythmias causing
&gt;1 unplanned visit or hospitalization in the last 12 months. 
</td>
</tr>
<tr>
<td>
<ol start="4" type="1">
<li>Severe impairment of exercise capacity with inability to exercise or
low 6MWT distance (&lt;300 m) or pVO<sub>2</sub> &lt;12 mL/kg/min or
&lt;50% predicted value, estimated to be of cardiac origin. 
</td>
</tr>
</tbody>
</table></li>
</ol></li>
</ol></li>
</ol></li>
</ol>
<table>
<tbody>
<tr>
<td>
All the following criteria must be present despite optimal medical
treatment: 
</td>
</tr>
<tr>
<td>
<ol type="1">
<li>Severe and persistent symptoms of heart failure [NYHA class III
(advanced) or IV]. 
</td>
</tr>
<tr>
<td>
<ol start="2" type="1">
<li>Severe cardiac dysfunction defined by at least one of the following:
<ul>
<li>
<p>
LVEF ≤30%
</p>
</li>
<li>
<p>
Isolated RV failure (e.g., ARVC)
</p>
</li>
<li>
<p>
Non-operable severe valve abnormalities
</p>
</li>
<li>
<p>
Non-operable severe congenital abnormalities
</p>
</li>
<li>
<p>
Persistently high (or increasing) BNP or NT-proBNP values and severe LV
diastolic dysfunction or structural abnormalities (according to the
definitions of HFpEF).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ol start="3" type="1">
<li>Episodes of pulmonary or systemic congestion requiring high-dose
i.v. diuretics (or diuretic combinations) or episodes of low output
requiring inotropes or vasoactive drugs or malignant arrhythmias causing
&gt;1 unplanned visit or hospitalization in the last 12 months. 
</td>
</tr>
<tr>
<td>
<ol start="4" type="1">
<li>Severe impairment of exercise capacity with inability to exercise or
low 6MWT distance (&lt;300 m) or pVO<sub>2</sub> &lt;12 mL/kg/min or
&lt;50% predicted value, estimated to be of cardiac origin. 
</td>
</tr>
</tbody>
</table></li>
</ol></li>
</ol></li>
</ol></li>
</ol>
<p>6MWT = 6-minute walk test; ARVC = arrhythmogenic right ventricular
cardiomyopathy; BNP = B-type natriuretic peptide; HFpEF = heart failure
with preserved ejection fraction; i.v. = intravenous; LV = left
ventricular; LVEF = left ventricular ejection fraction;
NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York
Heart Association; pVO<sub>2</sub> = peak oxygen consumption; RV = right
ventricular. Modified from <sup>376</sup>.</p>
<p>Table 13</p>
<p>Criteria for definition of advanced heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
All the following criteria must be present despite optimal medical
treatment: 
</td>
</tr>
<tr>
<td>
<ol type="1">
<li>Severe and persistent symptoms of heart failure [NYHA class III
(advanced) or IV]. 
</td>
</tr>
<tr>
<td>
<ol start="2" type="1">
<li>Severe cardiac dysfunction defined by at least one of the following:
<ul>
<li>
<p>
LVEF ≤30%
</p>
</li>
<li>
<p>
Isolated RV failure (e.g., ARVC)
</p>
</li>
<li>
<p>
Non-operable severe valve abnormalities
</p>
</li>
<li>
<p>
Non-operable severe congenital abnormalities
</p>
</li>
<li>
<p>
Persistently high (or increasing) BNP or NT-proBNP values and severe LV
diastolic dysfunction or structural abnormalities (according to the
definitions of HFpEF).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ol start="3" type="1">
<li>Episodes of pulmonary or systemic congestion requiring high-dose
i.v. diuretics (or diuretic combinations) or episodes of low output
requiring inotropes or vasoactive drugs or malignant arrhythmias causing
&gt;1 unplanned visit or hospitalization in the last 12 months. 
</td>
</tr>
<tr>
<td>
<ol start="4" type="1">
<li>Severe impairment of exercise capacity with inability to exercise or
low 6MWT distance (&lt;300 m) or pVO<sub>2</sub> &lt;12 mL/kg/min or
&lt;50% predicted value, estimated to be of cardiac origin. 
</td>
</tr>
</tbody>
</table></li>
</ol></li>
</ol></li>
</ol></li>
</ol>
<table>
<tbody>
<tr>
<td>
All the following criteria must be present despite optimal medical
treatment: 
</td>
</tr>
<tr>
<td>
<ol type="1">
<li>Severe and persistent symptoms of heart failure [NYHA class III
(advanced) or IV]. 
</td>
</tr>
<tr>
<td>
<ol start="2" type="1">
<li>Severe cardiac dysfunction defined by at least one of the following:
<ul>
<li>
<p>
LVEF ≤30%
</p>
</li>
<li>
<p>
Isolated RV failure (e.g., ARVC)
</p>
</li>
<li>
<p>
Non-operable severe valve abnormalities
</p>
</li>
<li>
<p>
Non-operable severe congenital abnormalities
</p>
</li>
<li>
<p>
Persistently high (or increasing) BNP or NT-proBNP values and severe LV
diastolic dysfunction or structural abnormalities (according to the
definitions of HFpEF).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ol start="3" type="1">
<li>Episodes of pulmonary or systemic congestion requiring high-dose
i.v. diuretics (or diuretic combinations) or episodes of low output
requiring inotropes or vasoactive drugs or malignant arrhythmias causing
&gt;1 unplanned visit or hospitalization in the last 12 months. 
</td>
</tr>
<tr>
<td>
<ol start="4" type="1">
<li>Severe impairment of exercise capacity with inability to exercise or
low 6MWT distance (&lt;300 m) or pVO<sub>2</sub> &lt;12 mL/kg/min or
&lt;50% predicted value, estimated to be of cardiac origin. 
</td>
</tr>
</tbody>
</table></li>
</ol></li>
</ol></li>
</ol></li>
</ol>
<p>6MWT = 6-minute walk test; ARVC = arrhythmogenic right ventricular
cardiomyopathy; BNP = B-type natriuretic peptide; HFpEF = heart failure
with preserved ejection fraction; i.v. = intravenous; LV = left
ventricular; LVEF = left ventricular ejection fraction;
NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York
Heart Association; pVO<sub>2</sub> = peak oxygen consumption; RV = right
ventricular. Modified from <sup>376</sup>.</p>
<p>The Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) profiles, developed to classify patients with a
potential indication for durable MCS devices, describes clinical
parameters and characteristics consistent with a need for advanced
therapies (<em>Table 14</em>).<sup>381</sup> This classification has
also been shown to be useful in estimating the prognosis of patients
undergoing urgent heart transplantation<sup>382</sup> or LV assist
device (LVAD) implantation,<sup>383</sup> and for risk assessment in
ambulatory advanced HF patients.<sup>384</sup></p>
<p>Table 14</p>
<p>Interagency Registry for Mechanically Assisted Circulatory Support
profile descriptions of patients with advanced heart failure</p>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Profile</th>
<th>Time frame for intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profile 1. Critical cardiogenic shock</strong> Patient with
life-threatening hypotension despite rapidly escalating inotropic
support, critical organ hypoperfusion, often confirmed by worsening
acidosis and/or lactate levels. “Crash and burn.” </td>
<td>Definitive intervention needed within hours. </td>
</tr>
<tr>
<td><strong>Profile 2. Progressive decline</strong> Patient with
declining function despite i.v. inotropic support, may be manifest by
worsening renal function, nutritional depletion, inability to restore
volume balance. “Sliding on inotropes.” Also describes declining status
in patients unable to tolerate inotropic therapy. </td>
<td>Definitive intervention needed within few days. </td>
</tr>
<tr>
<td><strong>Profile 3. Stable on inotrope or inotrope-dependent</strong>
Patient with stable blood pressure, organ function, nutrition, and
symptoms on continuous i.v. inotropic support (or a temporary
circulatory support device or both) but demonstrating repeated failure
to wean from support due to recurrent symptomatic hypotension or renal
dysfunction. “Dependent stability.” </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 4. Frequent Flyer</strong> Patient can be stabilized
close to normal volume status but experiences daily symptoms of
congestion at rest or during activities of daily living. Doses of
diuretics generally fluctuate at very high levels. More intensive
management and surveillance strategies should be considered, which may
in some cases reveal poor compliance that would compromise outcomes with
any therapy. Some patients may shuttle between 4 and 5. </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 5. Housebound</strong> Comfortable at rest and with
activities of daily living but unable to engage in any other activity,
living predominantly within the house. Patients are comfortable at rest
without congestive symptoms, but may have underlying refractory elevated
volume status, often with renal dysfunction. If underlying nutritional
status and organ function are marginal, patients may be more at risk
than INTERMACS 4, and require definitive intervention. </td>
<td>Variable urgency, depends upon maintenance of nutrition, organ
function, and activity. </td>
</tr>
<tr>
<td><strong>Profile 6. Exertion limited</strong> Patient without
evidence of fluid overload, comfortable at rest and with activities of
daily living and minor activities outside the home but fatigues after
the first few minutes of any meaningful activity. Attribution to cardiac
limitation requires careful measurement of peak oxygen consumption, in
some cases with haemodynamic monitoring, to confirm severity of cardiac
impairment. “Walking wounded.” </td>
<td>Variable, depends upon maintenance of nutrition, organ function, and
activity level. </td>
</tr>
<tr>
<td><strong>Profile 7. Advanced NYHA class III symptoms</strong> Patient
without current or recent episodes of unstable fluid balance, living
comfortably with meaningful activity limited to mild physical
exertion. </td>
<td>Heart transplantation or MCS may not be currently indicated. </td>
</tr>
<tr>
<td><strong>Modifiers for profiles</strong> </td>
<td><strong>Possible profiles that can be modified</strong> </td>
</tr>
<tr>
<td>Temporary MCS can modify profile only in hospitalized patients. They
include IABP, ECMO, TandemHeart, LVAD, Impella. </td>
<td>1, 2, 3 </td>
</tr>
<tr>
<td>Arrhythmia can modify any profile. They include recurrent
ventricular tachyarrhythmias that have recently contributed
substantially to clinical compromise, frequent ICD shocks or requirement
for external defibrillation, usually more than twice weekly. </td>
<td>1–7 </td>
</tr>
<tr>
<td>Frequent episodes of HF decompensation characterize patients
requiring frequent emergency visits or hospitalizations for diuretics,
ultrafiltration, or temporary i.v. vasoactive therapy. Frequent episodes
may be considered as at least two emergency visits/admissions in the
past 3 months or three in the past 6 months. </td>
<td>3 if at home, 4, 5, 6. Rarely for profile 7. </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Profile</th>
<th>Time frame for intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profile 1. Critical cardiogenic shock</strong> Patient with
life-threatening hypotension despite rapidly escalating inotropic
support, critical organ hypoperfusion, often confirmed by worsening
acidosis and/or lactate levels. “Crash and burn.” </td>
<td>Definitive intervention needed within hours. </td>
</tr>
<tr>
<td><strong>Profile 2. Progressive decline</strong> Patient with
declining function despite i.v. inotropic support, may be manifest by
worsening renal function, nutritional depletion, inability to restore
volume balance. “Sliding on inotropes.” Also describes declining status
in patients unable to tolerate inotropic therapy. </td>
<td>Definitive intervention needed within few days. </td>
</tr>
<tr>
<td><strong>Profile 3. Stable on inotrope or inotrope-dependent</strong>
Patient with stable blood pressure, organ function, nutrition, and
symptoms on continuous i.v. inotropic support (or a temporary
circulatory support device or both) but demonstrating repeated failure
to wean from support due to recurrent symptomatic hypotension or renal
dysfunction. “Dependent stability.” </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 4. Frequent Flyer</strong> Patient can be stabilized
close to normal volume status but experiences daily symptoms of
congestion at rest or during activities of daily living. Doses of
diuretics generally fluctuate at very high levels. More intensive
management and surveillance strategies should be considered, which may
in some cases reveal poor compliance that would compromise outcomes with
any therapy. Some patients may shuttle between 4 and 5. </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 5. Housebound</strong> Comfortable at rest and with
activities of daily living but unable to engage in any other activity,
living predominantly within the house. Patients are comfortable at rest
without congestive symptoms, but may have underlying refractory elevated
volume status, often with renal dysfunction. If underlying nutritional
status and organ function are marginal, patients may be more at risk
than INTERMACS 4, and require definitive intervention. </td>
<td>Variable urgency, depends upon maintenance of nutrition, organ
function, and activity. </td>
</tr>
<tr>
<td><strong>Profile 6. Exertion limited</strong> Patient without
evidence of fluid overload, comfortable at rest and with activities of
daily living and minor activities outside the home but fatigues after
the first few minutes of any meaningful activity. Attribution to cardiac
limitation requires careful measurement of peak oxygen consumption, in
some cases with haemodynamic monitoring, to confirm severity of cardiac
impairment. “Walking wounded.” </td>
<td>Variable, depends upon maintenance of nutrition, organ function, and
activity level. </td>
</tr>
<tr>
<td><strong>Profile 7. Advanced NYHA class III symptoms</strong> Patient
without current or recent episodes of unstable fluid balance, living
comfortably with meaningful activity limited to mild physical
exertion. </td>
<td>Heart transplantation or MCS may not be currently indicated. </td>
</tr>
<tr>
<td><strong>Modifiers for profiles</strong> </td>
<td><strong>Possible profiles that can be modified</strong> </td>
</tr>
<tr>
<td>Temporary MCS can modify profile only in hospitalized patients. They
include IABP, ECMO, TandemHeart, LVAD, Impella. </td>
<td>1, 2, 3 </td>
</tr>
<tr>
<td>Arrhythmia can modify any profile. They include recurrent
ventricular tachyarrhythmias that have recently contributed
substantially to clinical compromise, frequent ICD shocks or requirement
for external defibrillation, usually more than twice weekly. </td>
<td>1–7 </td>
</tr>
<tr>
<td>Frequent episodes of HF decompensation characterize patients
requiring frequent emergency visits or hospitalizations for diuretics,
ultrafiltration, or temporary i.v. vasoactive therapy. Frequent episodes
may be considered as at least two emergency visits/admissions in the
past 3 months or three in the past 6 months. </td>
<td>3 if at home, 4, 5, 6. Rarely for profile 7. </td>
</tr>
</tbody>
</table>
<p>ECMO = extracorporeal membrane oxygenation; HF = heart failure;
IABP =  intra-aortic balloon pump; ICD = implantable
cardioverter-defibrillator; INTERMACS = Interagency Registry for
Mechanically Assisted Circulatory Support; i.v. = intravenous;
LVAD = left ventricular assist device; MCS = mechanical circulatory
support; NYHA = New York Heart Association. Modified from
<sup>381</sup>.</p>
<p>Table 14</p>
<p>Interagency Registry for Mechanically Assisted Circulatory Support
profile descriptions of patients with advanced heart failure</p>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Profile</th>
<th>Time frame for intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profile 1. Critical cardiogenic shock</strong> Patient with
life-threatening hypotension despite rapidly escalating inotropic
support, critical organ hypoperfusion, often confirmed by worsening
acidosis and/or lactate levels. “Crash and burn.” </td>
<td>Definitive intervention needed within hours. </td>
</tr>
<tr>
<td><strong>Profile 2. Progressive decline</strong> Patient with
declining function despite i.v. inotropic support, may be manifest by
worsening renal function, nutritional depletion, inability to restore
volume balance. “Sliding on inotropes.” Also describes declining status
in patients unable to tolerate inotropic therapy. </td>
<td>Definitive intervention needed within few days. </td>
</tr>
<tr>
<td><strong>Profile 3. Stable on inotrope or inotrope-dependent</strong>
Patient with stable blood pressure, organ function, nutrition, and
symptoms on continuous i.v. inotropic support (or a temporary
circulatory support device or both) but demonstrating repeated failure
to wean from support due to recurrent symptomatic hypotension or renal
dysfunction. “Dependent stability.” </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 4. Frequent Flyer</strong> Patient can be stabilized
close to normal volume status but experiences daily symptoms of
congestion at rest or during activities of daily living. Doses of
diuretics generally fluctuate at very high levels. More intensive
management and surveillance strategies should be considered, which may
in some cases reveal poor compliance that would compromise outcomes with
any therapy. Some patients may shuttle between 4 and 5. </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 5. Housebound</strong> Comfortable at rest and with
activities of daily living but unable to engage in any other activity,
living predominantly within the house. Patients are comfortable at rest
without congestive symptoms, but may have underlying refractory elevated
volume status, often with renal dysfunction. If underlying nutritional
status and organ function are marginal, patients may be more at risk
than INTERMACS 4, and require definitive intervention. </td>
<td>Variable urgency, depends upon maintenance of nutrition, organ
function, and activity. </td>
</tr>
<tr>
<td><strong>Profile 6. Exertion limited</strong> Patient without
evidence of fluid overload, comfortable at rest and with activities of
daily living and minor activities outside the home but fatigues after
the first few minutes of any meaningful activity. Attribution to cardiac
limitation requires careful measurement of peak oxygen consumption, in
some cases with haemodynamic monitoring, to confirm severity of cardiac
impairment. “Walking wounded.” </td>
<td>Variable, depends upon maintenance of nutrition, organ function, and
activity level. </td>
</tr>
<tr>
<td><strong>Profile 7. Advanced NYHA class III symptoms</strong> Patient
without current or recent episodes of unstable fluid balance, living
comfortably with meaningful activity limited to mild physical
exertion. </td>
<td>Heart transplantation or MCS may not be currently indicated. </td>
</tr>
<tr>
<td><strong>Modifiers for profiles</strong> </td>
<td><strong>Possible profiles that can be modified</strong> </td>
</tr>
<tr>
<td>Temporary MCS can modify profile only in hospitalized patients. They
include IABP, ECMO, TandemHeart, LVAD, Impella. </td>
<td>1, 2, 3 </td>
</tr>
<tr>
<td>Arrhythmia can modify any profile. They include recurrent
ventricular tachyarrhythmias that have recently contributed
substantially to clinical compromise, frequent ICD shocks or requirement
for external defibrillation, usually more than twice weekly. </td>
<td>1–7 </td>
</tr>
<tr>
<td>Frequent episodes of HF decompensation characterize patients
requiring frequent emergency visits or hospitalizations for diuretics,
ultrafiltration, or temporary i.v. vasoactive therapy. Frequent episodes
may be considered as at least two emergency visits/admissions in the
past 3 months or three in the past 6 months. </td>
<td>3 if at home, 4, 5, 6. Rarely for profile 7. </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Profile</th>
<th>Time frame for intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profile 1. Critical cardiogenic shock</strong> Patient with
life-threatening hypotension despite rapidly escalating inotropic
support, critical organ hypoperfusion, often confirmed by worsening
acidosis and/or lactate levels. “Crash and burn.” </td>
<td>Definitive intervention needed within hours. </td>
</tr>
<tr>
<td><strong>Profile 2. Progressive decline</strong> Patient with
declining function despite i.v. inotropic support, may be manifest by
worsening renal function, nutritional depletion, inability to restore
volume balance. “Sliding on inotropes.” Also describes declining status
in patients unable to tolerate inotropic therapy. </td>
<td>Definitive intervention needed within few days. </td>
</tr>
<tr>
<td><strong>Profile 3. Stable on inotrope or inotrope-dependent</strong>
Patient with stable blood pressure, organ function, nutrition, and
symptoms on continuous i.v. inotropic support (or a temporary
circulatory support device or both) but demonstrating repeated failure
to wean from support due to recurrent symptomatic hypotension or renal
dysfunction. “Dependent stability.” </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 4. Frequent Flyer</strong> Patient can be stabilized
close to normal volume status but experiences daily symptoms of
congestion at rest or during activities of daily living. Doses of
diuretics generally fluctuate at very high levels. More intensive
management and surveillance strategies should be considered, which may
in some cases reveal poor compliance that would compromise outcomes with
any therapy. Some patients may shuttle between 4 and 5. </td>
<td>Definitive intervention elective over a period of weeks to few
months. </td>
</tr>
<tr>
<td><strong>Profile 5. Housebound</strong> Comfortable at rest and with
activities of daily living but unable to engage in any other activity,
living predominantly within the house. Patients are comfortable at rest
without congestive symptoms, but may have underlying refractory elevated
volume status, often with renal dysfunction. If underlying nutritional
status and organ function are marginal, patients may be more at risk
than INTERMACS 4, and require definitive intervention. </td>
<td>Variable urgency, depends upon maintenance of nutrition, organ
function, and activity. </td>
</tr>
<tr>
<td><strong>Profile 6. Exertion limited</strong> Patient without
evidence of fluid overload, comfortable at rest and with activities of
daily living and minor activities outside the home but fatigues after
the first few minutes of any meaningful activity. Attribution to cardiac
limitation requires careful measurement of peak oxygen consumption, in
some cases with haemodynamic monitoring, to confirm severity of cardiac
impairment. “Walking wounded.” </td>
<td>Variable, depends upon maintenance of nutrition, organ function, and
activity level. </td>
</tr>
<tr>
<td><strong>Profile 7. Advanced NYHA class III symptoms</strong> Patient
without current or recent episodes of unstable fluid balance, living
comfortably with meaningful activity limited to mild physical
exertion. </td>
<td>Heart transplantation or MCS may not be currently indicated. </td>
</tr>
<tr>
<td><strong>Modifiers for profiles</strong> </td>
<td><strong>Possible profiles that can be modified</strong> </td>
</tr>
<tr>
<td>Temporary MCS can modify profile only in hospitalized patients. They
include IABP, ECMO, TandemHeart, LVAD, Impella. </td>
<td>1, 2, 3 </td>
</tr>
<tr>
<td>Arrhythmia can modify any profile. They include recurrent
ventricular tachyarrhythmias that have recently contributed
substantially to clinical compromise, frequent ICD shocks or requirement
for external defibrillation, usually more than twice weekly. </td>
<td>1–7 </td>
</tr>
<tr>
<td>Frequent episodes of HF decompensation characterize patients
requiring frequent emergency visits or hospitalizations for diuretics,
ultrafiltration, or temporary i.v. vasoactive therapy. Frequent episodes
may be considered as at least two emergency visits/admissions in the
past 3 months or three in the past 6 months. </td>
<td>3 if at home, 4, 5, 6. Rarely for profile 7. </td>
</tr>
</tbody>
</table>
<p>ECMO = extracorporeal membrane oxygenation; HF = heart failure;
IABP =  intra-aortic balloon pump; ICD = implantable
cardioverter-defibrillator; INTERMACS = Interagency Registry for
Mechanically Assisted Circulatory Support; i.v. = intravenous;
LVAD = left ventricular assist device; MCS = mechanical circulatory
support; NYHA = New York Heart Association. Modified from
<sup>381</sup>.</p>
<p>Prognostic stratification is important to identify the ideal time for
referral to an appropriate centre (i.e. one capable of providing
advanced HF therapies), to properly convey expectations to patients and
families, and to plan treatment and follow-up strategies
(<em>Figure 4</em>).<sup>376</sup> Patients with contraindications to
MCS or heart transplantation should be considered for palliative care
(see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-10.2.4">section 10.2.4</a>).</p>
<p>Figure 4</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f4.jpeg?Expires=1689850106&amp;Signature=qhcgpGCLWmpoiGL~nb2Za4qIufDvNe72jmR1xv2tJ-HaV2PQK~9GmoPBmWCL48tW4macz23k3OFru98NkFU0aPAQwdXgJ9K1mn-fXGOfA5JCIf4Ku06Q7wHCS2zKSc3lH51BVSQUpcoL9fFty3Qp9AC9UV~DF-xbIXoRBdf-06dTcsBO58CEKMYJF2zw4dRr5DK4XRJ6Eqi5Xh3OpFfKQL2Yd53yFf7UVBUBY8IvsE4S3CSwDTeY9JKrRp0bRHh2lyboduoR4Gt3Co2rusY8O0PuEMYIpoZB2M5~ok34dX~TNKeaFNKesH2Pr8yWCl-h-OpJYQe1xgKTw~~-nlIU3w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Algorithm for the treatment of patients with advanced heart failure. BTB = bridge to bridge; BTC = bridge to candidacy; BTD = bridge to decision; BTR = bridge to recovery; BTT = bridge to transplantation; CA = cardiac amyloidosis; DT = destination therapy; ESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy; HF = heart failure; HFA = Heart Failure Association; HT = heart transplantation; INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support; LVAD = left ventricular assist device; LVAD-BTC = left ventricular assist device – bridge to candidacy; LVAD-DT = left ventricular assist device – destination therapy; MCS = mechanical circulatory support. aThis algorithm can be applied to all patients with advanced HF defined according to the ESC/HFA criteria,376 with exception of HCM, CA, arrhythmic storm, adult congenital heart disease, refractory angina. bRecurrent hospitalization, progressive end-organ failure, refractory congestion, inability to perform cardiopulmonary exercise test or peak oxygen consumption &lt;12 mL/min/kg or &lt;50% of expected value.385 Colour code for classes of recommendation: Green for Class of recommendation I and Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation)." />
<figcaption aria-hidden="true">Algorithm for the treatment of patients
with advanced heart failure. BTB = bridge to bridge; BTC = bridge to
candidacy; BTD = bridge to decision; BTR = bridge to recovery;
BTT = bridge to transplantation; CA = cardiac amyloidosis;
DT = destination therapy; ESC = European Society of Cardiology;
HCM = hypertrophic cardiomyopathy; HF = heart failure; HFA = Heart
Failure Association; HT = heart transplantation; INTERMACS = Interagency
Registry for Mechanically Assisted Circulatory Support; LVAD = left
ventricular assist device; LVAD-BTC = left ventricular assist device –
bridge to candidacy; LVAD-DT = left ventricular assist device –
destination therapy; MCS = mechanical circulatory support. aThis
algorithm can be applied to all patients with advanced HF defined
according to the ESC/HFA criteria,376 with exception of HCM, CA,
arrhythmic storm, adult congenital heart disease, refractory angina.
bRecurrent hospitalization, progressive end-organ failure, refractory
congestion, inability to perform cardiopulmonary exercise test or peak
oxygen consumption &lt;12 mL/min/kg or &lt;50% of expected value.385
Colour code for classes of recommendation: Green for Class of
recommendation I and Yellow for Class of recommendation IIa (see Table 1
for further details on classes of recommendation).</figcaption>
</figure>
<p>Algorithm for the treatment of patients with advanced heart failure.
BTB = bridge to bridge; BTC = bridge to candidacy; BTD = bridge to
decision; BTR = bridge to recovery; BTT = bridge to transplantation;
CA = cardiac amyloidosis; DT = destination therapy; ESC = European
Society of Cardiology; HCM = hypertrophic cardiomyopathy; HF = heart
failure; HFA = Heart Failure Association; HT = heart transplantation;
INTERMACS = Interagency Registry for Mechanically Assisted Circulatory
Support; LVAD = left ventricular assist device; LVAD-BTC = left
ventricular assist device – bridge to candidacy; LVAD-DT = left
ventricular assist device – destination therapy; MCS = mechanical
circulatory support. <sup>a</sup>This algorithm can be applied to all
patients with advanced HF defined according to the ESC/HFA
criteria,<sup>376</sup> with exception of HCM, CA, arrhythmic storm,
adult congenital heart disease, refractory angina. <sup>b</sup>Recurrent
hospitalization, progressive end-organ failure, refractory congestion,
inability to perform cardiopulmonary exercise test or peak oxygen
consumption &lt;12 mL/min/kg or &lt;50% of expected value.<sup>385</sup>
Colour code for classes of recommendation: Green for Class of
recommendation I and Yellow for Class of recommendation IIa (see
<em>Table 1</em> for further details on classes of recommendation).</p>
<p>Despite many prognostic parameters <em>(<a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 13</a>)</em>, predicting outcomes remains difficult and patients
are often referred to advanced HF centres too late. Identifying warning
signs in patients with non-advanced symptoms may allow early referral so
that MCS and heart transplantation may be offered before the development
of end-organ failure (<em>Figure 5</em>; <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 14</a>)</em>.<sup>376</sup><sup>,</sup><sup>386</sup> An
organizational model between centres with different levels of care
complexity, based on a ‘Hub and Spoke’ network is the key to good
patient management.<sup>376</sup></p>
<p>Figure 5</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f5.jpeg?Expires=1689850106&amp;Signature=GWItRwkN45i~-41ekjFYIDCbVfN6WU9aAe5FwkAha3QEK7U54VTdwrKQyzF3Y3a0gSVS-IqHCXI00hWjTPg2CJ7W5DV0y14VcIShMLLVtloXbwHeEN1u5aXASr5LULjnfKJAIItcW0YwGDSIF~xpjxDGtbUtCG-sMc6eu40v4s85N8eoobX9cWLIRcL-7rMUDNX1QbAbDRp3~40KE7kNlSANB87mRV3Jg6FhJWqnHBKEdI1BDHCNQK6tqIZZutTcRgw3oMUhbb196HM8ElH5zvR1GyZWDEULPZcQVtq8KCv3ZMPK4zjKyVFXUpJsUPHJJBgbo6qHJMbcWVRenPj~FQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Triage of patients with advanced heart failure and appropriate timing of referral.376 ARNI = angiotensin receptor-neprilysin inhibitor; CRT = cardiac resynchronization therapy; HF = heart failure; HT = heart transplantation; ICD = implantable cardioverter-defibrillator; LT-MCS = long-term mechanical circulatory support; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; RASi = renin-angiotensin system inhibitor; RV = right ventricular; SBP = systolic blood pressure; QOL = quality of life. aLimited life expectancy may be due by major comorbidities such as cancer, dementia, end-stage organ dysfunction; other conditions that may impair follow-up or worsen post-treatment prognosis include frailty, irreversible cognitive dysfunction, psychiatric disorder, or psychosocial issues." />
<figcaption aria-hidden="true">Triage of patients with advanced heart
failure and appropriate timing of referral.376 ARNI = angiotensin
receptor-neprilysin inhibitor; CRT = cardiac resynchronization therapy;
HF = heart failure; HT = heart transplantation; ICD = implantable
cardioverter-defibrillator; LT-MCS = long-term mechanical circulatory
support; LVEF = left ventricular ejection fraction; NYHA = New York
Heart Association; RASi = renin-angiotensin system inhibitor; RV = right
ventricular; SBP = systolic blood pressure; QOL = quality of life.
aLimited life expectancy may be due by major comorbidities such as
cancer, dementia, end-stage organ dysfunction; other conditions that may
impair follow-up or worsen post-treatment prognosis include frailty,
irreversible cognitive dysfunction, psychiatric disorder, or
psychosocial issues.</figcaption>
</figure>
<p>Triage of patients with advanced heart failure and appropriate timing
of referral.<sup>376</sup> ARNI = angiotensin receptor-neprilysin
inhibitor; CRT = cardiac resynchronization therapy; HF = heart failure;
HT = heart transplantation; ICD = implantable
cardioverter-defibrillator; LT-MCS = long-term mechanical circulatory
support; LVEF = left ventricular ejection fraction; NYHA = New York
Heart Association; RASi = renin-angiotensin system inhibitor; RV = right
ventricular; SBP = systolic blood pressure; QOL = quality of life.
<sup>a</sup>Limited life expectancy may be due by major comorbidities
such as cancer, dementia, end-stage organ dysfunction; other conditions
that may impair follow-up or worsen post-treatment prognosis include
frailty, irreversible cognitive dysfunction, psychiatric disorder, or
psychosocial issues.</p>
<h3 >10.2 Management</h3>
<p>In patients with advanced HF, pharmacological therapy and short-term
MCS may be needed until the implantation of long-term MCS or heart
transplantation becomes available.</p>
<h4 >10.2.1
Pharmacological therapy and renal replacement</h4>
<p>Inotropes may improve haemodynamic parameters, reducing congestion,
augmenting cardiac output, and aiding peripheral perfusion. Although not
proven, this may help to prevent worsening end-organ function.
Conversely, traditional inotropes may favor myocardial ischaemia and/or
tachyarrhythmias and worsen the clinical
course.<sup>387</sup><sup>,</sup><sup>388</sup> They can be used as
palliative therapy for the relief of symptoms in patients without other
treatment options. Intermittent long-term use of inotropes may be
considered in outpatients to improve functional class and
QOL.<sup>389</sup><sup>,</sup><sup>390</sup></p>
<p>Kidney dysfunction and loop diuretic resistance often characterize
the clinical course of patients with advanced HF. Doubling of the loop
diuretic dose is proposed, in the first instance, followed by
concomitant administration of thiazides or metolazone (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-11.3.3">section
11.3.3</a>).<sup>145</sup> In patients who fail to respond to
diuretic-based strategies, renal replacement therapies should be
considered. Ultrafiltration is one of the most common approaches. It may
be considered in those with diuretic resistance even if data about its
effects on outcomes are
unsettled.<sup>391</sup><sup>,</sup><sup>392</sup></p>
<h4 >10.2.2 Mechanical circulatory
support</h4>
<p>MCS can improve survival and symptoms of patients with advanced
HF.<sup>376</sup><sup>,</sup><sup>393</sup> The use of MCS should be
considered for the different scenarios listed in <em>Table 15</em>.
Indications for short- and long-term MCS should be based on the
INTERMACS profiles <em>(Table 14</em>, <em>Figure 4).</em></p>
<p><strong>Short-term mechanical circulatory support</strong></p>
<p>Short-term MCS devices are indicated to reverse critical end-organ
hypoperfusion and hypoxia in the setting of cardiogenic shock. They can
be used for a short, limited, period of time, from a few days up to
several weeks. The aim is to support the central nervous system and
organ perfusion, to reverse acidosis and multi-organ failure until the
patient’s outcome becomes clearer be that of cardiac recovery,
transition to durable MCS or heart transplantation, or, in some cases,
towards a more palliative approach. The care of patients on short-term
MCS is complex and requires dedicated expertise including having
specific plans for stopping support when neither cardiac nor brain
injury recovers. Short-term MCS should be used in patients with
INTERMACS profiles 1 or 2 as a bridge to decision (BTD), bridge to
recovery (BTR), bridge to bridge (BTB) for either long-term MCS or
urgent heart transplantation (<em>Figure 4</em>).<sup>394</sup> Further
details about short-term MCS are reported in the
_Supplementary__t_<em>ext 11.4</em>.</p>
<p><strong>Long-term mechanical circulatory support</strong></p>
<p>Long-term MCS is indicated in selected patients when MT is
insufficient or when short-term MCS has not led to cardiac recovery or
clinical improvement, to prolong life and improve QOL, or to keep the
patient alive until transplantation (bridge to transplantation, BTT) or
to reverse contraindications to heart transplantation (bridge to
candidacy, BTC), or as destination therapy (DT) (<em>Table 15</em>).</p>
<p>Table 15</p>
<p>Terms describing various indications for mechanical circulatory
support</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Bridge to decision (BTD)/ Bridge to bridge (BTB)</strong> 
</td>
<td>
Use of short-term MCS (ECMO or Impella) in patients with cardiogenic
shock until haemodynamics and end-organ perfusion are stabilized,
contraindications for long-term MCS are excluded (brain damage after
resuscitation) and additional therapeutic options including long-term
VAD therapy or heart transplant can be evaluated. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to candidacy (BTC)</strong> 
</td>
<td>
Use of MCS (usually LVAD) to improve end-organ function and/or to make
an ineligible patient eligible for heart transplantation. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to transplantation (BTT)</strong> 
</td>
<td>
Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise
at high risk of death before transplantation until a donor organ becomes
available. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to recovery (BTR)</strong> 
</td>
<td>
Use of MCS (short-term or long-term) to keep a patient alive until
cardiac function recovers sufficiently to remove MCS. 
</td>
</tr>
<tr>
<td>
<strong>Destination therapy (DT)</strong> 
</td>
<td>
Long-term use of MCS (LVAD) as an alternative to transplantation in
patients with end-stage HF ineligible for transplantation. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Bridge to decision (BTD)/ Bridge to bridge (BTB)</strong> 
</td>
<td>
Use of short-term MCS (ECMO or Impella) in patients with cardiogenic
shock until haemodynamics and end-organ perfusion are stabilized,
contraindications for long-term MCS are excluded (brain damage after
resuscitation) and additional therapeutic options including long-term
VAD therapy or heart transplant can be evaluated. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to candidacy (BTC)</strong> 
</td>
<td>
Use of MCS (usually LVAD) to improve end-organ function and/or to make
an ineligible patient eligible for heart transplantation. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to transplantation (BTT)</strong> 
</td>
<td>
Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise
at high risk of death before transplantation until a donor organ becomes
available. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to recovery (BTR)</strong> 
</td>
<td>
Use of MCS (short-term or long-term) to keep a patient alive until
cardiac function recovers sufficiently to remove MCS. 
</td>
</tr>
<tr>
<td>
<strong>Destination therapy (DT)</strong> 
</td>
<td>
Long-term use of MCS (LVAD) as an alternative to transplantation in
patients with end-stage HF ineligible for transplantation. 
</td>
</tr>
</tbody>
</table>
<p>BiVAD = biventricular assist device; ECMO = extracorporeal membrane
oxygenation; HF = heart failure; LVAD = left ventricular assist device;
MCS = mechanical circulatory support; TAH = total artificial heart;
VAD = ventricular assist device.</p>
<p>Table 15</p>
<p>Terms describing various indications for mechanical circulatory
support</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Bridge to decision (BTD)/ Bridge to bridge (BTB)</strong> 
</td>
<td>
Use of short-term MCS (ECMO or Impella) in patients with cardiogenic
shock until haemodynamics and end-organ perfusion are stabilized,
contraindications for long-term MCS are excluded (brain damage after
resuscitation) and additional therapeutic options including long-term
VAD therapy or heart transplant can be evaluated. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to candidacy (BTC)</strong> 
</td>
<td>
Use of MCS (usually LVAD) to improve end-organ function and/or to make
an ineligible patient eligible for heart transplantation. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to transplantation (BTT)</strong> 
</td>
<td>
Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise
at high risk of death before transplantation until a donor organ becomes
available. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to recovery (BTR)</strong> 
</td>
<td>
Use of MCS (short-term or long-term) to keep a patient alive until
cardiac function recovers sufficiently to remove MCS. 
</td>
</tr>
<tr>
<td>
<strong>Destination therapy (DT)</strong> 
</td>
<td>
Long-term use of MCS (LVAD) as an alternative to transplantation in
patients with end-stage HF ineligible for transplantation. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Bridge to decision (BTD)/ Bridge to bridge (BTB)</strong> 
</td>
<td>
Use of short-term MCS (ECMO or Impella) in patients with cardiogenic
shock until haemodynamics and end-organ perfusion are stabilized,
contraindications for long-term MCS are excluded (brain damage after
resuscitation) and additional therapeutic options including long-term
VAD therapy or heart transplant can be evaluated. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to candidacy (BTC)</strong> 
</td>
<td>
Use of MCS (usually LVAD) to improve end-organ function and/or to make
an ineligible patient eligible for heart transplantation. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to transplantation (BTT)</strong> 
</td>
<td>
Use of MCS (LVAD, BiVAD or TAH) to keep a patient alive who is otherwise
at high risk of death before transplantation until a donor organ becomes
available. 
</td>
</tr>
<tr>
<td>
<strong>Bridge to recovery (BTR)</strong> 
</td>
<td>
Use of MCS (short-term or long-term) to keep a patient alive until
cardiac function recovers sufficiently to remove MCS. 
</td>
</tr>
<tr>
<td>
<strong>Destination therapy (DT)</strong> 
</td>
<td>
Long-term use of MCS (LVAD) as an alternative to transplantation in
patients with end-stage HF ineligible for transplantation. 
</td>
</tr>
</tbody>
</table>
<p>BiVAD = biventricular assist device; ECMO = extracorporeal membrane
oxygenation; HF = heart failure; LVAD = left ventricular assist device;
MCS = mechanical circulatory support; TAH = total artificial heart;
VAD = ventricular assist device.</p>
<p>Long-term MCS should be considered in patients with INTERMACS
profiles 2 to 4 and also in patients with INTERMACS profile 5–6, when
they have high-risk characteristics. Patients with no irreversible
end-organ failure other than cardiac, recovering from INTERMACS level 1
while on short-term MCS, may also qualify for long-term MCS
(<em>Figure 4</em>).<sup>376</sup><sup>,</sup><sup>378</sup><sup>,</sup><sup>383</sup><sup>,</sup><sup>395–402</sup>
The characteristics of patients potentially eligible for implantation of
an LVAD are reported in <em>Table 16</em>.</p>
<p>Table 16</p>
<p>Patients potentially eligible for implantation of a left ventricular
assist device</p>
<table role="presentation">
<tbody>
<tr>
<td>
Patients with persistence of severe symptoms despite optimal medical and
device therapy, without severe right ventricular dysfunction and/or
severe TR, with a stable psychosocial background and absence of major
contraindications*, and who have at least one of the following: 
</td>
</tr>
<tr>
<td>
•LVEF &lt;25% and unable to exercise for HF or, if able to perform
cardiopulmonary exercise testing, with peak VO<sub>2</sub> &lt;12
mL/kg/min and/or &lt;50% predicted value. 
</td>
</tr>
<tr>
<td>
•≥3 HF hospitalizations in previous 12 months without an obvious
precipitating cause. 
</td>
</tr>
<tr>
<td>
•Dependence on i.v. inotropic therapy or temporary MCS. 
</td>
</tr>
<tr>
<td>
•Progressive end-organ dysfunction (worsening renal and/or hepatic
function, type II pulmonary hypertension, cardiac cachexia) due to
reduced perfusion and not to inadequately low ventricular filling
pressure (PCWP ≥20 mmHg and SBP ≤90 mmHg or cardiac index
≤2 L/min/m<sup>2</sup>). 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Patients with persistence of severe symptoms despite optimal medical and
device therapy, without severe right ventricular dysfunction and/or
severe TR, with a stable psychosocial background and absence of major
contraindications*, and who have at least one of the following: 
</td>
</tr>
<tr>
<td>
•LVEF &lt;25% and unable to exercise for HF or, if able to perform
cardiopulmonary exercise testing, with peak VO<sub>2</sub> &lt;12
mL/kg/min and/or &lt;50% predicted value. 
</td>
</tr>
<tr>
<td>
•≥3 HF hospitalizations in previous 12 months without an obvious
precipitating cause. 
</td>
</tr>
<tr>
<td>
•Dependence on i.v. inotropic therapy or temporary MCS. 
</td>
</tr>
<tr>
<td>
•Progressive end-organ dysfunction (worsening renal and/or hepatic
function, type II pulmonary hypertension, cardiac cachexia) due to
reduced perfusion and not to inadequately low ventricular filling
pressure (PCWP ≥20 mmHg and SBP ≤90 mmHg or cardiac index
≤2 L/min/m<sup>2</sup>). 
</td>
</tr>
</tbody>
</table>
<p>HF = heart failure; i.v. = intravenous; LVAD = left ventricular
assist device; LVEF = left ventricular ejection fraction;
MCS = mechanical circulatory support; PCWP = pulmonary capillary wedge
pressure; SBP = systolic blood pressure; TR = tricuspid regurgitation;
VO<sub>2</sub> = oxygen consumption.</p>
<p>*</p>
<p>Stable psychosocial background includes demonstrated understanding of
the technology and patient living in the same household with a caregiver
that will help the patient (i.e. living alone and poor psychosocial
background is LVAD contraindication). Major contraindications include
contraindication to long-term oral anticoagulation, infection, severe
renal dysfunction, ventricular arrhythmias.</p>
<p>Table 16</p>
<p>Patients potentially eligible for implantation of a left ventricular
assist device</p>
<table role="presentation">
<tbody>
<tr>
<td>
Patients with persistence of severe symptoms despite optimal medical and
device therapy, without severe right ventricular dysfunction and/or
severe TR, with a stable psychosocial background and absence of major
contraindications*, and who have at least one of the following: 
</td>
</tr>
<tr>
<td>
•LVEF &lt;25% and unable to exercise for HF or, if able to perform
cardiopulmonary exercise testing, with peak VO<sub>2</sub> &lt;12
mL/kg/min and/or &lt;50% predicted value. 
</td>
</tr>
<tr>
<td>
•≥3 HF hospitalizations in previous 12 months without an obvious
precipitating cause. 
</td>
</tr>
<tr>
<td>
•Dependence on i.v. inotropic therapy or temporary MCS. 
</td>
</tr>
<tr>
<td>
•Progressive end-organ dysfunction (worsening renal and/or hepatic
function, type II pulmonary hypertension, cardiac cachexia) due to
reduced perfusion and not to inadequately low ventricular filling
pressure (PCWP ≥20 mmHg and SBP ≤90 mmHg or cardiac index
≤2 L/min/m<sup>2</sup>). 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Patients with persistence of severe symptoms despite optimal medical and
device therapy, without severe right ventricular dysfunction and/or
severe TR, with a stable psychosocial background and absence of major
contraindications*, and who have at least one of the following: 
</td>
</tr>
<tr>
<td>
•LVEF &lt;25% and unable to exercise for HF or, if able to perform
cardiopulmonary exercise testing, with peak VO<sub>2</sub> &lt;12
mL/kg/min and/or &lt;50% predicted value. 
</td>
</tr>
<tr>
<td>
•≥3 HF hospitalizations in previous 12 months without an obvious
precipitating cause. 
</td>
</tr>
<tr>
<td>
•Dependence on i.v. inotropic therapy or temporary MCS. 
</td>
</tr>
<tr>
<td>
•Progressive end-organ dysfunction (worsening renal and/or hepatic
function, type II pulmonary hypertension, cardiac cachexia) due to
reduced perfusion and not to inadequately low ventricular filling
pressure (PCWP ≥20 mmHg and SBP ≤90 mmHg or cardiac index
≤2 L/min/m<sup>2</sup>). 
</td>
</tr>
</tbody>
</table>
<p>HF = heart failure; i.v. = intravenous; LVAD = left ventricular
assist device; LVEF = left ventricular ejection fraction;
MCS = mechanical circulatory support; PCWP = pulmonary capillary wedge
pressure; SBP = systolic blood pressure; TR = tricuspid regurgitation;
VO<sub>2</sub> = oxygen consumption.</p>
<p>*</p>
<p>Stable psychosocial background includes demonstrated understanding of
the technology and patient living in the same household with a caregiver
that will help the patient (i.e. living alone and poor psychosocial
background is LVAD contraindication). Major contraindications include
contraindication to long-term oral anticoagulation, infection, severe
renal dysfunction, ventricular arrhythmias.</p>
<p>The details of the devices and studies on long-term MCS are
summarized in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 15</a>.</em></p>
<p>Current 2-year survival rates in patients receiving the latest
continuous-flow LVADs are comparable to those after heart
transplantation, although adverse events negatively affect QOL. Among
patients with continuous flow LVADs, actuarial survival was reported of
80% at 1 year and 70% at 2
years.<sup>403</sup><sup>,</sup><sup>404</sup> Two-year survival was
84.5% and survival free of disabling stroke or need of reoperation for
LVAD malfunction was 76.9% with a centrifugal-flow LVAD in MOMENTUM
3.<sup>405</sup> The fully magnetically levitated centrifugal-flow LVAD
has significantly reduced pump thrombosis. In MOMENTUM 3, the need for
reoperation to replace a malfunctioning device was 2.3% per 24 months,
with only 0.6% per 24 months risk of pump replacement because of pump
thrombosis. Stroke (namely, disabling stroke), major bleeding, and
gastrointestinal haemorrhage were also lower in the centrifugal-flow
pump group than in the axial-flow pump group. However, the incidence of
all bleeding events, thromboembolism and driveline infection remained
similar to that with older devices.<sup>402</sup></p>
<p>Data on fully magnetically centrifugal-flow LVAD use in real-world
studies with the 2-year outcomes from the ELEVATE registry showed an
overall survival of 74.5%, with gastrointestinal bleeding in 9.7%,
stroke in 10.2%, and pump thrombosis in 1.5% of patients.<sup>406</sup>
According to the IMACS Registry, a new composite endpoint including QOL
and adverse events beyond survival was proposed to help in guiding
decision making. In this sense ‘living well at one year’ defined as
freedom from death, stroke, bleeding requiring operation, RV assist
device, pump replacement, or device-related infection within the first
year, was 56.8% after isolated, centrifugal flow-LVAD.<sup>383</sup></p>
<p>Although now outdated, REMATCH was the only RCT comparing an LVAD as
DT with OMT in patients with advanced HF, NYHA class IV and a
contraindication to transplantation. REMATCH showed lower all-cause
mortality with LVAD therapy when compared with medical treatment
(primary endpoint). However, there were high mortality rates at 2 years
in both arms.<sup>378</sup> Other studies were not randomized (INTrEPID,
ROADMAP)<sup>396</sup><sup>,</sup><sup>407</sup><sup>,</sup><sup>408</sup>
or compared different devices (ADVANCE, ENDURANCE, MOMENTUM
3).<sup>399</sup><sup>,</sup><sup>402</sup><sup>,</sup><sup>409</sup>
The two strategies of early LVAD implantation vs. medical treatment with
LVAD implantation only after serious deterioration of the patient’s
condition are currently being compared in a prospective trial, Early-VAD
(ClinicalTrials.gov Identifier: NCT02387112). Also, the Swedish
evaluation of LVAD (SweVAD) study is comparing the survival of patients
with advanced HF ineligible for heart transplantation prospectively
randomized to LVAD as DT vs. MT (ClinicalTrials.gov Identifier:
NCT02592499).<sup>410</sup></p>
<h4 >10.2.3 Heart transplantation</h4>
<p>Heart transplantation remains the gold standard for the treatment of
advanced HF in the absence of contraindications. Post-transplant 1-year
survival is around 90% with a median survival of 12.5
years.<sup>385</sup><sup>,</sup><sup>411</sup><sup>,</sup><sup>412</sup>
Transplantation significantly improves QOL and functional status,
although, for unclear reasons, the percentage of patients returning to
work is lower than expected.<sup>412</sup> Apart from primary graft
dysfunction, the main challenges after heart transplantation relate to
either the efficacy or side effects of immunosuppression
(e.g. rejection, infection, cardiac allograft vasculopathy, late graft
dysfunction, malignancy, renal failure, hypertension, diabetes
mellitus).</p>
<p>Organ donor shortage remains the main limitation to heart
transplantation. Thus, the donor heart criteria have now been extended
to allow an increased upper limit of the donor age, particularly in
Europe. Moreover, careful recipient selection is needed, based on
pre-transplant and post-transplant life expectancy (both are influenced
by pre-operative status and comorbidities).</p>
<p>The main indications and contraindications for heart transplantation
are listed in <em>Table
17</em>.<sup>376</sup><sup>,</sup><sup>385</sup></p>
<p>Table 17</p>
<p>Heart transplantation: indications and contraindications</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Indications</strong> 
</td>
</tr>
<tr>
<td>
Advanced HF<span
></span><span><sup>376</sup></span> 
</td>
</tr>
<tr>
<td>
No other therapeutic option, except for LVAD as BTT 
</td>
</tr>
<tr>
<td>
<strong>Contraindications</strong> 
</td>
</tr>
<tr>
<td>
Active infection<span
></span><span><sup>a</sup></span> 
</td>
</tr>
<tr>
<td>
Severe peripheral arterial or cerebrovascular disease 
</td>
</tr>
<tr>
<td>
Pharmacologic irreversible pulmonary hypertension (LVAD should be
considered to reverse elevated pulmonary vascular resistance with
subsequent re-evaluation to establish candidacy) 
</td>
</tr>
<tr>
<td>
Malignancy with poor prognosis (a collaboration with oncology
specialists should occur to stratify each patient as regards their risk
of tumour progression or recurrence which increases with the use of
immunosuppression) 
</td>
</tr>
<tr>
<td>
Irreversible liver dysfunction (cirrhosis) or irreversible renal
dysfunction (e.g. creatinine clearance &lt;30 mL/min/1.73 m²). Combined
heart-liver or heart-kidney transplant may be considered 
</td>
</tr>
<tr>
<td>
Systemic disease with multiorgan involvement 
</td>
</tr>
<tr>
<td>
Other serious comorbidity with poor prognosis 
</td>
</tr>
<tr>
<td>
Pre-transplant BMI &gt;35 kg/m² (weight loss is recommended to achieve a
BMI &lt;35 kg/m²) 
</td>
</tr>
<tr>
<td>
Current alcohol or drug abuse 
</td>
</tr>
<tr>
<td>
Psychological instability that jeopardizes proper follow-up and
intensive therapeutic regime after heart transplantation 
</td>
</tr>
<tr>
<td>
Insufficient social supports to achieve compliant care in the outpatient
setting 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Indications</strong> 
</td>
</tr>
<tr>
<td>
Advanced HF<span
></span><span><sup>376</sup></span> 
</td>
</tr>
<tr>
<td>
No other therapeutic option, except for LVAD as BTT 
</td>
</tr>
<tr>
<td>
<strong>Contraindications</strong> 
</td>
</tr>
<tr>
<td>
Active infection<span
></span><span><sup>a</sup></span> 
</td>
</tr>
<tr>
<td>
Severe peripheral arterial or cerebrovascular disease 
</td>
</tr>
<tr>
<td>
Pharmacologic irreversible pulmonary hypertension (LVAD should be
considered to reverse elevated pulmonary vascular resistance with
subsequent re-evaluation to establish candidacy) 
</td>
</tr>
<tr>
<td>
Malignancy with poor prognosis (a collaboration with oncology
specialists should occur to stratify each patient as regards their risk
of tumour progression or recurrence which increases with the use of
immunosuppression) 
</td>
</tr>
<tr>
<td>
Irreversible liver dysfunction (cirrhosis) or irreversible renal
dysfunction (e.g. creatinine clearance &lt;30 mL/min/1.73 m²). Combined
heart-liver or heart-kidney transplant may be considered 
</td>
</tr>
<tr>
<td>
Systemic disease with multiorgan involvement 
</td>
</tr>
<tr>
<td>
Other serious comorbidity with poor prognosis 
</td>
</tr>
<tr>
<td>
Pre-transplant BMI &gt;35 kg/m² (weight loss is recommended to achieve a
BMI &lt;35 kg/m²) 
</td>
</tr>
<tr>
<td>
Current alcohol or drug abuse 
</td>
</tr>
<tr>
<td>
Psychological instability that jeopardizes proper follow-up and
intensive therapeutic regime after heart transplantation 
</td>
</tr>
<tr>
<td>
Insufficient social supports to achieve compliant care in the outpatient
setting 
</td>
</tr>
</tbody>
</table>
<p>BMI = body mass index; BTT = bridge to transplantation; HF = heart
failure; LVAD =  left ventricular assist device.</p>
<p>a</p>
<p>Active infection is a relative contraindication to transplant
although in some cases of infected LVADs it may actually be an
indication.</p>
<p>Adapted from Crespo-Leiro et al.<sup>376</sup></p>
<p>Table 17</p>
<p>Heart transplantation: indications and contraindications</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Indications</strong> 
</td>
</tr>
<tr>
<td>
Advanced HF<span
></span><span><sup>376</sup></span> 
</td>
</tr>
<tr>
<td>
No other therapeutic option, except for LVAD as BTT 
</td>
</tr>
<tr>
<td>
<strong>Contraindications</strong> 
</td>
</tr>
<tr>
<td>
Active infection<span
></span><span><sup>a</sup></span> 
</td>
</tr>
<tr>
<td>
Severe peripheral arterial or cerebrovascular disease 
</td>
</tr>
<tr>
<td>
Pharmacologic irreversible pulmonary hypertension (LVAD should be
considered to reverse elevated pulmonary vascular resistance with
subsequent re-evaluation to establish candidacy) 
</td>
</tr>
<tr>
<td>
Malignancy with poor prognosis (a collaboration with oncology
specialists should occur to stratify each patient as regards their risk
of tumour progression or recurrence which increases with the use of
immunosuppression) 
</td>
</tr>
<tr>
<td>
Irreversible liver dysfunction (cirrhosis) or irreversible renal
dysfunction (e.g. creatinine clearance &lt;30 mL/min/1.73 m²). Combined
heart-liver or heart-kidney transplant may be considered 
</td>
</tr>
<tr>
<td>
Systemic disease with multiorgan involvement 
</td>
</tr>
<tr>
<td>
Other serious comorbidity with poor prognosis 
</td>
</tr>
<tr>
<td>
Pre-transplant BMI &gt;35 kg/m² (weight loss is recommended to achieve a
BMI &lt;35 kg/m²) 
</td>
</tr>
<tr>
<td>
Current alcohol or drug abuse 
</td>
</tr>
<tr>
<td>
Psychological instability that jeopardizes proper follow-up and
intensive therapeutic regime after heart transplantation 
</td>
</tr>
<tr>
<td>
Insufficient social supports to achieve compliant care in the outpatient
setting 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Indications</strong> 
</td>
</tr>
<tr>
<td>
Advanced HF<span
></span><span><sup>376</sup></span> 
</td>
</tr>
<tr>
<td>
No other therapeutic option, except for LVAD as BTT 
</td>
</tr>
<tr>
<td>
<strong>Contraindications</strong> 
</td>
</tr>
<tr>
<td>
Active infection<span
></span><span><sup>a</sup></span> 
</td>
</tr>
<tr>
<td>
Severe peripheral arterial or cerebrovascular disease 
</td>
</tr>
<tr>
<td>
Pharmacologic irreversible pulmonary hypertension (LVAD should be
considered to reverse elevated pulmonary vascular resistance with
subsequent re-evaluation to establish candidacy) 
</td>
</tr>
<tr>
<td>
Malignancy with poor prognosis (a collaboration with oncology
specialists should occur to stratify each patient as regards their risk
of tumour progression or recurrence which increases with the use of
immunosuppression) 
</td>
</tr>
<tr>
<td>
Irreversible liver dysfunction (cirrhosis) or irreversible renal
dysfunction (e.g. creatinine clearance &lt;30 mL/min/1.73 m²). Combined
heart-liver or heart-kidney transplant may be considered 
</td>
</tr>
<tr>
<td>
Systemic disease with multiorgan involvement 
</td>
</tr>
<tr>
<td>
Other serious comorbidity with poor prognosis 
</td>
</tr>
<tr>
<td>
Pre-transplant BMI &gt;35 kg/m² (weight loss is recommended to achieve a
BMI &lt;35 kg/m²) 
</td>
</tr>
<tr>
<td>
Current alcohol or drug abuse 
</td>
</tr>
<tr>
<td>
Psychological instability that jeopardizes proper follow-up and
intensive therapeutic regime after heart transplantation 
</td>
</tr>
<tr>
<td>
Insufficient social supports to achieve compliant care in the outpatient
setting 
</td>
</tr>
</tbody>
</table>
<p>BMI = body mass index; BTT = bridge to transplantation; HF = heart
failure; LVAD =  left ventricular assist device.</p>
<p>a</p>
<p>Active infection is a relative contraindication to transplant
although in some cases of infected LVADs it may actually be an
indication.</p>
<p>Adapted from Crespo-Leiro et al.<sup>376</sup></p>
<p>Active infection is a relative contraindication to transplant but in
some cases of infected LVADs it may actually be an indication. Elderly
age is not an absolute contraindication. Although patients aged &lt;65
years might be more appropriate candidates due to their overall life
expectancy, most programmes accept patients up to 70 years of age, and
biological age as well as chronological age must be taken into account.
Surgical complexity [previous sternotomies, mediastinal radiation, adult
congenital heart disease (ACHD)] should also be considered.</p>
<p>The decision pathway to transplantation or LVAD is never
straightforward and is unique to each patient. Eligibility for each
option may change according to the particular conditions of each
patient, which may also change over time. Other factors, not related to
the patient, such as time on the heart transplant waiting list, the
centre’s surgical experience, and resources, can also influence decision
making.<sup>413</sup></p>
<p>Recommendations for the treatment of patients with advanced heart
failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table45.jpeg?Expires=1689850106&amp;Signature=YQ5MhaX5ntqnMCNHhfjrjIeZuSLziyU2MsaQQnZl2vmcwxGlh2ZFaJ-dNWtzmNedmm-tCD3-~cLAMjjZ6OgK-8AGr2tbzMpllkUP6fYq6lAAfR4KeNdq2CO8ypMf4KliIJW84LJojlRcgtJ1lTOtFduXFGk6FELa1PI5b6nz3vxeMeH~JZUOW8AahfuVtlxEsw9oqoCf4Po5Sbi45W43JXD5vGRjjBBY8djMI4cQnhee85Bf9MTMRl5HkwOu1JVwWjlu6gyqcbXeF2XTwJvynew-P2xh6Xt8GR~54DxH3BKbrEtdMT0lkLkcHAveT3fYQ65pf~1tdFJ2UdpbBalJ~A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table45.jpeg?Expires=1689850106&amp;Signature=YQ5MhaX5ntqnMCNHhfjrjIeZuSLziyU2MsaQQnZl2vmcwxGlh2ZFaJ-dNWtzmNedmm-tCD3-~cLAMjjZ6OgK-8AGr2tbzMpllkUP6fYq6lAAfR4KeNdq2CO8ypMf4KliIJW84LJojlRcgtJ1lTOtFduXFGk6FELa1PI5b6nz3vxeMeH~JZUOW8AahfuVtlxEsw9oqoCf4Po5Sbi45W43JXD5vGRjjBBY8djMI4cQnhee85Bf9MTMRl5HkwOu1JVwWjlu6gyqcbXeF2XTwJvynew-P2xh6Xt8GR~54DxH3BKbrEtdMT0lkLkcHAveT3fYQ65pf~1tdFJ2UdpbBalJ~A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure; HFrEF = heart failure with reduced ejection
fraction; MCS = mechanical circulatory support.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the treatment of patients with advanced heart
failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table45.jpeg?Expires=1689850106&amp;Signature=YQ5MhaX5ntqnMCNHhfjrjIeZuSLziyU2MsaQQnZl2vmcwxGlh2ZFaJ-dNWtzmNedmm-tCD3-~cLAMjjZ6OgK-8AGr2tbzMpllkUP6fYq6lAAfR4KeNdq2CO8ypMf4KliIJW84LJojlRcgtJ1lTOtFduXFGk6FELa1PI5b6nz3vxeMeH~JZUOW8AahfuVtlxEsw9oqoCf4Po5Sbi45W43JXD5vGRjjBBY8djMI4cQnhee85Bf9MTMRl5HkwOu1JVwWjlu6gyqcbXeF2XTwJvynew-P2xh6Xt8GR~54DxH3BKbrEtdMT0lkLkcHAveT3fYQ65pf~1tdFJ2UdpbBalJ~A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table45.jpeg?Expires=1689850106&amp;Signature=YQ5MhaX5ntqnMCNHhfjrjIeZuSLziyU2MsaQQnZl2vmcwxGlh2ZFaJ-dNWtzmNedmm-tCD3-~cLAMjjZ6OgK-8AGr2tbzMpllkUP6fYq6lAAfR4KeNdq2CO8ypMf4KliIJW84LJojlRcgtJ1lTOtFduXFGk6FELa1PI5b6nz3vxeMeH~JZUOW8AahfuVtlxEsw9oqoCf4Po5Sbi45W43JXD5vGRjjBBY8djMI4cQnhee85Bf9MTMRl5HkwOu1JVwWjlu6gyqcbXeF2XTwJvynew-P2xh6Xt8GR~54DxH3BKbrEtdMT0lkLkcHAveT3fYQ65pf~1tdFJ2UdpbBalJ~A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure; HFrEF = heart failure with reduced ejection
fraction; MCS = mechanical circulatory support.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4 >10.2.4 Symptom control and
end-of-life care</h4>
<p>While the disease trajectory of each patient with HF is unique, there
is a generalizable pattern of gradual decline, punctuated by episodes of
acute deterioration leading either to sudden death or death due to
progressive HF. Communication about the disease trajectory and
anticipatory planning should start when a patient is diagnosed with
advanced HF. Indications for and key components of a palliative care
service are reported in <em>Tables 18</em> and
<em>19</em>.<sup>312</sup><sup>,</sup><sup>418</sup></p>
<p>A team-based approach to palliative and end-of-life care for patients
with HF has been proposed.<sup>419</sup> Specific models of palliative
care for patients with advanced HF have been also reported. They reduce
hospitalizations, without a clear effect on survival, and have some
effects on QOL and symptom
burden.<sup>420</sup><sup>,</sup><sup>421</sup></p>
<p>Table 18</p>
<p>Patients with heart failure in whom end-of-life care should be
considered</p>
<table role="presentation">
<tbody>
<tr>
<td>
Progressive functional decline (physical and mental) and dependence in
most activities of daily living. 
</td>
</tr>
<tr>
<td>
Severe heart failure symptoms with poor QOL despite optimal
pharmacological and non-pharmacological therapies. 
</td>
</tr>
<tr>
<td>
Frequent admissions to hospital or other serious episodes of
decompensation despite optimal treatment. 
</td>
</tr>
<tr>
<td>
Heart transplantation and MCS ruled out. 
</td>
</tr>
<tr>
<td>
Cardiac cachexia. 
</td>
</tr>
<tr>
<td>
Clinically judged to be close to end of life. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Progressive functional decline (physical and mental) and dependence in
most activities of daily living. 
</td>
</tr>
<tr>
<td>
Severe heart failure symptoms with poor QOL despite optimal
pharmacological and non-pharmacological therapies. 
</td>
</tr>
<tr>
<td>
Frequent admissions to hospital or other serious episodes of
decompensation despite optimal treatment. 
</td>
</tr>
<tr>
<td>
Heart transplantation and MCS ruled out. 
</td>
</tr>
<tr>
<td>
Cardiac cachexia. 
</td>
</tr>
<tr>
<td>
Clinically judged to be close to end of life. 
</td>
</tr>
</tbody>
</table>
<p>MCS = mechanical circulatory support; QOL = quality of life.</p>
<p>Table 18</p>
<p>Patients with heart failure in whom end-of-life care should be
considered</p>
<table role="presentation">
<tbody>
<tr>
<td>
Progressive functional decline (physical and mental) and dependence in
most activities of daily living. 
</td>
</tr>
<tr>
<td>
Severe heart failure symptoms with poor QOL despite optimal
pharmacological and non-pharmacological therapies. 
</td>
</tr>
<tr>
<td>
Frequent admissions to hospital or other serious episodes of
decompensation despite optimal treatment. 
</td>
</tr>
<tr>
<td>
Heart transplantation and MCS ruled out. 
</td>
</tr>
<tr>
<td>
Cardiac cachexia. 
</td>
</tr>
<tr>
<td>
Clinically judged to be close to end of life. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Progressive functional decline (physical and mental) and dependence in
most activities of daily living. 
</td>
</tr>
<tr>
<td>
Severe heart failure symptoms with poor QOL despite optimal
pharmacological and non-pharmacological therapies. 
</td>
</tr>
<tr>
<td>
Frequent admissions to hospital or other serious episodes of
decompensation despite optimal treatment. 
</td>
</tr>
<tr>
<td>
Heart transplantation and MCS ruled out. 
</td>
</tr>
<tr>
<td>
Cardiac cachexia. 
</td>
</tr>
<tr>
<td>
Clinically judged to be close to end of life. 
</td>
</tr>
</tbody>
</table>
<p>MCS = mechanical circulatory support; QOL = quality of life.</p>
<p>Table 19</p>
<p>Key components of palliative care service in patients with advanced
heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
Focus on improving or maintaining the QOL of a patient and his/her
family as well as possible until he/she dies. 
</td>
</tr>
<tr>
<td>
Frequent assessment of symptoms (including dyspnoea and pain) resulting
from advanced heart failure and other comorbidities and focus on symptom
relief. 
</td>
</tr>
<tr>
<td>
Access for the patient and his/her family to psychological support and
spiritual care according to need. 
</td>
</tr>
<tr>
<td>
Advanced care planning, taking into account preferences for place of
death and resuscitation (which may include deactivating devices, such as
ICD or long-term MCS that may require a multidisciplinary team
decision). 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Focus on improving or maintaining the QOL of a patient and his/her
family as well as possible until he/she dies. 
</td>
</tr>
<tr>
<td>
Frequent assessment of symptoms (including dyspnoea and pain) resulting
from advanced heart failure and other comorbidities and focus on symptom
relief. 
</td>
</tr>
<tr>
<td>
Access for the patient and his/her family to psychological support and
spiritual care according to need. 
</td>
</tr>
<tr>
<td>
Advanced care planning, taking into account preferences for place of
death and resuscitation (which may include deactivating devices, such as
ICD or long-term MCS that may require a multidisciplinary team
decision). 
</td>
</tr>
</tbody>
</table>
<p>ICD = implantable cardioverter-defibrillator; MCS = mechanical
circulatory support; QOL = quality of life.</p>
<p>Table 19</p>
<p>Key components of palliative care service in patients with advanced
heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
Focus on improving or maintaining the QOL of a patient and his/her
family as well as possible until he/she dies. 
</td>
</tr>
<tr>
<td>
Frequent assessment of symptoms (including dyspnoea and pain) resulting
from advanced heart failure and other comorbidities and focus on symptom
relief. 
</td>
</tr>
<tr>
<td>
Access for the patient and his/her family to psychological support and
spiritual care according to need. 
</td>
</tr>
<tr>
<td>
Advanced care planning, taking into account preferences for place of
death and resuscitation (which may include deactivating devices, such as
ICD or long-term MCS that may require a multidisciplinary team
decision). 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Focus on improving or maintaining the QOL of a patient and his/her
family as well as possible until he/she dies. 
</td>
</tr>
<tr>
<td>
Frequent assessment of symptoms (including dyspnoea and pain) resulting
from advanced heart failure and other comorbidities and focus on symptom
relief. 
</td>
</tr>
<tr>
<td>
Access for the patient and his/her family to psychological support and
spiritual care according to need. 
</td>
</tr>
<tr>
<td>
Advanced care planning, taking into account preferences for place of
death and resuscitation (which may include deactivating devices, such as
ICD or long-term MCS that may require a multidisciplinary team
decision). 
</td>
</tr>
</tbody>
</table>
<p>ICD = implantable cardioverter-defibrillator; MCS = mechanical
circulatory support; QOL = quality of life.</p>
<p>Symptom assessment should be performed on a regular basis. In
addition to clinical assessment, symptoms can be assessed using the
Numeric Rating Scale, the Edmonton Symptom Assessment Scale (ESAS) or
ESAS-HF, or the Integrated Palliative care Outcome Scale.</p>
<p>Treatment for symptoms needs to be considered and might include
additional intervention on top of OMT:</p>
<ul>
<li><p>Breathlessness: repeat doses of opioids may be considered for the
relief of dyspnoea; however, their effectiveness is not
demonstrated.<sup>422</sup><sup>,</sup><sup>423</sup> While using
opioids, all patients should be guided about opioid side effects such as
constipation and nausea, urinary retention, and mental status changes.
Benzodiazepines may be considered as a second- or third-line treatment,
when opioids and non-pharmacological measures have failed to control
breathlessness. Increasing the inspired oxygen concentration may provide
relief of dyspnoea.</p></li>
<li><p>Pain: non-pharmacologic management can be helpful. In addition,
opioid, oxycodone, hydromorphone, and fentanyl are generally viewed as
safe options and can be provided orally, intravenously, and
transdermally, especially in the hospital or in patient palliative care
or hospice setting.<sup>424</sup></p></li>
<li><p>Anxiety and depression: adequate conventional treatment should be
offered.</p></li>
</ul>
<p>Proactive decisions and advanced planning with regard to palliative
and end-of-life care discussions should be documented, regularly
reviewed, and routinely communicated to all those involved in the
patient’s care. Healthcare providers should make sure that patients’ and
carer preferences are followed, wherever possible. They should also take
into account that patients may choose not to, or may not be in a
position to, express preferences (e.g. due to symptoms of depression or
cognitive impairment).</p>
<h2 >11 Acute heart failure</h2>
<h3 >11.1 Epidemiology,
diagnosis and prognosis</h3>
<p>AHF refers to rapid or gradual onset of symptoms and/or signs of HF,
severe enough for the patient to seek urgent medical attention, leading
to an unplanned hospital admission or an emergency department visit.
Patients with AHF require urgent evaluation with subsequent initiation
or intensification of treatment, including i.v. therapies or procedures.
AHF is a leading cause of hospitalizations in subjects aged &gt;65 years
and is associated with high mortality and rehospitalization rates.
In-hospital mortality ranges from 4% to 10%.<sup>425–428</sup>
Post-discharge 1-year mortality can be 25–30% with up to more than 45%
deaths or readmission
rates.<sup>104</sup><sup>,</sup><sup>426</sup><sup>,</sup><sup>427</sup><sup>,</sup><sup>429</sup><sup>,</sup><sup>430</sup></p>
<p>AHF may be the first manifestation of HF (new onset) or, more
frequently, be due to an acute decompensation of chronic HF. Compared to
patients with acutely decompensated CHF, those with new onset HF may
have a higher in-hospital mortality<sup>425</sup> but have lower
post-discharge mortality and rehospitalization
rates.<sup>425</sup><sup>,</sup><sup>428</sup><sup>,</sup><sup>431</sup><sup>,</sup><sup>432</sup>
Specific extrinsic factors may precipitate, but not cause, AHF in
patients with pre-existing cardiac dysfunction <em>(<a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 16</a>)</em>. Clinical severity and in-hospital trajectory are
determined by the complex interplay between precipitants, the underlying
cardiac substrate, and the patient’s comorbidities.</p>
<p>The diagnostic workup of AHF starts at the time of the first medical
contact, and is continued throughout the initial patient pathway, aiming
to identify the clinical presentation and to diagnose and manage any
potentially reversible causes/precipitants/coexisting life-threatening
conditions in a timely manner (<em>Figure 6</em>). Diagnostic tests are
outlined at <em>Table 20</em>. In addition to clinical signs and
symptoms, diagnostic workup includes ECG and echocardiography, if
possible. Additional investigations, i.e. chest X-ray and lung
ultrasound may be used to confirm AHF diagnosis, especially when NP
testing is not available. Plasma NP levels (BNP or NT-proBNP or
MR-proANP) should be measured if the diagnosis is uncertain and a
point-of-care assay is available. Normal concentrations of NPs make the
diagnosis of AHF unlikely. Cut-offs for acute HF are: BNP &lt;100 pg/mL,
NT-proBNP &lt;300 pg/mL and MR-proANP &lt;120
pg/mL.<sup>74</sup><sup>,</sup><sup>433–435</sup> However, elevated NP
values are associated with a wide range of cardiac and non-cardiac
conditions <em>(<strong>Table 6</strong>)</em>. Low concentrations can
be detected in some patients with advanced decompensated end-stage HF,
obesity, flash pulmonary oedema or right-sided AHF. Higher levels can be
found in the patients with concomitant AF and/or reduced renal
function.<sup>74</sup></p>
<p>Figure 6</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f6.jpeg?Expires=1689850106&amp;Signature=QIHA~74u~pCZ2BaXRhj2GkHBl4jf2fYyq7V0dZLjqHhZIeBRiQSFVWDly88kFZ-WrHAIu-a-6oD8eUvM4qbW6NvsM0MfK9iVVQVVEL5nFM7FMWDzMhhJsbFCeeaf6HLbA~vvR8siQ8hG7udS5tSHXPt-HiQi271AWkfaLufAY1MXDst7BjNeGN2nPVkMMGOo6iOE1RuRG0WnFisITn~WXPVff7-G5LGnzYV1i27Elj0fB6XxPfwOj3w9rRsKj33xFV2Go27sOsEQt52kpzLa62gh7scUigM4wazgBCdyQ~3GYiBooQAzEG78GPICm-FiNKWQAi6j7cmbtgnqAlpBeg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Diagnostic workup of new onset acute heart failure. ACS  = acute coronary syndrome; BNP = B-type natriuretic peptide; CT = computed tomography; HF = heart failure; MR-proANP = mid-regional pro-atrial natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; TSH = thyroid-stimulating hormone. aInitial laboratory exams include troponin, serum creatinine, electrolytes, blood urea nitrogen or urea, TSH, liver function tests as well as D-dimer and procalcitonin when pulmonary embolism or infection are suspected, arterial blood gas analysis in case of respiratory distress, and lactate in case of hypoperfusion. bSpecific evaluation includes coronary angiography, in case of suspected ACS, and CT in case of suspected pulmonary embolism. cRule-in values for the diagnosis of acute HF: &gt;450 pg/mL if aged &lt;55 years, &gt;900 pg/mL if aged between 55 and 75 years and &gt;1800 pg/mL if aged &gt;75 years.433,434" />
<figcaption aria-hidden="true">Diagnostic workup of new onset acute
heart failure. ACS  = acute coronary syndrome; BNP = B-type natriuretic
peptide; CT = computed tomography; HF = heart failure;
MR-proANP = mid-regional pro-atrial natriuretic peptide;
NT-proBNP = N-terminal pro-B-type natriuretic peptide;
TSH = thyroid-stimulating hormone. aInitial laboratory exams include
troponin, serum creatinine, electrolytes, blood urea nitrogen or urea,
TSH, liver function tests as well as D-dimer and procalcitonin when
pulmonary embolism or infection are suspected, arterial blood gas
analysis in case of respiratory distress, and lactate in case of
hypoperfusion. bSpecific evaluation includes coronary angiography, in
case of suspected ACS, and CT in case of suspected pulmonary embolism.
cRule-in values for the diagnosis of acute HF: &gt;450 pg/mL if aged
&lt;55 years, &gt;900 pg/mL if aged between 55 and 75 years and &gt;1800
pg/mL if aged &gt;75 years.433,434</figcaption>
</figure>
<p>Diagnostic workup of new onset acute heart failure. ACS  = acute
coronary syndrome; BNP = B-type natriuretic peptide; CT = computed
tomography; HF = heart failure; MR-proANP = mid-regional pro-atrial
natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic
peptide; TSH = thyroid-stimulating hormone. <sup>a</sup>Initial
laboratory exams include troponin, serum creatinine, electrolytes, blood
urea nitrogen or urea, TSH, liver function tests as well as D-dimer and
procalcitonin when pulmonary embolism or infection are suspected,
arterial blood gas analysis in case of respiratory distress, and lactate
in case of hypoperfusion. <sup>b</sup>Specific evaluation includes
coronary angiography, in case of suspected ACS, and CT in case of
suspected pulmonary embolism. <sup>c</sup>Rule-in values for the
diagnosis of acute HF: &gt;450 pg/mL if aged &lt;55 years, &gt;900 pg/mL
if aged between 55 and 75 years and &gt;1800 pg/mL if aged &gt;75
years.<sup>433</sup><sup>,</sup><sup>434</sup></p>
<p>Table 20</p>
<p>Diagnostic tests in patients with acute heart failure</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th>Exam</th>
<th>Time of measurement</th>
<th>Possible findings</th>
<th>Diagnostic value for AHF</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG</strong> </td>
<td>Admission, during
hospitalization,<sup>a</sup><sup>,</sup><sup>b</sup> pre-discharge </td>
<td>Arrhythmias, myocardial ischaemia </td>
<td>Exclusion of ACS or arrhythmias </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Chest-X ray</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Congestion, lung infection </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>LUS</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> pre-discharge </td>
<td>Congestion </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>Echocardiography</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Congestion, cardiac dysfunction, mechanical causes </td>
<td>Major </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Natriuretic peptides (BNP, NT-proBNP,
MR-proANP)</strong> </td>
<td>Admission, pre-discharge </td>
<td>Congestion </td>
<td>High negative predictive value </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum troponin</strong> </td>
<td>Admission </td>
<td>Myocardial injury </td>
<td>Exclusion of ACS </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum creatinine</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Renal dysfunction </td>
<td>None </td>
<td>Recommended for prognostic assessment </td>
</tr>
<tr>
<td><strong>Serum electrolytes (sodium, potassium,
chloride)</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Electrolyte disorders </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>Iron status (transferrin, ferritin)</strong> </td>
<td>Pre-discharge </td>
<td>Iron depletion </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>TSH</strong> </td>
<td>Admission </td>
<td>Hypo- hyperthyroidism </td>
<td>None </td>
<td>Recommended when hypo-hyperthyroidism is suspected </td>
</tr>
<tr>
<td><strong>D-dimer</strong> </td>
<td>Admission </td>
<td>Pulmonary embolism </td>
<td>Useful to exclude pulmonary embolism </td>
<td>Recommended when pulmonary embolism is suspected </td>
</tr>
<tr>
<td><strong>Procalcitonin</strong> </td>
<td>Admission </td>
<td>Pneumonia </td>
<td>Useful for diagnosis of pneumonia </td>
<td>May be done when pneumonia is suspected </td>
</tr>
<tr>
<td><strong>Lactate</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Lactic acidosis </td>
<td>Useful to assess perfusion status </td>
<td>Recommended when peripheral hypoperfusion is suspected </td>
</tr>
<tr>
<td><strong>Pulse oximetry and arterial blood gas
analysis</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Respiratory failure </td>
<td>Useful to assess respiratory function </td>
<td>Recommended when respiratory failure is suspected </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th>Exam</th>
<th>Time of measurement</th>
<th>Possible findings</th>
<th>Diagnostic value for AHF</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG</strong> </td>
<td>Admission, during
hospitalization,<sup>a</sup><sup>,</sup><sup>b</sup> pre-discharge </td>
<td>Arrhythmias, myocardial ischaemia </td>
<td>Exclusion of ACS or arrhythmias </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Chest-X ray</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Congestion, lung infection </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>LUS</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> pre-discharge </td>
<td>Congestion </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>Echocardiography</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Congestion, cardiac dysfunction, mechanical causes </td>
<td>Major </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Natriuretic peptides (BNP, NT-proBNP,
MR-proANP)</strong> </td>
<td>Admission, pre-discharge </td>
<td>Congestion </td>
<td>High negative predictive value </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum troponin</strong> </td>
<td>Admission </td>
<td>Myocardial injury </td>
<td>Exclusion of ACS </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum creatinine</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Renal dysfunction </td>
<td>None </td>
<td>Recommended for prognostic assessment </td>
</tr>
<tr>
<td><strong>Serum electrolytes (sodium, potassium,
chloride)</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Electrolyte disorders </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>Iron status (transferrin, ferritin)</strong> </td>
<td>Pre-discharge </td>
<td>Iron depletion </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>TSH</strong> </td>
<td>Admission </td>
<td>Hypo- hyperthyroidism </td>
<td>None </td>
<td>Recommended when hypo-hyperthyroidism is suspected </td>
</tr>
<tr>
<td><strong>D-dimer</strong> </td>
<td>Admission </td>
<td>Pulmonary embolism </td>
<td>Useful to exclude pulmonary embolism </td>
<td>Recommended when pulmonary embolism is suspected </td>
</tr>
<tr>
<td><strong>Procalcitonin</strong> </td>
<td>Admission </td>
<td>Pneumonia </td>
<td>Useful for diagnosis of pneumonia </td>
<td>May be done when pneumonia is suspected </td>
</tr>
<tr>
<td><strong>Lactate</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Lactic acidosis </td>
<td>Useful to assess perfusion status </td>
<td>Recommended when peripheral hypoperfusion is suspected </td>
</tr>
<tr>
<td><strong>Pulse oximetry and arterial blood gas
analysis</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Respiratory failure </td>
<td>Useful to assess respiratory function </td>
<td>Recommended when respiratory failure is suspected </td>
</tr>
</tbody>
</table>
<p>ACS = acute coronary syndrome; AHF = acute heart failure;
BNP = B-type natriuretic peptide; ECG = electrocardiogram; LUS = lung
ultrasound; MR-proANP = mid-regional pro-atrial natriuretic peptide;
NT-proBNP = N-terminal pro-B-type natriuretic peptide;
TSH = thyroid-stimulating hormone.</p>
<p>a</p>
<p>Based on clinical conditions.</p>
<p>b</p>
<p>Continuous ECG monitoring can be considered based on clinical
conditions.</p>
<p>Table 20</p>
<p>Diagnostic tests in patients with acute heart failure</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th>Exam</th>
<th>Time of measurement</th>
<th>Possible findings</th>
<th>Diagnostic value for AHF</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG</strong> </td>
<td>Admission, during
hospitalization,<sup>a</sup><sup>,</sup><sup>b</sup> pre-discharge </td>
<td>Arrhythmias, myocardial ischaemia </td>
<td>Exclusion of ACS or arrhythmias </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Chest-X ray</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Congestion, lung infection </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>LUS</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> pre-discharge </td>
<td>Congestion </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>Echocardiography</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Congestion, cardiac dysfunction, mechanical causes </td>
<td>Major </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Natriuretic peptides (BNP, NT-proBNP,
MR-proANP)</strong> </td>
<td>Admission, pre-discharge </td>
<td>Congestion </td>
<td>High negative predictive value </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum troponin</strong> </td>
<td>Admission </td>
<td>Myocardial injury </td>
<td>Exclusion of ACS </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum creatinine</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Renal dysfunction </td>
<td>None </td>
<td>Recommended for prognostic assessment </td>
</tr>
<tr>
<td><strong>Serum electrolytes (sodium, potassium,
chloride)</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Electrolyte disorders </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>Iron status (transferrin, ferritin)</strong> </td>
<td>Pre-discharge </td>
<td>Iron depletion </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>TSH</strong> </td>
<td>Admission </td>
<td>Hypo- hyperthyroidism </td>
<td>None </td>
<td>Recommended when hypo-hyperthyroidism is suspected </td>
</tr>
<tr>
<td><strong>D-dimer</strong> </td>
<td>Admission </td>
<td>Pulmonary embolism </td>
<td>Useful to exclude pulmonary embolism </td>
<td>Recommended when pulmonary embolism is suspected </td>
</tr>
<tr>
<td><strong>Procalcitonin</strong> </td>
<td>Admission </td>
<td>Pneumonia </td>
<td>Useful for diagnosis of pneumonia </td>
<td>May be done when pneumonia is suspected </td>
</tr>
<tr>
<td><strong>Lactate</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Lactic acidosis </td>
<td>Useful to assess perfusion status </td>
<td>Recommended when peripheral hypoperfusion is suspected </td>
</tr>
<tr>
<td><strong>Pulse oximetry and arterial blood gas
analysis</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Respiratory failure </td>
<td>Useful to assess respiratory function </td>
<td>Recommended when respiratory failure is suspected </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th>Exam</th>
<th>Time of measurement</th>
<th>Possible findings</th>
<th>Diagnostic value for AHF</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG</strong> </td>
<td>Admission, during
hospitalization,<sup>a</sup><sup>,</sup><sup>b</sup> pre-discharge </td>
<td>Arrhythmias, myocardial ischaemia </td>
<td>Exclusion of ACS or arrhythmias </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Chest-X ray</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Congestion, lung infection </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>LUS</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> pre-discharge </td>
<td>Congestion </td>
<td>Confirmatory </td>
<td>May be considered </td>
</tr>
<tr>
<td><strong>Echocardiography</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Congestion, cardiac dysfunction, mechanical causes </td>
<td>Major </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Natriuretic peptides (BNP, NT-proBNP,
MR-proANP)</strong> </td>
<td>Admission, pre-discharge </td>
<td>Congestion </td>
<td>High negative predictive value </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum troponin</strong> </td>
<td>Admission </td>
<td>Myocardial injury </td>
<td>Exclusion of ACS </td>
<td>Recommended </td>
</tr>
<tr>
<td><strong>Serum creatinine</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Renal dysfunction </td>
<td>None </td>
<td>Recommended for prognostic assessment </td>
</tr>
<tr>
<td><strong>Serum electrolytes (sodium, potassium,
chloride)</strong> </td>
<td>Admission, during hospitalization,<sup>a</sup> pre-discharge </td>
<td>Electrolyte disorders </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>Iron status (transferrin, ferritin)</strong> </td>
<td>Pre-discharge </td>
<td>Iron depletion </td>
<td>None </td>
<td>Recommended for prognostic assessment and treatment </td>
</tr>
<tr>
<td><strong>TSH</strong> </td>
<td>Admission </td>
<td>Hypo- hyperthyroidism </td>
<td>None </td>
<td>Recommended when hypo-hyperthyroidism is suspected </td>
</tr>
<tr>
<td><strong>D-dimer</strong> </td>
<td>Admission </td>
<td>Pulmonary embolism </td>
<td>Useful to exclude pulmonary embolism </td>
<td>Recommended when pulmonary embolism is suspected </td>
</tr>
<tr>
<td><strong>Procalcitonin</strong> </td>
<td>Admission </td>
<td>Pneumonia </td>
<td>Useful for diagnosis of pneumonia </td>
<td>May be done when pneumonia is suspected </td>
</tr>
<tr>
<td><strong>Lactate</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Lactic acidosis </td>
<td>Useful to assess perfusion status </td>
<td>Recommended when peripheral hypoperfusion is suspected </td>
</tr>
<tr>
<td><strong>Pulse oximetry and arterial blood gas
analysis</strong> </td>
<td>Admission, during hospitalization<sup>a</sup> </td>
<td>Respiratory failure </td>
<td>Useful to assess respiratory function </td>
<td>Recommended when respiratory failure is suspected </td>
</tr>
</tbody>
</table>
<p>ACS = acute coronary syndrome; AHF = acute heart failure;
BNP = B-type natriuretic peptide; ECG = electrocardiogram; LUS = lung
ultrasound; MR-proANP = mid-regional pro-atrial natriuretic peptide;
NT-proBNP = N-terminal pro-B-type natriuretic peptide;
TSH = thyroid-stimulating hormone.</p>
<p>a</p>
<p>Based on clinical conditions.</p>
<p>b</p>
<p>Continuous ECG monitoring can be considered based on clinical
conditions.</p>
<p>Among other laboratory tests, troponin is useful for the detection of
acute coronary syndrome (ACS) although elevated levels are detected in
the vast majority of patients with AHF.<sup>436–438</sup> Blood urea
nitrogen or urea, serum creatinine, electrolytes (sodium, potassium,
chloride), and antigen carbohydrate 125 may help tailor
treatment.<sup>439</sup><sup>,</sup><sup>440</sup> Detection of abnormal
liver function identifies patients with a poor prognosis.<sup>441</sup>
Since both hypothyroidism and hyperthyroidism may precipitate AHF,
thyroid-stimulating hormone (TSH) should be assessed in those with newly
diagnosed AHF. Arterial blood gas analysis should be performed when a
precise measurement of O<sub>2</sub> and CO<sub>2</sub> partial pressure
is needed (i.e. patients with respiratory distress). Lactate and pH
levels should be measured in patients with cardiogenic shock. D-dimer
should be measured when acute pulmonary embolism is suspected.
Procalcitonin may be used for the diagnosis of pneumonia and antibiotic
therapy may have an indication when plasma levels are &gt;0.2 μg/L.
However, no impact of a strategy based on routine procalcitonin
measurements on outcomes was shown in a prospective, controlled,
trial.<sup>442</sup> Pulse oximetry should be measured routinely at the
time of first presentation of patients with AHF and continuous
monitoring may be needed in the first hours or
days.<sup>443</sup><sup>,</sup><sup>444</sup></p>
<h3 >11.2 Clinical presentations</h3>
<p>Four major clinical presentations can be described with possible
overlaps between them (<em>Table
21</em>).<sup>1</sup><sup>,</sup><sup>425</sup><sup>,</sup><sup>445</sup>
Clinical presentations are mainly based on the presence of signs of
congestion and/or peripheral hypoperfusion and require different
treatments (<em>Table
21</em>).<sup>1</sup><sup>,</sup><sup>425–427</sup><sup>,</sup><sup>432</sup><sup>,</sup><sup>446</sup><sup>,</sup><sup>447</sup></p>
<p>Table 21</p>
<p>Clinical presentations of acute heart failure</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Acute decompensated heart failure</th>
<th>Acute pulmonary oedema</th>
<th>Isolated right ventricular failure</th>
<th>Cardiogenic shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Main mechanisms</strong> </td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>LV dysfunction</p></li>
<li><p>Sodium and water renal retention</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased afterload and/or predominant LV diastolic
dysfunction</p></li>
<li><p>Valvular heart disease</p></li>
</ul>
<p>  | RV dysfunction and/or pre-capillary pulmonary hypertension  |
Severe cardiac dysfunction  | | <strong>Main cause of symptoms</strong> 
| Fluid accumulation, increased intraventricular pressure  | Fluid
redistribution to the lungs and acute respiratory failure  | Increased
central venous pressure and often systemic hypoperfusion  | Systemic
hypoperfusion  | | <strong>Onset</strong>  | Gradual (days)  | Rapid
(hours)  | Gradual or rapid  | Gradual or rapid  | | <strong>Main
haemodynamic abnormalities</strong>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low or normal cardiac output</p></li>
<li><p>Normal to low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Normal cardiac output</p></li>
<li><p>Normal to high SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased RVEDP</p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  | | <strong>Main clinical
presentations<sup>1</sup><sup>,</sup><sup>446</sup></strong>  | Wet and
warm OR Dry and cold  | Wet and warm<sup>b</sup>  | Dry and cold OR Wet
and cold  | Wet and cold  | | <strong>Main treatment</strong>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Vasodilators<sup>b</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics for peripheral congestion</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inotropic agents/vasopressors</p></li>
<li><p>Short-term MCS RRT</p></li>
</ul>
<p>  |</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Acute decompensated heart failure</th>
<th>Acute pulmonary oedema</th>
<th>Isolated right ventricular failure</th>
<th>Cardiogenic shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Main mechanisms</strong> </td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>LV dysfunction</p></li>
<li><p>Sodium and water renal retention</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased afterload and/or predominant LV diastolic
dysfunction</p></li>
<li><p>Valvular heart disease</p></li>
</ul>
<p>  | RV dysfunction and/or pre-capillary pulmonary hypertension  |
Severe cardiac dysfunction  | | <strong>Main cause of symptoms</strong> 
| Fluid accumulation, increased intraventricular pressure  | Fluid
redistribution to the lungs and acute respiratory failure  | Increased
central venous pressure and often systemic hypoperfusion  | Systemic
hypoperfusion  | | <strong>Onset</strong>  | Gradual (days)  | Rapid
(hours)  | Gradual or rapid  | Gradual or rapid  | | <strong>Main
haemodynamic abnormalities</strong>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low or normal cardiac output</p></li>
<li><p>Normal to low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Normal cardiac output</p></li>
<li><p>Normal to high SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased RVEDP</p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  | | <strong>Main clinical
presentations<sup>1</sup><sup>,</sup><sup>446</sup></strong>  | Wet and
warm OR Dry and cold  | Wet and warm<sup>b</sup>  | Dry and cold OR Wet
and cold  | Wet and cold  | | <strong>Main treatment</strong>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Vasodilators<sup>b</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics for peripheral congestion</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inotropic agents/vasopressors</p></li>
<li><p>Short-term MCS RRT</p></li>
</ul>
<p>  |</p>
<p>LV = left ventricular; LVEDP = left ventricular end-diastolic
pressure; MCS = mechanical circulatory support; PCWP = pulmonary
capillary wedge pressure; RV = right ventricular; RVEDP = right
ventricular end-diastolic pressure; RRT = renal replacement therapy;
SBP = systolic blood pressure.</p>
<p>a</p>
<p>May be normal with low cardiac output.</p>
<p>b</p>
<p>Wet and cold profile with need of inotropes and/or vasopressors may
rarely occur.</p>
<p>Table 21</p>
<p>Clinical presentations of acute heart failure</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Acute decompensated heart failure</th>
<th>Acute pulmonary oedema</th>
<th>Isolated right ventricular failure</th>
<th>Cardiogenic shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Main mechanisms</strong> </td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>LV dysfunction</p></li>
<li><p>Sodium and water renal retention</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased afterload and/or predominant LV diastolic
dysfunction</p></li>
<li><p>Valvular heart disease</p></li>
</ul>
<p>  | RV dysfunction and/or pre-capillary pulmonary hypertension  |
Severe cardiac dysfunction  | | <strong>Main cause of symptoms</strong> 
| Fluid accumulation, increased intraventricular pressure  | Fluid
redistribution to the lungs and acute respiratory failure  | Increased
central venous pressure and often systemic hypoperfusion  | Systemic
hypoperfusion  | | <strong>Onset</strong>  | Gradual (days)  | Rapid
(hours)  | Gradual or rapid  | Gradual or rapid  | | <strong>Main
haemodynamic abnormalities</strong>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low or normal cardiac output</p></li>
<li><p>Normal to low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Normal cardiac output</p></li>
<li><p>Normal to high SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased RVEDP</p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  | | <strong>Main clinical
presentations<sup>1</sup><sup>,</sup><sup>446</sup></strong>  | Wet and
warm OR Dry and cold  | Wet and warm<sup>b</sup>  | Dry and cold OR Wet
and cold  | Wet and cold  | | <strong>Main treatment</strong>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Vasodilators<sup>b</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics for peripheral congestion</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inotropic agents/vasopressors</p></li>
<li><p>Short-term MCS RRT</p></li>
</ul>
<p>  |</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Acute decompensated heart failure</th>
<th>Acute pulmonary oedema</th>
<th>Isolated right ventricular failure</th>
<th>Cardiogenic shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Main mechanisms</strong> </td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li><p>LV dysfunction</p></li>
<li><p>Sodium and water renal retention</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased afterload and/or predominant LV diastolic
dysfunction</p></li>
<li><p>Valvular heart disease</p></li>
</ul>
<p>  | RV dysfunction and/or pre-capillary pulmonary hypertension  |
Severe cardiac dysfunction  | | <strong>Main cause of symptoms</strong> 
| Fluid accumulation, increased intraventricular pressure  | Fluid
redistribution to the lungs and acute respiratory failure  | Increased
central venous pressure and often systemic hypoperfusion  | Systemic
hypoperfusion  | | <strong>Onset</strong>  | Gradual (days)  | Rapid
(hours)  | Gradual or rapid  | Gradual or rapid  | | <strong>Main
haemodynamic abnormalities</strong>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low or normal cardiac output</p></li>
<li><p>Normal to low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Normal cardiac output</p></li>
<li><p>Normal to high SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased RVEDP</p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Increased LVEDP and PCWP<sup>a</sup></p></li>
<li><p>Low cardiac output</p></li>
<li><p>Low SBP</p></li>
</ul>
<p>  | | <strong>Main clinical
presentations<sup>1</sup><sup>,</sup><sup>446</sup></strong>  | Wet and
warm OR Dry and cold  | Wet and warm<sup>b</sup>  | Dry and cold OR Wet
and cold  | Wet and cold  | | <strong>Main treatment</strong>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics</p></li>
<li><p>Vasodilators<sup>b</sup></p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Diuretics for peripheral congestion</p></li>
<li><p>Inotropic agents/vasopressors (if peripheral
hypoperfusion/hypotension)</p></li>
<li><p>Short-term MCS or RRT if needed</p></li>
</ul>
<p>  |</p>
<ul>
<li><p>Inotropic agents/vasopressors</p></li>
<li><p>Short-term MCS RRT</p></li>
</ul>
<p>  |</p>
<p>LV = left ventricular; LVEDP = left ventricular end-diastolic
pressure; MCS = mechanical circulatory support; PCWP = pulmonary
capillary wedge pressure; RV = right ventricular; RVEDP = right
ventricular end-diastolic pressure; RRT = renal replacement therapy;
SBP = systolic blood pressure.</p>
<p>a</p>
<p>May be normal with low cardiac output.</p>
<p>b</p>
<p>Wet and cold profile with need of inotropes and/or vasopressors may
rarely occur.</p>
<h4 >11.2.1 Acute decompensated
heart failure</h4>
<p>Acutely decompensated heart failure (ADHF) is the most common form of
AHF, accounting for 50–70% of
presentations.<sup>426</sup><sup>,</sup><sup>427</sup><sup>,</sup><sup>432</sup>
It usually occurs in patients with history of HF and previous cardiac
dysfunction across the spectrum of LVEF and may include RV dysfunction.
Distinct from the acute pulmonary oedema phenotype, it has a more
gradual onset, and the main alteration is progressive fluid retention
responsible for systemic congestion. Sometimes, congestion is associated
with hypoperfusion.<sup>426</sup> The objectives of treatment are
identification of precipitants, decongestion, and in rare instances,
correction of hypoperfusion (<em>Figure 7</em>).</p>
<p>Figure 7</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f7.jpeg?Expires=1689850106&amp;Signature=vJ5YgVQdjB4GYo96KTT6EklkPfhXrsA5Mv~nZeWU8LiOUQKIvSC92BTzwe5oEvgo1Nxcxm7M4FIIUmqEO444CFZnTQMONwoeJPi1uFhy2VjF406r~NIjwpkf5VfFuqgkFnAzfiCShH4x47R2EiSFupvzPHopSdcBhDPfNVO20pzjb-~F~REAhKxOYZNJW3H6FB2bnRBY3WZ-K8tbRKz7RHSJs0XCAFcjJiNtpcEvoP~RVGgZG3xgE67s0pzVaWAYq2LBUx5RRbBMwcl~iIwQXWhAkS45r4-8KFH5pdZS5E3KBBYitL2ndZ-sGQFlOtOsHTdNqCLXtKvaugZEe6IfQQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of acute decompensated heart failure. MCS = mechanical circulatory support. aAdequate diuretic doses to relieve congestion and close monitoring of diuresis is recommended (see Figure13) regardless of perfusion status." />
<figcaption aria-hidden="true">Management of acute decompensated heart
failure. MCS = mechanical circulatory support. aAdequate diuretic doses
to relieve congestion and close monitoring of diuresis is recommended
(see Figure13) regardless of perfusion status.</figcaption>
</figure>
<p>Management of acute decompensated heart failure. MCS = mechanical
circulatory support. <sup>a</sup>Adequate diuretic doses to relieve
congestion and close monitoring of diuresis is recommended (see
<em>Figure13</em>) regardless of perfusion status.</p>
<h4 >11.2.2 Acute pulmonary oedema</h4>
<p>Acute pulmonary oedema is related to lung congestion. Clinical
criteria for acute pulmonary oedema diagnosis include dyspnoea with
orthopnoea, respiratory failure (hypoxaemia-hypercapnia), tachypnoea,
&gt;25 breaths/min, and increased work of breathing.<sup>448</sup></p>
<p>Three therapies should be commenced, if indicated. First, oxygen,
given as continuous positive airway pressure, non-invasive
positive-pressure-ventilation and/or high-flow nasal cannula, should be
started. Second, i.v. diuretics should be administered, and third, i.v.
vasodilators may be given if systolic BP (SBP) is high, to reduce LV
afterload (<em>Figure 8</em>). In a few cases of advanced HF, acute
pulmonary oedema may be associated with low cardiac output and, in this
case, inotropes, vasopressors, and/or MCS are indicated to restore organ
perfusion.</p>
<p>Figure 8</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f8.jpeg?Expires=1689850106&amp;Signature=fC6Un5OHmRG27HJ5EbJYkNVUrWhM4gZFc8fDTctSyj1QMS3kjyGWZepJDNgXEa9Txq8wMvNoyM2cVR-hGzBpIG7tuttH5-t8amC2zOwaCI5pybJqLqJ8h6HoXH5VpbLxtALO28KQm~PrzqWDsIG0L7wqwNl~nbO1xlyjZDFCqRaFS5l5Uvw4TlIqluqHf7fiwuxsHZRGRZ-Pv3jFeqX45KTgTmgCjiBJYVxt41C8fa4vSPZJcvs-j9FFDZ0Xq9Y66b2SbSikk71sdd-InEWEnDAV8OiSamMO5dg2O~6Kty0cFxh80QtEeRUvYQyQ~Yk7-k9Gz-OQgoSwAKK8skX10Q__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of pulmonary oedema. MCS = mechanical circulatory support; RRT =  renal replacement therapy; SBP = systolic blood pressure." />
<figcaption aria-hidden="true">Management of pulmonary oedema.
MCS = mechanical circulatory support; RRT =  renal replacement therapy;
SBP = systolic blood pressure.</figcaption>
</figure>
<p>Management of pulmonary oedema. MCS = mechanical circulatory support;
RRT =  renal replacement therapy; SBP = systolic blood pressure.</p>
<h4 >11.2.3 Isolated right
ventricular failure</h4>
<p>RV failure is associated with increased RV and atrial pressure and
systemic congestion. RV failure may also impair LV filling, and
ultimately reduce systemic cardiac output, through ventricular
interdependence.<sup>449</sup></p>
<p>Diuretics are often the first option of therapy for venous
congestion. Noradrenaline and/or inotropes are indicated for low cardiac
output and haemodynamic instability. Inotropes reducing cardiac filling
pressures may be preferred (i.e. levosimendan, phosphodiesterase type
III inhibitors). Since inotropic agents may aggravate arterial
hypotension, they may be combined with norepinephrine if needed
(<em>Figure 9</em>).<sup>449</sup></p>
<p>Figure 9</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f9.jpeg?Expires=1689850106&amp;Signature=Zq5IBG9oVrA3AFdjAzLexTobdgMpP-4ZOrLT8Xb4kOKSTeHd67H7dpjMBqng2YiA85gC2qaTObGJ~kfDbJGJ8Fqb~gtbElCE7UBwOGmEOSCTeKC0pQsplKMjaF15ma3OXQUJwLHzwG41I5dXKo9SF2T2az5p8mQy5WYpY5T0zE3c9C6RmBQWTmtPFg-er2YNzODWwwdjQ261EpEKGFn8bhebpegtdvfNNJcSBnANjzdo874CvxLT6b8r-FWQY5r~Zsd3Nm-Prr2HO5TXhukoy2eH5WnZIQpynkpw-N03JQrgQKxOlDq2v7CKRbmp6A4zcWHf0ZOWltXflyV5d2JaGw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of right ventricular failure. ACS = acute coronary syndrome; RV = right ventricular; RVAD = right ventricular assist device. aInotropes alone in case of hypoperfusion without hypotension." />
<figcaption aria-hidden="true">Management of right ventricular failure.
ACS = acute coronary syndrome; RV = right ventricular; RVAD = right
ventricular assist device. aInotropes alone in case of hypoperfusion
without hypotension.</figcaption>
</figure>
<p>Management of right ventricular failure. ACS = acute coronary
syndrome; RV = right ventricular; RVAD = right ventricular assist
device. <sup>a</sup>Inotropes alone in case of hypoperfusion without
hypotension.</p>
<h4 >11.2.4 Cardiogenic shock</h4>
<p>Cardiogenic shock is a syndrome due to primary cardiac dysfunction
resulting in an inadequate cardiac output, comprising a life-threatening
state of tissue hypoperfusion, which can result in multi-organ failure
and death.<sup>450–452</sup> Cardiac insult causing severe impairment of
cardiac performance may be acute, as a result of the acute loss of
myocardial tissue (acute MI, myocarditis) or may be progressive as seen
in patients with chronic decompensated HF who may experience a decline
in disease stability as a result of the natural progression of advanced
HF and/or specific precipitants.<sup>426</sup></p>
<p>Diagnosis of cardiogenic shock mandates the presence of clinical
signs of hypoperfusion, such as cold sweated extremities, oliguria,
mental confusion, dizziness, narrow pulse pressure. In addition,
biochemical manifestations of hypoperfusion, elevated serum creatinine,
metabolic acidosis and elevated serum lactate are present and reflect
tissue hypoxia and alterations of cellular metabolism leading to organ
dysfunction.<sup>437</sup><sup>,</sup><sup>453</sup> Of note,
hypoperfusion is not always accompanied by hypotension, as BP may be
preserved by compensatory vasoconstriction (with/without pressor
agents), albeit at the cost of impaired tissue perfusion and
oxygenation.<sup>426</sup><sup>,</sup><sup>427</sup><sup>,</sup><sup>450</sup><sup>,</sup><sup>454</sup></p>
<p>Management of cardiogenic shock should start as early as possible.
Early identification and treatment of the underlying cause, concomitant
with haemodynamic stabilization and management of organ dysfunction, are
key components of its management (<em>Figure 10</em>, <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 11.1</a>; <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Figure 2</a></em>).</p>
<p>Figure 10</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f10.jpeg?Expires=1689850106&amp;Signature=FYw~~yZG5Pq68JjvMIJXn5DLJOgSo0TdQI94MDK5np2OK623Vr8MujtoO-Z3p8NyBHknFKKw2BSGgG7SMqnXz51y8ipuhfqi95eDhfHSNNO-T8Ubkdtgh5Yhoqg7PpkwBEJpdgFXVD1kYXm15PhmjIovj2l3URxQxUWjM11WcKGby7zPU9vduEdLnZ8BNhoydpaM8hoPnUCwCCJet-OW1NWFGFSWKjLq~ndVkR3f9aHP6x0IYJCK019KAuG91yDBOXOSx16lv3KKb16OmAUtU0D05m6wADK3ezXp2jd90E41PBWrhKKUKJwV8g1xo-SmtfIjnHPhyCR2blC52O7ZEw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of cardiogenic shock. ACS = acute coronary syndrome; BTT = bridge to transplantation; MCS = mechanical circulatory support; PCI = percutaneous coronary intervention. aPCI in ACS, pericardiocentesis in tamponade, mitral valve surgery in papillary muscle rupture. In case of interventricular septum rupture, MCS as BTT should be considered. bOther causes include acute valve regurgitation, pulmonary embolism, infection, acute myocarditis, arrhythmia (see Figure 12)." />
<figcaption aria-hidden="true">Management of cardiogenic shock.
ACS = acute coronary syndrome; BTT = bridge to transplantation;
MCS = mechanical circulatory support; PCI = percutaneous coronary
intervention. aPCI in ACS, pericardiocentesis in tamponade, mitral valve
surgery in papillary muscle rupture. In case of interventricular septum
rupture, MCS as BTT should be considered. bOther causes include acute
valve regurgitation, pulmonary embolism, infection, acute myocarditis,
arrhythmia (see Figure 12).</figcaption>
</figure>
<p>Management of cardiogenic shock. ACS = acute coronary syndrome;
BTT = bridge to transplantation; MCS = mechanical circulatory support;
PCI = percutaneous coronary intervention. <sup>a</sup>PCI in ACS,
pericardiocentesis in tamponade, mitral valve surgery in papillary
muscle rupture. In case of interventricular septum rupture, MCS as BTT
should be considered. <sup>b</sup>Other causes include acute valve
regurgitation, pulmonary embolism, infection, acute myocarditis,
arrhythmia (see <em>Figure 12</em>).</p>
<h3 >11.3 Management</h3>
<h4 >11.3.1 General aspects</h4>
<p>Management can be subdivided in three stages (pre-hospital,
in-hospital, and pre-discharge), having different goals and requiring
different approaches (<em>Figure 11</em>).</p>
<p><strong>Pre-hospital phase</strong></p>
<p>In the pre-hospital setting, AHF patients should benefit from
non-invasive monitoring, including pulse oximetry, BP, heart rate
respiratory rate, and a continuous ECG, instituted within minutes of
patient contact and in the ambulance if possible.<sup>305</sup> Oxygen
therapy may be given based on clinical judgment unless oxygen saturation
is &lt;90% in which case it should be administered. In patients with
respiratory distress, respiratory rate &gt;25 breaths/min, oxygen
saturation &lt;90%, non-invasive ventilation should be
initiated.<sup>444</sup><sup>,</sup><sup>448</sup> Although therapeutic
tools may be available in the prehospital setting, whether more
effective pre‐hospital care would alter the clinical outcome remains to
be proven in randomized clinical trials.<sup>455</sup> Furthermore,
pre-hospital management should not delay the rapid transfer of AHF
patients to the most appropriate medical
setting.<sup>455</sup><sup>,</sup><sup>456</sup></p>
<p><strong>In-hospital management</strong></p>
<p>Diagnostic workup and appropriate pharmacological and
non-pharmacological treatment must be started promptly and in parallel
(<em>Figure 12</em>). AHF patients are triaged to the appropriate level
of care according to the degree of haemodynamic instability and severity
of the critical illness. Disposition decisions are important components
of the initial phase of management (see <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 11.2</a> and <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Tables 17–19</a></em>).</p>
<p>The type and intensity of in-hospital monitoring depends on clinical
severity, settings of care and in-hospital course (see <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 11.3</a>). As AHF is a heterogeneous condition, management may
differ according to the main clinical presentation. Management starts
with the search for specific causes of
AHF.<sup>1</sup><sup>,</sup><sup>305</sup><sup>,</sup><sup>430</sup>
These include ACS, a hypertensive emergency, rapid arrhythmias or severe
bradycardia/conduction disturbance, acute mechanical causes such as
acute valve regurgitation or acute pulmonary embolism, infection,
including myocarditis, and tamponade (CHAMPIT) (<em>Figure 12</em>).
After exclusion of these conditions, which need to be treated/corrected
urgently, management of AHF differs according to the clinical
presentations (<em>Figures 7–10</em>).</p>
<p><strong>Pre-discharge phase</strong></p>
<p>Details on this phase are shown in <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-11.3.11">section
11.3.11</a>.</p>
<p>Figure 11</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f11.jpeg?Expires=1689850106&amp;Signature=m1VQqXsH8O-owY9-vNWD~QVuUxrkFao8-TrOygguVAgQpAIXblCpaebiFqGmW~iJ96iyVyqHVbIJtSngh0hPfpPNPffQyysc6q4Rwc6udqXxiCqUeF~-Qoz4wW~RMQeJXvG7IrJqFW8PlpU50XjGcVaCPUSSX-20uDxCMd3Oqw-UUemxYuBFF-10dMkhucXBYaIgXUhe2u9XP-arB6HFycnTzXI1iSd97kAVQ9FNaHzzKsy1~AVe5k0JfPDkdg1RdMioSFLwbjzWutLwJPzyVwgirTHIX59ps-ABg5gFovLb2eaZNZJBAw~kmG1gJJ6mr2ZHWMn0-wPVmwUupxaCRw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Stages of management of patients with acute heart failure. ICCU = intensive coronary care unit; ICU = intensive care unit." />
<figcaption aria-hidden="true">Stages of management of patients with
acute heart failure. ICCU = intensive coronary care unit;
ICU = intensive care unit.</figcaption>
</figure>
<p>Stages of management of patients with acute heart failure.
ICCU = intensive coronary care unit; ICU = intensive care unit.</p>
<p>Figure 12</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f12.jpeg?Expires=1689850106&amp;Signature=LxCl2sCoh7JXh4QuN8p2b9iU-uSSbnDJzuW~OwyGLw3zxQ-HNleGk38-8A9U4-VJxMwd11WzaOOhnmgNCu2hZM48Uc0Ms4P6efZOH8xwsTMrqz3Zx1nSfLxLImqXWi5TCqPF~uNsVLT3hO7a~5SuJRnr5oYogaHz9-dfVYjGxBoc0XgOjUadTTiUh8-ozJTih21lLyJ5aKVJA-FwdeCVxkh2CZ1wzu33hPzoGugmekBz4nWtpLYbLFppv5-c30qop1-l4jIAtAyZ0tWzLBjSUv7A-XNiwjtO~8l-uQtLx6TlHe9X2nLMQOfRHMWVmGtBHpNg2z1vZR2JKKCHOeLCog__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Initial management of acute heart failure. MCS = mechanical circulatory support. aAcute mechanical cause: myocardial rupture complicating acute coronary syndrome (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis. bSee Figures 7–10 for specific treatments according to different clinical presentations." />
<figcaption aria-hidden="true">Initial management of acute heart
failure. MCS = mechanical circulatory support. aAcute mechanical cause:
myocardial rupture complicating acute coronary syndrome (free wall
rupture, ventricular septal defect, acute mitral regurgitation), chest
trauma or cardiac intervention, acute native or prosthetic valve
incompetence secondary to endocarditis, aortic dissection or thrombosis.
bSee Figures 7–10 for specific treatments according to different
clinical presentations.</figcaption>
</figure>
<p>Initial management of acute heart failure. MCS = mechanical
circulatory support. <sup>a</sup>Acute mechanical cause: myocardial
rupture complicating acute coronary syndrome (free wall rupture,
ventricular septal defect, acute mitral regurgitation), chest trauma or
cardiac intervention, acute native or prosthetic valve incompetence
secondary to endocarditis, aortic dissection or thrombosis.
<sup>b</sup>See <em>Figures 7–10</em> for specific treatments according
to different clinical presentations.</p>
<h4 >11.3.2 Oxygen therapy
and/or ventilatory support</h4>
<p>In AHF, oxygen should not be used routinely in non-hypoxaemic
patients, as it causes vasoconstriction and a reduction in cardiac
output.<sup>457</sup> Oxygen therapy is recommended in patients with AHF
and SpO<sub>2</sub> &lt;90% or PaO<sub>2</sub> &lt;60 mmHg to correct
hypoxaemia. In chronic obstructive pulmonary disease (COPD),
hyper-oxygenation may increase ventilation–perfusion mismatch, suppress
ventilation and lead to hypercapnia. During oxygen therapy, acid-base
balance and SpO<sub>2</sub> should be monitored.</p>
<p>Non-invasive positive pressure ventilation, either continuous
positive airway pressure and pressure support, improves respiratory
failure, increases oxygenation and pH, and decreases the partial
pressure of carbon dioxide (pCO<sub>2</sub>) and work of breathing.
Although a large randomized trial had neutral results, meta-analyses
suggest it may improve dyspnoea and reduce the need for intubation and
mortality, compared with traditional oxygen
therapy.<sup>1</sup><sup>,</sup><sup>458</sup><sup>,</sup><sup>459</sup>
Non-invasive positive pressure ventilation should be started as soon as
possible in patients with respiratory distress (respiratory rate &gt;25
breaths/min, SpO<sub>2</sub> &lt;90%) to improve gas exchange and reduce
the rate of endotracheal
intubation.<sup>448</sup><sup>,</sup><sup>459</sup> The fraction of
inspired oxygen (FiO<sub>2</sub>) should be increased up to 100%, if
necessary, according to oxygen saturation level.</p>
<p>Blood pressure should be monitored regularly during non-invasive
positive pressure ventilation. The increase in intrathoracic pressure
with non-invasive positive pressure ventilation decreases venous return
and right and left ventricular preload. It may also decrease cardiac
output and BP and should therefore be used with caution in patients with
reduced preload reserve and hypotension. The increase in pulmonary
vascular resistance and RV afterload may also be detrimental in RV
dysfunction.<sup>448</sup></p>
<p>Intubation is recommended for progressive respiratory failure in
spite of oxygen administration or non-invasive ventilation (<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 20</a></em>).<sup>448</sup></p>
<h4 >11.3.3 Diuretics</h4>
<p>Intravenous diuretics are the cornerstone of AHF treatment. They
increase renal excretion of salt and water and are indicated for the
treatment of fluid overload and congestion in the vast majority of AHF
patients.</p>
<p>Loop diuretics are commonly used due to their rapid onset of action
and efficacy. Data defining their optimal dosing, timing, and method of
administration are limited. No difference in the primary efficacy
outcome of patients’ symptoms global assessment was shown with a
high-dose regimen, compared with a low-dose regimen, in the DOSE trial.
However, there was a greater relief of dyspnoea, change in weight and
net fluid loss (with no prognostic role for increases in serum
creatinine) in the higher-dose regimen.<sup>460–462</sup> High diuretic
doses may cause greater neurohormonal activation and electrolyte
abnormalities and are often associated with poorer outcomes, although a
cause and effect relation cannot be proven by these retrospective
analyses.<sup>463–466</sup> Based on these observations, it may be
appropriate, when starting i.v. diuretic treatment, to use low doses, to
assess the diuretic response and increase the dose when that is
insufficient.</p>
<p>Diuretic treatment should be started with an initial i.v. dose of
furosemide, or equivalent dose of bumetanide or torasemide,
corresponding to 1–2 times the daily oral dose taken by the patient
before admission. If the patient was not on oral diuretics, a starting
dose of 20–40 mg of furosemide, or a bolus of 10–20 mg i.v. torasemide,
can be used.<sup>145</sup><sup>,</sup><sup>467</sup> Furosemide can be
given as 2–3 daily boluses or as a continuous infusion. Daily single
bolus administrations are discouraged because of the possibility of
post-dosing sodium retention.<sup>145</sup><sup>,</sup><sup>461</sup>
With continuous infusion, a loading dose may be used to achieve steady
state earlier. Diuretic response should be evaluated shortly after start
of diuretic therapy and may be assessed by performing a spot urine
sodium content measurement after 2 or 6 h and/or by measuring the hourly
urine output. A satisfactory diuretic response can be defined as a urine
sodium content &gt;50–70 mEq/L at 2 h and/or by a urine output
&gt;100–150 mL/h during the first
6 h.<sup>145</sup><sup>,</sup><sup>468</sup> If there is an insufficient
diuretic response, the loop diuretic i.v. dose can be doubled, with a
further assessment of diuretic response.<sup>145</sup> If the diuretic
response remains inadequate, e.g. &lt;100 mL hourly diuresis despite
doubling loop diuretic dose, concomitant administration of other
diuretics acting at different sites, namely thiazides or metolazone or
acetazolamide, may be considered. However, this combination requires
careful monitoring of serum electrolytes and renal function (<em>Figure
13</em>).<sup>145</sup><sup>,</sup><sup>469</sup><sup>,</sup><sup>470</sup>
This strategy, based on early and frequent assessment of diuretic
response, allows starting treatment with relatively low doses of loop
diuretics, with frequent dose adjustments that may be less likely to
cause dehydration and increase in serum creatinine. The loop diuretic
dose should be progressively decreased when a significant negative fluid
balance has been obtained. However, it should be pointed out that this
algorithm is entirely based on expert opinion, to
date.<sup>145</sup><sup>,</sup><sup>461</sup></p>
<p>Transition to oral treatment should be commenced when the patient’s
clinical condition is stable. It is recommended that, after achievement
of congestion relief, oral loop diuretics are continued at the lowest
dose possible to avoid
congestion.<sup>463</sup><sup>,</sup><sup>471</sup> Care must also be
taken to avoid patients being discharged from hospital with persistent
congestion, as this is a major predictor of increased deaths and
rehospitalizations.<sup>462</sup><sup>,</sup><sup>472</sup> Hence, care
should be taken to achieve adequate decongestion and establish an
appropriate long-term diuretic dose before
discharge.<sup>427</sup><sup>,</sup><sup>473</sup></p>
<p>Figure 13</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f13.jpeg?Expires=1689850106&amp;Signature=ZhGVbreX9SM0xC5EjMN9xkhcnar8LkHasB9Acn7PZSddvGoo6cBmC34iaQhBDjNh3U9WmdLZ3H4hH0azrB~4jeXF0K3YyZeRwG3LKhewWsYbXnEnI4goTFkQ6jL1Srx8nSzcEd1iO0Khf3LlKYp0yHUluvKSaG4DK8u1tO4abrdSnT5UN4rclqshDlbtNzHYEYSgFzvX1gaY7E-0-1-aKPRHeZT7laTTsxXmTMPd0lf44mbXSIEf3zDGGRK7X320OY7dvbg946m64ww9SZDpthte0KiWUNvguJi1K-iPii9yd-zZnL12709kR2S~Ph~zgR3O0LdcdyvTt9Ft1ppV6w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Diuretic therapy (furosemide) in acute heart failure. i.v. = intravenous. aThe maximal daily dose for i.v. loop diuretics is generally considered furosemide 400–600 mg though up to 1000 mg may be considered in patients with severely impaired kidney function. bCombination therapy is the addition to the loop diuretic of a diuretic with a different site of action, e.g. thiazides or metolazone or acetazolamide. Modified from 145." />
<figcaption aria-hidden="true">Diuretic therapy (furosemide) in acute
heart failure. i.v. = intravenous. aThe maximal daily dose for i.v. loop
diuretics is generally considered furosemide 400–600 mg though up to
1000 mg may be considered in patients with severely impaired kidney
function. bCombination therapy is the addition to the loop diuretic of a
diuretic with a different site of action, e.g. thiazides or metolazone
or acetazolamide. Modified from 145.</figcaption>
</figure>
<p>Diuretic therapy (furosemide) in acute heart failure.
i.v. = intravenous. <sup>a</sup>The maximal daily dose for i.v. loop
diuretics is generally considered furosemide 400–600 mg though up to
1000 mg may be considered in patients with severely impaired kidney
function. <sup>b</sup>Combination therapy is the addition to the loop
diuretic of a diuretic with a different site of action, e.g. thiazides
or metolazone or acetazolamide. Modified from <sup>145</sup>.</p>
<h4 >11.3.4 Vasodilators</h4>
<p>Intravenous vasodilators, namely nitrates or nitroprusside (<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 21</a></em>), dilate venous and arterial vessels leading to a
reduction in venous return to the heart, less congestion, lower
afterload, increased stroke volume and consequent relief of symptoms.
Nitrates act mainly on peripheral veins whereas nitroprusside is more a
balanced arterial and venous
dilator.<sup>474</sup><sup>,</sup><sup>475</sup> Because of their
mechanisms of action, i.v. vasodilators may be more effective than
diuretics in those patients whose acute pulmonary oedema is caused by
increased afterload and fluid redistribution to the lungs in the absence
or with minimal fluid
accumulation.<sup>427</sup><sup>,</sup><sup>476–478</sup> However, two
recent randomized trials comparing usual care with early intensive and
sustained vasodilation failed to show a beneficial effect of i.v.
vasodilators vs. high-dose
diuretics.<sup>479</sup><sup>,</sup><sup>480</sup> No recommendation
favouring a regimen based on vasodilator treatment vs. usual care can
thus be given, to date.</p>
<p>Intravenous vasodilators may be considered to relieve AHF symptoms
when SBP is &gt;110 mmHg. They may be started at low doses and
uptitrated to achieve clinical improvement and BP control. Nitrates are
generally administered with an initial bolus followed by continuous
infusion. However, they may also be given as repeated boluses.
Nitroglycerine can be given as 1–2 mg boluses in severely hypertensive
patients with acute pulmonary oedema.<sup>477</sup> Care should be taken
to avoid hypotension due to an excessive decrease in preload and
afterload. For this reason, they should be used with extreme caution in
patients with LVH and/or severe aortic stenosis. However, favorable
effects were described in patients with LV systolic dysfunction and
aortic stenosis when vasodilators were given with careful monitoring of
haemodynamic parameters.<sup>481</sup></p>
<h4 >11.3.5 Inotropes</h4>
<p>Inotropes are still needed for treatment of patients with low cardiac
output and hypotension (<em>Table 22</em>). They should be reserved for
patients with LV systolic dysfunction, low cardiac output and low SBP
(e.g. &lt;90 mmHg) resulting in poor vital organ perfusion. However,
they must be used with caution starting at low doses and uptitrating
them with close monitoring.<sup>387</sup><sup>,</sup><sup>388</sup></p>
<p>Inotropes, especially those with adrenergic mechanisms, can cause
sinus tachycardia, increase ventricular rate in patients with AF, may
induce myocardial ischaemia and arrhythmias, and increase
mortality.<sup>387</sup><sup>,</sup><sup>388</sup><sup>,</sup><sup>430</sup><sup>,</sup><sup>478</sup>
Levosimendan or type-3-phosphodiesterase inhibitors may be preferred
over dobutamine for patients on beta-blockers as they act through
independent mechanisms.<sup>482</sup><sup>,</sup><sup>483</sup>
Excessive peripheral vasodilation and hypotension can be major
limitations of type-3-phosphodiestaerase inhibitors or levosimendan,
especially when administered at high doses and/or when commenced with a
bolus dose.<sup>482</sup><sup>,</sup><sup>484</sup></p>
<h4 >11.3.6 Vasopressors</h4>
<p>Vasopressors used for the treatment of AHF are reported in <em>Table
22</em>.</p>
<p>Among drugs with a prominent peripheral arterial vasoconstrictor
action, norepinephrine may be preferred in patients with severe
hypotension. The aim is to increase perfusion to the vital organs.
However, this is at the expense of an increase in LV afterload.
Therefore, a combination of norepinephrine and inotropic agents may be
considered, especially in patients with advanced HF and cardiogenic
shock.</p>
<p>Some studies, though with limitations, support the use of
norepinephrine as first choice, compared with dopamine or epinephrine.
Dopamine was compared with norepinephrine as a first-line vasopressor
therapy in patients with shock and was associated with more arrhythmic
events and with a greater mortality in patients with cardiogenic shock
but not in those with hypovolaemic or septic shock. Although the trial
included 1679 patients, significance was seen only in a subgroup
analysis of the 280 patients with cardiogenic shock and &lt;10% of the
patients had MI. As there were no data regarding revascularization, this
limits the generalizability of the results.<sup>485</sup> In another
prospective randomized trial epinephrine was compared with
norepinephrine in patients with cardiogenic shock due to acute
MI.<sup>486</sup> The trial was stopped prematurely due to a higher
incidence of refractory shock with epinephrine. Epinephrine was also
associated with higher heart rate and lactic acidosis. Despite
limitations related to its relatively small sample size, short time of
follow-up and lack of data regarding the maximum reached dose, the study
suggests superior efficacy and safety with norepinephrine. These data
are consistent with a meta-analysis including 2583 patients with
cardiogenic shock showing a three-fold increase in the risk of death
with epinephrine, compared with norepinephrine, in patients with
cardiogenic shock.<sup>487</sup> However, the lack of information about
dose, duration of treatment, and aetiology, makes these results
partially explorative.</p>
<p>Table 22</p>
<p>Inotropes and/or vasopressors used to treat acute heart failure</p>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Drug</th>
<th>Infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine </td>
<td>2–20 μg/kg/min (beta+) </td>
</tr>
<tr>
<td>Dopamine </td>
<td>3–5 μg/kg/min; inotropic (beta+) &gt;5 μg/kg/min: inotropic (beta+),
vasopressor (alpha+) </td>
</tr>
<tr>
<td>Milrinone </td>
<td>0.375–0.75 μg/kg/min </td>
</tr>
<tr>
<td>Enoximone </td>
<td>5–20 μg/kg/min </td>
</tr>
<tr>
<td>Levosimendan </td>
<td>0.1 μg/kg/min, which can be decreased to 0.05 or increased to 0.2
μg/kg/min </td>
</tr>
<tr>
<td>Norepinephrine </td>
<td>0.2–1.0 μg/kg/min </td>
</tr>
<tr>
<td>Epinephrine </td>
<td>0.05–0.5 μg/kg/min </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Drug</th>
<th>Infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine </td>
<td>2–20 μg/kg/min (beta+) </td>
</tr>
<tr>
<td>Dopamine </td>
<td>3–5 μg/kg/min; inotropic (beta+) &gt;5 μg/kg/min: inotropic (beta+),
vasopressor (alpha+) </td>
</tr>
<tr>
<td>Milrinone </td>
<td>0.375–0.75 μg/kg/min </td>
</tr>
<tr>
<td>Enoximone </td>
<td>5–20 μg/kg/min </td>
</tr>
<tr>
<td>Levosimendan </td>
<td>0.1 μg/kg/min, which can be decreased to 0.05 or increased to 0.2
μg/kg/min </td>
</tr>
<tr>
<td>Norepinephrine </td>
<td>0.2–1.0 μg/kg/min </td>
</tr>
<tr>
<td>Epinephrine </td>
<td>0.05–0.5 μg/kg/min </td>
</tr>
</tbody>
</table>
<p>Table 22</p>
<p>Inotropes and/or vasopressors used to treat acute heart failure</p>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Drug</th>
<th>Infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine </td>
<td>2–20 μg/kg/min (beta+) </td>
</tr>
<tr>
<td>Dopamine </td>
<td>3–5 μg/kg/min; inotropic (beta+) &gt;5 μg/kg/min: inotropic (beta+),
vasopressor (alpha+) </td>
</tr>
<tr>
<td>Milrinone </td>
<td>0.375–0.75 μg/kg/min </td>
</tr>
<tr>
<td>Enoximone </td>
<td>5–20 μg/kg/min </td>
</tr>
<tr>
<td>Levosimendan </td>
<td>0.1 μg/kg/min, which can be decreased to 0.05 or increased to 0.2
μg/kg/min </td>
</tr>
<tr>
<td>Norepinephrine </td>
<td>0.2–1.0 μg/kg/min </td>
</tr>
<tr>
<td>Epinephrine </td>
<td>0.05–0.5 μg/kg/min </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr>
<th>Drug</th>
<th>Infusion rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dobutamine </td>
<td>2–20 μg/kg/min (beta+) </td>
</tr>
<tr>
<td>Dopamine </td>
<td>3–5 μg/kg/min; inotropic (beta+) &gt;5 μg/kg/min: inotropic (beta+),
vasopressor (alpha+) </td>
</tr>
<tr>
<td>Milrinone </td>
<td>0.375–0.75 μg/kg/min </td>
</tr>
<tr>
<td>Enoximone </td>
<td>5–20 μg/kg/min </td>
</tr>
<tr>
<td>Levosimendan </td>
<td>0.1 μg/kg/min, which can be decreased to 0.05 or increased to 0.2
μg/kg/min </td>
</tr>
<tr>
<td>Norepinephrine </td>
<td>0.2–1.0 μg/kg/min </td>
</tr>
<tr>
<td>Epinephrine </td>
<td>0.05–0.5 μg/kg/min </td>
</tr>
</tbody>
</table>
<h4 >11.3.7 Opiates</h4>
<p>Opiates relieve dyspnoea and anxiety. They may be used as sedative
agents during non-invasive positive pressure ventilation to improve
patient adaptation. Dose-dependent side effects include nausea,
hypotension, bradycardia, and respiratory depression. Retrospective
analyses suggest that morphine administration is associated with a
greater frequency of mechanical ventilation, prolonged hospitalization,
more intensive care unit admissions, and increased
mortality.<sup>488–491</sup> Thus, routine use of opiates in AHF is not
recommended although they may be considered in selected patients,
particularly in case of severe/intractable pain or anxiety or in the
setting of palliation.</p>
<p>Recommendations for the initial treatment of acute heart failure</p>
<p>AHF = acute heart failure; i.v. = intravenous;
LMWH = low-molecular-weight heparin; PaO<sub>2</sub> = partial pressure
of oxygen; SBP = systolic blood pressure;
SpO<sub>2</sub> = transcutaneous oxygen saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the initial treatment of acute heart failure</p>
<p>AHF = acute heart failure; i.v. = intravenous;
LMWH = low-molecular-weight heparin; PaO<sub>2</sub> = partial pressure
of oxygen; SBP = systolic blood pressure;
SpO<sub>2</sub> = transcutaneous oxygen saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4 >11.3.8 Digoxin</h4>
<p>Digoxin should be considered in patients with AF with a rapid
ventricular rate (&gt;110 b.p.m.) despite beta-blockers (see also <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.1.1">section
12.1.1</a>).<sup>151</sup><sup>,</sup><sup>492</sup><sup>,</sup><sup>493</sup>
It can be given in boluses of 0.25–0.5 mg i.v., if not used previously.
However, in patients with comorbidities (i.e. CKD) or other factors
affecting digoxin metabolism (including other drugs) and/or the elderly,
the maintenance dose may be difficult to estimate theoretically and
measurements of serum digoxin concentrations should be performed.
Digitoxin is a potential alternative to digoxin and is currently being
evaluated in a randomized placebo-controlled trial (ClinicalTrials.gov
Identifier: NCT03783429).<sup>158</sup></p>
<h4 >11.3.9 Thromboembolism
prophylaxis</h4>
<p>Thromboembolism prophylaxis with heparin (e.g. low-molecular-weight
heparin) or another anticoagulant is recommended, unless contraindicated
or unnecessary (because of existing treatment with oral
anticoagulants).<sup>494</sup><sup>,</sup><sup>495</sup></p>
<h4 >11.3.10 Short-term
mechanical circulatory support</h4>
<p>In patients presenting with cardiogenic shock, short-term MCS may be
necessary to augment cardiac output and support end-organ perfusion.
Short-term MCS can be used as a BTR, BTD or BTB.<sup><span
></span>450-<span
></span>452</sup> The initial improvements in
cardiac output, BP and arterial lactate may be counterbalanced by
significant complications. High-quality evidence regarding outcomes
remains scarce. Hence, the unselected use of MCS in patients with
cardiogenic shock is not supported and they require specialist
multidisciplinary expertise for implantation and management, similar to
that outlined for advanced HF centres (<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 11</a>.4; <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 22</a></em>, see also <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-10.2.2">section
10.2.2</a>).<sup>376</sup><sup>,</sup><sup>496</sup> Recent studies show
that a ‘standardized team-based approach’ using predefined algorithms
for early MCS implant coupled with close monitoring (invasive
haemodynamics, lactate, markers of end-organ damage) may potentially
translate into improved survival.<sup>497–499</sup></p>
<p>The Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK-II)
trial showed no difference in 30-day, as well as in long-term, mortality
between intra-aortic balloon pump (IABP) and OMT in patients with
cardiogenic shock following acute MI who underwent early
revascularization.<sup>500–502</sup> According to these results, IABP is
not routinely recommended in cardiogenic shock post-MI. However, it may
still be considered in cardiogenic shock, especially if not due to ACS,
and refractory to drug therapy, as a BTD, BTR, or BTB.</p>
<p>Other short-term MCS were compared with IABP in small, randomized
trials and propensity-matched analyses with inconclusive
results.<sup>503–507</sup> Similarly, RCTs comparing extracorporeal
membrane oxygenation (ECMO) with IABP or MT are lacking. A meta-analysis
including only observational studies showed favourable outcomes in
patients with cardiogenic shock or cardiac arrest treated with
veno-arterial (VA)-ECMO compared to controls.<sup>508</sup> VA-ECMO may
also be considered in fulminant myocarditis and other conditions causing
severe cardiogenic shock.<sup>509</sup> Depending on the severity of
myocardial dysfunction and/or concomitant mitral or aortic
regurgitation, VA-ECMO may increase LV afterload with an increase in LV
end-diastolic pressure and pulmonary congestion. In these cases, LV
unloading is mandatory and can be achieved by means of
transeptal/ventricular apex vent or adding an unloading device such as
the Impella device.<sup>510</sup><sup>,</sup><sup>511</sup></p>
<p>Recommendations for the use of short-term mechanical circulatory
support in patients with cardiogenic shock</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table58.jpeg?Expires=1689850106&amp;Signature=M~g78f45Ez0QpTz2n8tOxbtQJybpBHU9wz6tjDlDpQjTafXgJGiDDvo49AHKDbYz-QtkTmC6Kw05FnCygmgEW-RrZnXDTN5hAbxNreCMRl2VjDPBbh90-0En9R~0MZ6MiLG1L1P5RiPqGZvKBzkzWSVwmSzXx4~yanjtBRkBglvndUgEYP2A3ICXC5iRXrItsEcpiUpoH78tpqeykOYlp4z6g05yvaD3PpO234dZbtraQ~cfZzTuGpKfquGLb97APRVVpyqivC1jXcwA-J4OWYvNiqp84gku7G6iqTYxU4Y9QxbThjvbAeDQYD9O8mSELLrqK1--L3WgvtaVC9IpEA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table58.jpeg?Expires=1689850106&amp;Signature=M~g78f45Ez0QpTz2n8tOxbtQJybpBHU9wz6tjDlDpQjTafXgJGiDDvo49AHKDbYz-QtkTmC6Kw05FnCygmgEW-RrZnXDTN5hAbxNreCMRl2VjDPBbh90-0En9R~0MZ6MiLG1L1P5RiPqGZvKBzkzWSVwmSzXx4~yanjtBRkBglvndUgEYP2A3ICXC5iRXrItsEcpiUpoH78tpqeykOYlp4z6g05yvaD3PpO234dZbtraQ~cfZzTuGpKfquGLb97APRVVpyqivC1jXcwA-J4OWYvNiqp84gku7G6iqTYxU4Y9QxbThjvbAeDQYD9O8mSELLrqK1--L3WgvtaVC9IpEA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to
recovery; IABP = intra-aortic balloon pump; MCS = mechanical circulatory
support; MI = myocardial infarction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the use of short-term mechanical circulatory
support in patients with cardiogenic shock</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table58.jpeg?Expires=1689850106&amp;Signature=M~g78f45Ez0QpTz2n8tOxbtQJybpBHU9wz6tjDlDpQjTafXgJGiDDvo49AHKDbYz-QtkTmC6Kw05FnCygmgEW-RrZnXDTN5hAbxNreCMRl2VjDPBbh90-0En9R~0MZ6MiLG1L1P5RiPqGZvKBzkzWSVwmSzXx4~yanjtBRkBglvndUgEYP2A3ICXC5iRXrItsEcpiUpoH78tpqeykOYlp4z6g05yvaD3PpO234dZbtraQ~cfZzTuGpKfquGLb97APRVVpyqivC1jXcwA-J4OWYvNiqp84gku7G6iqTYxU4Y9QxbThjvbAeDQYD9O8mSELLrqK1--L3WgvtaVC9IpEA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table58.jpeg?Expires=1689850106&amp;Signature=M~g78f45Ez0QpTz2n8tOxbtQJybpBHU9wz6tjDlDpQjTafXgJGiDDvo49AHKDbYz-QtkTmC6Kw05FnCygmgEW-RrZnXDTN5hAbxNreCMRl2VjDPBbh90-0En9R~0MZ6MiLG1L1P5RiPqGZvKBzkzWSVwmSzXx4~yanjtBRkBglvndUgEYP2A3ICXC5iRXrItsEcpiUpoH78tpqeykOYlp4z6g05yvaD3PpO234dZbtraQ~cfZzTuGpKfquGLb97APRVVpyqivC1jXcwA-J4OWYvNiqp84gku7G6iqTYxU4Y9QxbThjvbAeDQYD9O8mSELLrqK1--L3WgvtaVC9IpEA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>BTB = bridge to bridge; BTD = bridge to decision; BTR = bridge to
recovery; IABP = intra-aortic balloon pump; MCS = mechanical circulatory
support; MI = myocardial infarction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4
>11.3.11
Pre-discharge assessment and post-discharge management planning</h4>
<p>A significant proportion of patients with AHF are discharged with
minimal or no weight loss and, more importantly, persistent
congestion.<sup>427</sup><sup>,</sup><sup>472</sup> Persistent
congestion before discharge is associated with a higher risk of
readmission and mortality.<sup>426</sup><sup>,</sup><sup>472</sup>
Treatment, including diuretic dose, should therefore be optimized in
order to keep the patient free of congestion.</p>
<p>In those admitted with ADHF, oral OMT should be continued, except for
possible dose reduction or withdrawal if there is haemodynamic
instability (symptomatic hypotension), severely impaired renal function
or hyperkalaemia. Once haemodynamic stabilization is achieved with i.v.
therapy, treatment should be optimized before discharge.<sup>467</sup>
Treatment optimization has three major aims. First, to relieve
congestion. Second, to treat comorbidities, such as iron deficiency,
that have an impact on post-discharge outcome.<sup>512</sup> Third, to
initiate, or restart oral, OMT with beneficial effects on outcome. Doses
may be uptitrated before discharge and/or in the early post-discharge
phase.</p>
<p>Studies have shown that such optimization of medical treatment is
associated with a lower risk of 30-day readmission, although prospective
randomized trials have not been performed, to
date.<sup>103</sup><sup>,</sup><sup>467</sup><sup>,</sup><sup>513</sup>
Retrospective analyses show that discontinuation or dose reduction of
beta-blocker therapy during an AHF hospitalization is associated with
worse outcomes.<sup>514</sup> Initiation of ARNI in recently
hospitalized stable patients with HFrEF, including those who are
ACE-I/ARB naïve, is safe and may be considered in this
setting.<sup>106</sup><sup>,</sup><sup>107</sup> Safety and better
outcome have also been recently shown in a prospective randomized trial
with sotagliflozin in diabetic patients hospitalized for HF,
irrespective of their LVEF.<sup>136</sup></p>
<p>It is recommended to have one follow-up visit within 1 to 2 weeks
after discharge.<sup>515</sup><sup>,</sup><sup>516</sup> Components of
this follow-up visit should include monitoring of signs and symptoms of
HF, assessment of volume status, BP, heart rate, and laboratory
measurements including renal function, electrolytes, and possibly NPs.
Iron status and hepatic function should also be assessed when not done
before discharge. Based on clinical evaluation and laboratory exams,
further optimization and/or initiation of disease-modifying treatment
for HFrEF should occur. Retrospective studies show that such an approach
is associated with lower 30-day readmission rates although prospective
randomized trials have not been performed, to
date.<sup>513</sup><sup>,</sup><sup>516–518</sup></p>
<h2 >12 Cardiovascular
comorbidities</h2>
<h3 >12.1 Arrhythmias and
conduction disturbances</h3>
<h4 >12.1.1 Atrial fibrillation</h4>
<p>AF and HF frequently coexist.<sup>519</sup><sup>,</sup><sup>520</sup>
They can cause or exacerbate each other through mechanisms such as
structural cardiac remodelling, activation of neurohormonal systems, and
rate-related LV impairment.<sup>519–523</sup> The proportion of patients
with HF who develop AF increases with age and HF severity. When AF
causes HF the clinical course seems more favourable than with other
causes of HF (so called tachycardiomyopathy).<sup>524</sup> In contrast,
development of AF in patients with chronic HF is associated with worse
prognosis, including stroke and increased
mortality.<sup>525</sup><sup>,</sup><sup>526</sup></p>
<p>Recommendations for pre-discharge and early post-discharge follow-up
of patients hospitalized for acute heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table59.jpeg?Expires=1689850106&amp;Signature=1xlveFQz4xz0~YLvhFtTFubkkdWC9yAvbqVWBMsAtcOWBIJS434K18gbit-6zrVXFs0h2tjENOKUHyvRiFe-DRgjnRPlM-XLTNbCUgkU-B1qBP3wU3cJm7hy3hm2wRrK32j2uuBfrQGZ~Ck6QXi924pAN7RHy~XFaA6-NTAldJdrdQSPPgvL22C-VF4vWkj5LBVVe4uPGf9E0F0mMvtAxDEgutb519CKc-YBUL~PQfwsTiBOeP920srd11bnP88X~p9ajqiEokkUFaj7-eamYsw3-XuZZmu1RYMNMDXMG5Ndvhlt-UgCl0eRXuQfTshKqSYlfBPQkZTfWBsPzn43Nw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table59.jpeg?Expires=1689850106&amp;Signature=1xlveFQz4xz0~YLvhFtTFubkkdWC9yAvbqVWBMsAtcOWBIJS434K18gbit-6zrVXFs0h2tjENOKUHyvRiFe-DRgjnRPlM-XLTNbCUgkU-B1qBP3wU3cJm7hy3hm2wRrK32j2uuBfrQGZ~Ck6QXi924pAN7RHy~XFaA6-NTAldJdrdQSPPgvL22C-VF4vWkj5LBVVe4uPGf9E0F0mMvtAxDEgutb519CKc-YBUL~PQfwsTiBOeP920srd11bnP88X~p9ajqiEokkUFaj7-eamYsw3-XuZZmu1RYMNMDXMG5Ndvhlt-UgCl0eRXuQfTshKqSYlfBPQkZTfWBsPzn43Nw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HR = heart failure; TSAT = transferrin saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for pre-discharge and early post-discharge follow-up
of patients hospitalized for acute heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table59.jpeg?Expires=1689850106&amp;Signature=1xlveFQz4xz0~YLvhFtTFubkkdWC9yAvbqVWBMsAtcOWBIJS434K18gbit-6zrVXFs0h2tjENOKUHyvRiFe-DRgjnRPlM-XLTNbCUgkU-B1qBP3wU3cJm7hy3hm2wRrK32j2uuBfrQGZ~Ck6QXi924pAN7RHy~XFaA6-NTAldJdrdQSPPgvL22C-VF4vWkj5LBVVe4uPGf9E0F0mMvtAxDEgutb519CKc-YBUL~PQfwsTiBOeP920srd11bnP88X~p9ajqiEokkUFaj7-eamYsw3-XuZZmu1RYMNMDXMG5Ndvhlt-UgCl0eRXuQfTshKqSYlfBPQkZTfWBsPzn43Nw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table59.jpeg?Expires=1689850106&amp;Signature=1xlveFQz4xz0~YLvhFtTFubkkdWC9yAvbqVWBMsAtcOWBIJS434K18gbit-6zrVXFs0h2tjENOKUHyvRiFe-DRgjnRPlM-XLTNbCUgkU-B1qBP3wU3cJm7hy3hm2wRrK32j2uuBfrQGZ~Ck6QXi924pAN7RHy~XFaA6-NTAldJdrdQSPPgvL22C-VF4vWkj5LBVVe4uPGf9E0F0mMvtAxDEgutb519CKc-YBUL~PQfwsTiBOeP920srd11bnP88X~p9ajqiEokkUFaj7-eamYsw3-XuZZmu1RYMNMDXMG5Ndvhlt-UgCl0eRXuQfTshKqSYlfBPQkZTfWBsPzn43Nw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HR = heart failure; TSAT = transferrin saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>The management of patients with concomitant HF and AF is summarized
in <em>Figure  14</em>.<sup>7</sup><sup>,</sup><sup>521</sup> It
includes:</p>
<ol type="1">
<li><p>Identification and treatment of possible causes or triggers of
AF</p></li>
<li><p>Management of HF</p></li>
<li><p>Prevention of embolic events</p></li>
<li><p>Rate control</p></li>
<li><p>Rhythm control</p></li>
</ol>
<p>Figure 14</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f14.jpeg?Expires=1689850106&amp;Signature=gkRXv0RMEa3PgFUdZntFDDzz75F2t56-55069adqIYV0rZ3pa4bOrR8b~NLJe-X-BKOKBr12pG9ldmyKJLhuB4zYvcmjar8wz8jqqkw1yYyqRgTvVAb1PR3Dfk6Dltixxjr6s9Eqj2oDIvfmelkBdYfJ5OPC7y2prvA88-fWFoSw8LdMaVJQQw6KbiejDjEzhPYkrbO4NJsmqHHbZ9LktXItgF~w-uC7zINa28KBgYf5eUqYSFveRS02QNqzxLESZQw8r9YNqh-royXLzBeho~GDgbwI9d2xyhv6GJJ6RPVBzo5Q0M5J6a5UAQEekVYxgPSG-uVPOYseCK9WCcOh2Q__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of atrial fibrillation in patients with heart failure with reduced ejection fraction. AF = atrial fibrillation; AVN = atrioventricular node; ECV = electrical cardioversion; HF = heart failure; i.v. = intravenous; PV = pulmonary vein. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see Table 1 for further details on classes of recommendation)." />
<figcaption aria-hidden="true">Management of atrial fibrillation in
patients with heart failure with reduced ejection fraction. AF = atrial
fibrillation; AVN = atrioventricular node; ECV = electrical
cardioversion; HF = heart failure; i.v. = intravenous; PV = pulmonary
vein. Colour code for classes of recommendation: Green for Class of
recommendation I; Yellow for Class of recommendation IIa; Orange for
Class of recommendation IIb; Red for Class of recommendation III (see
Table 1 for further details on classes of recommendation).</figcaption>
</figure>
<p>Management of atrial fibrillation in patients with heart failure with
reduced ejection fraction. AF = atrial fibrillation;
AVN = atrioventricular node; ECV = electrical cardioversion; HF = heart
failure; i.v. = intravenous; PV = pulmonary vein. Colour code for
classes of recommendation: Green for Class of recommendation I; Yellow
for Class of recommendation IIa; Orange for Class of recommendation IIb;
Red for Class of recommendation III (see <em>Table 1</em> for further
details on classes of recommendation).</p>
<p><strong>Identification of triggers and management of heart
failure</strong></p>
<p>Potential causes or precipitating factors such as hyperthyroidism,
electrolyte disorders, uncontrolled hypertension, mitral valve disease,
and infection should be identified and corrected.</p>
<p>Worsening congestion due to AF should be managed with diuretics.
Congestion relief may reduce sympathetic drive and ventricular rate and
increase the chance of spontaneous return to SR. The presence of AF may
reduce or abolish the prognostic benefits of beta-blockers and renders
ivabradine ineffective.<sup>12</sup><sup>,</sup><sup>125</sup> Some
treatments for HF decrease the risk of developing AF, including ACE-I,
slightly, and CRT, probably.<sup>7</sup><sup>,</sup><sup>527</sup></p>
<p><strong>Prevention of embolic events</strong></p>
<p>Unless contraindicated, an oral, long-term anticoagulant is
recommended in all patients with HF and paroxysmal, persistent, or
permanent AF. Direct-acting oral anticoagulants (DOACs) are preferred
for the prevention of thromboembolic events in patients with AF and
without severe mitral stenosis and/or mechanical valve prosthesis, as
they have similar efficacy to vitamin K antagonists (VKAs) but a lower
risk of intracranial haemorrhage.<sup>528</sup></p>
<p>LA appendage closure can be considered in patients with HF and AF who
have a contraindication to oral anticoagulation though data from
randomized trials have not included patients with contraindications to
oral anticoagulants.<sup>529</sup><sup>,</sup><sup>530</sup></p>
<p><strong>Rate control</strong></p>
<p>Data regarding rate control are not conclusive for the patients with
AF and HF. A strategy of lenient rate control, defined by a resting
heart rate &lt;110 b.p.m., was compared to a strategy of strict rate
control, defined by a heart rate &lt;80 b.p.m. at rest and &lt;110
b.p.m. during moderate exercise, in RACE II and in a pooled analysis of
RACE and AFFIRM.<sup>152</sup><sup>,</sup><sup>531</sup> The studies
showed no differences in outcome between the two strategies. However,
only 10% of the patients in RACE II and 17% of those in the pooled
analysis had a history of HF hospitalization or NYHA class II–III,
respectively.<sup>152</sup><sup>,</sup><sup>531</sup> Higher heart rates
are associated with worse outcomes in observational
studies.<sup>532</sup><sup>,</sup><sup>533</sup> Thus, a lenient rate
control is an acceptable initial approach with, however, treatment
targeting a lower heart rate in case of persistent symptoms or cardiac
dysfunction likely related to tachycardia (e.g. tachycardia-induced
cardiomyopathy).<sup>7</sup><sup>,</sup><sup>534</sup></p>
<p>Beta-blockers can be used for rate control in patients with HFrEF or
HFmrEF because of their established safety in these patients (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5.3.2">section 5.3.2</a>).<sup>7</sup><sup>,</sup><sup>534</sup><sup>,</sup><sup>535</sup>
Digoxin or digitoxin can be considered when the ventricular rate remains
high, despite beta-blockers, or when beta-blockers are contraindicated
or not
tolerated.<sup>151</sup><sup>,</sup><sup>493</sup><sup>,</sup><sup>536</sup>
It may therefore be considered also an alternative to beta-blockers. For
patients with NYHA class IV and/or haemodynamic instability, i.v.
amiodarone can be considered to reduce ventricular rate.<sup>537</sup>
For HFpEF, there is a paucity of evidence to demonstrate efficacy of any
agent. The RATE-AF trial compared digoxin with bisoprolol in patients
with persistent AF and NYHA class II–IV symptoms. Compared with
bisoprolol, digoxin had the same effect on QOL at 6 months (primary
endpoint) and a better effect on EHRA and NYHA functional
class.<sup>536</sup> Only 19% of the patients had LVEF &lt;50% so that
most of the patients can be considered as having HFmrEF or
HFpEF.<sup>536</sup></p>
<p>AV node ablation can be considered in patients with poor ventricular
rate control despite medical treatment not eligible for rhythm control
by catheter ablation or in patients with biventricular
pacing.<sup>7</sup><sup>,</sup><sup>538–540</sup></p>
<p><strong>Rhythm control</strong></p>
<p>Urgent electrical cardioversion is recommended in the setting of
acute worsening HF in patients presenting with rapid ventricular rates
and haemodynamic instability, after consideration of the thromboembolic
risk. Cardioversion should be considered also to improve symptoms in
patients who have persistent and symptomatic AF, despite optimal
pharmacological management. In patients who do not receive chronic
therapy with oral anticoagulant and with AF onset &gt;48 h, at least 3
weeks of therapeutic anticoagulation or a transoesophageal
echocardiography is needed before cardioversion.<sup>7</sup> When
pharmacological cardioversion is preferred, amiodarone is the drug of
choice as other antiarrhythmic drugs (i.e. propafenone, flecainide,
dronedarone) are associated with worse outcomes in
HFrEF.<sup>186</sup><sup>,</sup><sup>534</sup><sup>,</sup><sup>541–544</sup>
Amiodarone can help maintain HF patients in SR after
cardioversion.<sup>545</sup><sup>,</sup><sup>546</sup></p>
<p>Trials including patients with HF and comparing rate control and
rhythm control strategies with the latter based on antiarrhythmic drugs
failed to show any benefit of one strategy over the
other.<sup>547–550</sup> More recently, EAST-AFNET 4, enrolling patients
with early AF, 28.6% with HF, was stopped early after a median follow-up
of 5.1 years for a lower occurrence of the primary outcome of death,
stroke, or hospitalization for worsening HF or ACS in the patients
assigned to early rhythm control vs. those assigned to usual
care.<sup>551</sup> However, the patients assigned to the rhythm control
strategy had a closer follow-up, which may have influenced their better
outcome. Catheter ablation was performed in a minority of the patients
in the rhythm control arm (19.4%).<sup>551</sup></p>
<p>LA catheter ablation was compared with MT, rate or rhythm control
strategy, in 363 patients with persistent or paroxysmal AF, LVEF &lt;35%
and an implanted device (ICD or CRT-D) enrolled in the CASTLE-AF
trial.<sup>552</sup> The primary endpoint of all-cause death or HF
hospitalizations occurred in fewer patients in the ablation group
vs. the MT group, 51 patients (28.5%) vs. 82 (44.6%) [hazard ratio (HR);
95% confidence interval (CI), 0.62; 0.43–0.87; <em>P</em> = 0.007].
Also, other endpoints, all-cause or CV death or worsening HF, were
reduced by catheter ablation.<sup>552</sup> This trial suggests that
catheter ablation can improve the prognosis of patients with HFrEF.
However, it enrolled a highly selected population, 363 of 3013 patients,
was not blinded, had crossovers between the two treatment strategies and
the number of events observed was low: 24 (13.4%) vs. 46 (25.0%)
all-cause deaths and 37 (20.7%) vs. 66 (35.9%) HF hospitalizations in
the ablation and MT groups, respectively.<sup>552</sup></p>
<p>The CABANA trial was an investigator-initiated, open-label,
multicentre, randomized trial enrolling 2204 patients with symptomatic
AF. The trial failed to show a benefit of AF ablation strategy over
medical care on the primary composite endpoint of death, disabling
stroke, serious bleeding, or cardiac arrest in the overall
population.<sup>553</sup> In an analysis of the 778 patients (35%) with
NYHA class symptoms &gt;II, the primary outcome occurred in 34 patients
(9.0%) in the catheter ablation group vs. 49 (12.3%) in the drug therapy
group (HR; 95% CI, 0.64; 0.41–0.99).<sup>554</sup> However, also in this
trial, the number of events was small and HF was defined based only on
symptoms with LVEF available in 73% of the patients and &gt;50% and
40–49% in 79% and 11.7% of the cases, respectively.<sup>554</sup> Both
CASTLE-AF and CABANA showed a highly significant effect of catheter
ablation on patients’ symptoms.<sup>552–554</sup></p>
<p>Two other prospective trials enrolled patients with HFrEF and
persistent AF, who were randomized to catheter ablation or MT in one
trial (AMICA trial, <em>n</em>  =  140), and to catheter ablation or
amiodarone in the other one (AATAC trial,
<em>n</em>  =  203).<sup>555</sup><sup>,</sup><sup>556</sup> The first
trial failed to show any difference in the LVEF increase between the two
groups.<sup>555</sup> The second trial showed superiority of catheter
ablation with respect of AF recurrence, the primary endpoint, with also
a reduction in unplanned hospitalizations and mortality.<sup>556</sup>
In contrast with the AMICA trial,<sup>555</sup> but in accordance with
CASTLE-AF,<sup>552</sup> AATAC also showed a benefit of catheter
ablation on LVEF.<sup>556</sup></p>
<p>In conclusion, there is insufficient evidence in favour of a strategy
of rhythm control with antiarrhythmic drugs vs. rate control in patients
with HF and AF.<sup>547–551</sup> The results of randomized trials with
catheter ablation vs. MT showed a consistent improvement in symptoms
whereas the results on mortality and hospitalization were obtained with
a relatively small number of events not permitting to draw definitive
conclusions.<sup>152</sup><sup>,</sup><sup>548–550</sup><sup>,</sup><sup>552–554</sup><sup>,</sup><sup>557</sup></p>
<p>Recommendations for the treatment of atrial fibrillation in patients
with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table62.jpeg?Expires=1689850106&amp;Signature=VqB2zUZdAX1a1-PIbI4VHUmQ0HT0EI~2iAgY~ZQvSDNJd3AtCRdPoxewCPyti~dSfEyWrfcysi8Vez5XANEV-h1iN6zbjvxsrNjWqgW94BF5G7uwpW73vSHqtkITD85nGmxjlvLR~8Z5ETjjnNNmQMCgqkmKYWdrHae~ou7PMNUVhsM1sqro4pnLeALxMIDW75S8vydAerIWYtKyISiCkWgDJYddlM0Kgk7sVRyFBF~4dPC51iC5HZVCcfHvwwrbha082kgHb8NWd5jhpjisiDQ1RfF-nT2cApYLrPhIxczeoo3bfyh3vogcwZ8MAOt1MesE8O55nrjezCeYr4xaaw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table62.jpeg?Expires=1689850106&amp;Signature=VqB2zUZdAX1a1-PIbI4VHUmQ0HT0EI~2iAgY~ZQvSDNJd3AtCRdPoxewCPyti~dSfEyWrfcysi8Vez5XANEV-h1iN6zbjvxsrNjWqgW94BF5G7uwpW73vSHqtkITD85nGmxjlvLR~8Z5ETjjnNNmQMCgqkmKYWdrHae~ou7PMNUVhsM1sqro4pnLeALxMIDW75S8vydAerIWYtKyISiCkWgDJYddlM0Kgk7sVRyFBF~4dPC51iC5HZVCcfHvwwrbha082kgHb8NWd5jhpjisiDQ1RfF-nT2cApYLrPhIxczeoo3bfyh3vogcwZ8MAOt1MesE8O55nrjezCeYr4xaaw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>AF = atrial fibrillation;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); DOAC = direct-acting oral anticoagulant; ECV = electrical
cardioversion; HF = heart failure; MT = medical therapy; VKA = vitamin K
antagonist.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the treatment of atrial fibrillation in patients
with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table62.jpeg?Expires=1689850106&amp;Signature=VqB2zUZdAX1a1-PIbI4VHUmQ0HT0EI~2iAgY~ZQvSDNJd3AtCRdPoxewCPyti~dSfEyWrfcysi8Vez5XANEV-h1iN6zbjvxsrNjWqgW94BF5G7uwpW73vSHqtkITD85nGmxjlvLR~8Z5ETjjnNNmQMCgqkmKYWdrHae~ou7PMNUVhsM1sqro4pnLeALxMIDW75S8vydAerIWYtKyISiCkWgDJYddlM0Kgk7sVRyFBF~4dPC51iC5HZVCcfHvwwrbha082kgHb8NWd5jhpjisiDQ1RfF-nT2cApYLrPhIxczeoo3bfyh3vogcwZ8MAOt1MesE8O55nrjezCeYr4xaaw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table62.jpeg?Expires=1689850106&amp;Signature=VqB2zUZdAX1a1-PIbI4VHUmQ0HT0EI~2iAgY~ZQvSDNJd3AtCRdPoxewCPyti~dSfEyWrfcysi8Vez5XANEV-h1iN6zbjvxsrNjWqgW94BF5G7uwpW73vSHqtkITD85nGmxjlvLR~8Z5ETjjnNNmQMCgqkmKYWdrHae~ou7PMNUVhsM1sqro4pnLeALxMIDW75S8vydAerIWYtKyISiCkWgDJYddlM0Kgk7sVRyFBF~4dPC51iC5HZVCcfHvwwrbha082kgHb8NWd5jhpjisiDQ1RfF-nT2cApYLrPhIxczeoo3bfyh3vogcwZ8MAOt1MesE8O55nrjezCeYr4xaaw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>AF = atrial fibrillation;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); DOAC = direct-acting oral anticoagulant; ECV = electrical
cardioversion; HF = heart failure; MT = medical therapy; VKA = vitamin K
antagonist.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h4 >12.1.2 Ventricular arrhythmias</h4>
<p>Ventricular arrhythmias may be a complication, and in some instances,
a cause of HF. Frequent ventricular premature beats (VPBs) may lead to
reversible systolic dysfunction. Possible factors may include
dyssynchrony and abnormal calcium handling.<sup>560</sup></p>
<p>Initial management of ventricular arrhythmias in HF should include
correction of potential precipitants (including electrolyte
abnormalities, particularly hypo/hyperkalaemia, and pro-arrhythmic
drugs) as well as the optimization of HF drug therapy. Although
ischaemia may be a triggering factor, revascularization has not been
shown to reduce risk of ventricular arrhythmias.<sup>561</sup></p>
<p>Amiodarone is effective also for suppression of ventricular
arrhythmias. However, it does not reduce the incidence of sudden cardiac
death or overall mortality.<sup>161</sup> For patients with premature
ventricular contraction (PVC)-induced CMP, amiodarone administration may
be considered to reduce recurrent arrhythmias and improve symptoms and
LV function, although its side effects should be taken into
consideration. Other drugs are discussed in <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850106&amp;Signature=OdOXt45iEajmdQhvb5Dn-N8uGW8NdjZe9YkeYDw-uw~m1GW96qnlzyo0afGbKaUFaszcOu5A9AWzflX~AKpK41OkTK0nirS7nYHWh-54Pp5vosZSeY4vHGb7OTdA7YitkwFGmREmy6ykY9oujgDnpTfCtayKv1t5oBH1hturiQZxIq-PGK~JX3PD0gHr~fhVJeyIF5KrukM-VqkCqnde3I77cBFEpOAlTp2RKXYLzPQpKZON1nrnivot53Rst~Y38aX~EEfElIGzgKMl-uv0eqEDWZ1GD4bchH33TkcbwUjI-0zIR52AabtB06pida2o0fYsp2IMPXhKcvv3qCzMoQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 12</a>.1.</em></p>
<p>Radiofrequency ablation of VPBs may improve LV function and,
possibly, outcomes in patients with tachycardiomyopathy when VPBs
contribute to LV dysfunction.<sup>562</sup> A sustained reduction in the
baseline PVC burden has been associated with a lower risk of cardiac
mortality, cardiac transplantation, or hospitalization for HF during
follow-up.<sup>563</sup><sup>,</sup><sup>564</sup></p>
<h4
>12.1.3
Symptomatic bradycardia, pauses and atrio-ventricular block</h4>
<p>Indications for pacemaker therapy do not differ in patients with HF
from those with other CV disease. There is ample evidence that RV pacing
may have an adverse effect on LV systolic function leading, in the long
term, to HF.<sup>565</sup> Patients with HFrEF requiring frequent
ventricular pacing, e.g. with AV block or slow AF, and who have systolic
dysfunction, should be implanted with CRT rather than a standard
pacemaker to avoid adverse outcomes, as shown in the BLOCK-HF
(Biventricular versus Right Ventricular Pacing in Heart Failure Patients
with Atrioventricular Block) trial.<sup>216</sup> In the quest for a
more physiological alternative to RV pacing, physiological pacing is
being increasingly adopted.<sup>566</sup> In a non-randomized comparison
of 304 consecutive patients with His bundle pacing and 433 consecutive
patients with RV pacing, the former group had less HF hospitalization
and a trend in reduced mortality.<sup>567</sup> Although the technique
is promising, more data are needed to confirm its role.</p>
<h3 >12.2 Chronic coronary syndromes</h3>
<p>CAD is the most common cause of HF in industrialized, middle-income,
and increasingly in low-income, countries. It should be considered as
possible cause of HF in all patients presenting with new onset HF.</p>
<p>The diagnostic workup of patients with HF and chronic coronary
syndromes (CCS) is reported in the recent 2019 ESC Guidelines on
CCS.<sup>5</sup> Patients with HF should be carefully evaluated to
assess signs and/or symptoms of CCS. Clinical and family histories,
physical examination, ECG and imaging tests are recommended.<sup>5</sup>
Documentation of ischaemia using non-invasive and invasive tests can be
difficult in patients with HF because of the possible exercise
intolerance and the effects of increased end-diastolic LV pressures.
Coronary angiography or CTCA can be performed to establish the presence
and extent of CAD and evaluate the potential indication for
revascularization (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-4.3">section 4.3</a>).<sup>5</sup></p>
<p><strong>12.2.1 Medical therapy</strong></p>
<p>Beta-blockers are the mainstay of therapy in patients with HFrEF and
CAD because of their prognostic
benefit.<sup>116–120</sup><sup>,</sup><sup>568</sup> Ivabradine should
be considered as an alternative to beta-blockers (when contraindicated)
or as additional anti-anginal therapy in patients in SR whose heart rate
is ≥70 b.p.m.<sup>139</sup><sup>,</sup><sup>569</sup> Other anti-anginal
drugs (e.g. amlodipine, felodipine, nicorandil, ranolazine, and oral or
transdermal nitrates) are effective for treating symptoms, although data
about their effects on outcomes are neutral or
lacking.<sup>5</sup><sup>,</sup><sup>570–574</sup> Trimetazidine seems
to have additive effects, such as improvement of LV function and
exercise capacity, in patients with HFrEF and CCS already on
beta-blockers.<sup>575–577</sup> Trimetazidine and other anti-anginal
drugs may be considered in patients with HF and angina despite
beta-blocker and/or ivabradine. Short-acting nitrates should be used
with caution in patients with HF as they cause hypotension. Diltiazem
and verapamil increase HF-related events in patients with HFrEF and are
contraindicated.<sup>578</sup></p>
<p>An algorithm for the use of anti-anginal medications in patients with
HFrEF is reported in <em>Figure 15</em>.</p>
<p>Figure 15</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f15.jpeg?Expires=1689850106&amp;Signature=cQpZDuDub~wvkmsa-Bpt4c2-nTSRYcQ0KGHSVxS3IlagpitVH1KjLQh~Eqm9udFffPbSQKxU7mrk1emJpwUteEcuf87kUbMElrwMYsvQ-5Sw6dnK8AAGXGtBk7xCX6NeD8ZG2t373NaehAQt2nwQ7G3g3gEvseOV4~ECXyoI-JkOoyyJCGAYOEpOGpqOwPMUS8unTN0TEJ9uBaEdOcdCxonQNhFLWLck1SPAtFAOjXQ~KY-WFAB7vZ1kgC0XxiziCfuz4R88NQnB2wKbJMwmGHq-MhQ~5w0ToQXfyzd5pE6xw5kfkNk9bu27JXpel6jiz-cVl0rhsZWFMl-NZTgUGQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Algorithm for the medical treatment of chronic coronary syndrome in patients with heart failure with reduced ejection fraction. CCS = chronic coronary syndrome; HFrEF = heart failure with reduced ejection fraction; HR = heart rate. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb; Red for Class of recommendation III (see Table 1 for further details on classes of recommendation)." />
<figcaption aria-hidden="true">Algorithm for the medical treatment of
chronic coronary syndrome in patients with heart failure with reduced
ejection fraction. CCS = chronic coronary syndrome; HFrEF = heart
failure with reduced ejection fraction; HR = heart rate. Colour code for
classes of recommendation: Green for Class of recommendation I; Yellow
for Class of recommendation IIa; Orange for Class of recommendation IIb;
Red for Class of recommendation III (see Table 1 for further details on
classes of recommendation).</figcaption>
</figure>
<p>Algorithm for the medical treatment of chronic coronary syndrome in
patients with heart failure with reduced ejection fraction.
CCS = chronic coronary syndrome; HFrEF = heart failure with reduced
ejection fraction; HR = heart rate. Colour code for classes of
recommendation: Green for Class of recommendation I; Yellow for Class of
recommendation IIa; Orange for Class of recommendation IIb; Red for
Class of recommendation III (see <em>Table 1</em> for further details on
classes of recommendation).</p>
<p>Beta-blockers, long-acting nitrates, calcium channel blockers (CCBs),
ivabradine, ranolazine, trimetazidine, nicorandil and their combinations
should be considered in HFpEF for angina relief but without a foreseen
benefit on HF and coronary end points.</p>
<p>Low-dose of rivaroxaban [2.5 mg twice daily (b.i.d.)] did not add
prognostic benefit in patients with HFrEF and CCS in the COMMANDER-HF
trial, a study to assess the effectiveness and safety of rivaroxaban in
reducing the risk of death, MI or stroke in participants with HF and CAD
following an episode of decompensated HF.<sup>579</sup> This trial
included patients with HFrEF and a recent episode of worsening HF
occurring within 21 days from the time of enrolment. These patients are
at high risk of HF-related events and these were the main cause of
deaths and hospitalizations in the trial. Rivaroxaban had no effect on
these events. In contrast, in a non-pre-specified subgroup analysis of
the COMPASS trial, low dose of rivaroxaban, on top of aspirin, was
associated with a reduction in ischaemic events in patients with HF,
mainly HFmrEF or HFpEF.<sup>580</sup> Based on these data, low-dose
rivaroxaban may be considered in patients with CAD (or peripheral artery
disease) and HF, LVEF &gt;40% and SR, when at high risk of stroke and
with a low haemorrhagic risk.</p>
<p><strong>12.2.2 Myocardial revascularization</strong></p>
<p>Data on the benefit of myocardial revascularization in patients with
HF are limited.</p>
<p>STICH compared coronary artery bypass grafting (CABG) with MT in
patients with CAD, amenable by CABG, and with reduced LV function (EF
≤35%). At a median follow-up of 56 months, there was no significant
difference between the CABG group and the MT group in the rate of death
from any cause, primary outcome of the trial.<sup>89</sup> The extended
follow-up report showed a significant reduction of death in the CABG
group vs. the control group (58.9% vs. 66.1%; HR 0.84; 95% CI,
0.73–0.97; <em>P</em>  =  0.02) over 10 years.<sup>581</sup> CV death
and the combined endpoint of all-cause death or hospitalization for CV
causes were also significantly reduced after CABG at 10 years of
follow-up.<sup>581</sup> Post hoc analyses of the STICH trial suggested
that neither myocardial viability, angina, nor ischaemia were related
with outcomes after
revascularization.<sup>92</sup><sup>,</sup><sup>93</sup><sup>,</sup><sup>582</sup>
The Heart Failure Revascularisation Trial (HEART) was under-powered,
with only 138 of the planned 800 patients to be enrolled, and failed to
show differences in outcomes between HF patients receiving CABG or
MT.<sup>583</sup></p>
<p>There are currently no reported RCTs comparing percutaneous coronary
intervention (PCI) with MT in patients with HFrEF. However, the
REVIVED-BCIS2 trial has finished recruitment (ClinicalTrials.gov
Identifier: NCT01920048).<sup>584</sup> There are also no randomized
studies comparing PCI with CABG as such randomized trials excluded
patients with HFrEF. In one prospective registry, including 4616
patients with multivessel disease and HFrEF, propensity-score matched
comparisons showed similar survival (mean follow-up 2.9 years) in PCI
vs. CABG group with PCIs associated with a higher risk of MI,
particularly in patients with incomplete revascularization, and CABG
associated with a higher risk of stroke.<sup>585</sup> A
propensity-matched analysis showed a significantly lower risk of death
or major CV events in diabetic patients with LV dysfunction and
multivessel disease treated with CABG compared with PCI.<sup>586</sup>
CABG was associated with better outcome than PCI also in patients with
moderate or severe LV dysfunction and left main or complex coronary
disease.<sup>587</sup><sup>,</sup><sup>588</sup> Two meta-analyses
confirmed that CABG is associated with better outcomes, including
mortality, MI, and repeated revascularization, compared with PCI and/or
MT.<sup>589</sup><sup>,</sup><sup>590</sup></p>
<p>Recommendations for myocardial revascularization in patients with
heart failure with reduced ejection fraction</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table64.jpeg?Expires=1689850106&amp;Signature=ZKNwwumRZuTxDgODNhT91ZLO7VlV0Fm5WeViUF~EYzZ5HjBxbRKKeNdPbjQSR1LIL4s3QUohRyW5DjOyktdCwZbJg0vuUH8KNHmBm5C08tZX50qRzG~ot4nxNeOrsjOuqs7t6Z6XQDe2djSiWW8EjDZGuFeYEJML7qpSKnXLBIM-AjpdXqMhcB9UL1RsANfCoBSub8T0FN8iF5A4chS2tHHCbeJtbCg0uKcjifxdmE9Pcdz-~zZeZcCFEiSUfbZX9K1d9EnbboiUp19K7yqKb9WwNhrQToywIRgSxJT3tq-BMnLBK3YgxQTAjuW9bEvSeV4XZAFP4ov8E1kx0Bc4VA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table64.jpeg?Expires=1689850106&amp;Signature=ZKNwwumRZuTxDgODNhT91ZLO7VlV0Fm5WeViUF~EYzZ5HjBxbRKKeNdPbjQSR1LIL4s3QUohRyW5DjOyktdCwZbJg0vuUH8KNHmBm5C08tZX50qRzG~ot4nxNeOrsjOuqs7t6Z6XQDe2djSiWW8EjDZGuFeYEJML7qpSKnXLBIM-AjpdXqMhcB9UL1RsANfCoBSub8T0FN8iF5A4chS2tHHCbeJtbCg0uKcjifxdmE9Pcdz-~zZeZcCFEiSUfbZX9K1d9EnbboiUp19K7yqKb9WwNhrQToywIRgSxJT3tq-BMnLBK3YgxQTAjuW9bEvSeV4XZAFP4ov8E1kx0Bc4VA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CABG = coronary artery bypass graft; CCS = chronic coronary syndrome;
HFrEF = heart failure with reduced ejection fraction; LAD = left
anterior descending artery; LVAD = left ventricular assist device;
OMT = optimal medical therapy; PCI = percutaneous coronary
intervention.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for myocardial revascularization in patients with
heart failure with reduced ejection fraction</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table64.jpeg?Expires=1689850106&amp;Signature=ZKNwwumRZuTxDgODNhT91ZLO7VlV0Fm5WeViUF~EYzZ5HjBxbRKKeNdPbjQSR1LIL4s3QUohRyW5DjOyktdCwZbJg0vuUH8KNHmBm5C08tZX50qRzG~ot4nxNeOrsjOuqs7t6Z6XQDe2djSiWW8EjDZGuFeYEJML7qpSKnXLBIM-AjpdXqMhcB9UL1RsANfCoBSub8T0FN8iF5A4chS2tHHCbeJtbCg0uKcjifxdmE9Pcdz-~zZeZcCFEiSUfbZX9K1d9EnbboiUp19K7yqKb9WwNhrQToywIRgSxJT3tq-BMnLBK3YgxQTAjuW9bEvSeV4XZAFP4ov8E1kx0Bc4VA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table64.jpeg?Expires=1689850106&amp;Signature=ZKNwwumRZuTxDgODNhT91ZLO7VlV0Fm5WeViUF~EYzZ5HjBxbRKKeNdPbjQSR1LIL4s3QUohRyW5DjOyktdCwZbJg0vuUH8KNHmBm5C08tZX50qRzG~ot4nxNeOrsjOuqs7t6Z6XQDe2djSiWW8EjDZGuFeYEJML7qpSKnXLBIM-AjpdXqMhcB9UL1RsANfCoBSub8T0FN8iF5A4chS2tHHCbeJtbCg0uKcjifxdmE9Pcdz-~zZeZcCFEiSUfbZX9K1d9EnbboiUp19K7yqKb9WwNhrQToywIRgSxJT3tq-BMnLBK3YgxQTAjuW9bEvSeV4XZAFP4ov8E1kx0Bc4VA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CABG = coronary artery bypass graft; CCS = chronic coronary syndrome;
HFrEF = heart failure with reduced ejection fraction; LAD = left
anterior descending artery; LVAD = left ventricular assist device;
OMT = optimal medical therapy; PCI = percutaneous coronary
intervention.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h3 >12.3 Valvular heart disease</h3>
<h4 >12.3.1 Aortic stenosis</h4>
<p>Aortic stenosis may cause or worsen HF by increasing LV afterload and
causing LV hypertrophy and remodelling.<sup>591</sup> When HF symptoms
occur in patients with severe aortic stenosis, prognosis is extremely
poor. No MT for aortic stenosis can improve outcomes. HF medical
treatment should be given to all HF patients with symptomatic severe
aortic stenosis. Care must be taken using vasodilators to avoid
hypotension. Importantly, possible improvement of symptoms after MT
should not delay intervention.</p>
<p>In the presence of suspected symptomatic and severe high-gradient
aortic stenosis (valve area ≤1 cm², mean gradient ≥40 mmHg), other
causes of high flow status must be excluded and corrected (i.e. anaemia,
hyperthyroidism, arteriovenous shunts) before proceeding to aortic valve
intervention.<sup>592</sup> An aortic valve intervention is recommended
in patients with HF symptoms and severe, high-gradient aortic stenosis,
regardless of LVEF. Management of patients with low-flow low-gradient
aortic stenosis is reported in <em>Figure 16</em>.<sup>592</sup></p>
<p>Intervention is recommended in patients with a life expectancy &gt;1
year, avoiding futility. Transcatheter aortic valve implantation (TAVI)
has been shown to be non-inferior to surgical aortic valve replacement
(SAVR) in reducing clinical events (including mortality and disabling
stroke) in patients at high and intermediate risk for
surgery.<sup>593–600</sup> In low-risk patients, mean age in the RCTs
comparing TAVI and SAVR was &gt;70 years and follow-up was restricted to
2 years. Therefore, SAVR is recommended in patients aged &lt;75 years
and at low surgical risk (STS-PROM score or EuroSCORE II &lt;4%),
whereas TAVI is recommended in those aged &gt;75 years or at
high/prohibitive surgical risk (STS-PROM score or EuroSCORE II &gt;8%).
In all the other cases, the choice between TAVI and SAVR should be made
by the Heart Team, weighing the pros and cons of each procedure,
according to age, life expectancy, individual patient preference and
other features including clinical and anatomical aspects. Aortic valve
interventions should be performed only in centres having both
interventional cardiology and cardiac surgery services on site and a
structured collaborative Heart Team approach.</p>
<p>Figure 16</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f16.jpeg?Expires=1689850106&amp;Signature=DPFk8JLewcYwkQxSnWmr0h2bio6P2pqb38aoh2cqa97~eGpGXvpZSbBiAsFy8-afH4ZD5Z~1yhsb8NnhpEpmweDAT11aZCbdy9eHwUiRiqd2JOlYxeVx8zFkAUeuWNaQUzBAd8o~MThpV47ILb67GskybQdERjmopKuR3aExaujQApiyvlD23J2CfnOq2OH9R236F0mCdWfkSW3LvLO2ZwzJouIj0fPHpMl1gcYUV6Y9NZlEtMRLfii2TDxwM13oi~zaDzUYxMzgIGdU005291rjlrSAETLRymTh74h7wLBs0xU2641O-kV1L328-Q--5s2bhe74zpRfw7Ler-5i7g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of patients with severe low-flow low-gradient aortic stenosis and heart failure. AS = aortic stenosis; CT  = computed tomography; EuroSCORE II = European System for Cardiac Operative Risk Evaluation II; LVEF = left ventricular ejection fraction; OMT = optimal medical therapy; SAVR = surgical aortic valve replacement; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI = transcatheter aortic valve implantation. aValve area ≤1 cm², peak velocity &lt;4.0 m/s, mean gradient &lt;40; stroke volume index ≤35 mL/m². bAge &gt;70 years, typical symptoms without other explanations, left ventricular hypertrophy or reduced left ventricular longitudinal function, mean gradient 30–40 mmHg, valve area ≤0.8 cm², stroke volume index ≤35 mL/m² assessed by techniques other than standard Doppler. cFlow reserve is defined as stroke volume index increase &gt;20%. dAS is very likely if calcium score is ≥3000 in men and ≥1600 in women. AS is likely if calcium score is ≥2000 in men and ≥1200 in women. AS is unlikely if calcium score is &lt;1600 in men and &lt;800 in women. eIncrease in valve area to &gt;1.0 cm² in response to flow increase (flow reserve) during dobutamine echo. fIncrease in mean gradient to at least 40 mmHg without significant change in valve area in response to flow increase (flow reserve) during dobutamine echo. gSAVR is recommended in patients aged &lt;75 years and low surgical risk (STS-PROM score or EuroSCORE II &lt;4%), whereas TAVI in those aged &gt;75 years or at high/prohibitive surgical risk (STS-PROM score or EuroSCORE II &gt;8%). In all the other cases, the choice between TAVI and SAVR is recommended to be decided by the Heart Team, weighing the pros and cons of each procedure, according to age, life expectancy, individual patient preference and features including clinical and anatomical aspects. Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa (see Table 1 for further details on classes of recommendation)." />
<figcaption aria-hidden="true">Management of patients with severe
low-flow low-gradient aortic stenosis and heart failure. AS = aortic
stenosis; CT  = computed tomography; EuroSCORE II = European System for
Cardiac Operative Risk Evaluation II; LVEF = left ventricular ejection
fraction; OMT = optimal medical therapy; SAVR = surgical aortic valve
replacement; STS-PROM = Society of Thoracic Surgeons Predicted Risk of
Mortality; TAVI = transcatheter aortic valve implantation. aValve area
≤1 cm², peak velocity &lt;4.0 m/s, mean gradient &lt;40; stroke volume
index ≤35 mL/m². bAge &gt;70 years, typical symptoms without other
explanations, left ventricular hypertrophy or reduced left ventricular
longitudinal function, mean gradient 30–40 mmHg, valve area ≤0.8 cm²,
stroke volume index ≤35 mL/m² assessed by techniques other than standard
Doppler. cFlow reserve is defined as stroke volume index increase
&gt;20%. dAS is very likely if calcium score is ≥3000 in men and ≥1600
in women. AS is likely if calcium score is ≥2000 in men and ≥1200 in
women. AS is unlikely if calcium score is &lt;1600 in men and &lt;800 in
women. eIncrease in valve area to &gt;1.0 cm² in response to flow
increase (flow reserve) during dobutamine echo. fIncrease in mean
gradient to at least 40 mmHg without significant change in valve area in
response to flow increase (flow reserve) during dobutamine echo. gSAVR
is recommended in patients aged &lt;75 years and low surgical risk
(STS-PROM score or EuroSCORE II &lt;4%), whereas TAVI in those aged
&gt;75 years or at high/prohibitive surgical risk (STS-PROM score or
EuroSCORE II &gt;8%). In all the other cases, the choice between TAVI
and SAVR is recommended to be decided by the Heart Team, weighing the
pros and cons of each procedure, according to age, life expectancy,
individual patient preference and features including clinical and
anatomical aspects. Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa (see
Table 1 for further details on classes of recommendation).</figcaption>
</figure>
<p>Management of patients with severe low-flow low-gradient aortic
stenosis and heart failure. AS = aortic stenosis; CT  = computed
tomography; EuroSCORE II = European System for Cardiac Operative Risk
Evaluation II; LVEF = left ventricular ejection fraction; OMT = optimal
medical therapy; SAVR = surgical aortic valve replacement;
STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality;
TAVI = transcatheter aortic valve implantation. <sup>a</sup>Valve area
≤1 cm², peak velocity &lt;4.0 m/s, mean gradient &lt;40; stroke volume
index ≤35 mL/m². <sup>b</sup>Age &gt;70 years, typical symptoms without
other explanations, left ventricular hypertrophy or reduced left
ventricular longitudinal function, mean gradient 30–40 mmHg, valve area
≤0.8 cm², stroke volume index ≤35 mL/m² assessed by techniques other
than standard Doppler. <sup>c</sup>Flow reserve is defined as stroke
volume index increase &gt;20%. <sup>d</sup>AS is very likely if calcium
score is ≥3000 in men and ≥1600 in women. AS is likely if calcium score
is ≥2000 in men and ≥1200 in women. AS is unlikely if calcium score is
&lt;1600 in men and &lt;800 in women. <sup>e</sup>Increase in valve area
to &gt;1.0 cm² in response to flow increase (flow reserve) during
dobutamine echo. <sup>f</sup>Increase in mean gradient to at least 40
mmHg without significant change in valve area in response to flow
increase (flow reserve) during dobutamine echo. <sup>g</sup>SAVR is
recommended in patients aged &lt;75 years and low surgical risk
(STS-PROM score or EuroSCORE II &lt;4%), whereas TAVI in those aged
&gt;75 years or at high/prohibitive surgical risk (STS-PROM score or
EuroSCORE II &gt;8%). In all the other cases, the choice between TAVI
and SAVR is recommended to be decided by the Heart Team, weighing the
pros and cons of each procedure, according to age, life expectancy,
individual patient preference and features including clinical and
anatomical aspects. Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa (see
<em>Table 1</em> for further details on classes of recommendation).</p>
<p>Balloon aortic valvuloplasty may be considered in highly symptomatic
patients with AHF (i.e. cardiogenic shock) as bridge to TAVI or SAVR, or
in advanced HF as BTR or DT.</p>
<h4 >12.3.2 Aortic regurgitation</h4>
<p>Severe aortic regurgitation can lead to progressive LV dilation with
subsequent dysfunction, HF, and poor prognosis.</p>
<p>MT can improve HF symptoms in patients with severe aortic
regurgitation. In particular, inhibitors of the RAAS can be
useful.<sup>601</sup> Beta-blockers should be cautiously used as they
prolong diastole and may worsen aortic regurgitation.</p>
<p>Aortic valve surgery is recommended in patients with severe aortic
regurgitation and HF symptoms regardless of
LVEF.<sup>592</sup><sup>,</sup><sup>602</sup><sup>,</sup><sup>603</sup>
In case of high or prohibitive surgical risk, TAVI has been used to
treat also aortic regurgitation.<sup>604</sup></p>
<h4 >12.3.3 Mitral regurgitation</h4>
<p><strong>Primary (organic) mitral regurgitation</strong></p>
<p>Primary mitral regurgitation (MR) is caused by abnormalities of the
valve apparatus and can cause HF.</p>
<p>Surgery, preferably repair, is recommended in patients with severe
primary MR and HF symptoms. If surgery is contraindicated or considered
at high risk, then percutaneous repair may be
considered.<sup>592</sup><sup>,</sup><sup>605</sup></p>
<p><strong>Secondary (functional) mitral regurgitation</strong></p>
<p>Secondary mitral regurgitation (SMR) is mostly a disease of the left
ventricle. It can also be caused by mitral annulus enlargement due to LA
dilation.<sup>606</sup> Moderate or severe SMR is associated with an
extremely poor prognosis in patients with
HF.<sup>607</sup><sup>,</sup><sup>608</sup> The assessment of MR
aetiology and severity should be performed by an experienced
echocardiographer applying a multi-parametric approach, and ideally in
stable patient conditions, after optimization of medical and
resynchronization therapies. Being SMR a dynamic condition,
echocardiographic quantification during exercise may be helpful in
patients with moderate SMR at rest and symptoms during physical
activity.<sup>609</sup> Early referral of patients with HF and moderate
or severe MR to a multidisciplinary Heart Team, including HF
specialists, is recommended for assessment and treatment planning. The
Heart Team has to verify, first of all, that the patient is on optimal
therapy, including CRT, when indicated (<em>Figure 17</em>).</p>
<p>In patients with severe SMR and HFrEF requiring revascularization,
mitral valve surgery and CABG should be considered. Isolated mitral
valve surgery may be considered in symptomatic patients with severe SMR
despite optimal therapy and low surgical risk.<sup>592</sup></p>
<p>Two randomized trials, MITRA-FR and COAPT, evaluated the
effectiveness of percutaneous edge-to-edge mitral valve repair plus OMT
compared to OMT alone, in symptomatic patients with reduced LVEF (15–40%
in MITRA-FR and 20–50% in COAPT) and moderate-to-severe or severe SMR
[effective regurgitant orifice area (EROA) ≥ 20 mm<sup>2</sup> in
MITRA-FR and EROA ≥ 30 mm<sup>2</sup> in COAPT].<sup>610–612</sup>
MITRA-FR failed to show any benefit from the intervention on all-cause
mortality or HF hospitalization at 12 months (primary endpoint; HR 1.16,
95% CI 0.73–1.84) and at 24
months.<sup>610</sup><sup>,</sup><sup>611</sup> In contrast, COAPT
showed a significant reduction in hospitalization for HF at 24 months
(primary endpoint; HR 0.53, 95% CI 0.40–0.70) and mortality (secondary
endpoint; HR 0.62, 95% CI 0.46–0.82).<sup>612</sup> Differences in
patient selection, concomitant MT, echocardiographic assessment,
procedural issues and severity of SMR in relation to the degree of LV
dilatation may be responsible for the diverging results of the MITRA-FR
and COAPT trials.<sup>613–615</sup> Thus, percutaneous edge-to-edge
mitral valve repair should be considered for outcome improvement only in
carefully selected patients who remain symptomatic (NYHA class II–IV)
despite OMT, with moderate-to-severe or severe SMR (EROA ≥30
mm<sup>2</sup>), favourable anatomical conditions, and fulfilling the
inclusion criteria of the COAPT study (i.e. LVEF 20–50%, LV end-systolic
diameter &lt;70 mm, systolic pulmonary pressure &lt;70 mmHg, absence of
moderate or severe RV dysfunction, absence of severe TR, absence of
haemodynamic instability)
(<em>Figure 17</em>).<sup>615</sup><sup>,</sup><sup>616</sup></p>
<p>Percutaneous edge-to-to edge mitral valve repair may also be
considered to improve symptoms in patients with advanced HF, severe SMR
and severe symptoms despite OMT. In these patients, cardiac
transplantation or LVAD implantation must also be
considered.<sup>376</sup><sup>,</sup><sup>617</sup></p>
<p>Other percutaneous mitral valve repair systems, such as indirect
annuloplasty, are available for treatment of SMR. This approach has a
shorter learning curve and lesser technical requirements than
percutaneous edge-to-to edge mitral valve repair and does not preclude
different procedures once it is performed. A sham-controlled randomized
trial testing a transcatheter indirect mitral annuloplasty device met
its primary endpoint of mitral regurgitant volume reduction with reverse
LV and LA remodelling at 12 months.<sup>618</sup> Further studies
confirmed favourable results on LA volumes and LV remodelling with
trends towards improvement in mean 6MWT distance and symptoms and a
reduction in HF hospitalizations in an IPD
meta-analysis.<sup>619–622</sup> Transcatheter mitral valve replacement
is also emerging as a possible alternative option, but randomized trials
are still lacking.<sup>623</sup></p>
<p>Figure 17</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f17.jpeg?Expires=1689850106&amp;Signature=1LkAYZZ2qA7YgNbE9GHnoPI5kpAEAFFklARS5aWMTIZe8h6zr30aOHhYI6wJumxO8Ggwg-XLpxA1GpVc7sSUvtgze6JdhxckRgl16oxON2E~ZPAMUdQR5ZZUlaVB5WdeMnAL9D897WQpbvZame6LpTD9lHBczhTWoLL84kS-sFJXjjdHv5nfVC0VgWAXOoPJ8f41a6fkd51ZH~0f6Y~BwnOKtxm9rc7RnwZq3T2qxBqbxDRWnKuVA6bAVDAZfbeZMsSbskHQefg5JlDfgghZmMHzlz1HkN6Vja15P5BgaxRTTpn1-gJM-nphBhqWgV7H0JdPERA430Qe04wvV8n0Rg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction. BTT = bridge to transplantation; CABG = coronary artery bypass graft; CRT = cardiac resynchronization therapy; EE = edge-to-edge; EROA = effective regurgitant orifice area; HF = heart failure; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; MCS = mechanical circulatory support; MT = medical therapy; NYHA = New York Heart Association; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; SMR = secondary mitral regurgitation; TR = tricuspid regurgitation. aNYHA class II–IV. bModerate-to-severe or severe (EROA ≥30 mm2). cAll of the following criteria must be fulfilled: LVEF 20–50%, LVESD &lt;70 mm, systolic pulmonary pressure &lt;70 mmHg, absence of moderate or severe right ventricular dysfunction or severe TR, absence of haemodynamic instability.612 Colour code for classes of recommendation: Green for Class of recommendation I; Yellow for Class of recommendation IIa; Orange for Class of recommendation IIb (see Table 1 for further details on classes of recommendation)." />
<figcaption aria-hidden="true">Management of secondary mitral
regurgitation in patients with heart failure with reduced ejection
fraction. BTT = bridge to transplantation; CABG = coronary artery bypass
graft; CRT = cardiac resynchronization therapy; EE = edge-to-edge;
EROA = effective regurgitant orifice area; HF = heart failure;
LVAD = left ventricular assist device; LVEF = left ventricular ejection
fraction; LVESD = left ventricular end-systolic diameter;
MCS = mechanical circulatory support; MT = medical therapy; NYHA = New
York Heart Association; OMT = optimal medical therapy;
PCI = percutaneous coronary intervention; SMR = secondary mitral
regurgitation; TR = tricuspid regurgitation. aNYHA class II–IV.
bModerate-to-severe or severe (EROA ≥30 mm2). cAll of the following
criteria must be fulfilled: LVEF 20–50%, LVESD &lt;70 mm, systolic
pulmonary pressure &lt;70 mmHg, absence of moderate or severe right
ventricular dysfunction or severe TR, absence of haemodynamic
instability.612 Colour code for classes of recommendation: Green for
Class of recommendation I; Yellow for Class of recommendation IIa;
Orange for Class of recommendation IIb (see Table 1 for further details
on classes of recommendation).</figcaption>
</figure>
<p>Management of secondary mitral regurgitation in patients with heart
failure with reduced ejection fraction. BTT = bridge to transplantation;
CABG = coronary artery bypass graft; CRT = cardiac resynchronization
therapy; EE = edge-to-edge; EROA = effective regurgitant orifice area;
HF = heart failure; LVAD = left ventricular assist device; LVEF = left
ventricular ejection fraction; LVESD = left ventricular end-systolic
diameter; MCS = mechanical circulatory support; MT = medical therapy;
NYHA = New York Heart Association; OMT = optimal medical therapy;
PCI = percutaneous coronary intervention; SMR = secondary mitral
regurgitation; TR = tricuspid regurgitation. <sup>a</sup>NYHA class
II–IV. <sup>b</sup>Moderate-to-severe or severe (EROA ≥30
mm<sup>2</sup>). <sup>c</sup>All of the following criteria must be
fulfilled: LVEF 20–50%, LVESD &lt;70 mm, systolic pulmonary pressure
&lt;70 mmHg, absence of moderate or severe right ventricular dysfunction
or severe TR, absence of haemodynamic instability.<sup>612</sup> Colour
code for classes of recommendation: Green for Class of recommendation I;
Yellow for Class of recommendation IIa; Orange for Class of
recommendation IIb (see <em>Table 1</em> for further details on classes
of recommendation).</p>
<p>Mitral valve interventions are not recommended in patients with a
life expectancy of &lt;1 year due to extra-cardiac
conditions.<sup>592</sup></p>
<p>Recommendations for the management of valvular heart disease in
patients with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table67.jpeg?Expires=1689850107&amp;Signature=Wtc17GGHztiAYdpnhxMAtsvWl26QnUP6d5RBuHw15z6sxbs4BdFulFd8EhwSJgRmms4YWQXa6kSBcbaT4WtvxNomdEvnpy0nIlj3OYGOTCS07jwzC1PdbWj7mmqRANH6k-KGtIs-RotlNInd9Ri3cdLqPXiq2rQDP-c-KhYKThKIkarLoS0FTMr~bDV~KVU~NhmoE5WibMIrzsIoZr6DaA1nWrFT6AwGtLi35-0f~mzEAconvzrwmno4xlg05yaw~ellyn5LJlkPymyTxlFPqVvq2HKySTkRbRlT-KuaxJUQ3FxbirVdHy-dC6gKkVEWNFdFhInAqndQobOH2U4PAw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table67.jpeg?Expires=1689850107&amp;Signature=Wtc17GGHztiAYdpnhxMAtsvWl26QnUP6d5RBuHw15z6sxbs4BdFulFd8EhwSJgRmms4YWQXa6kSBcbaT4WtvxNomdEvnpy0nIlj3OYGOTCS07jwzC1PdbWj7mmqRANH6k-KGtIs-RotlNInd9Ri3cdLqPXiq2rQDP-c-KhYKThKIkarLoS0FTMr~bDV~KVU~NhmoE5WibMIrzsIoZr6DaA1nWrFT6AwGtLi35-0f~mzEAconvzrwmno4xlg05yaw~ellyn5LJlkPymyTxlFPqVvq2HKySTkRbRlT-KuaxJUQ3FxbirVdHy-dC6gKkVEWNFdFhInAqndQobOH2U4PAw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CABG = coronary artery bypass graft; CAD = coronary artery disease;
LVEF = left ventricular ejection fraction; LVESD = left ventricular
end-systolic diameter; NYHA = New York Heart Association; OMT = optimal
medical therapy; SAVR = surgical aortic valve replacement;
TAVI = transcatheter aortic valve implantation; TR = tricuspid
regurgitation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>NYHA class II–IV.</p>
<p>d</p>
<p>All of the following criteria must be fulfilled: LVEF 20–50%, LVESD
&lt;70 mm, systolic pulmonary pressure &lt;70 mmHg, absence of moderate
or severe right ventricular dysfunction or severe TR, absence of
haemodynamic instability.<sup>612</sup></p>
<p>Recommendations for the management of valvular heart disease in
patients with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table67.jpeg?Expires=1689850107&amp;Signature=Wtc17GGHztiAYdpnhxMAtsvWl26QnUP6d5RBuHw15z6sxbs4BdFulFd8EhwSJgRmms4YWQXa6kSBcbaT4WtvxNomdEvnpy0nIlj3OYGOTCS07jwzC1PdbWj7mmqRANH6k-KGtIs-RotlNInd9Ri3cdLqPXiq2rQDP-c-KhYKThKIkarLoS0FTMr~bDV~KVU~NhmoE5WibMIrzsIoZr6DaA1nWrFT6AwGtLi35-0f~mzEAconvzrwmno4xlg05yaw~ellyn5LJlkPymyTxlFPqVvq2HKySTkRbRlT-KuaxJUQ3FxbirVdHy-dC6gKkVEWNFdFhInAqndQobOH2U4PAw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table67.jpeg?Expires=1689850107&amp;Signature=Wtc17GGHztiAYdpnhxMAtsvWl26QnUP6d5RBuHw15z6sxbs4BdFulFd8EhwSJgRmms4YWQXa6kSBcbaT4WtvxNomdEvnpy0nIlj3OYGOTCS07jwzC1PdbWj7mmqRANH6k-KGtIs-RotlNInd9Ri3cdLqPXiq2rQDP-c-KhYKThKIkarLoS0FTMr~bDV~KVU~NhmoE5WibMIrzsIoZr6DaA1nWrFT6AwGtLi35-0f~mzEAconvzrwmno4xlg05yaw~ellyn5LJlkPymyTxlFPqVvq2HKySTkRbRlT-KuaxJUQ3FxbirVdHy-dC6gKkVEWNFdFhInAqndQobOH2U4PAw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CABG = coronary artery bypass graft; CAD = coronary artery disease;
LVEF = left ventricular ejection fraction; LVESD = left ventricular
end-systolic diameter; NYHA = New York Heart Association; OMT = optimal
medical therapy; SAVR = surgical aortic valve replacement;
TAVI = transcatheter aortic valve implantation; TR = tricuspid
regurgitation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>NYHA class II–IV.</p>
<p>d</p>
<p>All of the following criteria must be fulfilled: LVEF 20–50%, LVESD
&lt;70 mm, systolic pulmonary pressure &lt;70 mmHg, absence of moderate
or severe right ventricular dysfunction or severe TR, absence of
haemodynamic instability.<sup>612</sup></p>
<h4 >12.3.4 Tricuspid regurgitation</h4>
<p>Tricuspid regurgitation (TR) can be caused by or be a consequence of
RV dysfunction and HF. The management of HF with TR includes MT
(i.e. diuretics, neurohormonal antagonists). Transcatheter therapy and
surgery may be considered in selected cases.<sup>592</sup> A
multidisciplinary Heart Team, including HF specialists, should be
considered for assessment and treatment planning.</p>
<p>Tricuspid valve surgery is recommended in patients with severe TR
requiring left-sided cardiac surgery. It should be also considered in
patients with moderate TR and tricuspid annulus dilatation requiring
left-sided cardiac surgery and in symptomatic patients with isolated
severe TR.<sup>592</sup> However, surgery in isolated TR is burdened by
high in-hospital mortality (8.8%) although the advanced stage of HF may
have influenced these data.<sup>624</sup> Transcatheter techniques have
recently emerged as potential treatment options of TR. Preliminary
results show improvement in TR severity and symptoms with low
complication rates.<sup>625</sup> Further prospective studies are needed
to show the prognostic impact of these treatments in HF patients.</p>
<h3 >12.4 Hypertension</h3>
<p>Arterial hypertension is a leading risk factor for the development of
HF. Almost two-thirds of HF patients have a past history of
hypertension.<sup>104</sup><sup>,</sup><sup>626</sup> Clinical trials
evaluating antihypertensive strategies and BP targets in patients with
HF and hypertension have not been performed.</p>
<p>Treatment of HFrEF is similar in hypertensive and normotensive
patients. Recommended medications, including neurohormonal antagonists
and diuretics, lower also BP. Lifestyle modifications, such as weight
loss, reduced sodium intake, and increased physical activity, are useful
adjunctive measures.<sup>4</sup> Uncontrolled hypertension in patients
with HFrEF is rare, provided the patient is receiving OMT at recommended
doses for HF. If further BP lowering is required, in absence of signs of
fluid overload, amlodipine and felodipine have been shown to be safe in
HFrEF and may be considered.<sup>570</sup><sup>,</sup><sup>571</sup>
Non-dihydropyridine CCBs (diltiazem and verapamil) and centrally acting
agents, such as moxonidine, are contraindicated as they are associated
with worse outcomes.<sup>627</sup> Alpha-blockers have no effects on
survival and are therefore not indicated.<sup>143</sup> They can be used
for the treatment of concomitant prostatic hyperplasia but should be
withdrawn in cases of hypotension.</p>
<p>Hypertension is the most important cause of HFpEF, with a prevalence
of 60% to 89%.<sup>39</sup> Patients with HFpEF also frequently have an
exaggerated hypertensive response to exercise and may present with
hypertensive acute pulmonary
oedema.<sup>628</sup><sup>,</sup><sup>629</sup> Antihypertensive agents,
including ACE-I, ARBs, beta-blockers, CCB, and diuretics reduce the
incidence of HF.<sup>630</sup><sup>,</sup><sup>631</sup> Reducing BP
leads also to LVH regression, the degree of which depends on the class
of drug used.<sup>4</sup> ARBs, ACE-I, and CCBs cause more effective LVH
regression than beta-blockers or diuretics.<sup>632</sup> Poorly
controlled hypertension may precipitate episodes of decompensation.
Causes of secondary hypertension, such as renal vascular or parenchymal
disease, primary aldosteronism and obstructive sleep apnoea (OSA),
should be ruled out or, if confirmed, considered for treatment.
Treatment of hypertension is an important issue in patients with HFpEF,
but the optimal treatment strategy is uncertain. The treatment strategy
used in HFrEF should also be considered in HFpEF.<sup>4</sup></p>
<p>BP targets are uncertain in both HFrEF and HFpEF. However, evaluation
of patient’s age and comorbidities (i.e. diabetes, CKD, CAD, valvular
heart disease and stroke) can be helpful to personalize the BP
target.<sup>4</sup> Every effort should be made to reach target doses of
evidence-based medications in HFrEF patients, despite slight
hypotension.<sup>4</sup><sup>,</sup><sup>633</sup> Conversely, in HFpEF
patients with LVH and limited preload reserve, hypotension should be
avoided.</p>
<h3 >12.5 Stroke</h3>
<p>HF and stroke frequently coexist because of an overlap of shared risk
factors and subsequent
mechanisms.<sup>519</sup><sup>,</sup><sup>634</sup> A higher risk of
stroke is present also in HF patients in
SR.<sup>39</sup><sup>,</sup><sup>426</sup><sup>,</sup><sup>635</sup><sup>,</sup><sup>–</sup><sup>637</sup>
AF confers an additional risk and patients with HF and AF have a
five-fold increased risk compared to the control
population.<sup>519</sup><sup>,</sup><sup>634</sup><sup>,</sup><sup>638</sup></p>
<p>As a temporal trend, the incidence of stroke is higher in the first
30 days after HF diagnosis or an episode of HF decompensation and
decreases in the first 6 months following the acute
event.<sup>637</sup><sup>,</sup><sup>639</sup> Patients with stroke and
HF have higher mortality, more severe neurological deficits and longer
hospital stays than those without
HF.<sup>637</sup><sup>,</sup><sup>640</sup> Similarly, patients with HF
and stroke have a higher mortality than patients without
stroke.<sup>640</sup> In COMMANDER-HF, 47.5% of strokes were either
disabling, 16.5%, or fatal, 31%.<sup>637</sup></p>
<p>Patients with HF and concomitant AF, including paroxysmal AF, have a
CHA<sub>2</sub>DS<sub>2</sub>-VASc score of at least 1 and have
therefore an indication to anticoagulation. The indication to
antithrombotic strategies in patients with HF and SR is controversial.
In the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction
(WARCEF) trial, warfarin reduced ischaemic stroke as compared with
aspirin, but increased major haemorrhages and did not influence the
primary endpoint of ischaemic stroke, intracerebral haemorrhage, or
death.<sup>641</sup> Meta-analyses confirm an increased risk of bleeding
outweighing ischaemic stroke prevention in placebo-controlled trials in
patients with HFrEF and SR.<sup>642</sup> In COMMANDER-HF, rivaroxaban
2.5 mg b.i.d. did not improve the composite outcome of all-cause
mortality, MI or stroke, nor did it favourably influence HF-related
deaths or HF hospitalizations.<sup>579</sup> There are no data to
support a routine strategy of anticoagulation in patients with HFrEF in
SR who do not have history of paroxysmal AF. However, low-dose
rivaroxaban may be considered in patients with concomitant CCS or
peripheral artery disease, a high risk of stroke and no major
haemorrhagic risk (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.2">section
12.2</a>).</p>
<p>Patients with visible intraventricular thrombus or at high thrombotic
risk, such as those with history of peripheral embolism or some patients
with PPCM or LV non-compaction (LVNC), should be considered for
anticoagulation.<sup>3</sup><sup>,</sup><sup>643–645</sup></p>
<h2 >13 Non-cardiovascular
comorbidities</h2>
<h3 >13.1 Diabetes</h3>
<p>Treatment of HF is similar in patients with and without
diabetes.<sup>6</sup><sup>,</sup><sup>646</sup> Conversely, antidiabetic
drugs differ in their effects in patients with HF and preference must be
given to drugs that are both safe and reduce HF-related
events.<sup>6</sup><sup>,</sup><sup>646</sup><sup>,</sup><sup>647</sup></p>
<p>The SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin,
ertugliflozin and sotagliflozin were studied in patients with
established CV disease in the EMPA-REG OUTCOME and VERTIS-CV trials,
with established CV disease or CV risk factors in the CANVAS and
DECLARE-TIMI 58 trials, and with CKD and CV risk in the SCORED trial,
respectively.<sup>293–297</sup> A small proportion of patients had a
history of HF. Empagliflozin and canagliflozin reduced the primary
composite endpoint of major CV adverse events, including CV death or
non-fatal MI or non-fatal stroke, and HF hospitalizations in EMPA-REG
OUTCOME and CANVAS,
respectively.<sup>293</sup><sup>,</sup><sup>294</sup> Empagliflozin also
reduced all-cause death or CV death alone.<sup>293</sup> The effects on
the primary endpoint were driven by the reduction in HF-related
events.<sup>293</sup><sup>,</sup><sup>294</sup> In DECLARE-TIMI 58,
dapagliflozin did not reduce major CV events but reduced the co-primary
efficacy endpoint of CV death or HF hospitalization and HF
hospitalization alone.<sup>295</sup> In VERTIS-CV, neither the primary
major CV event endpoint nor the key secondary outcome of CV death or HF
hospitalization were reduced significantly by ertugliflozin, although
there was a statistically significant reduction in HF hospitalization
and repeated hospitalizations.<sup>297</sup><sup>,</sup><sup>648</sup>
In SCORED, sotagliflozin reduced CV deaths and HF
hospitalizations.<sup>296</sup> In a meta-analysis of these trials and
one further trial in patients with CKD (CREDENCE), overall SGLT2
inhibitors reduced HF and CV hospitalization by 22%.<sup>649</sup> SGLT2
inhibitors were well tolerated, although they may cause genital fungal
skin infections and, rarely, diabetic ketoacidosis.<sup>293–295</sup>
Trial results with dapagliflozin and empagliflozin in patients with
HFrEF, with or without diabetes, and with the SGLT1/2 inhibitor
sotagliflozin in patients with type 2 diabetes stabilized after
hospitalization for acute HF or within 3 days after discharge, further
support the administration of these agents (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5.3.5">section 5.3.5</a>
and <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-11.3.11">section 11.3.11</a>).<sup>108</sup><sup>,</sup><sup>109</sup><sup>,</sup><sup>136</sup></p>
<p>EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and VERTIS-CV also showed
a reduction in worsening renal function, end-stage renal disease or
death from renal causes, with SGLT2 inhibitors.</p>
<p>Based on these results, the SGLT inhibitors canagliflozin,
dapagliflozin, empagliflozin, ertugliflozin or sotagliflozin are
recommended to prevent HF and CV death and worsening kidney function in
patients with type 2 diabetes and CV disease and/or CV risk factors, or
CKD. Dapagliflozin and empagliflozin are also indicated for the
treatment of patients with type 2 diabetes and HFrEF (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5.3.5">section 5.3.5</a>
and <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-11.2.4">section 11.2.4</a>)
and sotagliflozin was shown to reduce CV deaths and HF
rehospitalizations in patients recently hospitalized for
HF.<sup>6</sup><sup>,</sup><sup>296</sup><sup>,</sup><sup>646</sup><sup>,</sup><sup>647</sup><sup>,</sup><sup>650</sup></p>
<p>Metformin is thought to be safe in patients with HF, compared with
insulin and sulfonylureas, based on observational
studies.<sup>651</sup><sup>,</sup><sup>652</sup> However, it is not
recommended in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> or
hepatic impairment because of the risk of lactic acidosis. It has not
been studied in controlled outcome trials, to
date.<sup>6</sup><sup>,</sup><sup>646</sup></p>
<p>Regarding dipeptidyl peptidase-4 (DPP-4) inhibitors, HF
hospitalizations were increased by 27% in one trial with saxagliptin in
patients with diabetes.<sup>653</sup> However, no difference over
placebo for HF events was found with alogliptin, sitagliptin, and
linagliptin.<sup>654–656</sup> Vidagliptin was associated with an
increase in LV volumes and a numerically greater number of deaths and CV
events in a small trial in patients with diabetes and HF.<sup>657</sup>
Overall, the effects on mortality or CV events were neutral in the DPP-4
inhibitor trials and
meta-analyses.<sup>658</sup><sup>,</sup><sup>659</sup> These drugs are
therefore not recommended to reduce CV events in diabetic patients with
HF.</p>
<p>Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of
MI, stroke, and CV death in patients with diabetes, although probably do
not reduce incident HF.<sup>6</sup><sup>,</sup><sup>660</sup>
Liraglutide had no effect on LVEF, increased heart rate, and increased
serious cardiac events in a randomized placebo-controlled trial in
241 patients with HFrEF with and without diabetes.<sup>661</sup> Neutral
results on the primary endpoint were found in another trial in 300
patients with a numerical increase in deaths and HF hospitalizations,
compared with placebo.<sup>662</sup> GLP-1 receptor agonists are
therefore not recommended for the prevention of HF events.</p>
<p>Insulin is needed in patients with type 1 diabetes and to control
hyperglycaemia in some patients with type 2 diabetes, especially when
beta-cell function is exhausted. It is a sodium-retaining hormone and
concern has been raised that it may exacerbate fluid retention in
patients with HF. However, in a RCT that included patients with type 2
diabetes, impaired glucose tolerance, or impaired fasting glucose,
insulin did not increase the risk of incident HF.<sup>663</sup> Use of
insulin was associated with poorer outcomes in retrospective analyses of
randomized trials and administrative
databases.<sup>664</sup><sup>,</sup><sup>665</sup> If insulin is needed
in a patient with HF, the patient should be monitored for evidence of
worsening of HF after treatment initiation.</p>
<p>Sulfonylureas were associated with a higher risk of HF events in some
analyses.<sup>666</sup><sup>,</sup><sup>667</sup> Therefore, they are
not a preferred treatment in patients with HF and, if needed, patients
should be monitored for evidence of worsening of HF after treatment
initiation.<sup>6</sup><sup>,</sup><sup>646</sup> Thiazolidinediones
(glitazones) cause sodium and water retention and an increased risk of
worsening HF and hospitalization.<sup>668</sup> They are contraindicated
in patients with HF.</p>
<p>Recommendations for the treatment of diabetes in heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table69.jpeg?Expires=1689850107&amp;Signature=Ezswu~x-sQI1RnUpVXVpVS07RE~CtXcD9pk5JOEnpEUxzmbEK6AUge2zFByUg4G~V0TKgfTEBpTVsVrVGUuww2VxOInA0-qNgJzxWhBRpEejUy1y-xJBB-DfKgLX32W-3TbnN2P0vt1M~2fK3YTwxYNG4WA5d9XKk1k-AC1Gne8Dd462uHYX3mHTaLAfLYOirs7Q8QeiScRHApJUx5xdAcoCa9UKJtQD1yU9Lf6j8~hzfpelrdmt-P7D81nuDIoQ5d6kOVxwtoO06DTDIag95tCXmZDnQ2N96ffrxuOq6sGHzPydjRvJCpDLYjwwRASL3L1o2oHxVWtCKebyS7JstA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table69.jpeg?Expires=1689850107&amp;Signature=Ezswu~x-sQI1RnUpVXVpVS07RE~CtXcD9pk5JOEnpEUxzmbEK6AUge2zFByUg4G~V0TKgfTEBpTVsVrVGUuww2VxOInA0-qNgJzxWhBRpEejUy1y-xJBB-DfKgLX32W-3TbnN2P0vt1M~2fK3YTwxYNG4WA5d9XKk1k-AC1Gne8Dd462uHYX3mHTaLAfLYOirs7Q8QeiScRHApJUx5xdAcoCa9UKJtQD1yU9Lf6j8~hzfpelrdmt-P7D81nuDIoQ5d6kOVxwtoO06DTDIag95tCXmZDnQ2N96ffrxuOq6sGHzPydjRvJCpDLYjwwRASL3L1o2oHxVWtCKebyS7JstA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CV = cardiovascular; HF = heart failure; HFrEF = heart failure with
reduced ejection fraction; SGLT2 = sodium-glucose co-transporter 2;
T2DM = type 2 diabetes mellitus.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the treatment of diabetes in heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table69.jpeg?Expires=1689850107&amp;Signature=Ezswu~x-sQI1RnUpVXVpVS07RE~CtXcD9pk5JOEnpEUxzmbEK6AUge2zFByUg4G~V0TKgfTEBpTVsVrVGUuww2VxOInA0-qNgJzxWhBRpEejUy1y-xJBB-DfKgLX32W-3TbnN2P0vt1M~2fK3YTwxYNG4WA5d9XKk1k-AC1Gne8Dd462uHYX3mHTaLAfLYOirs7Q8QeiScRHApJUx5xdAcoCa9UKJtQD1yU9Lf6j8~hzfpelrdmt-P7D81nuDIoQ5d6kOVxwtoO06DTDIag95tCXmZDnQ2N96ffrxuOq6sGHzPydjRvJCpDLYjwwRASL3L1o2oHxVWtCKebyS7JstA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table69.jpeg?Expires=1689850107&amp;Signature=Ezswu~x-sQI1RnUpVXVpVS07RE~CtXcD9pk5JOEnpEUxzmbEK6AUge2zFByUg4G~V0TKgfTEBpTVsVrVGUuww2VxOInA0-qNgJzxWhBRpEejUy1y-xJBB-DfKgLX32W-3TbnN2P0vt1M~2fK3YTwxYNG4WA5d9XKk1k-AC1Gne8Dd462uHYX3mHTaLAfLYOirs7Q8QeiScRHApJUx5xdAcoCa9UKJtQD1yU9Lf6j8~hzfpelrdmt-P7D81nuDIoQ5d6kOVxwtoO06DTDIag95tCXmZDnQ2N96ffrxuOq6sGHzPydjRvJCpDLYjwwRASL3L1o2oHxVWtCKebyS7JstA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CV = cardiovascular; HF = heart failure; HFrEF = heart failure with
reduced ejection fraction; SGLT2 = sodium-glucose co-transporter 2;
T2DM = type 2 diabetes mellitus.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h3 >13.2 Thyroid disorders</h3>
<p>Assessment of thyroid function is recommended in all patients with HF
as both hypo- and hyperthyroidism may cause or precipitate
HF.<sup>669</sup> Subclinical hypothyroidism and isolated low
triiodothyronine levels were associated with poorer outcomes in
observational studies in patients with
HF.<sup>670</sup><sup>,</sup><sup>671</sup> Treatment of thyroid
disorders should be guided by general endocrine guidelines. There are no
randomized trials evaluating the efficacy of thyroid replacement therapy
in subclinical hypothyroidism, but there is a general agreement to
correct it when the TSH is &gt;10 mIU/L, particularly in patients &lt;70
years. Correction may also be considered at lower TSH levels (7–10
mIU/L).<sup>672–674</sup></p>
<h3 >13.3 Obesity</h3>
<p>Obesity is a risk factor for hypertension and CAD and is also
associated with an increased risk of HF. There is possibly a stronger
association with HFpEF.<sup>258</sup><sup>,</sup><sup>675–677</sup> Once
obese patients have HF, an obesity paradox has been described such that
overweight or mildly/moderately obese patients have a better prognosis
than leaner patients, particularly compared with those who are
underweight.<sup>678</sup><sup>,</sup><sup>679</sup> However, other
variables may influence this relationship and the obesity paradox is not
observed in patients with
diabetes.<sup>680</sup><sup>,</sup><sup>681</sup> Second, BMI does not
take into account body composition, e.g. the relation between lean
skeletal muscle mass and fat mass. Obese patients who are fit and have a
preserved skeletal muscle mass have better prognosis than obese
sarcopenic patients.<sup>682</sup> Waist circumference or the
waist-to-hip ratio, measuring visceral obesity, is less influenced by
muscle mass and may have a stronger relationship with outcomes than BMI,
especially in female
patients.<sup>683</sup><sup>,</sup><sup>684</sup></p>
<p>Body fat has a major impact on the diagnostic and prognostic value of
multiple parameters. Obese patients with HF have lower NP concentrations
due to increased expression of clearance receptors and augmented peptide
degradation by the adipose tissue.<sup>74</sup> Peak oxygen consumption
adjusted for body weight underestimates exercise capacity in obese
patients and an adjustment for lean body mass should be used for risk
stratification.<sup>96</sup></p>
<p>Obesity may be a major cause of HFpEF and obese HFpEF patients
display several pathophysiologic mechanisms that differ from non-obese
patients with
HFpEF.<sup>258</sup><sup>,</sup><sup>675–677</sup><sup>,</sup><sup>685</sup>
Caloric restriction and exercise training had additive beneficial
effects on exercise capacity and QOL of patients with obesity and HFpEF
in a randomized trial.<sup>337</sup></p>
<h3 >13.4 Frailty, cachexia,
sarcopenia</h3>
<p>Frailty is a multidimensional dynamic state, independent of age, that
makes the individual more vulnerable to the effect of
stressors.<sup>686</sup> HF and frailty are two distinct yet commonly
associated conditions. The assessment of frailty in patients with HF is
crucial as it is associated with both unfavourable outcomes and reduced
access to, and tolerance of, treatments. Several tools have been
proposed for frailty screening and assessment in different chronic
conditions, including HF. The HFA of ESC has developed a HF-specific
tool based on four major domains, clinical, psycho-cognitive,
functional, and social.<sup>686</sup></p>
<p>Frailty is more prevalent in patients with HF than in the general
population and may occur in up to 45% of the patients, according to a
recent meta-analysis.<sup>687</sup><sup>,</sup><sup>688</sup> Patients
with HF are up to six times more likely to be frail, and frail people
have a significantly increased risk of developing
HF.<sup>689</sup><sup>,</sup><sup>690</sup> Frailty is associated with a
higher risk of death, hospitalizations, and functional decline as well
as with a longer duration of hospital stay.<sup>691–693</sup> The
treatment of frailty in HF should be multifactorial and targeted to its
main components and may include physical rehabilitation with exercise
training, nutritional supplementation as well as an individualized
approach to treating comorbidities.<sup>686</sup></p>
<p>Cachexia is defined as a ‘complex metabolic syndrome associated with
underlying illness and characterized by loss of muscle with or without
loss of fat mass’.<sup>694</sup> Its major clinical feature is a &gt;5%
oedema-free body weight loss during the previous 12 months or
less.<sup>694</sup><sup>,</sup><sup>695</sup> Cachexia is a generalized
wasting process that may coexist with frailty and may occur in 5–15% of
patients with HF, especially those with HFrEF and more advanced disease
status. It is associated with reduced functional capacity and decreased
survival.<sup>695–698</sup> As it is associated with other chronic
diseases, such as cancer, alternative, non-cardiac causes for cachexia
should always be investigated.<sup>699</sup></p>
<p>Sarcopenia is defined by the presence of low muscle mass together
with low muscle function, strength, or performance.<sup>698</sup> It is
usually identified by an appendicular skeletal muscle mass, defined as
the sum of the muscle mass of the four limbs, 2 standard deviation below
the mean of a healthy reference group aged 18–40 years with a cut-off
value of 7.26 kg/m² for
men.<sup>688</sup><sup>,</sup><sup>700</sup><sup>,</sup><sup>701</sup>
It occurs physiologically with aging. However, it is accelerated by
chronic diseases, such as cancer and HF. Sarcopenia can be found in
20–50% of patients with HFrEF and is often associated with frailty and
increased morbidity and mortality. It is a major determinant of outcomes
outweighing the effect of body weight and
BMI.<sup>684</sup><sup>,</sup><sup>698</sup><sup>,</sup><sup>701</sup><sup>,</sup><sup>702</sup>
So far, the most effective strategy for sarcopenia treatment is
resistance exercise training, possibly combined with a protein intake of
1–1.5 g/kg/day.<sup>698</sup><sup>,</sup><sup>703</sup> Drug treatments,
including anabolic compounds like testosterone, growth hormone, ghrelin
receptor agonists, were tested in small studies, showing favourable
results mostly in terms of exercise capacity and muscle
strength.<sup>697</sup><sup>,</sup><sup>703–705</sup> There are no data
showing a favourable impact of sarcopenia treatment on outcomes.
However, exercise training has favourable effects in patients with HF
(see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-9.4">section 9.4</a>).<sup>95</sup><sup>,</sup><sup>323–329</sup></p>
<h3 >13.5 Iron deficiency and
anaemia</h3>
<p>Iron deficiency and anaemia are common in patients with HF, being
independently associated with reduced exercise capacity, recurrent HF
hospitalizations, and high CV and all-cause
mortality.<sup>706</sup><sup>,</sup><sup>707</sup> According to the
World Health Organization criteria, anaemia is defined as a haemoglobin
concentration &lt;12 g/dL in women and &lt;13 g/dL in men. In patients
with HF, iron deficiency is defined as either a serum ferritin
concentration &lt;100 ng/mL or 100–299 ng/mL with transferrin saturation
(TSAT) &lt;20%.<sup>708–710</sup> Ferritin tissue expression and
concentration in the peripheral blood is increased by inflammation and
several disorders such as infection, cancer, liver disease, and HF
itself. Hence, higher cut-off values have been applied for the
definition of iron deficiency in patients with HF.<sup>709–711</sup>
Another marker reflecting depleted intracellular iron can be high serum
soluble transferrin receptors, which derives from proteolysis of the
membrane transferrin receptor. Its synthesis is increased in case of
iron deficiency and is not affected by inflammation. High serum soluble
transferrin receptors identify patients at high risk of death beyond
standard prognostic variables.<sup>711</sup><sup>,</sup><sup>712</sup>
However, its applicability for iron supplementation therapy has not been
demonstrated yet.</p>
<p>Iron deficiency, which can be present independently of anaemia, is
present in up to 55% of chronic HF patients and in up to 80% of those
with AHF.<sup>713–716</sup> It may be caused by increased loss, reduced
intake or absorption (i.e. malnutrition, gut congestion) and/or impaired
iron metabolism caused by the chronic inflammatory activation of HF,
although the exact cause of iron deficiency in HF remains unknown. Iron
deficiency may impair functional capacity, precipitate circulatory
decompensation, promote skeletal muscle dysfunction, and is associated
with frailty, irrespective of anaemia.<sup>716–718</sup></p>
<p>It is recommended that all patients with HF are regularly screened
for anaemia and iron deficiency with full blood count, serum ferritin
concentration, and TSAT. The detection of anaemia and/or iron deficiency
should prompt appropriate investigation to define their cause.</p>
<p>Darbepoetin-alpha failed to reduce all-cause death or HF
hospitalization and increased the risk of thromboembolic events in the
only large-scale randomized trial in patients with HFrEF and mild to
moderate anaemia.<sup>719</sup> As a result, erythropoietin stimulating
agents are not indicated for the treatment of anaemia in HF.</p>
<p>Recommendations for the management of anaemia and iron deficiency in
patients with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table71.jpeg?Expires=1689850107&amp;Signature=JLwUFF-L42l6w5wJPgR8TQpKE6ScBHB2vi-hq2x7dGK74OBhKEaVeiskuyAbkbJ~mh4d4yfYmhQWM9GfzVrTIKuOwCXTnNwRH2Iwz6n0wPxVxT6i8AELuUKut-lQqj-dNL~1K9KujYjnUWW2hAnctZmEDBd3GtoQu9jUtR4TRNs6mxr4YsKU5p6ttZXSqgPS~0Q1apxIKiuERwmfq8WAHP4pD1yTU9WlfMXwlCPthMIg1xMzlL7GmSuYcIKE8tqij4~ropOB~vuaRMgFBP1V~HZkfBJt~-gJtrBEFw2aWlqOgXmXxVe6d8FsuzGU-6cklUzHanAvVR6mvjl6wJ0KPw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table71.jpeg?Expires=1689850107&amp;Signature=JLwUFF-L42l6w5wJPgR8TQpKE6ScBHB2vi-hq2x7dGK74OBhKEaVeiskuyAbkbJ~mh4d4yfYmhQWM9GfzVrTIKuOwCXTnNwRH2Iwz6n0wPxVxT6i8AELuUKut-lQqj-dNL~1K9KujYjnUWW2hAnctZmEDBd3GtoQu9jUtR4TRNs6mxr4YsKU5p6ttZXSqgPS~0Q1apxIKiuERwmfq8WAHP4pD1yTU9WlfMXwlCPthMIg1xMzlL7GmSuYcIKE8tqij4~ropOB~vuaRMgFBP1V~HZkfBJt~-gJtrBEFw2aWlqOgXmXxVe6d8FsuzGU-6cklUzHanAvVR6mvjl6wJ0KPw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure; LVEF = left ventricular ejection fraction;
QOL = quality of life; TSAT = transferrin saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the management of anaemia and iron deficiency in
patients with heart failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table71.jpeg?Expires=1689850107&amp;Signature=JLwUFF-L42l6w5wJPgR8TQpKE6ScBHB2vi-hq2x7dGK74OBhKEaVeiskuyAbkbJ~mh4d4yfYmhQWM9GfzVrTIKuOwCXTnNwRH2Iwz6n0wPxVxT6i8AELuUKut-lQqj-dNL~1K9KujYjnUWW2hAnctZmEDBd3GtoQu9jUtR4TRNs6mxr4YsKU5p6ttZXSqgPS~0Q1apxIKiuERwmfq8WAHP4pD1yTU9WlfMXwlCPthMIg1xMzlL7GmSuYcIKE8tqij4~ropOB~vuaRMgFBP1V~HZkfBJt~-gJtrBEFw2aWlqOgXmXxVe6d8FsuzGU-6cklUzHanAvVR6mvjl6wJ0KPw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table71.jpeg?Expires=1689850107&amp;Signature=JLwUFF-L42l6w5wJPgR8TQpKE6ScBHB2vi-hq2x7dGK74OBhKEaVeiskuyAbkbJ~mh4d4yfYmhQWM9GfzVrTIKuOwCXTnNwRH2Iwz6n0wPxVxT6i8AELuUKut-lQqj-dNL~1K9KujYjnUWW2hAnctZmEDBd3GtoQu9jUtR4TRNs6mxr4YsKU5p6ttZXSqgPS~0Q1apxIKiuERwmfq8WAHP4pD1yTU9WlfMXwlCPthMIg1xMzlL7GmSuYcIKE8tqij4~ropOB~vuaRMgFBP1V~HZkfBJt~-gJtrBEFw2aWlqOgXmXxVe6d8FsuzGU-6cklUzHanAvVR6mvjl6wJ0KPw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>HF = heart failure; LVEF = left ventricular ejection fraction;
QOL = quality of life; TSAT = transferrin saturation.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>RCTs have shown that iron supplementation with i.v. ferric
carboxymaltose is safe and improves symptoms, exercise capacity, and QOL
of patients with HFrEF and iron deficiency.<sup>720–723</sup>
Meta-analyses of RCTs showed also a reduction in the risk of the
combined endpoints of all-cause death or CV hospitalization, CV death or
HF hospitalization, CV death or recurrent CV or HF
hospitalizations.<sup>724</sup><sup>,</sup><sup>725</sup> The favourable
effects of iron supplementation were independent from anaemia
coexistence.<sup>726</sup> In AFFIRM-AHF, patients hospitalized for HF
with LVEF &lt;50% and concomitant iron deficiency were randomized to
i.v. ferric carboxymaltose or placebo, repeated at 6- and then 12-week
intervals if indicated according to repeat iron studies.<sup>512</sup>
Administration of ferric carboxymaltose did not significantly reduce the
primary composite outcome of total HF hospitalizations and CV death at
52 weeks (rate ratio 0.79, 95% CI 0.62–1.01, <em>P</em>  =  0.059).
However, it reduced the composite endpoint of first HF hospitalization
or CV death (HR 0.80, 95% CI 0.66–0.98, <em>P</em>  =  0.030) and total
HF hospitalizations (rate ratio 0.74, 95% CI 0.58–0.94,
<em>P</em>  =  0.013).<sup>512</sup> Therefore, iron supplementation
with i.v. ferric carboxymaltose should be considered for the improvement
of symptoms, exercise capacity, and QOL in patients with HF and LVEF
&lt;45%. It should also be considered for the reduction of HF
rehospitalizations in patients with LVEF &lt;50% recently hospitalized
for worsening HF. Ongoing trials are expected to provide more evidence
on the effects of ferric carboxymaltose in patients with HFpEF. In
addition, large outcomes trials with other iron formulations are ongoing
in HFrEF, HFpEF, and AHF.<sup>727</sup> Oral iron therapy is not
effective in iron repletion and did not improve exercise capacity in
patients with HFrEF and iron deficiency.<sup>728</sup> It is therefore
not recommended for the treatment of iron deficiency in the patients
with HF.</p>
<h3 >13.6 Kidney dysfunction</h3>
<p>CKD and HF frequently
coexist.<sup>471</sup><sup>,</sup><sup>707</sup><sup>,</sup><sup>729</sup>
They share common risk factors, such as diabetes or hypertension. CKD
may worsen CV function causing hypertension and vascular calcification.
HF may worsen renal function, through the effects of neurohormonal and
inflammatory activation, increased venous pressure and hypoperfusion.
Oxidative stress and fibrosis likely play a major role as pathogenic
mechanisms in HF with CKD.<sup>730</sup><sup>,</sup><sup>731</sup></p>
<p>While CKD and worsening renal function both appear more common in
HFpEF as compared to in HFmrEF and HFrEF, perhaps due to shared
pathophysiological mechanisms, they appear to be less associated with
worse outcomes in HFpEF than in HFmrEF and
HFrEF.<sup>732</sup><sup>,</sup><sup>733</sup></p>
<p>CKD is a major independent determinant of increased mortality and
morbidity in HF.<sup>471</sup><sup>,</sup><sup>734–736</sup> However,
there are settings in which changes in serum creatinine are not
associated with worse outcomes. When RAAS inhibitors, ARNI or SGLT2
inhibitors are started, the initial decrease in the glomerular
filtration pressure may decrease GFR and increase serum creatinine.
However, these changes are generally transient and occur despite
improvement in patient outcomes and slower worsening of renal function
in the long term. For instance, in EMPEROR-Reduced, the
placebo-corrected eGFR dip induced by empagliflozin at week 4 was of 2.4
mL/min/1.73 m² for patients with CKD and 2.7 mL/min/1.73 m² for those
without CKD, corresponding to a decrease from baseline of 5.2% and 3.8%,
respectively. This was followed by a slower slope of eGFR decline and by
a reduced rate of the composite kidney outcome with empagliflozin
vs. placebo, with no difference between patients with or without CKD at
baseline.<sup>109</sup><sup>,</sup><sup>737</sup></p>
<p>Thus, with respect to the initiation of RAAS inhibitors, ARNI or
SGLT2 inhibitors, a transient decrease in renal function should not
prompt their interruption. An increase in serum creatinine of &lt;50%
above baseline, as long as it is &lt;266 μmol/L (3 mg/dL), or a decrease
in eGFR of &lt;10% from baseline, as long as eGFR is &gt;25 mL/min/1.73
m², can be considered as acceptable (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5.3">section 5.3</a>
and <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 8</a></em>). Also, with respect to diuretic therapy, small and
transient rises in serum creatinine during treatment of acute HF are not
associated with poorer outcomes when the patient is free of
congestion.<sup>108</sup><sup>,</sup><sup>109</sup><sup>,</sup><sup>460–462</sup><sup>,</sup><sup>471</sup><sup>,</sup><sup>729</sup><sup>,</sup><sup>737–740</sup></p>
<p>Randomized trials have shown that patients with HF and concomitant
CKD are at higher risk of events but the beneficial effects of MT are
similar, if not greater, than in the patients with normal renal
function.<sup>206</sup><sup>,</sup><sup>471</sup><sup>,</sup><sup>741</sup><sup>,</sup><sup>742</sup>
Beta-blockers reduce mortality in HFrEF patients with moderate (eGFR
45–59 mL/min/1.73 m²) and moderately severe (eGFR 30–44 mL/min/1.73 m²)
renal dysfunction, whereas limited evidence is available regarding
patients with severe renal impairment (eGFR &lt;30 mL/min/1.73
m²).<sup>743</sup> Sacubitril/valsartan, compared with enalapril, led to
a slower decline in renal function, despite a slight increase in the
urinary albumin/creatinine ratio, and improved CV outcomes to a similar
extent in patients with CKD vs. the others in PARADIGM-HF.<sup>127</sup>
SGLT2 inhibitors lead to a slower decline in renal function, compared
with placebo, both in patients with HFrEF and in those with
CKD.<sup>108</sup><sup>,</sup><sup>109</sup><sup>,</sup><sup>737</sup><sup>,</sup><sup>738</sup><sup>,</sup><sup>744</sup>
The improvement in cardiac output after CRT or LVAD implantation may be
associated with, at least, a transient improvement in renal
function.<sup>471</sup><sup>,</sup><sup>745</sup><sup>,</sup><sup>746</sup>
The benefits of ICDs may be reduced in patients with severe renal
dysfunction because of the competing risk of non-arrhythmic causes of
death.<sup>747–749</sup></p>
<p>There is little direct evidence to support any recommendations for
treatment of HF patients with severe CKD as to date, RCTs excluded
patients with advanced stages of CKD, i.e. eGFR &lt;30
mL/min/1.73 m<sup>2</sup><sup>,</sup><em>(<a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 23</a>)</em>. Cut-off values for inclusion were lower in recent
trials: 25 mL/min/1.73 m<sup>2</sup> in DAPA-CKD, 20 mL/min/1.73 m² in
EMPEROR-Reduced and GALACTIC-HF, and 15 mL/min/1.73 m<sup>2</sup> in
VICTORIA,
respectively.<sup>109</sup><sup>,</sup><sup>141</sup><sup>,</sup><sup>737</sup><sup>,</sup><sup>738</sup><sup>,</sup><sup>750</sup>
Despite differences in baseline characteristics between patients with
severely impaired renal function and the others, no interaction between
drug effects and renal function was noted in subgroup analysis of these
trials.<sup>109</sup><sup>,</sup><sup>141</sup><sup>,</sup><sup>738</sup><sup>,</sup><sup>750</sup></p>
<h3
>13.7
Electrolyte disorders: hypokalaemia, hyperkalaemia, hyponatraemia,
hypochloraemia</h3>
<p>Electrolyte disturbances are frequent in patients with HF and may
often be iatrogenic.<sup>751</sup> Serum potassium levels have a
U-shaped relation with mortality with the lowest risk of death within a
relatively narrow range of 4 to 5 mmol/L.<sup>752–758</sup></p>
<p>Hypokalaemia is defined as serum potassium &lt;3.5 mmol/L and may
occur in up to 50% of patients with HF.<sup>759</sup> Hypokalaemia is
often induced by loop and thiazide diuretic administration. It may cause
lethal ventricular arrhythmias and increase CV mortality. Its treatment
includes the use of RAAS inhibitors, potassium-sparing diuretics, and
prescription of oral potassium supplements (i.e. potassium chloride
tablets). When oral administration is not possible, potassium
supplementation by infusion may be necessary (20 to 40 mmol of potassium
in 250–1000 mL of normal saline). Potassium-rich solution should be
infused at slow rate through a large vein using a venous catheter.</p>
<p>Hyperkalaemia is defined as serum potassium &gt;5 mmol/L and can be
classified as mild (&gt;5.0 to &lt;5.5 mmol/L), moderate (5.5 to 6.0
mmol/L), or severe (&gt;6.0 mmol/L).<sup>760</sup> It is associated with
an increased risk of hospitalization and
death.<sup>752</sup><sup>,</sup><sup>753</sup><sup>,</sup><sup>755</sup><sup>,</sup><sup>756</sup><sup>,</sup><sup>761</sup><sup>,</sup><sup>762</sup>
Hyperkalaemia can be associated with the administration of RAAS
inhibitors, CKD and increased absorption.<sup>760</sup> Among patients
with HF, the prevalence of hyperkalaemia at any given time among
patients with HF appears to be less than 5%,<sup>757</sup> but the
incidence is much higher, at up to 40% in chronic HF and 73% in CKD over
follow-up durations of approximately 1
year.<sup>753</sup><sup>,</sup><sup>756</sup><sup>,</sup><sup>757</sup><sup>,</sup><sup>763–765</sup>
In PARADIGM-HF, treatment with sacubitril/valsartan was associated with
lower risk of severe hyperkalaemia, compared with
enalapril.<sup>128</sup> Life-threatening hyperkalaemia requires
immediate treatment with a combination of calcium carbonate and/or
sodium bicarbonate, insulin, with or without glucose, and beta
adrenoceptor agonists [e.g. salbutamol, off-label use in some European
Union (EU) countries]. These agents favour potassium entry into the
cells and do not increase potassium excretion. Thus, they only provide
temporary benefit and rebound hyperkalaemia can occur after few hours.
Loop diuretics can be administered to facilitate potassium loss.</p>
<p>Potassium binders bind to potassium in the gastrointestinal tract
reducing its absorption. They can be used for acute and chronic
potassium lowering. They include sodium polystyrene sulfonate, calcium
polystyrene sulfonate, and the much better tolerated patiromer sorbitex
calcium and sodium zirconium cyclosilicate (SZC). Sodium polystyrene
sulfonate is still indicated in anuric or severely oliguric patients,
but it should not be used in the medium or long term as it may cause
severe gastrointestinal side effects, including bowel
necrosis.<sup>760</sup> Patiromer or SZC increase faecal potassium
excretion and act mainly in the colon. Both compounds are effective in
normalizing elevated potassium levels, maintaining normokalaemia over
time and preventing the recurrence of hyperkalaemia and can be
considered for treatment of hyperkalaemia<sup>766–768</sup> (see <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 24</a></em>).</p>
<p>Renal dysfunction and hyperkalaemia are the major causes of underuse
of RAAS inhibitors, particularly MRA, in clinical
practice.<sup>342</sup><sup>,</sup><sup>753</sup><sup>,</sup><sup>758</sup><sup>,</sup><sup>769–771</sup>
Administration of the potassium-lowering agents, patiromer or SZC, may
allow their initiation or uptitration in a larger proportion of
patients. This hypothesis was tested in double-blind,
placebo-controlled, randomized trials with patiromer or placebo
administration to patients with CKD and hyperkalaemia, or
discontinuation of RAAS inhibitors for hyperkalaemia, and with an
indication for spironolactone for HF and/or resistant hypertension.
Patiromer was more likely to lower serum potassium and decreased
episodes of hyperkalaemia than spironolactone initiation and
uptitration.<sup>772–775</sup> The ongoing RCT DIAMOND (NCT03888066) is
testing the impact on clinical outcomes of a strategy based on patiromer
administration, compared with placebo, in patients with HFrEF who are
hyperkalaemic while on RAAS inhibitors or with a history of
hyperkalaemia with subsequent reduction or discontinuation of a RAAS
inhibitor<sup>776</sup><sup>,</sup><sup>777</sup> (see <em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 13</a>.1</em>).</p>
<p>Hyponatraemia is defined as a serum sodium concentration lower than
136 mmol/L. It is common in HF and may be present in up to 30% of
patients admitted to hospital with HF. It reflects neurohormonal
activation and is a powerful independent marker of poor outcomes in
patients with acute or chronic
HF.<sup>778</sup><sup>,</sup><sup>779</sup></p>
<p>Severe hyponatraemia may cause neurologic symptoms (seizures,
obtundation, delirium) due to cerebral oedema and may require immediate
treatment with hypertonic saline with serum sodium increases by 1–2
mmol/L per hour, though less than 8 mmol/L in 24 h as a more rapid
correction increases the risk of myelinolysis. Intravenous treatment is
not required when hyponatraemia is less severe, e.g. &gt;124 mmol/L, and
in the absence of symptoms. As the pathogenesis of hyponatraemia in HF
is dilutional, e.g. caused by water retention induced by increased
vasopressin secretion, treatment is based on water restriction or
vasopressin antagonists. Fluid restrictions to less than 800–1000 mL/day
may be indicated to achieve a negative water balance and treat
hyponatraemia. Water restriction was associated with improved QOL in a
small, randomized study but with only slight increases in serum sodium
in an observational registry.<sup>780</sup><sup>,</sup><sup>781</sup>
Tolvaptan, an orally active selective arginine vasopressin V2 receptor
antagonist, can be considered to increase serum sodium and diuresis in
patients with persistent hyponatraemia and congestion. However, no
effects on outcomes have been shown in RCTs<sup>782–785</sup> (see
<em><a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
text 13</a>.1</em>). The infusion of hypertonic saline combined with
loop diuretics was associated with an increase in serum sodium levels
and greater diuretic efficacy in small trials and observational
studies.<sup>786–788</sup></p>
<p>Hypochloraemia (&lt;96 mmol/L) is a powerful independent predictor of
mortality in patients with acute and chronic
HF.<sup>439</sup><sup>,</sup><sup>789–792</sup> Serum chloride may have
a direct role in the control of renin secretion and the response to loop
or thiazide diuretics.<sup>439</sup><sup>,</sup><sup>793</sup> The
carbonic anhydrase inhibitor acetazolamide increases chloride
reabsorption causing a greater bicarbonate and sodium excretion in the
proximal tubule of the nephron. It can increase serum chloride levels
and diuresis in patients with severe HF at risk of diuretic
resistance.<sup>145</sup><sup>,</sup><sup>794</sup> It is currently
being tested in a multicentre randomized study in decompensated
HF.<sup>469</sup></p>
<h3 >13.8 Lung disease,
sleep-disordered breathing</h3>
<p>Overall, COPD affects about 20% of patients with HF and has a major
impact on symptoms and
outcomes.<sup>795</sup><sup>,</sup><sup>–</sup><sup>797</sup> Due to the
overlap in symptoms and signs, the differentiation between HF and COPD
may be difficult. Pulmonary function testing with spirometry is
recommended as the first diagnostic tool and should be considered in
patients with suspected COPD. For adequate interpretation, it should be
performed in stable and euvolaemic patients to avoid congestion related
to obstructive pulmonary function patterns. If there is uncertainty
about the reversibility of airflow obstruction, pneumology referral for
more sophisticated tests (bronchodilatatory test, bronchial provocation
tests, diffusion capacity) is
warranted.<sup>798</sup><sup>,</sup><sup>799</sup></p>
<p>Treatment of HF is generally well tolerated in COPD.<sup>800</sup>
Beta-blockers can worsen pulmonary function in individual patients but
are not contraindicated in either COPD or asthma, as stated in the
Global initiative for chronic Obstructive Lung Disease (GOLD) and the
Global INitiative for Asthma (GINA),
respectively.<sup>801</sup><sup>,</sup><sup>802</sup> GINA states that
asthma should not be regarded as an absolute contraindication to the use
of cardioselective beta-blockers (bisoprolol, metoprolol succinate, or
nebivolol) with consideration of relative risks and benefits. In
clinical practice, starting with low doses of cardioselective
beta-blockers combined with close monitoring for signs of airway
obstruction (wheezing, shortness of breath with lengthening of the
expiration) should be encouraged. Although not tested in HF patients,
inhaled corticosteroids and beta-adrenergic agonists do not seem to
increase CV events, including HF, in patients at high
risk.<sup>803</sup><sup>,</sup><sup>804</sup> Moreover, optimal COPD
management can improve cardiac function.<sup>805</sup></p>
<p>Sleep-disordered breathing occurs in more than one third of patients
with HF and is even more prevalent in patients with AHF. The most common
types are: central sleep apnoea (CSA, similar to Cheyne-Stokes
respiration), OSA, and a mixed pattern of the two. CSA and OSA have been
shown to be associated with a worse prognosis in HF. OSA is associated
with an increased risk of incident HF in men. CSA is the most common
form of sleep-disordered breathing in HFrEF and HFmrEF is the most
common cause of CSA.<sup>806</sup><sup>,</sup><sup>807</sup></p>
<p>Patients with HF can be investigated for sleep-disordered breathing.
History taking should involve partners. Questionnaires are instrumental
in identifying patients at risk. Home monitoring can usually identify
and distinguish the type of sleep apnoea. However, overnight
polysomnography remains the definitive investigation.<sup>807</sup> The
use of adaptive servo-ventilation in patients with HFrEF and
predominantly CSA is not recommended, based on the results of SERVE-HF,
which was neutral regarding the composite primary endpoint of death from
any cause or lifesaving CV intervention, but showed an increase in both
all-cause mortality and CV mortality with adaptive
servo-ventilation.<sup>808</sup> Transvenous phrenic nerve stimulation
was tested in a prospective, multicentre, randomized trial involving 151
patients with CSA.<sup>809</sup> The primary efficacy endpoint was the
reduction of the apnoea-hypopnoea index from baseline to 6 months and
was achieved by a larger percentage of patients with the active
treatment. Other measurements of sleep quality and QOL were improved and
no difference in any safety endpoint was found between active treatment
and control.<sup>809</sup> Similar results were observed in the 96
patients with HF.<sup>810</sup></p>
<p>Patients with HFrEF being considered for a sleep-disordered breathing
treatment with positive pressure airway mask must undergo formal sleep
study to document the predominant type of sleep apnoea (central
vs. obstructive). When sleep-disordered breathing is caused by OSA,
nocturnal hypoxaemia can be treated with nocturnal oxygen
supplementation, continuous positive airway pressure, bi-level positive
airway pressure, and adaptive servo-ventilation. However, none of these
interventions has been shown to have beneficial effects on outcomes in
HF.<sup>807</sup> When sleep-disordered breathing is caused by CSA,
positive pressure airway masks are contraindicated in HFrEF
patients.<sup>808</sup> In these patients, implantable phrenic nerve
stimulation can be considered for symptomatic relief.</p>
<h3 >13.9
Hyperlipidaemia and lipid-modifying therapy</h3>
<p>Two large RCTs, including mainly patients with HFrEF, as well as a
meta-analysis of 24 RCTs, showed no benefit of statin treatment on CV
mortality or stroke in patients with
HFrEF.<sup>811</sup><sup>,</sup><sup>812</sup> A reduction in HF
hospitalizations as well as a small reduction in MI was observed in a
meta-analysis of the CORONA and GISSI-HF trials.<sup>813–815</sup> Based
on current evidence, routine administration of statins in patients with
HF without other indications for their use (e.g. CAD) is not
recommended. Because there is no evidence of harm in patients on statin
treatment after the occurrence of HF, there is no need for statin
discontinuation for patients already treated.</p>
<h3 >13.10 Gout and arthritis</h3>
<p>Hyperuricemia is a common finding in patients with CHF with a
prevalence up to 50%.<sup>816</sup><sup>,</sup><sup>817</sup>
Hyperuricemia may be caused or aggravated by diuretic treatment and it
is related to symptoms, exercise capacity, severity of diastolic
dysfunction and long-term
prognosis.<sup>817</sup><sup>,</sup><sup>818</sup> For every 1 mg/dL
increase in serum uric acid levels the risk of all-cause mortality and
of HF hospitalization increases by 4% and 28%,
respectively.<sup>819</sup> Both febuxostat and allopurinol reduce uric
acid levels. However, allopurinol was associated with a lower rate of
all-cause death and CV death, compared with febuxostat, in a
prospective, multicentre, double-blind, non-inferiority trial enrolling
6190 patients with gout and CV disease, 20% with HF, with a median
follow-up of 32 months.<sup>820</sup> Allopurinol is therefore
recommended as the first-choice urate-lowering drug in HF patients with
no contraindication. There is no evidence that uric acid-lowering
treatment has beneficial effects on LV function, symptoms or outcomes of
patients with HF.<sup>821–823</sup></p>
<p>With respect to treatment of acute gout attacks, non-steroidal
anti-inflammatory drugs (NSAIDs) can worsen renal function and
precipitate acute HF decompensation. Colchicine should be preferred as
it is associated with less side effects.<sup>824</sup> However, it, too,
should be used with caution in patients with severe renal dysfunction
and is contraindicated in patients on dialysis. An increase in
ventricular vulnerability was shown in experimental
models.<sup>825</sup></p>
<p>Arthritis is a common comorbidity and is a common cause of both
self-taken and prescribed NSAIDs. These agents are relatively
contraindicated as they may precipitate acute decompensation in patients
with HF.<sup>826</sup> Rheumatoid arthritis is associated with a two- to
three-fold increase in the risk of HF and this increased risk is
independent of ischaemic heart disease, suggesting a direct role in HF
pathophysiology.<sup>827</sup><sup>,</sup><sup>828</sup> The safety of
disease-modifying drugs used for the treatment of rheumatoid arthritis
has not been established in HF. High doses of anti-tumour necrosis
factor alpha agents were associated with worsening HF in initial trials
and should be used with caution. No adverse effects were noted with
lower doses.<sup>829–831</sup></p>
<h3 >13.11 Erectile dysfunction</h3>
<p>Erectile dysfunction is a serious problem in HF patients due to its
association with CV risk factors, comorbidities (e.g. diabetes),
life-style (e.g. inactivity), and treatment (e.g. drugs).<sup>832</sup>
In the general population, the prevalence of erectile dysfunction is
estimated to be 50% in men aged ≥60, but erectile dysfunction can be
present in up to 81% of cardiac patients across different cultures and
ethnic groups.<sup>833</sup> Optimal assessment should include both
questions assessing the presence of erectile dysfunction and factors
that can be related to erectile dysfunction. Numerous classes of CV
drugs, particularly diuretics and beta-blockers, have been implicated
causing erectile dysfunction. However, the relationships between many
contemporary CV drugs and erectile dysfunction is not
clear.<sup>834</sup> For the treatment of erectile dysfunction,
phosphodiesterase type 5 inhibitors are generally safe and effective in
patients with compensated HF.<sup>834</sup><sup>,</sup><sup>835</sup> No
studies have shown one agent to be more effective or safer than the
others. However, phosphodiesterase type 5 inhibitors should not be used
in patients receiving nitrates and nitrates should not be administered
to patients within 24 h of sildenafil or vardenafil administration or
within 48 h of tadalafil administration.<sup>834</sup></p>
<h3 >13.12 Depression</h3>
<p>Depression affects 20% of patients with HF and is severe in half of
them. Its occurrence is higher in women and it is associated with worse
clinical status and a poor
prognosis.<sup>836</sup><sup>,</sup><sup>–</sup><sup>838</sup> Screening
using a validated questionnaire is recommended when there is a clinical
suspicion of depression. The Beck Depression Inventory and Cardiac
Depression Scale are the tools formally validated for the assessment of
depression in patients with HF. Other questionnaires (e.g. Geriatric
Depression Scale, Hamilton Depression Scale, Hospital Anxiety and
Depression Scale) can also be
used.<sup>837</sup><sup>,</sup><sup>838</sup></p>
<p>There is still no consensus on the best therapy for HF patients with
depression. Psychosocial intervention may improve depressive symptoms
but has no effect on prognosis of depressed patients with
HF.<sup>839</sup> Depressive symptoms may improve with selective
serotonin reuptake inhibitors but trials specifically designed to assess
the effect of these drugs in patients with HF and depression have failed
to show any significant benefit over placebo on both symptoms and
outcomes.<sup>840</sup><sup>,</sup><sup>841</sup> Interestingly,
patients improved also in the placebo arm showing the importance of
better care in these patients. Both trials showed the safety of
sertraline and escitalopram,
respectively.<sup>840</sup><sup>,</sup><sup>841</sup> Tricyclic
antidepressants should be avoided for the treatment of depression in HF
as they may cause hypotension, worsening HF, and
arrhythmias.<sup>837</sup><sup>,</sup><sup>838</sup></p>
<h3 >13.13 Cancer</h3>
<p>HF occurs in patients with cancer as a result of the interaction
among anticancer therapy, cancer itself, and patients’ CV background
(risk factors and coexisting CV disease).<sup>842–846</sup> Several
anticancer therapies may cause HF directly, thorough their cardiotoxic
effects (<em>Table 23</em>), or, indirectly, through other mechanisms,
such as myocarditis, ischaemia, systemic or pulmonary hypertension,
arrhythmias or valve
disease.<sup>844</sup><sup>,</sup><sup>845</sup><sup>,</sup><sup>847–852</sup>
HF, in turn, may affect cancer outcomes by depriving patients of
effective anticancer therapies.<sup>699</sup> Some epidemiological and
experimental evidence suggests a further reciprocal interaction between
cancer and HF with some, though not all, studies showing a higher
incidence rate of cancer in patients with HF.<sup>853–858</sup></p>
<p>Table 23</p>
<p>Cancer drugs causing heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Cancer therapy</strong> 
</td>
<td>
<strong>Indication</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Anthracycline chemotherapy</strong>
</p>
</li>
<li>
<p>
(doxorubicin, epirubicin, daunorubicin, idarubicin)
</p>
</li>
</ul>
 
</td>
<td>
Breast cancer, lymphoma, acute leukaemia, sarcoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>HER2-targeted therapies</strong>
</p>
</li>
<li>
<p>
(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib,
neratinib,
</p>
</li>
<li>
<p>
tucatinib)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
HER2+ breast cancer
</p>
</li>
<li>
<p>
HER2+ gastric cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>VEGF inhibitors</strong>
</p>
</li>
<li>
<p>
TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib,
cabozantinib, regorafenib, lenvatinib, vandetinib) and antibodies
(bevacizumab, ramucirumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon
cancer, sarcoma, GIST
</p>
</li>
<li>
<p>
Antibodies: breast cancer, ovarian cancer, gastric cancer,
gastro-oesophageal cancer, colon cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Multi-targeted kinase inhibitors:</strong>
</p>
</li>
<li>
<p>
second and third generation BCR-ABL TKIs (ponatinib, nilotinib,
dasatinib, bosutinib)
</p>
</li>
</ul>
 
</td>
<td>
Chronic myeloid leukaemia 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Proteasome inhibitors</strong>
</p>
</li>
<li>
<p>
(carfilzomib, bortezomib, ixazomib)
</p>
</li>
<li>
<p>
<strong>Immunomodulatory drugs</strong>
</p>
</li>
<li>
<p>
(lenalidomide, pomalidomide)
</p>
</li>
</ul>
 
</td>
<td>
Multiple myeloma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Combination RAF and MEK inhibitors</strong>
</p>
</li>
<li>
<p>
(dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+
binimetinib)
</p>
</li>
</ul>
 
</td>
<td>
RAF mutant melanoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Androgen deprivation therapies</strong>
</p>
</li>
<li>
<p>
GnRH agonists (goserelin, leuprorelin)
</p>
</li>
<li>
<p>
Antiandrogrens (abiraterone)
</p>
</li>
</ul>
 
</td>
<td>
Prostate cancer, breast cancer 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Immune checkpoint inhibitors:</strong>
</p>
</li>
<li>
<p>
anti-programmed cell death 1 inhibitors
</p>
</li>
<li>
<p>
(nivolumab, pembrolizumab)
</p>
</li>
<li>
<p>
anti-cytotoxic T-lymphocyte-associated
</p>
</li>
<li>
<p>
protein 4 inhibitor (ipilimumab)
</p>
</li>
<li>
<p>
anti-programmed death-ligand 1 inhibitors
</p>
</li>
<li>
<p>
(avelumab, atezolizumab, durvalumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
Melanoma (metastatic and adjuvant)
</p>
</li>
<li>
<p>
Metastatic renal cancer, non-small cell lung cancer, small cell lung
cancer, refractory Hodgkin’s lymphoma, metastatic triple negative breast
cancer, metastatic urothelial cancer, liver cancer, MMR-deficient cancer
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Cancer therapy</strong> 
</td>
<td>
<strong>Indication</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Anthracycline chemotherapy</strong>
</p>
</li>
<li>
<p>
(doxorubicin, epirubicin, daunorubicin, idarubicin)
</p>
</li>
</ul>
 
</td>
<td>
Breast cancer, lymphoma, acute leukaemia, sarcoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>HER2-targeted therapies</strong>
</p>
</li>
<li>
<p>
(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib,
neratinib,
</p>
</li>
<li>
<p>
tucatinib)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
HER2+ breast cancer
</p>
</li>
<li>
<p>
HER2+ gastric cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>VEGF inhibitors</strong>
</p>
</li>
<li>
<p>
TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib,
cabozantinib, regorafenib, lenvatinib, vandetinib) and antibodies
(bevacizumab, ramucirumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon
cancer, sarcoma, GIST
</p>
</li>
<li>
<p>
Antibodies: breast cancer, ovarian cancer, gastric cancer,
gastro-oesophageal cancer, colon cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Multi-targeted kinase inhibitors:</strong>
</p>
</li>
<li>
<p>
second and third generation BCR-ABL TKIs (ponatinib, nilotinib,
dasatinib, bosutinib)
</p>
</li>
</ul>
 
</td>
<td>
Chronic myeloid leukaemia 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Proteasome inhibitors</strong>
</p>
</li>
<li>
<p>
(carfilzomib, bortezomib, ixazomib)
</p>
</li>
<li>
<p>
<strong>Immunomodulatory drugs</strong>
</p>
</li>
<li>
<p>
(lenalidomide, pomalidomide)
</p>
</li>
</ul>
 
</td>
<td>
Multiple myeloma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Combination RAF and MEK inhibitors</strong>
</p>
</li>
<li>
<p>
(dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+
binimetinib)
</p>
</li>
</ul>
 
</td>
<td>
RAF mutant melanoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Androgen deprivation therapies</strong>
</p>
</li>
<li>
<p>
GnRH agonists (goserelin, leuprorelin)
</p>
</li>
<li>
<p>
Antiandrogrens (abiraterone)
</p>
</li>
</ul>
 
</td>
<td>
Prostate cancer, breast cancer 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Immune checkpoint inhibitors:</strong>
</p>
</li>
<li>
<p>
anti-programmed cell death 1 inhibitors
</p>
</li>
<li>
<p>
(nivolumab, pembrolizumab)
</p>
</li>
<li>
<p>
anti-cytotoxic T-lymphocyte-associated
</p>
</li>
<li>
<p>
protein 4 inhibitor (ipilimumab)
</p>
</li>
<li>
<p>
anti-programmed death-ligand 1 inhibitors
</p>
</li>
<li>
<p>
(avelumab, atezolizumab, durvalumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
Melanoma (metastatic and adjuvant)
</p>
</li>
<li>
<p>
Metastatic renal cancer, non-small cell lung cancer, small cell lung
cancer, refractory Hodgkin’s lymphoma, metastatic triple negative breast
cancer, metastatic urothelial cancer, liver cancer, MMR-deficient cancer
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>GIST = gastrointestinal stromal tumour; GnRH = gonadotropin-releasing
hormone; HER2 = human epidermal growth factor receptor 2;
MEK = mitogen-activated protein kinase; MMR = mismatch repair;
TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth
factor.</p>
<p>Table 23</p>
<p>Cancer drugs causing heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Cancer therapy</strong> 
</td>
<td>
<strong>Indication</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Anthracycline chemotherapy</strong>
</p>
</li>
<li>
<p>
(doxorubicin, epirubicin, daunorubicin, idarubicin)
</p>
</li>
</ul>
 
</td>
<td>
Breast cancer, lymphoma, acute leukaemia, sarcoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>HER2-targeted therapies</strong>
</p>
</li>
<li>
<p>
(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib,
neratinib,
</p>
</li>
<li>
<p>
tucatinib)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
HER2+ breast cancer
</p>
</li>
<li>
<p>
HER2+ gastric cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>VEGF inhibitors</strong>
</p>
</li>
<li>
<p>
TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib,
cabozantinib, regorafenib, lenvatinib, vandetinib) and antibodies
(bevacizumab, ramucirumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon
cancer, sarcoma, GIST
</p>
</li>
<li>
<p>
Antibodies: breast cancer, ovarian cancer, gastric cancer,
gastro-oesophageal cancer, colon cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Multi-targeted kinase inhibitors:</strong>
</p>
</li>
<li>
<p>
second and third generation BCR-ABL TKIs (ponatinib, nilotinib,
dasatinib, bosutinib)
</p>
</li>
</ul>
 
</td>
<td>
Chronic myeloid leukaemia 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Proteasome inhibitors</strong>
</p>
</li>
<li>
<p>
(carfilzomib, bortezomib, ixazomib)
</p>
</li>
<li>
<p>
<strong>Immunomodulatory drugs</strong>
</p>
</li>
<li>
<p>
(lenalidomide, pomalidomide)
</p>
</li>
</ul>
 
</td>
<td>
Multiple myeloma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Combination RAF and MEK inhibitors</strong>
</p>
</li>
<li>
<p>
(dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+
binimetinib)
</p>
</li>
</ul>
 
</td>
<td>
RAF mutant melanoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Androgen deprivation therapies</strong>
</p>
</li>
<li>
<p>
GnRH agonists (goserelin, leuprorelin)
</p>
</li>
<li>
<p>
Antiandrogrens (abiraterone)
</p>
</li>
</ul>
 
</td>
<td>
Prostate cancer, breast cancer 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Immune checkpoint inhibitors:</strong>
</p>
</li>
<li>
<p>
anti-programmed cell death 1 inhibitors
</p>
</li>
<li>
<p>
(nivolumab, pembrolizumab)
</p>
</li>
<li>
<p>
anti-cytotoxic T-lymphocyte-associated
</p>
</li>
<li>
<p>
protein 4 inhibitor (ipilimumab)
</p>
</li>
<li>
<p>
anti-programmed death-ligand 1 inhibitors
</p>
</li>
<li>
<p>
(avelumab, atezolizumab, durvalumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
Melanoma (metastatic and adjuvant)
</p>
</li>
<li>
<p>
Metastatic renal cancer, non-small cell lung cancer, small cell lung
cancer, refractory Hodgkin’s lymphoma, metastatic triple negative breast
cancer, metastatic urothelial cancer, liver cancer, MMR-deficient cancer
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Cancer therapy</strong> 
</td>
<td>
<strong>Indication</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Anthracycline chemotherapy</strong>
</p>
</li>
<li>
<p>
(doxorubicin, epirubicin, daunorubicin, idarubicin)
</p>
</li>
</ul>
 
</td>
<td>
Breast cancer, lymphoma, acute leukaemia, sarcoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>HER2-targeted therapies</strong>
</p>
</li>
<li>
<p>
(trastuzumab, pertuzumab, trastuzumab emtansine T-DM1, lapatinib,
neratinib,
</p>
</li>
<li>
<p>
tucatinib)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
HER2+ breast cancer
</p>
</li>
<li>
<p>
HER2+ gastric cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>VEGF inhibitors</strong>
</p>
</li>
<li>
<p>
TKIs (sunitinib, pazopanib, sorafenib, axitinib, tivozanib,
cabozantinib, regorafenib, lenvatinib, vandetinib) and antibodies
(bevacizumab, ramucirumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
VEGF TKIs: renal cancer, hepatocellular cancer, thyroid cancer, colon
cancer, sarcoma, GIST
</p>
</li>
<li>
<p>
Antibodies: breast cancer, ovarian cancer, gastric cancer,
gastro-oesophageal cancer, colon cancer
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Multi-targeted kinase inhibitors:</strong>
</p>
</li>
<li>
<p>
second and third generation BCR-ABL TKIs (ponatinib, nilotinib,
dasatinib, bosutinib)
</p>
</li>
</ul>
 
</td>
<td>
Chronic myeloid leukaemia 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Proteasome inhibitors</strong>
</p>
</li>
<li>
<p>
(carfilzomib, bortezomib, ixazomib)
</p>
</li>
<li>
<p>
<strong>Immunomodulatory drugs</strong>
</p>
</li>
<li>
<p>
(lenalidomide, pomalidomide)
</p>
</li>
</ul>
 
</td>
<td>
Multiple myeloma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Combination RAF and MEK inhibitors</strong>
</p>
</li>
<li>
<p>
(dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+
binimetinib)
</p>
</li>
</ul>
 
</td>
<td>
RAF mutant melanoma 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Androgen deprivation therapies</strong>
</p>
</li>
<li>
<p>
GnRH agonists (goserelin, leuprorelin)
</p>
</li>
<li>
<p>
Antiandrogrens (abiraterone)
</p>
</li>
</ul>
 
</td>
<td>
Prostate cancer, breast cancer 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Immune checkpoint inhibitors:</strong>
</p>
</li>
<li>
<p>
anti-programmed cell death 1 inhibitors
</p>
</li>
<li>
<p>
(nivolumab, pembrolizumab)
</p>
</li>
<li>
<p>
anti-cytotoxic T-lymphocyte-associated
</p>
</li>
<li>
<p>
protein 4 inhibitor (ipilimumab)
</p>
</li>
<li>
<p>
anti-programmed death-ligand 1 inhibitors
</p>
</li>
<li>
<p>
(avelumab, atezolizumab, durvalumab)
</p>
</li>
</ul>
 
</td>
<td>
<ul>
<li>
<p>
Melanoma (metastatic and adjuvant)
</p>
</li>
<li>
<p>
Metastatic renal cancer, non-small cell lung cancer, small cell lung
cancer, refractory Hodgkin’s lymphoma, metastatic triple negative breast
cancer, metastatic urothelial cancer, liver cancer, MMR-deficient cancer
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>GIST = gastrointestinal stromal tumour; GnRH = gonadotropin-releasing
hormone; HER2 = human epidermal growth factor receptor 2;
MEK = mitogen-activated protein kinase; MMR = mismatch repair;
TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth
factor.</p>
<p>The prevention of HF in patients with cancer undergoing potential
cardiotoxic therapies requires careful patient’s assessment and
management before, during, and after cancer therapy, preferably in the
context of an integrated Cardio-Oncology service
(<em>Figure 18</em>).<sup>845</sup><sup>,</sup><sup>859</sup><sup>,</sup><sup>860</sup>
A CV baseline risk assessment for all patients scheduled to receive
potentially cardiotoxic cancer therapies using the HFA-ICOS risk
assessment is advisable.<sup>846</sup> Baseline CV risk assessment forms
have been developed for different potentially cardiotoxic cancer
therapies. History of HF or CMP characterizes patients as being at very
high risk or at high risk for all cancer therapies, except anti-androgen
treatments for prostate cancer. An LVEF &lt;50% is an additional factor
for high-risk patients and elevated levels of NPs or troponin at
baseline are additional criteria of medium risk for most of the cancer
treatments.<sup>846</sup></p>
<p>During cancer treatment with potential cardiotoxic therapies, LV
systolic function can be monitored through echocardiography.
Chemotherapy should be reconsidered and treatment with an ACE-I and a
beta-blocker (preferably carvedilol) should be started in patients who
develop LV systolic dysfunction, defined as 10% or more absolute
reduction in LVEF to a value below
50%.<sup>844</sup><sup>,</sup><sup>861–864</sup> Global longitudinal
strain can detect cardiac dysfunction at an earlier
stage.<sup>865</sup><sup>,</sup><sup>866</sup> A ≥12% relative reduction
in global longitudinal strain was compared with an LVEF decline in a
prospective randomized trial in high-risk patients undergoing
potentially cardiotoxic chemotherapy. Compared to treatment based on
LVEF, treatment based on changes in global longitudinal strain led to
the same decrease in LVEF (primary endpoint) but with fewer patients who
developed cardiac dysfunction at the end of the study, thus suggesting
usefulness of global longitudinal strain for the early detection of
cardiotoxicity.<sup>867</sup> Promising results for the early detection
of cardiac dysfunction have also been obtained through monitoring of
biomarkers, such as NPs and
troponin.<sup>868</sup><sup>,</sup><sup>869</sup> Patients on
immunotherapy with immune checkpoint inhibitors are at increased risk of
myocarditis and should be monitored for related symptoms and signs and
by weekly assessment of cardiac troponin during at least the first 6
weeks of therapy and managed accordingly.<sup>870</sup></p>
<p>Timing of the imaging procedures and biomarkers assessment depend on
the anticancer treatment and patient’s risk profile
(<em>Figure 18</em>).<sup>865</sup> In general, all patients scheduled
for potential cardiotoxic therapies must undergo a baseline evaluation
that would define the level of risk for cardiotoxicity (low, medium, or
high) and the intensity of monitoring and follow-up during and after
cancer treatment.<sup>865</sup> Cancer survivors exposed to potentially
cardiotoxic therapies should be periodically monitored in the long term
as HF may develop several years after cancer
therapy.<sup>865</sup><sup>,</sup><sup>871</sup></p>
<p>Figure 18</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f18.jpeg?Expires=1689850107&amp;Signature=hADSftYLqAMPRy1oOKVVkTCOzPgh-TknEew1mxIuNDuvER8sFK0yoyC89czq8xxyYf4eY~sX8lmVgm1hAC3f6u7ZsmRZ4oruxsMlkMOrOtBmvFFHDMuriztHvRLRJCLxLt-Cgymg8PFkWssUMAVD~Ikij2TVi6RfJy7x7J5sePCyX~-Q2TGsWv1t1moDcGpYFPk4zESZALH52qq2VhyoocgxFwpVQqrbenfXHBoD~YSYJbj6Pguuj8vMnakJyEG32WOt5YF2Ad3jqpPJZaOT35KAgMfTGxyFAQi5Mq~7FoBpV9exK-n3kGytdlbJjDpFhkKTa24XOBtJdMWH4db6VA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of patients with cancer and heart failure. ECG = electrocardiogram; HER2 = human epidermal growth factor receptor 2; HF = heart failure; HFA = Heart Failure Association; ICOS = International Cardio-Oncology Society; MEK = mitogen-activated protein kinase; NP = natriuretic peptide; VEGF = vascular endothelial growth factor. aAnthracycline chemotherapy, trastuzumab and HER2 targeted therapies, VEGF inhibitors, proteasome inhibitors, combination RAF+MEK inhibitors. bLow, medium and high risk may be calculated using the HFA-ICOS baseline cardiovascular risk proformas.846cIncreased surveillance is intended between 1 and 4 weeks. dStandard surveillance is intended every 3 months. e5 yearly surveillance at follow-up = clinical review every 5 years with history, examination, NP and troponin levels, and echocardiogram.865" />
<figcaption aria-hidden="true">Management of patients with cancer and
heart failure. ECG = electrocardiogram; HER2 = human epidermal growth
factor receptor 2; HF = heart failure; HFA = Heart Failure Association;
ICOS = International Cardio-Oncology Society; MEK = mitogen-activated
protein kinase; NP = natriuretic peptide; VEGF = vascular endothelial
growth factor. aAnthracycline chemotherapy, trastuzumab and HER2
targeted therapies, VEGF inhibitors, proteasome inhibitors, combination
RAF+MEK inhibitors. bLow, medium and high risk may be calculated using
the HFA-ICOS baseline cardiovascular risk proformas.846cIncreased
surveillance is intended between 1 and 4 weeks. dStandard surveillance
is intended every 3 months. e5 yearly surveillance at
follow-up = clinical review every 5 years with history, examination, NP
and troponin levels, and echocardiogram.865</figcaption>
</figure>
<p>Management of patients with cancer and heart failure.
ECG = electrocardiogram; HER2 = human epidermal growth factor receptor
2; HF = heart failure; HFA = Heart Failure Association;
ICOS = International Cardio-Oncology Society; MEK = mitogen-activated
protein kinase; NP = natriuretic peptide; VEGF = vascular endothelial
growth factor. <sup>a</sup>Anthracycline chemotherapy, trastuzumab and
HER2 targeted therapies, VEGF inhibitors, proteasome inhibitors,
combination RAF+MEK inhibitors. <sup>b</sup>Low, medium and high risk
may be calculated using the HFA-ICOS baseline cardiovascular risk
proformas.<sup>846</sup><sup>,</sup><sup>c</sup>Increased surveillance
is intended between 1 and 4 weeks. <sup>d</sup>Standard surveillance is
intended every 3 months. <sup>e</sup>5 yearly surveillance at
follow-up = clinical review every 5 years with history, examination, NP
and troponin levels, and echocardiogram.<sup>865</sup></p>
<p>Recommendations for the management of patients with cancer and heart
failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table77.jpeg?Expires=1689850107&amp;Signature=NbqQ~-LmcVWgNHkmE1AfeHivCY~4~R48-Y8j7cR3gjax4Zdd0UfUKgM3OJYPY6iAfFHpTwUDCHb24RnPeQKkPBxX31X5cuyAEStbq8cYbJd4SRXEKluiMFfWe6iSRgkCe-e2TB~iyxTrTkBl9b-24Pbo7hD2pmLN6GQWDK~ZKIsFUbttn~GLOZC9GJSO0kK5N18-csXYbgYheM6fLsxLUVM-1orclvTktA2VHS-QYPBHwDgs2VLDrvcS9WzEtRbQYAWMwm86LsQ2QhU5nhNKEG0cSE9uCk-zslZga3WD8-uzJ~z~F3KPUmVhTqBEf5buUZWT~nLkXn6T9pXoLmYbEg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table77.jpeg?Expires=1689850107&amp;Signature=NbqQ~-LmcVWgNHkmE1AfeHivCY~4~R48-Y8j7cR3gjax4Zdd0UfUKgM3OJYPY6iAfFHpTwUDCHb24RnPeQKkPBxX31X5cuyAEStbq8cYbJd4SRXEKluiMFfWe6iSRgkCe-e2TB~iyxTrTkBl9b-24Pbo7hD2pmLN6GQWDK~ZKIsFUbttn~GLOZC9GJSO0kK5N18-csXYbgYheM6fLsxLUVM-1orclvTktA2VHS-QYPBHwDgs2VLDrvcS9WzEtRbQYAWMwm86LsQ2QhU5nhNKEG0cSE9uCk-zslZga3WD8-uzJ~z~F3KPUmVhTqBEf5buUZWT~nLkXn6T9pXoLmYbEg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>ACE-I = angiotensin-converting enzyme inhibitor; CV = cardiovascular;
LV = left ventricular; LVEF = left ventricular ejection fraction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the management of patients with cancer and heart
failure</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table77.jpeg?Expires=1689850107&amp;Signature=NbqQ~-LmcVWgNHkmE1AfeHivCY~4~R48-Y8j7cR3gjax4Zdd0UfUKgM3OJYPY6iAfFHpTwUDCHb24RnPeQKkPBxX31X5cuyAEStbq8cYbJd4SRXEKluiMFfWe6iSRgkCe-e2TB~iyxTrTkBl9b-24Pbo7hD2pmLN6GQWDK~ZKIsFUbttn~GLOZC9GJSO0kK5N18-csXYbgYheM6fLsxLUVM-1orclvTktA2VHS-QYPBHwDgs2VLDrvcS9WzEtRbQYAWMwm86LsQ2QhU5nhNKEG0cSE9uCk-zslZga3WD8-uzJ~z~F3KPUmVhTqBEf5buUZWT~nLkXn6T9pXoLmYbEg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table77.jpeg?Expires=1689850107&amp;Signature=NbqQ~-LmcVWgNHkmE1AfeHivCY~4~R48-Y8j7cR3gjax4Zdd0UfUKgM3OJYPY6iAfFHpTwUDCHb24RnPeQKkPBxX31X5cuyAEStbq8cYbJd4SRXEKluiMFfWe6iSRgkCe-e2TB~iyxTrTkBl9b-24Pbo7hD2pmLN6GQWDK~ZKIsFUbttn~GLOZC9GJSO0kK5N18-csXYbgYheM6fLsxLUVM-1orclvTktA2VHS-QYPBHwDgs2VLDrvcS9WzEtRbQYAWMwm86LsQ2QhU5nhNKEG0cSE9uCk-zslZga3WD8-uzJ~z~F3KPUmVhTqBEf5buUZWT~nLkXn6T9pXoLmYbEg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>ACE-I = angiotensin-converting enzyme inhibitor; CV = cardiovascular;
LV = left ventricular; LVEF = left ventricular ejection fraction.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h3 >13.14 Infection</h3>
<p>Infective disorders may worsen HF symptoms and be a precipitant
factor for AHF.<sup>872</sup><sup>,</sup><sup>873</sup> Severe sepsis
and pneumonia can cause myocardial injury and depress cardiac function
leading to cardiac dysfunction and HF and this risk is greater in
patients with a history of HF.<sup>873–875</sup> More recently, the
coronavirus disease 2019 (COVID-19) pandemic has emerged as a major
cause of morbidity and mortality as well as of HF
decompensation.<sup>873</sup><sup>,</sup><sup>876–878</sup> Specific
guidance is available.<sup>879</sup> General recommendations related to
infections are given in <em>Table 24</em>.</p>
<p>Influenza vaccination is associated with a reduced risk of all-cause
death in patients with HF in observational studies and retrospective
analyses.<sup>880–882</sup> Influenza and pneumococcal vaccination, as
well as COVID-19 vaccination, when available, should be considered in
patients with HF.<sup>879</sup><sup>,</sup><sup>883</sup></p>
<p>Table 24</p>
<p>Infections in patients with heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
Patients with HF are at increased risk of infections and have poorer
outcomes once infected. 
</td>
</tr>
<tr>
<td>
Telemonitoring avoids the risks of infections caused by close contact.
It is useful during pandemic conditions. 
</td>
</tr>
<tr>
<td>
Telemonitoring may be implemented for patients’ follow-up in pandemic
conditions. 
</td>
</tr>
<tr>
<td>
During pandemics, HF patients should be screened for infection at the
time of hospitalization, in case of urgent admissions, or before
elective hospitalizations. 
</td>
</tr>
<tr>
<td>
Careful assessment of fluid status, in addition to clinical signs of HF,
is mandatory during hospitalization in patients with concomitant sepsis.
Repeated measures of inferior vena cava diameter and collapsibility by
echocardiography may be used to assess fluid status. 
</td>
</tr>
<tr>
<td>
OMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2
inhibitors), should be continued in chronic HF patients whenever BP and
haemodynamic conditions permit and considering drug interaction with
infection related therapies and side effect profile. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Patients with HF are at increased risk of infections and have poorer
outcomes once infected. 
</td>
</tr>
<tr>
<td>
Telemonitoring avoids the risks of infections caused by close contact.
It is useful during pandemic conditions. 
</td>
</tr>
<tr>
<td>
Telemonitoring may be implemented for patients’ follow-up in pandemic
conditions. 
</td>
</tr>
<tr>
<td>
During pandemics, HF patients should be screened for infection at the
time of hospitalization, in case of urgent admissions, or before
elective hospitalizations. 
</td>
</tr>
<tr>
<td>
Careful assessment of fluid status, in addition to clinical signs of HF,
is mandatory during hospitalization in patients with concomitant sepsis.
Repeated measures of inferior vena cava diameter and collapsibility by
echocardiography may be used to assess fluid status. 
</td>
</tr>
<tr>
<td>
OMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2
inhibitors), should be continued in chronic HF patients whenever BP and
haemodynamic conditions permit and considering drug interaction with
infection related therapies and side effect profile. 
</td>
</tr>
</tbody>
</table>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; BP = blood pressure; HF = heart failure;
MRA = mineralocorticoid receptor antagonist; OMT = optimal medical
therapy; SGLT2 = sodium-glucose co-transporter 2.</p>
<p>Table 24</p>
<p>Infections in patients with heart failure</p>
<table role="presentation">
<tbody>
<tr>
<td>
Patients with HF are at increased risk of infections and have poorer
outcomes once infected. 
</td>
</tr>
<tr>
<td>
Telemonitoring avoids the risks of infections caused by close contact.
It is useful during pandemic conditions. 
</td>
</tr>
<tr>
<td>
Telemonitoring may be implemented for patients’ follow-up in pandemic
conditions. 
</td>
</tr>
<tr>
<td>
During pandemics, HF patients should be screened for infection at the
time of hospitalization, in case of urgent admissions, or before
elective hospitalizations. 
</td>
</tr>
<tr>
<td>
Careful assessment of fluid status, in addition to clinical signs of HF,
is mandatory during hospitalization in patients with concomitant sepsis.
Repeated measures of inferior vena cava diameter and collapsibility by
echocardiography may be used to assess fluid status. 
</td>
</tr>
<tr>
<td>
OMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2
inhibitors), should be continued in chronic HF patients whenever BP and
haemodynamic conditions permit and considering drug interaction with
infection related therapies and side effect profile. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
Patients with HF are at increased risk of infections and have poorer
outcomes once infected. 
</td>
</tr>
<tr>
<td>
Telemonitoring avoids the risks of infections caused by close contact.
It is useful during pandemic conditions. 
</td>
</tr>
<tr>
<td>
Telemonitoring may be implemented for patients’ follow-up in pandemic
conditions. 
</td>
</tr>
<tr>
<td>
During pandemics, HF patients should be screened for infection at the
time of hospitalization, in case of urgent admissions, or before
elective hospitalizations. 
</td>
</tr>
<tr>
<td>
Careful assessment of fluid status, in addition to clinical signs of HF,
is mandatory during hospitalization in patients with concomitant sepsis.
Repeated measures of inferior vena cava diameter and collapsibility by
echocardiography may be used to assess fluid status. 
</td>
</tr>
<tr>
<td>
OMT (including beta-blocker, ACE-I, ARB or ARNI, MRA and SGLT2
inhibitors), should be continued in chronic HF patients whenever BP and
haemodynamic conditions permit and considering drug interaction with
infection related therapies and side effect profile. 
</td>
</tr>
</tbody>
</table>
<p>ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin-receptor blocker; ARNI = angiotensin
receptor-neprilysin inhibitor; BP = blood pressure; HF = heart failure;
MRA = mineralocorticoid receptor antagonist; OMT = optimal medical
therapy; SGLT2 = sodium-glucose co-transporter 2.</p>
<h2 >14 Special conditions</h2>
<h3 >14.1 Pregnancy</h3>
<h4 >14.1.1 Pregnancy in
pre-existing heart failure</h4>
<p>Women with pre-existing HF have a higher risk of pregnancy-related CV
complications including HF decompensation. Moderate- and high-risk
patients according to the modified World Health Organization (mWHO)
class III–IV should be referred to a specialist centre with a
multidisciplinary Pregnancy Heart Team.<sup>884</sup> An algorithm for
the management of HF patients before and during pregnancy is reported in
<em>Figure 19</em>.</p>
<p>Pre-pregnancy management includes the modification of existing HF
medications to avoid foetal harm. ACE-Is, ARBs, ARNI, MRAs, ivabradine,
and SGLT2 inhibitors are contraindicated and should be stopped prior to
conception with close clinical and echocardiographic monitoring.
Beta-blockers should be continued and switched to beta-1-selective
blockers (bisoprolol, metoprolol succinate). Hydralazine, oral nitrates
and methyldopa can be started if required. Therapeutic anticoagulation
with low-molecular-weight heparin (LMWH), in the first and last
trimesters, and VKAs, with the usual target international normalized
ratios (INRs) or LMWH for the second trimester, is recommended for
patients with HF and AF. DOACs should be avoided.<sup>884</sup></p>
<p>Assessment of patients with HF in pre-pregnancy or at presentation
with a new pregnancy should include a clinical assessment (symptoms,
clinical examination, BP, SaO<sub>2</sub>), ECG and resting
echocardiography. The modalities of delivery should be planned by
cardiologists, obstetricians, and anaesthesiologists around 35 weeks in
a multidisciplinary Pregnancy Heart Team. Bimonthly assessments for
women in mWHO II–III, and monthly assessments for women with
pre-existing HF in mWHO III, must be performed. Women with advanced HF
(LVEF &lt;30%, NYHA class III–IV) in mWHO IV who are pregnant can be
referred to a specialist centre for counselling regarding any
consideration of termination of pregnancy. The decision regarding
modalities of delivery can be planned by cardiologists, obstetricians,
and anaesthesiologists around 35 weeks in a multidisciplinary Pregnancy
Heart Team and discussed with the patient.<sup>884</sup></p>
<p>Figure 19</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f19.jpeg?Expires=1689850107&amp;Signature=S0eUrKlclJ5S~7BN~wdYa5lUuS1RawlSt4EGc0sLyk~7T4iEXlkbYMWymqCGDNq1tElmtR-wdl-rPAVfFlelau2JqkptgeXSc62lIE~eotcEhumGncZNeTnb4-2DcULWg37wq~yMN2PRr7-z5umq-MzaN-WQ7GOpMskkSj3jA7CS47i87LqEuUkWbTJJIxfnEqUtNpZhR7dd3LC6LAbIR39IXtsTlIum~hEtBBRmQ5ZFuFSQIT5JZ-ebiZi4hS8NWkpeAV9lRSFnU-WEhQ5Z5AjmSddf0g7bwCj-k~~WsEejGY82dXh5LqqymEymuboanPMPQvfLPTniYwKaramJJg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of patients with heart failure before and during pregnancy. ECG = electrocardiogram; HF = heart failure; mWHO = modified World Health Organization. aAdvice regarding contraception, HF medication, to contact HF specialist when planning pregnancy." />
<figcaption aria-hidden="true">Management of patients with heart failure
before and during pregnancy. ECG = electrocardiogram; HF = heart
failure; mWHO = modified World Health Organization. aAdvice regarding
contraception, HF medication, to contact HF specialist when planning
pregnancy.</figcaption>
</figure>
<p>Management of patients with heart failure before and during
pregnancy. ECG = electrocardiogram; HF = heart failure; mWHO = modified
World Health Organization. <sup>a</sup>Advice regarding contraception,
HF medication, to contact HF specialist when planning pregnancy.</p>
<h4 >14.1.2 New heart
failure presenting during pregnancy</h4>
<p>The increased demands on ventricular function due to the increased
circulating volume and cardiac output of pregnancy can unmask
pre-existing, but previously undiagnosed, causes of HF such as CMPs and
valve diseases.<sup>885</sup> Symptoms are more likely to occur in the
second trimester when the demand for an increased cardiac output is the
highest. Severe emotionally stressful episodes during pregnancy and
delivery can also cause Takotsubo
syndrome.<sup>884</sup><sup>,</sup><sup>885</sup></p>
<p>PPCM presents as HF secondary to LV systolic dysfunction, usually
shown by an LVEF &lt;45%, occurring towards the end of pregnancy (third
trimester) or in the months following delivery without any other
identifiable cause. The majority of PPCM cases are diagnosed in
post-partum. The prevalence ranges from 1:100 in Nigeria to 1:1000 in
South Africa and 1:1500 in Germany.<sup>643</sup> Prospective large
cohort studies report a 6-month mortality ranging from 2.0% in Germany
to 12.6% in a 206 PPCM patient cohort from South
Africa.<sup>643</sup></p>
<p>PPCM frequently presents with acute HF but may also present with
ventricular arrhythmias and/or cardiac arrest. An LVEF &lt;30%, marked
LV dilatation, LV end-diastolic diameter &gt;6.0 cm, and RV involvement
are associated with adverse outcomes.<sup>643</sup> Cardiac recovery may
occur in the first 3–6 months though it may be delayed to up to 2 years.
Recovery rates vary among regions, from 75% to less than
50%.<sup>886–888</sup></p>
<p>Assessment and management of pregnant patients presenting with HF
depends upon the clinical setting and severity of presentation. Detailed
cardiac assessment with echocardiography, NP levels, foetal ultrasound
and foetal monitoring is recommended. In cases of new HF or if there is
diagnostic uncertainty non-contrast CMR may be considered.</p>
<p>Milder cases can be treated with oral diuretics, beta-blockers,
hydralazine and oral nitrates. Pregnant women presenting with signs of
acute HF require urgent hospital admission. In case of PPCM presenting
with severe HF and cardiogenic shock requiring inotropic or vasopressor
support, transfer to an advanced HF centre, where ECMO, LVAD and/or
cardiac transplantation can be performed, is recommended. Urgent
delivery by caesarean section (irrespective of gestation) should be
considered with MCS immediately available.</p>
<p>Adrenergic agents (dobutamine, adrenaline) may have detrimental
effects.<sup>889</sup> When a PPCM patient is haemodynamically unstable,
levosimendan or MCS may be considered. LVAD implantation as a BTT or BTR
should be considered in refractory cases of cardiogenic
shock.<sup>643</sup> Bromocriptine has been proposed for patients with
acute PPCM to reduce the production of a cleaved 16 kDa prolactin
fragment, which may contribute to the pathophysiology of PPCM.
Bromocriptine was tested in a randomized trial in 63 patients comparing
its long-term, 8 weeks, with its short-term, 1-week, treatment. It was
associated with recovery of LV function, with no difference between the
two regimens and in line with the results of a previous international
PPCM registry.<sup>890</sup><sup>,</sup><sup>891</sup> Bromocriptine may
be considered for treatment of PPCM. Untoward effects of treatment,
including deep venous thrombosis and cessation of lactation, must be
considered if it is initiated. It should therefore be accompanied by
prophylactic (or therapeutic) anticoagulation.</p>
<h3 >14.2 Cardiomyopathies</h3>
<h4 >14.2.1 Epidemiology and
diagnosis</h4>
<p>CMPs can be either inherited (genetic/familial) and/or acquired. They
can also be accelerated by disease modifiers.<sup>892–894</sup> They are
a heterogeneous group of diseases and are major causes of
HF.<sup>895</sup> DCM has an estimated prevalence of 1 in 250 to 1 in
500 of the general population, HCM ranges between 1 in 500 to 1 in 5000,
and AC is estimated to be present in around 1 in 1000 to 1 in
5000 persons.<sup>895</sup><sup>,</sup><sup>896</sup></p>
<p>Direct causes of CMPs include pathogenic gene variants (mutations),
toxins, auto-immunity, storage diseases, infections, and
tachyarrhythmias. Disease modifiers, conditions that may aggravate or
trigger a CMP, include epigenetic factors and acquired modifiers, such
as pregnancy and most CV comorbidities. It is important to consider this
key interaction between genetic and acquired causes during the
diagnostic workup.<sup>897</sup> Identification of an acquired cause of
the CMP does not exclude an underlying pathogenic gene variant, whereas
the latter may require an additional acquired cause and/or disease
modifier to become manifest clinically. The commonest causes and disease
modifiers are shown in <em>Table 25</em>.</p>
<p>Table 25</p>
<p>Possible causes and disease modifiers of most frequent
cardiomyopathies</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Cause</th>
<th>Disease modifier</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genetic mutations</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LMNA </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>TTN </td>
<td>x </td>
<td>x </td>
<td>DCM, (HCM) </td>
</tr>
<tr>
<td>RBM20 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>MYH7 </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>MYPC </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>TNNT </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>PLN </td>
<td>x </td>
<td> </td>
<td>DCM, HCM, AC </td>
</tr>
<tr>
<td>DSP </td>
<td>x </td>
<td>x </td>
<td>AC, DCM, myocarditis </td>
</tr>
<tr>
<td>SCN5a </td>
<td>x </td>
<td>x </td>
<td>AC, (DCM) </td>
</tr>
<tr>
<td>Tropomyosin-1 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>Haemochromatosis (HFE gene, C282Y) </td>
<td>x </td>
<td> </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Galactosidase-A (Fabry disease) </td>
<td>x </td>
<td> </td>
<td>HCM </td>
</tr>
<tr>
<td><strong>Neuromuscular disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic
dystrophy </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Syndromic disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial X-linked mutations </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Acquired diseases</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection (viruses) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Immuno-mediated diseases (rheumathoid arthritis, systemic lupus
erythematosus, dermatomyositis) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Toxic (alcohol, amphetamines, cocaine) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Drugs (anthracyclines, trastuzumab, immune checkpoint
inhibitors) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Overload (haemochromoatosis) </td>
<td>x </td>
<td>x </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Peripartum (pregnancy) </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Comorbidities with possible interactions with the gene
mutations and an effect on phenotype and outcome</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachy-arrhythmias </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td>Diabetes mellitus </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypertension </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypo- and hyperthyroidism </td>
<td> </td>
<td>x </td>
<td>DCM, HCM, myocarditis </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Cause</th>
<th>Disease modifier</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genetic mutations</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LMNA </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>TTN </td>
<td>x </td>
<td>x </td>
<td>DCM, (HCM) </td>
</tr>
<tr>
<td>RBM20 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>MYH7 </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>MYPC </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>TNNT </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>PLN </td>
<td>x </td>
<td> </td>
<td>DCM, HCM, AC </td>
</tr>
<tr>
<td>DSP </td>
<td>x </td>
<td>x </td>
<td>AC, DCM, myocarditis </td>
</tr>
<tr>
<td>SCN5a </td>
<td>x </td>
<td>x </td>
<td>AC, (DCM) </td>
</tr>
<tr>
<td>Tropomyosin-1 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>Haemochromatosis (HFE gene, C282Y) </td>
<td>x </td>
<td> </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Galactosidase-A (Fabry disease) </td>
<td>x </td>
<td> </td>
<td>HCM </td>
</tr>
<tr>
<td><strong>Neuromuscular disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic
dystrophy </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Syndromic disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial X-linked mutations </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Acquired diseases</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection (viruses) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Immuno-mediated diseases (rheumathoid arthritis, systemic lupus
erythematosus, dermatomyositis) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Toxic (alcohol, amphetamines, cocaine) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Drugs (anthracyclines, trastuzumab, immune checkpoint
inhibitors) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Overload (haemochromoatosis) </td>
<td>x </td>
<td>x </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Peripartum (pregnancy) </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Comorbidities with possible interactions with the gene
mutations and an effect on phenotype and outcome</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachy-arrhythmias </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td>Diabetes mellitus </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypertension </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypo- and hyperthyroidism </td>
<td> </td>
<td>x </td>
<td>DCM, HCM, myocarditis </td>
</tr>
</tbody>
</table>
<p>AC = arrhythmogenic cardiomyopathy; DCM = dilated cardiomyopathy;
DSP = desmoplakin; HCM = hypertrophic cardiomyopathy; LMNA = lamin A/C;
MYH7 (gene) = myosin heavy chain 7; MYPC = myosin-binding protein C;
PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20;
SCN5a = sodium channel alpha unit 5; TTN = titin; TNNT = troponin-T.</p>
<p>Table 25</p>
<p>Possible causes and disease modifiers of most frequent
cardiomyopathies</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Cause</th>
<th>Disease modifier</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genetic mutations</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LMNA </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>TTN </td>
<td>x </td>
<td>x </td>
<td>DCM, (HCM) </td>
</tr>
<tr>
<td>RBM20 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>MYH7 </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>MYPC </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>TNNT </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>PLN </td>
<td>x </td>
<td> </td>
<td>DCM, HCM, AC </td>
</tr>
<tr>
<td>DSP </td>
<td>x </td>
<td>x </td>
<td>AC, DCM, myocarditis </td>
</tr>
<tr>
<td>SCN5a </td>
<td>x </td>
<td>x </td>
<td>AC, (DCM) </td>
</tr>
<tr>
<td>Tropomyosin-1 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>Haemochromatosis (HFE gene, C282Y) </td>
<td>x </td>
<td> </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Galactosidase-A (Fabry disease) </td>
<td>x </td>
<td> </td>
<td>HCM </td>
</tr>
<tr>
<td><strong>Neuromuscular disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic
dystrophy </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Syndromic disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial X-linked mutations </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Acquired diseases</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection (viruses) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Immuno-mediated diseases (rheumathoid arthritis, systemic lupus
erythematosus, dermatomyositis) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Toxic (alcohol, amphetamines, cocaine) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Drugs (anthracyclines, trastuzumab, immune checkpoint
inhibitors) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Overload (haemochromoatosis) </td>
<td>x </td>
<td>x </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Peripartum (pregnancy) </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Comorbidities with possible interactions with the gene
mutations and an effect on phenotype and outcome</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachy-arrhythmias </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td>Diabetes mellitus </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypertension </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypo- and hyperthyroidism </td>
<td> </td>
<td>x </td>
<td>DCM, HCM, myocarditis </td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th></th>
<th>Cause</th>
<th>Disease modifier</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genetic mutations</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LMNA </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>TTN </td>
<td>x </td>
<td>x </td>
<td>DCM, (HCM) </td>
</tr>
<tr>
<td>RBM20 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>MYH7 </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>MYPC </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>TNNT </td>
<td>x </td>
<td> </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>PLN </td>
<td>x </td>
<td> </td>
<td>DCM, HCM, AC </td>
</tr>
<tr>
<td>DSP </td>
<td>x </td>
<td>x </td>
<td>AC, DCM, myocarditis </td>
</tr>
<tr>
<td>SCN5a </td>
<td>x </td>
<td>x </td>
<td>AC, (DCM) </td>
</tr>
<tr>
<td>Tropomyosin-1 </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td>Haemochromatosis (HFE gene, C282Y) </td>
<td>x </td>
<td> </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Galactosidase-A (Fabry disease) </td>
<td>x </td>
<td> </td>
<td>HCM </td>
</tr>
<tr>
<td><strong>Neuromuscular disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic
dystrophy </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Syndromic disorders</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial X-linked mutations </td>
<td>x </td>
<td> </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Acquired diseases</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection (viruses) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Immuno-mediated diseases (rheumathoid arthritis, systemic lupus
erythematosus, dermatomyositis) </td>
<td>x </td>
<td>x </td>
<td>Myocarditis, DCM </td>
</tr>
<tr>
<td>Toxic (alcohol, amphetamines, cocaine) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Drugs (anthracyclines, trastuzumab, immune checkpoint
inhibitors) </td>
<td>x </td>
<td>x </td>
<td>DCM, myocarditis </td>
</tr>
<tr>
<td>Overload (haemochromoatosis) </td>
<td>x </td>
<td>x </td>
<td>HCM, DCM </td>
</tr>
<tr>
<td>Peripartum (pregnancy) </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td><strong>Comorbidities with possible interactions with the gene
mutations and an effect on phenotype and outcome</strong> </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachy-arrhythmias </td>
<td>x </td>
<td>x </td>
<td>DCM </td>
</tr>
<tr>
<td>Diabetes mellitus </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypertension </td>
<td>x </td>
<td>x </td>
<td>DCM, HCM </td>
</tr>
<tr>
<td>Hypo- and hyperthyroidism </td>
<td> </td>
<td>x </td>
<td>DCM, HCM, myocarditis </td>
</tr>
</tbody>
</table>
<p>AC = arrhythmogenic cardiomyopathy; DCM = dilated cardiomyopathy;
DSP = desmoplakin; HCM = hypertrophic cardiomyopathy; LMNA = lamin A/C;
MYH7 (gene) = myosin heavy chain 7; MYPC = myosin-binding protein C;
PLN = phospholamban; RBM20 = ribonucleic acid binding motif 20;
SCN5a = sodium channel alpha unit 5; TTN = titin; TNNT = troponin-T.</p>
<p>The key elements of the diagnostic workup for all patients with HF
and CMP are reported in <em>Table
26</em>.<sup>892</sup><sup>,</sup><sup>894</sup><sup>,</sup><sup>895</sup><sup>,</sup><sup>898</sup><sup>,</sup><sup>899</sup>
Specifics aspects of diagnosis and treatment are summarized in
<em>Tables 27–29</em>. Clinical history, laboratory tests, and imaging
are the first-line investigations. Echocardiography is central for the
diagnosis and monitoring of HCM, DCM, and AC. CMR imaging provides more
detailed morphological and prognostic information and should be
performed at baseline. The prevalence of gene mutations may vary
according to the morphological phenotype or the underlying acquired
cause. Gene mutations occur in up to 40% of DCM, 60% of HCM, and 15% in
chemotherapy-induced, alcoholic or peripartum
CMPs.<sup>895</sup><sup>,</sup><sup>898</sup><sup>,</sup><sup>900–905</sup>
The prevalence of genetic mutations is over 10% also in non-familial
DCM.<sup>898</sup><sup>,</sup><sup>906</sup> Finding a pathogenic gene
variant in a patient with CMP allows better prediction of the disease
outcome and progression, may contribute to the indications for device
implantation and inform genetic counselling for families.</p>
<p>Endomyocardial biopsy (EMB) with immunohistochemical quantification
of inflammatory cells remains the gold standard investigation for the
identification of cardiac inflammation. It may confirm the diagnosis of
auto-immune disease in patients with DCM and suspected giant cell
myocarditis, eosinophilic myocarditis, vasculitis and
sarcoidosis.<sup>893</sup><sup>,</sup><sup>907</sup> It may also help
for the diagnosis of storage diseases, including amyloid or Fabry
disease, if imaging or genetic testing does not provide a definitive
diagnosis (see also <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>).
EMB might be considered also in HCM if genetic or acquired causes cannot
be identified. The risks and benefits of EBM should be evaluated and
this procedure should be reserved for specific situations where its
results may affect treatment.</p>
<p>Table 26</p>
<p>Initial diagnostic assessment in patients with suspected
cardiomyopathy</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>History</strong> including detailed questions on any systemic
disease, toxic agents (chemotherapy, alcohol, drugs), and familial
history of cardiac or neuromuscular disease, or sudden cardiac death in
family members at young age (&lt;50 years). 
</td>
</tr>
<tr>
<td>
<strong>Laboratory exams</strong> including cardiac and muscular
enzymes, liver and renal function, haemoglobin, white blood cell count
(including differential white blood cell count to detect eosinophilia),
natriuretic peptides, thyroid function tests, iron status, and markers
of systemic auto-immune disease (hsCRP, anti-nuclear antibodies, soluble
IL-2 receptor). 
</td>
</tr>
<tr>
<td>
<strong>Standard 12-lead ECG and echocardiography</strong> to detect
arrhythmias and assess cardiac structure and function and concomitant
abnormalities. 
</td>
</tr>
<tr>
<td>
<strong>Invasive coronary angiography or CTCA</strong> to rule out
significant CAD in patients with cardiac dysfunction. 
</td>
</tr>
<tr>
<td>
<strong>CMR imaging</strong> with T1 and T2 sequencing and LGE to
visualize structural changes, storage, infiltration, inflammation,
fibrosis and scarring. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and genetic testing</strong> should be
performed depending on age, family history, cardiac phenotype. 
</td>
</tr>
<tr>
<td>
<strong>24 or 48-hour ambulatory ECG monitoring</strong> to detect
atrial and ventricular arrhythmias. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>History</strong> including detailed questions on any systemic
disease, toxic agents (chemotherapy, alcohol, drugs), and familial
history of cardiac or neuromuscular disease, or sudden cardiac death in
family members at young age (&lt;50 years). 
</td>
</tr>
<tr>
<td>
<strong>Laboratory exams</strong> including cardiac and muscular
enzymes, liver and renal function, haemoglobin, white blood cell count
(including differential white blood cell count to detect eosinophilia),
natriuretic peptides, thyroid function tests, iron status, and markers
of systemic auto-immune disease (hsCRP, anti-nuclear antibodies, soluble
IL-2 receptor). 
</td>
</tr>
<tr>
<td>
<strong>Standard 12-lead ECG and echocardiography</strong> to detect
arrhythmias and assess cardiac structure and function and concomitant
abnormalities. 
</td>
</tr>
<tr>
<td>
<strong>Invasive coronary angiography or CTCA</strong> to rule out
significant CAD in patients with cardiac dysfunction. 
</td>
</tr>
<tr>
<td>
<strong>CMR imaging</strong> with T1 and T2 sequencing and LGE to
visualize structural changes, storage, infiltration, inflammation,
fibrosis and scarring. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and genetic testing</strong> should be
performed depending on age, family history, cardiac phenotype. 
</td>
</tr>
<tr>
<td>
<strong>24 or 48-hour ambulatory ECG monitoring</strong> to detect
atrial and ventricular arrhythmias. 
</td>
</tr>
</tbody>
</table>
<p>CAD = coronary artery disease; CMR = cardiac magnetic resonance;
CTCA = computed tomography coronary angiography;
ECG = electrocardiogram; hsCRP = high-sensitivity C-reactive protein;
IL-2 = interleukin-2; LGE = late gadolinium enhancement.</p>
<p>Table 26</p>
<p>Initial diagnostic assessment in patients with suspected
cardiomyopathy</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>History</strong> including detailed questions on any systemic
disease, toxic agents (chemotherapy, alcohol, drugs), and familial
history of cardiac or neuromuscular disease, or sudden cardiac death in
family members at young age (&lt;50 years). 
</td>
</tr>
<tr>
<td>
<strong>Laboratory exams</strong> including cardiac and muscular
enzymes, liver and renal function, haemoglobin, white blood cell count
(including differential white blood cell count to detect eosinophilia),
natriuretic peptides, thyroid function tests, iron status, and markers
of systemic auto-immune disease (hsCRP, anti-nuclear antibodies, soluble
IL-2 receptor). 
</td>
</tr>
<tr>
<td>
<strong>Standard 12-lead ECG and echocardiography</strong> to detect
arrhythmias and assess cardiac structure and function and concomitant
abnormalities. 
</td>
</tr>
<tr>
<td>
<strong>Invasive coronary angiography or CTCA</strong> to rule out
significant CAD in patients with cardiac dysfunction. 
</td>
</tr>
<tr>
<td>
<strong>CMR imaging</strong> with T1 and T2 sequencing and LGE to
visualize structural changes, storage, infiltration, inflammation,
fibrosis and scarring. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and genetic testing</strong> should be
performed depending on age, family history, cardiac phenotype. 
</td>
</tr>
<tr>
<td>
<strong>24 or 48-hour ambulatory ECG monitoring</strong> to detect
atrial and ventricular arrhythmias. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>History</strong> including detailed questions on any systemic
disease, toxic agents (chemotherapy, alcohol, drugs), and familial
history of cardiac or neuromuscular disease, or sudden cardiac death in
family members at young age (&lt;50 years). 
</td>
</tr>
<tr>
<td>
<strong>Laboratory exams</strong> including cardiac and muscular
enzymes, liver and renal function, haemoglobin, white blood cell count
(including differential white blood cell count to detect eosinophilia),
natriuretic peptides, thyroid function tests, iron status, and markers
of systemic auto-immune disease (hsCRP, anti-nuclear antibodies, soluble
IL-2 receptor). 
</td>
</tr>
<tr>
<td>
<strong>Standard 12-lead ECG and echocardiography</strong> to detect
arrhythmias and assess cardiac structure and function and concomitant
abnormalities. 
</td>
</tr>
<tr>
<td>
<strong>Invasive coronary angiography or CTCA</strong> to rule out
significant CAD in patients with cardiac dysfunction. 
</td>
</tr>
<tr>
<td>
<strong>CMR imaging</strong> with T1 and T2 sequencing and LGE to
visualize structural changes, storage, infiltration, inflammation,
fibrosis and scarring. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and genetic testing</strong> should be
performed depending on age, family history, cardiac phenotype. 
</td>
</tr>
<tr>
<td>
<strong>24 or 48-hour ambulatory ECG monitoring</strong> to detect
atrial and ventricular arrhythmias. 
</td>
</tr>
</tbody>
</table>
<p>CAD = coronary artery disease; CMR = cardiac magnetic resonance;
CTCA = computed tomography coronary angiography;
ECG = electrocardiogram; hsCRP = high-sensitivity C-reactive protein;
IL-2 = interleukin-2; LGE = late gadolinium enhancement.</p>
<h4 >14.2.2 Treatment</h4>
<p>The current pharmacological treatment of HF in DCM, HCM, or AC
patients does not differ from general HF management, except for peculiar
aspects reported in <em>Tables 27–29</em>. A pilot randomized study,
TRED-HF, investigated the possibility of withdrawing medical treatment
in those patients with non-ischaemic DCM who had had partial to complete
recovery of LVEF (&gt;40%). However, relapse of DCM within 6 months was
observed in 44% of patients, and rapid LV remodelling with early tissue
and functional changes, even amongst patients who did not relapse, was
found.<sup>271</sup><sup>,</sup><sup>908</sup></p>
<p>In a phase 3, randomized, double-blind, placebo-controlled trial
(EXPLORER-HCM), treatment with mavacamten improved exercise capacity,
LVOT obstruction, NYHA functional class, and health status in patients
with obstructive HCM. This offers the possibility of disease-specific
treatment for inherited CMPs. <sup>909</sup></p>
<p>ICD implantation should be considered for patients with DCM, HCM, or
AC (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">section 6</a>).<sup>895</sup><sup>,</sup><sup>910–912</sup>
The strength of the indication varies according to the clinical risk
factors for sudden cardiac death with higher priority being given to
those patients with significant LGE on CMR, younger age, or with a
specific familial/genetic phenotype (<em>Tables 27–29</em>). Risk models
for the prediction of ICD benefits were applied to the patients enrolled
in DANISH and may help for the indication to ICD implantation in
DCM.<sup>166</sup><sup>,</sup><sup>913</sup> Treatment of HCM and AC,
including indications for ICD, are detailed in previous
documents.<sup>895</sup><sup>,</sup><sup>896</sup><sup>,</sup><sup>899</sup><sup>,</sup><sup>912</sup><sup>,</sup><sup>914</sup><sup>,</sup><sup>915</sup></p>
<p>Table 27</p>
<p>Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy:
specific aspects of diagnosis and treatment</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Diagnostic criteria and definitions</strong><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>895</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 DCM: LV dilatation and systolic dysfunction in the absence of known
abnormal loading conditions or significant CAD.
</p>
</li>
<li>
<p>
 HNDC: LV or biventricular global systolic dysfunction (LVEF &lt;45%)
without dilatation in the absence of known abnormal loading conditions
or significant CAD.
</p>
</li>
<li>
<p>
 DCM and HNDC can be considered “familial” if two or more first- or
second-degree relatives have DCM or HNDC, or a first-degree relative has
autopsy proven DCM and sudden death at &lt;50 years of age.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong><span
></span><span><sup>892</sup></span><sup>,</sup><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>916</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> All patients with a diagnosis of DCM or
HNDC and all first-degree adult relatives of these patients and a
definite disease-causing mutation, regardless of their phenotype, in
order to identify genetically affected individuals at a preclinical
phase.
</p>
</li>
<li>
<p>
 First-degree adult relatives should have their evaluation repeated
every 5 years or less when aged &lt;50 years or non-diagnostic
abnormalities are found.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG, echocardiography and possibly CMR, must be
performed in first-degree relatives of patients.
</p>
</li>
<li>
<p>
 Results can identify patients with DCM or HNDC at highest risk of
arrhythmia and/or deserving other specific treatments. Early
identification of asymptomatic relatives may lead to early treatment and
prevention of progression to HF and proper genetic counseling.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<sup>a</sup></strong>: TTN, LMNA, MHC,
TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3,
actin alpha cardiac muscle, nexilin, tropomyosin-1, vinculin.
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered when there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong><span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> In suspected phenotypes requiring specific
treatments (i.e. giant cell myocarditis, eosinophilic myocarditis,
sarcoidosis, vasculitis, SLE, other systemic, auto-immune inflammatory
conditions, or storage diseases).
</p>
</li>
<li>
<p>
 <strong>Number of samples</strong>. A minimum of 5 but possibly at
least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for
RNA viruses/viral replication.<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span>
</p>
</li>
<li>
<p>
 <strong>Aetiology.</strong> Search for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by
quantitative rtPCR when a viral aetiology is suspected. Viral mRNA for
active viral replication should be assessed, if possible.
</p>
</li>
<li>
<p>
 Further assessment if indicated: CMV, HIV, <em>Borrelia
burgdorferi</em> (Lyme disease), <em>Coxiella burnetii</em> (Q-fever),
<em>Trypanosoma cruzi</em> (Chagas disease) and SARS-CoV-2.
</p>
</li>
<li>
<p>
 <strong>Immunohistochemistry</strong>. Quantification of CD3-, CD4-,
CD8- or CD45- staining lymphocytes and CD68 macrophages per
mm<sup>2</sup>; anti-HLA-DR.
</p>
</li>
<li>
<p>
 <strong>Histology</strong>. Haematoxylin and eosin staining, fibrosis
assessment with Masson’s Trichrome and Picrosirius Red, amyloid fibrils
detection with Congo Red.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span> 
</td>
</tr>
<tr>
<td>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections 5</a>
and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>) 
</td>
</tr>
<tr>
<td>
<strong>LMNA, RBM20, PLN and FLN mutation</strong>. Higher risk of
sudden cardiac death: early indication for primary prevention by ICD
implantation should be considered (guided by risk factors as
detailed).<span
></span><span><sup>920</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>TTN mutation.</strong> Higher rate of LV reverse remodeling (in
up to 70%), but a higher risk of atrial and ventricular
tachyarrhythmias. 
</td>
</tr>
<tr>
<td>
<strong>Lyme disease (<em>Borrelia</em>).</strong> Treatment with
doxycycline. 
</td>
</tr>
<tr>
<td>
<strong>Chagas disease (<em>Trypanosoma cruzi</em>).</strong> Specific
treatment according to current recommendations.<span
></span><span><sup>921</sup></span><sup>,</sup><span
></span><span><sup>922</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>Auto-immune/inflammatory.</strong> Consider immunosuppressive
therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis
or vasculitis, and in highly selected patients with increased cardiac
inflammation of unknown origin based upon multidisciplinary counselling
(cardiology and immunology). 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Diagnostic criteria and definitions</strong><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>895</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 DCM: LV dilatation and systolic dysfunction in the absence of known
abnormal loading conditions or significant CAD.
</p>
</li>
<li>
<p>
 HNDC: LV or biventricular global systolic dysfunction (LVEF &lt;45%)
without dilatation in the absence of known abnormal loading conditions
or significant CAD.
</p>
</li>
<li>
<p>
 DCM and HNDC can be considered “familial” if two or more first- or
second-degree relatives have DCM or HNDC, or a first-degree relative has
autopsy proven DCM and sudden death at &lt;50 years of age.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong><span
></span><span><sup>892</sup></span><sup>,</sup><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>916</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> All patients with a diagnosis of DCM or
HNDC and all first-degree adult relatives of these patients and a
definite disease-causing mutation, regardless of their phenotype, in
order to identify genetically affected individuals at a preclinical
phase.
</p>
</li>
<li>
<p>
 First-degree adult relatives should have their evaluation repeated
every 5 years or less when aged &lt;50 years or non-diagnostic
abnormalities are found.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG, echocardiography and possibly CMR, must be
performed in first-degree relatives of patients.
</p>
</li>
<li>
<p>
 Results can identify patients with DCM or HNDC at highest risk of
arrhythmia and/or deserving other specific treatments. Early
identification of asymptomatic relatives may lead to early treatment and
prevention of progression to HF and proper genetic counseling.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<sup>a</sup></strong>: TTN, LMNA, MHC,
TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3,
actin alpha cardiac muscle, nexilin, tropomyosin-1, vinculin.
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered when there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong><span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> In suspected phenotypes requiring specific
treatments (i.e. giant cell myocarditis, eosinophilic myocarditis,
sarcoidosis, vasculitis, SLE, other systemic, auto-immune inflammatory
conditions, or storage diseases).
</p>
</li>
<li>
<p>
 <strong>Number of samples</strong>. A minimum of 5 but possibly at
least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for
RNA viruses/viral replication.<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span>
</p>
</li>
<li>
<p>
 <strong>Aetiology.</strong> Search for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by
quantitative rtPCR when a viral aetiology is suspected. Viral mRNA for
active viral replication should be assessed, if possible.
</p>
</li>
<li>
<p>
 Further assessment if indicated: CMV, HIV, <em>Borrelia
burgdorferi</em> (Lyme disease), <em>Coxiella burnetii</em> (Q-fever),
<em>Trypanosoma cruzi</em> (Chagas disease) and SARS-CoV-2.
</p>
</li>
<li>
<p>
 <strong>Immunohistochemistry</strong>. Quantification of CD3-, CD4-,
CD8- or CD45- staining lymphocytes and CD68 macrophages per
mm<sup>2</sup>; anti-HLA-DR.
</p>
</li>
<li>
<p>
 <strong>Histology</strong>. Haematoxylin and eosin staining, fibrosis
assessment with Masson’s Trichrome and Picrosirius Red, amyloid fibrils
detection with Congo Red.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span> 
</td>
</tr>
<tr>
<td>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections 5</a>
and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>) 
</td>
</tr>
<tr>
<td>
<strong>LMNA, RBM20, PLN and FLN mutation</strong>. Higher risk of
sudden cardiac death: early indication for primary prevention by ICD
implantation should be considered (guided by risk factors as
detailed).<span
></span><span><sup>920</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>TTN mutation.</strong> Higher rate of LV reverse remodeling (in
up to 70%), but a higher risk of atrial and ventricular
tachyarrhythmias. 
</td>
</tr>
<tr>
<td>
<strong>Lyme disease (<em>Borrelia</em>).</strong> Treatment with
doxycycline. 
</td>
</tr>
<tr>
<td>
<strong>Chagas disease (<em>Trypanosoma cruzi</em>).</strong> Specific
treatment according to current recommendations.<span
></span><span><sup>921</sup></span><sup>,</sup><span
></span><span><sup>922</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>Auto-immune/inflammatory.</strong> Consider immunosuppressive
therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis
or vasculitis, and in highly selected patients with increased cardiac
inflammation of unknown origin based upon multidisciplinary counselling
(cardiology and immunology). 
</td>
</tr>
</tbody>
</table>
<p>BAG3 = Bcl2-associated athanogene 3; CAD = coronary artery disease;
CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DCM = dilated
cardiomyopathy; DNA = deoxyribonucleic acid; ECG = electrocardiogram;
FLN = filamin; HF = heart failure; HFrEF = heart failure with reduced
ejection fraction; HHV = human herpes virus; HIV = human
immunodeficiency virus; HLA-DR = human leukocyte antigen-DR isotype;
HNDC = hypokinetic non-dilated cardiomyopathy; ICD = implantable
cardioverter-defibrillator; LMNA = lamin A/C; LV = left ventricular;
LVEF = left ventricular ejection fraction; MHC = myosin heavy chain;
MYPC = myosin-binding protein C; mRNA = messenger ribonucleic acid;
NSVT = non-sustained ventricular tachycardia; PCR = polymerase chain
reaction; PLN = phospholamban; RBM20 = ribonucleic acid binding motif
20; RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase
chain reaction; SARS-CoV-2 = severe acute respiratory syndrome
coronavirus 2; SLE = systemic lupus erythematosus; TNNT = troponin-T;
TTN = titin.</p>
<p>a</p>
<p>This list of genes is not exhaustive, and will change over time, with
increasing knowledge of the pathogenicity. Contact the genetic
department to ask which core panel of genes they are using.</p>
<p>b</p>
<p>Risk factors in patients with a confirmed LMNA mutation: NSVT during
ambulatory ECG monitoring, LVEF &lt;45% at first evaluation, male sex
and non-missense mutations (insertion, deletion, truncations, or
mutations affecting splicing).</p>
<p>Table 27</p>
<p>Dilated cardiomyopathy or hypokinetic non-dilated cardiomyopathy:
specific aspects of diagnosis and treatment</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Diagnostic criteria and definitions</strong><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>895</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 DCM: LV dilatation and systolic dysfunction in the absence of known
abnormal loading conditions or significant CAD.
</p>
</li>
<li>
<p>
 HNDC: LV or biventricular global systolic dysfunction (LVEF &lt;45%)
without dilatation in the absence of known abnormal loading conditions
or significant CAD.
</p>
</li>
<li>
<p>
 DCM and HNDC can be considered “familial” if two or more first- or
second-degree relatives have DCM or HNDC, or a first-degree relative has
autopsy proven DCM and sudden death at &lt;50 years of age.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong><span
></span><span><sup>892</sup></span><sup>,</sup><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>916</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> All patients with a diagnosis of DCM or
HNDC and all first-degree adult relatives of these patients and a
definite disease-causing mutation, regardless of their phenotype, in
order to identify genetically affected individuals at a preclinical
phase.
</p>
</li>
<li>
<p>
 First-degree adult relatives should have their evaluation repeated
every 5 years or less when aged &lt;50 years or non-diagnostic
abnormalities are found.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG, echocardiography and possibly CMR, must be
performed in first-degree relatives of patients.
</p>
</li>
<li>
<p>
 Results can identify patients with DCM or HNDC at highest risk of
arrhythmia and/or deserving other specific treatments. Early
identification of asymptomatic relatives may lead to early treatment and
prevention of progression to HF and proper genetic counseling.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<sup>a</sup></strong>: TTN, LMNA, MHC,
TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3,
actin alpha cardiac muscle, nexilin, tropomyosin-1, vinculin.
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered when there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong><span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> In suspected phenotypes requiring specific
treatments (i.e. giant cell myocarditis, eosinophilic myocarditis,
sarcoidosis, vasculitis, SLE, other systemic, auto-immune inflammatory
conditions, or storage diseases).
</p>
</li>
<li>
<p>
 <strong>Number of samples</strong>. A minimum of 5 but possibly at
least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for
RNA viruses/viral replication.<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span>
</p>
</li>
<li>
<p>
 <strong>Aetiology.</strong> Search for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by
quantitative rtPCR when a viral aetiology is suspected. Viral mRNA for
active viral replication should be assessed, if possible.
</p>
</li>
<li>
<p>
 Further assessment if indicated: CMV, HIV, <em>Borrelia
burgdorferi</em> (Lyme disease), <em>Coxiella burnetii</em> (Q-fever),
<em>Trypanosoma cruzi</em> (Chagas disease) and SARS-CoV-2.
</p>
</li>
<li>
<p>
 <strong>Immunohistochemistry</strong>. Quantification of CD3-, CD4-,
CD8- or CD45- staining lymphocytes and CD68 macrophages per
mm<sup>2</sup>; anti-HLA-DR.
</p>
</li>
<li>
<p>
 <strong>Histology</strong>. Haematoxylin and eosin staining, fibrosis
assessment with Masson’s Trichrome and Picrosirius Red, amyloid fibrils
detection with Congo Red.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span> 
</td>
</tr>
<tr>
<td>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections 5</a>
and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>) 
</td>
</tr>
<tr>
<td>
<strong>LMNA, RBM20, PLN and FLN mutation</strong>. Higher risk of
sudden cardiac death: early indication for primary prevention by ICD
implantation should be considered (guided by risk factors as
detailed).<span
></span><span><sup>920</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>TTN mutation.</strong> Higher rate of LV reverse remodeling (in
up to 70%), but a higher risk of atrial and ventricular
tachyarrhythmias. 
</td>
</tr>
<tr>
<td>
<strong>Lyme disease (<em>Borrelia</em>).</strong> Treatment with
doxycycline. 
</td>
</tr>
<tr>
<td>
<strong>Chagas disease (<em>Trypanosoma cruzi</em>).</strong> Specific
treatment according to current recommendations.<span
></span><span><sup>921</sup></span><sup>,</sup><span
></span><span><sup>922</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>Auto-immune/inflammatory.</strong> Consider immunosuppressive
therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis
or vasculitis, and in highly selected patients with increased cardiac
inflammation of unknown origin based upon multidisciplinary counselling
(cardiology and immunology). 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Diagnostic criteria and definitions</strong><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>895</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 DCM: LV dilatation and systolic dysfunction in the absence of known
abnormal loading conditions or significant CAD.
</p>
</li>
<li>
<p>
 HNDC: LV or biventricular global systolic dysfunction (LVEF &lt;45%)
without dilatation in the absence of known abnormal loading conditions
or significant CAD.
</p>
</li>
<li>
<p>
 DCM and HNDC can be considered “familial” if two or more first- or
second-degree relatives have DCM or HNDC, or a first-degree relative has
autopsy proven DCM and sudden death at &lt;50 years of age.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong><span
></span><span><sup>892</sup></span><sup>,</sup><span
></span><span><sup>894</sup></span><sup>,</sup><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>916</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> All patients with a diagnosis of DCM or
HNDC and all first-degree adult relatives of these patients and a
definite disease-causing mutation, regardless of their phenotype, in
order to identify genetically affected individuals at a preclinical
phase.
</p>
</li>
<li>
<p>
 First-degree adult relatives should have their evaluation repeated
every 5 years or less when aged &lt;50 years or non-diagnostic
abnormalities are found.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG, echocardiography and possibly CMR, must be
performed in first-degree relatives of patients.
</p>
</li>
<li>
<p>
 Results can identify patients with DCM or HNDC at highest risk of
arrhythmia and/or deserving other specific treatments. Early
identification of asymptomatic relatives may lead to early treatment and
prevention of progression to HF and proper genetic counseling.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<sup>a</sup></strong>: TTN, LMNA, MHC,
TNNT, troponin-C, MYPC, RBM20, PLN, sodium channel alpha unit, BAG3,
actin alpha cardiac muscle, nexilin, tropomyosin-1, vinculin.
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered when there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong><span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> In suspected phenotypes requiring specific
treatments (i.e. giant cell myocarditis, eosinophilic myocarditis,
sarcoidosis, vasculitis, SLE, other systemic, auto-immune inflammatory
conditions, or storage diseases).
</p>
</li>
<li>
<p>
 <strong>Number of samples</strong>. A minimum of 5 but possibly at
least 7 samples: 3 for pathology, 2 for infection (DNA, PCR) and 2 for
RNA viruses/viral replication.<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span>
</p>
</li>
<li>
<p>
 <strong>Aetiology.</strong> Search for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and coxsackie) by
quantitative rtPCR when a viral aetiology is suspected. Viral mRNA for
active viral replication should be assessed, if possible.
</p>
</li>
<li>
<p>
 Further assessment if indicated: CMV, HIV, <em>Borrelia
burgdorferi</em> (Lyme disease), <em>Coxiella burnetii</em> (Q-fever),
<em>Trypanosoma cruzi</em> (Chagas disease) and SARS-CoV-2.
</p>
</li>
<li>
<p>
 <strong>Immunohistochemistry</strong>. Quantification of CD3-, CD4-,
CD8- or CD45- staining lymphocytes and CD68 macrophages per
mm<sup>2</sup>; anti-HLA-DR.
</p>
</li>
<li>
<p>
 <strong>Histology</strong>. Haematoxylin and eosin staining, fibrosis
assessment with Masson’s Trichrome and Picrosirius Red, amyloid fibrils
detection with Congo Red.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span> 
</td>
</tr>
<tr>
<td>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections 5</a>
and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>) 
</td>
</tr>
<tr>
<td>
<strong>LMNA, RBM20, PLN and FLN mutation</strong>. Higher risk of
sudden cardiac death: early indication for primary prevention by ICD
implantation should be considered (guided by risk factors as
detailed).<span
></span><span><sup>920</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>TTN mutation.</strong> Higher rate of LV reverse remodeling (in
up to 70%), but a higher risk of atrial and ventricular
tachyarrhythmias. 
</td>
</tr>
<tr>
<td>
<strong>Lyme disease (<em>Borrelia</em>).</strong> Treatment with
doxycycline. 
</td>
</tr>
<tr>
<td>
<strong>Chagas disease (<em>Trypanosoma cruzi</em>).</strong> Specific
treatment according to current recommendations.<span
></span><span><sup>921</sup></span><sup>,</sup><span
></span><span><sup>922</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>Auto-immune/inflammatory.</strong> Consider immunosuppressive
therapy in giant cell myocarditis, eosinophilic myocarditis, sarcoidosis
or vasculitis, and in highly selected patients with increased cardiac
inflammation of unknown origin based upon multidisciplinary counselling
(cardiology and immunology). 
</td>
</tr>
</tbody>
</table>
<p>BAG3 = Bcl2-associated athanogene 3; CAD = coronary artery disease;
CMR = cardiac magnetic resonance; CMV = cytomegalovirus; DCM = dilated
cardiomyopathy; DNA = deoxyribonucleic acid; ECG = electrocardiogram;
FLN = filamin; HF = heart failure; HFrEF = heart failure with reduced
ejection fraction; HHV = human herpes virus; HIV = human
immunodeficiency virus; HLA-DR = human leukocyte antigen-DR isotype;
HNDC = hypokinetic non-dilated cardiomyopathy; ICD = implantable
cardioverter-defibrillator; LMNA = lamin A/C; LV = left ventricular;
LVEF = left ventricular ejection fraction; MHC = myosin heavy chain;
MYPC = myosin-binding protein C; mRNA = messenger ribonucleic acid;
NSVT = non-sustained ventricular tachycardia; PCR = polymerase chain
reaction; PLN = phospholamban; RBM20 = ribonucleic acid binding motif
20; RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase
chain reaction; SARS-CoV-2 = severe acute respiratory syndrome
coronavirus 2; SLE = systemic lupus erythematosus; TNNT = troponin-T;
TTN = titin.</p>
<p>a</p>
<p>This list of genes is not exhaustive, and will change over time, with
increasing knowledge of the pathogenicity. Contact the genetic
department to ask which core panel of genes they are using.</p>
<p>b</p>
<p>Risk factors in patients with a confirmed LMNA mutation: NSVT during
ambulatory ECG monitoring, LVEF &lt;45% at first evaluation, male sex
and non-missense mutations (insertion, deletion, truncations, or
mutations affecting splicing).</p>
<p>Table 28</p>
<p>Hypertrophic cardiomyopathy: specific aspects of diagnosis and
treatment</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Definition</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 Wall thickness &gt;14 mm in one or more LV myocardial segments not
sufficiently explained solely by abnormal loading conditions.
</p>
</li>
<li>
<p>
 LVOTO ≥30 mmHg at rest or exercise, asymmetric hypertrophy, or
increased LGE in a patchy mid-wall pattern in the most hypertrophied
segment, further suggest the presence of HCM.
</p>
</li>
<li>
<p>
 It can be considered familial when two or more first- or second-degree
relatives with HCM or a first-degree relative with autopsy proven HCM
and sudden death at &lt;50 years of age are detected.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Differential diagnosis</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 It might be difficult with physiological hypertrophy induced by intense
athletic training, severe hypertension or aortic stenosis and with
isolated septal hypertrophy. Consider a genetic HCM if the degree of LV
hypertrophy is disproportionate with respect to the acquired trigger.
</p>
</li>
<li>
<p>
 Consider amyloidosis as a cause when increased thickness of the
interatrial septum, AV valve and/or RV free wall are detected (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> Must be offered to all patients with a
diagnosis of HCM to identify a possible underlying genetic cause and to
all first-degree adult relatives of patients with HCM and a definite
disease-causing mutation, regardless of their phenotype, in order to
identify genetically affected individuals at a preclinical phase.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG and echocardiography, must be performed in
first-degree relatives who have the same definite disease-causing
mutation as the index patient.
</p>
</li>
<li>
<p>
 When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<span
></span><span><sup>a</sup></span></strong>
(sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT,
Troponin-C, MYPC, RMB20, PLN, Sodium channel alpha unit, BAG3, Actin
Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.<span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>924–926</sup></span>
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered if there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
<li>
<p>
 <strong>Specific conditions.</strong>
</p>
</li>
<li>
<p>
 Muscular weakness: consider mitochondrial X-linked mutations, glycogen
storage disorders, FHLI mutations, Friedreich’s ataxia.
</p>
</li>
<li>
<p>
 Syndromic conditions (cognitive, visual impairment, drooping eyelid):
consider mitochondrial X-linked mutations, Noonan syndrome, Danon
disease.
</p>
</li>
<li>
<p>
 Café au lait spots (lentigines): consider Leopard/Noonan syndrome
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
<strong>Indication.</strong> It may be considered when the baseline
clinical assessment suggests cardiac inflammation or storage disease
which cannot be diagnosed by other means<span
></span><span><sup>896</sup></span> (see also
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">Section
14.6</a>). 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>With LVOTO</strong>
<ul>
<li>
<p>
 Avoid hypovolaemia (dehydration), arterial and venous dilators
(nitrates and phosphodiesterase type 5 inhibitors), and digoxin.
</p>
</li>
<li>
<p>
 Use non-vasodilating beta-blockers or use verapamil if beta-blockers
non-tolerated or ineffective.
</p>
</li>
<li>
<p>
 Low-dose loop or thiazide diuretics must be used with caution to
improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.
</p>
</li>
<li>
<p>
 Invasive treatment (septal reduction therapy by alcohol ablation or
myomectomy), in experienced centres, may be considered in those patients
with a resting or maximum provoked LVOT ≥50 mmHg and/or who remain
symptomatic (NYHA class III or IV, syncope) despite OMT.
</p>
</li>
<li>
<p>
 Novel drugs or devices may be considered once available.<span
></span><span><sup>909</sup></span><sup>,</sup><span
></span><span><sup>927</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Symptomatic without LVOTO</strong>
<ul>
<li>
<p>
 Cautious use of low-dose loop or thiazide diuretics avoiding
hypovolaemia.
</p>
</li>
<li>
<p>
 Verapamil/diltiazem if LVEF &gt;50% and beta-blockers are not tolerated
or ineffective.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Indication to ICD</strong>
<ul>
<li>
<p>
 Based on sudden cardiac death risk models.<span
></span><span><sup>928–930</sup></span>
</p>
</li>
<li>
<p>
 Consider ICD implantation if:
</p>
<ul>
<li>
<p>
  - family history of sudden cardiac death in one or more first degree
relatives under 40 years of age or sudden cardiac death in a first
degree relative with confirmed HCM at any age;
</p>
</li>
<li>
<p>
  - NSVT;
</p>
</li>
<li>
<p>
  - unexplained syncope.<span
></span><span><sup>931</sup></span>
</p>
</li>
</ul>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Fabry disease</strong>
</p>
</li>
<li>
<p>
 Enzyme replacement therapy (alpha-galactosidase A deficiency).<span
></span><span><sup>895</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Amyloidosis.</strong> See <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>
and <em>Figure <span ></span>21.</em> 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Definition</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 Wall thickness &gt;14 mm in one or more LV myocardial segments not
sufficiently explained solely by abnormal loading conditions.
</p>
</li>
<li>
<p>
 LVOTO ≥30 mmHg at rest or exercise, asymmetric hypertrophy, or
increased LGE in a patchy mid-wall pattern in the most hypertrophied
segment, further suggest the presence of HCM.
</p>
</li>
<li>
<p>
 It can be considered familial when two or more first- or second-degree
relatives with HCM or a first-degree relative with autopsy proven HCM
and sudden death at &lt;50 years of age are detected.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Differential diagnosis</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 It might be difficult with physiological hypertrophy induced by intense
athletic training, severe hypertension or aortic stenosis and with
isolated septal hypertrophy. Consider a genetic HCM if the degree of LV
hypertrophy is disproportionate with respect to the acquired trigger.
</p>
</li>
<li>
<p>
 Consider amyloidosis as a cause when increased thickness of the
interatrial septum, AV valve and/or RV free wall are detected (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> Must be offered to all patients with a
diagnosis of HCM to identify a possible underlying genetic cause and to
all first-degree adult relatives of patients with HCM and a definite
disease-causing mutation, regardless of their phenotype, in order to
identify genetically affected individuals at a preclinical phase.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG and echocardiography, must be performed in
first-degree relatives who have the same definite disease-causing
mutation as the index patient.
</p>
</li>
<li>
<p>
 When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<span
></span><span><sup>a</sup></span></strong>
(sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT,
Troponin-C, MYPC, RMB20, PLN, Sodium channel alpha unit, BAG3, Actin
Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.<span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>924–926</sup></span>
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered if there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
<li>
<p>
 <strong>Specific conditions.</strong>
</p>
</li>
<li>
<p>
 Muscular weakness: consider mitochondrial X-linked mutations, glycogen
storage disorders, FHLI mutations, Friedreich’s ataxia.
</p>
</li>
<li>
<p>
 Syndromic conditions (cognitive, visual impairment, drooping eyelid):
consider mitochondrial X-linked mutations, Noonan syndrome, Danon
disease.
</p>
</li>
<li>
<p>
 Café au lait spots (lentigines): consider Leopard/Noonan syndrome
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
<strong>Indication.</strong> It may be considered when the baseline
clinical assessment suggests cardiac inflammation or storage disease
which cannot be diagnosed by other means<span
></span><span><sup>896</sup></span> (see also
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">Section
14.6</a>). 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>With LVOTO</strong>
<ul>
<li>
<p>
 Avoid hypovolaemia (dehydration), arterial and venous dilators
(nitrates and phosphodiesterase type 5 inhibitors), and digoxin.
</p>
</li>
<li>
<p>
 Use non-vasodilating beta-blockers or use verapamil if beta-blockers
non-tolerated or ineffective.
</p>
</li>
<li>
<p>
 Low-dose loop or thiazide diuretics must be used with caution to
improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.
</p>
</li>
<li>
<p>
 Invasive treatment (septal reduction therapy by alcohol ablation or
myomectomy), in experienced centres, may be considered in those patients
with a resting or maximum provoked LVOT ≥50 mmHg and/or who remain
symptomatic (NYHA class III or IV, syncope) despite OMT.
</p>
</li>
<li>
<p>
 Novel drugs or devices may be considered once available.<span
></span><span><sup>909</sup></span><sup>,</sup><span
></span><span><sup>927</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Symptomatic without LVOTO</strong>
<ul>
<li>
<p>
 Cautious use of low-dose loop or thiazide diuretics avoiding
hypovolaemia.
</p>
</li>
<li>
<p>
 Verapamil/diltiazem if LVEF &gt;50% and beta-blockers are not tolerated
or ineffective.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Indication to ICD</strong>
<ul>
<li>
<p>
 Based on sudden cardiac death risk models.<span
></span><span><sup>928–930</sup></span>
</p>
</li>
<li>
<p>
 Consider ICD implantation if:
</p>
<ul>
<li>
<p>
  - family history of sudden cardiac death in one or more first degree
relatives under 40 years of age or sudden cardiac death in a first
degree relative with confirmed HCM at any age;
</p>
</li>
<li>
<p>
  - NSVT;
</p>
</li>
<li>
<p>
  - unexplained syncope.<span
></span><span><sup>931</sup></span>
</p>
</li>
</ul>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Fabry disease</strong>
</p>
</li>
<li>
<p>
 Enzyme replacement therapy (alpha-galactosidase A deficiency).<span
></span><span><sup>895</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Amyloidosis.</strong> See <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>
and <em>Figure <span ></span>21.</em> 
</td>
</tr>
</tbody>
</table>
<p>AV = atrio-ventricular; BAG3 = Bcl2-associated athanogene 3;
ECG = electrocardiogram; HCM = hypertrophic cardiomyopathy;
ICD = implantable cardioverter-defibrillator; LGE = late gadolinium
enhancement; LMNA = lamin A/C; LV = left ventricular; LVEF = left
ventricular ejection fraction; LVOT = left ventricular outflow tract;
LVOTO = left ventricular outflow tract obstruction; MHC = myosin heavy
chain; MYPC = myosin-binding protein C; NSVT = non-sustained ventricular
tachycardia; NYHA = New York Heart Association; OMT = optimal medical
therapy; PLN = phospholamban; RMB20 = ribonucleic acid binding motif 20;
RV = right ventricular; TNNT = troponin-T; TTN = titin.</p>
<p>a</p>
<p>The list of genes is not exhaustive, and will change over time, with
increasing knowledge of the pathogenicity. Contact the genetic
department to ask which core panel of genes they are using.</p>
<p>Table 28</p>
<p>Hypertrophic cardiomyopathy: specific aspects of diagnosis and
treatment</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Definition</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 Wall thickness &gt;14 mm in one or more LV myocardial segments not
sufficiently explained solely by abnormal loading conditions.
</p>
</li>
<li>
<p>
 LVOTO ≥30 mmHg at rest or exercise, asymmetric hypertrophy, or
increased LGE in a patchy mid-wall pattern in the most hypertrophied
segment, further suggest the presence of HCM.
</p>
</li>
<li>
<p>
 It can be considered familial when two or more first- or second-degree
relatives with HCM or a first-degree relative with autopsy proven HCM
and sudden death at &lt;50 years of age are detected.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Differential diagnosis</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 It might be difficult with physiological hypertrophy induced by intense
athletic training, severe hypertension or aortic stenosis and with
isolated septal hypertrophy. Consider a genetic HCM if the degree of LV
hypertrophy is disproportionate with respect to the acquired trigger.
</p>
</li>
<li>
<p>
 Consider amyloidosis as a cause when increased thickness of the
interatrial septum, AV valve and/or RV free wall are detected (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> Must be offered to all patients with a
diagnosis of HCM to identify a possible underlying genetic cause and to
all first-degree adult relatives of patients with HCM and a definite
disease-causing mutation, regardless of their phenotype, in order to
identify genetically affected individuals at a preclinical phase.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG and echocardiography, must be performed in
first-degree relatives who have the same definite disease-causing
mutation as the index patient.
</p>
</li>
<li>
<p>
 When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<span
></span><span><sup>a</sup></span></strong>
(sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT,
Troponin-C, MYPC, RMB20, PLN, Sodium channel alpha unit, BAG3, Actin
Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.<span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>924–926</sup></span>
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered if there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
<li>
<p>
 <strong>Specific conditions.</strong>
</p>
</li>
<li>
<p>
 Muscular weakness: consider mitochondrial X-linked mutations, glycogen
storage disorders, FHLI mutations, Friedreich’s ataxia.
</p>
</li>
<li>
<p>
 Syndromic conditions (cognitive, visual impairment, drooping eyelid):
consider mitochondrial X-linked mutations, Noonan syndrome, Danon
disease.
</p>
</li>
<li>
<p>
 Café au lait spots (lentigines): consider Leopard/Noonan syndrome
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
<strong>Indication.</strong> It may be considered when the baseline
clinical assessment suggests cardiac inflammation or storage disease
which cannot be diagnosed by other means<span
></span><span><sup>896</sup></span> (see also
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">Section
14.6</a>). 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>With LVOTO</strong>
<ul>
<li>
<p>
 Avoid hypovolaemia (dehydration), arterial and venous dilators
(nitrates and phosphodiesterase type 5 inhibitors), and digoxin.
</p>
</li>
<li>
<p>
 Use non-vasodilating beta-blockers or use verapamil if beta-blockers
non-tolerated or ineffective.
</p>
</li>
<li>
<p>
 Low-dose loop or thiazide diuretics must be used with caution to
improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.
</p>
</li>
<li>
<p>
 Invasive treatment (septal reduction therapy by alcohol ablation or
myomectomy), in experienced centres, may be considered in those patients
with a resting or maximum provoked LVOT ≥50 mmHg and/or who remain
symptomatic (NYHA class III or IV, syncope) despite OMT.
</p>
</li>
<li>
<p>
 Novel drugs or devices may be considered once available.<span
></span><span><sup>909</sup></span><sup>,</sup><span
></span><span><sup>927</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Symptomatic without LVOTO</strong>
<ul>
<li>
<p>
 Cautious use of low-dose loop or thiazide diuretics avoiding
hypovolaemia.
</p>
</li>
<li>
<p>
 Verapamil/diltiazem if LVEF &gt;50% and beta-blockers are not tolerated
or ineffective.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Indication to ICD</strong>
<ul>
<li>
<p>
 Based on sudden cardiac death risk models.<span
></span><span><sup>928–930</sup></span>
</p>
</li>
<li>
<p>
 Consider ICD implantation if:
</p>
<ul>
<li>
<p>
  - family history of sudden cardiac death in one or more first degree
relatives under 40 years of age or sudden cardiac death in a first
degree relative with confirmed HCM at any age;
</p>
</li>
<li>
<p>
  - NSVT;
</p>
</li>
<li>
<p>
  - unexplained syncope.<span
></span><span><sup>931</sup></span>
</p>
</li>
</ul>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Fabry disease</strong>
</p>
</li>
<li>
<p>
 Enzyme replacement therapy (alpha-galactosidase A deficiency).<span
></span><span><sup>895</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Amyloidosis.</strong> See <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>
and <em>Figure <span ></span>21.</em> 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Definition</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 Wall thickness &gt;14 mm in one or more LV myocardial segments not
sufficiently explained solely by abnormal loading conditions.
</p>
</li>
<li>
<p>
 LVOTO ≥30 mmHg at rest or exercise, asymmetric hypertrophy, or
increased LGE in a patchy mid-wall pattern in the most hypertrophied
segment, further suggest the presence of HCM.
</p>
</li>
<li>
<p>
 It can be considered familial when two or more first- or second-degree
relatives with HCM or a first-degree relative with autopsy proven HCM
and sudden death at &lt;50 years of age are detected.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Differential diagnosis</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 It might be difficult with physiological hypertrophy induced by intense
athletic training, severe hypertension or aortic stenosis and with
isolated septal hypertrophy. Consider a genetic HCM if the degree of LV
hypertrophy is disproportionate with respect to the acquired trigger.
</p>
</li>
<li>
<p>
 Consider amyloidosis as a cause when increased thickness of the
interatrial septum, AV valve and/or RV free wall are detected (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>).
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling and testing</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication.</strong> Must be offered to all patients with a
diagnosis of HCM to identify a possible underlying genetic cause and to
all first-degree adult relatives of patients with HCM and a definite
disease-causing mutation, regardless of their phenotype, in order to
identify genetically affected individuals at a preclinical phase.
</p>
</li>
<li>
<p>
 Clinical evaluation, ECG and echocardiography, must be performed in
first-degree relatives who have the same definite disease-causing
mutation as the index patient.
</p>
</li>
<li>
<p>
 When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
<li>
<p>
 <strong>Minimal set of genes<span
></span><span><sup>a</sup></span></strong>
(sarcomeric gene mutation in up to 60% of cases): TTN, LMNA, MHC, TNNT,
Troponin-C, MYPC, RMB20, PLN, Sodium channel alpha unit, BAG3, Actin
Alpha Cardiac Muscle, Nexilin, Tropomyosin-1, Vinculin.<span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>924–926</sup></span>
</p>
</li>
<li>
<p>
 The use of additional sequencing for the analysis of very large panel
of genes may be considered if there is a clear familial history or
structural phenotype, by preference combined with family segregation.
</p>
</li>
<li>
<p>
 <strong>Specific conditions.</strong>
</p>
</li>
<li>
<p>
 Muscular weakness: consider mitochondrial X-linked mutations, glycogen
storage disorders, FHLI mutations, Friedreich’s ataxia.
</p>
</li>
<li>
<p>
 Syndromic conditions (cognitive, visual impairment, drooping eyelid):
consider mitochondrial X-linked mutations, Noonan syndrome, Danon
disease.
</p>
</li>
<li>
<p>
 Café au lait spots (lentigines): consider Leopard/Noonan syndrome
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
<strong>Indication.</strong> It may be considered when the baseline
clinical assessment suggests cardiac inflammation or storage disease
which cannot be diagnosed by other means<span
></span><span><sup>896</sup></span> (see also
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">Section
14.6</a>). 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong><span
></span><span><sup>895</sup></span><sup>,</sup><span
></span><span><sup>896</sup></span><sup>,</sup><span
></span><span><sup>923</sup></span> 
</td>
</tr>
<tr>
<td>
<strong>With LVOTO</strong>
<ul>
<li>
<p>
 Avoid hypovolaemia (dehydration), arterial and venous dilators
(nitrates and phosphodiesterase type 5 inhibitors), and digoxin.
</p>
</li>
<li>
<p>
 Use non-vasodilating beta-blockers or use verapamil if beta-blockers
non-tolerated or ineffective.
</p>
</li>
<li>
<p>
 Low-dose loop or thiazide diuretics must be used with caution to
improve dyspnoea associated with LVOTO, but avoiding hypovolaemia.
</p>
</li>
<li>
<p>
 Invasive treatment (septal reduction therapy by alcohol ablation or
myomectomy), in experienced centres, may be considered in those patients
with a resting or maximum provoked LVOT ≥50 mmHg and/or who remain
symptomatic (NYHA class III or IV, syncope) despite OMT.
</p>
</li>
<li>
<p>
 Novel drugs or devices may be considered once available.<span
></span><span><sup>909</sup></span><sup>,</sup><span
></span><span><sup>927</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Symptomatic without LVOTO</strong>
<ul>
<li>
<p>
 Cautious use of low-dose loop or thiazide diuretics avoiding
hypovolaemia.
</p>
</li>
<li>
<p>
 Verapamil/diltiazem if LVEF &gt;50% and beta-blockers are not tolerated
or ineffective.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Indication to ICD</strong>
<ul>
<li>
<p>
 Based on sudden cardiac death risk models.<span
></span><span><sup>928–930</sup></span>
</p>
</li>
<li>
<p>
 Consider ICD implantation if:
</p>
<ul>
<li>
<p>
  - family history of sudden cardiac death in one or more first degree
relatives under 40 years of age or sudden cardiac death in a first
degree relative with confirmed HCM at any age;
</p>
</li>
<li>
<p>
  - NSVT;
</p>
</li>
<li>
<p>
  - unexplained syncope.<span
></span><span><sup>931</sup></span>
</p>
</li>
</ul>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Fabry disease</strong>
</p>
</li>
<li>
<p>
 Enzyme replacement therapy (alpha-galactosidase A deficiency).<span
></span><span><sup>895</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Amyloidosis.</strong> See <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-14.6">section 14.6</a>
and <em>Figure <span ></span>21.</em> 
</td>
</tr>
</tbody>
</table>
<p>AV = atrio-ventricular; BAG3 = Bcl2-associated athanogene 3;
ECG = electrocardiogram; HCM = hypertrophic cardiomyopathy;
ICD = implantable cardioverter-defibrillator; LGE = late gadolinium
enhancement; LMNA = lamin A/C; LV = left ventricular; LVEF = left
ventricular ejection fraction; LVOT = left ventricular outflow tract;
LVOTO = left ventricular outflow tract obstruction; MHC = myosin heavy
chain; MYPC = myosin-binding protein C; NSVT = non-sustained ventricular
tachycardia; NYHA = New York Heart Association; OMT = optimal medical
therapy; PLN = phospholamban; RMB20 = ribonucleic acid binding motif 20;
RV = right ventricular; TNNT = troponin-T; TTN = titin.</p>
<p>a</p>
<p>The list of genes is not exhaustive, and will change over time, with
increasing knowledge of the pathogenicity. Contact the genetic
department to ask which core panel of genes they are using.</p>
<p>Table 29</p>
<p>Arrhythmogenic cardiomyopathy: specific aspects of diagnosis and
treatment<sup>912</sup><sup>,</sup><sup>915</sup><sup>,</sup><sup>932</sup></p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Definition</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
Inherited heart muscle disease characterized by progressive fibrofatty
replacement of the RV myocardium which may act as a substrate for
ventricular arrhythmias, unexplained syncope and/or sudden cardiac
death.
</p>
</li>
<li>
<p>
LV involvement and systolic dysfunction occurs in &gt;30% of AC
patients, therefore its phenotype may overlap with DCM.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Diagnosis</strong><span
></span><span><sup>933</sup></span> 
</td>
</tr>
<tr>
<td>
Based upon the evaluation of a combination of the genetic factors (most
cases autosomal dominant desmosomal mutations), documentation of
ventricular arrhythmias and imaging criteria (echocardiography and MRI)
of RV dysplasia with the fibrofatty replacement either or not confirmed
by EMB. Specific ECG abnormalities can be present or absent. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling/testing</strong><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>912</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Indication.</strong> Must be offered to all patients with a
suspected AC and has to be offered to all first-degree adult relatives
of patients with AC and a definite disease-causing mutation, regardless
of their phenotype in order to identify genetically affected individuals
at a preclinical phase.
</p>
</li>
<li>
<p>
Genetic family screening can be also indicated for arrhythmic risk
stratification purposes.
</p>
</li>
<li>
<p>
Clinical evaluation, ECG, echocardiography and possibly CMR have to be
performed in first-degree relatives who have the same definite
disease-causing mutation as the index patient.
</p>
</li>
<li>
<p>
When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
</ul>
<strong>Minimal set of genes:</strong>
<ul>
<li>
<p>
Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2,
DSG2 and DSC2<sup>a</sup>
</p>
</li>
<li>
<p>
With frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3,
desmin, α-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2, TRPM4 or
PLN variants in particular.
</p>
</li>
<li>
<p>
If mild LV hypertrophy: consider TNNT variants.
</p>
</li>
<li>
<p>
Cutaneous abnormalities, palmar and plantar hyperkeratosis: consider
rare recessive mutations leading to Carvajal syndrome and Naxos disease.
Plakoglobin (JUP).
</p>
</li>
<li>
<p>
With CMR presentation of myocarditis along AC: consider <em>DSP</em>
gene variants.<span
></span><span><sup>934</sup></span><sup>,</sup><span
></span><span><sup>935</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
It should be reserved to highly selected cases after all non-invasive
studies have been assessed. Fibrofatty replacement with or without
replacement type fibrosis at RV septal biopsies are the characteristic
findings. EMB has low sensitivity for the diagnosis of AC in cases of
focal distribution. 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections
5</a> and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>).
</p>
</li>
<li>
<p>
Competitive sports should be avoided, limit activities to leisure-time
activities.<span
></span><span><sup>936</sup></span>
</p>
</li>
<li>
<p>
In patients with ventricular arrhythmias: beta-blockers must be titrated
to the maximally tolerated dose as first-line therapy. Amiodarone can be
considered in addition to beta-blockers or if beta-blockers
contraindicated or not tolerated; ICD implantation is indicated if
history of aborted sudden cardiac death or sustained and/or
haemodynamically poorly tolerated ventricular tachycardia.<span
></span><span><sup>910–912</sup></span>
</p>
</li>
<li>
<p>
In patients with no ventricular arrhythmias: ICD can be considered (see
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6.1">section
6.1</a>) even in patients with LMNA or FLNC gene mutations and LVEF
&lt;45%.<span
></span><span><sup>912</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Definition</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
Inherited heart muscle disease characterized by progressive fibrofatty
replacement of the RV myocardium which may act as a substrate for
ventricular arrhythmias, unexplained syncope and/or sudden cardiac
death.
</p>
</li>
<li>
<p>
LV involvement and systolic dysfunction occurs in &gt;30% of AC
patients, therefore its phenotype may overlap with DCM.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Diagnosis</strong><span
></span><span><sup>933</sup></span> 
</td>
</tr>
<tr>
<td>
Based upon the evaluation of a combination of the genetic factors (most
cases autosomal dominant desmosomal mutations), documentation of
ventricular arrhythmias and imaging criteria (echocardiography and MRI)
of RV dysplasia with the fibrofatty replacement either or not confirmed
by EMB. Specific ECG abnormalities can be present or absent. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling/testing</strong><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>912</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Indication.</strong> Must be offered to all patients with a
suspected AC and has to be offered to all first-degree adult relatives
of patients with AC and a definite disease-causing mutation, regardless
of their phenotype in order to identify genetically affected individuals
at a preclinical phase.
</p>
</li>
<li>
<p>
Genetic family screening can be also indicated for arrhythmic risk
stratification purposes.
</p>
</li>
<li>
<p>
Clinical evaluation, ECG, echocardiography and possibly CMR have to be
performed in first-degree relatives who have the same definite
disease-causing mutation as the index patient.
</p>
</li>
<li>
<p>
When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
</ul>
<strong>Minimal set of genes:</strong>
<ul>
<li>
<p>
Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2,
DSG2 and DSC2<sup>a</sup>
</p>
</li>
<li>
<p>
With frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3,
desmin, α-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2, TRPM4 or
PLN variants in particular.
</p>
</li>
<li>
<p>
If mild LV hypertrophy: consider TNNT variants.
</p>
</li>
<li>
<p>
Cutaneous abnormalities, palmar and plantar hyperkeratosis: consider
rare recessive mutations leading to Carvajal syndrome and Naxos disease.
Plakoglobin (JUP).
</p>
</li>
<li>
<p>
With CMR presentation of myocarditis along AC: consider <em>DSP</em>
gene variants.<span
></span><span><sup>934</sup></span><sup>,</sup><span
></span><span><sup>935</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
It should be reserved to highly selected cases after all non-invasive
studies have been assessed. Fibrofatty replacement with or without
replacement type fibrosis at RV septal biopsies are the characteristic
findings. EMB has low sensitivity for the diagnosis of AC in cases of
focal distribution. 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections
5</a> and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>).
</p>
</li>
<li>
<p>
Competitive sports should be avoided, limit activities to leisure-time
activities.<span
></span><span><sup>936</sup></span>
</p>
</li>
<li>
<p>
In patients with ventricular arrhythmias: beta-blockers must be titrated
to the maximally tolerated dose as first-line therapy. Amiodarone can be
considered in addition to beta-blockers or if beta-blockers
contraindicated or not tolerated; ICD implantation is indicated if
history of aborted sudden cardiac death or sustained and/or
haemodynamically poorly tolerated ventricular tachycardia.<span
></span><span><sup>910–912</sup></span>
</p>
</li>
<li>
<p>
In patients with no ventricular arrhythmias: ICD can be considered (see
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6.1">section
6.1</a>) even in patients with LMNA or FLNC gene mutations and LVEF
&lt;45%.<span
></span><span><sup>912</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>AC = arrhythmogenic cardiomyopathy; BAG3 = Bcl2-associated
athanogene 3; CMR = cardiac magnetic resonance; DCM = dilated
cardiomyopathy; DSC2 = desmocollin 2; DSG2 = desmoglein 2;
DSP = desmoplakin; ECG = electrocardiogram; EMB = endomyocardial biopsy;
FLN = filamin; FLNC = filamin C; HF = heart failure; HFrEF = heart
failure with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; JUP = junction plakoglobin;
KCNH2 = potassium voltage-gated channel subfamily H member 2;
KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM
domain binding 3; LMNA = lamin A/C; LV = left ventricular; LVEF = left
ventricular ejection fraction; MRI = magnetic resonance imaging;
NKX2-5 = NK2 transcription factor related, locus 5; PLN = phospholamban;
PKP2 = plakophilin 2; RMB20 = ribonucleic acid binding motif 20;
RV = right ventricular; SCN5A = sodium channel alpha subunit 5;
TMEM43 = transmembrane protein 43; TNNT = troponin-T; TRPM4 = transient
receptor potential cation channel subfamily M member 4.</p>
<p>Table 29</p>
<p>Arrhythmogenic cardiomyopathy: specific aspects of diagnosis and
treatment<sup>912</sup><sup>,</sup><sup>915</sup><sup>,</sup><sup>932</sup></p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Definition</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
Inherited heart muscle disease characterized by progressive fibrofatty
replacement of the RV myocardium which may act as a substrate for
ventricular arrhythmias, unexplained syncope and/or sudden cardiac
death.
</p>
</li>
<li>
<p>
LV involvement and systolic dysfunction occurs in &gt;30% of AC
patients, therefore its phenotype may overlap with DCM.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Diagnosis</strong><span
></span><span><sup>933</sup></span> 
</td>
</tr>
<tr>
<td>
Based upon the evaluation of a combination of the genetic factors (most
cases autosomal dominant desmosomal mutations), documentation of
ventricular arrhythmias and imaging criteria (echocardiography and MRI)
of RV dysplasia with the fibrofatty replacement either or not confirmed
by EMB. Specific ECG abnormalities can be present or absent. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling/testing</strong><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>912</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Indication.</strong> Must be offered to all patients with a
suspected AC and has to be offered to all first-degree adult relatives
of patients with AC and a definite disease-causing mutation, regardless
of their phenotype in order to identify genetically affected individuals
at a preclinical phase.
</p>
</li>
<li>
<p>
Genetic family screening can be also indicated for arrhythmic risk
stratification purposes.
</p>
</li>
<li>
<p>
Clinical evaluation, ECG, echocardiography and possibly CMR have to be
performed in first-degree relatives who have the same definite
disease-causing mutation as the index patient.
</p>
</li>
<li>
<p>
When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
</ul>
<strong>Minimal set of genes:</strong>
<ul>
<li>
<p>
Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2,
DSG2 and DSC2<sup>a</sup>
</p>
</li>
<li>
<p>
With frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3,
desmin, α-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2, TRPM4 or
PLN variants in particular.
</p>
</li>
<li>
<p>
If mild LV hypertrophy: consider TNNT variants.
</p>
</li>
<li>
<p>
Cutaneous abnormalities, palmar and plantar hyperkeratosis: consider
rare recessive mutations leading to Carvajal syndrome and Naxos disease.
Plakoglobin (JUP).
</p>
</li>
<li>
<p>
With CMR presentation of myocarditis along AC: consider <em>DSP</em>
gene variants.<span
></span><span><sup>934</sup></span><sup>,</sup><span
></span><span><sup>935</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
It should be reserved to highly selected cases after all non-invasive
studies have been assessed. Fibrofatty replacement with or without
replacement type fibrosis at RV septal biopsies are the characteristic
findings. EMB has low sensitivity for the diagnosis of AC in cases of
focal distribution. 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections
5</a> and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>).
</p>
</li>
<li>
<p>
Competitive sports should be avoided, limit activities to leisure-time
activities.<span
></span><span><sup>936</sup></span>
</p>
</li>
<li>
<p>
In patients with ventricular arrhythmias: beta-blockers must be titrated
to the maximally tolerated dose as first-line therapy. Amiodarone can be
considered in addition to beta-blockers or if beta-blockers
contraindicated or not tolerated; ICD implantation is indicated if
history of aborted sudden cardiac death or sustained and/or
haemodynamically poorly tolerated ventricular tachycardia.<span
></span><span><sup>910–912</sup></span>
</p>
</li>
<li>
<p>
In patients with no ventricular arrhythmias: ICD can be considered (see
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6.1">section
6.1</a>) even in patients with LMNA or FLNC gene mutations and LVEF
&lt;45%.<span
></span><span><sup>912</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Definition</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
Inherited heart muscle disease characterized by progressive fibrofatty
replacement of the RV myocardium which may act as a substrate for
ventricular arrhythmias, unexplained syncope and/or sudden cardiac
death.
</p>
</li>
<li>
<p>
LV involvement and systolic dysfunction occurs in &gt;30% of AC
patients, therefore its phenotype may overlap with DCM.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Diagnosis</strong><span
></span><span><sup>933</sup></span> 
</td>
</tr>
<tr>
<td>
Based upon the evaluation of a combination of the genetic factors (most
cases autosomal dominant desmosomal mutations), documentation of
ventricular arrhythmias and imaging criteria (echocardiography and MRI)
of RV dysplasia with the fibrofatty replacement either or not confirmed
by EMB. Specific ECG abnormalities can be present or absent. 
</td>
</tr>
<tr>
<td>
<strong>Genetic counselling/testing</strong><span
></span><span><sup>898</sup></span><sup>,</sup><span
></span><span><sup>912</sup></span> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
<strong>Indication.</strong> Must be offered to all patients with a
suspected AC and has to be offered to all first-degree adult relatives
of patients with AC and a definite disease-causing mutation, regardless
of their phenotype in order to identify genetically affected individuals
at a preclinical phase.
</p>
</li>
<li>
<p>
Genetic family screening can be also indicated for arrhythmic risk
stratification purposes.
</p>
</li>
<li>
<p>
Clinical evaluation, ECG, echocardiography and possibly CMR have to be
performed in first-degree relatives who have the same definite
disease-causing mutation as the index patient.
</p>
</li>
<li>
<p>
When no definite genetic mutation is identified in the index patient or
genetic testing is not performed, clinical evaluation with ECG and
echocardiography should be considered in first-degree adult relatives
and repeated every 2–5 years or less if non-diagnostic abnormalities are
present.
</p>
</li>
</ul>
<strong>Minimal set of genes:</strong>
<ul>
<li>
<p>
Desmosomal, mostly with isolated RV involvement: plakoglobin, DSP, PKP2,
DSG2 and DSC2<sup>a</sup>
</p>
</li>
<li>
<p>
With frequent LV involvement/DCM: DSP, FLNC, SCN5A, TMEM43, FLN, LDB3,
desmin, α-actinin, BAG3, NKX2-5, RBM20, SCN5A, KCNQ1, KCNH2, TRPM4 or
PLN variants in particular.
</p>
</li>
<li>
<p>
If mild LV hypertrophy: consider TNNT variants.
</p>
</li>
<li>
<p>
Cutaneous abnormalities, palmar and plantar hyperkeratosis: consider
rare recessive mutations leading to Carvajal syndrome and Naxos disease.
Plakoglobin (JUP).
</p>
</li>
<li>
<p>
With CMR presentation of myocarditis along AC: consider <em>DSP</em>
gene variants.<span
></span><span><sup>934</sup></span><sup>,</sup><span
></span><span><sup>935</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Endomyocardial biopsy</strong> 
</td>
</tr>
<tr>
<td>
It should be reserved to highly selected cases after all non-invasive
studies have been assessed. Fibrofatty replacement with or without
replacement type fibrosis at RV septal biopsies are the characteristic
findings. EMB has low sensitivity for the diagnosis of AC in cases of
focal distribution. 
</td>
</tr>
<tr>
<td>
<strong>Therapeutic options</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
HF treatment for HFrEF (see <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-5">sections
5</a> and <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6">6</a>).
</p>
</li>
<li>
<p>
Competitive sports should be avoided, limit activities to leisure-time
activities.<span
></span><span><sup>936</sup></span>
</p>
</li>
<li>
<p>
In patients with ventricular arrhythmias: beta-blockers must be titrated
to the maximally tolerated dose as first-line therapy. Amiodarone can be
considered in addition to beta-blockers or if beta-blockers
contraindicated or not tolerated; ICD implantation is indicated if
history of aborted sudden cardiac death or sustained and/or
haemodynamically poorly tolerated ventricular tachycardia.<span
></span><span><sup>910–912</sup></span>
</p>
</li>
<li>
<p>
In patients with no ventricular arrhythmias: ICD can be considered (see
<span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-6.1">section
6.1</a>) even in patients with LMNA or FLNC gene mutations and LVEF
&lt;45%.<span
></span><span><sup>912</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>AC = arrhythmogenic cardiomyopathy; BAG3 = Bcl2-associated
athanogene 3; CMR = cardiac magnetic resonance; DCM = dilated
cardiomyopathy; DSC2 = desmocollin 2; DSG2 = desmoglein 2;
DSP = desmoplakin; ECG = electrocardiogram; EMB = endomyocardial biopsy;
FLN = filamin; FLNC = filamin C; HF = heart failure; HFrEF = heart
failure with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; JUP = junction plakoglobin;
KCNH2 = potassium voltage-gated channel subfamily H member 2;
KCNQ1 = potassium voltage-gated channel subfamily Q member 1; LDB3 = LIM
domain binding 3; LMNA = lamin A/C; LV = left ventricular; LVEF = left
ventricular ejection fraction; MRI = magnetic resonance imaging;
NKX2-5 = NK2 transcription factor related, locus 5; PLN = phospholamban;
PKP2 = plakophilin 2; RMB20 = ribonucleic acid binding motif 20;
RV = right ventricular; SCN5A = sodium channel alpha subunit 5;
TMEM43 = transmembrane protein 43; TNNT = troponin-T; TRPM4 = transient
receptor potential cation channel subfamily M member 4.</p>
<h3 >14.3 Left ventricular
non-compaction</h3>
<p>LVNC is a very rare congenital CMP characterized by endomyocardial
trabeculations that increase in number and prominence. In most cases,
including when the condition is caused by mutations in the MYH7 or
MYBPC3 gene, LVNC is inherited in an autosomal dominant
pattern.<sup>644</sup><sup>,</sup><sup>937</sup><sup>,</sup><sup>938</sup>
A clear overlap exists in families with DCM and HCM phenotypes. Quite
commonly individuals with features of LVNC are found in families where
other affected relatives have typical HCM or DCM. Therefore, LVNC is not
treated as a separate disease entity, but as a separate rare
presentation of a genetic susceptibility to either HCM or
DCM.<sup>939</sup></p>
<h3 >14.4 Atrial disease</h3>
<h4 >14.4.1 Definition</h4>
<p>Atrial disease, also termed atrial failure or myopathy, can be
defined as a complex of subclinical structural, electrophysiological,
and functional changes that affect the atria with the potential to
produce clinical
consequences.<sup>606</sup><sup>,</sup><sup>940</sup><sup>,</sup><sup>941</sup>
It has been suggested that atrial disease links the pathophysiology of
HF, especially HFpEF, with AF, as they often coexist, are closely
inter-related and share common risk
factors.<sup>606</sup><sup>,</sup><sup>685</sup><sup>,</sup><sup>942</sup><sup>,</sup><sup>943</sup></p>
<h4 >14.4.2 Diagnosis</h4>
<p>Atrial size and function can be evaluated by multimodality imaging
including two- and three-dimensional echocardiography, myocardial
deformation, computed tomography (CT) and CMR.<sup>944</sup> Cardiac
biomarkers, including high-sensitivity cardiac troponins and NPs, may
assess pathophysiological aspects of atrial disease.<sup>945–947</sup>
The increased levels of NPs in AF may also be an indicator of an
underlying atrial disease.<sup>942</sup><sup>,</sup><sup>948</sup> A
comprehensive characterization of atrial disease combining clinical,
imaging, biochemical and molecular features is, however, still
lacking.</p>
<h4 >14.4.3 Management</h4>
<p>Atrial disease is an emerging therapeutic target in the prevention of
AF, systemic thromboembolism, and perhaps HFpEF.<sup>949</sup> As atrial
disease appears to result from the intersection of shared risk factors
and comorbidities predisposing to both AF and HF, diabetes mellitus,
hypertension, obesity, smoking, and physical inactivity may be of
paramount importance for its
development.<sup>7</sup><sup>,</sup><sup>950</sup> Effective management
of HF and AF (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.1.1">section 12.1.1</a>),
as well as treatment of mitral regurgitation (see <a
href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-12.3.3">section 12.3.3</a>),
may also be important to counteract atrial disease progression.</p>
<h3 >14.5 Myocarditis</h3>
<h4 >14.5.1 Epidemiology and
diagnosis</h4>
<p>The incidence of acute myocarditis is estimated to be 1.5 million
cases per year globally.<sup>951</sup> The contribution of myocarditis
as a cause of HF varies by age and region from approximately 0.5% to
4.0%.<sup>918</sup><sup>,</sup><sup>952</sup> Chronic, EMB proven,
inflammation can be found in 9% to 30% of adult patients with a
DCM.<sup>918</sup><sup>,</sup><sup>953</sup> The most frequent potential
aetiologies triggering acute myocarditis in Europe are reported in
<em>Table 30</em>.</p>
<p>Table 30</p>
<p>Aetiologies to be considered triggering acute
myocarditis<sup>917</sup></p>
<table role="presentation">
<tbody>
<tr>
<td colspan="2">
<strong>Infectious</strong> 
</td>
</tr>
<tr>
<td>
Viral 
</td>
<td>
Parvovirus B19, human herpes virus-6, Epstein-Barr virus, enteroviruses,
(coxsackievirus, adenovirus), CMV, HIV, SARS-CoV-2 
</td>
</tr>
<tr>
<td>
Others 
</td>
<td>
<em>Borrelia, Coxiella burnetii</em> (Q-fever) 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Systemic disease</strong> 
</td>
</tr>
<tr>
<td>
Auto-immune and others 
</td>
<td>
Sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, SLE,
ANCA-positive vasculitis, rheumatoid arthritis, any other auto-immune
disease 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Toxic</strong> 
</td>
</tr>
<tr>
<td>
Medications 
</td>
<td>
Immune check point inhibitors, anthracyclines, clozapine, adrenergic
drugs, 5-fluorouracil 
</td>
</tr>
<tr>
<td>
Other agents 
</td>
<td>
Alcohol, amphetamines, cocaine 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td colspan="2">
<strong>Infectious</strong> 
</td>
</tr>
<tr>
<td>
Viral 
</td>
<td>
Parvovirus B19, human herpes virus-6, Epstein-Barr virus, enteroviruses,
(coxsackievirus, adenovirus), CMV, HIV, SARS-CoV-2 
</td>
</tr>
<tr>
<td>
Others 
</td>
<td>
<em>Borrelia, Coxiella burnetii</em> (Q-fever) 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Systemic disease</strong> 
</td>
</tr>
<tr>
<td>
Auto-immune and others 
</td>
<td>
Sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, SLE,
ANCA-positive vasculitis, rheumatoid arthritis, any other auto-immune
disease 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Toxic</strong> 
</td>
</tr>
<tr>
<td>
Medications 
</td>
<td>
Immune check point inhibitors, anthracyclines, clozapine, adrenergic
drugs, 5-fluorouracil 
</td>
</tr>
<tr>
<td>
Other agents 
</td>
<td>
Alcohol, amphetamines, cocaine 
</td>
</tr>
</tbody>
</table>
<p>ANCA = antineutrophil cytoplasmic antibody; CMV = cytomegalovirus;
HIV = human immunodeficiency virus; SARS-CoV-2 = severe acute
respiratory syndrome coronavirus 2; SLE = systemic lupus
erythematosus.</p>
<p>Table 30</p>
<p>Aetiologies to be considered triggering acute
myocarditis<sup>917</sup></p>
<table role="presentation">
<tbody>
<tr>
<td colspan="2">
<strong>Infectious</strong> 
</td>
</tr>
<tr>
<td>
Viral 
</td>
<td>
Parvovirus B19, human herpes virus-6, Epstein-Barr virus, enteroviruses,
(coxsackievirus, adenovirus), CMV, HIV, SARS-CoV-2 
</td>
</tr>
<tr>
<td>
Others 
</td>
<td>
<em>Borrelia, Coxiella burnetii</em> (Q-fever) 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Systemic disease</strong> 
</td>
</tr>
<tr>
<td>
Auto-immune and others 
</td>
<td>
Sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, SLE,
ANCA-positive vasculitis, rheumatoid arthritis, any other auto-immune
disease 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Toxic</strong> 
</td>
</tr>
<tr>
<td>
Medications 
</td>
<td>
Immune check point inhibitors, anthracyclines, clozapine, adrenergic
drugs, 5-fluorouracil 
</td>
</tr>
<tr>
<td>
Other agents 
</td>
<td>
Alcohol, amphetamines, cocaine 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td colspan="2">
<strong>Infectious</strong> 
</td>
</tr>
<tr>
<td>
Viral 
</td>
<td>
Parvovirus B19, human herpes virus-6, Epstein-Barr virus, enteroviruses,
(coxsackievirus, adenovirus), CMV, HIV, SARS-CoV-2 
</td>
</tr>
<tr>
<td>
Others 
</td>
<td>
<em>Borrelia, Coxiella burnetii</em> (Q-fever) 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Systemic disease</strong> 
</td>
</tr>
<tr>
<td>
Auto-immune and others 
</td>
<td>
Sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, SLE,
ANCA-positive vasculitis, rheumatoid arthritis, any other auto-immune
disease 
</td>
</tr>
<tr>
<td colspan="2">
<strong>Toxic</strong> 
</td>
</tr>
<tr>
<td>
Medications 
</td>
<td>
Immune check point inhibitors, anthracyclines, clozapine, adrenergic
drugs, 5-fluorouracil 
</td>
</tr>
<tr>
<td>
Other agents 
</td>
<td>
Alcohol, amphetamines, cocaine 
</td>
</tr>
</tbody>
</table>
<p>ANCA = antineutrophil cytoplasmic antibody; CMV = cytomegalovirus;
HIV = human immunodeficiency virus; SARS-CoV-2 = severe acute
respiratory syndrome coronavirus 2; SLE = systemic lupus
erythematosus.</p>
<p>The clinical presentation of acute myocarditis may vary from mild
symptoms to cardiogenic shock. Workup for the diagnosis of acute
myocarditis in patients with HF is reported in <em>Table 31</em> and
<em>Figure 20</em>. Specific criteria about biopsies and CMR are
reported in <em>Tables 32</em> and <em>33</em>.</p>
<p>Table 31</p>
<p>Diagnostic workup in suspected acute myocarditis</p>
<table role="presentation">
<tbody>
<tr>
<td colspan="4">
<strong>Definition of suspected acute myocarditis</strong> 
</td>
</tr>
<tr>
<td colspan="4">
Clinical presentation + ≥1 mandatory diagnostic test being positive (by
preference CMR) in the absence of significant coronary artery, valvular
or congenital heart disease, or other causes. 
</td>
</tr>
<tr>
<td colspan="2">
 
</td>
<td>
<strong>Sensitivity</strong> 
</td>
<td>
<strong>Specificity</strong> 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Clinical presentation</strong> 
</td>
</tr>
<tr>
<td colspan="2">
Acute/new onset chest pain, dyspnoea, signs of left and/or right HF,
and/or unexplained arrhythmias or aborted sudden death. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Mandatory diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
ECG 
</td>
<td>
New and dynamic ST-T abnormalities, including pseudo-infarct ST segment
elevation, atrial or ventricular arrhythmias, AV blocks, QRS
abnormalities. 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Laboratory tests 
</td>
<td>
<ul>
<li>
<p>
Elevated troponins with dynamic changes consistent with myocardial
necrosis.
</p>
</li>
<li>
<p>
Standard tests including white blood cells count to exclude
eosinophilia.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
</ul>
 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Echocardiography 
</td>
<td>
New structural or function abnormalities, regional wall motion
abnormalities or global ventricular dysfunction without ventricular
dilatation or with, generally mild, dilatation, increased wall thickness
due to myocardial oedema, pericardial effusion, intracardiac thrombi,
not explained by other conditions (e.g., CAD, ACS or valvular heart
disease). 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CMR 
</td>
<td>
Oedema, inflammation and fibrosis detection, quantification and
localization through T1 and T2 mapping, extracellular volume assessment
and LGE (see <em>Table <span
></span>33</em>).<span
></span><span><sup>955</sup></span><sup>,</sup><span
></span><span><sup>956</sup></span> 
</td>
<td>
High 
</td>
<td>
Intermediate 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Additional diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
Coronary angiography or CTCA 
</td>
<td>
Excludes significant CAD or ACS in clinically suspected myocarditis. 
</td>
<td>
High 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Endomyocardial biopsy 
</td>
<td>
For diagnosis and indication to specific treatment (see <em>Table <span
></span>32</em>). 
</td>
<td>
Intermediate 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Cardiac PET 
</td>
<td>
May be useful in patients who cannot undergo CMR or with suspected
systemic autoimmune disease or cardiac sarcoidosis.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>957</sup></span> 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td rowspan="3">
Additional laboratory test 
</td>
<td>
Skeletal muscle enzymes, liver and renal function, natriuretic peptides,
thyroid function tests, iron status, markers of systemic autoimmune
disease. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CRP elevated in 80–90% patients.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span> 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
PCR testing of common cardiotropic viruses. It can detect systemic
infection but does not prove cardiac infection and cannot substitute
viral genome analysis on EMB samples.<span
></span><span><sup>917</sup></span>
</p>
</li>
<li>
<p>
Circulating IgG antibodies to cardiotropic viruses are common in the
absence of viral myocarditis. Very limited diagnostic usefulness.<span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span>
</p>
</li>
<li>
<p>
Specific test for SARS-CoV-2, Borrelia, HIV or CMV if clinical
suspicion.
</p>
</li>
</ul>
 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td colspan="4">
<strong>Definition of suspected acute myocarditis</strong> 
</td>
</tr>
<tr>
<td colspan="4">
Clinical presentation + ≥1 mandatory diagnostic test being positive (by
preference CMR) in the absence of significant coronary artery, valvular
or congenital heart disease, or other causes. 
</td>
</tr>
<tr>
<td colspan="2">
 
</td>
<td>
<strong>Sensitivity</strong> 
</td>
<td>
<strong>Specificity</strong> 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Clinical presentation</strong> 
</td>
</tr>
<tr>
<td colspan="2">
Acute/new onset chest pain, dyspnoea, signs of left and/or right HF,
and/or unexplained arrhythmias or aborted sudden death. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Mandatory diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
ECG 
</td>
<td>
New and dynamic ST-T abnormalities, including pseudo-infarct ST segment
elevation, atrial or ventricular arrhythmias, AV blocks, QRS
abnormalities. 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Laboratory tests 
</td>
<td>
<ul>
<li>
<p>
Elevated troponins with dynamic changes consistent with myocardial
necrosis.
</p>
</li>
<li>
<p>
Standard tests including white blood cells count to exclude
eosinophilia.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
</ul>
 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Echocardiography 
</td>
<td>
New structural or function abnormalities, regional wall motion
abnormalities or global ventricular dysfunction without ventricular
dilatation or with, generally mild, dilatation, increased wall thickness
due to myocardial oedema, pericardial effusion, intracardiac thrombi,
not explained by other conditions (e.g., CAD, ACS or valvular heart
disease). 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CMR 
</td>
<td>
Oedema, inflammation and fibrosis detection, quantification and
localization through T1 and T2 mapping, extracellular volume assessment
and LGE (see <em>Table <span
></span>33</em>).<span
></span><span><sup>955</sup></span><sup>,</sup><span
></span><span><sup>956</sup></span> 
</td>
<td>
High 
</td>
<td>
Intermediate 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Additional diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
Coronary angiography or CTCA 
</td>
<td>
Excludes significant CAD or ACS in clinically suspected myocarditis. 
</td>
<td>
High 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Endomyocardial biopsy 
</td>
<td>
For diagnosis and indication to specific treatment (see <em>Table <span
></span>32</em>). 
</td>
<td>
Intermediate 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Cardiac PET 
</td>
<td>
May be useful in patients who cannot undergo CMR or with suspected
systemic autoimmune disease or cardiac sarcoidosis.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>957</sup></span> 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td rowspan="3">
Additional laboratory test 
</td>
<td>
Skeletal muscle enzymes, liver and renal function, natriuretic peptides,
thyroid function tests, iron status, markers of systemic autoimmune
disease. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CRP elevated in 80–90% patients.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span> 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
PCR testing of common cardiotropic viruses. It can detect systemic
infection but does not prove cardiac infection and cannot substitute
viral genome analysis on EMB samples.<span
></span><span><sup>917</sup></span>
</p>
</li>
<li>
<p>
Circulating IgG antibodies to cardiotropic viruses are common in the
absence of viral myocarditis. Very limited diagnostic usefulness.<span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span>
</p>
</li>
<li>
<p>
Specific test for SARS-CoV-2, Borrelia, HIV or CMV if clinical
suspicion.
</p>
</li>
</ul>
 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
</tbody>
</table>
<p>ACS = acute coronary syndrome; AV = atrio-ventricular; CAD = coronary
artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus;
CRP = C-reactive protein; CTCA = computed tomography coronary
angiography; ECG = electrocardiogram; EMB = endomyocardial biopsy;
HF = heart failure; HIV = human immunodeficiency virus;
IgG = immunoglobulin G; LGE = late gadolinium enhancement;
PCR = polymerase chain reaction; PET = positron emission tomography;
QRS = Q, R and S waves (combination of three of the graphical
deflections); SARS-CoV-2 = severe acute respiratory syndrome
coronavirus 2; ST = ST segment of the electrocardiogram; ST-T = ST
segment and T wave of the electrocardiogram.</p>
<p>Table 31</p>
<p>Diagnostic workup in suspected acute myocarditis</p>
<table role="presentation">
<tbody>
<tr>
<td colspan="4">
<strong>Definition of suspected acute myocarditis</strong> 
</td>
</tr>
<tr>
<td colspan="4">
Clinical presentation + ≥1 mandatory diagnostic test being positive (by
preference CMR) in the absence of significant coronary artery, valvular
or congenital heart disease, or other causes. 
</td>
</tr>
<tr>
<td colspan="2">
 
</td>
<td>
<strong>Sensitivity</strong> 
</td>
<td>
<strong>Specificity</strong> 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Clinical presentation</strong> 
</td>
</tr>
<tr>
<td colspan="2">
Acute/new onset chest pain, dyspnoea, signs of left and/or right HF,
and/or unexplained arrhythmias or aborted sudden death. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Mandatory diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
ECG 
</td>
<td>
New and dynamic ST-T abnormalities, including pseudo-infarct ST segment
elevation, atrial or ventricular arrhythmias, AV blocks, QRS
abnormalities. 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Laboratory tests 
</td>
<td>
<ul>
<li>
<p>
Elevated troponins with dynamic changes consistent with myocardial
necrosis.
</p>
</li>
<li>
<p>
Standard tests including white blood cells count to exclude
eosinophilia.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
</ul>
 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Echocardiography 
</td>
<td>
New structural or function abnormalities, regional wall motion
abnormalities or global ventricular dysfunction without ventricular
dilatation or with, generally mild, dilatation, increased wall thickness
due to myocardial oedema, pericardial effusion, intracardiac thrombi,
not explained by other conditions (e.g., CAD, ACS or valvular heart
disease). 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CMR 
</td>
<td>
Oedema, inflammation and fibrosis detection, quantification and
localization through T1 and T2 mapping, extracellular volume assessment
and LGE (see <em>Table <span
></span>33</em>).<span
></span><span><sup>955</sup></span><sup>,</sup><span
></span><span><sup>956</sup></span> 
</td>
<td>
High 
</td>
<td>
Intermediate 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Additional diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
Coronary angiography or CTCA 
</td>
<td>
Excludes significant CAD or ACS in clinically suspected myocarditis. 
</td>
<td>
High 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Endomyocardial biopsy 
</td>
<td>
For diagnosis and indication to specific treatment (see <em>Table <span
></span>32</em>). 
</td>
<td>
Intermediate 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Cardiac PET 
</td>
<td>
May be useful in patients who cannot undergo CMR or with suspected
systemic autoimmune disease or cardiac sarcoidosis.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>957</sup></span> 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td rowspan="3">
Additional laboratory test 
</td>
<td>
Skeletal muscle enzymes, liver and renal function, natriuretic peptides,
thyroid function tests, iron status, markers of systemic autoimmune
disease. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CRP elevated in 80–90% patients.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span> 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
PCR testing of common cardiotropic viruses. It can detect systemic
infection but does not prove cardiac infection and cannot substitute
viral genome analysis on EMB samples.<span
></span><span><sup>917</sup></span>
</p>
</li>
<li>
<p>
Circulating IgG antibodies to cardiotropic viruses are common in the
absence of viral myocarditis. Very limited diagnostic usefulness.<span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span>
</p>
</li>
<li>
<p>
Specific test for SARS-CoV-2, Borrelia, HIV or CMV if clinical
suspicion.
</p>
</li>
</ul>
 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td colspan="4">
<strong>Definition of suspected acute myocarditis</strong> 
</td>
</tr>
<tr>
<td colspan="4">
Clinical presentation + ≥1 mandatory diagnostic test being positive (by
preference CMR) in the absence of significant coronary artery, valvular
or congenital heart disease, or other causes. 
</td>
</tr>
<tr>
<td colspan="2">
 
</td>
<td>
<strong>Sensitivity</strong> 
</td>
<td>
<strong>Specificity</strong> 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Clinical presentation</strong> 
</td>
</tr>
<tr>
<td colspan="2">
Acute/new onset chest pain, dyspnoea, signs of left and/or right HF,
and/or unexplained arrhythmias or aborted sudden death. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Mandatory diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
ECG 
</td>
<td>
New and dynamic ST-T abnormalities, including pseudo-infarct ST segment
elevation, atrial or ventricular arrhythmias, AV blocks, QRS
abnormalities. 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Laboratory tests 
</td>
<td>
<ul>
<li>
<p>
Elevated troponins with dynamic changes consistent with myocardial
necrosis.
</p>
</li>
<li>
<p>
Standard tests including white blood cells count to exclude
eosinophilia.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
</ul>
 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
Echocardiography 
</td>
<td>
New structural or function abnormalities, regional wall motion
abnormalities or global ventricular dysfunction without ventricular
dilatation or with, generally mild, dilatation, increased wall thickness
due to myocardial oedema, pericardial effusion, intracardiac thrombi,
not explained by other conditions (e.g., CAD, ACS or valvular heart
disease). 
</td>
<td>
High 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CMR 
</td>
<td>
Oedema, inflammation and fibrosis detection, quantification and
localization through T1 and T2 mapping, extracellular volume assessment
and LGE (see <em>Table <span
></span>33</em>).<span
></span><span><sup>955</sup></span><sup>,</sup><span
></span><span><sup>956</sup></span> 
</td>
<td>
High 
</td>
<td>
Intermediate 
</td>
</tr>
<tr>
<td colspan="4">
<strong>Additional diagnostic tests</strong> 
</td>
</tr>
<tr>
<td>
Coronary angiography or CTCA 
</td>
<td>
Excludes significant CAD or ACS in clinically suspected myocarditis. 
</td>
<td>
High 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Endomyocardial biopsy 
</td>
<td>
For diagnosis and indication to specific treatment (see <em>Table <span
></span>32</em>). 
</td>
<td>
Intermediate 
</td>
<td>
High 
</td>
</tr>
<tr>
<td>
Cardiac PET 
</td>
<td>
May be useful in patients who cannot undergo CMR or with suspected
systemic autoimmune disease or cardiac sarcoidosis.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>957</sup></span> 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td rowspan="3">
Additional laboratory test 
</td>
<td>
Skeletal muscle enzymes, liver and renal function, natriuretic peptides,
thyroid function tests, iron status, markers of systemic autoimmune
disease. 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
CRP elevated in 80–90% patients.<span
></span><span><sup>919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span> 
</td>
<td>
Intermediate 
</td>
<td>
Low 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
PCR testing of common cardiotropic viruses. It can detect systemic
infection but does not prove cardiac infection and cannot substitute
viral genome analysis on EMB samples.<span
></span><span><sup>917</sup></span>
</p>
</li>
<li>
<p>
Circulating IgG antibodies to cardiotropic viruses are common in the
absence of viral myocarditis. Very limited diagnostic usefulness.<span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span>
</p>
</li>
<li>
<p>
Specific test for SARS-CoV-2, Borrelia, HIV or CMV if clinical
suspicion.
</p>
</li>
</ul>
 
</td>
<td>
Low 
</td>
<td>
Low 
</td>
</tr>
</tbody>
</table>
<p>ACS = acute coronary syndrome; AV = atrio-ventricular; CAD = coronary
artery disease; CMR = cardiac magnetic resonance; CMV = cytomegalovirus;
CRP = C-reactive protein; CTCA = computed tomography coronary
angiography; ECG = electrocardiogram; EMB = endomyocardial biopsy;
HF = heart failure; HIV = human immunodeficiency virus;
IgG = immunoglobulin G; LGE = late gadolinium enhancement;
PCR = polymerase chain reaction; PET = positron emission tomography;
QRS = Q, R and S waves (combination of three of the graphical
deflections); SARS-CoV-2 = severe acute respiratory syndrome
coronavirus 2; ST = ST segment of the electrocardiogram; ST-T = ST
segment and T wave of the electrocardiogram.</p>
<p>Table 32</p>
<p>Endomyocardial biopsy in patients with suspected myocarditis</p>
<table role="presentation">
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong> (see also <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-4.3">section
4.3</a>).
</p>
</li>
<li>
<p>
 Progressive or persistent severe cardiac dysfunction and/or
life-threatening ventricular arrhythmias and/or Mobitz type 2
second-degree or higher AV block with lack of short-term (&lt;1-2 weeks)
expected response to usual medical treatment.
</p>
</li>
<li>
<p>
 The aim is to identify aetiology and to indicate specific treatment
(e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac
sarcoidosis, systemic inflammatory disorders).<span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>958</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Number and sites of the samples</strong>
</p>
</li>
<li>
<p>
 A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for
infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left
and/or right ventricle. CMR or PET guided sampling may be
considered.<span
></span><span><sup>919</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Aetiology</strong>
</p>
</li>
<li>
<p>
 Quantitative PCR viral genome analysis for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and
coxsackievirus) by rtPCR.
</p>
</li>
<li>
<p>
 Viral mRNA for active viral replication may be assessed although it has
low sensitivity.
</p>
</li>
<li>
<p>
 On indication, search for CMV, HIV, <em>Borrelia, Coxiella
burnetii</em> (Q-fever) and SARS-CoV-2.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnosis of inflammation</strong>
</p>
</li>
<li>
<p>
 Immunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45
antibodies for lymphocytes and anti-CD68 antibodies for macrophages and
anti-HLA-DR antibodies.<span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>959</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Therapeutic implications</strong>
</p>
</li>
<li>
<p>
 <strong>Immunosuppressive therapy</strong> may be indicated based on
the results of EMB as in giant cell myocarditis or eosinophilic
myocarditis and, possibly, also in sarcoidosis, vasculitis or selected
patients with increased cardiac inflammation of unknown origin based
upon multidisciplinary counselling.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
<li>
<p>
 <strong>Antibiotics:</strong> <em>Borrelia</em> (Lyme disease).
</p>
</li>
<li>
<p>
 <strong>Antiviral therapy:</strong> HIV, CMV, HHV6 pending on load and
viral replication (mRNA).
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong> (see also <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-4.3">section
4.3</a>).
</p>
</li>
<li>
<p>
 Progressive or persistent severe cardiac dysfunction and/or
life-threatening ventricular arrhythmias and/or Mobitz type 2
second-degree or higher AV block with lack of short-term (&lt;1-2 weeks)
expected response to usual medical treatment.
</p>
</li>
<li>
<p>
 The aim is to identify aetiology and to indicate specific treatment
(e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac
sarcoidosis, systemic inflammatory disorders).<span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>958</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Number and sites of the samples</strong>
</p>
</li>
<li>
<p>
 A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for
infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left
and/or right ventricle. CMR or PET guided sampling may be
considered.<span
></span><span><sup>919</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Aetiology</strong>
</p>
</li>
<li>
<p>
 Quantitative PCR viral genome analysis for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and
coxsackievirus) by rtPCR.
</p>
</li>
<li>
<p>
 Viral mRNA for active viral replication may be assessed although it has
low sensitivity.
</p>
</li>
<li>
<p>
 On indication, search for CMV, HIV, <em>Borrelia, Coxiella
burnetii</em> (Q-fever) and SARS-CoV-2.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnosis of inflammation</strong>
</p>
</li>
<li>
<p>
 Immunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45
antibodies for lymphocytes and anti-CD68 antibodies for macrophages and
anti-HLA-DR antibodies.<span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>959</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Therapeutic implications</strong>
</p>
</li>
<li>
<p>
 <strong>Immunosuppressive therapy</strong> may be indicated based on
the results of EMB as in giant cell myocarditis or eosinophilic
myocarditis and, possibly, also in sarcoidosis, vasculitis or selected
patients with increased cardiac inflammation of unknown origin based
upon multidisciplinary counselling.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
<li>
<p>
 <strong>Antibiotics:</strong> <em>Borrelia</em> (Lyme disease).
</p>
</li>
<li>
<p>
 <strong>Antiviral therapy:</strong> HIV, CMV, HHV6 pending on load and
viral replication (mRNA).
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>CMR = cardiac magnetic resonance; CMV = cytomegalovirus;
DNA = deoxyribonucleic acid; EMB = endomyocardial biopsy; HHV = human
herpes virus; HIV = human immunodeficiency virus; HLA-DR = human
leucocyte antigen-DR isotype; mRNA = messenger ribonucleic acid;
PCR = polymerase chain reaction; PET = positron emission tomography;
RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase chain
reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus
2.</p>
<p>Table 32</p>
<p>Endomyocardial biopsy in patients with suspected myocarditis</p>
<table role="presentation">
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong> (see also <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-4.3">section
4.3</a>).
</p>
</li>
<li>
<p>
 Progressive or persistent severe cardiac dysfunction and/or
life-threatening ventricular arrhythmias and/or Mobitz type 2
second-degree or higher AV block with lack of short-term (&lt;1-2 weeks)
expected response to usual medical treatment.
</p>
</li>
<li>
<p>
 The aim is to identify aetiology and to indicate specific treatment
(e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac
sarcoidosis, systemic inflammatory disorders).<span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>958</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Number and sites of the samples</strong>
</p>
</li>
<li>
<p>
 A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for
infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left
and/or right ventricle. CMR or PET guided sampling may be
considered.<span
></span><span><sup>919</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Aetiology</strong>
</p>
</li>
<li>
<p>
 Quantitative PCR viral genome analysis for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and
coxsackievirus) by rtPCR.
</p>
</li>
<li>
<p>
 Viral mRNA for active viral replication may be assessed although it has
low sensitivity.
</p>
</li>
<li>
<p>
 On indication, search for CMV, HIV, <em>Borrelia, Coxiella
burnetii</em> (Q-fever) and SARS-CoV-2.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnosis of inflammation</strong>
</p>
</li>
<li>
<p>
 Immunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45
antibodies for lymphocytes and anti-CD68 antibodies for macrophages and
anti-HLA-DR antibodies.<span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>959</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Therapeutic implications</strong>
</p>
</li>
<li>
<p>
 <strong>Immunosuppressive therapy</strong> may be indicated based on
the results of EMB as in giant cell myocarditis or eosinophilic
myocarditis and, possibly, also in sarcoidosis, vasculitis or selected
patients with increased cardiac inflammation of unknown origin based
upon multidisciplinary counselling.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
<li>
<p>
 <strong>Antibiotics:</strong> <em>Borrelia</em> (Lyme disease).
</p>
</li>
<li>
<p>
 <strong>Antiviral therapy:</strong> HIV, CMV, HHV6 pending on load and
viral replication (mRNA).
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong> (see also <span
></span><a href="https://academic.oup.com/eurheartj/article/42/36/3599/6358045?login=true#ehab368-4.3">section
4.3</a>).
</p>
</li>
<li>
<p>
 Progressive or persistent severe cardiac dysfunction and/or
life-threatening ventricular arrhythmias and/or Mobitz type 2
second-degree or higher AV block with lack of short-term (&lt;1-2 weeks)
expected response to usual medical treatment.
</p>
</li>
<li>
<p>
 The aim is to identify aetiology and to indicate specific treatment
(e.g. giant cell myocarditis, eosinophilic myocarditis, cardiac
sarcoidosis, systemic inflammatory disorders).<span
></span><span><sup>97</sup></span><sup>,</sup><span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>958</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Number and sites of the samples</strong>
</p>
</li>
<li>
<p>
 A minimum of 5 but possibly at least 7 samples, 3 for pathology, 2 for
infections (DNA, PCR) and 2 for RNA viruses/viral replication. Left
and/or right ventricle. CMR or PET guided sampling may be
considered.<span
></span><span><sup>919</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Aetiology</strong>
</p>
</li>
<li>
<p>
 Quantitative PCR viral genome analysis for common cardiotrophic viruses
(parvovirus B19, HHV4, HHV6, enteroviruses, adenovirus and
coxsackievirus) by rtPCR.
</p>
</li>
<li>
<p>
 Viral mRNA for active viral replication may be assessed although it has
low sensitivity.
</p>
</li>
<li>
<p>
 On indication, search for CMV, HIV, <em>Borrelia, Coxiella
burnetii</em> (Q-fever) and SARS-CoV-2.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnosis of inflammation</strong>
</p>
</li>
<li>
<p>
 Immunohistochemistry with staining for anti-CD3-, CD4-, CD8- or CD45
antibodies for lymphocytes and anti-CD68 antibodies for macrophages and
anti-HLA-DR antibodies.<span
></span><span><sup>907</sup></span><sup>,</sup><span
></span><span><sup>917</sup></span><sup>,</sup><span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>959</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Therapeutic implications</strong>
</p>
</li>
<li>
<p>
 <strong>Immunosuppressive therapy</strong> may be indicated based on
the results of EMB as in giant cell myocarditis or eosinophilic
myocarditis and, possibly, also in sarcoidosis, vasculitis or selected
patients with increased cardiac inflammation of unknown origin based
upon multidisciplinary counselling.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span>
</p>
</li>
<li>
<p>
 <strong>Antibiotics:</strong> <em>Borrelia</em> (Lyme disease).
</p>
</li>
<li>
<p>
 <strong>Antiviral therapy:</strong> HIV, CMV, HHV6 pending on load and
viral replication (mRNA).
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>CMR = cardiac magnetic resonance; CMV = cytomegalovirus;
DNA = deoxyribonucleic acid; EMB = endomyocardial biopsy; HHV = human
herpes virus; HIV = human immunodeficiency virus; HLA-DR = human
leucocyte antigen-DR isotype; mRNA = messenger ribonucleic acid;
PCR = polymerase chain reaction; PET = positron emission tomography;
RNA = ribonucleic acid; rtPCR = reverse transcriptase polymerase chain
reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus
2.</p>
<p>Table 33</p>
<p>Cardiac magnetic resonance in patients with suspected
myocarditis<sup>955</sup><sup>,</sup><sup>956</sup></p>
<table role="presentation">
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong>
</p>
</li>
<li>
<p>
 Indicated at baseline, in all patients with clinical history + ECG,
elevated troponin or echocardiographic abnormalities, and significant
CAD excluded or unlikely.
</p>
</li>
<li>
<p>
 Advised at follow-up in patients with persistent dysfunction at
echocardiography, arrhythmias or ECG abnormalities.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Main findings</strong>
</p>
</li>
<li>
<p>
 At baseline: T1-weighted (inflammation, injury) and T2-weighted
(oedema) sequences, extracellular volume and LGE within 2 weeks after
symptom onset.<span
></span><span><sup>956</sup></span><sup>,</sup><span
></span><span><sup>960</sup></span>
</p>
</li>
<li>
<p>
 At follow up: LGE to evaluate the degree of scarring, T1 and T2 to
identify persistent inflammation.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnostic significance</strong>
</p>
</li>
<li>
<p>
 At least one T2-based criterion (global or regional increase of
myocardial T2 relaxation time or an increased signal intensity in
T2-weighted images), with at least one T1-based criterion (increased
myocardial T1, extracellular volume, or LGE) in the acute phase.
</p>
</li>
<li>
<p>
 Only one (i.e., T2-based or T1-based) marker may still support a
diagnosis of acute myocardial inflammation in an appropriate clinical
scenario, albeit with less specificity in the acute phase.
</p>
</li>
<li>
<p>
 A negative T1/T2 scan does not exclude a still ongoing inflammatory
process in the chronic phase.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong>
</p>
</li>
<li>
<p>
 Indicated at baseline, in all patients with clinical history + ECG,
elevated troponin or echocardiographic abnormalities, and significant
CAD excluded or unlikely.
</p>
</li>
<li>
<p>
 Advised at follow-up in patients with persistent dysfunction at
echocardiography, arrhythmias or ECG abnormalities.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Main findings</strong>
</p>
</li>
<li>
<p>
 At baseline: T1-weighted (inflammation, injury) and T2-weighted
(oedema) sequences, extracellular volume and LGE within 2 weeks after
symptom onset.<span
></span><span><sup>956</sup></span><sup>,</sup><span
></span><span><sup>960</sup></span>
</p>
</li>
<li>
<p>
 At follow up: LGE to evaluate the degree of scarring, T1 and T2 to
identify persistent inflammation.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnostic significance</strong>
</p>
</li>
<li>
<p>
 At least one T2-based criterion (global or regional increase of
myocardial T2 relaxation time or an increased signal intensity in
T2-weighted images), with at least one T1-based criterion (increased
myocardial T1, extracellular volume, or LGE) in the acute phase.
</p>
</li>
<li>
<p>
 Only one (i.e., T2-based or T1-based) marker may still support a
diagnosis of acute myocardial inflammation in an appropriate clinical
scenario, albeit with less specificity in the acute phase.
</p>
</li>
<li>
<p>
 A negative T1/T2 scan does not exclude a still ongoing inflammatory
process in the chronic phase.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>CAD = coronary artery disease; CMR = cardiac magnetic resonance;
ECG = electrocardiogram; LGE = late gadolinium enhancement.</p>
<p>a</p>
<p>It takes at least 3 months before CMR signs of oedema (secondary to
inflammation in the acute phase/baseline) disappear. At 6 months, T1 or
T2 signs of oedema should have disappeared if inflammation would be
completely absent. Still, the absence of T1 or T2 oedema does not
exclude chronic low-grade inflammation.</p>
<p>Table 33</p>
<p>Cardiac magnetic resonance in patients with suspected
myocarditis<sup>955</sup><sup>,</sup><sup>956</sup></p>
<table role="presentation">
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong>
</p>
</li>
<li>
<p>
 Indicated at baseline, in all patients with clinical history + ECG,
elevated troponin or echocardiographic abnormalities, and significant
CAD excluded or unlikely.
</p>
</li>
<li>
<p>
 Advised at follow-up in patients with persistent dysfunction at
echocardiography, arrhythmias or ECG abnormalities.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Main findings</strong>
</p>
</li>
<li>
<p>
 At baseline: T1-weighted (inflammation, injury) and T2-weighted
(oedema) sequences, extracellular volume and LGE within 2 weeks after
symptom onset.<span
></span><span><sup>956</sup></span><sup>,</sup><span
></span><span><sup>960</sup></span>
</p>
</li>
<li>
<p>
 At follow up: LGE to evaluate the degree of scarring, T1 and T2 to
identify persistent inflammation.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnostic significance</strong>
</p>
</li>
<li>
<p>
 At least one T2-based criterion (global or regional increase of
myocardial T2 relaxation time or an increased signal intensity in
T2-weighted images), with at least one T1-based criterion (increased
myocardial T1, extracellular volume, or LGE) in the acute phase.
</p>
</li>
<li>
<p>
 Only one (i.e., T2-based or T1-based) marker may still support a
diagnosis of acute myocardial inflammation in an appropriate clinical
scenario, albeit with less specificity in the acute phase.
</p>
</li>
<li>
<p>
 A negative T1/T2 scan does not exclude a still ongoing inflammatory
process in the chronic phase.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Indication</strong>
</p>
</li>
<li>
<p>
 Indicated at baseline, in all patients with clinical history + ECG,
elevated troponin or echocardiographic abnormalities, and significant
CAD excluded or unlikely.
</p>
</li>
<li>
<p>
 Advised at follow-up in patients with persistent dysfunction at
echocardiography, arrhythmias or ECG abnormalities.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Main findings</strong>
</p>
</li>
<li>
<p>
 At baseline: T1-weighted (inflammation, injury) and T2-weighted
(oedema) sequences, extracellular volume and LGE within 2 weeks after
symptom onset.<span
></span><span><sup>956</sup></span><sup>,</sup><span
></span><span><sup>960</sup></span>
</p>
</li>
<li>
<p>
 At follow up: LGE to evaluate the degree of scarring, T1 and T2 to
identify persistent inflammation.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Diagnostic significance</strong>
</p>
</li>
<li>
<p>
 At least one T2-based criterion (global or regional increase of
myocardial T2 relaxation time or an increased signal intensity in
T2-weighted images), with at least one T1-based criterion (increased
myocardial T1, extracellular volume, or LGE) in the acute phase.
</p>
</li>
<li>
<p>
 Only one (i.e., T2-based or T1-based) marker may still support a
diagnosis of acute myocardial inflammation in an appropriate clinical
scenario, albeit with less specificity in the acute phase.
</p>
</li>
<li>
<p>
 A negative T1/T2 scan does not exclude a still ongoing inflammatory
process in the chronic phase.<span
></span><span><sup>a</sup></span>
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>CAD = coronary artery disease; CMR = cardiac magnetic resonance;
ECG = electrocardiogram; LGE = late gadolinium enhancement.</p>
<p>a</p>
<p>It takes at least 3 months before CMR signs of oedema (secondary to
inflammation in the acute phase/baseline) disappear. At 6 months, T1 or
T2 signs of oedema should have disappeared if inflammation would be
completely absent. Still, the absence of T1 or T2 oedema does not
exclude chronic low-grade inflammation.</p>
<p>Figure 20</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f20.jpeg?Expires=1689850107&amp;Signature=xQqiEbe0ajU420UFq73WhA0qgS042vL0NkP4RP8kVOcFAr-ClRjjBxm83FevGy1G4mBGe20cYkQ479gZ7NPxwxFDuEr8qCf~dXDNCFAw60P2xZsWhe2dPtnyxRMTuXtpgkVvcrRj11EhKHAwY2-qAlVTwkn3NP9FeOwJgeOA1Vquxt9RoaBFk97-pLAY5AwL-lgDGfZ4FhCOeRqqXwruSL0TzoTZ~RuvonbWZjX6Qi2-mPLadJDfmqHSaiNrZGl~UlUByIxxcHCDU8ihJCWvDA799sYLZPm4lWMv7ygIdiS2rYK4yV7ETp~ien05LxgDkZl1CaMp9ezjomrx1my6JQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Management of patients with heart failure and acute myocarditis. ACS = acute coronary syndrome; CAD = coronary artery disease; CAG = coronary artery angiogram; CMR = cardiac magnetic resonance; CT = computed tomography; ECG = electrocardiogram; EMB = endomyocardial biopsy; HF = heart failure; MCS = mechanical circulatory support. aTo exclude CAD/ACS." />
<figcaption aria-hidden="true">Management of patients with heart failure
and acute myocarditis. ACS = acute coronary syndrome; CAD = coronary
artery disease; CAG = coronary artery angiogram; CMR = cardiac magnetic
resonance; CT = computed tomography; ECG = electrocardiogram;
EMB = endomyocardial biopsy; HF = heart failure; MCS = mechanical
circulatory support. aTo exclude CAD/ACS.</figcaption>
</figure>
<p>Management of patients with heart failure and acute myocarditis.
ACS = acute coronary syndrome; CAD = coronary artery disease;
CAG = coronary artery angiogram; CMR = cardiac magnetic resonance;
CT = computed tomography; ECG = electrocardiogram; EMB = endomyocardial
biopsy; HF = heart failure; MCS = mechanical circulatory support.
<sup>a</sup>To exclude CAD/ACS.</p>
<h4 >14.5.2 Treatment</h4>
<p>Hospitalization for at least 48 h may be useful for patients with
acute myocarditis and HF, especially when troponins are elevated and
when cardiac dysfunction, and/or arrhythmias are present at initial
presentation.</p>
<p>Despite the lack of evidence in the specific setting of acute
myocarditis, treatment of HFrEF is recommended in the presence of
systolic LV dysfunction. Immunosuppression is only indicated in selected
cases of acute myocarditis (<em>Table 34</em>). Once cardiac enzymes
decrease, arrhythmias are absent, and cardiac systolic dysfunction is
stabilized, standard HF therapy should be continued for at least
6 months (see also <em>Figure 20</em>).</p>
<p>Table 34</p>
<p>Treatment and follow-up of acute myocarditis</p>
<table role="presentation">
<tbody>
<tr>
<td>
HF therapy should be started if LV systolic dysfunction is present at
presentation and should be continued for at least 6 months upon complete
functional recovery (EF &gt;50%).<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression for at least 6–12 months is required in acute
myocarditis with clinical or EMB evidence of auto-immune disease,
including giant cell myocarditis, vasculitis or sarcoidosis.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>953</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>961</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression is not advised on a routine basis in acute myocarditis
without clinical or EMB-based evidence of auto-immune disease.<span
></span><span><sup>917</sup></span> Initial
empirical administration of i.v. corticosteroids may be taken into
consideration in cases of high suspicion of immune-mediated myocarditis
especially if complicated by acute HF, malignant arrhythmias and/or high
degree AV block.<span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>962</sup></span> 
</td>
</tr>
<tr>
<td>
Intense sporting activities should be avoided as long as symptoms,
cardiac enzymes elevated or ECG/imaging abnormalities are present and
last for at least 6 months since complete recovery.<span
></span><span><sup>936</sup></span> 
</td>
</tr>
<tr>
<td>
Yearly follow-up for at least 4 years, with an ECG and echocardiography,
is needed as acute myocarditis may lead to DCM in up to 20% of cases. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
HF therapy should be started if LV systolic dysfunction is present at
presentation and should be continued for at least 6 months upon complete
functional recovery (EF &gt;50%).<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression for at least 6–12 months is required in acute
myocarditis with clinical or EMB evidence of auto-immune disease,
including giant cell myocarditis, vasculitis or sarcoidosis.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>953</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>961</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression is not advised on a routine basis in acute myocarditis
without clinical or EMB-based evidence of auto-immune disease.<span
></span><span><sup>917</sup></span> Initial
empirical administration of i.v. corticosteroids may be taken into
consideration in cases of high suspicion of immune-mediated myocarditis
especially if complicated by acute HF, malignant arrhythmias and/or high
degree AV block.<span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>962</sup></span> 
</td>
</tr>
<tr>
<td>
Intense sporting activities should be avoided as long as symptoms,
cardiac enzymes elevated or ECG/imaging abnormalities are present and
last for at least 6 months since complete recovery.<span
></span><span><sup>936</sup></span> 
</td>
</tr>
<tr>
<td>
Yearly follow-up for at least 4 years, with an ECG and echocardiography,
is needed as acute myocarditis may lead to DCM in up to 20% of cases. 
</td>
</tr>
</tbody>
</table>
<p>AV = atrio-ventricular; DCM = dilated cardiomyopathy;
ECG = electrocardiogram; EF = ejection fraction; EMB = endomyocardial
biopsy; HF = heart failure; i.v. = intravenous; LV = left
ventricular.</p>
<p>Table 34</p>
<p>Treatment and follow-up of acute myocarditis</p>
<table role="presentation">
<tbody>
<tr>
<td>
HF therapy should be started if LV systolic dysfunction is present at
presentation and should be continued for at least 6 months upon complete
functional recovery (EF &gt;50%).<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression for at least 6–12 months is required in acute
myocarditis with clinical or EMB evidence of auto-immune disease,
including giant cell myocarditis, vasculitis or sarcoidosis.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>953</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>961</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression is not advised on a routine basis in acute myocarditis
without clinical or EMB-based evidence of auto-immune disease.<span
></span><span><sup>917</sup></span> Initial
empirical administration of i.v. corticosteroids may be taken into
consideration in cases of high suspicion of immune-mediated myocarditis
especially if complicated by acute HF, malignant arrhythmias and/or high
degree AV block.<span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>962</sup></span> 
</td>
</tr>
<tr>
<td>
Intense sporting activities should be avoided as long as symptoms,
cardiac enzymes elevated or ECG/imaging abnormalities are present and
last for at least 6 months since complete recovery.<span
></span><span><sup>936</sup></span> 
</td>
</tr>
<tr>
<td>
Yearly follow-up for at least 4 years, with an ECG and echocardiography,
is needed as acute myocarditis may lead to DCM in up to 20% of cases. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
HF therapy should be started if LV systolic dysfunction is present at
presentation and should be continued for at least 6 months upon complete
functional recovery (EF &gt;50%).<span
></span><span><sup>918</sup></span><sup>,</sup><span
></span><span><sup>919</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression for at least 6–12 months is required in acute
myocarditis with clinical or EMB evidence of auto-immune disease,
including giant cell myocarditis, vasculitis or sarcoidosis.<span
></span><span><sup>98</sup></span><sup>,</sup><span
></span><span><sup>917–919</sup></span><sup>,</sup><span
></span><span><sup>953</sup></span><sup>,</sup><span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>961</sup></span> 
</td>
</tr>
<tr>
<td>
Immunosuppression is not advised on a routine basis in acute myocarditis
without clinical or EMB-based evidence of auto-immune disease.<span
></span><span><sup>917</sup></span> Initial
empirical administration of i.v. corticosteroids may be taken into
consideration in cases of high suspicion of immune-mediated myocarditis
especially if complicated by acute HF, malignant arrhythmias and/or high
degree AV block.<span
></span><span><sup>954</sup></span><sup>,</sup><span
></span><span><sup>962</sup></span> 
</td>
</tr>
<tr>
<td>
Intense sporting activities should be avoided as long as symptoms,
cardiac enzymes elevated or ECG/imaging abnormalities are present and
last for at least 6 months since complete recovery.<span
></span><span><sup>936</sup></span> 
</td>
</tr>
<tr>
<td>
Yearly follow-up for at least 4 years, with an ECG and echocardiography,
is needed as acute myocarditis may lead to DCM in up to 20% of cases. 
</td>
</tr>
</tbody>
</table>
<p>AV = atrio-ventricular; DCM = dilated cardiomyopathy;
ECG = electrocardiogram; EF = ejection fraction; EMB = endomyocardial
biopsy; HF = heart failure; i.v. = intravenous; LV = left
ventricular.</p>
<p>Immunosuppression has been considered for treatment of patients with
chronic cardiac inflammation at EMB and no evidence of active viral
infection.<sup>918</sup><sup>,</sup><sup>919</sup> This was associated
with an improvement in cardiac function in small studies and with better
outcomes in a retrospective observational
study.<sup>953</sup><sup>,</sup><sup>963</sup><sup>,</sup><sup>964</sup>
Prospective trials with old or newer immunosuppressive/immunomodulatory
drugs are needed. A placebo-controlled trial testing the effects of
immunoadsorption with i.v. immunoglobulins on LV function is ongoing and
other treatment options are being tested.<sup>919</sup></p>
<h3 >14.6 Amyloidosis</h3>
<h4 >14.6.1 Epidemiology and
diagnosis</h4>
<p>CA or amyloid cardiomyopathy is still an underdiagnosed cause of
HF.<sup>895</sup><sup>,</sup><sup>965</sup><sup>,</sup><sup>966</sup>
The two most prevalent forms of CA are light chain immunoglobulin (AL)
and transthyretin (ATTR) amyloidosis. ATTR includes the wild-type
(&gt;90% of cases), and the hereditary or variant type (&lt;10% of
cases). It is estimated that 6% to 16% of all patients with unexplained
LVH or HFpEF at hospitalization or severe aortic stenosis undergoing
aortic valve replacement, aged above 65 years, may have
wtTTR-CA.<sup>967–972</sup></p>
<p>Diagnosis and treatment of CA were recently reviewed.<sup>973</sup>
Age &gt;65 years and HF along with a LV wall thickness &gt;12 mm at
echocardiography are major criteria for the suspicion of
CA.<sup>973</sup> Criteria for a suspicion of CA and to confirm
diagnosis are reported in <em>Table 35, <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Table 25</a></em>, and
<em>Figure 21</em>.<sup>973</sup><sup>,</sup><sup>974</sup> Cardiac
imaging and EMB or extra-cardiac biopsy are needed for the diagnosis of
AL-CA in patients with abnormal haematological tests
(<em>Figure 21</em>). Technetium-labelled <sup>99m</sup>Tc-PYP or DPD or
HMDP scintigraphy with planar and SPECT imaging has a specificity and
positive predictive value for TTR-CA of up to 100%.<sup>975</sup> In
contrast, CMR has a sensitivity and specificity of 85% and 92%,
respectively.<sup>966</sup><sup>,</sup><sup>976</sup> The hereditary
form should be excluded by genetic testing. EMB is the gold standard for
the diagnosis of TTR-CA with nearly 100% sensitivity and specificity if
specimens are collected from &gt;4 multiple sites and tested for amyloid
deposits by Congo red staining.<sup>966</sup> However, a biopsy is not
needed with a grade 2–3 positivity of scintigraphy with SPECT
(<em>Figure 21</em>).<sup>973</sup></p>
<p>Table 35</p>
<p>“Red flags” for most common forms of cardiac amyloidosis</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type</th>
<th>Red Flag</th>
<th>TTR</th>
<th>AL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Extracardiac</strong> </td>
<td>Polyneuropathy </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td>Dysautonomia </td>
<td>X </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Skin bruising </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Macroglossia </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Deafness </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Bilateral carpal tunnel syndrome </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Ruptured biceps tendon </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Lumbar spinal stenosis </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Vitreous deposits </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Family history </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Renal insufficiency </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Proteinuria </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac</strong> </td>
<td><strong>Clinical</strong> Hypotension or normotensive if previously
hypertensive </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>ECG</strong></p>
<p>Pseudo-infarct ECG pattern</p>
<p>Low/decreased QRS voltage to degree of LV thickness</p>
<p>AV conduction disease</p>
<p>  | X X X  | X X X  | | <strong>Laboratory</strong> Disproportionally
elevated NT-proBNP to degree of HF Persisting elevated troponin levels 
| X X  | X X  | |</p>
<p><strong>Echocardiography</strong></p>
<p>Granular sparkling of myocardium</p>
<p>Increased right ventricular wall thickness</p>
<p>Increased AV valve thickness</p>
<p>Pericardial effusion</p>
<p>Reduced longitudinal strain with apical sparing pattern</p>
<p>  | X X X X X  | X X X X X  | |</p>
<p><strong>CMR</strong></p>
<p>Subendocardial LGE</p>
<p>Elevated native T1 values</p>
<p>Increased extracellular volume</p>
<p>Abnormal gadolinium kinetics</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type</th>
<th>Red Flag</th>
<th>TTR</th>
<th>AL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Extracardiac</strong> </td>
<td>Polyneuropathy </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td>Dysautonomia </td>
<td>X </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Skin bruising </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Macroglossia </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Deafness </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Bilateral carpal tunnel syndrome </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Ruptured biceps tendon </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Lumbar spinal stenosis </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Vitreous deposits </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Family history </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Renal insufficiency </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Proteinuria </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac</strong> </td>
<td><strong>Clinical</strong> Hypotension or normotensive if previously
hypertensive </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>ECG</strong></p>
<p>Pseudo-infarct ECG pattern</p>
<p>Low/decreased QRS voltage to degree of LV thickness</p>
<p>AV conduction disease</p>
<p>  | X X X  | X X X  | | <strong>Laboratory</strong> Disproportionally
elevated NT-proBNP to degree of HF Persisting elevated troponin levels 
| X X  | X X  | |</p>
<p><strong>Echocardiography</strong></p>
<p>Granular sparkling of myocardium</p>
<p>Increased right ventricular wall thickness</p>
<p>Increased AV valve thickness</p>
<p>Pericardial effusion</p>
<p>Reduced longitudinal strain with apical sparing pattern</p>
<p>  | X X X X X  | X X X X X  | |</p>
<p><strong>CMR</strong></p>
<p>Subendocardial LGE</p>
<p>Elevated native T1 values</p>
<p>Increased extracellular volume</p>
<p>Abnormal gadolinium kinetics</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<p>AL = light chain immunoglobulin; AV = atrio-ventricular; CA = cardiac
amyloidosis; CMR = cardiac magnetic resonance; ECG = electrocardiogram;
HF = heart failure; LGE = late gadolinium enhancement; LV = left
ventricular; NT-proBNP = N-terminal pro-B-type natriuretic peptide;
QRS = Q, R and S waves (combination of three of the graphical
deflections); TTR = transthyretin.</p>
<p>Modified from<sup>973</sup>.</p>
<p>a</p>
<p>Hereditary TTR-CA.</p>
<p>Table 35</p>
<p>“Red flags” for most common forms of cardiac amyloidosis</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type</th>
<th>Red Flag</th>
<th>TTR</th>
<th>AL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Extracardiac</strong> </td>
<td>Polyneuropathy </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td>Dysautonomia </td>
<td>X </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Skin bruising </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Macroglossia </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Deafness </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Bilateral carpal tunnel syndrome </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Ruptured biceps tendon </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Lumbar spinal stenosis </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Vitreous deposits </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Family history </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Renal insufficiency </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Proteinuria </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac</strong> </td>
<td><strong>Clinical</strong> Hypotension or normotensive if previously
hypertensive </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>ECG</strong></p>
<p>Pseudo-infarct ECG pattern</p>
<p>Low/decreased QRS voltage to degree of LV thickness</p>
<p>AV conduction disease</p>
<p>  | X X X  | X X X  | | <strong>Laboratory</strong> Disproportionally
elevated NT-proBNP to degree of HF Persisting elevated troponin levels 
| X X  | X X  | |</p>
<p><strong>Echocardiography</strong></p>
<p>Granular sparkling of myocardium</p>
<p>Increased right ventricular wall thickness</p>
<p>Increased AV valve thickness</p>
<p>Pericardial effusion</p>
<p>Reduced longitudinal strain with apical sparing pattern</p>
<p>  | X X X X X  | X X X X X  | |</p>
<p><strong>CMR</strong></p>
<p>Subendocardial LGE</p>
<p>Elevated native T1 values</p>
<p>Increased extracellular volume</p>
<p>Abnormal gadolinium kinetics</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr>
<th>Type</th>
<th>Red Flag</th>
<th>TTR</th>
<th>AL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Extracardiac</strong> </td>
<td>Polyneuropathy </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td>Dysautonomia </td>
<td>X </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Skin bruising </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Macroglossia </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Deafness </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Bilateral carpal tunnel syndrome </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Ruptured biceps tendon </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Lumbar spinal stenosis </td>
<td>X </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Vitreous deposits </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Family history </td>
<td>X<sup>a</sup> </td>
<td> </td>
<td></td>
</tr>
<tr>
<td>Renal insufficiency </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td>Proteinuria </td>
<td> </td>
<td>X </td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac</strong> </td>
<td><strong>Clinical</strong> Hypotension or normotensive if previously
hypertensive </td>
<td>X </td>
<td>X </td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>ECG</strong></p>
<p>Pseudo-infarct ECG pattern</p>
<p>Low/decreased QRS voltage to degree of LV thickness</p>
<p>AV conduction disease</p>
<p>  | X X X  | X X X  | | <strong>Laboratory</strong> Disproportionally
elevated NT-proBNP to degree of HF Persisting elevated troponin levels 
| X X  | X X  | |</p>
<p><strong>Echocardiography</strong></p>
<p>Granular sparkling of myocardium</p>
<p>Increased right ventricular wall thickness</p>
<p>Increased AV valve thickness</p>
<p>Pericardial effusion</p>
<p>Reduced longitudinal strain with apical sparing pattern</p>
<p>  | X X X X X  | X X X X X  | |</p>
<p><strong>CMR</strong></p>
<p>Subendocardial LGE</p>
<p>Elevated native T1 values</p>
<p>Increased extracellular volume</p>
<p>Abnormal gadolinium kinetics</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>X</p>
<p>  |</p>
<p>AL = light chain immunoglobulin; AV = atrio-ventricular; CA = cardiac
amyloidosis; CMR = cardiac magnetic resonance; ECG = electrocardiogram;
HF = heart failure; LGE = late gadolinium enhancement; LV = left
ventricular; NT-proBNP = N-terminal pro-B-type natriuretic peptide;
QRS = Q, R and S waves (combination of three of the graphical
deflections); TTR = transthyretin.</p>
<p>Modified from<sup>973</sup>.</p>
<p>a</p>
<p>Hereditary TTR-CA.</p>
<p>Figure 21</p>
<figure>
<img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368f21.jpeg?Expires=1689850107&amp;Signature=1qoYL4Qgnigwo2gXASnRUaEY6r7PpcbGCN4WO7AVXR0db7oHd~g98cGN5aWeoIhxT8TQmVl57dx3~ruBMXxkEuG9NDSPQa~clkrRfNlUcnpYBEd5XXe-i3y6NH4PZQr4bOCHWhhkHCA01esQKGvsMDWhEnjsT7NmTRKWuWhe18-Wv7IB0-rn5-pLHb-4dZKUa0AKIClN4m0~9rjWdzgcGb63q-WhUh00mdflVWKUwLb7zHI9IEZdaiC6tpeYwfHc7YX3JE6M7iP80AjA-i8AIiWjA87LzuJgYf5U2yrY0YyfcXOejA0N5IgRIMO9bJ0sdQrnGrpA6OyXSIjX2ZVU2A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="Diagnosis and treatment of cardiac amyloidosis in heart failure patients. Based on.973 ATTR =  transthyretin amyloidosis; CMR =  cardiac magnetic resonance; DPD =  3,3-diphosphono1,2-propanodicarboxylic acid; HF =  heart failure; HMDP =  hydroxymethylene diphosphonate; LV = left ventricular; SPECT =  single-photon emission computed tomography; 99mTc-PYP =  technetium-labelled 99mTc-pyrophosphate. aRed flags are listed in Table 35. bGenerally requires endomyocardial biopsy for a diagnosis of the cardiac subtype. cRequires biopsy that may be cardiac or abdominal." />
<figcaption aria-hidden="true">Diagnosis and treatment of cardiac
amyloidosis in heart failure patients. Based on.973 ATTR = 
transthyretin amyloidosis; CMR =  cardiac magnetic resonance; DPD = 
3,3-diphosphono1,2-propanodicarboxylic acid; HF =  heart failure;
HMDP =  hydroxymethylene diphosphonate; LV = left ventricular; SPECT = 
single-photon emission computed tomography; 99mTc-PYP = 
technetium-labelled 99mTc-pyrophosphate. aRed flags are listed in
Table 35. bGenerally requires endomyocardial biopsy for a diagnosis of
the cardiac subtype. cRequires biopsy that may be cardiac or
abdominal.</figcaption>
</figure>
<p>Diagnosis and treatment of cardiac amyloidosis in heart failure
patients. Based on.<sup>973</sup> ATTR =  transthyretin amyloidosis;
CMR =  cardiac magnetic resonance; DPD = 
3,3-diphosphono1,2-propanodicarboxylic acid; HF =  heart failure;
HMDP =  hydroxymethylene diphosphonate; LV = left ventricular; SPECT = 
single-photon emission computed tomography; 99mTc-PYP = 
technetium-labelled <sup>99m</sup>Tc-pyrophosphate. <sup>a</sup>Red
flags are listed in <em>Table 35</em>. <sup>b</sup>Generally requires
endomyocardial biopsy for a diagnosis of the cardiac subtype.
<sup>c</sup>Requires biopsy that may be cardiac or abdominal.</p>
<h4 >14.6.2 Therapy of
amyloidosis and heart failure</h4>
<p>Maintenance of euvolaemia is central to management but is challenging
due to the markedly reduced ventricular capacitance.<sup>977</sup> If HF
symptoms are present, a loop diuretic, possibly with an MRA, may be
given, but orthostatic hypotension may cause intolerance. Beta-blockers,
digitalis, ACE-I, ARBs, or ARNI may not be well tolerated because of
hypotension, and their place in CA treatment is unsettled. Their
withdrawal must be often considered due to hypotension and/or
bradycardia.<sup>973</sup><sup>,</sup><sup>974</sup> CCB should be
avoided as they may cause severe hypotension and fatigue, or form
complexes with amyloid.<sup>966</sup></p>
<p>Amyloid infiltration of the atrial wall leads to atrial myopathy and
electromechanical dissociation with high embolic risk. Patients with CA
and history of AF should receive anticoagulation. There is no evidence
to support anticoagulation for patients in SR,
yet.<sup>7</sup><sup>,</sup><sup>978</sup> Amiodarone is the preferred
antiarrhythmic agent.<sup>973</sup></p>
<p>Therapy of AL-CA is based on treatment of the underlying
haematological problem with chemotherapy or autologous stem-cell
transplant.</p>
<p>TTR stabilization and reduction of its production are the basis of
TTR-CA treatment. Liver and/or cardiac transplantation can be considered
only in end-stage disease of familial TTR-CA. Tafamidis reduced
all-cause mortality and CV hospitalizations in cardiac or non-cardiac
biopsy-proven hereditary and wtTTR-CA, mainly in those patients with
NYHA class I and II at baseline. Functional improvement occurred within
6 months, whereas the decrease in mortality took nearly 2 years to
occur.<sup>979</sup><sup>,</sup><sup>980</sup> Intravenous patisiran, a
small RNA interfering molecule, or subcutaneous inotersen, antisense
oligonucleotide against TTR, may be considered in those patients with
combined hTTR-polyneuropathy and CA
(<em>Figure 21</em>).<sup>981</sup><sup>,</sup><sup>982</sup> Off-label
use of diflunisal may be considered in wtTTR-CA in combination with a
proton pump inhibitor.<sup>983</sup></p>
<h3 >14.7 Iron overload
cardiomyopathy</h3>
<p>Iron overload results either from genetically determined increased
intestinal iron absorption in the context of hereditary haemochromatosis
(primary iron overload) or from multiple blood transfusions required for
the management of haematological conditions such as beta-thalassaemia
(secondary iron overload).<sup>984</sup> In iron overload, the iron
binding capacity of transferrin is saturated and non-transferrin-bound
iron enters cardiomyocytes through L-type calcium channels, causing
oxidative myocardial damage.<sup>985</sup> Additional iron-induced
complications, such as liver disease and endocrine abnormalities,
further contribute to cardiac
deterioration.<sup>986</sup><sup>,</sup><sup>987</sup> The end result is
the development of iron overload cardiomyopathy (IOCM), which may have
either a restrictive or a dilated phenotype, the former potentially
evolving to the latter as the disease advances. Myocardial iron
deposition can be accurately estimated by the CMRT2* technique; T2*
values are correlated with left and right ventricular systolic function
and predict the development of iron-induced HF or
arrhythmias.<sup>984</sup> Prevention of IOCM is successfully
accomplished with iron chelators, including deferoxamine, deferiprone,
and deferasirox, while established IOCM may be completely reversed by
intensified and combined iron chelation therapy.<sup>985</sup></p>
<p>Recommendations for the treatment of transthyretin
amyloidosis-cardiac amyloidosis</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table88.jpeg?Expires=1689850107&amp;Signature=Bo-gUUqaynIs6ayVO75Yrb5~ERxiIpsPy8wt-GXzFM~RMiqA9Ipws7j5~CgGS4-qDv1oZWZwqGeVzt9n7E0WG-xD6dPLdLc6XEiadD~bTRvJ4S1cmmZfwj8tmgGik33zYNuAFHwGXLj2viByJ0NHhai4MaWyBEFtQOfyTSPmnMGz3vmX~D5tTGydnAkKZD-LqJOc07-hVh-xMKrBPj5DSYHOeVOjD-yl3Fe1x2NF-k2~0uki-OX1YxIMpC18-1CGgtyQnXIzY500nj6xndiJv4eF5QRpFKvjTe1nVIBSkFjFijb4DM~9Y0UJoVlCDTt2SioOiFjWuonz4i0AYKakoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table88.jpeg?Expires=1689850107&amp;Signature=Bo-gUUqaynIs6ayVO75Yrb5~ERxiIpsPy8wt-GXzFM~RMiqA9Ipws7j5~CgGS4-qDv1oZWZwqGeVzt9n7E0WG-xD6dPLdLc6XEiadD~bTRvJ4S1cmmZfwj8tmgGik33zYNuAFHwGXLj2viByJ0NHhai4MaWyBEFtQOfyTSPmnMGz3vmX~D5tTGydnAkKZD-LqJOc07-hVh-xMKrBPj5DSYHOeVOjD-yl3Fe1x2NF-k2~0uki-OX1YxIMpC18-1CGgtyQnXIzY500nj6xndiJv4eF5QRpFKvjTe1nVIBSkFjFijb4DM~9Y0UJoVlCDTt2SioOiFjWuonz4i0AYKakoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CA = cardiac amyloidosis; CV = cardiovascular; hTTR = hereditary
transthyretin; NYHA = New York Heart Association; wtTTR = wild-type
transthyretin.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>Recommendations for the treatment of transthyretin
amyloidosis-cardiac amyloidosis</p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table88.jpeg?Expires=1689850107&amp;Signature=Bo-gUUqaynIs6ayVO75Yrb5~ERxiIpsPy8wt-GXzFM~RMiqA9Ipws7j5~CgGS4-qDv1oZWZwqGeVzt9n7E0WG-xD6dPLdLc6XEiadD~bTRvJ4S1cmmZfwj8tmgGik33zYNuAFHwGXLj2viByJ0NHhai4MaWyBEFtQOfyTSPmnMGz3vmX~D5tTGydnAkKZD-LqJOc07-hVh-xMKrBPj5DSYHOeVOjD-yl3Fe1x2NF-k2~0uki-OX1YxIMpC18-1CGgtyQnXIzY500nj6xndiJv4eF5QRpFKvjTe1nVIBSkFjFijb4DM~9Y0UJoVlCDTt2SioOiFjWuonz4i0AYKakoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p><img
src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/m_ehab368table88.jpeg?Expires=1689850107&amp;Signature=Bo-gUUqaynIs6ayVO75Yrb5~ERxiIpsPy8wt-GXzFM~RMiqA9Ipws7j5~CgGS4-qDv1oZWZwqGeVzt9n7E0WG-xD6dPLdLc6XEiadD~bTRvJ4S1cmmZfwj8tmgGik33zYNuAFHwGXLj2viByJ0NHhai4MaWyBEFtQOfyTSPmnMGz3vmX~D5tTGydnAkKZD-LqJOc07-hVh-xMKrBPj5DSYHOeVOjD-yl3Fe1x2NF-k2~0uki-OX1YxIMpC18-1CGgtyQnXIzY500nj6xndiJv4eF5QRpFKvjTe1nVIBSkFjFijb4DM~9Y0UJoVlCDTt2SioOiFjWuonz4i0AYKakoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
alt="graphic" /> </p>
<p>CA = cardiac amyloidosis; CV = cardiovascular; hTTR = hereditary
transthyretin; NYHA = New York Heart Association; wtTTR = wild-type
transthyretin.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<h3 >14.8 Adult congenital heart
disease</h3>
<p>The management of ACHD has been reviewed in detail in a recent ESC
guideline.<sup>988</sup> HF is a common problem affecting 20–50% of the
ACHD population, and an important cause of death.<sup>989</sup> The
pathophysiology of cardiac dysfunction in ACHD is often different from
non-congenital (acquired) heart disease, in particular in those with: a
systemic right ventricle (RV), a failing subpulmonary ventricle, a
single ventricle,<sup>988</sup> surgery-related injury, chronic
pressure/volume overload in systemic and sub-pulmonary ventricles, and
those with hypertrophy or non-compaction induced by gene mutations.
Therefore, extrapolation of current HF treatment guidelines to ACHD
patients is not always appropriate. In addition, the few available data
on HF treatments in ACHD patients are often inconclusive and are derived
from small patient cohorts. As a consequence, ACHD specific
recommendations are mostly based on clinical experience or position
statements.<sup>990</sup></p>
<p>Importantly, ACHD patients with HF should be referred to expert
centres. The general principles of management, while awaiting transfer
to specialist centres, is summarized in <em>Table 36</em>.</p>
<p>Table 36</p>
<p>Treatment of adult congenital heart disease and heart failure in
specialized centres</p>
<table role="presentation">
<tbody>
<tr>
<td>
ACHD patients with chronic HF should be referred to specialized
centres. 
</td>
</tr>
<tr>
<td>
Specific guidelines for medical treatment of chronic HF in ACHD are
lacking, and practitioners should follow the current guidelines for
medical treatment of HF. It remains unknown whether the long-term use of
neurohormonal modulators affects clinical outcomes and prognosis in
ACHD. 
</td>
</tr>
<tr>
<td>
Sacubitril/valsartan may decrease morbidity,<span
></span><span><sup>991–993</sup></span>
however, no recommendation can be made at this moment based on the
retrospective or anecdotical nature of these observations. 
</td>
</tr>
<tr>
<td>
Co-morbidities in HF such as diabetes mellitus, AF, CSA, iron
deficiency, and cachexia should be treated according to specific
recommendations reported in this document. 
</td>
</tr>
<tr>
<td>
In a biventricular circulation, patients with an impaired systemic LV
should be treated with conventional HF therapy; this may also be
considered in symptomatic patients with a failing systemic right
ventricle. 
</td>
</tr>
<tr>
<td>
Diuretics are recommended to control symptoms of fluid retention. 
</td>
</tr>
<tr>
<td>
Treatment of symptomatic patients with a failing single ventricle in a
Fontan circulation, or in the case of a persistent right-to-left shunt,
should always be carefully initiated, taking the labile balance of
ventricular preload and systemic afterload into account. 
</td>
</tr>
<tr>
<td>
CRT may be a therapeutic option in ACHD patients with HF, but evidence
in this specific setting is still lacking. Efficacy of CRT will depend
on the underlying structural and functional substrate, such as anatomy
of the systemic ventricle (left, right, or functionally single),
presence and degree of structural systemic AV valve regurgitation,
primary myocardial disease or scarring, and type of electrical
conduction delay.<span
></span><span><sup>988</sup></span> 
</td>
</tr>
<tr>
<td>
Treatment of acute HF in ACHD patients should be in an expert centre,
with proper knowledge of inotropes, the availability of extracorporeal
membrane oxygenation, and advanced bridging techniques.<span
></span><span><sup>988</sup></span><sup>,</sup><span
></span><span><sup>994</sup></span> 
</td>
</tr>
<tr>
<td>
Timely evaluation for transplantation by ACHD HF specialists in a
transplant centre with ACHD expertise is recommended. 
</td>
</tr>
<tr>
<td>
Ventricular assist devices can bridge patients to transplantation, or in
a subgroup of patients, may be an option as destination therapy. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
ACHD patients with chronic HF should be referred to specialized
centres. 
</td>
</tr>
<tr>
<td>
Specific guidelines for medical treatment of chronic HF in ACHD are
lacking, and practitioners should follow the current guidelines for
medical treatment of HF. It remains unknown whether the long-term use of
neurohormonal modulators affects clinical outcomes and prognosis in
ACHD. 
</td>
</tr>
<tr>
<td>
Sacubitril/valsartan may decrease morbidity,<span
></span><span><sup>991–993</sup></span>
however, no recommendation can be made at this moment based on the
retrospective or anecdotical nature of these observations. 
</td>
</tr>
<tr>
<td>
Co-morbidities in HF such as diabetes mellitus, AF, CSA, iron
deficiency, and cachexia should be treated according to specific
recommendations reported in this document. 
</td>
</tr>
<tr>
<td>
In a biventricular circulation, patients with an impaired systemic LV
should be treated with conventional HF therapy; this may also be
considered in symptomatic patients with a failing systemic right
ventricle. 
</td>
</tr>
<tr>
<td>
Diuretics are recommended to control symptoms of fluid retention. 
</td>
</tr>
<tr>
<td>
Treatment of symptomatic patients with a failing single ventricle in a
Fontan circulation, or in the case of a persistent right-to-left shunt,
should always be carefully initiated, taking the labile balance of
ventricular preload and systemic afterload into account. 
</td>
</tr>
<tr>
<td>
CRT may be a therapeutic option in ACHD patients with HF, but evidence
in this specific setting is still lacking. Efficacy of CRT will depend
on the underlying structural and functional substrate, such as anatomy
of the systemic ventricle (left, right, or functionally single),
presence and degree of structural systemic AV valve regurgitation,
primary myocardial disease or scarring, and type of electrical
conduction delay.<span
></span><span><sup>988</sup></span> 
</td>
</tr>
<tr>
<td>
Treatment of acute HF in ACHD patients should be in an expert centre,
with proper knowledge of inotropes, the availability of extracorporeal
membrane oxygenation, and advanced bridging techniques.<span
></span><span><sup>988</sup></span><sup>,</sup><span
></span><span><sup>994</sup></span> 
</td>
</tr>
<tr>
<td>
Timely evaluation for transplantation by ACHD HF specialists in a
transplant centre with ACHD expertise is recommended. 
</td>
</tr>
<tr>
<td>
Ventricular assist devices can bridge patients to transplantation, or in
a subgroup of patients, may be an option as destination therapy. 
</td>
</tr>
</tbody>
</table>
<p>ACHD = adult congenital heart disease; AF = atrial fibrillation;
AV = atrioventricular; CRT = cardiac resynchronization therapy;
CSA = central sleep apnoea; HF = heart failure; LV = left
ventricular.</p>
<p>Table 36</p>
<p>Treatment of adult congenital heart disease and heart failure in
specialized centres</p>
<table role="presentation">
<tbody>
<tr>
<td>
ACHD patients with chronic HF should be referred to specialized
centres. 
</td>
</tr>
<tr>
<td>
Specific guidelines for medical treatment of chronic HF in ACHD are
lacking, and practitioners should follow the current guidelines for
medical treatment of HF. It remains unknown whether the long-term use of
neurohormonal modulators affects clinical outcomes and prognosis in
ACHD. 
</td>
</tr>
<tr>
<td>
Sacubitril/valsartan may decrease morbidity,<span
></span><span><sup>991–993</sup></span>
however, no recommendation can be made at this moment based on the
retrospective or anecdotical nature of these observations. 
</td>
</tr>
<tr>
<td>
Co-morbidities in HF such as diabetes mellitus, AF, CSA, iron
deficiency, and cachexia should be treated according to specific
recommendations reported in this document. 
</td>
</tr>
<tr>
<td>
In a biventricular circulation, patients with an impaired systemic LV
should be treated with conventional HF therapy; this may also be
considered in symptomatic patients with a failing systemic right
ventricle. 
</td>
</tr>
<tr>
<td>
Diuretics are recommended to control symptoms of fluid retention. 
</td>
</tr>
<tr>
<td>
Treatment of symptomatic patients with a failing single ventricle in a
Fontan circulation, or in the case of a persistent right-to-left shunt,
should always be carefully initiated, taking the labile balance of
ventricular preload and systemic afterload into account. 
</td>
</tr>
<tr>
<td>
CRT may be a therapeutic option in ACHD patients with HF, but evidence
in this specific setting is still lacking. Efficacy of CRT will depend
on the underlying structural and functional substrate, such as anatomy
of the systemic ventricle (left, right, or functionally single),
presence and degree of structural systemic AV valve regurgitation,
primary myocardial disease or scarring, and type of electrical
conduction delay.<span
></span><span><sup>988</sup></span> 
</td>
</tr>
<tr>
<td>
Treatment of acute HF in ACHD patients should be in an expert centre,
with proper knowledge of inotropes, the availability of extracorporeal
membrane oxygenation, and advanced bridging techniques.<span
></span><span><sup>988</sup></span><sup>,</sup><span
></span><span><sup>994</sup></span> 
</td>
</tr>
<tr>
<td>
Timely evaluation for transplantation by ACHD HF specialists in a
transplant centre with ACHD expertise is recommended. 
</td>
</tr>
<tr>
<td>
Ventricular assist devices can bridge patients to transplantation, or in
a subgroup of patients, may be an option as destination therapy. 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
ACHD patients with chronic HF should be referred to specialized
centres. 
</td>
</tr>
<tr>
<td>
Specific guidelines for medical treatment of chronic HF in ACHD are
lacking, and practitioners should follow the current guidelines for
medical treatment of HF. It remains unknown whether the long-term use of
neurohormonal modulators affects clinical outcomes and prognosis in
ACHD. 
</td>
</tr>
<tr>
<td>
Sacubitril/valsartan may decrease morbidity,<span
></span><span><sup>991–993</sup></span>
however, no recommendation can be made at this moment based on the
retrospective or anecdotical nature of these observations. 
</td>
</tr>
<tr>
<td>
Co-morbidities in HF such as diabetes mellitus, AF, CSA, iron
deficiency, and cachexia should be treated according to specific
recommendations reported in this document. 
</td>
</tr>
<tr>
<td>
In a biventricular circulation, patients with an impaired systemic LV
should be treated with conventional HF therapy; this may also be
considered in symptomatic patients with a failing systemic right
ventricle. 
</td>
</tr>
<tr>
<td>
Diuretics are recommended to control symptoms of fluid retention. 
</td>
</tr>
<tr>
<td>
Treatment of symptomatic patients with a failing single ventricle in a
Fontan circulation, or in the case of a persistent right-to-left shunt,
should always be carefully initiated, taking the labile balance of
ventricular preload and systemic afterload into account. 
</td>
</tr>
<tr>
<td>
CRT may be a therapeutic option in ACHD patients with HF, but evidence
in this specific setting is still lacking. Efficacy of CRT will depend
on the underlying structural and functional substrate, such as anatomy
of the systemic ventricle (left, right, or functionally single),
presence and degree of structural systemic AV valve regurgitation,
primary myocardial disease or scarring, and type of electrical
conduction delay.<span
></span><span><sup>988</sup></span> 
</td>
</tr>
<tr>
<td>
Treatment of acute HF in ACHD patients should be in an expert centre,
with proper knowledge of inotropes, the availability of extracorporeal
membrane oxygenation, and advanced bridging techniques.<span
></span><span><sup>988</sup></span><sup>,</sup><span
></span><span><sup>994</sup></span> 
</td>
</tr>
<tr>
<td>
Timely evaluation for transplantation by ACHD HF specialists in a
transplant centre with ACHD expertise is recommended. 
</td>
</tr>
<tr>
<td>
Ventricular assist devices can bridge patients to transplantation, or in
a subgroup of patients, may be an option as destination therapy. 
</td>
</tr>
</tbody>
</table>
<p>ACHD = adult congenital heart disease; AF = atrial fibrillation;
AV = atrioventricular; CRT = cardiac resynchronization therapy;
CSA = central sleep apnoea; HF = heart failure; LV = left
ventricular.</p>
<h2 >15 Key messages</h2>
<ol type="1">
<li><p>Patients with HF are classified based on their LVEF. Those with a
LVEF between 41% and 49% are defined as ‘mildly reduced LVEF’
(HFmrEF).</p></li>
<li><p>Measurement of NPs and echocardiography have key roles in the
diagnosis of HF.</p></li>
<li><p>ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors are
recommended as cornerstone therapies for patients with HFrEF.</p></li>
<li><p>ICDs are recommended in selected patients with HFrEF of an
ischaemic aetiology and should be considered in those with a
non-ischaemic aetiology.</p></li>
<li><p>CRT-P/D is recommended in those patients with HFrEF, in sinus
rhythm, with a LBBB ≥150 ms and should be considered in those with a
LBBB ≥130–149 ms or non-LBBB ≥150 ms.</p></li>
<li><p>Advanced HF strategies (heart transplantation/MCS) may be
appropriate in selected patients.</p></li>
<li><p>ACE-I/ARNI, beta-blockers, and MRA may be considered in patients
with HFmrEF.</p></li>
<li><p>The diagnosis of HFpEF requires objective evidence of cardiac
structural, or functional abnormalities as well as elevated plasma NP
concentrations consistent with the presence of LV diastolic dysfunction
and raised LV filling pressures. A diastolic stress test is recommended
when these markers are equivocal.</p></li>
<li><p>To date, no treatment has been shown to reduce mortality and
morbidity in patients with HFpEF.</p></li>
<li><p>It is recommended that all patients with HF be enrolled in a
multidisciplinary HF-MP.</p></li>
<li><p>Exercise is recommended for all patients who are able, to improve
exercise capacity and QOL, and reduce HF hospitalization.</p></li>
<li><p>Patients with advanced HF refractory to medical/device therapy
and who do not have absolute contraindications should be referred for
consideration of heart transplantation. MCS should also be considered as
BTT or DT in selected patients.</p></li>
<li><p>Four major clinical presentations of acute HF may occur: ADHF,
acute pulmonary oedema, RV failure, and cardiogenic shock.</p></li>
<li><p>Treatment of acute HF is based on diuretics for congestion,
inotropes, and short- term MCS for peripheral hypoperfusion.</p></li>
<li><p>Patients hospitalized for HF should be carefully evaluated to
exclude persistent signs of congestion. Oral treatment should be
optimized before discharge.</p></li>
<li><p>In addition to oral anticoagulation, a strategy of rhythm control
including catheter ablation should be considered in patients whose
symptoms and/or cardiac dysfunction are associated with AF.</p></li>
<li><p>SAVR or TAVI, as advised by the Heart Team, are recommended in
patients with symptomatic severe aortic valve stenosis.</p></li>
<li><p>Patients with isolated significant SMR and COAPT criteria should
be considered for percutaneous edge-to-edge repair, whereas those with
SMR and CAD, who need revascularization, should be considered for
surgery.</p></li>
<li><p>It is recommended that patients with type II diabetes are treated
with SGLT2 inhibitors.</p></li>
<li><p>Patients should be periodically screened for anaemia and iron
deficiency and i.v. iron supplementation with ferric carboxymaltose
should be considered in symptomatic patients with LVEF &lt;45% and iron
deficiency, and in patients recently hospitalized for HF and with LVEF
≤50% and iron deficiency.</p></li>
</ol>
<h2 >16 Gaps in evidence</h2>
<p>Major advances in the diagnosis and treatment of patients with HF
have occurred over recent years. Strong evidence for new treatment
options have been given by recent RCTs and HF management may undergo
major changes in the next years. New discoveries, however, pose new
challenges and many areas with lack of evidence still remain. The
following is a short list of selected, common issues that deserve to be
addressed in future clinical research.</p>
<ol type="1">
<li><p><strong>Definition and epidemiology</strong></p>
<ul>
<li><p>Further research into the underlying characteristics,
pathophysiology, and diagnosis of HFmrEF and HFpEF</p></li>
<li><p>Consensus about normal values/ranges of EF</p></li>
<li><p>Better phenotyping of HFpEF</p></li>
<li><p>More information on the incidence and prevalence of ‘recovered
LV’ systolic function</p></li>
</ul></li>
<li><p><strong>Diagnosis</strong></p>
<ul>
<li><p>Definitive studies on the role of biomarkers, focusing on their
additive value in the diagnosis of HF</p></li>
<li><p>More randomized studies on screening for HF in asymptomatic
subjects that may translate into improved outcomes</p></li>
<li><p>Studies on biomarkers showing the impact on outcome of their
measurements for the identification of subjects at risk of developing HF
as well as to guide treatment in patients with HF</p></li>
<li><p>Validated diagnostic protocols for the diagnosis of HFmrEF and
HFpEF</p></li>
</ul></li>
<li><p><strong>Pharmacotherapy of CHF</strong></p>
<ul>
<li><p>Pragmatic studies on the order of adding disease-modifying drugs
for HFrEF</p></li>
<li><p>Specific therapies for HFmrEF and HFpEF and, likely, their
different phenotypes</p></li>
<li><p>More data and prospective clinical trials of HFrEF therapies in
patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup></p></li>
<li><p>Further evidence from prospective RCTs for the treatment of
specific HF phenotypes: myocarditis, cardiotoxicity, inherited CMPs,
PPCM, amyloidosis</p></li>
<li><p>Management strategies and therapies for ‘recovered LV’ systolic
function</p></li>
<li><p>More evidence on the effects of fluid restriction, dietary salt
restriction, and nutrition</p></li>
</ul></li>
<li><p><strong>Devices and interventions</strong></p>
<ul>
<li><p>Indications for ICDs in specific subgroups of HFmrEF/HFpEF and
optimal selection of ICD candidates in HFrEF, including patients with
ischaemic and non-ischaemic cardiomyopathy</p></li>
<li><p>More research on CRT efficacy in AF</p></li>
<li><p>Further prospective randomized studies showing the impact on
outcomes of AF ablation strategies compared to OMT in HF
patients</p></li>
<li><p>Further research on the percutaneous treatment of valve heart
disease and its impact on patients’ outcomes and QOL</p></li>
<li><p>Larger RCTs on CCM and baroreceptor stimulation in HFrEF</p></li>
</ul></li>
<li><p><strong>Disease management</strong></p>
<ul>
<li><p>The role of remote monitoring strategies in HF in the post
COVID-19 era</p></li>
<li><p>Studies on optimal models for follow-up of stable HF
patients</p></li>
<li><p>Studies to determine specific options for palliative
care</p></li>
</ul></li>
<li><p><strong>Advanced HF</strong></p>
<ul>
<li><p>Better definition of risk profiles according to INTERMACS and
other classifications</p></li>
<li><p>RCTs to establish the effects on outcomes of long-term MCS in
hospitalized patients as well as in ambulatory outpatients (for instance
INTERMACS 4–6 profiles)</p></li>
<li><p>Advances in long-term MCS, including strategies to reduce the
risk of bleeding, thromboembolic events, and infection</p></li>
<li><p>Advances in medical treatment for the many patients who cannot
undergo MCS or heart transplantation including development of treatment
strategies, novel inotropes or myotropes for patients with advanced
HF</p></li>
</ul></li>
<li><p><strong>AHF</strong></p>
<ul>
<li><p>Better definition and classification of patient phenotypes to
facilitate improved treatment</p></li>
<li><p>Evidence-based use of imaging techniques and biomarkers that have
an impact on patients’ clinical course</p></li>
<li><p>Development of better strategies for congestion relief, including
monitoring of diuretic administration, and/or to improve organ
perfusion</p></li>
<li><p>Identification of treatments with an impact on post-discharge
outcomes</p></li>
<li><p>New devices for short-term MCS</p></li>
<li><p>Definition of evidence-based treatment options and therapeutic
algorithms for patients with cardiogenic shock</p></li>
</ul></li>
<li><p><strong>CV comorbidities</strong></p>
<ul>
<li><p>RCTs showing best strategies for the treatment of ventricular
arrhythmias</p></li>
<li><p>RCTs to establish the role of coronary revascularization
procedures in different patient subsets</p></li>
<li><p>RCTs to establish the impact on patients’ outcomes and/or QOL of
percutaneous treatment of mitral or tricuspid valve disease in patients
with HF</p></li>
</ul></li>
<li><p><strong>Non-CV comorbidities</strong></p>
<ul>
<li><p>RCTs addressing cachexia and/or sarcopenia and/or frailty and
showing the impact of treatment on QOL and/or outcome</p></li>
<li><p>RCTs of medical therapies or devices in patients with severe CKD
and HF</p></li>
<li><p>RCTs showing the effects on outcomes of medical treatment of
electrolyte abnormalities</p></li>
<li><p>RCTs showing the effects on outcomes of treatment of CSA</p></li>
<li><p>Prospective studies showing the impact on outcomes and/or QOL of
early diagnosis, better prevention and treatment of cardiotoxicity of
cancer therapies</p></li>
<li><p>Better treatment of infections and prevention of cardiac injury
with infection</p></li>
</ul></li>
<li><p><strong>Special conditions</strong></p></li>
</ol>
<pre><code>-   RCTs of treatment for PPCM
    
-   Better phenotyping of CMPs through genetic testing, biomarkers and imaging modalities, and tailoring of therapy
    
-   RCTs of treatment of different types of myocarditis, including immunosuppressive therapies
    
-   RCTs of new treatments of different forms of cardiac amyloid
    
-   Better definition and treatment of LA myopathy.
    </code></pre>
<h2 >17
‘What to do’ and ‘what not to do’ messages from the guidelines</h2>
<p>ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial
fibrillation; AHF = acute heart failure; ARB = angiotensin-receptor
blocker; ARNI = angiotensin receptor-neprilysin inhibitor;
AV = atrio-ventricular; BNP = B-type natriuretic peptide;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); CMP = cardiomyopathy; CMR = cardiac magnetic resonance;
CRT = cardiac resynchronization therapy; CSA = central sleep apnoea;
CV = cardiovascular; DOAC = direct-acting oral anticoagulant;
DPP-4 = dipeptidyl peptidase-4; ECG = electrocardiogram;
ECV = electrical cardioversion; HbA1c = glycated haemoglobin; HF = heart
failure; HFmrEF = heart failure with mildly reduced ejection fraction;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; hTTR = hereditary transthyretin;
IABP = intra-aortic balloon pump; ICD = implantable
cardioverter-defibrillator; LBBB = left bundle branch block;
LMWH = low-molecular-weight heparin; LV = left ventricular/ventricle;
LVEF = left ventricular ejection fraction; MCS = mechanical circulatory
support; MI = myocardial infarction; MRA = mineralocorticoid receptor
antagonist; NSAID = non-steroidal anti-inflammatory drug;
NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York
Heart Association; OMT = optimal medical therapy;
PaO<sub>2</sub> = partial pressure of oxygen; QOL = quality of life;
QRS = Q, R, and S waves (on an ECG); RV = right ventricular;
SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose
co-transporter 2; SpO<sub>2</sub> = transcutaneous oxygen saturation;
SR = sinus rhythm; T2DM = type 2 diabetes mellitus; TAVI = transcatheter
aortic valve implantation; TSAT = transferrin saturation;
VAD = ventricular assist device; VKA = vitamin K antagonist;
wtTTR-CA = wild-type transthyretin cardiac amyloidosis.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>References are listed in section 4.2 for this item.</p>
<p>d</p>
<p>In those who are able to adhere to the exercise programme.</p>
<p>ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial
fibrillation; AHF = acute heart failure; ARB = angiotensin-receptor
blocker; ARNI = angiotensin receptor-neprilysin inhibitor;
AV = atrio-ventricular; BNP = B-type natriuretic peptide;
CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure or left
ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes,
Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
(score); CMP = cardiomyopathy; CMR = cardiac magnetic resonance;
CRT = cardiac resynchronization therapy; CSA = central sleep apnoea;
CV = cardiovascular; DOAC = direct-acting oral anticoagulant;
DPP-4 = dipeptidyl peptidase-4; ECG = electrocardiogram;
ECV = electrical cardioversion; HbA1c = glycated haemoglobin; HF = heart
failure; HFmrEF = heart failure with mildly reduced ejection fraction;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; hTTR = hereditary transthyretin;
IABP = intra-aortic balloon pump; ICD = implantable
cardioverter-defibrillator; LBBB = left bundle branch block;
LMWH = low-molecular-weight heparin; LV = left ventricular/ventricle;
LVEF = left ventricular ejection fraction; MCS = mechanical circulatory
support; MI = myocardial infarction; MRA = mineralocorticoid receptor
antagonist; NSAID = non-steroidal anti-inflammatory drug;
NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York
Heart Association; OMT = optimal medical therapy;
PaO<sub>2</sub> = partial pressure of oxygen; QOL = quality of life;
QRS = Q, R, and S waves (on an ECG); RV = right ventricular;
SAVR = surgical aortic valve replacement; SGLT2 = sodium-glucose
co-transporter 2; SpO<sub>2</sub> = transcutaneous oxygen saturation;
SR = sinus rhythm; T2DM = type 2 diabetes mellitus; TAVI = transcatheter
aortic valve implantation; TSAT = transferrin saturation;
VAD = ventricular assist device; VKA = vitamin K antagonist;
wtTTR-CA = wild-type transthyretin cardiac amyloidosis.</p>
<p>a</p>
<p>Class of recommendation.</p>
<p>b</p>
<p>Level of evidence.</p>
<p>c</p>
<p>References are listed in section 4.2 for this item.</p>
<p>d</p>
<p>In those who are able to adhere to the exercise programme.</p>
<h2 >18 Quality indicators</h2>
<p>QIs are tools that may be used to evaluate care quality, including
that of processes of care and clinical outcomes.<sup>995</sup> They may
also serve as a mechanism for enhancing adherence to guideline
recommendations, through quality assurance endeavours and benchmarking
of care providers.<sup>996</sup> As such, the role of QIs in driving
quality improvement is increasingly recognized and attracts interest
from healthcare authorities, professional organizations, payers, and the
public.<sup>997</sup></p>
<p>The ESC recognizes the need for measuring and reporting quality and
outcomes of CV care. The methodology by which the ESC QIs are developed
has been published<sup>997</sup> and, to date, a suite of QIs for an
initial tranche of CV conditions has been
produced.<sup>998</sup><sup>,</sup><sup>999</sup> To facilitate quality
improvement initiatives, the disease-specific ESC QIs are included in
corresponding ESC Clinical Practice
Guidelines.<sup>7</sup><sup>,</sup><sup>1000</sup> This is further
enhanced by way of their integration in the ESC registries, such as the
EURObservational Research Programme (EORP) and the European Unified
Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)
project.<sup>1001</sup></p>
<p>For patients with HF, QIs may help healthcare providers to
simultaneously operationalize discrete guideline recommendations and
enable the discrimination between missed opportunities and appropriate
care. Furthermore, QIs allow the capture of patients’ experience. As
such, and in parallel with the writing of these guidelines, a suite of
QIs for the evaluation of care and outcomes for patients with HF was
developed. These QIs, alongside their specifications and development
process are published separately with a short summary shown in
<em>Table 37</em>.</p>
<p>Table 37</p>
<p>Main European Society of Cardiology quality indicators for the
evaluation of care and outcomes for patients with heart failure (<em>a
full list is published in a separate article</em>)</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Domain 1. Structural QIs<span
></span><span><sup>a</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Centre should have a dedicated multidisciplinary team
to manage patients with HF</strong> 
</td>
</tr>
<tr>
<td>
<strong>Numerator:</strong> Availability of a dedicated
multidisciplinary team to manage patients with HF. 
</td>
</tr>
<tr>
<td>
<strong>Domain 2. Patient assessment<span
></span><span><sup>b</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Proportion of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2): Proportion of patients with HF who have a
documentation of their ECG findings</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their ECG findings.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3): Proportion of patients with HF who have their NPs
measured</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their NPs levels.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Domain 3. Initial treatment</strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1). Proportion of patients with HFrEF who are prescribed
the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol
succinate, or nebivolol in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed <strong>the beta-blocker</strong> bisoprolol, carvedilol,
sustained-release metoprolol succinate, or nebivolol.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for <strong>the beta-blocker</strong> bisoprolol,
carvedilol, sustained-release metoprolol succinate, and nebivolol.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2). Proportion of patients with HFrEF who are prescribed
ACE inhibitor, ARB or ARNI in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an ACE inhibitor, ARB or ARNI.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for ACE inhibitors, ARBs and ARNI.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3). Proportion of patients with HF who are prescribed
diuretic therapy if they have evidence of fluid retention</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF, with evidence
of fluid retention who are prescribed diuretic therapy.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF who have
evidence of fluid retention and no contraindications for diuretic
therapy.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (4): Proportion of patients with HFrEF who are prescribed
an MRA in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an MRA.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for MRA.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (5): Proportion of patients with HFrEF who are prescribed a
SGLT2 inhibitor in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed a SGLT2 inhibitor.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for SGLT2 inhibitor.
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Domain 1. Structural QIs<span
></span><span><sup>a</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Centre should have a dedicated multidisciplinary team
to manage patients with HF</strong> 
</td>
</tr>
<tr>
<td>
<strong>Numerator:</strong> Availability of a dedicated
multidisciplinary team to manage patients with HF. 
</td>
</tr>
<tr>
<td>
<strong>Domain 2. Patient assessment<span
></span><span><sup>b</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Proportion of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2): Proportion of patients with HF who have a
documentation of their ECG findings</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their ECG findings.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3): Proportion of patients with HF who have their NPs
measured</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their NPs levels.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Domain 3. Initial treatment</strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1). Proportion of patients with HFrEF who are prescribed
the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol
succinate, or nebivolol in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed <strong>the beta-blocker</strong> bisoprolol, carvedilol,
sustained-release metoprolol succinate, or nebivolol.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for <strong>the beta-blocker</strong> bisoprolol,
carvedilol, sustained-release metoprolol succinate, and nebivolol.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2). Proportion of patients with HFrEF who are prescribed
ACE inhibitor, ARB or ARNI in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an ACE inhibitor, ARB or ARNI.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for ACE inhibitors, ARBs and ARNI.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3). Proportion of patients with HF who are prescribed
diuretic therapy if they have evidence of fluid retention</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF, with evidence
of fluid retention who are prescribed diuretic therapy.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF who have
evidence of fluid retention and no contraindications for diuretic
therapy.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (4): Proportion of patients with HFrEF who are prescribed
an MRA in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an MRA.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for MRA.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (5): Proportion of patients with HFrEF who are prescribed a
SGLT2 inhibitor in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed a SGLT2 inhibitor.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for SGLT2 inhibitor.
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor
blocker; ARNI = angiotensin receptor-neprilysin inhibitor; HF = heart
failure; HFmrEF = heart failure with mildly reduced ejection fraction;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; IHD = ischaemic heart disease; LBBB = left
bundle branch block; LVEF = left ventricular ejection fraction;
MRA = mineralocorticoid receptor antagonist; NP = natriuretic peptide;
NYHA = New York Heart Association; OMT = optimal medical therapy;
QI = quality indicator; SGLT2 = sodium-glucose co-transporter 2.</p>
<p>a</p>
<p>Structural QIs are binary measurements (Yes/No), and thus, have only
numerator definitions.</p>
<p>b</p>
<p>Blood tests include urea, creatinine, electrolytes, full blood count,
glucose, glycated haemoglobin, thyroid-stimulating hormone, liver
function test, lipids, and iron profile.</p>
<p>Table 37</p>
<p>Main European Society of Cardiology quality indicators for the
evaluation of care and outcomes for patients with heart failure (<em>a
full list is published in a separate article</em>)</p>
<table role="presentation">
<tbody>
<tr>
<td>
<strong>Domain 1. Structural QIs<span
></span><span><sup>a</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Centre should have a dedicated multidisciplinary team
to manage patients with HF</strong> 
</td>
</tr>
<tr>
<td>
<strong>Numerator:</strong> Availability of a dedicated
multidisciplinary team to manage patients with HF. 
</td>
</tr>
<tr>
<td>
<strong>Domain 2. Patient assessment<span
></span><span><sup>b</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Proportion of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2): Proportion of patients with HF who have a
documentation of their ECG findings</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their ECG findings.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3): Proportion of patients with HF who have their NPs
measured</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their NPs levels.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Domain 3. Initial treatment</strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1). Proportion of patients with HFrEF who are prescribed
the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol
succinate, or nebivolol in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed <strong>the beta-blocker</strong> bisoprolol, carvedilol,
sustained-release metoprolol succinate, or nebivolol.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for <strong>the beta-blocker</strong> bisoprolol,
carvedilol, sustained-release metoprolol succinate, and nebivolol.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2). Proportion of patients with HFrEF who are prescribed
ACE inhibitor, ARB or ARNI in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an ACE inhibitor, ARB or ARNI.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for ACE inhibitors, ARBs and ARNI.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3). Proportion of patients with HF who are prescribed
diuretic therapy if they have evidence of fluid retention</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF, with evidence
of fluid retention who are prescribed diuretic therapy.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF who have
evidence of fluid retention and no contraindications for diuretic
therapy.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (4): Proportion of patients with HFrEF who are prescribed
an MRA in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an MRA.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for MRA.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (5): Proportion of patients with HFrEF who are prescribed a
SGLT2 inhibitor in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed a SGLT2 inhibitor.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for SGLT2 inhibitor.
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<table>
<tbody>
<tr>
<td>
<strong>Domain 1. Structural QIs<span
></span><span><sup>a</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Centre should have a dedicated multidisciplinary team
to manage patients with HF</strong> 
</td>
</tr>
<tr>
<td>
<strong>Numerator:</strong> Availability of a dedicated
multidisciplinary team to manage patients with HF. 
</td>
</tr>
<tr>
<td>
<strong>Domain 2. Patient assessment<span
></span><span><sup>b</sup></span></strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1): Proportion of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF)</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their HF clinical type (HFrEF, HFmrEF, HFpEF).
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2): Proportion of patients with HF who have a
documentation of their ECG findings</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their ECG findings.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3): Proportion of patients with HF who have their NPs
measured</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF who have a
documentation of their NPs levels.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Domain 3. Initial treatment</strong> 
</td>
</tr>
<tr>
<td>
<strong>Main (1). Proportion of patients with HFrEF who are prescribed
the beta-blocker bisoprolol, carvedilol, sustained-release metoprolol
succinate, or nebivolol in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed <strong>the beta-blocker</strong> bisoprolol, carvedilol,
sustained-release metoprolol succinate, or nebivolol.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for <strong>the beta-blocker</strong> bisoprolol,
carvedilol, sustained-release metoprolol succinate, and nebivolol.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (2). Proportion of patients with HFrEF who are prescribed
ACE inhibitor, ARB or ARNI in the absence of any
contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an ACE inhibitor, ARB or ARNI.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for ACE inhibitors, ARBs and ARNI.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (3). Proportion of patients with HF who are prescribed
diuretic therapy if they have evidence of fluid retention</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HF, with evidence
of fluid retention who are prescribed diuretic therapy.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HF who have
evidence of fluid retention and no contraindications for diuretic
therapy.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (4): Proportion of patients with HFrEF who are prescribed
an MRA in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed an MRA.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for MRA.
</p>
</li>
</ul>
 
</td>
</tr>
<tr>
<td>
<strong>Main (5): Proportion of patients with HFrEF who are prescribed a
SGLT2 inhibitor in the absence of any contraindications</strong> 
</td>
</tr>
<tr>
<td>
<ul>
<li>
<p>
 <strong>Numerator:</strong> Number of patients with HFrEF who are
prescribed a SGLT2 inhibitor.
</p>
</li>
<li>
<p>
 <strong>Denominator:</strong> Number of patients with HFrEF without any
contraindications for SGLT2 inhibitor.
</p>
</li>
</ul>
 
</td>
</tr>
</tbody>
</table>
<p>ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor
blocker; ARNI = angiotensin receptor-neprilysin inhibitor; HF = heart
failure; HFmrEF = heart failure with mildly reduced ejection fraction;
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart
failure with reduced ejection fraction; ICD = implantable
cardioverter-defibrillator; IHD = ischaemic heart disease; LBBB = left
bundle branch block; LVEF = left ventricular ejection fraction;
MRA = mineralocorticoid receptor antagonist; NP = natriuretic peptide;
NYHA = New York Heart Association; OMT = optimal medical therapy;
QI = quality indicator; SGLT2 = sodium-glucose co-transporter 2.</p>
<p>a</p>
<p>Structural QIs are binary measurements (Yes/No), and thus, have only
numerator definitions.</p>
<p>b</p>
<p>Blood tests include urea, creatinine, electrolytes, full blood count,
glucose, glycated haemoglobin, thyroid-stimulating hormone, liver
function test, lipids, and iron profile.</p>
<h2 >19 Supplementary data</h2>
<p>Supplementary data with additional <a
href="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/42/36/10.1093_eurheartj_ehab368/3/ehab368_supplementary_data.zip?Expires=1689850107&amp;Signature=MVztUVHMBTIYNmepJjSw6fSbF6-Ol1JrBrxRjBPHU-ybQhbq1k-agY934IsuYbbLwbURMEVvoEeoLVKcwgB1MgAbfQ9tcJFc9pbcceg0WB~MspISChCavl9C6jYKdbaSq-eKUkDft4PpxYzJuzJcbtSRPdaV61DlKxemEYoeXWCddCFuRqJ6OpuPLUIPqntMClj1EUTFFJfFTfTUeacm5dfDdO68jAYUP9J3nedYf6PIxdW7Tmw4H8iDGcstPjlg06wW-3-7R9Ic-YiXu1g4D7xCSnFmOWKJMGtz5woEhsJxBOHwJgqlQlcGTPc4ZfHd4KuSpfxjahCud7ByjVuQnw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA">Supplementary
Figures, Tables</a>, and text complementing the full text are available
on the <em>European Heart Journal</em> website and via the ESC website
at <a
href="http://www.escardio.org/guidelines">www.escardio.org/guidelines</a>.</p>
<h2 >20 Author information</h2>
<p><strong>Author/Task Force Member Affiliations: Marianna
Adamo</strong>, Medical and Surgical Specialties, Radiological Sciences
and Public, ASST Spedali Civili di Brescia, Brescia, Italy;
<strong>Andreas Baumbach</strong>, Barts Heart Centre, Queen Mary
University of London, London, United Kingdom; <strong>Michael
Böhm</strong>, Klinik für Innere Medizin III, Saarland University,
Homburg/Saar, Saarland, Germany; <strong>Haran Burri</strong>,
Cardiology, University Hospital of Geneva, Geneva, Switzerland;
<strong>Jelena Čelutkienė</strong>, Clinic of Cardiac and Vascular
Diseases, Vilnius University, Faculty of Medicine, Vilnius, Lithuania;
<strong>Ovidiu Chioncel</strong>, Emergency Institute for Cardiovascular
Diseases ‘Prof. Dr.C.C.Iliescu’, University of Medicine Carol Davila,
Bucuresti, Romania; <strong>John G.F. Cleland</strong>, Robertson Centre
for Biostatistics and Clinical Trials, Institute of Health &amp;
Wellbeing, Glasgow, Lanarkshire, United Kingdom; <strong>Andrew J.S.
Coats</strong>, University of Warwick, Coventry, United Kingdom;
<strong>Maria G. Crespo-Leiro</strong>, Cardiology, Complexo
Hospitalario Universitario A Coruña (CHUAC), CIBERCV, Universidade da
Coruña (UDC), Instituto de Investigación Biomedica de A Coruña (INIBIC),
La Coruña, Spain; <strong>Dimitrios Farmakis</strong>, University of
Cyprus Medical School, Nicosia, Cyprus; <strong>Roy S. Gardner</strong>,
Scottish National Advanced Heart Failure Service, Golden Jubilee
National Hospital, Clyderbank, Glasgow, Scotland, United Kingdom;
<strong>Martine Gilard</strong>, Cardiology, Brest University, Brest,
France; <strong>Stephane Heymans</strong>, Department of Cardiology,
Maastricht University, CARIM School for Cardiovascular Diseases,
Maastricht, Netherlands; <strong>Arno W. Hoes</strong>, University
Medical Center Utrecht, Utrecht, Netherlands; <strong>Tiny
Jaarsma</strong>, Department of Health, Medicine and Caring Science,
Linköping University, Linköping, Sweden; <strong>Ewa A.
Jankowska</strong>, Department of Heart Diseases, Wroclaw Medical
University, Wroclaw, Poland; <strong>Mitja Lainscak</strong>, Division
of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia;
<strong>Carolyn S.P. Lam</strong>, National Heart Centre Singapore and
Duke-National University of Singapore, Singapore; <strong>Alexander R.
Lyon</strong>, Department of Cardiology, Royal Brompton Hospital,
London, United Kingdom; <strong>John J.V. McMurray</strong>, British
Heart Foundation Cardiovascular Research Centre, University of Glasgow,
Glasgow, Scotland, United Kingdom; <strong>Alexandre Mebazaa</strong>,
Anesthesiology and Critical Care, Université de Paris - Hôpital
Lariboisière, Paris, France; <strong>Richard Mindham</strong>, United
Kingdom, ESC Patient Forum, Sophia Antipolis, France; <strong>Claudio
Muneretto</strong>, Cardiothoracic Surgery, Asst Spedali Civili
University of Brescia, Brescia, Italy; <strong>Massimo Francesco
Piepoli</strong>, Cardiology, Guglielmo da Saliceto Hospital, AUSL
Piacenza, Piacenza, Italy; <strong>Susanna Price</strong>, Cardiology
&amp; Adult Intensive Care Unit, Royal Brompton Hospital, London, United
Kingdom; <strong>Giuseppe M.C. Rosano</strong>, IRCCS San Raffaele,
Roma, Italy; <strong>Frank Ruschitzka</strong>, Department of
Cardiology, University Hospital Zurich, Zurich, Switzerland;
<strong>Anne Kathrine Skibelund</strong>, Denmark, ESC Patient Forum,
Sophia Antipolis, France.</p>
<p><strong>Author/Task Force Member affiliations: listed in Author
information.</strong></p>
<p><strong>ESC Clinical Practice Guidelines Committee (CPG): listed in
the Appendix.</strong></p>
<p><strong>ESC subspecialty communities having participated in the
development of this document:</strong></p>
<p><strong>Associations</strong>: Association for Acute CardioVascular
Care (ACVC), Association of Cardiovascular Nursing &amp; Allied
Professions (ACNAP), European Association of Cardiovascular Imaging
(EACVI), European Association of Preventive Cardiology (EAPC), European
Association of Percutaneous Cardiovascular Interventions (EAPCI),
European Heart Rhythm Association (EHRA), Heart Failure Association
(HFA).</p>
<p><strong>Councils</strong>: Council of Cardio-Oncology, Council on
Basic Cardiovascular Science, Council on Valvular Heart Disease.</p>
<p><strong>Working Groups</strong>: Adult Congenital Heart Disease,
Cardiovascular Pharmacotherapy, Cardiovascular Regenerative and
Reparative Medicine, Cardiovascular Surgery, e-Cardiology, Myocardial
and Pericardial Diseases, Myocardial Function.</p>
<p><strong>Patient Forum</strong></p>
<p>The content of these European Society of Cardiology (ESC) Guidelines
has been published for personal and educational use only. No commercial
use is authorized. No part of the ESC Guidelines may be translated or
reproduced in any form without written permission from the ESC.
Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the <em>European Heart
Journal</em> and the party authorized to handle such permissions on
behalf of the ESC (<a
href="mailto:journals.permissions@oup.com">journals.permissions@oup.com</a>).</p>
<p><strong>Disclaimer:</strong> The ESC Guidelines represent the views
of the ESC and were produced after careful consideration of the
scientific and medical knowledge and the evidence available at the time
of their publication. The ESC is not responsible in the event of any
contradiction, discrepancy and/or ambiguity between the ESC Guidelines
and any other official recommendations or guidelines issued by the
relevant public health authorities, in particular in relation to good
use of healthcare or therapeutic strategies. Health professionals are
encouraged to take the ESC Guidelines fully into account when exercising
their clinical judgment, as well as in the determination and the
implementation of preventive, diagnostic or therapeutic medical
strategies; however, the ESC Guidelines do not override, in any way
whatsoever, the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of each
patient’s health condition and in consultation with that patient and,
where appropriate and/or necessary, the patient’s caregiver. Nor do the
ESC Guidelines exempt health professionals from taking into full and
careful consideration the relevant official updated recommendations or
guidelines issued by the competent public health authorities, in order
to manage each patient’s case in light of the scientifically accepted
data pursuant to their respective ethical and professional obligations.
It is also the health professional’s responsibility to verify the
applicable rules and regulations relating to drugs and medical devices
at the time of prescription.</p>
<h3 >21 Appendix</h3>
<p><strong>ESC Scientific Document Group</strong></p>
<p>Includes Document Reviewers and ESC National Cardiac Societies.</p>
<p><strong>Document Reviewers:</strong> Rudolf A. de Boer (CPG Review
Coordinator) (Netherlands), P. Christian Schulze (CPG Review
Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans
(France), Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany),
Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Johann Bauersachs
(Germany), Antoni Bayes-Genis (Spain), Michael A. Borger (Germany),
Werner Budts (Belgium), Maja Cikes (Croatia), Kevin Damman
(Netherlands), Victoria Delgado (Netherlands), Paul Dendale (Belgium),
Polychronis Dilaveris (Greece), Heinz Drexel (Austria), Justin Ezekowitz
(Canada), Volkmar Falk (Germany), Laurent Fauchier (France), Gerasimos
Filippatos (Greece), Alan Fraser (United Kingdom), Norbert Frey
(Germany), Chris P. Gale (United Kingdom), Finn Gustafsson (Denmark),
Julie Harris (United Kingdom), Bernard Iung (France), Stefan Janssens
(Belgium), Mariell Jessup (United States of America), Aleksandra Konradi
(Russia), Dipak Kotecha (United Kingdom), Ekatirini Lambrinou (Cyprus),
Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany), Christophe
Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva (United
Kingdom), Aleš Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lars
H. Lund (Sweden), Donna Mancini (United States of America), Josep Masip
(Spain), Davor Milicic (Croatia), Christian Mueller (Switzerland),
Holger Nef (Germany), Jens-Cosedis Nielsen (Denmark), Lis Neubeck
(United Kingdom), Michel Noutsias (Germany), Steffen E. Petersen (United
Kingdom), Anna Sonia Petronio (Italy), Piotr Ponikowski (Poland), Eva
Prescott (Denmark), Amina Rakisheva (Kazakhstan), Dimitrios Richter
(Greece), Evgeny Schlyakhto (Russia), Petar Seferovic (Serbia), Michele
Senni (Italy), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Carlo
Gabriele Tocchetti (Italy), Rhian Touyz (United Kingdom), Carsten
Tschoepe (Germany), Johannes Waltenberger (Germany).</p>
<p><strong>ESC National Cardiac Societies</strong> actively involved in
the review process of the 2021 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure:</p>
<p><strong>Algeria:</strong> Algerian Society of Cardiology, Messaad
Krim; <strong>Armenia:</strong> Armenian Cardiologists Association,
Hamlet Hayrapetyan; <strong>Austria:</strong> Austrian Society of
Cardiology, Deddo Moertl; <strong>Azerbaijan:</strong> Azerbaijan
Society of Cardiology, Isakh Mustafayev; <strong>Belarus:</strong>
Belorussian Scientific Society of Cardiologists, Alena Kurlianskaya;
<strong>Belgium:</strong> Belgian Society of Cardiology, Michel Depauw;
<strong>Bosnia and Herzegovina:</strong> Association of Cardiologists of
Bosnia and Herzegovina, Zumreta Kušljugić; <strong>Bulgaria:</strong>
Bulgarian Society of Cardiology, Plamen Gatzov;
<strong>Croatia:</strong> Croatian Cardiac Society, Davor Milicic;
<strong>Cyprus:</strong> Cyprus Society of Cardiology, Petros
Agathangelou; <strong>Czech Republic:</strong> Czech Society of
Cardiology, Vojtěch Melenovský; <strong>Denmark:</strong> Danish Society
of Cardiology, Brian Bridal Løgstrup; <strong>Egypt:</strong> Egyptian
Society of Cardiology, Ahmed Magdy Mostafa; <strong>Estonia:</strong>
Estonian Society of Cardiology, Tiina Uuetoa; <strong>Finland:</strong>
Finnish Cardiac Society, Johan Lassus; <strong>France:</strong> French
Society of Cardiology, Damien Logeart; <strong>Georgia:</strong>
Georgian Society of Cardiology, Zviad Kipiani; <strong>Germany:</strong>
German Cardiac Society, Johann Bauersachs; <strong>Greece:</strong>
Hellenic Society of Cardiology, Christina Chrysohoou;
<strong>Hungary:</strong> Hungarian Society of Cardiology, Róbert Sepp;
<strong>Iceland:</strong> Icelandic Society of Cardiology, Inga Jóna
Ingimarsdóttir; <strong>Ireland:</strong> Irish Cardiac Society, Jim
O’Neill; <strong>Israel:</strong> Israel Heart Society, Israel Gotsman;
<strong>Italy:</strong> Italian Federation of Cardiology, Massimo
Iacoviello; <strong>Kazakhstan:</strong> Association of Cardiologists of
Kazakhstan, Amina Rakisheva; <strong>Kosovo (Republic of):</strong>
Kosovo Society of Cardiology, Gani Bajraktari;
<strong>Kyrgyzstan:</strong> Kyrgyz Society of Cardiology, Olga
Lunegova, <strong>Latvia:</strong> Latvian Society of Cardiology, Ginta
Kamzola; <strong>Lebanon:</strong> Lebanese Society of Cardiology, Tony
Abdel Massih; <strong>Libya:</strong> Libyan Cardiac Society, Hisham
Benlamin; <strong>Lithuania:</strong> Lithuanian Society of Cardiology,
DianaŽaliaduonytė; <strong>Luxembourg:</strong> Luxembourg Society of
Cardiology, Stephanie Noppe; <strong>Malta:</strong> Maltese Cardiac
Society, Alice Moore; <strong>Moldova (Republic of):</strong> Moldavian
Society of Cardiology, Eleonora Vataman; <strong>Montenegro:</strong>
Montenegro Society of Cardiology, Aneta Boskovic;
<strong>Morocco:</strong> Moroccan Society of Cardiology, Ahmed Bennis;
<strong>Netherlands:</strong> Netherlands Society of Cardiology, Olivier
C. Manintveld; <strong>North Macedonia</strong>: North Macedonian
Society of Cardiology, Elizabeta Srbinovska Kostovska;
<strong>Norway:</strong> Norwegian Society of Cardiology, Geeta Gulati;
<strong>Poland:</strong> Polish Cardiac Society, Ewa
Straburzyńska-Migaj; <strong>Portugal:</strong> Portuguese Society of
Cardiology, José Silva-Cardoso; <strong>Romania:</strong> Romanian
Society of Cardiology, Roxana Cristina Rimbaş; <strong>Russian
Federation:</strong> Russian Society of Cardiology, Yury Lopatin;
<strong>San Marino:</strong> San Marino Society of Cardiology, Marina
Foscoli; <strong>Serbia:</strong> Cardiology Society of Serbia, Sinisa
Stojkovic; <strong>Slovakia:</strong> Slovak Society of Cardiology, Eva
Goncalvesova; <strong>Slovenia:</strong> Slovenian Society of
Cardiology, Zlatko Fras; <strong>Spain:</strong> Spanish Society of
Cardiology, Javier Segovia; <strong>Sweden:</strong> Swedish Society of
Cardiology, Krister Lindmark; <strong>Switzerland:</strong> Swiss
Society of Cardiology, Micha T. Maeder; <strong>Syrian Arab
Republic:</strong> Syrian Cardiovascular Association, Walid Bsata;
<strong>Tunisia:</strong> Tunisian Society of Cardiology and
Cardio-Vascular Surgery, Leila Abid; <strong>Turkey:</strong> Turkish
Society of Cardiology, Hakan Altay; <strong>Ukraine:</strong> Ukrainian
Association of Cardiology, Leonid Voronkov; <strong>United Kingdom of
Great Britain and Northern Ireland:</strong> British Cardiovascular
Society, Ceri Davies, <strong>Uzbekistan:</strong> Association of
Cardiologists of Uzbekistan, Timur Abdullaev.</p>
<p><strong>ESC Clinical Practice Guidelines Committee (CPG):</strong>
Colin N. Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt), Victor Aboyans (France), Sotiris Antoniou (United Kingdom),
Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach
(United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė
(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),
Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale (United
Kingdom), Sigrun Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma
(Sweden), Aleksandra Konradi (Russia), Konstantinos C. Koskinas
(Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen
(Norway), Jens-Cosedis Nielsen (Denmark), Steffen E. Petersen (United
Kingdom), Eva Prescott (Denmark), Lis Neubeck (United Kingdom), Amina
Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United
Kingdom).</p>
<h2 >22 References</h2>
<p>1</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Falk</p>
<p>V</p>
<p>,</p>
<p>Gonzalez-Juanatey</p>
<p>JR</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Jessup</p>
<p>M</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Nihoyannopoulos</p>
<p>P</p>
<p>,</p>
<p>Parissis</p>
<p>JT</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Riley</p>
<p>JP</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Ruilope</p>
<p>LM</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2016 ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure: The Task Force for the diagnosis and treatment of
acute and chronic heart failure of the European Society of Cardiology
(ESC). Developed with the special contribution of the Heart Failure
Association (HFA) of the ESC</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>2129</p>
<p>–</p>
<p>2200</p>
<p>.</p>
<p>2</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Agewall</p>
<p>S</p>
<p>,</p>
<p>Albus</p>
<p>C</p>
<p>,</p>
<p>Brotons</p>
<p>C</p>
<p>,</p>
<p>Catapano</p>
<p>AL</p>
<p>,</p>
<p>Cooney</p>
<p>MT</p>
<p>,</p>
<p>Corra</p>
<p>U</p>
<p>,</p>
<p>Cosyns</p>
<p>B</p>
<p>,</p>
<p>Deaton</p>
<p>C</p>
<p>,</p>
<p>Graham</p>
<p>I</p>
<p>,</p>
<p>Hall</p>
<p>MS</p>
<p>,</p>
<p>Hobbs</p>
<p>FDR</p>
<p>,</p>
<p>Lochen</p>
<p>ML</p>
<p>,</p>
<p>Lollgen</p>
<p>H</p>
<p>,</p>
<p>Marques-Vidal</p>
<p>P</p>
<p>,</p>
<p>Perk</p>
<p>J</p>
<p>,</p>
<p>Prescott</p>
<p>E</p>
<p>,</p>
<p>Redon</p>
<p>J</p>
<p>,</p>
<p>Richter</p>
<p>DJ</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Smulders</p>
<p>Y</p>
<p>,</p>
<p>Tiberi</p>
<p>M</p>
<p>,</p>
<p>van der Worp</p>
<p>HB</p>
<p>,</p>
<p>van Dis</p>
<p>I</p>
<p>,</p>
<p>Verschuren</p>
<p>WMM</p>
<p>,</p>
<p>Binno</p>
<p>S</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2016 European Guidelines on cardiovascular disease prevention in
clinical practice: The Sixth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (constituted by representatives of 10 societies and by
invited experts)Developed with the special contribution of the European
Association for Cardiovascular Prevention &amp; Rehabilitation
(EACPR)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>2315</p>
<p>–</p>
<p>2381</p>
<p>.</p>
<p>3</p>
<p>Ibanez</p>
<p>B</p>
<p>,</p>
<p>James</p>
<p>S</p>
<p>,</p>
<p>Agewall</p>
<p>S</p>
<p>,</p>
<p>Antunes</p>
<p>MJ</p>
<p>,</p>
<p>Bucciarelli-Ducci</p>
<p>C</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Caforio</p>
<p>ALP</p>
<p>,</p>
<p>Crea</p>
<p>F</p>
<p>,</p>
<p>Goudevenos</p>
<p>JA</p>
<p>,</p>
<p>Halvorsen</p>
<p>S</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Kastrati</p>
<p>A</p>
<p>,</p>
<p>Lenzen</p>
<p>MJ</p>
<p>,</p>
<p>Prescott</p>
<p>E</p>
<p>,</p>
<p>Roffi</p>
<p>M</p>
<p>,</p>
<p>Valgimigli</p>
<p>M</p>
<p>,</p>
<p>Varenhorst</p>
<p>C</p>
<p>,</p>
<p>Vranckx</p>
<p>P</p>
<p>,</p>
<p>Widimsky</p>
<p>P</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2017 ESC Guidelines for the management of acute myocardial infarction
in patients presenting with ST-segment elevation: The Task Force for the
management of acute myocardial infarction in patients presenting with
ST-segment elevation of the European Society of Cardiology (ESC)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>119</p>
<p>–</p>
<p>177</p>
<p>.</p>
<p>4</p>
<p>Williams</p>
<p>B</p>
<p>,</p>
<p>Mancia</p>
<p>G</p>
<p>,</p>
<p>Spiering</p>
<p>W</p>
<p>,</p>
<p>Agabiti Rosei</p>
<p>E</p>
<p>,</p>
<p>Azizi</p>
<p>M</p>
<p>,</p>
<p>Burnier</p>
<p>M</p>
<p>,</p>
<p>Clement</p>
<p>DL</p>
<p>,</p>
<p>Coca</p>
<p>A</p>
<p>,</p>
<p>de Simone</p>
<p>G</p>
<p>,</p>
<p>Dominiczak</p>
<p>A</p>
<p>,</p>
<p>Kahan</p>
<p>T</p>
<p>,</p>
<p>Mahfoud</p>
<p>F</p>
<p>,</p>
<p>Redon</p>
<p>J</p>
<p>,</p>
<p>Ruilope</p>
<p>L</p>
<p>,</p>
<p>Zanchetti</p>
<p>A</p>
<p>,</p>
<p>Kerins</p>
<p>M</p>
<p>,</p>
<p>Kjeldsen</p>
<p>SE</p>
<p>,</p>
<p>Kreutz</p>
<p>R</p>
<p>,</p>
<p>Laurent</p>
<p>S</p>
<p>,</p>
<p>Lip</p>
<p>GYH</p>
<p>,</p>
<p>McManus</p>
<p>R</p>
<p>,</p>
<p>Narkiewicz</p>
<p>K</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Schmieder</p>
<p>RE</p>
<p>,</p>
<p>Shlyakhto</p>
<p>E</p>
<p>,</p>
<p>Tsioufis</p>
<p>C</p>
<p>,</p>
<p>Aboyans</p>
<p>V</p>
<p>,</p>
<p>Desormais</p>
<p>I</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2018 ESC/ESH Guidelines for the management of arterial
hypertension</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>3021</p>
<p>–</p>
<p>3104</p>
<p>.</p>
<p>5</p>
<p>Knuuti</p>
<p>J</p>
<p>,</p>
<p>Wijns</p>
<p>W</p>
<p>,</p>
<p>Saraste</p>
<p>A</p>
<p>,</p>
<p>Capodanno</p>
<p>D</p>
<p>,</p>
<p>Barbato</p>
<p>E</p>
<p>,</p>
<p>Funck-Brentano</p>
<p>C</p>
<p>,</p>
<p>Prescott</p>
<p>E</p>
<p>,</p>
<p>Storey</p>
<p>RF</p>
<p>,</p>
<p>Deaton</p>
<p>C</p>
<p>,</p>
<p>Cuisset</p>
<p>T</p>
<p>,</p>
<p>Agewall</p>
<p>S</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Escaned</p>
<p>J</p>
<p>,</p>
<p>Gersh</p>
<p>BJ</p>
<p>,</p>
<p>Svitil</p>
<p>P</p>
<p>,</p>
<p>Gilard</p>
<p>M</p>
<p>,</p>
<p>Hasdai</p>
<p>D</p>
<p>,</p>
<p>Hatala</p>
<p>R</p>
<p>,</p>
<p>Mahfoud</p>
<p>F</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Muneretto</p>
<p>C</p>
<p>,</p>
<p>Valgimigli</p>
<p>M</p>
<p>,</p>
<p>Achenbach</p>
<p>S</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2019 ESC Guidelines for the diagnosis and management of chronic
coronary syndromes</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>407</p>
<p>–</p>
<p>477</p>
<p>.</p>
<p>6</p>
<p>Cosentino</p>
<p>F</p>
<p>,</p>
<p>Grant</p>
<p>PJ</p>
<p>,</p>
<p>Aboyans</p>
<p>V</p>
<p>,</p>
<p>Bailey</p>
<p>CJ</p>
<p>,</p>
<p>Ceriello</p>
<p>A</p>
<p>,</p>
<p>Delgado</p>
<p>V</p>
<p>,</p>
<p>Federici</p>
<p>M</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Grobbee</p>
<p>DE</p>
<p>,</p>
<p>Hansen</p>
<p>TB</p>
<p>,</p>
<p>Huikuri</p>
<p>HV</p>
<p>,</p>
<p>Johansson</p>
<p>I</p>
<p>,</p>
<p>Juni</p>
<p>P</p>
<p>,</p>
<p>Lettino</p>
<p>M</p>
<p>,</p>
<p>Marx</p>
<p>N</p>
<p>,</p>
<p>Mellbin</p>
<p>LG</p>
<p>,</p>
<p>Ostgren</p>
<p>CJ</p>
<p>,</p>
<p>Rocca</p>
<p>B</p>
<p>,</p>
<p>Roffi</p>
<p>M</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Sousa-Uva</p>
<p>M</p>
<p>,</p>
<p>Valensi</p>
<p>P</p>
<p>,</p>
<p>Wheeler</p>
<p>DC</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular
diseases developed in collaboration with the EASD</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>255</p>
<p>–</p>
<p>323</p>
<p>.</p>
<p>7</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Potpara</p>
<p>T</p>
<p>,</p>
<p>Dagres</p>
<p>N</p>
<p>,</p>
<p>Arbelo</p>
<p>E</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Blomstrom-Lundqvist</p>
<p>C</p>
<p>,</p>
<p>Boriani</p>
<p>G</p>
<p>,</p>
<p>Castella</p>
<p>M</p>
<p>,</p>
<p>Dan</p>
<p>GA</p>
<p>,</p>
<p>Dilaveris</p>
<p>PE</p>
<p>,</p>
<p>Fauchier</p>
<p>L</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Kalman</p>
<p>JM</p>
<p>,</p>
<p>La Meir</p>
<p>M</p>
<p>,</p>
<p>Lane</p>
<p>DA</p>
<p>,</p>
<p>Lebeau</p>
<p>JP</p>
<p>,</p>
<p>Lettino</p>
<p>M</p>
<p>,</p>
<p>Lip</p>
<p>GYH</p>
<p>,</p>
<p>Pinto</p>
<p>FJ</p>
<p>,</p>
<p>Thomas</p>
<p>GN</p>
<p>,</p>
<p>Valgimigli</p>
<p>M</p>
<p>,</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Van Putte</p>
<p>BP</p>
<p>,</p>
<p>Watkins</p>
<p>CL</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2020 ESC Guidelines for the diagnosis and management of atrial
fibrillation developed in collaboration with the European Association
for Cardio-Thoracic Surgery (EACTS</p>
<p>).</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>373</p>
<p>–</p>
<p>498</p>
<p>.</p>
<p>8</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Liu</p>
<p>J</p>
<p>,</p>
<p>Lam</p>
<p>CS</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Rosano</p>
<p>GM</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Heart failure with mid-range ejection fraction in CHARM:
characteristics, outcomes and effect of candesartan across the entire
ejection fraction spectrum</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1230</p>
<p>–</p>
<p>1239</p>
<p>.</p>
<p>9</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>Desai</p>
<p>A</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>McKinlay</p>
<p>S</p>
<p>,</p>
<p>Fleg</p>
<p>JL</p>
<p>,</p>
<p>Sopko</p>
<p>G</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>TOPCAT Investigators</p>
<p>.</p>
<p>Influence of ejection fraction on outcomes and efficacy of
spironolactone in patients with heart failure with preserved ejection
fraction</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>455</p>
<p>–</p>
<p>462</p>
<p>.</p>
<p>10</p>
<p>Abdul-Rahim</p>
<p>AH</p>
<p>,</p>
<p>Shen</p>
<p>L</p>
<p>,</p>
<p>Rush</p>
<p>CJ</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Lees</p>
<p>KR</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>VICCTA-Heart Failure Collaborators. Effect of digoxin in patients
with heart failure and mid-range (borderline) left ventricular ejection
fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1139</p>
<p>–</p>
<p>1145</p>
<p>.</p>
<p>11</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>Adamus</p>
<p>J</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Polonski</p>
<p>L</p>
<p>,</p>
<p>Taylor</p>
<p>J</p>
<p>PEP-CHF Investigators</p>
<p>.</p>
<p>The perindopril in elderly people with chronic heart failure
(PEP-CHF) study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2006</p>
<p>;</p>
<p>27</p>
<p>:</p>
<p>2338</p>
<p>–</p>
<p>2345</p>
<p>.</p>
<p>12</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Bunting</p>
<p>KV</p>
<p>,</p>
<p>Flather</p>
<p>MD</p>
<p>,</p>
<p>Altman</p>
<p>DG</p>
<p>,</p>
<p>Holmes</p>
<p>J</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Manzano</p>
<p>L</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>von Lueder</p>
<p>TG</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Andersson</p>
<p>B</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rigby</p>
<p>AS</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>Hjalmarson</p>
<p>A</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Beta-blockers in Heart Failure Collaborative Group</p>
<p>.</p>
<p>Beta-blockers for heart failure with reduced, mid-range, and
preserved ejection fraction: an individual patient-level analysis of
double-blind randomized trials</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>26</p>
<p>–</p>
<p>35</p>
<p>.</p>
<p>13</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Ge</p>
<p>J</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Martinez</p>
<p>F</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Boytsov</p>
<p>SA</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Cleland</p>
<p>J</p>
<p>,</p>
<p>Dungen</p>
<p>HD</p>
<p>,</p>
<p>Goncalvesova</p>
<p>E</p>
<p>,</p>
<p>Katova</p>
<p>T</p>
<p>,</p>
<p>Kerr Saraiva</p>
<p>JF</p>
<p>,</p>
<p>Lelonek</p>
<p>M</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Zhou</p>
<p>J</p>
<p>,</p>
<p>Rizkala</p>
<p>AR</p>
<p>,</p>
<p>Gong</p>
<p>J</p>
<p>,</p>
<p>Shi</p>
<p>VC</p>
<p>,</p>
<p>Lefkowitz</p>
<p>MP</p>
<p>PARAGON-HF Investigators and Committees</p>
<p>.</p>
<p>Angiotensin-neprilysin inhibition in heart failure with preserved
ejection fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>381</p>
<p>:</p>
<p>1609</p>
<p>–</p>
<p>1620</p>
<p>.</p>
<p>14</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Piotr</p>
<p>P</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Time to rename the middle child of heart failure: heart failure with
mildly reduced ejection fraction</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>2353</p>
<p>–</p>
<p>2355</p>
<p>.</p>
<p>15</p>
<p>Bozkurt</p>
<p>B</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Tsutsui</p>
<p>H</p>
<p>,</p>
<p>Abdelhamid</p>
<p>CM</p>
<p>,</p>
<p>Adamopoulos</p>
<p>S</p>
<p>,</p>
<p>Albert</p>
<p>N</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Atherton</p>
<p>J</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Drazner</p>
<p>MH</p>
<p>,</p>
<p>Michael Felker</p>
<p>G</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Fiuzat</p>
<p>M</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Gomez-Mesa</p>
<p>JE</p>
<p>,</p>
<p>Heidenreich</p>
<p>P</p>
<p>,</p>
<p>Imamura</p>
<p>T</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Januzzi</p>
<p>J</p>
<p>,</p>
<p>Khazanie</p>
<p>P</p>
<p>,</p>
<p>Kinugawa</p>
<p>K</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Matsue</p>
<p>Y</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Ohtani</p>
<p>T</p>
<p>,</p>
<p>Francesco Piepoli</p>
<p>M</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Sakata</p>
<p>Y</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Yamamoto</p>
<p>K</p>
<p>,</p>
<p>Yancy</p>
<p>C</p>
<p>,</p>
<p>Zhang</p>
<p>J</p>
<p>,</p>
<p>Zieroth</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Universal definition and classification of heart failure: a report of
the Heart Failure Society of America, Heart Failure Association of the
European Society of Cardiology, Japanese Heart Failure Society and
Writing Committee of the Universal Definition of Heart Failure: Endorsed
by the Canadian Heart Failure Society, Heart Failure Association of
India, Cardiac Society of Australia and New Zealand, and Chinese Heart
Failure Association</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>352</p>
<p>–</p>
<p>380</p>
<p>.</p>
<p>16</p>
<p>Galderisi</p>
<p>M</p>
<p>,</p>
<p>Cosyns</p>
<p>B</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Cardim</p>
<p>N</p>
<p>,</p>
<p>Delgado</p>
<p>V</p>
<p>,</p>
<p>Di Salvo</p>
<p>G</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Sade</p>
<p>LE</p>
<p>,</p>
<p>Ernande</p>
<p>L</p>
<p>,</p>
<p>Garbi</p>
<p>M</p>
<p>,</p>
<p>Grapsa</p>
<p>J</p>
<p>,</p>
<p>Hagendorff</p>
<p>A</p>
<p>,</p>
<p>Kamp</p>
<p>O</p>
<p>,</p>
<p>Magne</p>
<p>J</p>
<p>,</p>
<p>Santoro</p>
<p>C</p>
<p>,</p>
<p>Stefanidis</p>
<p>A</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Popescu</p>
<p>B</p>
<p>,</p>
<p>Habib</p>
<p>G</p>
<p>,</p>
<p>EACVI Scientific Documents Committee</p>
<p>.</p>
<p>Standardization of adult transthoracic echocardiography reporting in
agreement with recent chamber quantification, diastolic function, and
heart valve disease recommendations: an expert consensus document of the
European Association of Cardiovascular Imaging</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Imaging</p>
<p>2017</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>1301</p>
<p>–</p>
<p>1310</p>
<p>.</p>
<p>17</p>
<p>Arrigo</p>
<p>M</p>
<p>,</p>
<p>Huber</p>
<p>LC</p>
<p>,</p>
<p>Winnik</p>
<p>S</p>
<p>,</p>
<p>Mikulicic</p>
<p>F</p>
<p>,</p>
<p>Guidetti</p>
<p>F</p>
<p>,</p>
<p>Frank</p>
<p>M</p>
<p>,</p>
<p>Flammer</p>
<p>AJ</p>
<p>,</p>
<p>Ruschitzka</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Right ventricular failure: pathophysiology, diagnosis and
treatment</p>
<p>.</p>
<p>Card Fail Rev</p>
<p>2019</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>140</p>
<p>–</p>
<p>146</p>
<p>.</p>
<p>18</p>
<p>Gorter</p>
<p>TM</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Borlaug</p>
<p>BA</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Guazzi</p>
<p>M</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Paulus</p>
<p>WJ</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Triposkiadis</p>
<p>F</p>
<p>,</p>
<p>Wachter</p>
<p>R</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>de Boer</p>
<p>RA.</p>
<p>Right heart dysfunction and failure in heart failure with preserved
ejection fraction: mechanisms and management. Position statement on
behalf of the Heart Failure Association of the European Society of
Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>16</p>
<p>–</p>
<p>37</p>
<p>.</p>
<p>19</p>
<p>Caraballo</p>
<p>C</p>
<p>,</p>
<p>Desai</p>
<p>NR</p>
<p>,</p>
<p>Mulder</p>
<p>H</p>
<p>,</p>
<p>Alhanti</p>
<p>B</p>
<p>,</p>
<p>Wilson</p>
<p>FP</p>
<p>,</p>
<p>Fiuzat</p>
<p>M</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Lindenfeld</p>
<p>J</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>,</p>
<p>Cohen</p>
<p>LS</p>
<p>,</p>
<p>Ahmad</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Clinical implications of the New York Heart Association
classification</p>
<p>.</p>
<p>J Am Heart Assoc</p>
<p>2019</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>e014240</p>
<p>.</p>
<p>20</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Desai</p>
<p>A</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Rouleau</p>
<p>J</p>
<p>,</p>
<p>Shi</p>
<p>V</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Efficacy of sacubitril/valsartan relative to a prior decompensation:
the PARADIGM-HF trial</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>816</p>
<p>–</p>
<p>822</p>
<p>.</p>
<p>21</p>
<p>Conrad</p>
<p>N</p>
<p>,</p>
<p>Judge</p>
<p>A</p>
<p>,</p>
<p>Tran</p>
<p>J</p>
<p>,</p>
<p>Mohseni</p>
<p>H</p>
<p>,</p>
<p>Hedgecott</p>
<p>D</p>
<p>,</p>
<p>Crespillo</p>
<p>AP</p>
<p>,</p>
<p>Allison</p>
<p>M</p>
<p>,</p>
<p>Hemingway</p>
<p>H</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Rahimi</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Temporal trends and patterns in heart failure incidence: a
population-based study of 4 million individuals</p>
<p>.</p>
<p>Lancet</p>
<p>2018</p>
<p>;</p>
<p>391</p>
<p>:</p>
<p>572</p>
<p>–</p>
<p>580</p>
<p>.</p>
<p>22</p>
<p>Dunlay</p>
<p>SM</p>
<p>,</p>
<p>Roger</p>
<p>VL.</p>
<p>Understanding the epidemic of heart failure: past, present, and
future</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2014</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>404</p>
<p>–</p>
<p>415</p>
<p>.</p>
<p>23</p>
<p>Roth</p>
<p>GA</p>
<p>,</p>
<p>Forouzanfar</p>
<p>MH</p>
<p>,</p>
<p>Moran</p>
<p>AE</p>
<p>,</p>
<p>Barber</p>
<p>R</p>
<p>,</p>
<p>Nguyen</p>
<p>G</p>
<p>,</p>
<p>Feigin</p>
<p>VL</p>
<p>,</p>
<p>Naghavi</p>
<p>M</p>
<p>,</p>
<p>Mensah</p>
<p>GA</p>
<p>,</p>
<p>Murray</p>
<p>CJ.</p>
<p>Demographic and epidemiologic drivers of global cardiovascular
mortality</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>372</p>
<p>:</p>
<p>1333</p>
<p>–</p>
<p>1341</p>
<p>.</p>
<p>24</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Global public health burden of heart failure</p>
<p>.</p>
<p>Card Fail Rev</p>
<p>2017</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>7</p>
<p>–</p>
<p>11</p>
<p>.</p>
<p>25</p>
<p>Meyer</p>
<p>S</p>
<p>,</p>
<p>Brouwers</p>
<p>FP</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Gansevoort</p>
<p>RT</p>
<p>,</p>
<p>van der Harst</p>
<p>P</p>
<p>,</p>
<p>Rienstra</p>
<p>M</p>
<p>,</p>
<p>van Gelder</p>
<p>IC</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>van Gilst</p>
<p>WH</p>
<p>,</p>
<p>van der Meer</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Sex differences in new-onset heart failure</p>
<p>.</p>
<p>Clin Res Cardiol</p>
<p>2015</p>
<p>;</p>
<p>104</p>
<p>:</p>
<p>342</p>
<p>–</p>
<p>350</p>
<p>.</p>
<p>26</p>
<p>Brouwers</p>
<p>FP</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>van der Harst</p>
<p>P</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Gansevoort</p>
<p>RT</p>
<p>,</p>
<p>Bakker</p>
<p>SJ</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>van Gilst</p>
<p>WH.</p>
<p>Incidence and epidemiology of new onset heart failure with preserved
vs. reduced ejection fraction in a community-based cohort: 11-year
follow-up of PREVEND</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>1424</p>
<p>–</p>
<p>1431</p>
<p>.</p>
<p>27</p>
<p>GBD 2017 Disease and Injury Incidence and Prevalence
Collaborators</p>
<p>.</p>
<p>Global, regional, and national incidence, prevalence, and years lived
with disability for 354 diseases and injuries for 195 countries and
territories, 1990-2017: a systematic analysis for the Global Burden of
Disease Study 2017</p>
<p>.</p>
<p>Lancet</p>
<p>2018</p>
<p>;</p>
<p>392</p>
<p>:</p>
<p>1789</p>
<p>–</p>
<p>1858</p>
<p>.</p>
<p>28</p>
<p>Roger</p>
<p>VL.</p>
<p>Epidemiology of heart failure</p>
<p>.</p>
<p>Circ Res</p>
<p>2013</p>
<p>;</p>
<p>113</p>
<p>:</p>
<p>646</p>
<p>–</p>
<p>659</p>
<p>.</p>
<p>29</p>
<p>Mosterd</p>
<p>A</p>
<p>,</p>
<p>Hoes</p>
<p>AW.</p>
<p>Clinical epidemiology of heart failure</p>
<p>.</p>
<p>Heart</p>
<p>2007</p>
<p>;</p>
<p>93</p>
<p>:</p>
<p>1137</p>
<p>–</p>
<p>1146</p>
<p>.</p>
<p>30</p>
<p>Smeets</p>
<p>M</p>
<p>,</p>
<p>Vaes</p>
<p>B</p>
<p>,</p>
<p>Mamouris</p>
<p>P</p>
<p>,</p>
<p>Van Den Akker</p>
<p>M</p>
<p>,</p>
<p>Van Pottelbergh</p>
<p>G</p>
<p>,</p>
<p>Goderis</p>
<p>G</p>
<p>,</p>
<p>Janssens</p>
<p>S</p>
<p>,</p>
<p>Aertgeerts</p>
<p>B</p>
<p>,</p>
<p>Henrard</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Burden of heart failure in Flemish general practices: a
registry-based study in the Intego database</p>
<p>.</p>
<p>BMJ Open</p>
<p>2019</p>
<p>;</p>
<p>9</p>
<p>:</p>
<p>e022972</p>
<p>.</p>
<p>31</p>
<p>Virani</p>
<p>SS</p>
<p>,</p>
<p>Alonso</p>
<p>A</p>
<p>,</p>
<p>Benjamin</p>
<p>EJ</p>
<p>,</p>
<p>Bittencourt</p>
<p>MS</p>
<p>,</p>
<p>Callaway</p>
<p>CW</p>
<p>,</p>
<p>Carson</p>
<p>AP</p>
<p>,</p>
<p>Chamberlain</p>
<p>AM</p>
<p>,</p>
<p>Chang</p>
<p>AR</p>
<p>,</p>
<p>Cheng</p>
<p>S</p>
<p>,</p>
<p>Delling</p>
<p>FN</p>
<p>,</p>
<p>Djousse</p>
<p>L</p>
<p>,</p>
<p>Elkind</p>
<p>MSV</p>
<p>,</p>
<p>Ferguson</p>
<p>JF</p>
<p>,</p>
<p>Fornage</p>
<p>M</p>
<p>,</p>
<p>Khan</p>
<p>SS</p>
<p>,</p>
<p>Kissela</p>
<p>BM</p>
<p>,</p>
<p>Knutson</p>
<p>KL</p>
<p>,</p>
<p>Kwan</p>
<p>TW</p>
<p>,</p>
<p>Lackland</p>
<p>DT</p>
<p>,</p>
<p>Lewis</p>
<p>TT</p>
<p>,</p>
<p>Lichtman</p>
<p>JH</p>
<p>,</p>
<p>Longenecker</p>
<p>CT</p>
<p>,</p>
<p>Loop</p>
<p>MS</p>
<p>,</p>
<p>Lutsey</p>
<p>PL</p>
<p>,</p>
<p>Martin</p>
<p>SS</p>
<p>,</p>
<p>Matsushita</p>
<p>K</p>
<p>,</p>
<p>Moran</p>
<p>AE</p>
<p>,</p>
<p>Mussolino</p>
<p>ME</p>
<p>,</p>
<p>Perak</p>
<p>AM</p>
<p>,</p>
<p>Rosamond</p>
<p>WD</p>
<p>,</p>
<p>Roth</p>
<p>GA</p>
<p>,</p>
<p>Sampson</p>
<p>UKA</p>
<p>,</p>
<p>Satou</p>
<p>GM</p>
<p>,</p>
<p>Schroeder</p>
<p>EB</p>
<p>,</p>
<p>Shah</p>
<p>SH</p>
<p>,</p>
<p>Shay</p>
<p>CM</p>
<p>,</p>
<p>Spartano</p>
<p>NL</p>
<p>,</p>
<p>Stokes</p>
<p>A</p>
<p>,</p>
<p>Tirschwell</p>
<p>DL</p>
<p>,</p>
<p>VanWagner</p>
<p>LB</p>
<p>,</p>
<p>Tsao</p>
<p>CW</p>
<p>,</p>
<p>American Heart Association Council on Epidemiology and Prevention
Statistics Committee and Stroke Statistics Subcommittee</p>
<p>.</p>
<p>Heart disease and stroke statistics—2020 update: a report from the
American Heart Association</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>e139</p>
<p>–</p>
<p>e596</p>
<p>.</p>
<p>32</p>
<p>van Riet</p>
<p>EE</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Limburg</p>
<p>A</p>
<p>,</p>
<p>Landman</p>
<p>MA</p>
<p>,</p>
<p>van der Hoeven</p>
<p>H</p>
<p>,</p>
<p>Rutten</p>
<p>FH.</p>
<p>Prevalence of unrecognized heart failure in older persons with
shortness of breath on exertion</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>772</p>
<p>–</p>
<p>777</p>
<p>.</p>
<p>33</p>
<p>van Riet</p>
<p>EE</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Wagenaar</p>
<p>KP</p>
<p>,</p>
<p>Limburg</p>
<p>A</p>
<p>,</p>
<p>Landman</p>
<p>MA</p>
<p>,</p>
<p>Rutten</p>
<p>FH.</p>
<p>Epidemiology of heart failure: the prevalence of heart failure and
ventricular dysfunction in older adults over time. A systematic
review</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>242</p>
<p>–</p>
<p>252</p>
<p>.</p>
<p>34</p>
<p>Benjamin</p>
<p>EJ</p>
<p>,</p>
<p>Virani</p>
<p>SS</p>
<p>,</p>
<p>Callaway</p>
<p>CW</p>
<p>,</p>
<p>Chamberlain</p>
<p>AM</p>
<p>,</p>
<p>Chang</p>
<p>AR</p>
<p>,</p>
<p>Cheng</p>
<p>S</p>
<p>,</p>
<p>Chiuve</p>
<p>SE</p>
<p>,</p>
<p>Cushman</p>
<p>M</p>
<p>,</p>
<p>Delling</p>
<p>FN</p>
<p>,</p>
<p>Deo</p>
<p>R</p>
<p>,</p>
<p>de Ferranti</p>
<p>SD</p>
<p>,</p>
<p>Ferguson</p>
<p>JF</p>
<p>,</p>
<p>Fornage</p>
<p>M</p>
<p>,</p>
<p>Gillespie</p>
<p>C</p>
<p>,</p>
<p>Isasi</p>
<p>CR</p>
<p>,</p>
<p>Jimenez</p>
<p>MC</p>
<p>,</p>
<p>Jordan</p>
<p>LC</p>
<p>,</p>
<p>Judd</p>
<p>SE</p>
<p>,</p>
<p>Lackland</p>
<p>D</p>
<p>,</p>
<p>Lichtman</p>
<p>JH</p>
<p>,</p>
<p>Lisabeth</p>
<p>L</p>
<p>,</p>
<p>Liu</p>
<p>S</p>
<p>,</p>
<p>Longenecker</p>
<p>CT</p>
<p>,</p>
<p>Lutsey</p>
<p>PL</p>
<p>,</p>
<p>Mackey</p>
<p>JS</p>
<p>,</p>
<p>Matchar</p>
<p>DB</p>
<p>,</p>
<p>Matsushita</p>
<p>K</p>
<p>,</p>
<p>Mussolino</p>
<p>ME</p>
<p>,</p>
<p>Nasir</p>
<p>K</p>
<p>,</p>
<p>O’Flaherty</p>
<p>M</p>
<p>,</p>
<p>Palaniappan</p>
<p>LP</p>
<p>,</p>
<p>Pandey</p>
<p>A</p>
<p>,</p>
<p>Pandey</p>
<p>DK</p>
<p>,</p>
<p>Reeves</p>
<p>MJ</p>
<p>,</p>
<p>Ritchey</p>
<p>MD</p>
<p>,</p>
<p>Rodriguez</p>
<p>CJ</p>
<p>,</p>
<p>Roth</p>
<p>GA</p>
<p>,</p>
<p>Rosamond</p>
<p>WD</p>
<p>,</p>
<p>Sampson</p>
<p>UKA</p>
<p>,</p>
<p>Satou</p>
<p>GM</p>
<p>,</p>
<p>Shah</p>
<p>SH</p>
<p>,</p>
<p>Spartano</p>
<p>NL</p>
<p>,</p>
<p>Tirschwell</p>
<p>DL</p>
<p>,</p>
<p>Tsao</p>
<p>CW</p>
<p>,</p>
<p>Voeks</p>
<p>JH</p>
<p>,</p>
<p>Willey</p>
<p>JZ</p>
<p>,</p>
<p>Wilkins</p>
<p>JT</p>
<p>,</p>
<p>Wu</p>
<p>JH</p>
<p>,</p>
<p>Alger</p>
<p>HM</p>
<p>,</p>
<p>Wong</p>
<p>SS</p>
<p>,</p>
<p>Muntner</p>
<p>P</p>
<p>,</p>
<p>American Heart Association Council on Epidemiology and Prevention
Statistics Committee and Stroke Statistics Subcommittee. Heart disease
and stroke statistics—2018 update: a report from the American Heart
Association</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>137</p>
<p>:</p>
<p>e67</p>
<p>–</p>
<p>e492</p>
<p>.</p>
<p>35</p>
<p>Ceia</p>
<p>F</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Mota</p>
<p>T</p>
<p>,</p>
<p>Morais</p>
<p>H</p>
<p>,</p>
<p>Matias</p>
<p>F</p>
<p>,</p>
<p>de Sousa</p>
<p>A</p>
<p>,</p>
<p>Oliveira</p>
<p>A</p>
<p>,</p>
<p>EPICA Investigators</p>
<p>.</p>
<p>Prevalence of chronic heart failure in Southwestern Europe: the EPICA
study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2002</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>531</p>
<p>–</p>
<p>539</p>
<p>.</p>
<p>36</p>
<p>Bibbins-Domingo</p>
<p>K</p>
<p>,</p>
<p>Pletcher</p>
<p>MJ</p>
<p>,</p>
<p>Lin</p>
<p>F</p>
<p>,</p>
<p>Vittinghoff</p>
<p>E</p>
<p>,</p>
<p>Gardin</p>
<p>JM</p>
<p>,</p>
<p>Arynchyn</p>
<p>A</p>
<p>,</p>
<p>Lewis</p>
<p>CE</p>
<p>,</p>
<p>Williams</p>
<p>OD</p>
<p>,</p>
<p>Hulley</p>
<p>SB.</p>
<p>Racial differences in incident heart failure among young adults</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2009</p>
<p>;</p>
<p>360</p>
<p>:</p>
<p>1179</p>
<p>–</p>
<p>1190</p>
<p>.</p>
<p>37</p>
<p>Bleumink</p>
<p>GS</p>
<p>,</p>
<p>Knetsch</p>
<p>AM</p>
<p>,</p>
<p>Sturkenboom</p>
<p>MC</p>
<p>,</p>
<p>Straus</p>
<p>SM</p>
<p>,</p>
<p>Hofman</p>
<p>A</p>
<p>,</p>
<p>Deckers</p>
<p>JW</p>
<p>,</p>
<p>Witteman</p>
<p>JC</p>
<p>,</p>
<p>Stricker</p>
<p>BH.</p>
<p>Quantifying the heart failure epidemic: prevalence, incidence rate,
lifetime risk and prognosis of heart failure The Rotterdam Study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2004</p>
<p>;</p>
<p>25</p>
<p>:</p>
<p>1614</p>
<p>–</p>
<p>1619</p>
<p>.</p>
<p>38</p>
<p>Koh</p>
<p>AS</p>
<p>,</p>
<p>Tay</p>
<p>WT</p>
<p>,</p>
<p>Teng</p>
<p>THK</p>
<p>,</p>
<p>Vedin</p>
<p>O</p>
<p>,</p>
<p>Benson</p>
<p>L</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>A comprehensive population-based characterization of heart failure
with mid-range ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1624</p>
<p>–</p>
<p>1634</p>
<p>.</p>
<p>39</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Lund</p>
<p>L</p>
<p>,</p>
<p>Ambrosio</p>
<p>GA</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Epidemiology and one-year outcomes in patients with chronic heart
failure and preserved, mid-range and reduced ejection fraction: an
analysis of the ESC Heart Failure Long-Term Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1574</p>
<p>–</p>
<p>1585</p>
<p>.</p>
<p>40</p>
<p>Shah</p>
<p>RU</p>
<p>,</p>
<p>Klein</p>
<p>L</p>
<p>,</p>
<p>Lloyd-Jones</p>
<p>DM.</p>
<p>Heart failure in women: epidemiology, biology and treatment</p>
<p>.</p>
<p>Womens Health (Lond)</p>
<p>2009</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>517</p>
<p>–</p>
<p>527</p>
<p>.</p>
<p>41</p>
<p>Roger</p>
<p>VL</p>
<p>,</p>
<p>Weston</p>
<p>SA</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Hellermann-Homan</p>
<p>JP</p>
<p>,</p>
<p>Killian</p>
<p>J</p>
<p>,</p>
<p>Yawn</p>
<p>BP</p>
<p>,</p>
<p>Jacobsen</p>
<p>SJ.</p>
<p>Trends in heart failure incidence and survival in a community-based
population</p>
<p>.</p>
<p>JAMA</p>
<p>2004</p>
<p>;</p>
<p>292</p>
<p>:</p>
<p>344</p>
<p>–</p>
<p>350</p>
<p>.</p>
<p>42</p>
<p>Vedin</p>
<p>O</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Koh</p>
<p>AS</p>
<p>,</p>
<p>Benson</p>
<p>L</p>
<p>,</p>
<p>Teng</p>
<p>THK</p>
<p>,</p>
<p>Tay</p>
<p>WT</p>
<p>,</p>
<p>Braun</p>
<p>OO</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Significance of ischemic heart disease in patients with heart failure
and preserved, midrange, and reduced ejection fraction: a nationwide
cohort study</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>10</p>
<p>:e003875.</p>
<p>43</p>
<p>Kapoor</p>
<p>JR</p>
<p>,</p>
<p>Kapoor</p>
<p>R</p>
<p>,</p>
<p>Ju</p>
<p>C</p>
<p>,</p>
<p>Heidenreich</p>
<p>PA</p>
<p>,</p>
<p>Eapen</p>
<p>ZJ</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Yancy</p>
<p>CW</p>
<p>,</p>
<p>Fonarow</p>
<p>GC.</p>
<p>Precipitating clinical factors, heart failure characterization, and
outcomes in patients hospitalized with heart failure with reduced,
borderline, and preserved ejection fraction</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>464</p>
<p>–</p>
<p>472</p>
<p>.</p>
<p>44</p>
<p>Heiat</p>
<p>A</p>
<p>,</p>
<p>Gross</p>
<p>CP</p>
<p>,</p>
<p>Krumholz</p>
<p>HM.</p>
<p>Representation of the elderly, women, and minorities in heart failure
clinical trials</p>
<p>.</p>
<p>Arch Intern Med</p>
<p>2002</p>
<p>;</p>
<p>162</p>
<p>:</p>
<p>1682</p>
<p>–</p>
<p>1688</p>
<p>.</p>
<p>45</p>
<p>Gerber</p>
<p>Y</p>
<p>,</p>
<p>Weston</p>
<p>SA</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Chamberlain</p>
<p>AM</p>
<p>,</p>
<p>Manemann</p>
<p>SM</p>
<p>,</p>
<p>Jiang</p>
<p>R</p>
<p>,</p>
<p>Killian</p>
<p>JM</p>
<p>,</p>
<p>Roger</p>
<p>VL.</p>
<p>A contemporary appraisal of the heart failure epidemic in Olmsted
County, Minnesota, 2000 to 2010</p>
<p>.</p>
<p>JAMA Intern Med</p>
<p>2015</p>
<p>;</p>
<p>175</p>
<p>:</p>
<p>996</p>
<p>–</p>
<p>1004</p>
<p>.</p>
<p>46</p>
<p>Tsao</p>
<p>CW</p>
<p>,</p>
<p>Lyass</p>
<p>A</p>
<p>,</p>
<p>Enserro</p>
<p>D</p>
<p>,</p>
<p>Larson</p>
<p>MG</p>
<p>,</p>
<p>Ho</p>
<p>JE</p>
<p>,</p>
<p>Kizer</p>
<p>JR</p>
<p>,</p>
<p>Gottdiener</p>
<p>JS</p>
<p>,</p>
<p>Psaty</p>
<p>BM</p>
<p>,</p>
<p>Vasan</p>
<p>RS.</p>
<p>Temporal trends in the incidence of and mortality associated with
heart failure with preserved and reduced ejection fraction</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>678</p>
<p>–</p>
<p>685</p>
<p>.</p>
<p>47</p>
<p>Motiejunaite</p>
<p>J</p>
<p>,</p>
<p>Akiyama</p>
<p>E</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Choi</p>
<p>DJ</p>
<p>,</p>
<p>Kavoliuniene</p>
<p>A</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Parenica</p>
<p>J</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Kajimoto</p>
<p>K</p>
<p>,</p>
<p>Sato</p>
<p>N</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Matsue</p>
<p>Y</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Ezekowitz</p>
<p>JA</p>
<p>,</p>
<p>Ahmed</p>
<p>A</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Gayat</p>
<p>E</p>
<p>,</p>
<p>Regitz-Zagrosek</p>
<p>V</p>
<p>,</p>
<p>Mebazaa</p>
<ol type="A">
<li></li>
</ol>
<p>The association of long-term outcome and biological sex in patients
with acute heart failure from different geographic regions</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>1357</p>
<p>–</p>
<p>1364</p>
<p>.</p>
<p>48</p>
<p>Dunlay</p>
<p>SM</p>
<p>,</p>
<p>Roger</p>
<p>VL</p>
<p>,</p>
<p>Weston</p>
<p>SA</p>
<p>,</p>
<p>Jiang</p>
<p>R</p>
<p>,</p>
<p>Redfield</p>
<ol start="2000" type="I">
<li></li>
</ol>
<p>Longitudinal changes in ejection fraction in heart failure patients
with preserved and reduced ejection fraction</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2012</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>720</p>
<p>–</p>
<p>726</p>
<p>.</p>
<p>49</p>
<p>Clarke</p>
<p>CL</p>
<p>,</p>
<p>Grunwald</p>
<p>GK</p>
<p>,</p>
<p>Allen</p>
<p>LA</p>
<p>,</p>
<p>Baron</p>
<p>AE</p>
<p>,</p>
<p>Peterson</p>
<p>PN</p>
<p>,</p>
<p>Brand</p>
<p>DW</p>
<p>,</p>
<p>Magid</p>
<p>DJ</p>
<p>,</p>
<p>Masoudi</p>
<p>FA.</p>
<p>Natural history of left ventricular ejection fraction in patients
with heart failure</p>
<p>.</p>
<p>Circ Cardiovasc Qual Outcomes</p>
<p>2013</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>680</p>
<p>–</p>
<p>686</p>
<p>.</p>
<p>50</p>
<p>Tsuji</p>
<p>K</p>
<p>,</p>
<p>Sakata</p>
<p>Y</p>
<p>,</p>
<p>Nochioka</p>
<p>K</p>
<p>,</p>
<p>Miura</p>
<p>M</p>
<p>,</p>
<p>Yamauchi</p>
<p>T</p>
<p>,</p>
<p>Onose</p>
<p>T</p>
<p>,</p>
<p>Abe</p>
<p>R</p>
<p>,</p>
<p>Oikawa</p>
<p>T</p>
<p>,</p>
<p>Kasahara</p>
<p>S</p>
<p>,</p>
<p>Sato</p>
<p>M</p>
<p>,</p>
<p>Shiroto</p>
<p>T</p>
<p>,</p>
<p>Takahashi</p>
<p>J</p>
<p>,</p>
<p>Miyata</p>
<p>S</p>
<p>,</p>
<p>Shimokawa</p>
<p>H</p>
<p>,</p>
<p>CHART-2 Investigators. Characterization of heart failure patients
with mid-range left ventricular ejection fraction–a report from the
CHART-2 Study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1258</p>
<p>–</p>
<p>1269</p>
<p>.</p>
<p>51</p>
<p>Rastogi</p>
<p>A</p>
<p>,</p>
<p>Novak</p>
<p>E</p>
<p>,</p>
<p>Platts</p>
<p>AE</p>
<p>,</p>
<p>Mann</p>
<ol start="550" type="I">
<li></li>
</ol>
<p>Epidemiology, pathophysiology and clinical outcomes for heart failure
patients with a mid-range ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1597</p>
<p>–</p>
<p>1605</p>
<p>.</p>
<p>52</p>
<p>Lupon</p>
<p>J</p>
<p>,</p>
<p>Gavidia-Bovadilla</p>
<p>G</p>
<p>,</p>
<p>Ferrer</p>
<p>E</p>
<p>,</p>
<p>de Antonio</p>
<p>M</p>
<p>,</p>
<p>Perera-Lluna</p>
<p>A</p>
<p>,</p>
<p>Lopez-Ayerbe</p>
<p>J</p>
<p>,</p>
<p>Domingo</p>
<p>M</p>
<p>,</p>
<p>Nunez</p>
<p>J</p>
<p>,</p>
<p>Zamora</p>
<p>E</p>
<p>,</p>
<p>Moliner</p>
<p>P</p>
<p>,</p>
<p>Diaz-Ruata</p>
<p>P</p>
<p>,</p>
<p>Santesmases</p>
<p>J</p>
<p>,</p>
<p>Bayes-Genis A. Dynamic trajectories of left ventricular ejection
fraction in heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>72</p>
<p>:</p>
<p>591</p>
<p>–</p>
<p>601</p>
<p>.</p>
<p>53</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Ariti</p>
<p>CA</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Maggioni</p>
<p>A</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Squire</p>
<p>IB</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Dobson</p>
<p>J</p>
<p>,</p>
<p>Poppe</p>
<p>KK</p>
<p>,</p>
<p>Whalley</p>
<p>GA</p>
<p>,</p>
<p>Doughty</p>
<p>RN</p>
<p>,</p>
<p>Meta-Analysis Global Group in Chronic Heart Failure</p>
<p>.</p>
<p>Predicting survival in heart failure: a risk score based on 39 372
patients from 30 studies</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>1404</p>
<p>–</p>
<p>1413</p>
<p>.</p>
<p>54</p>
<p>Barasa</p>
<p>A</p>
<p>,</p>
<p>Schaufelberger</p>
<p>M</p>
<p>,</p>
<p>Lappas</p>
<p>G</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Dellborg</p>
<p>M</p>
<p>,</p>
<p>Rosengren</p>
<ol type="A">
<li></li>
</ol>
<p>Heart failure in young adults: 20-year trends in hospitalization,
aetiology, and case fatality in Sweden</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2014</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>25</p>
<p>–</p>
<p>32</p>
<p>.</p>
<p>55</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Macintyre</p>
<p>K</p>
<p>,</p>
<p>Simpson</p>
<p>CR</p>
<p>,</p>
<p>Lewsey</p>
<p>JD</p>
<p>,</p>
<p>Stewart</p>
<p>S</p>
<p>,</p>
<p>Redpath</p>
<p>A</p>
<p>,</p>
<p>Chalmers</p>
<p>JW</p>
<p>,</p>
<p>Capewell</p>
<p>S</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Long-term trends in first hospitalization for heart failure and
subsequent survival between 1986 and 2003: a population study of 5.1
million people</p>
<p>.</p>
<p>Circulation</p>
<p>2009</p>
<p>;</p>
<p>119</p>
<p>:</p>
<p>515</p>
<p>–</p>
<p>523</p>
<p>.</p>
<p>56</p>
<p>Dunlay</p>
<p>SM</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Weston</p>
<p>SA</p>
<p>,</p>
<p>Therneau</p>
<p>TM</p>
<p>,</p>
<p>Hall Long</p>
<p>K</p>
<p>,</p>
<p>Shah</p>
<p>ND</p>
<p>,</p>
<p>Roger</p>
<p>VL.</p>
<p>Hospitalizations after heart failure diagnosis a community
perspective</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>54</p>
<p>:</p>
<p>1695</p>
<p>–</p>
<p>1702</p>
<p>.</p>
<p>57</p>
<p>Taylor</p>
<p>CJ</p>
<p>,</p>
<p>Ordonez-Mena</p>
<p>JM</p>
<p>,</p>
<p>Roalfe</p>
<p>AK</p>
<p>,</p>
<p>Lay-Flurrie</p>
<p>S</p>
<p>,</p>
<p>Jones</p>
<p>NR</p>
<p>,</p>
<p>Marshall</p>
<p>T</p>
<p>,</p>
<p>Hobbs</p>
<p>FDR.</p>
<p>Trends in survival after a diagnosis of heart failure in the United
Kingdom 2000-2017: population based cohort study</p>
<p>.</p>
<p>BMJ</p>
<p>2019</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>l223</p>
<p>.</p>
<p>58</p>
<p>Lorenzoni</p>
<p>G</p>
<p>,</p>
<p>Azzolina</p>
<p>D</p>
<p>,</p>
<p>Lanera</p>
<p>C</p>
<p>,</p>
<p>Brianti</p>
<p>G</p>
<p>,</p>
<p>Gregori</p>
<p>D</p>
<p>,</p>
<p>Vanuzzo</p>
<p>D</p>
<p>,</p>
<p>Baldi</p>
<ol type="I">
<li></li>
</ol>
<p>Time trends in first hospitalization for heart failure in a
community-based population</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2018</p>
<p>;</p>
<p>271</p>
<p>:</p>
<p>195</p>
<p>–</p>
<p>199</p>
<p>.</p>
<p>59</p>
<p>Mosterd</p>
<p>A</p>
<p>,</p>
<p>Reitsma</p>
<p>JB</p>
<p>,</p>
<p>Grobbee</p>
<p>DE.</p>
<p>Angiotensin converting enzyme inhibition and hospitalisation rates
for heart failure in the Netherlands, 1980 to 1999: the end of an
epidemic?</p>
<p>Heart</p>
<p>2002</p>
<p>;</p>
<p>87</p>
<p>:</p>
<p>75</p>
<p>–</p>
<p>76</p>
<p>.</p>
<p>60</p>
<p>Chen</p>
<p>J</p>
<p>,</p>
<p>Hsieh</p>
<p>AF</p>
<p>,</p>
<p>Dharmarajan</p>
<p>K</p>
<p>,</p>
<p>Masoudi</p>
<p>FA</p>
<p>,</p>
<p>Krumholz</p>
<p>HM.</p>
<p>National trends in heart failure hospitalization after acute
myocardial infarction for Medicare beneficiaries: 1998-2010</p>
<p>.</p>
<p>Circulation</p>
<p>2013</p>
<p>;</p>
<p>128</p>
<p>:</p>
<p>2577</p>
<p>–</p>
<p>2584</p>
<p>.</p>
<p>61</p>
<p>Lawson</p>
<p>CA</p>
<p>,</p>
<p>Zaccardi</p>
<p>F</p>
<p>,</p>
<p>Squire</p>
<p>I</p>
<p>,</p>
<p>Ling</p>
<p>S</p>
<p>,</p>
<p>Davies</p>
<p>MJ</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Mamas</p>
<p>MA</p>
<p>,</p>
<p>Khunti</p>
<p>K</p>
<p>,</p>
<p>Kadam</p>
<p>UT.</p>
<p>20-year trends in cause-specific heart failure outcomes by sex,
socioeconomic status, and place of diagnosis: a population-based
study</p>
<p>.</p>
<p>Lancet Public Health</p>
<p>2019</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>e406</p>
<p>–</p>
<p>e420</p>
<p>.</p>
<p>62</p>
<p>Al-Mohammad</p>
<p>A</p>
<p>,</p>
<p>Mant</p>
<p>J</p>
<p>,</p>
<p>Laramee</p>
<p>P</p>
<p>,</p>
<p>Swain</p>
<p>S</p>
<p>,</p>
<p>Chronic Heart Failure Guideline Development Group</p>
<p>.</p>
<p>Diagnosis and management of adults with chronic heart failure:
summary of updated NICE guidance</p>
<p>.</p>
<p>BMJ</p>
<p>2010</p>
<p>;</p>
<p>341</p>
<p>:</p>
<p>c4130</p>
<p>.</p>
<p>63</p>
<p>Mant</p>
<p>J</p>
<p>,</p>
<p>Doust</p>
<p>J</p>
<p>,</p>
<p>Roalfe</p>
<p>A</p>
<p>,</p>
<p>Barton</p>
<p>P</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Glasziou</p>
<p>P</p>
<p>,</p>
<p>Mant</p>
<p>D</p>
<p>,</p>
<p>McManus</p>
<p>RJ</p>
<p>,</p>
<p>Holder</p>
<p>R</p>
<p>,</p>
<p>Deeks</p>
<p>J</p>
<p>,</p>
<p>Fletcher</p>
<p>K</p>
<p>,</p>
<p>Qume</p>
<p>M</p>
<p>,</p>
<p>Sohanpal</p>
<p>S</p>
<p>,</p>
<p>Sanders</p>
<p>S</p>
<p>,</p>
<p>Hobbs</p>
<p>FD.</p>
<p>Systematic review and individual patient data meta-analysis of
diagnosis of heart failure, with modelling of implications of different
diagnostic strategies in primary care</p>
<p>.</p>
<p>Health Technol Assess</p>
<p>2009</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>207, iii</p>
<p>.</p>
<p>64</p>
<p>Davie</p>
<p>AP</p>
<p>,</p>
<p>Francis</p>
<p>CM</p>
<p>,</p>
<p>Caruana</p>
<p>L</p>
<p>,</p>
<p>Sutherland</p>
<p>GR</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Assessing diagnosis in heart failure: which features are any use?</p>
<p>QJM</p>
<p>1997</p>
<p>;</p>
<p>90</p>
<p>:</p>
<p>335</p>
<p>–</p>
<p>339</p>
<p>.</p>
<p>65</p>
<p>Oudejans</p>
<p>I</p>
<p>,</p>
<p>Mosterd</p>
<p>A</p>
<p>,</p>
<p>Bloemen</p>
<p>JA</p>
<p>,</p>
<p>Valk</p>
<p>MJ</p>
<p>,</p>
<p>van Velzen</p>
<p>E</p>
<p>,</p>
<p>Wielders</p>
<p>JP</p>
<p>,</p>
<p>Zuithoff</p>
<p>NP</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Hoes</p>
<p>AW.</p>
<p>Clinical evaluation of geriatric outpatients with suspected heart
failure: value of symptoms, signs, and additional tests</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>518</p>
<p>–</p>
<p>527</p>
<p>.</p>
<p>66</p>
<p>Kelder</p>
<p>JC</p>
<p>,</p>
<p>Cramer</p>
<p>MJ</p>
<p>,</p>
<p>van Wijngaarden</p>
<p>J</p>
<p>,</p>
<p>van Tooren</p>
<p>R</p>
<p>,</p>
<p>Mosterd</p>
<p>A</p>
<p>,</p>
<p>Moons</p>
<p>KG</p>
<p>,</p>
<p>Lammers</p>
<p>JW</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Grobbee</p>
<p>DE</p>
<p>,</p>
<p>Hoes</p>
<p>AW.</p>
<p>The diagnostic value of physical examination and additional testing
in primary care patients with suspected heart failure</p>
<p>.</p>
<p>Circulation</p>
<p>2011</p>
<p>;</p>
<p>124</p>
<p>:</p>
<p>2865</p>
<p>–</p>
<p>2873</p>
<p>.</p>
<p>67</p>
<p>Thibodeau</p>
<p>JT</p>
<p>,</p>
<p>Turer</p>
<p>AT</p>
<p>,</p>
<p>Gualano</p>
<p>SK</p>
<p>,</p>
<p>Ayers</p>
<p>CR</p>
<p>,</p>
<p>Velez-Martinez</p>
<p>M</p>
<p>,</p>
<p>Mishkin</p>
<p>JD</p>
<p>,</p>
<p>Patel</p>
<p>PC</p>
<p>,</p>
<p>Mammen</p>
<p>PP</p>
<p>,</p>
<p>Markham</p>
<p>DW</p>
<p>,</p>
<p>Levine</p>
<p>BD</p>
<p>,</p>
<p>Drazner</p>
<p>MH.</p>
<p>Characterization of a novel symptom of advanced heart failure:
bendopnea</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>2</p>
<p>:</p>
<p>24</p>
<p>–</p>
<p>31</p>
<p>.</p>
<p>68</p>
<p>Gohar</p>
<p>A</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>den Ruijter</p>
<p>H</p>
<p>,</p>
<p>Kelder</p>
<p>JC</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Mockel</p>
<p>M</p>
<p>,</p>
<p>Hoes</p>
<p>AW.</p>
<p>Mid-regional pro-atrial natriuretic peptide for the early detection
of non-acute heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1219</p>
<p>–</p>
<p>1227</p>
<p>.</p>
<p>69</p>
<p>Hildebrandt</p>
<p>P</p>
<p>,</p>
<p>Collinson</p>
<p>PO.</p>
<p>Amino-terminal pro-B-type natriuretic peptide testing to assist the
diagnostic evaluation of heart failure in symptomatic primary care
patients</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2008</p>
<p>;</p>
<p>101</p>
<p>:</p>
<p>25</p>
<p>–</p>
<p>28</p>
<p>.</p>
<p>70</p>
<p>Maisel</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Adams</p>
<p>K</p>
<p>Jr.,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Aspromonte</p>
<p>N</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>DeMaria</p>
<p>A</p>
<p>,</p>
<p>Di Somma</p>
<p>S</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Jourdain</p>
<p>P</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Liu</p>
<p>PP</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>McDonald</p>
<p>K</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Nieminen</p>
<p>MS</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Tubaro</p>
<p>M</p>
<p>,</p>
<p>Valle</p>
<p>R</p>
<p>,</p>
<p>Vanderhyden</p>
<p>M</p>
<p>,</p>
<p>Yancy</p>
<p>CW</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Braunwald</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>State of the art: using natriuretic peptide levels in clinical
practice</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2008</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>824</p>
<p>–</p>
<p>839</p>
<p>.</p>
<p>71</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Galderisi</p>
<p>M</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Goliasch</p>
<p>G</p>
<p>,</p>
<p>Cardim</p>
<p>N</p>
<p>,</p>
<p>Magne</p>
<p>J</p>
<p>,</p>
<p>Laginha</p>
<p>S</p>
<p>,</p>
<p>Hagendorff</p>
<p>A</p>
<p>,</p>
<p>Haland</p>
<p>TF</p>
<p>,</p>
<p>Aaberge</p>
<p>L</p>
<p>,</p>
<p>Martinez</p>
<p>C</p>
<p>,</p>
<p>Rapacciuolo</p>
<p>A</p>
<p>,</p>
<p>Santoro</p>
<p>C</p>
<p>,</p>
<p>Ilardi</p>
<p>F</p>
<p>,</p>
<p>Postolache</p>
<p>A</p>
<p>,</p>
<p>Dulgheru</p>
<p>R</p>
<p>,</p>
<p>Mateescu</p>
<p>AD</p>
<p>,</p>
<p>Beladan</p>
<p>CC</p>
<p>,</p>
<p>Deleanu</p>
<p>D</p>
<p>,</p>
<p>Marchetta</p>
<p>S</p>
<p>,</p>
<p>Auffret</p>
<p>V</p>
<p>,</p>
<p>Schwammenthal</p>
<p>E</p>
<p>,</p>
<p>Habib</p>
<p>G</p>
<p>,</p>
<p>Popescu</p>
<p>BA.</p>
<p>Echo-Doppler estimation of left ventricular filling pressure: results
of the multicentre EACVI Euro-Filling study</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Imaging</p>
<p>2017</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>961</p>
<p>–</p>
<p>968</p>
<p>.</p>
<p>72</p>
<p>Gardner</p>
<p>RS</p>
<p>,</p>
<p>Ozalp</p>
<p>F</p>
<p>,</p>
<p>Murday</p>
<p>AJ</p>
<p>,</p>
<p>Robb</p>
<p>SD</p>
<p>,</p>
<p>McDonagh</p>
<p>TA.</p>
<p>N-terminal pro-brain natriuretic peptide. A new gold standard in
predicting mortality in patients with advanced heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2003</p>
<p>;</p>
<p>24</p>
<p>:</p>
<p>1735</p>
<p>–</p>
<p>1743</p>
<p>.</p>
<p>73</p>
<p>Roberts</p>
<p>E</p>
<p>,</p>
<p>Ludman</p>
<p>AJ</p>
<p>,</p>
<p>Dworzynski</p>
<p>K</p>
<p>,</p>
<p>Al-Mohammad</p>
<p>A</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Mant</p>
<p>J</p>
<p>,</p>
<p>NICE Guideline Development Group for Acute Heart Failure</p>
<p>.</p>
<p>The diagnostic accuracy of the natriuretic peptides in heart failure:
systematic review and diagnostic meta-analysis in the acute care
setting</p>
<p>.</p>
<p>BMJ</p>
<p>2015</p>
<p>;</p>
<p>350</p>
<p>:</p>
<p>h910</p>
<p>.</p>
<p>74</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>McDonald</p>
<p>K</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Maisel</p>
<p>A</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Kozhuharov</p>
<p>N</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Meijers</p>
<p>WC</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>T</p>
<p>,</p>
<p>Richards</p>
<p>M</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>Jr,</p>
<p>Heart Failure Association of the European Society of Cardiology</p>
<p>.</p>
<p>Heart Failure Association of the European Society of Cardiology
practical guidance on the use of natriuretic peptide concentrations</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>715</p>
<p>–</p>
<p>731</p>
<p>.</p>
<p>75</p>
<p>Madamanchi</p>
<p>C</p>
<p>,</p>
<p>Alhosaini</p>
<p>H</p>
<p>,</p>
<p>Sumida</p>
<p>A</p>
<p>,</p>
<p>Runge</p>
<p>MS.</p>
<p>Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and
diagnostic implications for heart failure</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2014</p>
<p>;</p>
<p>176</p>
<p>:</p>
<p>611</p>
<p>–</p>
<p>617</p>
<p>.</p>
<p>76</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Struthers</p>
<p>AD</p>
<p>,</p>
<p>Wood</p>
<p>DA</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Thompson</p>
<p>SG</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>PA</p>
<p>,</p>
<p>Sutton</p>
<p>GC.</p>
<p>Value of natriuretic peptides in assessment of patients with possible
new heart failure in primary care</p>
<p>.</p>
<p>Lancet</p>
<p>1997</p>
<p>;</p>
<p>350</p>
<p>:</p>
<p>1349</p>
<p>–</p>
<p>1353</p>
<p>.</p>
<p>77</p>
<p>Zaphiriou</p>
<p>A</p>
<p>,</p>
<p>Robb</p>
<p>S</p>
<p>,</p>
<p>Murray-Thomas</p>
<p>T</p>
<p>,</p>
<p>Mendez</p>
<p>G</p>
<p>,</p>
<p>Fox</p>
<p>K</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Hardman</p>
<p>SM</p>
<p>,</p>
<p>Dargie</p>
<p>HJ</p>
<p>,</p>
<p>Cowie</p>
<p>MR.</p>
<p>The diagnostic accuracy of plasma BNP and NTproBNP in patients
referred from primary care with suspected heart failure: results of the
UK natriuretic peptide study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2005</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>537</p>
<p>–</p>
<p>541</p>
<p>.</p>
<p>78</p>
<p>Kelder</p>
<p>JC</p>
<p>,</p>
<p>Cramer</p>
<p>MJ</p>
<p>,</p>
<p>Verweij</p>
<p>WM</p>
<p>,</p>
<p>Grobbee</p>
<p>DE</p>
<p>,</p>
<p>Hoes</p>
<p>AW.</p>
<p>Clinical utility of three B-type natriuretic peptide assays for the
initial diagnostic assessment of new slow-onset heart failure</p>
<p>.</p>
<p>J Card Fail</p>
<p>2011</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>729</p>
<p>–</p>
<p>734</p>
<p>.</p>
<p>79</p>
<p>Verdu</p>
<p>JM</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Domingo</p>
<p>M</p>
<p>,</p>
<p>Lupon</p>
<p>J</p>
<p>,</p>
<p>Gomez</p>
<p>M</p>
<p>,</p>
<p>Molina</p>
<p>L</p>
<p>,</p>
<p>Casacuberta</p>
<p>JM</p>
<p>,</p>
<p>Munoz</p>
<p>MA</p>
<p>,</p>
<p>Mena</p>
<p>A</p>
<p>,</p>
<p>Bruguera-Cortada</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Rapid point-of-care NT-proBNP optimal cut-off point for heart failure
diagnosis in primary care</p>
<p>.</p>
<p>Rev Esp Cardiol (Engl Ed)</p>
<p>2012</p>
<p>;</p>
<p>65</p>
<p>:</p>
<p>613</p>
<p>–</p>
<p>619</p>
<p>.</p>
<p>80</p>
<p>Taylor</p>
<p>CJ</p>
<p>,</p>
<p>Roalfe</p>
<p>AK</p>
<p>,</p>
<p>Iles</p>
<p>R</p>
<p>,</p>
<p>Hobbs</p>
<p>FR</p>
<p>,</p>
<p>investigators</p>
<p>R</p>
<p>,</p>
<p>Barton</p>
<p>P</p>
<p>,</p>
<p>Deeks</p>
<p>J</p>
<p>,</p>
<p>McCahon</p>
<p>D</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Sutton</p>
<p>G</p>
<p>,</p>
<p>Davis</p>
<p>RC</p>
<p>,</p>
<p>Mant</p>
<p>J</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Tait</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Primary care REFerral for EchocaRdiogram (REFER) in heart failure: a
diagnostic accuracy study</p>
<p>.</p>
<p>Br J Gen Pract</p>
<p>2017</p>
<p>;</p>
<p>67</p>
<p>:</p>
<p>e94</p>
<p>–</p>
<p>e102</p>
<p>.</p>
<p>81</p>
<p>Sicari</p>
<p>R</p>
<p>,</p>
<p>Nihoyannopoulos</p>
<p>P</p>
<p>,</p>
<p>Evangelista</p>
<p>A</p>
<p>,</p>
<p>Kasprzak</p>
<p>J</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Poldermans</p>
<p>D</p>
<p>,</p>
<p>Voigt</p>
<p>JU</p>
<p>,</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>European Association of Echocardiography</p>
<p>.</p>
<p>Stress Echocardiography Expert Consensus Statement–Executive Summary:
European Association of Echocardiography (EAE) (a registered branch of
the ESC)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2009</p>
<p>;</p>
<p>30</p>
<p>:</p>
<p>278</p>
<p>–</p>
<p>289</p>
<p>.</p>
<p>82</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Pellikka</p>
<p>PA</p>
<p>,</p>
<p>Budts</p>
<p>W</p>
<p>,</p>
<p>Chaudhry</p>
<p>FA</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Dulgheru</p>
<p>R</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Garbi</p>
<p>M</p>
<p>,</p>
<p>Ha</p>
<p>JW</p>
<p>,</p>
<p>Kane</p>
<p>GC</p>
<p>,</p>
<p>Kreeger</p>
<p>J</p>
<p>,</p>
<p>Mertens</p>
<p>L</p>
<p>,</p>
<p>Pibarot</p>
<p>P</p>
<p>,</p>
<p>Picano</p>
<p>E</p>
<p>,</p>
<p>Ryan</p>
<p>T</p>
<p>,</p>
<p>Tsutsui</p>
<p>JM</p>
<p>,</p>
<p>Varga</p>
<ol type="A">
<li></li>
</ol>
<p>The clinical use of stress echocardiography in non-ischaemic heart
disease: recommendations from the European Association of Cardiovascular
Imaging and the American Society of Echocardiography</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Imaging</p>
<p>2016</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>1191</p>
<p>–</p>
<p>1229</p>
<p>.</p>
<p>83</p>
<p>Gonzalez</p>
<p>JA</p>
<p>,</p>
<p>Kramer</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Role of imaging techniques for diagnosis, prognosis and management of
heart failure patients: cardiac magnetic resonance</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2015</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>276</p>
<p>–</p>
<p>283</p>
<p>.</p>
<p>84</p>
<p>Messroghli</p>
<p>DR</p>
<p>,</p>
<p>Moon</p>
<p>JC</p>
<p>,</p>
<p>Ferreira</p>
<p>VM</p>
<p>,</p>
<p>Grosse-Wortmann</p>
<p>L</p>
<p>,</p>
<p>He</p>
<p>T</p>
<p>,</p>
<p>Kellman</p>
<p>P</p>
<p>,</p>
<p>Mascherbauer</p>
<p>J</p>
<p>,</p>
<p>Nezafat</p>
<p>R</p>
<p>,</p>
<p>Salerno</p>
<p>M</p>
<p>,</p>
<p>Schelbert</p>
<p>EB</p>
<p>,</p>
<p>Taylor</p>
<p>AJ</p>
<p>,</p>
<p>Thompson</p>
<p>R</p>
<p>,</p>
<p>Ugander</p>
<p>M</p>
<p>,</p>
<p>van Heeswijk</p>
<p>RB</p>
<p>,</p>
<p>Friedrich</p>
<p>MG.</p>
<p>Clinical recommendations for cardiovascular magnetic resonance
mapping of T1, T2, T2 and extracellular volume: a consensus statement by
the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the
European Association for Cardiovascular Imaging (EACVI)</p>
<p>.</p>
<p>J Cardiovasc Magn Reson</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>75</p>
<p>.</p>
<p>85</p>
<p>Witteles</p>
<p>RM</p>
<p>,</p>
<p>Bokhari</p>
<p>S</p>
<p>,</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Falk</p>
<p>RH</p>
<p>,</p>
<p>Fine</p>
<p>NM</p>
<p>,</p>
<p>Gospodinova</p>
<p>M</p>
<p>,</p>
<p>Obici</p>
<p>L</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Garcia-Pavia</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Screening for transthyretin amyloid cardiomyopathy in everyday
practice</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>709</p>
<p>–</p>
<p>716</p>
<p>.</p>
<p>86</p>
<p>Gupta</p>
<p>DK</p>
<p>,</p>
<p>Wang</p>
<p>TJ.</p>
<p>Natriuretic peptides and cardiometabolic health</p>
<p>.</p>
<p>Circ J</p>
<p>2015</p>
<p>;</p>
<p>79</p>
<p>:</p>
<p>1647</p>
<p>–</p>
<p>1655</p>
<p>.</p>
<p>87</p>
<p>Zois</p>
<p>NE</p>
<p>,</p>
<p>Bartels</p>
<p>ED</p>
<p>,</p>
<p>Hunter</p>
<p>I</p>
<p>,</p>
<p>Kousholt</p>
<p>BS</p>
<p>,</p>
<p>Olsen</p>
<p>LH</p>
<p>,</p>
<p>Goetze</p>
<p>JP.</p>
<p>Natriuretic peptides in cardiometabolic regulation and disease</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2014</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>403</p>
<p>–</p>
<p>412</p>
<p>.</p>
<p>88</p>
<p>Nishikimi</p>
<p>T</p>
<p>,</p>
<p>Kuwahara</p>
<p>K</p>
<p>,</p>
<p>Nakao</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Current biochemistry, molecular biology, and clinical relevance of
natriuretic peptides</p>
<p>.</p>
<p>J Cardiol</p>
<p>2011</p>
<p>;</p>
<p>57</p>
<p>:</p>
<p>131</p>
<p>–</p>
<p>140</p>
<p>.</p>
<p>89</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Deja</p>
<p>MA</p>
<p>,</p>
<p>Jain</p>
<p>A</p>
<p>,</p>
<p>Sopko</p>
<p>G</p>
<p>,</p>
<p>Marchenko</p>
<p>A</p>
<p>,</p>
<p>Ali</p>
<p>IS</p>
<p>,</p>
<p>Pohost</p>
<p>G</p>
<p>,</p>
<p>Gradinac</p>
<p>S</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Yii</p>
<p>M</p>
<p>,</p>
<p>Prabhakaran</p>
<p>D</p>
<p>,</p>
<p>Szwed</p>
<p>H</p>
<p>,</p>
<p>Ferrazzi</p>
<p>P</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Panchavinnin</p>
<p>P</p>
<p>,</p>
<p>She</p>
<p>L</p>
<p>,</p>
<p>Bonow</p>
<p>RO</p>
<p>,</p>
<p>Rankin</p>
<p>GR</p>
<p>,</p>
<p>Jones</p>
<p>RH</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>, STICH Investigators</p>
<p>Coronary-artery bypass surgery in patients with left ventricular
dysfunction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>1607</p>
<p>–</p>
<p>1616</p>
<p>.</p>
<p>90</p>
<p>Allman</p>
<p>KC</p>
<p>,</p>
<p>Shaw</p>
<p>LJ</p>
<p>,</p>
<p>Hachamovitch</p>
<p>R</p>
<p>,</p>
<p>Udelson</p>
<p>JE.</p>
<p>Myocardial viability testing and impact of revascularization on
prognosis in patients with coronary artery disease and left ventricular
dysfunction: a meta-analysis</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2002</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>1151</p>
<p>–</p>
<p>1158</p>
<p>.</p>
<p>91</p>
<p>Ling</p>
<p>LF</p>
<p>,</p>
<p>Marwick</p>
<p>TH</p>
<p>,</p>
<p>Flores</p>
<p>DR</p>
<p>,</p>
<p>Jaber</p>
<p>WA</p>
<p>,</p>
<p>Brunken</p>
<p>RC</p>
<p>,</p>
<p>Cerqueira</p>
<p>MD</p>
<p>,</p>
<p>Hachamovitch</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Identification of therapeutic benefit from revascularization in
patients with left ventricular systolic dysfunction: inducible ischemia
versus hibernating myocardium</p>
<p>.</p>
<p>Circ Cardiovasc Imaging</p>
<p>2013</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>363</p>
<p>–</p>
<p>372</p>
<p>.</p>
<p>92</p>
<p>Bonow</p>
<p>RO</p>
<p>,</p>
<p>Maurer</p>
<p>G</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Holly</p>
<p>TA</p>
<p>,</p>
<p>Binkley</p>
<p>PF</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>Drozdz</p>
<p>J</p>
<p>,</p>
<p>Farsky</p>
<p>PS</p>
<p>,</p>
<p>Feldman</p>
<p>AM</p>
<p>,</p>
<p>Doenst</p>
<p>T</p>
<p>,</p>
<p>Michler</p>
<p>RE</p>
<p>,</p>
<p>Berman</p>
<p>DS</p>
<p>,</p>
<p>Nicolau</p>
<p>JC</p>
<p>,</p>
<p>Pellikka</p>
<p>PA</p>
<p>,</p>
<p>Wrobel</p>
<p>K</p>
<p>,</p>
<p>Alotti</p>
<p>N</p>
<p>,</p>
<p>Asch</p>
<p>FM</p>
<p>,</p>
<p>Favaloro</p>
<p>LE</p>
<p>,</p>
<p>She</p>
<p>L</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Jones</p>
<p>RH</p>
<p>,</p>
<p>Panza</p>
<p>JA</p>
<p>,</p>
<p>STICH Trial Investigators</p>
<p>.</p>
<p>Myocardial viability and survival in ischemic left ventricular
dysfunction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>1617</p>
<p>–</p>
<p>1625</p>
<p>.</p>
<p>93</p>
<p>Panza</p>
<p>JA</p>
<p>,</p>
<p>Ellis</p>
<p>AM</p>
<p>,</p>
<p>Al-Khalidi</p>
<p>HR</p>
<p>,</p>
<p>Holly</p>
<p>TA</p>
<p>,</p>
<p>Berman</p>
<p>DS</p>
<p>,</p>
<p>Oh</p>
<p>JK</p>
<p>,</p>
<p>Pohost</p>
<p>GM</p>
<p>,</p>
<p>Sopko</p>
<p>G</p>
<p>,</p>
<p>Chrzanowski</p>
<p>L</p>
<p>,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Kukulski</p>
<p>T</p>
<p>,</p>
<p>Favaloro</p>
<p>LE</p>
<p>,</p>
<p>Maurer</p>
<p>G</p>
<p>,</p>
<p>Farsky</p>
<p>PS</p>
<p>,</p>
<p>Tan</p>
<p>RS</p>
<p>,</p>
<p>Asch</p>
<p>FM</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Bonow</p>
<p>RO.</p>
<p>Myocardial viability and long-term outcomes in ischemic
cardiomyopathy</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>381</p>
<p>:</p>
<p>739</p>
<p>–</p>
<p>748</p>
<p>.</p>
<p>94</p>
<p>Corra</p>
<p>U</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Adamopoulos</p>
<p>S</p>
<p>,</p>
<p>Agostoni</p>
<p>P</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Conraads</p>
<p>V</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Piotrowicz</p>
<p>E</p>
<p>,</p>
<p>Schmid</p>
<p>JP</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Ponikowski</p>
<p>PP.</p>
<p>Cardiopulmonary exercise testing in systolic heart failure in 2014:
the evolving prognostic role: a position paper from the Committee on
Exercise Physiology and Training of the Heart Failure Association of the
ESC</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>929</p>
<p>–</p>
<p>941</p>
<p>.</p>
<p>95</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Conraads</p>
<p>V</p>
<p>,</p>
<p>Corra</p>
<p>U</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Francis</p>
<p>DP</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>McMurray</p>
<p>J</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Piotrowicz</p>
<p>E</p>
<p>,</p>
<p>Schmid</p>
<p>JP</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Solal</p>
<p>AC</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Gielen</p>
<p>S</p>
<p>,</p>
<p>Giannuzzi</p>
<p>P</p>
<p>,</p>
<p>Ponikowski</p>
<p>PP.</p>
<p>Exercise training in heart failure: from theory to practice. A
consensus document of the Heart Failure Association and the European
Association for Cardiovascular Prevention and Rehabilitation</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>347</p>
<p>–</p>
<p>357</p>
<p>.</p>
<p>96</p>
<p>Corra</p>
<p>U</p>
<p>,</p>
<p>Agostoni</p>
<p>PG</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Crespo Leiro</p>
<p>MG</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Hairola</p>
<p>VP</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Riley</p>
<p>J</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Piepoli</p>
<p>MF.</p>
<p>Role of cardiopulmonary exercise testing in clinical stratification
in heart failure. A position paper from the Committee on Exercise
Physiology and Training of the Heart Failure Association of the European
Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>3</p>
<p>–</p>
<p>15</p>
<p>.</p>
<p>97</p>
<p>Cooper</p>
<p>LT</p>
<p>,</p>
<p>Baughman</p>
<p>KL</p>
<p>,</p>
<p>Feldman</p>
<p>AM</p>
<p>,</p>
<p>Frustaci</p>
<p>A</p>
<p>,</p>
<p>Jessup</p>
<p>M</p>
<p>,</p>
<p>Kuhl</p>
<p>U</p>
<p>,</p>
<p>Levine</p>
<p>GN</p>
<p>,</p>
<p>Narula</p>
<p>J</p>
<p>,</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Towbin</p>
<p>J</p>
<p>,</p>
<p>Virmani</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>The role of endomyocardial biopsy in the management of cardiovascular
disease: a scientific statement from the American Heart Association, the
American College of Cardiology, and the European Society of Cardiology
Endorsed by the Heart Failure Society of America and the Heart Failure
Association of the European Society of Cardiology</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2007</p>
<p>;</p>
<p>28</p>
<p>:</p>
<p>3076</p>
<p>–</p>
<p>3093</p>
<p>.</p>
<p>98</p>
<p>Cooper</p>
<p>LT</p>
<p>Jr,</p>
<p>Berry</p>
<p>GJ</p>
<p>,</p>
<p>Shabetai</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Idiopathic giant-cell myocarditis–natural history and treatment.
Multicenter Giant Cell Myocarditis Study Group Investigators</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1997</p>
<p>;</p>
<p>336</p>
<p>:</p>
<p>1860</p>
<p>–</p>
<p>1866</p>
<p>.</p>
<p>99</p>
<p>Lang</p>
<p>RM</p>
<p>,</p>
<p>Badano</p>
<p>LP</p>
<p>,</p>
<p>Mor-Avi</p>
<p>V</p>
<p>,</p>
<p>Afilalo</p>
<p>J</p>
<p>,</p>
<p>Armstrong</p>
<p>A</p>
<p>,</p>
<p>Ernande</p>
<p>L</p>
<p>,</p>
<p>Flachskampf</p>
<p>FA</p>
<p>,</p>
<p>Foster</p>
<p>E</p>
<p>,</p>
<p>Goldstein</p>
<p>SA</p>
<p>,</p>
<p>Kuznetsova</p>
<p>T</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Muraru</p>
<p>D</p>
<p>,</p>
<p>Picard</p>
<p>MH</p>
<p>,</p>
<p>Rietzschel</p>
<p>ER</p>
<p>,</p>
<p>Rudski</p>
<p>L</p>
<p>,</p>
<p>Spencer</p>
<p>KT</p>
<p>,</p>
<p>Tsang</p>
<p>W</p>
<p>,</p>
<p>Voigt</p>
<p>JU.</p>
<p>Recommendations for cardiac chamber quantification by
echocardiography in adults: an update from the American Society of
Echocardiography and the European Association of Cardiovascular
Imaging</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Imaging</p>
<p>2015</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>233</p>
<p>–</p>
<p>270</p>
<p>.</p>
<p>100</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Shah</p>
<p>AN</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Bonow</p>
<p>RO</p>
<p>,</p>
<p>Rosano</p>
<p>GM</p>
<p>,</p>
<p>Taylor</p>
<p>S</p>
<p>,</p>
<p>Kupfer</p>
<p>S</p>
<p>,</p>
<p>Misselwitz</p>
<p>F</p>
<p>,</p>
<p>Sharma</p>
<p>A</p>
<p>,</p>
<p>Fonarow</p>
<p>GC.</p>
<p>Recognizing hospitalized heart failure as an entity and developing
new therapies to improve outcomes: academics’, clinicians’, industry’s,
regulators’, and payers’ perspectives</p>
<p>.</p>
<p>Heart Fail Clin</p>
<p>2013</p>
<p>;</p>
<p>9</p>
<p>:</p>
<p>285</p>
<p>–</p>
<p>290</p>
<p>, v-vi.</p>
<p>101</p>
<p>Ambrosy</p>
<p>AP</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Greene</p>
<p>SJ</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Nodari</p>
<p>S</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Sato</p>
<p>N</p>
<p>,</p>
<p>Shah</p>
<p>AN</p>
<p>,</p>
<p>Gheorghiade</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>The global health and economic burden of hospitalizations for heart
failure: lessons learned from hospitalized heart failure registries</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>1123</p>
<p>–</p>
<p>1133</p>
<p>.</p>
<p>102</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Schroeder</p>
<p>S</p>
<p>,</p>
<p>Atar</p>
<p>D</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Ceconi</p>
<p>C</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Crisp</p>
<p>A</p>
<p>,</p>
<p>Dominjon</p>
<p>F</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Ghofrani</p>
<p>HA</p>
<p>,</p>
<p>Gropper</p>
<p>S</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Hlatky</p>
<p>MA</p>
<p>,</p>
<p>Holcomb</p>
<p>R</p>
<p>,</p>
<p>Honarpour</p>
<p>N</p>
<p>,</p>
<p>Jukema</p>
<p>JW</p>
<p>,</p>
<p>Kim</p>
<p>AM</p>
<p>,</p>
<p>Kunz</p>
<p>M</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>Le Floch</p>
<p>C</p>
<p>,</p>
<p>Landmesser</p>
<p>U</p>
<p>,</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Prasad</p>
<p>K</p>
<p>,</p>
<p>Revkin</p>
<p>J</p>
<p>,</p>
<p>Rosano</p>
<p>GM</p>
<p>,</p>
<p>Somaratne</p>
<p>R</p>
<p>,</p>
<p>Stough</p>
<p>WG</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Ruschitzka</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Traditional and new composite endpoints in heart failure clinical
trials: facilitating comprehensive efficacy assessments and improving
trial efficiency</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>482</p>
<p>–</p>
<p>489</p>
<p>.</p>
<p>103</p>
<p>Gayat</p>
<p>E</p>
<p>,</p>
<p>Arrigo</p>
<p>M</p>
<p>,</p>
<p>Littnerova</p>
<p>S</p>
<p>,</p>
<p>Sato</p>
<p>N</p>
<p>,</p>
<p>Parenica</p>
<p>J</p>
<p>,</p>
<p>Ishihara</p>
<p>S</p>
<p>,</p>
<p>Spinar</p>
<p>J</p>
<p>,</p>
<p>Muller</p>
<p>C</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>AlHabib</p>
<p>KF</p>
<p>,</p>
<p>Choi</p>
<p>DJ</p>
<p>,</p>
<p>Park</p>
<p>JJ</p>
<p>,</p>
<p>Zhang</p>
<p>Y</p>
<p>,</p>
<p>Zhang</p>
<p>J</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>Jr.,</p>
<p>Kajimoto</p>
<p>K</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Network</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Heart failure oral therapies at discharge are associated with better
outcome in acute heart failure: a propensity-score matched study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>345</p>
<p>–</p>
<p>354</p>
<p>.</p>
<p>104</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Delgado Jimenez</p>
<p>JF</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Hradec</p>
<p>J</p>
<p>,</p>
<p>Amir</p>
<p>O</p>
<p>,</p>
<p>Logeart</p>
<p>D</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Drozdz</p>
<p>J</p>
<p>,</p>
<p>Goncalvesova</p>
<p>E</p>
<p>,</p>
<p>Hassanein</p>
<p>M</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Tousoulis</p>
<p>D</p>
<p>,</p>
<p>Kavoliuniene</p>
<p>A</p>
<p>,</p>
<p>Fruhwald</p>
<p>F</p>
<p>,</p>
<p>Fazlibegovic</p>
<p>E</p>
<p>,</p>
<p>Temizhan</p>
<p>A</p>
<p>,</p>
<p>Gatzov</p>
<p>P</p>
<p>,</p>
<p>Erglis</p>
<p>A</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Heart Failure Association of the European Society of Cardiology</p>
<p>.</p>
<p>European Society of Cardiology Heart Failure Long-Term Registry
(ESC-HF-LT): 1-year follow-up outcomes and differences across
regions</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>613</p>
<p>–</p>
<p>625</p>
<p>.</p>
<p>105</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Gong</p>
<p>J</p>
<p>,</p>
<p>Lefkowitz</p>
<p>MP</p>
<p>,</p>
<p>Rizkala</p>
<p>AR</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Shi</p>
<p>VC</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>PARADIGM-HF Investigators and</p>
<p>Committees.</p>
<p>Angiotensin-neprilysin inhibition versus enalapril in heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2014</p>
<p>;</p>
<p>371</p>
<p>:</p>
<p>993</p>
<p>–</p>
<p>1004</p>
<p>.</p>
<p>106</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Morrow</p>
<p>DA</p>
<p>,</p>
<p>DeVore</p>
<p>AD</p>
<p>,</p>
<p>Duffy</p>
<p>CI</p>
<p>,</p>
<p>Ambrosy</p>
<p>AP</p>
<p>,</p>
<p>McCague</p>
<p>K</p>
<p>,</p>
<p>Rocha</p>
<p>R</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>PIONEER-HF Investigators</p>
<p>.</p>
<p>Angiotensin-neprilysin inhibition in acute decompensated heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>380</p>
<p>:</p>
<p>539</p>
<p>–</p>
<p>548</p>
<p>.</p>
<p>107</p>
<p>Wachter</p>
<p>R</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Belohlavek</p>
<p>J</p>
<p>,</p>
<p>Straburzynska-Migaj</p>
<p>E</p>
<p>,</p>
<p>Witte</p>
<p>KK</p>
<p>,</p>
<p>Kobalava</p>
<p>Z</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Goncalvesova</p>
<p>E</p>
<p>,</p>
<p>Cavusoglu</p>
<p>Y</p>
<p>,</p>
<p>Fernandez</p>
<p>A</p>
<p>,</p>
<p>Chaaban</p>
<p>S</p>
<p>,</p>
<p>Bohmer</p>
<p>E</p>
<p>,</p>
<p>Pouleur</p>
<p>AC</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Tribouilloy</p>
<p>C</p>
<p>,</p>
<p>Lonn</p>
<p>E</p>
<p>Buraiki ALJ, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H, Bao
W, Butylin D, Pascual-Figal D</p>
<p>,</p>
<p>TRANSITION Investigators</p>
<p>.</p>
<p>Initiation of sacubitril/valsartan in haemodynamically stabilised
heart failure patients in hospital or early after discharge: primary
results of the randomised TRANSITION study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>998</p>
<p>–</p>
<p>1007</p>
<p>.</p>
<p>108</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Inzucchi</p>
<p>SE</p>
<p>,</p>
<p>Køber</p>
<p>L</p>
<p>,</p>
<p>Kosiborod</p>
<p>MN</p>
<p>,</p>
<p>Martinez</p>
<p>FA</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Bělohlávek</p>
<p>J</p>
<p>,</p>
<p>Böhm</p>
<p>M</p>
<p>,</p>
<p>Chiang</p>
<p>C-E</p>
<p>,</p>
<p>Chopra</p>
<p>VK</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Diez</p>
<p>M</p>
<p>,</p>
<p>Drozdz</p>
<p>J</p>
<p>,</p>
<p>Dukát</p>
<p>A</p>
<p>,</p>
<p>Ge</p>
<p>J</p>
<p>,</p>
<p>Howlett</p>
<p>JG</p>
<p>,</p>
<p>Katova</p>
<p>T</p>
<p>,</p>
<p>Kitakaze</p>
<p>M</p>
<p>,</p>
<p>Ljungman</p>
<p>CEA</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Nicolau</p>
<p>JC</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Vinh</p>
<p>PN</p>
<p>,</p>
<p>Schou</p>
<p>M</p>
<p>,</p>
<p>Tereshchenko</p>
<p>S</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Held</p>
<p>C</p>
<p>,</p>
<p>DeMets</p>
<p>DL</p>
<p>,</p>
<p>Docherty</p>
<p>KF</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Bengtsson</p>
<p>O</p>
<p>,</p>
<p>Sjöstrand</p>
<p>M</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>DAPA-HF Trial Committees and Investigators.</p>
<p>Dapagliflozin in patients with heart failure and reduced ejection
fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>381</p>
<p>:</p>
<p>1995</p>
<p>–</p>
<p>2008</p>
<p>.</p>
<p>109</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Carson</p>
<p>P</p>
<p>,</p>
<p>Januzzi</p>
<p>J</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Tsutsui</p>
<p>H</p>
<p>,</p>
<p>Brueckmann</p>
<p>M</p>
<p>,</p>
<p>Jamal</p>
<p>W</p>
<p>,</p>
<p>Kimura</p>
<p>K</p>
<p>,</p>
<p>Schnee</p>
<p>J</p>
<p>,</p>
<p>Zeller</p>
<p>C</p>
<p>,</p>
<p>Cotton</p>
<p>D</p>
<p>,</p>
<p>Bocchi</p>
<p>E</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Choi</p>
<p>DJ</p>
<p>,</p>
<p>Chopra</p>
<p>V</p>
<p>,</p>
<p>Chuquiure</p>
<p>E</p>
<p>,</p>
<p>Giannetti</p>
<p>N</p>
<p>,</p>
<p>Janssens</p>
<p>S</p>
<p>,</p>
<p>Zhang</p>
<p>J</p>
<p>,</p>
<p>Gonzalez Juanatey</p>
<p>JR</p>
<p>,</p>
<p>Kaul</p>
<p>S</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Nicholls</p>
<p>SJ</p>
<p>,</p>
<p>Perrone</p>
<p>S</p>
<p>,</p>
<p>Pina</p>
<p>I</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Seronde</p>
<p>MF</p>
<p>,</p>
<p>Spinar</p>
<p>J</p>
<p>,</p>
<p>Squire</p>
<p>I</p>
<p>,</p>
<p>Taddei</p>
<p>S</p>
<p>,</p>
<p>Wanner</p>
<p>C</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>EMPEROR-Reduced Trial Investigators</p>
<p>.</p>
<p>Cardiovascular and renal outcomes with empagliflozin in heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>1413</p>
<p>–</p>
<p>1424</p>
<p>.</p>
<p>110</p>
<p>The CONSENSUS Trial Study Group. Enalapril for congestive heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1987</p>
<p>;</p>
<p>317</p>
<p>:</p>
<p>1349</p>
<p>–</p>
<p>1351</p>
<p>.</p>
<p>111</p>
<p>Garg</p>
<p>R</p>
<p>,</p>
<p>Yusuf</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Overview of randomized trials of angiotensin-converting enzyme
inhibitors on mortality and morbidity in patients with heart failure.
Collaborative Group on ACE Inhibitor Trials</p>
<p>.</p>
<p>JAMA</p>
<p>1995</p>
<p>;</p>
<p>273</p>
<p>:</p>
<p>1450</p>
<p>–</p>
<p>1456</p>
<p>.</p>
<p>112</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>PA</p>
<p>,</p>
<p>Armstrong</p>
<p>PW</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Horowitz</p>
<p>JD</p>
<p>,</p>
<p>Massie</p>
<p>BM</p>
<p>,</p>
<p>Ryden</p>
<p>L</p>
<p>,</p>
<p>Thygesen</p>
<p>K</p>
<p>,</p>
<p>Uretsky</p>
<p>BF.</p>
<p>Comparative effects of low and high doses of the
angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and
mortality in chronic heart failure. ATLAS Study Group</p>
<p>.</p>
<p>Circulation</p>
<p>1999</p>
<p>;</p>
<p>100</p>
<p>:</p>
<p>2312</p>
<p>–</p>
<p>2318</p>
<p>.</p>
<p>113</p>
<p>SOLVD</p>
<p>Investigators</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Davis</p>
<p>CE</p>
<p>,</p>
<p>Hood</p>
<p>WB</p>
<p>,</p>
<p>Cohn</p>
<p>JN.</p>
<p>Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1991</p>
<p>;</p>
<p>325</p>
<p>:</p>
<p>293</p>
<p>–</p>
<p>302</p>
<p>.</p>
<p>114</p>
<p>MERIT-HF Study Group</p>
<p>.</p>
<p>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)</p>
<p>.</p>
<p>Lancet</p>
<p>1999</p>
<p>;</p>
<p>353</p>
<p>:</p>
<p>2001</p>
<p>–</p>
<p>2007</p>
<p>.</p>
<p>115</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Bristow</p>
<p>MR</p>
<p>,</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Colucci</p>
<p>WS</p>
<p>,</p>
<p>Fowler</p>
<p>MB</p>
<p>,</p>
<p>Gilbert</p>
<p>EM</p>
<p>,</p>
<p>Shusterman</p>
<p>NH.</p>
<p>The effect of carvedilol on morbidity and mortality in patients with
chronic heart failure. U.S. Carvedilol Heart Failure Study Group</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1996</p>
<p>;</p>
<p>334</p>
<p>:</p>
<p>1349</p>
<p>–</p>
<p>1355</p>
<p>.</p>
<p>116</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Fowler</p>
<p>MB</p>
<p>,</p>
<p>Katus</p>
<p>HA</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Mohacsi</p>
<p>P</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>Castaigne</p>
<p>A</p>
<p>,</p>
<p>Roecker</p>
<p>EB</p>
<p>,</p>
<p>Schultz</p>
<p>MK</p>
<p>,</p>
<p>DeMets</p>
<p>DL</p>
<p>,</p>
<p>Carvedilol Prospective Randomized Cumulative Survival Study Group.
Effect of carvedilol on survival in severe chronic heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2001</p>
<p>;</p>
<p>344</p>
<p>:</p>
<p>1651</p>
<p>–</p>
<p>1658</p>
<p>.</p>
<p>117</p>
<p>Hjalmarson</p>
<p>A</p>
<p>,</p>
<p>Goldstein</p>
<p>S</p>
<p>,</p>
<p>Fagerberg</p>
<p>B</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>Waagstein</p>
<p>F</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>El Allaf</p>
<p>D</p>
<p>,</p>
<p>Vitovec</p>
<p>J</p>
<p>,</p>
<p>Aldershvile</p>
<p>J</p>
<p>,</p>
<p>Halinen</p>
<p>M</p>
<p>,</p>
<p>Dietz</p>
<p>R</p>
<p>,</p>
<p>Neuhaus</p>
<p>KL</p>
<p>,</p>
<p>Janosi</p>
<p>A</p>
<p>,</p>
<p>Thorgeirsson</p>
<p>G</p>
<p>,</p>
<p>Dunselman</p>
<p>PH</p>
<p>,</p>
<p>Gullestad</p>
<p>L</p>
<p>,</p>
<p>Kuch</p>
<p>J</p>
<p>,</p>
<p>Herlitz</p>
<p>J</p>
<p>,</p>
<p>Rickenbacher</p>
<p>P</p>
<p>,</p>
<p>Ball</p>
<p>S</p>
<p>,</p>
<p>Gottlieb</p>
<p>S</p>
<p>,</p>
<p>Deedwania</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Effects of controlled-release metoprolol on total mortality,
hospitalizations, and well-being in patients with heart failure: the
Metoprolol CR/XL Randomized Intervention Trial in congestive heart
failure (MERIT-HF). MERIT-HF Study Group</p>
<p>.</p>
<p>JAMA</p>
<p>2000</p>
<p>;</p>
<p>283</p>
<p>:</p>
<p>1295</p>
<p>–</p>
<p>1302</p>
<p>.</p>
<p>118</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Fowler</p>
<p>MB</p>
<p>,</p>
<p>Roecker</p>
<p>EB</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Katus</p>
<p>HA</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Mohacsi</p>
<p>P</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>Staiger</p>
<p>C</p>
<p>,</p>
<p>Holcslaw</p>
<p>TL</p>
<p>,</p>
<p>Amann-Zalan</p>
<p>I</p>
<p>,</p>
<p>DeMets</p>
<p>DL</p>
<p>,</p>
<p>Carvedilol Prospective Randomized Cumulative Survival Study Group.
Effect of carvedilol on the morbidity of patients with severe chronic
heart failure: results of the carvedilol prospective randomized
cumulative survival (COPERNICUS) study</p>
<p>.</p>
<p>Circulation</p>
<p>2002</p>
<p>;</p>
<p>106</p>
<p>:</p>
<p>2194</p>
<p>–</p>
<p>2199</p>
<p>.</p>
<p>119</p>
<p>Flather</p>
<p>MD</p>
<p>,</p>
<p>Shibata</p>
<p>MC</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Borbola</p>
<p>J</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Dumitrascu</p>
<p>D</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>Lechat</p>
<p>P</p>
<p>,</p>
<p>Soler-Soler</p>
<p>J</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Spinarova</p>
<p>L</p>
<p>,</p>
<p>Toman</p>
<p>J</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Thompson</p>
<p>SG</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>PA</p>
<p>,</p>
<p>SENIORS Investigators. Randomized trial to determine the effect of
nebivolol on mortality and cardiovascular hospital admission in elderly
patients with heart failure (SENIORS</p>
<p>).</p>
<p>Eur Heart J</p>
<p>2005</p>
<p>;</p>
<p>26</p>
<p>:</p>
<p>215</p>
<p>–</p>
<p>225</p>
<p>.</p>
<p>120</p>
<p>CIBIS-II Investigators and Committees</p>
<p>.</p>
<p>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a
randomised trial</p>
<p>.</p>
<p>Lancet</p>
<p>1999</p>
<p>;</p>
<p>353</p>
<p>:</p>
<p>9</p>
<p>–</p>
<p>13</p>
<p>.</p>
<p>121</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Remme</p>
<p>WJ</p>
<p>,</p>
<p>Cody</p>
<p>R</p>
<p>,</p>
<p>Castaigne</p>
<p>A</p>
<p>,</p>
<p>Perez</p>
<p>A</p>
<p>,</p>
<p>Palensky</p>
<p>J</p>
<p>,</p>
<p>Wittes</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>The effect of spironolactone on morbidity and mortality in patients
with severe heart failure. Randomized Aldactone Evaluation Study
Investigators</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1999</p>
<p>;</p>
<p>341</p>
<p>:</p>
<p>709</p>
<p>–</p>
<p>717</p>
<p>.</p>
<p>122</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Shi</p>
<p>H</p>
<p>,</p>
<p>Vincent</p>
<p>J</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>EMPHASIS-HF Study Group</p>
<p>.</p>
<p>Eplerenone in patients with systolic heart failure and mild
symptoms</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>11</p>
<p>–</p>
<p>21</p>
<p>.</p>
<p>123</p>
<p>Fowler</p>
<p>MB.</p>
<p>Effects of beta blockers on symptoms and functional capacity in heart
failure</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>1997</p>
<p>;</p>
<p>80</p>
<p>:</p>
<p>55L</p>
<p>–</p>
<p>58L</p>
<p>.</p>
<p>124</p>
<p>Willenheimer</p>
<p>R</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Silke</p>
<p>B</p>
<p>,</p>
<p>Erdmann</p>
<p>E</p>
<p>,</p>
<p>Follath</p>
<p>F</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Skene</p>
<p>A</p>
<p>,</p>
<p>van de Ven</p>
<p>L</p>
<p>,</p>
<p>Verkenne</p>
<p>P</p>
<p>,</p>
<p>Lechat</p>
<p>P</p>
<p>,</p>
<p>CIBIS III Investigators</p>
<p>.</p>
<p>Effect on survival and hospitalization of initiating treatment for
chronic heart failure with bisoprolol followed by enalapril, as compared
with the opposite sequence: results of the randomized Cardiac
Insufficiency Bisoprolol Study (CIBIS) III</p>
<p>.</p>
<p>Circulation</p>
<p>2005</p>
<p>;</p>
<p>112</p>
<p>:</p>
<p>2426</p>
<p>–</p>
<p>2435</p>
<p>.</p>
<p>125</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Holmes</p>
<p>J</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Altman</p>
<p>DG</p>
<p>,</p>
<p>Manzano</p>
<p>L</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Lip</p>
<p>GY</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Andersson</p>
<p>B</p>
<p>,</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>von Lueder</p>
<p>TG</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Shibata</p>
<p>MC</p>
<p>,</p>
<p>Rigby</p>
<p>A</p>
<p>,</p>
<p>Flather</p>
<p>MD</p>
<p>,</p>
<p>Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta
blockers in patients with heart failure plus atrial fibrillation: an
individual-patient data meta-analysis</p>
<p>.</p>
<p>Lancet</p>
<p>2014</p>
<p>;</p>
<p>384</p>
<p>:</p>
<p>2235</p>
<p>–</p>
<p>2243</p>
<p>.</p>
<p>126</p>
<p>Seferovic</p>
<p>JP</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Seidelmann</p>
<p>SB</p>
<p>,</p>
<p>Seely</p>
<p>EW</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>Shi</p>
<p>VC</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Effect of sacubitril/valsartan versus enalapril on glycaemic control
in patients with heart failure and diabetes: a post-hoc analysis from
the PARADIGM-HF trial</p>
<p>.</p>
<p>Lancet Diabetes Endocrinol</p>
<p>2017</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>333</p>
<p>–</p>
<p>340</p>
<p>.</p>
<p>127</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Gori</p>
<p>M</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Lefkowitz</p>
<p>MP</p>
<p>,</p>
<p>Prescott</p>
<p>MF</p>
<p>,</p>
<p>Shi</p>
<p>VC</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Renal effects and associated outcomes during angiotensin-neprilysin
inhibition in heart failure</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>489</p>
<p>–</p>
<p>498</p>
<p>.</p>
<p>128</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>Shi</p>
<p>V</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Reduced risk of hyperkalemia during treatment of heart failure with
mineralocorticoid receptor antagonists by use of sacubitril/valsartan
compared with enalapril: a secondary analysis of the PARADIGM-HF
Trial</p>
<p>.</p>
<p>JAMA Cardiol</p>
<p>2017</p>
<p>;</p>
<p>2</p>
<p>:</p>
<p>79</p>
<p>–</p>
<p>85</p>
<p>.</p>
<p>129</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Kachadourian</p>
<p>J</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rouleau</p>
<p>J</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>Shi</p>
<p>V</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Reduced loop diuretic use in patients taking sacubitril/valsartan
compared with enalapril: the PARADIGM-HF trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>337</p>
<p>–</p>
<p>341</p>
<p>.</p>
<p>130</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Kachadourian</p>
<p>J</p>
<p>,</p>
<p>Pearson</p>
<p>SM</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rouleau</p>
<p>J</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>Shi</p>
<p>V</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Incidence, predictors, and outcomes associated with hypotensive
episodes among heart failure patients receiving sacubitril/valsartan or
enalapril: the PARADIGM-HF trial (Prospective Comparison of Angiotensin
Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme
Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart
Failure</p>
<p>).</p>
<p>Circ Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:e004745.</p>
<p>131</p>
<p>Morrow</p>
<p>DA</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>DeVore</p>
<p>AD</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Duffy</p>
<p>CI</p>
<p>,</p>
<p>Ambrosy</p>
<p>AP</p>
<p>,</p>
<p>Gurmu</p>
<p>Y</p>
<p>,</p>
<p>McCague</p>
<p>K</p>
<p>,</p>
<p>Rocha</p>
<p>R</p>
<p>,</p>
<p>Braunwald</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>Clinical outcomes in patients with acute decompensated heart failure
randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF
trial</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>2285</p>
<p>–</p>
<p>2288</p>
<p>.</p>
<p>132</p>
<p>Kosiborod</p>
<p>MN</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Docherty</p>
<p>KF</p>
<p>,</p>
<p>Diez</p>
<p>M</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Nicolau</p>
<p>JC</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Kitakaze</p>
<p>M</p>
<p>,</p>
<p>DeMets</p>
<p>DL</p>
<p>,</p>
<p>Inzucchi</p>
<p>SE</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Martinez</p>
<p>FA</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Bengtsson</p>
<p>O</p>
<p>,</p>
<p>Lindholm</p>
<p>D</p>
<p>,</p>
<p>Niklasson</p>
<p>A</p>
<p>,</p>
<p>Sjostrand</p>
<p>M</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Effects of dapagliflozin on symptoms, function, and quality of life
in patients with heart failure and reduced ejection fraction: results
from the DAPA-HF trial</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>90</p>
<p>–</p>
<p>99</p>
<p>.</p>
<p>133</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Khan</p>
<p>MS</p>
<p>,</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Giannetti</p>
<p>N</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Brueckmann</p>
<p>M</p>
<p>,</p>
<p>Jamal</p>
<p>W</p>
<p>,</p>
<p>Vedin</p>
<p>O</p>
<p>,</p>
<p>Peil</p>
<p>B</p>
<p>,</p>
<p>Zeller</p>
<p>C</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and
health-related quality of life outcomes in patients with heart failure
with reduced ejection fraction: the EMPEROR-Reduced trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>1203</p>
<p>–</p>
<p>1212</p>
<p>.</p>
<p>134</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Brueckmann</p>
<p>M</p>
<p>,</p>
<p>Ofstad</p>
<p>AP</p>
<p>,</p>
<p>Pfarr</p>
<p>E</p>
<p>,</p>
<p>Jamal</p>
<p>W</p>
<p>,</p>
<p>Packer</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>SGLT2 inhibitors in patients with heart failure with reduced ejection
fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials</p>
<p>.</p>
<p>Lancet</p>
<p>2020</p>
<p>;</p>
<p>396</p>
<p>:</p>
<p>819</p>
<p>–</p>
<p>829</p>
<p>.</p>
<p>135</p>
<p>Jackson</p>
<p>AM</p>
<p>,</p>
<p>Dewan</p>
<p>P</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Belohlavek</p>
<p>J</p>
<p>,</p>
<p>Bengtsson</p>
<p>O</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Boulton</p>
<p>DW</p>
<p>,</p>
<p>Chopra</p>
<p>VK</p>
<p>,</p>
<p>DeMets</p>
<p>DL</p>
<p>,</p>
<p>Docherty</p>
<p>KF</p>
<p>,</p>
<p>Dukat</p>
<p>A</p>
<p>,</p>
<p>Greasley</p>
<p>PJ</p>
<p>,</p>
<p>Howlett</p>
<p>JG</p>
<p>,</p>
<p>Inzucchi</p>
<p>SE</p>
<p>,</p>
<p>Katova</p>
<p>T</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Kosiborod</p>
<p>MN</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>Lindholm</p>
<p>D</p>
<p>,</p>
<p>Ljungman</p>
<p>CEA</p>
<p>,</p>
<p>Martinez</p>
<p>FA</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>Sjostrand</p>
<p>M</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Tereshchenko</p>
<p>S</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Dapagliflozin and diuretic use in patients with heart failure and
reduced ejection fraction in DAPA-HF</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>142</p>
<p>:</p>
<p>1040</p>
<p>–</p>
<p>1054</p>
<p>.</p>
<p>136</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Szarek</p>
<p>M</p>
<p>,</p>
<p>Steg</p>
<p>PG</p>
<p>,</p>
<p>Cannon</p>
<p>CP</p>
<p>,</p>
<p>Leiter</p>
<p>LA</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Lewis</p>
<p>JB</p>
<p>,</p>
<p>Riddle</p>
<p>MC</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Testani</p>
<p>JM</p>
<p>,</p>
<p>Wilcox</p>
<p>CS</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Lopes</p>
<p>RD</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Lapuerta</p>
<p>P</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with
diabetes and recent worsening heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2021</p>
<p>;</p>
<p>384</p>
<p>:</p>
<p>117</p>
<p>–</p>
<p>128</p>
<p>.</p>
<p>137</p>
<p>Faris</p>
<p>R</p>
<p>,</p>
<p>Flather</p>
<p>M</p>
<p>,</p>
<p>Purcell</p>
<p>H</p>
<p>,</p>
<p>Henein</p>
<p>M</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>P</p>
<p>,</p>
<p>Coats</p>
<ol type="A">
<li></li>
</ol>
<p>Current evidence supporting the role of diuretics in heart failure: a
meta analysis of randomised controlled trials</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2002</p>
<p>;</p>
<p>82</p>
<p>:</p>
<p>149</p>
<p>–</p>
<p>158</p>
<p>.</p>
<p>138</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Held</p>
<p>P</p>
<p>,</p>
<p>Michelson</p>
<p>EL</p>
<p>,</p>
<p>Olofsson</p>
<p>B</p>
<p>,</p>
<p>Ostergren</p>
<p>J</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>CHARM Investigators and Committees. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function intolerant to angiotensin-converting-enzyme
inhibitors: the CHARM-Alternative trial</p>
<p>.</p>
<p>Lancet</p>
<p>2003</p>
<p>;</p>
<p>362</p>
<p>:</p>
<p>772</p>
<p>–</p>
<p>776</p>
<p>.</p>
<p>139</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Borer</p>
<p>JS</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Dubost-Brama</p>
<p>A</p>
<p>,</p>
<p>Lerebours</p>
<p>G</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>SHIFT Investigators</p>
<p>.</p>
<p>Ivabradine and outcomes in chronic heart failure (SHIFT): a
randomised placebo-controlled study</p>
<p>.</p>
<p>Lancet</p>
<p>2010</p>
<p>;</p>
<p>376</p>
<p>:</p>
<p>875</p>
<p>–</p>
<p>885</p>
<p>.</p>
<p>140</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Borer</p>
<p>J</p>
<p>,</p>
<p>Robertson</p>
<p>M</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>SHIFT Investigators</p>
<p>.</p>
<p>Effects on outcomes of heart rate reduction by ivabradine in patients
with congestive heart failure: is there an influence of beta-blocker
dose?: findings from the SHIFT (Systolic Heart failure treatment with
the I(f) inhibitor ivabradine Trial) study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2012</p>
<p>;</p>
<p>59</p>
<p>:</p>
<p>1938</p>
<p>–</p>
<p>1945</p>
<p>.</p>
<p>141</p>
<p>Armstrong</p>
<p>PW</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Ezekowitz</p>
<p>J</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Jia</p>
<p>G</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Patel</p>
<p>MJ</p>
<p>,</p>
<p>Roessig</p>
<p>L</p>
<p>,</p>
<p>Koglin</p>
<p>J</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>VICTORIA Study Group</p>
<p>.</p>
<p>Vericiguat in patients with heart failure and reduced ejection
fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>382</p>
<p>:</p>
<p>1883</p>
<p>–</p>
<p>1893</p>
<p>.</p>
<p>142</p>
<p>Taylor</p>
<p>AL</p>
<p>,</p>
<p>Ziesche</p>
<p>S</p>
<p>,</p>
<p>Yancy</p>
<p>C</p>
<p>,</p>
<p>Carson</p>
<p>P</p>
<p>,</p>
<p>D’Agostino</p>
<p>R</p>
<p>Jr.,</p>
<p>Ferdinand</p>
<p>K</p>
<p>,</p>
<p>Taylor</p>
<p>M</p>
<p>,</p>
<p>Adams</p>
<p>K</p>
<p>,</p>
<p>Sabolinski</p>
<p>M</p>
<p>,</p>
<p>Worcel</p>
<p>M</p>
<p>,</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>African-American Heart Failure Trial Investigators</p>
<p>.</p>
<p>Combination of isosorbide dinitrate and hydralazine in blacks with
heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2004</p>
<p>;</p>
<p>351</p>
<p>:</p>
<p>2049</p>
<p>–</p>
<p>2057</p>
<p>.</p>
<p>143</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Archibald</p>
<p>DG</p>
<p>,</p>
<p>Ziesche</p>
<p>S</p>
<p>,</p>
<p>Franciosa</p>
<p>JA</p>
<p>,</p>
<p>Harston</p>
<p>WE</p>
<p>,</p>
<p>Tristani</p>
<p>FE</p>
<p>,</p>
<p>Dunkman</p>
<p>WB</p>
<p>,</p>
<p>Jacobs</p>
<p>W</p>
<p>,</p>
<p>Francis</p>
<p>GS</p>
<p>,</p>
<p>Flohr</p>
<p>KH.</p>
<p>Effect of vasodilator therapy on mortality in chronic congestive
heart failure. Results of a Veterans Administration Cooperative
Study</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1986</p>
<p>;</p>
<p>314</p>
<p>:</p>
<p>1547</p>
<p>–</p>
<p>1552</p>
<p>.</p>
<p>144</p>
<p>Digitalis Investigation Group</p>
<p>.</p>
<p>The effect of digoxin on mortality and morbidity in patients with
heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1997</p>
<p>;</p>
<p>336</p>
<p>:</p>
<p>525</p>
<p>–</p>
<p>533</p>
<p>.</p>
<p>145</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Martens</p>
<p>P</p>
<p>,</p>
<p>Testani</p>
<p>JM</p>
<p>,</p>
<p>Tang</p>
<p>WHW</p>
<p>,</p>
<p>Orso</p>
<p>F</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<p>AJ.</p>
<p>The use of diuretics in heart failure with congestion – a position
statement from the Heart Failure Association of the European Society of
Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>137</p>
<p>–</p>
<p>155</p>
<p>.</p>
<p>146</p>
<p>Rohde</p>
<p>LE</p>
<p>,</p>
<p>Rover</p>
<p>MM</p>
<p>,</p>
<p>Figueiredo Neto</p>
<p>JA</p>
<p>,</p>
<p>Danzmann</p>
<p>LC</p>
<p>,</p>
<p>Bertoldi</p>
<p>EG</p>
<p>,</p>
<p>Simoes</p>
<p>MV</p>
<p>,</p>
<p>Silvestre</p>
<p>OM</p>
<p>,</p>
<p>Ribeiro</p>
<p>ALP</p>
<p>,</p>
<p>Moura</p>
<p>LZ</p>
<p>,</p>
<p>Beck-da-Silva</p>
<p>L</p>
<p>,</p>
<p>Prado</p>
<p>D</p>
<p>,</p>
<p>Sant’Anna</p>
<p>RT</p>
<p>,</p>
<p>Bridi</p>
<p>LH</p>
<p>,</p>
<p>Zimerman</p>
<p>A</p>
<p>,</p>
<p>Raupp da Rosa</p>
<p>P</p>
<p>,</p>
<p>Biolo</p>
<ol type="A">
<li></li>
</ol>
<p>Short-term diuretic withdrawal in stable outpatients with mild heart
failure and no fluid retention receiving optimal therapy: a
double-blind, multicentre, randomized trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>3605</p>
<p>–</p>
<p>3612</p>
<p>.</p>
<p>147</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Tognoni</p>
<p>G</p>
<p>,</p>
<p>Valsartan Heart Failure Trial Investigators. A randomized trial of
the angiotensin-receptor blocker valsartan in chronic heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2001</p>
<p>;</p>
<p>345</p>
<p>:</p>
<p>1667</p>
<p>–</p>
<p>1675</p>
<p>.</p>
<p>148</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Borer</p>
<p>J</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Gonzalez-Juanatey</p>
<p>JR</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Lopez-Sendon</p>
<p>J</p>
<p>,</p>
<p>Reil</p>
<p>JC</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Tavazzi</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Heart rate at baseline influences the effect of ivabradine on
cardiovascular outcomes in chronic heart failure: analysis from the
SHIFT study</p>
<p>.</p>
<p>Clin Res Cardiol</p>
<p>2013</p>
<p>;</p>
<p>102</p>
<p>:</p>
<p>11</p>
<p>–</p>
<p>22</p>
<p>.</p>
<p>149</p>
<p>Ouyang</p>
<p>AJ</p>
<p>,</p>
<p>Lv</p>
<p>YN</p>
<p>,</p>
<p>Zhong</p>
<p>HL</p>
<p>,</p>
<p>Wen</p>
<p>JH</p>
<p>,</p>
<p>Wei</p>
<p>XH</p>
<p>,</p>
<p>Peng</p>
<p>HW</p>
<p>,</p>
<p>Zhou</p>
<p>J</p>
<p>,</p>
<p>Liu</p>
<p>LL.</p>
<p>Meta-analysis of digoxin use and risk of mortality in patients with
atrial fibrillation</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2015</p>
<p>;</p>
<p>115</p>
<p>:</p>
<p>901</p>
<p>–</p>
<p>906</p>
<p>.</p>
<p>150</p>
<p>Vamos</p>
<p>M</p>
<p>,</p>
<p>Erath</p>
<p>JW</p>
<p>,</p>
<p>Hohnloser</p>
<p>SH.</p>
<p>Digoxin-associated mortality: a systematic review and meta-analysis
of the literature</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1831</p>
<p>–</p>
<p>1838</p>
<p>.</p>
<p>151</p>
<p>Ziff</p>
<p>OJ</p>
<p>,</p>
<p>Lane</p>
<p>DA</p>
<p>,</p>
<p>Samra</p>
<p>M</p>
<p>,</p>
<p>Griffith</p>
<p>M</p>
<p>,</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>Lip</p>
<p>GY</p>
<p>,</p>
<p>Steeds</p>
<p>RP</p>
<p>,</p>
<p>Townend</p>
<p>J</p>
<p>,</p>
<p>Kotecha</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Safety and efficacy of digoxin: systematic review and meta-analysis
of observational and controlled trial data</p>
<p>.</p>
<p>BMJ</p>
<p>2015</p>
<p>;</p>
<p>351</p>
<p>:</p>
<p>h4451</p>
<p>.</p>
<p>152</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Groenveld</p>
<p>HF</p>
<p>,</p>
<p>Crijns</p>
<p>HJ</p>
<p>,</p>
<p>Tuininga</p>
<p>YS</p>
<p>,</p>
<p>Tijssen</p>
<p>JG</p>
<p>,</p>
<p>Alings</p>
<p>AM</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>Bergsma-Kadijk</p>
<p>JA</p>
<p>,</p>
<p>Cornel</p>
<p>JH</p>
<p>,</p>
<p>Kamp</p>
<p>O</p>
<p>,</p>
<p>Tukkie</p>
<p>R</p>
<p>,</p>
<p>Bosker</p>
<p>HA</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Van den Berg</p>
<p>MP</p>
<p>,</p>
<p>RACE II Investigators</p>
<p>.</p>
<p>Lenient versus strict rate control in patients with atrial
fibrillation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2010</p>
<p>;</p>
<p>362</p>
<p>:</p>
<p>1363</p>
<p>–</p>
<p>1373</p>
<p>.</p>
<p>153</p>
<p>Bavishi</p>
<p>C</p>
<p>,</p>
<p>Khan</p>
<p>AR</p>
<p>,</p>
<p>Ather</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Digoxin in patients with atrial fibrillation and heart failure: a
meta-analysis</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2015</p>
<p>;</p>
<p>188</p>
<p>:</p>
<p>99</p>
<p>–</p>
<p>101</p>
<p>.</p>
<p>154</p>
<p>Freeman</p>
<p>JV</p>
<p>,</p>
<p>Reynolds</p>
<p>K</p>
<p>,</p>
<p>Fang</p>
<p>M</p>
<p>,</p>
<p>Udaltsova</p>
<p>N</p>
<p>,</p>
<p>Steimle</p>
<p>A</p>
<p>,</p>
<p>Pomernacki</p>
<p>NK</p>
<p>,</p>
<p>Borowsky</p>
<p>LH</p>
<p>,</p>
<p>Harrison</p>
<p>TN</p>
<p>,</p>
<p>Singer</p>
<p>DE</p>
<p>,</p>
<p>Go</p>
<p>AS.</p>
<p>Digoxin and risk of death in adults with atrial fibrillation: the
ATRIA-CVRN study</p>
<p>.</p>
<p>Circ Arrhythm Electrophysiol</p>
<p>2015</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>49</p>
<p>–</p>
<p>58</p>
<p>.</p>
<p>155</p>
<p>Washam</p>
<p>JB</p>
<p>,</p>
<p>Stevens</p>
<p>SR</p>
<p>,</p>
<p>Lokhnygina</p>
<p>Y</p>
<p>,</p>
<p>Halperin</p>
<p>JL</p>
<p>,</p>
<p>Breithardt</p>
<p>G</p>
<p>,</p>
<p>Singer</p>
<p>DE</p>
<p>,</p>
<p>Mahaffey</p>
<p>KW</p>
<p>,</p>
<p>Hankey</p>
<p>GJ</p>
<p>,</p>
<p>Berkowitz</p>
<p>SD</p>
<p>,</p>
<p>Nessel</p>
<p>CC</p>
<p>,</p>
<p>Fox</p>
<p>KA</p>
<p>,</p>
<p>Califf</p>
<p>RM</p>
<p>,</p>
<p>Piccini</p>
<p>JP</p>
<p>,</p>
<p>Patel</p>
<p>MR</p>
<p>, ROCKET Steering Committee and Investigators. Digoxin use in
patients with atrial fibrillation AF and adverse cardiovascular
outcomes: retrospective analysis of the Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with Vitamin a K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET
AF).</p>
<p>Lancet</p>
<p>2015</p>
<p>;</p>
<p>385</p>
<p>:</p>
<p>2363</p>
<p>–</p>
<p>2370</p>
<p>.</p>
<p>156</p>
<p>Rathore</p>
<p>SS</p>
<p>,</p>
<p>Curtis</p>
<p>JP</p>
<p>,</p>
<p>Wang</p>
<p>Y</p>
<p>,</p>
<p>Bristow</p>
<p>MR</p>
<p>,</p>
<p>Krumholz</p>
<p>HM.</p>
<p>Association of serum digoxin concentration and outcomes in patients
with heart failure</p>
<p>.</p>
<p>JAMA</p>
<p>2003</p>
<p>;</p>
<p>289</p>
<p>:</p>
<p>871</p>
<p>–</p>
<p>878</p>
<p>.</p>
<p>157</p>
<p>Adams</p>
<p>KF</p>
<p>Jr.,</p>
<p>Patterson</p>
<p>JH</p>
<p>,</p>
<p>Gattis</p>
<p>WA</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Lee</p>
<p>CR</p>
<p>,</p>
<p>Schwartz</p>
<p>TA</p>
<p>,</p>
<p>Gheorghiade</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Relationship of serum digoxin concentration to mortality and
morbidity in women in the Digitalis Investigation Group trial: a
retrospective analysis</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2005</p>
<p>;</p>
<p>46</p>
<p>:</p>
<p>497</p>
<p>–</p>
<p>504</p>
<p>.</p>
<p>158</p>
<p>Bavendiek</p>
<p>U</p>
<p>,</p>
<p>Berliner</p>
<p>D</p>
<p>,</p>
<p>Davila</p>
<p>LA</p>
<p>,</p>
<p>Schwab</p>
<p>J</p>
<p>,</p>
<p>Maier</p>
<p>L</p>
<p>,</p>
<p>Philipp</p>
<p>SA</p>
<p>,</p>
<p>Rieth</p>
<p>A</p>
<p>,</p>
<p>Westenfeld</p>
<p>R</p>
<p>,</p>
<p>Piorkowski</p>
<p>C</p>
<p>,</p>
<p>Weber</p>
<p>K</p>
<p>,</p>
<p>Hanselmann</p>
<p>A</p>
<p>,</p>
<p>Oldhafer</p>
<p>M</p>
<p>,</p>
<p>Schallhorn</p>
<p>S</p>
<p>,</p>
<p>von der Leyen</p>
<p>H</p>
<p>,</p>
<p>Schroder</p>
<p>C</p>
<p>,</p>
<p>Veltmann</p>
<p>C</p>
<p>,</p>
<p>Stork</p>
<p>S</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Koch</p>
<p>A</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>DIGIT-HF Investigators and Committees</p>
<p>.</p>
<p>Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve
ouTcomes in patients with advanced chronic Heart Failure): a randomized,
double-blind, placebo-controlled study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>676</p>
<p>–</p>
<p>684</p>
<p>.</p>
<p>159</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Adams</p>
<p>KF</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Arias-Mendoza</p>
<p>A</p>
<p>,</p>
<p>Biering-Sorensen</p>
<p>T</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Bonderman</p>
<p>D</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Corbalan</p>
<p>R</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Echeverria</p>
<p>LE</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Goncalvesova</p>
<p>E</p>
<p>,</p>
<p>Goudev</p>
<p>AR</p>
<p>,</p>
<p>Howlett</p>
<p>JG</p>
<p>,</p>
<p>Lanfear</p>
<p>DE</p>
<p>,</p>
<p>Li</p>
<p>J</p>
<p>,</p>
<p>Lund</p>
<p>M</p>
<p>,</p>
<p>Macdonald</p>
<p>P</p>
<p>,</p>
<p>Mareev</p>
<p>V</p>
<p>,</p>
<p>Momomura</p>
<p>SI</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Ramires</p>
<p>FJA</p>
<p>,</p>
<p>Serpytis</p>
<p>P</p>
<p>,</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Spinar</p>
<p>J</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Tomcsanyi</p>
<p>J</p>
<p>,</p>
<p>Vandekerckhove</p>
<p>H</p>
<p>,</p>
<p>Vinereanu</p>
<p>D</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Sharpsten</p>
<p>L</p>
<p>,</p>
<p>Legg</p>
<p>JC</p>
<p>,</p>
<p>Varin</p>
<p>C</p>
<p>,</p>
<p>Honarpour</p>
<p>N</p>
<p>,</p>
<p>Abbasi</p>
<p>SA</p>
<p>,</p>
<p>Malik</p>
<p>FI</p>
<p>,</p>
<p>Kurtz</p>
<p>CE</p>
<p>,</p>
<p>GALACTIC-HF Investigators</p>
<p>.</p>
<p>Cardiac myosin activation with omecamtiv mecarbil in systolic heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2021</p>
<p>;</p>
<p>384</p>
<p>:</p>
<p>105</p>
<p>–</p>
<p>116</p>
<p>.</p>
<p>160</p>
<p>Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF,
Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP,
Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad
F, Zile MR, McMurray JJV.</p>
<p>Declining risk of sudden death in heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2017</p>
<p>;</p>
<p>377</p>
<p>:</p>
<p>41</p>
<p>–</p>
<p>51</p>
<p>.</p>
<p>161</p>
<p>Bardy</p>
<p>GH</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Poole</p>
<p>JE</p>
<p>,</p>
<p>Packer</p>
<p>DL</p>
<p>,</p>
<p>Boineau</p>
<p>R</p>
<p>,</p>
<p>Domanski</p>
<p>M</p>
<p>,</p>
<p>Troutman</p>
<p>C</p>
<p>,</p>
<p>Anderson</p>
<p>J</p>
<p>,</p>
<p>Johnson</p>
<p>G</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Clapp-Channing</p>
<p>N</p>
<p>,</p>
<p>Davidson-Ray</p>
<p>LD</p>
<p>,</p>
<p>Fraulo</p>
<p>ES</p>
<p>,</p>
<p>Fishbein</p>
<p>DP</p>
<p>,</p>
<p>Luceri</p>
<p>RM</p>
<p>,</p>
<p>Ip</p>
<p>JH</p>
<p>,</p>
<p>Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators.
Amiodarone or an implantable cardioverter-defibrillator for congestive
heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2005</p>
<p>;</p>
<p>352</p>
<p>:</p>
<p>225</p>
<p>–</p>
<p>237</p>
<p>.</p>
<p>162</p>
<p>Connolly</p>
<p>SJ</p>
<p>,</p>
<p>Hallstrom</p>
<p>AP</p>
<p>,</p>
<p>Cappato</p>
<p>R</p>
<p>,</p>
<p>Schron</p>
<p>EB</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Zipes</p>
<p>DP</p>
<p>,</p>
<p>Greene</p>
<p>HL</p>
<p>,</p>
<p>Boczor</p>
<p>S</p>
<p>,</p>
<p>Domanski</p>
<p>M</p>
<p>,</p>
<p>Follmann</p>
<p>D</p>
<p>,</p>
<p>Gent</p>
<p>M</p>
<p>,</p>
<p>Roberts</p>
<p>RS</p>
<p>,  </p>
<p>investigators of the AVID, CASH and CIDS studies. Meta-analysis of
the implantable cardioverter defibrillator secondary prevention
trials</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2000</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>2071</p>
<p>–</p>
<p>2078</p>
<p>.</p>
<p>163</p>
<p>Antiarrhythmics versus Implantable Defibrillators (AVID)
Investigators</p>
<p>.</p>
<p>A comparison of antiarrhythmic-drug therapy with implantable
defibrillators in patients resuscitated from near-fatal ventricular
arrhythmias</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1997</p>
<p>;</p>
<p>337</p>
<p>:</p>
<p>1576</p>
<p>–</p>
<p>1583</p>
<p>.</p>
<p>164</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Cappato</p>
<p>R</p>
<p>,</p>
<p>Siebels</p>
<p>J</p>
<p>,</p>
<p>Ruppel</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Randomized comparison of antiarrhythmic drug therapy with implantable
defibrillators in patients resuscitated from cardiac arrest: the Cardiac
Arrest Study Hamburg (CASH)</p>
<p>.</p>
<p>Circulation</p>
<p>2000</p>
<p>;</p>
<p>102</p>
<p>:</p>
<p>748</p>
<p>–</p>
<p>754</p>
<p>.</p>
<p>165</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Hall</p>
<p>WJ</p>
<p>,</p>
<p>Klein</p>
<p>H</p>
<p>,</p>
<p>Wilber</p>
<p>DJ</p>
<p>,</p>
<p>Cannom</p>
<p>DS</p>
<p>,</p>
<p>Daubert</p>
<p>JP</p>
<p>,</p>
<p>Higgins</p>
<p>SL</p>
<p>,</p>
<p>Brown</p>
<p>MW</p>
<p>,</p>
<p>Andrews</p>
<p>ML</p>
<p>,</p>
<p>Multicenter Automatic Defibrillator Implantation Trial II
Investigators</p>
<p>.</p>
<p>Prophylactic implantation of a defibrillator in patients with
myocardial infarction and reduced ejection fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2002</p>
<p>;</p>
<p>346</p>
<p>:</p>
<p>877</p>
<p>–</p>
<p>883</p>
<p>.</p>
<p>166</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Thune</p>
<p>JJ</p>
<p>,</p>
<p>Nielsen</p>
<p>JC</p>
<p>,</p>
<p>Haarbo</p>
<p>J</p>
<p>,</p>
<p>Videbaek</p>
<p>L</p>
<p>,</p>
<p>Korup</p>
<p>E</p>
<p>,</p>
<p>Jensen</p>
<p>G</p>
<p>,</p>
<p>Hildebrandt</p>
<p>P</p>
<p>,</p>
<p>Steffensen</p>
<p>FH</p>
<p>,</p>
<p>Bruun</p>
<p>NE</p>
<p>,</p>
<p>Eiskjaer</p>
<p>H</p>
<p>,</p>
<p>Brandes</p>
<p>A</p>
<p>,</p>
<p>Thogersen</p>
<p>AM</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Egstrup</p>
<p>K</p>
<p>,</p>
<p>Videbaek</p>
<p>R</p>
<p>,</p>
<p>Hassager</p>
<p>C</p>
<p>,</p>
<p>Svendsen</p>
<p>JH</p>
<p>,</p>
<p>Hofsten</p>
<p>DE</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Pehrson</p>
<p>S</p>
<p>,</p>
<p>DANISH Investigators</p>
<p>.</p>
<p>Defibrillator implantation in patients with nonischemic systolic
heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2016</p>
<p>;</p>
<p>375</p>
<p>:</p>
<p>1221</p>
<p>–</p>
<p>1230</p>
<p>.</p>
<p>167</p>
<p>Beggs</p>
<p>SAS</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Jackson</p>
<p>CE</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Gardner</p>
<p>RS.</p>
<p>Non-ischaemic cardiomyopathy, sudden death and implantable
defibrillators: a review and meta-analysis</p>
<p>.</p>
<p>Heart</p>
<p>2018</p>
<p>;</p>
<p>104</p>
<p>:</p>
<p>144</p>
<p>–</p>
<p>150</p>
<p>.</p>
<p>168</p>
<p>Merchant</p>
<p>FM</p>
<p>,</p>
<p>Jones</p>
<p>P</p>
<p>,</p>
<p>Wehrenberg</p>
<p>S</p>
<p>,</p>
<p>Lloyd</p>
<p>MS</p>
<p>,</p>
<p>Saxon</p>
<p>LA.</p>
<p>Incidence of defibrillator shocks after elective generator exchange
following uneventful first battery life</p>
<p>.</p>
<p>J Am Heart Assoc</p>
<p>2014</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>e001289</p>
<p>.</p>
<p>169</p>
<p>Yap</p>
<p>SC</p>
<p>,</p>
<p>Schaer</p>
<p>BA</p>
<p>,</p>
<p>Bhagwandien</p>
<p>RE</p>
<p>,</p>
<p>Kuhne</p>
<p>M</p>
<p>,</p>
<p>Dabiri Abkenari</p>
<p>L</p>
<p>,</p>
<p>Osswald</p>
<p>S</p>
<p>,</p>
<p>Szili-Torok</p>
<p>T</p>
<p>,</p>
<p>Sticherling</p>
<p>C</p>
<p>,</p>
<p>Theuns</p>
<p>DA.</p>
<p>Evaluation of the need of elective implantable
cardioverter-defibrillator generator replacement in primary prevention
patients without prior appropriate ICD therapy</p>
<p>.</p>
<p>Heart</p>
<p>2014</p>
<p>;</p>
<p>100</p>
<p>:</p>
<p>1188</p>
<p>–</p>
<p>1192</p>
<p>.</p>
<p>170</p>
<p>Kini</p>
<p>V</p>
<p>,</p>
<p>Soufi</p>
<p>MK</p>
<p>,</p>
<p>Deo</p>
<p>R</p>
<p>,</p>
<p>Epstein</p>
<p>AE</p>
<p>,</p>
<p>Bala</p>
<p>R</p>
<p>,</p>
<p>Riley</p>
<p>M</p>
<p>,</p>
<p>Groeneveld</p>
<p>PW</p>
<p>,</p>
<p>Shalaby</p>
<p>A</p>
<p>,</p>
<p>Dixit</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Appropriateness of primary prevention implantable
cardioverter-defibrillators at the time of generator replacement: are
indications still met?</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>2388</p>
<p>–</p>
<p>2394</p>
<p>.</p>
<p>171</p>
<p>Erkapic</p>
<p>D</p>
<p>,</p>
<p>Sperzel</p>
<p>J</p>
<p>,</p>
<p>Stiller</p>
<p>S</p>
<p>,</p>
<p>Meltendorf</p>
<p>U</p>
<p>,</p>
<p>Mermi</p>
<p>J</p>
<p>,</p>
<p>Wegscheider</p>
<p>K</p>
<p>,</p>
<p>Hugl</p>
<p>B</p>
<p>,</p>
<p>Investigators</p>
<ol type="I">
<li></li>
</ol>
<p>Long-term benefit of implantable cardioverter/defibrillator therapy
after elective device replacement: results of the INcidence free
SUrvival after ICD REplacement (INSURE) trial–a prospective multicentre
study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>130</p>
<p>–</p>
<p>137</p>
<p>.</p>
<p>172</p>
<p>Alsheikh-Ali</p>
<p>AA</p>
<p>,</p>
<p>Homer</p>
<p>M</p>
<p>,</p>
<p>Maddukuri</p>
<p>PV</p>
<p>,</p>
<p>Kalsmith</p>
<p>B</p>
<p>,</p>
<p>Estes</p>
<p>NA</p>
<p>3rd,</p>
<p>Link</p>
<p>MS.</p>
<p>Time-dependence of appropriate implantable defibrillator therapy in
patients with ischemic cardiomyopathy</p>
<p>.</p>
<p>J Cardiovasc Electrophysiol</p>
<p>2008</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>784</p>
<p>–</p>
<p>789</p>
<p>.</p>
<p>173</p>
<p>Opreanu</p>
<p>M</p>
<p>,</p>
<p>Wan</p>
<p>C</p>
<p>,</p>
<p>Singh</p>
<p>V</p>
<p>,</p>
<p>Salehi</p>
<p>N</p>
<p>,</p>
<p>Ahmad</p>
<p>J</p>
<p>,</p>
<p>Szymkiewicz</p>
<p>SJ</p>
<p>,</p>
<p>Thakur</p>
<p>RK.</p>
<p>Wearable cardioverter-defibrillator as a bridge to cardiac
transplantation: a national database analysis</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2015</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>1305</p>
<p>–</p>
<p>1309</p>
<p>.</p>
<p>174</p>
<p>Zishiri</p>
<p>ET</p>
<p>,</p>
<p>Williams</p>
<p>S</p>
<p>,</p>
<p>Cronin</p>
<p>EM</p>
<p>,</p>
<p>Blackstone</p>
<p>EH</p>
<p>,</p>
<p>Ellis</p>
<p>SG</p>
<p>,</p>
<p>Roselli</p>
<p>EE</p>
<p>,</p>
<p>Smedira</p>
<p>NG</p>
<p>,</p>
<p>Gillinov</p>
<p>AM</p>
<p>,</p>
<p>Glad</p>
<p>JA</p>
<p>,</p>
<p>Tchou</p>
<p>PJ</p>
<p>,</p>
<p>Szymkiewicz</p>
<p>SJ</p>
<p>,</p>
<p>Chung</p>
<p>MK.</p>
<p>Early risk of mortality after coronary artery revascularization in
patients with left ventricular dysfunction and potential role of the
wearable cardioverter defibrillator</p>
<p>.</p>
<p>Circ Arrhythm Electrophysiol</p>
<p>2013</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>117</p>
<p>–</p>
<p>128</p>
<p>.</p>
<p>175</p>
<p>Kutyifa</p>
<p>V</p>
<p>,</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Klein</p>
<p>H</p>
<p>,</p>
<p>Biton</p>
<p>Y</p>
<p>,</p>
<p>McNitt</p>
<p>S</p>
<p>,</p>
<p>MacKecknie</p>
<p>B</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Goldenberg</p>
<ol type="I">
<li></li>
</ol>
<p>Use of the wearable cardioverter defibrillator in high-risk cardiac
patients: data from the Prospective Registry of Patients Using the
Wearable Cardioverter Defibrillator (WEARIT-II Registry)</p>
<p>.</p>
<p>Circulation</p>
<p>2015</p>
<p>;</p>
<p>132</p>
<p>:</p>
<p>1613</p>
<p>–</p>
<p>1619</p>
<p>.</p>
<p>176</p>
<p>Kutyifa</p>
<p>V</p>
<p>,</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Klein</p>
<p>HU</p>
<p>,</p>
<p>McNitt</p>
<p>S</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Goldenberg</p>
<ol type="I">
<li></li>
</ol>
<p>One-year follow-up of the Prospective Registry of Patients Using the
Wearable Defibrillator (WEARIT-II Registry)</p>
<p>.</p>
<p>Pacing Clin Electrophysiol</p>
<p>2018</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>1307</p>
<p>–</p>
<p>1313</p>
<p>.</p>
<p>177</p>
<p>Hohnloser</p>
<p>SH</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Dorian</p>
<p>P</p>
<p>,</p>
<p>Roberts</p>
<p>RS</p>
<p>,</p>
<p>Hampton</p>
<p>JR</p>
<p>,</p>
<p>Hatala</p>
<p>R</p>
<p>,</p>
<p>Fain</p>
<p>E</p>
<p>,</p>
<p>Gent</p>
<p>M</p>
<p>,</p>
<p>Connolly</p>
<p>SJ</p>
<p>,</p>
<p>DINAMIT Investigators</p>
<p>.</p>
<p>Prophylactic use of an implantable cardioverter-defibrillator after
acute myocardial infarction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2004</p>
<p>;</p>
<p>351</p>
<p>:</p>
<p>2481</p>
<p>–</p>
<p>2488</p>
<p>.</p>
<p>178</p>
<p>Steinbeck</p>
<p>G</p>
<p>,</p>
<p>Andresen</p>
<p>D</p>
<p>,</p>
<p>Seidl</p>
<p>K</p>
<p>,</p>
<p>Brachmann</p>
<p>J</p>
<p>,</p>
<p>Hoffmann</p>
<p>E</p>
<p>,</p>
<p>Wojciechowski</p>
<p>D</p>
<p>,</p>
<p>Kornacewicz-Jach</p>
<p>Z</p>
<p>,</p>
<p>Sredniawa</p>
<p>B</p>
<p>,</p>
<p>Lupkovics</p>
<p>G</p>
<p>,</p>
<p>Hofgartner</p>
<p>F</p>
<p>,</p>
<p>Lubinski</p>
<p>A</p>
<p>,</p>
<p>Rosenqvist</p>
<p>M</p>
<p>,</p>
<p>Habets</p>
<p>A</p>
<p>,</p>
<p>Wegscheider</p>
<p>K</p>
<p>,</p>
<p>Senges</p>
<p>J</p>
<p>IRIS Investigators</p>
<p>.</p>
<p>Defibrillator implantation early after myocardial infarction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2009</p>
<p>;</p>
<p>361</p>
<p>:</p>
<p>1427</p>
<p>–</p>
<p>1436</p>
<p>.</p>
<p>179</p>
<p>Sanders</p>
<p>GD</p>
<p>,</p>
<p>Hlatky</p>
<p>MA</p>
<p>,</p>
<p>Owens</p>
<p>DK.</p>
<p>Cost-effectiveness of implantable cardioverter-defibrillators</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2005</p>
<p>;</p>
<p>353</p>
<p>:</p>
<p>1471</p>
<p>–</p>
<p>1480</p>
<p>.</p>
<p>180</p>
<p>Steinberg</p>
<p>BA</p>
<p>,</p>
<p>Al-Khatib</p>
<p>SM</p>
<p>,</p>
<p>Edwards</p>
<p>R</p>
<p>,</p>
<p>Han</p>
<p>J</p>
<p>,</p>
<p>Bardy</p>
<p>GH</p>
<p>,</p>
<p>Bigger</p>
<p>JT</p>
<p>,</p>
<p>Buxton</p>
<p>AE</p>
<p>,</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Steinman</p>
<p>R</p>
<p>,</p>
<p>Dorian</p>
<p>P</p>
<p>,</p>
<p>Hallstrom</p>
<p>A</p>
<p>,</p>
<p>Cappato</p>
<p>R</p>
<p>,</p>
<p>Kadish</p>
<p>AH</p>
<p>,</p>
<p>Kudenchuk</p>
<p>PJ</p>
<p>,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Inoue</p>
<p>LY</p>
<p>,</p>
<p>Sanders</p>
<p>GD.</p>
<p>Outcomes of implantable cardioverter-defibrillator use in patients
with comorbidities: results from a combined analysis of 4 randomized
clinical trials</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>2</p>
<p>:</p>
<p>623</p>
<p>–</p>
<p>629</p>
<p>.</p>
<p>181</p>
<p>Raphael</p>
<p>CE</p>
<p>,</p>
<p>Finegold</p>
<p>JA</p>
<p>,</p>
<p>Barron</p>
<p>AJ</p>
<p>,</p>
<p>Whinnett</p>
<p>ZI</p>
<p>,</p>
<p>Mayet</p>
<p>J</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Levy</p>
<p>WC</p>
<p>,</p>
<p>Francis</p>
<p>DP.</p>
<p>The effect of duration of follow-up and presence of competing risk on
lifespan-gain from implantable cardioverter defibrillator therapy: who
benefits the most?</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1676</p>
<p>–</p>
<p>1688</p>
<p>.</p>
<p>182</p>
<p>Miller</p>
<p>RJ</p>
<p>,</p>
<p>Howlett</p>
<p>JG</p>
<p>,</p>
<p>Exner</p>
<p>DV</p>
<p>,</p>
<p>Campbell</p>
<p>PM</p>
<p>,</p>
<p>Grant</p>
<p>AD</p>
<p>,</p>
<p>Wilton</p>
<p>SB.</p>
<p>Baseline functional class and therapeutic efficacy of common heart
failure interventions: a systematic review and meta-analysis</p>
<p>.</p>
<p>Can J Cardiol</p>
<p>2015</p>
<p>;</p>
<p>31</p>
<p>:</p>
<p>792</p>
<p>–</p>
<p>799</p>
<p>.</p>
<p>183</p>
<p>Hess</p>
<p>PL</p>
<p>,</p>
<p>Al-Khatib</p>
<p>SM</p>
<p>,</p>
<p>Han</p>
<p>JY</p>
<p>,</p>
<p>Edwards</p>
<p>R</p>
<p>,</p>
<p>Bardy</p>
<p>GH</p>
<p>,</p>
<p>Bigger</p>
<p>JT</p>
<p>,</p>
<p>Buxton</p>
<p>A</p>
<p>,</p>
<p>Cappato</p>
<p>R</p>
<p>,</p>
<p>Dorian</p>
<p>P</p>
<p>,</p>
<p>Hallstrom</p>
<p>A</p>
<p>,</p>
<p>Kadish</p>
<p>AH</p>
<p>,</p>
<p>Kudenchuk</p>
<p>PJ</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Steinman</p>
<p>R</p>
<p>,</p>
<p>Inoue</p>
<p>LY</p>
<p>,</p>
<p>Sanders</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Survival benefit of the primary prevention implantable
cardioverter-defibrillator among older patients: does age matter? An
analysis of pooled data from 5 clinical trials</p>
<p>.</p>
<p>Circ Cardiovasc Qual Outcomes</p>
<p>2015</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>179</p>
<p>–</p>
<p>186</p>
<p>.</p>
<p>184</p>
<p>Connolly</p>
<p>SJ</p>
<p>,</p>
<p>Gent</p>
<p>M</p>
<p>,</p>
<p>Roberts</p>
<p>RS</p>
<p>,</p>
<p>Dorian</p>
<p>P</p>
<p>,</p>
<p>Roy</p>
<p>D</p>
<p>,</p>
<p>Sheldon</p>
<p>RS</p>
<p>,</p>
<p>Mitchell</p>
<p>LB</p>
<p>,</p>
<p>Green</p>
<p>MS</p>
<p>,</p>
<p>Klein</p>
<p>GJ</p>
<p>,</p>
<p>O’Brien</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Canadian implantable defibrillator study (CIDS): a randomized trial
of the implantable cardioverter defibrillator against amiodarone</p>
<p>.</p>
<p>Circulation</p>
<p>2000</p>
<p>;</p>
<p>101</p>
<p>:</p>
<p>1297</p>
<p>–</p>
<p>1302</p>
<p>.</p>
<p>185</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Gotzsche</p>
<p>O</p>
<p>,</p>
<p>Levy</p>
<p>S</p>
<p>,</p>
<p>Crijns</p>
<p>H</p>
<p>,</p>
<p>Amlie</p>
<p>J</p>
<p>,</p>
<p>Carlsen</p>
<p>J</p>
<p>,</p>
<p>Dronedarone Study Group</p>
<p>.</p>
<p>Increased mortality after dronedarone therapy for severe heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2008</p>
<p>;</p>
<p>358</p>
<p>:</p>
<p>2678</p>
<p>–</p>
<p>2687</p>
<p>.</p>
<p>186</p>
<p>Echt</p>
<p>DS</p>
<p>,</p>
<p>Liebson</p>
<p>PR</p>
<p>,</p>
<p>Mitchell</p>
<p>LB</p>
<p>,</p>
<p>Peters</p>
<p>RW</p>
<p>,</p>
<p>Obias-Manno</p>
<p>D</p>
<p>,</p>
<p>Barker</p>
<p>AH</p>
<p>,</p>
<p>Arensberg</p>
<p>D</p>
<p>,</p>
<p>Baker</p>
<p>A</p>
<p>,</p>
<p>Friedman</p>
<p>L</p>
<p>,</p>
<p>Greene</p>
<p>HL.</p>
<p>Mortality and morbidity in patients receiving encainide, flecainide,
or placebo. The Cardiac Arrhythmia Suppression Trial</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1991</p>
<p>;</p>
<p>324</p>
<p>:</p>
<p>781</p>
<p>–</p>
<p>788</p>
<p>.</p>
<p>187</p>
<p>Theuns</p>
<p>DA</p>
<p>,</p>
<p>Smith</p>
<p>T</p>
<p>,</p>
<p>Hunink</p>
<p>MG</p>
<p>,</p>
<p>Bardy</p>
<p>GH</p>
<p>,</p>
<p>Jordaens</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Effectiveness of prophylactic implantation of
cardioverter-defibrillators without cardiac resynchronization therapy in
patients with ischaemic or non-ischaemic heart disease: a systematic
review and meta-analysis</p>
<p>.</p>
<p>Europace</p>
<p>2010</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>1564</p>
<p>–</p>
<p>1570</p>
<p>.</p>
<p>188</p>
<p>Elming</p>
<p>MB</p>
<p>,</p>
<p>Nielsen</p>
<p>JC</p>
<p>,</p>
<p>Haarbo</p>
<p>J</p>
<p>,</p>
<p>Videbaek</p>
<p>L</p>
<p>,</p>
<p>Korup</p>
<p>E</p>
<p>,</p>
<p>Signorovitch</p>
<p>J</p>
<p>,</p>
<p>Olesen</p>
<p>LL</p>
<p>,</p>
<p>Hildebrandt</p>
<p>P</p>
<p>,</p>
<p>Steffensen</p>
<p>FH</p>
<p>,</p>
<p>Bruun</p>
<p>NE</p>
<p>,</p>
<p>Eiskjaer</p>
<p>H</p>
<p>,</p>
<p>Brandes</p>
<p>A</p>
<p>,</p>
<p>Thogersen</p>
<p>AM</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Egstrup</p>
<p>K</p>
<p>,</p>
<p>Videbaek</p>
<p>R</p>
<p>,</p>
<p>Hassager</p>
<p>C</p>
<p>,</p>
<p>Svendsen</p>
<p>JH</p>
<p>,</p>
<p>Hofsten</p>
<p>DE</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Pehrson</p>
<p>S</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Thune</p>
<p>JJ.</p>
<p>Age and outcomes of primary prevention implantable
cardioverter-defibrillators in patients with nonischemic systolic heart
failure</p>
<p>.</p>
<p>Circulation</p>
<p>2017</p>
<p>;</p>
<p>136</p>
<p>:</p>
<p>1772</p>
<p>–</p>
<p>1780</p>
<p>.</p>
<p>189</p>
<p>Selvanayagam</p>
<p>JB</p>
<p>,</p>
<p>Hartshorne</p>
<p>T</p>
<p>,</p>
<p>Billot</p>
<p>L</p>
<p>,</p>
<p>Grover</p>
<p>S</p>
<p>,</p>
<p>Hillis</p>
<p>GS</p>
<p>,</p>
<p>Jung</p>
<p>W</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Prasad</p>
<p>S</p>
<p>,</p>
<p>McGavigan</p>
<p>AD.</p>
<p>Cardiovascular magnetic resonance-GUIDEd management of mild to
moderate left ventricular systolic dysfunction (CMR GUIDE): Study
protocol for a randomized controlled trial</p>
<p>.</p>
<p>Ann Noninvasive Electrocardiol</p>
<p>2017</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>e12420</p>
<p>.</p>
<p>190</p>
<p>Leyva</p>
<p>F</p>
<p>,</p>
<p>Zegard</p>
<p>A</p>
<p>,</p>
<p>Acquaye</p>
<p>E</p>
<p>,</p>
<p>Gubran</p>
<p>C</p>
<p>,</p>
<p>Taylor</p>
<p>R</p>
<p>,</p>
<p>Foley</p>
<p>PWX</p>
<p>,</p>
<p>Umar</p>
<p>F</p>
<p>,</p>
<p>Patel</p>
<p>K</p>
<p>,</p>
<p>Panting</p>
<p>J</p>
<p>,</p>
<p>Marshall</p>
<p>H</p>
<p>,</p>
<p>Qiu</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Outcomes of cardiac resynchronization therapy with or without
defibrillation in patients with nonischemic cardiomyopathy</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>70</p>
<p>:</p>
<p>1216</p>
<p>–</p>
<p>1227</p>
<p>.</p>
<p>191</p>
<p>Di Marco</p>
<p>A</p>
<p>,</p>
<p>Anguera</p>
<p>I</p>
<p>,</p>
<p>Schmitt</p>
<p>M</p>
<p>,</p>
<p>Klem</p>
<p>I</p>
<p>,</p>
<p>Neilan</p>
<p>TG</p>
<p>,</p>
<p>White</p>
<p>JA</p>
<p>,</p>
<p>Sramko</p>
<p>M</p>
<p>,</p>
<p>Masci</p>
<p>PG</p>
<p>,</p>
<p>Barison</p>
<p>A</p>
<p>,</p>
<p>McKenna</p>
<p>P</p>
<p>,</p>
<p>Mordi</p>
<p>I</p>
<p>,</p>
<p>Haugaa</p>
<p>KH</p>
<p>,</p>
<p>Leyva</p>
<p>F</p>
<p>,</p>
<p>Rodriguez Capitan</p>
<p>J</p>
<p>,</p>
<p>Satoh</p>
<p>H</p>
<p>,</p>
<p>Nabeta</p>
<p>T</p>
<p>,</p>
<p>Dallaglio</p>
<p>PD</p>
<p>,</p>
<p>Campbell</p>
<p>NG</p>
<p>,</p>
<p>Sabate</p>
<p>X</p>
<p>,</p>
<p>Cequier</p>
<ol type="A">
<li></li>
</ol>
<p>Late gadolinium enhancement and the risk for ventricular arrhythmias
or sudden death in dilated cardiomyopathy: systematic review and
meta-analysis</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>28</p>
<p>–</p>
<p>38</p>
<p>.</p>
<p>192</p>
<p>Gulati</p>
<p>A</p>
<p>,</p>
<p>Jabbour</p>
<p>A</p>
<p>,</p>
<p>Ismail</p>
<p>TF</p>
<p>,</p>
<p>Guha</p>
<p>K</p>
<p>,</p>
<p>Khwaja</p>
<p>J</p>
<p>,</p>
<p>Raza</p>
<p>S</p>
<p>,</p>
<p>Morarji</p>
<p>K</p>
<p>,</p>
<p>Brown</p>
<p>TD</p>
<p>,</p>
<p>Ismail</p>
<p>NA</p>
<p>,</p>
<p>Dweck</p>
<p>MR</p>
<p>,</p>
<p>Di Pietro</p>
<p>E</p>
<p>,</p>
<p>Roughton</p>
<p>M</p>
<p>,</p>
<p>Wage</p>
<p>R</p>
<p>,</p>
<p>Daryani</p>
<p>Y</p>
<p>,</p>
<p>O’Hanlon</p>
<p>R</p>
<p>,</p>
<p>Sheppard</p>
<p>MN</p>
<p>,</p>
<p>Alpendurada</p>
<p>F</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Cook</p>
<p>SA</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Assomull</p>
<p>RG</p>
<p>,</p>
<p>Pennell</p>
<p>DJ</p>
<p>,</p>
<p>Prasad</p>
<p>SK.</p>
<p>Association of fibrosis with mortality and sudden cardiac death in
patients with nonischemic dilated cardiomyopathy</p>
<p>.</p>
<p>JAMA</p>
<p>2013</p>
<p>;</p>
<p>309</p>
<p>:</p>
<p>896</p>
<p>–</p>
<p>908</p>
<p>.</p>
<p>193</p>
<p>Stewart</p>
<p>GC</p>
<p>,</p>
<p>Weintraub</p>
<p>JR</p>
<p>,</p>
<p>Pratibhu</p>
<p>PP</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>Camuso</p>
<p>JM</p>
<p>,</p>
<p>Brooks</p>
<p>K</p>
<p>,</p>
<p>Tsang</p>
<p>SW</p>
<p>,</p>
<p>Anello</p>
<p>MS</p>
<p>,</p>
<p>Nguyen</p>
<p>VT</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>Nohria</p>
<p>A</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Stevenson</p>
<p>LW.</p>
<p>Patient expectations from implantable defibrillators to prevent death
in heart failure</p>
<p>.</p>
<p>J Card Fail</p>
<p>2010</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>106</p>
<p>–</p>
<p>113</p>
<p>.</p>
<p>194</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Schuger</p>
<p>C</p>
<p>,</p>
<p>Beck</p>
<p>CA</p>
<p>,</p>
<p>Brown</p>
<p>MW</p>
<p>,</p>
<p>Cannom</p>
<p>DS</p>
<p>,</p>
<p>Daubert</p>
<p>JP</p>
<p>,</p>
<p>Estes</p>
<p>NA</p>
<p>3rd,</p>
<p>Greenberg</p>
<p>H</p>
<p>,</p>
<p>Hall</p>
<p>WJ</p>
<p>,</p>
<p>Huang</p>
<p>DT</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>Klein</p>
<p>H</p>
<p>,</p>
<p>McNitt</p>
<p>S</p>
<p>,</p>
<p>Olshansky</p>
<p>B</p>
<p>,</p>
<p>Shoda</p>
<p>M</p>
<p>,</p>
<p>Wilber</p>
<p>D</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>MADIT-RIT Trial Investigators</p>
<p>.</p>
<p>Reduction in inappropriate therapy and mortality through ICD
programming</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2012</p>
<p>;</p>
<p>367</p>
<p>:</p>
<p>2275</p>
<p>–</p>
<p>2283</p>
<p>.</p>
<p>195</p>
<p>Healey</p>
<p>JS</p>
<p>,</p>
<p>Hohnloser</p>
<p>SH</p>
<p>,</p>
<p>Glikson</p>
<p>M</p>
<p>,</p>
<p>Neuzner</p>
<p>J</p>
<p>,</p>
<p>Mabo</p>
<p>P</p>
<p>,</p>
<p>Vinolas</p>
<p>X</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>O’Hara</p>
<p>G</p>
<p>,</p>
<p>VanErven</p>
<p>L</p>
<p>,</p>
<p>Gadler</p>
<p>F</p>
<p>,</p>
<p>Pogue</p>
<p>J</p>
<p>,</p>
<p>Appl</p>
<p>U</p>
<p>,</p>
<p>Gilkerson</p>
<p>J</p>
<p>,</p>
<p>Pochet</p>
<p>T</p>
<p>,</p>
<p>Stein</p>
<p>KM</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Chrolavicius</p>
<p>S</p>
<p>,</p>
<p>Meeks</p>
<p>B</p>
<p>,</p>
<p>Foldesi</p>
<p>C</p>
<p>,</p>
<p>Thibault</p>
<p>B</p>
<p>,</p>
<p>Connolly</p>
<p>SJ</p>
<p>, Shockless</p>
<p>IMPLant Evaluation Investigators. Cardioverter defibrillator
implantation without induction of ventricular fibrillation: a
single-blind, non-inferiority, randomised controlled trial (SIMPLE)</p>
<p>.</p>
<p>Lancet</p>
<p>2015</p>
<p>;</p>
<p>385</p>
<p>:</p>
<p>785</p>
<p>–</p>
<p>791</p>
<p>.</p>
<p>196</p>
<p>Gasparini</p>
<p>M</p>
<p>,</p>
<p>Proclemer</p>
<p>A</p>
<p>,</p>
<p>Klersy</p>
<p>C</p>
<p>,</p>
<p>Kloppe</p>
<p>A</p>
<p>,</p>
<p>Lunati</p>
<p>M</p>
<p>,</p>
<p>Ferrer</p>
<p>JB</p>
<p>,</p>
<p>Hersi</p>
<p>A</p>
<p>,</p>
<p>Gulaj</p>
<p>M</p>
<p>,</p>
<p>Wijfels</p>
<p>MC</p>
<p>,</p>
<p>Santi</p>
<p>E</p>
<p>,</p>
<p>Manotta</p>
<p>L</p>
<p>,</p>
<p>Arenal</p>
<ol type="A">
<li></li>
</ol>
<p>Effect of long-detection interval vs standard-detection interval for
implantable cardioverter-defibrillators on antitachycardia pacing and
shock delivery: the ADVANCE III randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2013</p>
<p>;</p>
<p>309</p>
<p>:</p>
<p>1903</p>
<p>–</p>
<p>1911</p>
<p>.</p>
<p>197</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Buga</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Device therapy: defibrillators–a shocking therapy for
cardiomyopathy?</p>
<p>Nat Rev Cardiol</p>
<p>2010</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>69</p>
<p>–</p>
<p>70</p>
<p>.</p>
<p>198</p>
<p>Wilkoff</p>
<p>BL</p>
<p>,</p>
<p>Cook</p>
<p>JR</p>
<p>,</p>
<p>Epstein</p>
<p>AE</p>
<p>,</p>
<p>Greene</p>
<p>HL</p>
<p>,</p>
<p>Hallstrom</p>
<p>AP</p>
<p>,</p>
<p>Hsia</p>
<p>H</p>
<p>,</p>
<p>Kutalek</p>
<p>SP</p>
<p>,</p>
<p>Sharma</p>
<p>A</p>
<p>,</p>
<p>Dual Chamber and VVI Implantable Defibrillator Trial Investigators.
Dual-chamber pacing or ventricular backup pacing in patients with an
implantable defibrillator: the Dual Chamber and VVI Implantable
Defibrillator (DAVID) Trial</p>
<p>.</p>
<p>JAMA</p>
<p>2002</p>
<p>;</p>
<p>288</p>
<p>:</p>
<p>3115</p>
<p>–</p>
<p>3123</p>
<p>.</p>
<p>199</p>
<p>Boersma</p>
<p>L</p>
<p>,</p>
<p>Barr</p>
<p>C</p>
<p>,</p>
<p>Knops</p>
<p>R</p>
<p>,</p>
<p>Theuns</p>
<p>D</p>
<p>,</p>
<p>Eckardt</p>
<p>L</p>
<p>,</p>
<p>Neuzil</p>
<p>P</p>
<p>,</p>
<p>Scholten</p>
<p>M</p>
<p>,</p>
<p>Hood</p>
<p>M</p>
<p>,</p>
<p>Kuschyk</p>
<p>J</p>
<p>,</p>
<p>Jones</p>
<p>P</p>
<p>,</p>
<p>Duffy</p>
<p>E</p>
<p>,</p>
<p>Husby</p>
<p>M</p>
<p>,</p>
<p>Stein</p>
<p>K</p>
<p>,</p>
<p>Lambiase</p>
<p>PD</p>
<p>,</p>
<p>Group</p>
<p>EI.</p>
<p>Implant and midterm outcomes of the subcutaneous implantable
cardioverter-defibrillator registry: the EFFORTLESS study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>70</p>
<p>:</p>
<p>830</p>
<p>–</p>
<p>841</p>
<p>.</p>
<p>200</p>
<p>Burke</p>
<p>MC</p>
<p>,</p>
<p>Gold</p>
<p>MR</p>
<p>,</p>
<p>Knight</p>
<p>BP</p>
<p>,</p>
<p>Barr</p>
<p>CS</p>
<p>,</p>
<p>Theuns</p>
<p>D</p>
<p>,</p>
<p>Boersma</p>
<p>LVA</p>
<p>,</p>
<p>Knops</p>
<p>RE</p>
<p>,</p>
<p>Weiss</p>
<p>R</p>
<p>,</p>
<p>Leon</p>
<p>AR</p>
<p>,</p>
<p>Herre</p>
<p>JM</p>
<p>,</p>
<p>Husby</p>
<p>M</p>
<p>,</p>
<p>Stein</p>
<p>KM</p>
<p>,</p>
<p>Lambiase</p>
<p>PD.</p>
<p>Safety and efficacy of the totally subcutaneous implantable
defibrillator: 2-year results from a pooled analysis of the IDE study
and EFFORTLESS registry</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2015</p>
<p>;</p>
<p>65</p>
<p>:</p>
<p>1605</p>
<p>–</p>
<p>1615</p>
<p>.</p>
<p>201</p>
<p>Priori</p>
<p>SG</p>
<p>,</p>
<p>Blomstrom-Lundqvist</p>
<p>C</p>
<p>,</p>
<p>Mazzanti</p>
<p>A</p>
<p>,</p>
<p>Blom</p>
<p>N</p>
<p>,</p>
<p>Borggrefe</p>
<p>M</p>
<p>,</p>
<p>Camm</p>
<p>J</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Fitzsimons</p>
<p>D</p>
<p>,</p>
<p>Hatala</p>
<p>R</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>Kjeldsen</p>
<p>K</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Hernandez-Madrid</p>
<p>A</p>
<p>,</p>
<p>Nikolaou</p>
<p>N</p>
<p>,</p>
<p>Norekval</p>
<p>TM</p>
<p>,</p>
<p>Spaulding</p>
<p>C</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2015 ESC Guidelines for the management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death: The Task Force
for the Management of Patients with Ventricular Arrhythmias and the
Prevention of Sudden Cardiac Death of the European Society of Cardiology
(ESC). Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>2793</p>
<p>–</p>
<p>2867</p>
<p>.</p>
<p>202</p>
<p>Knops</p>
<p>RE</p>
<p>,</p>
<p>Olde Nordkamp</p>
<p>LRA</p>
<p>,</p>
<p>Delnoy</p>
<p>PHM</p>
<p>,</p>
<p>Boersma</p>
<p>LVA</p>
<p>,</p>
<p>Kuschyk</p>
<p>J</p>
<p>,</p>
<p>El-Chami</p>
<p>MF</p>
<p>,</p>
<p>Bonnemeier</p>
<p>H</p>
<p>,</p>
<p>Behr</p>
<p>ER</p>
<p>,</p>
<p>Brouwer</p>
<p>TF</p>
<p>,</p>
<p>Kaab</p>
<p>S</p>
<p>,</p>
<p>Mittal</p>
<p>S</p>
<p>,</p>
<p>Quast</p>
<p>ABE</p>
<p>,</p>
<p>Smeding</p>
<p>L</p>
<p>,</p>
<p>van der Stuijt</p>
<p>W</p>
<p>,</p>
<p>de Weger</p>
<p>A</p>
<p>,</p>
<p>de Wilde</p>
<p>KC</p>
<p>,</p>
<p>Bijsterveld</p>
<p>NR</p>
<p>,</p>
<p>Richter</p>
<p>S</p>
<p>,</p>
<p>Brouwer</p>
<p>MA</p>
<p>,</p>
<p>de Groot</p>
<p>JR</p>
<p>,</p>
<p>Kooiman</p>
<p>KM</p>
<p>,</p>
<p>Lambiase</p>
<p>PD</p>
<p>,</p>
<p>Neuzil</p>
<p>P</p>
<p>,</p>
<p>Vernooy</p>
<p>K</p>
<p>,</p>
<p>Alings</p>
<p>M</p>
<p>,</p>
<p>Betts</p>
<p>TR</p>
<p>,</p>
<p>Bracke</p>
<p>F</p>
<p>,</p>
<p>Burke</p>
<p>MC</p>
<p>,</p>
<p>de Jong</p>
<p>J</p>
<p>,</p>
<p>Wright</p>
<p>DJ</p>
<p>,</p>
<p>Tijssen</p>
<p>JGP</p>
<p>,</p>
<p>Wilde</p>
<p>AAM</p>
<p>,</p>
<p>PRAETORIAN Investigators</p>
<p>.</p>
<p>Subcutaneous or transvenous defibrillator therapy</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>526</p>
<p>–</p>
<p>536</p>
<p>.</p>
<p>203</p>
<p>Duncker</p>
<p>D</p>
<p>,</p>
<p>Konig</p>
<p>T</p>
<p>,</p>
<p>Hohmann</p>
<p>S</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Veltmann</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Avoiding untimely implantable cardioverter/defibrillator implantation
by intensified heart failure therapy optimization supported by the
wearable cardioverter/defibrillator–the PROLONG Study</p>
<p>.</p>
<p>J Am Heart Assoc</p>
<p>2017</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>e004512</p>
<p>.</p>
<p>204</p>
<p>Olgin</p>
<p>JE</p>
<p>,</p>
<p>Pletcher</p>
<p>MJ</p>
<p>,</p>
<p>Vittinghoff</p>
<p>E</p>
<p>,</p>
<p>Wranicz</p>
<p>J</p>
<p>,</p>
<p>Malik</p>
<p>R</p>
<p>,</p>
<p>Morin</p>
<p>DP</p>
<p>,</p>
<p>Zweibel</p>
<p>S</p>
<p>,</p>
<p>Buxton</p>
<p>AE</p>
<p>,</p>
<p>Elayi</p>
<p>CS</p>
<p>,</p>
<p>Chung</p>
<p>EH</p>
<p>,</p>
<p>Rashba</p>
<p>E</p>
<p>,</p>
<p>Borggrefe</p>
<p>M</p>
<p>,</p>
<p>Hue</p>
<p>TF</p>
<p>,</p>
<p>Maguire</p>
<p>C</p>
<p>,</p>
<p>Lin</p>
<p>F</p>
<p>,</p>
<p>Simon</p>
<p>JA</p>
<p>,</p>
<p>Hulley</p>
<p>S</p>
<p>,</p>
<p>Lee</p>
<p>BK</p>
<p>,</p>
<p>VEST Investigators</p>
<p>.</p>
<p>Wearable cardioverter-defibrillator after myocardial infarction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>379</p>
<p>:</p>
<p>1205</p>
<p>–</p>
<p>1215</p>
<p>.</p>
<p>205</p>
<p>Cazeau</p>
<p>S</p>
<p>,</p>
<p>Leclercq</p>
<p>C</p>
<p>,</p>
<p>Lavergne</p>
<p>T</p>
<p>,</p>
<p>Walker</p>
<p>S</p>
<p>,</p>
<p>Varma</p>
<p>C</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Garrigue</p>
<p>S</p>
<p>,</p>
<p>Kappenberger</p>
<p>L</p>
<p>,</p>
<p>Haywood</p>
<p>GA</p>
<p>,</p>
<p>Santini</p>
<p>M</p>
<p>,</p>
<p>Bailleul</p>
<p>C</p>
<p>,</p>
<p>Daubert</p>
<p>JC</p>
<p>,</p>
<p>Multisite Stimulation in Cardiomyopathies (MUSTIC) Study
Investigators. Effects of multisite biventricular pacing in patients
with heart failure and intraventricular conduction delay</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2001</p>
<p>;</p>
<p>344</p>
<p>:</p>
<p>873</p>
<p>–</p>
<p>880</p>
<p>.</p>
<p>206</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Daubert</p>
<p>JC</p>
<p>,</p>
<p>Erdmann</p>
<p>E</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Gras</p>
<p>D</p>
<p>,</p>
<p>Kappenberger</p>
<p>L</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Cardiac Resynchronization-Heart Failure (CARE-HF) Study
Investigators. The effect of cardiac resynchronization on morbidity and
mortality in heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2005</p>
<p>;</p>
<p>352</p>
<p>:</p>
<p>1539</p>
<p>–</p>
<p>1549</p>
<p>.</p>
<p>207</p>
<p>Daubert</p>
<p>C</p>
<p>,</p>
<p>Gold</p>
<p>MR</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Ghio</p>
<p>S</p>
<p>,</p>
<p>Hassager</p>
<p>C</p>
<p>,</p>
<p>Goode</p>
<p>G</p>
<p>,</p>
<p>Szili-Torok</p>
<p>T</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>REVERSE</p>
<p>Study Group</p>
<p>.</p>
<p>Prevention of disease progression by cardiac resynchronization
therapy in patients with asymptomatic or mildly symptomatic left
ventricular dysfunction: insights from the European cohort of the
REVERSE (Resynchronization Reverses Remodeling in Systolic Left
Ventricular Dysfunction) trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>54</p>
<p>:</p>
<p>1837</p>
<p>–</p>
<p>1846</p>
<p>.</p>
<p>208</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Daubert</p>
<p>JC</p>
<p>,</p>
<p>Erdmann</p>
<p>E</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Gras</p>
<p>D</p>
<p>,</p>
<p>Kappenberger</p>
<p>L</p>
<p>,</p>
<p>Tavazzi</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Longer-term effects of cardiac resynchronization therapy on mortality
in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF)
trial extension phase]</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2006</p>
<p>;</p>
<p>27</p>
<p>:</p>
<p>1928</p>
<p>–</p>
<p>1932</p>
<p>.</p>
<p>209</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Erdmann</p>
<p>E</p>
<p>,</p>
<p>Gras</p>
<p>D</p>
<p>,</p>
<p>Kappenberger</p>
<p>L</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Daubert</p>
<p>JC.</p>
<p>Long-term mortality with cardiac resynchronization therapy in the
Cardiac Resynchronization-Heart Failure (CARE-HF) trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2012</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>628</p>
<p>–</p>
<p>634</p>
<p>.</p>
<p>210</p>
<p>Bristow</p>
<p>MR</p>
<p>,</p>
<p>Saxon</p>
<p>LA</p>
<p>,</p>
<p>Boehmer</p>
<p>J</p>
<p>,</p>
<p>Krueger</p>
<p>S</p>
<p>,</p>
<p>Kass</p>
<p>DA</p>
<p>,</p>
<p>De Marco</p>
<p>T</p>
<p>,</p>
<p>Carson</p>
<p>P</p>
<p>,</p>
<p>DiCarlo</p>
<p>L</p>
<p>,</p>
<p>DeMets</p>
<p>D</p>
<p>,</p>
<p>White</p>
<p>BG</p>
<p>,</p>
<p>DeVries</p>
<p>DW</p>
<p>,</p>
<p>Feldman</p>
<p>AM</p>
<p>,</p>
<p>Comparison of Medical Therapy Pacing and Defibrillation in Heart
Failure (COMPANION) Investigators. Cardiac-resynchronization therapy
with or without an implantable defibrillator in advanced chronic heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2004</p>
<p>;</p>
<p>350</p>
<p>:</p>
<p>2140</p>
<p>–</p>
<p>2150</p>
<p>.</p>
<p>211</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Gold</p>
<p>MR</p>
<p>,</p>
<p>Young</p>
<p>JB</p>
<p>,</p>
<p>Claude Daubert</p>
<p>J</p>
<p>,</p>
<p>Sherfesee</p>
<p>L</p>
<p>,</p>
<p>Wells</p>
<p>GA</p>
<p>,</p>
<p>Tang</p>
<p>AS.</p>
<p>An individual patient meta-analysis of five randomized trials
assessing the effects of cardiac resynchronization therapy on morbidity
and mortality in patients with symptomatic heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>3547</p>
<p>–</p>
<p>3556</p>
<p>.</p>
<p>212</p>
<p>Tang</p>
<p>AS</p>
<p>,</p>
<p>Wells</p>
<p>GA</p>
<p>,</p>
<p>Talajic</p>
<p>M</p>
<p>,</p>
<p>Arnold</p>
<p>MO</p>
<p>,</p>
<p>Sheldon</p>
<p>R</p>
<p>,</p>
<p>Connolly</p>
<p>S</p>
<p>,</p>
<p>Hohnloser</p>
<p>SH</p>
<p>,</p>
<p>Nichol</p>
<p>G</p>
<p>,</p>
<p>Birnie</p>
<p>DH</p>
<p>,</p>
<p>Sapp</p>
<p>JL</p>
<p>,</p>
<p>Yee</p>
<p>R</p>
<p>,</p>
<p>Healey</p>
<p>JS</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Resynchronization-Defibrillation for Ambulatory Heart Failure Trial
Investigators. Cardiac-resynchronization therapy for mild-to-moderate
heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2010</p>
<p>;</p>
<p>363</p>
<p>:</p>
<p>2385</p>
<p>–</p>
<p>2395</p>
<p>.</p>
<p>213</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Hall</p>
<p>WJ</p>
<p>,</p>
<p>Cannom</p>
<p>DS</p>
<p>,</p>
<p>Klein</p>
<p>H</p>
<p>,</p>
<p>Brown</p>
<p>MW</p>
<p>,</p>
<p>Daubert</p>
<p>JP</p>
<p>,</p>
<p>Estes</p>
<p>NA</p>
<p>3rd,</p>
<p>Foster</p>
<p>E</p>
<p>,</p>
<p>Greenberg</p>
<p>H</p>
<p>,</p>
<p>Higgins</p>
<p>SL</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Wilber</p>
<p>D</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>MADIT-CRT Trial Investigators</p>
<p>.</p>
<p>Cardiac-resynchronization therapy for the prevention of heart-failure
events</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2009</p>
<p>;</p>
<p>361</p>
<p>:</p>
<p>1329</p>
<p>–</p>
<p>1338</p>
<p>.</p>
<p>214</p>
<p>Goldenberg</p>
<p>I</p>
<p>,</p>
<p>Kutyifa</p>
<p>V</p>
<p>,</p>
<p>Klein</p>
<p>HU</p>
<p>,</p>
<p>Cannom</p>
<p>DS</p>
<p>,</p>
<p>Brown</p>
<p>MW</p>
<p>,</p>
<p>Dan</p>
<p>A</p>
<p>,</p>
<p>Daubert</p>
<p>JP</p>
<p>,</p>
<p>Estes</p>
<p>NA</p>
<p>3rd,</p>
<p>Foster</p>
<p>E</p>
<p>,</p>
<p>Greenberg</p>
<p>H</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>Klempfner</p>
<p>R</p>
<p>,</p>
<p>Kuniss</p>
<p>M</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Quesada</p>
<p>A</p>
<p>,</p>
<p>Viskin</p>
<p>S</p>
<p>,</p>
<p>McNitt</p>
<p>S</p>
<p>,</p>
<p>Polonsky</p>
<p>B</p>
<p>,</p>
<p>Ghanem</p>
<p>A</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Wilber</p>
<p>D</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Moss</p>
<p>AJ.</p>
<p>Survival with cardiac-resynchronization therapy in mild heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2014</p>
<p>;</p>
<p>370</p>
<p>:</p>
<p>1694</p>
<p>–</p>
<p>1701</p>
<p>.</p>
<p>215</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Gold</p>
<p>MR</p>
<p>,</p>
<p>St John Sutton</p>
<p>M</p>
<p>,</p>
<p>Ghio</p>
<p>S</p>
<p>,</p>
<p>Daubert</p>
<p>C</p>
<p>REVERSE (REsynchronization reVErses Remodeling in Systolic left
vEntricular dysfunction) Study Group</p>
<p>.</p>
<p>Randomized trial of cardiac resynchronization in mildly symptomatic
heart failure patients and in asymptomatic patients with left
ventricular dysfunction and previous heart failure symptoms</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2008</p>
<p>;</p>
<p>52</p>
<p>:</p>
<p>1834</p>
<p>–</p>
<p>1843</p>
<p>.</p>
<p>216</p>
<p>Curtis</p>
<p>AB</p>
<p>,</p>
<p>Worley</p>
<p>SJ</p>
<p>,</p>
<p>Adamson</p>
<p>PB</p>
<p>,</p>
<p>Chung</p>
<p>ES</p>
<p>,</p>
<p>Niazi</p>
<p>I</p>
<p>,</p>
<p>Sherfesee</p>
<p>L</p>
<p>,</p>
<p>Shinn</p>
<p>T</p>
<p>,</p>
<p>Sutton</p>
<p>MS</p>
<p>,</p>
<p>Biventricular versus Right Ventricular Pacing in Heart Failure
Patients with Atrioventricular Block (BLOCK AF) Trial Investigators</p>
<p>.</p>
<p>Biventricular pacing for atrioventricular block and systolic
dysfunction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2013</p>
<p>;</p>
<p>368</p>
<p>:</p>
<p>1585</p>
<p>–</p>
<p>1593</p>
<p>.</p>
<p>217</p>
<p>Brignole</p>
<p>M</p>
<p>,</p>
<p>Botto</p>
<p>G</p>
<p>,</p>
<p>Mont</p>
<p>L</p>
<p>,</p>
<p>Iacopino</p>
<p>S</p>
<p>,</p>
<p>De Marchi</p>
<p>G</p>
<p>,</p>
<p>Oddone</p>
<p>D</p>
<p>,</p>
<p>Luzi</p>
<p>M</p>
<p>,</p>
<p>Tolosana</p>
<p>JM</p>
<p>,</p>
<p>Navazio</p>
<p>A</p>
<p>,</p>
<p>Menozzi</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Cardiac resynchronization therapy in patients undergoing
atrioventricular junction ablation for permanent atrial fibrillation: a
randomized trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2011</p>
<p>;</p>
<p>32</p>
<p>:</p>
<p>2420</p>
<p>–</p>
<p>2429</p>
<p>.</p>
<p>218</p>
<p>Stavrakis</p>
<p>S</p>
<p>,</p>
<p>Garabelli</p>
<p>P</p>
<p>,</p>
<p>Reynolds</p>
<p>DW.</p>
<p>Cardiac resynchronization therapy after atrioventricular junction
ablation for symptomatic atrial fibrillation: a meta-analysis</p>
<p>.</p>
<p>Europace</p>
<p>2012</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>1490</p>
<p>–</p>
<p>1497</p>
<p>.</p>
<p>219</p>
<p>Leclercq</p>
<p>C</p>
<p>,</p>
<p>Walker</p>
<p>S</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Clementy</p>
<p>J</p>
<p>,</p>
<p>Marshall</p>
<p>AJ</p>
<p>,</p>
<p>Ritter</p>
<p>P</p>
<p>,</p>
<p>Djiane</p>
<p>P</p>
<p>,</p>
<p>Mabo</p>
<p>P</p>
<p>,</p>
<p>Levy</p>
<p>T</p>
<p>,</p>
<p>Gadler</p>
<p>F</p>
<p>,</p>
<p>Bailleul</p>
<p>C</p>
<p>,</p>
<p>Daubert</p>
<p>JC.</p>
<p>Comparative effects of permanent biventricular and
right-univentricular pacing in heart failure patients with chronic
atrial fibrillation</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2002</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>1780</p>
<p>–</p>
<p>1787</p>
<p>.</p>
<p>220</p>
<p>Woods</p>
<p>B</p>
<p>,</p>
<p>Hawkins</p>
<p>N</p>
<p>,</p>
<p>Mealing</p>
<p>S</p>
<p>,</p>
<p>Sutton</p>
<p>A</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Beshai</p>
<p>JF</p>
<p>,</p>
<p>Klein</p>
<p>H</p>
<p>,</p>
<p>Sculpher</p>
<p>M</p>
<p>,</p>
<p>Plummer</p>
<p>CJ</p>
<p>,</p>
<p>Cowie</p>
<p>MR.</p>
<p>Individual patient data network meta-analysis of mortality effects of
implantable cardiac devices</p>
<p>.</p>
<p>Heart</p>
<p>2015</p>
<p>;</p>
<p>101</p>
<p>:</p>
<p>1800</p>
<p>–</p>
<p>1806</p>
<p>.</p>
<p>221</p>
<p>Gage</p>
<p>RM</p>
<p>,</p>
<p>Burns</p>
<p>KV</p>
<p>,</p>
<p>Bank</p>
<p>AJ.</p>
<p>Echocardiographic and clinical response to cardiac resynchronization
therapy in heart failure patients with and without previous right
ventricular pacing</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>1199</p>
<p>–</p>
<p>1205</p>
<p>.</p>
<p>222</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Singh</p>
<p>JP</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Borer</p>
<p>JS</p>
<p>,</p>
<p>Brugada</p>
<p>J</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Gorcsan</p>
<p>J</p>
<p>3rd,</p>
<p>Gras</p>
<p>D</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Sogaard</p>
<p>P</p>
<p>,</p>
<p>Holzmeister</p>
<p>J</p>
<p>,</p>
<p>EchoCRT Study Group</p>
<p>.</p>
<p>Cardiac-resynchronization therapy in heart failure with a narrow QRS
complex</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2013</p>
<p>;</p>
<p>369</p>
<p>:</p>
<p>1395</p>
<p>–</p>
<p>1405</p>
<p>.</p>
<p>223</p>
<p>Steffel</p>
<p>J</p>
<p>,</p>
<p>Robertson</p>
<p>M</p>
<p>,</p>
<p>Singh</p>
<p>JP</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Borer</p>
<p>JS</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Gorcsan</p>
<p>J</p>
<p>3rd,</p>
<p>Gras</p>
<p>D</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Sogaard</p>
<p>P</p>
<p>,</p>
<p>Holzmeister</p>
<p>J</p>
<p>,</p>
<p>Brugada</p>
<p>J</p>
<p>,</p>
<p>Ruschitzka</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>The effect of QRS duration on cardiac resynchronization therapy in
patients with a narrow QRS complex: a subgroup analysis of the EchoCRT
trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1983</p>
<p>–</p>
<p>1989</p>
<p>.</p>
<p>224</p>
<p>Zusterzeel</p>
<p>R</p>
<p>,</p>
<p>Selzman</p>
<p>KA</p>
<p>,</p>
<p>Sanders</p>
<p>WE</p>
<p>,</p>
<p>Canos</p>
<p>DA</p>
<p>,</p>
<p>O’Callaghan</p>
<p>KM</p>
<p>,</p>
<p>Carpenter</p>
<p>JL</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>Strauss</p>
<p>DG.</p>
<p>Cardiac resynchronization therapy in women: US Food and Drug
Administration meta-analysis of patient-level data</p>
<p>.</p>
<p>JAMA Intern Med</p>
<p>2014</p>
<p>;</p>
<p>174</p>
<p>:</p>
<p>1340</p>
<p>–</p>
<p>1348</p>
<p>.</p>
<p>225</p>
<p>Sohaib</p>
<p>SM</p>
<p>,</p>
<p>Finegold</p>
<p>JA</p>
<p>,</p>
<p>Nijjer</p>
<p>SS</p>
<p>,</p>
<p>Hossain</p>
<p>R</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Levy</p>
<p>WC</p>
<p>,</p>
<p>Sutton</p>
<p>R</p>
<p>,</p>
<p>Kanagaratnam</p>
<p>P</p>
<p>,</p>
<p>Francis</p>
<p>DP</p>
<p>,</p>
<p>Whinnett</p>
<p>ZI.</p>
<p>Opportunity to increase life span in narrow QRS cardiac
resynchronization therapy recipients by deactivating ventricular pacing:
evidence from randomized controlled trials</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>327</p>
<p>–</p>
<p>336</p>
<p>.</p>
<p>226</p>
<p>Greenberg</p>
<p>H</p>
<p>,</p>
<p>Case</p>
<p>RB</p>
<p>,</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>Brown</p>
<p>MW</p>
<p>,</p>
<p>Carroll</p>
<p>ER</p>
<p>,</p>
<p>Andrews</p>
<p>ML</p>
<p>MADIT-II Investigators</p>
<p>.</p>
<p>Analysis of mortality events in the Multicenter Automatic
Defibrillator Implantation Trial (MADIT-II)</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2004</p>
<p>;</p>
<p>43</p>
<p>:</p>
<p>1459</p>
<p>–</p>
<p>1465</p>
<p>.</p>
<p>227</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Gold</p>
<p>MR</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>St John Sutton</p>
<p>M</p>
<p>,</p>
<p>Ghio</p>
<p>S</p>
<p>,</p>
<p>Cerkvenik</p>
<p>J</p>
<p>,</p>
<p>Daubert</p>
<p>C</p>
<p>,</p>
<p>REsynchronization reVErses Remodeling in Systolic left vEntricular
dysfunction Study Group</p>
<p>.</p>
<p>Long-term impact of cardiac resynchronization therapy in mild heart
failure: 5-year results from the REsynchronization reVErses Remodeling
in Systolic left vEntricular dysfunction (REVERSE) study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>2592</p>
<p>–</p>
<p>2599</p>
<p>.</p>
<p>228</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Mareev</p>
<p>Y</p>
<p>,</p>
<p>Linde</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Reflections on EchoCRT: sound guidance on QRS duration and morphology
for CRT?</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1948</p>
<p>–</p>
<p>1951</p>
<p>.</p>
<p>229</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Stahlberg</p>
<p>M</p>
<p>,</p>
<p>Benson</p>
<p>L</p>
<p>,</p>
<p>Braunschweig</p>
<p>F</p>
<p>,</p>
<p>Edner</p>
<p>M</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Alehagen</p>
<p>U</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Gender, underutilization of cardiac resynchronization therapy, and
prognostic impact of QRS prolongation and left bundle branch block in
heart failure</p>
<p>.</p>
<p>Europace</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>424</p>
<p>–</p>
<p>431</p>
<p>.</p>
<p>230</p>
<p>Cunnington</p>
<p>C</p>
<p>,</p>
<p>Kwok</p>
<p>CS</p>
<p>,</p>
<p>Satchithananda</p>
<p>DK</p>
<p>,</p>
<p>Patwala</p>
<p>A</p>
<p>,</p>
<p>Khan</p>
<p>MA</p>
<p>,</p>
<p>Zaidi</p>
<p>A</p>
<p>,</p>
<p>Ahmed</p>
<p>FZ</p>
<p>,</p>
<p>Mamas</p>
<p>MA.</p>
<p>Cardiac resynchronisation therapy is not associated with a reduction
in mortality or heart failure hospitalisation in patients with non-left
bundle branch block QRS morphology: meta-analysis of randomised
controlled trials</p>
<p>.</p>
<p>Heart</p>
<p>2015</p>
<p>;</p>
<p>101</p>
<p>:</p>
<p>1456</p>
<p>–</p>
<p>1462</p>
<p>.</p>
<p>231</p>
<p>Doshi</p>
<p>RN</p>
<p>,</p>
<p>Daoud</p>
<p>EG</p>
<p>,</p>
<p>Fellows</p>
<p>C</p>
<p>,</p>
<p>Turk</p>
<p>K</p>
<p>,</p>
<p>Duran</p>
<p>A</p>
<p>,</p>
<p>Hamdan</p>
<p>MH</p>
<p>,</p>
<p>Pires</p>
<p>LA</p>
<p>PAVE Study Group</p>
<p>.</p>
<p>Left ventricular-based cardiac stimulation post AV nodal ablation
evaluation (the PAVE study)</p>
<p>.</p>
<p>J Cardiovasc Electrophysiol</p>
<p>2005</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>1160</p>
<p>–</p>
<p>1165</p>
<p>.</p>
<p>232</p>
<p>Koplan</p>
<p>BA</p>
<p>,</p>
<p>Kaplan</p>
<p>AJ</p>
<p>,</p>
<p>Weiner</p>
<p>S</p>
<p>,</p>
<p>Jones</p>
<p>PW</p>
<p>,</p>
<p>Seth</p>
<p>M</p>
<p>,</p>
<p>Christman</p>
<p>SA.</p>
<dl>
<dt>Heart failure decompensation and all-cause mortality in relation to
percent biventricular pacing in patients with heart failure</dt>
<dd>
<p>is a goal</p>
</dd>
</dl>
<p>of 100% biventricular pacing necessary? J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>355</p>
<p>–</p>
<p>360</p>
<p>.</p>
<p>233</p>
<p>Hawkins</p>
<p>NM</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Burgess</p>
<p>MI</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Selecting patients for cardiac resynchronization therapy: the fallacy
of echocardiographic dyssynchrony</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>1944</p>
<p>–</p>
<p>1959</p>
<p>.</p>
<p>234</p>
<p>Beela</p>
<p>AS</p>
<p>,</p>
<p>Unlu</p>
<p>S</p>
<p>,</p>
<p>Duchenne</p>
<p>J</p>
<p>,</p>
<p>Ciarka</p>
<p>A</p>
<p>,</p>
<p>Daraban</p>
<p>AM</p>
<p>,</p>
<p>Kotrc</p>
<p>M</p>
<p>,</p>
<p>Aarones</p>
<p>M</p>
<p>,</p>
<p>Szulik</p>
<p>M</p>
<p>,</p>
<p>Winter</p>
<p>S</p>
<p>,</p>
<p>Penicka</p>
<p>M</p>
<p>,</p>
<p>Neskovic</p>
<p>AN</p>
<p>,</p>
<p>Kukulski</p>
<p>T</p>
<p>,</p>
<p>Aakhus</p>
<p>S</p>
<p>,</p>
<p>Willems</p>
<p>R</p>
<p>,</p>
<p>Fehske</p>
<p>W</p>
<p>,</p>
<p>Faber</p>
<p>L</p>
<p>,</p>
<p>Stankovic</p>
<p>I</p>
<p>,</p>
<p>Voigt</p>
<p>JU.</p>
<p>Assessment of mechanical dyssynchrony can improve the prognostic
value of guideline-based patient selection for cardiac resynchronization
therapy</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Imaging</p>
<p>2019</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>66</p>
<p>–</p>
<p>74</p>
<p>.</p>
<p>235</p>
<p>Khan</p>
<p>FZ</p>
<p>,</p>
<p>Virdee</p>
<p>MS</p>
<p>,</p>
<p>Palmer</p>
<p>CR</p>
<p>,</p>
<p>Pugh</p>
<p>PJ</p>
<p>,</p>
<p>O’Halloran</p>
<p>D</p>
<p>,</p>
<p>Elsik</p>
<p>M</p>
<p>,</p>
<p>Read</p>
<p>PA</p>
<p>,</p>
<p>Begley</p>
<p>D</p>
<p>,</p>
<p>Fynn</p>
<p>SP</p>
<p>,</p>
<p>Dutka</p>
<p>DP.</p>
<p>Targeted left ventricular lead placement to guide cardiac
resynchronization therapy: the TARGET study: a randomized, controlled
trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2012</p>
<p>;</p>
<p>59</p>
<p>:</p>
<p>1509</p>
<p>–</p>
<p>1518</p>
<p>.</p>
<p>236</p>
<p>Saba</p>
<p>S</p>
<p>,</p>
<p>Marek</p>
<p>J</p>
<p>,</p>
<p>Schwartzman</p>
<p>D</p>
<p>,</p>
<p>Jain</p>
<p>S</p>
<p>,</p>
<p>Adelstein</p>
<p>E</p>
<p>,</p>
<p>White</p>
<p>P</p>
<p>,</p>
<p>Oyenuga</p>
<p>OA</p>
<p>,</p>
<p>Onishi</p>
<p>T</p>
<p>,</p>
<p>Soman</p>
<p>P</p>
<p>,</p>
<p>Gorcsan</p>
<p>J</p>
<p>3rd</p>
<p>Echocardiography-guided left ventricular lead placement for cardiac
resynchronization therapy: results of the Speckle Tracking Assisted
Resynchronization Therapy for Electrode Region trial</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>427</p>
<p>–</p>
<p>434</p>
<p>.</p>
<p>237</p>
<p>Kosmala</p>
<p>W</p>
<p>,</p>
<p>Marwick</p>
<p>TH.</p>
<p>Meta-analysis of effects of optimization of cardiac resynchronization
therapy on left ventricular function, exercise capacity, and quality of
life in patients with heart failure</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2014</p>
<p>;</p>
<p>113</p>
<p>:</p>
<p>988</p>
<p>–</p>
<p>994</p>
<p>.</p>
<p>238</p>
<p>Whinnett</p>
<p>ZI</p>
<p>,</p>
<p>Francis</p>
<p>DP</p>
<p>,</p>
<p>Denis</p>
<p>A</p>
<p>,</p>
<p>Willson</p>
<p>K</p>
<p>,</p>
<p>Pascale</p>
<p>P</p>
<p>,</p>
<p>van Geldorp</p>
<p>I</p>
<p>,</p>
<p>De Guillebon</p>
<p>M</p>
<p>,</p>
<p>Ploux</p>
<p>S</p>
<p>,</p>
<p>Ellenbogen</p>
<p>K</p>
<p>,</p>
<p>Haissaguerre</p>
<p>M</p>
<p>,</p>
<p>Ritter</p>
<p>P</p>
<p>,</p>
<p>Bordachar</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Comparison of different invasive hemodynamic methods for AV delay
optimization in patients with cardiac resynchronization therapy:
implications for clinical trial design and clinical practice</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2013</p>
<p>;</p>
<p>168</p>
<p>:</p>
<p>2228</p>
<p>–</p>
<p>2237</p>
<p>.</p>
<p>239</p>
<p>Daubert</p>
<p>C</p>
<p>,</p>
<p>Behar</p>
<p>N</p>
<p>,</p>
<p>Martins</p>
<p>RP</p>
<p>,</p>
<p>Mabo</p>
<p>P</p>
<p>,</p>
<p>Leclercq</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Avoiding non-responders to cardiac resynchronization therapy: a
practical guide</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>1463</p>
<p>–</p>
<p>1472</p>
<p>.</p>
<p>240</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Auricchio</p>
<p>A</p>
<p>,</p>
<p>Martens</p>
<p>P</p>
<p>,</p>
<p>Witte</p>
<p>K</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Delgado</p>
<p>V</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Vernooy</p>
<p>K</p>
<p>,</p>
<p>Leyva</p>
<p>F</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Israel</p>
<p>CW</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Boriani</p>
<p>G</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Berruezo</p>
<p>A</p>
<p>,</p>
<p>Traykov</p>
<p>V</p>
<p>,</p>
<p>Yousef</p>
<p>Z</p>
<p>,</p>
<p>Kalarus</p>
<p>Z</p>
<p>,</p>
<p>Cosedis Nielsen</p>
<p>J</p>
<p>,</p>
<p>Steffel</p>
<p>J</p>
<p>,</p>
<p>Vardas</p>
<p>P</p>
<p>,</p>
<p>Coats</p>
<p>A</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Heidbuchel</p>
<p>H</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Leclercq</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Optimized implementation of cardiac resynchronization therapy: a call
for action for referral and optimization of care: a joint position
statement from the Heart Failure Association (HFA), European Heart
Rhythm Association (EHRA), and European Association of Cardiovascular
Imaging (EACVI) of the European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2349</p>
<p>–</p>
<p>2369</p>
<p>.</p>
<p>240a</p>
<p>Glikson M, Nielsen JC, Michowitz Y, Kronborg MB, Auricchio A, Barbash
IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats
AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE,
Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM; ESC
Scientific Document Group.</p>
<p>2021 ESC Guidelines on cardiac pacing and cardiac resynchronization
therapy.</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>; doi: 10.1093/eurheartj/ehab364 [Epub ahead of print].</p>
<p>241</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Goldsmith</p>
<p>RL</p>
<p>,</p>
<p>Lindenfeld</p>
<p>J</p>
<p>,</p>
<p>Reddy</p>
<p>VY</p>
<p>,</p>
<p>Carson</p>
<p>PE</p>
<p>,</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>Saville</p>
<p>B</p>
<p>,</p>
<p>Parise</p>
<p>H</p>
<p>,</p>
<p>Chan</p>
<p>R</p>
<p>,</p>
<p>Wiegn</p>
<p>P</p>
<p>,</p>
<p>Hastings</p>
<p>JL</p>
<p>,</p>
<p>Kaplan</p>
<p>AJ</p>
<p>,</p>
<p>Edelmann</p>
<p>F</p>
<p>,</p>
<p>Luthje</p>
<p>L</p>
<p>,</p>
<p>Kahwash</p>
<p>R</p>
<p>,</p>
<p>Tomassoni</p>
<p>GF</p>
<p>,</p>
<p>Gutterman</p>
<p>DD</p>
<p>,</p>
<p>Stagg</p>
<p>A</p>
<p>,</p>
<p>Burkhoff</p>
<p>D</p>
<p>,</p>
<p>Hasenfuss</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>A randomized controlled trial to evaluate the safety and efficacy of
cardiac contractility modulation</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>874</p>
<p>–</p>
<p>883</p>
<p>.</p>
<p>242</p>
<p>NICE: National Institute for Health and Care Excellence</p>
<p>.</p>
<p>Interventional procedures guidance. Cardiac contractility modulation
device implantation for heart failure</p>
<p>. <a
href="http://www.nice.org.uk/guidance/ipg655">www.nice.org.uk/guidance/ipg655</a>
(</p>
<p>28 May 2021</p>
<p>).</p>
<p>243</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Weaver</p>
<p>FA</p>
<p>,</p>
<p>Butter</p>
<p>C</p>
<p>,</p>
<p>Ducharme</p>
<p>A</p>
<p>,</p>
<p>Halbach</p>
<p>M</p>
<p>,</p>
<p>Klug</p>
<p>D</p>
<p>,</p>
<p>Lovett</p>
<p>EG</p>
<p>,</p>
<p>Muller-Ehmsen</p>
<p>J</p>
<p>,</p>
<p>Schafer</p>
<p>JE</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Swarup</p>
<p>V</p>
<p>,</p>
<p>Wachter</p>
<p>R</p>
<p>,</p>
<p>Little</p>
<p>WC.</p>
<p>Baroreflex activation therapy for the treatment of heart failure with
a reduced ejection fraction</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>487</p>
<p>–</p>
<p>496</p>
<p>.</p>
<p>244</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Lindenfeld</p>
<p>J</p>
<p>,</p>
<p>Weaver</p>
<p>FA</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Galle</p>
<p>E</p>
<p>,</p>
<p>Rogers</p>
<p>T</p>
<p>,</p>
<p>Abraham</p>
<p>WT.</p>
<p>Baroreflex activation therapy in patients with heart failure with
reduced ejection fraction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2020</p>
<p>;</p>
<p>76</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>13</p>
<p>.</p>
<p>245</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Held</p>
<p>P</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Michelson</p>
<p>EL</p>
<p>,</p>
<p>Olofsson</p>
<p>B</p>
<p>,</p>
<p>Ostergren</p>
<p>J</p>
<p>, CHARM Investigators and Committees</p>
<p>Effects of candesartan in patients with chronic heart failure and
preserved left-ventricular ejection fraction: the CHARM-Preserved
trial</p>
<p>.</p>
<p>Lancet</p>
<p>2003</p>
<p>;</p>
<p>362</p>
<p>:</p>
<p>777</p>
<p>–</p>
<p>781</p>
<p>.</p>
<p>246</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Assmann</p>
<p>SF</p>
<p>,</p>
<p>Boineau</p>
<p>R</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Clausell</p>
<p>N</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Fleg</p>
<p>JL</p>
<p>,</p>
<p>Gordeev</p>
<p>I</p>
<p>,</p>
<p>Harty</p>
<p>B</p>
<p>,</p>
<p>Heitner</p>
<p>JF</p>
<p>,</p>
<p>Kenwood</p>
<p>CT</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Probstfield</p>
<p>JL</p>
<p>,</p>
<p>Shaburishvili</p>
<p>T</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>Yang</p>
<p>S</p>
<p>,</p>
<p>McKinlay</p>
<p>SM</p>
<p>,</p>
<p>TOPCAT Investigators</p>
<p>.</p>
<p>Spironolactone for heart failure with preserved ejection fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2014</p>
<p>;</p>
<p>370</p>
<p>:</p>
<p>1383</p>
<p>–</p>
<p>1392</p>
<p>.</p>
<p>247</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA,
Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B,
Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi
V, Rizkala A, Lefkowitz M, McMurray JJV.</p>
<p>Sacubitril/valsartan across the spectrum of ejection fraction in
heart failure</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>352</p>
<p>–</p>
<p>361</p>
<p>.</p>
<p>248</p>
<p>Rogers</p>
<p>JK</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Michelson</p>
<p>EL</p>
<p>,</p>
<p>Ostergren</p>
<p>J</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Yusuf</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Analysing recurrent hospitalizations in heart failure: a review of
statistical methodology, with application to CHARM-Preserved</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>33</p>
<p>–</p>
<p>40</p>
<p>.</p>
<p>249</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Babalis</p>
<p>D</p>
<p>,</p>
<p>Roughton</p>
<p>M</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>PA</p>
<p>,</p>
<p>Flather</p>
<p>MD</p>
<p>SENIORS Investigators</p>
<p>.</p>
<p>Beta-blockade with nebivolol in elderly heart failure patients with
impaired and preserved left ventricular ejection fraction: data from
SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and
Rehospitalization in Seniors With Heart Failure)</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>2150</p>
<p>–</p>
<p>2158</p>
<p>.</p>
<p>250</p>
<p>Hai</p>
<p>OY</p>
<p>,</p>
<p>Mentz</p>
<p>RJ</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Gasparini</p>
<p>M</p>
<p>,</p>
<p>De Ferrari</p>
<p>GM</p>
<p>,</p>
<p>Daubert</p>
<p>JC</p>
<p>,</p>
<p>Holzmeister</p>
<p>J</p>
<p>,</p>
<p>Lam</p>
<p>CS</p>
<p>,</p>
<p>Pochet</p>
<p>T</p>
<p>,</p>
<p>Vincent</p>
<p>A</p>
<p>,</p>
<p>Linde</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Cardiac resynchronization therapy in heart failure patients with less
severe left ventricular dysfunction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>135</p>
<p>–</p>
<p>143</p>
<p>.</p>
<p>251</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Feldman</p>
<p>T</p>
<p>,</p>
<p>Ricciardi</p>
<p>MJ</p>
<p>,</p>
<p>Kahwash</p>
<p>R</p>
<p>,</p>
<p>Lilly</p>
<p>S</p>
<p>,</p>
<p>Litwin</p>
<p>S</p>
<p>,</p>
<p>Nielsen</p>
<p>CD</p>
<p>,</p>
<p>van der Harst</p>
<p>P</p>
<p>,</p>
<p>Hoendermis</p>
<p>E</p>
<p>,</p>
<p>Penicka</p>
<p>M</p>
<p>,</p>
<p>Bartunek</p>
<p>J</p>
<p>,</p>
<p>Fail</p>
<p>PS</p>
<p>,</p>
<p>Kaye</p>
<p>DM</p>
<p>,</p>
<p>Walton</p>
<p>A</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Walker</p>
<p>N</p>
<p>,</p>
<p>Basuray</p>
<p>A</p>
<p>,</p>
<p>Yakubov</p>
<p>S</p>
<p>,</p>
<p>Hummel</p>
<p>SL</p>
<p>,</p>
<p>Chetcuti</p>
<p>S</p>
<p>,</p>
<p>Forde-McLean</p>
<p>R</p>
<p>,</p>
<p>Herrmann</p>
<p>HC</p>
<p>,</p>
<p>Burkhoff</p>
<p>D</p>
<p>,</p>
<p>Massaro</p>
<p>JM</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Mauri</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>One-year safety and clinical outcomes of a transcatheter interatrial
shunt device for the treatment of heart failure with preserved ejection
fraction in the Reduce Elevated Left Atrial Pressure in Patients With
Heart Failure (REDUCE LAP-HF I) Trial: a randomized clinical trial</p>
<p>.</p>
<p>JAMA Cardiol</p>
<p>2018</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>968</p>
<p>–</p>
<p>977</p>
<p>.</p>
<p>252</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Held</p>
<p>P</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Michelson</p>
<p>EL</p>
<p>,</p>
<p>Olofsson</p>
<p>B</p>
<p>,</p>
<p>Ostergren</p>
<p>J</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Pocock</p>
<p>S</p>
<p>,</p>
<p>CHARM Investigators and Committees</p>
<p>.</p>
<p>Effects of candesartan on mortality and morbidity in patients with
chronic heart failure: the CHARM-Overall programme</p>
<p>.</p>
<p>Lancet</p>
<p>2003</p>
<p>;</p>
<p>362</p>
<p>:</p>
<p>759</p>
<p>–</p>
<p>766</p>
<p>.</p>
<p>253</p>
<p>Dewan</p>
<p>P</p>
<p>,</p>
<p>Jackson</p>
<p>A</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Interactions between left ventricular ejection fraction, sex and
effect of neurohumoral modulators in heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>898</p>
<p>–</p>
<p>901</p>
<p>.</p>
<p>254</p>
<p>Campbell</p>
<p>RT</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Redefining heart failure phenotypes based on ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1634</p>
<p>–</p>
<p>1635</p>
<p>.</p>
<p>255</p>
<p>Echocardiographic Normal Ranges Meta-Analysis of the Left Heart
Collaboration</p>
<p>.</p>
<p>Ethnic-specific normative reference values for echocardiographic LA
and LV size, LV mass, and systolic function: the EchoNoRMAL Study</p>
<p>.</p>
<p>JACC Cardiovasc Imaging</p>
<p>2015</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>656</p>
<p>–</p>
<p>665</p>
<p>.</p>
<p>256</p>
<p>Wehner</p>
<p>GJ</p>
<p>,</p>
<p>Jing</p>
<p>L</p>
<p>,</p>
<p>Haggerty</p>
<p>CM</p>
<p>,</p>
<p>Suever</p>
<p>JD</p>
<p>,</p>
<p>Leader</p>
<p>JB</p>
<p>,</p>
<p>Hartzel</p>
<p>DN</p>
<p>,</p>
<p>Kirchner</p>
<p>HL</p>
<p>,</p>
<p>Manus</p>
<p>JNA</p>
<p>,</p>
<p>James</p>
<p>N</p>
<p>,</p>
<p>Ayar</p>
<p>Z</p>
<p>,</p>
<p>Gladding</p>
<p>P</p>
<p>,</p>
<p>Good</p>
<p>CW</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Fornwalt</p>
<p>BK.</p>
<p>Routinely reported ejection fraction and mortality in clinical
practice: where does the nadir of risk lie?</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>1249</p>
<p>–</p>
<p>1257</p>
<p>.</p>
<p>257</p>
<p>Stewart</p>
<p>S</p>
<p>,</p>
<p>Playford</p>
<p>D</p>
<p>,</p>
<p>Scalia</p>
<p>GM</p>
<p>,</p>
<p>Currie</p>
<p>P</p>
<p>,</p>
<p>Celermajer</p>
<p>DS</p>
<p>,</p>
<p>Prior</p>
<p>D</p>
<p>,</p>
<p>Codde</p>
<p>J</p>
<p>,</p>
<p>Strange</p>
<p>G</p>
<p>,</p>
<p>NEDA Investigators. Ejection fraction and mortality: a nationwide
register-based cohort study of 499 153 women and men</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>406</p>
<p>–</p>
<p>416</p>
<p>.</p>
<p>258</p>
<p>Borlaug</p>
<p>BA.</p>
<p>Evaluation and management of heart failure with preserved ejection
fraction</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2020</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>559</p>
<p>–</p>
<p>573</p>
<p>.</p>
<p>259</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Fraser</p>
<p>AG</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Edelmann</p>
<p>F</p>
<p>,</p>
<p>Fu</p>
<p>M</p>
<p>,</p>
<p>Guazzi</p>
<p>M</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Melenovsky</p>
<p>V</p>
<p>,</p>
<p>Morris</p>
<p>DA</p>
<p>,</p>
<p>Nagel</p>
<p>E</p>
<p>,</p>
<p>Pieske-Kraigher</p>
<p>E</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Vasan</p>
<p>RS</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Paulus</p>
<p>WJ</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>How to diagnose heart failure with preserved ejection fraction: the
HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart
Failure Association (HFA) of the European Society of Cardiology
(ESC)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>3297</p>
<p>–</p>
<p>3317</p>
<p>.</p>
<p>260</p>
<p>Ho</p>
<p>JE</p>
<p>,</p>
<p>Zern</p>
<p>EK</p>
<p>,</p>
<p>Wooster</p>
<p>L</p>
<p>,</p>
<p>Bailey</p>
<p>CS</p>
<p>,</p>
<p>Cunningham</p>
<p>T</p>
<p>,</p>
<p>Eisman</p>
<p>AS</p>
<p>,</p>
<p>Hardin</p>
<p>KM</p>
<p>,</p>
<p>Zampierollo</p>
<p>GA</p>
<p>,</p>
<p>Jarolim</p>
<p>P</p>
<p>,</p>
<p>Pappagianopoulos</p>
<p>PP</p>
<p>,</p>
<p>Malhotra</p>
<p>R</p>
<p>,</p>
<p>Nayor</p>
<p>M</p>
<p>,</p>
<p>Lewis</p>
<p>GD.</p>
<p>Differential clinical profiles, exercise responses, and outcomes
associated with existing HFpEF definitions</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>140</p>
<p>:</p>
<p>353</p>
<p>–</p>
<p>365</p>
<p>.</p>
<p>261</p>
<p>Reddy</p>
<p>YNV</p>
<p>,</p>
<p>Carter</p>
<p>RE</p>
<p>,</p>
<p>Obokata</p>
<p>M</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Borlaug</p>
<p>BA.</p>
<p>A simple, evidence-based approach to help guide diagnosis of heart
failure with preserved ejection fraction</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>138</p>
<p>:</p>
<p>861</p>
<p>–</p>
<p>870</p>
<p>.</p>
<p>262</p>
<p>Segar</p>
<p>MW</p>
<p>,</p>
<p>Patel</p>
<p>KV</p>
<p>,</p>
<p>Berry</p>
<p>JD</p>
<p>,</p>
<p>Grodin</p>
<p>JL</p>
<p>,</p>
<p>Pandey</p>
<ol type="A">
<li></li>
</ol>
<p>Generalizability and implications of the H2FPEF score in a cohort of
patients with heart failure with preserved ejection fraction</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>1851</p>
<p>–</p>
<p>1853</p>
<p>.</p>
<p>263</p>
<p>Myhre</p>
<p>PL</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Shah</p>
<p>AM</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>Rouleau</p>
<p>J</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Application of the H2 FPEF score to a global clinical trial of
patients with heart failure with preserved ejection fraction: the TOPCAT
trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1288</p>
<p>–</p>
<p>1291</p>
<p>.</p>
<p>264</p>
<p>Sepehrvand</p>
<p>N</p>
<p>,</p>
<p>Alemayehu</p>
<p>W</p>
<p>,</p>
<p>Dyck</p>
<p>GJB</p>
<p>,</p>
<p>Dyck</p>
<p>JRB</p>
<p>,</p>
<p>Anderson</p>
<p>T</p>
<p>,</p>
<p>Howlett</p>
<p>J</p>
<p>,</p>
<p>Paterson</p>
<p>I</p>
<p>,</p>
<p>McAlister</p>
<p>FA</p>
<p>,</p>
<p>Ezekowitz</p>
<p>JA.</p>
<p>External validation of the H2F-PEF model in diagnosing patients with
heart failure and preserved ejection fraction</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>2377</p>
<p>–</p>
<p>2379</p>
<p>.</p>
<p>265</p>
<p>Sueta</p>
<p>D</p>
<p>,</p>
<p>Yamamoto</p>
<p>E</p>
<p>,</p>
<p>Nishihara</p>
<p>T</p>
<p>,</p>
<p>Tokitsu</p>
<p>T</p>
<p>,</p>
<p>Fujisue</p>
<p>K</p>
<p>,</p>
<p>Oike</p>
<p>F</p>
<p>,</p>
<p>Takae</p>
<p>M</p>
<p>,</p>
<p>Usuku</p>
<p>H</p>
<p>,</p>
<p>Takashio</p>
<p>S</p>
<p>,</p>
<p>Arima</p>
<p>Y</p>
<p>,</p>
<p>Suzuki</p>
<p>S</p>
<p>,</p>
<p>Nakamura</p>
<p>T</p>
<p>,</p>
<p>Ito</p>
<p>M</p>
<p>,</p>
<p>Kanazawa</p>
<p>H</p>
<p>,</p>
<p>Sakamoto</p>
<p>K</p>
<p>,</p>
<p>Kaikita</p>
<p>K</p>
<p>,</p>
<p>Tsujita</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>H2FPEF score as a prognostic value in HFpEF patients</p>
<p>.</p>
<p>Am J Hypertens</p>
<p>2019</p>
<p>;</p>
<p>32</p>
<p>:</p>
<p>1082</p>
<p>–</p>
<p>1090</p>
<p>.</p>
<p>266</p>
<p>Barandiaran Aizpurua</p>
<p>A</p>
<p>,</p>
<p>Sanders-van Wijk</p>
<p>S</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Henkens</p>
<p>M</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Beussink-Nelson</p>
<p>L</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>van Empel</p>
<p>VPM.</p>
<p>Validation of the HFA-PEFF score for the diagnosis of heart failure
with preserved ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>413</p>
<p>–</p>
<p>421</p>
<p>.</p>
<p>267</p>
<p>Sanders-van Wijk</p>
<p>S</p>
<p>,</p>
<p>Barandiaran Aizpurua</p>
<p>A</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Henkens</p>
<p>M</p>
<p>,</p>
<p>Weerts</p>
<p>J</p>
<p>,</p>
<p>Knackstedt</p>
<p>C</p>
<p>,</p>
<p>Uszko-Lencer</p>
<p>N</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>van Empel</p>
<ol start="22" type="A">
<li></li>
</ol>
<p>The HFA-PEFF and H2 FPEF scores largely disagree in classifying
patients with suspected heart failure with preserved ejection
fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021;</p>
<p>23</p>
<p>:838–840.</p>
<p>268</p>
<p>Selvaraj</p>
<p>S</p>
<p>,</p>
<p>Myhre</p>
<p>PL</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Matsushita</p>
<p>K</p>
<p>,</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Borlaug</p>
<p>BA</p>
<p>,</p>
<p>Shah</p>
<p>AM</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Application of diagnostic algorithms for heart failure with preserved
ejection fraction to the community</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>640</p>
<p>–</p>
<p>653</p>
<p>.</p>
<p>269</p>
<p>Ouwerkerk</p>
<p>W</p>
<p>,</p>
<p>Tromp</p>
<p>J</p>
<p>,</p>
<p>Jin</p>
<p>X</p>
<p>,</p>
<p>Jaufeerally</p>
<p>F</p>
<p>,</p>
<p>Yeo</p>
<p>PSD</p>
<p>,</p>
<p>Leong</p>
<p>KTG</p>
<p>,</p>
<p>Ong</p>
<p>HY</p>
<p>,</p>
<p>Ling</p>
<p>LH</p>
<p>,</p>
<p>Loh</p>
<p>SY</p>
<p>,</p>
<p>Sim</p>
<p>D</p>
<p>,</p>
<p>Lee</p>
<p>S</p>
<p>,</p>
<p>Soon</p>
<p>D</p>
<p>,</p>
<p>Chin</p>
<p>C</p>
<p>,</p>
<p>Richards</p>
<p>AM</p>
<p>,</p>
<p>Lam</p>
<p>CSP.</p>
<p>Heart failure with preserved ejection fraction diagnostic scores in
an Asian population</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1737</p>
<p>–</p>
<p>1739</p>
<p>.</p>
<p>270</p>
<p>Playford</p>
<p>D</p>
<p>,</p>
<p>Strange</p>
<p>G</p>
<p>,</p>
<p>Celermajer</p>
<p>DS</p>
<p>,</p>
<p>Evans</p>
<p>G</p>
<p>,</p>
<p>Scalia</p>
<p>GM</p>
<p>,</p>
<p>Stewart</p>
<p>S</p>
<p>,</p>
<p>Prior</p>
<p>D</p>
<p>NEDA Investigators</p>
<p>.</p>
<p>Diastolic dysfunction and mortality in 436 360 men and women: the
National Echo Database Australia (NEDA)</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Imaging</p>
<p>2021</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>505</p>
<p>–</p>
<p>515</p>
<p>.</p>
<p>271</p>
<p>Halliday</p>
<p>BP</p>
<p>,</p>
<p>Wassall</p>
<p>R</p>
<p>,</p>
<p>Lota</p>
<p>AS</p>
<p>,</p>
<p>Khalique</p>
<p>Z</p>
<p>,</p>
<p>Gregson</p>
<p>J</p>
<p>,</p>
<p>Newsome</p>
<p>S</p>
<p>,</p>
<p>Jackson</p>
<p>R</p>
<p>,</p>
<p>Rahneva</p>
<p>T</p>
<p>,</p>
<p>Wage</p>
<p>R</p>
<p>,</p>
<p>Smith</p>
<p>G</p>
<p>,</p>
<p>Venneri</p>
<p>L</p>
<p>,</p>
<p>Tayal</p>
<p>U</p>
<p>,</p>
<p>Auger</p>
<p>D</p>
<p>,</p>
<p>Midwinter</p>
<p>W</p>
<p>,</p>
<p>Whiffin</p>
<p>N</p>
<p>,</p>
<p>Rajani</p>
<p>R</p>
<p>,</p>
<p>Dungu</p>
<p>JN</p>
<p>,</p>
<p>Pantazis</p>
<p>A</p>
<p>,</p>
<p>Cook</p>
<p>SA</p>
<p>,</p>
<p>Ware</p>
<p>JS</p>
<p>,</p>
<p>Baksi</p>
<p>AJ</p>
<p>,</p>
<p>Pennell</p>
<p>DJ</p>
<p>,</p>
<p>Rosen</p>
<p>SD</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Prasad</p>
<p>SK.</p>
<p>Withdrawal of pharmacological treatment for heart failure in patients
with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot,
randomised trial</p>
<p>.</p>
<p>Lancet</p>
<p>2019</p>
<p>;</p>
<p>393</p>
<p>:</p>
<p>61</p>
<p>–</p>
<p>73</p>
<p>.</p>
<p>272</p>
<p>Lupon</p>
<p>J</p>
<p>,</p>
<p>Gavidia-Bovadilla</p>
<p>G</p>
<p>,</p>
<p>Ferrer</p>
<p>E</p>
<p>,</p>
<p>de Antonio</p>
<p>M</p>
<p>,</p>
<p>Perera-Lluna</p>
<p>A</p>
<p>,</p>
<p>Lopez-Ayerbe</p>
<p>J</p>
<p>,</p>
<p>Domingo</p>
<p>M</p>
<p>,</p>
<p>Nunez</p>
<p>J</p>
<p>,</p>
<p>Zamora</p>
<p>E</p>
<p>,</p>
<p>Moliner</p>
<p>P</p>
<p>,</p>
<p>Santiago-Vacas</p>
<p>E</p>
<p>,</p>
<p>Santesmases</p>
<p>J</p>
<p>,</p>
<p>Bayes-Genis A. Heart failure with preserved ejection fraction
infrequently evolves toward a reduced phenotype in long-term
survivors</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>e005652</p>
<p>.</p>
<p>273</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Vedin</p>
<p>O</p>
<p>,</p>
<p>D’Amario</p>
<p>D</p>
<p>,</p>
<p>Uijl</p>
<p>A</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Prevalence and prognostic implications of longitudinal ejection
fraction change in heart failure</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>306</p>
<p>–</p>
<p>317</p>
<p>.</p>
<p>274</p>
<p>Nauta</p>
<p>JF</p>
<p>,</p>
<p>Hummel</p>
<p>YM</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>van Melle</p>
<p>JP.</p>
<p>Correlation with invasive left ventricular filling pressures and
prognostic relevance of the echocardiographic diastolic parameters used
in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI
recommendations: a systematic review in patients with heart failure with
preserved ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1303</p>
<p>–</p>
<p>1311</p>
<p>.</p>
<p>275</p>
<p>Sharifov</p>
<p>OF</p>
<p>,</p>
<p>Schiros</p>
<p>CG</p>
<p>,</p>
<p>Aban</p>
<p>I</p>
<p>,</p>
<p>Denney</p>
<p>TS</p>
<p>,</p>
<p>Gupta</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Diagnostic accuracy of tissue Doppler index E/e’ for evaluating left
ventricular filling pressure and diastolic dysfunction/heart failure
with preserved ejection fraction: a systematic review and
meta-analysis</p>
<p>.</p>
<p>J Am Heart Assoc</p>
<p>2016</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>e002078</p>
<p>.</p>
<p>276</p>
<p>Eisman</p>
<p>AS</p>
<p>,</p>
<p>Shah</p>
<p>RV</p>
<p>,</p>
<p>Dhakal</p>
<p>BP</p>
<p>,</p>
<p>Pappagianopoulos</p>
<p>PP</p>
<p>,</p>
<p>Wooster</p>
<p>L</p>
<p>,</p>
<p>Bailey</p>
<p>C</p>
<p>,</p>
<p>Cunningham</p>
<p>TF</p>
<p>,</p>
<p>Hardin</p>
<p>KM</p>
<p>,</p>
<p>Baggish</p>
<p>AL</p>
<p>,</p>
<p>Ho</p>
<p>JE</p>
<p>,</p>
<p>Malhotra</p>
<p>R</p>
<p>,</p>
<p>Lewis</p>
<p>GD.</p>
<p>Pulmonary capillary wedge pressure patterns during exercise predict
exercise capacity and incident heart failure</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:e004750.</p>
<p>277</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>Adamus</p>
<p>J</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Gray</p>
<p>CS</p>
<p>,</p>
<p>Lye</p>
<p>M</p>
<p>,</p>
<p>O’Mahony</p>
<p>D</p>
<p>,</p>
<p>Polonski</p>
<p>L</p>
<p>,</p>
<p>Taylor</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Perindopril for elderly people with chronic heart failure: the
PEP-CHF study. The PEP Investigators</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>1999</p>
<p>;</p>
<p>1</p>
<p>:</p>
<p>211</p>
<p>–</p>
<p>217</p>
<p>.</p>
<p>278</p>
<p>Massie</p>
<p>BM</p>
<p>,</p>
<p>Carson</p>
<p>PE</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>McKelvie</p>
<p>R</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Anderson</p>
<p>S</p>
<p>,</p>
<p>Donovan</p>
<p>M</p>
<p>,</p>
<p>Iverson</p>
<p>E</p>
<p>,</p>
<p>Staiger</p>
<p>C</p>
<p>,</p>
<p>Ptaszynska</p>
<p>A</p>
<p>,</p>
<p>I-PRESERVE Investigators</p>
<p>.</p>
<p>Irbesartan in patients with heart failure and preserved ejection
fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2008</p>
<p>;</p>
<p>359</p>
<p>:</p>
<p>2456</p>
<p>–</p>
<p>2467</p>
<p>.</p>
<p>279</p>
<p>Ahmed</p>
<p>A</p>
<p>,</p>
<p>Rich</p>
<p>MW</p>
<p>,</p>
<p>Fleg</p>
<p>JL</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Young</p>
<p>JB</p>
<p>,</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Love</p>
<p>TE</p>
<p>,</p>
<p>Aronow</p>
<p>WS</p>
<p>,</p>
<p>Adams</p>
<p>KF</p>
<p>Jr,</p>
<p>Gheorghiade</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Effects of digoxin on morbidity and mortality in diastolic heart
failure: the Ancillary Digitalis Investigation Group trial</p>
<p>.</p>
<p>Circulation</p>
<p>2006</p>
<p>;</p>
<p>114</p>
<p>:</p>
<p>397</p>
<p>–</p>
<p>403</p>
<p>.</p>
<p>280</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Levine</p>
<p>JA</p>
<p>,</p>
<p>Koepp</p>
<p>GA</p>
<p>,</p>
<p>Borlaug</p>
<p>BA</p>
<p>,</p>
<p>Chen</p>
<p>HH</p>
<p>,</p>
<p>LeWinter</p>
<p>MM</p>
<p>,</p>
<p>Joseph</p>
<p>SM</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Cole</p>
<p>RT</p>
<p>,</p>
<p>Reeves</p>
<p>GR</p>
<p>,</p>
<p>Tedford</p>
<p>RJ</p>
<p>,</p>
<p>Tang</p>
<p>WH</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Shah</p>
<p>MR</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>NHLBI Heart Failure Clinical Research Network</p>
<p>.</p>
<p>Isosorbide mononitrate in heart failure with preserved ejection
fraction</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>373</p>
<p>:</p>
<p>2314</p>
<p>–</p>
<p>2324</p>
<p>.</p>
<p>281</p>
<p>Borlaug</p>
<p>BA</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Lewis</p>
<p>GD</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Levine</p>
<p>JA</p>
<p>,</p>
<p>Koepp</p>
<p>GA</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>LeWinter</p>
<p>MM</p>
<p>,</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>Margulies</p>
<p>KB</p>
<p>,</p>
<p>Smith</p>
<p>AL</p>
<p>,</p>
<p>Tang</p>
<p>WHW</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Chen</p>
<p>HH</p>
<p>,</p>
<p>Davila-Roman</p>
<p>VG</p>
<p>,</p>
<p>McNulty</p>
<p>S</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>National Heart, Lung, and Blood Institute Heart Failure Clinical
Research Network</p>
<p>.</p>
<p>Effect of inorganic nitrite vs placebo on exercise capacity among
patients with heart failure with preserved ejection fraction: the
INDIE-HFpEF randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2018</p>
<p>;</p>
<p>320</p>
<p>:</p>
<p>1764</p>
<p>–</p>
<p>1773</p>
<p>.</p>
<p>282</p>
<p>Armstrong</p>
<p>PW</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Ezekowitz</p>
<p>J</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>She</p>
<p>L</p>
<p>,</p>
<p>Vlajnic</p>
<p>V</p>
<p>,</p>
<p>Carvalho</p>
<p>F</p>
<p>,</p>
<p>Bamber</p>
<p>L</p>
<p>,</p>
<p>Blaustein</p>
<p>RO</p>
<p>,</p>
<p>Roessig</p>
<p>L</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>VITALITY-HFpEF Study Group</p>
<p>.</p>
<p>Effect of vericiguat vs placebo on quality of life in patients with
heart failure and preserved ejection fraction: the VITALITY-HFpEF
randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2020</p>
<p>;</p>
<p>324</p>
<p>:</p>
<p>1512</p>
<p>–</p>
<p>1521</p>
<p>.</p>
<p>283</p>
<p>Udelson</p>
<p>JE</p>
<p>,</p>
<p>Lewis</p>
<p>GD</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Burnett</p>
<p>J</p>
<p>Jr.,</p>
<p>Parker</p>
<p>J</p>
<p>,</p>
<p>Seferovic</p>
<p>JP</p>
<p>,</p>
<p>Wilson</p>
<p>P</p>
<p>,</p>
<p>Mittleman</p>
<p>RS</p>
<p>,</p>
<p>Profy</p>
<p>AT</p>
<p>,</p>
<p>Konstam</p>
<p>MA.</p>
<p>Effect of praliciguat on peak rate of oxygen consumption in patients
with heart failure with preserved ejection fraction: the CAPACITY HFpEF
randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2020</p>
<p>;</p>
<p>324</p>
<p>:</p>
<p>1522</p>
<p>–</p>
<p>1531</p>
<p>.</p>
<p>284</p>
<p>Omar</p>
<p>W</p>
<p>,</p>
<p>Pandey</p>
<p>A</p>
<p>,</p>
<p>Haykowsky</p>
<p>MJ</p>
<p>,</p>
<p>Berry</p>
<p>JD</p>
<p>,</p>
<p>Lavie</p>
<p>CJ.</p>
<p>The evolving role of cardiorespiratory fitness and exercise in
prevention and management of heart failure</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2018</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>75</p>
<p>–</p>
<p>80</p>
<p>.</p>
<p>285</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Upadhya</p>
<p>B</p>
<p>,</p>
<p>Reeves</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Hospitalizations and prognosis in elderly patients with heart failure
and preserved ejection fraction: time to treat the whole patient</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>442</p>
<p>–</p>
<p>444</p>
<p>.</p>
<p>286</p>
<p>Wood</p>
<p>AM</p>
<p>,</p>
<p>Kaptoge</p>
<p>S</p>
<p>,</p>
<p>Butterworth</p>
<p>AS</p>
<p>,</p>
<p>Willeit</p>
<p>P</p>
<p>,</p>
<p>Warnakula</p>
<p>S</p>
<p>,</p>
<p>Bolton</p>
<p>T</p>
<p>,</p>
<p>Paige</p>
<p>E</p>
<p>,</p>
<p>Paul</p>
<p>DS</p>
<p>,</p>
<p>Sweeting</p>
<p>M</p>
<p>,</p>
<p>Burgess</p>
<p>S</p>
<p>,</p>
<p>Bell</p>
<p>S</p>
<p>,</p>
<p>Astle</p>
<p>W</p>
<p>,</p>
<p>Stevens</p>
<p>D</p>
<p>,</p>
<p>Koulman</p>
<p>A</p>
<p>,</p>
<p>Selmer</p>
<p>RM</p>
<p>,</p>
<p>Verschuren</p>
<p>WMM</p>
<p>,</p>
<p>Sato</p>
<p>S</p>
<p>,</p>
<p>Njolstad</p>
<p>I</p>
<p>,</p>
<p>Woodward</p>
<p>M</p>
<p>,</p>
<p>Salomaa</p>
<p>V</p>
<p>,</p>
<p>Nordestgaard</p>
<p>BG</p>
<p>,</p>
<p>Yeap</p>
<p>BB</p>
<p>,</p>
<p>Fletcher</p>
<p>A</p>
<p>,</p>
<p>Melander</p>
<p>O</p>
<p>,</p>
<p>Kuller</p>
<p>LH</p>
<p>,</p>
<p>Balkau</p>
<p>B</p>
<p>,</p>
<p>Marmot</p>
<p>M</p>
<p>,</p>
<p>Koenig</p>
<p>W</p>
<p>,</p>
<p>Casiglia</p>
<p>E</p>
<p>,</p>
<p>Cooper</p>
<p>C</p>
<p>,</p>
<p>Arndt</p>
<p>V</p>
<p>,</p>
<p>Franco</p>
<p>OH</p>
<p>,</p>
<p>Wennberg</p>
<p>P</p>
<p>,</p>
<p>Gallacher</p>
<p>J</p>
<p>,</p>
<p>de la Camara</p>
<p>AG</p>
<p>,</p>
<p>Volzke</p>
<p>H</p>
<p>,</p>
<p>Dahm</p>
<p>CC</p>
<p>,</p>
<p>Dale</p>
<p>CE</p>
<p>,</p>
<p>Bergmann</p>
<p>MM</p>
<p>,</p>
<p>Crespo</p>
<p>CJ</p>
<p>,</p>
<p>van der Schouw</p>
<p>YT</p>
<p>,</p>
<p>Kaaks</p>
<p>R</p>
<p>,</p>
<p>Simons</p>
<p>LA</p>
<p>,</p>
<p>Lagiou</p>
<p>P</p>
<p>,</p>
<p>Schoufour</p>
<p>JD</p>
<p>,</p>
<p>Boer</p>
<p>JMA</p>
<p>,</p>
<p>Key</p>
<p>TJ</p>
<p>,</p>
<p>Rodriguez</p>
<p>B</p>
<p>,</p>
<p>Moreno-Iribas</p>
<p>C</p>
<p>,</p>
<p>Davidson</p>
<p>KW</p>
<p>,</p>
<p>Taylor</p>
<p>JO</p>
<p>,</p>
<p>Sacerdote</p>
<p>C</p>
<p>,</p>
<p>Wallace</p>
<p>RB</p>
<p>,</p>
<p>Quiros</p>
<p>JR</p>
<p>,</p>
<p>Tumino</p>
<p>R</p>
<p>,</p>
<p>Blazer</p>
<p>DG</p>
<p>2nd,</p>
<p>Linneberg</p>
<p>A</p>
<p>,</p>
<p>Daimon</p>
<p>M</p>
<p>,</p>
<p>Panico</p>
<p>S</p>
<p>,</p>
<p>Howard</p>
<p>B</p>
<p>,</p>
<p>Skeie</p>
<p>G</p>
<p>,</p>
<p>Strandberg</p>
<p>T</p>
<p>,</p>
<p>Weiderpass</p>
<p>E</p>
<p>,</p>
<p>Nietert</p>
<p>PJ</p>
<p>,</p>
<p>Psaty</p>
<p>BM</p>
<p>,</p>
<p>Kromhout</p>
<p>D</p>
<p>,</p>
<p>Salamanca-Fernandez</p>
<p>E</p>
<p>,</p>
<p>Kiechl</p>
<p>S</p>
<p>,</p>
<p>Krumholz</p>
<p>HM</p>
<p>,</p>
<p>Grioni</p>
<p>S</p>
<p>,</p>
<p>Palli</p>
<p>D</p>
<p>,</p>
<p>Huerta</p>
<p>JM</p>
<p>,</p>
<p>Price</p>
<p>J</p>
<p>,</p>
<p>Sundstrom</p>
<p>J</p>
<p>,</p>
<p>Arriola</p>
<p>L</p>
<p>,</p>
<p>Arima</p>
<p>H</p>
<p>,</p>
<p>Travis</p>
<p>RC</p>
<p>,</p>
<p>Panagiotakos</p>
<p>DB</p>
<p>,</p>
<p>Karakatsani</p>
<p>A</p>
<p>,</p>
<p>Trichopoulou</p>
<p>A</p>
<p>,</p>
<p>Kuhn</p>
<p>T</p>
<p>,</p>
<p>Grobbee</p>
<p>DE</p>
<p>,</p>
<p>Barrett-Connor</p>
<p>E</p>
<p>,</p>
<p>van Schoor</p>
<p>N</p>
<p>,</p>
<p>Boeing</p>
<p>H</p>
<p>,</p>
<p>Overvad</p>
<p>K</p>
<p>,</p>
<p>Kauhanen</p>
<p>J</p>
<p>,</p>
<p>Wareham</p>
<p>N</p>
<p>,</p>
<p>Langenberg</p>
<p>C</p>
<p>,</p>
<p>Forouhi</p>
<p>N</p>
<p>,</p>
<p>Wennberg</p>
<p>M</p>
<p>,</p>
<p>Despres</p>
<p>JP</p>
<p>,</p>
<p>Cushman</p>
<p>M</p>
<p>,</p>
<p>Cooper</p>
<p>JA</p>
<p>,</p>
<p>Rodriguez</p>
<p>CJ</p>
<p>,</p>
<p>Sakurai</p>
<p>M</p>
<p>,</p>
<p>Shaw</p>
<p>JE</p>
<p>,</p>
<p>Knuiman</p>
<p>M</p>
<p>,</p>
<p>Voortman</p>
<p>T</p>
<p>,</p>
<p>Meisinger</p>
<p>C</p>
<p>,</p>
<p>Tjonneland</p>
<p>A</p>
<p>,</p>
<p>Brenner</p>
<p>H</p>
<p>,</p>
<p>Palmieri</p>
<p>L</p>
<p>,</p>
<p>Dallongeville</p>
<p>J</p>
<p>,</p>
<p>Brunner</p>
<p>EJ</p>
<p>,</p>
<p>Assmann</p>
<p>G</p>
<p>,</p>
<p>Trevisan</p>
<p>M</p>
<p>,</p>
<p>Gillum</p>
<p>RF</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Lazo</p>
<p>M</p>
<p>,</p>
<p>Thompson</p>
<p>SG</p>
<p>,</p>
<p>Ferrari</p>
<p>P</p>
<p>,</p>
<p>Leon</p>
<p>DA</p>
<p>,</p>
<p>Smith</p>
<p>GD</p>
<p>,</p>
<p>Peto</p>
<p>R</p>
<p>,</p>
<p>Jackson</p>
<p>R</p>
<p>,</p>
<p>Banks</p>
<p>E</p>
<p>,</p>
<p>Di Angelantonio</p>
<p>E</p>
<p>,</p>
<p>Danesh</p>
<p>J</p>
<p>,</p>
<p>Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study
Group</p>
<p>.</p>
<p>Risk thresholds for alcohol consumption: combined analysis of
individual-participant data for 599 912 current drinkers in 83
prospective studies</p>
<p>.</p>
<p>Lancet</p>
<p>2018</p>
<p>;</p>
<p>391</p>
<p>:</p>
<p>1513</p>
<p>–</p>
<p>1523</p>
<p>.</p>
<p>287</p>
<p>Kostis</p>
<p>JB</p>
<p>,</p>
<p>Davis</p>
<p>BR</p>
<p>,</p>
<p>Cutler</p>
<p>J</p>
<p>,</p>
<p>Grimm</p>
<p>RH</p>
<p>Jr.,</p>
<p>Berge</p>
<p>KG</p>
<p>,</p>
<p>Cohen</p>
<p>JD</p>
<p>,</p>
<p>Lacy</p>
<p>CR</p>
<p>,</p>
<p>Perry</p>
<p>HM</p>
<p>Jr.,</p>
<p>Blaufox</p>
<p>MD</p>
<p>,</p>
<p>Wassertheil-Smoller</p>
<p>S</p>
<p>,</p>
<p>Black</p>
<p>HR</p>
<p>,</p>
<p>Schron</p>
<p>E</p>
<p>,</p>
<p>Berkson</p>
<p>DM</p>
<p>,</p>
<p>Curb</p>
<p>JD</p>
<p>,</p>
<p>Smith</p>
<p>WM</p>
<p>,</p>
<p>McDonald</p>
<p>R</p>
<p>,</p>
<p>Applegate</p>
<p>WB.</p>
<p>Prevention of heart failure by antihypertensive drug treatment in
older persons with isolated systolic hypertension. SHEP Cooperative
Research Group</p>
<p>.</p>
<p>JAMA</p>
<p>1997</p>
<p>;</p>
<p>278</p>
<p>:</p>
<p>212</p>
<p>–</p>
<p>216</p>
<p>.</p>
<p>288</p>
<p>Group</p>
<p>SR</p>
<p>,</p>
<p>Wright</p>
<p>JT</p>
<p>Jr.,</p>
<p>Williamson</p>
<p>JD</p>
<p>,</p>
<p>Whelton</p>
<p>PK</p>
<p>,</p>
<p>Snyder</p>
<p>JK</p>
<p>,</p>
<p>Sink</p>
<p>KM</p>
<p>,</p>
<p>Rocco</p>
<p>MV</p>
<p>,</p>
<p>Reboussin</p>
<p>DM</p>
<p>,</p>
<p>Rahman</p>
<p>M</p>
<p>,</p>
<p>Oparil</p>
<p>S</p>
<p>,</p>
<p>Lewis</p>
<p>CE</p>
<p>,</p>
<p>Kimmel</p>
<p>PL</p>
<p>,</p>
<p>Johnson</p>
<p>KC</p>
<p>,</p>
<p>Goff</p>
<p>DC</p>
<p>Jr,</p>
<p>Fine</p>
<p>LJ</p>
<p>,</p>
<p>Cutler</p>
<p>JA</p>
<p>,</p>
<p>Cushman</p>
<p>WC</p>
<p>,</p>
<p>Cheung</p>
<p>AK</p>
<p>,</p>
<p>Ambrosius</p>
<p>WT.</p>
<p>A randomized trial of intensive versus standard blood-pressure
control</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>373</p>
<p>:</p>
<p>2103</p>
<p>–</p>
<p>2116</p>
<p>.</p>
<p>289</p>
<p>Sciarretta</p>
<p>S</p>
<p>,</p>
<p>Palano</p>
<p>F</p>
<p>,</p>
<p>Tocci</p>
<p>G</p>
<p>,</p>
<p>Baldini</p>
<p>R</p>
<p>,</p>
<p>Volpe</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Antihypertensive treatment and development of heart failure in
hypertension: a Bayesian network meta-analysis of studies in patients
with hypertension and high cardiovascular risk</p>
<p>.</p>
<p>Arch Intern Med</p>
<p>2011</p>
<p>;</p>
<p>171</p>
<p>:</p>
<p>384</p>
<p>–</p>
<p>394</p>
<p>.</p>
<p>290</p>
<p>Beckett</p>
<p>NS</p>
<p>,</p>
<p>Peters</p>
<p>R</p>
<p>,</p>
<p>Fletcher</p>
<p>AE</p>
<p>,</p>
<p>Staessen</p>
<p>JA</p>
<p>,</p>
<p>Liu</p>
<p>L</p>
<p>,</p>
<p>Dumitrascu</p>
<p>D</p>
<p>,</p>
<p>Stoyanovsky</p>
<p>V</p>
<p>,</p>
<p>Antikainen</p>
<p>RL</p>
<p>,</p>
<p>Nikitin</p>
<p>Y</p>
<p>,</p>
<p>Anderson</p>
<p>C</p>
<p>,</p>
<p>Belhani</p>
<p>A</p>
<p>,</p>
<p>Forette</p>
<p>F</p>
<p>,</p>
<p>Rajkumar</p>
<p>C</p>
<p>,</p>
<p>Thijs</p>
<p>L</p>
<p>,</p>
<p>Banya</p>
<p>W</p>
<p>,</p>
<p>Bulpitt</p>
<p>CJ</p>
<p>HYVET Study Group.</p>
<p>Treatment of hypertension in patients 80 years of age or older</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2008</p>
<p>;</p>
<p>358</p>
<p>:</p>
<p>1887</p>
<p>–</p>
<p>1898</p>
<p>.</p>
<p>291</p>
<p>Scirica</p>
<p>BM</p>
<p>,</p>
<p>Morrow</p>
<p>DA</p>
<p>,</p>
<p>Cannon</p>
<p>CP</p>
<p>,</p>
<p>Ray</p>
<p>KK</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>Jarolim</p>
<p>P</p>
<p>,</p>
<p>Shui</p>
<p>A</p>
<p>,</p>
<p>McCabe</p>
<p>CH</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>PROVE IT-TIMI Investigators</p>
<p>.</p>
<p>Intensive statin therapy and the risk of hospitalization for heart
failure after an acute coronary syndrome in the PROVE IT-TIMI 22
study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2006</p>
<p>;</p>
<p>47</p>
<p>:</p>
<p>2326</p>
<p>–</p>
<p>2331</p>
<p>.</p>
<p>292</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Pedersen</p>
<p>TR</p>
<p>,</p>
<p>Olsson</p>
<p>AG</p>
<p>,</p>
<p>Faergeman</p>
<p>O</p>
<p>,</p>
<p>Pyorala</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>The effects of simvastatin on the incidence of heart failure in
patients with coronary heart disease</p>
<p>.</p>
<p>J Card Fail</p>
<p>1997</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>249</p>
<p>–</p>
<p>254</p>
<p>.</p>
<p>293</p>
<p>Zinman</p>
<p>B</p>
<p>,</p>
<p>Wanner</p>
<p>C</p>
<p>,</p>
<p>Lachin</p>
<p>JM</p>
<p>,</p>
<p>Fitchett</p>
<p>D</p>
<p>,</p>
<p>Bluhmki</p>
<p>E</p>
<p>,</p>
<p>Hantel</p>
<p>S</p>
<p>,</p>
<p>Mattheus</p>
<p>M</p>
<p>,</p>
<p>Devins</p>
<p>T</p>
<p>,</p>
<p>Johansen</p>
<p>OE</p>
<p>,</p>
<p>Woerle</p>
<p>HJ</p>
<p>,</p>
<p>Broedl</p>
<p>UC</p>
<p>,</p>
<p>Inzucchi</p>
<p>SE</p>
<p>,</p>
<p>EMPA-REG OUTCOME Investigators</p>
<p>.</p>
<p>Empagliflozin, cardiovascular outcomes, and mortality in type 2
diabetes</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>373</p>
<p>:</p>
<p>2117</p>
<p>–</p>
<p>2128</p>
<p>.</p>
<p>294</p>
<p>Neal</p>
<p>B</p>
<p>,</p>
<p>Perkovic</p>
<p>V</p>
<p>,</p>
<p>Mahaffey</p>
<p>KW</p>
<p>,</p>
<p>de Zeeuw</p>
<p>D</p>
<p>,</p>
<p>Fulcher</p>
<p>G</p>
<p>,</p>
<p>Erondu</p>
<p>N</p>
<p>,</p>
<p>Shaw</p>
<p>W</p>
<p>,</p>
<p>Law</p>
<p>G</p>
<p>,</p>
<p>Desai</p>
<p>M</p>
<p>,</p>
<p>Matthews</p>
<p>DR</p>
<p>CANVAS Program Collaborative Group</p>
<p>.</p>
<p>Canagliflozin and cardiovascular and renal events in type 2
diabetes</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2017</p>
<p>;</p>
<p>377</p>
<p>:</p>
<p>644</p>
<p>–</p>
<p>657</p>
<p>.</p>
<p>295</p>
<p>Wiviott</p>
<p>SD</p>
<p>,</p>
<p>Raz</p>
<p>I</p>
<p>,</p>
<p>Bonaca</p>
<p>MP</p>
<p>,</p>
<p>Mosenzon</p>
<p>O</p>
<p>,</p>
<p>Kato</p>
<p>ET</p>
<p>,</p>
<p>Cahn</p>
<p>A</p>
<p>,</p>
<p>Silverman</p>
<p>MG</p>
<p>,</p>
<p>Zelniker</p>
<p>TA</p>
<p>,</p>
<p>Kuder</p>
<p>JF</p>
<p>,</p>
<p>Murphy</p>
<p>SA</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Leiter</p>
<p>LA</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Wilding</p>
<p>JPH</p>
<p>,</p>
<p>Ruff</p>
<p>CT</p>
<p>,</p>
<p>Gause-Nilsson</p>
<p>IAM</p>
<p>,</p>
<p>Fredriksson</p>
<p>M</p>
<p>,</p>
<p>Johansson</p>
<p>PA</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular
outcomes in type 2 diabetes</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>380</p>
<p>:</p>
<p>347</p>
<p>–</p>
<p>357</p>
<p>.</p>
<p>296</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Szarek</p>
<p>M</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Cannon</p>
<p>CP</p>
<p>,</p>
<p>Leiter</p>
<p>LA</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Lewis</p>
<p>JB</p>
<p>,</p>
<p>Riddle</p>
<p>MC</p>
<p>,</p>
<p>Inzucchi</p>
<p>SE</p>
<p>,</p>
<p>Kosiborod</p>
<p>MN</p>
<p>,</p>
<p>Cherney</p>
<p>DZI</p>
<p>,</p>
<p>Dwyer</p>
<p>JP</p>
<p>,</p>
<p>Scirica</p>
<p>BM</p>
<p>,</p>
<p>Bailey</p>
<p>CJ</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Ray</p>
<p>KK</p>
<p>,</p>
<p>Udell</p>
<p>JA</p>
<p>,</p>
<p>Lopes</p>
<p>RD</p>
<p>,</p>
<p>Lapuerta</p>
<p>P</p>
<p>,</p>
<p>Steg</p>
<p>PG</p>
<p>,</p>
<p>SCORED Investigators</p>
<p>.</p>
<p>Sotagliflozin in patients with diabetes and chronic kidney
disease</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>384</p>
<p>:</p>
<p>129</p>
<p>–</p>
<p>139</p>
<p>.</p>
<p>297</p>
<p>Cannon</p>
<p>CP</p>
<p>,</p>
<p>Pratley</p>
<p>R</p>
<p>,</p>
<p>Dagogo-Jack</p>
<p>S</p>
<p>,</p>
<p>Mancuso</p>
<p>J</p>
<p>,</p>
<p>Huyck</p>
<p>S</p>
<p>,</p>
<p>Masiukiewicz</p>
<p>U</p>
<p>,</p>
<p>Charbonnel</p>
<p>B</p>
<p>,</p>
<p>Frederich</p>
<p>R</p>
<p>,</p>
<p>Gallo</p>
<p>S</p>
<p>,</p>
<p>Cosentino</p>
<p>F</p>
<p>,</p>
<p>Shih</p>
<p>WJ</p>
<p>,</p>
<p>Gantz</p>
<p>I</p>
<p>,</p>
<p>Terra</p>
<p>SG</p>
<p>,</p>
<p>Cherney</p>
<p>DZI</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin
in type 2 diabetes</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>1425</p>
<p>–</p>
<p>1435</p>
<p>.</p>
<p>298</p>
<p>Suskin</p>
<p>N</p>
<p>,</p>
<p>Sheth</p>
<p>T</p>
<p>,</p>
<p>Negassa</p>
<p>A</p>
<p>,</p>
<p>Yusuf</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Relationship of current and past smoking to mortality and morbidity
in patients with left ventricular dysfunction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2001</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>1677</p>
<p>–</p>
<p>1682</p>
<p>.</p>
<p>299</p>
<p>Dorans</p>
<p>KS</p>
<p>,</p>
<p>Mostofsky</p>
<p>E</p>
<p>,</p>
<p>Levitan</p>
<p>EB</p>
<p>,</p>
<p>Hakansson</p>
<p>N</p>
<p>,</p>
<p>Wolk</p>
<p>A</p>
<p>,</p>
<p>Mittleman</p>
<p>MA.</p>
<p>Alcohol and incident heart failure among middle-aged and elderly men:
cohort of Swedish men</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>422</p>
<p>–</p>
<p>427</p>
<p>.</p>
<p>300</p>
<p>Goncalves</p>
<p>A</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Rosamond</p>
<p>W</p>
<p>,</p>
<p>Deswal</p>
<p>A</p>
<p>,</p>
<p>Aguilar</p>
<p>D</p>
<p>,</p>
<p>Shah</p>
<p>AM</p>
<p>,</p>
<p>Cheng</p>
<p>S</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Alcohol consumption and risk of heart failure: the Atherosclerosis
Risk in Communities Study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>939</p>
<p>–</p>
<p>945</p>
<p>.</p>
<p>301</p>
<p>Pandey</p>
<p>A</p>
<p>,</p>
<p>Garg</p>
<p>S</p>
<p>,</p>
<p>Khunger</p>
<p>M</p>
<p>,</p>
<p>Darden</p>
<p>D</p>
<p>,</p>
<p>Ayers</p>
<p>C</p>
<p>,</p>
<p>Kumbhani</p>
<p>DJ</p>
<p>,</p>
<p>Mayo</p>
<p>HG</p>
<p>,</p>
<p>de Lemos</p>
<p>JA</p>
<p>,</p>
<p>Berry</p>
<p>JD.</p>
<p>Dose-response relationship between physical activity and risk of
heart failure: a meta-analysis</p>
<p>.</p>
<p>Circulation</p>
<p>2015</p>
<p>;</p>
<p>132</p>
<p>:</p>
<p>1786</p>
<p>–</p>
<p>1794</p>
<p>.</p>
<p>302</p>
<p>Padwal</p>
<p>R</p>
<p>,</p>
<p>McAlister</p>
<p>FA</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Rich</p>
<p>M</p>
<p>,</p>
<p>Pocock</p>
<p>S</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Maggioni</p>
<p>A</p>
<p>,</p>
<p>Gamble</p>
<p>G</p>
<p>,</p>
<p>Ariti</p>
<p>C</p>
<p>,</p>
<p>Earle</p>
<p>N</p>
<p>,</p>
<p>Whalley</p>
<p>G</p>
<p>,</p>
<p>Poppe</p>
<p>KK</p>
<p>,</p>
<p>Doughty</p>
<p>RN</p>
<p>,</p>
<p>Bayes-Genis A, Meta-analysis Global Group in Chronic Heart Failure
(MAGGIC). The obesity paradox in heart failure patients with preserved
versus reduced ejection fraction: a meta-analysis of individual patient
data</p>
<p>.</p>
<p>Int J Obes (Lond</p>
<p><em>)</em></p>
<p>2014</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>1110</p>
<p>–</p>
<p>1114</p>
<p>.</p>
<p>303</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>Blue</p>
<p>L</p>
<p>,</p>
<p>Clark</p>
<p>AL</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Ekman</p>
<p>I</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>McDonald</p>
<p>K</p>
<p>,</p>
<p>Ryder</p>
<p>M</p>
<p>,</p>
<p>Stromberg</p>
<p>A</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>European Society of Cardiology Heart Failure Association Committee on
Patient Care</p>
<p>.</p>
<p>European Society of Cardiology Heart Failure Association Standards
for delivering heart failure care</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>235</p>
<p>–</p>
<p>241</p>
<p>.</p>
<p>304</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Blue</p>
<p>L</p>
<p>,</p>
<p>Clark</p>
<p>AL</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Ekman</p>
<p>I</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Ryder</p>
<p>M</p>
<p>,</p>
<p>Stewart</p>
<p>S</p>
<p>,</p>
<p>Stromberg</p>
<p>A</p>
<p>,</p>
<p>Jaarsma</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Self-care management of heart failure: practical recommendations from
the Patient Care Committee of the Heart Failure Association of the
European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>115</p>
<p>–</p>
<p>126</p>
<p>.</p>
<p>305</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Levy</p>
<p>P</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Laribi</p>
<p>S</p>
<p>,</p>
<p>Ristic</p>
<p>AD</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Riley</p>
<p>JP</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>deFilippi</p>
<p>C</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Maggioni</p>
<p>A</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Leite-Moreira</p>
<p>AF</p>
<p>,</p>
<p>Bellou</p>
<p>A</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Recommendations on pre-hospital and early hospital management of
acute heart failure: a consensus paper from the Heart Failure
Association of the European Society of Cardiology, the European Society
of Emergency Medicine and the Society of Academic Emergency
Medicine–short version</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1958</p>
<p>–</p>
<p>1966</p>
<p>.</p>
<p>306</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>Gardner</p>
<p>RS</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Nielsen</p>
<p>OW</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Heart Failure Association of the European Society of Cardiology
specialist heart failure curriculum</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>151</p>
<p>–</p>
<p>162</p>
<p>.</p>
<p>307</p>
<p>Riley</p>
<p>JP</p>
<p>,</p>
<p>Astin</p>
<p>F</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Deaton</p>
<p>CM</p>
<p>,</p>
<p>Kienhorst</p>
<p>J</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>Rushton</p>
<p>CA</p>
<p>,</p>
<p>Stromberg</p>
<p>A</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Heart Failure Association of the European Society of Cardiology heart
failure nurse curriculum</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>736</p>
<p>–</p>
<p>743</p>
<p>.</p>
<p>308</p>
<p>Van Spall</p>
<p>HGC</p>
<p>,</p>
<p>Rahman</p>
<p>T</p>
<p>,</p>
<p>Mytton</p>
<p>O</p>
<p>,</p>
<p>Ramasundarahettige</p>
<p>C</p>
<p>,</p>
<p>Ibrahim</p>
<p>Q</p>
<p>,</p>
<p>Kabali</p>
<p>C</p>
<p>,</p>
<p>Coppens</p>
<p>M</p>
<p>,</p>
<p>Brian Haynes</p>
<p>R</p>
<p>,</p>
<p>Connolly</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Comparative effectiveness of transitional care services in patients
discharged from the hospital with heart failure: a systematic review and
network meta-analysis</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1427</p>
<p>–</p>
<p>1443</p>
<p>.</p>
<p>309</p>
<p>Jonkman</p>
<p>NH</p>
<p>,</p>
<p>Westland</p>
<p>H</p>
<p>,</p>
<p>Groenwold</p>
<p>RH</p>
<p>,</p>
<p>Agren</p>
<p>S</p>
<p>,</p>
<p>Anguita</p>
<p>M</p>
<p>,</p>
<p>Blue</p>
<p>L</p>
<p>,</p>
<p>Bruggink-Andre de la Porte</p>
<p>PW</p>
<p>,</p>
<p>DeWalt</p>
<p>DA</p>
<p>,</p>
<p>Hebert</p>
<p>PL</p>
<p>,</p>
<p>Heisler</p>
<p>M</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Kempen</p>
<p>GI</p>
<p>,</p>
<p>Leventhal</p>
<p>ME</p>
<p>,</p>
<p>Lok</p>
<p>DJ</p>
<p>,</p>
<p>Martensson</p>
<p>J</p>
<p>,</p>
<p>Muniz</p>
<p>J</p>
<p>,</p>
<p>Otsu</p>
<p>H</p>
<p>,</p>
<p>Peters-Klimm</p>
<p>F</p>
<p>,</p>
<p>Rich</p>
<p>MW</p>
<p>,</p>
<p>Riegel</p>
<p>B</p>
<p>,</p>
<p>Stromberg</p>
<p>A</p>
<p>,</p>
<p>Tsuyuki</p>
<p>RT</p>
<p>,</p>
<p>Trappenburg</p>
<p>JC</p>
<p>,</p>
<p>Schuurmans</p>
<p>MJ</p>
<p>,</p>
<p>Hoes</p>
<p>AW.</p>
<p>What are effective program characteristics of self-management
interventions in patients with heart failure? An individual patient data
meta-analysis</p>
<p>.</p>
<p>J Card Fail</p>
<p>2016</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>861</p>
<p>–</p>
<p>871</p>
<p>.</p>
<p>310</p>
<p>Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management
interventions for heart failure. <em>Cochrane Database Syst Rev</em>
2019;<strong>1</strong>:CD002752.</p>
<p>311</p>
<p>Kalogirou</p>
<p>F</p>
<p>,</p>
<p>Forsyth</p>
<p>F</p>
<p>,</p>
<p>Kyriakou</p>
<p>M</p>
<p>,</p>
<p>Mantle</p>
<p>R</p>
<p>,</p>
<p>Deaton</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Heart failure disease management: a systematic review of
effectiveness in heart failure with preserved ejection fraction</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>194</p>
<p>–</p>
<p>212</p>
<p>.</p>
<p>312</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Prager Geller</p>
<p>T</p>
<p>,</p>
<p>Baruah</p>
<p>R</p>
<p>,</p>
<p>Beattie</p>
<p>JM</p>
<p>,</p>
<p>Boyne</p>
<p>J</p>
<p>,</p>
<p>de Stoutz</p>
<p>N</p>
<p>,</p>
<p>Di Stolfo</p>
<p>G</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Skibelund</p>
<p>AK</p>
<p>,</p>
<p>Uchmanowicz</p>
<p>I</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Ben Gal</p>
<p>T</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Stromberg</p>
<p>A</p>
<p>,</p>
<p>Jaarsma</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Integration of a palliative approach into heart failure care: a
European Society of Cardiology Heart Failure Association position
paper</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2327</p>
<p>–</p>
<p>2339</p>
<p>.</p>
<p>313</p>
<p>Kyriakou</p>
<p>M</p>
<p>,</p>
<p>Middleton</p>
<p>N</p>
<p>,</p>
<p>Ktisti</p>
<p>S</p>
<p>,</p>
<p>Philippou</p>
<p>K</p>
<p>,</p>
<p>Lambrinou</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>Supportive care interventions to promote health-related quality of
life in patients living with heart failure: a systematic review and
meta-analysis</p>
<p>.</p>
<p>Heart Lung Circ</p>
<p>2020</p>
<p>;</p>
<p>29</p>
<p>:</p>
<p>1633</p>
<p>–</p>
<p>1647</p>
<p>.</p>
<p>314</p>
<p>Feltner</p>
<p>C</p>
<p>,</p>
<p>Jones</p>
<p>CD</p>
<p>,</p>
<p>Cene</p>
<p>CW</p>
<p>,</p>
<p>Zheng</p>
<p>ZJ</p>
<p>,</p>
<p>Sueta</p>
<p>CA</p>
<p>,</p>
<p>Coker-Schwimmer</p>
<p>EJ</p>
<p>,</p>
<p>Arvanitis</p>
<p>M</p>
<p>,</p>
<p>Lohr</p>
<p>KN</p>
<p>,</p>
<p>Middleton</p>
<p>JC</p>
<p>,</p>
<p>Jonas</p>
<p>DE.</p>
<p>Transitional care interventions to prevent readmissions for persons
with heart failure: a systematic review and meta-analysis</p>
<p>.</p>
<p>Ann Intern Med</p>
<p>2014</p>
<p>;</p>
<p>160</p>
<p>:</p>
<p>774</p>
<p>–</p>
<p>784</p>
<p>.</p>
<p>315</p>
<p>Blue</p>
<p>L</p>
<p>,</p>
<p>Lang</p>
<p>E</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Davie</p>
<p>AP</p>
<p>,</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>Murdoch</p>
<p>DR</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Connolly</p>
<p>E</p>
<p>,</p>
<p>Norrie</p>
<p>J</p>
<p>,</p>
<p>Round</p>
<p>CE</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Morrison</p>
<p>CE.</p>
<p>Randomised controlled trial of specialist nurse intervention in heart
failure</p>
<p>.</p>
<p>BMJ</p>
<p>2001</p>
<p>;</p>
<p>323</p>
<p>:</p>
<p>715</p>
<p>–</p>
<p>718</p>
<p>.</p>
<p>316</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Kalogirou</p>
<p>F</p>
<p>,</p>
<p>Lamnisos</p>
<p>D</p>
<p>,</p>
<p>Sourtzi</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Effectiveness of heart failure management programmes with nurse-led
discharge planning in reducing re-admissions: a systematic review and
meta-analysis</p>
<p>.</p>
<p>Int J Nurs Stud</p>
<p>2012</p>
<p>;</p>
<p>49</p>
<p>:</p>
<p>610</p>
<p>–</p>
<p>624</p>
<p>.</p>
<p>317</p>
<p>Stewart</p>
<p>S</p>
<p>,</p>
<p>Vandenbroek</p>
<p>AJ</p>
<p>,</p>
<p>Pearson</p>
<p>S</p>
<p>,</p>
<p>Horowitz</p>
<p>JD.</p>
<p>Prolonged beneficial effects of a home-based intervention on
unplanned readmissions and mortality among patients with congestive
heart failure</p>
<p>.</p>
<p>Arch Intern Med</p>
<p>1999</p>
<p>;</p>
<p>159</p>
<p>:</p>
<p>257</p>
<p>–</p>
<p>261</p>
<p>.</p>
<p>318</p>
<p>Ekman</p>
<p>I</p>
<p>,</p>
<p>Wolf</p>
<p>A</p>
<p>,</p>
<p>Olsson</p>
<p>LE</p>
<p>,</p>
<p>Taft</p>
<p>C</p>
<p>,</p>
<p>Dudas</p>
<p>K</p>
<p>,</p>
<p>Schaufelberger</p>
<p>M</p>
<p>,</p>
<p>Swedberg</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Effects of person-centred care in patients with chronic heart
failure: the PCC-HF study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2012</p>
<p>;</p>
<p>33</p>
<p>:</p>
<p>1112</p>
<p>–</p>
<p>1119</p>
<p>.</p>
<p>319</p>
<p>Riegel</p>
<p>B</p>
<p>,</p>
<p>Bennett</p>
<p>JA</p>
<p>,</p>
<p>Davis</p>
<p>A</p>
<p>,</p>
<p>Carlson</p>
<p>B</p>
<p>,</p>
<p>Montague</p>
<p>J</p>
<p>,</p>
<p>Robin</p>
<p>H</p>
<p>,</p>
<p>Glaser</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Cognitive impairment in heart failure: issues of measurement and
etiology</p>
<p>.</p>
<p>Am J Crit Care</p>
<p>2002</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>520</p>
<p>–</p>
<p>528</p>
<p>.</p>
<p>320</p>
<p>Laufs</p>
<p>U</p>
<p>,</p>
<p>Rettig-Ewen</p>
<p>V</p>
<p>,</p>
<p>Bohm</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Strategies to improve drug adherence</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2011</p>
<p>;</p>
<p>32</p>
<p>:</p>
<p>264</p>
<p>–</p>
<p>268</p>
<p>.</p>
<p>321</p>
<p>Abraityte</p>
<p>A</p>
<p>,</p>
<p>Aukrust</p>
<p>P</p>
<p>,</p>
<p>Kou</p>
<p>L</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Young</p>
<p>J</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Gullestad</p>
<p>L</p>
<p>,</p>
<p>Ueland</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>T cell and monocyte/macrophage activation markers associate with
adverse outcome, but give limited prognostic value in anemic patients
with heart failure: results from RED-HF</p>
<p>.</p>
<p>Clin Res Cardiol</p>
<p>2019</p>
<p>;</p>
<p>108</p>
<p>:</p>
<p>133</p>
<p>–</p>
<p>141</p>
<p>.</p>
<p>322</p>
<p>Flynn</p>
<p>KE</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Lin</p>
<p>L</p>
<p>,</p>
<p>Blumenthal</p>
<p>JA</p>
<p>,</p>
<p>Ellis</p>
<p>SJ</p>
<p>,</p>
<p>Fine</p>
<p>LJ</p>
<p>,</p>
<p>Howlett</p>
<p>JG</p>
<p>,</p>
<p>Keteyian</p>
<p>SJ</p>
<p>,</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Kraus</p>
<p>WE</p>
<p>,</p>
<p>Miller</p>
<p>NH</p>
<p>,</p>
<p>Schulman</p>
<p>KA</p>
<p>,</p>
<p>Spertus</p>
<p>JA</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Weinfurt</p>
<p>KP</p>
<p>HF-ACTION Investigators</p>
<p>.</p>
<p>Effects of exercise training on health status in patients with
chronic heart failure: HF-ACTION randomized controlled trial</p>
<p>.</p>
<p>JAMA</p>
<p>2009</p>
<p>;</p>
<p>301</p>
<p>:</p>
<p>1451</p>
<p>–</p>
<p>1459</p>
<p>.</p>
<p>323</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Keteyian</p>
<p>SJ</p>
<p>,</p>
<p>Cooper</p>
<p>LS</p>
<p>,</p>
<p>Ellis</p>
<p>SJ</p>
<p>,</p>
<p>Leifer</p>
<p>ES</p>
<p>,</p>
<p>Kraus</p>
<p>WE</p>
<p>,</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Blumenthal</p>
<p>JA</p>
<p>,</p>
<p>Rendall</p>
<p>DS</p>
<p>,</p>
<p>Miller</p>
<p>NH</p>
<p>,</p>
<p>Fleg</p>
<p>JL</p>
<p>,</p>
<p>Schulman</p>
<p>KA</p>
<p>,</p>
<p>McKelvie</p>
<p>RS</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>HF-ACTION Investigators</p>
<p>.</p>
<p>Efficacy and safety of exercise training in patients with chronic
heart failure: HF-ACTION randomized controlled trial</p>
<p>.</p>
<p>JAMA</p>
<p>2009</p>
<p>;</p>
<p>301</p>
<p>:</p>
<p>1439</p>
<p>–</p>
<p>1450</p>
<p>.</p>
<p>324</p>
<p>Taylor</p>
<p>RS</p>
<p>,</p>
<p>Walker</p>
<p>S</p>
<p>,</p>
<p>Smart</p>
<p>NA</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Warren</p>
<p>FC</p>
<p>,</p>
<p>Ciani</p>
<p>O</p>
<p>,</p>
<p>Whellan</p>
<p>D</p>
<p>,</p>
<p>O’Connor</p>
<p>C</p>
<p>,</p>
<p>Keteyian</p>
<p>SJ</p>
<p>,</p>
<p>Coats</p>
<p>A</p>
<p>,</p>
<p>Davos</p>
<p>CH</p>
<p>,</p>
<p>Dalal</p>
<p>HM</p>
<p>,</p>
<p>Dracup</p>
<p>K</p>
<p>,</p>
<p>Evangelista</p>
<p>LS</p>
<p>,</p>
<p>Jolly</p>
<p>K</p>
<p>,</p>
<p>Myers</p>
<p>J</p>
<p>,</p>
<p>Nilsson</p>
<p>BB</p>
<p>,</p>
<p>Passino</p>
<p>C</p>
<p>,</p>
<p>Witham</p>
<p>MD</p>
<p>,</p>
<p>Yeh</p>
<p>GY</p>
<p>,</p>
<p>ExTraMATCH II Collaboration</p>
<p>.</p>
<p>Impact of exercise rehabilitation on exercise capacity and
quality-of-life in heart failure: individual participant
meta-analysis</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>73</p>
<p>:</p>
<p>1430</p>
<p>–</p>
<p>1443</p>
<p>.</p>
<p>325</p>
<p>Taylor</p>
<p>RS</p>
<p>,</p>
<p>Walker</p>
<p>S</p>
<p>,</p>
<p>Smart</p>
<p>NA</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Warren</p>
<p>FC</p>
<p>,</p>
<p>Ciani</p>
<p>O</p>
<p>,</p>
<p>O’Connor</p>
<p>C</p>
<p>,</p>
<p>Whellan</p>
<p>D</p>
<p>,</p>
<p>Keteyian</p>
<p>SJ</p>
<p>,</p>
<p>Coats</p>
<p>A</p>
<p>,</p>
<p>Davos</p>
<p>CH</p>
<p>,</p>
<p>Dalal</p>
<p>HM</p>
<p>,</p>
<p>Dracup</p>
<p>K</p>
<p>,</p>
<p>Evangelista</p>
<p>L</p>
<p>,</p>
<p>Jolly</p>
<p>K</p>
<p>,</p>
<p>Myers</p>
<p>J</p>
<p>,</p>
<p>McKelvie</p>
<p>RS</p>
<p>,</p>
<p>Nilsson</p>
<p>BB</p>
<p>,</p>
<p>Passino</p>
<p>C</p>
<p>,</p>
<p>Witham</p>
<p>MD</p>
<p>,</p>
<p>Yeh</p>
<p>GY</p>
<p>,</p>
<p>Zwisler</p>
<p>AO</p>
<p>,</p>
<p>ExTraMATCH II Collaboration</p>
<p>.</p>
<p>Impact of exercise-based cardiac rehabilitation in patients with
heart failure (ExTraMATCH II) on mortality and hospitalisation: an
individual patient data meta-analysis of randomised trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1735</p>
<p>–</p>
<p>1743</p>
<p>.</p>
<p>326</p>
<p>Pandey</p>
<p>A</p>
<p>,</p>
<p>Parashar</p>
<p>A</p>
<p>,</p>
<p>Kumbhani</p>
<p>D</p>
<p>,</p>
<p>Agarwal</p>
<p>S</p>
<p>,</p>
<p>Garg</p>
<p>J</p>
<p>,</p>
<p>Kitzman</p>
<p>D</p>
<p>,</p>
<p>Levine</p>
<p>B</p>
<p>,</p>
<p>Drazner</p>
<p>M</p>
<p>,</p>
<p>Berry</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Exercise training in patients with heart failure and preserved
ejection fraction: meta-analysis of randomized control trials</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>33</p>
<p>–</p>
<p>40</p>
<p>.</p>
<p>327</p>
<p>Taylor</p>
<p>RS</p>
<p>,</p>
<p>Long</p>
<p>L</p>
<p>,</p>
<p>Mordi</p>
<p>IR</p>
<p>,</p>
<p>Madsen</p>
<p>MT</p>
<p>,</p>
<p>Davies</p>
<p>EJ</p>
<p>,</p>
<p>Dalal</p>
<p>H</p>
<p>,</p>
<p>Rees</p>
<p>K</p>
<p>,</p>
<p>Singh</p>
<p>SJ</p>
<p>,</p>
<p>Gluud</p>
<p>C</p>
<p>,</p>
<p>Zwisler</p>
<p>AD.</p>
<p>Exercise-based rehabilitation for heart failure: Cochrane Systematic
Review, meta-analysis, and trial sequential analysis</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>691</p>
<p>–</p>
<p>705</p>
<p>.</p>
<p>328</p>
<p>Taylor</p>
<p>RS</p>
<p>,</p>
<p>Walker</p>
<p>S</p>
<p>,</p>
<p>Ciani</p>
<p>O</p>
<p>,</p>
<p>Warren</p>
<p>F</p>
<p>,</p>
<p>Smart</p>
<p>NA</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Davos</p>
<p>CH.</p>
<p>Exercise-based cardiac rehabilitation for chronic heart failure: the
EXTRAMATCH II individual participant data meta-analysis</p>
<p>.</p>
<p>Health Technol Assess</p>
<p>2019</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>98</p>
<p>.</p>
<p>329</p>
<p>Cooper</p>
<p>LB</p>
<p>,</p>
<p>Mentz</p>
<p>RJ</p>
<p>,</p>
<p>Sun</p>
<p>JL</p>
<p>,</p>
<p>Schulte</p>
<p>PJ</p>
<p>,</p>
<p>Fleg</p>
<p>JL</p>
<p>,</p>
<p>Cooper</p>
<p>LS</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>Leifer</p>
<p>ES</p>
<p>,</p>
<p>Kraus</p>
<p>WE</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Keteyian</p>
<p>SJ</p>
<p>,</p>
<p>O’Connor</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Psychosocial factors, exercise adherence, and outcomes in heart
failure patients: insights from Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training (HF-ACTION)</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>1044</p>
<p>–</p>
<p>1051</p>
<p>.</p>
<p>330</p>
<p>Gomes Neto</p>
<p>M</p>
<p>,</p>
<p>Duraes</p>
<p>AR</p>
<p>,</p>
<p>Conceicao</p>
<p>LSR</p>
<p>,</p>
<p>Saquetto</p>
<p>MB</p>
<p>,</p>
<p>Ellingsen</p>
<p>O</p>
<p>,</p>
<p>Carvalho</p>
<p>VO.</p>
<p>High intensity interval training versus moderate intensity continuous
training on exercise capacity and quality of life in patients with heart
failure with reduced ejection fraction: a systematic review and
meta-analysis</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2018</p>
<p>;</p>
<p>261</p>
<p>:</p>
<p>134</p>
<p>–</p>
<p>141</p>
<p>.</p>
<p>331</p>
<p>Ellingsen</p>
<p>O</p>
<p>,</p>
<p>Halle</p>
<p>M</p>
<p>,</p>
<p>Conraads</p>
<p>V</p>
<p>,</p>
<p>Stoylen</p>
<p>A</p>
<p>,</p>
<p>Dalen</p>
<p>H</p>
<p>,</p>
<p>Delagardelle</p>
<p>C</p>
<p>,</p>
<p>Larsen</p>
<p>AI</p>
<p>,</p>
<p>Hole</p>
<p>T</p>
<p>,</p>
<p>Mezzani</p>
<p>A</p>
<p>,</p>
<p>Van Craenenbroeck</p>
<p>EM</p>
<p>,</p>
<p>Videm</p>
<p>V</p>
<p>,</p>
<p>Beckers</p>
<p>P</p>
<p>,</p>
<p>Christle</p>
<p>JW</p>
<p>,</p>
<p>Winzer</p>
<p>E</p>
<p>,</p>
<p>Mangner</p>
<p>N</p>
<p>,</p>
<p>Woitek</p>
<p>F</p>
<p>,</p>
<p>Hollriegel</p>
<p>R</p>
<p>,</p>
<p>Pressler</p>
<p>A</p>
<p>,</p>
<p>Monk-Hansen</p>
<p>T</p>
<p>,</p>
<p>Snoer</p>
<p>M</p>
<p>,</p>
<p>Feiereisen</p>
<p>P</p>
<p>,</p>
<p>Valborgland</p>
<p>T</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Hambrecht</p>
<p>R</p>
<p>,</p>
<p>Gielen</p>
<p>S</p>
<p>,</p>
<p>Karlsen</p>
<p>T</p>
<p>,</p>
<p>Prescott</p>
<p>E</p>
<p>,</p>
<p>Linke</p>
<p>A</p>
<p>,</p>
<p>SMARTEX Heart Failure Study Group. High-intensity interval training
in patients with heart failure with reduced ejection fraction</p>
<p>.</p>
<p>Circulation</p>
<p>2017</p>
<p>;</p>
<p>135</p>
<p>:</p>
<p>839</p>
<p>–</p>
<p>849</p>
<p>.</p>
<p>332</p>
<p>Edelmann</p>
<p>F</p>
<p>,</p>
<p>Gelbrich</p>
<p>G</p>
<p>,</p>
<p>Dungen</p>
<p>HD</p>
<p>,</p>
<p>Frohling</p>
<p>S</p>
<p>,</p>
<p>Wachter</p>
<p>R</p>
<p>,</p>
<p>Stahrenberg</p>
<p>R</p>
<p>,</p>
<p>Binder</p>
<p>L</p>
<p>,</p>
<p>Topper</p>
<p>A</p>
<p>,</p>
<p>Lashki</p>
<p>DJ</p>
<p>,</p>
<p>Schwarz</p>
<p>S</p>
<p>,</p>
<p>Herrmann-Lingen</p>
<p>C</p>
<p>,</p>
<p>Loffler</p>
<p>M</p>
<p>,</p>
<p>Hasenfuss</p>
<p>G</p>
<p>,</p>
<p>Halle</p>
<p>M</p>
<p>,</p>
<p>Pieske</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Exercise training improves exercise capacity and diastolic function
in patients with heart failure with preserved ejection fraction: results
of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot
study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2011</p>
<p>;</p>
<p>58</p>
<p>:</p>
<p>1780</p>
<p>–</p>
<p>1791</p>
<p>.</p>
<p>333</p>
<p>Nolte</p>
<p>K</p>
<p>,</p>
<p>Herrmann-Lingen</p>
<p>C</p>
<p>,</p>
<p>Wachter</p>
<p>R</p>
<p>,</p>
<p>Gelbrich</p>
<p>G</p>
<p>,</p>
<p>Dungen</p>
<p>HD</p>
<p>,</p>
<p>Duvinage</p>
<p>A</p>
<p>,</p>
<p>Hoischen</p>
<p>N</p>
<p>,</p>
<p>von Oehsen</p>
<p>K</p>
<p>,</p>
<p>Schwarz</p>
<p>S</p>
<p>,</p>
<p>Hasenfuss</p>
<p>G</p>
<p>,</p>
<p>Halle</p>
<p>M</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Edelmann</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Effects of exercise training on different quality of life dimensions
in heart failure with preserved ejection fraction: the Ex-DHF-P
trial</p>
<p>.</p>
<p>Eur J Prev Cardiol</p>
<p>2015</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>582</p>
<p>–</p>
<p>593</p>
<p>.</p>
<p>334</p>
<p>Ismail</p>
<p>H</p>
<p>,</p>
<p>McFarlane</p>
<p>JR</p>
<p>,</p>
<p>Nojoumian</p>
<p>AH</p>
<p>,</p>
<p>Dieberg</p>
<p>G</p>
<p>,</p>
<p>Smart</p>
<p>NA.</p>
<p>Clinical outcomes and cardiovascular responses to different exercise
training intensities in patients with heart failure: a systematic review
and meta-analysis</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>1</p>
<p>:</p>
<p>514</p>
<p>–</p>
<p>522</p>
<p>.</p>
<p>335</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Brubaker</p>
<p>PH</p>
<p>,</p>
<p>Herrington</p>
<p>DM</p>
<p>,</p>
<p>Morgan</p>
<p>TM</p>
<p>,</p>
<p>Stewart</p>
<p>KP</p>
<p>,</p>
<p>Hundley</p>
<p>WG</p>
<p>,</p>
<p>Abdelhamed</p>
<p>A</p>
<p>,</p>
<p>Haykowsky</p>
<p>MJ.</p>
<p>Effect of endurance exercise training on endothelial function and
arterial stiffness in older patients with heart failure and preserved
ejection fraction: a randomized, controlled, single-blind trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2013</p>
<p>;</p>
<p>62</p>
<p>:</p>
<p>584</p>
<p>–</p>
<p>592</p>
<p>.</p>
<p>336</p>
<p>Ismail</p>
<p>H</p>
<p>,</p>
<p>McFarlane</p>
<p>J</p>
<p>,</p>
<p>Smart</p>
<p>NA.</p>
<p>Is exercise training beneficial for heart failure patients taking
beta-adrenergic blockers? A systematic review and meta-analysis</p>
<p>.</p>
<p>Congest Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>61</p>
<p>–</p>
<p>69</p>
<p>.</p>
<p>337</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Brubaker</p>
<p>P</p>
<p>,</p>
<p>Morgan</p>
<p>T</p>
<p>,</p>
<p>Haykowsky</p>
<p>M</p>
<p>,</p>
<p>Hundley</p>
<p>G</p>
<p>,</p>
<p>Kraus</p>
<p>WE</p>
<p>,</p>
<p>Eggebeen</p>
<p>J</p>
<p>,</p>
<p>Nicklas</p>
<p>BJ.</p>
<p>Effect of caloric restriction or aerobic exercise training on peak
oxygen consumption and quality of life in obese older patients with
heart failure with preserved ejection fraction: a randomized clinical
trial</p>
<p>.</p>
<p>JAMA</p>
<p>2016</p>
<p>;</p>
<p>315</p>
<p>:</p>
<p>36</p>
<p>–</p>
<p>46</p>
<p>.</p>
<p>338</p>
<p>Taylor</p>
<p>RS</p>
<p>,</p>
<p>Sagar</p>
<p>VA</p>
<p>,</p>
<p>Davies</p>
<p>EJ</p>
<p>,</p>
<p>Briscoe</p>
<p>S</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Dalal</p>
<p>H</p>
<p>,</p>
<p>Lough</p>
<p>F</p>
<p>,</p>
<p>Rees</p>
<p>K</p>
<p>,</p>
<p>Singh</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Exercise-based rehabilitation for heart failure</p>
<p>.</p>
<p>Cochrane Database Syst Rev</p>
<p>2014</p>
<p>:CD003331.</p>
<p>339</p>
<p>Schou</p>
<p>M</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Videbaek</p>
<p>L</p>
<p>,</p>
<p>Tuxen</p>
<p>C</p>
<p>,</p>
<p>Keller</p>
<p>N</p>
<p>,</p>
<p>Handberg</p>
<p>J</p>
<p>,</p>
<p>Sejr Knudsen</p>
<p>A</p>
<p>,</p>
<p>Espersen</p>
<p>G</p>
<p>,</p>
<p>Markenvard</p>
<p>J</p>
<p>,</p>
<p>Egstrup</p>
<p>K</p>
<p>,</p>
<p>Ulriksen</p>
<p>H</p>
<p>,</p>
<p>Hildebrandt</p>
<p>PR</p>
<p>,</p>
<p>the NorthStar Investigators, all members of The Danish Heart Failure
Clinics Network</p>
<p>.</p>
<p>Extended heart failure clinic follow-up in low-risk patients: a
randomized clinical trial (NorthStar)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>432</p>
<p>–</p>
<p>442</p>
<p>.</p>
<p>340</p>
<p>Thorvaldsen</p>
<p>T</p>
<p>,</p>
<p>Benson</p>
<p>L</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Edner</p>
<p>M</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Use of evidence-based therapy and survival in heart failure in Sweden
2003-2012</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>503</p>
<p>–</p>
<p>511</p>
<p>.</p>
<p>341</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Braunschweig</p>
<p>F</p>
<p>,</p>
<p>Benson</p>
<p>L</p>
<p>,</p>
<p>Stahlberg</p>
<p>M</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Linde</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Association between demographic, organizational, clinical, and
socio-economic characteristics and underutilization of cardiac
resynchronization therapy: results from the Swedish Heart Failure
Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1270</p>
<p>–</p>
<p>1279</p>
<p>.</p>
<p>342</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Carrero</p>
<p>JJ</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Factors associated with underuse of mineralocorticoid receptor
antagonists in heart failure with reduced ejection fraction: an analysis
of 11 215 patients from the Swedish Heart Failure Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1326</p>
<p>–</p>
<p>1334</p>
<p>.</p>
<p>343</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Carrero</p>
<p>JJ</p>
<p>,</p>
<p>Farahmand</p>
<p>B</p>
<p>,</p>
<p>Henriksson</p>
<p>KM</p>
<p>,</p>
<p>Jonsson</p>
<p>A</p>
<p>,</p>
<p>Jernberg</p>
<p>T</p>
<p>,</p>
<p>Dahlstrom</p>
<ol start="21" type="A">
<li></li>
</ol>
<p>Association between enrolment in a heart failure quality registry and
subsequent mortality–a nationwide cohort study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1107</p>
<p>–</p>
<p>1116</p>
<p>.</p>
<p>344</p>
<p>Clark</p>
<p>AL</p>
<p>,</p>
<p>Goode</p>
<p>K</p>
<p>,</p>
<p>Cleland</p>
<p>JG.</p>
<p>The prevalence and incidence of left bundle branch block in ambulant
patients with chronic heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2008</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>696</p>
<p>–</p>
<p>702</p>
<p>.</p>
<p>345</p>
<p>Troughton</p>
<p>RW</p>
<p>,</p>
<p>Frampton</p>
<p>CM</p>
<p>,</p>
<p>Yandle</p>
<p>TG</p>
<p>,</p>
<p>Espiner</p>
<p>EA</p>
<p>,</p>
<p>Nicholls</p>
<p>MG</p>
<p>,</p>
<p>Richards</p>
<p>AM.</p>
<p>Treatment of heart failure guided by plasma aminoterminal brain
natriuretic peptide (N-BNP) concentrations</p>
<p>.</p>
<p>Lancet</p>
<p>2000</p>
<p>;</p>
<p>355</p>
<p>:</p>
<p>1126</p>
<p>–</p>
<p>1130</p>
<p>.</p>
<p>346</p>
<p>Berger</p>
<p>R</p>
<p>,</p>
<p>Moertl</p>
<p>D</p>
<p>,</p>
<p>Peter</p>
<p>S</p>
<p>,</p>
<p>Ahmadi</p>
<p>R</p>
<p>,</p>
<p>Huelsmann</p>
<p>M</p>
<p>,</p>
<p>Yamuti</p>
<p>S</p>
<p>,</p>
<p>Wagner</p>
<p>B</p>
<p>,</p>
<p>Pacher</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>N-terminal pro-B-type natriuretic peptide-guided, intensive patient
management in addition to multidisciplinary care in chronic heart
failure a 3-arm, prospective, randomized pilot study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2010</p>
<p>;</p>
<p>55</p>
<p>:</p>
<p>645</p>
<p>–</p>
<p>653</p>
<p>.</p>
<p>347</p>
<p>Jourdain</p>
<p>P</p>
<p>,</p>
<p>Jondeau</p>
<p>G</p>
<p>,</p>
<p>Funck</p>
<p>F</p>
<p>,</p>
<p>Gueffet</p>
<p>P</p>
<p>,</p>
<p>Le Helloco</p>
<p>A</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Aupetit</p>
<p>JF</p>
<p>,</p>
<p>Aumont</p>
<p>MC</p>
<p>,</p>
<p>Galinier</p>
<p>M</p>
<p>,</p>
<p>Eicher</p>
<p>JC</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Juilliere</p>
<ol start="25" type="A">
<li></li>
</ol>
<p>Plasma brain natriuretic peptide-guided therapy to improve outcome in
heart failure: the STARS-BNP Multicenter Study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2007</p>
<p>;</p>
<p>49</p>
<p>:</p>
<p>1733</p>
<p>–</p>
<p>1739</p>
<p>.</p>
<p>348</p>
<p>Lainchbury</p>
<p>JG</p>
<p>,</p>
<p>Troughton</p>
<p>RW</p>
<p>,</p>
<p>Strangman</p>
<p>KM</p>
<p>,</p>
<p>Frampton</p>
<p>CM</p>
<p>,</p>
<p>Pilbrow</p>
<p>A</p>
<p>,</p>
<p>Yandle</p>
<p>TG</p>
<p>,</p>
<p>Hamid</p>
<p>AK</p>
<p>,</p>
<p>Nicholls</p>
<p>MG</p>
<p>,</p>
<p>Richards</p>
<p>AM.</p>
<p>N-terminal pro-B-type natriuretic peptide-guided treatment for
chronic heart failure: results from the BATTLESCARRED
(NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and
Death) trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>55</p>
<p>:</p>
<p>53</p>
<p>–</p>
<p>60</p>
<p>.</p>
<p>349</p>
<p>Pfisterer</p>
<p>M</p>
<p>,</p>
<p>Buser</p>
<p>P</p>
<p>,</p>
<p>Rickli</p>
<p>H</p>
<p>,</p>
<p>Gutmann</p>
<p>M</p>
<p>,</p>
<p>Erne</p>
<p>P</p>
<p>,</p>
<p>Rickenbacher</p>
<p>P</p>
<p>,</p>
<p>Vuillomenet</p>
<p>A</p>
<p>,</p>
<p>Jeker</p>
<p>U</p>
<p>,</p>
<p>Dubach</p>
<p>P</p>
<p>,</p>
<p>Beer</p>
<p>H</p>
<p>,</p>
<p>Yoon</p>
<p>SI</p>
<p>,</p>
<p>Suter</p>
<p>T</p>
<p>,</p>
<p>Osterhues</p>
<p>HH</p>
<p>,</p>
<p>Schieber</p>
<p>MM</p>
<p>,</p>
<p>Hilti</p>
<p>P</p>
<p>,</p>
<p>Schindler</p>
<p>R</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>, TIME-CHF Investigators</p>
<p>BNP-guided vs symptom-guided heart failure therapy: the Trial of
Intensified vs Standard Medical Therapy in Elderly Patients With
Congestive Heart Failure (TIME-CHF) randomized trial</p>
<p>.</p>
<p>JAMA</p>
<p>2009</p>
<p>;</p>
<p>301</p>
<p>:</p>
<p>383</p>
<p>–</p>
<p>392</p>
<p>.</p>
<p>350</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Adams</p>
<p>KF</p>
<p>,</p>
<p>Ezekowitz</p>
<p>JA</p>
<p>,</p>
<p>Fiuzat</p>
<p>M</p>
<p>,</p>
<p>Houston-Miller</p>
<p>N</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>Jr.,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>Passmore</p>
<p>G</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Yang</p>
<p>H</p>
<p>,</p>
<p>Cooper</p>
<p>LS</p>
<p>,</p>
<p>Leifer</p>
<p>ES</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>O’Connor</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Effect of natriuretic peptide-guided therapy on hospitalization or
cardiovascular mortality in high-risk patients with heart failure and
reduced ejection fraction: a randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2017</p>
<p>;</p>
<p>318</p>
<p>:</p>
<p>713</p>
<p>–</p>
<p>720</p>
<p>.</p>
<p>351</p>
<p>Porapakkham</p>
<p>P</p>
<p>,</p>
<p>Porapakkham</p>
<p>P</p>
<p>,</p>
<p>Zimmet</p>
<p>H</p>
<p>,</p>
<p>Billah</p>
<p>B</p>
<p>,</p>
<p>Krum</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>B-type natriuretic peptide-guided heart failure therapy: a
meta-analysis</p>
<p>.</p>
<p>Arch Intern Med</p>
<p>2010</p>
<p>;</p>
<p>170</p>
<p>:</p>
<p>507</p>
<p>–</p>
<p>514</p>
<p>.</p>
<p>352</p>
<p>Troughton</p>
<p>RW</p>
<p>,</p>
<p>Frampton</p>
<p>CM</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Pfisterer</p>
<p>M</p>
<p>,</p>
<p>Eurlings</p>
<p>LW</p>
<p>,</p>
<p>Erntell</p>
<p>H</p>
<p>,</p>
<p>Persson</p>
<p>H</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Moertl</p>
<p>D</p>
<p>,</p>
<p>Karlstrom</p>
<p>P</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Gaggin</p>
<p>HK</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>,</p>
<p>Berger</p>
<p>R</p>
<p>,</p>
<p>Richards</p>
<p>AM</p>
<p>,</p>
<p>Pinto</p>
<p>YM</p>
<p>,</p>
<p>Nicholls</p>
<p>MG.</p>
<p>Effect of B-type natriuretic peptide-guided treatment of chronic
heart failure on total mortality and hospitalization: an individual
patient meta-analysis</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2014</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>1559</p>
<p>–</p>
<p>1567</p>
<p>.</p>
<p>353</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Fisher</p>
<p>LD</p>
<p>,</p>
<p>Chiang</p>
<p>YT</p>
<p>,</p>
<p>Latini</p>
<p>R</p>
<p>,</p>
<p>Masson</p>
<p>S</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Glazer</p>
<p>RD</p>
<p>,</p>
<p>Tognoni</p>
<p>G</p>
<p>,</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Val-HeFT Investigators</p>
<p>.</p>
<p>Changes in brain natriuretic peptide and norepinephrine over time and
mortality and morbidity in the Valsartan Heart Failure Trial
(Val-HeFT)</p>
<p>.</p>
<p>Circulation</p>
<p>2003</p>
<p>;</p>
<p>107</p>
<p>:</p>
<p>1278</p>
<p>–</p>
<p>1283</p>
<p>.</p>
<p>354</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Prescott</p>
<p>MF</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Gong</p>
<p>J</p>
<p>,</p>
<p>Shi</p>
<p>VC</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Prognostic implications of changes in N-terminal pro-B-type
natriuretic peptide in patients with heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2016</p>
<p>;</p>
<p>68</p>
<p>:</p>
<p>2425</p>
<p>–</p>
<p>2436</p>
<p>.</p>
<p>355</p>
<p>Brahmbhatt</p>
<p>DH</p>
<p>,</p>
<p>Cowie</p>
<p>MR.</p>
<p>Remote management of heart failure: an overview of telemonitoring
technologies</p>
<p>.</p>
<p>Card Fail Rev</p>
<p>2019</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>86</p>
<p>–</p>
<p>92</p>
<p>.</p>
<p>356</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Clark</p>
<p>RA</p>
<p>,</p>
<p>Pellicori</p>
<p>P</p>
<p>,</p>
<p>Inglis</p>
<p>SC.</p>
<p>Caring for people with heart failure and many other medical problems
through and beyond the COVID-19 pandemic: the advantages of universal
access to home telemonitoring</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>995</p>
<p>–</p>
<p>998</p>
<p>.</p>
<p>357</p>
<p>Inglis</p>
<p>SC</p>
<p>,</p>
<p>Clark</p>
<p>RA</p>
<p>,</p>
<p>Dierckx</p>
<p>R</p>
<p>,</p>
<p>Prieto-Merino</p>
<p>D</p>
<p>,</p>
<p>Cleland</p>
<p>JG.</p>
<p>Structured telephone support or non-invasive telemonitoring for
patients with heart failure</p>
<p>.</p>
<p>Heart</p>
<p>2017</p>
<p>;</p>
<p>103</p>
<p>:</p>
<p>255</p>
<p>–</p>
<p>257</p>
<p>.</p>
<p>358</p>
<p>Frederix</p>
<p>I</p>
<p>,</p>
<p>Caiani</p>
<p>EG</p>
<p>,</p>
<p>Dendale</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>S</p>
<p>,</p>
<p>Bax</p>
<p>J</p>
<p>,</p>
<p>Bohm</p>
<p>A</p>
<p>,</p>
<p>Cowie</p>
<p>M</p>
<p>,</p>
<p>Crawford</p>
<p>J</p>
<p>,</p>
<p>de Groot</p>
<p>N</p>
<p>,</p>
<p>Dilaveris</p>
<p>P</p>
<p>,</p>
<p>Hansen</p>
<p>T</p>
<p>,</p>
<p>Koehler</p>
<p>F</p>
<p>,</p>
<p>Krstacic</p>
<p>G</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Meier</p>
<p>P</p>
<p>,</p>
<p>Neubeck</p>
<p>L</p>
<p>,</p>
<p>Parati</p>
<p>G</p>
<p>,</p>
<p>Piotrowicz</p>
<p>E</p>
<p>,</p>
<p>Tubaro</p>
<p>M</p>
<p>,</p>
<p>van der Velde</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>ESC e-Cardiology Working Group Position Paper: Overcoming challenges
in digital health implementation in cardiovascular medicine</p>
<p>.</p>
<p>Eur J Prev Cardiol</p>
<p>2019</p>
<p>;</p>
<p>26</p>
<p>:</p>
<p>1166</p>
<p>–</p>
<p>1177</p>
<p>.</p>
<p>359</p>
<p>Lin</p>
<p>MH</p>
<p>,</p>
<p>Yuan</p>
<p>WL</p>
<p>,</p>
<p>Huang</p>
<p>TC</p>
<p>,</p>
<p>Zhang</p>
<p>HF</p>
<p>,</p>
<p>Mai</p>
<p>JT</p>
<p>,</p>
<p>Wang</p>
<p>JF.</p>
<p>Clinical effectiveness of telemedicine for chronic heart failure: a
systematic review and meta-analysis</p>
<p>.</p>
<p>J Investig Med</p>
<p>2017</p>
<p>;</p>
<p>65</p>
<p>:</p>
<p>899</p>
<p>–</p>
<p>911</p>
<p>.</p>
<p>360</p>
<p>Adamson</p>
<p>PB</p>
<p>,</p>
<p>Ginn</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Bourge</p>
<p>RC</p>
<p>,</p>
<p>Abraham</p>
<p>WT.</p>
<p>Remote haemodynamic-guided care for patients with chronic heart
failure: a meta-analysis of completed trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>426</p>
<p>–</p>
<p>433</p>
<p>.</p>
<p>361</p>
<p>Chaudhry</p>
<p>SI</p>
<p>,</p>
<p>Mattera</p>
<p>JA</p>
<p>,</p>
<p>Curtis</p>
<p>JP</p>
<p>,</p>
<p>Spertus</p>
<p>JA</p>
<p>,</p>
<p>Herrin</p>
<p>J</p>
<p>,</p>
<p>Lin</p>
<p>Z</p>
<p>,</p>
<p>Phillips</p>
<p>CO</p>
<p>,</p>
<p>Hodshon</p>
<p>BV</p>
<p>,</p>
<p>Cooper</p>
<p>LS</p>
<p>,</p>
<p>Krumholz</p>
<p>HM.</p>
<p>Telemonitoring in patients with heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2010</p>
<p>;</p>
<p>363</p>
<p>:</p>
<p>2301</p>
<p>–</p>
<p>2309</p>
<p>.</p>
<p>362</p>
<p>Koehler</p>
<p>F</p>
<p>,</p>
<p>Winkler</p>
<p>S</p>
<p>,</p>
<p>Schieber</p>
<p>M</p>
<p>,</p>
<p>Sechtem</p>
<p>U</p>
<p>,</p>
<p>Stangl</p>
<p>K</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Boll</p>
<p>H</p>
<p>,</p>
<p>Baumann</p>
<p>G</p>
<p>,</p>
<p>Honold</p>
<p>M</p>
<p>,</p>
<p>Koehler</p>
<p>K</p>
<p>,</p>
<p>Gelbrich</p>
<p>G</p>
<p>,</p>
<p>Kirwan</p>
<p>BA</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Telemedical Interventional Monitoring in Heart Failure
Investigators</p>
<p>.</p>
<p>Impact of remote telemedical management on mortality and
hospitalizations in ambulatory patients with chronic heart failure: the
telemedical interventional monitoring in heart failure study</p>
<p>.</p>
<p>Circulation</p>
<p>2011</p>
<p>;</p>
<p>123</p>
<p>:</p>
<p>1873</p>
<p>–</p>
<p>1880</p>
<p>.</p>
<p>363</p>
<p>Koehler</p>
<p>F</p>
<p>,</p>
<p>Koehler</p>
<p>K</p>
<p>,</p>
<p>Deckwart</p>
<p>O</p>
<p>,</p>
<p>Prescher</p>
<p>S</p>
<p>,</p>
<p>Wegscheider</p>
<p>K</p>
<p>,</p>
<p>Winkler</p>
<p>S</p>
<p>,</p>
<p>Vettorazzi</p>
<p>E</p>
<p>,</p>
<p>Polze</p>
<p>A</p>
<p>,</p>
<p>Stangl</p>
<p>K</p>
<p>,</p>
<p>Hartmann</p>
<p>O</p>
<p>,</p>
<p>Marx</p>
<p>A</p>
<p>,</p>
<p>Neuhaus</p>
<p>P</p>
<p>,</p>
<p>Scherf</p>
<p>M</p>
<p>,</p>
<p>Kirwan</p>
<p>BA</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Telemedical Interventional Management in Heart Failure II (TIM-HF2),
a randomised, controlled trial investigating the impact of telemedicine
on unplanned cardiovascular hospitalisations and mortality in heart
failure patients: study design and description of the intervention</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1485</p>
<p>–</p>
<p>1493</p>
<p>.</p>
<p>364</p>
<p>Koehler</p>
<p>F</p>
<p>,</p>
<p>Koehler</p>
<p>K</p>
<p>,</p>
<p>Deckwart</p>
<p>O</p>
<p>,</p>
<p>Prescher</p>
<p>S</p>
<p>,</p>
<p>Wegscheider</p>
<p>K</p>
<p>,</p>
<p>Kirwan</p>
<p>BA</p>
<p>,</p>
<p>Winkler</p>
<p>S</p>
<p>,</p>
<p>Vettorazzi</p>
<p>E</p>
<p>,</p>
<p>Bruch</p>
<p>L</p>
<p>,</p>
<p>Oeff</p>
<p>M</p>
<p>,</p>
<p>Zugck</p>
<p>C</p>
<p>,</p>
<p>Doerr</p>
<p>G</p>
<p>,</p>
<p>Naegele</p>
<p>H</p>
<p>,</p>
<p>Stork</p>
<p>S</p>
<p>,</p>
<p>Butter</p>
<p>C</p>
<p>,</p>
<p>Sechtem</p>
<p>U</p>
<p>,</p>
<p>Angermann</p>
<p>C</p>
<p>,</p>
<p>Gola</p>
<p>G</p>
<p>,</p>
<p>Prondzinsky</p>
<p>R</p>
<p>,</p>
<p>Edelmann</p>
<p>F</p>
<p>,</p>
<p>Spethmann</p>
<p>S</p>
<p>,</p>
<p>Schellong</p>
<p>SM</p>
<p>,</p>
<p>Schulze</p>
<p>PC</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Wellge</p>
<p>B</p>
<p>,</p>
<p>Schoebel</p>
<p>C</p>
<p>,</p>
<p>Tajsic</p>
<p>M</p>
<p>,</p>
<p>Dreger</p>
<p>H</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Stangl</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Efficacy of telemedical interventional management in patients with
heart failure (TIM-HF2): a randomised, controlled, parallel-group,
unmasked trial</p>
<p>.</p>
<p>Lancet</p>
<p>2018</p>
<p>;</p>
<p>392</p>
<p>:</p>
<p>1047</p>
<p>–</p>
<p>1057</p>
<p>.</p>
<p>365</p>
<p>Kalter-Leibovici</p>
<p>O</p>
<p>,</p>
<p>Freimark</p>
<p>D</p>
<p>,</p>
<p>Freedman</p>
<p>LS</p>
<p>,</p>
<p>Kaufman</p>
<p>G</p>
<p>,</p>
<p>Ziv</p>
<p>A</p>
<p>,</p>
<p>Murad</p>
<p>H</p>
<p>,</p>
<p>Benderly</p>
<p>M</p>
<p>,</p>
<p>Silverman</p>
<p>BG</p>
<p>,</p>
<p>Friedman</p>
<p>N</p>
<p>,</p>
<p>Cukierman-Yaffe</p>
<p>T</p>
<p>,</p>
<p>Asher</p>
<p>E</p>
<p>,</p>
<p>Grupper</p>
<p>A</p>
<p>,</p>
<p>Goldman</p>
<p>D</p>
<p>,</p>
<p>Amitai</p>
<p>M</p>
<p>,</p>
<p>Matetzky</p>
<p>S</p>
<p>,</p>
<p>Shani</p>
<p>M</p>
<p>,</p>
<p>Silber</p>
<p>H</p>
<p>,</p>
<p>Israel Heart Failure Disease Management Study investigators. Disease
management in the treatment of patients with chronic heart failure who
have universal access to health care: a randomized controlled trial</p>
<p>.</p>
<p>BMC Med</p>
<p>2017</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>90</p>
<p>.</p>
<p>366</p>
<p>Jayaram</p>
<p>NM</p>
<p>,</p>
<p>Khariton</p>
<p>Y</p>
<p>,</p>
<p>Krumholz</p>
<p>HM</p>
<p>,</p>
<p>Chaudhry</p>
<p>SI</p>
<p>,</p>
<p>Mattera</p>
<p>J</p>
<p>,</p>
<p>Tang</p>
<p>F</p>
<p>,</p>
<p>Herrin</p>
<p>J</p>
<p>,</p>
<p>Hodshon</p>
<p>B</p>
<p>,</p>
<p>Spertus</p>
<p>JA.</p>
<p>Impact of telemonitoring on health status</p>
<p>.</p>
<p>Circ Cardiovasc Qual Outcomes</p>
<p>2017</p>
<p>;</p>
<p>10</p>
<p>:e004148.</p>
<p>367</p>
<p>Shochat</p>
<p>MK</p>
<p>,</p>
<p>Shotan</p>
<p>A</p>
<p>,</p>
<p>Blondheim</p>
<p>DS</p>
<p>,</p>
<p>Kazatsker</p>
<p>M</p>
<p>,</p>
<p>Dahan</p>
<p>I</p>
<p>,</p>
<p>Asif</p>
<p>A</p>
<p>,</p>
<p>Rozenman</p>
<p>Y</p>
<p>,</p>
<p>Kleiner</p>
<p>I</p>
<p>,</p>
<p>Weinstein</p>
<p>JM</p>
<p>,</p>
<p>Frimerman</p>
<p>A</p>
<p>,</p>
<p>Vasilenko</p>
<p>L</p>
<p>,</p>
<p>Meisel</p>
<p>SR.</p>
<p>Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic
heart failure patients: a randomized controlled trial (IMPEDANCE-HF
Trial)</p>
<p>.</p>
<p>J Card Fail</p>
<p>2016</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>713</p>
<p>–</p>
<p>722</p>
<p>.</p>
<p>368</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Braunschweig</p>
<p>F</p>
<p>,</p>
<p>Conraads</p>
<p>V</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Jondeau</p>
<p>G</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>Aguilera</p>
<p>RM</p>
<p>,</p>
<p>Lunati</p>
<p>M</p>
<p>,</p>
<p>Yu</p>
<p>CM</p>
<p>,</p>
<p>Gerritse</p>
<p>B</p>
<p>,</p>
<p>Borggrefe</p>
<p>M</p>
<p>,</p>
<p>DOT-HF Investigators</p>
<p>.</p>
<p>Intrathoracic impedance monitoring, audible patient alerts, and
outcome in patients with heart failure</p>
<p>.</p>
<p>Circulation</p>
<p>2011</p>
<p>;</p>
<p>124</p>
<p>:</p>
<p>1719</p>
<p>–</p>
<p>1726</p>
<p>.</p>
<p>369</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Taborsky</p>
<p>M</p>
<p>,</p>
<p>Glikson</p>
<p>M</p>
<p>,</p>
<p>Heinrich</p>
<p>U</p>
<p>,</p>
<p>Schumacher</p>
<p>B</p>
<p>,</p>
<p>Katz</p>
<p>A</p>
<p>,</p>
<p>Brachmann</p>
<p>J</p>
<p>,</p>
<p>Lewalter</p>
<p>T</p>
<p>,</p>
<p>Goette</p>
<p>A</p>
<p>,</p>
<p>Block</p>
<p>M</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>Sack</p>
<p>S</p>
<p>,</p>
<p>Husser</p>
<p>D</p>
<p>,</p>
<p>Piorkowski</p>
<p>C</p>
<p>,</p>
<p>Sogaard</p>
<p>P</p>
<p>IN-TIME Study Group</p>
<p>.</p>
<p>Implant-based multiparameter telemonitoring of patients with heart
failure (IN-TIME): a randomised controlled trial</p>
<p>.</p>
<p>Lancet</p>
<p>2014</p>
<p>;</p>
<p>384</p>
<p>:</p>
<p>583</p>
<p>–</p>
<p>590</p>
<p>.</p>
<p>370</p>
<p>Morgan</p>
<p>JM</p>
<p>,</p>
<p>Kitt</p>
<p>S</p>
<p>,</p>
<p>Gill</p>
<p>J</p>
<p>,</p>
<p>McComb</p>
<p>JM</p>
<p>,</p>
<p>Ng</p>
<p>GA</p>
<p>,</p>
<p>Raftery</p>
<p>J</p>
<p>,</p>
<p>Roderick</p>
<p>P</p>
<p>,</p>
<p>Seed</p>
<p>A</p>
<p>,</p>
<p>Williams</p>
<p>SG</p>
<p>,</p>
<p>Witte</p>
<p>KK</p>
<p>,</p>
<p>Wright</p>
<p>DJ</p>
<p>,</p>
<p>Harris</p>
<p>S</p>
<p>,</p>
<p>Cowie</p>
<p>MR.</p>
<p>Remote management of heart failure using implantable electronic
devices</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>2352</p>
<p>–</p>
<p>2360</p>
<p>.</p>
<p>371</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Drexler</p>
<p>H</p>
<p>,</p>
<p>Oswald</p>
<p>H</p>
<p>,</p>
<p>Rybak</p>
<p>K</p>
<p>,</p>
<p>Bosch</p>
<p>R</p>
<p>,</p>
<p>Butter</p>
<p>C</p>
<p>,</p>
<p>Klein</p>
<p>G</p>
<p>,</p>
<p>Gerritse</p>
<p>B</p>
<p>,</p>
<p>Monteiro</p>
<p>J</p>
<p>,</p>
<p>Israel</p>
<p>C</p>
<p>,</p>
<p>Bimmel</p>
<p>D</p>
<p>,</p>
<p>Kaab</p>
<p>S</p>
<p>,</p>
<p>Huegl</p>
<p>B</p>
<p>,</p>
<p>Brachmann</p>
<p>J</p>
<p>,</p>
<p>OptiLink HF Study Investigators</p>
<p>.</p>
<p>Fluid status telemedicine alerts for heart failure: a randomized
controlled trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>3154</p>
<p>–</p>
<p>3163</p>
<p>.</p>
<p>372</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Bourge</p>
<p>RC</p>
<p>,</p>
<p>Lindenfeld</p>
<p>JA</p>
<p>,</p>
<p>Bauman</p>
<p>JG</p>
<p>,</p>
<p>Adamson</p>
<p>PB</p>
<p>,</p>
<p>CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery
pressure to guide adjustment of chronic heart failure therapy: complete
follow-up results from the CHAMPION randomised trial</p>
<p>.</p>
<p>Lancet</p>
<p>2016</p>
<p>;</p>
<p>387</p>
<p>:</p>
<p>453</p>
<p>–</p>
<p>461</p>
<p>.</p>
<p>373</p>
<p>Lindenfeld</p>
<p>J</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Maisel</p>
<p>A</p>
<p>,</p>
<p>Zile</p>
<p>M</p>
<p>,</p>
<p>Smart</p>
<p>F</p>
<p>,</p>
<p>Costanzo</p>
<p>MR</p>
<p>,</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Ducharme</p>
<p>A</p>
<p>,</p>
<p>Sears</p>
<p>SF</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Paul</p>
<p>S</p>
<p>,</p>
<p>Sood</p>
<p>P</p>
<p>,</p>
<p>Johnson</p>
<p>N</p>
<p>,</p>
<p>Ginn</p>
<p>G</p>
<p>,</p>
<p>Adamson</p>
<p>PB.</p>
<p>Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF)</p>
<p>.</p>
<p>Am Heart J</p>
<p>2019</p>
<p>;</p>
<p>214</p>
<p>:</p>
<p>18</p>
<p>–</p>
<p>27</p>
<p>.</p>
<p>374</p>
<p>Dierckx</p>
<p>R</p>
<p>,</p>
<p>Inglis</p>
<p>SC</p>
<p>,</p>
<p>Clark</p>
<p>RA</p>
<p>,</p>
<p>Prieto-Merino</p>
<p>D</p>
<p>,</p>
<p>Cleland</p>
<p>JG.</p>
<p>Telemedicine in heart failure: new insights from the Cochrane
meta-analyses</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>304</p>
<p>–</p>
<p>306</p>
<p>.</p>
<p>375</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Ewald</p>
<p>GA</p>
<p>,</p>
<p>Allen</p>
<p>LA</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Westlake Canary</p>
<p>CA</p>
<p>,</p>
<p>Colvin-Adams</p>
<p>M</p>
<p>,</p>
<p>Dickinson</p>
<p>MG</p>
<p>,</p>
<p>Levy</p>
<p>P</p>
<p>,</p>
<p>Stough</p>
<p>WG</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Albert</p>
<p>NM</p>
<p>,</p>
<p>Krishnamani</p>
<p>R</p>
<p>,</p>
<p>Rich</p>
<p>MW</p>
<p>,</p>
<p>Walsh</p>
<p>MN</p>
<p>,</p>
<p>Bonnell</p>
<p>MR</p>
<p>,</p>
<p>Carson</p>
<p>PE</p>
<p>,</p>
<p>Chan</p>
<p>MC</p>
<p>,</p>
<p>Dries</p>
<p>DL</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Hershberger</p>
<p>RE</p>
<p>,</p>
<p>Katz</p>
<p>SD</p>
<p>,</p>
<p>Moore</p>
<p>S</p>
<p>,</p>
<p>Rodgers</p>
<p>JE</p>
<p>,</p>
<p>Rogers</p>
<p>JG</p>
<p>,</p>
<p>Vest</p>
<p>AR</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Heart Failure Society of America Guidelines Committee</p>
<p>.</p>
<p>Advanced (stage D) heart failure: a statement from the Heart Failure
Society of America Guidelines Committee</p>
<p>.</p>
<p>J Card Fail</p>
<p>2015</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>519</p>
<p>–</p>
<p>534</p>
<p>.</p>
<p>376</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Milicic</p>
<p>D</p>
<p>,</p>
<p>Costanzo</p>
<p>MR</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Tsui</p>
<p>S</p>
<p>,</p>
<p>Barge-Caballero</p>
<p>E</p>
<p>,</p>
<p>De Jonge</p>
<p>N</p>
<p>,</p>
<p>Frigerio</p>
<p>M</p>
<p>,</p>
<p>Hamdan</p>
<p>R</p>
<p>,</p>
<p>Hasin</p>
<p>T</p>
<p>,</p>
<p>Hulsmann</p>
<p>M</p>
<p>,</p>
<p>Nalbantgil</p>
<p>S</p>
<p>,</p>
<p>Potena</p>
<p>L</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Gkouziouta</p>
<p>A</p>
<p>,</p>
<p>Ruhparwar</p>
<p>A</p>
<p>,</p>
<p>Ristic</p>
<p>AD</p>
<p>,</p>
<p>Straburzynska-Migaj</p>
<p>E</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Ruschitzka</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Advanced heart failure: a position statement of the Heart Failure
Association of the European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1505</p>
<p>–</p>
<p>1535</p>
<p>.</p>
<p>377</p>
<p>Truby</p>
<p>LK</p>
<p>,</p>
<p>Rogers</p>
<p>JG.</p>
<p>Advanced heart failure: epidemiology, diagnosis, and therapeutic
approaches</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>523</p>
<p>–</p>
<p>536</p>
<p>.</p>
<p>378</p>
<p>Rose</p>
<p>EA</p>
<p>,</p>
<p>Gelijns</p>
<p>AC</p>
<p>,</p>
<p>Moskowitz</p>
<p>AJ</p>
<p>,</p>
<p>Heitjan</p>
<p>DF</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Dembitsky</p>
<p>W</p>
<p>,</p>
<p>Long</p>
<p>JW</p>
<p>,</p>
<p>Ascheim</p>
<p>DD</p>
<p>,</p>
<p>Tierney</p>
<p>AR</p>
<p>,</p>
<p>Levitan</p>
<p>RG</p>
<p>,</p>
<p>Watson</p>
<p>JT</p>
<p>,</p>
<p>Meier</p>
<p>P</p>
<p>,</p>
<p>Ronan</p>
<p>NS</p>
<p>,</p>
<p>Shapiro</p>
<p>PA</p>
<p>,</p>
<p>Lazar</p>
<p>RM</p>
<p>,</p>
<p>Miller</p>
<p>LW</p>
<p>,</p>
<p>Gupta</p>
<p>L</p>
<p>,</p>
<p>Frazier</p>
<p>OH</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>Oz</p>
<p>MC</p>
<p>,</p>
<p>Poirier</p>
<p>VL</p>
<p>,</p>
<p>Randomized Evaluation of Mechanical Assistance for the Treatment of
Congestive Heart Failure (REMATCH) Study Group</p>
<p>.</p>
<p>Long-term use of a left ventricular assist device for end-stage heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2001</p>
<p>;</p>
<p>345</p>
<p>:</p>
<p>1435</p>
<p>–</p>
<p>1443</p>
<p>.</p>
<p>379</p>
<p>Ammar</p>
<p>KA</p>
<p>,</p>
<p>Jacobsen</p>
<p>SJ</p>
<p>,</p>
<p>Mahoney</p>
<p>DW</p>
<p>,</p>
<p>Kors</p>
<p>JA</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Burnett</p>
<p>JC</p>
<p>Jr.,</p>
<p>Rodeheffer</p>
<p>RJ.</p>
<p>Prevalence and prognostic significance of heart failure stages:
application of the American College of Cardiology/American Heart
Association heart failure staging criteria in the community</p>
<p>.</p>
<p>Circulation</p>
<p>2007</p>
<p>;</p>
<p>115</p>
<p>:</p>
<p>1563</p>
<p>–</p>
<p>1570</p>
<p>.</p>
<p>380</p>
<p>Xanthakis</p>
<p>V</p>
<p>,</p>
<p>Enserro</p>
<p>DM</p>
<p>,</p>
<p>Larson</p>
<p>MG</p>
<p>,</p>
<p>Wollert</p>
<p>KC</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>,</p>
<p>Levy</p>
<p>D</p>
<p>,</p>
<p>Aragam</p>
<p>J</p>
<p>,</p>
<p>Benjamin</p>
<p>EJ</p>
<p>,</p>
<p>Cheng</p>
<p>S</p>
<p>,</p>
<p>Wang</p>
<p>TJ</p>
<p>,</p>
<p>Mitchell</p>
<p>GF</p>
<p>,</p>
<p>Vasan</p>
<p>RS.</p>
<p>Prevalence, neurohormonal correlates, and prognosis of heart failure
stages in the community</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>808</p>
<p>–</p>
<p>815</p>
<p>.</p>
<p>381</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Pagani</p>
<p>FD</p>
<p>,</p>
<p>Young</p>
<p>JB</p>
<p>,</p>
<p>Jessup</p>
<p>M</p>
<p>,</p>
<p>Miller</p>
<p>L</p>
<p>,</p>
<p>Kormos</p>
<p>RL</p>
<p>,</p>
<p>Naftel</p>
<p>DC</p>
<p>,</p>
<p>Ulisney</p>
<p>K</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>Kirklin</p>
<p>JK.</p>
<p>INTERMACS profiles of advanced heart failure: the current picture</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2009</p>
<p>;</p>
<p>28</p>
<p>:</p>
<p>535</p>
<p>–</p>
<p>541</p>
<p>.</p>
<p>382</p>
<p>Barge-Caballero</p>
<p>E</p>
<p>,</p>
<p>Segovia-Cubero</p>
<p>J</p>
<p>,</p>
<p>Almenar-Bonet</p>
<p>L</p>
<p>,</p>
<p>Gonzalez-Vilchez</p>
<p>F</p>
<p>,</p>
<p>Villa-Arranz</p>
<p>A</p>
<p>,</p>
<p>Delgado-Jimenez</p>
<p>J</p>
<p>,</p>
<p>Lage-Galle</p>
<p>E</p>
<p>,</p>
<p>Perez-Villa</p>
<p>F</p>
<p>,</p>
<p>Lambert-Rodriguez</p>
<p>JL</p>
<p>,</p>
<p>Manito-Lorite</p>
<p>N</p>
<p>,</p>
<p>Arizon-Del Prado</p>
<p>JM</p>
<p>,</p>
<p>Brossa-Loidi</p>
<p>V</p>
<p>,</p>
<p>Pascual-Figal</p>
<p>D</p>
<p>,</p>
<p>Fuente-Galan Lde</p>
<p>L</p>
<p>,</p>
<p>Sanz-Julve</p>
<p>M</p>
<p>,</p>
<p>Muniz-Garcia</p>
<p>J</p>
<p>,</p>
<p>Crespo-Leiro</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Preoperative INTERMACS profiles determine postoperative outcomes in
critically ill patients undergoing emergency heart transplantation:
analysis of the Spanish National Heart Transplant Registry</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>763</p>
<p>–</p>
<p>772</p>
<p>.</p>
<p>383</p>
<p>Goldstein</p>
<p>DJ</p>
<p>,</p>
<p>Meyns</p>
<p>B</p>
<p>,</p>
<p>Xie</p>
<p>R</p>
<p>,</p>
<p>Cowger</p>
<p>J</p>
<p>,</p>
<p>Pettit</p>
<p>S</p>
<p>,</p>
<p>Nakatani</p>
<p>T</p>
<p>,</p>
<p>Netuka</p>
<p>I</p>
<p>,</p>
<p>Shaw</p>
<p>S</p>
<p>,</p>
<p>Yanase</p>
<p>M</p>
<p>,</p>
<p>Kirklin</p>
<p>JK.</p>
<p>Third annual report from the ISHLT Mechanically Assisted Circulatory
Support Registry: a comparison of centrifugal and axial continuous-flow
left ventricular assist devices</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2019</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>352</p>
<p>–</p>
<p>363</p>
<p>.</p>
<p>384</p>
<p>Kittleson</p>
<p>MM</p>
<p>,</p>
<p>Shah</p>
<p>P</p>
<p>,</p>
<p>Lala</p>
<p>A</p>
<p>,</p>
<p>McLean</p>
<p>RC</p>
<p>,</p>
<p>Pamboukian</p>
<p>S</p>
<p>,</p>
<p>Horstmanshof</p>
<p>DA</p>
<p>,</p>
<p>Thibodeau</p>
<p>J</p>
<p>,</p>
<p>Shah</p>
<p>K</p>
<p>,</p>
<p>Teuteberg</p>
<p>J</p>
<p>,</p>
<p>Gilotra</p>
<p>NA</p>
<p>,</p>
<p>Taddei-Peters</p>
<p>WC</p>
<p>,</p>
<p>Cascino</p>
<p>TM</p>
<p>,</p>
<p>Richards</p>
<p>B</p>
<p>,</p>
<p>Khalatbari</p>
<p>S</p>
<p>,</p>
<p>Jeffries</p>
<p>N</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Mann</p>
<p>D</p>
<p>,</p>
<p>Aaronson</p>
<p>KD</p>
<p>,</p>
<p>Stewart</p>
<p>GC</p>
<p>,</p>
<p>REVIVAL Investigators</p>
<p>.</p>
<p>INTERMACS profiles and outcomes of ambulatory advanced heart failure
patients: a report from the REVIVAL Registry</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2020</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>16</p>
<p>–</p>
<p>26</p>
<p>.</p>
<p>385</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Canter</p>
<p>CE</p>
<p>,</p>
<p>Hannan</p>
<p>MM</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>Uber</p>
<p>PA</p>
<p>,</p>
<p>Baran</p>
<p>DA</p>
<p>,</p>
<p>Danziger-Isakov</p>
<p>L</p>
<p>,</p>
<p>Kirklin</p>
<p>JK</p>
<p>,</p>
<p>Kirk</p>
<p>R</p>
<p>,</p>
<p>Kushwaha</p>
<p>SS</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Potena</p>
<p>L</p>
<p>,</p>
<p>Ross</p>
<p>HJ</p>
<p>,</p>
<p>Taylor</p>
<p>DO</p>
<p>,</p>
<p>Verschuuren</p>
<p>EAM</p>
<p>,</p>
<p>Zuckermann</p>
<p>A</p>
<p>,</p>
<p>International Society for Heart Lung Transplantation (ISHLT)
Infectious Diseases, Pediatric and Heart Failure and Transplantation
Councils</p>
<p>.</p>
<p>The 2016 International Society for Heart Lung Transplantation listing
criteria for heart transplantation: a 10-year update</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2016</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>23</p>
<p>.</p>
<p>386</p>
<p>Baumwol</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>“I need help”–a mnemonic to aid timely referral in advanced heart
failure</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2017</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>593</p>
<p>–</p>
<p>594</p>
<p>.</p>
<p>387</p>
<p>Maack</p>
<p>C</p>
<p>,</p>
<p>Eschenhagen</p>
<p>T</p>
<p>,</p>
<p>Hamdani</p>
<p>N</p>
<p>,</p>
<p>Heinzel</p>
<p>FR</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Manstein</p>
<p>DJ</p>
<p>,</p>
<p>Metzger</p>
<p>J</p>
<p>,</p>
<p>Papp</p>
<p>Z</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Balligand</p>
<p>JL</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Brutsaert</p>
<p>D</p>
<p>,</p>
<p>Carrier</p>
<p>L</p>
<p>,</p>
<p>Chlopicki</p>
<p>S</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Dietl</p>
<p>A</p>
<p>,</p>
<p>Fischmeister</p>
<p>R</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Holzmeister</p>
<p>J</p>
<p>,</p>
<p>de Keulenaer</p>
<p>G</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>Linke</p>
<p>WA</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Ristic</p>
<p>A</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Skouri</p>
<p>H</p>
<p>,</p>
<p>Zimmermann</p>
<p>WH</p>
<p>,</p>
<p>Mebazaa</p>
<ol type="A">
<li></li>
</ol>
<p>Treatments targeting inotropy</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>3626</p>
<p>–</p>
<p>3644</p>
<p>.</p>
<p>388</p>
<p>Ahmad</p>
<p>T</p>
<p>,</p>
<p>Miller</p>
<p>PE</p>
<p>,</p>
<p>McCullough</p>
<p>M</p>
<p>,</p>
<p>Desai</p>
<p>NR</p>
<p>,</p>
<p>Riello</p>
<p>R</p>
<p>,</p>
<p>Psotka</p>
<p>M</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Allen</p>
<p>LA</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Lindenfeld</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Why has positive inotropy failed in chronic heart failure? Lessons
from prior inotrope trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1064</p>
<p>–</p>
<p>1078</p>
<p>.</p>
<p>389</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Manito</p>
<p>N</p>
<p>,</p>
<p>Segovia-Cubero</p>
<p>J</p>
<p>,</p>
<p>Delgado</p>
<p>J</p>
<p>,</p>
<p>Garcia Pinilla</p>
<p>JM</p>
<p>,</p>
<p>Almenar</p>
<p>L</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Sionis</p>
<p>A</p>
<p>,</p>
<p>Blasco</p>
<p>T</p>
<p>,</p>
<p>Pascual-Figal</p>
<p>D</p>
<p>,</p>
<p>Gonzalez-Vilchez</p>
<p>F</p>
<p>,</p>
<p>Lambert-Rodriguez</p>
<p>JL</p>
<p>,</p>
<p>Grau</p>
<p>M</p>
<p>,</p>
<p>Bruguera</p>
<p>J</p>
<p>,</p>
<p>LION-HEART Study Investigators</p>
<p>.</p>
<p>Efficacy and safety of intermittent intravenous outpatient
administration of levosimendan in patients with advanced heart failure:
the LION-HEART multicentre randomised trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1128</p>
<p>–</p>
<p>1136</p>
<p>.</p>
<p>390</p>
<p>Nizamic</p>
<p>T</p>
<p>,</p>
<p>Murad</p>
<p>MH</p>
<p>,</p>
<p>Allen</p>
<p>LA</p>
<p>,</p>
<p>McIlvennan</p>
<p>CK</p>
<p>,</p>
<p>Wordingham</p>
<p>SE</p>
<p>,</p>
<p>Matlock</p>
<p>DD</p>
<p>,</p>
<p>Dunlay</p>
<p>SM.</p>
<p>Ambulatory inotrope infusions in advanced heart failure: a systematic
review and meta-analysis</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>757</p>
<p>–</p>
<p>767</p>
<p>.</p>
<p>391</p>
<p>Bart</p>
<p>BA</p>
<p>,</p>
<p>Goldsmith</p>
<p>SR</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Bull</p>
<p>DA</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Deswal</p>
<p>A</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>LeWinter</p>
<p>MM</p>
<p>,</p>
<p>Ofili</p>
<p>EO</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Chen</p>
<p>HH</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Ibarra</p>
<p>JC</p>
<p>,</p>
<p>Mascette</p>
<p>AM</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>Heart Failure Clinical Research Network. Ultrafiltration in
decompensated heart failure with cardiorenal syndrome</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2012</p>
<p>;</p>
<p>367</p>
<p>:</p>
<p>2296</p>
<p>–</p>
<p>2304</p>
<p>.</p>
<p>392</p>
<p>Costanzo</p>
<p>MR</p>
<p>,</p>
<p>Guglin</p>
<p>ME</p>
<p>,</p>
<p>Saltzberg</p>
<p>MT</p>
<p>,</p>
<p>Jessup</p>
<p>ML</p>
<p>,</p>
<p>Bart</p>
<p>BA</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Jaski</p>
<p>BE</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Feller</p>
<p>ED</p>
<p>,</p>
<p>Haas</p>
<p>GJ</p>
<p>,</p>
<p>Anderson</p>
<p>AS</p>
<p>,</p>
<p>Schollmeyer</p>
<p>MP</p>
<p>,</p>
<p>Sobotka</p>
<p>PA</p>
<p>,</p>
<p>UNLOAD Trial Investigators. Ultrafiltration versus intravenous
diuretics for patients hospitalized for acute decompensated heart
failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2007</p>
<p>;</p>
<p>49</p>
<p>:</p>
<p>675</p>
<p>–</p>
<p>683</p>
<p>.</p>
<p>393</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Rogers</p>
<p>JG.</p>
<p>Left ventricular assist device therapy in advanced heart failure:
patient selection and outcomes</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>595</p>
<p>–</p>
<p>602</p>
<p>.</p>
<p>394</p>
<p>Barge-Caballero</p>
<p>E</p>
<p>,</p>
<p>Almenar-Bonet</p>
<p>L</p>
<p>,</p>
<p>Gonzalez-Vilchez</p>
<p>F</p>
<p>,</p>
<p>Lambert-Rodriguez</p>
<p>JL</p>
<p>,</p>
<p>Gonzalez-Costello</p>
<p>J</p>
<p>,</p>
<p>Segovia-Cubero</p>
<p>J</p>
<p>,</p>
<p>Castel-Lavilla</p>
<p>MA</p>
<p>,</p>
<p>Delgado-Jimenez</p>
<p>J</p>
<p>,</p>
<p>Garrido-Bravo</p>
<p>IP</p>
<p>,</p>
<p>Rangel-Sousa</p>
<p>D</p>
<p>,</p>
<p>Martinez-Selles</p>
<p>M</p>
<p>,</p>
<p>De la Fuente-Galan</p>
<p>L</p>
<p>,</p>
<p>Rabago-AracilJuan-</p>
<p>G</p>
<p>,</p>
<p>Sanz-Julve</p>
<p>M</p>
<p>,</p>
<p>Hervas-Sotomayor</p>
<p>D</p>
<p>,</p>
<p>Mirabet-Perez</p>
<p>S</p>
<p>,</p>
<p>Muniz</p>
<p>J</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG.</p>
<p>Clinical outcomes of temporary mechanical circulatory support as a
direct bridge to heart transplantation: a nationwide Spanish
registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>178</p>
<p>–</p>
<p>186</p>
<p>.</p>
<p>395</p>
<p>Potapov</p>
<p>EV</p>
<p>,</p>
<p>Antonides</p>
<p>C</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Combes</p>
<p>A</p>
<p>,</p>
<p>Farber</p>
<p>G</p>
<p>,</p>
<p>Hannan</p>
<p>MM</p>
<p>,</p>
<p>Kukucka</p>
<p>M</p>
<p>,</p>
<p>de Jonge</p>
<p>N</p>
<p>,</p>
<p>Loforte</p>
<p>A</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Mohacsi</p>
<p>P</p>
<p>,</p>
<p>Morshuis</p>
<p>M</p>
<p>,</p>
<p>Netuka</p>
<p>I</p>
<p>,</p>
<p>Ozbaran</p>
<p>M</p>
<p>,</p>
<p>Pappalardo</p>
<p>F</p>
<p>,</p>
<p>Scandroglio</p>
<p>AM</p>
<p>,</p>
<p>Schweiger</p>
<p>M</p>
<p>,</p>
<p>Tsui</p>
<p>S</p>
<p>,</p>
<p>Zimpfer</p>
<p>D</p>
<p>,</p>
<p>Gustafsson</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>2019 EACTS Expert Consensus on long-term mechanical circulatory
support</p>
<p>.</p>
<p>Eur J Cardiothorac Surg</p>
<p>2019</p>
<p>;</p>
<p>56</p>
<p>:</p>
<p>230</p>
<p>–</p>
<p>270</p>
<p>.</p>
<p>396</p>
<p>Rogers</p>
<p>JG</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Lansman</p>
<p>SL</p>
<p>,</p>
<p>Gass</p>
<p>A</p>
<p>,</p>
<p>Portner</p>
<p>PM</p>
<p>,</p>
<p>Pasque</p>
<p>MK</p>
<p>,</p>
<p>Pierson</p>
<p>RN</p>
<p>3rd,</p>
<p>INTrEPID Investigators</p>
<p>.</p>
<p>Chronic mechanical circulatory support for inotrope-dependent heart
failure patients who are not transplant candidates: results of the
INTrEPID Trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2007</p>
<p>;</p>
<p>50</p>
<p>:</p>
<p>741</p>
<p>–</p>
<p>747</p>
<p>.</p>
<p>397</p>
<p>Slaughter</p>
<p>MS</p>
<p>,</p>
<p>Rogers</p>
<p>JG</p>
<p>,</p>
<p>Milano</p>
<p>CA</p>
<p>,</p>
<p>Russell</p>
<p>SD</p>
<p>,</p>
<p>Conte</p>
<p>JV</p>
<p>,</p>
<p>Feldman</p>
<p>D</p>
<p>,</p>
<p>Sun</p>
<p>B</p>
<p>,</p>
<p>Tatooles</p>
<p>AJ</p>
<p>,</p>
<p>Delgado</p>
<p>RM</p>
<p>3rd,</p>
<p>Long</p>
<p>JW</p>
<p>,</p>
<p>Wozniak</p>
<p>TC</p>
<p>,</p>
<p>Ghumman</p>
<p>W</p>
<p>,</p>
<p>Farrar</p>
<p>DJ</p>
<p>,</p>
<p>Frazier</p>
<p>OH</p>
<p>,</p>
<p>HeartMate</p>
<p>II</p>
<p>Investigators</p>
<p>.</p>
<p>Advanced heart failure treated with continuous-flow left ventricular
assist device</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2009</p>
<p>;</p>
<p>361</p>
<p>:</p>
<p>2241</p>
<p>–</p>
<p>2251</p>
<p>.</p>
<p>398</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Naka</p>
<p>Y</p>
<p>,</p>
<p>Boyle</p>
<p>AJ</p>
<p>,</p>
<p>Gonzalez-Stawinski</p>
<p>G</p>
<p>,</p>
<p>John</p>
<p>R</p>
<p>,</p>
<p>Jorde</p>
<p>U</p>
<p>,</p>
<p>Russell</p>
<p>SD</p>
<p>,</p>
<p>Conte</p>
<p>JV</p>
<p>,</p>
<p>Aaronson</p>
<p>KD</p>
<p>,</p>
<p>McGee</p>
<p>EC</p>
<p>Jr.,</p>
<p>Cotts</p>
<p>WG</p>
<p>,</p>
<p>DeNofrio</p>
<p>D</p>
<p>,</p>
<p>Pham</p>
<p>DT</p>
<p>,</p>
<p>Farrar</p>
<p>DJ</p>
<p>,</p>
<p>Pagani</p>
<p>FD.</p>
<p>Results of the post-U.S. Food and Drug Administration-approval study
with a continuous flow left ventricular assist device as a bridge to
heart transplantation: a prospective study using the INTERMACS
(Interagency Registry for Mechanically Assisted Circulatory Support)</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2011</p>
<p>;</p>
<p>57</p>
<p>:</p>
<p>1890</p>
<p>–</p>
<p>1898</p>
<p>.</p>
<p>399</p>
<p>Rogers</p>
<p>JG</p>
<p>,</p>
<p>Pagani</p>
<p>FD</p>
<p>,</p>
<p>Tatooles</p>
<p>AJ</p>
<p>,</p>
<p>Bhat</p>
<p>G</p>
<p>,</p>
<p>Slaughter</p>
<p>MS</p>
<p>,</p>
<p>Birks</p>
<p>EJ</p>
<p>,</p>
<p>Boyce</p>
<p>SW</p>
<p>,</p>
<p>Najjar</p>
<p>SS</p>
<p>,</p>
<p>Jeevanandam</p>
<p>V</p>
<p>,</p>
<p>Anderson</p>
<p>AS</p>
<p>,</p>
<p>Gregoric</p>
<p>ID</p>
<p>,</p>
<p>Mallidi</p>
<p>H</p>
<p>,</p>
<p>Leadley</p>
<p>K</p>
<p>,</p>
<p>Aaronson</p>
<p>KD</p>
<p>,</p>
<p>Frazier</p>
<p>OH</p>
<p>,</p>
<p>Milano</p>
<p>CA.</p>
<p>Intrapericardial left ventricular assist device for advanced heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2017</p>
<p>;</p>
<p>376</p>
<p>:</p>
<p>451</p>
<p>–</p>
<p>460</p>
<p>.</p>
<p>400</p>
<p>Truby</p>
<p>LK</p>
<p>,</p>
<p>Farr</p>
<p>MA</p>
<p>,</p>
<p>Garan</p>
<p>AR</p>
<p>,</p>
<p>Givens</p>
<p>R</p>
<p>,</p>
<p>Restaino</p>
<p>SW</p>
<p>,</p>
<p>Latif</p>
<p>F</p>
<p>,</p>
<p>Takayama</p>
<p>H</p>
<p>,</p>
<p>Naka</p>
<p>Y</p>
<p>,</p>
<p>Takeda</p>
<p>K</p>
<p>,</p>
<p>Topkara</p>
<p>VK.</p>
<p>Impact of bridge to transplantation with continuous-flow left
ventricular assist devices on posttransplantation mortality</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>140</p>
<p>:</p>
<p>459</p>
<p>–</p>
<p>469</p>
<p>.</p>
<p>401</p>
<p>Goldstein</p>
<p>DJ</p>
<p>,</p>
<p>Naka</p>
<p>Y</p>
<p>,</p>
<p>Horstmanshof</p>
<p>D</p>
<p>,</p>
<p>Ravichandran</p>
<p>AK</p>
<p>,</p>
<p>Schroder</p>
<p>J</p>
<p>,</p>
<p>Ransom</p>
<p>J</p>
<p>,</p>
<p>Itoh</p>
<p>A</p>
<p>,</p>
<p>Uriel</p>
<p>N</p>
<p>,</p>
<p>Cleveland</p>
<p>JC</p>
<p>Jr.,</p>
<p>Raval</p>
<p>NY</p>
<p>,</p>
<p>Cogswell</p>
<p>R</p>
<p>,</p>
<p>Suarez</p>
<p>EE</p>
<p>,</p>
<p>Lowes</p>
<p>BD</p>
<p>,</p>
<p>Kim</p>
<p>G</p>
<p>,</p>
<p>Bonde</p>
<p>P</p>
<p>,</p>
<p>Sheikh</p>
<p>FH</p>
<p>,</p>
<p>Sood</p>
<p>P</p>
<p>,</p>
<p>Farrar</p>
<p>DJ</p>
<p>,</p>
<p>Mehra</p>
<p>MR.</p>
<p>Association of clinical outcomes with left ventricular assist device
use by bridge to transplant or destination therapy intent: the
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical
Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized
Clinical Trial</p>
<p>.</p>
<p>JAMA Cardiol</p>
<p>2020</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>411</p>
<p>–</p>
<p>419</p>
<p>.</p>
<p>402</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Uriel</p>
<p>N</p>
<p>,</p>
<p>Naka</p>
<p>Y</p>
<p>,</p>
<p>Cleveland</p>
<p>JC</p>
<p>Jr.,</p>
<p>Yuzefpolskaya</p>
<p>M</p>
<p>,</p>
<p>Salerno</p>
<p>CT</p>
<p>,</p>
<p>Walsh</p>
<p>MN</p>
<p>,</p>
<p>Milano</p>
<p>CA</p>
<p>,</p>
<p>Patel</p>
<p>CB</p>
<p>,</p>
<p>Hutchins</p>
<p>SW</p>
<p>,</p>
<p>Ransom</p>
<p>J</p>
<p>,</p>
<p>Ewald</p>
<p>GA</p>
<p>,</p>
<p>Itoh</p>
<p>A</p>
<p>,</p>
<p>Raval</p>
<p>NY</p>
<p>,</p>
<p>Silvestry</p>
<p>SC</p>
<p>,</p>
<p>Cogswell</p>
<p>R</p>
<p>,</p>
<p>John</p>
<p>R</p>
<p>,</p>
<p>Bhimaraj</p>
<p>A</p>
<p>,</p>
<p>Bruckner</p>
<p>BA</p>
<p>,</p>
<p>Lowes</p>
<p>BD</p>
<p>,</p>
<p>Um</p>
<p>JY</p>
<p>,</p>
<p>Jeevanandam</p>
<p>V</p>
<p>,</p>
<p>Sayer</p>
<p>G</p>
<p>,</p>
<p>Mangi</p>
<p>AA</p>
<p>,</p>
<p>Molina</p>
<p>EJ</p>
<p>,</p>
<p>Sheikh</p>
<p>F</p>
<p>,</p>
<p>Aaronson</p>
<p>K</p>
<p>,</p>
<p>Pagani</p>
<p>FD</p>
<p>,</p>
<p>Cotts</p>
<p>WG</p>
<p>,</p>
<p>Tatooles</p>
<p>AJ</p>
<p>,</p>
<p>Babu</p>
<p>A</p>
<p>,</p>
<p>Chomsky</p>
<p>D</p>
<p>,</p>
<p>Katz</p>
<p>JN</p>
<p>,</p>
<p>Tessmann</p>
<p>PB</p>
<p>,</p>
<p>Dean</p>
<p>D</p>
<p>,</p>
<p>Krishnamoorthy</p>
<p>A</p>
<p>,</p>
<p>Chuang</p>
<p>J</p>
<p>,</p>
<p>Topuria</p>
<p>I</p>
<p>,</p>
<p>Sood</p>
<p>P</p>
<p>,</p>
<p>Goldstein</p>
<p>DJ</p>
<p>MOMENTUM 3 Investigators.</p>
<p>A fully magnetically levitated left ventricular assist device – final
report</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>380</p>
<p>:</p>
<p>1618</p>
<p>–</p>
<p>1627</p>
<p>.</p>
<p>403</p>
<p>Kirklin</p>
<p>JK</p>
<p>,</p>
<p>Naftel</p>
<p>DC</p>
<p>,</p>
<p>Pagani</p>
<p>FD</p>
<p>,</p>
<p>Kormos</p>
<p>RL</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Blume</p>
<p>ED</p>
<p>,</p>
<p>Myers</p>
<p>SL</p>
<p>,</p>
<p>Miller</p>
<p>MA</p>
<p>,</p>
<p>Baldwin</p>
<p>JT</p>
<p>,</p>
<p>Young</p>
<p>JB.</p>
<p>Seventh INTERMACS annual report: 15,000 patients and counting</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2015</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>1495</p>
<p>–</p>
<p>1504</p>
<p>.</p>
<p>404</p>
<p>Theochari</p>
<p>CA</p>
<p>,</p>
<p>Michalopoulos</p>
<p>G</p>
<p>,</p>
<p>Oikonomou</p>
<p>EK</p>
<p>,</p>
<p>Giannopoulos</p>
<p>S</p>
<p>,</p>
<p>Doulamis</p>
<p>IP</p>
<p>,</p>
<p>Villela</p>
<p>MA</p>
<p>,</p>
<p>Kokkinidis</p>
<p>DG.</p>
<p>Heart transplantation versus left ventricular assist devices as
destination therapy or bridge to transplantation for 1-year mortality: a
systematic review and meta-analysis</p>
<p>.</p>
<p>Ann Cardiothorac Surg</p>
<p>2018</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>3</p>
<p>–</p>
<p>11</p>
<p>.</p>
<p>405</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Goldstein</p>
<p>DJ</p>
<p>,</p>
<p>Uriel</p>
<p>N</p>
<p>,</p>
<p>Cleveland</p>
<p>JC</p>
<p>Jr.,</p>
<p>Yuzefpolskaya</p>
<p>M</p>
<p>,</p>
<p>Salerno</p>
<p>C</p>
<p>,</p>
<p>Walsh</p>
<p>MN</p>
<p>,</p>
<p>Milano</p>
<p>CA</p>
<p>,</p>
<p>Patel</p>
<p>CB</p>
<p>,</p>
<p>Ewald</p>
<p>GA</p>
<p>,</p>
<p>Itoh</p>
<p>A</p>
<p>,</p>
<p>Dean</p>
<p>D</p>
<p>,</p>
<p>Krishnamoorthy</p>
<p>A</p>
<p>,</p>
<p>Cotts</p>
<p>WG</p>
<p>,</p>
<p>Tatooles</p>
<p>AJ</p>
<p>,</p>
<p>Jorde</p>
<p>UP</p>
<p>,</p>
<p>Bruckner</p>
<p>BA</p>
<p>,</p>
<p>Estep</p>
<p>JD</p>
<p>,</p>
<p>Jeevanandam</p>
<p>V</p>
<p>,</p>
<p>Sayer</p>
<p>G</p>
<p>,</p>
<p>Horstmanshof</p>
<p>D</p>
<p>,</p>
<p>Long</p>
<p>JW</p>
<p>,</p>
<p>Gulati</p>
<p>S</p>
<p>,</p>
<p>Skipper</p>
<p>ER</p>
<p>,</p>
<p>O’Connell</p>
<p>JB</p>
<p>,</p>
<p>Heatley</p>
<p>G</p>
<p>,</p>
<p>Sood</p>
<p>P</p>
<p>,</p>
<p>Naka</p>
<p>Y</p>
<p>MOMENTUM 3 Investigators</p>
<p>.</p>
<p>Two-year outcomes with a magnetically levitated cardiac pump in heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>378</p>
<p>:</p>
<p>1386</p>
<p>–</p>
<p>1395</p>
<p>.</p>
<p>406</p>
<p>Zimpfer</p>
<p>D</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Potapov</p>
<p>E</p>
<p>,</p>
<p>Pya</p>
<p>Y</p>
<p>,</p>
<p>Schmitto</p>
<p>J</p>
<p>,</p>
<p>Berchtold-Herz</p>
<p>M</p>
<p>,</p>
<p>Morshuis</p>
<p>M</p>
<p>,</p>
<p>Shaw</p>
<p>SM</p>
<p>,</p>
<p>Saeed</p>
<p>D</p>
<p>,</p>
<p>Lavee</p>
<p>J</p>
<p>,</p>
<p>Heatley</p>
<p>G</p>
<p>,</p>
<p>Gazzola</p>
<p>C</p>
<p>,</p>
<p>Garbade</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Two-year outcome after implantation of a full magnetically levitated
left ventricular assist device: results from the ELEVATE Registry</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>3801</p>
<p>–</p>
<p>3809</p>
<p>.</p>
<p>407</p>
<p>Estep</p>
<p>JD</p>
<p>,</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Horstmanshof</p>
<p>DA</p>
<p>,</p>
<p>Milano</p>
<p>CA</p>
<p>,</p>
<p>Selzman</p>
<p>CH</p>
<p>,</p>
<p>Shah</p>
<p>KB</p>
<p>,</p>
<p>Loebe</p>
<p>M</p>
<p>,</p>
<p>Moazami</p>
<p>N</p>
<p>,</p>
<p>Long</p>
<p>JW</p>
<p>,</p>
<p>Stehlik</p>
<p>J</p>
<p>,</p>
<p>Kasirajan</p>
<p>V</p>
<p>,</p>
<p>Haas</p>
<p>DC</p>
<p>,</p>
<p>O’Connell</p>
<p>JB</p>
<p>,</p>
<p>Boyle</p>
<p>AJ</p>
<p>,</p>
<p>Farrar</p>
<p>DJ</p>
<p>,</p>
<p>Rogers</p>
<p>JG</p>
<p>,</p>
<p>ROADMAP Study Investigators</p>
<p>.</p>
<p>Risk assessment and comparative effectiveness of left ventricular
assist device and medical management in ambulatory heart failure
patients: results from the ROADMAP study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2015</p>
<p>;</p>
<p>66</p>
<p>:</p>
<p>1747</p>
<p>–</p>
<p>1761</p>
<p>.</p>
<p>408</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Estep</p>
<p>JD</p>
<p>,</p>
<p>Horstmanshof</p>
<p>DA</p>
<p>,</p>
<p>Milano</p>
<p>CA</p>
<p>,</p>
<p>Stehlik</p>
<p>J</p>
<p>,</p>
<p>Shah</p>
<p>KB</p>
<p>,</p>
<p>Bruckner</p>
<p>BA</p>
<p>,</p>
<p>Lee</p>
<p>S</p>
<p>,</p>
<p>Long</p>
<p>JW</p>
<p>,</p>
<p>Selzman</p>
<p>CH</p>
<p>,</p>
<p>Kasirajan</p>
<p>V</p>
<p>,</p>
<p>Haas</p>
<p>DC</p>
<p>,</p>
<p>Boyle</p>
<p>AJ</p>
<p>,</p>
<p>Chuang</p>
<p>J</p>
<p>,</p>
<p>Farrar</p>
<p>DJ</p>
<p>,</p>
<p>Rogers</p>
<p>JG</p>
<p>,</p>
<p>ROADMAP Study Investigators</p>
<p>.</p>
<p>Risk assessment and comparative effectiveness of left ventricular
assist device and medical management in ambulatory heart failure
patients: the ROADMAP study 2-year results</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>518</p>
<p>–</p>
<p>527</p>
<p>.</p>
<p>409</p>
<p>Slaughter</p>
<p>MS</p>
<p>,</p>
<p>Pagani</p>
<p>FD</p>
<p>,</p>
<p>McGee</p>
<p>EC</p>
<p>,</p>
<p>Birks</p>
<p>EJ</p>
<p>,</p>
<p>Cotts</p>
<p>WG</p>
<p>,</p>
<p>Gregoric</p>
<p>I</p>
<p>,</p>
<p>Howard Frazier</p>
<p>O</p>
<p>,</p>
<p>Icenogle</p>
<p>T</p>
<p>,</p>
<p>Najjar</p>
<p>SS</p>
<p>,</p>
<p>Boyce</p>
<p>SW</p>
<p>,</p>
<p>Acker</p>
<p>MA</p>
<p>,</p>
<p>John</p>
<p>R</p>
<p>,</p>
<p>Hathaway</p>
<p>DR</p>
<p>,</p>
<p>Najarian</p>
<p>KB</p>
<p>,</p>
<p>Aaronson</p>
<p>KD</p>
<p>,</p>
<p>HeartWare Bridge to Transplant ADVANCE Trial Investigators. HeartWare
ventricular assist system for bridge to transplant: combined results of
the bridge to transplant and continued access protocol trial</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2013</p>
<p>;</p>
<p>32</p>
<p>:</p>
<p>675</p>
<p>–</p>
<p>683</p>
<p>.</p>
<p>410</p>
<p>Karason</p>
<p>K</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Dalen</p>
<p>M</p>
<p>,</p>
<p>Bjorklund</p>
<p>E</p>
<p>,</p>
<p>Grinnemo</p>
<p>K</p>
<p>,</p>
<p>Braun</p>
<p>O</p>
<p>,</p>
<p>Nilsson</p>
<p>J</p>
<p>,</p>
<p>van der Wal</p>
<p>H</p>
<p>,</p>
<p>Holm</p>
<p>J</p>
<p>,</p>
<p>Hubbert</p>
<p>L</p>
<p>,</p>
<p>Lindmark</p>
<p>K</p>
<p>,</p>
<p>Szabo</p>
<p>B</p>
<p>,</p>
<p>Holmberg</p>
<p>E</p>
<p>,</p>
<p>Dellgren</p>
<p>G</p>
<p>,</p>
<p>SweVAD Investigators</p>
<p>.</p>
<p>Randomized trial of a left ventricular assist device as destination
therapy versus guideline-directed medical therapy in patients with
advanced heart failure. Rationale and design of the SWEdish evaluation
of left Ventricular Assist Device (SweVAD) trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>739</p>
<p>–</p>
<p>750</p>
<p>.</p>
<p>411</p>
<p>Khush</p>
<p>KK</p>
<p>,</p>
<p>Cherikh</p>
<p>WS</p>
<p>,</p>
<p>Chambers</p>
<p>DC</p>
<p>,</p>
<p>Harhay</p>
<p>MO</p>
<p>,</p>
<p>Hayes</p>
<p>D</p>
<p>Jr.,</p>
<p>Hsich</p>
<p>E</p>
<p>,</p>
<p>Meiser</p>
<p>B</p>
<p>,</p>
<p>Potena</p>
<p>L</p>
<p>,</p>
<p>Robinson</p>
<p>A</p>
<p>,</p>
<p>Rossano</p>
<p>JW</p>
<p>,</p>
<p>Sadavarte</p>
<p>A</p>
<p>,</p>
<p>Singh</p>
<p>TP</p>
<p>,</p>
<p>Zuckermann</p>
<p>A</p>
<p>,</p>
<p>Stehlik</p>
<p>J</p>
<p>,</p>
<p>International Society for Heart and Lung Transplantation</p>
<p>.</p>
<p>The International Thoracic Organ Transplant Registry of the
International Society for Heart and Lung Transplantation: Thirty-sixth
adult heart transplantation report–2019; focus theme: donor and
recipient size match</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2019</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>1056</p>
<p>–</p>
<p>1066</p>
<p>.</p>
<p>412</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Edwards</p>
<p>LB</p>
<p>,</p>
<p>Kucheryavaya</p>
<p>AY</p>
<p>,</p>
<p>Dipchand</p>
<p>AI</p>
<p>,</p>
<p>Benden</p>
<p>C</p>
<p>,</p>
<p>Christie</p>
<p>JD</p>
<p>,</p>
<p>Dobbels</p>
<p>F</p>
<p>,</p>
<p>Kirk</p>
<p>R</p>
<p>,</p>
<p>Rahmel</p>
<p>AO</p>
<p>,</p>
<p>Yusen</p>
<p>RD</p>
<p>,</p>
<p>Stehlik</p>
<p>J</p>
<p>,</p>
<p>International</p>
<p>Society</p>
<p>,</p>
<p>for</p>
<p>H</p>
<p>Heart and Lung Transplantation</p>
<p>.</p>
<p>The Registry of the International Society for Heart and Lung
Transplantation: Thirtieth official adult heart transplant report–2013;
focus theme: age</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2013</p>
<p>;</p>
<p>32</p>
<p>:</p>
<p>951</p>
<p>–</p>
<p>964</p>
<p>.</p>
<p>413</p>
<p>Guglin</p>
<p>M</p>
<p>,</p>
<p>Zucker</p>
<p>MJ</p>
<p>,</p>
<p>Borlaug</p>
<p>BA</p>
<p>,</p>
<p>Breen</p>
<p>E</p>
<p>,</p>
<p>Cleveland</p>
<p>J</p>
<p>,</p>
<p>Johnson</p>
<p>MR</p>
<p>,</p>
<p>Panjrath</p>
<p>GS</p>
<p>,</p>
<p>Patel</p>
<p>JK</p>
<p>,</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Bozkurt</p>
<p>B</p>
<p>,</p>
<p>ACC Heart Failure and Transplant Member Section and Leadership
Council</p>
<p>.</p>
<p>Evaluation for heart transplantation and LVAD implantation: JACC
Council perspectives</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2020</p>
<p>;</p>
<p>75</p>
<p>:</p>
<p>1471</p>
<p>–</p>
<p>1487</p>
<p>.</p>
<p>414</p>
<p>Bernhardt</p>
<p>AM</p>
<p>,</p>
<p>Schloglhofer</p>
<p>T</p>
<p>,</p>
<p>Lauenroth</p>
<p>V</p>
<p>,</p>
<p>Mueller</p>
<p>F</p>
<p>,</p>
<p>Mueller</p>
<p>M</p>
<p>,</p>
<p>Schoede</p>
<p>A</p>
<p>,</p>
<p>Klopsch</p>
<p>C</p>
<p>,</p>
<p>Driveline Expert STagINg and carE DESTINE study group, a Ventricular
Assist Device Driveline Infection Study Group. Prevention and early
treatment of driveline infections in ventricular assist device patients
– the DESTINE staging proposal and the first standard of care
protocol</p>
<p>.</p>
<p>J Crit Care</p>
<p>2020</p>
<p>;</p>
<p>56</p>
<p>:</p>
<p>106</p>
<p>–</p>
<p>112</p>
<p>.</p>
<p>415</p>
<p>DeFilippis</p>
<p>EM</p>
<p>,</p>
<p>Breathett</p>
<p>K</p>
<p>,</p>
<p>Donald</p>
<p>EM</p>
<p>,</p>
<p>Nakagawa</p>
<p>S</p>
<p>,</p>
<p>Takeda</p>
<p>K</p>
<p>,</p>
<p>Takayama</p>
<p>H</p>
<p>,</p>
<p>Truby</p>
<p>LK</p>
<p>,</p>
<p>Sayer</p>
<p>G</p>
<p>,</p>
<p>Colombo</p>
<p>PC</p>
<p>,</p>
<p>Yuzefpolskaya</p>
<p>M</p>
<p>,</p>
<p>Uriel</p>
<p>N</p>
<p>,</p>
<p>Farr</p>
<p>MA</p>
<p>,</p>
<p>Topkara</p>
<p>VK.</p>
<p>Psychosocial risk and its association with outcomes in
continuous-flow left ventricular assist device patients</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>e006910</p>
<p>.</p>
<p>416</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>La Rocca</p>
<p>HB</p>
<p>,</p>
<p>Castiello</p>
<p>T</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Marques-Sule</p>
<p>E</p>
<p>,</p>
<p>Plymen</p>
<p>CM</p>
<p>,</p>
<p>Piper</p>
<p>SE</p>
<p>,</p>
<p>Riegel</p>
<p>B</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Ben Gal</p>
<p>T</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Lopatin</p>
<p>Y</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Moura</p>
<p>B</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Stromberg</p>
<ol type="A">
<li></li>
</ol>
<p>Self-care of heart failure patients: practical management
recommendations from the Heart Failure Association of the European
Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>157</p>
<p>–</p>
<p>174</p>
<p>.</p>
<p>417</p>
<p>Jorde</p>
<p>UP</p>
<p>,</p>
<p>Kushwaha</p>
<p>SS</p>
<p>,</p>
<p>Tatooles</p>
<p>AJ</p>
<p>,</p>
<p>Naka</p>
<p>Y</p>
<p>,</p>
<p>Bhat</p>
<p>G</p>
<p>,</p>
<p>Long</p>
<p>JW</p>
<p>,</p>
<p>Horstmanshof</p>
<p>DA</p>
<p>,</p>
<p>Kormos</p>
<p>RL</p>
<p>,</p>
<p>Teuteberg</p>
<p>JJ</p>
<p>,</p>
<p>Slaughter</p>
<p>MS</p>
<p>,</p>
<p>Birks</p>
<p>EJ</p>
<p>,</p>
<p>Farrar</p>
<p>DJ</p>
<p>,</p>
<p>Park</p>
<p>SJ</p>
<p>,</p>
<p>HeartMate II Clinical Investigators</p>
<p>.</p>
<p>Results of the destination therapy post-food and drug administration
approval study with a continuous flow left ventricular assist device: a
prospective study using the INTERMACS registry (Interagency Registry for
Mechanically Assisted Circulatory Support)</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>1751</p>
<p>–</p>
<p>1757</p>
<p>.</p>
<p>418</p>
<p>Sahlollbey</p>
<p>N</p>
<p>,</p>
<p>Lee</p>
<p>CKS</p>
<p>,</p>
<p>Shirin</p>
<p>A</p>
<p>,</p>
<p>Joseph</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>The impact of palliative care on clinical and patient-centred
outcomes in patients with advanced heart failure: a systematic review of
randomized controlled trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2340</p>
<p>–</p>
<p>2346</p>
<p>.</p>
<p>419</p>
<p>Fendler</p>
<p>TJ</p>
<p>,</p>
<p>Swetz</p>
<p>KM</p>
<p>,</p>
<p>Allen</p>
<p>LA.</p>
<p>Team-based palliative and end-of-life care for heart failure</p>
<p>.</p>
<p>Heart Fail Clin</p>
<p>2015</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>479</p>
<p>–</p>
<p>498</p>
<p>.</p>
<p>420</p>
<p>Brannstrom</p>
<p>M</p>
<p>,</p>
<p>Boman</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Effects of person-centred and integrated chronic heart failure and
palliative home care. PREFER: a randomized controlled study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>1142</p>
<p>–</p>
<p>1151</p>
<p>.</p>
<p>421</p>
<p>O’Donnell</p>
<p>AE</p>
<p>,</p>
<p>Schaefer</p>
<p>KG</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>DeVoe</p>
<p>K</p>
<p>,</p>
<p>Walsh</p>
<p>K</p>
<p>,</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Desai</p>
<p>AS.</p>
<p>Social worker-aided palliative care intervention in high-risk
patients with Heart Failure (SWAP-HF): a pilot randomized clinical
trial</p>
<p>.</p>
<p>JAMA Cardiol</p>
<p>2018</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>516</p>
<p>–</p>
<p>519</p>
<p>.</p>
<p>422</p>
<p>Johnson</p>
<p>MJ</p>
<p>,</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>Harkness</p>
<p>A</p>
<p>,</p>
<p>McKay</p>
<p>SE</p>
<p>,</p>
<p>Dargie</p>
<p>HJ.</p>
<p>Morphine for the relief of breathlessness in patients with chronic
heart failure–a pilot study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2002</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>753</p>
<p>–</p>
<p>756</p>
<p>.</p>
<p>423</p>
<p>Oxberry</p>
<p>SG</p>
<p>,</p>
<p>Bland</p>
<p>JM</p>
<p>,</p>
<p>Clark</p>
<p>AL</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Johnson</p>
<p>MJ.</p>
<p>Repeat dose opioids may be effective for breathlessness in chronic
heart failure if given for long enough</p>
<p>.</p>
<p>J Palliat Med</p>
<p>2013</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>250</p>
<p>–</p>
<p>255</p>
<p>.</p>
<p>424</p>
<p>Blinderman</p>
<p>CD</p>
<p>,</p>
<p>Billings</p>
<p>JA.</p>
<p>Comfort care for patients dying in the hospital</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>373</p>
<p>:</p>
<p>2549</p>
<p>–</p>
<p>2561</p>
<p>.</p>
<p>425</p>
<p>Nieminen</p>
<p>MS</p>
<p>,</p>
<p>Brutsaert</p>
<p>D</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Drexler</p>
<p>H</p>
<p>,</p>
<p>Follath</p>
<p>F</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Hochadel</p>
<p>M</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Lopez-Sendon</p>
<p>JL</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>EuroHeart Survey Investigators, Heart Failure Association of the
European Society of Cardiology</p>
<p>.</p>
<p>EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute
heart failure patients: description of population</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2006</p>
<p>;</p>
<p>27</p>
<p>:</p>
<p>2725</p>
<p>–</p>
<p>2736</p>
<p>.</p>
<p>426</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Coats</p>
<p>AJ</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Lopez-Fernandez</p>
<p>S</p>
<p>,</p>
<p>Miani</p>
<p>D</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>ESC</p>
<p>Heart</p>
<p>Failure Long-Term Registry Investigators. Clinical phenotypes and
outcome of patients hospitalized for acute heart failure: the ESC Heart
Failure Long-Term Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1242</p>
<p>–</p>
<p>1254</p>
<p>.</p>
<p>427</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>ESC-EORP-HFA Heart Failure Long-Term Registry Investigators</p>
<p>.</p>
<p>Acute heart failure congestion and perfusion status – impact of the
clinical classification on in-hospital and long-term outcomes: insights
from the ESC-EORP-HFA heart failure long-term registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1338</p>
<p>–</p>
<p>1352</p>
<p>.</p>
<p>428</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Garcia Sarasola</p>
<p>A</p>
<p>,</p>
<p>Fuenzalida</p>
<p>C</p>
<p>,</p>
<p>Calderon</p>
<p>S</p>
<p>,</p>
<p>Jacob</p>
<p>J</p>
<p>,</p>
<p>Aguirre</p>
<p>A</p>
<p>,</p>
<p>Wu</p>
<p>DM</p>
<p>,</p>
<p>Rizzi</p>
<p>MA</p>
<p>,</p>
<p>Malchair</p>
<p>P</p>
<p>,</p>
<p>Haro</p>
<p>A</p>
<p>,</p>
<p>Herrera</p>
<p>S</p>
<p>,</p>
<p>Gil</p>
<p>V</p>
<p>,</p>
<p>Martin-Sanchez</p>
<p>FJ</p>
<p>,</p>
<p>Llorens</p>
<p>P</p>
<p>,</p>
<p>Herrero Puente</p>
<p>P</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Dominguez Rodriguez</p>
<p>A</p>
<p>,</p>
<p>Muller</p>
<p>CE</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Alquezar-Arbe</p>
<p>A</p>
<p>,</p>
<p>ICA-SEMES Research Group</p>
<p>.</p>
<p>Departments involved during the first episode of acute heart failure
and subsequent emergency department revisits and rehospitalisations: an
outlook through the NOVICA cohort</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1231</p>
<p>–</p>
<p>1244</p>
<p>.</p>
<p>429</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Dobson</p>
<p>J</p>
<p>,</p>
<p>Pocock</p>
<p>S</p>
<p>,</p>
<p>Skali</p>
<p>H</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Young</p>
<p>JB</p>
<p>,</p>
<p>Michelson</p>
<p>EL</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Candesartan in Heart failure: Assessment of Reduction in Mortality
and morbidity (CHARM) Investigators</p>
<p>.</p>
<p>Influence of nonfatal hospitalization for heart failure on subsequent
mortality in patients with chronic heart failure</p>
<p>.</p>
<p>Circulation</p>
<p>2007</p>
<p>;</p>
<p>116</p>
<p>:</p>
<p>1482</p>
<p>–</p>
<p>1487</p>
<p>.</p>
<p>430</p>
<p>Tomasoni</p>
<p>D</p>
<p>,</p>
<p>Lombardi</p>
<p>CM</p>
<p>,</p>
<p>Sbolli</p>
<p>M</p>
<p>,</p>
<p>Cotter</p>
<p>G</p>
<p>,</p>
<p>Metra</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Acute heart failure: more questions than answers</p>
<p>.</p>
<p>Prog Cardiovasc Dis</p>
<p>2020</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>599</p>
<p>–</p>
<p>606</p>
<p>.</p>
<p>431</p>
<p>Butt</p>
<p>JH</p>
<p>,</p>
<p>Fosbol</p>
<p>EL</p>
<p>,</p>
<p>Gerds</p>
<p>TA</p>
<p>,</p>
<p>Andersson</p>
<p>C</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Madelaire</p>
<p>C</p>
<p>,</p>
<p>Kristensen</p>
<p>SL</p>
<p>,</p>
<p>Gislason</p>
<p>GH</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Schou</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Readmission and death in patients admitted with new-onset versus
worsening of chronic heart failure: insights from a nationwide
cohort</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1777</p>
<p>–</p>
<p>1785</p>
<p>.</p>
<p>432</p>
<p>Javaloyes</p>
<p>P</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Gil</p>
<p>V</p>
<p>,</p>
<p>Martin-Sanchez</p>
<p>FJ</p>
<p>,</p>
<p>Jacob</p>
<p>J</p>
<p>,</p>
<p>Herrero</p>
<p>P</p>
<p>,</p>
<p>Takagi</p>
<p>K</p>
<p>,</p>
<p>Alquezar-Arbe</p>
<p>A</p>
<p>,</p>
<p>Lopez Diez</p>
<p>MP</p>
<p>,</p>
<p>Martin</p>
<p>E</p>
<p>,</p>
<p>Bibiano</p>
<p>C</p>
<p>,</p>
<p>Escoda</p>
<p>R</p>
<p>,</p>
<p>Gil</p>
<p>C</p>
<p>,</p>
<p>Fuentes</p>
<p>M</p>
<p>,</p>
<p>Llopis Garcia</p>
<p>G</p>
<p>,</p>
<p>Alvarez Perez</p>
<p>JM</p>
<p>,</p>
<p>Jerez</p>
<p>A</p>
<p>,</p>
<p>Tost</p>
<p>J</p>
<p>,</p>
<p>Llauger</p>
<p>L</p>
<p>,</p>
<p>Romero</p>
<p>R</p>
<p>,</p>
<p>Garrido</p>
<p>JM</p>
<p>,</p>
<p>Rodriguez-Adrada</p>
<p>E</p>
<p>,</p>
<p>Sanchez</p>
<p>C</p>
<p>,</p>
<p>Rossello</p>
<p>X</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Llorens</p>
<p>P</p>
<p>,</p>
<p>ICA-SEMES Research Group</p>
<p>.</p>
<p>Clinical phenotypes of acute heart failure based on signs and
symptoms of perfusion and congestion at emergency department
presentation and their relationship with patient management and
outcomes</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1353</p>
<p>–</p>
<p>1365</p>
<p>.</p>
<p>433</p>
<p>Januzzi</p>
<p>JL</p>
<p>,</p>
<p>van Kimmenade</p>
<p>R</p>
<p>,</p>
<p>Lainchbury</p>
<p>J</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>Ordonez-Llanos</p>
<p>J</p>
<p>,</p>
<p>Santalo-Bel</p>
<p>M</p>
<p>,</p>
<p>Pinto</p>
<p>YM</p>
<p>,</p>
<p>Richards</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>NT-proBNP testing for diagnosis and short-term prognosis in acute
destabilized heart failure: an international pooled analysis of 1256
patients: the International Collaborative of NT-proBNP Study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2006</p>
<p>;</p>
<p>27</p>
<p>:</p>
<p>330</p>
<p>–</p>
<p>337</p>
<p>.</p>
<p>434</p>
<p>Januzzi</p>
<p>JL</p>
<p>Jr,</p>
<p>Chen-Tournoux</p>
<p>AA</p>
<p>,</p>
<p>Christenson</p>
<p>RH</p>
<p>,</p>
<p>Doros</p>
<p>G</p>
<p>,</p>
<p>Hollander</p>
<p>JE</p>
<p>,</p>
<p>Levy</p>
<p>PD</p>
<p>,</p>
<p>Nagurney</p>
<p>JT</p>
<p>,</p>
<p>Nowak</p>
<p>RM</p>
<p>,</p>
<p>Pang</p>
<p>PS</p>
<p>,</p>
<p>Patel</p>
<p>D</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Rivers</p>
<p>EJ</p>
<p>,</p>
<p>Walters</p>
<p>EL</p>
<p>,</p>
<p>Gaggin HK, ICON-RELOADED Investigators. N-terminal pro-B-type
natriuretic peptide in the emergency department: the ICON-RELOADED
study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>1191</p>
<p>–</p>
<p>1200</p>
<p>.</p>
<p>435</p>
<p>Maisel</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Nowak</p>
<p>R</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Landsberg</p>
<p>JW</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Mockel</p>
<p>M</p>
<p>,</p>
<p>Hogan</p>
<p>C</p>
<p>,</p>
<p>Wu</p>
<p>AH</p>
<p>,</p>
<p>Richards</p>
<p>M</p>
<p>,</p>
<p>Clopton</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Di Somma</p>
<p>S</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Ng</p>
<p>L</p>
<p>,</p>
<p>Daniels</p>
<p>LB</p>
<p>,</p>
<p>Neath</p>
<p>SX</p>
<p>,</p>
<p>Christenson</p>
<p>R</p>
<p>,</p>
<p>Potocki</p>
<p>M</p>
<p>,</p>
<p>McCord</p>
<p>J</p>
<p>,</p>
<p>Terracciano</p>
<p>G</p>
<p>,</p>
<p>Kremastinos</p>
<p>D</p>
<p>,</p>
<p>Hartmann</p>
<p>O</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Bergmann</p>
<p>A</p>
<p>,</p>
<p>Morgenthaler</p>
<p>NG</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Mid-region pro-hormone markers for diagnosis and prognosis in acute
dyspnea: results from the BACH (Biomarkers in Acute Heart Failure)
trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2010</p>
<p>;</p>
<p>55</p>
<p>:</p>
<p>2062</p>
<p>–</p>
<p>2076</p>
<p>.</p>
<p>436</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Collins</p>
<p>SP</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Gayat</p>
<p>E</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Laine</p>
<p>M</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Lommi</p>
<p>J</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Mortara</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Pentikainen</p>
<p>M</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Polyzogopoulou</p>
<p>E</p>
<p>,</p>
<p>Rudiger</p>
<p>A</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Sionis</p>
<p>A</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>Varpula</p>
<p>M</p>
<p>,</p>
<p>Weinstein</p>
<p>JM</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB.</p>
<p>Acute coronary syndromes and acute heart failure: a diagnostic
dilemma and high-risk combination. A statement from the Acute Heart
Failure Committee of the Heart Failure Association of the European
Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1298</p>
<p>–</p>
<p>1314</p>
<p>.</p>
<p>437</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Banaszewski</p>
<p>M</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Collins</p>
<p>SP</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Flammer</p>
<p>AJ</p>
<p>,</p>
<p>Fuhrmann</p>
<p>V</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Legrand</p>
<p>M</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Papp</p>
<p>Z</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Platz</p>
<p>E</p>
<p>,</p>
<p>Rudiger</p>
<p>A</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Schafer</p>
<p>A</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Skouri</p>
<p>H</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Mebazaa</p>
<ol type="A">
<li></li>
</ol>
<p>Organ dysfunction, injury and failure in acute heart failure: from
pathophysiology to diagnosis and management. A review on behalf of the
Acute Heart Failure Committee of the Heart Failure Association (HFA) of
the European Society of Cardiology (ESC)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>821</p>
<p>–</p>
<p>836</p>
<p>.</p>
<p>438</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Collins</p>
<p>SP</p>
<p>,</p>
<p>De Backer</p>
<p>D</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Gayat</p>
<p>E</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Mortara</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Nieminen</p>
<p>MS</p>
<p>,</p>
<p>Rudiger</p>
<p>A</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Sionis</p>
<p>A</p>
<p>,</p>
<p>Vieillard-Baron</p>
<p>A</p>
<p>,</p>
<p>Weinstein</p>
<p>JM</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Riley</p>
<p>JP.</p>
<p>Comprehensive in-hospital monitoring in acute heart failure:
applications for clinical practice and future directions for research. A
statement from the Acute Heart Failure Committee of the Heart Failure
Association (HFA) of the European Society of Cardiology (ESC)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1081</p>
<p>–</p>
<p>1099</p>
<p>.</p>
<p>439</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Hanberg</p>
<p>JS</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Cotter</p>
<p>G</p>
<p>,</p>
<p>Davison</p>
<p>B</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Bloomfield</p>
<p>DM</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>Hypochloremia, diuretic resistance, and outcome in patients with
acute heart failure</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>9</p>
<p>.</p>
<p>440</p>
<p>Nunez</p>
<p>J</p>
<p>,</p>
<p>Llacer</p>
<p>P</p>
<p>,</p>
<p>Garcia-Blas</p>
<p>S</p>
<p>,</p>
<p>Bonanad</p>
<p>C</p>
<p>,</p>
<p>Ventura</p>
<p>S</p>
<p>,</p>
<p>Nunez</p>
<p>JM</p>
<p>,</p>
<p>Sanchez</p>
<p>R</p>
<p>,</p>
<p>Facila</p>
<p>L</p>
<p>,</p>
<p>de la Espriella</p>
<p>R</p>
<p>,</p>
<p>Vaquer</p>
<p>JM</p>
<p>,</p>
<p>Cordero</p>
<p>A</p>
<p>,</p>
<p>Roque</p>
<p>M</p>
<p>,</p>
<p>Chamorro</p>
<p>C</p>
<p>,</p>
<p>Bodi</p>
<p>V</p>
<p>,</p>
<p>Valero</p>
<p>E</p>
<p>,</p>
<p>Santas</p>
<p>E</p>
<p>,</p>
<p>Moreno</p>
<p>MDC</p>
<p>,</p>
<p>Minana</p>
<p>G</p>
<p>,</p>
<p>Carratala</p>
<p>A</p>
<p>,</p>
<p>Rodriguez</p>
<p>E</p>
<p>,</p>
<p>Mollar</p>
<p>A</p>
<p>,</p>
<p>Palau</p>
<p>P</p>
<p>,</p>
<p>Bosch</p>
<p>MJ</p>
<p>,</p>
<p>Bertomeu-Gonzalez</p>
<p>V</p>
<p>,</p>
<p>Lupon</p>
<p>J</p>
<p>,</p>
<p>Navarro</p>
<p>J</p>
<p>,</p>
<p>Chorro</p>
<p>FJ</p>
<p>,</p>
<p>Gorriz</p>
<p>JL</p>
<p>,</p>
<p>Sanchis</p>
<p>J</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Bayes-Genis A. CA125-guided diuretic treatment versus usual care in
patients with acute heart failure and renal dysfunction</p>
<p>.</p>
<p>Am J Med</p>
<p>2020</p>
<p>;</p>
<p>133</p>
<p>:</p>
<p>370</p>
<p>–</p>
<p>380</p>
<p>e374.</p>
<p>441</p>
<p>Nikolaou</p>
<p>M</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Seronde</p>
<p>MF</p>
<p>,</p>
<p>Kivikko</p>
<p>M</p>
<p>,</p>
<p>Laribi</p>
<p>S</p>
<p>,</p>
<p>Paugam-Burtz</p>
<p>C</p>
<p>,</p>
<p>Cai</p>
<p>D</p>
<p>,</p>
<p>Pohjanjousi</p>
<p>P</p>
<p>,</p>
<p>Laterre</p>
<p>PF</p>
<p>,</p>
<p>Deye</p>
<p>N</p>
<p>,</p>
<p>Poder</p>
<p>P</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Mebazaa</p>
<ol type="A">
<li></li>
</ol>
<p>Liver function abnormalities, clinical profile, and outcome in acute
decompensated heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>742</p>
<p>–</p>
<p>749</p>
<p>.</p>
<p>442</p>
<p>Mockel</p>
<p>M</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Slagman</p>
<p>AC</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Schou</p>
<p>M</p>
<p>,</p>
<p>Vollert</p>
<p>JO</p>
<p>,</p>
<p>Wiemer</p>
<p>JC</p>
<p>,</p>
<p>Ebmeyer</p>
<p>S</p>
<p>Martín-Sánchez FJ, Maisel AS, Giannitsis E.</p>
<p>Improve Management of acute heart failure with ProcAlCiTonin in
EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in
Cardiology (BIC) 18</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>267</p>
<p>–</p>
<p>275</p>
<p>.</p>
<p>443</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>De Mendoza</p>
<p>D</p>
<p>,</p>
<p>Planas</p>
<p>K</p>
<p>,</p>
<p>Paez</p>
<p>J</p>
<p>,</p>
<p>Sanchez</p>
<p>B</p>
<p>,</p>
<p>Cancio</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Peripheral venous blood gases and pulse-oximetry in acute cardiogenic
pulmonary oedema</p>
<p>.</p>
<p>Eur Heart J Acute Cardiovasc Care</p>
<p>2012</p>
<p>;</p>
<p>1</p>
<p>:</p>
<p>275</p>
<p>–</p>
<p>280</p>
<p>.</p>
<p>444</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Gaya</p>
<p>M</p>
<p>,</p>
<p>Paez</p>
<p>J</p>
<p>,</p>
<p>Betbese</p>
<p>A</p>
<p>,</p>
<p>Vecilla</p>
<p>F</p>
<p>,</p>
<p>Manresa</p>
<p>R</p>
<p>,</p>
<p>Ruiz</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Pulse oximetry in the diagnosis of acute heart failure</p>
<p>.</p>
<p>Rev Esp Cardiol (Engl Ed)</p>
<p>2012</p>
<p>;</p>
<p>65</p>
<p>:</p>
<p>879</p>
<p>–</p>
<p>884</p>
<p>.</p>
<p>445</p>
<p>Nieminen</p>
<p>MS</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Drexler</p>
<p>H</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Jondeau</p>
<p>G</p>
<p>,</p>
<p>Hasin</p>
<p>Y</p>
<p>,</p>
<p>Lopez-Sendon</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Rhodes</p>
<p>A</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Priori</p>
<p>SG</p>
<p>,</p>
<p>Garcia</p>
<p>MA</p>
<p>,</p>
<p>Blanc</p>
<p>JJ</p>
<p>,</p>
<p>Budaj</p>
<p>A</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Dean</p>
<p>V</p>
<p>,</p>
<p>Deckers</p>
<p>J</p>
<p>,</p>
<p>Burgos</p>
<p>EF</p>
<p>,</p>
<p>Lekakis</p>
<p>J</p>
<p>,</p>
<p>Lindahl</p>
<p>B</p>
<p>,</p>
<p>Mazzotta</p>
<p>G</p>
<p>,</p>
<p>Morais</p>
<p>J</p>
<p>,</p>
<p>Oto</p>
<p>A</p>
<p>,</p>
<p>Smiseth</p>
<p>OA</p>
<p>,</p>
<p>Garcia</p>
<p>MA</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Albuquerque</p>
<p>A</p>
<p>,</p>
<p>Conthe</p>
<p>P</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>M</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>Follath</p>
<p>F</p>
<p>,</p>
<p>Gavazzi</p>
<p>A</p>
<p>,</p>
<p>Janssens</p>
<p>U</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Morais</p>
<p>J</p>
<p>,</p>
<p>Moreno</p>
<p>R</p>
<p>,</p>
<p>Singer</p>
<p>M</p>
<p>,</p>
<p>Singh</p>
<p>S</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>Thygesen</p>
<p>K</p>
<p>,</p>
<p>ESC Committe for Practice Guideline</p>
<p>(CPG)</p>
<p>.</p>
<p>Executive summary of the guidelines on the diagnosis and treatment of
acute heart failure: the Task Force on Acute Heart Failure of the
European Society of Cardiology</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2005</p>
<p>;</p>
<p>26</p>
<p>:</p>
<p>384</p>
<p>–</p>
<p>416</p>
<p>.</p>
<p>446</p>
<p>Nohria</p>
<p>A</p>
<p>,</p>
<p>Tsang</p>
<p>SW</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>Jarcho</p>
<p>JA</p>
<p>,</p>
<p>Mudge</p>
<p>GH</p>
<p>,</p>
<p>Stevenson</p>
<p>LW.</p>
<p>Clinical assessment identifies hemodynamic profiles that predict
outcomes in patients admitted with heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2003</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>1797</p>
<p>–</p>
<p>1804</p>
<p>.</p>
<p>447</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Follath</p>
<p>F</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Barsuk</p>
<p>JH</p>
<p>,</p>
<p>Blair</p>
<p>JE</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Drazner</p>
<p>MH</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Jondeau</p>
<p>G</p>
<p>,</p>
<p>Sendon</p>
<p>JL</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Nieminen</p>
<p>M</p>
<p>,</p>
<p>Pang</p>
<p>PS</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Rhodes</p>
<p>A</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>European Society of Cardiology, European Society of Intensive Care
Medicine. Assessing and grading congestion in acute heart failure: a
scientific statement from the acute heart failure committee of the Heart
Failure Association of the European Society of Cardiology and endorsed
by the European Society of Intensive Care Medicine</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2010</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>423</p>
<p>–</p>
<p>433</p>
<p>.</p>
<p>448</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Cullen</p>
<p>L</p>
<p>,</p>
<p>Martin-Sanchez</p>
<p>FJ</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Maisel</p>
<p>AS</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Vrints</p>
<p>C</p>
<p>,</p>
<p>Christ</p>
<p>M</p>
<p>,</p>
<p>Cowie</p>
<p>M</p>
<p>,</p>
<p>Platz</p>
<p>E</p>
<p>,</p>
<p>McMurray</p>
<p>J</p>
<p>,</p>
<p>DiSomma</p>
<p>S</p>
<p>,</p>
<p>Zeymer</p>
<p>U</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Lettino</p>
<p>M</p>
<p>,</p>
<p>Tavares</p>
<p>M</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Acute Heart Failure Study Group of the Acute Cardiovascular Care
Association and the Committee on Acute Heart Failure of the Heart
Failure Association of the European Society of Cardiology</p>
<p>.</p>
<p>Indications and practical approach to non-invasive ventilation in
acute heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>17</p>
<p>–</p>
<p>25</p>
<p>.</p>
<p>449</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Bettex</p>
<p>D</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Falk</p>
<p>V</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Gibbs</p>
<p>S</p>
<p>,</p>
<p>Leite-Moreira</p>
<p>A</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Naeije</p>
<p>R</p>
<p>,</p>
<p>Nordegraaf</p>
<p>AV</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Riley</p>
<p>JP</p>
<p>,</p>
<p>Ristic</p>
<p>A</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Rudiger</p>
<p>A</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Sztrymf</p>
<p>B</p>
<p>,</p>
<p>Vieillard-Baron</p>
<p>A</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Konstantinides</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Contemporary management of acute right ventricular failure: a
statement from the Heart Failure Association and the Working Group on
Pulmonary Circulation and Right Ventricular Function of the European
Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>226</p>
<p>–</p>
<p>241</p>
<p>.</p>
<p>450</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Desch</p>
<p>S</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Antohi</p>
<p>EL</p>
<p>,</p>
<p>Arrigo</p>
<p>M</p>
<p>,</p>
<p>Gal</p>
<p>TB</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Collins</p>
<p>SP</p>
<p>,</p>
<p>DeBacker</p>
<p>D</p>
<p>,</p>
<p>Iliescu</p>
<p>VA</p>
<p>,</p>
<p>Jankowska</p>
<p>E</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Keramida</p>
<p>K</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Mortara</p>
<p>A</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Nikolaou</p>
<p>M</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Vieillard-Baron</p>
<p>A</p>
<p>,</p>
<p>Weinstein</p>
<p>JM</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Seferovic</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Epidemiology, pathophysiology and contemporary management of
cardiogenic shock – a position statement from the Heart Failure
Association of the European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1315</p>
<p>–</p>
<p>1341</p>
<p>.</p>
<p>451</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Ohman</p>
<p>EM</p>
<p>,</p>
<p>de Waha-Thiele</p>
<p>S</p>
<p>,</p>
<p>Zeymer</p>
<p>U</p>
<p>,</p>
<p>Desch</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Management of cardiogenic shock complicating myocardial infarction:
an update 2019</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>2671</p>
<p>–</p>
<p>2683</p>
<p>.</p>
<p>452</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Combes</p>
<p>A</p>
<p>,</p>
<p>van Diepen</p>
<p>S</p>
<p>,</p>
<p>Hollinger</p>
<p>A</p>
<p>,</p>
<p>Katz</p>
<p>JN</p>
<p>,</p>
<p>Landoni</p>
<p>G</p>
<p>,</p>
<p>Hajjar</p>
<p>LA</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Lebreton</p>
<p>G</p>
<p>,</p>
<p>Montalescot</p>
<p>G</p>
<p>,</p>
<p>Park</p>
<p>JJ</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Sionis</p>
<p>A</p>
<p>,</p>
<p>Yannopolos</p>
<p>D</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Levy</p>
<p>B</p>
<p>,</p>
<p>Thiele</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Management of cardiogenic shock complicating myocardial
infarction</p>
<p>.</p>
<p>Intensive Care Med</p>
<p>2018</p>
<p>;</p>
<p>44</p>
<p>:</p>
<p>760</p>
<p>–</p>
<p>773</p>
<p>.</p>
<p>453</p>
<p>Zymlinski</p>
<p>R</p>
<p>,</p>
<p>Biegus</p>
<p>J</p>
<p>,</p>
<p>Sokolski</p>
<p>M</p>
<p>,</p>
<p>Siwolowski</p>
<p>P</p>
<p>,</p>
<p>Nawrocka-Millward</p>
<p>S</p>
<p>,</p>
<p>Todd</p>
<p>J</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Cotter</p>
<p>G</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Ponikowski</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Increased blood lactate is prevalent and identifies poor prognosis in
patients with acute heart failure without overt peripheral
hypoperfusion</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1011</p>
<p>–</p>
<p>1018</p>
<p>.</p>
<p>454</p>
<p>Menon</p>
<p>V</p>
<p>,</p>
<p>Slater</p>
<p>JN</p>
<p>,</p>
<p>White</p>
<p>HD</p>
<p>,</p>
<p>Sleeper</p>
<p>LA</p>
<p>,</p>
<p>Cocke</p>
<p>T</p>
<p>,</p>
<p>Hochman</p>
<p>JS.</p>
<p>Acute myocardial infarction complicated by systemic hypoperfusion
without hypotension: report of the SHOCK trial registry</p>
<p>.</p>
<p>Am J Med</p>
<p>2000</p>
<p>;</p>
<p>108</p>
<p>:</p>
<p>374</p>
<p>–</p>
<p>380</p>
<p>.</p>
<p>455</p>
<p>Harjola</p>
<p>P</p>
<p>,</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Martin-Sanchez</p>
<p>FJ</p>
<p>,</p>
<p>Escalada</p>
<p>X</p>
<p>,</p>
<p>Freund</p>
<p>Y</p>
<p>,</p>
<p>Penaloza</p>
<p>A</p>
<p>,</p>
<p>Christ</p>
<p>M</p>
<p>,</p>
<p>Cone</p>
<p>DC</p>
<p>,</p>
<p>Laribi</p>
<p>S</p>
<p>,</p>
<p>Kuisma</p>
<p>M</p>
<p>,</p>
<p>Tarvasmaki</p>
<p>T</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>EMS-AHF Study Group</p>
<p>.</p>
<p>Pre-hospital management protocols and perceived difficulty in
diagnosing acute heart failure</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>289</p>
<p>–</p>
<p>296</p>
<p>.</p>
<p>456</p>
<p>Takahashi</p>
<p>M</p>
<p>,</p>
<p>Kohsaka</p>
<p>S</p>
<p>,</p>
<p>Miyata</p>
<p>H</p>
<p>,</p>
<p>Yoshikawa</p>
<p>T</p>
<p>,</p>
<p>Takagi</p>
<p>A</p>
<p>,</p>
<p>Harada</p>
<p>K</p>
<p>,</p>
<p>Miyamoto</p>
<p>T</p>
<p>,</p>
<p>Sakai</p>
<p>T</p>
<p>,</p>
<p>Nagao</p>
<p>K</p>
<p>,</p>
<p>Sato</p>
<p>N</p>
<p>,</p>
<p>Takayama</p>
<p>M</p>
<p>,</p>
<p>Tokyo CCU Network Council</p>
<p>.</p>
<p>Association between prehospital time interval and short-term outcome
in acute heart failure patients</p>
<p>.</p>
<p>J Card Fail</p>
<p>2011</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>742</p>
<p>–</p>
<p>747</p>
<p>.</p>
<p>457</p>
<p>Park</p>
<p>JH</p>
<p>,</p>
<p>Balmain</p>
<p>S</p>
<p>,</p>
<p>Berry</p>
<p>C</p>
<p>,</p>
<p>Morton</p>
<p>JJ</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Potentially detrimental cardiovascular effects of oxygen in patients
with chronic left ventricular systolic dysfunction</p>
<p>.</p>
<p>Heart</p>
<p>2010</p>
<p>;</p>
<p>96</p>
<p>:</p>
<p>533</p>
<p>–</p>
<p>538</p>
<p>.</p>
<p>458</p>
<p>Gray</p>
<p>A</p>
<p>,</p>
<p>Goodacre</p>
<p>S</p>
<p>,</p>
<p>Newby</p>
<p>DE</p>
<p>,</p>
<p>Masson</p>
<p>M</p>
<p>,</p>
<p>Sampson</p>
<p>F</p>
<p>,</p>
<p>Nicholl</p>
<p>J</p>
<p>,</p>
<p>3CPO Trialists Noninvasive ventilation in acute cardiogenic pulmonary
edema</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2008</p>
<p>;</p>
<p>359</p>
<p>:</p>
<p>142</p>
<p>–</p>
<p>151</p>
<p>.</p>
<p>459</p>
<p>Weng</p>
<p>CL</p>
<p>,</p>
<p>Zhao</p>
<p>YT</p>
<p>,</p>
<p>Liu</p>
<p>QH</p>
<p>,</p>
<p>Fu</p>
<p>CJ</p>
<p>,</p>
<p>Sun</p>
<p>F</p>
<p>,</p>
<p>Ma</p>
<p>YL</p>
<p>,</p>
<p>Chen</p>
<p>YW</p>
<p>,</p>
<p>He</p>
<p>QY.</p>
<p>Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary
edema</p>
<p>.</p>
<p>Ann Intern Med</p>
<p>2010</p>
<p>;</p>
<p>152</p>
<p>:</p>
<p>590</p>
<p>–</p>
<p>600</p>
<p>.</p>
<p>460</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Bull</p>
<p>DA</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Goldsmith</p>
<p>SR</p>
<p>,</p>
<p>LeWinter</p>
<p>MM</p>
<p>,</p>
<p>Deswal</p>
<p>A</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Ofili</p>
<p>EO</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Kfoury</p>
<p>AG</p>
<p>,</p>
<p>Chen</p>
<p>HH</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>Bart</p>
<p>BA</p>
<p>,</p>
<p>Mascette</p>
<p>AM</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Network</p>
<p>NHFCR.</p>
<p>Diuretic strategies in patients with acute decompensated heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>797</p>
<p>–</p>
<p>805</p>
<p>.</p>
<p>461</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Ellison</p>
<p>DH</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Cox</p>
<p>ZL</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>Diuretic therapy for patients with heart failure: JACC
state-of-the-art review</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2020</p>
<p>;</p>
<p>75</p>
<p>:</p>
<p>1178</p>
<p>–</p>
<p>1195</p>
<p>.</p>
<p>462</p>
<p>Brisco</p>
<p>MA</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Hanberg</p>
<p>JS</p>
<p>,</p>
<p>Wilson</p>
<p>FP</p>
<p>,</p>
<p>Parikh</p>
<p>CR</p>
<p>,</p>
<p>Coca</p>
<p>SG</p>
<p>,</p>
<p>Tang</p>
<p>WH</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>Relevance of changes in serum creatinine during a heart failure trial
of decongestive strategies: insights from the DOSE trial</p>
<p>.</p>
<p>J Card Fail</p>
<p>2016</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>753</p>
<p>–</p>
<p>760</p>
<p>.</p>
<p>463</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>Waagstein</p>
<p>F</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Loop diuretics, renal function and clinical outcome in patients with
heart failure and reduced ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>328</p>
<p>–</p>
<p>336</p>
<p>.</p>
<p>464</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Martens</p>
<p>P</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Lang</p>
<p>CC</p>
<p>,</p>
<p>Ng</p>
<p>LL</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Samani</p>
<p>NJ</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Mullens</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Higher doses of loop diuretics limit uptitration of
angiotensin-converting enzyme inhibitors in patients with heart failure
and reduced ejection fraction</p>
<p>.</p>
<p>Clin Res Cardiol</p>
<p>2020</p>
<p>;</p>
<p>109</p>
<p>:</p>
<p>1048</p>
<p>–</p>
<p>1059</p>
<p>.</p>
<p>465</p>
<p>Cubbon</p>
<p>RM</p>
<p>,</p>
<p>Woolston</p>
<p>A</p>
<p>,</p>
<p>Adams</p>
<p>B</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Gilthorpe</p>
<p>MS</p>
<p>,</p>
<p>Baxter</p>
<p>PD</p>
<p>,</p>
<p>Kearney</p>
<p>LC</p>
<p>,</p>
<p>Mercer</p>
<p>B</p>
<p>,</p>
<p>Rajwani</p>
<p>A</p>
<p>,</p>
<p>Batin</p>
<p>PD</p>
<p>,</p>
<p>Kahn</p>
<p>M</p>
<p>,</p>
<p>Sapsford</p>
<p>RJ</p>
<p>,</p>
<p>Witte</p>
<p>KK</p>
<p>,</p>
<p>Kearney</p>
<p>MT.</p>
<p>Prospective development and validation of a model to predict heart
failure hospitalisation</p>
<p>.</p>
<p>Heart</p>
<p>2014</p>
<p>;</p>
<p>100</p>
<p>:</p>
<p>923</p>
<p>–</p>
<p>929</p>
<p>.</p>
<p>466</p>
<p>Kapelios</p>
<p>CJ</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Diaz-Molina</p>
<p>B</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Moura</p>
<p>B</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Heart Failure Long-Term Registry Investigators Group</p>
<p>.</p>
<p>Association between loop diuretic dose changes and outcomes in
chronic heart failure: observations from the ESC-EORP heart failure
long-term registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1424</p>
<p>–</p>
<p>1437</p>
<p>.</p>
<p>467</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Levy</p>
<p>P</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Laribi</p>
<p>S</p>
<p>,</p>
<p>Ristic</p>
<p>AD</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Riley</p>
<p>JP</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>deFilippi</p>
<p>C</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Maggioni</p>
<p>A</p>
<p>,</p>
<p>McMurray</p>
<p>J</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Leite-Moreira</p>
<p>AF</p>
<p>,</p>
<p>Bellou</p>
<p>A</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Recommendations on pre-hospital &amp; early hospital management of
acute heart failure: a consensus paper from the Heart Failure
Association of the European Society of Cardiology, the European Society
of Emergency Medicine and the Society of Academic Emergency Medicine</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>544</p>
<p>–</p>
<p>558</p>
<p>.</p>
<p>468</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Coster</p>
<p>JE</p>
<p>,</p>
<p>Krikken</p>
<p>JA</p>
<p>,</p>
<p>van Deursen</p>
<p>VM</p>
<p>,</p>
<p>Krijnen</p>
<p>HK</p>
<p>,</p>
<p>Hofman</p>
<p>M</p>
<p>,</p>
<p>Nieuwland</p>
<p>W</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>van der Meer</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Clinical importance of urinary sodium excretion in acute heart
failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1438</p>
<p>–</p>
<p>1447</p>
<p>.</p>
<p>469</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Verbrugge</p>
<p>FH</p>
<p>,</p>
<p>Nijst</p>
<p>P</p>
<p>,</p>
<p>Martens</p>
<p>P</p>
<p>,</p>
<p>Tartaglia</p>
<p>K</p>
<p>,</p>
<p>Theunissen</p>
<p>E</p>
<p>,</p>
<p>Bruckers</p>
<p>L</p>
<p>,</p>
<p>Droogne</p>
<p>W</p>
<p>,</p>
<p>Troisfontaines</p>
<p>P</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Dupont</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Rationale and design of the ADVOR (Acetazolamide in Decompensated
Heart Failure with Volume Overload) trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1591</p>
<p>–</p>
<p>1600</p>
<p>.</p>
<p>470</p>
<p>Cox</p>
<p>ZL</p>
<p>,</p>
<p>Hung</p>
<p>R</p>
<p>,</p>
<p>Lenihan</p>
<p>DJ</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>Diuretic strategies for loop diuretic resistance in acute heart
failure: the 3T trial</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>157</p>
<p>–</p>
<p>168</p>
<p>.</p>
<p>471</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>The kidney in heart failure: an update</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1437</p>
<p>–</p>
<p>1444</p>
<p>.</p>
<p>472</p>
<p>Ambrosy</p>
<p>AP</p>
<p>,</p>
<p>Pang</p>
<p>PS</p>
<p>,</p>
<p>Khan</p>
<p>S</p>
<p>,</p>
<p>Konstam</p>
<p>MA</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Traver</p>
<p>B</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Cook</p>
<p>T</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Burnett</p>
<p>JC</p>
<p>Jr.,</p>
<p>Grinfeld</p>
<p>L</p>
<p>,</p>
<p>Udelson</p>
<p>JE</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Gheorghiade</p>
<p>M</p>
<p>EVEREST Trial Investigators. Clinical course and predictive value of
congestion during hospitalization in patients admitted for worsening
signs and symptoms of heart failure with reduced ejection fraction:
findings from the EVEREST trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>835</p>
<p>–</p>
<p>843</p>
<p>.</p>
<p>473</p>
<p>Faselis</p>
<p>C</p>
<p>,</p>
<p>Arundel</p>
<p>C</p>
<p>,</p>
<p>Patel</p>
<p>S</p>
<p>,</p>
<p>Lam</p>
<p>PH</p>
<p>,</p>
<p>Gottlieb</p>
<p>SS</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Deedwania</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Sheriff</p>
<p>HM</p>
<p>,</p>
<p>Zeng</p>
<p>Q</p>
<p>,</p>
<p>Morgan</p>
<p>CJ</p>
<p>,</p>
<p>Wopperer</p>
<p>S</p>
<p>,</p>
<p>Nguyen</p>
<p>T</p>
<p>,</p>
<p>Allman</p>
<p>RM</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Ahmed</p>
<ol type="A">
<li></li>
</ol>
<p>Loop diuretic prescription and 30-day outcomes in older patients with
heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2020</p>
<p>;</p>
<p>76</p>
<p>:</p>
<p>669</p>
<p>–</p>
<p>679</p>
<p>.</p>
<p>474</p>
<p>Sharon</p>
<p>A</p>
<p>,</p>
<p>Shpirer</p>
<p>I</p>
<p>,</p>
<p>Kaluski</p>
<p>E</p>
<p>,</p>
<p>Moshkovitz</p>
<p>Y</p>
<p>,</p>
<p>Milovanov</p>
<p>O</p>
<p>,</p>
<p>Polak</p>
<p>R</p>
<p>,</p>
<p>Blatt</p>
<p>A</p>
<p>,</p>
<p>Simovitz</p>
<p>A</p>
<p>,</p>
<p>Shaham</p>
<p>O</p>
<p>,</p>
<p>Faigenberg</p>
<p>Z</p>
<p>,</p>
<p>Metzger</p>
<p>M</p>
<p>,</p>
<p>Stav</p>
<p>D</p>
<p>,</p>
<p>Yogev</p>
<p>R</p>
<p>,</p>
<p>Golik</p>
<p>A</p>
<p>,</p>
<p>Krakover</p>
<p>R</p>
<p>,</p>
<p>Vered</p>
<p>Z</p>
<p>,</p>
<p>Cotter</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>High-dose intravenous isosorbide-dinitrate is safer and better than
Bi-PAP ventilation combined with conventional treatment for severe
pulmonary edema</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2000</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>832</p>
<p>–</p>
<p>837</p>
<p>.</p>
<p>475</p>
<p>Publication Committee for the VMAC Investigators (Vasodilatation in
the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin
for treatment of decompensated congestive heart failure: a randomized
controlled trial</p>
<p>.</p>
<p>JAMA</p>
<p>2002</p>
<p>;</p>
<p>287</p>
<p>:</p>
<p>1531</p>
<p>–</p>
<p>1540</p>
<p>.</p>
<p>476</p>
<p>Cotter</p>
<p>G</p>
<p>,</p>
<p>Metzkor</p>
<p>E</p>
<p>,</p>
<p>Kaluski</p>
<p>E</p>
<p>,</p>
<p>Faigenberg</p>
<p>Z</p>
<p>,</p>
<p>Miller</p>
<p>R</p>
<p>,</p>
<p>Simovitz</p>
<p>A</p>
<p>,</p>
<p>Shaham</p>
<p>O</p>
<p>,</p>
<p>Marghitay</p>
<p>D</p>
<p>,</p>
<p>Koren</p>
<p>M</p>
<p>,</p>
<p>Blatt</p>
<p>A</p>
<p>,</p>
<p>Moshkovitz</p>
<p>Y</p>
<p>,</p>
<p>Zaidenstein</p>
<p>R</p>
<p>,</p>
<p>Golik</p>
<ol type="A">
<li></li>
</ol>
<p>Randomised trial of high-dose isosorbide dinitrate plus low-dose
furosemide versus high-dose furosemide plus low-dose isosorbide
dinitrate in severe pulmonary oedema</p>
<p>.</p>
<p>Lancet</p>
<p>1998</p>
<p>;</p>
<p>351</p>
<p>:</p>
<p>389</p>
<p>–</p>
<p>393</p>
<p>.</p>
<p>477</p>
<p>Levy</p>
<p>P</p>
<p>,</p>
<p>Compton</p>
<p>S</p>
<p>,</p>
<p>Welch</p>
<p>R</p>
<p>,</p>
<p>Delgado</p>
<p>G</p>
<p>,</p>
<p>Jennett</p>
<p>A</p>
<p>,</p>
<p>Penugonda</p>
<p>N</p>
<p>,</p>
<p>Dunne</p>
<p>R</p>
<p>,</p>
<p>Zalenski</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Treatment of severe decompensated heart failure with high-dose
intravenous nitroglycerin: a feasibility and outcome analysis</p>
<p>.</p>
<p>Ann Emerg Med</p>
<p>2007</p>
<p>;</p>
<p>50</p>
<p>:</p>
<p>144</p>
<p>–</p>
<p>152</p>
<p>.</p>
<p>478</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Motiejunaite</p>
<p>J</p>
<p>,</p>
<p>Gayat</p>
<p>E</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Akiyama</p>
<p>E</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Julve</p>
<p>MS</p>
<p>,</p>
<p>Roig</p>
<p>E</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>ESC Heart Failure Long-Term Registry Investigators. Long-term safety
of intravenous cardiovascular agents in acute heart failure: results
from the European Society of Cardiology heart failure long-term
registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>332</p>
<p>–</p>
<p>341</p>
<p>.</p>
<p>479</p>
<p>Kozhuharov</p>
<p>N</p>
<p>,</p>
<p>Goudev</p>
<p>A</p>
<p>,</p>
<p>Flores</p>
<p>D</p>
<p>,</p>
<p>Maeder</p>
<p>MT</p>
<p>,</p>
<p>Walter</p>
<p>J</p>
<p>,</p>
<p>Shrestha</p>
<p>S</p>
<p>,</p>
<p>Gualandro</p>
<p>DM</p>
<p>,</p>
<p>de Oliveira Junior</p>
<p>MT</p>
<p>,</p>
<p>Sabti</p>
<p>Z</p>
<p>,</p>
<p>Muller</p>
<p>B</p>
<p>,</p>
<p>Noveanu</p>
<p>M</p>
<p>,</p>
<p>Socrates</p>
<p>T</p>
<p>,</p>
<p>Ziller</p>
<p>R</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>Sionis</p>
<p>A</p>
<p>,</p>
<p>Simon</p>
<p>P</p>
<p>,</p>
<p>Michou</p>
<p>E</p>
<p>,</p>
<p>Gujer</p>
<p>S</p>
<p>,</p>
<p>Gori</p>
<p>T</p>
<p>,</p>
<p>Wenzel</p>
<p>P</p>
<p>,</p>
<p>Pfister</p>
<p>O</p>
<p>,</p>
<p>Conen</p>
<p>D</p>
<p>,</p>
<p>Kapos</p>
<p>I</p>
<p>,</p>
<p>Kobza</p>
<p>R</p>
<p>,</p>
<p>Rickli</p>
<p>H</p>
<p>,</p>
<p>Breidthardt</p>
<p>T</p>
<p>,</p>
<p>Munzel</p>
<p>T</p>
<p>,</p>
<p>Erne</p>
<p>P</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Investigators</p>
<p>G</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Erne</p>
<p>P</p>
<p>,</p>
<p>Muller</p>
<p>B</p>
<p>,</p>
<p>Rickli</p>
<p>H</p>
<p>,</p>
<p>Maeder</p>
<p>M</p>
<p>,</p>
<p>Tavares de Oliveira</p>
<p>M</p>
<p>Jr,</p>
<p>Munzel</p>
<p>T</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>Sionis</p>
<p>A</p>
<p>,</p>
<p>Goudev</p>
<p>A</p>
<p>,</p>
<p>Dimov</p>
<p>B</p>
<p>,</p>
<p>Hartwiger</p>
<p>S</p>
<p>,</p>
<p>Arenja</p>
<p>N</p>
<p>,</p>
<p>Glatz</p>
<p>B</p>
<p>,</p>
<p>Herr</p>
<p>N</p>
<p>,</p>
<p>Isenrich</p>
<p>R</p>
<p>,</p>
<p>Mosimann</p>
<p>T</p>
<p>,</p>
<p>Twerenbold</p>
<p>R</p>
<p>,</p>
<p>Boeddinghaus</p>
<p>J</p>
<p>,</p>
<p>Nestelberger</p>
<p>T</p>
<p>,</p>
<p>Puelacher</p>
<p>C</p>
<p>,</p>
<p>Freese</p>
<p>M</p>
<p>,</p>
<p>Vogele</p>
<p>J</p>
<p>,</p>
<p>Meissner</p>
<p>K</p>
<p>,</p>
<p>Martin</p>
<p>J</p>
<p>,</p>
<p>Strebel</p>
<p>I</p>
<p>,</p>
<p>Wussler</p>
<p>D</p>
<p>,</p>
<p>Schumacher</p>
<p>C</p>
<p>,</p>
<p>Osswald</p>
<p>S</p>
<p>,</p>
<p>Vogt</p>
<p>F</p>
<p>,</p>
<p>Hilti</p>
<p>J</p>
<p>,</p>
<p>Barata</p>
<p>S</p>
<p>,</p>
<p>Schneider</p>
<p>D</p>
<p>,</p>
<p>Schwarz</p>
<p>J</p>
<p>,</p>
<p>Fitze</p>
<p>B</p>
<p>,</p>
<p>Hartwiger</p>
<p>S</p>
<p>,</p>
<p>Arenja</p>
<p>N</p>
<p>,</p>
<p>Glatz</p>
<p>B</p>
<p>,</p>
<p>Herr</p>
<p>N</p>
<p>,</p>
<p>Isenrich</p>
<p>R</p>
<p>,</p>
<p>Mosimann</p>
<p>T</p>
<p>,</p>
<p>Twerenbold</p>
<p>R</p>
<p>,</p>
<p>Boeddinghaus</p>
<p>J</p>
<p>,</p>
<p>Nestelberger</p>
<p>T</p>
<p>,</p>
<p>Puelacher</p>
<p>C</p>
<p>,</p>
<p>Freese</p>
<p>M</p>
<p>,</p>
<p>Vogele</p>
<p>J</p>
<p>,</p>
<p>Meissner</p>
<p>K</p>
<p>,</p>
<p>Martin</p>
<p>J</p>
<p>,</p>
<p>Strebel</p>
<p>I</p>
<p>,</p>
<p>Wussler</p>
<p>D</p>
<p>,</p>
<p>Schumacher</p>
<p>C</p>
<p>,</p>
<p>Osswald</p>
<p>S</p>
<p>,</p>
<p>Vogt</p>
<p>F</p>
<p>,</p>
<p>Hilti</p>
<p>J</p>
<p>,</p>
<p>Barata</p>
<p>S</p>
<p>,</p>
<p>Schneider</p>
<p>D</p>
<p>,</p>
<p>Schwarz</p>
<p>J</p>
<p>,</p>
<p>Fitze</p>
<p>B</p>
<p>,</p>
<p>Arenja</p>
<p>N</p>
<p>,</p>
<p>Rentsch</p>
<p>K</p>
<p>,</p>
<p>Bossa</p>
<p>A</p>
<p>,</p>
<p>Jallad</p>
<p>S</p>
<p>,</p>
<p>Soeiro</p>
<p>A</p>
<p>,</p>
<p>Georgiev</p>
<p>D</p>
<p>,</p>
<p>Jansen</p>
<p>T</p>
<p>,</p>
<p>Gebel</p>
<p>G</p>
<p>,</p>
<p>Bossard</p>
<p>M</p>
<p>,</p>
<p>Christ</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Effect of a strategy of comprehensive vasodilation vs usual care on
mortality and heart failure rehospitalization among patients with acute
heart failure: the GALACTIC randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2019</p>
<p>;</p>
<p>322</p>
<p>:</p>
<p>2292</p>
<p>–</p>
<p>2302</p>
<p>.</p>
<p>480</p>
<p>Freund</p>
<p>Y</p>
<p>,</p>
<p>Cachanado</p>
<p>M</p>
<p>,</p>
<p>Delannoy</p>
<p>Q</p>
<p>,</p>
<p>Laribi</p>
<p>S</p>
<p>,</p>
<p>Yordanov</p>
<p>Y</p>
<p>,</p>
<p>Gorlicki</p>
<p>J</p>
<p>,</p>
<p>Chouihed</p>
<p>T</p>
<p>,</p>
<p>Feral-Pierssens</p>
<p>AL</p>
<p>,</p>
<p>Truchot</p>
<p>J</p>
<p>,</p>
<p>Desmettre</p>
<p>T</p>
<p>,</p>
<p>Occelli</p>
<p>C</p>
<p>,</p>
<p>Bobbia</p>
<p>X</p>
<p>,</p>
<p>Khellaf</p>
<p>M</p>
<p>,</p>
<p>Ganansia</p>
<p>O</p>
<p>,</p>
<p>Bokobza</p>
<p>J</p>
<p>,</p>
<p>Balen</p>
<p>F</p>
<p>,</p>
<p>Beaune</p>
<p>S</p>
<p>,</p>
<p>Bloom</p>
<p>B</p>
<p>,</p>
<p>Simon</p>
<p>T</p>
<p>,</p>
<p>Mebazaa</p>
<ol type="A">
<li></li>
</ol>
<p>Effect of an emergency department care bundle on 30-day hospital
discharge and survival among elderly patients with acute heart failure:
the ELISABETH randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2020</p>
<p>;</p>
<p>324</p>
<p>:</p>
<p>1948</p>
<p>–</p>
<p>1956</p>
<p>.</p>
<p>481</p>
<p>Khot</p>
<p>UN</p>
<p>,</p>
<p>Novaro</p>
<p>GM</p>
<p>,</p>
<p>Popovic</p>
<p>ZB</p>
<p>,</p>
<p>Mills</p>
<p>RM</p>
<p>,</p>
<p>Thomas</p>
<p>JD</p>
<p>,</p>
<p>Tuzcu</p>
<p>EM</p>
<p>,</p>
<p>Hammer</p>
<p>D</p>
<p>,</p>
<p>Nissen</p>
<p>SE</p>
<p>,</p>
<p>Francis</p>
<p>GS.</p>
<p>Nitroprusside in critically ill patients with left ventricular
dysfunction and aortic stenosis</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2003</p>
<p>;</p>
<p>348</p>
<p>:</p>
<p>1756</p>
<p>–</p>
<p>1763</p>
<p>.</p>
<p>482</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Nieminen</p>
<p>MS</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Salon</p>
<p>JE</p>
<p>,</p>
<p>Thakkar</p>
<p>R</p>
<p>,</p>
<p>Padley</p>
<p>RJ</p>
<p>,</p>
<p>Huang</p>
<p>B</p>
<p>,</p>
<p>Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart
failure patients on beta-blockers in SURVIVE</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2009</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>304</p>
<p>–</p>
<p>311</p>
<p>.</p>
<p>483</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Nodari</p>
<p>S</p>
<p>,</p>
<p>D’Aloia</p>
<p>A</p>
<p>,</p>
<p>Muneretto</p>
<p>C</p>
<p>,</p>
<p>Robertson</p>
<p>AD</p>
<p>,</p>
<p>Bristow</p>
<p>MR</p>
<p>,</p>
<p>Dei Cas L. Beta-blocker therapy influences the hemodynamic response
to inotropic agents in patients with heart failure: a randomized
comparison of dobutamine and enoximone before and after chronic
treatment with metoprolol or carvedilol</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2002</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>1248</p>
<p>–</p>
<p>1258</p>
<p>.</p>
<p>484</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Colucci</p>
<p>W</p>
<p>,</p>
<p>Fisher</p>
<p>L</p>
<p>,</p>
<p>Massie</p>
<p>BM</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Young</p>
<p>J</p>
<p>,</p>
<p>Padley</p>
<p>RJ</p>
<p>,</p>
<p>Thakkar</p>
<p>R</p>
<p>,</p>
<p>Delgado-Herrera</p>
<p>L</p>
<p>,</p>
<p>Salon</p>
<p>J</p>
<p>,</p>
<p>Garratt</p>
<p>C</p>
<p>,</p>
<p>Huang</p>
<p>B</p>
<p>,</p>
<p>Sarapohja</p>
<p>T</p>
<p>,</p>
<p>REVIVE Heart Failure Study Group</p>
<p>.</p>
<p>Effect of levosimendan on the short-term clinical course of patients
with acutely decompensated heart failure</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>1</p>
<p>:</p>
<p>103</p>
<p>–</p>
<p>111</p>
<p>.</p>
<p>485</p>
<p>De Backer</p>
<p>D</p>
<p>,</p>
<p>Biston</p>
<p>P</p>
<p>,</p>
<p>Devriendt</p>
<p>J</p>
<p>,</p>
<p>Madl</p>
<p>C</p>
<p>,</p>
<p>Chochrad</p>
<p>D</p>
<p>,</p>
<p>Aldecoa</p>
<p>C</p>
<p>,</p>
<p>Brasseur</p>
<p>A</p>
<p>,</p>
<p>Defrance</p>
<p>P</p>
<p>,</p>
<p>Gottignies</p>
<p>P</p>
<p>,</p>
<p>Vincent</p>
<p>JL</p>
<p>,</p>
<p>SOAP II Investigators. Comparison of dopamine and norepinephrine in
the treatment of shock</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2010</p>
<p>;</p>
<p>362</p>
<p>:</p>
<p>779</p>
<p>–</p>
<p>789</p>
<p>.</p>
<p>486</p>
<p>Levy</p>
<p>B</p>
<p>,</p>
<p>Clere-Jehl</p>
<p>R</p>
<p>,</p>
<p>Legras</p>
<p>A</p>
<p>,</p>
<p>Morichau-Beauchant</p>
<p>T</p>
<p>,</p>
<p>Leone</p>
<p>M</p>
<p>,</p>
<p>Frederique</p>
<p>G</p>
<p>,</p>
<p>Quenot</p>
<p>JP</p>
<p>,</p>
<p>Kimmoun</p>
<p>A</p>
<p>,</p>
<p>Cariou</p>
<p>A</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Meziani</p>
<p>F</p>
<p>,</p>
<p>Louis</p>
<p>G</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Duarte</p>
<p>K</p>
<p>,</p>
<p>Girerd</p>
<p>N</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Vignon</p>
<p>P</p>
<p>,</p>
<p>Collaborators</p>
<p>.</p>
<p>Epinephrine versus norepinephrine for cardiogenic shock after acute
myocardial infarction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>72</p>
<p>:</p>
<p>173</p>
<p>–</p>
<p>182</p>
<p>.</p>
<p>487</p>
<p>Leopold</p>
<p>V</p>
<p>,</p>
<p>Gayat</p>
<p>E</p>
<p>,</p>
<p>Pirracchio</p>
<p>R</p>
<p>,</p>
<p>Spinar</p>
<p>J</p>
<p>,</p>
<p>Parenica</p>
<p>J</p>
<p>,</p>
<p>Tarvasmaki</p>
<p>T</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Champion</p>
<p>S</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Valente</p>
<p>S</p>
<p>,</p>
<p>Urban</p>
<p>P</p>
<p>,</p>
<p>Chua</p>
<p>HR</p>
<p>,</p>
<p>Bellomo</p>
<p>R</p>
<p>,</p>
<p>Popovic</p>
<p>B</p>
<p>,</p>
<p>Ouweneel</p>
<p>DM</p>
<p>,</p>
<p>Henriques</p>
<p>JPS</p>
<p>,</p>
<p>Simonis</p>
<p>G</p>
<p>,</p>
<p>Levy</p>
<p>B</p>
<p>,</p>
<p>Kimmoun</p>
<p>A</p>
<p>,</p>
<p>Gaudard</p>
<p>P</p>
<p>,</p>
<p>Basir</p>
<p>MB</p>
<p>,</p>
<p>Markota</p>
<p>A</p>
<p>,</p>
<p>Adler</p>
<p>C</p>
<p>,</p>
<p>Reuter</p>
<p>H</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Chouihed</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Epinephrine and short-term survival in cardiogenic shock: an
individual data meta-analysis of 2583 patients</p>
<p>.</p>
<p>Intensive Care Med</p>
<p>2018</p>
<p>;</p>
<p>44</p>
<p>:</p>
<p>847</p>
<p>–</p>
<p>856</p>
<p>.</p>
<p>488</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Hollander</p>
<p>JE</p>
<p>,</p>
<p>Diercks</p>
<p>DB</p>
<p>,</p>
<p>Lopatin</p>
<p>M</p>
<p>,</p>
<p>Fonarow</p>
<p>G</p>
<p>,</p>
<p>Emerman</p>
<ol start="150" type="I">
<li></li>
</ol>
<p>Morphine and outcomes in acute decompensated heart failure: an ADHERE
analysis</p>
<p>.</p>
<p>Emerg Med J</p>
<p>2008</p>
<p>;</p>
<p>25</p>
<p>:</p>
<p>205</p>
<p>–</p>
<p>209</p>
<p>.</p>
<p>489</p>
<p>Gil</p>
<p>V</p>
<p>,</p>
<p>Dominguez-Rodriguez</p>
<p>A</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Miro</p>
<ol start="15" type="A">
<li></li>
</ol>
<p>Morphine use in the treatment of acute cardiogenic pulmonary edema
and its effects on patient outcome: a systematic review</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2019</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>81</p>
<p>–</p>
<p>88</p>
<p>.</p>
<p>490</p>
<p>Miro</p>
<p>O</p>
<p>,</p>
<p>Gil</p>
<p>V</p>
<p>,</p>
<p>Martin-Sanchez</p>
<p>FJ</p>
<p>,</p>
<p>Herrero-Puente</p>
<p>P</p>
<p>,</p>
<p>Jacob</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Harjola</p>
<p>VP</p>
<p>,</p>
<p>Rios</p>
<p>J</p>
<p>,</p>
<p>Hollander</p>
<p>JE</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Llorens</p>
<p>P</p>
<p>,</p>
<p>ICA-SEMES Research Group</p>
<p>.</p>
<p>Morphine use in the ED and outcomes of patients with acute heart
failure: a propensity score-matching analysis based on the EAHFE
registry</p>
<p>.</p>
<p>Chest</p>
<p>2017</p>
<p>;</p>
<p>152</p>
<p>:</p>
<p>821</p>
<p>–</p>
<p>832</p>
<p>.</p>
<p>491</p>
<p>Caspi</p>
<p>O</p>
<p>,</p>
<p>Naami</p>
<p>R</p>
<p>,</p>
<p>Halfin</p>
<p>E</p>
<p>,</p>
<p>Aronson</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Adverse dose-dependent effects of morphine therapy in acute heart
failure</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2019</p>
<p>;</p>
<p>293</p>
<p>:</p>
<p>131</p>
<p>–</p>
<p>136</p>
<p>.</p>
<p>492</p>
<p>Sethi</p>
<p>NJ</p>
<p>,</p>
<p>Nielsen</p>
<p>EE</p>
<p>,</p>
<p>Safi</p>
<p>S</p>
<p>,</p>
<p>Feinberg</p>
<p>J</p>
<p>,</p>
<p>Gluud</p>
<p>C</p>
<p>,</p>
<p>Jakobsen</p>
<p>JC.</p>
<p>Digoxin for atrial fibrillation and atrial flutter: a systematic
review with meta-analysis and trial sequential analysis of randomised
clinical trials</p>
<p>.</p>
<p>PLoS One</p>
<p>2018</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>e0193924</p>
<p>.</p>
<p>493</p>
<p>Khand</p>
<p>AU</p>
<p>,</p>
<p>Rankin</p>
<p>AC</p>
<p>,</p>
<p>Martin</p>
<p>W</p>
<p>,</p>
<p>Taylor</p>
<p>J</p>
<p>,</p>
<p>Gemmell</p>
<p>I</p>
<p>,</p>
<p>Cleland</p>
<p>JG.</p>
<p>Carvedilol alone or in combination with digoxin for the management of
atrial fibrillation in patients with heart failure?</p>
<p>J Am Coll Cardiol</p>
<p>2003</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>1944</p>
<p>–</p>
<p>1951</p>
<p>.</p>
<p>494</p>
<p>Tebbe</p>
<p>U</p>
<p>,</p>
<p>Schellong</p>
<p>SM</p>
<p>,</p>
<p>Haas</p>
<p>S</p>
<p>,</p>
<p>Gerlach</p>
<p>HE</p>
<p>,</p>
<p>Abletshauser</p>
<p>C</p>
<p>,</p>
<p>Sieder</p>
<p>C</p>
<p>,</p>
<p>Bramlage</p>
<p>P</p>
<p>,</p>
<p>Riess</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Certoparin versus unfractionated heparin to prevent venous
thromboembolic events in patients hospitalized because of heart failure:
a subgroup analysis of the randomized, controlled CERTIFY study</p>
<p>.</p>
<p>Am Heart J</p>
<p>2011</p>
<p>;</p>
<p>161</p>
<p>:</p>
<p>322</p>
<p>–</p>
<p>328</p>
<p>.</p>
<p>495</p>
<p>Dentali</p>
<p>F</p>
<p>,</p>
<p>Douketis</p>
<p>JD</p>
<p>,</p>
<p>Gianni</p>
<p>M</p>
<p>,</p>
<p>Lim</p>
<p>W</p>
<p>,</p>
<p>Crowther</p>
<p>MA.</p>
<p>Meta-analysis: anticoagulant prophylaxis to prevent symptomatic
venous thromboembolism in hospitalized medical patients</p>
<p>.</p>
<p>Ann Intern Med</p>
<p>2007</p>
<p>;</p>
<p>146</p>
<p>:</p>
<p>278</p>
<p>–</p>
<p>288</p>
<p>.</p>
<p>496</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Lopatin</p>
<p>Y</p>
<p>,</p>
<p>Jankowska</p>
<p>E</p>
<p>,</p>
<p>Polovina</p>
<p>M</p>
<p>,</p>
<p>Anguita-Sanchez</p>
<p>M</p>
<p>,</p>
<p>Stork</p>
<p>S</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Milicic</p>
<p>D</p>
<p>,</p>
<p>Milinkovic</p>
<p>I</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Heart Failure Association Board of the European Society of
Cardiology. Heart Failure Association of the European Society of
Cardiology quality of care centres programme: design and accreditation
document</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>763</p>
<p>–</p>
<p>774</p>
<p>.</p>
<p>497</p>
<p>Tehrani</p>
<p>BN</p>
<p>,</p>
<p>Truesdell</p>
<p>AG</p>
<p>,</p>
<p>Sherwood</p>
<p>MW</p>
<p>,</p>
<p>Desai</p>
<p>S</p>
<p>,</p>
<p>Tran</p>
<p>HA</p>
<p>,</p>
<p>Epps</p>
<p>KC</p>
<p>,</p>
<p>Singh</p>
<p>R</p>
<p>,</p>
<p>Psotka</p>
<p>M</p>
<p>,</p>
<p>Shah</p>
<p>P</p>
<p>,</p>
<p>Cooper</p>
<p>LB</p>
<p>,</p>
<p>Rosner</p>
<p>C</p>
<p>,</p>
<p>Raja</p>
<p>A</p>
<p>,</p>
<p>Barnett</p>
<p>SD</p>
<p>,</p>
<p>Saulino</p>
<p>P</p>
<p>,</p>
<p>deFilippi</p>
<p>CR</p>
<p>,</p>
<p>Gurbel</p>
<p>PA</p>
<p>,</p>
<p>Murphy</p>
<p>CE</p>
<p>,</p>
<p>O’Connor</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Standardized team-based care for cardiogenic shock</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>73</p>
<p>:</p>
<p>1659</p>
<p>–</p>
<p>1669</p>
<p>.</p>
<p>498</p>
<p>Basir</p>
<p>MB</p>
<p>,</p>
<p>Kapur</p>
<p>NK</p>
<p>,</p>
<p>Patel</p>
<p>K</p>
<p>,</p>
<p>Salam</p>
<p>MA</p>
<p>,</p>
<p>Schreiber</p>
<p>T</p>
<p>,</p>
<p>Kaki</p>
<p>A</p>
<p>,</p>
<p>Hanson</p>
<p>I</p>
<p>,</p>
<p>Almany</p>
<p>S</p>
<p>,</p>
<p>Timmis</p>
<p>S</p>
<p>,</p>
<p>Dixon</p>
<p>S</p>
<p>,</p>
<p>Kolski</p>
<p>B</p>
<p>,</p>
<p>Todd</p>
<p>J</p>
<p>,</p>
<p>Senter</p>
<p>S</p>
<p>,</p>
<p>Marso</p>
<p>S</p>
<p>,</p>
<p>Lasorda</p>
<p>D</p>
<p>,</p>
<p>Wilkins</p>
<p>C</p>
<p>,</p>
<p>Lalonde</p>
<p>T</p>
<p>,</p>
<p>Attallah</p>
<p>A</p>
<p>,</p>
<p>Larkin</p>
<p>T</p>
<p>,</p>
<p>Dupont</p>
<p>A</p>
<p>,</p>
<p>Marshall</p>
<p>J</p>
<p>,</p>
<p>Patel</p>
<p>N</p>
<p>,</p>
<p>Overly</p>
<p>T</p>
<p>,</p>
<p>Green</p>
<p>M</p>
<p>,</p>
<p>Tehrani</p>
<p>B</p>
<p>,</p>
<p>Truesdell</p>
<p>AG</p>
<p>,</p>
<p>Sharma</p>
<p>R</p>
<p>,</p>
<p>Akhtar</p>
<p>Y</p>
<p>,</p>
<p>McRae</p>
<p>T</p>
<p>3rd,</p>
<p>O’Neill</p>
<p>B</p>
<p>,</p>
<p>Finley</p>
<p>J</p>
<p>,</p>
<p>Rahman</p>
<p>A</p>
<p>,</p>
<p>Foster</p>
<p>M</p>
<p>,</p>
<p>Askari</p>
<p>R</p>
<p>,</p>
<p>Goldsweig</p>
<p>A</p>
<p>,</p>
<p>Martin</p>
<p>S</p>
<p>,</p>
<p>Bharadwaj</p>
<p>A</p>
<p>,</p>
<p>Khuddus</p>
<p>M</p>
<p>,</p>
<p>Caputo</p>
<p>C</p>
<p>,</p>
<p>Korpas</p>
<p>D</p>
<p>,</p>
<p>Cawich</p>
<p>I</p>
<p>,</p>
<p>McAllister</p>
<p>D</p>
<p>,</p>
<p>Blank</p>
<p>N</p>
<p>,</p>
<p>Alraies</p>
<p>MC</p>
<p>,</p>
<p>Fisher</p>
<p>R</p>
<p>,</p>
<p>Khandelwal</p>
<p>A</p>
<p>,</p>
<p>Alaswad</p>
<p>K</p>
<p>,</p>
<p>Lemor</p>
<p>A</p>
<p>,</p>
<p>Johnson</p>
<p>T</p>
<p>,</p>
<p>Hacala</p>
<p>M</p>
<p>,</p>
<p>O’Neill</p>
<p>WW</p>
<p>,</p>
<p>National Cardiogenic Shock Initiative Investigators. Improved
outcomes associated with the use of shock protocols: updates from the
National Cardiogenic Shock Initiative</p>
<p>.</p>
<p>Catheter Cardiovasc Interv</p>
<p>2019</p>
<p>;</p>
<p>93</p>
<p>:</p>
<p>1173</p>
<p>–</p>
<p>1183</p>
<p>.</p>
<p>499</p>
<p>Tehrani</p>
<p>BN</p>
<p>,</p>
<p>Truesdell</p>
<p>AG</p>
<p>,</p>
<p>Psotka</p>
<p>MA</p>
<p>,</p>
<p>Rosner</p>
<p>C</p>
<p>,</p>
<p>Singh</p>
<p>R</p>
<p>,</p>
<p>Sinha</p>
<p>SS</p>
<p>,</p>
<p>Damluji</p>
<p>AA</p>
<p>,</p>
<p>Batchelor</p>
<p>WB.</p>
<p>A standardized and comprehensive approach to the management of
cardiogenic shock</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>879</p>
<p>–</p>
<p>891</p>
<p>.</p>
<p>500</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Zeymer</p>
<p>U</p>
<p>,</p>
<p>Neumann</p>
<p>FJ</p>
<p>,</p>
<p>Ferenc</p>
<p>M</p>
<p>,</p>
<p>Olbrich</p>
<p>HG</p>
<p>,</p>
<p>Hausleiter</p>
<p>J</p>
<p>,</p>
<p>Richardt</p>
<p>G</p>
<p>,</p>
<p>Hennersdorf</p>
<p>M</p>
<p>,</p>
<p>Empen</p>
<p>K</p>
<p>,</p>
<p>Fuernau</p>
<p>G</p>
<p>,</p>
<p>Desch</p>
<p>S</p>
<p>,</p>
<p>Eitel</p>
<p>I</p>
<p>,</p>
<p>Hambrecht</p>
<p>R</p>
<p>,</p>
<p>Fuhrmann</p>
<p>J</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Ebelt</p>
<p>H</p>
<p>,</p>
<p>Schneider</p>
<p>S</p>
<p>,</p>
<p>Schuler</p>
<p>G</p>
<p>,</p>
<p>Werdan</p>
<p>K</p>
<p>,</p>
<p>IABP-SHOCK II Trial Investigators</p>
<p>.</p>
<p>Intraaortic balloon support for myocardial infarction with
cardiogenic shock</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2012</p>
<p>;</p>
<p>367</p>
<p>:</p>
<p>1287</p>
<p>–</p>
<p>1296</p>
<p>.</p>
<p>501</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Zeymer</p>
<p>U</p>
<p>,</p>
<p>Neumann</p>
<p>FJ</p>
<p>,</p>
<p>Ferenc</p>
<p>M</p>
<p>,</p>
<p>Olbrich</p>
<p>HG</p>
<p>,</p>
<p>Hausleiter</p>
<p>J</p>
<p>,</p>
<p>de Waha</p>
<p>A</p>
<p>,</p>
<p>Richardt</p>
<p>G</p>
<p>,</p>
<p>Hennersdorf</p>
<p>M</p>
<p>,</p>
<p>Empen</p>
<p>K</p>
<p>,</p>
<p>Fuernau</p>
<p>G</p>
<p>,</p>
<p>Desch</p>
<p>S</p>
<p>,</p>
<p>Eitel</p>
<p>I</p>
<p>,</p>
<p>Hambrecht</p>
<p>R</p>
<p>,</p>
<p>Lauer</p>
<p>B</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Ebelt</p>
<p>H</p>
<p>,</p>
<p>Schneider</p>
<p>S</p>
<p>,</p>
<p>Werdan</p>
<p>K</p>
<p>,</p>
<p>Schuler</p>
<p>G</p>
<p>,</p>
<p>Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II)
trial investigators</p>
<p>.</p>
<p>Intra-aortic balloon counterpulsation in acute myocardial infarction
complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results
of a randomised, open-label trial</p>
<p>.</p>
<p>Lancet</p>
<p>2013</p>
<p>;</p>
<p>382</p>
<p>:</p>
<p>1638</p>
<p>–</p>
<p>1645</p>
<p>.</p>
<p>502</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Zeymer</p>
<p>U</p>
<p>,</p>
<p>Thelemann</p>
<p>N</p>
<p>,</p>
<p>Neumann</p>
<p>FJ</p>
<p>,</p>
<p>Hausleiter</p>
<p>J</p>
<p>,</p>
<p>Abdel-Wahab</p>
<p>M</p>
<p>,</p>
<p>Meyer-Saraei</p>
<p>R</p>
<p>,</p>
<p>Fuernau</p>
<p>G</p>
<p>,</p>
<p>Eitel</p>
<p>I</p>
<p>,</p>
<p>Hambrecht</p>
<p>R</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Werdan</p>
<p>K</p>
<p>,</p>
<p>Felix</p>
<p>SB</p>
<p>,</p>
<p>Hennersdorf</p>
<p>M</p>
<p>,</p>
<p>Schneider</p>
<p>S</p>
<p>,</p>
<p>Ouarrak</p>
<p>T</p>
<p>,</p>
<p>Desch</p>
<p>S</p>
<p>,</p>
<p>de Waha-Thiele</p>
<p>S</p>
<p>,</p>
<p>IABP-SHOCK II Trial Investigators</p>
<p>.</p>
<p>Intraaortic balloon pump in cardiogenic shock complicating acute
myocardial infarction: long-term 6-year outcome of the randomized
IABP-SHOCK II Trial</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>395</p>
<p>–</p>
<p>403</p>
<p>.</p>
<p>503</p>
<p>Seyfarth</p>
<p>M</p>
<p>,</p>
<p>Sibbing</p>
<p>D</p>
<p>,</p>
<p>Bauer</p>
<p>I</p>
<p>,</p>
<p>Frohlich</p>
<p>G</p>
<p>,</p>
<p>Bott-Flugel</p>
<p>L</p>
<p>,</p>
<p>Byrne</p>
<p>R</p>
<p>,</p>
<p>Dirschinger</p>
<p>J</p>
<p>,</p>
<p>Kastrati</p>
<p>A</p>
<p>,</p>
<p>Schomig</p>
<ol type="A">
<li></li>
</ol>
<p>A randomized clinical trial to evaluate the safety and efficacy of a
percutaneous left ventricular assist device versus intra-aortic balloon
pumping for treatment of cardiogenic shock caused by myocardial
infarction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2008</p>
<p>;</p>
<p>52</p>
<p>:</p>
<p>1584</p>
<p>–</p>
<p>1588</p>
<p>.</p>
<p>504</p>
<p>Ouweneel</p>
<p>DM</p>
<p>,</p>
<p>Eriksen</p>
<p>E</p>
<p>,</p>
<p>Sjauw</p>
<p>KD</p>
<p>,</p>
<p>van Dongen</p>
<p>IM</p>
<p>,</p>
<p>Hirsch</p>
<p>A</p>
<p>,</p>
<p>Packer</p>
<p>EJ</p>
<p>,</p>
<p>Vis</p>
<p>MM</p>
<p>,</p>
<p>Wykrzykowska</p>
<p>JJ</p>
<p>,</p>
<p>Koch</p>
<p>KT</p>
<p>,</p>
<p>Baan</p>
<p>J</p>
<p>,</p>
<p>de Winter</p>
<p>RJ</p>
<p>,</p>
<p>Piek</p>
<p>JJ</p>
<p>,</p>
<p>Lagrand</p>
<p>WK</p>
<p>,</p>
<p>de Mol</p>
<p>BA</p>
<p>,</p>
<p>Tijssen</p>
<p>JG</p>
<p>,</p>
<p>Henriques</p>
<p>JP.</p>
<p>Percutaneous mechanical circulatory support versus intra-aortic
balloon pump in cardiogenic shock after acute myocardial infarction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>69</p>
<p>:</p>
<p>278</p>
<p>–</p>
<p>287</p>
<p>.</p>
<p>505</p>
<p>Schrage</p>
<p>B</p>
<p>,</p>
<p>Ibrahim</p>
<p>K</p>
<p>,</p>
<p>Loehn</p>
<p>T</p>
<p>,</p>
<p>Werner</p>
<p>N</p>
<p>,</p>
<p>Sinning</p>
<p>JM</p>
<p>,</p>
<p>Pappalardo</p>
<p>F</p>
<p>,</p>
<p>Pieri</p>
<p>M</p>
<p>,</p>
<p>Skurk</p>
<p>C</p>
<p>,</p>
<p>Lauten</p>
<p>A</p>
<p>,</p>
<p>Landmesser</p>
<p>U</p>
<p>,</p>
<p>Westenfeld</p>
<p>R</p>
<p>,</p>
<p>Horn</p>
<p>P</p>
<p>,</p>
<p>Pauschinger</p>
<p>M</p>
<p>,</p>
<p>Eckner</p>
<p>D</p>
<p>,</p>
<p>Twerenbold</p>
<p>R</p>
<p>,</p>
<p>Nordbeck</p>
<p>P</p>
<p>,</p>
<p>Salinger</p>
<p>T</p>
<p>,</p>
<p>Abel</p>
<p>P</p>
<p>,</p>
<p>Empen</p>
<p>K</p>
<p>,</p>
<p>Busch</p>
<p>MC</p>
<p>,</p>
<p>Felix</p>
<p>SB</p>
<p>,</p>
<p>Sieweke</p>
<p>JT</p>
<p>,</p>
<p>Moller</p>
<p>JE</p>
<p>,</p>
<p>Pareek</p>
<p>N</p>
<p>,</p>
<p>Hill</p>
<p>J</p>
<p>,</p>
<p>MacCarthy</p>
<p>P</p>
<p>,</p>
<p>Bergmann</p>
<p>MW</p>
<p>,</p>
<p>Henriques</p>
<p>JPS</p>
<p>,</p>
<p>Mobius-Winkler</p>
<p>S</p>
<p>,</p>
<p>Schulze</p>
<p>PC</p>
<p>,</p>
<p>Ouarrak</p>
<p>T</p>
<p>,</p>
<p>Zeymer</p>
<p>U</p>
<p>,</p>
<p>Schneider</p>
<p>S</p>
<p>,</p>
<p>Blankenberg</p>
<p>S</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Schafer</p>
<p>A</p>
<p>,</p>
<p>Westermann</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Impella support for acute myocardial infarction complicated by
cardiogenic shock</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>1249</p>
<p>–</p>
<p>1258</p>
<p>.</p>
<p>506</p>
<p>Dhruva</p>
<p>SS</p>
<p>,</p>
<p>Ross</p>
<p>JS</p>
<p>,</p>
<p>Mortazavi</p>
<p>BJ</p>
<p>,</p>
<p>Hurley</p>
<p>NC</p>
<p>,</p>
<p>Krumholz</p>
<p>HM</p>
<p>,</p>
<p>Curtis</p>
<p>JP</p>
<p>,</p>
<p>Berkowitz</p>
<p>A</p>
<p>,</p>
<p>Masoudi</p>
<p>FA</p>
<p>,</p>
<p>Messenger</p>
<p>JC</p>
<p>,</p>
<p>Parzynski</p>
<p>CS</p>
<p>,</p>
<p>Ngufor</p>
<p>C</p>
<p>,</p>
<p>Girotra</p>
<p>S</p>
<p>,</p>
<p>Amin</p>
<p>AP</p>
<p>,</p>
<p>Shah</p>
<p>ND</p>
<p>,</p>
<p>Desai</p>
<p>NR.</p>
<p>Association of use of an intravascular microaxial left ventricular
assist device vs intra-aortic balloon pump with in-hospital mortality
and major bleeding among patients with acute myocardial infarction
complicated by cardiogenic shock</p>
<p>.</p>
<p>JAMA</p>
<p>2020</p>
<p>;</p>
<p>323</p>
<p>:</p>
<p>734</p>
<p>–</p>
<p>745</p>
<p>.</p>
<p>507</p>
<p>Kar</p>
<p>B</p>
<p>,</p>
<p>Gregoric</p>
<p>ID</p>
<p>,</p>
<p>Basra</p>
<p>SS</p>
<p>,</p>
<p>Idelchik</p>
<p>GM</p>
<p>,</p>
<p>Loyalka</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>The percutaneous ventricular assist device in severe refractory
cardiogenic shock</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2011</p>
<p>;</p>
<p>57</p>
<p>:</p>
<p>688</p>
<p>–</p>
<p>696</p>
<p>.</p>
<p>508</p>
<p>Ouweneel</p>
<p>DM</p>
<p>,</p>
<p>Schotborgh</p>
<p>JV</p>
<p>,</p>
<p>Limpens</p>
<p>J</p>
<p>,</p>
<p>Sjauw</p>
<p>KD</p>
<p>,</p>
<p>Engstrom</p>
<p>AE</p>
<p>,</p>
<p>Lagrand</p>
<p>WK</p>
<p>,</p>
<p>Cherpanath</p>
<p>TGV</p>
<p>,</p>
<p>Driessen</p>
<p>AHG</p>
<p>,</p>
<p>de Mol</p>
<p>B</p>
<p>,</p>
<p>Henriques</p>
<p>JPS.</p>
<p>Extracorporeal life support during cardiac arrest and cardiogenic
shock: a systematic review and meta-analysis</p>
<p>.</p>
<p>Intensive Care Med</p>
<p>2016</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>1922</p>
<p>–</p>
<p>1934</p>
<p>.</p>
<p>509</p>
<p>Combes</p>
<p>A</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Slutsky</p>
<p>AS</p>
<p>,</p>
<p>Brodie</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Temporary circulatory support for cardiogenic shock</p>
<p>.</p>
<p>Lancet</p>
<p>2020</p>
<p>;</p>
<p>396</p>
<p>:</p>
<p>199</p>
<p>–</p>
<p>212</p>
<p>.</p>
<p>510</p>
<p>Pappalardo</p>
<p>F</p>
<p>,</p>
<p>Schulte</p>
<p>C</p>
<p>,</p>
<p>Pieri</p>
<p>M</p>
<p>,</p>
<p>Schrage</p>
<p>B</p>
<p>,</p>
<p>Contri</p>
<p>R</p>
<p>,</p>
<p>Soeffker</p>
<p>G</p>
<p>,</p>
<p>Greco</p>
<p>T</p>
<p>,</p>
<p>Lembo</p>
<p>R</p>
<p>,</p>
<p>Mullerleile</p>
<p>K</p>
<p>,</p>
<p>Colombo</p>
<p>A</p>
<p>,</p>
<p>Sydow</p>
<p>K</p>
<p>,</p>
<p>De Bonis</p>
<p>M</p>
<p>,</p>
<p>Wagner</p>
<p>F</p>
<p>,</p>
<p>Reichenspurner</p>
<p>H</p>
<p>,</p>
<p>Blankenberg</p>
<p>S</p>
<p>,</p>
<p>Zangrillo</p>
<p>A</p>
<p>,</p>
<p>Westermann</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Concomitant implantation of Impella((R)) on top of veno-arterial
extracorporeal membrane oxygenation may improve survival of patients
with cardiogenic shock</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>404</p>
<p>–</p>
<p>412</p>
<p>.</p>
<p>511</p>
<p>Anderson</p>
<p>MB</p>
<p>,</p>
<p>Goldstein</p>
<p>J</p>
<p>,</p>
<p>Milano</p>
<p>C</p>
<p>,</p>
<p>Morris</p>
<p>LD</p>
<p>,</p>
<p>Kormos</p>
<p>RL</p>
<p>,</p>
<p>Bhama</p>
<p>J</p>
<p>,</p>
<p>Kapur</p>
<p>NK</p>
<p>,</p>
<p>Bansal</p>
<p>A</p>
<p>,</p>
<p>Garcia</p>
<p>J</p>
<p>,</p>
<p>Baker</p>
<p>JN</p>
<p>,</p>
<p>Silvestry</p>
<p>S</p>
<p>,</p>
<p>Holman</p>
<p>WL</p>
<p>,</p>
<p>Douglas</p>
<p>PS</p>
<p>,</p>
<p>O’Neill</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Benefits of a novel percutaneous ventricular assist device for right
heart failure: the prospective RECOVER RIGHT study of the Impella RP
device</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2015</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>1549</p>
<p>–</p>
<p>1560</p>
<p>.</p>
<p>512</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Kirwan</p>
<p>BA</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Dorobantu</p>
<p>M</p>
<p>,</p>
<p>Drozdz</p>
<p>J</p>
<p>,</p>
<p>Fabien</p>
<p>V</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Gohring</p>
<p>UM</p>
<p>,</p>
<p>Keren</p>
<p>A</p>
<p>,</p>
<p>Khintibidze</p>
<p>I</p>
<p>,</p>
<p>Kragten</p>
<p>H</p>
<p>,</p>
<p>Martinez</p>
<p>FA</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Milicic</p>
<p>D</p>
<p>,</p>
<p>Nicolau</p>
<p>JC</p>
<p>,</p>
<p>Ohlsson</p>
<p>M</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Pascual-Figal</p>
<p>DA</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Sim</p>
<p>D</p>
<p>,</p>
<p>Skouri</p>
<p>H</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Lewis</p>
<p>BS</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Danchin</p>
<p>N</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Dargie</p>
<p>HJ</p>
<p>,</p>
<p>Motro</p>
<p>M</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Friede</p>
<p>T</p>
<p>,</p>
<p>Jensen</p>
<p>KH</p>
<p>,</p>
<p>Pocock</p>
<p>S</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>AFFIRM-AHF Investigators</p>
<p>.</p>
<p>Ferric carboxymaltose for iron deficiency at discharge after acute
heart failure: a multicentre, double-blind, randomised, controlled
trial</p>
<p>.</p>
<p>Lancet</p>
<p>2020</p>
<p>;</p>
<p>396</p>
<p>:</p>
<p>1895</p>
<p>–</p>
<p>1904</p>
<p>.</p>
<p>513</p>
<p>Bhagat</p>
<p>AA</p>
<p>,</p>
<p>Greene</p>
<p>SJ</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Butler</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Initiation, continuation, switching, and withdrawal of heart failure
medical therapies during hospitalization</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>12</p>
<p>.</p>
<p>514</p>
<p>Prins</p>
<p>KW</p>
<p>,</p>
<p>Neill</p>
<p>JM</p>
<p>,</p>
<p>Tyler</p>
<p>JO</p>
<p>,</p>
<p>Eckman</p>
<p>PM</p>
<p>,</p>
<p>Duval</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Effects of beta-blocker withdrawal in acute decompensated heart
failure: a systematic review and meta-analysis</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>647</p>
<p>–</p>
<p>653</p>
<p>.</p>
<p>515</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Bonow</p>
<p>RO</p>
<p>,</p>
<p>Dei Cas</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Postdischarge assessment after a heart failure hospitalization: the
next step forward</p>
<p>.</p>
<p>Circulation</p>
<p>2010</p>
<p>;</p>
<p>122</p>
<p>:</p>
<p>1782</p>
<p>–</p>
<p>1785</p>
<p>.</p>
<p>516</p>
<p>Greene</p>
<p>SJ</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Khan</p>
<p>SS</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Gheorghiade</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>The vulnerable phase after hospitalization for heart failure</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2015</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>220</p>
<p>–</p>
<p>229</p>
<p>.</p>
<p>517</p>
<p>Lee</p>
<p>KK</p>
<p>,</p>
<p>Yang</p>
<p>J</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Steimle</p>
<p>AE</p>
<p>,</p>
<p>Go</p>
<p>AS.</p>
<p>Post-discharge Follow-up characteristics associated with 30-day
readmission after heart failure hospitalization</p>
<p>.</p>
<p>Med Care</p>
<p>2016</p>
<p>;</p>
<p>54</p>
<p>:</p>
<p>365</p>
<p>–</p>
<p>372</p>
<p>.</p>
<p>518</p>
<p>Edmonston</p>
<p>DL</p>
<p>,</p>
<p>Wu</p>
<p>J</p>
<p>,</p>
<p>Matsouaka</p>
<p>RA</p>
<p>,</p>
<p>Yancy</p>
<p>C</p>
<p>,</p>
<p>Heidenreich</p>
<p>P</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>Hernandez</p>
<p>A</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>DeVore</p>
<p>AD.</p>
<p>Association of post-discharge specialty outpatient visits with
readmissions and mortality in high-risk heart failure patients</p>
<p>.</p>
<p>Am Heart J</p>
<p>2019</p>
<p>;</p>
<p>212</p>
<p>:</p>
<p>101</p>
<p>–</p>
<p>112</p>
<p>.</p>
<p>519</p>
<p>Ling</p>
<p>LH</p>
<p>,</p>
<p>Kistler</p>
<p>PM</p>
<p>,</p>
<p>Kalman</p>
<p>JM</p>
<p>,</p>
<p>Schilling</p>
<p>RJ</p>
<p>,</p>
<p>Hunter</p>
<p>RJ.</p>
<p>Comorbidity of atrial fibrillation and heart failure</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2016</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>131</p>
<p>–</p>
<p>147</p>
<p>.</p>
<p>520</p>
<p>Carlisle</p>
<p>MA</p>
<p>,</p>
<p>Fudim</p>
<p>M</p>
<p>,</p>
<p>DeVore</p>
<p>AD</p>
<p>,</p>
<p>Piccini</p>
<p>JP.</p>
<p>Heart failure and atrial fibrillation, like fire and fury</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>447</p>
<p>–</p>
<p>456</p>
<p>.</p>
<p>521</p>
<p>Gorenek</p>
<p>B</p>
<p>,</p>
<p>Halvorsen</p>
<p>S</p>
<p>,</p>
<p>Kudaiberdieva</p>
<p>G</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Lettino</p>
<p>M</p>
<p>,</p>
<p>Marin</p>
<p>F</p>
<p>,</p>
<p>Masip</p>
<p>J</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Okutucu</p>
<p>S</p>
<p>,</p>
<p>Poess</p>
<p>J</p>
<p>,</p>
<p>Potpara</p>
<p>TS</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Lip</p>
<p>GYH.</p>
<p>Atrial fibrillation in acute heart failure: a position statement from
the Acute Cardiovascular Care Association and European Heart Rhythm
Association of the European Society of Cardiology</p>
<p>.</p>
<p>Eur Heart J Acute Cardiovasc Care</p>
<p>2020</p>
<p>;</p>
<p>9</p>
<p>:</p>
<p>348</p>
<p>–</p>
<p>357</p>
<p>.</p>
<p>522</p>
<p>Slawik</p>
<p>J</p>
<p>,</p>
<p>Adrian</p>
<p>L</p>
<p>,</p>
<p>Hohl</p>
<p>M</p>
<p>,</p>
<p>Lothschutz</p>
<p>S</p>
<p>,</p>
<p>Laufs</p>
<p>U</p>
<p>,</p>
<p>Bohm</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic
signalling involving paracrine effects of transforming growth factor
beta and connective tissue growth factor</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>482</p>
<p>–</p>
<p>491</p>
<p>.</p>
<p>523</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Lam</p>
<p>CS</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Rienstra</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Heart failure with preserved ejection fraction and atrial
fibrillation: vicious twins</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2016</p>
<p>;</p>
<p>68</p>
<p>:</p>
<p>2217</p>
<p>–</p>
<p>2228</p>
<p>.</p>
<p>524</p>
<p>Smit</p>
<p>MD</p>
<p>,</p>
<p>Moes</p>
<p>ML</p>
<p>,</p>
<p>Maass</p>
<p>AH</p>
<p>,</p>
<p>Achekar</p>
<p>ID</p>
<p>,</p>
<p>Van Geel</p>
<p>PP</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Van Gelder</p>
<p>IC.</p>
<p>The importance of whether atrial fibrillation or heart failure
develops first</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2012</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>1030</p>
<p>–</p>
<p>1040</p>
<p>.</p>
<p>525</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Olsson</p>
<p>LG</p>
<p>,</p>
<p>Charlesworth</p>
<p>A</p>
<p>,</p>
<p>Cleland</p>
<p>J</p>
<p>,</p>
<p>Hanrath</p>
<p>P</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Poole-Wilson</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Prognostic relevance of atrial fibrillation in patients with chronic
heart failure on long-term treatment with beta-blockers: results from
COMET</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2005</p>
<p>;</p>
<p>26</p>
<p>:</p>
<p>1303</p>
<p>–</p>
<p>1308</p>
<p>.</p>
<p>526</p>
<p>Mogensen</p>
<p>UM</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Køber</p>
<p>L</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>PARADIGM-HF and ATMOSPHERE Investigators and Committees. Type of
atrial fibrillation and outcomes in patients with heart failure and
reduced ejection fraction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>70</p>
<p>:</p>
<p>2490</p>
<p>–</p>
<p>2500</p>
<p>.</p>
<p>527</p>
<p>Hoppe</p>
<p>UC</p>
<p>,</p>
<p>Casares</p>
<p>JM</p>
<p>,</p>
<p>Eiskjaer</p>
<p>H</p>
<p>,</p>
<p>Hagemann</p>
<p>A</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Erdmann</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>Effect of cardiac resynchronization on the incidence of atrial
fibrillation in patients with severe heart failure</p>
<p>.</p>
<p>Circulation</p>
<p>2006</p>
<p>;</p>
<p>114</p>
<p>:</p>
<p>18</p>
<p>–</p>
<p>25</p>
<p>.</p>
<p>528</p>
<p>Ruff</p>
<p>CT</p>
<p>,</p>
<p>Giugliano</p>
<p>RP</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>Hoffman</p>
<p>EB</p>
<p>,</p>
<p>Deenadayalu</p>
<p>N</p>
<p>,</p>
<p>Ezekowitz</p>
<p>MD</p>
<p>,</p>
<p>Camm</p>
<p>AJ</p>
<p>,</p>
<p>Weitz</p>
<p>JI</p>
<p>,</p>
<p>Lewis</p>
<p>BS</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Yamashita</p>
<p>T</p>
<p>,</p>
<p>Antman</p>
<p>EM.</p>
<p>Comparison of the efficacy and safety of new oral anticoagulants with
warfarin in patients with atrial fibrillation: a meta-analysis of
randomised trials</p>
<p>.</p>
<p>Lancet</p>
<p>2014</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>955</p>
<p>–</p>
<p>962</p>
<p>.</p>
<p>529</p>
<p>Reddy</p>
<p>VY</p>
<p>,</p>
<p>Doshi</p>
<p>SK</p>
<p>,</p>
<p>Sievert</p>
<p>H</p>
<p>,</p>
<p>Buchbinder</p>
<p>M</p>
<p>,</p>
<p>Neuzil</p>
<p>P</p>
<p>,</p>
<p>Huber</p>
<p>K</p>
<p>,</p>
<p>Halperin</p>
<p>JL</p>
<p>,</p>
<p>Holmes</p>
<p>D</p>
<p>,</p>
<p>PROTECT AF Investigators</p>
<p>.</p>
<p>Percutaneous left atrial appendage closure for stroke prophylaxis in
patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF
(Watchman Left Atrial Appendage System for Embolic Protection in
Patients with Atrial Fibrillation) trial</p>
<p>.</p>
<p>Circulation</p>
<p>2013</p>
<p>;</p>
<p>127</p>
<p>:</p>
<p>720</p>
<p>–</p>
<p>729</p>
<p>.</p>
<p>530</p>
<p>Holmes</p>
<p>DR</p>
<p>Jr.,</p>
<p>Kar</p>
<p>S</p>
<p>,</p>
<p>Price</p>
<p>MJ</p>
<p>,</p>
<p>Whisenant</p>
<p>B</p>
<p>,</p>
<p>Sievert</p>
<p>H</p>
<p>,</p>
<p>Doshi</p>
<p>SK</p>
<p>,</p>
<p>Huber</p>
<p>K</p>
<p>,</p>
<p>Reddy</p>
<p>VY.</p>
<p>Prospective randomized evaluation of the Watchman Left Atrial
Appendage Closure device in patients with atrial fibrillation versus
long-term warfarin therapy: the PREVAIL trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>64</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>12</p>
<p>.</p>
<p>531</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Wyse</p>
<p>DG</p>
<p>,</p>
<p>Chandler</p>
<p>ML</p>
<p>,</p>
<p>Cooper</p>
<p>HA</p>
<p>,</p>
<p>Olshansky</p>
<p>B</p>
<p>,</p>
<p>Hagens</p>
<p>VE</p>
<p>,</p>
<p>Crijns</p>
<p>HJ</p>
<p>,</p>
<p>RACE and AFFIRM Investigators. Does intensity of rate-control
influence outcome in atrial fibrillation? An analysis of pooled data
from the RACE and AFFIRM studies</p>
<p>.</p>
<p>Europace</p>
<p>2006</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>935</p>
<p>–</p>
<p>942</p>
<p>.</p>
<p>532</p>
<p>Hess</p>
<p>PL</p>
<p>,</p>
<p>Sheng</p>
<p>S</p>
<p>,</p>
<p>Matsouaka</p>
<p>R</p>
<p>,</p>
<p>DeVore</p>
<p>AD</p>
<p>,</p>
<p>Heidenreich</p>
<p>PA</p>
<p>,</p>
<p>Yancy</p>
<p>CW</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Allen</p>
<p>LA</p>
<p>,</p>
<p>Peterson</p>
<p>PN</p>
<p>,</p>
<p>Ho</p>
<p>PM</p>
<p>,</p>
<p>Lewis</p>
<p>WR</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Piccini</p>
<p>JP.</p>
<p>Strict versus lenient versus poor rate control among patients with
atrial fibrillation and heart failure (from the Get With The Guidelines
– Heart Failure Program)</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2020</p>
<p>;</p>
<p>125</p>
<p>:</p>
<p>894</p>
<p>–</p>
<p>900</p>
<p>.</p>
<p>533</p>
<p>Sartipy</p>
<p>U</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Fu</p>
<p>M</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Association of heart rate with mortality in sinus rhythm and atrial
fibrillation in heart failure with preserved ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>471</p>
<p>–</p>
<p>479</p>
<p>.</p>
<p>534</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Rienstra</p>
<p>M</p>
<p>,</p>
<p>Crijns</p>
<p>HJ</p>
<p>,</p>
<p>Olshansky</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Rate control in atrial fibrillation</p>
<p>.</p>
<p>Lancet</p>
<p>2016</p>
<p>;</p>
<p>388</p>
<p>:</p>
<p>818</p>
<p>–</p>
<p>828</p>
<p>.</p>
<p>535</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Flather</p>
<p>MD</p>
<p>,</p>
<p>Altman</p>
<p>DG</p>
<p>,</p>
<p>Holmes</p>
<p>J</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Manzano</p>
<p>L</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Andersson</p>
<p>B</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>von Lueder</p>
<p>TG</p>
<p>,</p>
<p>Rigby</p>
<p>AS</p>
<p>,</p>
<p>Hjalmarson</p>
<p>A</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Beta-Blockers in Heart Failure Collaborative Group. Heart rate and
rhythm and the benefit of beta-blockers in patients with heart
failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>69</p>
<p>:</p>
<p>2885</p>
<p>–</p>
<p>2896</p>
<p>.</p>
<p>536</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Bunting</p>
<p>KV</p>
<p>,</p>
<p>Gill</p>
<p>SK</p>
<p>,</p>
<p>Mehta</p>
<p>S</p>
<p>,</p>
<p>Stanbury</p>
<p>M</p>
<p>,</p>
<p>Jones</p>
<p>JC</p>
<p>,</p>
<p>Haynes</p>
<p>S</p>
<p>,</p>
<p>Calvert</p>
<p>MJ</p>
<p>,</p>
<p>Deeks</p>
<p>JJ</p>
<p>,</p>
<p>Steeds</p>
<p>RP</p>
<p>,</p>
<p>Strauss</p>
<p>VY</p>
<p>,</p>
<p>Rahimi</p>
<p>K</p>
<p>,</p>
<p>Camm</p>
<p>AJ</p>
<p>,</p>
<p>Griffith</p>
<p>M</p>
<p>,</p>
<p>Lip</p>
<p>GYH</p>
<p>,</p>
<p>Townend</p>
<p>JN</p>
<p>,</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>Rate Control Therapy Evaluation in Permanent Atrial Fibrillation
(RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control
in atrial fibrillation on patient-reported quality of life: the RATE-AF
randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2020</p>
<p>;</p>
<p>324</p>
<p>:</p>
<p>2497</p>
<p>–</p>
<p>2508</p>
<p>.</p>
<p>537</p>
<p>Hofmann</p>
<p>R</p>
<p>,</p>
<p>Steinwender</p>
<p>C</p>
<p>,</p>
<p>Kammler</p>
<p>J</p>
<p>,</p>
<p>Kypta</p>
<p>A</p>
<p>,</p>
<p>Leisch</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Effects of a high dose intravenous bolus amiodarone in patients with
atrial fibrillation and a rapid ventricular rate</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2006</p>
<p>;</p>
<p>110</p>
<p>:</p>
<p>27</p>
<p>–</p>
<p>32</p>
<p>.</p>
<p>538</p>
<p>Wood</p>
<p>MA</p>
<p>,</p>
<p>Brown-Mahoney</p>
<p>C</p>
<p>,</p>
<p>Kay</p>
<p>GN</p>
<p>,</p>
<p>Ellenbogen</p>
<p>KA.</p>
<p>Clinical outcomes after ablation and pacing therapy for atrial
fibrillation: a meta-analysis</p>
<p>.</p>
<p>Circulation</p>
<p>2000</p>
<p>;</p>
<p>101</p>
<p>:</p>
<p>1138</p>
<p>–</p>
<p>1144</p>
<p>.</p>
<p>539</p>
<p>Lim</p>
<p>KT</p>
<p>,</p>
<p>Davis</p>
<p>MJ</p>
<p>,</p>
<p>Powell</p>
<p>A</p>
<p>,</p>
<p>Arnolda</p>
<p>L</p>
<p>,</p>
<p>Moulden</p>
<p>K</p>
<p>,</p>
<p>Bulsara</p>
<p>M</p>
<p>,</p>
<p>Weerasooriya</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Ablate and pace strategy for atrial fibrillation: long-term outcome
of AIRCRAFT trial</p>
<p>.</p>
<p>Europace</p>
<p>2007</p>
<p>;</p>
<p>9</p>
<p>:</p>
<p>498</p>
<p>–</p>
<p>505</p>
<p>.</p>
<p>540</p>
<p>Gasparini</p>
<p>M</p>
<p>,</p>
<p>Kloppe</p>
<p>A</p>
<p>,</p>
<p>Lunati</p>
<p>M</p>
<p>,</p>
<p>Anselme</p>
<p>F</p>
<p>,</p>
<p>Landolina</p>
<p>M</p>
<p>,</p>
<p>Martinez-Ferrer</p>
<p>JB</p>
<p>,</p>
<p>Proclemer</p>
<p>A</p>
<p>,</p>
<p>Morani</p>
<p>G</p>
<p>,</p>
<p>Biffi</p>
<p>M</p>
<p>,</p>
<p>Ricci</p>
<p>R</p>
<p>,</p>
<p>Rordorf</p>
<p>R</p>
<p>,</p>
<p>Mangoni</p>
<p>L</p>
<p>,</p>
<p>Manotta</p>
<p>L</p>
<p>,</p>
<p>Grammatico</p>
<p>A</p>
<p>,</p>
<p>Leyva</p>
<p>F</p>
<p>,</p>
<p>Boriani</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Atrioventricular junction ablation in patients with atrial
fibrillation treated with cardiac resynchronization therapy: positive
impact on ventricular arrhythmias, implantable
cardioverter-defibrillator therapies and hospitalizations</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1472</p>
<p>–</p>
<p>1481</p>
<p>.</p>
<p>541</p>
<p>Deedwania</p>
<p>PC</p>
<p>,</p>
<p>Singh</p>
<p>BN</p>
<p>,</p>
<p>Ellenbogen</p>
<p>K</p>
<p>,</p>
<p>Fisher</p>
<p>S</p>
<p>,</p>
<p>Fletcher</p>
<p>R</p>
<p>,</p>
<p>Singh</p>
<p>SN.</p>
<p>Spontaneous conversion and maintenance of sinus rhythm by amiodarone
in patients with heart failure and atrial fibrillation: observations
from the Veterans Affairs Congestive Heart Failure Survival Trial of
Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs
CHF-STAT Investigators</p>
<p>.</p>
<p>Circulation</p>
<p>1998</p>
<p>;</p>
<p>98</p>
<p>:</p>
<p>2574</p>
<p>–</p>
<p>2579</p>
<p>.</p>
<p>542</p>
<p>Antiarrhythmic Drug Evaluation Group (A.D.E</p>
<p>.G.).</p>
<p>A multicentre, randomized trial on the benefit/risk profile of
amiodarone, flecainide and propafenone in patients with cardiac disease
and complex ventricular arrhythmias</p>
<p>.</p>
<p>Eur Heart J</p>
<p>1992</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>1251</p>
<p>–</p>
<p>1258</p>
<p>.</p>
<p>543</p>
<p>Connolly</p>
<p>SJ</p>
<p>,</p>
<p>Camm</p>
<p>AJ</p>
<p>,</p>
<p>Halperin</p>
<p>JL</p>
<p>,</p>
<p>Joyner</p>
<p>C</p>
<p>,</p>
<p>Alings</p>
<p>M</p>
<p>,</p>
<p>Amerena</p>
<p>J</p>
<p>,</p>
<p>Atar</p>
<p>D</p>
<p>,</p>
<p>Avezum</p>
<p>A</p>
<p>,</p>
<p>Blomstrom</p>
<p>P</p>
<p>,</p>
<p>Borggrefe</p>
<p>M</p>
<p>,</p>
<p>Budaj</p>
<p>A</p>
<p>,</p>
<p>Chen</p>
<p>SA</p>
<p>,</p>
<p>Ching</p>
<p>CK</p>
<p>,</p>
<p>Commerford</p>
<p>P</p>
<p>,</p>
<p>Dans</p>
<p>A</p>
<p>,</p>
<p>Davy</p>
<p>JM</p>
<p>,</p>
<p>Delacretaz</p>
<p>E</p>
<p>,</p>
<p>Di Pasquale</p>
<p>G</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Dorian</p>
<p>P</p>
<p>,</p>
<p>Flaker</p>
<p>G</p>
<p>,</p>
<p>Golitsyn</p>
<p>S</p>
<p>,</p>
<p>Gonzalez-Hermosillo</p>
<p>A</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Heidbuchel</p>
<p>H</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>Kim</p>
<p>JS</p>
<p>,</p>
<p>Lanas</p>
<p>F</p>
<p>,</p>
<p>Lewis</p>
<p>BS</p>
<p>,</p>
<p>Merino</p>
<p>JL</p>
<p>,</p>
<p>Morillo</p>
<p>C</p>
<p>,</p>
<p>Murin</p>
<p>J</p>
<p>,</p>
<p>Narasimhan</p>
<p>C</p>
<p>,</p>
<p>Paolasso</p>
<p>E</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Peters</p>
<p>NS</p>
<p>,</p>
<p>Sim</p>
<p>KH</p>
<p>,</p>
<p>Stiles</p>
<p>MK</p>
<p>,</p>
<p>Tanomsup</p>
<p>S</p>
<p>,</p>
<p>Toivonen</p>
<p>L</p>
<p>,</p>
<p>Tomcsanyi</p>
<p>J</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Tse</p>
<p>HF</p>
<p>,</p>
<p>Vardas</p>
<p>P</p>
<p>,</p>
<p>Vinereanu</p>
<p>D</p>
<p>,</p>
<p>Xavier</p>
<p>D</p>
<p>,</p>
<p>Zhu</p>
<p>J</p>
<p>,</p>
<p>Zhu</p>
<p>JR</p>
<p>,</p>
<p>Baret-Cormel</p>
<p>L</p>
<p>,</p>
<p>Weinling</p>
<p>E</p>
<p>,</p>
<p>Staiger</p>
<p>C</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Chrolavicius</p>
<p>S</p>
<p>,</p>
<p>Afzal</p>
<p>R</p>
<p>,</p>
<p>Hohnloser</p>
<p>SH</p>
<p>,</p>
<p>PALLAS Investigators</p>
<p>.</p>
<p>Dronedarone in high-risk permanent atrial fibrillation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>365</p>
<p>:</p>
<p>2268</p>
<p>–</p>
<p>2276</p>
<p>.</p>
<p>544</p>
<p>Chatterjee</p>
<p>S</p>
<p>,</p>
<p>Ghosh</p>
<p>J</p>
<p>,</p>
<p>Lichstein</p>
<p>E</p>
<p>,</p>
<p>Aikat</p>
<p>S</p>
<p>,</p>
<p>Mukherjee</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Meta-analysis of cardiovascular outcomes with dronedarone in patients
with atrial fibrillation or heart failure</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2012</p>
<p>;</p>
<p>110</p>
<p>:</p>
<p>607</p>
<p>–</p>
<p>613</p>
<p>.</p>
<p>545</p>
<p>Shelton</p>
<p>RJ</p>
<p>,</p>
<p>Clark</p>
<p>AL</p>
<p>,</p>
<p>Goode</p>
<p>K</p>
<p>,</p>
<p>Rigby</p>
<p>AS</p>
<p>,</p>
<p>Houghton</p>
<p>T</p>
<p>,</p>
<p>Kaye</p>
<p>GC</p>
<p>,</p>
<p>Cleland</p>
<p>JG.</p>
<p>A randomised, controlled study of rate versus rhythm control in
patients with chronic atrial fibrillation and heart failure: (CAFE-II
Study)</p>
<p>.</p>
<p>Heart</p>
<p>2009</p>
<p>;</p>
<p>95</p>
<p>:</p>
<p>924</p>
<p>–</p>
<p>930</p>
<p>.</p>
<p>546</p>
<p>Capucci</p>
<p>A</p>
<p>,</p>
<p>Villani</p>
<p>GQ</p>
<p>,</p>
<p>Aschieri</p>
<p>D</p>
<p>,</p>
<p>Rosi</p>
<p>A</p>
<p>,</p>
<p>Piepoli</p>
<p>MF.</p>
<p>Oral amiodarone increases the efficacy of direct-current
cardioversion in restoration of sinus rhythm in patients with chronic
atrial fibrillation</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2000</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>66</p>
<p>–</p>
<p>73</p>
<p>.</p>
<p>547</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Hagens</p>
<p>VE</p>
<p>,</p>
<p>Bosker</p>
<p>HA</p>
<p>,</p>
<p>Kingma</p>
<p>JH</p>
<p>,</p>
<p>Kamp</p>
<p>O</p>
<p>,</p>
<p>Kingma</p>
<p>T</p>
<p>,</p>
<p>Said</p>
<p>SA</p>
<p>,</p>
<p>Darmanata</p>
<p>JI</p>
<p>,</p>
<p>Timmermans</p>
<p>AJ</p>
<p>,</p>
<p>Tijssen</p>
<p>JG</p>
<p>,</p>
<p>Crijns</p>
<p>HJ</p>
<p>,</p>
<p>Rate Control versus Electrical Cardioversion for Persistent Atrial
Fibrillation Study Group</p>
<p>.</p>
<p>A comparison of rate control and rhythm control in patients with
recurrent persistent atrial fibrillation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2002</p>
<p>;</p>
<p>347</p>
<p>:</p>
<p>1834</p>
<p>–</p>
<p>1840</p>
<p>.</p>
<p>548</p>
<p>Wyse</p>
<p>DG</p>
<p>,</p>
<p>Waldo</p>
<p>AL</p>
<p>,</p>
<p>DiMarco</p>
<p>JP</p>
<p>,</p>
<p>Domanski</p>
<p>MJ</p>
<p>,</p>
<p>Rosenberg</p>
<p>Y</p>
<p>,</p>
<p>Schron</p>
<p>EB</p>
<p>,</p>
<p>Kellen</p>
<p>JC</p>
<p>,</p>
<p>Greene</p>
<p>HL</p>
<p>,</p>
<p>Mickel</p>
<p>MC</p>
<p>,</p>
<p>Dalquist</p>
<p>JE</p>
<p>,</p>
<p>Corley</p>
<p>SD</p>
<p>,</p>
<p>Atrial Fibrillation Follow-up Investigation of Rhythm Management
(AFFIRM) Investigators. A comparison of rate control and rhythm control
in patients with atrial fibrillation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2002</p>
<p>;</p>
<p>347</p>
<p>:</p>
<p>1825</p>
<p>–</p>
<p>1833</p>
<p>.</p>
<p>549</p>
<p>Carlsson</p>
<p>J</p>
<p>,</p>
<p>Miketic</p>
<p>S</p>
<p>,</p>
<p>Windeler</p>
<p>J</p>
<p>,</p>
<p>Cuneo</p>
<p>A</p>
<p>,</p>
<p>Haun</p>
<p>S</p>
<p>,</p>
<p>Micus</p>
<p>S</p>
<p>,</p>
<p>Walter</p>
<p>S</p>
<p>,</p>
<p>Tebbe</p>
<p>U</p>
<p>,</p>
<p>STAF Investigators</p>
<p>.</p>
<p>Randomized trial of rate-control versus rhythm-control in persistent
atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation
(STAF) study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2003</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>1690</p>
<p>–</p>
<p>1696</p>
<p>.</p>
<p>550</p>
<p>Roy</p>
<p>D</p>
<p>,</p>
<p>Talajic</p>
<p>M</p>
<p>,</p>
<p>Nattel</p>
<p>S</p>
<p>,</p>
<p>Wyse</p>
<p>DG</p>
<p>,</p>
<p>Dorian</p>
<p>P</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Bourassa</p>
<p>MG</p>
<p>,</p>
<p>Arnold</p>
<p>JM</p>
<p>,</p>
<p>Buxton</p>
<p>AE</p>
<p>,</p>
<p>Camm</p>
<p>AJ</p>
<p>,</p>
<p>Connolly</p>
<p>SJ</p>
<p>,</p>
<p>Dubuc</p>
<p>M</p>
<p>,</p>
<p>Ducharme</p>
<p>A</p>
<p>,</p>
<p>Guerra</p>
<p>PG</p>
<p>,</p>
<p>Hohnloser</p>
<p>SH</p>
<p>,</p>
<p>Lambert</p>
<p>J</p>
<p>,</p>
<p>Le Heuzey</p>
<p>JY</p>
<p>,</p>
<p>O’Hara</p>
<p>G</p>
<p>,</p>
<p>Pedersen</p>
<p>OD</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Singh</p>
<p>BN</p>
<p>,</p>
<p>Stevenson</p>
<p>LW</p>
<p>,</p>
<p>Stevenson</p>
<p>WG</p>
<p>,</p>
<p>Thibault</p>
<p>B</p>
<p>,</p>
<p>Waldo</p>
<p>AL</p>
<p>Atrial Fibrillation and Congestive Heart Failure Investigators</p>
<p>Rhythm control versus rate control for atrial fibrillation and heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2008</p>
<p>;</p>
<p>358</p>
<p>:</p>
<p>2667</p>
<p>–</p>
<p>2677</p>
<p>.</p>
<p>551</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>Camm</p>
<p>AJ</p>
<p>,</p>
<p>Goette</p>
<p>A</p>
<p>,</p>
<p>Brandes</p>
<p>A</p>
<p>,</p>
<p>Eckardt</p>
<p>L</p>
<p>,</p>
<p>Elvan</p>
<p>A</p>
<p>,</p>
<p>Fetsch</p>
<p>T</p>
<p>,</p>
<p>van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Haase</p>
<p>D</p>
<p>,</p>
<p>Haegeli</p>
<p>LM</p>
<p>,</p>
<p>Hamann</p>
<p>F</p>
<p>,</p>
<p>Heidbuchel</p>
<p>H</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Kautzner</p>
<p>J</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Mont</p>
<p>L</p>
<p>,</p>
<p>Ng</p>
<p>GA</p>
<p>,</p>
<p>Rekosz</p>
<p>J</p>
<p>,</p>
<p>Schoen</p>
<p>N</p>
<p>,</p>
<p>Schotten</p>
<p>U</p>
<p>,</p>
<p>Suling</p>
<p>A</p>
<p>,</p>
<p>Taggeselle</p>
<p>J</p>
<p>,</p>
<p>Themistoclakis</p>
<p>S</p>
<p>,</p>
<p>Vettorazzi</p>
<p>E</p>
<p>,</p>
<p>Vardas</p>
<p>P</p>
<p>,</p>
<p>Wegscheider</p>
<p>K</p>
<p>,</p>
<p>Willems</p>
<p>S</p>
<p>,</p>
<p>Crijns</p>
<p>H</p>
<p>,</p>
<p>Breithardt</p>
<p>G</p>
<p>,</p>
<p>EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in
patients with atrial fibrillation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>1305</p>
<p>–</p>
<p>1316</p>
<p>.</p>
<p>552</p>
<p>Marrouche</p>
<p>NF</p>
<p>,</p>
<p>Brachmann</p>
<p>J</p>
<p>,</p>
<p>Andresen</p>
<p>D</p>
<p>,</p>
<p>Siebels</p>
<p>J</p>
<p>,</p>
<p>Boersma</p>
<p>L</p>
<p>,</p>
<p>Jordaens</p>
<p>L</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Pokushalov</p>
<p>E</p>
<p>,</p>
<p>Sanders</p>
<p>P</p>
<p>,</p>
<p>Proff</p>
<p>J</p>
<p>,</p>
<p>Schunkert</p>
<p>H</p>
<p>,</p>
<p>Christ</p>
<p>H</p>
<p>,</p>
<p>Vogt</p>
<p>J</p>
<p>,</p>
<p>Bansch</p>
<p>D</p>
<p>,</p>
<p>CASTLE-AF Investigators</p>
<p>.</p>
<p>Catheter ablation for atrial fibrillation with heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>378</p>
<p>:</p>
<p>417</p>
<p>–</p>
<p>427</p>
<p>.</p>
<p>553</p>
<p>Packer</p>
<p>DL</p>
<p>,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Robb</p>
<p>RA</p>
<p>,</p>
<p>Monahan</p>
<p>KH</p>
<p>,</p>
<p>Bahnson</p>
<p>TD</p>
<p>,</p>
<p>Poole</p>
<p>JE</p>
<p>,</p>
<p>Noseworthy</p>
<p>PA</p>
<p>,</p>
<p>Rosenberg</p>
<p>YD</p>
<p>,</p>
<p>Jeffries</p>
<p>N</p>
<p>,</p>
<p>Mitchell</p>
<p>LB</p>
<p>,</p>
<p>Flaker</p>
<p>GC</p>
<p>,</p>
<p>Pokushalov</p>
<p>E</p>
<p>,</p>
<p>Romanov</p>
<p>A</p>
<p>,</p>
<p>Bunch</p>
<p>TJ</p>
<p>,</p>
<p>Noelker</p>
<p>G</p>
<p>,</p>
<p>Ardashev</p>
<p>A</p>
<p>,</p>
<p>Revishvili</p>
<p>A</p>
<p>,</p>
<p>Wilber</p>
<p>DJ</p>
<p>,</p>
<p>Cappato</p>
<p>R</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Davies</p>
<p>DW</p>
<p>,</p>
<p>Kowey</p>
<p>PR</p>
<p>,</p>
<p>Naccarelli</p>
<p>GV</p>
<p>,</p>
<p>Reiffel</p>
<p>JA</p>
<p>,</p>
<p>Piccini</p>
<p>JP</p>
<p>,</p>
<p>Silverstein</p>
<p>AP</p>
<p>,</p>
<p>Al-Khalidi</p>
<p>HR</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>CABANA Investigators</p>
<p>.</p>
<p>Effect of catheter ablation vs antiarrhythmic drug therapy on
mortality, stroke, bleeding, and cardiac arrest among patients with
atrial fibrillation: the CABANA randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2019</p>
<p>;</p>
<p>321</p>
<p>:</p>
<p>1261</p>
<p>–</p>
<p>1274</p>
<p>.</p>
<p>554</p>
<p>Packer</p>
<p>DL</p>
<p>,</p>
<p>Piccini</p>
<p>JP</p>
<p>,</p>
<p>Monahan</p>
<p>KH</p>
<p>,</p>
<p>Al-Khalidi</p>
<p>HR</p>
<p>,</p>
<p>Silverstein</p>
<p>AP</p>
<p>,</p>
<p>Noseworthy</p>
<p>PA</p>
<p>,</p>
<p>Poole</p>
<p>JE</p>
<p>,</p>
<p>Bahnson</p>
<p>TD</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>CABANA Investigators</p>
<p>.</p>
<p>Ablation versus drug therapy for atrial fibrillation in heart
failure: results from the CABANA trial</p>
<p>.</p>
<p>Circulation</p>
<p>2021</p>
<p>;</p>
<p>143</p>
<p>:</p>
<p>1377</p>
<p>–</p>
<p>1390</p>
<p>.</p>
<p>555</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Zahn</p>
<p>R</p>
<p>,</p>
<p>Arentz</p>
<p>T</p>
<p>,</p>
<p>Seidl</p>
<p>K</p>
<p>,</p>
<p>Schluter</p>
<p>M</p>
<p>,</p>
<p>Tilz</p>
<p>RR</p>
<p>,</p>
<p>Piorkowski</p>
<p>C</p>
<p>,</p>
<p>Geller</p>
<p>L</p>
<p>,</p>
<p>Kleemann</p>
<p>T</p>
<p>,</p>
<p>Hindricks</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Catheter ablation versus best medical therapy in patients with
persistent atrial fibrillation and congestive heart failure: the
randomized AMICA trial</p>
<p>.</p>
<p>Circ Arrhythm Electrophysiol</p>
<p>2019</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>e007731</p>
<p>.</p>
<p>556</p>
<p>Di Biase</p>
<p>L</p>
<p>,</p>
<p>Mohanty</p>
<p>P</p>
<p>,</p>
<p>Mohanty</p>
<p>S</p>
<p>,</p>
<p>Santangeli</p>
<p>P</p>
<p>,</p>
<p>Trivedi</p>
<p>C</p>
<p>,</p>
<p>Lakkireddy</p>
<p>D</p>
<p>,</p>
<p>Reddy</p>
<p>M</p>
<p>,</p>
<p>Jais</p>
<p>P</p>
<p>,</p>
<p>Themistoclakis</p>
<p>S</p>
<p>,</p>
<p>Dello Russo</p>
<p>A</p>
<p>,</p>
<p>Casella</p>
<p>M</p>
<p>,</p>
<p>Pelargonio</p>
<p>G</p>
<p>,</p>
<p>Narducci</p>
<p>ML</p>
<p>,</p>
<p>Schweikert</p>
<p>R</p>
<p>,</p>
<p>Neuzil</p>
<p>P</p>
<p>,</p>
<p>Sanchez</p>
<p>J</p>
<p>,</p>
<p>Horton</p>
<p>R</p>
<p>,</p>
<p>Beheiry</p>
<p>S</p>
<p>,</p>
<p>Hongo</p>
<p>R</p>
<p>,</p>
<p>Hao</p>
<p>S</p>
<p>,</p>
<p>Rossillo</p>
<p>A</p>
<p>,</p>
<p>Forleo</p>
<p>G</p>
<p>,</p>
<p>Tondo</p>
<p>C</p>
<p>,</p>
<p>Burkhardt</p>
<p>JD</p>
<p>,</p>
<p>Haissaguerre</p>
<p>M</p>
<p>,</p>
<p>Natale</p>
<ol type="A">
<li></li>
</ol>
<p>Ablation versus amiodarone for treatment of persistent atrial
fibrillation in patients with congestive heart failure and an implanted
device: results from the AATAC multicenter randomized trial</p>
<p>.</p>
<p>Circulation</p>
<p>2016</p>
<p>;</p>
<p>133</p>
<p>:</p>
<p>1637</p>
<p>–</p>
<p>1644</p>
<p>.</p>
<p>557</p>
<p>Mark</p>
<p>DB</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Sheng</p>
<p>S</p>
<p>,</p>
<p>Piccini</p>
<p>JP</p>
<p>,</p>
<p>Baloch</p>
<p>KN</p>
<p>,</p>
<p>Monahan</p>
<p>KH</p>
<p>,</p>
<p>Daniels</p>
<p>MR</p>
<p>,</p>
<p>Bahnson</p>
<p>TD</p>
<p>,</p>
<p>Poole</p>
<p>JE</p>
<p>,</p>
<p>Rosenberg</p>
<p>Y</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Packer</p>
<p>DL</p>
<p>,</p>
<p>CABANA Investigators</p>
<p>.</p>
<p>Effect of catheter ablation vs medical therapy on quality of life
among patients with atrial fibrillation: the CABANA randomized clinical
trial</p>
<p>.</p>
<p>JAMA</p>
<p>2019</p>
<p>;</p>
<p>321</p>
<p>:</p>
<p>1275</p>
<p>–</p>
<p>1285</p>
<p>.</p>
<p>558</p>
<p>Xiong</p>
<p>Q</p>
<p>,</p>
<p>Lau</p>
<p>YC</p>
<p>,</p>
<p>Senoo</p>
<p>K</p>
<p>,</p>
<p>Lane</p>
<p>DA</p>
<p>,</p>
<p>Hong</p>
<p>K</p>
<p>,</p>
<p>Lip</p>
<p>GY.</p>
<p>Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with
concomitant atrial fibrillation and heart failure: a systemic review and
meta-analysis of randomized trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>1192</p>
<p>–</p>
<p>1200</p>
<p>.</p>
<p>559</p>
<p>Nielsen</p>
<p>PB</p>
<p>,</p>
<p>Larsen</p>
<p>TB</p>
<p>,</p>
<p>Skjoth</p>
<p>F</p>
<p>,</p>
<p>Overvad</p>
<p>TF</p>
<p>,</p>
<p>Lip</p>
<p>GY.</p>
<p>Stroke and thromboembolic event rates in atrial fibrillation
according to different guideline treatment thresholds: a nationwide
cohort study</p>
<p>.</p>
<p>Sci Rep</p>
<p>2016</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>27410</p>
<p>.</p>
<p>560</p>
<p>Latchamsetty</p>
<p>R</p>
<p>,</p>
<p>Bogun</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Premature ventricular complex-induced cardiomyopathy</p>
<p>.</p>
<p>JACC Clin Electrophysiol</p>
<p>2019</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>537</p>
<p>–</p>
<p>550</p>
<p>.</p>
<p>561</p>
<p>Mondesert</p>
<p>B</p>
<p>,</p>
<p>Khairy</p>
<p>P</p>
<p>,</p>
<p>Schram</p>
<p>G</p>
<p>,</p>
<p>Shohoudi</p>
<p>A</p>
<p>,</p>
<p>Talajic</p>
<p>M</p>
<p>,</p>
<p>Andrade</p>
<p>JG</p>
<p>,</p>
<p>Dubuc</p>
<p>M</p>
<p>,</p>
<p>Guerra</p>
<p>PG</p>
<p>,</p>
<p>Macle</p>
<p>L</p>
<p>,</p>
<p>Roy</p>
<p>D</p>
<p>,</p>
<p>Dyrda</p>
<p>K</p>
<p>,</p>
<p>Thibault</p>
<p>B</p>
<p>,</p>
<p>Barrero</p>
<p>M</p>
<p>,</p>
<p>Diaz</p>
<p>A</p>
<p>,</p>
<p>Kouz</p>
<p>S</p>
<p>,</p>
<p>McNicoll</p>
<p>S</p>
<p>,</p>
<p>Nowakowska</p>
<p>D</p>
<p>,</p>
<p>Rivard</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Impact of revascularization in patients with sustained ventricular
arrhythmias, prior myocardial infarction, and preserved left ventricular
ejection fraction</p>
<p>.</p>
<p>Heart Rhythm</p>
<p>2016</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>1221</p>
<p>–</p>
<p>1227</p>
<p>.</p>
<p>562</p>
<p>Yarlagadda</p>
<p>RK</p>
<p>,</p>
<p>Iwai</p>
<p>S</p>
<p>,</p>
<p>Stein</p>
<p>KM</p>
<p>,</p>
<p>Markowitz</p>
<p>SM</p>
<p>,</p>
<p>Shah</p>
<p>BK</p>
<p>,</p>
<p>Cheung</p>
<p>JW</p>
<p>,</p>
<p>Tan</p>
<p>V</p>
<p>,</p>
<p>Lerman</p>
<p>BB</p>
<p>,</p>
<p>Mittal</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Reversal of cardiomyopathy in patients with repetitive monomorphic
ventricular ectopy originating from the right ventricular outflow
tract</p>
<p>.</p>
<p>Circulation</p>
<p>2005</p>
<p>;</p>
<p>112</p>
<p>:</p>
<p>1092</p>
<p>–</p>
<p>1097</p>
<p>.</p>
<p>563</p>
<p>Berruezo</p>
<p>A</p>
<p>,</p>
<p>Penela</p>
<p>D</p>
<p>,</p>
<p>Jauregui</p>
<p>B</p>
<p>,</p>
<p>Soto-Iglesias</p>
<p>D</p>
<p>,</p>
<p>Aguinaga</p>
<p>L</p>
<p>,</p>
<p>Ordonez</p>
<p>A</p>
<p>,</p>
<p>Fernandez-Armenta</p>
<p>J</p>
<p>,</p>
<p>Martinez</p>
<p>M</p>
<p>,</p>
<p>Tercedor</p>
<p>L</p>
<p>,</p>
<p>Bisbal</p>
<p>F</p>
<p>,</p>
<p>Acosta</p>
<p>J</p>
<p>,</p>
<p>Marti-Almor</p>
<p>J</p>
<p>,</p>
<p>Acena</p>
<p>M</p>
<p>,</p>
<p>Anguera</p>
<p>I</p>
<p>,</p>
<p>Rossi</p>
<p>L</p>
<p>,</p>
<p>Linhart</p>
<p>M</p>
<p>,</p>
<p>Borras</p>
<p>R</p>
<p>,</p>
<p>Doltra</p>
<p>A</p>
<p>,</p>
<p>Sanchez</p>
<p>P</p>
<p>,</p>
<p>Ortiz-Perez</p>
<p>JT</p>
<p>,</p>
<p>Perea</p>
<p>RJ</p>
<p>,</p>
<p>Prat-Gonzalez</p>
<p>S</p>
<p>,</p>
<p>Teres</p>
<p>C</p>
<p>,</p>
<p>Bosch</p>
<ol start="24" type="A">
<li></li>
</ol>
<p>Mortality and morbidity reduction after frequent premature
ventricular complexes ablation in patients with left ventricular
systolic dysfunction</p>
<p>.</p>
<p>Europace</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1079</p>
<p>–</p>
<p>1087</p>
<p>.</p>
<p>564</p>
<p>Cronin</p>
<p>EM</p>
<p>,</p>
<p>Bogun</p>
<p>FM</p>
<p>,</p>
<p>Maury</p>
<p>P</p>
<p>,</p>
<p>Peichl</p>
<p>P</p>
<p>,</p>
<p>Chen</p>
<p>M</p>
<p>,</p>
<p>Namboodiri</p>
<p>N</p>
<p>,</p>
<p>Aguinaga</p>
<p>L</p>
<p>,</p>
<p>Leite</p>
<p>LR</p>
<p>,</p>
<p>Al-Khatib</p>
<p>SM</p>
<p>,</p>
<p>Anter</p>
<p>E</p>
<p>,</p>
<p>Berruezo</p>
<p>A</p>
<p>,</p>
<p>Callans</p>
<p>DJ</p>
<p>,</p>
<p>Chung</p>
<p>MK</p>
<p>,</p>
<p>Cuculich</p>
<p>P</p>
<p>,</p>
<p>d’Avila</p>
<p>A</p>
<p>,</p>
<p>Deal</p>
<p>BJ</p>
<p>,</p>
<p>Della Bella</p>
<p>P</p>
<p>,</p>
<p>Deneke</p>
<p>T</p>
<p>,</p>
<p>Dickfeld</p>
<p>TM</p>
<p>,</p>
<p>Hadid</p>
<p>C</p>
<p>,</p>
<p>Haqqani</p>
<p>HM</p>
<p>,</p>
<p>Kay</p>
<p>GN</p>
<p>,</p>
<p>Latchamsetty</p>
<p>R</p>
<p>,</p>
<p>Marchlinski</p>
<p>F</p>
<p>,</p>
<p>Miller</p>
<p>JM</p>
<p>,</p>
<p>Nogami</p>
<p>A</p>
<p>,</p>
<p>Patel</p>
<p>AR</p>
<p>,</p>
<p>Pathak</p>
<p>RK</p>
<p>,</p>
<p>Saenz Morales</p>
<p>LC</p>
<p>,</p>
<p>Santangeli</p>
<p>P</p>
<p>,</p>
<p>Sapp</p>
<p>JL</p>
<p>,</p>
<p>Sarkozy</p>
<p>A</p>
<p>,</p>
<p>Soejima</p>
<p>K</p>
<p>,</p>
<p>Stevenson</p>
<p>WG</p>
<p>,</p>
<p>Tedrow</p>
<p>UB</p>
<p>,</p>
<p>Tzou</p>
<p>WS</p>
<p>,</p>
<p>Varma</p>
<p>N</p>
<p>,</p>
<p>Zeppenfeld</p>
<p>K</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2019</p>
<p>HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation
of ventricular arrhythmias</p>
<p>.</p>
<p>Europace</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1143</p>
<p>–</p>
<p>1144</p>
<p>.</p>
<p>565</p>
<p>Cho</p>
<p>SW</p>
<p>,</p>
<p>Gwag</p>
<p>HB</p>
<p>,</p>
<p>Hwang</p>
<p>JK</p>
<p>,</p>
<p>Chun</p>
<p>KJ</p>
<p>,</p>
<p>Park</p>
<p>KM</p>
<p>,</p>
<p>On</p>
<p>YK</p>
<p>,</p>
<p>Kim</p>
<p>JS</p>
<p>,</p>
<p>Park</p>
<p>SJ.</p>
<p>Clinical features, predictors, and long-term prognosis of
pacing-induced cardiomyopathy</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>643</p>
<p>–</p>
<p>651</p>
<p>.</p>
<p>566</p>
<p>Vijayaraman</p>
<p>P</p>
<p>,</p>
<p>Herweg</p>
<p>B</p>
<p>,</p>
<p>Ellenbogen</p>
<p>KA</p>
<p>,</p>
<p>Gajek</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>His-optimized cardiac resynchronization therapy to maximize
electrical resynchronization: a feasibility study</p>
<p>.</p>
<p>Circ Arrhythm Electrophysiol</p>
<p>2019</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>e006934</p>
<p>.</p>
<p>567</p>
<p>Abdelrahman</p>
<p>M</p>
<p>,</p>
<p>Subzposh</p>
<p>FA</p>
<p>,</p>
<p>Beer</p>
<p>D</p>
<p>,</p>
<p>Durr</p>
<p>B</p>
<p>,</p>
<p>Naperkowski</p>
<p>A</p>
<p>,</p>
<p>Sun</p>
<p>H</p>
<p>,</p>
<p>Oren</p>
<p>JW</p>
<p>,</p>
<p>Dandamudi</p>
<p>G</p>
<p>,</p>
<p>Vijayaraman</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Clinical outcomes of His bundle pacing compared to right ventricular
pacing</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>2319</p>
<p>–</p>
<p>2330</p>
<p>.</p>
<p>568</p>
<p>Ziff</p>
<p>OJ</p>
<p>,</p>
<p>Samra</p>
<p>M</p>
<p>,</p>
<p>Howard</p>
<p>JP</p>
<p>,</p>
<p>Bromage</p>
<p>DI</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Francis</p>
<p>DP</p>
<p>,</p>
<p>Kotecha</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Beta-blocker efficacy across different cardiovascular indications: an
umbrella review and meta-analytic assessment</p>
<p>.</p>
<p>BMC Med</p>
<p>2020</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>103</p>
<p>.</p>
<p>569</p>
<p>Fox</p>
<p>K</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Steg</p>
<p>PG</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>Robertson</p>
<p>M</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>BEAUTIFUL Investigators</p>
<p>.</p>
<p>Relationship between ivabradine treatment and cardiovascular outcomes
in patients with stable coronary artery disease and left ventricular
systolic dysfunction with limiting angina: a subgroup analysis of the
randomized, controlled BEAUTIFUL trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2009</p>
<p>;</p>
<p>30</p>
<p>:</p>
<p>2337</p>
<p>–</p>
<p>2345</p>
<p>.</p>
<p>570</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Ghali</p>
<p>JK</p>
<p>,</p>
<p>Pressler</p>
<p>ML</p>
<p>,</p>
<p>Carson</p>
<p>PE</p>
<p>,</p>
<p>Belkin</p>
<p>RN</p>
<p>,</p>
<p>Miller</p>
<p>AB</p>
<p>,</p>
<p>Neuberg</p>
<p>GW</p>
<p>,</p>
<p>Frid</p>
<p>D</p>
<p>,</p>
<p>Wertheimer</p>
<p>JH</p>
<p>,</p>
<p>Cropp</p>
<p>AB</p>
<p>,</p>
<p>DeMets</p>
<ol start="550" type="I">
<li></li>
</ol>
<p>Effect of amlodipine on morbidity and mortality in severe chronic
heart failure. Prospective Randomized Amlodipine Survival Evaluation
Study Group</p>
<p>.</p>
<p>N Engl J Med</p>
<p>1996</p>
<p>;</p>
<p>335</p>
<p>:</p>
<p>1107</p>
<p>–</p>
<p>1114</p>
<p>.</p>
<p>571</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Ziesche</p>
<p>S</p>
<p>,</p>
<p>Smith</p>
<p>R</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Dunkman</p>
<p>WB</p>
<p>,</p>
<p>Loeb</p>
<p>H</p>
<p>,</p>
<p>Cintron</p>
<p>G</p>
<p>,</p>
<p>Boden</p>
<p>W</p>
<p>,</p>
<p>Baruch</p>
<p>L</p>
<p>,</p>
<p>Rochin</p>
<p>P</p>
<p>,</p>
<p>Loss</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Effect of the calcium antagonist felodipine as supplementary
vasodilator therapy in patients with chronic heart failure treated with
enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study
Group</p>
<p>.</p>
<p>Circulation</p>
<p>1997</p>
<p>;</p>
<p>96</p>
<p>:</p>
<p>856</p>
<p>–</p>
<p>863</p>
<p>.</p>
<p>572</p>
<p>IONA Study Group</p>
<p>.</p>
<p>Effect of nicorandil on coronary events in patients with stable
angina: the Impact Of Nicorandil in Angina (IONA) randomised trial</p>
<p>.</p>
<p>Lancet</p>
<p>2002</p>
<p>;</p>
<p>359</p>
<p>:</p>
<p>1269</p>
<p>–</p>
<p>1275</p>
<p>.</p>
<p>573</p>
<p>Kanamasa</p>
<p>K</p>
<p>,</p>
<p>Hayashi</p>
<p>T</p>
<p>,</p>
<p>Kimura</p>
<p>A</p>
<p>,</p>
<p>Ikeda</p>
<p>A</p>
<p>,</p>
<p>Ishikawa</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Long-term, continuous treatment with both oral and transdermal
nitrates increases cardiac events in healed myocardial infarction
patients</p>
<p>.</p>
<p>Angiology</p>
<p>2002</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>399</p>
<p>–</p>
<p>408</p>
<p>.</p>
<p>574</p>
<p>Wilson</p>
<p>SR</p>
<p>,</p>
<p>Scirica</p>
<p>BM</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>Murphy</p>
<p>SA</p>
<p>,</p>
<p>Karwatowska-Prokopczuk</p>
<p>E</p>
<p>,</p>
<p>Buros</p>
<p>JL</p>
<p>,</p>
<p>Chaitman</p>
<p>BR</p>
<p>,</p>
<p>Morrow</p>
<p>DA.</p>
<p>Efficacy of ranolazine in patients with chronic angina observations
from the randomized, double-blind, placebo-controlled MERLIN-TIMI
(Metabolic Efficiency With Ranolazine for Less Ischemia in
Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>1510</p>
<p>–</p>
<p>1516</p>
<p>.</p>
<p>575</p>
<p>Gao</p>
<p>D</p>
<p>,</p>
<p>Ning</p>
<p>N</p>
<p>,</p>
<p>Niu</p>
<p>X</p>
<p>,</p>
<p>Hao</p>
<p>G</p>
<p>,</p>
<p>Meng</p>
<ol start="26" type="A">
<li></li>
</ol>
<p>Trimetazidine: a meta-analysis of randomised controlled trials in
heart failure</p>
<p>.</p>
<p>Heart</p>
<p>2011</p>
<p>;</p>
<p>97</p>
<p>:</p>
<p>278</p>
<p>–</p>
<p>286</p>
<p>.</p>
<p>576</p>
<p>Vitale</p>
<p>C</p>
<p>,</p>
<p>Wajngaten</p>
<p>M</p>
<p>,</p>
<p>Sposato</p>
<p>B</p>
<p>,</p>
<p>Gebara</p>
<p>O</p>
<p>,</p>
<p>Rossini</p>
<p>P</p>
<p>,</p>
<p>Fini</p>
<p>M</p>
<p>,</p>
<p>Volterrani</p>
<p>M</p>
<p>,</p>
<p>Rosano</p>
<p>GM.</p>
<p>Trimetazidine improves left ventricular function and quality of life
in elderly patients with coronary artery disease</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2004</p>
<p>;</p>
<p>25</p>
<p>:</p>
<p>1814</p>
<p>–</p>
<p>1821</p>
<p>.</p>
<p>577</p>
<p>Zhang</p>
<p>L</p>
<p>,</p>
<p>Lu</p>
<p>Y</p>
<p>,</p>
<p>Jiang</p>
<p>H</p>
<p>,</p>
<p>Zhang</p>
<p>L</p>
<p>,</p>
<p>Sun</p>
<p>A</p>
<p>,</p>
<p>Zou</p>
<p>Y</p>
<p>,</p>
<p>Ge</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Additional use of trimetazidine in patients with chronic heart
failure: a meta-analysis</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2012</p>
<p>;</p>
<p>59</p>
<p>:</p>
<p>913</p>
<p>–</p>
<p>922</p>
<p>.</p>
<p>578</p>
<p>Goldstein</p>
<p>RE</p>
<p>,</p>
<p>Boccuzzi</p>
<p>SJ</p>
<p>,</p>
<p>Cruess</p>
<p>D</p>
<p>,</p>
<p>Nattel</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Diltiazem increases late-onset congestive heart failure in
postinfarction patients with early reduction in ejection fraction. The
Adverse Experience Committee; and the Multicenter Diltiazem
Postinfarction Research Group</p>
<p>.</p>
<p>Circulation</p>
<p>1991</p>
<p>;</p>
<p>83</p>
<p>:</p>
<p>52</p>
<p>–</p>
<p>60</p>
<p>.</p>
<p>579</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Byra</p>
<p>WM</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Fu</p>
<p>M</p>
<p>,</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Neaton</p>
<p>JD</p>
<p>,</p>
<p>Nessel</p>
<p>CC</p>
<p>,</p>
<p>Spiro</p>
<p>TE</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Greenberg</p>
<p>B</p>
<p>,</p>
<p>COMMANDER HF Investigators</p>
<p>.</p>
<p>Rivaroxaban in patients with heart failure, sinus rhythm, and
coronary disease</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>379</p>
<p>:</p>
<p>1332</p>
<p>–</p>
<p>1342</p>
<p>.</p>
<p>580</p>
<p>Branch</p>
<p>KR</p>
<p>,</p>
<p>Probstfield</p>
<p>JL</p>
<p>,</p>
<p>Eikelboom</p>
<p>JW</p>
<p>,</p>
<p>Bosch</p>
<p>J</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Cheng</p>
<p>RK</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Avezum</p>
<p>A</p>
<p>,</p>
<p>Fox</p>
<p>KAA</p>
<p>,</p>
<p>Connolly</p>
<p>SJ</p>
<p>,</p>
<p>Shestakovska</p>
<p>O</p>
<p>,</p>
<p>Yusuf</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Rivaroxaban with or without aspirin in patients with heart failure
and chronic coronary or peripheral artery disease</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>140</p>
<p>:</p>
<p>529</p>
<p>–</p>
<p>537</p>
<p>.</p>
<p>581</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Jones</p>
<p>RH</p>
<p>,</p>
<p>Al-Khalidi</p>
<p>HR</p>
<p>,</p>
<p>Hill</p>
<p>JA</p>
<p>,</p>
<p>Panza</p>
<p>JA</p>
<p>,</p>
<p>Michler</p>
<p>RE</p>
<p>,</p>
<p>Bonow</p>
<p>RO</p>
<p>,</p>
<p>Doenst</p>
<p>T</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Oh</p>
<p>JK</p>
<p>,</p>
<p>She</p>
<p>L</p>
<p>,</p>
<p>Moore</p>
<p>VL</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>Sopko</p>
<p>G</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>STICHES Investigators</p>
<p>.</p>
<p>Coronary-artery bypass surgery in patients with ischemic
cardiomyopathy</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2016</p>
<p>;</p>
<p>374</p>
<p>:</p>
<p>1511</p>
<p>–</p>
<p>1520</p>
<p>.</p>
<p>582</p>
<p>Panza</p>
<p>JA</p>
<p>,</p>
<p>Holly</p>
<p>TA</p>
<p>,</p>
<p>Asch</p>
<p>FM</p>
<p>,</p>
<p>She</p>
<p>L</p>
<p>,</p>
<p>Pellikka</p>
<p>PA</p>
<p>,</p>
<p>Velazquez</p>
<p>EJ</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Borges-Neto</p>
<p>S</p>
<p>,</p>
<p>Farsky</p>
<p>PS</p>
<p>,</p>
<p>Jones</p>
<p>RH</p>
<p>,</p>
<p>Berman</p>
<p>DS</p>
<p>,</p>
<p>Bonow</p>
<p>RO.</p>
<p>Inducible myocardial ischemia and outcomes in patients with coronary
artery disease and left ventricular dysfunction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2013</p>
<p>;</p>
<p>61</p>
<p>:</p>
<p>1860</p>
<p>–</p>
<p>1870</p>
<p>.</p>
<p>583</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Calvert</p>
<p>M</p>
<p>,</p>
<p>Freemantle</p>
<p>N</p>
<p>,</p>
<p>Arrow</p>
<p>Y</p>
<p>,</p>
<p>Ball</p>
<p>SG</p>
<p>,</p>
<p>Bonser</p>
<p>RS</p>
<p>,</p>
<p>Chattopadhyay</p>
<p>S</p>
<p>,</p>
<p>Norell</p>
<p>MS</p>
<p>,</p>
<p>Pennell</p>
<p>DJ</p>
<p>,</p>
<p>Senior</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>The Heart Failure Revascularisation Trial (HEART)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>227</p>
<p>–</p>
<p>233</p>
<p>.</p>
<p>584</p>
<p>Perera</p>
<p>D</p>
<p>,</p>
<p>Clayton</p>
<p>T</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Greenwood</p>
<p>JP</p>
<p>,</p>
<p>O’Kane</p>
<p>PD</p>
<p>,</p>
<p>Evans</p>
<p>R</p>
<p>,</p>
<p>Sculpher</p>
<p>M</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Gershlick</p>
<p>A</p>
<p>,</p>
<p>de Belder</p>
<p>M</p>
<p>,</p>
<p>Redwood</p>
<p>S</p>
<p>,</p>
<p>Carr-White</p>
<p>G</p>
<p>,</p>
<p>Marber</p>
<p>M</p>
<p>,</p>
<p>REVIVED Investigators</p>
<p>.</p>
<p>Percutaneous revascularization for ischemic ventricular dysfunction:
rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary
intervention for ischemic cardiomyopathy</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>517</p>
<p>–</p>
<p>526</p>
<p>.</p>
<p>585</p>
<p>Bangalore</p>
<p>S</p>
<p>,</p>
<p>Guo</p>
<p>Y</p>
<p>,</p>
<p>Samadashvili</p>
<p>Z</p>
<p>,</p>
<p>Blecker</p>
<p>S</p>
<p>,</p>
<p>Hannan</p>
<p>EL.</p>
<p>Revascularization in patients with multivessel coronary artery
disease and severe left ventricular systolic dysfunction:
everolimus-eluting stents versus coronary artery bypass graft
surgery</p>
<p>.</p>
<p>Circulation</p>
<p>2016</p>
<p>;</p>
<p>133</p>
<p>:</p>
<p>2132</p>
<p>–</p>
<p>2140</p>
<p>.</p>
<p>586</p>
<p>Nagendran</p>
<p>J</p>
<p>,</p>
<p>Bozso</p>
<p>SJ</p>
<p>,</p>
<p>Norris</p>
<p>CM</p>
<p>,</p>
<p>McAlister</p>
<p>FA</p>
<p>,</p>
<p>Appoo</p>
<p>JJ</p>
<p>,</p>
<p>Moon</p>
<p>MC</p>
<p>,</p>
<p>Freed</p>
<p>DH</p>
<p>,</p>
<p>Nagendran</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Coronary artery bypass surgery improves outcomes in patients with
diabetes and left ventricular dysfunction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>819</p>
<p>–</p>
<p>827</p>
<p>.</p>
<p>587</p>
<p>Park</p>
<p>S</p>
<p>,</p>
<p>Ahn</p>
<p>JM</p>
<p>,</p>
<p>Kim</p>
<p>TO</p>
<p>,</p>
<p>Park</p>
<p>H</p>
<p>,</p>
<p>Kang</p>
<p>DY</p>
<p>,</p>
<p>Lee</p>
<p>PH</p>
<p>,</p>
<p>Jeong</p>
<p>YJ</p>
<p>,</p>
<p>Hyun</p>
<p>J</p>
<p>,</p>
<p>Lee</p>
<p>J</p>
<p>,</p>
<p>Kim</p>
<p>JH</p>
<p>,</p>
<p>Yang</p>
<p>Y</p>
<p>,</p>
<p>Choe</p>
<p>K</p>
<p>,</p>
<p>Park</p>
<p>SJ</p>
<p>,</p>
<p>Park</p>
<p>DW</p>
<p>,</p>
<p>IRIS-MAIN Registry Investigators. Revascularization in patients with
left main coronary artery disease and left ventricular dysfunction</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2020</p>
<p>;</p>
<p>76</p>
<p>:</p>
<p>1395</p>
<p>–</p>
<p>1406</p>
<p>.</p>
<p>588</p>
<p>Marui</p>
<p>A</p>
<p>,</p>
<p>Kimura</p>
<p>T</p>
<p>,</p>
<p>Nishiwaki</p>
<p>N</p>
<p>,</p>
<p>Mitsudo</p>
<p>K</p>
<p>,</p>
<p>Komiya</p>
<p>T</p>
<p>,</p>
<p>Hanyu</p>
<p>M</p>
<p>,</p>
<p>Shiomi</p>
<p>H</p>
<p>,</p>
<p>Tanaka</p>
<p>S</p>
<p>,</p>
<p>Sakata</p>
<p>R</p>
<p>,</p>
<p>CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Comparison of
five-year outcomes of coronary artery bypass grafting versus
percutaneous coronary intervention in patients with left ventricular
ejection fractions &lt;/ = 50% versus &gt;50% (from the CREDO-Kyoto
PCI/CABG Registry Cohort-2)</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2014</p>
<p>;</p>
<p>114</p>
<p>:</p>
<p>988</p>
<p>–</p>
<p>996</p>
<p>.</p>
<p>589</p>
<p>Wolff</p>
<p>G</p>
<p>,</p>
<p>Dimitroulis</p>
<p>D</p>
<p>,</p>
<p>Andreotti</p>
<p>F</p>
<p>,</p>
<p>Kolodziejczak</p>
<p>M</p>
<p>,</p>
<p>Jung</p>
<p>C</p>
<p>,</p>
<p>Scicchitano</p>
<p>P</p>
<p>,</p>
<p>Devito</p>
<p>F</p>
<p>,</p>
<p>Zito</p>
<p>A</p>
<p>,</p>
<p>Occhipinti</p>
<p>M</p>
<p>,</p>
<p>Castiglioni</p>
<p>B</p>
<p>,</p>
<p>Calveri</p>
<p>G</p>
<p>,</p>
<p>Maisano</p>
<p>F</p>
<p>,</p>
<p>Ciccone</p>
<p>MM</p>
<p>,</p>
<p>De Servi</p>
<p>S</p>
<p>,</p>
<p>Navarese</p>
<p>EP.</p>
<p>Survival benefits of invasive versus conservative strategies in heart
failure in patients with reduced ejection fraction and coronary artery
disease: a meta-analysis</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>10</p>
<p>:e003255.</p>
<p>590</p>
<p>Gaudino</p>
<p>M</p>
<p>,</p>
<p>Hameed</p>
<p>I</p>
<p>,</p>
<p>Khan</p>
<p>FM</p>
<p>,</p>
<p>Tam</p>
<p>DY</p>
<p>,</p>
<p>Rahouma</p>
<p>M</p>
<p>,</p>
<p>Yongle</p>
<p>R</p>
<p>,</p>
<p>Naik</p>
<p>A</p>
<p>,</p>
<p>Di Franco</p>
<p>A</p>
<p>,</p>
<p>Demetres</p>
<p>M</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Jolicoeur</p>
<p>EM</p>
<p>,</p>
<p>Girardi</p>
<p>LN</p>
<p>,</p>
<p>Fremes</p>
<p>SE.</p>
<p>Treatment strategies in ischaemic left ventricular dysfunction: a
network meta-analysis</p>
<p>.</p>
<p>Eur J Cardiothorac Surg</p>
<p>2021</p>
<p>;</p>
<p>59</p>
<p>:</p>
<p>293</p>
<p>–</p>
<p>301</p>
<p>.</p>
<p>591</p>
<p>Genereux</p>
<p>P</p>
<p>,</p>
<p>Pibarot</p>
<p>P</p>
<p>,</p>
<p>Redfors</p>
<p>B</p>
<p>,</p>
<p>Mack</p>
<p>MJ</p>
<p>,</p>
<p>Makkar</p>
<p>RR</p>
<p>,</p>
<p>Jaber</p>
<p>WA</p>
<p>,</p>
<p>Svensson</p>
<p>LG</p>
<p>,</p>
<p>Kapadia</p>
<p>S</p>
<p>,</p>
<p>Tuzcu</p>
<p>EM</p>
<p>,</p>
<p>Thourani</p>
<p>VH</p>
<p>,</p>
<p>Babaliaros</p>
<p>V</p>
<p>,</p>
<p>Herrmann</p>
<p>HC</p>
<p>,</p>
<p>Szeto</p>
<p>WY</p>
<p>,</p>
<p>Cohen</p>
<p>DJ</p>
<p>,</p>
<p>Lindman</p>
<p>BR</p>
<p>,</p>
<p>McAndrew</p>
<p>T</p>
<p>,</p>
<p>Alu</p>
<p>MC</p>
<p>,</p>
<p>Douglas</p>
<p>PS</p>
<p>,</p>
<p>Hahn</p>
<p>RT</p>
<p>,</p>
<p>Kodali</p>
<p>SK</p>
<p>,</p>
<p>Smith</p>
<p>CR</p>
<p>,</p>
<p>Miller</p>
<p>DC</p>
<p>,</p>
<p>Webb</p>
<p>JG</p>
<p>,</p>
<p>Leon</p>
<p>MB.</p>
<p>Staging classification of aortic stenosis based on the extent of
cardiac damage</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>3351</p>
<p>–</p>
<p>3358</p>
<p>.</p>
<p>592</p>
<p>Vahanian</p>
<p>A</p>
<p>,</p>
<p>Beyersdorf F, Praz F, Milojevic M, Baldus S, Johann B, Capodanno D,
Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M,
Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast PD, Rafael Sádaba
J, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group</p>
<p>.</p>
<p>2021 ESC/EACTS Guidelines for the management of valvular heart
disease</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>; doi:10.1093/eurheartj/ehab395.</p>
<p>593</p>
<p>Leon</p>
<p>MB</p>
<p>,</p>
<p>Smith</p>
<p>CR</p>
<p>,</p>
<p>Mack</p>
<p>M</p>
<p>,</p>
<p>Miller</p>
<p>DC</p>
<p>,</p>
<p>Moses</p>
<p>JW</p>
<p>,</p>
<p>Svensson</p>
<p>LG</p>
<p>,</p>
<p>Tuzcu</p>
<p>EM</p>
<p>,</p>
<p>Webb</p>
<p>JG</p>
<p>,</p>
<p>Fontana</p>
<p>GP</p>
<p>,</p>
<p>Makkar</p>
<p>RR</p>
<p>,</p>
<p>Brown</p>
<p>DL</p>
<p>,</p>
<p>Block</p>
<p>PC</p>
<p>,</p>
<p>Guyton</p>
<p>RA</p>
<p>,</p>
<p>Pichard</p>
<p>AD</p>
<p>,</p>
<p>Bavaria</p>
<p>JE</p>
<p>,</p>
<p>Herrmann</p>
<p>HC</p>
<p>,</p>
<p>Douglas</p>
<p>PS</p>
<p>,</p>
<p>Petersen</p>
<p>JL</p>
<p>,</p>
<p>Akin</p>
<p>JJ</p>
<p>,</p>
<p>Anderson</p>
<p>WN</p>
<p>,</p>
<p>Wang</p>
<p>D</p>
<p>,</p>
<p>Pocock</p>
<p>S</p>
<p>,</p>
<p>PARTNER Trial Investigators. Transcatheter aortic-valve implantation
for aortic stenosis in patients who cannot undergo surgery</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2010</p>
<p>;</p>
<p>363</p>
<p>:</p>
<p>1597</p>
<p>–</p>
<p>1607</p>
<p>.</p>
<p>594</p>
<p>Smith</p>
<p>CR</p>
<p>,</p>
<p>Leon</p>
<p>MB</p>
<p>,</p>
<p>Mack</p>
<p>MJ</p>
<p>,</p>
<p>Miller</p>
<p>DC</p>
<p>,</p>
<p>Moses</p>
<p>JW</p>
<p>,</p>
<p>Svensson</p>
<p>LG</p>
<p>,</p>
<p>Tuzcu</p>
<p>EM</p>
<p>,</p>
<p>Webb</p>
<p>JG</p>
<p>,</p>
<p>Fontana</p>
<p>GP</p>
<p>,</p>
<p>Makkar</p>
<p>RR</p>
<p>,</p>
<p>Williams</p>
<p>M</p>
<p>,</p>
<p>Dewey</p>
<p>T</p>
<p>,</p>
<p>Kapadia</p>
<p>S</p>
<p>,</p>
<p>Babaliaros</p>
<p>V</p>
<p>,</p>
<p>Thourani</p>
<p>VH</p>
<p>,</p>
<p>Corso</p>
<p>P</p>
<p>,</p>
<p>Pichard</p>
<p>AD</p>
<p>,</p>
<p>Bavaria</p>
<p>JE</p>
<p>,</p>
<p>Herrmann</p>
<p>HC</p>
<p>,</p>
<p>Akin</p>
<p>JJ</p>
<p>,</p>
<p>Anderson</p>
<p>WN</p>
<p>,</p>
<p>Wang</p>
<p>D</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>PARTNER Trial Investigators. Transcatheter versus surgical
aortic-valve replacement in high-risk patients</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>2187</p>
<p>–</p>
<p>2198</p>
<p>.</p>
<p>595</p>
<p>Adams</p>
<p>DH</p>
<p>,</p>
<p>Popma</p>
<p>JJ</p>
<p>,</p>
<p>Reardon</p>
<p>MJ</p>
<p>,</p>
<p>Yakubov</p>
<p>SJ</p>
<p>,</p>
<p>Coselli</p>
<p>JS</p>
<p>,</p>
<p>Deeb</p>
<p>GM</p>
<p>,</p>
<p>Gleason</p>
<p>TG</p>
<p>,</p>
<p>Buchbinder</p>
<p>M</p>
<p>,</p>
<p>Hermiller</p>
<p>J</p>
<p>Jr,</p>
<p>Kleiman</p>
<p>NS</p>
<p>,</p>
<p>Chetcuti</p>
<p>S</p>
<p>,</p>
<p>Heiser</p>
<p>J</p>
<p>,</p>
<p>Merhi</p>
<p>W</p>
<p>,</p>
<p>Zorn</p>
<p>G</p>
<p>,</p>
<p>Tadros</p>
<p>P</p>
<p>,</p>
<p>Robinson</p>
<p>N</p>
<p>,</p>
<p>Petrossian</p>
<p>G</p>
<p>,</p>
<p>Hughes</p>
<p>GC</p>
<p>,</p>
<p>Harrison</p>
<p>JK</p>
<p>,</p>
<p>Conte</p>
<p>J</p>
<p>,</p>
<p>Maini</p>
<p>B</p>
<p>,</p>
<p>Mumtaz</p>
<p>M</p>
<p>,</p>
<p>Chenoweth</p>
<p>S</p>
<p>,</p>
<p>Oh</p>
<p>JK</p>
<p>,</p>
<p>US CoreValve Clinical Investigators. Transcatheter aortic-valve
replacement with a self-expanding prosthesis</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2014</p>
<p>;</p>
<p>370</p>
<p>:</p>
<p>1790</p>
<p>–</p>
<p>1798</p>
<p>.</p>
<p>596</p>
<p>Popma</p>
<p>JJ</p>
<p>,</p>
<p>Adams</p>
<p>DH</p>
<p>,</p>
<p>Reardon</p>
<p>MJ</p>
<p>,</p>
<p>Yakubov</p>
<p>SJ</p>
<p>,</p>
<p>Kleiman</p>
<p>NS</p>
<p>,</p>
<p>Heimansohn</p>
<p>D</p>
<p>,</p>
<p>Hermiller</p>
<p>J</p>
<p>Jr.,</p>
<p>Hughes</p>
<p>GC</p>
<p>,</p>
<p>Harrison</p>
<p>JK</p>
<p>,</p>
<p>Coselli</p>
<p>J</p>
<p>,</p>
<p>Diez</p>
<p>J</p>
<p>,</p>
<p>Kafi</p>
<p>A</p>
<p>,</p>
<p>Schreiber</p>
<p>T</p>
<p>,</p>
<p>Gleason</p>
<p>TG</p>
<p>,</p>
<p>Conte</p>
<p>J</p>
<p>,</p>
<p>Buchbinder</p>
<p>M</p>
<p>,</p>
<p>Deeb</p>
<p>GM</p>
<p>,</p>
<p>Carabello</p>
<p>B</p>
<p>,</p>
<p>Serruys</p>
<p>PW</p>
<p>,</p>
<p>Chenoweth</p>
<p>S</p>
<p>,</p>
<p>Oh</p>
<p>JK</p>
<p>,</p>
<p>CoreValve United States Clinical Investigators. Transcatheter aortic
valve replacement using a self-expanding bioprosthesis in patients with
severe aortic stenosis at extreme risk for surgery</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>1972</p>
<p>–</p>
<p>1981</p>
<p>.</p>
<p>597</p>
<p>Leon</p>
<p>MB</p>
<p>,</p>
<p>Smith</p>
<p>CR</p>
<p>,</p>
<p>Mack</p>
<p>MJ</p>
<p>,</p>
<p>Makkar</p>
<p>RR</p>
<p>,</p>
<p>Svensson</p>
<p>LG</p>
<p>,</p>
<p>Kodali</p>
<p>SK</p>
<p>,</p>
<p>Thourani</p>
<p>VH</p>
<p>,</p>
<p>Tuzcu</p>
<p>EM</p>
<p>,</p>
<p>Miller</p>
<p>DC</p>
<p>,</p>
<p>Herrmann</p>
<p>HC</p>
<p>,</p>
<p>Doshi</p>
<p>D</p>
<p>,</p>
<p>Cohen</p>
<p>DJ</p>
<p>,</p>
<p>Pichard</p>
<p>AD</p>
<p>,</p>
<p>Kapadia</p>
<p>S</p>
<p>,</p>
<p>Dewey</p>
<p>T</p>
<p>,</p>
<p>Babaliaros</p>
<p>V</p>
<p>,</p>
<p>Szeto</p>
<p>WY</p>
<p>,</p>
<p>Williams</p>
<p>MR</p>
<p>,</p>
<p>Kereiakes</p>
<p>D</p>
<p>,</p>
<p>Zajarias</p>
<p>A</p>
<p>,</p>
<p>Greason</p>
<p>KL</p>
<p>,</p>
<p>Whisenant</p>
<p>BK</p>
<p>,</p>
<p>Hodson</p>
<p>RW</p>
<p>,</p>
<p>Moses</p>
<p>JW</p>
<p>,</p>
<p>Trento</p>
<p>A</p>
<p>,</p>
<p>Brown</p>
<p>DL</p>
<p>,</p>
<p>Fearon</p>
<p>WF</p>
<p>,</p>
<p>Pibarot</p>
<p>P</p>
<p>,</p>
<p>Hahn</p>
<p>RT</p>
<p>,</p>
<p>Jaber</p>
<p>WA</p>
<p>,</p>
<p>Anderson</p>
<p>WN</p>
<p>,</p>
<p>Alu</p>
<p>MC</p>
<p>,</p>
<p>Webb</p>
<p>JG</p>
<p>, PARTNER 2 Investigators</p>
<p>Transcatheter or surgical aortic-valve replacement in
intermediate-risk patients</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2016</p>
<p>;</p>
<p>374</p>
<p>:</p>
<p>1609</p>
<p>–</p>
<p>1620</p>
<p>.</p>
<p>598</p>
<p>Reardon</p>
<p>MJ</p>
<p>,</p>
<p>Van Mieghem</p>
<p>NM</p>
<p>,</p>
<p>Popma</p>
<p>JJ</p>
<p>,</p>
<p>Kleiman</p>
<p>NS</p>
<p>,</p>
<p>Sondergaard</p>
<p>L</p>
<p>,</p>
<p>Mumtaz</p>
<p>M</p>
<p>,</p>
<p>Adams</p>
<p>DH</p>
<p>,</p>
<p>Deeb</p>
<p>GM</p>
<p>,</p>
<p>Maini</p>
<p>B</p>
<p>,</p>
<p>Gada</p>
<p>H</p>
<p>,</p>
<p>Chetcuti</p>
<p>S</p>
<p>,</p>
<p>Gleason</p>
<p>T</p>
<p>,</p>
<p>Heiser</p>
<p>J</p>
<p>,</p>
<p>Lange</p>
<p>R</p>
<p>,</p>
<p>Merhi</p>
<p>W</p>
<p>,</p>
<p>Oh</p>
<p>JK</p>
<p>,</p>
<p>Olsen</p>
<p>PS</p>
<p>,</p>
<p>Piazza</p>
<p>N</p>
<p>,</p>
<p>Williams</p>
<p>M</p>
<p>,</p>
<p>Windecker</p>
<p>S</p>
<p>,</p>
<p>Yakubov</p>
<p>SJ</p>
<p>,</p>
<p>Grube</p>
<p>E</p>
<p>,</p>
<p>Makkar</p>
<p>R</p>
<p>,</p>
<p>Lee</p>
<p>JS</p>
<p>,</p>
<p>Conte</p>
<p>J</p>
<p>,</p>
<p>Vang</p>
<p>E</p>
<p>,</p>
<p>Nguyen</p>
<p>H</p>
<p>,</p>
<p>Chang</p>
<p>Y</p>
<p>,</p>
<p>Mugglin</p>
<p>AS</p>
<p>,</p>
<p>Serruys</p>
<p>PW</p>
<p>,</p>
<p>Kappetein</p>
<p>AP</p>
<p>,</p>
<p>SURTAVI Investigators</p>
<p>.</p>
<p>Surgical or transcatheter aortic-valve replacement in
intermediate-risk patients</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2017</p>
<p>;</p>
<p>376</p>
<p>:</p>
<p>1321</p>
<p>–</p>
<p>1331</p>
<p>.</p>
<p>599</p>
<p>Popma</p>
<p>JJ</p>
<p>,</p>
<p>Deeb</p>
<p>GM</p>
<p>,</p>
<p>Yakubov</p>
<p>SJ</p>
<p>,</p>
<p>Mumtaz</p>
<p>M</p>
<p>,</p>
<p>Gada</p>
<p>H</p>
<p>,</p>
<p>O’Hair</p>
<p>D</p>
<p>,</p>
<p>Bajwa</p>
<p>T</p>
<p>,</p>
<p>Heiser</p>
<p>JC</p>
<p>,</p>
<p>Merhi</p>
<p>W</p>
<p>,</p>
<p>Kleiman</p>
<p>NS</p>
<p>,</p>
<p>Askew</p>
<p>J</p>
<p>,</p>
<p>Sorajja</p>
<p>P</p>
<p>,</p>
<p>Rovin</p>
<p>J</p>
<p>,</p>
<p>Chetcuti</p>
<p>SJ</p>
<p>,</p>
<p>Adams</p>
<p>DH</p>
<p>,</p>
<p>Teirstein</p>
<p>PS</p>
<p>,</p>
<p>Zorn</p>
<p>GL</p>
<p>3rd,</p>
<p>Forrest</p>
<p>JK</p>
<p>,</p>
<p>Tchetche</p>
<p>D</p>
<p>,</p>
<p>Resar</p>
<p>J</p>
<p>,</p>
<p>Walton</p>
<p>A</p>
<p>,</p>
<p>Piazza</p>
<p>N</p>
<p>,</p>
<p>Ramlawi</p>
<p>B</p>
<p>,</p>
<p>Robinson</p>
<p>N</p>
<p>,</p>
<p>Petrossian</p>
<p>G</p>
<p>,</p>
<p>Gleason</p>
<p>TG</p>
<p>,</p>
<p>Oh</p>
<p>JK</p>
<p>,</p>
<p>Boulware</p>
<p>MJ</p>
<p>,</p>
<p>Qiao</p>
<p>H</p>
<p>,</p>
<p>Mugglin</p>
<p>AS</p>
<p>,</p>
<p>Reardon</p>
<p>MJ</p>
<p>,</p>
<p>Evolut Low Risk Trial Investigators</p>
<p>.</p>
<p>Transcatheter aortic-valve replacement with a self-expanding valve in
low-risk patients</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>380</p>
<p>:</p>
<p>1706</p>
<p>–</p>
<p>1715</p>
<p>.</p>
<p>600</p>
<p>Mack</p>
<p>MJ</p>
<p>,</p>
<p>Leon</p>
<p>MB</p>
<p>,</p>
<p>Thourani</p>
<p>VH</p>
<p>,</p>
<p>Makkar</p>
<p>R</p>
<p>,</p>
<p>Kodali</p>
<p>SK</p>
<p>,</p>
<p>Russo</p>
<p>M</p>
<p>,</p>
<p>Kapadia</p>
<p>SR</p>
<p>,</p>
<p>Malaisrie</p>
<p>SC</p>
<p>,</p>
<p>Cohen</p>
<p>DJ</p>
<p>,</p>
<p>Pibarot</p>
<p>P</p>
<p>,</p>
<p>Leipsic</p>
<p>J</p>
<p>,</p>
<p>Hahn</p>
<p>RT</p>
<p>,</p>
<p>Blanke</p>
<p>P</p>
<p>,</p>
<p>Williams</p>
<p>MR</p>
<p>,</p>
<p>McCabe</p>
<p>JM</p>
<p>,</p>
<p>Brown</p>
<p>DL</p>
<p>,</p>
<p>Babaliaros</p>
<p>V</p>
<p>,</p>
<p>Goldman</p>
<p>S</p>
<p>,</p>
<p>Szeto</p>
<p>WY</p>
<p>,</p>
<p>Genereux</p>
<p>P</p>
<p>,</p>
<p>Pershad</p>
<p>A</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Alu</p>
<p>MC</p>
<p>,</p>
<p>Webb</p>
<p>JG</p>
<p>,</p>
<p>Smith</p>
<p>CR</p>
<p>,</p>
<p>PARTNER 3 Investigators. Transcatheter aortic-valve replacement with
a balloon-expandable valve in low-risk patients</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>380</p>
<p>:</p>
<p>1695</p>
<p>–</p>
<p>1705</p>
<p>.</p>
<p>601</p>
<p>Elder</p>
<p>DH</p>
<p>,</p>
<p>Wei</p>
<p>L</p>
<p>,</p>
<p>Szwejkowski</p>
<p>BR</p>
<p>,</p>
<p>Libianto</p>
<p>R</p>
<p>,</p>
<p>Nadir</p>
<p>A</p>
<p>,</p>
<p>Pauriah</p>
<p>M</p>
<p>,</p>
<p>Rekhraj</p>
<p>S</p>
<p>,</p>
<p>Lim</p>
<p>TK</p>
<p>,</p>
<p>George</p>
<p>J</p>
<p>,</p>
<p>Doney</p>
<p>A</p>
<p>,</p>
<p>Pringle</p>
<p>SD</p>
<p>,</p>
<p>Choy</p>
<p>AM</p>
<p>,</p>
<p>Struthers</p>
<p>AD</p>
<p>,</p>
<p>Lang</p>
<ol start="200" type="I">
<li></li>
</ol>
<p>The impact of renin-angiotensin-aldosterone system blockade on heart
failure outcomes and mortality in patients identified to have aortic
regurgitation: a large population cohort study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2011</p>
<p>;</p>
<p>58</p>
<p>:</p>
<p>2084</p>
<p>–</p>
<p>2091</p>
<p>.</p>
<p>602</p>
<p>Chaliki</p>
<p>HP</p>
<p>,</p>
<p>Mohty</p>
<p>D</p>
<p>,</p>
<p>Avierinos</p>
<p>JF</p>
<p>,</p>
<p>Scott</p>
<p>CG</p>
<p>,</p>
<p>Schaff</p>
<p>HV</p>
<p>,</p>
<p>Tajik</p>
<p>AJ</p>
<p>,</p>
<p>Enriquez-Sarano</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Outcomes after aortic valve replacement in patients with severe
aortic regurgitation and markedly reduced left ventricular function</p>
<p>.</p>
<p>Circulation</p>
<p>2002</p>
<p>;</p>
<p>106</p>
<p>:</p>
<p>2687</p>
<p>–</p>
<p>2693</p>
<p>.</p>
<p>603</p>
<p>Tornos</p>
<p>P</p>
<p>,</p>
<p>Sambola</p>
<p>A</p>
<p>,</p>
<p>Permanyer-Miralda</p>
<p>G</p>
<p>,</p>
<p>Evangelista</p>
<p>A</p>
<p>,</p>
<p>Gomez</p>
<p>Z</p>
<p>,</p>
<p>Soler-Soler</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Long-term outcome of surgically treated aortic regurgitation:
influence of guideline adherence toward early surgery</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2006</p>
<p>;</p>
<p>47</p>
<p>:</p>
<p>1012</p>
<p>–</p>
<p>1017</p>
<p>.</p>
<p>604</p>
<p>Yoon</p>
<p>SH</p>
<p>,</p>
<p>Schmidt</p>
<p>T</p>
<p>,</p>
<p>Bleiziffer</p>
<p>S</p>
<p>,</p>
<p>Schofer</p>
<p>N</p>
<p>,</p>
<p>Fiorina</p>
<p>C</p>
<p>,</p>
<p>Munoz-Garcia</p>
<p>AJ</p>
<p>,</p>
<p>Yzeiraj</p>
<p>E</p>
<p>,</p>
<p>Amat-Santos</p>
<p>IJ</p>
<p>,</p>
<p>Tchetche</p>
<p>D</p>
<p>,</p>
<p>Jung</p>
<p>C</p>
<p>,</p>
<p>Fujita</p>
<p>B</p>
<p>,</p>
<p>Mangieri</p>
<p>A</p>
<p>,</p>
<p>Deutsch</p>
<p>MA</p>
<p>,</p>
<p>Ubben</p>
<p>T</p>
<p>,</p>
<p>Deuschl</p>
<p>F</p>
<p>,</p>
<p>Kuwata</p>
<p>S</p>
<p>,</p>
<p>De Biase</p>
<p>C</p>
<p>,</p>
<p>Williams</p>
<p>T</p>
<p>,</p>
<p>Dhoble</p>
<p>A</p>
<p>,</p>
<p>Kim</p>
<p>WK</p>
<p>,</p>
<p>Ferrari</p>
<p>E</p>
<p>,</p>
<p>Barbanti</p>
<p>M</p>
<p>,</p>
<p>Vollema</p>
<p>EM</p>
<p>,</p>
<p>Miceli</p>
<p>A</p>
<p>,</p>
<p>Giannini</p>
<p>C</p>
<p>,</p>
<p>Attizzani</p>
<p>GF</p>
<p>,</p>
<p>Kong</p>
<p>WKF</p>
<p>,</p>
<p>Gutierrez-Ibanes</p>
<p>E</p>
<p>,</p>
<p>Jimenez Diaz</p>
<p>VA</p>
<p>,</p>
<p>Wijeysundera</p>
<p>HC</p>
<p>,</p>
<p>Kaneko</p>
<p>H</p>
<p>,</p>
<p>Chakravarty</p>
<p>T</p>
<p>,</p>
<p>Makar</p>
<p>M</p>
<p>,</p>
<p>Sievert</p>
<p>H</p>
<p>,</p>
<p>Hengstenberg</p>
<p>C</p>
<p>,</p>
<p>Prendergast</p>
<p>BD</p>
<p>,</p>
<p>Vincent</p>
<p>F</p>
<p>,</p>
<p>Abdel-Wahab</p>
<p>M</p>
<p>,</p>
<p>Nombela-Franco</p>
<p>L</p>
<p>,</p>
<p>Silaschi</p>
<p>M</p>
<p>,</p>
<p>Tarantini</p>
<p>G</p>
<p>,</p>
<p>Butter</p>
<p>C</p>
<p>,</p>
<p>Ensminger</p>
<p>SM</p>
<p>,</p>
<p>Hildick-Smith</p>
<p>D</p>
<p>,</p>
<p>Petronio</p>
<p>AS</p>
<p>,</p>
<p>Yin</p>
<p>WH</p>
<p>,</p>
<p>De Marco</p>
<p>F</p>
<p>,</p>
<p>Testa</p>
<p>L</p>
<p>,</p>
<p>Van Mieghem</p>
<p>NM</p>
<p>,</p>
<p>Whisenant</p>
<p>BK</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Colombo</p>
<p>A</p>
<p>,</p>
<p>Kar</p>
<p>S</p>
<p>,</p>
<p>Moris</p>
<p>C</p>
<p>,</p>
<p>Delgado</p>
<p>V</p>
<p>,</p>
<p>Maisano</p>
<p>F</p>
<p>,</p>
<p>Nietlispach</p>
<p>F</p>
<p>,</p>
<p>Mack</p>
<p>MJ</p>
<p>,</p>
<p>Schofer</p>
<p>J</p>
<p>,</p>
<p>Schaefer</p>
<p>U</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Frerker</p>
<p>C</p>
<p>,</p>
<p>Latib</p>
<p>A</p>
<p>,</p>
<p>Makkar</p>
<p>RR.</p>
<p>Transcatheter aortic valve replacement in pure native aortic valve
regurgitation</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>70</p>
<p>:</p>
<p>2752</p>
<p>–</p>
<p>2763</p>
<p>.</p>
<p>605</p>
<p>Feldman</p>
<p>T</p>
<p>,</p>
<p>Foster</p>
<p>E</p>
<p>,</p>
<p>Glower</p>
<p>DD</p>
<p>,</p>
<p>Kar</p>
<p>S</p>
<p>,</p>
<p>Rinaldi</p>
<p>MJ</p>
<p>,</p>
<p>Fail</p>
<p>PS</p>
<p>,</p>
<p>Smalling</p>
<p>RW</p>
<p>,</p>
<p>Siegel</p>
<p>R</p>
<p>,</p>
<p>Rose</p>
<p>GA</p>
<p>,</p>
<p>Engeron</p>
<p>E</p>
<p>,</p>
<p>Loghin</p>
<p>C</p>
<p>,</p>
<p>Trento</p>
<p>A</p>
<p>,</p>
<p>Skipper</p>
<p>ER</p>
<p>,</p>
<p>Fudge</p>
<p>T</p>
<p>,</p>
<p>Letsou</p>
<p>GV</p>
<p>,</p>
<p>Massaro</p>
<p>JM</p>
<p>,</p>
<p>Mauri</p>
<p>L</p>
<p>EVEREST II Investigators</p>
<p>.</p>
<p>Percutaneous repair or surgery for mitral regurgitation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2011</p>
<p>;</p>
<p>364</p>
<p>:</p>
<p>1395</p>
<p>–</p>
<p>1406</p>
<p>.</p>
<p>606</p>
<p>Tamargo</p>
<p>M</p>
<p>,</p>
<p>Obokata</p>
<p>M</p>
<p>,</p>
<p>Reddy</p>
<p>YNV</p>
<p>,</p>
<p>Pislaru</p>
<p>SV</p>
<p>,</p>
<p>Lin</p>
<p>G</p>
<p>,</p>
<p>Egbe</p>
<p>AC</p>
<p>,</p>
<p>Nishimura</p>
<p>RA</p>
<p>,</p>
<p>Borlaug</p>
<p>BA.</p>
<p>Functional mitral regurgitation and left atrial myopathy in heart
failure with preserved ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>489</p>
<p>–</p>
<p>498</p>
<p>.</p>
<p>607</p>
<p>Dziadzko</p>
<p>V</p>
<p>,</p>
<p>Clavel</p>
<p>MA</p>
<p>,</p>
<p>Dziadzko</p>
<p>M</p>
<p>,</p>
<p>Medina-Inojosa</p>
<p>JR</p>
<p>,</p>
<p>Michelena</p>
<p>H</p>
<p>,</p>
<p>Maalouf</p>
<p>J</p>
<p>,</p>
<p>Nkomo</p>
<p>V</p>
<p>,</p>
<p>Thapa</p>
<p>P</p>
<p>,</p>
<p>Enriquez-Sarano</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Outcome and undertreatment of mitral regurgitation: a community
cohort study</p>
<p>.</p>
<p>Lancet</p>
<p>2018</p>
<p>;</p>
<p>391</p>
<p>:</p>
<p>960</p>
<p>–</p>
<p>969</p>
<p>.</p>
<p>608</p>
<p>Goliasch</p>
<p>G</p>
<p>,</p>
<p>Bartko</p>
<p>PE</p>
<p>,</p>
<p>Pavo</p>
<p>N</p>
<p>,</p>
<p>Neuhold</p>
<p>S</p>
<p>,</p>
<p>Wurm</p>
<p>R</p>
<p>,</p>
<p>Mascherbauer</p>
<p>J</p>
<p>,</p>
<p>Lang</p>
<p>IM</p>
<p>,</p>
<p>Strunk</p>
<p>G</p>
<p>,</p>
<p>Hulsmann</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Refining the prognostic impact of functional mitral regurgitation in
chronic heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>39</p>
<p>–</p>
<p>46</p>
<p>.</p>
<p>609</p>
<p>Bertrand</p>
<p>PB</p>
<p>,</p>
<p>Schwammenthal</p>
<p>E</p>
<p>,</p>
<p>Levine</p>
<p>RA</p>
<p>,</p>
<p>Vandervoort</p>
<p>PM.</p>
<p>Exercise dynamics in secondary mitral regurgitation: pathophysiology
and therapeutic implications</p>
<p>.</p>
<p>Circulation</p>
<p>2017</p>
<p>;</p>
<p>135</p>
<p>:</p>
<p>297</p>
<p>–</p>
<p>314</p>
<p>.</p>
<p>610</p>
<p>Obadia</p>
<p>JF</p>
<p>,</p>
<p>Messika-Zeitoun</p>
<p>D</p>
<p>,</p>
<p>Leurent</p>
<p>G</p>
<p>,</p>
<p>Iung</p>
<p>B</p>
<p>,</p>
<p>Bonnet</p>
<p>G</p>
<p>,</p>
<p>Piriou</p>
<p>N</p>
<p>,</p>
<p>Lefevre</p>
<p>T</p>
<p>,</p>
<p>Piot</p>
<p>C</p>
<p>,</p>
<p>Rouleau</p>
<p>F</p>
<p>,</p>
<p>Carrie</p>
<p>D</p>
<p>,</p>
<p>Nejjari</p>
<p>M</p>
<p>,</p>
<p>Ohlmann</p>
<p>P</p>
<p>,</p>
<p>Leclercq</p>
<p>F</p>
<p>,</p>
<p>Saint Etienne</p>
<p>C</p>
<p>,</p>
<p>Teiger</p>
<p>E</p>
<p>,</p>
<p>Leroux</p>
<p>L</p>
<p>,</p>
<p>Karam</p>
<p>N</p>
<p>,</p>
<p>Michel</p>
<p>N</p>
<p>,</p>
<p>Gilard</p>
<p>M</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Trochu</p>
<p>JN</p>
<p>,</p>
<p>Cormier</p>
<p>B</p>
<p>,</p>
<p>Armoiry</p>
<p>X</p>
<p>,</p>
<p>Boutitie</p>
<p>F</p>
<p>,</p>
<p>Maucort-Boulch</p>
<p>D</p>
<p>,</p>
<p>Barnel</p>
<p>C</p>
<p>,</p>
<p>Samson</p>
<p>G</p>
<p>,</p>
<p>Guerin</p>
<p>P</p>
<p>,</p>
<p>Vahanian</p>
<p>A</p>
<p>,</p>
<p>Mewton</p>
<p>N</p>
<p>,</p>
<p>MITRA-FR Investigators</p>
<p>.</p>
<p>Percutaneous repair or medical treatment for secondary mitral
regurgitation</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>379</p>
<p>:</p>
<p>2297</p>
<p>–</p>
<p>2306</p>
<p>.</p>
<p>611</p>
<p>Iung</p>
<p>B</p>
<p>,</p>
<p>Armoiry</p>
<p>X</p>
<p>,</p>
<p>Vahanian</p>
<p>A</p>
<p>,</p>
<p>Boutitie</p>
<p>F</p>
<p>,</p>
<p>Mewton</p>
<p>N</p>
<p>,</p>
<p>Trochu</p>
<p>JN</p>
<p>,</p>
<p>Lefevre</p>
<p>T</p>
<p>,</p>
<p>Messika-Zeitoun</p>
<p>D</p>
<p>,</p>
<p>Guerin</p>
<p>P</p>
<p>,</p>
<p>Cormier</p>
<p>B</p>
<p>,</p>
<p>Brochet</p>
<p>E</p>
<p>,</p>
<p>Thibault</p>
<p>H</p>
<p>,</p>
<p>Himbert</p>
<p>D</p>
<p>,</p>
<p>Thivolet</p>
<p>S</p>
<p>,</p>
<p>Leurent</p>
<p>G</p>
<p>,</p>
<p>Bonnet</p>
<p>G</p>
<p>,</p>
<p>Donal</p>
<p>E</p>
<p>,</p>
<p>Piriou</p>
<p>N</p>
<p>,</p>
<p>Piot</p>
<p>C</p>
<p>,</p>
<p>Habib</p>
<p>G</p>
<p>,</p>
<p>Rouleau</p>
<p>F</p>
<p>,</p>
<p>Carrie</p>
<p>D</p>
<p>,</p>
<p>Nejjari</p>
<p>M</p>
<p>,</p>
<p>Ohlmann</p>
<p>P</p>
<p>,</p>
<p>Saint Etienne</p>
<p>C</p>
<p>,</p>
<p>Leroux</p>
<p>L</p>
<p>,</p>
<p>Gilard</p>
<p>M</p>
<p>,</p>
<p>Samson</p>
<p>G</p>
<p>,</p>
<p>Rioufol</p>
<p>G</p>
<p>,</p>
<p>Maucort-Boulch</p>
<p>D</p>
<p>,</p>
<p>Obadia</p>
<p>JF</p>
<p>,</p>
<p>MITRA-FR Investigators</p>
<p>.</p>
<p>Percutaneous repair or medical treatment for secondary mitral
regurgitation: outcomes at 2 years</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1619</p>
<p>–</p>
<p>1627</p>
<p>.</p>
<p>612</p>
<p>Stone</p>
<p>GW</p>
<p>,</p>
<p>Lindenfeld</p>
<p>J</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Kar</p>
<p>S</p>
<p>,</p>
<p>Lim</p>
<p>DS</p>
<p>,</p>
<p>Mishell</p>
<p>JM</p>
<p>,</p>
<p>Whisenant</p>
<p>B</p>
<p>,</p>
<p>Grayburn</p>
<p>PA</p>
<p>,</p>
<p>Rinaldi</p>
<p>M</p>
<p>,</p>
<p>Kapadia</p>
<p>SR</p>
<p>,</p>
<p>Rajagopal</p>
<p>V</p>
<p>,</p>
<p>Sarembock</p>
<p>IJ</p>
<p>,</p>
<p>Brieke</p>
<p>A</p>
<p>,</p>
<p>Marx</p>
<p>SO</p>
<p>,</p>
<p>Cohen</p>
<p>DJ</p>
<p>,</p>
<p>Weissman</p>
<p>NJ</p>
<p>,</p>
<p>Mack</p>
<p>MJ</p>
<p>,</p>
<p>COAPT Investigators</p>
<p>.</p>
<p>Transcatheter mitral-valve repair in patients with heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>379</p>
<p>:</p>
<p>2307</p>
<p>–</p>
<p>2318</p>
<p>.</p>
<p>613</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Adamo</p>
<p>M</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Alfieri</p>
<p>O</p>
<p>,</p>
<p>Vahanian</p>
<ol type="A">
<li></li>
</ol>
<p>Treatment of functional mitral regurgitation in chronic heart
failure: can we get a ‘proof of concept’ from the MITRA-FR and COAPT
trials?</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>852</p>
<p>–</p>
<p>861</p>
<p>.</p>
<p>614</p>
<p>Grayburn</p>
<p>PA</p>
<p>,</p>
<p>Sannino</p>
<p>A</p>
<p>,</p>
<p>Packer</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Proportionate and disproportionate functional mitral regurgitation: a
new conceptual framework that reconciles the results of the MITRA-FR and
COAPT trials</p>
<p>.</p>
<p>JACC Cardiovasc Imaging</p>
<p>2019</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>353</p>
<p>–</p>
<p>362</p>
<p>.</p>
<p>615</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Baumbach</p>
<p>A</p>
<p>,</p>
<p>Alfieri</p>
<p>O</p>
<p>,</p>
<p>von Bardeleben</p>
<p>RS</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Boveda</p>
<p>S</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Dagres</p>
<p>N</p>
<p>,</p>
<p>Deneke</p>
<p>T</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Hausleiter</p>
<p>J</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Leclercq</p>
<p>C</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Mewton</p>
<p>N</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Muneretto</p>
<p>C</p>
<p>,</p>
<p>Obadia</p>
<p>JF</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Praz</p>
<p>F</p>
<p>,</p>
<p>Rudolph</p>
<p>V</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Vahanian</p>
<p>A</p>
<p>,</p>
<p>Windecker</p>
<p>S</p>
<p>,</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Heidbuchel</p>
<p>H</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Prendergast</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>The management of secondary mitral regurgitation in patients with
heart failure: a joint position statement from the Heart Failure
Association (HFA), European Association of Cardiovascular Imaging
(EACVI), European Heart Rhythm Association (EHRA), and European
Association of Percutaneous Cardiovascular Interventions (EAPCI) of the
ESC</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>1254</p>
<p>–</p>
<p>1269</p>
<p>.</p>
<p>616</p>
<p>Adamo</p>
<p>M</p>
<p>,</p>
<p>Fiorelli</p>
<p>F</p>
<p>,</p>
<p>Melica</p>
<p>B</p>
<p>,</p>
<p>D’Ortona</p>
<p>R</p>
<p>,</p>
<p>Lupi</p>
<p>L</p>
<p>,</p>
<p>Giannini</p>
<p>C</p>
<p>,</p>
<p>Silva</p>
<p>G</p>
<p>,</p>
<p>Fiorina</p>
<p>C</p>
<p>,</p>
<p>Branca</p>
<p>L</p>
<p>,</p>
<p>Chiari</p>
<p>E</p>
<p>,</p>
<p>Chizzola</p>
<p>G</p>
<p>,</p>
<p>Spontoni</p>
<p>P</p>
<p>,</p>
<p>Espada Guerreiro</p>
<p>C</p>
<p>,</p>
<p>Curello</p>
<p>S</p>
<p>,</p>
<p>Petronio</p>
<p>AS</p>
<p>,</p>
<p>Metra</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>COAPT-like profile predicts long-term outcomes in patients with
secondary mitral regurgitation undergoing MitraClip implantation</p>
<p>.</p>
<p>JACC Cardiovasc Interv</p>
<p>2021</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>15</p>
<p>–</p>
<p>25</p>
<p>.</p>
<p>617</p>
<p>Godino</p>
<p>C</p>
<p>,</p>
<p>Munafo</p>
<p>A</p>
<p>,</p>
<p>Scotti</p>
<p>A</p>
<p>,</p>
<p>Estevez-Loureiro</p>
<p>R</p>
<p>,</p>
<p>Portoles Hernandez</p>
<p>A</p>
<p>,</p>
<p>Arzamendi</p>
<p>D</p>
<p>,</p>
<p>Fernandez Peregrina</p>
<p>E</p>
<p>,</p>
<p>Taramasso</p>
<p>M</p>
<p>,</p>
<p>Fam</p>
<p>NP</p>
<p>,</p>
<p>Ho</p>
<p>EC</p>
<p>,</p>
<p>Asgar</p>
<p>A</p>
<p>,</p>
<p>Vitrella</p>
<p>G</p>
<p>,</p>
<p>Raineri</p>
<p>C</p>
<p>,</p>
<p>Adamo</p>
<p>M</p>
<p>,</p>
<p>Fiorina</p>
<p>C</p>
<p>,</p>
<p>Montalto</p>
<p>C</p>
<p>,</p>
<p>Fraccaro</p>
<p>C</p>
<p>,</p>
<p>Giannini</p>
<p>C</p>
<p>,</p>
<p>Fiorelli</p>
<p>F</p>
<p>,</p>
<p>Popolo Rubbio</p>
<p>A</p>
<p>,</p>
<p>Ooms</p>
<p>JF</p>
<p>,</p>
<p>Compagnone</p>
<p>M</p>
<p>,</p>
<p>Maffeo</p>
<p>D</p>
<p>,</p>
<p>Bettari</p>
<p>L</p>
<p>,</p>
<p>Furholz</p>
<p>M</p>
<p>,</p>
<p>Tamburino</p>
<p>C</p>
<p>,</p>
<p>Petronio</p>
<p>AS</p>
<p>,</p>
<p>Grasso</p>
<p>C</p>
<p>,</p>
<p>Agricola</p>
<p>E</p>
<p>,</p>
<p>Van Mieghem</p>
<p>NM</p>
<p>,</p>
<p>Tarantini</p>
<p>G</p>
<p>,</p>
<p>Curello</p>
<p>S</p>
<p>,</p>
<p>Praz</p>
<p>F</p>
<p>,</p>
<p>Pascual</p>
<p>I</p>
<p>,</p>
<p>Potena</p>
<p>L</p>
<p>,</p>
<p>Colombo</p>
<p>A</p>
<p>,</p>
<p>Maisano</p>
<p>F</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Margonato</p>
<p>A</p>
<p>,</p>
<p>Crimi</p>
<p>G</p>
<p>,</p>
<p>Saia</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>MitraClip in secondary mitral regurgitation as a bridge to heart
transplantation: 1-year outcomes from the International MitraBridge
Registry</p>
<p>.</p>
<p>J Heart Lung Transplant</p>
<p>2020</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>1353</p>
<p>–</p>
<p>1362</p>
<p>.</p>
<p>618</p>
<p>Witte</p>
<p>KK</p>
<p>,</p>
<p>Lipiecki</p>
<p>J</p>
<p>,</p>
<p>Siminiak</p>
<p>T</p>
<p>,</p>
<p>Meredith</p>
<p>IT</p>
<p>,</p>
<p>Malkin</p>
<p>CJ</p>
<p>,</p>
<p>Goldberg</p>
<p>SL</p>
<p>,</p>
<p>Stark</p>
<p>MA</p>
<p>,</p>
<p>von Bardeleben</p>
<p>RS</p>
<p>,</p>
<p>Cremer</p>
<p>PC</p>
<p>,</p>
<p>Jaber</p>
<p>WA</p>
<p>,</p>
<p>Celermajer</p>
<p>DS</p>
<p>,</p>
<p>Kaye</p>
<p>DM</p>
<p>,</p>
<p>Sievert</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>The REDUCE FMR trial: a randomized sham-controlled study of
percutaneous mitral annuloplasty in functional mitral regurgitation</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>945</p>
<p>–</p>
<p>955</p>
<p>.</p>
<p>619</p>
<p>Geyer</p>
<p>M</p>
<p>,</p>
<p>Keller</p>
<p>K</p>
<p>,</p>
<p>Sotiriou</p>
<p>E</p>
<p>,</p>
<p>Tamm</p>
<p>AR</p>
<p>,</p>
<p>Ruf</p>
<p>TF</p>
<p>,</p>
<p>Kreidel</p>
<p>F</p>
<p>,</p>
<p>Beiras-Fernandez</p>
<p>A</p>
<p>,</p>
<p>Gori</p>
<p>T</p>
<p>,</p>
<p>Schulz</p>
<p>E</p>
<p>,</p>
<p>Munzel</p>
<p>T</p>
<p>,</p>
<p>von Bardeleben</p>
<p>RS.</p>
<p>Association of transcatheter direct mitral annuloplasty with acute
anatomic, haemodynamic, and clinical outcomes in severe mitral valve
regurgitation</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>3336</p>
<p>–</p>
<p>3344</p>
<p>.</p>
<p>620</p>
<p>Giallauria</p>
<p>F</p>
<p>,</p>
<p>Di Lorenzo</p>
<p>A</p>
<p>,</p>
<p>Parlato</p>
<p>A</p>
<p>,</p>
<p>Testa</p>
<p>C</p>
<p>,</p>
<p>Bobbio</p>
<p>E</p>
<p>,</p>
<p>Vigorito</p>
<p>C</p>
<p>,</p>
<p>Coats</p>
<p>AJS.</p>
<p>Individual patient data meta-analysis of the effects of the
CARILLON<sup>®</sup> mitral contour system</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>3383</p>
<p>–</p>
<p>3391</p>
<p>.</p>
<p>621</p>
<p>Lipiecki</p>
<p>J</p>
<p>,</p>
<p>Fahrat</p>
<p>H</p>
<p>,</p>
<p>Monzy</p>
<p>S</p>
<p>,</p>
<p>Caillot</p>
<p>N</p>
<p>,</p>
<p>Siminiak</p>
<p>T</p>
<p>,</p>
<p>Johnson</p>
<p>T</p>
<p>,</p>
<p>Vogt</p>
<p>S</p>
<p>,</p>
<p>Stark</p>
<p>MA</p>
<p>,</p>
<p>Goldberg</p>
<p>SL.</p>
<p>Long-term prognosis of patients treated by coronary sinus-based
percutaneous annuloplasty: single centre experience</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:3329–3335.</p>
<p>622</p>
<p>Ruf</p>
<p>TF</p>
<p>,</p>
<p>Kreidel</p>
<p>F</p>
<p>,</p>
<p>Tamm</p>
<p>AR</p>
<p>,</p>
<p>Geyer</p>
<p>M</p>
<p>,</p>
<p>Hahad</p>
<p>O</p>
<p>,</p>
<p>Zirbs</p>
<p>JC</p>
<p>,</p>
<p>Schwidtal</p>
<p>BL</p>
<p>,</p>
<p>Beiras-Fernandez</p>
<p>A</p>
<p>,</p>
<p>Witte</p>
<p>KK</p>
<p>,</p>
<p>Munzel</p>
<p>T</p>
<p>,</p>
<p>von Bardeleben</p>
<p>RS.</p>
<p>Transcatheter indirect mitral annuloplasty induces annular and left
atrial remodelling in secondary mitral regurgitation</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>1400</p>
<p>–</p>
<p>1408</p>
<p>.</p>
<p>623</p>
<p>Sorajja</p>
<p>P</p>
<p>,</p>
<p>Moat</p>
<p>N</p>
<p>,</p>
<p>Badhwar</p>
<p>V</p>
<p>,</p>
<p>Walters</p>
<p>D</p>
<p>,</p>
<p>Paone</p>
<p>G</p>
<p>,</p>
<p>Bethea</p>
<p>B</p>
<p>,</p>
<p>Bae</p>
<p>R</p>
<p>,</p>
<p>Dahle</p>
<p>G</p>
<p>,</p>
<p>Mumtaz</p>
<p>M</p>
<p>,</p>
<p>Grayburn</p>
<p>P</p>
<p>,</p>
<p>Kapadia</p>
<p>S</p>
<p>,</p>
<p>Babaliaros</p>
<p>V</p>
<p>,</p>
<p>Guerrero</p>
<p>M</p>
<p>,</p>
<p>Satler</p>
<p>L</p>
<p>,</p>
<p>Thourani</p>
<p>V</p>
<p>,</p>
<p>Bedogni</p>
<p>F</p>
<p>,</p>
<p>Rizik</p>
<p>D</p>
<p>,</p>
<p>Denti</p>
<p>P</p>
<p>,</p>
<p>Dumonteil</p>
<p>N</p>
<p>,</p>
<p>Modine</p>
<p>T</p>
<p>,</p>
<p>Sinhal</p>
<p>A</p>
<p>,</p>
<p>Chuang</p>
<p>ML</p>
<p>,</p>
<p>Popma</p>
<p>JJ</p>
<p>,</p>
<p>Blanke</p>
<p>P</p>
<p>,</p>
<p>Leipsic</p>
<p>J</p>
<p>,</p>
<p>Muller</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Initial feasibility study of a new transcatheter mitral prosthesis:
the first 100 patients</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>73</p>
<p>:</p>
<p>1250</p>
<p>–</p>
<p>1260</p>
<p>.</p>
<p>624</p>
<p>Zack</p>
<p>CJ</p>
<p>,</p>
<p>Fender</p>
<p>EA</p>
<p>,</p>
<p>Chandrashekar</p>
<p>P</p>
<p>,</p>
<p>Reddy</p>
<p>YNV</p>
<p>,</p>
<p>Bennett</p>
<p>CE</p>
<p>,</p>
<p>Stulak</p>
<p>JM</p>
<p>,</p>
<p>Miller</p>
<p>VM</p>
<p>,</p>
<p>Nishimura</p>
<p>RA.</p>
<p>National trends and outcomes in isolated tricuspid valve surgery</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>70</p>
<p>:</p>
<p>2953</p>
<p>–</p>
<p>2960</p>
<p>.</p>
<p>625</p>
<p>Taramasso</p>
<p>M</p>
<p>,</p>
<p>Benfari</p>
<p>G</p>
<p>,</p>
<p>van der Bijl</p>
<p>P</p>
<p>,</p>
<p>Alessandrini</p>
<p>H</p>
<p>,</p>
<p>Attinger-Toller</p>
<p>A</p>
<p>,</p>
<p>Biasco</p>
<p>L</p>
<p>,</p>
<p>Lurz</p>
<p>P</p>
<p>,</p>
<p>Braun</p>
<p>D</p>
<p>,</p>
<p>Brochet</p>
<p>E</p>
<p>,</p>
<p>Connelly</p>
<p>KA</p>
<p>,</p>
<p>de Bruijn</p>
<p>S</p>
<p>,</p>
<p>Denti</p>
<p>P</p>
<p>,</p>
<p>Deuschl</p>
<p>F</p>
<p>,</p>
<p>Estevez-Loureiro</p>
<p>R</p>
<p>,</p>
<p>Fam</p>
<p>N</p>
<p>,</p>
<p>Frerker</p>
<p>C</p>
<p>,</p>
<p>Gavazzoni</p>
<p>M</p>
<p>,</p>
<p>Hausleiter</p>
<p>J</p>
<p>,</p>
<p>Ho</p>
<p>E</p>
<p>,</p>
<p>Juliard</p>
<p>JM</p>
<p>,</p>
<p>Kaple</p>
<p>R</p>
<p>,</p>
<p>Besler</p>
<p>C</p>
<p>,</p>
<p>Kodali</p>
<p>S</p>
<p>,</p>
<p>Kreidel</p>
<p>F</p>
<p>,</p>
<p>Kuck</p>
<p>KH</p>
<p>,</p>
<p>Latib</p>
<p>A</p>
<p>,</p>
<p>Lauten</p>
<p>A</p>
<p>,</p>
<p>Monivas</p>
<p>V</p>
<p>,</p>
<p>Mehr</p>
<p>M</p>
<p>,</p>
<p>Muntane-Carol</p>
<p>G</p>
<p>,</p>
<p>Nazif</p>
<p>T</p>
<p>,</p>
<p>Nickening</p>
<p>G</p>
<p>,</p>
<p>Pedrazzini</p>
<p>G</p>
<p>,</p>
<p>Philippon</p>
<p>F</p>
<p>,</p>
<p>Pozzoli</p>
<p>A</p>
<p>,</p>
<p>Praz</p>
<p>F</p>
<p>,</p>
<p>Puri</p>
<p>R</p>
<p>,</p>
<p>Rodes-Cabau</p>
<p>J</p>
<p>,</p>
<p>Schafer</p>
<p>U</p>
<p>,</p>
<p>Schofer</p>
<p>J</p>
<p>,</p>
<p>Sievert</p>
<p>H</p>
<p>,</p>
<p>Tang</p>
<p>GHL</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Topilsky</p>
<p>Y</p>
<p>,</p>
<p>Rommel</p>
<p>KP</p>
<p>,</p>
<p>Delgado</p>
<p>V</p>
<p>,</p>
<p>Vahanian</p>
<p>A</p>
<p>,</p>
<p>Von Bardeleben</p>
<p>RS</p>
<p>,</p>
<p>Webb</p>
<p>JG</p>
<p>,</p>
<p>Weber</p>
<p>M</p>
<p>,</p>
<p>Windecker</p>
<p>S</p>
<p>,</p>
<p>Winkel</p>
<p>M</p>
<p>,</p>
<p>Zuber</p>
<p>M</p>
<p>,</p>
<p>Leon</p>
<p>MB</p>
<p>,</p>
<p>Hahn</p>
<p>RT</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Enriquez-Sarano</p>
<p>M</p>
<p>,</p>
<p>Maisano</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Transcatheter versus medical treatment of patients with symptomatic
severe tricuspid regurgitation</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>74</p>
<p>:</p>
<p>2998</p>
<p>–</p>
<p>3008</p>
<p>.</p>
<p>626</p>
<p>Rapsomaniki</p>
<p>E</p>
<p>,</p>
<p>Timmis</p>
<p>A</p>
<p>,</p>
<p>George</p>
<p>J</p>
<p>,</p>
<p>Pujades-Rodriguez</p>
<p>M</p>
<p>,</p>
<p>Shah</p>
<p>AD</p>
<p>,</p>
<p>Denaxas</p>
<p>S</p>
<p>,</p>
<p>White</p>
<p>IR</p>
<p>,</p>
<p>Caulfield</p>
<p>MJ</p>
<p>,</p>
<p>Deanfield</p>
<p>JE</p>
<p>,</p>
<p>Smeeth</p>
<p>L</p>
<p>,</p>
<p>Williams</p>
<p>B</p>
<p>,</p>
<p>Hingorani</p>
<p>A</p>
<p>,</p>
<p>Hemingway</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Blood pressure and incidence of twelve cardiovascular diseases:
lifetime risks, healthy life-years lost, and age-specific associations
in 1.25 million people</p>
<p>.</p>
<p>Lancet</p>
<p>2014</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>1899</p>
<p>–</p>
<p>1911</p>
<p>.</p>
<p>627</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Rouleau</p>
<p>J</p>
<p>,</p>
<p>Sharpe</p>
<p>N</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Straub</p>
<p>M</p>
<p>,</p>
<p>Wiltse</p>
<p>C</p>
<p>,</p>
<p>Wright</p>
<p>TJ</p>
<p>MOXCON Investigators</p>
<p>.</p>
<p>Adverse mortality effect of central sympathetic inhibition with
sustained-release moxonidine in patients with heart failure (MOXCON)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2003</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>659</p>
<p>–</p>
<p>667</p>
<p>.</p>
<p>628</p>
<p>Kato</p>
<p>S</p>
<p>,</p>
<p>Onishi</p>
<p>K</p>
<p>,</p>
<p>Yamanaka</p>
<p>T</p>
<p>,</p>
<p>Takamura</p>
<p>T</p>
<p>,</p>
<p>Dohi</p>
<p>K</p>
<p>,</p>
<p>Yamada</p>
<p>N</p>
<p>,</p>
<p>Wada</p>
<p>H</p>
<p>,</p>
<p>Nobori</p>
<p>T</p>
<p>,</p>
<p>Ito</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Exaggerated hypertensive response to exercise in patients with
diastolic heart failure</p>
<p>.</p>
<p>Hypertens Res</p>
<p>2008</p>
<p>;</p>
<p>31</p>
<p>:</p>
<p>679</p>
<p>–</p>
<p>684</p>
<p>.</p>
<p>629</p>
<p>Uijl</p>
<p>A</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Vaartjes</p>
<p>I</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Brugts</p>
<p>JJ</p>
<p>,</p>
<p>Linssen</p>
<p>GCM</p>
<p>,</p>
<p>van Empel</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Asselbergs</p>
<p>FW</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Koudstaal</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Identification of distinct phenotypic clusters in heart failure with
preserved ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:973–982.</p>
<p>630</p>
<p>Thomopoulos</p>
<p>C</p>
<p>,</p>
<p>Parati</p>
<p>G</p>
<p>,</p>
<p>Zanchetti</p>
<ol type="A">
<li></li>
</ol>
<p>Effects of blood pressure-lowering treatment on cardiovascular
outcomes and mortality: 14 - effects of different classes of
antihypertensive drugs in older and younger patients: overview and
meta-analysis</p>
<p>.</p>
<p>J Hypertens</p>
<p>2018</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>1637</p>
<p>–</p>
<p>1647</p>
<p>.</p>
<p>631</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Pareek</p>
<p>M</p>
<p>,</p>
<p>Kristensen</p>
<p>AMD</p>
<p>,</p>
<p>Biering-Sorensen</p>
<p>T</p>
<p>,</p>
<p>Byrne</p>
<p>C</p>
<p>,</p>
<p>Almarzooq</p>
<p>Z</p>
<p>,</p>
<p>Olesen</p>
<p>TB</p>
<p>,</p>
<p>Olsen</p>
<p>MH</p>
<p>,</p>
<p>Bhatt</p>
<ol start="550" type="I">
<li></li>
</ol>
<p>Prevention of heart failure events with intensive versus standard
blood pressure lowering across the spectrum of kidney function and
albuminuria: a SPRINT substudy</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>384</p>
<p>–</p>
<p>392</p>
<p>.</p>
<p>632</p>
<p>Fagard</p>
<p>RH</p>
<p>,</p>
<p>Celis</p>
<p>H</p>
<p>,</p>
<p>Thijs</p>
<p>L</p>
<p>,</p>
<p>Wouters</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Regression of left ventricular mass by antihypertensive treatment: a
meta-analysis of randomized comparative studies</p>
<p>.</p>
<p>Hypertension</p>
<p>2009</p>
<p>;</p>
<p>54</p>
<p>:</p>
<p>1084</p>
<p>–</p>
<p>1091</p>
<p>.</p>
<p>633</p>
<p>Cautela</p>
<p>J</p>
<p>,</p>
<p>Tartiere</p>
<p>JM</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Bellemain-Appaix</p>
<p>A</p>
<p>,</p>
<p>Theron</p>
<p>A</p>
<p>,</p>
<p>Tibi</p>
<p>T</p>
<p>,</p>
<p>Januzzi</p>
<p>JL</p>
<p>Jr.,</p>
<p>Roubille</p>
<p>F</p>
<p>,</p>
<p>Girerd</p>
<ol start="14" type="A">
<li></li>
</ol>
<p>Management of low blood pressure in ambulatory heart failure with
reduced ejection fraction patients</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1357</p>
<p>–</p>
<p>1365</p>
<p>.</p>
<p>634</p>
<p>Kang</p>
<p>SH</p>
<p>,</p>
<p>Kim</p>
<p>J</p>
<p>,</p>
<p>Park</p>
<p>JJ</p>
<p>,</p>
<p>Oh</p>
<p>IY</p>
<p>,</p>
<p>Yoon</p>
<p>CH</p>
<p>,</p>
<p>Kim</p>
<p>HJ</p>
<p>,</p>
<p>Kim</p>
<p>K</p>
<p>,</p>
<p>Choi</p>
<p>DJ.</p>
<p>Risk of stroke in congestive heart failure with and without atrial
fibrillation</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2017</p>
<p>;</p>
<p>248</p>
<p>:</p>
<p>182</p>
<p>–</p>
<p>187</p>
<p>.</p>
<p>635</p>
<p>Abdul-Rahim</p>
<p>AH</p>
<p>,</p>
<p>Perez</p>
<p>AC</p>
<p>,</p>
<p>Fulton</p>
<p>RL</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Latini</p>
<p>R</p>
<p>,</p>
<p>Tognoni</p>
<p>G</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Lip</p>
<p>GY</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Lees</p>
<p>KR</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Investigators of the Controlled Rosuvastatin Multinational Study in
Heart Failure (CORONA), GISSI-Heart Failure (GISSI-HF) Committees and
Investigators. Risk of stroke in chronic heart failure patients without
atrial fibrillation: analysis of the Controlled Rosuvastatin in
Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per
lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure
(GISSI-HF) trials</p>
<p>.</p>
<p>Circulation</p>
<p>2015</p>
<p>;</p>
<p>131</p>
<p>:</p>
<p>1486</p>
<p>–</p>
<p>1494; discussion 1494</p>
<p>.</p>
<p>636</p>
<p>Abdul-Rahim</p>
<p>AH</p>
<p>,</p>
<p>Perez</p>
<p>AC</p>
<p>,</p>
<p>MacIsaac</p>
<p>RL</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Carson</p>
<p>PE</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>McKelvie</p>
<p>RS</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Lip</p>
<p>GYH</p>
<p>,</p>
<p>Lees</p>
<p>KR</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Candesartan in Heart failure Assessment of Reduction in Mortality and
Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart
Failure with Preserved Systolic Function (I-Preserve) Steering
Committees. Risk of stroke in chronic heart failure patients with
preserved ejection fraction, but without atrial fibrillation: analysis
of the CHARM-Preserved and I-Preserve trials</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>742</p>
<p>–</p>
<p>750</p>
<p>.</p>
<p>637</p>
<p>Mehra</p>
<p>MR</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Fu</p>
<p>M</p>
<p>,</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Byra</p>
<p>WM</p>
<p>,</p>
<p>Spiro</p>
<p>TE</p>
<p>,</p>
<p>Deng</p>
<p>H</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Greenberg</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>A comprehensive analysis of the effects of rivaroxaban on stroke or
transient ischaemic attack in patients with heart failure, coronary
artery disease, and sinus rhythm: the COMMANDER HF trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>3593</p>
<p>–</p>
<p>3602</p>
<p>.</p>
<p>638</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Chudasama</p>
<p>R</p>
<p>,</p>
<p>Lane</p>
<p>DA</p>
<p>,</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>Lip</p>
<p>GY.</p>
<p>Atrial fibrillation and heart failure due to reduced versus preserved
ejection fraction: a systematic review and meta-analysis of death and
adverse outcomes</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2016</p>
<p>;</p>
<p>203</p>
<p>:</p>
<p>660</p>
<p>–</p>
<p>666</p>
<p>.</p>
<p>639</p>
<p>Adelborg</p>
<p>K</p>
<p>,</p>
<p>Szepligeti</p>
<p>S</p>
<p>,</p>
<p>Sundboll</p>
<p>J</p>
<p>,</p>
<p>Horvath-Puho</p>
<p>E</p>
<p>,</p>
<p>Henderson</p>
<p>VW</p>
<p>,</p>
<p>Ording</p>
<p>A</p>
<p>,</p>
<p>Pedersen</p>
<p>L</p>
<p>,</p>
<p>Sorensen</p>
<p>HT.</p>
<p>Risk of stroke in patients with heart failure: a population-based
30-year cohort study</p>
<p>.</p>
<p>Stroke</p>
<p>2017</p>
<p>;</p>
<p>48</p>
<p>:</p>
<p>1161</p>
<p>–</p>
<p>1168</p>
<p>.</p>
<p>640</p>
<p>Witt</p>
<p>BJ</p>
<p>,</p>
<p>Brown</p>
<p>RD</p>
<p>Jr,</p>
<p>Jacobsen</p>
<p>SJ</p>
<p>,</p>
<p>Weston</p>
<p>SA</p>
<p>,</p>
<p>Ballman</p>
<p>KV</p>
<p>,</p>
<p>Meverden</p>
<p>RA</p>
<p>,</p>
<p>Roger</p>
<p>VL.</p>
<p>Ischemic stroke after heart failure: a community-based study</p>
<p>.</p>
<p>Am Heart J</p>
<p>2006</p>
<p>;</p>
<p>152</p>
<p>:</p>
<p>102</p>
<p>–</p>
<p>109</p>
<p>.</p>
<p>641</p>
<p>Homma</p>
<p>S</p>
<p>,</p>
<p>Thompson</p>
<p>JL</p>
<p>,</p>
<p>Pullicino</p>
<p>PM</p>
<p>,</p>
<p>Levin</p>
<p>B</p>
<p>,</p>
<p>Freudenberger</p>
<p>RS</p>
<p>,</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Ammon</p>
<p>SE</p>
<p>,</p>
<p>Graham</p>
<p>S</p>
<p>,</p>
<p>Sacco</p>
<p>RL</p>
<p>,</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>Mohr</p>
<p>JP</p>
<p>,</p>
<p>Massie</p>
<p>BM</p>
<p>,</p>
<p>Labovitz</p>
<p>AJ</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Lok</p>
<p>DJ</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Estol</p>
<p>CJ</p>
<p>,</p>
<p>Lip</p>
<p>GY</p>
<p>,</p>
<p>Di Tullio</p>
<p>MR</p>
<p>,</p>
<p>Sanford</p>
<p>AR</p>
<p>,</p>
<p>Mejia</p>
<p>V</p>
<p>,</p>
<p>Gabriel</p>
<p>AP</p>
<p>,</p>
<p>del Valle</p>
<p>ML</p>
<p>,</p>
<p>Buchsbaum</p>
<p>R</p>
<p>, WARCEF Investigators</p>
<p>Warfarin and aspirin in patients with heart failure and sinus
rhythm</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2012</p>
<p>;</p>
<p>366</p>
<p>:</p>
<p>1859</p>
<p>–</p>
<p>1869</p>
<p>.</p>
<p>642</p>
<p>Hopper</p>
<p>I</p>
<p>,</p>
<p>Skiba</p>
<p>M</p>
<p>,</p>
<p>Krum</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Updated meta-analysis on antithrombotic therapy in patients with
heart failure and sinus rhythm</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>69</p>
<p>–</p>
<p>78</p>
<p>.</p>
<p>643</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Konig</p>
<p>T</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Mbakwem</p>
<p>A</p>
<p>,</p>
<p>Hamdan</p>
<p>R</p>
<p>,</p>
<p>Jackson</p>
<p>AM</p>
<p>,</p>
<p>Forsyth</p>
<p>P</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Johnson</p>
<p>MR</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Sliwa</p>
<ol start="11" type="A">
<li></li>
</ol>
<p>Pathophysiology, diagnosis and management of peripartum
cardiomyopathy: a position statement from the Heart Failure Association
of the European Society of Cardiology Study Group on peripartum
cardiomyopathy</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>827</p>
<p>–</p>
<p>843</p>
<p>.</p>
<p>644</p>
<p>Singh</p>
<p>DP</p>
<p>,</p>
<p>Patel</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Left ventricular non-compaction cardiomyopathy. In:</p>
<p>StatPearls [Internet].</p>
<p>Treasure Island (FL</p>
<p>):</p>
<p>StatPearls Publishing</p>
<p>;</p>
<p>2021</p>
<p>; PMID 30725710.</p>
<p>645</p>
<p>Subahi</p>
<p>A</p>
<p>,</p>
<p>Hassan</p>
<p>AAI</p>
<p>,</p>
<p>Abubakar</p>
<p>H</p>
<p>,</p>
<p>Ibrahim</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Isolated left ventricular non-compaction (LVNC) and recurrent
strokes: to anticoagulate or not to anticoagulate, that is the
question</p>
<p>.</p>
<p>BMJ Case Rep</p>
<p>2017</p>
<p>;</p>
<p>2017</p>
<p>:bcr2017220954.</p>
<p>646</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Paulus</p>
<p>WJ</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Cosentino</p>
<p>F</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Lopatin</p>
<p>Y</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Theodorakis</p>
<p>MJ</p>
<p>,</p>
<p>Wiggers</p>
<p>H</p>
<p>,</p>
<p>Lekakis</p>
<p>J</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Mamas</p>
<p>MA</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Seferovic</p>
<p>JP</p>
<p>,</p>
<p>Logue</p>
<p>J</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Riley</p>
<p>JP</p>
<p>,</p>
<p>Milinkovic</p>
<p>I</p>
<p>,</p>
<p>Polovina</p>
<p>M</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Type 2 diabetes mellitus and heart failure: a position statement from
the Heart Failure Association of the European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>853</p>
<p>–</p>
<p>872</p>
<p>.</p>
<p>647</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Huelsmann</p>
<p>M</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Polovina</p>
<p>MM</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Seferovic</p>
<p>J</p>
<p>,</p>
<p>Sari</p>
<p>I</p>
<p>,</p>
<p>Cosentino</p>
<p>F</p>
<p>,</p>
<p>Ambrosio</p>
<p>G</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>De Boer</p>
<p>RA</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Lopatin</p>
<p>Y</p>
<p>,</p>
<p>Volterrani</p>
<p>M</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Lyon</p>
<p>A</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Anker</p>
<p>S</p>
<p>,</p>
<p>Rosano</p>
<p>GMC.</p>
<p>European Society of Cardiology/Heart Failure Association position
paper on the role and safety of new glucose-lowering drugs in patients
with heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>196</p>
<p>–</p>
<p>213</p>
<p>.</p>
<p>648</p>
<p>Cosentino</p>
<p>F</p>
<p>,</p>
<p>Cannon</p>
<p>CP</p>
<p>,</p>
<p>Cherney</p>
<p>DZI</p>
<p>,</p>
<p>Masiukiewicz</p>
<p>U</p>
<p>,</p>
<p>Pratley</p>
<p>R</p>
<p>,</p>
<p>Dagogo-Jack</p>
<p>S</p>
<p>,</p>
<p>Frederich</p>
<p>R</p>
<p>,</p>
<p>Charbonnel</p>
<p>B</p>
<p>,</p>
<p>Mancuso</p>
<p>J</p>
<p>,</p>
<p>Shih</p>
<p>WJ</p>
<p>,</p>
<p>Terra</p>
<p>SG</p>
<p>,</p>
<p>Cater</p>
<p>NB</p>
<p>,</p>
<p>Gantz</p>
<p>I</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>VERTIS CV Investigators</p>
<p>.</p>
<p>Efficacy of ertugliflozin on heart failure-related events in patients
with type 2 diabetes mellitus and established atherosclerotic
cardiovascular disease: results of the VERTIS CV trial</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>142</p>
<p>:</p>
<p>2205</p>
<p>–</p>
<p>2215</p>
<p>.</p>
<p>649</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Shih</p>
<p>WJ</p>
<p>,</p>
<p>Cosentino</p>
<p>F</p>
<p>,</p>
<p>Charbonnel</p>
<p>B</p>
<p>,</p>
<p>Cherney</p>
<p>DZI</p>
<p>,</p>
<p>Dagogo-Jack</p>
<p>S</p>
<p>,</p>
<p>Pratley</p>
<p>R</p>
<p>,</p>
<p>Greenberg</p>
<p>M</p>
<p>,</p>
<p>Wang</p>
<p>S</p>
<p>,</p>
<p>Huyck</p>
<p>S</p>
<p>,</p>
<p>Gantz</p>
<p>I</p>
<p>,</p>
<p>Terra</p>
<p>SG</p>
<p>,</p>
<p>Masiukiewicz</p>
<p>U</p>
<p>,</p>
<p>Cannon</p>
<p>CP.</p>
<p>Association of SGLT2 inhibitors with cardiovascular and kidney
outcomes in patients with type 2 diabetes: a meta-analysis</p>
<p>.</p>
<p>JAMA Cardiol</p>
<p>2021</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>148</p>
<p>–</p>
<p>158</p>
<p>.</p>
<p>650</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Drexel</p>
<p>H</p>
<p>,</p>
<p>Ben Gal</p>
<p>T</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Anker</p>
<p>MS</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Lewis</p>
<p>BS</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Milicic</p>
<p>D</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Volterrani</p>
<p>M</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Coats</p>
<p>AJS.</p>
<p>Clinical practice update on heart failure 2019: pharmacotherapy,
procedures, devices and patient management. An expert consensus meeting
report of the Heart Failure Association of the European Society of
Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1169</p>
<p>–</p>
<p>1186</p>
<p>.</p>
<p>651</p>
<p>Eurich</p>
<p>DT</p>
<p>,</p>
<p>Weir</p>
<p>DL</p>
<p>,</p>
<p>Majumdar</p>
<p>SR</p>
<p>,</p>
<p>Tsuyuki</p>
<p>RT</p>
<p>,</p>
<p>Johnson</p>
<p>JA</p>
<p>,</p>
<p>Tjosvold</p>
<p>L</p>
<p>,</p>
<p>Vanderloo</p>
<p>SE</p>
<p>,</p>
<p>McAlister</p>
<p>FA.</p>
<p>Comparative safety and effectiveness of metformin in patients with
diabetes mellitus and heart failure: systematic review of observational
studies involving 34,000 patients</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>395</p>
<p>–</p>
<p>402</p>
<p>.</p>
<p>652</p>
<p>Andersson</p>
<p>C</p>
<p>,</p>
<p>Olesen</p>
<p>JB</p>
<p>,</p>
<p>Hansen</p>
<p>PR</p>
<p>,</p>
<p>Weeke</p>
<p>P</p>
<p>,</p>
<p>Norgaard</p>
<p>ML</p>
<p>,</p>
<p>Jorgensen</p>
<p>CH</p>
<p>,</p>
<p>Lange</p>
<p>T</p>
<p>,</p>
<p>Abildstrom</p>
<p>SZ</p>
<p>,</p>
<p>Schramm</p>
<p>TK</p>
<p>,</p>
<p>Vaag</p>
<p>A</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Gislason</p>
<p>GH.</p>
<p>Metformin treatment is associated with a low risk of mortality in
diabetic patients with heart failure: a retrospective nationwide cohort
study</p>
<p>.</p>
<p>Diabetologia</p>
<p>2010</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>2546</p>
<p>–</p>
<p>2553</p>
<p>.</p>
<p>653</p>
<p>Scirica</p>
<p>BM</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>Steg</p>
<p>PG</p>
<p>,</p>
<p>Davidson</p>
<p>J</p>
<p>,</p>
<p>Hirshberg</p>
<p>B</p>
<p>,</p>
<p>Ohman</p>
<p>P</p>
<p>,</p>
<p>Frederich</p>
<p>R</p>
<p>,</p>
<p>Wiviott</p>
<p>SD</p>
<p>,</p>
<p>Hoffman</p>
<p>EB</p>
<p>,</p>
<p>Cavender</p>
<p>MA</p>
<p>,</p>
<p>Udell</p>
<p>JA</p>
<p>,</p>
<p>Desai</p>
<p>NR</p>
<p>,</p>
<p>Mosenzon</p>
<p>O</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Ray</p>
<p>KK</p>
<p>,</p>
<p>Leiter</p>
<p>LA</p>
<p>,</p>
<p>Raz</p>
<p>I</p>
<p>,</p>
<p>SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes mellitus</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2013</p>
<p>;</p>
<p>369</p>
<p>:</p>
<p>1317</p>
<p>–</p>
<p>1326</p>
<p>.</p>
<p>654</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Cannon</p>
<p>CP</p>
<p>,</p>
<p>Cushman</p>
<p>WC</p>
<p>,</p>
<p>Bakris</p>
<p>GL</p>
<p>,</p>
<p>Menon</p>
<p>V</p>
<p>,</p>
<p>Perez</p>
<p>AT</p>
<p>,</p>
<p>Fleck</p>
<p>PR</p>
<p>,</p>
<p>Mehta</p>
<p>CR</p>
<p>,</p>
<p>Kupfer</p>
<p>S</p>
<p>,</p>
<p>Wilson</p>
<p>C</p>
<p>,</p>
<p>Lam</p>
<p>H</p>
<p>,</p>
<p>White</p>
<p>WB</p>
<p>,</p>
<p>EXAMINE Investigators. Heart failure and mortality outcomes in
patients with type 2 diabetes taking alogliptin versus placebo in
EXAMINE: a multicentre, randomised, double-blind trial</p>
<p>.</p>
<p>Lancet</p>
<p>2015</p>
<p>;</p>
<p>385</p>
<p>:</p>
<p>2067</p>
<p>–</p>
<p>2076</p>
<p>.</p>
<p>655</p>
<p>Green</p>
<p>JB</p>
<p>,</p>
<p>Bethel</p>
<p>MA</p>
<p>,</p>
<p>Armstrong</p>
<p>PW</p>
<p>,</p>
<p>Buse</p>
<p>JB</p>
<p>,</p>
<p>Engel</p>
<p>SS</p>
<p>,</p>
<p>Garg</p>
<p>J</p>
<p>,</p>
<p>Josse</p>
<p>R</p>
<p>,</p>
<p>Kaufman</p>
<p>KD</p>
<p>,</p>
<p>Koglin</p>
<p>J</p>
<p>,</p>
<p>Korn</p>
<p>S</p>
<p>,</p>
<p>Lachin</p>
<p>JM</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Pencina</p>
<p>MJ</p>
<p>,</p>
<p>Standl</p>
<p>E</p>
<p>,</p>
<p>Stein</p>
<p>PP</p>
<p>,</p>
<p>Suryawanshi</p>
<p>S</p>
<p>,</p>
<p>Van de Werf</p>
<p>F</p>
<p>,</p>
<p>Peterson</p>
<p>ED</p>
<p>,</p>
<p>Holman</p>
<p>RR</p>
<p>,</p>
<p>TECOS Study Group</p>
<p>.</p>
<p>Effect of sitagliptin on cardiovascular outcomes in type 2
diabetes</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>373</p>
<p>:</p>
<p>232</p>
<p>–</p>
<p>242</p>
<p>.</p>
<p>656</p>
<p>Rosenstock</p>
<p>J</p>
<p>,</p>
<p>Perkovic</p>
<p>V</p>
<p>,</p>
<p>Johansen</p>
<p>OE</p>
<p>,</p>
<p>Cooper</p>
<p>ME</p>
<p>,</p>
<p>Kahn</p>
<p>SE</p>
<p>,</p>
<p>Marx</p>
<p>N</p>
<p>,</p>
<p>Alexander</p>
<p>JH</p>
<p>,</p>
<p>Pencina</p>
<p>M</p>
<p>,</p>
<p>Toto</p>
<p>RD</p>
<p>,</p>
<p>Wanner</p>
<p>C</p>
<p>,</p>
<p>Zinman</p>
<p>B</p>
<p>,</p>
<p>Woerle</p>
<p>HJ</p>
<p>,</p>
<p>Baanstra</p>
<p>D</p>
<p>,</p>
<p>Pfarr</p>
<p>E</p>
<p>,</p>
<p>Schnaidt</p>
<p>S</p>
<p>,</p>
<p>Meinicke</p>
<p>T</p>
<p>,</p>
<p>George</p>
<p>JT</p>
<p>,</p>
<p>von Eynatten</p>
<p>M</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>, CARMELINA Investigators</p>
<p>Effect of linagliptin vs placebo on major cardiovascular events in
adults with type 2 diabetes and high cardiovascular and renal risk: the
CARMELINA randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2019</p>
<p>;</p>
<p>321</p>
<p>:</p>
<p>69</p>
<p>–</p>
<p>79</p>
<p>.</p>
<p>657</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Bolli</p>
<p>GB</p>
<p>,</p>
<p>Lukashevich</p>
<p>V</p>
<p>,</p>
<p>Kozlovski</p>
<p>P</p>
<p>,</p>
<p>Kothny</p>
<p>W</p>
<p>,</p>
<p>Lewsey</p>
<p>JD</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>VIVIDD Trial Committees and Investigators. Effects of vildagliptin on
ventricular function in patients with type 2 diabetes mellitus and heart
failure: a randomized placebo-controlled trial</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>8</p>
<p>–</p>
<p>17</p>
<p>.</p>
<p>658</p>
<p>Sinha</p>
<p>B</p>
<p>,</p>
<p>Ghosal</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors
and GLP1 receptor analogues on cardiovascular death, myocardial
infarction, stroke and hospitalization for heart failure</p>
<p>.</p>
<p>Diabetes Res Clin Pract</p>
<p>2019</p>
<p>;</p>
<p>150</p>
<p>:</p>
<p>8</p>
<p>–</p>
<p>16</p>
<p>.</p>
<p>659</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>D’Amore</p>
<p>C</p>
<p>,</p>
<p>Federici</p>
<p>M</p>
<p>,</p>
<p>De Martino</p>
<p>F</p>
<p>,</p>
<p>Dellegrottaglie</p>
<p>S</p>
<p>,</p>
<p>Marciano</p>
<p>C</p>
<p>,</p>
<p>Ferrazzano</p>
<p>F</p>
<p>,</p>
<p>Losco</p>
<p>T</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Trimarco</p>
<p>B</p>
<p>,</p>
<p>Rosano</p>
<p>GM</p>
<p>,</p>
<p>Perrone-Filardi</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose
linked cotransporter-2 inhibitors on cardiovascular events in patients
with type 2 diabetes mellitus: a meta-analysis</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2016</p>
<p>;</p>
<p>220</p>
<p>:</p>
<p>595</p>
<p>–</p>
<p>601</p>
<p>.</p>
<p>660</p>
<p>Kristensen</p>
<p>SL</p>
<p>,</p>
<p>Rorth</p>
<p>R</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Docherty</p>
<p>KF</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Preiss</p>
<p>D</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor
agonists in patients with type 2 diabetes: a systematic review and
meta-analysis of cardiovascular outcome trials</p>
<p>.</p>
<p>Lancet Diabetes Endocrinol</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>776</p>
<p>–</p>
<p>785</p>
<p>.</p>
<p>661</p>
<p>Jorsal</p>
<p>A</p>
<p>,</p>
<p>Kistorp</p>
<p>C</p>
<p>,</p>
<p>Holmager</p>
<p>P</p>
<p>,</p>
<p>Tougaard</p>
<p>RS</p>
<p>,</p>
<p>Nielsen</p>
<p>R</p>
<p>,</p>
<p>Hanselmann</p>
<p>A</p>
<p>,</p>
<p>Nilsson</p>
<p>B</p>
<p>,</p>
<p>Moller</p>
<p>JE</p>
<p>,</p>
<p>Hjort</p>
<p>J</p>
<p>,</p>
<p>Rasmussen</p>
<p>J</p>
<p>,</p>
<p>Boesgaard</p>
<p>TW</p>
<p>,</p>
<p>Schou</p>
<p>M</p>
<p>,</p>
<p>Videbaek</p>
<p>L</p>
<p>,</p>
<p>Gustafsson</p>
<p>I</p>
<p>,</p>
<p>Flyvbjerg</p>
<p>A</p>
<p>,</p>
<p>Wiggers</p>
<p>H</p>
<p>,</p>
<p>Tarnow</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Effect of liraglutide, a glucagon-like peptide-1 analogue, on left
ventricular function in stable chronic heart failure patients with and
without diabetes (LIVE)-a multicentre, double-blind, randomised,
placebo-controlled trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>69</p>
<p>–</p>
<p>77</p>
<p>.</p>
<p>662</p>
<p>Margulies</p>
<p>KB</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Oliveira</p>
<p>GH</p>
<p>,</p>
<p>Cole</p>
<p>R</p>
<p>,</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>Whellan</p>
<p>DJ</p>
<p>,</p>
<p>Kiernan</p>
<p>MS</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Shah</p>
<p>MR</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>Cappola</p>
<p>TP</p>
<p>,</p>
<p>NHLBI Heart Failure Clinical Research Network</p>
<p>.</p>
<p>Effects of liraglutide on clinical stability among patients with
advanced heart failure and reduced ejection fraction: a randomized
clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2016</p>
<p>;</p>
<p>316</p>
<p>:</p>
<p>500</p>
<p>–</p>
<p>508</p>
<p>.</p>
<p>663</p>
<p>Gerstein</p>
<p>HC</p>
<p>,</p>
<p>Jung</p>
<p>H</p>
<p>,</p>
<p>Ryden</p>
<p>L</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Gilbert</p>
<p>RE</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>ORIGIN Investigators</p>
<p>.</p>
<p>Effect of basal insulin glargine on first and recurrent episodes of
heart failure hospitalization: the ORIGIN trial (Outcome Reduction With
Initial Glargine Intervention)</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>137</p>
<p>:</p>
<p>88</p>
<p>–</p>
<p>90</p>
<p>.</p>
<p>664</p>
<p>Cosmi</p>
<p>F</p>
<p>,</p>
<p>Shen</p>
<p>L</p>
<p>,</p>
<p>Magnoli</p>
<p>M</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Cohn</p>
<p>JN</p>
<p>,</p>
<p>Cosmi</p>
<p>D</p>
<p>,</p>
<p>De Berardis</p>
<p>G</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Franzosi</p>
<p>MG</p>
<p>,</p>
<p>Gullestad</p>
<p>L</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Lepore</p>
<p>V</p>
<p>,</p>
<p>Lucisano</p>
<p>G</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Masson</p>
<p>S</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Nicolucci</p>
<p>A</p>
<p>,</p>
<p>Petrarolo</p>
<p>V</p>
<p>,</p>
<p>Robusto</p>
<p>F</p>
<p>,</p>
<p>Staszewsky</p>
<p>L</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Teli</p>
<p>R</p>
<p>,</p>
<p>Tognoni</p>
<p>G</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Latini</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Treatment with insulin is associated with worse outcome in patients
with chronic heart failure and diabetes</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>888</p>
<p>–</p>
<p>895</p>
<p>.</p>
<p>665</p>
<p>Shen</p>
<p>L</p>
<p>,</p>
<p>Rorth</p>
<p>R</p>
<p>,</p>
<p>Cosmi</p>
<p>D</p>
<p>,</p>
<p>Kristensen</p>
<p>SL</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Cosmi</p>
<p>F</p>
<p>,</p>
<p>Latini</p>
<p>R</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Carson</p>
<p>PE</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>McKelvie</p>
<p>RS</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Staszewsky</p>
<p>L</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Huynh</p>
<p>T</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Insulin treatment and clinical outcomes in patients with diabetes and
heart failure with preserved ejection fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>974</p>
<p>–</p>
<p>984</p>
<p>.</p>
<p>666</p>
<p>Tzoulaki</p>
<p>I</p>
<p>,</p>
<p>Molokhia</p>
<p>M</p>
<p>,</p>
<p>Curcin</p>
<p>V</p>
<p>,</p>
<p>Little</p>
<p>MP</p>
<p>,</p>
<p>Millett</p>
<p>CJ</p>
<p>,</p>
<p>Ng</p>
<p>A</p>
<p>,</p>
<p>Hughes</p>
<p>RI</p>
<p>,</p>
<p>Khunti</p>
<p>K</p>
<p>,</p>
<p>Wilkins</p>
<p>MR</p>
<p>,</p>
<p>Majeed</p>
<p>A</p>
<p>,</p>
<p>Elliott</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Risk of cardiovascular disease and all cause mortality among patients
with type 2 diabetes prescribed oral antidiabetes drugs: retrospective
cohort study using UK general practice research database</p>
<p>.</p>
<p>BMJ</p>
<p>2009</p>
<p>;</p>
<p>339</p>
<p>:</p>
<p>b4731</p>
<p>.</p>
<p>667</p>
<p>Roumie</p>
<p>CL</p>
<p>,</p>
<p>Min</p>
<p>JY</p>
<p>,</p>
<p>D’Agostino McGowan</p>
<p>L</p>
<p>,</p>
<p>Presley</p>
<p>C</p>
<p>,</p>
<p>Grijalva</p>
<p>CG</p>
<p>,</p>
<p>Hackstadt</p>
<p>AJ</p>
<p>,</p>
<p>Hung</p>
<p>AM</p>
<p>,</p>
<p>Greevy</p>
<p>RA</p>
<p>,</p>
<p>Elasy</p>
<p>T</p>
<p>,</p>
<p>Griffin</p>
<p>MR.</p>
<p>Comparative safety of sulfonylurea and metformin monotherapy on the
risk of heart failure: a cohort study</p>
<p>.</p>
<p>J Am Heart Assoc</p>
<p>2017</p>
<p>;</p>
<p>6</p>
<p>.</p>
<p>668</p>
<p>Lago</p>
<p>RM</p>
<p>,</p>
<p>Singh</p>
<p>PP</p>
<p>,</p>
<p>Nesto</p>
<p>RW.</p>
<p>Congestive heart failure and cardiovascular death in patients with
prediabetes and type 2 diabetes given thiazolidinediones: a
meta-analysis of randomised clinical trials</p>
<p>.</p>
<p>Lancet</p>
<p>2007</p>
<p>;</p>
<p>370</p>
<p>:</p>
<p>1129</p>
<p>–</p>
<p>1136</p>
<p>.</p>
<p>669</p>
<p>Vargas-Uricoechea</p>
<p>H</p>
<p>,</p>
<p>Bonelo-Perdomo</p>
<ol type="A">
<li></li>
</ol>
<p>Thyroid dysfunction and heart failure: mechanisms and
associations</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2017</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>48</p>
<p>–</p>
<p>58</p>
<p>.</p>
<p>670</p>
<p>Kannan</p>
<p>L</p>
<p>,</p>
<p>Shaw</p>
<p>PA</p>
<p>,</p>
<p>Morley</p>
<p>MP</p>
<p>,</p>
<p>Brandimarto</p>
<p>J</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>Cappola</p>
<p>TP</p>
<p>,</p>
<p>Cappola</p>
<p>AR</p>
<p>Thyroid dysfunction in heart failure and cardiovascular outcomes</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>e005266</p>
<p>.</p>
<p>671</p>
<p>Sato</p>
<p>Y</p>
<p>,</p>
<p>Yoshihisa</p>
<p>A</p>
<p>,</p>
<p>Kimishima</p>
<p>Y</p>
<p>,</p>
<p>Kiko</p>
<p>T</p>
<p>,</p>
<p>Kanno</p>
<p>Y</p>
<p>,</p>
<p>Yokokawa</p>
<p>T</p>
<p>,</p>
<p>Abe</p>
<p>S</p>
<p>,</p>
<p>Misaka</p>
<p>T</p>
<p>,</p>
<p>Sato</p>
<p>T</p>
<p>,</p>
<p>Oikawa</p>
<p>M</p>
<p>,</p>
<p>Kobayashi</p>
<p>A</p>
<p>,</p>
<p>Yamaki</p>
<p>T</p>
<p>,</p>
<p>Kunii</p>
<p>H</p>
<p>,</p>
<p>Nakazato</p>
<p>K</p>
<p>,</p>
<p>Takeishi</p>
<ol start="25" type="A">
<li></li>
</ol>
<p>Low T3 syndrome is associated with high mortality in hospitalized
patients with heart failure</p>
<p>.</p>
<p>J Card Fail</p>
<p>2019</p>
<p>;</p>
<p>25</p>
<p>:</p>
<p>195</p>
<p>–</p>
<p>203</p>
<p>.</p>
<p>672</p>
<p>Stott</p>
<p>DJ</p>
<p>,</p>
<p>Rodondi</p>
<p>N</p>
<p>,</p>
<p>Kearney</p>
<p>PM</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Westendorp</p>
<p>RGJ</p>
<p>,</p>
<p>Mooijaart</p>
<p>SP</p>
<p>,</p>
<p>Sattar</p>
<p>N</p>
<p>,</p>
<p>Aubert</p>
<p>CE</p>
<p>,</p>
<p>Aujesky</p>
<p>D</p>
<p>,</p>
<p>Bauer</p>
<p>DC</p>
<p>,</p>
<p>Baumgartner</p>
<p>C</p>
<p>,</p>
<p>Blum</p>
<p>MR</p>
<p>,</p>
<p>Browne</p>
<p>JP</p>
<p>,</p>
<p>Byrne</p>
<p>S</p>
<p>,</p>
<p>Collet</p>
<p>TH</p>
<p>,</p>
<p>Dekkers</p>
<p>OM</p>
<p>,</p>
<p>den Elzen</p>
<p>WPJ</p>
<p>,</p>
<p>Du Puy</p>
<p>RS</p>
<p>,</p>
<p>Ellis</p>
<p>G</p>
<p>,</p>
<p>Feller</p>
<p>M</p>
<p>,</p>
<p>Floriani</p>
<p>C</p>
<p>,</p>
<p>Hendry</p>
<p>K</p>
<p>,</p>
<p>Hurley</p>
<p>C</p>
<p>,</p>
<p>Jukema</p>
<p>JW</p>
<p>,</p>
<p>Kean</p>
<p>S</p>
<p>,</p>
<p>Kelly</p>
<p>M</p>
<p>,</p>
<p>Krebs</p>
<p>D</p>
<p>,</p>
<p>Langhorne</p>
<p>P</p>
<p>,</p>
<p>McCarthy</p>
<p>G</p>
<p>,</p>
<p>McCarthy</p>
<p>V</p>
<p>,</p>
<p>McConnachie</p>
<p>A</p>
<p>,</p>
<p>McDade</p>
<p>M</p>
<p>,</p>
<p>Messow</p>
<p>M</p>
<p>,</p>
<p>O’Flynn</p>
<p>A</p>
<p>,</p>
<p>O’Riordan</p>
<p>D</p>
<p>,</p>
<p>Poortvliet</p>
<p>RKE</p>
<p>,</p>
<p>Quinn</p>
<p>TJ</p>
<p>,</p>
<p>Russell</p>
<p>A</p>
<p>,</p>
<p>Sinnott</p>
<p>C</p>
<p>,</p>
<p>Smit</p>
<p>JWA</p>
<p>,</p>
<p>Van Dorland</p>
<p>HA</p>
<p>,</p>
<p>Walsh</p>
<p>KA</p>
<p>,</p>
<p>Walsh</p>
<p>EK</p>
<p>,</p>
<p>Watt</p>
<p>T</p>
<p>,</p>
<p>Wilson</p>
<p>R</p>
<p>,</p>
<p>Gussekloo</p>
<p>J</p>
<p>TRUST Study Group</p>
<p>.</p>
<p>Thyroid hormone therapy for older adults with subclinical
hypothyroidism</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2017</p>
<p>;</p>
<p>376</p>
<p>:</p>
<p>2534</p>
<p>–</p>
<p>2544</p>
<p>.</p>
<p>673</p>
<p>Feller</p>
<p>M</p>
<p>,</p>
<p>Snel</p>
<p>M</p>
<p>,</p>
<p>Moutzouri</p>
<p>E</p>
<p>,</p>
<p>Bauer</p>
<p>DC</p>
<p>,</p>
<p>de Montmollin</p>
<p>M</p>
<p>,</p>
<p>Aujesky</p>
<p>D</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Gussekloo</p>
<p>J</p>
<p>,</p>
<p>Kearney</p>
<p>PM</p>
<p>,</p>
<p>Mooijaart</p>
<p>S</p>
<p>,</p>
<p>Quinn</p>
<p>T</p>
<p>,</p>
<p>Stott</p>
<p>D</p>
<p>,</p>
<p>Westendorp</p>
<p>R</p>
<p>,</p>
<p>Rodondi</p>
<p>N</p>
<p>,</p>
<p>Dekkers</p>
<p>OM.</p>
<p>Association of thyroid hormone therapy with quality of life and
thyroid-related symptoms in patients with subclinical hypothyroidism: a
systematic review and meta-analysis</p>
<p>.</p>
<p>JAMA</p>
<p>2018</p>
<p>;</p>
<p>320</p>
<p>:</p>
<p>1349</p>
<p>–</p>
<p>1359</p>
<p>.</p>
<p>674</p>
<p>Peeters</p>
<p>RP.</p>
<p>Subclinical hypothyroidism</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2017</p>
<p>;</p>
<p>376</p>
<p>:</p>
<p>2556</p>
<p>–</p>
<p>2565</p>
<p>.</p>
<p>675</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Maurer</p>
<p>MS</p>
<p>,</p>
<p>Borlaug</p>
<p>BA.</p>
<p>Characterization of the inflammatory-metabolic phenotype of heart
failure and a preserved ejection fraction: a hypothesis to explain
influence of sex on the evolution and potential treatment of the
disease</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1551</p>
<p>–</p>
<p>1567</p>
<p>.</p>
<p>676</p>
<p>Obokata</p>
<p>M</p>
<p>,</p>
<p>Reddy</p>
<p>YNV</p>
<p>,</p>
<p>Pislaru</p>
<p>SV</p>
<p>,</p>
<p>Melenovsky</p>
<p>V</p>
<p>,</p>
<p>Borlaug</p>
<p>BA.</p>
<p>Evidence supporting the existence of a distinct obese phenotype of
heart failure with preserved ejection fraction</p>
<p>.</p>
<p>Circulation</p>
<p>2017</p>
<p>;</p>
<p>136</p>
<p>:</p>
<p>6</p>
<p>–</p>
<p>19</p>
<p>.</p>
<p>677</p>
<p>Rao</p>
<p>VN</p>
<p>,</p>
<p>Fudim</p>
<p>M</p>
<p>,</p>
<p>Mentz</p>
<p>RJ</p>
<p>,</p>
<p>Michos</p>
<p>ED</p>
<p>,</p>
<p>Felker</p>
<p>GM.</p>
<p>Regional adiposity and heart failure with preserved ejection
fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1540</p>
<p>–</p>
<p>1550</p>
<p>.</p>
<p>678</p>
<p>Carbone</p>
<p>S</p>
<p>,</p>
<p>Lavie</p>
<p>CJ</p>
<p>,</p>
<p>Arena</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Obesity and heart failure: focus on the obesity paradox</p>
<p>.</p>
<p>Mayo Clin Proc</p>
<p>2017</p>
<p>;</p>
<p>92</p>
<p>:</p>
<p>266</p>
<p>–</p>
<p>279</p>
<p>.</p>
<p>679</p>
<p>Horwich</p>
<p>TB</p>
<p>,</p>
<p>Fonarow</p>
<p>GC</p>
<p>,</p>
<p>Clark</p>
<p>AL.</p>
<p>Obesity and the obesity paradox in heart failure</p>
<p>.</p>
<p>Prog Cardiovasc Dis</p>
<p>2018</p>
<p>;</p>
<p>61</p>
<p>:</p>
<p>151</p>
<p>–</p>
<p>156</p>
<p>.</p>
<p>680</p>
<p>Adamopoulos</p>
<p>C</p>
<p>,</p>
<p>Meyer</p>
<p>P</p>
<p>,</p>
<p>Desai</p>
<p>RV</p>
<p>,</p>
<p>Karatzidou</p>
<p>K</p>
<p>,</p>
<p>Ovalle</p>
<p>F</p>
<p>,</p>
<p>White</p>
<p>M</p>
<p>,</p>
<p>Aban</p>
<p>I</p>
<p>,</p>
<p>Love</p>
<p>TE</p>
<p>,</p>
<p>Deedwania</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Ahmed</p>
<ol type="A">
<li></li>
</ol>
<p>Absence of obesity paradox in patients with chronic heart failure and
diabetes mellitus: a propensity-matched study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>200</p>
<p>–</p>
<p>206</p>
<p>.</p>
<p>681</p>
<p>Zamora</p>
<p>E</p>
<p>,</p>
<p>Lupon</p>
<p>J</p>
<p>,</p>
<p>Enjuanes</p>
<p>C</p>
<p>,</p>
<p>Pascual-Figal</p>
<p>D</p>
<p>,</p>
<p>de Antonio</p>
<p>M</p>
<p>,</p>
<p>Domingo</p>
<p>M</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Vila</p>
<p>J</p>
<p>,</p>
<p>Penafiel</p>
<p>J</p>
<p>,</p>
<p>Farre</p>
<p>N</p>
<p>,</p>
<p>Alonso</p>
<p>N</p>
<p>,</p>
<p>Santesmases</p>
<p>J</p>
<p>,</p>
<p>Troya</p>
<p>M</p>
<p>,</p>
<p>Bayes-Genis</p>
<ol type="A">
<li></li>
</ol>
<p>No benefit from the obesity paradox for diabetic patients with heart
failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>851</p>
<p>–</p>
<p>858</p>
<p>.</p>
<p>682</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Corra</p>
<p>U</p>
<p>,</p>
<p>Veglia</p>
<p>F</p>
<p>,</p>
<p>Bonomi</p>
<p>A</p>
<p>,</p>
<p>Salvioni</p>
<p>E</p>
<p>,</p>
<p>Cattadori</p>
<p>G</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Lombardi</p>
<p>C</p>
<p>,</p>
<p>Sinagra</p>
<p>G</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>Raimondo</p>
<p>R</p>
<p>,</p>
<p>Re</p>
<p>F</p>
<p>,</p>
<p>Magri</p>
<p>D</p>
<p>,</p>
<p>Belardinelli</p>
<p>R</p>
<p>,</p>
<p>Parati</p>
<p>G</p>
<p>,</p>
<p>Mina</p>
<p>C</p>
<p>,</p>
<p>Scardovi</p>
<p>AB</p>
<p>,</p>
<p>Guazzi</p>
<p>M</p>
<p>,</p>
<p>Cicoira</p>
<p>M</p>
<p>,</p>
<p>Scrutinio</p>
<p>D</p>
<p>,</p>
<p>Di Lenarda</p>
<p>A</p>
<p>,</p>
<p>Bussotti</p>
<p>M</p>
<p>,</p>
<p>Frigerio</p>
<p>M</p>
<p>,</p>
<p>Correale</p>
<p>M</p>
<p>,</p>
<p>Villani</p>
<p>GQ</p>
<p>,</p>
<p>Paolillo</p>
<p>S</p>
<p>,</p>
<p>Passino</p>
<p>C</p>
<p>,</p>
<p>Agostoni</p>
<p>P</p>
<p>,</p>
<p>MECKI Score Research Group</p>
<p>.</p>
<p>Exercise tolerance can explain the obesity paradox in patients with
systolic heart failure: data from the MECKI Score Research Group</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>545</p>
<p>–</p>
<p>553</p>
<p>.</p>
<p>683</p>
<p>Streng</p>
<p>KW</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Ng</p>
<p>LL</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Samani</p>
<p>NJ</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Zwinderman</p>
<p>AH</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Lang</p>
<ol start="200" type="I">
<li></li>
</ol>
<p>Waist-to-hip ratio and mortality in heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1269</p>
<p>–</p>
<p>1277</p>
<p>.</p>
<p>684</p>
<p>Carbone</p>
<p>S</p>
<p>,</p>
<p>Elagizi</p>
<p>A</p>
<p>,</p>
<p>Lavie</p>
<p>CJ.</p>
<p>Obesity and mortality risk in heart failure: when adipose tissue
distribution matters</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1278</p>
<p>–</p>
<p>1280</p>
<p>.</p>
<p>685</p>
<p>Packer</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Do most patients with obesity or type 2 diabetes, and atrial
fibrillation, also have undiagnosed heart failure? A critical conceptual
framework for understanding mechanisms and improving diagnosis and
treatment</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>214</p>
<p>–</p>
<p>227</p>
<p>.</p>
<p>686</p>
<p>Vitale</p>
<p>C</p>
<p>,</p>
<p>Jankowska</p>
<p>E</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Coats</p>
<p>AJ.</p>
<p>Heart Failure Association/European Society of Cardiology position
paper on frailty in patients with heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1299</p>
<p>–</p>
<p>1305</p>
<p>.</p>
<p>687</p>
<p>Denfeld</p>
<p>QE</p>
<p>,</p>
<p>Winters-Stone</p>
<p>K</p>
<p>,</p>
<p>Mudd</p>
<p>JO</p>
<p>,</p>
<p>Gelow</p>
<p>JM</p>
<p>,</p>
<p>Kurdi</p>
<p>S</p>
<p>,</p>
<p>Lee</p>
<p>CS.</p>
<p>The prevalence of frailty in heart failure: a systematic review and
meta-analysis</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2017</p>
<p>;</p>
<p>236</p>
<p>:</p>
<p>283</p>
<p>–</p>
<p>289</p>
<p>.</p>
<p>688</p>
<p>Bielecka-Dabrowa</p>
<p>A</p>
<p>,</p>
<p>Ebner</p>
<p>N</p>
<p>,</p>
<p>Dos Santos</p>
<p>MR</p>
<p>,</p>
<p>Ishida</p>
<p>J</p>
<p>,</p>
<p>Hasenfuss</p>
<p>G</p>
<p>,</p>
<p>von Haehling</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Cachexia, muscle wasting, and frailty in cardiovascular disease</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2314</p>
<p>–</p>
<p>2326</p>
<p>.</p>
<p>689</p>
<p>Khan</p>
<p>H</p>
<p>,</p>
<p>Kalogeropoulos</p>
<p>AP</p>
<p>,</p>
<p>Georgiopoulou</p>
<p>VV</p>
<p>,</p>
<p>Newman</p>
<p>AB</p>
<p>,</p>
<p>Harris</p>
<p>TB</p>
<p>,</p>
<p>Rodondi</p>
<p>N</p>
<p>,</p>
<p>Bauer</p>
<p>DC</p>
<p>,</p>
<p>Kritchevsky</p>
<p>SB</p>
<p>,</p>
<p>Butler</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Frailty and risk for heart failure in older adults: the health,
aging, and body composition study</p>
<p>.</p>
<p>Am Heart J</p>
<p>2013</p>
<p>;</p>
<p>166</p>
<p>:</p>
<p>887</p>
<p>–</p>
<p>894</p>
<p>.</p>
<p>690</p>
<p>Woods</p>
<p>NF</p>
<p>,</p>
<p>LaCroix</p>
<p>AZ</p>
<p>,</p>
<p>Gray</p>
<p>SL</p>
<p>,</p>
<p>Aragaki</p>
<p>A</p>
<p>,</p>
<p>Cochrane</p>
<p>BB</p>
<p>,</p>
<p>Brunner</p>
<p>RL</p>
<p>,</p>
<p>Masaki</p>
<p>K</p>
<p>,</p>
<p>Murray</p>
<p>A</p>
<p>,</p>
<p>Newman</p>
<p>AB</p>
<p>,</p>
<p>Women’s Health Initiative</p>
<p>.</p>
<p>Frailty: emergence and consequences in women aged 65 and older in the
Women’s Health Initiative Observational Study</p>
<p>.</p>
<p>J Am Geriatr Soc</p>
<p>2005</p>
<p>;</p>
<p>53</p>
<p>:</p>
<p>1321</p>
<p>–</p>
<p>1330</p>
<p>.</p>
<p>691</p>
<p>Vidan</p>
<p>MT</p>
<p>,</p>
<p>Blaya-Novakova</p>
<p>V</p>
<p>,</p>
<p>Sanchez</p>
<p>E</p>
<p>,</p>
<p>Ortiz</p>
<p>J</p>
<p>,</p>
<p>Serra-Rexach</p>
<p>JA</p>
<p>,</p>
<p>Bueno</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Prevalence and prognostic impact of frailty and its components in
non-dependent elderly patients with heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>869</p>
<p>–</p>
<p>875</p>
<p>.</p>
<p>692</p>
<p>Dewan</p>
<p>P</p>
<p>,</p>
<p>Jackson</p>
<p>A</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Shen</p>
<p>L</p>
<p>,</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>The prevalence and importance of frailty in heart failure with
reduced ejection fraction – an analysis of PARADIGM-HF and
ATMOSPHERE</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2123</p>
<p>–</p>
<p>2133</p>
<p>.</p>
<p>693</p>
<p>Sanders</p>
<p>NA</p>
<p>,</p>
<p>Supiano</p>
<p>MA</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>Liu</p>
<p>J</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Fang</p>
<p>JC.</p>
<p>The frailty syndrome and outcomes in the TOPCAT trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1570</p>
<p>–</p>
<p>1577</p>
<p>.</p>
<p>694</p>
<p>Evans</p>
<p>WJ</p>
<p>,</p>
<p>Morley</p>
<p>JE</p>
<p>,</p>
<p>Argiles</p>
<p>J</p>
<p>,</p>
<p>Bales</p>
<p>C</p>
<p>,</p>
<p>Baracos</p>
<p>V</p>
<p>,</p>
<p>Guttridge</p>
<p>D</p>
<p>,</p>
<p>Jatoi</p>
<p>A</p>
<p>,</p>
<p>Kalantar-Zadeh</p>
<p>K</p>
<p>,</p>
<p>Lochs</p>
<p>H</p>
<p>,</p>
<p>Mantovani</p>
<p>G</p>
<p>,</p>
<p>Marks</p>
<p>D</p>
<p>,</p>
<p>Mitch</p>
<p>WE</p>
<p>,</p>
<p>Muscaritoli</p>
<p>M</p>
<p>,</p>
<p>Najand</p>
<p>A</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Rossi Fanelli</p>
<p>F</p>
<p>,</p>
<p>Schambelan</p>
<p>M</p>
<p>,</p>
<p>Schols</p>
<p>A</p>
<p>,</p>
<p>Schuster</p>
<p>M</p>
<p>,</p>
<p>Thomas</p>
<p>D</p>
<p>,</p>
<p>Wolfe</p>
<p>R</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Cachexia: a new definition</p>
<p>.</p>
<p>Clin Nutr</p>
<p>2008</p>
<p>;</p>
<p>27</p>
<p>:</p>
<p>793</p>
<p>–</p>
<p>799</p>
<p>.</p>
<p>695</p>
<p>Loncar</p>
<p>G</p>
<p>,</p>
<p>Springer</p>
<p>J</p>
<p>,</p>
<p>Anker</p>
<p>M</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Lainscak</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Cardiac cachexia: hic et nunc</p>
<p>.</p>
<p>J Cachexia Sarcopenia Muscle</p>
<p>2016</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>246</p>
<p>–</p>
<p>260</p>
<p>.</p>
<p>696</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Springer</p>
<p>J</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Cardiac cachexia: a systematic overview</p>
<p>.</p>
<p>Pharmacol Ther</p>
<p>2009</p>
<p>;</p>
<p>121</p>
<p>:</p>
<p>227</p>
<p>–</p>
<p>252</p>
<p>.</p>
<p>697</p>
<p>Anker</p>
<p>MS</p>
<p>,</p>
<p>Holcomb</p>
<p>R</p>
<p>,</p>
<p>Muscaritoli</p>
<p>M</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Haverkamp</p>
<p>W</p>
<p>,</p>
<p>Jatoi</p>
<p>A</p>
<p>,</p>
<p>Morley</p>
<p>JE</p>
<p>,</p>
<p>Strasser</p>
<p>F</p>
<p>,</p>
<p>Landmesser</p>
<p>U</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Orphan disease status of cancer cachexia in the USA and in the
European Union: a systematic review</p>
<p>.</p>
<p>J Cachexia Sarcopenia Muscle</p>
<p>2019</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>22</p>
<p>–</p>
<p>34</p>
<p>.</p>
<p>698</p>
<p>Bauer</p>
<p>J</p>
<p>,</p>
<p>Morley</p>
<p>JE</p>
<p>,</p>
<p>Schols</p>
<p>A</p>
<p>,</p>
<p>Ferrucci</p>
<p>L</p>
<p>,</p>
<p>Cruz-Jentoft</p>
<p>AJ</p>
<p>,</p>
<p>Dent</p>
<p>E</p>
<p>,</p>
<p>Baracos</p>
<p>VE</p>
<p>,</p>
<p>Crawford</p>
<p>JA</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Heymsfield</p>
<p>SB</p>
<p>,</p>
<p>Jatoi</p>
<p>A</p>
<p>,</p>
<p>Kalantar-Zadeh</p>
<p>K</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Landi</p>
<p>F</p>
<p>,</p>
<p>Laviano</p>
<p>A</p>
<p>,</p>
<p>Mancuso</p>
<p>M</p>
<p>,</p>
<p>Muscaritoli</p>
<p>M</p>
<p>,</p>
<p>Prado</p>
<p>CM</p>
<p>,</p>
<p>Strasser</p>
<p>F</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Sarcopenia: a time for action. An SCWD position paper</p>
<p>.</p>
<p>J Cachexia Sarcopenia Muscle</p>
<p>2019</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>956</p>
<p>–</p>
<p>961</p>
<p>.</p>
<p>699</p>
<p>Ameri</p>
<p>P</p>
<p>,</p>
<p>Canepa</p>
<p>M</p>
<p>,</p>
<p>Anker</p>
<p>MS</p>
<p>,</p>
<p>Belenkov</p>
<p>Y</p>
<p>,</p>
<p>Bergler-Klein</p>
<p>J</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Lopez-Fernandez</p>
<p>T</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Pudil</p>
<p>R</p>
<p>,</p>
<p>Ruschitska</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Coats</p>
<p>A</p>
<p>,</p>
<p>Suter</p>
<p>T</p>
<p>,</p>
<p>Von Haehling</p>
<p>S</p>
<p>,</p>
<p>Ciardiello</p>
<p>F</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Heart Failure Association Cardio-Oncology Study Group of the European
Society of Cardiology</p>
<p>.</p>
<p>Cancer diagnosis in patients with heart failure: epidemiology,
clinical implications and gaps in knowledge</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>879</p>
<p>–</p>
<p>887</p>
<p>.</p>
<p>700</p>
<p>Fonseca</p>
<p>G</p>
<p>,</p>
<p>Dos Santos</p>
<p>MR</p>
<p>,</p>
<p>de Souza</p>
<p>FR</p>
<p>,</p>
<p>Takayama</p>
<p>L</p>
<p>,</p>
<p>Rodrigues Pereira</p>
<p>RM</p>
<p>,</p>
<p>Negrao</p>
<p>CE</p>
<p>,</p>
<p>Alves</p>
<p>MNN.</p>
<p>Discriminating sarcopenia in overweight/obese male patients with
heart failure: the influence of body mass index</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>84</p>
<p>–</p>
<p>91</p>
<p>.</p>
<p>701</p>
<p>Emami</p>
<p>A</p>
<p>,</p>
<p>Saitoh</p>
<p>M</p>
<p>,</p>
<p>Valentova</p>
<p>M</p>
<p>,</p>
<p>Sandek</p>
<p>A</p>
<p>,</p>
<p>Evertz</p>
<p>R</p>
<p>,</p>
<p>Ebner</p>
<p>N</p>
<p>,</p>
<p>Loncar</p>
<p>G</p>
<p>,</p>
<p>Springer</p>
<p>J</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Hasenfuss</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>von Haehling</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Comparison of sarcopenia and cachexia in men with chronic heart
failure: results from the Studies Investigating Co-morbidities
Aggravating Heart Failure (SICA-HF</p>
<p>).</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1580</p>
<p>–</p>
<p>1587</p>
<p>.</p>
<p>702</p>
<p>Fulster</p>
<p>S</p>
<p>,</p>
<p>Tacke</p>
<p>M</p>
<p>,</p>
<p>Sandek</p>
<p>A</p>
<p>,</p>
<p>Ebner</p>
<p>N</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>von Haehling</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Muscle wasting in patients with chronic heart failure: results from
the studies investigating co-morbidities aggravating heart failure
(SICA-HF</p>
<p>).</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>512</p>
<p>–</p>
<p>519</p>
<p>.</p>
<p>703</p>
<p>Springer</p>
<p>J</p>
<p>,</p>
<p>Springer</p>
<p>JI</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Muscle wasting and sarcopenia in heart failure and beyond: update
2017</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>492</p>
<p>–</p>
<p>498</p>
<p>.</p>
<p>704</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Ebner</p>
<p>N</p>
<p>,</p>
<p>Dos Santos</p>
<p>MR</p>
<p>,</p>
<p>Springer</p>
<p>J</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Muscle wasting and cachexia in heart failure: mechanisms and
therapies</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2017</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>323</p>
<p>–</p>
<p>341</p>
<p>.</p>
<p>705</p>
<p>Caminiti</p>
<p>G</p>
<p>,</p>
<p>Volterrani</p>
<p>M</p>
<p>,</p>
<p>Iellamo</p>
<p>F</p>
<p>,</p>
<p>Marazzi</p>
<p>G</p>
<p>,</p>
<p>Massaro</p>
<p>R</p>
<p>,</p>
<p>Miceli</p>
<p>M</p>
<p>,</p>
<p>Mammi</p>
<p>C</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Fini</p>
<p>M</p>
<p>,</p>
<p>Rosano</p>
<p>GM.</p>
<p>Effect of long-acting testosterone treatment on functional exercise
capacity, skeletal muscle performance, insulin resistance, and
baroreflex sensitivity in elderly patients with chronic heart failure a
double-blind, placebo-controlled, randomized study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2009</p>
<p>;</p>
<p>54</p>
<p>:</p>
<p>919</p>
<p>–</p>
<p>927</p>
<p>.</p>
<p>706</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Gupta</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Anemia and iron deficiency in heart failure: current concepts and
emerging therapies</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>138</p>
<p>:</p>
<p>80</p>
<p>–</p>
<p>98</p>
<p>.</p>
<p>707</p>
<p>Iorio</p>
<p>A</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Barbati</p>
<p>G</p>
<p>,</p>
<p>Greene</p>
<p>SJ</p>
<p>,</p>
<p>Poli</p>
<p>S</p>
<p>,</p>
<p>Zambon</p>
<p>E</p>
<p>,</p>
<p>Di Nora</p>
<p>C</p>
<p>,</p>
<p>Cioffi</p>
<p>G</p>
<p>,</p>
<p>Tarantini</p>
<p>L</p>
<p>,</p>
<p>Gavazzi</p>
<p>A</p>
<p>,</p>
<p>Sinagra</p>
<p>G</p>
<p>,</p>
<p>Di Lenarda</p>
<ol type="A">
<li></li>
</ol>
<p>Prevalence and prognostic impact of non-cardiac co-morbidities in
heart failure outpatients with preserved and reduced ejection fraction:
a community-based study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1257</p>
<p>–</p>
<p>1266</p>
<p>.</p>
<p>708</p>
<p>Okonko</p>
<p>DO</p>
<p>,</p>
<p>Mandal</p>
<p>AK</p>
<p>,</p>
<p>Missouris</p>
<p>CG</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>PA.</p>
<p>Disordered iron homeostasis in chronic heart failure: prevalence,
predictors, and relation to anemia, exercise capacity, and survival</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2011</p>
<p>;</p>
<p>58</p>
<p>:</p>
<p>1241</p>
<p>–</p>
<p>1251</p>
<p>.</p>
<p>709</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Sindone</p>
<p>A</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Kindermann</p>
<p>I</p>
<p>,</p>
<p>Manito</p>
<p>N</p>
<p>,</p>
<p>Pfister</p>
<p>O</p>
<p>,</p>
<p>Pohjantahti-Maaroos</p>
<p>H</p>
<p>,</p>
<p>Taylor</p>
<p>J</p>
<p>,</p>
<p>Comin-Colet J. Screening, diagnosis and treatment of iron deficiency
in chronic heart failure: putting the 2016 European Society of
Cardiology heart failure guidelines into clinical practice</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1664</p>
<p>–</p>
<p>1672</p>
<p>.</p>
<p>710</p>
<p>Cappellini</p>
<p>MD</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>de Francisco</p>
<p>A</p>
<p>,</p>
<p>Dignass</p>
<p>A</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Lam</p>
<p>CS</p>
<p>,</p>
<p>Macdougall</p>
<p>IC</p>
<p>,</p>
<p>Rogler</p>
<p>G</p>
<p>,</p>
<p>Camaschella</p>
<p>C</p>
<p>,</p>
<p>Kadir</p>
<p>R</p>
<p>,</p>
<p>Kassebaum</p>
<p>NJ</p>
<p>,</p>
<p>Spahn</p>
<p>DR</p>
<p>,</p>
<p>Taher</p>
<p>AT</p>
<p>,</p>
<p>Musallam</p>
<p>KM</p>
<p>,</p>
<p>IRON CORE Group</p>
<p>.</p>
<p>Iron deficiency across chronic inflammatory conditions: international
expert opinion on definition, diagnosis, and management</p>
<p>.</p>
<p>Am J Hematol</p>
<p>2017</p>
<p>;</p>
<p>92</p>
<p>:</p>
<p>1068</p>
<p>–</p>
<p>1078</p>
<p>.</p>
<p>711</p>
<p>Lopez</p>
<p>A</p>
<p>,</p>
<p>Cacoub</p>
<p>P</p>
<p>,</p>
<p>Macdougall</p>
<p>IC</p>
<p>,</p>
<p>Peyrin-Biroulet L. Iron deficiency anaemia</p>
<p>.</p>
<p>Lancet</p>
<p>2016</p>
<p>;</p>
<p>387</p>
<p>:</p>
<p>907</p>
<p>–</p>
<p>916</p>
<p>.</p>
<p>712</p>
<p>Sierpinski</p>
<p>R</p>
<p>,</p>
<p>Josiak</p>
<p>K</p>
<p>,</p>
<p>Suchocki</p>
<p>T</p>
<p>,</p>
<p>Wojtas-Polc</p>
<p>K</p>
<p>,</p>
<p>Mazur</p>
<p>G</p>
<p>,</p>
<p>Butrym</p>
<p>A</p>
<p>,</p>
<p>Rozentryt</p>
<p>P</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Kosmala</p>
<p>W</p>
<p>,</p>
<p>Przewlocka-Kosmala</p>
<p>M</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Nowak</p>
<p>J</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Jankowska</p>
<p>EA.</p>
<p>High soluble transferrin receptor in patients with heart failure: a
measure of iron deficiency and a strong predictor of mortality</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020 Oct 27. doi: 10.1002/ejhf.2036 [Epub ahead of print].</p>
<p>713</p>
<p>Rocha</p>
<p>BML</p>
<p>,</p>
<p>Cunha</p>
<p>GJL</p>
<p>,</p>
<p>Falcao Menezes</p>
<p>LF.</p>
<p>The burden of iron deficiency in heart failure: therapeutic
approach</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>782</p>
<p>–</p>
<p>793</p>
<p>.</p>
<p>714</p>
<p>Klip</p>
<p>IT</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Enjuanes</p>
<p>C</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Lok</p>
<p>DJ</p>
<p>,</p>
<p>Rosentryt</p>
<p>P</p>
<p>,</p>
<p>Torrens</p>
<p>A</p>
<p>,</p>
<p>Polonski</p>
<p>L</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Jankowska</p>
<p>EA.</p>
<p>Iron deficiency in chronic heart failure: an international pooled
analysis</p>
<p>.</p>
<p>Am Heart J</p>
<p>2013</p>
<p>;</p>
<p>165</p>
<p>:</p>
<p>575</p>
<p>–</p>
<p>582.e3</p>
<p>.</p>
<p>715</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Rozentryt</p>
<p>P</p>
<p>,</p>
<p>Witkowska</p>
<p>A</p>
<p>,</p>
<p>Nowak</p>
<p>J</p>
<p>,</p>
<p>Hartmann</p>
<p>O</p>
<p>,</p>
<p>Ponikowska</p>
<p>B</p>
<p>,</p>
<p>Borodulin-Nadzieja</p>
<p>L</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Polonski</p>
<p>L</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Ponikowski</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Iron deficiency: an ominous sign in patients with systolic chronic
heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2010</p>
<p>;</p>
<p>31</p>
<p>:</p>
<p>1872</p>
<p>–</p>
<p>1880</p>
<p>.</p>
<p>716</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Iron deficiency and cardiovascular disease</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2015</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>659</p>
<p>–</p>
<p>669</p>
<p>.</p>
<p>717</p>
<p>Stugiewicz</p>
<p>M</p>
<p>,</p>
<p>Tkaczyszyn</p>
<p>M</p>
<p>,</p>
<p>Kasztura</p>
<p>M</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Jankowska</p>
<p>EA.</p>
<p>The influence of iron deficiency on the functioning of skeletal
muscles: experimental evidence and clinical implications</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>762</p>
<p>–</p>
<p>773</p>
<p>.</p>
<p>718</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Malyszko</p>
<p>J</p>
<p>,</p>
<p>Ardehali</p>
<p>H</p>
<p>,</p>
<p>Koc-Zorawska</p>
<p>E</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Macdougall</p>
<p>IC</p>
<p>,</p>
<p>Weiss</p>
<p>G</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Ponikowski</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Iron status in patients with chronic heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>827</p>
<p>–</p>
<p>834</p>
<p>.</p>
<p>719</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Young</p>
<p>JB</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Cheng</p>
<p>S</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>O’Connor</p>
<p>C</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Sun</p>
<p>Y</p>
<p>,</p>
<p>Tendera</p>
<p>M</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>RED-HF Committees, RED-HF Investigators</p>
<p>.</p>
<p>Treatment of anemia with darbepoetin alfa in systolic heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2013</p>
<p>;</p>
<p>368</p>
<p>:</p>
<p>1210</p>
<p>–</p>
<p>1219</p>
<p>.</p>
<p>720</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Comin Colet</p>
<p>J</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Willenheimer</p>
<p>R</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Drexler</p>
<p>H</p>
<p>,</p>
<p>Luscher</p>
<p>TF</p>
<p>,</p>
<p>Bart</p>
<p>B</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Niegowska</p>
<p>J</p>
<p>,</p>
<p>Kirwan</p>
<p>BA</p>
<p>,</p>
<p>Mori</p>
<p>C</p>
<p>,</p>
<p>von Eisenhart Rothe</p>
<p>B</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Poole-Wilson</p>
<p>PA</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>FAIR-HF Trial Investigators</p>
<p>.</p>
<p>Ferric carboxymaltose in patients with heart failure and iron
deficiency</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2009</p>
<p>;</p>
<p>361</p>
<p>:</p>
<p>2436</p>
<p>–</p>
<p>2448</p>
<p>.</p>
<p>721</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Johnson</p>
<p>P</p>
<p>,</p>
<p>Luscher</p>
<p>TF</p>
<p>,</p>
<p>Mori</p>
<p>C</p>
<p>,</p>
<p>Willenheimer</p>
<p>R</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>The effect of intravenous ferric carboxymaltose on health-related
quality of life in patients with chronic heart failure and iron
deficiency: a subanalysis of the FAIR-HF study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:</p>
<p>30</p>
<p>–</p>
<p>38</p>
<p>.</p>
<p>722</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Ertl</p>
<p>G</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Mareev</p>
<p>V</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Levesque</p>
<p>V</p>
<p>,</p>
<p>Mori</p>
<p>C</p>
<p>,</p>
<p>Roubert</p>
<p>B</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>CONFIRM-HF Investigators</p>
<p>.</p>
<p>Beneficial effects of long-term intravenous iron therapy with ferric
carboxymaltose in patients with symptomatic heart failure and iron
deficiency</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>657</p>
<p>–</p>
<p>668</p>
<p>.</p>
<p>723</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Doletsky</p>
<p>A</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Macdougall</p>
<p>IC</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Roubert</p>
<p>B</p>
<p>,</p>
<p>Zakin</p>
<p>L</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>EFFECT-HF Investigators</p>
<p>.</p>
<p>Effect of ferric carboxymaltose on exercise capacity in patients with
chronic heart failure and iron deficiency</p>
<p>.</p>
<p>Circulation</p>
<p>2017</p>
<p>;</p>
<p>136</p>
<p>:</p>
<p>1374</p>
<p>–</p>
<p>1383</p>
<p>.</p>
<p>724</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Tkaczyszyn</p>
<p>M</p>
<p>,</p>
<p>Suchocki</p>
<p>T</p>
<p>,</p>
<p>Drozd</p>
<p>M</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Banasiak</p>
<p>W</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Ponikowski</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Effects of intravenous iron therapy in iron-deficient patients with
systolic heart failure: a meta-analysis of randomized controlled
trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>786</p>
<p>–</p>
<p>795</p>
<p>.</p>
<p>725</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Kirwan</p>
<p>BA</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Comin-Colet</p>
<p>J</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Luscher</p>
<p>TF</p>
<p>,</p>
<p>Arutyunov</p>
<p>GP</p>
<p>,</p>
<p>Motro</p>
<p>M</p>
<p>,</p>
<p>Mori</p>
<p>C</p>
<p>,</p>
<p>Roubert</p>
<p>B</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Ponikowski</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Effects of ferric carboxymaltose on hospitalisations and mortality
rates in iron-deficient heart failure patients: an individual patient
data meta-analysis</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>125</p>
<p>–</p>
<p>133</p>
<p>.</p>
<p>726</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Colet</p>
<p>JC</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Luscher</p>
<p>TF</p>
<p>,</p>
<p>Willenheimer</p>
<p>R</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Gaudesius</p>
<p>G</p>
<p>,</p>
<p>Mori</p>
<p>C</p>
<p>,</p>
<p>von Eisenhart Rothe</p>
<p>B</p>
<p>,</p>
<p>Greenlaw</p>
<p>N</p>
<p>,</p>
<p>Ford</p>
<p>I</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Intravenous ferric carboxymaltose in iron-deficient chronic heart
failure patients with and without anaemia: a subanalysis of the FAIR-HF
trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>1267</p>
<p>–</p>
<p>1276</p>
<p>.</p>
<p>727</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Ebner</p>
<p>N</p>
<p>,</p>
<p>Evertz</p>
<p>R</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Iron deficiency in heart failure: an overview</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>36</p>
<p>–</p>
<p>46</p>
<p>.</p>
<p>728</p>
<p>Lewis</p>
<p>GD</p>
<p>,</p>
<p>Malhotra</p>
<p>R</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Smith</p>
<p>A</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Tang</p>
<p>WHW</p>
<p>,</p>
<p>LaRue</p>
<p>SJ</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Van Buren</p>
<p>P</p>
<p>,</p>
<p>Whellan</p>
<p>D</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Shah</p>
<p>MR</p>
<p>,</p>
<p>Desvigne-Nickens</p>
<p>P</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Braunwald</p>
<p>E</p>
<p>,</p>
<p>NHLBI Heart Failure Clinical Research Network. Effect of oral iron
repletion on exercise capacity in patients with heart failure with
reduced ejection fraction and iron deficiency: the IRONOUT HF randomized
clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2017</p>
<p>;</p>
<p>317</p>
<p>:</p>
<p>1958</p>
<p>–</p>
<p>1966</p>
<p>.</p>
<p>729</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Testani</p>
<p>JM</p>
<p>,</p>
<p>Martens</p>
<p>P</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Tang</p>
<p>WHW</p>
<p>,</p>
<p>Skouri</p>
<p>H</p>
<p>,</p>
<p>Verbrugge</p>
<p>FH</p>
<p>,</p>
<p>Orso</p>
<p>F</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Ural</p>
<p>D</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<ol type="A">
<li></li>
</ol>
<p>Evaluation of kidney function throughout the heart failure trajectory
– a position statement from the Heart Failure Association of the
European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>584</p>
<p>–</p>
<p>603</p>
<p>.</p>
<p>730</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Verhaar</p>
<p>MC</p>
<p>,</p>
<p>Paulus</p>
<p>WJ</p>
<p>,</p>
<p>Duncker</p>
<p>DJ</p>
<p>,</p>
<p>Cheng</p>
<p>C</p>
<p>,</p>
<p>van Heerebeek</p>
<p>L</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>Lam</p>
<p>CS</p>
<p>,</p>
<p>Navis</p>
<p>G</p>
<p>,</p>
<p>Voors</p>
<p>AA.</p>
<p>Connecting heart failure with preserved ejection fraction and renal
dysfunction: the role of endothelial dysfunction and inflammation</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>588</p>
<p>–</p>
<p>598</p>
<p>.</p>
<p>731</p>
<p>van der Pol</p>
<p>A</p>
<p>,</p>
<p>van Gilst</p>
<p>WH</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>van der Meer</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Treating oxidative stress in heart failure: past, present and
future</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>425</p>
<p>–</p>
<p>435</p>
<p>.</p>
<p>732</p>
<p>Lofman</p>
<p>I</p>
<p>,</p>
<p>Szummer</p>
<p>K</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Jernberg</p>
<p>T</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Associations with and prognostic impact of chronic kidney disease in
heart failure with preserved, mid-range, and reduced ejection
fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1606</p>
<p>–</p>
<p>1614</p>
<p>.</p>
<p>733</p>
<p>Lofman</p>
<p>I</p>
<p>,</p>
<p>Szummer</p>
<p>K</p>
<p>,</p>
<p>Evans</p>
<p>M</p>
<p>,</p>
<p>Carrero</p>
<p>JJ</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Jernberg</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Incidence of, associations with and prognostic impact of worsening
renal function in heart failure with different ejection fraction
categories</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2019</p>
<p>;</p>
<p>124</p>
<p>:</p>
<p>1575</p>
<p>–</p>
<p>1583</p>
<p>.</p>
<p>734</p>
<p>Schefold</p>
<p>JC</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Hasenfuss</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>von Haehling</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Heart failure and kidney dysfunction: epidemiology, mechanisms and
management</p>
<p>.</p>
<p>Nat Rev Nephrol</p>
<p>2016</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>610</p>
<p>–</p>
<p>623</p>
<p>.</p>
<p>735</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Valente</p>
<p>MA</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Hillege</p>
<p>HL.</p>
<p>Renal impairment, worsening renal function, and outcome in patients
with heart failure: an updated meta-analysis</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2014</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>455</p>
<p>–</p>
<p>469</p>
<p>.</p>
<p>736</p>
<p>Braunwald</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>Diabetes, heart failure, and renal dysfunction: the vicious
circles</p>
<p>.</p>
<p>Prog Cardiovasc Dis</p>
<p>2019</p>
<p>;</p>
<p>62</p>
<p>:</p>
<p>298</p>
<p>–</p>
<p>302</p>
<p>.</p>
<p>737</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Zeller</p>
<p>C</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Hauske</p>
<p>SJ</p>
<p>,</p>
<p>Brueckmann</p>
<p>M</p>
<p>,</p>
<p>Pfarr</p>
<p>E</p>
<p>,</p>
<p>Schnee</p>
<p>J</p>
<p>,</p>
<p>Wanner</p>
<p>C</p>
<p>,</p>
<p>Packer</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Cardiac and kidney benefits of empagliflozin in heart failure across
the spectrum of kidney function: insights from EMPEROR-Reduced</p>
<p>.</p>
<p>Circulation</p>
<p>2021</p>
<p>;</p>
<p>143</p>
<p>:</p>
<p>310</p>
<p>–</p>
<p>321</p>
<p>.</p>
<p>738</p>
<p>Heerspink</p>
<p>HJL</p>
<p>,</p>
<p>Stefansson</p>
<p>BV</p>
<p>,</p>
<p>Correa-Rotter</p>
<p>R</p>
<p>,</p>
<p>Chertow</p>
<p>GM</p>
<p>,</p>
<p>Greene</p>
<p>T</p>
<p>,</p>
<p>Hou</p>
<p>FF</p>
<p>,</p>
<p>Mann</p>
<p>JFE</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Lindberg</p>
<p>M</p>
<p>,</p>
<p>Rossing</p>
<p>P</p>
<p>,</p>
<p>Sjostrom</p>
<p>CD</p>
<p>,</p>
<p>Toto</p>
<p>RD</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>Wheeler</p>
<p>DC</p>
<p>, DAPA</p>
<p>-CKD Trial Committees and Investigators. Dapagliflozin in patients
with chronic kidney disease</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2020</p>
<p>;</p>
<p>383</p>
<p>:</p>
<p>1436</p>
<p>–</p>
<p>1446</p>
<p>.</p>
<p>739</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Davison</p>
<p>B</p>
<p>,</p>
<p>Bettari</p>
<p>L</p>
<p>,</p>
<p>Sun</p>
<p>H</p>
<p>,</p>
<p>Edwards</p>
<p>C</p>
<p>,</p>
<p>Lazzarini</p>
<p>V</p>
<p>,</p>
<p>Piovanelli</p>
<p>B</p>
<p>,</p>
<p>Carubelli</p>
<p>V</p>
<p>,</p>
<p>Bugatti</p>
<p>S</p>
<p>,</p>
<p>Lombardi</p>
<p>C</p>
<p>,</p>
<p>Cotter</p>
<p>G</p>
<p>,</p>
<p>Dei Cas L. Is worsening renal function an ominous prognostic sign in
patients with acute heart failure? The role of congestion and its
interaction with renal function</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2012</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>54</p>
<p>–</p>
<p>62</p>
<p>.</p>
<p>740</p>
<p>Testani</p>
<p>JM</p>
<p>,</p>
<p>Kimmel</p>
<p>SE</p>
<p>,</p>
<p>Dries</p>
<p>DL</p>
<p>,</p>
<p>Coca</p>
<p>SG.</p>
<p>Prognostic importance of early worsening renal function after
initiation of angiotensin-converting enzyme inhibitor therapy in
patients with cardiac dysfunction</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>685</p>
<p>–</p>
<p>691</p>
<p>.</p>
<p>741</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Tang</p>
<p>WH</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Lassus</p>
<p>J</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Current evidence on treatment of patients with chronic systolic heart
failure and renal insufficiency: practical considerations from published
data</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>853</p>
<p>–</p>
<p>871</p>
<p>.</p>
<p>742</p>
<p>House</p>
<p>AA.</p>
<p>Management of heart failure in advancing CKD: core curriculum
2018</p>
<p>.</p>
<p>Am J Kidney Dis</p>
<p>2018</p>
<p>;</p>
<p>72</p>
<p>:</p>
<p>284</p>
<p>–</p>
<p>295</p>
<p>.</p>
<p>743</p>
<p>Kotecha</p>
<p>D</p>
<p>,</p>
<p>Gill</p>
<p>SK</p>
<p>,</p>
<p>Flather</p>
<p>MD</p>
<p>,</p>
<p>Holmes</p>
<p>J</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Manzano</p>
<p>L</p>
<p>,</p>
<p>von Lueder</p>
<p>TG</p>
<p>,</p>
<p>Rigby</p>
<p>AS</p>
<p>,</p>
<p>Andersson</p>
<p>B</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Redon</p>
<p>J</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Beta-Blockers in Heart Failure Collaborative Group. Impact of renal
impairment on beta-blocker efficacy in patients with heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>74</p>
<p>:</p>
<p>2893</p>
<p>–</p>
<p>2904</p>
<p>.</p>
<p>744</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Docherty</p>
<p>KF</p>
<p>,</p>
<p>Heerspink</p>
<p>HJL</p>
<p>,</p>
<p>Anand</p>
<p>IS</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Chopra</p>
<p>V</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Ge</p>
<p>J</p>
<p>,</p>
<p>Kitakaze</p>
<p>M</p>
<p>,</p>
<p>Merkley</p>
<p>B</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Shou</p>
<p>M</p>
<p>,</p>
<p>Tereshchenko</p>
<p>S</p>
<p>,</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Vinh</p>
<p>PN</p>
<p>,</p>
<p>Inzucchi</p>
<p>SE</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Kosiborod</p>
<p>MN</p>
<p>,</p>
<p>Martinez</p>
<p>FA</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>Bengtsson</p>
<p>O</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>Sjostrand</p>
<p>M</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Efficacy of dapagliflozin on renal function and outcomes in patients
with heart failure with reduced ejection fraction: results of
DAPA-HF</p>
<p>.</p>
<p>Circulation</p>
<p>2021</p>
<p>;</p>
<p>143</p>
<p>:</p>
<p>298</p>
<p>–</p>
<p>309</p>
<p>.</p>
<p>745</p>
<p>Boerrigter</p>
<p>G</p>
<p>,</p>
<p>Costello-Boerrigter</p>
<p>LC</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>Sutton</p>
<p>MG</p>
<p>,</p>
<p>Heublein</p>
<p>DM</p>
<p>,</p>
<p>Kruger</p>
<p>KM</p>
<p>,</p>
<p>Hill</p>
<p>MR</p>
<p>,</p>
<p>McCullough</p>
<p>PA</p>
<p>,</p>
<p>Burnett</p>
<p>JC</p>
<p>Jr.</p>
<p>Cardiac resynchronization therapy improves renal function in human
heart failure with reduced glomerular filtration rate</p>
<p>.</p>
<p>J Card Fail</p>
<p>2008</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>539</p>
<p>–</p>
<p>546</p>
<p>.</p>
<p>746</p>
<p>Roehm</p>
<p>B</p>
<p>,</p>
<p>Vest</p>
<p>AR</p>
<p>,</p>
<p>Weiner</p>
<p>DE.</p>
<p>Left ventricular assist devices kidney disease and dialysis</p>
<p>.</p>
<p>Am J Kidney Dis</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>257</p>
<p>–</p>
<p>266</p>
<p>.</p>
<p>747</p>
<p>Goldenberg</p>
<p>I</p>
<p>,</p>
<p>Moss</p>
<p>AJ</p>
<p>,</p>
<p>McNitt</p>
<p>S</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Andrews</p>
<p>ML</p>
<p>,</p>
<p>Hall</p>
<p>WJ</p>
<p>,</p>
<p>Greenberg</p>
<p>H</p>
<p>,</p>
<p>Case</p>
<p>RB</p>
<p>,</p>
<p>Multicenter Automatic Defibrillator Implantation Trial-II
Investigators. Relations among renal function, risk of sudden cardiac
death, and benefit of the implanted cardiac defibrillator in patients
with ischemic left ventricular dysfunction</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2006</p>
<p>;</p>
<p>98</p>
<p>:</p>
<p>485</p>
<p>–</p>
<p>490</p>
<p>.</p>
<p>748</p>
<p>Goldenberg</p>
<p>I</p>
<p>,</p>
<p>Younis</p>
<p>A</p>
<p>,</p>
<p>Aktas</p>
<p>MK</p>
<p>,</p>
<p>McNitt</p>
<p>S</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Kutyifa</p>
<ol start="22" type="A">
<li></li>
</ol>
<p>Competing risk analysis of ventricular arrhythmia events in heart
failure patients with moderately compromised renal dysfunction</p>
<p>.</p>
<p>Europace</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1384</p>
<p>–</p>
<p>1390</p>
<p>.</p>
<p>749</p>
<p>Coiro</p>
<p>S</p>
<p>,</p>
<p>Girerd</p>
<p>N</p>
<p>,</p>
<p>Sharma</p>
<p>A</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Tritto</p>
<p>I</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Ambrosio</p>
<p>G</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Moss</p>
<p>A</p>
<p>,</p>
<p>Zannad</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Association of diabetes and kidney function according to age and
systolic function with the incidence of sudden cardiac death and
non-sudden cardiac death in myocardial infarction survivors with heart
failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1248</p>
<p>–</p>
<p>1258</p>
<p>.</p>
<p>750</p>
<p>Teerlink</p>
<p>JR</p>
<p>,</p>
<p>Diaz</p>
<p>R</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Adams</p>
<p>KF</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Arias-Mendoza</p>
<p>A</p>
<p>,</p>
<p>Biering-Sorensen</p>
<p>T</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Bonderman</p>
<p>D</p>
<p>,</p>
<p>Cleland</p>
<p>JGF</p>
<p>,</p>
<p>Corbalan</p>
<p>R</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Echeverria Correa</p>
<p>LE</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Goncalvesova</p>
<p>E</p>
<p>,</p>
<p>Goudev</p>
<p>AR</p>
<p>,</p>
<p>Howlett</p>
<p>JG</p>
<p>,</p>
<p>Lanfear</p>
<p>DE</p>
<p>,</p>
<p>Lund</p>
<p>M</p>
<p>,</p>
<p>Macdonald</p>
<p>P</p>
<p>,</p>
<p>Mareev</p>
<p>V</p>
<p>,</p>
<p>Momomura</p>
<p>SI</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Parkhomenko</p>
<p>A</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Ramires</p>
<p>FJA</p>
<p>,</p>
<p>Serpytis</p>
<p>P</p>
<p>,</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Spinar</p>
<p>J</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Tomcsanyi</p>
<p>J</p>
<p>,</p>
<p>Vandekerckhove</p>
<p>H</p>
<p>,</p>
<p>Vinereanu</p>
<p>D</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Yilmaz</p>
<p>MB</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Sharpsten</p>
<p>L</p>
<p>,</p>
<p>Legg</p>
<p>JC</p>
<p>,</p>
<p>Abbasi</p>
<p>SA</p>
<p>,</p>
<p>Varin</p>
<p>C</p>
<p>,</p>
<p>Malik</p>
<p>FI</p>
<p>,</p>
<p>Kurtz</p>
<p>CE</p>
<p>GALACTIC-HF Investigators</p>
<p>.</p>
<p>Omecamtiv mecarbil in chronic heart failure with reduced ejection
fraction: GALACTIC-HF baseline characteristics and comparison with
contemporary clinical trials</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2160</p>
<p>–</p>
<p>2171</p>
<p>.</p>
<p>751</p>
<p>Urso</p>
<p>C</p>
<p>,</p>
<p>Brucculeri</p>
<p>S</p>
<p>,</p>
<p>Caimi</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Acid-base and electrolyte abnormalities in heart failure:
pathophysiology and implications</p>
<p>.</p>
<p>Heart Fail Rev</p>
<p>2015</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>493</p>
<p>–</p>
<p>503</p>
<p>.</p>
<p>752</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Vijayakumar</p>
<p>S</p>
<p>,</p>
<p>Pitt</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Need to revisit heart failure treatment guidelines for hyperkalaemia
management during the use of mineralocorticoid receptor antagonists</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1247</p>
<p>–</p>
<p>1251</p>
<p>.</p>
<p>753</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Randomized Aldactone Evaluation Study (RALES) Investigators.
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in
patients with severe heart failure treated with a mineralocorticoid
receptor antagonist</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>573</p>
<p>–</p>
<p>579</p>
<p>.</p>
<p>754</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Dobre</p>
<p>D</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Shi</p>
<p>H</p>
<p>,</p>
<p>Messig</p>
<p>M</p>
<p>,</p>
<p>Vincent</p>
<p>J</p>
<p>,</p>
<p>Girerd</p>
<p>N</p>
<p>,</p>
<p>Bakris</p>
<p>G</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Zannad</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Incidence, determinants, and prognostic significance of hyperkalemia
and worsening renal function in patients with heart failure receiving
the mineralocorticoid receptor antagonist eplerenone or placebo in
addition to optimal medical therapy: results from the Eplerenone in Mild
Patients Hospitalization and Survival Study in Heart Failure
(EMPHASIS-HF</p>
<p>).</p>
<p>Circ Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>51</p>
<p>–</p>
<p>58</p>
<p>.</p>
<p>755</p>
<p>Nunez</p>
<p>J</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Nunez</p>
<p>E</p>
<p>,</p>
<p>Bodi</p>
<p>V</p>
<p>,</p>
<p>Minana</p>
<p>G</p>
<p>,</p>
<p>Santas</p>
<p>E</p>
<p>,</p>
<p>Chorro</p>
<p>FJ</p>
<p>,</p>
<p>Mollar</p>
<p>A</p>
<p>,</p>
<p>Carratala</p>
<p>A</p>
<p>,</p>
<p>Navarro</p>
<p>J</p>
<p>,</p>
<p>Gorriz</p>
<p>JL</p>
<p>,</p>
<p>Lupon</p>
<p>J</p>
<p>,</p>
<p>Husser</p>
<p>O</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Sanchis</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Long-term potassium monitoring and dynamics in heart failure and risk
of mortality</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>137</p>
<p>:</p>
<p>1320</p>
<p>–</p>
<p>1330</p>
<p>.</p>
<p>756</p>
<p>Linde</p>
<p>C</p>
<p>,</p>
<p>Qin</p>
<p>L</p>
<p>,</p>
<p>Bakhai</p>
<p>A</p>
<p>,</p>
<p>Furuland</p>
<p>H</p>
<p>,</p>
<p>Evans</p>
<p>M</p>
<p>,</p>
<p>Ayoubkhani</p>
<p>D</p>
<p>,</p>
<p>Palaka</p>
<p>E</p>
<p>,</p>
<p>Bennett</p>
<p>H</p>
<p>,</p>
<p>McEwan</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Serum potassium and clinical outcomes in heart failure patients:
results of risk calculations in 21 334 patients in the UK</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>280</p>
<p>–</p>
<p>290</p>
<p>.</p>
<p>757</p>
<p>Cooper</p>
<p>LB</p>
<p>,</p>
<p>Benson</p>
<p>L</p>
<p>,</p>
<p>Mentz</p>
<p>RJ</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>DeVore</p>
<p>AD</p>
<p>,</p>
<p>Carrero</p>
<p>JJ</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Lund</p>
<p>LH.</p>
<p>Association between potassium level and outcomes in heart failure
with reduced ejection fraction: a cohort study from the Swedish Heart
Failure Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1390</p>
<p>–</p>
<p>1398</p>
<p>.</p>
<p>758</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>McDonagh</p>
<p>T</p>
<p>,</p>
<p>Sahuquillo</p>
<p>A</p>
<p>,</p>
<p>Penco</p>
<p>M</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Heart Failure Long-Term Registry Investigators Group</p>
<p>.</p>
<p>Unravelling the interplay between hyperkalaemia,
renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data
from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart
Failure Long-Term Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1378</p>
<p>–</p>
<p>1389</p>
<p>.</p>
<p>759</p>
<p>Ahmed</p>
<p>A</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Love</p>
<p>TE</p>
<p>,</p>
<p>Tallaj</p>
<p>J</p>
<p>,</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Ekundayo</p>
<p>OJ</p>
<p>,</p>
<p>Pitt</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>A propensity-matched study of the association of low serum potassium
levels and mortality in chronic heart failure</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2007</p>
<p>;</p>
<p>28</p>
<p>:</p>
<p>1334</p>
<p>–</p>
<p>1343</p>
<p>.</p>
<p>760</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Tamargo</p>
<p>J</p>
<p>,</p>
<p>Kjeldsen</p>
<p>KP</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Agewall</p>
<p>S</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Ceconi</p>
<p>C</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Drexel</p>
<p>H</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Kaski</p>
<p>JC</p>
<p>,</p>
<p>Lund</p>
<p>L</p>
<p>,</p>
<p>Niessner</p>
<p>A</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Schmidt</p>
<p>TA</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Wassmann</p>
<p>S</p>
<p>,</p>
<p>Walther</p>
<p>T</p>
<p>,</p>
<p>Lewis</p>
<p>BS.</p>
<p>Expert consensus document on the management of hyperkalaemia in
patients with cardiovascular disease treated with renin angiotensin
aldosterone system inhibitors: coordinated by the Working Group on
Cardiovascular Pharmacotherapy of the European Society of Cardiology</p>
<p>.</p>
<p>Eur Heart J Cardiovasc Pharmacother</p>
<p>2018</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>180</p>
<p>–</p>
<p>188</p>
<p>.</p>
<p>761</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Mogensen</p>
<p>UM</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Zile</p>
<p>MR</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>McMurray</p>
<p>JJV.</p>
<p>Serum potassium in the PARADIGM-HF trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2056</p>
<p>–</p>
<p>2064</p>
<p>.</p>
<p>762</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Duarte</p>
<p>K</p>
<p>,</p>
<p>Girerd</p>
<p>N</p>
<p>,</p>
<p>Karoui</p>
<p>M</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Pocock</p>
<p>S</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Pitt</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Cardiovascular risk associated with serum potassium in the context of
mineralocorticoid receptor antagonist use in patients with heart failure
and left ventricular dysfunction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1402</p>
<p>–</p>
<p>1411</p>
<p>.</p>
<p>763</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Liu</p>
<p>J</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Fleg</p>
<p>J</p>
<p>,</p>
<p>Lewis</p>
<p>EF</p>
<p>,</p>
<p>McKinlay</p>
<p>S</p>
<p>,</p>
<p>O’Meara</p>
<p>E</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Sweitzer</p>
<p>NK</p>
<p>,</p>
<p>Solomon</p>
<p>S</p>
<p>,</p>
<p>Pitt</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Incident hyperkalemia, hypokalemia, and clinical outcomes during
spironolactone treatment of heart failure with preserved ejection
fraction: analysis of the TOPCAT trial</p>
<p>.</p>
<p>J Card Fail</p>
<p>2018</p>
<p>;</p>
<p>24</p>
<p>:</p>
<p>313</p>
<p>–</p>
<p>320</p>
<p>.</p>
<p>764</p>
<p>Desai</p>
<p>AS.</p>
<p>Hyperkalemia in patients with heart failure: incidence, prevalence,
and management</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2009</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>272</p>
<p>–</p>
<p>280</p>
<p>.</p>
<p>765</p>
<p>Savarese</p>
<p>G</p>
<p>,</p>
<p>Xu</p>
<p>H</p>
<p>,</p>
<p>Trevisan</p>
<p>M</p>
<p>,</p>
<p>Dahlstrom</p>
<p>U</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Carrero</p>
<p>JJ.</p>
<p>Incidence, predictors, and outcome associations of dyskalemia in
heart failure with preserved, mid-range, and reduced ejection
fraction</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>65</p>
<p>–</p>
<p>76</p>
<p>.</p>
<p>766</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Spoletini</p>
<p>I</p>
<p>,</p>
<p>Agewall</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Pharmacology of new treatments for hyperkalaemia: patiromer and
sodium zirconium cyclosilicate</p>
<p>.</p>
<p>Eur Heart J Suppl</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>A28</p>
<p>–</p>
<p>A33</p>
<p>.</p>
<p>767</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Kosiborod</p>
<p>M</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Pina</p>
<p>IL</p>
<p>,</p>
<p>McCullough</p>
<p>PA</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Rasmussen</p>
<p>HS</p>
<p>,</p>
<p>Lavin</p>
<p>PT</p>
<p>,</p>
<p>Singh</p>
<p>B</p>
<p>,</p>
<p>Yang</p>
<p>A</p>
<p>,</p>
<p>Deedwania</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Maintenance of serum potassium with sodium zirconium cyclosilicate
(ZS-9) in heart failure patients: results from a phase 3 randomized,
double-blind, placebo-controlled trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>1050</p>
<p>–</p>
<p>1056</p>
<p>.</p>
<p>768</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Bakris</p>
<p>GL</p>
<p>,</p>
<p>Bushinsky</p>
<p>DA</p>
<p>,</p>
<p>Garza</p>
<p>D</p>
<p>,</p>
<p>Mayo</p>
<p>MR</p>
<p>,</p>
<p>Stasiv</p>
<p>Y</p>
<p>,</p>
<p>Christ-Schmidt</p>
<p>H</p>
<p>,</p>
<p>Berman</p>
<p>L</p>
<p>,</p>
<p>Weir</p>
<p>MR.</p>
<p>Effect of patiromer on reducing serum potassium and preventing
recurrent hyperkalaemia in patients with heart failure and chronic
kidney disease on RAAS inhibitors</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>1057</p>
<p>–</p>
<p>1065</p>
<p>.</p>
<p>769</p>
<p>Trevisan</p>
<p>M</p>
<p>,</p>
<p>de Deco</p>
<p>P</p>
<p>,</p>
<p>Xu</p>
<p>H</p>
<p>,</p>
<p>Evans</p>
<p>M</p>
<p>,</p>
<p>Lindholm</p>
<p>B</p>
<p>,</p>
<p>Bellocco</p>
<p>R</p>
<p>,</p>
<p>Barany</p>
<p>P</p>
<p>,</p>
<p>Jernberg</p>
<p>T</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Carrero</p>
<p>JJ.</p>
<p>Incidence, predictors and clinical management of hyperkalaemia in new
users of mineralocorticoid receptor antagonists</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1217</p>
<p>–</p>
<p>1226</p>
<p>.</p>
<p>770</p>
<p>Ferreira</p>
<p>JP</p>
<p>,</p>
<p>Rossello</p>
<p>X</p>
<p>,</p>
<p>Pocock</p>
<p>SJ</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Rouleau</p>
<p>JL</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Zannad</p>
<ol start="6" type="A">
<li></li>
</ol>
<p>Spironolactone dose in heart failure with preserved ejection
fraction: findings from TOPCAT</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1615</p>
<p>–</p>
<p>1624</p>
<p>.</p>
<p>771</p>
<p>Volterrani</p>
<p>M</p>
<p>,</p>
<p>Perrone</p>
<p>V</p>
<p>,</p>
<p>Sangiorgi</p>
<p>D</p>
<p>,</p>
<p>Giacomini</p>
<p>E</p>
<p>,</p>
<p>Iellamo</p>
<p>F</p>
<p>,</p>
<p>Degli Esposti L, LHUs Study Group. Effects of hyperkalaemia and
non-adherence to renin-angiotensin-aldosterone system inhibitor therapy
in patients with heart failure in Italy: a propensity-matched study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2049</p>
<p>–</p>
<p>2055</p>
<p>.</p>
<p>772</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Bushinsky</p>
<p>DA</p>
<p>,</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Huang</p>
<p>IZ</p>
<p>,</p>
<p>Investigators</p>
<p>PEARL-HF</p>
<p>.</p>
<p>Evaluation of the efficacy and safety of RLY5016, a polymeric
potassium binder, in a double-blind, placebo-controlled study in
patients with chronic heart failure (the PEARL-HF) trial</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2011</p>
<p>;</p>
<p>32</p>
<p>:</p>
<p>820</p>
<p>–</p>
<p>828</p>
<p>.</p>
<p>773</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Bakris</p>
<p>GL</p>
<p>,</p>
<p>Weir</p>
<p>MR</p>
<p>,</p>
<p>Freeman</p>
<p>MW</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Mayo</p>
<p>MR</p>
<p>,</p>
<p>Garza</p>
<p>D</p>
<p>,</p>
<p>Zawadzki</p>
<p>R</p>
<p>,</p>
<p>Berman</p>
<p>L</p>
<p>,</p>
<p>Bushinsky</p>
<p>DA.</p>
<p>Long-term effects of patiromer for hyperkalaemia treatment in
patients with mild heart failure and diabetic nephropathy on
angiotensin-converting enzymes/angiotensin receptor blockers: results
from AMETHYST-DN</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>592</p>
<p>–</p>
<p>602</p>
<p>.</p>
<p>774</p>
<p>Agarwal</p>
<p>R</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Romero</p>
<p>A</p>
<p>,</p>
<p>Garza</p>
<p>D</p>
<p>,</p>
<p>Mayo</p>
<p>MR</p>
<p>,</p>
<p>Warren</p>
<p>S</p>
<p>,</p>
<p>Ma</p>
<p>J</p>
<p>,</p>
<p>White</p>
<p>WB</p>
<p>,</p>
<p>Williams</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Patiromer versus placebo to enable spironolactone use in patients
with resistant hypertension and chronic kidney disease (AMBER): a phase
2, randomised, double-blind, placebo-controlled trial</p>
<p>.</p>
<p>Lancet</p>
<p>2019</p>
<p>;</p>
<p>394</p>
<p>:</p>
<p>1540</p>
<p>–</p>
<p>1550</p>
<p>.</p>
<p>775</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Williams</p>
<p>B</p>
<p>,</p>
<p>Mayo</p>
<p>MR</p>
<p>,</p>
<p>Warren</p>
<p>S</p>
<p>,</p>
<p>Arthur</p>
<p>S</p>
<p>,</p>
<p>Ackourey</p>
<p>G</p>
<p>,</p>
<p>White</p>
<p>WB</p>
<p>,</p>
<p>Agarwal</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Patiromer versus placebo to enable spironolactone use in patients
with resistant hypertension and chronic kidney disease (AMBER): results
in the pre-specified subgroup with heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1462</p>
<p>–</p>
<p>1471</p>
<p>.</p>
<p>776</p>
<p>Pitt</p>
<p>B</p>
<p>,</p>
<p>Bushinsky</p>
<p>DA</p>
<p>,</p>
<p>Kitzman</p>
<p>DW</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Rossignol</p>
<p>P</p>
<p>,</p>
<p>Du Mond</p>
<p>C</p>
<p>,</p>
<p>Garza</p>
<p>D</p>
<p>,</p>
<p>Berman</p>
<p>L</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>, Patiromer Investigators</p>
<p>Evaluation of an individualized dose titration regimen of patiromer
to prevent hyperkalaemia in patients with heart failure and chronic
kidney disease</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>257</p>
<p>–</p>
<p>266</p>
<p>.</p>
<p>777</p>
<p>Ali</p>
<p>W</p>
<p>,</p>
<p>Bakris</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Evolution of patiromer use: a review</p>
<p>.</p>
<p>Curr Cardiol Rep</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>94</p>
<p>.</p>
<p>778</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Kremastinos</p>
<p>DT</p>
<p>,</p>
<p>Gheorghiade</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Hyponatremia in heart failure</p>
<p>.</p>
<p>Heart Fail Rev</p>
<p>2009</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>59</p>
<p>–</p>
<p>63</p>
<p>.</p>
<p>779</p>
<p>Rodriguez</p>
<p>M</p>
<p>,</p>
<p>Hernandez</p>
<p>M</p>
<p>,</p>
<p>Cheungpasitporn</p>
<p>W</p>
<p>,</p>
<p>Kashani</p>
<p>KB</p>
<p>,</p>
<p>Riaz</p>
<p>I</p>
<p>,</p>
<p>Rangaswami</p>
<p>J</p>
<p>,</p>
<p>Herzog</p>
<p>E</p>
<p>,</p>
<p>Guglin</p>
<p>M</p>
<p>,</p>
<p>Krittanawong</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Hyponatremia in heart failure: pathogenesis and management</p>
<p>.</p>
<p>Curr Cardiol Rev</p>
<p>2019</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>252</p>
<p>–</p>
<p>261</p>
<p>.</p>
<p>780</p>
<p>Albert</p>
<p>NM</p>
<p>,</p>
<p>Nutter</p>
<p>B</p>
<p>,</p>
<p>Forney</p>
<p>J</p>
<p>,</p>
<p>Slifcak</p>
<p>E</p>
<p>,</p>
<p>Tang</p>
<p>WH.</p>
<p>A randomized controlled pilot study of outcomes of strict allowance
of fluid therapy in hyponatremic heart failure (SALT-HF)</p>
<p>.</p>
<p>J Card Fail</p>
<p>2013</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>9</p>
<p>.</p>
<p>781</p>
<p>Dunlap</p>
<p>ME</p>
<p>,</p>
<p>Hauptman</p>
<p>PJ</p>
<p>,</p>
<p>Amin</p>
<p>AN</p>
<p>,</p>
<p>Chase</p>
<p>SL</p>
<p>,</p>
<p>Chiodo</p>
<p>JA</p>
<p>3rd,</p>
<p>Chiong</p>
<p>JR</p>
<p>,</p>
<p>Dasta</p>
<p>JF.</p>
<p>Current management of hyponatremia in acute heart failure: a report
from the Hyponatremia Registry for Patients With Euvolemic and
Hypervolemic Hyponatremia (HN Registry)</p>
<p>.</p>
<p>J Am Heart Assoc</p>
<p>2017</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>e005261</p>
<p>.</p>
<p>782</p>
<p>Konstam</p>
<p>MA</p>
<p>,</p>
<p>Gheorghiade</p>
<p>M</p>
<p>,</p>
<p>Burnett</p>
<p>JC</p>
<p>Jr,</p>
<p>Grinfeld</p>
<p>L</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Udelson</p>
<p>JE</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Cook</p>
<p>T</p>
<p>,</p>
<p>Ouyang</p>
<p>J</p>
<p>,</p>
<p>Zimmer</p>
<p>C</p>
<p>,</p>
<p>Orlandi</p>
<p>C</p>
<p>,</p>
<p>Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study
With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in
patients hospitalized for worsening heart failure: the EVEREST Outcome
Trial</p>
<p>.</p>
<p>JAMA</p>
<p>2007</p>
<p>;</p>
<p>297</p>
<p>:</p>
<p>1319</p>
<p>–</p>
<p>1331</p>
<p>.</p>
<p>783</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>Mentz</p>
<p>RJ</p>
<p>,</p>
<p>Cole</p>
<p>RT</p>
<p>,</p>
<p>Adams</p>
<p>KF</p>
<p>,</p>
<p>Egnaczyk</p>
<p>GF</p>
<p>,</p>
<p>Fiuzat</p>
<p>M</p>
<p>,</p>
<p>Patel</p>
<p>CB</p>
<p>,</p>
<p>Echols</p>
<p>M</p>
<p>,</p>
<p>Khouri</p>
<p>MG</p>
<p>,</p>
<p>Tauras</p>
<p>JM</p>
<p>,</p>
<p>Gupta</p>
<p>D</p>
<p>,</p>
<p>Monds</p>
<p>P</p>
<p>,</p>
<p>Roberts</p>
<p>R</p>
<p>,</p>
<p>O’Connor</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Efficacy and safety of tolvaptan in patients hospitalized with acute
heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>69</p>
<p>:</p>
<p>1399</p>
<p>–</p>
<p>1406</p>
<p>.</p>
<p>784</p>
<p>Matsue</p>
<p>Y</p>
<p>,</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Suzuki</p>
<p>M</p>
<p>,</p>
<p>Torii</p>
<p>S</p>
<p>,</p>
<p>Yamaguchi</p>
<p>S</p>
<p>,</p>
<p>Fukamizu</p>
<p>S</p>
<p>,</p>
<p>Ono</p>
<p>Y</p>
<p>,</p>
<p>Fujii</p>
<p>H</p>
<p>,</p>
<p>Kitai</p>
<p>T</p>
<p>,</p>
<p>Nishioka</p>
<p>T</p>
<p>,</p>
<p>Sugi</p>
<p>K</p>
<p>,</p>
<p>Onishi</p>
<p>Y</p>
<p>,</p>
<p>Noda</p>
<p>M</p>
<p>,</p>
<p>Kagiyama</p>
<p>N</p>
<p>,</p>
<p>Satoh</p>
<p>Y</p>
<p>,</p>
<p>Yoshida</p>
<p>K</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Voors</p>
<p>AA</p>
<p>,</p>
<p>Goldsmith</p>
<p>SR.</p>
<p>Early treatment with tolvaptan improves diuretic response in acute
heart failure with renal dysfunction</p>
<p>.</p>
<p>Clin Res Cardiol</p>
<p>2017</p>
<p>;</p>
<p>106</p>
<p>:</p>
<p>802</p>
<p>–</p>
<p>812</p>
<p>.</p>
<p>785</p>
<p>Konstam</p>
<p>MA</p>
<p>,</p>
<p>Kiernan</p>
<p>M</p>
<p>,</p>
<p>Chandler</p>
<p>A</p>
<p>,</p>
<p>Dhingra</p>
<p>R</p>
<p>,</p>
<p>Mody</p>
<p>FV</p>
<p>,</p>
<p>Eisen</p>
<p>H</p>
<p>,</p>
<p>Haught</p>
<p>WH</p>
<p>,</p>
<p>Wagoner</p>
<p>L</p>
<p>,</p>
<p>Gupta</p>
<p>D</p>
<p>,</p>
<p>Patten</p>
<p>R</p>
<p>,</p>
<p>Gordon</p>
<p>P</p>
<p>,</p>
<p>Korr</p>
<p>K</p>
<p>,</p>
<p>Fileccia</p>
<p>R</p>
<p>,</p>
<p>Pressler</p>
<p>SJ</p>
<p>,</p>
<p>Gregory</p>
<p>D</p>
<p>,</p>
<p>Wedge</p>
<p>P</p>
<p>,</p>
<p>Dowling</p>
<p>D</p>
<p>,</p>
<p>Romeling</p>
<p>M</p>
<p>,</p>
<p>Konstam</p>
<p>JM</p>
<p>,</p>
<p>Massaro</p>
<p>JM</p>
<p>,</p>
<p>Udelson</p>
<p>JE</p>
<p>,</p>
<p>SECRET of CHF Investigators, Coordinators, and Committee Members.
Short-term effects of tolvaptan in patients with acute heart failure and
volume overload</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>69</p>
<p>:</p>
<p>1409</p>
<p>–</p>
<p>1419</p>
<p>.</p>
<p>786</p>
<p>Licata</p>
<p>G</p>
<p>,</p>
<p>Di Pasquale</p>
<p>P</p>
<p>,</p>
<p>Parrinello</p>
<p>G</p>
<p>,</p>
<p>Cardinale</p>
<p>A</p>
<p>,</p>
<p>Scandurra</p>
<p>A</p>
<p>,</p>
<p>Follone</p>
<p>G</p>
<p>,</p>
<p>Argano</p>
<p>C</p>
<p>,</p>
<p>Tuttolomondo</p>
<p>A</p>
<p>,</p>
<p>Paterna</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Effects of high-dose furosemide and small-volume hypertonic saline
solution infusion in comparison with a high dose of furosemide as bolus
in refractory congestive heart failure: long-term effects</p>
<p>.</p>
<p>Am Heart J</p>
<p>2003</p>
<p>;</p>
<p>145</p>
<p>:</p>
<p>459</p>
<p>–</p>
<p>466</p>
<p>.</p>
<p>787</p>
<p>Paterna</p>
<p>S</p>
<p>,</p>
<p>Di Pasquale</p>
<p>P</p>
<p>,</p>
<p>Parrinello</p>
<p>G</p>
<p>,</p>
<p>Amato</p>
<p>P</p>
<p>,</p>
<p>Cardinale</p>
<p>A</p>
<p>,</p>
<p>Follone</p>
<p>G</p>
<p>,</p>
<p>Giubilato</p>
<p>A</p>
<p>,</p>
<p>Licata</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Effects of high-dose furosemide and small-volume hypertonic saline
solution infusion in comparison with a high dose of furosemide as a
bolus, in refractory congestive heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2000</p>
<p>;</p>
<p>2</p>
<p>:</p>
<p>305</p>
<p>–</p>
<p>313</p>
<p>.</p>
<p>788</p>
<p>Griffin</p>
<p>M</p>
<p>,</p>
<p>Soufer</p>
<p>A</p>
<p>,</p>
<p>Goljo</p>
<p>E</p>
<p>,</p>
<p>Colna</p>
<p>M</p>
<p>,</p>
<p>Rao</p>
<p>VS</p>
<p>,</p>
<p>Jeon</p>
<p>S</p>
<p>,</p>
<p>Raghavendra</p>
<p>P</p>
<p>,</p>
<p>D’Ambrosi</p>
<p>J</p>
<p>,</p>
<p>Riello</p>
<p>R</p>
<p>,</p>
<p>Coca</p>
<p>SG</p>
<p>,</p>
<p>Mahoney</p>
<p>D</p>
<p>,</p>
<p>Jacoby</p>
<p>D</p>
<p>,</p>
<p>Ahmad</p>
<p>T</p>
<p>,</p>
<p>Chen</p>
<p>M</p>
<p>,</p>
<p>Tang</p>
<p>WHW</p>
<p>,</p>
<p>Turner</p>
<p>J</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Wilson</p>
<p>FP</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>Real world use of hypertonic saline in refractory acute decompensated
heart failure: a U.S. center’s experience</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>8</p>
<p>:</p>
<p>199</p>
<p>–</p>
<p>208</p>
<p>.</p>
<p>789</p>
<p>Cuthbert</p>
<p>JJ</p>
<p>,</p>
<p>Pellicori</p>
<p>P</p>
<p>,</p>
<p>Rigby</p>
<p>A</p>
<p>,</p>
<p>Pan</p>
<p>D</p>
<p>,</p>
<p>Kazmi</p>
<p>S</p>
<p>,</p>
<p>Shah</p>
<p>P</p>
<p>,</p>
<p>Clark</p>
<p>AL.</p>
<p>Low serum chloride in patients with chronic heart failure: clinical
associations and prognostic significance</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1426</p>
<p>–</p>
<p>1435</p>
<p>.</p>
<p>790</p>
<p>Testani</p>
<p>JM</p>
<p>,</p>
<p>Hanberg</p>
<p>JS</p>
<p>,</p>
<p>Arroyo</p>
<p>JP</p>
<p>,</p>
<p>Brisco</p>
<p>MA</p>
<p>,</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Wilson</p>
<p>FP</p>
<p>,</p>
<p>Bellumkonda</p>
<p>L</p>
<p>,</p>
<p>Jacoby</p>
<p>D</p>
<p>,</p>
<p>Tang</p>
<p>WH</p>
<p>,</p>
<p>Parikh</p>
<p>CR.</p>
<p>Hypochloraemia is strongly and independently associated with
mortality in patients with chronic heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>660</p>
<p>–</p>
<p>668</p>
<p>.</p>
<p>791</p>
<p>Marchenko</p>
<p>R</p>
<p>,</p>
<p>Sigal</p>
<p>A</p>
<p>,</p>
<p>Wasser</p>
<p>TE</p>
<p>,</p>
<p>Reyer</p>
<p>J</p>
<p>,</p>
<p>Green</p>
<p>J</p>
<p>,</p>
<p>Mercogliano</p>
<p>C</p>
<p>,</p>
<p>Khan</p>
<p>MS</p>
<p>,</p>
<p>Donato</p>
<p>AA.</p>
<p>Hypochloraemia and 30 day readmission rate in patients with acute
decompensated heart failure</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>903</p>
<p>–</p>
<p>907</p>
<p>.</p>
<p>792</p>
<p>Grodin</p>
<p>JL</p>
<p>,</p>
<p>Simon</p>
<p>J</p>
<p>,</p>
<p>Hachamovitch</p>
<p>R</p>
<p>,</p>
<p>Wu</p>
<p>Y</p>
<p>,</p>
<p>Jackson</p>
<p>G</p>
<p>,</p>
<p>Halkar</p>
<p>M</p>
<p>,</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Testani</p>
<p>JM</p>
<p>,</p>
<p>Tang</p>
<p>WH.</p>
<p>Prognostic role of serum chloride levels in acute decompensated heart
failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2015</p>
<p>;</p>
<p>66</p>
<p>:</p>
<p>659</p>
<p>–</p>
<p>666</p>
<p>.</p>
<p>793</p>
<p>Hanberg</p>
<p>JS</p>
<p>,</p>
<p>Rao</p>
<p>V</p>
<p>,</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Laur</p>
<p>O</p>
<p>,</p>
<p>Brisco</p>
<p>MA</p>
<p>,</p>
<p>Perry Wilson</p>
<p>F</p>
<p>,</p>
<p>Grodin</p>
<p>JL</p>
<p>,</p>
<p>Assefa</p>
<p>M</p>
<p>,</p>
<p>Samuel Broughton</p>
<p>J</p>
<p>,</p>
<p>Planavsky</p>
<p>NJ</p>
<p>,</p>
<p>Ahmad</p>
<p>T</p>
<p>,</p>
<p>Bellumkonda</p>
<p>L</p>
<p>,</p>
<p>Tang</p>
<p>WH</p>
<p>,</p>
<p>Parikh</p>
<p>CR</p>
<p>,</p>
<p>Testani</p>
<p>JM.</p>
<p>Hypochloremia and diuretic resistance in heart failure: mechanistic
insights</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>9</p>
<p>.</p>
<p>794</p>
<p>Verbrugge</p>
<p>FH</p>
<p>,</p>
<p>Martens</p>
<p>P</p>
<p>,</p>
<p>Ameloot</p>
<p>K</p>
<p>,</p>
<p>Haemels</p>
<p>V</p>
<p>,</p>
<p>Penders</p>
<p>J</p>
<p>,</p>
<p>Dupont</p>
<p>M</p>
<p>,</p>
<p>Tang</p>
<p>WHW</p>
<p>,</p>
<p>Droogne</p>
<p>W</p>
<p>,</p>
<p>Mullens</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Acetazolamide to increase natriuresis in congestive heart failure at
high risk for diuretic resistance</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1415</p>
<p>–</p>
<p>1422</p>
<p>.</p>
<p>795</p>
<p>Axson</p>
<p>EL</p>
<p>,</p>
<p>Ragutheeswaran</p>
<p>K</p>
<p>,</p>
<p>Sundaram</p>
<p>V</p>
<p>,</p>
<p>Bloom</p>
<p>CI</p>
<p>,</p>
<p>Bottle</p>
<p>A</p>
<p>,</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Quint</p>
<p>JK.</p>
<p>Hospitalisation and mortality in patients with comorbid COPD and
heart failure: a systematic review and meta-analysis</p>
<p>.</p>
<p>Respir Res</p>
<p>2020</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>54</p>
<p>.</p>
<p>796</p>
<p>Canepa</p>
<p>M</p>
<p>,</p>
<p>Straburzynska-Migaj</p>
<p>E</p>
<p>,</p>
<p>Drozdz</p>
<p>J</p>
<p>,</p>
<p>Fernandez-Vivancos</p>
<p>C</p>
<p>,</p>
<p>Pinilla</p>
<p>JMG</p>
<p>,</p>
<p>Nyolczas</p>
<p>N</p>
<p>,</p>
<p>Temporelli</p>
<p>PL</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Ferrari</p>
<p>R</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>ESC-HFA Heart Failure Long-Term Registry Investigators</p>
<p>.</p>
<p>Characteristics, treatments and 1-year prognosis of hospitalized and
ambulatory heart failure patients with chronic obstructive pulmonary
disease in the European Society of Cardiology Heart Failure Long-Term
Registry</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>100</p>
<p>–</p>
<p>110</p>
<p>.</p>
<p>797</p>
<p>Uijl</p>
<p>A</p>
<p>,</p>
<p>Koudstaal</p>
<p>S</p>
<p>,</p>
<p>Direk</p>
<p>K</p>
<p>,</p>
<p>Denaxas</p>
<p>S</p>
<p>,</p>
<p>Groenwold</p>
<p>RHH</p>
<p>,</p>
<p>Banerjee</p>
<p>A</p>
<p>,</p>
<p>Hoes</p>
<p>AW</p>
<p>,</p>
<p>Hemingway</p>
<p>H</p>
<p>,</p>
<p>Asselbergs</p>
<p>FW.</p>
<p>Risk factors for incident heart failure in age- and sex-specific
strata: a population-based cohort using linked electronic health
records</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1197</p>
<p>–</p>
<p>1206</p>
<p>.</p>
<p>798</p>
<p>Caravita</p>
<p>S</p>
<p>,</p>
<p>Vachiery</p>
<p>JL.</p>
<p>Obstructive ventilatory disorder in heart failure–caused by the heart
or the lung?</p>
<p>Curr Heart Fail Rep</p>
<p>2016</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>310</p>
<p>–</p>
<p>318</p>
<p>.</p>
<p>799</p>
<p>Magnussen</p>
<p>H</p>
<p>,</p>
<p>Canepa</p>
<p>M</p>
<p>,</p>
<p>Zambito</p>
<p>PE</p>
<p>,</p>
<p>Brusasco</p>
<p>V</p>
<p>,</p>
<p>Meinertz</p>
<p>T</p>
<p>,</p>
<p>Rosenkranz</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>What can we learn from pulmonary function testing in heart
failure?</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1222</p>
<p>–</p>
<p>1229</p>
<p>.</p>
<p>800</p>
<p>Canepa</p>
<p>M</p>
<p>,</p>
<p>Franssen</p>
<p>FME</p>
<p>,</p>
<p>Olschewski</p>
<p>H</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Rosenkranz</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Diagnostic and therapeutic gaps in patients with heart failure and
chronic obstructive pulmonary disease</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>823</p>
<p>–</p>
<p>833</p>
<p>.</p>
<p>802</p>
<p>Global Initiative for Asthma. Global Strategy for Asthma Management
and Prevention</p>
<p>,</p>
<p>2019</p>
<p>. <a href="http://www.ginasthma.org/">www.ginasthma.org</a> (28 May
2021).</p>
<p>803</p>
<p>Brook</p>
<p>RD</p>
<p>,</p>
<p>Anderson</p>
<p>JA</p>
<p>,</p>
<p>Calverley</p>
<p>PM</p>
<p>,</p>
<p>Celli</p>
<p>BR</p>
<p>,</p>
<p>Crim</p>
<p>C</p>
<p>,</p>
<p>Denvir</p>
<p>MA</p>
<p>,</p>
<p>Magder</p>
<p>S</p>
<p>,</p>
<p>Martinez</p>
<p>FJ</p>
<p>,</p>
<p>Rajagopalan</p>
<p>S</p>
<p>,</p>
<p>Vestbo</p>
<p>J</p>
<p>,</p>
<p>Yates</p>
<p>J</p>
<p>,</p>
<p>Newby</p>
<p>DE</p>
<p>,</p>
<p>SUMMIT Investigators</p>
<p>.</p>
<p>Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid
in patients with COPD at high cardiovascular risk</p>
<p>.</p>
<p>Heart</p>
<p>2017</p>
<p>;</p>
<p>103</p>
<p>:</p>
<p>1536</p>
<p>–</p>
<p>1542</p>
<p>.</p>
<p>804</p>
<p>Vestbo</p>
<p>J</p>
<p>,</p>
<p>Anderson</p>
<p>JA</p>
<p>,</p>
<p>Brook</p>
<p>RD</p>
<p>,</p>
<p>Calverley</p>
<p>PM</p>
<p>,</p>
<p>Celli</p>
<p>BR</p>
<p>,</p>
<p>Crim</p>
<p>C</p>
<p>,</p>
<p>Martinez</p>
<p>F</p>
<p>,</p>
<p>Yates</p>
<p>J</p>
<p>,</p>
<p>Newby</p>
<p>DE</p>
<p>,</p>
<p>SUMMIT Investigators</p>
<p>.</p>
<p>Fluticasone furoate and vilanterol and survival in chronic
obstructive pulmonary disease with heightened cardiovascular risk
(SUMMIT): a double-blind randomised controlled trial</p>
<p>.</p>
<p>Lancet</p>
<p>2016</p>
<p>;</p>
<p>387</p>
<p>:</p>
<p>1817</p>
<p>–</p>
<p>1826</p>
<p>.</p>
<p>805</p>
<p>Hohlfeld</p>
<p>JM</p>
<p>,</p>
<p>Vogel-Claussen</p>
<p>J</p>
<p>,</p>
<p>Biller</p>
<p>H</p>
<p>,</p>
<p>Berliner</p>
<p>D</p>
<p>,</p>
<p>Berschneider</p>
<p>K</p>
<p>,</p>
<p>Tillmann</p>
<p>HC</p>
<p>,</p>
<p>Hiltl</p>
<p>S</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Welte</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Effect of lung deflation with indacaterol plus glycopyrronium on
ventricular filling in patients with hyperinflation and COPD (CLAIM): a
double-blind, randomised, crossover, placebo-controlled, single-centre
trial</p>
<p>.</p>
<p>Lancet Respir Med</p>
<p>2018</p>
<p>;</p>
<p>6</p>
<p>:</p>
<p>368</p>
<p>–</p>
<p>378</p>
<p>.</p>
<p>806</p>
<p>Pearse</p>
<p>SG</p>
<p>,</p>
<p>Cowie</p>
<p>MR.</p>
<p>Sleep-disordered breathing in heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>353</p>
<p>–</p>
<p>361</p>
<p>.</p>
<p>807</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Gallagher</p>
<p>AM.</p>
<p>Sleep disordered breathing and heart failure: what does the future
hold?</p>
<p>JACC Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>5</p>
<p>:</p>
<p>715</p>
<p>–</p>
<p>723</p>
<p>.</p>
<p>808</p>
<p>Cowie</p>
<p>MR</p>
<p>,</p>
<p>Woehrle</p>
<p>H</p>
<p>,</p>
<p>Wegscheider</p>
<p>K</p>
<p>,</p>
<p>Angermann</p>
<p>C</p>
<p>,</p>
<p>d’Ortho</p>
<p>MP</p>
<p>,</p>
<p>Erdmann</p>
<p>E</p>
<p>,</p>
<p>Levy</p>
<p>P</p>
<p>,</p>
<p>Simonds</p>
<p>AK</p>
<p>,</p>
<p>Somers</p>
<p>VK</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Teschler</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Adaptive servo-ventilation for central sleep apnea in systolic heart
failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2015</p>
<p>;</p>
<p>373</p>
<p>:</p>
<p>1095</p>
<p>–</p>
<p>1105</p>
<p>.</p>
<p>809</p>
<p>Costanzo</p>
<p>MR</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Javaheri</p>
<p>S</p>
<p>,</p>
<p>Augostini</p>
<p>R</p>
<p>,</p>
<p>Goldberg</p>
<p>L</p>
<p>,</p>
<p>Holcomb</p>
<p>R</p>
<p>,</p>
<p>Kao</p>
<p>A</p>
<p>,</p>
<p>Khayat</p>
<p>RN</p>
<p>,</p>
<p>Oldenburg</p>
<p>O</p>
<p>,</p>
<p>Stellbrink</p>
<p>C</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>remedé System Pivotal Trial Study Group. Transvenous neurostimulation
for central sleep apnoea: a randomised controlled trial</p>
<p>.</p>
<p>Lancet</p>
<p>2016</p>
<p>;</p>
<p>388</p>
<p>:</p>
<p>974</p>
<p>–</p>
<p>982</p>
<p>.</p>
<p>810</p>
<p>Costanzo</p>
<p>MR</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Coats</p>
<p>A</p>
<p>,</p>
<p>Javaheri</p>
<p>S</p>
<p>,</p>
<p>Augostini</p>
<p>R</p>
<p>,</p>
<p>Goldberg</p>
<p>LR</p>
<p>,</p>
<p>Holcomb</p>
<p>R</p>
<p>,</p>
<p>Kao</p>
<p>A</p>
<p>,</p>
<p>Khayat</p>
<p>RN</p>
<p>,</p>
<p>Oldenburg</p>
<p>O</p>
<p>,</p>
<p>Stellbrink</p>
<p>C</p>
<p>,</p>
<p>McKane</p>
<p>S</p>
<p>,</p>
<p>Abraham</p>
<p>WT</p>
<p>,</p>
<p>remedé System Pivotal Trial Study Group. Phrenic nerve stimulation to
treat patients with central sleep apnoea and heart failure</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1746</p>
<p>–</p>
<p>1754</p>
<p>.</p>
<p>811</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Apetrei</p>
<p>E</p>
<p>,</p>
<p>Barrios</p>
<p>V</p>
<p>,</p>
<p>Böhm</p>
<p>M</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Cornel</p>
<p>JH</p>
<p>,</p>
<p>Dunselman</p>
<p>P</p>
<p>,</p>
<p>Fonseca</p>
<p>C</p>
<p>,</p>
<p>Goudev</p>
<p>A</p>
<p>,</p>
<p>Grande</p>
<p>P</p>
<p>,</p>
<p>Gullestad</p>
<p>L</p>
<p>,</p>
<p>Hjalmarson</p>
<p>A</p>
<p>,</p>
<p>Hradec</p>
<p>J</p>
<p>,</p>
<p>Jánosi</p>
<p>A</p>
<p>,</p>
<p>Kamenský</p>
<p>G</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Korewicki</p>
<p>J</p>
<p>,</p>
<p>Kuusi</p>
<p>T</p>
<p>,</p>
<p>Mach</p>
<p>F</p>
<p>,</p>
<p>Mareev</p>
<p>V</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Ranjith</p>
<p>N</p>
<p>,</p>
<p>Schaufelberger</p>
<p>M</p>
<p>,</p>
<p>Vanhaecke</p>
<p>J</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Waagstein</p>
<p>F</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>CORONA Group</p>
<p>.</p>
<p>Rosuvastatin in older patients with systolic heart failure</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2007</p>
<p>;</p>
<p>357</p>
<p>:</p>
<p>2248</p>
<p>–</p>
<p>2261</p>
<p>.</p>
<p>812</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Marchioli</p>
<p>R</p>
<p>,</p>
<p>Barlera</p>
<p>S</p>
<p>,</p>
<p>Franzosi</p>
<p>MG</p>
<p>,</p>
<p>Latini</p>
<p>R</p>
<p>,</p>
<p>Lucci</p>
<p>D</p>
<p>,</p>
<p>Nicolosi</p>
<p>GL</p>
<p>,</p>
<p>Porcu</p>
<p>M</p>
<p>,</p>
<p>Tognoni</p>
<p>G</p>
<p>,</p>
<p>GISSI-HF Investigators</p>
<p>.</p>
<p>Effect of rosuvastatin in patients with chronic heart failure (the
GISSI-HF trial): a randomised, double-blind, placebo-controlled
trial</p>
<p>.</p>
<p>Lancet</p>
<p>2008</p>
<p>;</p>
<p>372</p>
<p>:</p>
<p>1231</p>
<p>–</p>
<p>1239</p>
<p>.</p>
<p>813</p>
<p>Al-Gobari</p>
<p>M</p>
<p>,</p>
<p>Le</p>
<p>HH</p>
<p>,</p>
<p>Fall</p>
<p>M</p>
<p>,</p>
<p>Gueyffier</p>
<p>F</p>
<p>,</p>
<p>Burnand</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>No benefits of statins for sudden cardiac death prevention in
patients with heart failure and reduced ejection fraction: a
meta-analysis of randomized controlled trials</p>
<p>.</p>
<p>PLoS One</p>
<p>2017</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>e0171168</p>
<p>.</p>
<p>814</p>
<p>Rogers</p>
<p>JK</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Perez</p>
<p>AC</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Gullestad</p>
<p>L</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Wedel</p>
<p>H</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Pocock</p>
<p>SJ.</p>
<p>Effect of rosuvastatin on repeat heart failure hospitalizations: the
CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart
Failure)</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>2</p>
<p>:</p>
<p>289</p>
<p>–</p>
<p>297</p>
<p>.</p>
<p>815</p>
<p>Feinstein</p>
<p>MJ</p>
<p>,</p>
<p>Jhund</p>
<p>P</p>
<p>,</p>
<p>Kang</p>
<p>J</p>
<p>,</p>
<p>Ning</p>
<p>H</p>
<p>,</p>
<p>Maggioni</p>
<p>A</p>
<p>,</p>
<p>Wikstrand</p>
<p>J</p>
<p>,</p>
<p>Kjekshus</p>
<p>J</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>McMurray</p>
<p>J</p>
<p>,</p>
<p>Lloyd-Jones</p>
<p>DM.</p>
<p>Do statins reduce the risk of myocardial infarction in patients with
heart failure? A pooled individual-level reanalysis of CORONA and
GISSI-HF</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2015</p>
<p>;</p>
<p>17</p>
<p>:</p>
<p>434</p>
<p>–</p>
<p>441</p>
<p>.</p>
<p>816</p>
<p>Thanassoulis</p>
<p>G</p>
<p>,</p>
<p>Brophy</p>
<p>JM</p>
<p>,</p>
<p>Richard</p>
<p>H</p>
<p>,</p>
<p>Pilote</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Gout, allopurinol use, and heart failure outcomes</p>
<p>.</p>
<p>Arch Intern Med</p>
<p>2010</p>
<p>;</p>
<p>170</p>
<p>:</p>
<p>1358</p>
<p>–</p>
<p>1364</p>
<p>.</p>
<p>817</p>
<p>Borghi</p>
<p>C</p>
<p>,</p>
<p>Palazzuoli</p>
<p>A</p>
<p>,</p>
<p>Landolfo</p>
<p>M</p>
<p>,</p>
<p>Cosentino</p>
<ol start="5" type="A">
<li></li>
</ol>
<p>Hyperuricemia: a novel old disorder-relationship and potential
mechanisms in heart failure</p>
<p>.</p>
<p>Heart Fail Rev</p>
<p>2020</p>
<p>;</p>
<p>25</p>
<p>:</p>
<p>43</p>
<p>–</p>
<p>51</p>
<p>.</p>
<p>818</p>
<p>Doehner</p>
<p>W</p>
<p>,</p>
<p>Springer</p>
<p>J</p>
<p>,</p>
<p>Landmesser</p>
<p>U</p>
<p>,</p>
<p>Struthers</p>
<p>AD</p>
<p>,</p>
<p>Anker</p>
<p>SD.</p>
<p>Uric acid in chronic heart failure–current pathophysiological
concepts</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2008</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>1269</p>
<p>–</p>
<p>1270</p>
<p>.</p>
<p>819</p>
<p>Huang</p>
<p>H</p>
<p>,</p>
<p>Huang</p>
<p>B</p>
<p>,</p>
<p>Li</p>
<p>Y</p>
<p>,</p>
<p>Huang</p>
<p>Y</p>
<p>,</p>
<p>Li</p>
<p>J</p>
<p>,</p>
<p>Yao</p>
<p>H</p>
<p>,</p>
<p>Jing</p>
<p>X</p>
<p>,</p>
<p>Chen</p>
<p>J</p>
<p>,</p>
<p>Wang</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Uric acid and risk of heart failure: a systematic review and
meta-analysis</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2014</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>15</p>
<p>–</p>
<p>24</p>
<p>.</p>
<p>820</p>
<p>White</p>
<p>WB</p>
<p>,</p>
<p>Saag</p>
<p>KG</p>
<p>,</p>
<p>Becker</p>
<p>MA</p>
<p>,</p>
<p>Borer</p>
<p>JS</p>
<p>,</p>
<p>Gorelick</p>
<p>PB</p>
<p>,</p>
<p>Whelton</p>
<p>A</p>
<p>,</p>
<p>Hunt</p>
<p>B</p>
<p>,</p>
<p>Castillo</p>
<p>M</p>
<p>,</p>
<p>Gunawardhana</p>
<p>L</p>
<p>,</p>
<p>CARES Investigators</p>
<p>.</p>
<p>Cardiovascular safety of febuxostat or allopurinol in patients with
gout</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>378</p>
<p>:</p>
<p>1200</p>
<p>–</p>
<p>1210</p>
<p>.</p>
<p>821</p>
<p>Hare</p>
<p>JM</p>
<p>,</p>
<p>Mangal</p>
<p>B</p>
<p>,</p>
<p>Brown</p>
<p>J</p>
<p>,</p>
<p>Fisher</p>
<p>C</p>
<p>Jr.,</p>
<p>Freudenberger</p>
<p>R</p>
<p>,</p>
<p>Colucci</p>
<p>WS</p>
<p>,</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>Liu</p>
<p>P</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Schwarz</p>
<p>RP</p>
<p>,</p>
<p>OPT-CHF Investigators</p>
<p>.</p>
<p>Impact of oxypurinol in patients with symptomatic heart failure.
Results of the OPT-CHF study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2008</p>
<p>;</p>
<p>51</p>
<p>:</p>
<p>2301</p>
<p>–</p>
<p>2309</p>
<p>.</p>
<p>822</p>
<p>Ogino</p>
<p>K</p>
<p>,</p>
<p>Kato</p>
<p>M</p>
<p>,</p>
<p>Furuse</p>
<p>Y</p>
<p>,</p>
<p>Kinugasa</p>
<p>Y</p>
<p>,</p>
<p>Ishida</p>
<p>K</p>
<p>,</p>
<p>Osaki</p>
<p>S</p>
<p>,</p>
<p>Kinugawa</p>
<p>T</p>
<p>,</p>
<p>Igawa</p>
<p>O</p>
<p>,</p>
<p>Hisatome</p>
<p>I</p>
<p>,</p>
<p>Shigemasa</p>
<p>C</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Doehner</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Uric acid-lowering treatment with benzbromarone in patients with
heart failure: a double-blind placebo-controlled crossover preliminary
study</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2010</p>
<p>;</p>
<p>3</p>
<p>:</p>
<p>73</p>
<p>–</p>
<p>81</p>
<p>.</p>
<p>823</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Anstrom</p>
<p>KJ</p>
<p>,</p>
<p>Redfield</p>
<p>MM</p>
<p>,</p>
<p>Deswal</p>
<p>A</p>
<p>,</p>
<p>Haddad</p>
<p>H</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Tang</p>
<p>WH</p>
<p>,</p>
<p>Dunlap</p>
<p>ME</p>
<p>,</p>
<p>LeWinter</p>
<p>MM</p>
<p>,</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>Felker</p>
<p>GM</p>
<p>,</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Goldsmith</p>
<p>SR</p>
<p>,</p>
<p>Ofili</p>
<p>EO</p>
<p>,</p>
<p>Saltzberg</p>
<p>MT</p>
<p>,</p>
<p>Margulies</p>
<p>KB</p>
<p>,</p>
<p>Cappola</p>
<p>TP</p>
<p>,</p>
<p>Konstam</p>
<p>MA</p>
<p>,</p>
<p>Semigran</p>
<p>MJ</p>
<p>,</p>
<p>McNulty</p>
<p>SE</p>
<p>,</p>
<p>Lee</p>
<p>KL</p>
<p>,</p>
<p>Shah</p>
<p>MR</p>
<p>,</p>
<p>Hernandez</p>
<p>AF</p>
<p>,</p>
<p>NHLBI Heart Failure Clinical Research Network. Effects of xanthine
oxidase inhibition in hyperuricemic heart failure patients: the Xanthine
Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF)
study</p>
<p>.</p>
<p>Circulation</p>
<p>2015</p>
<p>;</p>
<p>131</p>
<p>:</p>
<p>1763</p>
<p>–</p>
<p>1771</p>
<p>.</p>
<p>824</p>
<p>Verma</p>
<p>S</p>
<p>,</p>
<p>Eikelboom</p>
<p>JW</p>
<p>,</p>
<p>Nidorf</p>
<p>SM</p>
<p>,</p>
<p>Al-Omran</p>
<p>M</p>
<p>,</p>
<p>Gupta</p>
<p>N</p>
<p>,</p>
<p>Teoh</p>
<p>H</p>
<p>,</p>
<p>Friedrich</p>
<p>JO.</p>
<p>Colchicine in cardiac disease: a systematic review and meta-analysis
of randomized controlled trials</p>
<p>.</p>
<p>BMC Cardiovasc Disord</p>
<p>2015</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>96</p>
<p>.</p>
<p>825</p>
<p>Frommeyer</p>
<p>G</p>
<p>,</p>
<p>Krawczyk</p>
<p>J</p>
<p>,</p>
<p>Dechering</p>
<p>DG</p>
<p>,</p>
<p>Kochhauser</p>
<p>S</p>
<p>,</p>
<p>Leitz</p>
<p>P</p>
<p>,</p>
<p>Fehr</p>
<p>M</p>
<p>,</p>
<p>Eckardt</p>
<ol start="12" type="A">
<li></li>
</ol>
<p>Colchicine increases ventricular vulnerability in an experimental
whole-heart model</p>
<p>.</p>
<p>Basic Clin Pharmacol Toxicol</p>
<p>2017</p>
<p>;</p>
<p>120</p>
<p>:</p>
<p>505</p>
<p>–</p>
<p>508</p>
<p>.</p>
<p>826</p>
<p>Arfe</p>
<p>A</p>
<p>,</p>
<p>Scotti</p>
<p>L</p>
<p>,</p>
<p>Varas-Lorenzo</p>
<p>C</p>
<p>,</p>
<p>Nicotra</p>
<p>F</p>
<p>,</p>
<p>Zambon</p>
<p>A</p>
<p>,</p>
<p>Kollhorst</p>
<p>B</p>
<p>,</p>
<p>Schink</p>
<p>T</p>
<p>,</p>
<p>Garbe</p>
<p>E</p>
<p>,</p>
<p>Herings</p>
<p>R</p>
<p>,</p>
<p>Straatman</p>
<p>H</p>
<p>,</p>
<p>Schade</p>
<p>R</p>
<p>,</p>
<p>Villa</p>
<p>M</p>
<p>,</p>
<p>Lucchi</p>
<p>S</p>
<p>,</p>
<p>Valkhoff</p>
<p>V</p>
<p>,</p>
<p>Romio</p>
<p>S</p>
<p>,</p>
<p>Thiessard</p>
<p>F</p>
<p>,</p>
<p>Schuemie</p>
<p>M</p>
<p>,</p>
<p>Pariente</p>
<p>A</p>
<p>,</p>
<p>Sturkenboom</p>
<p>M</p>
<p>,</p>
<p>Corrao</p>
<p>G</p>
<p>,</p>
<p>Safety of Non-steroidal Anti-inflammatory Drugs Project
Consortium</p>
<p>.</p>
<p>Non-steroidal anti-inflammatory drugs and risk of heart failure in
four European countries: nested case-control study</p>
<p>.</p>
<p>BMJ</p>
<p>2016</p>
<p>;</p>
<p>354</p>
<p>:</p>
<p>i4857</p>
<p>.</p>
<p>827</p>
<p>Khalid</p>
<p>Y</p>
<p>,</p>
<p>Dasu</p>
<p>N</p>
<p>,</p>
<p>Shah</p>
<p>A</p>
<p>,</p>
<p>Brown</p>
<p>K</p>
<p>,</p>
<p>Kaell</p>
<p>A</p>
<p>,</p>
<p>Levine</p>
<p>A</p>
<p>,</p>
<p>Dasu</p>
<p>K</p>
<p>,</p>
<p>Raminfard</p>
<ol type="A">
<li></li>
</ol>
<p>Incidence of congestive heart failure in rheumatoid arthritis: a
review of literature and meta-regression analysis</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>3745</p>
<p>–</p>
<p>3753</p>
<p>.</p>
<p>828</p>
<p>Mantel</p>
<p>A</p>
<p>,</p>
<p>Holmqvist</p>
<p>M</p>
<p>,</p>
<p>Andersson</p>
<p>DC</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Askling</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Association between rheumatoid arthritis and risk of ischemic and
nonischemic heart failure</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2017</p>
<p>;</p>
<p>69</p>
<p>:</p>
<p>1275</p>
<p>–</p>
<p>1285</p>
<p>.</p>
<p>829</p>
<p>Chung</p>
<p>ES</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Lo</p>
<p>KH</p>
<p>,</p>
<p>Fasanmade</p>
<p>AA</p>
<p>,</p>
<p>Willerson</p>
<p>JT</p>
<p>,</p>
<p>Anti-TNF Therapy Against Congestive Heart Failure Investigators.
Randomized, double-blind, placebo-controlled, pilot trial of infliximab,
a chimeric monoclonal antibody to tumor necrosis factor-alpha, in
patients with moderate-to-severe heart failure: results of the anti-TNF
Therapy Against Congestive Heart Failure (ATTACH) trial</p>
<p>.</p>
<p>Circulation</p>
<p>2003</p>
<p>;</p>
<p>107</p>
<p>:</p>
<p>3133</p>
<p>–</p>
<p>3140</p>
<p>.</p>
<p>830</p>
<p>Mann</p>
<p>DL</p>
<p>,</p>
<p>McMurray</p>
<p>JJ</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Borer</p>
<p>JS</p>
<p>,</p>
<p>Colucci</p>
<p>WS</p>
<p>,</p>
<p>Djian</p>
<p>J</p>
<p>,</p>
<p>Drexler</p>
<p>H</p>
<p>,</p>
<p>Feldman</p>
<p>A</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Krum</p>
<p>H</p>
<p>,</p>
<p>Liu</p>
<p>P</p>
<p>,</p>
<p>Nieminen</p>
<p>M</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Waldenstrom</p>
<p>A</p>
<p>,</p>
<p>Warren</p>
<p>M</p>
<p>,</p>
<p>Westheim</p>
<p>A</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Fleming</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Targeted anticytokine therapy in patients with chronic heart failure:
results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)</p>
<p>.</p>
<p>Circulation</p>
<p>2004</p>
<p>;</p>
<p>109</p>
<p>:</p>
<p>1594</p>
<p>–</p>
<p>1602</p>
<p>.</p>
<p>831</p>
<p>Kotyla</p>
<p>PJ.</p>
<p>Bimodal function of anti-TNF treatment: shall we be concerned about
anti-TNF treatment in patients with rheumatoid arthritis and heart
failure?</p>
<p>Int J Mol Sci</p>
<p>2018</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>1739</p>
<p>.</p>
<p>832</p>
<p>Baumhakel</p>
<p>M</p>
<p>,</p>
<p>Schlimmer</p>
<p>N</p>
<p>,</p>
<p>Kratz</p>
<p>M</p>
<p>,</p>
<p>Hackett</p>
<p>G</p>
<p>,</p>
<p>Jackson</p>
<p>G</p>
<p>,</p>
<p>Bohm</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Cardiovascular risk, drugs and erectile function–a systematic
analysis</p>
<p>.</p>
<p>Int J Clin Pract</p>
<p>2011</p>
<p>;</p>
<p>65</p>
<p>:</p>
<p>289</p>
<p>–</p>
<p>298</p>
<p>.</p>
<p>833</p>
<p>Jaarsma</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Sexual function of patients with heart failure: facts and numbers</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>3</p>
<p>–</p>
<p>7</p>
<p>.</p>
<p>834</p>
<p>Levine</p>
<p>AB</p>
<p>,</p>
<p>Punihaole</p>
<p>D</p>
<p>,</p>
<p>Levine</p>
<p>TB.</p>
<p>Characterization of the role of nitric oxide and its clinical
applications</p>
<p>.</p>
<p>Cardiology</p>
<p>2012</p>
<p>;</p>
<p>122</p>
<p>:</p>
<p>55</p>
<p>–</p>
<p>68</p>
<p>.</p>
<p>835</p>
<p>Giannetta</p>
<p>E</p>
<p>,</p>
<p>Feola</p>
<p>T</p>
<p>,</p>
<p>Gianfrilli</p>
<p>D</p>
<p>,</p>
<p>Pofi</p>
<p>R</p>
<p>,</p>
<p>Dall’Armi</p>
<p>V</p>
<p>,</p>
<p>Badagliacca</p>
<p>R</p>
<p>,</p>
<p>Barbagallo</p>
<p>F</p>
<p>,</p>
<p>Lenzi</p>
<p>A</p>
<p>,</p>
<p>Isidori</p>
<p>AM.</p>
<p>Is chronic inhibition of phosphodiesterase type 5 cardioprotective
and safe? A meta-analysis of randomized controlled trials</p>
<p>.</p>
<p>BMC Med</p>
<p>2014</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>185</p>
<p>.</p>
<p>836</p>
<p>Angermann</p>
<p>CE</p>
<p>,</p>
<p>Ertl</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Depression, anxiety, and cognitive impairment: comorbid mental health
disorders in heart failure</p>
<p>.</p>
<p>Curr Heart Fail Rep</p>
<p>2018</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>398</p>
<p>–</p>
<p>410</p>
<p>.</p>
<p>837</p>
<p>Sbolli</p>
<p>M</p>
<p>,</p>
<p>Fiuzat</p>
<p>M</p>
<p>,</p>
<p>Cani</p>
<p>D</p>
<p>,</p>
<p>O’Connor</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Depression and heart failure: the lonely comorbidity</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2007</p>
<p>–</p>
<p>2017</p>
<p>.</p>
<p>838</p>
<p>Jha</p>
<p>MK</p>
<p>,</p>
<p>Qamar</p>
<p>A</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Charney</p>
<p>DS</p>
<p>,</p>
<p>Murrough</p>
<p>JW.</p>
<p>Screening and management of depression in patients with
cardiovascular disease: JACC state-of-the-art review</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>73</p>
<p>:</p>
<p>1827</p>
<p>–</p>
<p>1845</p>
<p>.</p>
<p>839</p>
<p>Berkman</p>
<p>LF</p>
<p>,</p>
<p>Blumenthal</p>
<p>J</p>
<p>,</p>
<p>Burg</p>
<p>M</p>
<p>,</p>
<p>Carney</p>
<p>RM</p>
<p>,</p>
<p>Catellier</p>
<p>D</p>
<p>,</p>
<p>Cowan</p>
<p>MJ</p>
<p>,</p>
<p>Czajkowski</p>
<p>SM</p>
<p>,</p>
<p>DeBusk</p>
<p>R</p>
<p>,</p>
<p>Hosking</p>
<p>J</p>
<p>,</p>
<p>Jaffe</p>
<p>A</p>
<p>,</p>
<p>Kaufmann</p>
<p>PG</p>
<p>,</p>
<p>Mitchell</p>
<p>P</p>
<p>,</p>
<p>Norman</p>
<p>J</p>
<p>,</p>
<p>Powell</p>
<p>LH</p>
<p>,</p>
<p>Raczynski</p>
<p>JM</p>
<p>,</p>
<p>Schneiderman</p>
<p>N</p>
<p>,</p>
<p>Enhancing Recovery in Coronary Heart Disease Patients Investigators.
Effects of treating depression and low perceived social support on
clinical events after myocardial infarction: the Enhancing Recovery in
Coronary Heart Disease Patients (ENRICHD) randomized trial</p>
<p>.</p>
<p>JAMA</p>
<p>2003</p>
<p>;</p>
<p>289</p>
<p>:</p>
<p>3106</p>
<p>–</p>
<p>3116</p>
<p>.</p>
<p>840</p>
<p>O’Connor</p>
<p>CM</p>
<p>,</p>
<p>Jiang</p>
<p>W</p>
<p>,</p>
<p>Kuchibhatla</p>
<p>M</p>
<p>,</p>
<p>Silva</p>
<p>SG</p>
<p>,</p>
<p>Cuffe</p>
<p>MS</p>
<p>,</p>
<p>Callwood</p>
<p>DD</p>
<p>,</p>
<p>Zakhary</p>
<p>B</p>
<p>,</p>
<p>Stough</p>
<p>WG</p>
<p>,</p>
<p>Arias</p>
<p>RM</p>
<p>,</p>
<p>Rivelli</p>
<p>SK</p>
<p>,</p>
<p>Krishnan</p>
<p>R</p>
<p>SADHART-CHF Investigators</p>
<p>.</p>
<p>Safety and efficacy of sertraline for depression in patients with
heart failure: results of the SADHART-CHF (Sertraline Against Depression
and Heart Disease in Chronic Heart Failure) trial</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2010</p>
<p>;</p>
<p>56</p>
<p>:</p>
<p>692</p>
<p>–</p>
<p>699</p>
<p>.</p>
<p>841</p>
<p>Angermann</p>
<p>CE</p>
<p>,</p>
<p>Gelbrich</p>
<p>G</p>
<p>,</p>
<p>Stork</p>
<p>S</p>
<p>,</p>
<p>Gunold</p>
<p>H</p>
<p>,</p>
<p>Edelmann</p>
<p>F</p>
<p>,</p>
<p>Wachter</p>
<p>R</p>
<p>,</p>
<p>Schunkert</p>
<p>H</p>
<p>,</p>
<p>Graf</p>
<p>T</p>
<p>,</p>
<p>Kindermann</p>
<p>I</p>
<p>,</p>
<p>Haass</p>
<p>M</p>
<p>,</p>
<p>Blankenberg</p>
<p>S</p>
<p>,</p>
<p>Pankuweit</p>
<p>S</p>
<p>,</p>
<p>Prettin</p>
<p>C</p>
<p>,</p>
<p>Gottwik</p>
<p>M</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Faller</p>
<p>H</p>
<p>,</p>
<p>Deckert</p>
<p>J</p>
<p>,</p>
<p>Ertl</p>
<p>G</p>
<p>,</p>
<p>MOOD-HF Study Investigators and Committee Members. Effect of
escitalopram on all-cause mortality and hospitalization in patients with
heart failure and depression: the MOOD-HF randomized clinical trial</p>
<p>.</p>
<p>JAMA</p>
<p>2016</p>
<p>;</p>
<p>315</p>
<p>:</p>
<p>2683</p>
<p>–</p>
<p>2693</p>
<p>.</p>
<p>842</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Meijers</p>
<p>WC</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ.</p>
<p>Cancer and heart disease: associations and relations</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1515</p>
<p>–</p>
<p>1525</p>
<p>.</p>
<p>843</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Mantzourani</p>
<p>M</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Anthracycline-induced cardiomyopathy: secrets and lies</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>907</p>
<p>–</p>
<p>909</p>
<p>.</p>
<p>844</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Rodriguez Munoz</p>
<p>D</p>
<p>,</p>
<p>Aboyans</p>
<p>V</p>
<p>,</p>
<p>Asteggiano</p>
<p>R</p>
<p>,</p>
<p>Galderisi</p>
<p>M</p>
<p>,</p>
<p>Habib</p>
<p>G</p>
<p>,</p>
<p>Lenihan</p>
<p>DJ</p>
<p>,</p>
<p>Lip</p>
<p>GY</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Lopez Fernandez</p>
<p>T</p>
<p>,</p>
<p>Mohty</p>
<p>D</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Tamargo</p>
<p>J</p>
<p>,</p>
<p>Torbicki</p>
<p>A</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Aboyans</p>
<p>V</p>
<p>,</p>
<p>Achenbach</p>
<p>S</p>
<p>,</p>
<p>Agewall</p>
<p>S</p>
<p>,</p>
<p>Badimon</p>
<p>L</p>
<p>,</p>
<p>Baron-Esquivias</p>
<p>G</p>
<p>,</p>
<p>Baumgartner</p>
<p>H</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Carerj</p>
<p>S</p>
<p>,</p>
<p>Dean</p>
<p>V</p>
<p>,</p>
<p>Erol</p>
<p>C</p>
<p>,</p>
<p>Fitzsimons</p>
<p>D</p>
<p>,</p>
<p>Gaemperli</p>
<p>O</p>
<p>,</p>
<p>Kirchhof</p>
<p>P</p>
<p>,</p>
<p>Kolh</p>
<p>P</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Lip</p>
<p>GY</p>
<p>,</p>
<p>Nihoyannopoulos</p>
<p>P</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Roffi</p>
<p>M</p>
<p>,</p>
<p>Torbicki</p>
<p>A</p>
<p>,</p>
<p>Vaz Carneiro</p>
<p>A</p>
<p>,</p>
<p>Windecker</p>
<p>S</p>
<p>, Authors/Task Force Members, ESC Committee for Practice Guidelines,
Document Reviewers.</p>
<p>2016 ESC Position Paper on cancer treatments and cardiovascular
toxicity developed under the auspices of the ESC Committee for Practice
Guidelines: The Task Force for cancer treatments and cardiovascular
toxicity of the European Society of Cardiology (ESC)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>9</p>
<p>–</p>
<p>42</p>
<p>.</p>
<p>845</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Gottfridsson</p>
<p>C</p>
<p>,</p>
<p>Asteggiano</p>
<p>R</p>
<p>,</p>
<p>Atar</p>
<p>D</p>
<p>,</p>
<p>Badimon</p>
<p>L</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Cardinale</p>
<p>D</p>
<p>,</p>
<p>Cardone</p>
<p>A</p>
<p>,</p>
<p>Feijen</p>
<p>EAM</p>
<p>,</p>
<p>Ferdinandy</p>
<p>P</p>
<p>,</p>
<p>Lopez-Fernandez</p>
<p>T</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Maduro</p>
<p>JH</p>
<p>,</p>
<p>Moslehi</p>
<p>J</p>
<p>,</p>
<p>Omland</p>
<p>T</p>
<p>,</p>
<p>Plana Gomez</p>
<p>JC</p>
<p>,</p>
<p>Scott</p>
<p>J</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Minotti</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>The cancer patient and cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2290</p>
<p>–</p>
<p>2309</p>
<p>.</p>
<p>846</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Dent</p>
<p>S</p>
<p>,</p>
<p>Stanway</p>
<p>S</p>
<p>,</p>
<p>Earl</p>
<p>H</p>
<p>,</p>
<p>Brezden-Masley</p>
<p>C</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Moslehi</p>
<p>JJ</p>
<p>,</p>
<p>Groarke</p>
<p>JD</p>
<p>,</p>
<p>Bergler-Klein</p>
<p>J</p>
<p>,</p>
<p>Khoo</p>
<p>V</p>
<p>,</p>
<p>Tan</p>
<p>LL</p>
<p>,</p>
<p>Anker</p>
<p>MS</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Maack</p>
<p>C</p>
<p>,</p>
<p>Pudil</p>
<p>R</p>
<p>,</p>
<p>Barac</p>
<p>A</p>
<p>,</p>
<p>Thavendiranathan</p>
<p>P</p>
<p>,</p>
<p>Ky</p>
<p>B</p>
<p>,</p>
<p>Neilan</p>
<p>TG</p>
<p>,</p>
<p>Belenkov</p>
<p>Y</p>
<p>,</p>
<p>Rosen</p>
<p>SD</p>
<p>,</p>
<p>Iakobishvili</p>
<p>Z</p>
<p>,</p>
<p>Sverdlov</p>
<p>AL</p>
<p>,</p>
<p>Hajjar</p>
<p>LA</p>
<p>,</p>
<p>Macedo</p>
<p>AVS</p>
<p>,</p>
<p>Manisty</p>
<p>C</p>
<p>,</p>
<p>Ciardiello</p>
<p>F</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Skouri</p>
<p>H</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Cardinale</p>
<p>D</p>
<p>,</p>
<p>Witteles</p>
<p>RM</p>
<p>,</p>
<p>Fradley</p>
<p>MG</p>
<p>,</p>
<p>Herrmann</p>
<p>J</p>
<p>,</p>
<p>Cornell</p>
<p>RF</p>
<p>,</p>
<p>Wechelaker</p>
<p>A</p>
<p>,</p>
<p>Mauro</p>
<p>MJ</p>
<p>,</p>
<p>Milojkovic</p>
<p>D</p>
<p>,</p>
<p>de Lavallade</p>
<p>H</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Andres</p>
<p>MS</p>
<p>,</p>
<p>Wright</p>
<p>DJ</p>
<p>,</p>
<p>Lopez-Fernandez</p>
<p>T</p>
<p>,</p>
<p>Plummer</p>
<p>C</p>
<p>,</p>
<p>Lenihan</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Baseline cardiovascular risk assessment in cancer patients scheduled
to receive cardiotoxic cancer therapies: a position statement and new
risk assessment tools from the Cardio-Oncology Study Group of the Heart
Failure Association of the European Society of Cardiology in
collaboration with the International Cardio-Oncology Society</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1945</p>
<p>–</p>
<p>1960</p>
<p>.</p>
<p>847</p>
<p>Ganatra</p>
<p>S</p>
<p>,</p>
<p>Carver</p>
<p>JR</p>
<p>,</p>
<p>Hayek</p>
<p>SS</p>
<p>,</p>
<p>Ky</p>
<p>B</p>
<p>,</p>
<p>Leja</p>
<p>MJ</p>
<p>,</p>
<p>Lenihan</p>
<p>DJ</p>
<p>,</p>
<p>Lenneman</p>
<p>C</p>
<p>,</p>
<p>Mousavi</p>
<p>N</p>
<p>,</p>
<p>Park</p>
<p>JH</p>
<p>,</p>
<p>Perales</p>
<p>MA</p>
<p>,</p>
<p>Ryan</p>
<p>TD</p>
<p>,</p>
<p>Scherrer-Crosbie</p>
<p>M</p>
<p>,</p>
<p>Steingart</p>
<p>RM</p>
<p>,</p>
<p>Yang</p>
<p>EH</p>
<p>,</p>
<p>Zaha</p>
<p>V</p>
<p>,</p>
<p>Barac</p>
<p>A</p>
<p>,</p>
<p>Liu</p>
<p>JE.</p>
<p>Chimeric antigen receptor T-cell therapy for cancer and heart: JACC
council perspectives</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>74</p>
<p>:</p>
<p>3153</p>
<p>–</p>
<p>3163</p>
<p>.</p>
<p>848</p>
<p>Lenneman</p>
<p>CG</p>
<p>,</p>
<p>Sawyer</p>
<p>DB.</p>
<p>Cardio-oncology: an update on cardiotoxicity of cancer-related
treatment</p>
<p>.</p>
<p>Circ Res</p>
<p>2016</p>
<p>;</p>
<p>118</p>
<p>:</p>
<p>1008</p>
<p>–</p>
<p>1020</p>
<p>.</p>
<p>849</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Yousaf</p>
<p>N</p>
<p>,</p>
<p>Battisti</p>
<p>NML</p>
<p>,</p>
<p>Moslehi</p>
<p>J</p>
<p>,</p>
<p>Larkin</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Immune checkpoint inhibitors and cardiovascular toxicity</p>
<p>.</p>
<p>Lancet Oncol</p>
<p>2018</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>e447</p>
<p>–</p>
<p>e458</p>
<p>.</p>
<p>850</p>
<p>Boekel</p>
<p>NB</p>
<p>,</p>
<p>Duane</p>
<p>FK</p>
<p>,</p>
<p>Jacobse</p>
<p>JN</p>
<p>,</p>
<p>Hauptmann</p>
<p>M</p>
<p>,</p>
<p>Schaapveld</p>
<p>M</p>
<p>,</p>
<p>Sonke</p>
<p>GS</p>
<p>,</p>
<p>Gietema</p>
<p>JA</p>
<p>,</p>
<p>Hooning</p>
<p>MJ</p>
<p>,</p>
<p>Seynaeve</p>
<p>CM</p>
<p>,</p>
<p>Maas</p>
<p>A</p>
<p>,</p>
<p>Darby</p>
<p>SC</p>
<p>,</p>
<p>Aleman</p>
<p>BMP</p>
<p>,</p>
<p>Taylor</p>
<p>CW</p>
<p>,</p>
<p>van Leeuwen</p>
<p>FE.</p>
<p>Heart failure after treatment for breast cancer</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>366</p>
<p>–</p>
<p>374</p>
<p>.</p>
<p>851</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Parissis</p>
<p>J</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Insights into onco-cardiology: atrial fibrillation in cancer</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2014</p>
<p>;</p>
<p>63</p>
<p>:</p>
<p>945</p>
<p>–</p>
<p>953</p>
<p>.</p>
<p>852</p>
<p>Tromp</p>
<p>J</p>
<p>,</p>
<p>Boerman</p>
<p>LM</p>
<p>,</p>
<p>Sama</p>
<p>IE</p>
<p>,</p>
<p>Maass</p>
<p>S</p>
<p>,</p>
<p>Maduro</p>
<p>JH</p>
<p>,</p>
<p>Hummel</p>
<p>YM</p>
<p>,</p>
<p>Berger</p>
<p>MY</p>
<p>,</p>
<p>de Bock</p>
<p>GH</p>
<p>,</p>
<p>Gietema</p>
<p>JA</p>
<p>,</p>
<p>Berendsen</p>
<p>AJ</p>
<p>,</p>
<p>van der Meer</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Long-term survivors of early breast cancer treated with chemotherapy
are characterized by a pro-inflammatory biomarker profile compared to
matched controls</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1239</p>
<p>–</p>
<p>1246</p>
<p>.</p>
<p>853</p>
<p>Hasin</p>
<p>T</p>
<p>,</p>
<p>Gerber</p>
<p>Y</p>
<p>,</p>
<p>Weston</p>
<p>SA</p>
<p>,</p>
<p>Jiang</p>
<p>R</p>
<p>,</p>
<p>Killian</p>
<p>JM</p>
<p>,</p>
<p>Manemann</p>
<p>SM</p>
<p>,</p>
<p>Cerhan</p>
<p>JR</p>
<p>,</p>
<p>Roger</p>
<p>VL.</p>
<p>Heart failure after myocardial infarction is associated with
increased risk of cancer</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2016</p>
<p>;</p>
<p>68</p>
<p>:</p>
<p>265</p>
<p>–</p>
<p>271</p>
<p>.</p>
<p>854</p>
<p>Banke</p>
<p>A</p>
<p>,</p>
<p>Schou</p>
<p>M</p>
<p>,</p>
<p>Videbaek</p>
<p>L</p>
<p>,</p>
<p>Moller</p>
<p>JE</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Gustafsson</p>
<p>F</p>
<p>,</p>
<p>Dahl</p>
<p>JS</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Hildebrandt</p>
<p>PR</p>
<p>,</p>
<p>Gislason</p>
<p>GH.</p>
<p>Incidence of cancer in patients with chronic heart failure: a
long-term follow-up study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>260</p>
<p>–</p>
<p>266</p>
<p>.</p>
<p>855</p>
<p>Meijers</p>
<p>WC</p>
<p>,</p>
<p>de Boer</p>
<p>RA.</p>
<p>Common risk factors for heart failure and cancer</p>
<p>.</p>
<p>Cardiovasc Res</p>
<p>2019</p>
<p>;</p>
<p>115</p>
<p>:</p>
<p>844</p>
<p>–</p>
<p>853</p>
<p>.</p>
<p>856</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Hulot</p>
<p>JS</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Aboumsallem</p>
<p>JP</p>
<p>,</p>
<p>Ameri</p>
<p>P</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Bertero</p>
<p>E</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Dodion</p>
<p>P</p>
<p>,</p>
<p>Eschenhagen</p>
<p>T</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Bayes-Genis</p>
<p>A</p>
<p>,</p>
<p>Jager</p>
<p>D</p>
<p>,</p>
<p>Jankowska</p>
<p>EA</p>
<p>,</p>
<p>Kitsis</p>
<p>RN</p>
<p>,</p>
<p>Konety</p>
<p>SH</p>
<p>,</p>
<p>Larkin</p>
<p>J</p>
<p>,</p>
<p>Lehmann</p>
<p>L</p>
<p>,</p>
<p>Lenihan</p>
<p>DJ</p>
<p>,</p>
<p>Maack</p>
<p>C</p>
<p>,</p>
<p>Moslehi</p>
<p>JJ</p>
<p>,</p>
<p>Muller</p>
<p>OJ</p>
<p>,</p>
<p>Nowak-Sliwinska</p>
<p>P</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Pudil</p>
<p>R</p>
<p>,</p>
<p>Rainer</p>
<p>PP</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Sawyer</p>
<p>D</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Suter</p>
<p>T</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Van Laake</p>
<p>LW</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Backs</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Common mechanistic pathways in cancer and heart failure. A scientific
roadmap on behalf of the Translational Research Committee of the Heart
Failure Association (HFA) of the European Society of Cardiology
(ESC)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2272</p>
<p>–</p>
<p>2289</p>
<p>.</p>
<p>857</p>
<p>Selvaraj</p>
<p>S</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Djousse</p>
<p>L</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Chen</p>
<p>J</p>
<p>,</p>
<p>Imran</p>
<p>TF</p>
<p>,</p>
<p>Qazi</p>
<p>S</p>
<p>,</p>
<p>Sesso</p>
<p>HD</p>
<p>,</p>
<p>Gaziano</p>
<p>JM</p>
<p>Schrag D.</p>
<p>Lack of association between heart failure and incident cancer</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>1501</p>
<p>–</p>
<p>1510</p>
<p>.</p>
<p>858</p>
<p>Meijers</p>
<p>WC</p>
<p>,</p>
<p>Maglione</p>
<p>M</p>
<p>,</p>
<p>Bakker</p>
<p>SJL</p>
<p>,</p>
<p>Oberhuber</p>
<p>R</p>
<p>,</p>
<p>Kieneker</p>
<p>LM</p>
<p>,</p>
<p>de Jong</p>
<p>S</p>
<p>,</p>
<p>Haubner</p>
<p>BJ</p>
<p>,</p>
<p>Nagengast</p>
<p>WB</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>van der Vegt</p>
<p>B</p>
<p>,</p>
<p>van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Westenbrink</p>
<p>BD</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Sillje</p>
<p>HHW</p>
<p>,</p>
<p>de Boer</p>
<p>RA.</p>
<p>Heart failure stimulates tumor growth by circulating factors</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>138</p>
<p>:</p>
<p>678</p>
<p>–</p>
<p>691</p>
<p>.</p>
<p>859</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Lopez-Fernandez</p>
<p>T</p>
<p>,</p>
<p>Galderisi</p>
<p>M</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Van der Meer</p>
<p>P</p>
<p>,</p>
<p>Cohen Solal</p>
<p>A</p>
<p>,</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Jerusalem</p>
<p>G</p>
<p>,</p>
<p>Moonen</p>
<p>M</p>
<p>,</p>
<p>Aboyans</p>
<p>V</p>
<p>,</p>
<p>Bax</p>
<p>JJ</p>
<p>,</p>
<p>Asteggiano</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Cardio-oncology services: rationale, organization, and
implementation</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>1756</p>
<p>–</p>
<p>1763</p>
<p>.</p>
<p>860</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Keramida</p>
<p>K</p>
<p>,</p>
<p>Filippatos</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>How to build a cardio-oncology service?</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1732</p>
<p>–</p>
<p>1734</p>
<p>.</p>
<p>861</p>
<p>Cardinale</p>
<p>D</p>
<p>,</p>
<p>Colombo</p>
<p>A</p>
<p>,</p>
<p>Lamantia</p>
<p>G</p>
<p>,</p>
<p>Colombo</p>
<p>N</p>
<p>,</p>
<p>Civelli</p>
<p>M</p>
<p>,</p>
<p>De Giacomi</p>
<p>G</p>
<p>,</p>
<p>Rubino</p>
<p>M</p>
<p>,</p>
<p>Veglia</p>
<p>F</p>
<p>,</p>
<p>Fiorentini</p>
<p>C</p>
<p>,</p>
<p>Cipolla</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Anthracycline-induced cardiomyopathy: clinical relevance and response
to pharmacologic therapy</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2010</p>
<p>;</p>
<p>55</p>
<p>:</p>
<p>213</p>
<p>–</p>
<p>220</p>
<p>.</p>
<p>862</p>
<p>Cardinale</p>
<p>D</p>
<p>,</p>
<p>Colombo</p>
<p>A</p>
<p>,</p>
<p>Bacchiani</p>
<p>G</p>
<p>,</p>
<p>Tedeschi</p>
<p>I</p>
<p>,</p>
<p>Meroni</p>
<p>CA</p>
<p>,</p>
<p>Veglia</p>
<p>F</p>
<p>,</p>
<p>Civelli</p>
<p>M</p>
<p>,</p>
<p>Lamantia</p>
<p>G</p>
<p>,</p>
<p>Colombo</p>
<p>N</p>
<p>,</p>
<p>Curigliano</p>
<p>G</p>
<p>,</p>
<p>Fiorentini</p>
<p>C</p>
<p>,</p>
<p>Cipolla</p>
<ol start="900" type="I">
<li></li>
</ol>
<p>Early detection of anthracycline cardiotoxicity and improvement with
heart failure therapy</p>
<p>.</p>
<p>Circulation</p>
<p>2015</p>
<p>;</p>
<p>131</p>
<p>:</p>
<p>1981</p>
<p>–</p>
<p>1988</p>
<p>.</p>
<p>863</p>
<p>Gulati</p>
<p>G</p>
<p>,</p>
<p>Heck</p>
<p>SL</p>
<p>,</p>
<p>Ree</p>
<p>AH</p>
<p>,</p>
<p>Hoffmann</p>
<p>P</p>
<p>,</p>
<p>Schulz-Menger</p>
<p>J</p>
<p>,</p>
<p>Fagerland</p>
<p>MW</p>
<p>,</p>
<p>Gravdehaug</p>
<p>B</p>
<p>,</p>
<p>von Knobelsdorff-Brenkenhoff</p>
<p>F</p>
<p>,</p>
<p>Bratland</p>
<p>A</p>
<p>,</p>
<p>Storas</p>
<p>TH</p>
<p>,</p>
<p>Hagve</p>
<p>TA</p>
<p>,</p>
<p>Rosjo</p>
<p>H</p>
<p>,</p>
<p>Steine</p>
<p>K</p>
<p>,</p>
<p>Geisler</p>
<p>J</p>
<p>,</p>
<p>Omland</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Prevention of cardiac dysfunction during adjuvant breast cancer
therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled,
double-blind clinical trial of candesartan and metoprolol</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>1671</p>
<p>–</p>
<p>1680</p>
<p>.</p>
<p>864</p>
<p>Pituskin</p>
<p>E</p>
<p>,</p>
<p>Mackey</p>
<p>JR</p>
<p>,</p>
<p>Koshman</p>
<p>S</p>
<p>,</p>
<p>Jassal</p>
<p>D</p>
<p>,</p>
<p>Pitz</p>
<p>M</p>
<p>,</p>
<p>Haykowsky</p>
<p>MJ</p>
<p>,</p>
<p>Pagano</p>
<p>JJ</p>
<p>,</p>
<p>Chow</p>
<p>K</p>
<p>,</p>
<p>Thompson</p>
<p>RB</p>
<p>,</p>
<p>Vos</p>
<p>LJ</p>
<p>,</p>
<p>Ghosh</p>
<p>S</p>
<p>,</p>
<p>Oudit</p>
<p>GY</p>
<p>,</p>
<p>Ezekowitz</p>
<p>JA</p>
<p>,</p>
<p>Paterson</p>
<ol start="501" type="I">
<li></li>
</ol>
<p>Multidisciplinary approach to novel therapies in cardio-oncology
research (MANTICORE 101-Breast): a randomized trial for the prevention
of trastuzumab-associated cardiotoxicity</p>
<p>.</p>
<p>J Clin Oncol</p>
<p>2017</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>870</p>
<p>–</p>
<p>877</p>
<p>.</p>
<p>865</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Pudil</p>
<p>R</p>
<p>,</p>
<p>Lopez-Fernandez</p>
<p>T</p>
<p>,</p>
<p>Grapsa</p>
<p>J</p>
<p>,</p>
<p>Nihoyannopoulos</p>
<p>P</p>
<p>,</p>
<p>Bergler-Klein</p>
<p>J</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>von Haehling</p>
<p>S</p>
<p>,</p>
<p>Barberis</p>
<p>V</p>
<p>,</p>
<p>Flachskampf</p>
<p>FA</p>
<p>,</p>
<p>Ceponiene</p>
<p>I</p>
<p>,</p>
<p>Haegler-Laube</p>
<p>E</p>
<p>,</p>
<p>Suter</p>
<p>T</p>
<p>,</p>
<p>Lapinskas</p>
<p>T</p>
<p>,</p>
<p>Prasad</p>
<p>S</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Wechalekar</p>
<p>K</p>
<p>,</p>
<p>Anker</p>
<p>MS</p>
<p>,</p>
<p>Iakobishvili</p>
<p>Z</p>
<p>,</p>
<p>Bucciarelli-Ducci</p>
<p>C</p>
<p>,</p>
<p>Schulz-Menger</p>
<p>J</p>
<p>,</p>
<p>Cosyns</p>
<p>B</p>
<p>,</p>
<p>Gaemperli</p>
<p>O</p>
<p>,</p>
<p>Belenkov</p>
<p>Y</p>
<p>,</p>
<p>Hulot</p>
<p>JS</p>
<p>,</p>
<p>Galderisi</p>
<p>M</p>
<p>,</p>
<p>Lancellotti</p>
<p>P</p>
<p>,</p>
<p>Bax</p>
<p>J</p>
<p>,</p>
<p>Marwick</p>
<p>TH</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Piepoli</p>
<p>M</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Moura</p>
<p>B</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Asteggiano</p>
<p>R</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Lyon</p>
<p>AR.</p>
<p>Role of cardiovascular imaging in cancer patients receiving
cardiotoxic therapies: a position statement on behalf of the Heart
Failure Association (HFA), the European Association of Cardiovascular
Imaging (EACVI) and the Cardio-Oncology Council of the European Society
of Cardiology (ESC)</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1504</p>
<p>–</p>
<p>1524</p>
<p>.</p>
<p>866</p>
<p>Keramida</p>
<p>K</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Bingcang</p>
<p>J</p>
<p>,</p>
<p>Sulemane</p>
<p>S</p>
<p>,</p>
<p>Sutherland</p>
<p>S</p>
<p>,</p>
<p>Bingcang</p>
<p>RA</p>
<p>,</p>
<p>Ramachandran</p>
<p>K</p>
<p>,</p>
<p>Tzavara</p>
<p>C</p>
<p>,</p>
<p>Charalampopoulos</p>
<p>G</p>
<p>,</p>
<p>Filippiadis</p>
<p>D</p>
<p>,</p>
<p>Kouris</p>
<p>N</p>
<p>,</p>
<p>Nihoyannopoulos</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Longitudinal changes of right ventricular deformation mechanics
during trastuzumab therapy in breast cancer patients</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>529</p>
<p>–</p>
<p>535</p>
<p>.</p>
<p>867</p>
<p>Thavendiranathan</p>
<p>P</p>
<p>,</p>
<p>Negishi</p>
<p>T</p>
<p>,</p>
<p>Somerset</p>
<p>E</p>
<p>,</p>
<p>Negishi</p>
<p>K</p>
<p>,</p>
<p>Penicka</p>
<p>M</p>
<p>,</p>
<p>Lemieux</p>
<p>J</p>
<p>,</p>
<p>Aakhus</p>
<p>S</p>
<p>,</p>
<p>Miyazaki</p>
<p>S</p>
<p>,</p>
<p>Shirazi</p>
<p>M</p>
<p>,</p>
<p>Galderisi</p>
<p>M</p>
<p>,</p>
<p>Marwick</p>
<p>TH</p>
<p>, SUCCOUR Investigators</p>
<p>Strain-guided management of potentially cardiotoxic cancer
therapy</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2021</p>
<p>;</p>
<p>77</p>
<p>:</p>
<p>392</p>
<p>–</p>
<p>401</p>
<p>.</p>
<p>868</p>
<p>Michel</p>
<p>L</p>
<p>,</p>
<p>Mincu</p>
<p>RI</p>
<p>,</p>
<p>Mahabadi</p>
<p>AA</p>
<p>,</p>
<p>Settelmeier</p>
<p>S</p>
<p>,</p>
<p>Al-Rashid</p>
<p>F</p>
<p>,</p>
<p>Rassaf</p>
<p>T</p>
<p>,</p>
<p>Totzeck</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Troponins and brain natriuretic peptides for the prediction of
cardiotoxicity in cancer patients: a meta-analysis</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>350</p>
<p>–</p>
<p>361</p>
<p>.</p>
<p>869</p>
<p>Pudil</p>
<p>R</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Henriksen</p>
<p>PA</p>
<p>,</p>
<p>Lenihan</p>
<p>D</p>
<p>,</p>
<p>Dent</p>
<p>S</p>
<p>,</p>
<p>Barac</p>
<p>A</p>
<p>,</p>
<p>Stanway</p>
<p>S</p>
<p>,</p>
<p>Moslehi</p>
<p>J</p>
<p>,</p>
<p>Suter</p>
<p>TM</p>
<p>,</p>
<p>Ky</p>
<p>B</p>
<p>,</p>
<p>Sterba</p>
<p>M</p>
<p>,</p>
<p>Cardinale</p>
<p>D</p>
<p>,</p>
<p>Cohen-Solal</p>
<p>A</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Bergler-Klein</p>
<p>J</p>
<p>,</p>
<p>Anker</p>
<p>MS</p>
<p>,</p>
<p>Von Haehling</p>
<p>S</p>
<p>,</p>
<p>Belenkov</p>
<p>Y</p>
<p>,</p>
<p>Iakobishvili</p>
<p>Z</p>
<p>,</p>
<p>Maack</p>
<p>C</p>
<p>,</p>
<p>Ciardiello</p>
<p>F</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Lainscak</p>
<p>M</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Bax</p>
<p>J</p>
<p>,</p>
<p>Hulot</p>
<p>JS</p>
<p>,</p>
<p>Skouri</p>
<p>H</p>
<p>,</p>
<p>Hagler-Laube</p>
<p>ES</p>
<p>,</p>
<p>Asteggiano</p>
<p>R</p>
<p>,</p>
<p>Fernandez</p>
<p>TL</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Lyon</p>
<p>AR.</p>
<p>Role of serum biomarkers in cancer patients receiving cardiotoxic
cancer therapies: a position statement from the Cardio-Oncology Study
Group of the Heart Failure Association and the Cardio-Oncology Council
of the European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1966</p>
<p>–</p>
<p>1983</p>
<p>.</p>
<p>870</p>
<p>Hu</p>
<p>JR</p>
<p>,</p>
<p>Florido</p>
<p>R</p>
<p>,</p>
<p>Lipson</p>
<p>EJ</p>
<p>,</p>
<p>Naidoo</p>
<p>J</p>
<p>,</p>
<p>Ardehali</p>
<p>R</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Padera</p>
<p>RF</p>
<p>,</p>
<p>Johnson</p>
<p>DB</p>
<p>,</p>
<p>Moslehi</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Cardiovascular toxicities associated with immune checkpoint
inhibitors</p>
<p>.</p>
<p>Cardiovasc Res</p>
<p>2019</p>
<p>;</p>
<p>115</p>
<p>:</p>
<p>854</p>
<p>–</p>
<p>868</p>
<p>.</p>
<p>871</p>
<p>Banke</p>
<p>A</p>
<p>,</p>
<p>Fosbol</p>
<p>EL</p>
<p>,</p>
<p>Moller</p>
<p>JE</p>
<p>,</p>
<p>Gislason</p>
<p>GH</p>
<p>,</p>
<p>Andersen</p>
<p>M</p>
<p>,</p>
<p>Bernsdorf</p>
<p>M</p>
<p>,</p>
<p>Jensen</p>
<p>MB</p>
<p>,</p>
<p>Schou</p>
<p>M</p>
<p>,</p>
<p>Ejlertsen</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Long-term effect of epirubicin on incidence of heart failure in women
with breast cancer: insight from a randomized clinical trial</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>1447</p>
<p>–</p>
<p>1453</p>
<p>.</p>
<p>872</p>
<p>Platz</p>
<p>E</p>
<p>,</p>
<p>Jhund</p>
<p>PS</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Pfeffer</p>
<p>MA</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Granger</p>
<p>CB</p>
<p>,</p>
<p>Yusuf</p>
<p>S</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>McMurray</p>
<p>JJ.</p>
<p>Prevalence and prognostic importance of precipitating factors leading
to heart failure hospitalization: recurrent hospitalizations and
mortality</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>295</p>
<p>–</p>
<p>303</p>
<p>.</p>
<p>873</p>
<p>Tomasoni</p>
<p>D</p>
<p>,</p>
<p>Italia</p>
<p>L</p>
<p>,</p>
<p>Adamo</p>
<p>M</p>
<p>,</p>
<p>Inciardi</p>
<p>RM</p>
<p>,</p>
<p>Lombardi</p>
<p>CM</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Metra</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>COVID 19 and heart failure: from infection to inflammation and
angiotensin II stimulation. Searching for evidence from a new
disease</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>957</p>
<p>–</p>
<p>966</p>
<p>;</p>
<p>23</p>
<p>:512–526.</p>
<p>874</p>
<p>Corrales-Medina</p>
<p>VF</p>
<p>,</p>
<p>Alvarez</p>
<p>KN</p>
<p>,</p>
<p>Weissfeld</p>
<p>LA</p>
<p>,</p>
<p>Angus</p>
<p>DC</p>
<p>,</p>
<p>Chirinos</p>
<p>JA</p>
<p>,</p>
<p>Chang</p>
<p>CC</p>
<p>,</p>
<p>Newman</p>
<p>A</p>
<p>,</p>
<p>Loehr</p>
<p>L</p>
<p>,</p>
<p>Folsom</p>
<p>AR</p>
<p>,</p>
<p>Elkind</p>
<p>MS</p>
<p>,</p>
<p>Lyles</p>
<p>MF</p>
<p>,</p>
<p>Kronmal</p>
<p>RA</p>
<p>,</p>
<p>Yende</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Association between hospitalization for pneumonia and subsequent risk
of cardiovascular disease</p>
<p>.</p>
<p>JAMA</p>
<p>2015</p>
<p>;</p>
<p>313</p>
<p>:</p>
<p>264</p>
<p>–</p>
<p>274</p>
<p>.</p>
<p>875</p>
<p>Violi</p>
<p>F</p>
<p>,</p>
<p>Cangemi</p>
<p>R</p>
<p>,</p>
<p>Falcone</p>
<p>M</p>
<p>,</p>
<p>Taliani</p>
<p>G</p>
<p>,</p>
<p>Pieralli</p>
<p>F</p>
<p>,</p>
<p>Vannucchi</p>
<p>V</p>
<p>,</p>
<p>Nozzoli</p>
<p>C</p>
<p>,</p>
<p>Venditti</p>
<p>M</p>
<p>,</p>
<p>Chirinos</p>
<p>JA</p>
<p>,</p>
<p>Corrales-Medina</p>
<p>VF</p>
<p>,</p>
<p>SIXTUS Study Group. Cardiovascular complications and short-term
mortality risk in community-acquired pneumonia</p>
<p>.</p>
<p>Clin Infect Dis</p>
<p>2017</p>
<p>;</p>
<p>64</p>
<p>:</p>
<p>1486</p>
<p>–</p>
<p>1493</p>
<p>.</p>
<p>876</p>
<p>Rey</p>
<p>JR</p>
<p>,</p>
<p>Caro-Codon</p>
<p>J</p>
<p>,</p>
<p>Rosillo</p>
<p>SO</p>
<p>,</p>
<p>Iniesta</p>
<p>AM</p>
<p>,</p>
<p>Castrejon-Castrejon</p>
<p>S</p>
<p>,</p>
<p>Marco-Clement</p>
<p>I</p>
<p>,</p>
<p>Martin-Polo</p>
<p>L</p>
<p>,</p>
<p>Merino-Argos</p>
<p>C</p>
<p>,</p>
<p>Rodriguez-Sotelo</p>
<p>L</p>
<p>,</p>
<p>Garcia-Veas</p>
<p>JM</p>
<p>,</p>
<p>Martinez-Marin</p>
<p>LA</p>
<p>,</p>
<p>Martinez-Cossiani</p>
<p>M</p>
<p>,</p>
<p>Buno</p>
<p>A</p>
<p>,</p>
<p>Gonzalez-Valle</p>
<p>L</p>
<p>,</p>
<p>Herrero</p>
<p>A</p>
<p>,</p>
<p>Lopez-Sendon</p>
<p>JL</p>
<p>,</p>
<p>Merino</p>
<p>JL</p>
<p>,</p>
<p>CARD-COVID Investigators</p>
<p>.</p>
<p>Heart failure in COVID-19 patients: prevalence, incidence and
prognostic implications</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2205</p>
<p>–</p>
<p>2215</p>
<p>.</p>
<p>877</p>
<p>Cannata</p>
<p>A</p>
<p>,</p>
<p>Bromage</p>
<p>DI</p>
<p>,</p>
<p>Rind</p>
<p>IA</p>
<p>,</p>
<p>Gregorio</p>
<p>C</p>
<p>,</p>
<p>Bannister</p>
<p>C</p>
<p>,</p>
<p>Albarjas</p>
<p>M</p>
<p>,</p>
<p>Piper</p>
<p>S</p>
<p>,</p>
<p>Shah</p>
<p>AM</p>
<p>,</p>
<p>McDonagh</p>
<p>TA.</p>
<p>Temporal trends in decompensated heart failure and outcomes during
COVID-19: a multisite report from heart failure referral centres in
London</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2219</p>
<p>–</p>
<p>2224</p>
<p>.</p>
<p>878</p>
<p>Konig</p>
<p>S</p>
<p>,</p>
<p>Hohenstein</p>
<p>S</p>
<p>,</p>
<p>Meier-Hellmann</p>
<p>A</p>
<p>,</p>
<p>Kuhlen</p>
<p>R</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Bollmann</p>
<p>A</p>
<p>,</p>
<p>Helios Hospitals G. In-hospital care in acute heart failure during
the COVID-19 pandemic: insights from the German-wide Helios hospital
network</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>2190</p>
<p>–</p>
<p>2201</p>
<p>.</p>
<p>879</p>
<p>Zhang</p>
<p>Y</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Zheng</p>
<p>Z</p>
<p>,</p>
<p>Adamo</p>
<p>M</p>
<p>,</p>
<p>Ambrosio</p>
<p>G</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Butler</p>
<p>J</p>
<p>,</p>
<p>Xu</p>
<p>D</p>
<p>,</p>
<p>Mao</p>
<p>J</p>
<p>,</p>
<p>Khan</p>
<p>MS</p>
<p>,</p>
<p>Bai</p>
<p>L</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Tang</p>
<p>Q</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>Zhang</p>
<p>S</p>
<p>,</p>
<p>Gao</p>
<p>C</p>
<p>,</p>
<p>Zhou</p>
<p>S</p>
<p>,</p>
<p>Senni</p>
<p>M</p>
<p>,</p>
<p>Zhang</p>
<p>J</p>
<p>,</p>
<p>Metra</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Management of heart failure patients with COVID-19: a joint position
paper of the Chinese Heart Failure Association &amp; National Heart
Failure Committee and the Heart Failure Association of the European
Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>941</p>
<p>–</p>
<p>956</p>
<p>.</p>
<p>880</p>
<p>Modin</p>
<p>D</p>
<p>,</p>
<p>Jorgensen</p>
<p>ME</p>
<p>,</p>
<p>Gislason</p>
<p>G</p>
<p>,</p>
<p>Jensen</p>
<p>JS</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Hegde</p>
<p>SM</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Biering-Sorensen</p>
<ol start="20" type="A">
<li></li>
</ol>
<p>Influenza vaccine in heart failure</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>575</p>
<p>–</p>
<p>586</p>
<p>.</p>
<p>881</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Claggett</p>
<p>B</p>
<p>,</p>
<p>Udell</p>
<p>JA</p>
<p>,</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Zile</p>
<p>M</p>
<p>,</p>
<p>Rouleau</p>
<p>J</p>
<p>,</p>
<p>Swedberg</p>
<p>K</p>
<p>,</p>
<p>Desai</p>
<p>AS</p>
<p>,</p>
<p>Lefkowitz</p>
<p>M</p>
<p>,</p>
<p>Shi</p>
<p>V</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>PARADIGM-HF Investigators</p>
<p>.</p>
<p>Influenza vaccination in patients with chronic heart failure: the
PARADIGM-HF trial</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2016</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>152</p>
<p>–</p>
<p>158</p>
<p>.</p>
<p>882</p>
<p>Gotsman</p>
<p>I</p>
<p>,</p>
<p>Shuvy</p>
<p>M</p>
<p>,</p>
<p>Tahiroglu</p>
<p>I</p>
<p>,</p>
<p>Zwas</p>
<p>DR</p>
<p>,</p>
<p>Keren</p>
<ol type="A">
<li></li>
</ol>
<p>Influenza vaccination and outcome in heart failure</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2020</p>
<p>;</p>
<p>128</p>
<p>:</p>
<p>134</p>
<p>–</p>
<p>139</p>
<p>.</p>
<p>883</p>
<p>Bhatt</p>
<p>AS</p>
<p>,</p>
<p>Jering</p>
<p>KS</p>
<p>,</p>
<p>Vaduganathan</p>
<p>M</p>
<p>,</p>
<p>Claggett</p>
<p>BL</p>
<p>,</p>
<p>Cunningham</p>
<p>JW</p>
<p>,</p>
<p>Rosenthal</p>
<p>N</p>
<p>,</p>
<p>Signorovitch</p>
<p>J</p>
<p>,</p>
<p>Thune</p>
<p>JJ</p>
<p>,</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>Solomon</p>
<p>SD.</p>
<p>Clinical outcomes in patients with heart failure hospitalized with
COVID-19</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>9</p>
<p>:</p>
<p>65</p>
<p>–</p>
<p>73</p>
<p>.</p>
<p>884</p>
<p>Regitz-Zagrosek</p>
<p>V</p>
<p>,</p>
<p>Roos-Hesselink</p>
<p>JW</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Blomström-Lundqvist</p>
<p>C</p>
<p>,</p>
<p>Cífková</p>
<p>R</p>
<p>,</p>
<p>De Bonis</p>
<p>M</p>
<p>,</p>
<p>Iung</p>
<p>B</p>
<p>,</p>
<p>Johnson</p>
<p>MR</p>
<p>,</p>
<p>Kintscher</p>
<p>U</p>
<p>,</p>
<p>Kranke</p>
<p>P</p>
<p>,</p>
<p>Lang</p>
<p>IM</p>
<p>,</p>
<p>Morais</p>
<p>J</p>
<p>,</p>
<p>Pieper</p>
<p>PG</p>
<p>,</p>
<p>Presbitero</p>
<p>P</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Seeland</p>
<p>U</p>
<p>,</p>
<p>Simoncini</p>
<p>T</p>
<p>,</p>
<p>Swan</p>
<p>L</p>
<p>,</p>
<p>Warnes</p>
<p>CA</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2018 ESC Guidelines for the management of cardiovascular diseases
during pregnancy</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>3165</p>
<p>–</p>
<p>3241</p>
<p>.</p>
<p>885</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>Frogoudaki</p>
<p>A</p>
<p>,</p>
<p>Johnson</p>
<p>MR</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Hamdan</p>
<p>R</p>
<p>,</p>
<p>Jackson</p>
<p>AM</p>
<p>,</p>
<p>Ibrahim</p>
<p>B</p>
<p>,</p>
<p>Mbakwem</p>
<p>A</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>Regitz-Zagrosek</p>
<p>V</p>
<p>,</p>
<p>Omerovic</p>
<p>E</p>
<p>,</p>
<p>Roos-Hesselink</p>
<p>J</p>
<p>,</p>
<p>Gatzoulis</p>
<p>M</p>
<p>,</p>
<p>Tutarel</p>
<p>O</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Muller</p>
<p>C</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Jankowska</p>
<p>E</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Rosano</p>
<p>G</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Bauersachs</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Risk stratification and management of women with cardiomyopathy/heart
failure planning pregnancy or presenting during/after pregnancy: a
position statement from the Heart Failure Association of the European
Society of Cardiology Study Group on Peripartum Cardiomyopathy</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:527–540.</p>
<p>886</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Petrie</p>
<p>MC</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Mebazaa</p>
<p>A</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Jackson</p>
<p>AM</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Laroche</p>
<p>C</p>
<p>,</p>
<p>Regitz-Zagrosek</p>
<p>V</p>
<p>,</p>
<p>Schaufelberger</p>
<p>M</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Roos-Hesselink</p>
<p>JW</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>van Spaendonck-Zwarts</p>
<p>K</p>
<p>,</p>
<p>Mbakwem</p>
<p>A</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Mouquet</p>
<p>F</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Johnson</p>
<p>MR</p>
<p>,</p>
<p>Hamdan</p>
<p>R</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>McMurray</p>
<p>JJV</p>
<p>,</p>
<p>Bauersachs</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Clinical presentation, management, and 6-month outcomes in women with
peripartum cardiomyopathy: an ESC EORP registry</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>3787</p>
<p>–</p>
<p>3797</p>
<p>.</p>
<p>887</p>
<p>Davis</p>
<p>MB</p>
<p>,</p>
<p>Arany</p>
<p>Z</p>
<p>,</p>
<p>McNamara</p>
<p>DM</p>
<p>,</p>
<p>Goland</p>
<p>S</p>
<p>,</p>
<p>Elkayam</p>
<ol start="21" type="A">
<li></li>
</ol>
<p>Peripartum cardiomyopathy: JACC state-of-the-art review</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2020</p>
<p>;</p>
<p>75</p>
<p>:</p>
<p>207</p>
<p>–</p>
<p>221</p>
<p>.</p>
<p>888</p>
<p>Moulig</p>
<p>V</p>
<p>,</p>
<p>Pfeffer</p>
<p>TJ</p>
<p>,</p>
<p>Ricke-Hoch</p>
<p>M</p>
<p>,</p>
<p>Schlothauer</p>
<p>S</p>
<p>,</p>
<p>Koenig</p>
<p>T</p>
<p>,</p>
<p>Schwab</p>
<p>J</p>
<p>,</p>
<p>Berliner</p>
<p>D</p>
<p>,</p>
<p>Pfister</p>
<p>R</p>
<p>,</p>
<p>Michels</p>
<p>G</p>
<p>,</p>
<p>Haghikia</p>
<p>A</p>
<p>,</p>
<p>Falk</p>
<p>CS</p>
<p>,</p>
<p>Duncker</p>
<p>D</p>
<p>,</p>
<p>Veltmann</p>
<p>C</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Bauersachs</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Long-term follow-up in peripartum cardiomyopathy patients with
contemporary treatment: low mortality, high cardiac recovery, but
significant cardiovascular co-morbidities</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1534</p>
<p>–</p>
<p>1542</p>
<p>.</p>
<p>889</p>
<p>Stapel</p>
<p>B</p>
<p>,</p>
<p>Kohlhaas</p>
<p>M</p>
<p>,</p>
<p>Ricke-Hoch</p>
<p>M</p>
<p>,</p>
<p>Haghikia</p>
<p>A</p>
<p>,</p>
<p>Erschow</p>
<p>S</p>
<p>,</p>
<p>Knuuti</p>
<p>J</p>
<p>,</p>
<p>Silvola</p>
<p>JM</p>
<p>,</p>
<p>Roivainen</p>
<p>A</p>
<p>,</p>
<p>Saraste</p>
<p>A</p>
<p>,</p>
<p>Nickel</p>
<p>AG</p>
<p>,</p>
<p>Saar</p>
<p>JA</p>
<p>,</p>
<p>Sieve</p>
<p>I</p>
<p>,</p>
<p>Pietzsch</p>
<p>S</p>
<p>,</p>
<p>Muller</p>
<p>M</p>
<p>,</p>
<p>Bogeski</p>
<p>I</p>
<p>,</p>
<p>Kappl</p>
<p>R</p>
<p>,</p>
<p>Jauhiainen</p>
<p>M</p>
<p>,</p>
<p>Thackeray</p>
<p>JT</p>
<p>,</p>
<p>Scherr</p>
<p>M</p>
<p>,</p>
<p>Bengel</p>
<p>FM</p>
<p>,</p>
<p>Hagl</p>
<p>C</p>
<p>,</p>
<p>Tudorache</p>
<p>I</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Maack</p>
<p>C</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Low STAT3 expression sensitizes to toxic effects of beta-adrenergic
receptor stimulation in peripartum cardiomyopathy</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>349</p>
<p>–</p>
<p>361</p>
<p>.</p>
<p>890</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Haghikia</p>
<p>A</p>
<p>,</p>
<p>Berliner</p>
<p>D</p>
<p>,</p>
<p>Vogel-Claussen</p>
<p>J</p>
<p>,</p>
<p>Schwab</p>
<p>J</p>
<p>,</p>
<p>Franke</p>
<p>A</p>
<p>,</p>
<p>Schwarzkopf</p>
<p>M</p>
<p>,</p>
<p>Ehlermann</p>
<p>P</p>
<p>,</p>
<p>Pfister</p>
<p>R</p>
<p>,</p>
<p>Michels</p>
<p>G</p>
<p>,</p>
<p>Westenfeld</p>
<p>R</p>
<p>,</p>
<p>Stangl</p>
<p>V</p>
<p>,</p>
<p>Kindermann</p>
<p>I</p>
<p>,</p>
<p>Kuhl</p>
<p>U</p>
<p>,</p>
<p>Angermann</p>
<p>CE</p>
<p>,</p>
<p>Schlitt</p>
<p>A</p>
<p>,</p>
<p>Fischer</p>
<p>D</p>
<p>,</p>
<p>Podewski</p>
<p>E</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Bauersachs</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Bromocriptine for the treatment of peripartum cardiomyopathy: a
multicentre randomized study</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>2671</p>
<p>–</p>
<p>2679</p>
<p>.</p>
<p>891</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Blauwet</p>
<p>L</p>
<p>,</p>
<p>Tibazarwa</p>
<p>K</p>
<p>,</p>
<p>Libhaber</p>
<p>E</p>
<p>,</p>
<p>Smedema</p>
<p>JP</p>
<p>,</p>
<p>Becker</p>
<p>A</p>
<p>,</p>
<p>McMurray</p>
<p>J</p>
<p>,</p>
<p>Yamac</p>
<p>H</p>
<p>,</p>
<p>Labidi</p>
<p>S</p>
<p>,</p>
<p>Struman</p>
<p>I</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Evaluation of bromocriptine in the treatment of acute severe
peripartum cardiomyopathy: a proof-of-concept pilot study</p>
<p>.</p>
<p>Circulation</p>
<p>2010</p>
<p>;</p>
<p>121</p>
<p>:</p>
<p>1465</p>
<p>–</p>
<p>1473</p>
<p>.</p>
<p>892</p>
<p>Arbustini</p>
<p>E</p>
<p>,</p>
<p>Narula</p>
<p>N</p>
<p>,</p>
<p>Dec</p>
<p>GW</p>
<p>,</p>
<p>Reddy</p>
<p>KS</p>
<p>,</p>
<p>Greenberg</p>
<p>B</p>
<p>,</p>
<p>Kushwaha</p>
<p>S</p>
<p>,</p>
<p>Marwick</p>
<p>T</p>
<p>,</p>
<p>Pinney</p>
<p>S</p>
<p>,</p>
<p>Bellazzi</p>
<p>R</p>
<p>,</p>
<p>Favalli</p>
<p>V</p>
<p>,</p>
<p>Kramer</p>
<p>C</p>
<p>,</p>
<p>Roberts</p>
<p>R</p>
<p>,</p>
<p>Zoghbi</p>
<p>WA</p>
<p>,</p>
<p>Bonow</p>
<p>R</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Fuster</p>
<p>V</p>
<p>,</p>
<p>Narula</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>The MOGE(S) classification for a phenotype-genotype nomenclature of
cardiomyopathy: endorsed by the World Heart Federation</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2013</p>
<p>;</p>
<p>62</p>
<p>:</p>
<p>2046</p>
<p>–</p>
<p>2072</p>
<p>.</p>
<p>893</p>
<p>Hazebroek</p>
<p>MR</p>
<p>,</p>
<p>Kemna</p>
<p>MJ</p>
<p>,</p>
<p>Schalla</p>
<p>S</p>
<p>,</p>
<p>Sanders-van Wijk</p>
<p>S</p>
<p>,</p>
<p>Gerretsen</p>
<p>SC</p>
<p>,</p>
<p>Dennert</p>
<p>R</p>
<p>,</p>
<p>Merken</p>
<p>J</p>
<p>,</p>
<p>Kuznetsova</p>
<p>T</p>
<p>,</p>
<p>Staessen</p>
<p>JA</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>van Paassen</p>
<p>P</p>
<p>,</p>
<p>Cohen Tervaert</p>
<p>JW</p>
<p>,</p>
<p>Heymans</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Prevalence and prognostic relevance of cardiac involvement in
ANCA-associated vasculitis: eosinophilic granulomatosis with
polyangiitis and granulomatosis with polyangiitis</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2015</p>
<p>;</p>
<p>199</p>
<p>:</p>
<p>170</p>
<p>–</p>
<p>179</p>
<p>.</p>
<p>894</p>
<p>Pinto</p>
<p>YM</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Arbustini</p>
<p>E</p>
<p>,</p>
<p>Adler</p>
<p>Y</p>
<p>,</p>
<p>Anastasakis</p>
<p>A</p>
<p>,</p>
<p>Bohm</p>
<p>M</p>
<p>,</p>
<p>Duboc</p>
<p>D</p>
<p>,</p>
<p>Gimeno</p>
<p>J</p>
<p>,</p>
<p>de Groote</p>
<p>P</p>
<p>,</p>
<p>Imazio</p>
<p>M</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Klingel</p>
<p>K</p>
<p>,</p>
<p>Komajda</p>
<p>M</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>Linhart</p>
<p>A</p>
<p>,</p>
<p>Mogensen</p>
<p>J</p>
<p>,</p>
<p>Moon</p>
<p>J</p>
<p>,</p>
<p>Pieper</p>
<p>PG</p>
<p>,</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Schueler</p>
<p>S</p>
<p>,</p>
<p>Zamorano</p>
<p>JL</p>
<p>,</p>
<p>Caforio</p>
<p>AL</p>
<p>,</p>
<p>Charron</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Proposal for a revised definition of dilated cardiomyopathy,
hypokinetic non-dilated cardiomyopathy, and its implications for
clinical practice: a position statement of the ESC working group on
myocardial and pericardial diseases</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>1850</p>
<p>–</p>
<p>1858</p>
<p>.</p>
<p>895</p>
<p>Seferovic</p>
<p>PM</p>
<p>,</p>
<p>Polovina</p>
<p>M</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Arad</p>
<p>M</p>
<p>,</p>
<p>Gal</p>
<p>TB</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Felix</p>
<p>SB</p>
<p>,</p>
<p>Arbustini</p>
<p>E</p>
<p>,</p>
<p>Caforio</p>
<p>ALP</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Gialafos</p>
<p>E</p>
<p>,</p>
<p>Kanjuh</p>
<p>V</p>
<p>,</p>
<p>Krljanac</p>
<p>G</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>Linhart</p>
<p>A</p>
<p>,</p>
<p>Lyon</p>
<p>AR</p>
<p>,</p>
<p>Maksimovic</p>
<p>R</p>
<p>,</p>
<p>Milicic</p>
<p>D</p>
<p>,</p>
<p>Milinkovic</p>
<p>I</p>
<p>,</p>
<p>Noutsias</p>
<p>M</p>
<p>,</p>
<p>Oto</p>
<p>A</p>
<p>,</p>
<p>Oto</p>
<p>O</p>
<p>,</p>
<p>Pavlovic</p>
<p>SU</p>
<p>,</p>
<p>Piepoli</p>
<p>MF</p>
<p>,</p>
<p>Ristic</p>
<p>AD</p>
<p>,</p>
<p>Rosano</p>
<p>GMC</p>
<p>,</p>
<p>Seggewiss</p>
<p>H</p>
<p>,</p>
<p>Asanin</p>
<p>M</p>
<p>,</p>
<p>Seferovic</p>
<p>JP</p>
<p>,</p>
<p>Ruschitzka</p>
<p>F</p>
<p>,</p>
<p>Celutkiene</p>
<p>J</p>
<p>,</p>
<p>Jaarsma</p>
<p>T</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Moura</p>
<p>B</p>
<p>,</p>
<p>Hill</p>
<p>L</p>
<p>,</p>
<p>Volterrani</p>
<p>M</p>
<p>,</p>
<p>Lopatin</p>
<p>Y</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Backs</p>
<p>J</p>
<p>,</p>
<p>Mullens</p>
<p>W</p>
<p>,</p>
<p>Chioncel</p>
<p>O</p>
<p>,</p>
<p>de Boer</p>
<p>RA</p>
<p>,</p>
<p>Anker</p>
<p>S</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Coats</p>
<p>AJS</p>
<p>,</p>
<p>Tschope</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Heart failure in cardiomyopathies: a position paper from the Heart
Failure Association of the European Society of Cardiology</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>553</p>
<p>–</p>
<p>576</p>
<p>.</p>
<p>896</p>
<p>members</p>
<p>Authors/Task Force</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Anastasakis</p>
<p>A</p>
<p>,</p>
<p>Borger</p>
<p>MA</p>
<p>,</p>
<p>Borggrefe</p>
<p>M</p>
<p>,</p>
<p>Cecchi</p>
<p>F</p>
<p>,</p>
<p>Charron</p>
<p>P</p>
<p>,</p>
<p>Hagege</p>
<p>AA</p>
<p>,</p>
<p>Lafont</p>
<p>A</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>Mahrholdt</p>
<p>H</p>
<p>,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Mogensen</p>
<p>J</p>
<p>,</p>
<p>Nihoyannopoulos</p>
<p>P</p>
<p>,</p>
<p>Nistri</p>
<p>S</p>
<p>,</p>
<p>Pieper</p>
<p>PG</p>
<p>,</p>
<p>Pieske</p>
<p>B</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Tillmanns</p>
<p>C</p>
<p>,</p>
<p>Watkins</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>2014</p>
<p>ESC Guidelines on diagnosis and management of hypertrophic
cardiomyopathy: The Task Force for the Diagnosis and Management of
Hypertrophic Cardiomyopathy of the European Society of Cardiology
(ESC)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2014</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>2733</p>
<p>–</p>
<p>2779</p>
<p>.</p>
<p>897</p>
<p>Bondue</p>
<p>A</p>
<p>,</p>
<p>Arbustini</p>
<p>E</p>
<p>,</p>
<p>Bianco</p>
<p>A</p>
<p>,</p>
<p>Ciccarelli</p>
<p>M</p>
<p>,</p>
<p>Dawson</p>
<p>D</p>
<p>,</p>
<p>De Rosa</p>
<p>M</p>
<p>,</p>
<p>Hamdani</p>
<p>N</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Meder</p>
<p>B</p>
<p>,</p>
<p>Leite-Moreira</p>
<p>AF</p>
<p>,</p>
<p>Thum</p>
<p>T</p>
<p>,</p>
<p>Tocchetti</p>
<p>CG</p>
<p>,</p>
<p>Varricchi</p>
<p>G</p>
<p>,</p>
<p>Van der Velden</p>
<p>J</p>
<p>,</p>
<p>Walsh</p>
<p>R</p>
<p>,</p>
<p>Heymans</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Complex roads from genotype to phenotype in dilated cardiomyopathy:
scientific update from the Working Group of Myocardial Function of the
European Society of Cardiology</p>
<p>.</p>
<p>Cardiovasc Res</p>
<p>2018</p>
<p>;</p>
<p>114</p>
<p>:</p>
<p>1287</p>
<p>–</p>
<p>1303</p>
<p>.</p>
<p>898</p>
<p>Hershberger</p>
<p>RE</p>
<p>,</p>
<p>Givertz</p>
<p>MM</p>
<p>,</p>
<p>Ho</p>
<p>CY</p>
<p>,</p>
<p>Judge</p>
<p>DP</p>
<p>,</p>
<p>Kantor</p>
<p>PF</p>
<p>,</p>
<p>McBride</p>
<p>KL</p>
<p>,</p>
<p>Morales</p>
<p>A</p>
<p>,</p>
<p>Taylor</p>
<p>MRG</p>
<p>,</p>
<p>Vatta</p>
<p>M</p>
<p>,</p>
<p>Ware</p>
<p>SM.</p>
<p>Genetic evaluation of cardiomyopathy–a Heart Failure Society of
America practice guideline</p>
<p>.</p>
<p>J Card Fail</p>
<p>2018</p>
<p>;</p>
<p>24</p>
<p>:</p>
<p>281</p>
<p>–</p>
<p>302</p>
<p>.</p>
<p>899</p>
<p>Merlo</p>
<p>M</p>
<p>,</p>
<p>Cannata</p>
<p>A</p>
<p>,</p>
<p>Gobbo</p>
<p>M</p>
<p>,</p>
<p>Stolfo</p>
<p>D</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Sinagra</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Evolving concepts in dilated cardiomyopathy</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>20</p>
<p>:</p>
<p>228</p>
<p>–</p>
<p>239</p>
<p>.</p>
<p>900</p>
<p>Linschoten</p>
<p>M</p>
<p>,</p>
<p>Teske</p>
<p>AJ</p>
<p>,</p>
<p>Baas</p>
<p>AF</p>
<p>,</p>
<p>Vink</p>
<p>A</p>
<p>,</p>
<p>Dooijes</p>
<p>D</p>
<p>,</p>
<p>Baars</p>
<p>HF</p>
<p>,</p>
<p>Asselbergs</p>
<p>FW.</p>
<p>Truncating titin (TTN) variants in chemotherapy-induced
cardiomyopathy</p>
<p>.</p>
<p>J Card Fail</p>
<p>2017</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>476</p>
<p>–</p>
<p>479</p>
<p>.</p>
<p>901</p>
<p>Wasielewski</p>
<p>M</p>
<p>,</p>
<p>van Spaendonck-Zwarts</p>
<p>KY</p>
<p>,</p>
<p>Westerink</p>
<p>ND</p>
<p>,</p>
<p>Jongbloed</p>
<p>JD</p>
<p>,</p>
<p>Postma</p>
<p>A</p>
<p>,</p>
<p>Gietema</p>
<p>JA</p>
<p>,</p>
<p>van Tintelen</p>
<p>JP</p>
<p>,</p>
<p>van den Berg</p>
<p>MP.</p>
<p>Potential genetic predisposition for anthracycline-associated
cardiomyopathy in families with dilated cardiomyopathy</p>
<p>.</p>
<p>Open Heart</p>
<p>2014</p>
<p>;</p>
<p>1</p>
<p>:</p>
<p>e000116</p>
<p>.</p>
<p>902</p>
<p>Ware</p>
<p>JS</p>
<p>,</p>
<p>Amor-Salamanca</p>
<p>A</p>
<p>,</p>
<p>Tayal</p>
<p>U</p>
<p>,</p>
<p>Govind</p>
<p>R</p>
<p>,</p>
<p>Serrano</p>
<p>I</p>
<p>,</p>
<p>Salazar-Mendiguchia</p>
<p>J</p>
<p>,</p>
<p>Garcia-Pinilla</p>
<p>JM</p>
<p>,</p>
<p>Pascual-Figal</p>
<p>DA</p>
<p>,</p>
<p>Nunez</p>
<p>J</p>
<p>,</p>
<p>Guzzo-Merello</p>
<p>G</p>
<p>,</p>
<p>Gonzalez-Vioque</p>
<p>E</p>
<p>,</p>
<p>Bardaji</p>
<p>A</p>
<p>,</p>
<p>Manito</p>
<p>N</p>
<p>,</p>
<p>Lopez-Garrido</p>
<p>MA</p>
<p>,</p>
<p>Padron-Barthe</p>
<p>L</p>
<p>,</p>
<p>Edwards</p>
<p>E</p>
<p>,</p>
<p>Whiffin</p>
<p>N</p>
<p>,</p>
<p>Walsh</p>
<p>R</p>
<p>,</p>
<p>Buchan</p>
<p>RJ</p>
<p>,</p>
<p>Midwinter</p>
<p>W</p>
<p>,</p>
<p>Wilk</p>
<p>A</p>
<p>,</p>
<p>Prasad</p>
<p>S</p>
<p>,</p>
<p>Pantazis</p>
<p>A</p>
<p>,</p>
<p>Baski</p>
<p>J</p>
<p>,</p>
<p>O’Regan</p>
<p>DP</p>
<p>,</p>
<p>Alonso-Pulpon</p>
<p>L</p>
<p>,</p>
<p>Cook</p>
<p>SA</p>
<p>,</p>
<p>Lara-Pezzi</p>
<p>E</p>
<p>,</p>
<p>Barton</p>
<p>PJ</p>
<p>,</p>
<p>Garcia-Pavia</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Genetic etiology for alcohol-induced cardiac toxicity</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>71</p>
<p>:</p>
<p>2293</p>
<p>–</p>
<p>2302</p>
<p>.</p>
<p>903</p>
<p>Ware</p>
<p>JS</p>
<p>,</p>
<p>Li</p>
<p>J</p>
<p>,</p>
<p>Mazaika</p>
<p>E</p>
<p>,</p>
<p>Yasso</p>
<p>CM</p>
<p>,</p>
<p>DeSouza</p>
<p>T</p>
<p>,</p>
<p>Cappola</p>
<p>TP</p>
<p>,</p>
<p>Tsai</p>
<p>EJ</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Kamiya</p>
<p>CA</p>
<p>,</p>
<p>Mazzarotto</p>
<p>F</p>
<p>,</p>
<p>Cook</p>
<p>SA</p>
<p>,</p>
<p>Halder</p>
<p>I</p>
<p>,</p>
<p>Prasad</p>
<p>SK</p>
<p>,</p>
<p>Pisarcik</p>
<p>J</p>
<p>,</p>
<p>Hanley-Yanez</p>
<p>K</p>
<p>,</p>
<p>Alharethi</p>
<p>R</p>
<p>,</p>
<p>Damp</p>
<p>J</p>
<p>,</p>
<p>Hsich</p>
<p>E</p>
<p>,</p>
<p>Elkayam</p>
<p>U</p>
<p>,</p>
<p>Sheppard</p>
<p>R</p>
<p>,</p>
<p>Kealey</p>
<p>A</p>
<p>,</p>
<p>Alexis</p>
<p>J</p>
<p>,</p>
<p>Ramani</p>
<p>G</p>
<p>,</p>
<p>Safirstein</p>
<p>J</p>
<p>,</p>
<p>Boehmer</p>
<p>J</p>
<p>,</p>
<p>Pauly</p>
<p>DF</p>
<p>,</p>
<p>Wittstein</p>
<p>IS</p>
<p>,</p>
<p>Thohan</p>
<p>V</p>
<p>,</p>
<p>Zucker</p>
<p>MJ</p>
<p>,</p>
<p>Liu</p>
<p>P</p>
<p>,</p>
<p>Gorcsan</p>
<p>J</p>
<p>3rd,</p>
<p>McNamara</p>
<p>DM</p>
<p>,</p>
<p>Seidman</p>
<p>CE</p>
<p>,</p>
<p>Seidman</p>
<p>JG</p>
<p>,</p>
<p>Arany</p>
<p>Z</p>
<p>,</p>
<p>IPAC Investigators</p>
<p>Imac</p>
<p>.</p>
<p>Shared genetic predisposition in peripartum and dilated
cardiomyopathies</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2016</p>
<p>;</p>
<p>374</p>
<p>:</p>
<p>233</p>
<p>–</p>
<p>241</p>
<p>.</p>
<p>904</p>
<p>van Spaendonck-Zwarts</p>
<p>KY</p>
<p>,</p>
<p>Posafalvi</p>
<p>A</p>
<p>,</p>
<p>van den Berg</p>
<p>MP</p>
<p>,</p>
<p>Hilfiker-Kleiner</p>
<p>D</p>
<p>,</p>
<p>Bollen</p>
<p>IA</p>
<p>,</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Alders</p>
<p>M</p>
<p>,</p>
<p>Almomani</p>
<p>R</p>
<p>,</p>
<p>van Langen</p>
<p>IM</p>
<p>,</p>
<p>van der Meer</p>
<p>P</p>
<p>,</p>
<p>Sinke</p>
<p>RJ</p>
<p>,</p>
<p>van der Velden</p>
<p>J</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>van Tintelen</p>
<p>JP</p>
<p>,</p>
<p>Jongbloed</p>
<p>JD.</p>
<p>Titin gene mutations are common in families with both peripartum
cardiomyopathy and dilated cardiomyopathy</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2014</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>2165</p>
<p>–</p>
<p>2173</p>
<p>.</p>
<p>905</p>
<p>Choi</p>
<p>SH</p>
<p>,</p>
<p>Weng</p>
<p>LC</p>
<p>,</p>
<p>Roselli</p>
<p>C</p>
<p>,</p>
<p>Lin</p>
<p>H</p>
<p>,</p>
<p>Haggerty</p>
<p>CM</p>
<p>,</p>
<p>Shoemaker</p>
<p>MB</p>
<p>,</p>
<p>Barnard</p>
<p>J</p>
<p>,</p>
<p>Arking</p>
<p>DE</p>
<p>,</p>
<p>Chasman</p>
<p>DI</p>
<p>,</p>
<p>Albert</p>
<p>CM</p>
<p>,</p>
<p>Chaffin</p>
<p>M</p>
<p>,</p>
<p>Tucker</p>
<p>NR</p>
<p>,</p>
<p>Smith</p>
<p>JD</p>
<p>,</p>
<p>Gupta</p>
<p>N</p>
<p>,</p>
<p>Gabriel</p>
<p>S</p>
<p>,</p>
<p>Margolin</p>
<p>L</p>
<p>,</p>
<p>Shea</p>
<p>MA</p>
<p>,</p>
<p>Shaffer</p>
<p>CM</p>
<p>,</p>
<p>Yoneda</p>
<p>ZT</p>
<p>,</p>
<p>Boerwinkle</p>
<p>E</p>
<p>,</p>
<p>Smith</p>
<p>NL</p>
<p>,</p>
<p>Silverman</p>
<p>EK</p>
<p>,</p>
<p>Redline</p>
<p>S</p>
<p>,</p>
<p>Vasan</p>
<p>RS</p>
<p>,</p>
<p>Burchard</p>
<p>EG</p>
<p>,</p>
<p>Gogarten</p>
<p>SM</p>
<p>,</p>
<p>Laurie</p>
<p>C</p>
<p>,</p>
<p>Blackwell</p>
<p>TW</p>
<p>,</p>
<p>Abecasis</p>
<p>G</p>
<p>,</p>
<p>Carey</p>
<p>DJ</p>
<p>,</p>
<p>Fornwalt</p>
<p>BK</p>
<p>,</p>
<p>Smelser</p>
<p>DT</p>
<p>,</p>
<p>Baras</p>
<p>A</p>
<p>,</p>
<p>Dewey</p>
<p>FE</p>
<p>,</p>
<p>Jaquish</p>
<p>CE</p>
<p>,</p>
<p>Papanicolaou</p>
<p>GJ</p>
<p>,</p>
<p>Sotoodehnia</p>
<p>N</p>
<p>,</p>
<p>Van Wagoner</p>
<p>DR</p>
<p>,</p>
<p>Psaty</p>
<p>BM</p>
<p>,</p>
<p>Kathiresan</p>
<p>S</p>
<p>,</p>
<p>Darbar</p>
<p>D</p>
<p>,</p>
<p>Alonso</p>
<p>A</p>
<p>,</p>
<p>Heckbert</p>
<p>SR</p>
<p>,</p>
<p>Chung</p>
<p>MK</p>
<p>,</p>
<p>Roden</p>
<p>DM</p>
<p>,</p>
<p>Benjamin</p>
<p>EJ</p>
<p>,</p>
<p>Murray</p>
<p>MF</p>
<p>,</p>
<p>Lunetta</p>
<p>KL</p>
<p>,</p>
<p>Lubitz</p>
<p>SA</p>
<p>,</p>
<p>Ellinor</p>
<p>PT</p>
<p>,</p>
<p>DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine
(TOPMed) Consortium. Association between titin loss-of-function variants
and early-onset atrial fibrillation</p>
<p>.</p>
<p>JAMA</p>
<p>2018</p>
<p>;</p>
<p>320</p>
<p>:</p>
<p>2354</p>
<p>–</p>
<p>2364</p>
<p>.</p>
<p>906</p>
<p>Hazebroek</p>
<p>MR</p>
<p>,</p>
<p>Krapels</p>
<p>I</p>
<p>,</p>
<p>Verdonschot</p>
<p>J</p>
<p>,</p>
<p>van den Wijngaard</p>
<p>A</p>
<p>,</p>
<p>Vanhoutte</p>
<p>E</p>
<p>,</p>
<p>Hoos</p>
<p>M</p>
<p>,</p>
<p>Snijders</p>
<p>L</p>
<p>,</p>
<p>van Montfort</p>
<p>L</p>
<p>,</p>
<p>Witjens</p>
<p>M</p>
<p>,</p>
<p>Dennert</p>
<p>R</p>
<p>,</p>
<p>Crijns</p>
<p>H</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Brunner</p>
<p>HG</p>
<p>,</p>
<p>Heymans</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Prevalence of pathogenic gene mutations and prognosis do not differ
in isolated left ventricular dysfunction compared with dilated
cardiomyopathy</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>e004682</p>
<p>.</p>
<p>907</p>
<p>Leone</p>
<p>O</p>
<p>,</p>
<p>Veinot</p>
<p>JP</p>
<p>,</p>
<p>Angelini</p>
<p>A</p>
<p>,</p>
<p>Baandrup</p>
<p>UT</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Berry</p>
<p>G</p>
<p>,</p>
<p>Bruneval</p>
<p>P</p>
<p>,</p>
<p>Burke</p>
<p>M</p>
<p>,</p>
<p>Butany</p>
<p>J</p>
<p>,</p>
<p>Calabrese</p>
<p>F</p>
<p>,</p>
<p>d’Amati</p>
<p>G</p>
<p>,</p>
<p>Edwards</p>
<p>WD</p>
<p>,</p>
<p>Fallon</p>
<p>JT</p>
<p>,</p>
<p>Fishbein</p>
<p>MC</p>
<p>,</p>
<p>Gallagher</p>
<p>PJ</p>
<p>,</p>
<p>Halushka</p>
<p>MK</p>
<p>,</p>
<p>McManus</p>
<p>B</p>
<p>,</p>
<p>Pucci</p>
<p>A</p>
<p>,</p>
<p>Rodriguez</p>
<p>ER</p>
<p>,</p>
<p>Saffitz</p>
<p>JE</p>
<p>,</p>
<p>Sheppard</p>
<p>MN</p>
<p>,</p>
<p>Steenbergen</p>
<p>C</p>
<p>,</p>
<p>Stone</p>
<p>JR</p>
<p>,</p>
<p>Tan</p>
<p>C</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>van der Wal</p>
<p>AC</p>
<p>,</p>
<p>Winters</p>
<p>GL.</p>
<p>2011 consensus statement on endomyocardial biopsy from the
Association for European Cardiovascular Pathology and the Society for
Cardiovascular Pathology</p>
<p>.</p>
<p>Cardiovasc Pathol</p>
<p>2012</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>245</p>
<p>–</p>
<p>274</p>
<p>.</p>
<p>908</p>
<p>Halliday</p>
<p>BP</p>
<p>,</p>
<p>Owen</p>
<p>R</p>
<p>,</p>
<p>Gregson</p>
<p>J</p>
<p>Vassiliou VS, Chen X, Wage R, Lota AS, Khalique Z, Tayal U,
Hammersley DJ, Jones RE, Baksi AJ, Cowie MR, Cleland JGF, Pennell DJ,
Prasad SK.</p>
<p>Myocardial remodelling after withdrawing therapy for heart failure in
patients with recovered dilated cardiomyopathy: insights from
TRED-HF</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>293</p>
<p>–</p>
<p>301</p>
<p>.</p>
<p>909</p>
<p>Olivotto</p>
<p>I</p>
<p>,</p>
<p>Oreziak</p>
<p>A</p>
<p>,</p>
<p>Barriales-Villa</p>
<p>R</p>
<p>,</p>
<p>Abraham</p>
<p>TP</p>
<p>,</p>
<p>Masri</p>
<p>A</p>
<p>,</p>
<p>Garcia-Pavia</p>
<p>P</p>
<p>,</p>
<p>Saberi</p>
<p>S</p>
<p>,</p>
<p>Lakdawala</p>
<p>NK</p>
<p>,</p>
<p>Wheeler</p>
<p>MT</p>
<p>,</p>
<p>Owens</p>
<p>A</p>
<p>,</p>
<p>Kubanek</p>
<p>M</p>
<p>,</p>
<p>Wojakowski</p>
<p>W</p>
<p>,</p>
<p>Jensen</p>
<p>MK</p>
<p>,</p>
<p>Gimeno-Blanes</p>
<p>J</p>
<p>,</p>
<p>Afshar</p>
<p>K</p>
<p>,</p>
<p>Myers</p>
<p>J</p>
<p>,</p>
<p>Hegde</p>
<p>SM</p>
<p>,</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Sehnert</p>
<p>AJ</p>
<p>,</p>
<p>Zhang</p>
<p>D</p>
<p>,</p>
<p>Li</p>
<p>W</p>
<p>,</p>
<p>Bhattacharya</p>
<p>M</p>
<p>,</p>
<p>Edelberg</p>
<p>JM</p>
<p>,</p>
<p>Waldman</p>
<p>CB</p>
<p>,</p>
<p>Lester</p>
<p>SJ</p>
<p>,</p>
<p>Wang</p>
<p>A</p>
<p>,</p>
<p>Ho</p>
<p>CY</p>
<p>,</p>
<p>Jacoby</p>
<p>D</p>
<p>,</p>
<p>EXPLORER-HCM Study Investigators. Mavacamten for treatment of
symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a
randomised, double-blind, placebo-controlled, phase 3 trial</p>
<p>.</p>
<p>Lancet</p>
<p>2020</p>
<p>;</p>
<p>396</p>
<p>:</p>
<p>759</p>
<p>–</p>
<p>769</p>
<p>.</p>
<p>910</p>
<p>Cadrin-Tourigny</p>
<p>J</p>
<p>,</p>
<p>Bosman</p>
<p>LP</p>
<p>,</p>
<p>Nozza</p>
<p>A</p>
<p>,</p>
<p>Wang</p>
<p>W</p>
<p>,</p>
<p>Tadros</p>
<p>R</p>
<p>,</p>
<p>Bhonsale</p>
<p>A</p>
<p>,</p>
<p>Bourfiss</p>
<p>M</p>
<p>,</p>
<p>Fortier</p>
<p>A</p>
<p>,</p>
<p>Lie</p>
<p>OH</p>
<p>,</p>
<p>Saguner</p>
<p>AM</p>
<p>,</p>
<p>Svensson</p>
<p>A</p>
<p>,</p>
<p>Andorin</p>
<p>A</p>
<p>,</p>
<p>Tichnell</p>
<p>C</p>
<p>,</p>
<p>Murray</p>
<p>B</p>
<p>,</p>
<p>Zeppenfeld</p>
<p>K</p>
<p>,</p>
<p>van den Berg</p>
<p>MP</p>
<p>,</p>
<p>Asselbergs</p>
<p>FW</p>
<p>,</p>
<p>Wilde</p>
<p>AAM</p>
<p>,</p>
<p>Krahn</p>
<p>AD</p>
<p>,</p>
<p>Talajic</p>
<p>M</p>
<p>,</p>
<p>Rivard</p>
<p>L</p>
<p>,</p>
<p>Chelko</p>
<p>S</p>
<p>,</p>
<p>Zimmerman</p>
<p>SL</p>
<p>,</p>
<p>Kamel</p>
<p>IR</p>
<p>,</p>
<p>Crosson</p>
<p>JE</p>
<p>,</p>
<p>Judge</p>
<p>DP</p>
<p>,</p>
<p>Yap</p>
<p>SC</p>
<p>,</p>
<p>van der Heijden</p>
<p>JF</p>
<p>,</p>
<p>Tandri</p>
<p>H</p>
<p>,</p>
<p>Jongbloed</p>
<p>JDH</p>
<p>,</p>
<p>Guertin</p>
<p>MC</p>
<p>,</p>
<p>van Tintelen</p>
<p>JP</p>
<p>,</p>
<p>Platonov</p>
<p>PG</p>
<p>,</p>
<p>Duru</p>
<p>F</p>
<p>,</p>
<p>Haugaa</p>
<p>KH</p>
<p>,</p>
<p>Khairy</p>
<p>P</p>
<p>,</p>
<p>Hauer</p>
<p>RNW</p>
<p>,</p>
<p>Calkins</p>
<p>H</p>
<p>,</p>
<p>Te Riele</p>
<p>A</p>
<p>,</p>
<p>James</p>
<p>CA.</p>
<p>A new prediction model for ventricular arrhythmias in arrhythmogenic
right ventricular cardiomyopathy</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>1850</p>
<p>–</p>
<p>1858</p>
<p>.</p>
<p>911</p>
<p>Leren</p>
<p>IS</p>
<p>,</p>
<p>Saberniak</p>
<p>J</p>
<p>,</p>
<p>Haland</p>
<p>TF</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Haugaa</p>
<p>KH.</p>
<p>Combination of ECG and echocardiography for identification of
arrhythmic events in early ARVC</p>
<p>.</p>
<p>JACC Cardiovasc Imaging</p>
<p>2017</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>503</p>
<p>–</p>
<p>513</p>
<p>.</p>
<p>912</p>
<p>Towbin</p>
<p>JA</p>
<p>,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Abrams</p>
<p>DJ</p>
<p>,</p>
<p>Ackerman</p>
<p>MJ</p>
<p>,</p>
<p>Calkins</p>
<p>H</p>
<p>,</p>
<p>Darrieux</p>
<p>FCC</p>
<p>,</p>
<p>Daubert</p>
<p>JP</p>
<p>,</p>
<p>de Chillou</p>
<p>C</p>
<p>,</p>
<p>DePasquale</p>
<p>EC</p>
<p>,</p>
<p>Desai</p>
<p>MY</p>
<p>,</p>
<p>Estes</p>
<p>NAM</p>
<p>3rd,</p>
<p>Hua</p>
<p>W</p>
<p>,</p>
<p>Indik</p>
<p>JH</p>
<p>,</p>
<p>Ingles</p>
<p>J</p>
<p>,</p>
<p>James</p>
<p>CA</p>
<p>,</p>
<p>John</p>
<p>RM</p>
<p>,</p>
<p>Judge</p>
<p>DP</p>
<p>,</p>
<p>Keegan</p>
<p>R</p>
<p>,</p>
<p>Krahn</p>
<p>AD</p>
<p>,</p>
<p>Link</p>
<p>MS</p>
<p>,</p>
<p>Marcus</p>
<p>FI</p>
<p>,</p>
<p>McLeod</p>
<p>CJ</p>
<p>,</p>
<p>Mestroni</p>
<p>L</p>
<p>,</p>
<p>Priori</p>
<p>SG</p>
<p>,</p>
<p>Saffitz</p>
<p>JE</p>
<p>,</p>
<p>Sanatani</p>
<p>S</p>
<p>,</p>
<p>Shimizu</p>
<p>W</p>
<p>,</p>
<p>van Tintelen</p>
<p>JP</p>
<p>,</p>
<p>Wilde</p>
<p>AAM</p>
<p>,</p>
<p>Zareba</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>2019</p>
<p>HRS expert consensus statement on evaluation, risk stratification,
and management of arrhythmogenic cardiomyopathy</p>
<p>.</p>
<p>Heart Rhythm</p>
<p>2019</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>e301</p>
<p>–</p>
<p>e372</p>
<p>.</p>
<p>913</p>
<p>Kristensen</p>
<p>SL</p>
<p>,</p>
<p>Levy</p>
<p>WC</p>
<p>,</p>
<p>Shadman</p>
<p>R</p>
<p>,</p>
<p>Nielsen</p>
<p>JC</p>
<p>,</p>
<p>Haarbo</p>
<p>J</p>
<p>,</p>
<p>Videbaek</p>
<p>L</p>
<p>,</p>
<p>Bruun</p>
<p>NE</p>
<p>,</p>
<p>Eiskjaer</p>
<p>H</p>
<p>,</p>
<p>Wiggers</p>
<p>H</p>
<p>,</p>
<p>Brandes</p>
<p>A</p>
<p>,</p>
<p>Thogersen</p>
<p>AM</p>
<p>,</p>
<p>Hassager</p>
<p>C</p>
<p>,</p>
<p>Svendsen</p>
<p>JH</p>
<p>,</p>
<p>Hofsten</p>
<p>DE</p>
<p>,</p>
<p>Torp-Pedersen</p>
<p>C</p>
<p>,</p>
<p>Pehrson</p>
<p>S</p>
<p>,</p>
<p>Signorovitch</p>
<p>J</p>
<p>,</p>
<p>Kober</p>
<p>L</p>
<p>,</p>
<p>Thune</p>
<p>JJ.</p>
<p>Risk models for prediction of implantable cardioverter-defibrillator
benefit: insights from the DANISH trial</p>
<p>.</p>
<p>JACC Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>717</p>
<p>–</p>
<p>724</p>
<p>.</p>
<p>914</p>
<p>Corrado</p>
<p>D</p>
<p>,</p>
<p>Wichter</p>
<p>T</p>
<p>,</p>
<p>Link</p>
<p>MS</p>
<p>,</p>
<p>Hauer</p>
<p>R</p>
<p>,</p>
<p>Marchlinski</p>
<p>F</p>
<p>,</p>
<p>Anastasakis</p>
<p>A</p>
<p>,</p>
<p>Bauce</p>
<p>B</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Brunckhorst</p>
<p>C</p>
<p>,</p>
<p>Tsatsopoulou</p>
<p>A</p>
<p>,</p>
<p>Tandri</p>
<p>H</p>
<p>,</p>
<p>Paul</p>
<p>M</p>
<p>,</p>
<p>Schmied</p>
<p>C</p>
<p>,</p>
<p>Pelliccia</p>
<p>A</p>
<p>,</p>
<p>Duru</p>
<p>F</p>
<p>,</p>
<p>Protonotarios</p>
<p>N</p>
<p>,</p>
<p>Estes</p>
<p>NA</p>
<p>3rd,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>Marcus</p>
<p>FI</p>
<p>,</p>
<p>Calkins</p>
<ol start="8" type="A">
<li></li>
</ol>
<p>Treatment of arrhythmogenic right ventricular
cardiomyopathy/dysplasia: an international task force consensus
statement</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>3227</p>
<p>–</p>
<p>3237</p>
<p>.</p>
<p>915</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Anastasakis</p>
<p>A</p>
<p>,</p>
<p>Asimaki</p>
<p>A</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Bauce</p>
<p>B</p>
<p>,</p>
<p>Brooke</p>
<p>MA</p>
<p>,</p>
<p>Calkins</p>
<p>H</p>
<p>,</p>
<p>Corrado</p>
<p>D</p>
<p>,</p>
<p>Duru</p>
<p>F</p>
<p>,</p>
<p>Green</p>
<p>KJ</p>
<p>,</p>
<p>Judge</p>
<p>DP</p>
<p>,</p>
<p>Kelsell</p>
<p>D</p>
<p>,</p>
<p>Lambiase</p>
<p>PD</p>
<p>,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Pilichou</p>
<p>K</p>
<p>,</p>
<p>Protonotarios</p>
<p>A</p>
<p>,</p>
<p>Saffitz</p>
<p>JE</p>
<p>,</p>
<p>Syrris</p>
<p>P</p>
<p>,</p>
<p>Tandri</p>
<p>H</p>
<p>,</p>
<p>Te Riele</p>
<p>A</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>Tsatsopoulou</p>
<p>A</p>
<p>,</p>
<p>Tintelen</p>
<p>JP.</p>
<p>Definition and treatment of arrhythmogenic cardiomyopathy: an updated
expert panel report</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>955</p>
<p>–</p>
<p>964</p>
<p>.</p>
<p>916</p>
<p>Mazzarotto</p>
<p>F</p>
<p>,</p>
<p>Tayal</p>
<p>U</p>
<p>,</p>
<p>Buchan</p>
<p>RJ</p>
<p>,</p>
<p>Midwinter</p>
<p>W</p>
<p>,</p>
<p>Wilk</p>
<p>A</p>
<p>,</p>
<p>Whiffin</p>
<p>N</p>
<p>,</p>
<p>Govind</p>
<p>R</p>
<p>,</p>
<p>Mazaika</p>
<p>E</p>
<p>,</p>
<p>de Marvao</p>
<p>A</p>
<p>,</p>
<p>Dawes</p>
<p>TJW</p>
<p>,</p>
<p>Felkin</p>
<p>LE</p>
<p>,</p>
<p>Ahmad</p>
<p>M</p>
<p>,</p>
<p>Theotokis</p>
<p>PI</p>
<p>,</p>
<p>Edwards</p>
<p>E</p>
<p>,</p>
<p>Ing</p>
<p>AY</p>
<p>,</p>
<p>Thomson</p>
<p>KL</p>
<p>,</p>
<p>Chan</p>
<p>LLH</p>
<p>,</p>
<p>Sim</p>
<p>D</p>
<p>,</p>
<p>Baksi</p>
<p>AJ</p>
<p>,</p>
<p>Pantazis</p>
<p>A</p>
<p>,</p>
<p>Roberts</p>
<p>AM</p>
<p>,</p>
<p>Watkins</p>
<p>H</p>
<p>,</p>
<p>Funke</p>
<p>B</p>
<p>,</p>
<p>O’Regan</p>
<p>DP</p>
<p>,</p>
<p>Olivotto</p>
<p>I</p>
<p>,</p>
<p>Barton</p>
<p>PJR</p>
<p>,</p>
<p>Prasad</p>
<p>SK</p>
<p>,</p>
<p>Cook</p>
<p>SA</p>
<p>,</p>
<p>Ware</p>
<p>JS</p>
<p>,</p>
<p>Walsh</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Reevaluating the genetic contribution of monogenic dilated
cardiomyopathy</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>387</p>
<p>–</p>
<p>398</p>
<p>.</p>
<p>917</p>
<p>Caforio</p>
<p>AL</p>
<p>,</p>
<p>Pankuweit</p>
<p>S</p>
<p>,</p>
<p>Arbustini</p>
<p>E</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Gimeno-Blanes</p>
<p>J</p>
<p>,</p>
<p>Felix</p>
<p>SB</p>
<p>,</p>
<p>Fu</p>
<p>M</p>
<p>,</p>
<p>Helio</p>
<p>T</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Jahns</p>
<p>R</p>
<p>,</p>
<p>Klingel</p>
<p>K</p>
<p>,</p>
<p>Linhart</p>
<p>A</p>
<p>,</p>
<p>Maisch</p>
<p>B</p>
<p>,</p>
<p>McKenna</p>
<p>W</p>
<p>,</p>
<p>Mogensen</p>
<p>J</p>
<p>,</p>
<p>Pinto</p>
<p>YM</p>
<p>,</p>
<p>Ristic</p>
<p>A</p>
<p>,</p>
<p>Schultheiss</p>
<p>HP</p>
<p>,</p>
<p>Seggewiss</p>
<p>H</p>
<p>,</p>
<p>Tavazzi</p>
<p>L</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>Yilmaz</p>
<p>A</p>
<p>,</p>
<p>Charron</p>
<p>P</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases</p>
<p>.</p>
<p>Current state of knowledge on aetiology, diagnosis, management, and
therapy of myocarditis: a position statement of the European Society of
Cardiology Working Group on Myocardial and Pericardial Diseases</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2013</p>
<p>;</p>
<p>34</p>
<p>:2636-2648, 2648a-2648d.</p>
<p>918</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Eriksson</p>
<p>U</p>
<p>,</p>
<p>Lehtonen</p>
<p>J</p>
<p>,</p>
<p>Cooper</p>
<p>LT</p>
<p>Jr.</p>
<p>The quest for new approaches in myocarditis and inflammatory
cardiomyopathy</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2016</p>
<p>;</p>
<p>68</p>
<p>:</p>
<p>2348</p>
<p>–</p>
<p>2364</p>
<p>.</p>
<p>919</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>Ammirati</p>
<p>E</p>
<p>,</p>
<p>Bozkurt</p>
<p>B</p>
<p>,</p>
<p>Caforio</p>
<p>ALP</p>
<p>,</p>
<p>Cooper</p>
<p>LT</p>
<p>,</p>
<p>Felix</p>
<p>SB</p>
<p>,</p>
<p>Hare</p>
<p>JM</p>
<p>,</p>
<p>Heidecker</p>
<p>B</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Hubner</p>
<p>N</p>
<p>,</p>
<p>Kelle</p>
<p>S</p>
<p>,</p>
<p>Klingel</p>
<p>K</p>
<p>,</p>
<p>Maatz</p>
<p>H</p>
<p>,</p>
<p>Parwani</p>
<p>AS</p>
<p>,</p>
<p>Spillmann</p>
<p>F</p>
<p>,</p>
<p>Starling</p>
<p>RC</p>
<p>,</p>
<p>Tsutsui</p>
<p>H</p>
<p>,</p>
<p>Seferovic</p>
<p>P</p>
<p>,</p>
<p>Van Linthout</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Myocarditis and inflammatory cardiomyopathy: current evidence and
future directions</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2021</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>169</p>
<p>–</p>
<p>193</p>
<p>.</p>
<p>920</p>
<p>Wahbi</p>
<p>K</p>
<p>,</p>
<p>Ben Yaou</p>
<p>R</p>
<p>,</p>
<p>Gandjbakhch</p>
<p>E</p>
<p>,</p>
<p>Anselme</p>
<p>F</p>
<p>,</p>
<p>Gossios</p>
<p>T</p>
<p>,</p>
<p>Lakdawala</p>
<p>NK</p>
<p>,</p>
<p>Stalens</p>
<p>C</p>
<p>,</p>
<p>Sacher</p>
<p>F</p>
<p>,</p>
<p>Babuty</p>
<p>D</p>
<p>,</p>
<p>Trochu</p>
<p>JN</p>
<p>,</p>
<p>Moubarak</p>
<p>G</p>
<p>,</p>
<p>Savvatis</p>
<p>K</p>
<p>,</p>
<p>Porcher</p>
<p>R</p>
<p>,</p>
<p>Laforet</p>
<p>P</p>
<p>,</p>
<p>Fayssoil</p>
<p>A</p>
<p>,</p>
<p>Marijon</p>
<p>E</p>
<p>,</p>
<p>Stojkovic</p>
<p>T</p>
<p>,</p>
<p>Behin</p>
<p>A</p>
<p>,</p>
<p>Leonard-Louis</p>
<p>S</p>
<p>,</p>
<p>Sole</p>
<p>G</p>
<p>,</p>
<p>Labombarda</p>
<p>F</p>
<p>,</p>
<p>Richard</p>
<p>P</p>
<p>,</p>
<p>Metay</p>
<p>C</p>
<p>,</p>
<p>Quijano-Roy</p>
<p>S</p>
<p>,</p>
<p>Dabaj</p>
<p>I</p>
<p>,</p>
<p>Klug</p>
<p>D</p>
<p>,</p>
<p>Vantyghem</p>
<p>MC</p>
<p>,</p>
<p>Chevalier</p>
<p>P</p>
<p>,</p>
<p>Ambrosi</p>
<p>P</p>
<p>,</p>
<p>Salort</p>
<p>E</p>
<p>,</p>
<p>Sadoul</p>
<p>N</p>
<p>,</p>
<p>Waintraub</p>
<p>X</p>
<p>,</p>
<p>Chikhaoui</p>
<p>K</p>
<p>,</p>
<p>Mabo</p>
<p>P</p>
<p>,</p>
<p>Combes</p>
<p>N</p>
<p>,</p>
<p>Maury</p>
<p>P</p>
<p>,</p>
<p>Sellal</p>
<p>JM</p>
<p>,</p>
<p>Tedrow</p>
<p>UB</p>
<p>,</p>
<p>Kalman</p>
<p>JM</p>
<p>,</p>
<p>Vohra</p>
<p>J</p>
<p>,</p>
<p>Androulakis</p>
<p>AFA</p>
<p>,</p>
<p>Zeppenfeld</p>
<p>K</p>
<p>,</p>
<p>Thompson</p>
<p>T</p>
<p>,</p>
<p>Barnerias</p>
<p>C</p>
<p>,</p>
<p>Becane</p>
<p>HM</p>
<p>,</p>
<p>Bieth</p>
<p>E</p>
<p>,</p>
<p>Boccara</p>
<p>F</p>
<p>,</p>
<p>Bonnet</p>
<p>D</p>
<p>,</p>
<p>Bouhour</p>
<p>F</p>
<p>,</p>
<p>Boule</p>
<p>S</p>
<p>,</p>
<p>Brehin</p>
<p>AC</p>
<p>,</p>
<p>Chapon</p>
<p>F</p>
<p>,</p>
<p>Cintas</p>
<p>P</p>
<p>,</p>
<p>Cuisset</p>
<p>JM</p>
<p>,</p>
<p>Davy</p>
<p>JM</p>
<p>,</p>
<p>De Sandre-Giovannoli</p>
<p>A</p>
<p>,</p>
<p>Demurger</p>
<p>F</p>
<p>,</p>
<p>Desguerre</p>
<p>I</p>
<p>,</p>
<p>Dieterich</p>
<p>K</p>
<p>,</p>
<p>Durigneux</p>
<p>J</p>
<p>,</p>
<p>Echaniz-Laguna</p>
<p>A</p>
<p>,</p>
<p>Eschalier</p>
<p>R</p>
<p>,</p>
<p>Ferreiro</p>
<p>A</p>
<p>,</p>
<p>Ferrer</p>
<p>X</p>
<p>,</p>
<p>Francannet</p>
<p>C</p>
<p>,</p>
<p>Fradin</p>
<p>M</p>
<p>,</p>
<p>Gaborit</p>
<p>B</p>
<p>,</p>
<p>Gay</p>
<p>A</p>
<p>,</p>
<p>Hagege</p>
<p>A</p>
<p>,</p>
<p>Isapof</p>
<p>A</p>
<p>,</p>
<p>Jeru</p>
<p>I</p>
<p>,</p>
<p>Juntas Morales</p>
<p>R</p>
<p>,</p>
<p>Lagrue</p>
<p>E</p>
<p>,</p>
<p>Lamblin</p>
<p>N</p>
<p>,</p>
<p>Lascols</p>
<p>O</p>
<p>,</p>
<p>Laugel</p>
<p>V</p>
<p>,</p>
<p>Lazarus</p>
<p>A</p>
<p>,</p>
<p>Leturcq</p>
<p>F</p>
<p>,</p>
<p>Levy</p>
<p>N</p>
<p>,</p>
<p>Magot</p>
<p>A</p>
<p>,</p>
<p>Manel</p>
<p>V</p>
<p>,</p>
<p>Martins</p>
<p>R</p>
<p>,</p>
<p>Mayer</p>
<p>M</p>
<p>,</p>
<p>Mercier</p>
<p>S</p>
<p>,</p>
<p>Meune</p>
<p>C</p>
<p>,</p>
<p>Michaud</p>
<p>M</p>
<p>,</p>
<p>Minot-Myhie</p>
<p>MC</p>
<p>,</p>
<p>Muchir</p>
<p>A</p>
<p>,</p>
<p>Nadaj-Pakleza</p>
<p>A</p>
<p>,</p>
<p>Pereon</p>
<p>Y</p>
<p>,</p>
<p>Petiot</p>
<p>P</p>
<p>,</p>
<p>Petit</p>
<p>F</p>
<p>,</p>
<p>Praline</p>
<p>J</p>
<p>,</p>
<p>Rollin</p>
<p>A</p>
<p>,</p>
<p>Sabouraud</p>
<p>P</p>
<p>,</p>
<p>Sarret</p>
<p>C</p>
<p>,</p>
<p>Schaeffer</p>
<p>S</p>
<p>,</p>
<p>Taithe</p>
<p>F</p>
<p>,</p>
<p>Tard</p>
<p>C</p>
<p>,</p>
<p>Tiffreau</p>
<p>V</p>
<p>,</p>
<p>Toutain</p>
<p>A</p>
<p>,</p>
<p>Vatier</p>
<p>C</p>
<p>,</p>
<p>Walther-Louvier</p>
<p>U</p>
<p>,</p>
<p>Eymard</p>
<p>B</p>
<p>,</p>
<p>Charron</p>
<p>P</p>
<p>,</p>
<p>Vigouroux</p>
<p>C</p>
<p>,</p>
<p>Bonne</p>
<p>G</p>
<p>,</p>
<p>Kumar</p>
<p>S</p>
<p>,</p>
<p>Elliott</p>
<p>P</p>
<p>,</p>
<p>Duboc</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Development and validation of a new risk prediction score for
life-threatening ventricular tachyarrhythmias in laminopathies</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>140</p>
<p>:</p>
<p>293</p>
<p>–</p>
<p>302</p>
<p>.</p>
<p>921</p>
<p>Echeverria</p>
<p>LE</p>
<p>,</p>
<p>Marcus</p>
<p>R</p>
<p>,</p>
<p>Novick</p>
<p>G</p>
<p>,</p>
<p>Sosa-Estani</p>
<p>S</p>
<p>,</p>
<p>Ralston</p>
<p>K</p>
<p>,</p>
<p>Zaidel</p>
<p>EJ</p>
<p>,</p>
<p>Forsyth</p>
<p>C, ALP RI</p>
<p>,</p>
<p>Mendoza</p>
<p>I</p>
<p>,</p>
<p>Falconi</p>
<p>ML</p>
<p>,</p>
<p>Mitelman</p>
<p>J</p>
<p>,</p>
<p>Morillo</p>
<p>CA</p>
<p>,</p>
<p>Pereiro</p>
<p>AC</p>
<p>,</p>
<p>Pinazo</p>
<p>MJ</p>
<p>,</p>
<p>Salvatella</p>
<p>R</p>
<p>,</p>
<p>Martinez</p>
<p>F</p>
<p>,</p>
<p>Perel</p>
<p>P</p>
<p>,</p>
<p>Liprandi</p>
<p>AS</p>
<p>,</p>
<p>Pineiro</p>
<p>DJ</p>
<p>,</p>
<p>Molina</p>
<p>GR.</p>
<p>WHF IASC roadmap on Chagas disease</p>
<p>.</p>
<p>Glob Heart</p>
<p>2020</p>
<p>;</p>
<p>15</p>
<p>:</p>
<p>26</p>
<p>.</p>
<p>922</p>
<p>Martinez</p>
<p>F</p>
<p>,</p>
<p>Perna</p>
<p>E</p>
<p>,</p>
<p>Perrone</p>
<p>SV</p>
<p>,</p>
<p>Liprandi</p>
<p>AS.</p>
<p>Chagas disease and heart failure: an expanding issue worldwide</p>
<p>.</p>
<p>Eur Cardiol</p>
<p>2019</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>82</p>
<p>–</p>
<p>88</p>
<p>.</p>
<p>923</p>
<p>Ommen</p>
<p>SR</p>
<p>,</p>
<p>Mital</p>
<p>S</p>
<p>,</p>
<p>Burke</p>
<p>MA</p>
<p>,</p>
<p>Day</p>
<p>SM</p>
<p>,</p>
<p>Deswal</p>
<p>A</p>
<p>,</p>
<p>Elliott</p>
<p>P</p>
<p>,</p>
<p>Evanovich</p>
<p>LL</p>
<p>,</p>
<p>Hung</p>
<p>J</p>
<p>,</p>
<p>Joglar</p>
<p>JA</p>
<p>,</p>
<p>Kantor</p>
<p>P</p>
<p>,</p>
<p>Kimmelstiel</p>
<p>C</p>
<p>,</p>
<p>Kittleson</p>
<p>M</p>
<p>,</p>
<p>Link</p>
<p>MS</p>
<p>,</p>
<p>Maron</p>
<p>MS</p>
<p>,</p>
<p>Martinez</p>
<p>MW</p>
<p>,</p>
<p>Miyake</p>
<p>CY</p>
<p>,</p>
<p>Schaff</p>
<p>HV</p>
<p>,</p>
<p>Semsarian</p>
<p>C</p>
<p>,</p>
<p>Sorajja</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>2020 AHA/ACC Guideline for the diagnosis and treatment of patients
with hypertrophic cardiomyopathy: executive summary: a report of the
American College of Cardiology/American Heart Association Joint
Committee on Clinical Practice Guidelines</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>142</p>
<p>:</p>
<p>e533</p>
<p>–</p>
<p>e557</p>
<p>.</p>
<p>924</p>
<p>Walsh</p>
<p>R</p>
<p>,</p>
<p>Mazzarotto</p>
<p>F</p>
<p>,</p>
<p>Whiffin</p>
<p>N</p>
<p>,</p>
<p>Buchan</p>
<p>R</p>
<p>,</p>
<p>Midwinter</p>
<p>W</p>
<p>,</p>
<p>Wilk</p>
<p>A</p>
<p>,</p>
<p>Li</p>
<p>N</p>
<p>,</p>
<p>Felkin</p>
<p>L</p>
<p>,</p>
<p>Ingold</p>
<p>N</p>
<p>,</p>
<p>Govind</p>
<p>R</p>
<p>,</p>
<p>Ahmad</p>
<p>M</p>
<p>,</p>
<p>Mazaika</p>
<p>E</p>
<p>,</p>
<p>Allouba</p>
<p>M</p>
<p>,</p>
<p>Zhang</p>
<p>X</p>
<p>,</p>
<p>de Marvao</p>
<p>A</p>
<p>,</p>
<p>Day</p>
<p>SM</p>
<p>,</p>
<p>Ashley</p>
<p>E</p>
<p>,</p>
<p>Colan</p>
<p>SD</p>
<p>,</p>
<p>Michels</p>
<p>M</p>
<p>,</p>
<p>Pereira</p>
<p>AC</p>
<p>,</p>
<p>Jacoby</p>
<p>D</p>
<p>,</p>
<p>Ho</p>
<p>CY</p>
<p>,</p>
<p>Thomson</p>
<p>KL</p>
<p>,</p>
<p>Watkins</p>
<p>H</p>
<p>,</p>
<p>Barton</p>
<p>PJR</p>
<p>,</p>
<p>Olivotto</p>
<p>I</p>
<p>,</p>
<p>Cook</p>
<p>SA</p>
<p>,</p>
<p>Ware</p>
<p>JS.</p>
<p>Quantitative approaches to variant classification increase the yield
and precision of genetic testing in Mendelian diseases: the case of
hypertrophic cardiomyopathy</p>
<p>.</p>
<p>Genome Med</p>
<p>2019</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>5</p>
<p>.</p>
<p>925</p>
<p>Ingles</p>
<p>J</p>
<p>,</p>
<p>Goldstein</p>
<p>J</p>
<p>,</p>
<p>Thaxton</p>
<p>C</p>
<p>,</p>
<p>Caleshu</p>
<p>C</p>
<p>,</p>
<p>Corty</p>
<p>EW</p>
<p>,</p>
<p>Crowley</p>
<p>SB</p>
<p>,</p>
<p>Dougherty</p>
<p>K</p>
<p>,</p>
<p>Harrison</p>
<p>SM</p>
<p>,</p>
<p>McGlaughon</p>
<p>J</p>
<p>,</p>
<p>Milko</p>
<p>LV</p>
<p>,</p>
<p>Morales</p>
<p>A</p>
<p>,</p>
<p>Seifert</p>
<p>BA</p>
<p>,</p>
<p>Strande</p>
<p>N</p>
<p>,</p>
<p>Thomson</p>
<p>K</p>
<p>,</p>
<p>Peter van Tintelen</p>
<p>J</p>
<p>,</p>
<p>Wallace</p>
<p>K</p>
<p>,</p>
<p>Walsh</p>
<p>R</p>
<p>,</p>
<p>Wells</p>
<p>Q</p>
<p>,</p>
<p>Whiffin</p>
<p>N</p>
<p>,</p>
<p>Witkowski</p>
<p>L</p>
<p>,</p>
<p>Semsarian</p>
<p>C</p>
<p>,</p>
<p>Ware</p>
<p>JS</p>
<p>,</p>
<p>Hershberger</p>
<p>RE</p>
<p>,</p>
<p>Funke</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Evaluating the clinical validity of hypertrophic cardiomyopathy
genes</p>
<p>.</p>
<p>Circ Genom Precis Med</p>
<p>2019</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>e002460</p>
<p>.</p>
<p>926</p>
<p>Thomson</p>
<p>KL</p>
<p>,</p>
<p>Ormondroyd</p>
<p>E</p>
<p>,</p>
<p>Harper</p>
<p>AR</p>
<p>,</p>
<p>Dent</p>
<p>T</p>
<p>,</p>
<p>McGuire</p>
<p>K</p>
<p>,</p>
<p>Baksi</p>
<p>J</p>
<p>,</p>
<p>Blair</p>
<p>E</p>
<p>,</p>
<p>Brennan</p>
<p>P</p>
<p>,</p>
<p>Buchan</p>
<p>R</p>
<p>,</p>
<p>Bueser</p>
<p>T</p>
<p>,</p>
<p>Campbell</p>
<p>C</p>
<p>,</p>
<p>Carr-White</p>
<p>G</p>
<p>,</p>
<p>Cook</p>
<p>S</p>
<p>,</p>
<p>Daniels</p>
<p>M</p>
<p>,</p>
<p>Deevi</p>
<p>SVV</p>
<p>,</p>
<p>Goodship</p>
<p>J</p>
<p>,</p>
<p>Hayesmoore</p>
<p>JBG</p>
<p>,</p>
<p>Henderson</p>
<p>A</p>
<p>,</p>
<p>Lamb</p>
<p>T</p>
<p>,</p>
<p>Prasad</p>
<p>S</p>
<p>,</p>
<p>Rayner-Matthews</p>
<p>P</p>
<p>,</p>
<p>Robert</p>
<p>L</p>
<p>,</p>
<p>Sneddon</p>
<p>L</p>
<p>,</p>
<p>Stark</p>
<p>H</p>
<p>,</p>
<p>Walsh</p>
<p>R</p>
<p>,</p>
<p>Ware</p>
<p>JS</p>
<p>,</p>
<p>Farrall</p>
<p>M</p>
<p>,</p>
<p>Watkins</p>
<p>HC</p>
<p>,</p>
<p>NIHR BioResource - Rare Diseases Consortium</p>
<p>.</p>
<p>Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome
sequencing data in sarcomere negative cases has negligible diagnostic
yield</p>
<p>.</p>
<p>Genet Med</p>
<p>2019</p>
<p>;</p>
<p>21</p>
<p>:</p>
<p>1576</p>
<p>–</p>
<p>1584</p>
<p>.</p>
<p>927</p>
<p>Tuohy</p>
<p>CV</p>
<p>,</p>
<p>Kaul</p>
<p>S</p>
<p>,</p>
<p>Song</p>
<p>HK</p>
<p>,</p>
<p>Nazer</p>
<p>B</p>
<p>,</p>
<p>Heitner</p>
<p>SB.</p>
<p>Hypertrophic cardiomyopathy: the future of treatment</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>228</p>
<p>–</p>
<p>240</p>
<p>.</p>
<p>928</p>
<p>O’Mahony</p>
<p>C</p>
<p>,</p>
<p>Akhtar</p>
<p>MM</p>
<p>,</p>
<p>Anastasiou</p>
<p>Z</p>
<p>,</p>
<p>Guttmann</p>
<p>OP</p>
<p>,</p>
<p>Vriesendorp</p>
<p>PA</p>
<p>,</p>
<p>Michels</p>
<p>M</p>
<p>,</p>
<p>Magri</p>
<p>D</p>
<p>,</p>
<p>Autore</p>
<p>C</p>
<p>,</p>
<p>Fernandez</p>
<p>A</p>
<p>,</p>
<p>Ochoa</p>
<p>JP</p>
<p>,</p>
<p>Leong</p>
<p>KMW</p>
<p>,</p>
<p>Varnava</p>
<p>AM</p>
<p>,</p>
<p>Monserrat</p>
<p>L</p>
<p>,</p>
<p>Anastasakis</p>
<p>A</p>
<p>,</p>
<p>Garcia-Pavia</p>
<p>P</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Biagini</p>
<p>E</p>
<p>,</p>
<p>Gimeno</p>
<p>JR</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>Omar</p>
<p>RZ</p>
<p>,</p>
<p>Elliott</p>
<p>PM.</p>
<p>Effectiveness of the 2014 European Society of Cardiology guideline on
sudden cardiac death in hypertrophic cardiomyopathy: a systematic review
and meta-analysis</p>
<p>.</p>
<p>Heart</p>
<p>2019</p>
<p>;</p>
<p>105</p>
<p>:</p>
<p>623</p>
<p>–</p>
<p>631</p>
<p>.</p>
<p>929</p>
<p>O’Mahony</p>
<p>C</p>
<p>,</p>
<p>Jichi</p>
<p>F</p>
<p>,</p>
<p>Ommen</p>
<p>SR</p>
<p>,</p>
<p>Christiaans</p>
<p>I</p>
<p>,</p>
<p>Arbustini</p>
<p>E</p>
<p>,</p>
<p>Garcia-Pavia</p>
<p>P</p>
<p>,</p>
<p>Cecchi</p>
<p>F</p>
<p>,</p>
<p>Olivotto</p>
<p>I</p>
<p>,</p>
<p>Kitaoka</p>
<p>H</p>
<p>,</p>
<p>Gotsman</p>
<p>I</p>
<p>,</p>
<p>Carr-White</p>
<p>G</p>
<p>,</p>
<p>Mogensen</p>
<p>J</p>
<p>,</p>
<p>Antoniades</p>
<p>L</p>
<p>,</p>
<p>Mohiddin</p>
<p>SA</p>
<p>,</p>
<p>Maurer</p>
<p>MS</p>
<p>,</p>
<p>Tang</p>
<p>HC</p>
<p>,</p>
<p>Geske</p>
<p>JB</p>
<p>,</p>
<p>Siontis</p>
<p>KC</p>
<p>,</p>
<p>Mahmoud</p>
<p>KD</p>
<p>,</p>
<p>Vermeer</p>
<p>A</p>
<p>,</p>
<p>Wilde</p>
<p>A</p>
<p>,</p>
<p>Favalli</p>
<p>V</p>
<p>,</p>
<p>Guttmann</p>
<p>OP</p>
<p>,</p>
<p>Gallego-Delgado</p>
<p>M</p>
<p>,</p>
<p>Dominguez</p>
<p>F</p>
<p>,</p>
<p>Tanini</p>
<p>I</p>
<p>,</p>
<p>Kubo</p>
<p>T</p>
<p>,</p>
<p>Keren</p>
<p>A</p>
<p>,</p>
<p>Bueser</p>
<p>T</p>
<p>,</p>
<p>Waters</p>
<p>S</p>
<p>,</p>
<p>Issa</p>
<p>IF</p>
<p>,</p>
<p>Malcolmson</p>
<p>J</p>
<p>,</p>
<p>Burns</p>
<p>T</p>
<p>,</p>
<p>Sekhri</p>
<p>N</p>
<p>,</p>
<p>Hoeger</p>
<p>CW</p>
<p>,</p>
<p>Omar</p>
<p>RZ</p>
<p>,</p>
<p>Elliott</p>
<p>PM.</p>
<p>International external validation study of the 2014 European Society
of Cardiology Guidelines on Sudden Cardiac Death Prevention in
Hypertrophic Cardiomyopathy (EVIDENCE-HCM)</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>137</p>
<p>:</p>
<p>1015</p>
<p>–</p>
<p>1023</p>
<p>.</p>
<p>930</p>
<p>O’Mahony</p>
<p>C</p>
<p>,</p>
<p>Jichi</p>
<p>F</p>
<p>,</p>
<p>Pavlou</p>
<p>M</p>
<p>,</p>
<p>Monserrat</p>
<p>L</p>
<p>,</p>
<p>Anastasakis</p>
<p>A</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Biagini</p>
<p>E</p>
<p>,</p>
<p>Gimeno</p>
<p>JR</p>
<p>,</p>
<p>Limongelli</p>
<p>G</p>
<p>,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Omar</p>
<p>RZ</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Hypertrophic Cardiomyopathy Outcomes Investigators</p>
<p>.</p>
<p>A novel clinical risk prediction model for sudden cardiac death in
hypertrophic cardiomyopathy (HCM risk-SCD)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2014</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>2010</p>
<p>–</p>
<p>2020</p>
<p>.</p>
<p>931</p>
<p>Brignole</p>
<p>M</p>
<p>,</p>
<p>Moya</p>
<p>A</p>
<p>,</p>
<p>de Lange</p>
<p>FJ</p>
<p>,</p>
<p>Deharo</p>
<p>JC</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Fanciulli</p>
<p>A</p>
<p>,</p>
<p>Fedorowski</p>
<p>A</p>
<p>,</p>
<p>Furlan</p>
<p>R</p>
<p>,</p>
<p>Kenny</p>
<p>RA</p>
<p>,</p>
<p>Martin</p>
<p>A</p>
<p>,</p>
<p>Probst</p>
<p>V</p>
<p>,</p>
<p>Reed</p>
<p>MJ</p>
<p>,</p>
<p>Rice</p>
<p>CP</p>
<p>,</p>
<p>Sutton</p>
<p>R</p>
<p>,</p>
<p>Ungar</p>
<p>A</p>
<p>,</p>
<p>van Dijk</p>
<p>JG</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2018</p>
<p>ESC Guidelines for the diagnosis and management of syncope</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>1883</p>
<p>–</p>
<p>1948</p>
<p>.</p>
<p>932</p>
<p>Marcus</p>
<p>FI</p>
<p>,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Sherrill</p>
<p>D</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Bauce</p>
<p>B</p>
<p>,</p>
<p>Bluemke</p>
<p>DA</p>
<p>,</p>
<p>Calkins</p>
<p>H</p>
<p>,</p>
<p>Corrado</p>
<p>D</p>
<p>,</p>
<p>Cox</p>
<p>MG</p>
<p>,</p>
<p>Daubert</p>
<p>JP</p>
<p>,</p>
<p>Fontaine</p>
<p>G</p>
<p>,</p>
<p>Gear</p>
<p>K</p>
<p>,</p>
<p>Hauer</p>
<p>R</p>
<p>,</p>
<p>Nava</p>
<p>A</p>
<p>,</p>
<p>Picard</p>
<p>MH</p>
<p>,</p>
<p>Protonotarios</p>
<p>N</p>
<p>,</p>
<p>Saffitz</p>
<p>JE</p>
<p>,</p>
<p>Sanborn</p>
<p>DM</p>
<p>,</p>
<p>Steinberg</p>
<p>JS</p>
<p>,</p>
<p>Tandri</p>
<p>H</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>Towbin</p>
<p>JA</p>
<p>,</p>
<p>Tsatsopoulou</p>
<p>A</p>
<p>,</p>
<p>Wichter</p>
<p>T</p>
<p>,</p>
<p>Zareba</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Diagnosis of arrhythmogenic right ventricular
cardiomyopathy/dysplasia: proposed modification of the task force
criteria</p>
<p>.</p>
<p>Circulation</p>
<p>2010</p>
<p>;</p>
<p>121</p>
<p>:</p>
<p>1533</p>
<p>–</p>
<p>1541</p>
<p>.</p>
<p>933</p>
<p>Corrado</p>
<p>D</p>
<p>,</p>
<p>van Tintelen</p>
<p>PJ</p>
<p>,</p>
<p>McKenna</p>
<p>WJ</p>
<p>,</p>
<p>Hauer</p>
<p>RNW</p>
<p>,</p>
<p>Anastastakis</p>
<p>A</p>
<p>,</p>
<p>Asimaki</p>
<p>A</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Bauce</p>
<p>B</p>
<p>,</p>
<p>Brunckhorst</p>
<p>C</p>
<p>,</p>
<p>Bucciarelli-Ducci</p>
<p>C</p>
<p>,</p>
<p>Duru</p>
<p>F</p>
<p>,</p>
<p>Elliott</p>
<p>P</p>
<p>,</p>
<p>Hamilton</p>
<p>RM</p>
<p>,</p>
<p>Haugaa</p>
<p>KH</p>
<p>,</p>
<p>James</p>
<p>CA</p>
<p>,</p>
<p>Judge</p>
<p>D</p>
<p>,</p>
<p>Link</p>
<p>MS</p>
<p>,</p>
<p>Marchlinski</p>
<p>FE</p>
<p>,</p>
<p>Mazzanti</p>
<p>A</p>
<p>,</p>
<p>Mestroni</p>
<p>L</p>
<p>,</p>
<p>Pantazis</p>
<p>A</p>
<p>,</p>
<p>Pelliccia</p>
<p>A</p>
<p>,</p>
<p>Marra</p>
<p>MP</p>
<p>,</p>
<p>Pilichou</p>
<p>K</p>
<p>,</p>
<p>Platonov</p>
<p>PGA</p>
<p>,</p>
<p>Protonotarios</p>
<p>A</p>
<p>,</p>
<p>Rampazzo</p>
<p>A</p>
<p>,</p>
<p>Saffitz</p>
<p>JE</p>
<p>,</p>
<p>Saguner</p>
<p>AM</p>
<p>,</p>
<p>Schmied</p>
<p>C</p>
<p>,</p>
<p>Sharma</p>
<p>S</p>
<p>,</p>
<p>Tandri</p>
<p>H</p>
<p>,</p>
<p>Te Riele</p>
<p>A</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>Tsatsopoulou</p>
<p>A</p>
<p>,</p>
<p>Zareba</p>
<p>W</p>
<p>,</p>
<p>Zorzi</p>
<p>A</p>
<p>,</p>
<p>Wichter</p>
<p>T</p>
<p>,</p>
<p>Marcus</p>
<p>FI</p>
<p>,</p>
<p>Calkins</p>
<p>H</p>
<p>,</p>
<p>International Experts</p>
<p>.</p>
<p>Arrhythmogenic right ventricular cardiomyopathy: evaluation of the
current diagnostic criteria and differential diagnosis</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>1414</p>
<p>–</p>
<p>1429</p>
<p>.</p>
<p>934</p>
<p>Reichl</p>
<p>K</p>
<p>,</p>
<p>Kreykes</p>
<p>SE</p>
<p>,</p>
<p>Martin</p>
<p>CM</p>
<p>,</p>
<p>Shenoy</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>Desmoplakin variant-associated arrhythmogenic cardiomyopathy
presenting as acute myocarditis</p>
<p>.</p>
<p>Circ Genom Precis Med</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>e002373</p>
<p>.</p>
<p>935</p>
<p>Lopez-Ayala</p>
<p>JM</p>
<p>,</p>
<p>Pastor-Quirante</p>
<p>F</p>
<p>,</p>
<p>Gonzalez-Carrillo</p>
<p>J</p>
<p>,</p>
<p>Lopez-Cuenca</p>
<p>D</p>
<p>,</p>
<p>Sanchez-Munoz</p>
<p>JJ</p>
<p>,</p>
<p>Oliva-Sandoval</p>
<p>MJ</p>
<p>,</p>
<p>Gimeno</p>
<p>JR.</p>
<p>Genetics of myocarditis in arrhythmogenic right ventricular
dysplasia</p>
<p>.</p>
<p>Heart Rhythm</p>
<p>2015</p>
<p>;</p>
<p>12</p>
<p>:</p>
<p>766</p>
<p>–</p>
<p>773</p>
<p>.</p>
<p>936</p>
<p>Pelliccia</p>
<p>A</p>
<p>,</p>
<p>Solberg</p>
<p>EE</p>
<p>,</p>
<p>Papadakis</p>
<p>M</p>
<p>,</p>
<p>Adami</p>
<p>PE</p>
<p>,</p>
<p>Biffi</p>
<p>A</p>
<p>,</p>
<p>Caselli</p>
<p>S</p>
<p>,</p>
<p>La Gerche</p>
<p>A</p>
<p>,</p>
<p>Niebauer</p>
<p>J</p>
<p>,</p>
<p>Pressler</p>
<p>A</p>
<p>,</p>
<p>Schmied</p>
<p>CM</p>
<p>,</p>
<p>Serratosa</p>
<p>L</p>
<p>,</p>
<p>Halle</p>
<p>M</p>
<p>,</p>
<p>Van Buuren</p>
<p>F</p>
<p>,</p>
<p>Borjesson</p>
<p>M</p>
<p>,</p>
<p>Carre</p>
<p>F</p>
<p>,</p>
<p>Panhuyzen-Goedkoop</p>
<p>NM</p>
<p>,</p>
<p>Heidbuchel</p>
<p>H</p>
<p>,</p>
<p>Olivotto</p>
<p>I</p>
<p>,</p>
<p>Corrado</p>
<p>D</p>
<p>,</p>
<p>Sinagra</p>
<p>G</p>
<p>,</p>
<p>Sharma</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Recommendations for participation in competitive and leisure time
sport in athletes with cardiomyopathies, myocarditis, and pericarditis:
position statement of the Sport Cardiology Section of the European
Association of Preventive Cardiology (EAPC)</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>19</p>
<p>–</p>
<p>33</p>
<p>.</p>
<p>937</p>
<p>Sedaghat-Hamedani</p>
<p>F</p>
<p>,</p>
<p>Haas</p>
<p>J</p>
<p>,</p>
<p>Zhu</p>
<p>F</p>
<p>,</p>
<p>Geier</p>
<p>C</p>
<p>,</p>
<p>Kayvanpour</p>
<p>E</p>
<p>,</p>
<p>Liss</p>
<p>M</p>
<p>,</p>
<p>Lai</p>
<p>A</p>
<p>,</p>
<p>Frese</p>
<p>K</p>
<p>,</p>
<p>Pribe-Wolferts</p>
<p>R</p>
<p>,</p>
<p>Amr</p>
<p>A</p>
<p>,</p>
<p>Li</p>
<p>DT</p>
<p>,</p>
<p>Samani</p>
<p>OS</p>
<p>,</p>
<p>Carstensen</p>
<p>A</p>
<p>,</p>
<p>Bordalo</p>
<p>DM</p>
<p>,</p>
<p>Muller</p>
<p>M</p>
<p>,</p>
<p>Fischer</p>
<p>C</p>
<p>,</p>
<p>Shao</p>
<p>J</p>
<p>,</p>
<p>Wang</p>
<p>J</p>
<p>,</p>
<p>Nie</p>
<p>M</p>
<p>,</p>
<p>Yuan</p>
<p>L</p>
<p>,</p>
<p>Hassfeld</p>
<p>S</p>
<p>,</p>
<p>Schwartz</p>
<p>C</p>
<p>,</p>
<p>Zhou</p>
<p>M</p>
<p>,</p>
<p>Zhou</p>
<p>Z</p>
<p>,</p>
<p>Shu</p>
<p>Y</p>
<p>,</p>
<p>Wang</p>
<p>M</p>
<p>,</p>
<p>Huang</p>
<p>K</p>
<p>,</p>
<p>Zeng</p>
<p>Q</p>
<p>,</p>
<p>Cheng</p>
<p>L</p>
<p>,</p>
<p>Fehlmann</p>
<p>T</p>
<p>,</p>
<p>Ehlermann</p>
<p>P</p>
<p>,</p>
<p>Keller</p>
<p>A</p>
<p>,</p>
<p>Dieterich</p>
<p>C</p>
<p>,</p>
<p>Streckfuss-Bomeke</p>
<p>K</p>
<p>,</p>
<p>Liao</p>
<p>Y</p>
<p>,</p>
<p>Gotthardt</p>
<p>M</p>
<p>,</p>
<p>Katus</p>
<p>HA</p>
<p>,</p>
<p>Meder</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Clinical genetics and outcome of left ventricular non-compaction
cardiomyopathy</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>3449</p>
<p>–</p>
<p>3460</p>
<p>.</p>
<p>938</p>
<p>Towbin</p>
<p>JA</p>
<p>,</p>
<p>Lorts</p>
<p>A</p>
<p>,</p>
<p>Jefferies</p>
<p>JL.</p>
<p>Left ventricular non-compaction cardiomyopathy</p>
<p>.</p>
<p>Lancet</p>
<p>2015</p>
<p>;</p>
<p>386</p>
<p>:</p>
<p>813</p>
<p>–</p>
<p>825</p>
<p>.</p>
<p>939</p>
<p>Towbin</p>
<p>JA</p>
<p>,</p>
<p>Jefferies</p>
<p>JL.</p>
<p>Cardiomyopathies due to left ventricular noncompaction, mitochondrial
and storage diseases, and inborn errors of metabolism</p>
<p>.</p>
<p>Circ Res</p>
<p>2017</p>
<p>;</p>
<p>121</p>
<p>:</p>
<p>838</p>
<p>–</p>
<p>854</p>
<p>.</p>
<p>940</p>
<p>Shen</p>
<p>MJ</p>
<p>,</p>
<p>Arora</p>
<p>R</p>
<p>,</p>
<p>Jalife</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Atrial myopathy</p>
<p>.</p>
<p>JACC Basic Transl Sci</p>
<p>2019</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>640</p>
<p>–</p>
<p>654</p>
<p>.</p>
<p>941</p>
<p>Reddy</p>
<p>YNV</p>
<p>,</p>
<p>Borlaug</p>
<p>BA.</p>
<p>Left atrial myopathy in heart failure with preserved ejection
fraction</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>486</p>
<p>–</p>
<p>488</p>
<p>.</p>
<p>942</p>
<p>Reddy</p>
<p>YNV</p>
<p>,</p>
<p>Obokata</p>
<p>M</p>
<p>,</p>
<p>Gersh</p>
<p>BJ</p>
<p>,</p>
<p>Borlaug</p>
<p>BA.</p>
<p>High prevalence of occult heart failure with preserved ejection
fraction among patients with atrial fibrillation and dyspnea</p>
<p>.</p>
<p>Circulation</p>
<p>2018</p>
<p>;</p>
<p>137</p>
<p>:</p>
<p>534</p>
<p>–</p>
<p>535</p>
<p>.</p>
<p>943</p>
<p>Packer</p>
<p>M</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Lund</p>
<p>LH</p>
<p>,</p>
<p>Redfield</p>
<ol start="2000" type="I">
<li></li>
</ol>
<p>Interdependence of atrial fibrillation and heart failure with a
preserved ejection fraction reflects a common underlying atrial and
ventricular myopathy</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>4</p>
<p>–</p>
<p>6</p>
<p>.</p>
<p>944</p>
<p>To</p>
<p>AC</p>
<p>,</p>
<p>Flamm</p>
<p>SD</p>
<p>,</p>
<p>Marwick</p>
<p>TH</p>
<p>,</p>
<p>Klein</p>
<p>AL.</p>
<p>Clinical utility of multimodality LA imaging: assessment of size,
function, and structure</p>
<p>.</p>
<p>JACC Cardiovasc Imaging</p>
<p>2011</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>788</p>
<p>–</p>
<p>798</p>
<p>.</p>
<p>945</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Apple</p>
<p>FS.</p>
<p>High-sensitivity cardiac troponin assays for cardiovascular risk
stratification in the general population</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2020</p>
<p>;</p>
<p>41</p>
<p>:</p>
<p>4050</p>
<p>–</p>
<p>4056</p>
<p>.</p>
<p>946</p>
<p>Westermann</p>
<p>D</p>
<p>,</p>
<p>Neumann</p>
<p>JT</p>
<p>,</p>
<p>Sorensen</p>
<p>NA</p>
<p>,</p>
<p>Blankenberg</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>High-sensitivity assays for troponin in patients with cardiac
disease</p>
<p>.</p>
<p>Nat Rev Cardiol</p>
<p>2017</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>472</p>
<p>–</p>
<p>483</p>
<p>.</p>
<p>947</p>
<p>Santema</p>
<p>BT</p>
<p>,</p>
<p>Kloosterman</p>
<p>M</p>
<p>,</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Mordi</p>
<p>I</p>
<p>,</p>
<p>Lang</p>
<p>CC</p>
<p>,</p>
<p>Lam</p>
<p>CSP</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Cleland</p>
<p>JG</p>
<p>,</p>
<p>Dickstein</p>
<p>K</p>
<p>,</p>
<p>Filippatos</p>
<p>G</p>
<p>,</p>
<p>Van der Harst</p>
<p>P</p>
<p>,</p>
<p>Hillege</p>
<p>HL</p>
<p>,</p>
<p>Ter Maaten</p>
<p>JM</p>
<p>,</p>
<p>Metra</p>
<p>M</p>
<p>,</p>
<p>Ng</p>
<p>LL</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Samani</p>
<p>NJ</p>
<p>,</p>
<p>Van Veldhuisen</p>
<p>DJ</p>
<p>,</p>
<p>Zwinderman</p>
<p>AH</p>
<p>,</p>
<p>Zannad</p>
<p>F</p>
<p>,</p>
<p>Damman</p>
<p>K</p>
<p>,</p>
<p>Van der Meer</p>
<p>P</p>
<p>,</p>
<p>Rienstra</p>
<p>M</p>
<p>,</p>
<p>Voors</p>
<p>AA.</p>
<p>Comparing biomarker profiles of patients with heart failure: atrial
fibrillation vs. sinus rhythm and reduced vs. preserved ejection
fraction</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2018</p>
<p>;</p>
<p>39</p>
<p>:</p>
<p>3867</p>
<p>–</p>
<p>3875</p>
<p>.</p>
<p>948</p>
<p>Richards</p>
<p>M</p>
<p>,</p>
<p>Di Somma</p>
<p>S</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Nowak</p>
<p>R</p>
<p>,</p>
<p>Peacock</p>
<p>WF</p>
<p>,</p>
<p>Ponikowski</p>
<p>P</p>
<p>,</p>
<p>Mockel</p>
<p>M</p>
<p>,</p>
<p>Hogan</p>
<p>C</p>
<p>,</p>
<p>Wu</p>
<p>AH</p>
<p>,</p>
<p>Clopton</p>
<p>P</p>
<p>,</p>
<p>Filippatos</p>
<p>GS</p>
<p>,</p>
<p>Anand</p>
<p>I</p>
<p>,</p>
<p>Ng</p>
<p>L</p>
<p>,</p>
<p>Daniels</p>
<p>LB</p>
<p>,</p>
<p>Neath</p>
<p>SX</p>
<p>,</p>
<p>Shah</p>
<p>K</p>
<p>,</p>
<p>Christenson</p>
<p>R</p>
<p>,</p>
<p>Hartmann</p>
<p>O</p>
<p>,</p>
<p>Anker</p>
<p>SD</p>
<p>,</p>
<p>Maisel</p>
<ol type="A">
<li></li>
</ol>
<p>Atrial fibrillation impairs the diagnostic performance of cardiac
natriuretic peptides in dyspneic patients: results from the BACH Study
(Biomarkers in ACute Heart</p>
<p>Failure). JACC Heart Fail</p>
<p>2013</p>
<p>;</p>
<p>1</p>
<p>:</p>
<p>192</p>
<p>–</p>
<p>199</p>
<p>.</p>
<p>949</p>
<p>Kamel</p>
<p>H</p>
<p>,</p>
<p>Longstreth</p>
<p>WT</p>
<p>Jr.,</p>
<p>Tirschwell</p>
<p>DL</p>
<p>,</p>
<p>Kronmal</p>
<p>RA</p>
<p>,</p>
<p>Broderick</p>
<p>JP</p>
<p>,</p>
<p>Palesch</p>
<p>YY</p>
<p>,</p>
<p>Meinzer</p>
<p>C</p>
<p>,</p>
<p>Dillon</p>
<p>C</p>
<p>,</p>
<p>Ewing</p>
<p>I</p>
<p>,</p>
<p>Spilker</p>
<p>JA</p>
<p>,</p>
<p>Di Tullio</p>
<p>MR</p>
<p>,</p>
<p>Hod</p>
<p>EA</p>
<p>,</p>
<p>Soliman</p>
<p>EZ</p>
<p>,</p>
<p>Chaturvedi</p>
<p>S</p>
<p>,</p>
<p>Moy</p>
<p>CS</p>
<p>,</p>
<p>Janis</p>
<p>S</p>
<p>,</p>
<p>Elkind</p>
<p>MS.</p>
<p>The AtRial Cardiopathy and Antithrombotic Drugs In prevention After
cryptogenic stroke randomized trial: rationale and methods</p>
<p>.</p>
<p>Int J Stroke</p>
<p>2019</p>
<p>;</p>
<p>14</p>
<p>:</p>
<p>207</p>
<p>–</p>
<p>214</p>
<p>.</p>
<p>950</p>
<p>Zelniker</p>
<p>TA</p>
<p>,</p>
<p>Bonaca</p>
<p>MP</p>
<p>,</p>
<p>Furtado</p>
<p>RHM</p>
<p>,</p>
<p>Mosenzon</p>
<p>O</p>
<p>,</p>
<p>Kuder</p>
<p>JF</p>
<p>,</p>
<p>Murphy</p>
<p>SA</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Leiter</p>
<p>LA</p>
<p>,</p>
<p>McGuire</p>
<p>DK</p>
<p>,</p>
<p>Wilding</p>
<p>JPH</p>
<p>,</p>
<p>Budaj</p>
<p>A</p>
<p>,</p>
<p>Kiss</p>
<p>RG</p>
<p>,</p>
<p>Padilla</p>
<p>F</p>
<p>,</p>
<p>Gause-Nilsson</p>
<p>I</p>
<p>,</p>
<p>Langkilde</p>
<p>AM</p>
<p>,</p>
<p>Raz</p>
<p>I</p>
<p>,</p>
<p>Sabatine</p>
<p>MS</p>
<p>,</p>
<p>Wiviott</p>
<p>SD.</p>
<p>Effect of dapagliflozin on atrial fibrillation in patients with type
2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>1227</p>
<p>–</p>
<p>1234</p>
<p>.</p>
<p>951</p>
<p>Global Burden of Disease Study Collaborators</p>
<p>.</p>
<p>Global, regional, and national incidence, prevalence, and years lived
with disability for 301 acute and chronic diseases and injuries in 188
countries, 1990-2013: a systematic analysis for the Global Burden of
Disease Study 2013</p>
<p>.</p>
<p>Lancet</p>
<p>2015</p>
<p>;</p>
<p>386</p>
<p>:</p>
<p>743</p>
<p>–</p>
<p>800</p>
<p>.</p>
<p>952</p>
<p>Cooper</p>
<p>LT</p>
<p>Jr,</p>
<p>Keren</p>
<p>A</p>
<p>,</p>
<p>Sliwa</p>
<p>K</p>
<p>,</p>
<p>Matsumori</p>
<p>A</p>
<p>,</p>
<p>Mensah</p>
<p>GA.</p>
<p>The global burden of myocarditis: part 1: a systematic literature
review for the Global Burden of Diseases, Injuries, and Risk Factors
2010 study</p>
<p>.</p>
<p>Glob Heart</p>
<p>2014</p>
<p>;</p>
<p>9</p>
<p>:</p>
<p>121</p>
<p>–</p>
<p>129</p>
<p>.</p>
<p>953</p>
<p>Merken</p>
<p>J</p>
<p>,</p>
<p>Hazebroek</p>
<p>M</p>
<p>,</p>
<p>Van Paassen</p>
<p>P</p>
<p>,</p>
<p>Verdonschot</p>
<p>J</p>
<p>,</p>
<p>Van Empel</p>
<p>V</p>
<p>,</p>
<p>Knackstedt</p>
<p>C</p>
<p>,</p>
<p>Abdul Hamid</p>
<p>M</p>
<p>,</p>
<p>Seiler</p>
<p>M</p>
<p>,</p>
<p>Kolb</p>
<p>J</p>
<p>,</p>
<p>Hoermann</p>
<p>P</p>
<p>,</p>
<p>Ensinger</p>
<p>C</p>
<p>,</p>
<p>Brunner-La Rocca</p>
<p>HP</p>
<p>,</p>
<p>Poelzl</p>
<p>G</p>
<p>,</p>
<p>Heymans</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Immunosuppressive therapy improves both short- and long-term
prognosis in patients with virus-negative nonfulminant inflammatory
cardiomyopathy</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:</p>
<p>e004228</p>
<p>.</p>
<p>954</p>
<p>Ammirati</p>
<p>E</p>
<p>,</p>
<p>Frigerio</p>
<p>M</p>
<p>,</p>
<p>Adler</p>
<p>ED</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Birnie</p>
<p>DH</p>
<p>,</p>
<p>Brambatti</p>
<p>M</p>
<p>,</p>
<p>Friedrich</p>
<p>MG</p>
<p>,</p>
<p>Klingel</p>
<p>K</p>
<p>,</p>
<p>Lehtonen</p>
<p>J</p>
<p>,</p>
<p>Moslehi</p>
<p>JJ</p>
<p>,</p>
<p>Pedrotti</p>
<p>P</p>
<p>,</p>
<p>Rimoldi</p>
<p>OE</p>
<p>,</p>
<p>Schultheiss</p>
<p>HP</p>
<p>,</p>
<p>Tschope</p>
<p>C</p>
<p>,</p>
<p>Cooper</p>
<p>LT</p>
<p>Jr.,</p>
<p>Camici</p>
<p>PG.</p>
<p>Management of acute myocarditis and chronic inflammatory
cardiomyopathy: an expert consensus document</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>e007405</p>
<p>.</p>
<p>955</p>
<p>Grigoratos</p>
<p>C</p>
<p>,</p>
<p>Di Bella</p>
<p>G</p>
<p>,</p>
<p>Aquaro</p>
<p>GD.</p>
<p>Diagnostic and prognostic role of cardiac magnetic resonance in acute
myocarditis</p>
<p>.</p>
<p>Heart Fail Rev</p>
<p>2019</p>
<p>;</p>
<p>24</p>
<p>:</p>
<p>81</p>
<p>–</p>
<p>90</p>
<p>.</p>
<p>956</p>
<p>Ferreira</p>
<p>VM</p>
<p>,</p>
<p>Schulz-Menger</p>
<p>J</p>
<p>,</p>
<p>Holmvang</p>
<p>G</p>
<p>,</p>
<p>Kramer</p>
<p>CM</p>
<p>,</p>
<p>Carbone</p>
<p>I</p>
<p>,</p>
<p>Sechtem</p>
<p>U</p>
<p>,</p>
<p>Kindermann</p>
<p>I</p>
<p>,</p>
<p>Gutberlet</p>
<p>M</p>
<p>,</p>
<p>Cooper</p>
<p>LT</p>
<p>,</p>
<p>Liu</p>
<p>P</p>
<p>,</p>
<p>Friedrich</p>
<p>MG.</p>
<p>Cardiovascular magnetic resonance in nonischemic myocardial
inflammation: expert recommendations</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2018</p>
<p>;</p>
<p>72</p>
<p>:</p>
<p>3158</p>
<p>–</p>
<p>3176</p>
<p>.</p>
<p>957</p>
<p>Birnie</p>
<p>DH</p>
<p>,</p>
<p>Nery</p>
<p>PB</p>
<p>,</p>
<p>Ha</p>
<p>AC</p>
<p>,</p>
<p>Beanlands RS. Cardiac sarcoidosis</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2016</p>
<p>;</p>
<p>68</p>
<p>:</p>
<p>411</p>
<p>–</p>
<p>421</p>
<p>.</p>
<p>958</p>
<p>Bang</p>
<p>V</p>
<p>,</p>
<p>Ganatra</p>
<p>S</p>
<p>,</p>
<p>Shah</p>
<p>SP</p>
<p>,</p>
<p>Dani</p>
<p>SS</p>
<p>,</p>
<p>Neilan</p>
<p>TG</p>
<p>,</p>
<p>Thavendiranathan</p>
<p>P</p>
<p>,</p>
<p>Resnic</p>
<p>FS</p>
<p>,</p>
<p>Piemonte</p>
<p>TC</p>
<p>,</p>
<p>Barac</p>
<p>A</p>
<p>,</p>
<p>Patel</p>
<p>R</p>
<p>,</p>
<p>Sharma</p>
<p>A</p>
<p>,</p>
<p>Parikh</p>
<p>R</p>
<p>,</p>
<p>Chaudhry</p>
<p>GM</p>
<p>,</p>
<p>Vesely</p>
<p>M</p>
<p>,</p>
<p>Hayek</p>
<p>SS</p>
<p>,</p>
<p>Leja</p>
<p>M</p>
<p>,</p>
<p>Venesy</p>
<p>D</p>
<p>,</p>
<p>Patten</p>
<p>R</p>
<p>,</p>
<p>Lenihan</p>
<p>D</p>
<p>,</p>
<p>Nohria</p>
<p>A</p>
<p>,</p>
<p>Cooper</p>
<p>LT.</p>
<p>Management of patients with giant cell myocarditis: JACC review topic
of the week</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2021</p>
<p>;</p>
<p>77</p>
<p>:</p>
<p>1122</p>
<p>–</p>
<p>1134</p>
<p>.</p>
<p>959</p>
<p>Sinagra</p>
<p>G</p>
<p>,</p>
<p>Porcari</p>
<p>A</p>
<p>,</p>
<p>Gentile</p>
<p>P</p>
<p>,</p>
<p>Artico</p>
<p>J</p>
<p>,</p>
<p>Fabris</p>
<p>E</p>
<p>,</p>
<p>Bussani</p>
<p>R</p>
<p>,</p>
<p>Merlo</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Viral presence-guided immunomodulation in lymphocytic myocarditis: an
update</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>211</p>
<p>–</p>
<p>216</p>
<p>.</p>
<p>960</p>
<p>Gannon</p>
<p>MP</p>
<p>,</p>
<p>Schaub</p>
<p>E</p>
<p>,</p>
<p>Grines</p>
<p>CL</p>
<p>,</p>
<p>Saba</p>
<p>SG.</p>
<p>State of the art: evaluation and prognostication of myocarditis using
cardiac MRI</p>
<p>.</p>
<p>J Magn Reson Imaging</p>
<p>2019</p>
<p>;</p>
<p>49</p>
<p>:</p>
<p>e122</p>
<p>–</p>
<p>e131</p>
<p>.</p>
<p>961</p>
<p>Maisch</p>
<p>B</p>
<p>,</p>
<p>Hufnagel</p>
<p>G</p>
<p>,</p>
<p>Kolsch</p>
<p>S</p>
<p>,</p>
<p>Funck</p>
<p>R</p>
<p>,</p>
<p>Richter</p>
<p>A</p>
<p>,</p>
<p>Rupp</p>
<p>H</p>
<p>,</p>
<p>Herzum</p>
<p>M</p>
<p>,</p>
<p>Pankuweit</p>
<ol start="19" type="A">
<li></li>
</ol>
<p>Treatment of inflammatory dilated cardiomyopathy and
(peri)myocarditis with immunosuppression and i.v. immunoglobulins</p>
<p>.</p>
<p>Herz</p>
<p>2004</p>
<p>;</p>
<p>29</p>
<p>:</p>
<p>624</p>
<p>–</p>
<p>636</p>
<p>.</p>
<p>962</p>
<p>Kociol</p>
<p>RD</p>
<p>,</p>
<p>Cooper</p>
<p>LT</p>
<p>,</p>
<p>Fang</p>
<p>JC</p>
<p>,</p>
<p>Moslehi</p>
<p>JJ</p>
<p>,</p>
<p>Pang</p>
<p>PS</p>
<p>,</p>
<p>Sabe</p>
<p>MA</p>
<p>,</p>
<p>Shah</p>
<p>RV</p>
<p>,</p>
<p>Sims</p>
<p>DB</p>
<p>,</p>
<p>Thiene</p>
<p>G</p>
<p>,</p>
<p>Vardeny</p>
<p>O</p>
<p>,</p>
<p>American Heart Association Heart Failure Transplantation Committee of
the Council on Clinical Cardiology</p>
<p>.</p>
<p>Recognition and initial management of fulminant myocarditis: a
scientific statement from the American Heart Association</p>
<p>.</p>
<p>Circulation</p>
<p>2020</p>
<p>;</p>
<p>141</p>
<p>:</p>
<p>e69</p>
<p>–</p>
<p>e92</p>
<p>.</p>
<p>963</p>
<p>Felix</p>
<p>SB</p>
<p>,</p>
<p>Staudt</p>
<p>A</p>
<p>,</p>
<p>Dorffel</p>
<p>WV</p>
<p>,</p>
<p>Stangl</p>
<p>V</p>
<p>,</p>
<p>Merkel</p>
<p>K</p>
<p>,</p>
<p>Pohl</p>
<p>M</p>
<p>,</p>
<p>Docke</p>
<p>WD</p>
<p>,</p>
<p>Morgera</p>
<p>S</p>
<p>,</p>
<p>Neumayer</p>
<p>HH</p>
<p>,</p>
<p>Wernecke</p>
<p>KD</p>
<p>,</p>
<p>Wallukat</p>
<p>G</p>
<p>,</p>
<p>Stangl</p>
<p>K</p>
<p>,</p>
<p>Baumann</p>
<ol start="7" type="A">
<li></li>
</ol>
<p>Hemodynamic effects of immunoadsorption and subsequent immunoglobulin
substitution in dilated cardiomyopathy: three-month results from a
randomized study</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2000</p>
<p>;</p>
<p>35</p>
<p>:</p>
<p>1590</p>
<p>–</p>
<p>1598</p>
<p>.</p>
<p>964</p>
<p>Bajaj</p>
<p>NS</p>
<p>,</p>
<p>Gupta</p>
<p>K</p>
<p>,</p>
<p>Gharpure</p>
<p>N</p>
<p>,</p>
<p>Pate</p>
<p>M</p>
<p>,</p>
<p>Chopra</p>
<p>L</p>
<p>,</p>
<p>Kalra</p>
<p>R</p>
<p>,</p>
<p>Prabhu</p>
<p>SD.</p>
<p>Effect of immunomodulation on cardiac remodelling and outcomes in
heart failure: a quantitative synthesis of the literature</p>
<p>.</p>
<p>ESC Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>7</p>
<p>:</p>
<p>1319</p>
<p>–</p>
<p>1330</p>
<p>.</p>
<p>965</p>
<p>Martinez-Naharro</p>
<p>A</p>
<p>,</p>
<p>Hawkins</p>
<p>PN</p>
<p>,</p>
<p>Fontana</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Cardiac amyloidosis</p>
<p>.</p>
<p>Clin Med (Lond)</p>
<p>2018</p>
<p>;</p>
<p>18</p>
<p>:</p>
<p>s30</p>
<p>–</p>
<p>s35</p>
<p>.</p>
<p>966</p>
<p>Ruberg</p>
<p>FL</p>
<p>,</p>
<p>Grogan</p>
<p>M</p>
<p>,</p>
<p>Hanna</p>
<p>M</p>
<p>,</p>
<p>Kelly</p>
<p>JW</p>
<p>,</p>
<p>Maurer</p>
<p>MS.</p>
<p>Transthyretin amyloid cardiomyopathy: JACC state-of-the-art
review</p>
<p>.</p>
<p>J Am Coll Cardiol</p>
<p>2019</p>
<p>;</p>
<p>73</p>
<p>:</p>
<p>2872</p>
<p>–</p>
<p>2891</p>
<p>.</p>
<p>967</p>
<p>Gonzalez-Lopez</p>
<p>E</p>
<p>,</p>
<p>Gallego-Delgado</p>
<p>M</p>
<p>,</p>
<p>Guzzo-Merello</p>
<p>G</p>
<p>,</p>
<p>de Haro-Del Moral</p>
<p>FJ</p>
<p>,</p>
<p>Cobo-Marcos</p>
<p>M</p>
<p>,</p>
<p>Robles</p>
<p>C</p>
<p>,</p>
<p>Bornstein</p>
<p>B</p>
<p>,</p>
<p>Salas</p>
<p>C</p>
<p>,</p>
<p>Lara-Pezzi</p>
<p>E</p>
<p>,</p>
<p>Alonso-Pulpon</p>
<p>L</p>
<p>,</p>
<p>Garcia-Pavia</p>
<ol start="16" type="A">
<li></li>
</ol>
<p>Wild-type transthyretin amyloidosis as a cause of heart failure with
preserved ejection fraction</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2015</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>2585</p>
<p>–</p>
<p>2594</p>
<p>.</p>
<p>968</p>
<p>Helder</p>
<p>MR</p>
<p>,</p>
<p>Schaff</p>
<p>HV</p>
<p>,</p>
<p>Nishimura</p>
<p>RA</p>
<p>,</p>
<p>Gersh</p>
<p>BJ</p>
<p>,</p>
<p>Dearani</p>
<p>JA</p>
<p>,</p>
<p>Ommen</p>
<p>SR</p>
<p>,</p>
<p>Mereuta</p>
<p>OM</p>
<p>,</p>
<p>Theis</p>
<p>JD</p>
<p>,</p>
<p>Dogan</p>
<p>A</p>
<p>,</p>
<p>Edwards</p>
<p>WD.</p>
<p>Impact of incidental amyloidosis on the prognosis of patients with
hypertrophic cardiomyopathy undergoing septal myectomy for left
ventricular outflow tract obstruction</p>
<p>.</p>
<p>Am J Cardiol</p>
<p>2014</p>
<p>;</p>
<p>114</p>
<p>:</p>
<p>1396</p>
<p>–</p>
<p>1399</p>
<p>.</p>
<p>969</p>
<p>Treibel</p>
<p>TA</p>
<p>,</p>
<p>Fontana</p>
<p>M</p>
<p>,</p>
<p>Gilbertson</p>
<p>JA</p>
<p>,</p>
<p>Castelletti</p>
<p>S</p>
<p>,</p>
<p>White</p>
<p>SK</p>
<p>,</p>
<p>Scully</p>
<p>PR</p>
<p>,</p>
<p>Roberts</p>
<p>N</p>
<p>,</p>
<p>Hutt</p>
<p>DF</p>
<p>,</p>
<p>Rowczenio</p>
<p>DM</p>
<p>,</p>
<p>Whelan</p>
<p>CJ</p>
<p>,</p>
<p>Ashworth</p>
<p>MA</p>
<p>,</p>
<p>Gillmore</p>
<p>JD</p>
<p>,</p>
<p>Hawkins</p>
<p>PN</p>
<p>,</p>
<p>Moon</p>
<p>JC.</p>
<p>Occult transthyretin cardiac amyloid in severe calcific aortic
stenosis: prevalence and prognosis in patients undergoing surgical
aortic valve replacement</p>
<p>.</p>
<p>Circ Cardiovasc Imaging</p>
<p>2016</p>
<p>;</p>
<p>9</p>
<p>.</p>
<p>970</p>
<p>Cavalcante</p>
<p>JL</p>
<p>,</p>
<p>Rijal</p>
<p>S</p>
<p>,</p>
<p>Abdelkarim</p>
<p>I</p>
<p>,</p>
<p>Althouse</p>
<p>AD</p>
<p>,</p>
<p>Sharbaugh</p>
<p>MS</p>
<p>,</p>
<p>Fridman</p>
<p>Y</p>
<p>,</p>
<p>Soman</p>
<p>P</p>
<p>,</p>
<p>Forman</p>
<p>DE</p>
<p>,</p>
<p>Schindler</p>
<p>JT</p>
<p>,</p>
<p>Gleason</p>
<p>TG</p>
<p>,</p>
<p>Lee</p>
<p>JS</p>
<p>,</p>
<p>Schelbert</p>
<p>EB.</p>
<p>Cardiac amyloidosis is prevalent in older patients with aortic
stenosis and carries worse prognosis</p>
<p>.</p>
<p>J Cardiovasc Magn Reson</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>98</p>
<p>.</p>
<p>971</p>
<p>Castano</p>
<p>A</p>
<p>,</p>
<p>Narotsky</p>
<p>DL</p>
<p>,</p>
<p>Hamid</p>
<p>N</p>
<p>,</p>
<p>Khalique</p>
<p>OK</p>
<p>,</p>
<p>Morgenstern</p>
<p>R</p>
<p>,</p>
<p>DeLuca</p>
<p>A</p>
<p>,</p>
<p>Rubin</p>
<p>J</p>
<p>,</p>
<p>Chiuzan</p>
<p>C</p>
<p>,</p>
<p>Nazif</p>
<p>T</p>
<p>,</p>
<p>Vahl</p>
<p>T</p>
<p>,</p>
<p>George</p>
<p>I</p>
<p>,</p>
<p>Kodali</p>
<p>S</p>
<p>,</p>
<p>Leon</p>
<p>MB</p>
<p>,</p>
<p>Hahn</p>
<p>R</p>
<p>,</p>
<p>Bokhari</p>
<p>S</p>
<p>,</p>
<p>Maurer</p>
<p>MS.</p>
<p>Unveiling transthyretin cardiac amyloidosis and its predictors among
elderly patients with severe aortic stenosis undergoing transcatheter
aortic valve replacement</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2017</p>
<p>;</p>
<p>38</p>
<p>:</p>
<p>2879</p>
<p>–</p>
<p>2887</p>
<p>.</p>
<p>972</p>
<p>Nitsche</p>
<p>C</p>
<p>,</p>
<p>Aschauer</p>
<p>S</p>
<p>,</p>
<p>Kammerlander</p>
<p>AA</p>
<p>,</p>
<p>Schneider</p>
<p>M</p>
<p>,</p>
<p>Poschner</p>
<p>T</p>
<p>,</p>
<p>Duca</p>
<p>F</p>
<p>,</p>
<p>Binder</p>
<p>C</p>
<p>,</p>
<p>Koschutnik</p>
<p>M</p>
<p>,</p>
<p>Stiftinger</p>
<p>J</p>
<p>,</p>
<p>Goliasch</p>
<p>G</p>
<p>,</p>
<p>Siller-Matula</p>
<p>J</p>
<p>,</p>
<p>Winter</p>
<p>MP</p>
<p>,</p>
<p>Anvari-Pirsch</p>
<p>A</p>
<p>,</p>
<p>Andreas</p>
<p>M</p>
<p>,</p>
<p>Geppert</p>
<p>A</p>
<p>,</p>
<p>Beitzke</p>
<p>D</p>
<p>,</p>
<p>Loewe</p>
<p>C</p>
<p>,</p>
<p>Hacker</p>
<p>M</p>
<p>,</p>
<p>Agis</p>
<p>H</p>
<p>,</p>
<p>Kain</p>
<p>R</p>
<p>,</p>
<p>Lang</p>
<p>I</p>
<p>,</p>
<p>Bonderman</p>
<p>D</p>
<p>,</p>
<p>Hengstenberg</p>
<p>C</p>
<p>,</p>
<p>Mascherbauer</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Light-chain and transthyretin cardiac amyloidosis in severe aortic
stenosis: prevalence, screening possibilities, and outcome</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2020</p>
<p>;</p>
<p>22</p>
<p>:</p>
<p>1852</p>
<p>–</p>
<p>1862</p>
<p>.</p>
<p>973</p>
<p>Garcia-Pavia</p>
<p>P</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Adler</p>
<p>Y</p>
<p>,</p>
<p>Arad</p>
<p>M</p>
<p>,</p>
<p>Basso</p>
<p>C</p>
<p>,</p>
<p>Brucato</p>
<p>A</p>
<p>,</p>
<p>Burazor</p>
<p>I</p>
<p>,</p>
<p>Caforio</p>
<p>ALP</p>
<p>,</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Eriksson</p>
<p>U</p>
<p>,</p>
<p>Fontana</p>
<p>M</p>
<p>,</p>
<p>Gillmore</p>
<p>JD</p>
<p>,</p>
<p>Gonzalez-Lopez</p>
<p>E</p>
<p>,</p>
<p>Grogan</p>
<p>M</p>
<p>,</p>
<p>Heymans</p>
<p>S</p>
<p>,</p>
<p>Imazio</p>
<p>M</p>
<p>,</p>
<p>Kindermann</p>
<p>I</p>
<p>,</p>
<p>Kristen</p>
<p>AV</p>
<p>,</p>
<p>Maurer</p>
<p>MS</p>
<p>,</p>
<p>Merlini</p>
<p>G</p>
<p>,</p>
<p>Pantazis</p>
<p>A</p>
<p>,</p>
<p>Pankuweit</p>
<p>S</p>
<p>,</p>
<p>Rigopoulos</p>
<p>AG</p>
<p>,</p>
<p>Linhart</p>
<ol type="A">
<li></li>
</ol>
<p>Diagnosis and treatment of cardiac amyloidosis. A position statement
of the European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>512</p>
<p>–</p>
<p>526</p>
<p>.</p>
<p>974</p>
<p>Boldrini</p>
<p>M</p>
<p>,</p>
<p>Cappelli</p>
<p>F</p>
<p>,</p>
<p>Chacko</p>
<p>L</p>
<p>,</p>
<p>Restrepo-Cordoba</p>
<p>MA</p>
<p>,</p>
<p>Lopez-Sainz</p>
<p>A</p>
<p>,</p>
<p>Giannoni</p>
<p>A</p>
<p>,</p>
<p>Aimo</p>
<p>A</p>
<p>,</p>
<p>Baggiano</p>
<p>A</p>
<p>,</p>
<p>Martinez-Naharro</p>
<p>A</p>
<p>,</p>
<p>Whelan</p>
<p>C</p>
<p>,</p>
<p>Quarta</p>
<p>C</p>
<p>,</p>
<p>Passino</p>
<p>C</p>
<p>,</p>
<p>Castiglione</p>
<p>V</p>
<p>,</p>
<p>Chubuchnyi</p>
<p>V</p>
<p>,</p>
<p>Spini</p>
<p>V</p>
<p>,</p>
<p>Taddei</p>
<p>C</p>
<p>,</p>
<p>Vergaro</p>
<p>G</p>
<p>,</p>
<p>Petrie</p>
<p>A</p>
<p>,</p>
<p>Ruiz-Guerrero</p>
<p>L</p>
<p>,</p>
<p>Monivas</p>
<p>V</p>
<p>,</p>
<p>Mingo-Santos</p>
<p>S</p>
<p>,</p>
<p>Mirelis</p>
<p>JG</p>
<p>,</p>
<p>Dominguez</p>
<p>F</p>
<p>,</p>
<p>Gonzalez-Lopez</p>
<p>E</p>
<p>,</p>
<p>Perlini</p>
<p>S</p>
<p>,</p>
<p>Pontone</p>
<p>G</p>
<p>,</p>
<p>Gillmore</p>
<p>J</p>
<p>,</p>
<p>Hawkins</p>
<p>PN</p>
<p>,</p>
<p>Garcia-Pavia</p>
<p>P</p>
<p>,</p>
<p>Emdin</p>
<p>M</p>
<p>,</p>
<p>Fontana</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Multiparametric echocardiography scores for the diagnosis of cardiac
amyloidosis</p>
<p>.</p>
<p>JACC Cardiovasc Imaging</p>
<p>2020</p>
<p>;</p>
<p>13</p>
<p>:</p>
<p>909</p>
<p>–</p>
<p>920</p>
<p>.</p>
<p>975</p>
<p>Gillmore</p>
<p>JD</p>
<p>,</p>
<p>Maurer</p>
<p>MS</p>
<p>,</p>
<p>Falk</p>
<p>RH</p>
<p>,</p>
<p>Merlini</p>
<p>G</p>
<p>,</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Dispenzieri</p>
<p>A</p>
<p>,</p>
<p>Wechalekar</p>
<p>AD</p>
<p>,</p>
<p>Berk</p>
<p>JL</p>
<p>,</p>
<p>Quarta</p>
<p>CC</p>
<p>,</p>
<p>Grogan</p>
<p>M</p>
<p>,</p>
<p>Lachmann</p>
<p>HJ</p>
<p>,</p>
<p>Bokhari</p>
<p>S</p>
<p>,</p>
<p>Castano</p>
<p>A</p>
<p>,</p>
<p>Dorbala</p>
<p>S</p>
<p>,</p>
<p>Johnson</p>
<p>GB</p>
<p>,</p>
<p>Glaudemans</p>
<p>AW</p>
<p>,</p>
<p>Rezk</p>
<p>T</p>
<p>,</p>
<p>Fontana</p>
<p>M</p>
<p>,</p>
<p>Palladini</p>
<p>G</p>
<p>,</p>
<p>Milani</p>
<p>P</p>
<p>,</p>
<p>Guidalotti</p>
<p>PL</p>
<p>,</p>
<p>Flatman</p>
<p>K</p>
<p>,</p>
<p>Lane</p>
<p>T</p>
<p>,</p>
<p>Vonberg</p>
<p>FW</p>
<p>,</p>
<p>Whelan</p>
<p>CJ</p>
<p>,</p>
<p>Moon</p>
<p>JC</p>
<p>,</p>
<p>Ruberg</p>
<p>FL</p>
<p>,</p>
<p>Miller</p>
<p>EJ</p>
<p>,</p>
<p>Hutt</p>
<p>DF</p>
<p>,</p>
<p>Hazenberg</p>
<p>BP</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>Hawkins</p>
<p>PN.</p>
<p>Nonbiopsy diagnosis of cardiac transthyretin amyloidosis</p>
<p>.</p>
<p>Circulation</p>
<p>2016</p>
<p>;</p>
<p>133</p>
<p>:</p>
<p>2404</p>
<p>–</p>
<p>2412</p>
<p>.</p>
<p>976</p>
<p>Zhao</p>
<p>L</p>
<p>,</p>
<p>Tian</p>
<p>Z</p>
<p>,</p>
<p>Fang</p>
<ol start="17" type="A">
<li></li>
</ol>
<p>Diagnostic accuracy of cardiovascular magnetic resonance for patients
with suspected cardiac amyloidosis: a systematic review and
meta-analysis</p>
<p>.</p>
<p>BMC Cardiovasc Disord</p>
<p>2016</p>
<p>;</p>
<p>16</p>
<p>:</p>
<p>129</p>
<p>.</p>
<p>977</p>
<p>Bhuiyan</p>
<p>T</p>
<p>,</p>
<p>Helmke</p>
<p>S</p>
<p>,</p>
<p>Patel</p>
<p>AR</p>
<p>,</p>
<p>Ruberg</p>
<p>FL</p>
<p>,</p>
<p>Packman</p>
<p>J</p>
<p>,</p>
<p>Cheung</p>
<p>K</p>
<p>,</p>
<p>Grogan</p>
<p>D</p>
<p>,</p>
<p>Maurer</p>
<p>MS.</p>
<p>Pressure-volume relationships in patients with transthyretin (ATTR)
cardiac amyloidosis secondary to V122I mutations and wild-type
transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2011</p>
<p>;</p>
<p>4</p>
<p>:</p>
<p>121</p>
<p>–</p>
<p>128</p>
<p>.</p>
<p>978</p>
<p>Cheung</p>
<p>CC</p>
<p>,</p>
<p>Roston</p>
<p>TM</p>
<p>,</p>
<p>Andrade</p>
<p>JG</p>
<p>,</p>
<p>Bennett</p>
<p>MT</p>
<p>,</p>
<p>Davis</p>
<p>MK.</p>
<p>Arrhythmias in cardiac amyloidosis: challenges in risk stratification
and treatment</p>
<p>.</p>
<p>Can J Cardiol</p>
<p>2020</p>
<p>;</p>
<p>36</p>
<p>:</p>
<p>416</p>
<p>–</p>
<p>423</p>
<p>.</p>
<p>979</p>
<p>Maurer</p>
<p>MS</p>
<p>,</p>
<p>Schwartz</p>
<p>JH</p>
<p>,</p>
<p>Gundapaneni</p>
<p>B</p>
<p>,</p>
<p>Elliott</p>
<p>PM</p>
<p>,</p>
<p>Merlini</p>
<p>G</p>
<p>,</p>
<p>Waddington-Cruz</p>
<p>M</p>
<p>,</p>
<p>Kristen</p>
<p>AV</p>
<p>,</p>
<p>Grogan</p>
<p>M</p>
<p>,</p>
<p>Witteles</p>
<p>R</p>
<p>,</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Drachman</p>
<p>BM</p>
<p>,</p>
<p>Shah</p>
<p>SJ</p>
<p>,</p>
<p>Hanna</p>
<p>M</p>
<p>,</p>
<p>Judge</p>
<p>DP</p>
<p>,</p>
<p>Barsdorf</p>
<p>AI</p>
<p>,</p>
<p>Huber</p>
<p>P</p>
<p>,</p>
<p>Patterson</p>
<p>TA</p>
<p>,</p>
<p>Riley</p>
<p>S</p>
<p>,</p>
<p>Schumacher</p>
<p>J</p>
<p>,</p>
<p>Stewart</p>
<p>M</p>
<p>,</p>
<p>Sultan</p>
<p>MB</p>
<p>,</p>
<p>Rapezzi</p>
<p>C</p>
<p>,</p>
<p>ATTR-ACT Study Investigators. Tafamidis treatment for patients with
transthyretin amyloid cardiomyopathy</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>379</p>
<p>:</p>
<p>1007</p>
<p>–</p>
<p>1016</p>
<p>.</p>
<p>980</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Garcia-Pavia</p>
<p>P</p>
<p>,</p>
<p>Hanna</p>
<p>M</p>
<p>,</p>
<p>Judge</p>
<p>DP</p>
<p>,</p>
<p>Merlini</p>
<p>G</p>
<p>,</p>
<p>Gundapaneni</p>
<p>B</p>
<p>,</p>
<p>Patterson</p>
<p>TA</p>
<p>,</p>
<p>Riley</p>
<p>S</p>
<p>,</p>
<p>Schwartz</p>
<p>JH</p>
<p>,</p>
<p>Sultan</p>
<p>MB</p>
<p>,</p>
<p>Witteles</p>
<ol start="18" type="A">
<li></li>
</ol>
<p>Efficacy and safety of tafamidis doses in the Tafamidis in
Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term
extension study</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>277</p>
<p>–</p>
<p>285</p>
<p>.</p>
<p>981</p>
<p>Solomon</p>
<p>SD</p>
<p>,</p>
<p>Adams</p>
<p>D</p>
<p>,</p>
<p>Kristen</p>
<p>A</p>
<p>,</p>
<p>Grogan</p>
<p>M</p>
<p>,</p>
<p>Gonzalez-Duarte</p>
<p>A</p>
<p>,</p>
<p>Maurer</p>
<p>MS</p>
<p>,</p>
<p>Merlini</p>
<p>G</p>
<p>,</p>
<p>Damy</p>
<p>T</p>
<p>,</p>
<p>Slama</p>
<p>MS</p>
<p>,</p>
<p>Brannagan</p>
<p>TH</p>
<p>3rd,</p>
<p>Dispenzieri</p>
<p>A</p>
<p>,</p>
<p>Berk</p>
<p>JL</p>
<p>,</p>
<p>Shah</p>
<p>AM</p>
<p>,</p>
<p>Garg</p>
<p>P</p>
<p>,</p>
<p>Vaishnaw</p>
<p>A</p>
<p>,</p>
<p>Karsten</p>
<p>V</p>
<p>,</p>
<p>Chen</p>
<p>J</p>
<p>,</p>
<p>Gollob</p>
<p>J</p>
<p>,</p>
<p>Vest</p>
<p>J</p>
<p>,</p>
<p>Suhr</p>
<ol start="15" type="A">
<li></li>
</ol>
<p>Effects of patisiran, an RNA interference therapeutic, on cardiac
parameters in patients with hereditary transthyretin-mediated
amyloidosis</p>
<p>.</p>
<p>Circulation</p>
<p>2019</p>
<p>;</p>
<p>139</p>
<p>:</p>
<p>431</p>
<p>–</p>
<p>443</p>
<p>.</p>
<p>982</p>
<p>Suhr</p>
<p>OB</p>
<p>,</p>
<p>Coelho</p>
<p>T</p>
<p>,</p>
<p>Buades</p>
<p>J</p>
<p>,</p>
<p>Pouget</p>
<p>J</p>
<p>,</p>
<p>Conceicao</p>
<p>I</p>
<p>,</p>
<p>Berk</p>
<p>J</p>
<p>,</p>
<p>Schmidt</p>
<p>H</p>
<p>,</p>
<p>Waddington-Cruz</p>
<p>M</p>
<p>,</p>
<p>Campistol</p>
<p>JM</p>
<p>,</p>
<p>Bettencourt</p>
<p>BR</p>
<p>,</p>
<p>Vaishnaw</p>
<p>A</p>
<p>,</p>
<p>Gollob</p>
<p>J</p>
<p>,</p>
<p>Adams</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Efficacy and safety of patisiran for familial amyloidotic
polyneuropathy: a phase II multi-dose study</p>
<p>.</p>
<p>Orphanet J Rare Dis</p>
<p>2015</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>109</p>
<p>.</p>
<p>983</p>
<p>Rosenblum</p>
<p>H</p>
<p>,</p>
<p>Castano</p>
<p>A</p>
<p>,</p>
<p>Alvarez</p>
<p>J</p>
<p>,</p>
<p>Goldsmith</p>
<p>J</p>
<p>,</p>
<p>Helmke</p>
<p>S</p>
<p>,</p>
<p>Maurer</p>
<p>MS.</p>
<p>TTR (transthyretin) stabilizers are associated with improved survival
in patients with TTR cardiac amyloidosis</p>
<p>.</p>
<p>Circ Heart Fail</p>
<p>2018</p>
<p>;</p>
<p>11</p>
<p>:e004769.</p>
<p>984</p>
<p>Kremastinos</p>
<p>DT</p>
<p>,</p>
<p>Farmakis</p>
<ol start="4" type="A">
<li></li>
</ol>
<p>Iron overload cardiomyopathy in clinical practice</p>
<p>.</p>
<p>Circulation</p>
<p>2011</p>
<p>;</p>
<p>124</p>
<p>:</p>
<p>2253</p>
<p>–</p>
<p>2263</p>
<p>.</p>
<p>985</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Triposkiadis</p>
<p>F</p>
<p>,</p>
<p>Lekakis</p>
<p>J</p>
<p>,</p>
<p>Parissis</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Heart failure in haemoglobinopathies: pathophysiology, clinical
phenotypes, and management</p>
<p>.</p>
<p>Eur J Heart Fail</p>
<p>2017</p>
<p>;</p>
<p>19</p>
<p>:</p>
<p>479</p>
<p>–</p>
<p>489</p>
<p>.</p>
<p>986</p>
<p>Aessopos</p>
<p>A</p>
<p>,</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Deftereos</p>
<p>S</p>
<p>,</p>
<p>Tsironi</p>
<p>M</p>
<p>,</p>
<p>Tassiopoulos</p>
<p>S</p>
<p>,</p>
<p>Moyssakis</p>
<p>I</p>
<p>,</p>
<p>Karagiorga</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Thalassemia heart disease: a comparative evaluation of thalassemia
major and thalassemia intermedia</p>
<p>.</p>
<p>Chest</p>
<p>2005</p>
<p>;</p>
<p>127</p>
<p>:</p>
<p>1523</p>
<p>–</p>
<p>1530</p>
<p>.</p>
<p>987</p>
<p>Farmakis</p>
<p>D</p>
<p>,</p>
<p>Aessopos</p>
<ol type="A">
<li></li>
</ol>
<p>Pulmonary hypertension associated with hemoglobinopathies: prevalent
but overlooked</p>
<p>.</p>
<p>Circulation</p>
<p>2011</p>
<p>;</p>
<p>123</p>
<p>:</p>
<p>1227</p>
<p>–</p>
<p>1232</p>
<p>.</p>
<p>988</p>
<p>Baumgartner</p>
<p>H</p>
<p>,</p>
<p>De Backer</p>
<p>J</p>
<p>,</p>
<p>Babu-Narayan</p>
<p>SV</p>
<p>,</p>
<p>Budts</p>
<p>W</p>
<p>,</p>
<p>Chessa</p>
<p>M</p>
<p>,</p>
<p>Diller</p>
<p>GP</p>
<p>,</p>
<p>Lung</p>
<p>B</p>
<p>,</p>
<p>Kluin</p>
<p>J</p>
<p>,</p>
<p>Lang</p>
<p>IM</p>
<p>,</p>
<p>Meijboom</p>
<p>F</p>
<p>,</p>
<p>Moons</p>
<p>P</p>
<p>,</p>
<p>Mulder</p>
<p>BJM</p>
<p>,</p>
<p>Oechslin</p>
<p>E</p>
<p>,</p>
<p>Roos-Hesselink</p>
<p>JW</p>
<p>,</p>
<p>Schwerzmann</p>
<p>M</p>
<p>,</p>
<p>Sondergaard</p>
<p>L</p>
<p>,</p>
<p>Zeppenfeld</p>
<p>K</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2020 ESC Guidelines for the management of adult congenital heart
disease</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>563</p>
<p>–</p>
<p>645</p>
<p>.</p>
<p>989</p>
<p>Diller</p>
<p>GP</p>
<p>,</p>
<p>Kempny</p>
<p>A</p>
<p>,</p>
<p>Alonso-Gonzalez</p>
<p>R</p>
<p>,</p>
<p>Swan</p>
<p>L</p>
<p>,</p>
<p>Uebing</p>
<p>A</p>
<p>,</p>
<p>Li</p>
<p>W</p>
<p>,</p>
<p>Babu-Narayan</p>
<p>S</p>
<p>,</p>
<p>Wort</p>
<p>SJ</p>
<p>,</p>
<p>Dimopoulos</p>
<p>K</p>
<p>,</p>
<p>Gatzoulis</p>
<p>MA.</p>
<p>Survival prospects and circumstances of death in contemporary adult
congenital heart disease patients under follow-up at a large tertiary
centre</p>
<p>.</p>
<p>Circulation</p>
<p>2015</p>
<p>;</p>
<p>132</p>
<p>:</p>
<p>2118</p>
<p>–</p>
<p>2125</p>
<p>.</p>
<p>990</p>
<p>Budts</p>
<p>W</p>
<p>,</p>
<p>Roos-Hesselink</p>
<p>J</p>
<p>,</p>
<p>Radle-Hurst</p>
<p>T</p>
<p>,</p>
<p>Eicken</p>
<p>A</p>
<p>,</p>
<p>McDonagh</p>
<p>TA</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Crespo-Leiro</p>
<p>MG</p>
<p>,</p>
<p>Walker</p>
<p>F</p>
<p>,</p>
<p>Frogoudaki</p>
<p>AA.</p>
<p>Treatment of heart failure in adult congenital heart disease: a
position paper of the Working Group of Grown-Up Congenital Heart Disease
and the Heart Failure Association of the European Society of
Cardiology</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2016</p>
<p>;</p>
<p>37</p>
<p>:</p>
<p>1419</p>
<p>–</p>
<p>1427</p>
<p>.</p>
<p>991</p>
<p>Lluri</p>
<p>G</p>
<p>,</p>
<p>Lin</p>
<p>J</p>
<p>,</p>
<p>Reardon</p>
<p>L</p>
<p>,</p>
<p>Miner</p>
<p>P</p>
<p>,</p>
<p>Whalen</p>
<p>K</p>
<p>,</p>
<p>Aboulhosn</p>
<ol start="10" type="A">
<li></li>
</ol>
<p>Early experience with sacubitril/valsartan in adult patients with
congenital heart disease</p>
<p>.</p>
<p>World J Pediatr Congenit Heart Surg</p>
<p>2019</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>292</p>
<p>–</p>
<p>295</p>
<p>.</p>
<p>992</p>
<p>Appadurai</p>
<p>V</p>
<p>,</p>
<p>Thoreau</p>
<p>J</p>
<p>,</p>
<p>Malpas</p>
<p>T</p>
<p>,</p>
<p>Nicolae</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Sacubitril/valsartan in adult congenital heart disease patients with
chronic heart failure – a single centre case series and call for an
international registry</p>
<p>.</p>
<p>Heart Lung Circ</p>
<p>2020</p>
<p>;</p>
<p>29</p>
<p>:</p>
<p>137</p>
<p>–</p>
<p>141</p>
<p>.</p>
<p>993</p>
<p>Maurer</p>
<p>SJ</p>
<p>,</p>
<p>Pujol Salvador</p>
<p>C</p>
<p>,</p>
<p>Schiele</p>
<p>S</p>
<p>,</p>
<p>Hager</p>
<p>A</p>
<p>,</p>
<p>Ewert</p>
<p>P</p>
<p>,</p>
<p>Tutarel</p>
<ol start="15" type="A">
<li></li>
</ol>
<p>Sacubitril/valsartan for heart failure in adults with complex
congenital heart disease</p>
<p>.</p>
<p>Int J Cardiol</p>
<p>2020</p>
<p>;</p>
<p>300</p>
<p>:</p>
<p>137</p>
<p>–</p>
<p>140</p>
<p>.</p>
<p>994</p>
<p>Van De Bruaene</p>
<p>A</p>
<p>,</p>
<p>Meier</p>
<p>L</p>
<p>,</p>
<p>Droogne</p>
<p>W</p>
<p>,</p>
<p>De Meester</p>
<p>P</p>
<p>,</p>
<p>Troost</p>
<p>E</p>
<p>,</p>
<p>Gewillig</p>
<p>M</p>
<p>,</p>
<p>Budts</p>
<ol start="23" type="A">
<li></li>
</ol>
<p>Management of acute heart failure in adult patients with congenital
heart disease</p>
<p>.</p>
<p>Heart Fail Rev</p>
<p>2018</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>1</p>
<p>–</p>
<p>14</p>
<p>.</p>
<p>995</p>
<p>Minchin</p>
<p>M</p>
<p>,</p>
<p>Roland</p>
<p>M</p>
<p>,</p>
<p>Richardson</p>
<p>J</p>
<p>,</p>
<p>Rowark</p>
<p>S</p>
<p>,</p>
<p>Guthrie</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>Quality of care in the United Kingdom after removal of financial
incentives</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2018</p>
<p>;</p>
<p>379</p>
<p>:</p>
<p>948</p>
<p>–</p>
<p>957</p>
<p>.</p>
<p>996</p>
<p>Song</p>
<p>Z</p>
<p>,</p>
<p>Ji</p>
<p>Y</p>
<p>,</p>
<p>Safran</p>
<p>DG</p>
<p>,</p>
<p>Chernew</p>
<p>ME.</p>
<p>Health care spending, utilization, and quality 8 years into global
payment</p>
<p>.</p>
<p>N Engl J Med</p>
<p>2019</p>
<p>;</p>
<p>381</p>
<p>:</p>
<p>252</p>
<p>–</p>
<p>263</p>
<p>.</p>
<p>997</p>
<p>Aktaa</p>
<p>S</p>
<p>,</p>
<p>Batra</p>
<p>G</p>
<p>,</p>
<p>Wallentin</p>
<p>L</p>
<p>,</p>
<p>Baigent</p>
<p>C</p>
<p>,</p>
<p>Erlinge</p>
<p>D</p>
<p>,</p>
<p>James</p>
<p>S</p>
<p>,</p>
<p>Ludman</p>
<p>P</p>
<p>,</p>
<p>Maggioni</p>
<p>AP</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Weston</p>
<p>C</p>
<p>,</p>
<p>Casadei</p>
<p>B</p>
<p>,</p>
<p>Gale</p>
<p>CP.</p>
<p>European Society of Cardiology methodology for the development of
quality indicators for the quantification of cardiovascular care and
outcomes</p>
<p>.</p>
<p>Eur Heart J Qual Care Clin Outcomes</p>
<p>2020</p>
<p>. doi: 10.1093/ehjqcco/qcaa069.</p>
<p>998</p>
<p>Arbelo</p>
<p>E</p>
<p>,</p>
<p>Aktaa</p>
<p>S</p>
<p>,</p>
<p>Bollmann</p>
<p>A</p>
<p>,</p>
<p>D’Avila</p>
<p>A</p>
<p>,</p>
<p>Drossart</p>
<p>I</p>
<p>,</p>
<p>Dwight</p>
<p>J</p>
<p>,</p>
<p>Hills</p>
<p>MT</p>
<p>,</p>
<p>Hindricks</p>
<p>G</p>
<p>,</p>
<p>Kusumoto</p>
<p>FM</p>
<p>,</p>
<p>Lane</p>
<p>DA</p>
<p>,</p>
<p>Lau</p>
<p>DH</p>
<p>,</p>
<p>Lettino</p>
<p>M</p>
<p>,</p>
<p>Lip</p>
<p>GYH</p>
<p>,</p>
<p>Lobban</p>
<p>T</p>
<p>,</p>
<p>Pak</p>
<p>HN</p>
<p>,</p>
<p>Potpara</p>
<p>T</p>
<p>,</p>
<p>Saenz</p>
<p>LC</p>
<p>,</p>
<p>Van Gelder</p>
<p>IC</p>
<p>,</p>
<p>Varosy</p>
<p>P</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Dagres</p>
<p>N</p>
<p>,</p>
<p>Reviewers</p>
<p>,</p>
<p>Boveda</p>
<p>S</p>
<p>,</p>
<p>Deneke</p>
<p>T</p>
<p>,</p>
<p>Defaye</p>
<p>P</p>
<p>,</p>
<p>Conte</p>
<p>G</p>
<p>,</p>
<p>Lenarczyk</p>
<p>R</p>
<p>,</p>
<p>Providencia</p>
<p>R</p>
<p>,</p>
<p>Guerra</p>
<p>JM</p>
<p>,</p>
<p>Takahashi</p>
<p>Y</p>
<p>,</p>
<p>Pisani</p>
<p>C</p>
<p>,</p>
<p>Nava</p>
<p>S</p>
<p>,</p>
<p>Sarkozy</p>
<p>A</p>
<p>,</p>
<p>Glotzer</p>
<p>TV</p>
<p>,</p>
<p>Martins Oliveira</p>
<ol start="13" type="A">
<li></li>
</ol>
<p>Quality indicators for the care and outcomes of adults with atrial
fibrillation</p>
<p>.</p>
<p>Europace</p>
<p>2021</p>
<p>;</p>
<p>23</p>
<p>:</p>
<p>494</p>
<p>–</p>
<p>495</p>
<p>.</p>
<p>999</p>
<p>Schiele</p>
<p>F</p>
<p>,</p>
<p>Aktaa</p>
<p>S</p>
<p>,</p>
<p>Rossello</p>
<p>X</p>
<p>,</p>
<p>Ahrens</p>
<p>I</p>
<p>,</p>
<p>Claeys</p>
<p>MJ</p>
<p>,</p>
<p>Collet</p>
<p>JP</p>
<p>,</p>
<p>Fox</p>
<p>KAA</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Huber</p>
<p>K</p>
<p>,</p>
<p>Iakobishvili</p>
<p>Z</p>
<p>,</p>
<p>Keys</p>
<p>A</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Leonardi</p>
<p>S</p>
<p>,</p>
<p>Lettino</p>
<p>M</p>
<p>,</p>
<p>Masoudi</p>
<p>FA</p>
<p>,</p>
<p>Price</p>
<p>S</p>
<p>,</p>
<p>Quinn</p>
<p>T</p>
<p>,</p>
<p>Swahn</p>
<p>E</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Timmis</p>
<p>A</p>
<p>,</p>
<p>Tubaro</p>
<p>M</p>
<p>,</p>
<p>Vrints</p>
<p>CJM</p>
<p>,</p>
<p>Walker</p>
<p>D</p>
<p>,</p>
<p>Bueno</p>
<p>H</p>
<p>,</p>
<p>Scientific Document Group</p>
<p>ESC</p>
<p>,</p>
<p>Halvorsen</p>
<p>S</p>
<p>,</p>
<p>Jernberg</p>
<p>T</p>
<p>,</p>
<p>Jortveit</p>
<p>J</p>
<p>,</p>
<p>Blondal</p>
<p>M</p>
<p>,</p>
<p>Ibanez</p>
<p>B</p>
<p>,</p>
<p>Hassager</p>
<ol start="3" type="A">
<li></li>
</ol>
<p>2020 Update of the quality indicators for acute myocardial
infarction: a position paper of the Association for Acute Cardiovascular
Care: the study group for quality indicators from the ACVC and the
NSTE-ACS guideline group</p>
<p>.</p>
<p>Eur Heart J Acute Cardiovasc Care</p>
<p>2021</p>
<p>;</p>
<p>10</p>
<p>:</p>
<p>224</p>
<p>–</p>
<p>233</p>
<p>.</p>
<p>1000</p>
<p>Collet</p>
<p>JP</p>
<p>,</p>
<p>Thiele</p>
<p>H</p>
<p>,</p>
<p>Barbato</p>
<p>E</p>
<p>,</p>
<p>Barthelemy</p>
<p>O</p>
<p>,</p>
<p>Bauersachs</p>
<p>J</p>
<p>,</p>
<p>Bhatt</p>
<p>DL</p>
<p>,</p>
<p>Dendale</p>
<p>P</p>
<p>,</p>
<p>Dorobantu</p>
<p>M</p>
<p>,</p>
<p>Edvardsen</p>
<p>T</p>
<p>,</p>
<p>Folliguet</p>
<p>T</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Gilard</p>
<p>M</p>
<p>,</p>
<p>Jobs</p>
<p>A</p>
<p>,</p>
<p>Juni</p>
<p>P</p>
<p>,</p>
<p>Lambrinou</p>
<p>E</p>
<p>,</p>
<p>Lewis</p>
<p>BS</p>
<p>,</p>
<p>Mehilli</p>
<p>J</p>
<p>,</p>
<p>Meliga</p>
<p>E</p>
<p>,</p>
<p>Merkely</p>
<p>B</p>
<p>,</p>
<p>Mueller</p>
<p>C</p>
<p>,</p>
<p>Roffi</p>
<p>M</p>
<p>,</p>
<p>Rutten</p>
<p>FH</p>
<p>,</p>
<p>Sibbing</p>
<p>D</p>
<p>,</p>
<p>Siontis</p>
<p>GCM</p>
<p>,</p>
<p>ESC Scientific Document Group</p>
<p>.</p>
<p>2020 ESC Guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2021</p>
<p>;</p>
<p>42</p>
<p>:</p>
<p>1289</p>
<p>–</p>
<p>1367</p>
<p>.</p>
<p>1001</p>
<p>Wallentin</p>
<p>L</p>
<p>,</p>
<p>Gale</p>
<p>CP</p>
<p>,</p>
<p>Maggioni</p>
<p>A</p>
<p>,</p>
<p>Bardinet</p>
<p>I</p>
<p>,</p>
<p>Casadei</p>
<ol start="2" type="A">
<li></li>
</ol>
<p>EuroHeart: European Unified Registries On Heart Care Evaluation and
Randomized Trials</p>
<p>.</p>
<p>Eur Heart J</p>
<p>2019</p>
<p>;</p>
<p>40</p>
<p>:</p>
<p>2745</p>
<p>–</p>
<p>2749</p>
<p>.</p>
<h2 >Author notes</h2>
<p>* Corresponding authors: The two chairpersons contributed equally to
the document.</p>
<p>This article has been co-published with permission in the
<em>European Heart Journal</em> and <em>European Journal of Heart
Failure</em>. © the European Society of Cardiology 2021. All rights
reserved. The articles are identical except for minor stylistic and
spelling differences in keeping with each journal’s style. Either
citation can be used when citing this article. For permissions, please
email journals.permissions@oup.com.</p>
<h2 >Supplementary data</h2>
<p>Advertisement intended for healthcare professionals</p>
<h3 >Citations</h3>
<h3 >Views</h3>
<h3 >Altmetric</h3>
<p><a
href="https://www.altmetric.com/details.php?domain=academic.oup.com&amp;citation_id=112448446"><img
src="https://badges.altmetric.com/?size=128&amp;score=1511&amp;types=mbrttwfd"
alt="Article has an altmetric score of 1511" /></a></p>
<h3 >Email alerts</h3>
<h3 >Related articles in PubMed</h3>
<h3 >Citing articles via</h3>
<ul>
<li><h3 >Latest</h3></li>
<li><h3 >Most Read</h3></li>
<li><h3 >Most Cited</h3></li>
</ul>
<p>More from Oxford Academic</p>
<p>Advertisement intended for healthcare professionals</p>
